11058428
D013256_D013119 NONE steroid_2\NN\14727670|NONE_0 (r_compound) myopathy_3\NN\14204950|further_17|,_10|naturally_18|and_28|be_85 (r_nsubj) recovers_4\VBZ\2210855|NONE_0 (l_conj) be_15\VB\14625458|further_102|,_95|myopathy_85|naturally_67|and_57 (l_attr) recording_18\NN\6791372|improvement_46|may_14|._150 (l_cc) of_30\IN\0|just_83|a_78|of_66|,_10 (l_pobj) protection_32\NN\407535|instead_15 (l_relcl) methylprednisolone_34\NN\0|any_20 (l_dobj) offers_35\VBZ\7160883|that_24 (l_prep) to_36\IN\0|NONE_0 (l_pobj) injury_40\NN\14052046|NONE_0
D013256_D013119 NONE steroid_26\NN\14727670|NONE_0 (r_compound) myopathy_27\NNS\14204950|NONE_0 (r_pobj) from_24\IN\0|this_28|natural_23|motor_15 (r_prep) recovery_23\NN\7357388|NONE_0 (r_pobj) of_19\IN\0|just_17|a_12|,_56|of_66 (r_prep) recording_18\NN\6791372|improvement_46|may_14|._150 (l_cc) of_30\IN\0|just_83|a_78|of_66|,_10 (l_pobj) protection_32\NN\407535|instead_15 (l_relcl) methylprednisolone_34\NN\0|any_20 (l_dobj) offers_35\VBZ\7160883|that_24 (l_prep) to_36\IN\0|NONE_0 (l_pobj) injury_40\NN\14052046|NONE_0
D013256_D009135 NONE steroid_2\NN\14727670|NONE_0 (r_compound) myopathy_3\NN\14204950|further_17|,_10|naturally_18|and_28|be_85
D013256_D009135 NONE steroid_2\NN\14727670|NONE_0 (r_compound) myopathy_3\NN\14204950|further_17|,_10|naturally_18|and_28|be_85 (r_nsubj) recovers_4\VBZ\2210855|NONE_0 (l_conj) be_15\VB\14625458|further_102|,_95|myopathy_85|naturally_67|and_57 (l_attr) recording_18\NN\6791372|improvement_46|may_14|._150 (l_prep) of_19\IN\0|just_17|a_12|,_56|of_66 (l_pobj) recovery_23\NN\7357388|NONE_0 (l_prep) from_24\IN\0|this_28|natural_23|motor_15 (l_pobj) myopathy_27\NNS\14204950|NONE_0
D013256_D009135 NONE steroid_26\NN\14727670|NONE_0 (r_compound) myopathy_27\NNS\14204950|NONE_0 (r_pobj) from_24\IN\0|this_28|natural_23|motor_15 (r_prep) recovery_23\NN\7357388|NONE_0 (r_pobj) of_19\IN\0|just_17|a_12|,_56|of_66 (r_prep) recording_18\NN\6791372|improvement_46|may_14|._150 (r_attr) be_15\VB\14625458|further_102|,_95|myopathy_85|naturally_67|and_57 (r_conj) recovers_4\VBZ\2210855|NONE_0 (l_nsubj) myopathy_3\NN\14204950|further_17|,_10|naturally_18|and_28|be_85
D013256_D009135 NONE steroid_26\NN\14727670|NONE_0 (r_compound) myopathy_27\NNS\14204950|NONE_0
D000305_D009135 NONE corticosteroid_13\NN\14745635|NONE_0 (r_pobj) of_11\IN\0|the_16|myopathy_24|cause_71 (r_prep) possibility_10\NN\5944958|NONE_0 (l_prep) myopathy_14\NNS\14204950|the_40|of_24|cause_47
D000305_D009135 NONE corticosteroid_21\NN\14745635|NONE_0 (r_nsubj) myopathy_22\NNS\14204950|that_81|methylprednisolone_72|may_31
D008775_D009135 CID methylprednisolone_19\NN\0|that_15|may_19 (r_nsubj) cause_21\VB\7323922|the_87|of_71|myopathy_47 (r_acl) possibility_10\NN\5944958|NONE_0 (l_prep) myopathy_14\NNS\14204950|the_40|of_24|cause_47
D008775_D009135 CID methylprednisolone_34\NN\0|any_20 (r_relcl) protection_32\NN\407535|instead_15 (r_pobj) of_30\IN\0|just_83|a_78|of_66|,_10 (r_cc) recording_18\NN\6791372|improvement_46|may_14|._150 (r_attr) be_15\VB\14625458|further_102|,_95|myopathy_85|naturally_67|and_57 (r_conj) recovers_4\VBZ\2210855|NONE_0 (l_nsubj) myopathy_3\NN\14204950|further_17|,_10|naturally_18|and_28|be_85
D008775_D009135 CID methylprednisolone_34\NN\0|any_20 (r_relcl) protection_32\NN\407535|instead_15 (r_pobj) of_30\IN\0|just_83|a_78|of_66|,_10 (r_cc) recording_18\NN\6791372|improvement_46|may_14|._150 (l_prep) of_19\IN\0|just_17|a_12|,_56|of_66 (l_pobj) recovery_23\NN\7357388|NONE_0 (l_prep) from_24\IN\0|this_28|natural_23|motor_15 (l_pobj) myopathy_27\NNS\14204950|NONE_0
D008775_D009135 CID methylprednisolone_14\NN\0|that_9|may_41|myopathy_72 (r_nsubj) cause_19\VB\7323922|the_70 (l_ccomp) myopathy_22\NNS\14204950|that_81|methylprednisolone_72|may_31
D008775_D013119 NONE methylprednisolone_3\NN\0|may_19|harm_31|._58 (r_nsubj) do_5\VB\7447641|NONE_0 (l_dobj) harm_7\NN\14052046|methylprednisolone_31|may_12|._27 (l_prep) for_8\IN\0|more_10 (l_pobj) injury_11\NN\14052046|NONE_0
D008775_D013119 NONE methylprednisolone_16\NN\0|because_77|standard_30|._79 (r_nsubj) became_17\VBD\146138|NONE_0 (l_prep) because_0\IN\0|methylprednisolone_77|standard_107|._156 (l_pobj) studies_8\NNP\635850|of_41 (l_compound) injury_7\NNP\14052046|the_31|national_27|(_15|nascis_16|,_23
D008775_D013119 NONE methylprednisolone_16\NN\0|because_77|standard_30|._79 (r_nsubj) became_17\VBD\146138|NONE_0 (l_attr) standard_19\NN\13577171|because_107|methylprednisolone_30|._49 (l_prep) for_22\IN\0|the_21|of_8 (l_pobj) injury_27\NN\14052046|NONE_0
D008775_D013119 NONE methylprednisolone_34\NN\0|any_20 (l_dobj) offers_35\VBZ\7160883|that_24 (l_prep) to_36\IN\0|NONE_0 (l_pobj) injury_40\NN\14052046|NONE_0
7785794
D008790_D007022 CID metoprolol_32\NN\2832168|NONE_0 (r_pobj) of_31\IN\0|concomitant_16 (r_prep) use_30\NN\407535|NONE_0 (r_pobj) with_28\IN\0|a_50|therapeutic_48|of_31 (r_prep) dose_22\NN\3740161|days_25 (r_pobj) after_19\IN\0|woman_78|with_62|._90 (r_prep) presented_9\VBN\2137132|NONE_0 (l_prep) with_10\IN\0|woman_16|after_62|._152 (l_pobj) block_13\NN\21939|NONE_0 (l_conj) hypotension_16\NN\14057371|complete_36|heart_27|and_15
D004298_D007022 NONE dopamine_28\NN\14807737|such_8 (r_pobj) as_27\IN\14622893|pressor_20 (r_prep) agents_25\NNS\7347|NONE_0 (r_pobj) of_23\IN\0|high_11 (r_prep) doses_22\NNS\3740161|multiple_54|of_40 (r_conj) uses_14\NNS\407535|even_19 (r_pobj) with_12\IN\0|to_54|hypotensive_44|,_7 (r_prep) remain_4\VB\2604760|patient_21|._165 (l_acomp) hypotensive_5\JJ\10405694|to_10|,_37|with_44
D004280_D007022 NONE dobutamine_30\NN\0|and_4 (r_conj) dopamine_28\NN\14807737|such_8 (r_pobj) as_27\IN\14622893|pressor_20 (r_prep) agents_25\NNS\7347|NONE_0 (r_pobj) of_23\IN\0|high_11 (r_prep) doses_22\NNS\3740161|multiple_54|of_40 (r_conj) uses_14\NNS\407535|even_19 (r_pobj) with_12\IN\0|to_54|hypotensive_44|,_7 (r_prep) remain_4\VB\2604760|patient_21|._165 (l_acomp) hypotensive_5\JJ\10405694|to_10|,_37|with_44
D001285_D007022 NONE atropine_17\NN\14712692|NONE_0 (r_pobj) of_15\IN\0|multiple_14|doses_40 (r_prep) uses_14\NNS\407535|even_19 (r_pobj) with_12\IN\0|to_54|hypotensive_44|,_7 (r_prep) remain_4\VB\2604760|patient_21|._165 (l_acomp) hypotensive_5\JJ\10405694|to_10|,_37|with_44
D008790_D006327 CID metoprolol_11\NN\2832168|refractory_77|cardiogenic_66|and_48|block_29|after_23|and_4|._20 (r_conj) shock_2\NN\7510495|NONE_0 (l_conj) block_6\NN\21939|refractory_48|cardiogenic_37|and_19|after_6|and_25|metoprolol_29|._49
D008790_D006327 CID metoprolol_32\NN\2832168|NONE_0 (r_pobj) of_31\IN\0|concomitant_16 (r_prep) use_30\NN\407535|NONE_0 (r_pobj) with_28\IN\0|a_50|therapeutic_48|of_31 (r_prep) dose_22\NN\3740161|days_25 (r_pobj) after_19\IN\0|woman_78|with_62|._90 (r_prep) presented_9\VBN\2137132|NONE_0 (l_prep) with_10\IN\0|woman_16|after_62|._152 (l_pobj) block_13\NN\21939|NONE_0
D008790_D012770 NONE metoprolol_11\NN\2832168|refractory_77|cardiogenic_66|and_48|block_29|after_23|and_4|._20 (r_conj) shock_2\NN\7510495|NONE_0
D004280_D006327 NONE dobutamine_30\NN\0|and_4 (r_conj) dopamine_28\NN\14807737|such_8 (r_pobj) as_27\IN\14622893|pressor_20 (r_prep) agents_25\NNS\7347|NONE_0 (r_pobj) of_23\IN\0|high_11 (r_prep) doses_22\NNS\3740161|multiple_54|of_40 (r_conj) uses_14\NNS\407535|even_19 (r_pobj) with_12\IN\0|to_54|hypotensive_44|,_7 (r_prep) remain_4\VB\2604760|patient_21|._165 (l_acomp) hypotensive_5\JJ\10405694|to_10|,_37|with_44 (l_prep) with_6\IN\0|NONE_0 (l_pobj) block_9\NN\21939|NONE_0
D002122_D006327 NONE chloride_9\NN\14818238|NONE_0 (l_conj) hypotension_13\NN\14057371|intravenous_45|calcium_33|,_17 (l_conj) block_17\NN\21939|the_46|refractory_42|and_19
D014700_D007022 CID verapamil_27\NN\2938514|NONE_0 (r_pobj) of_23\IN\0|a_19|therapeutic_17|with_31 (r_prep) dose_22\NN\3740161|days_25 (r_pobj) after_19\IN\0|woman_78|with_62|._90 (r_prep) presented_9\VBN\2137132|NONE_0 (l_prep) with_10\IN\0|woman_16|after_62|._152 (l_pobj) block_13\NN\21939|NONE_0 (l_conj) hypotension_16\NN\14057371|complete_36|heart_27|and_15
D002122_D007022 NONE chloride_9\NN\14818238|NONE_0 (l_conj) hypotension_13\NN\14057371|intravenous_45|calcium_33|,_17
D004298_D006327 NONE dopamine_28\NN\14807737|such_8 (r_pobj) as_27\IN\14622893|pressor_20 (r_prep) agents_25\NNS\7347|NONE_0 (r_pobj) of_23\IN\0|high_11 (r_prep) doses_22\NNS\3740161|multiple_54|of_40 (r_conj) uses_14\NNS\407535|even_19 (r_pobj) with_12\IN\0|to_54|hypotensive_44|,_7 (r_prep) remain_4\VB\2604760|patient_21|._165 (l_acomp) hypotensive_5\JJ\10405694|to_10|,_37|with_44 (l_prep) with_6\IN\0|NONE_0 (l_pobj) block_9\NN\21939|NONE_0
D014700_D012770 NONE verapamil_8\NN\2938514|NONE_0 (r_compound) sr_9\NNP\14625458|NONE_0 (r_pobj) after_7\IN\0|refractory_54|cardiogenic_43|and_25|block_6|and_19|metoprolol_23|._43 (r_prep) shock_2\NN\7510495|NONE_0
D001285_D006327 NONE atropine_17\NN\14712692|NONE_0 (r_pobj) of_15\IN\0|multiple_14|doses_40 (r_prep) uses_14\NNS\407535|even_19 (r_pobj) with_12\IN\0|to_54|hypotensive_44|,_7 (r_prep) remain_4\VB\2604760|patient_21|._165 (l_acomp) hypotensive_5\JJ\10405694|to_10|,_37|with_44 (l_prep) with_6\IN\0|NONE_0 (l_pobj) block_9\NN\21939|NONE_0
D014700_D006327 CID verapamil_8\NN\2938514|NONE_0 (r_compound) sr_9\NNP\14625458|NONE_0 (r_pobj) after_7\IN\0|refractory_54|cardiogenic_43|and_25|block_6|and_19|metoprolol_23|._43 (r_prep) shock_2\NN\7510495|NONE_0 (l_conj) block_6\NN\21939|refractory_48|cardiogenic_37|and_19|after_6|and_25|metoprolol_29|._49
D014700_D006327 CID verapamil_27\NN\2938514|NONE_0 (r_pobj) of_23\IN\0|a_19|therapeutic_17|with_31 (r_prep) dose_22\NN\3740161|days_25 (r_pobj) after_19\IN\0|woman_78|with_62|._90 (r_prep) presented_9\VBN\2137132|NONE_0 (l_prep) with_10\IN\0|woman_16|after_62|._152 (l_pobj) block_13\NN\21939|NONE_0
3057041
C020976_D006255 NONE azelastine_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|safety_13 (r_prep) trial_16\NN\786195|,_53|dose_42|,_38|groups_27|and_11|in_51 (r_conj) efficacy_13\NN\5199286|,_47|blind_38|._115 (l_prep) in_24\IN\13603305|,_104|dose_93|,_89|groups_78|and_62|trial_51 (l_pobj) treatment_26\NN\654885|NONE_0 (l_prep) of_27\IN\0|the_14 (l_pobj) rhinitis_30\NN\14336539|NONE_0
C020976_D006255 NONE azelastine_0\NNP\0|was_45|with_58|._237 (r_nsubjpass) compared_8\VBN\644583|NONE_0 (l_prep) with_9\IN\0|azelastine_58|was_13|._179 (l_pobj) maleate_11\NN\2718811|NONE_0 (l_prep) for_14\IN\0|chlorpheniramine_37|and_12|placebo_8 (l_pobj) efficacy_15\NN\5199286|NONE_0 (l_prep) in_18\IN\13603305|and_11|safety_7 (l_pobj) treatment_20\NN\654885|NONE_0 (l_prep) of_21\IN\0|the_14|in_28 (l_pobj) rhinitis_24\NN\14336539|NONE_0
C020976_D006255 NONE azelastine_0\NNP\0|be_22|._86 (r_nsubj) appears_1\VBZ\2604760|NONE_0 (l_xcomp) be_3\VB\14625458|azelastine_22|._64 (l_attr) medication_8\NN\3247620|to_26 (l_prep) for_9\IN\0|a_31|safe_29|,_25|efficacious_23 (l_pobj) rhinitis_12\NN\14336539|NONE_0
C020976_D006970 CID azelastine_16\NN\0|the_14|dose_5 (r_compound) group_17\NN\2137|only_33 (r_pobj) in_11\IN\13603305|drowsiness_87|were_47|significantly_32|over_18|._33 (r_prep) increased_6\VBN\169651|NONE_0 (l_nsubjpass) drowsiness_0\VB\14015731|were_40|significantly_55|over_69|in_87|._120
D002744_D006255 NONE chlorpheniramine_20\NN\0|,_2 (r_conj) azelastine_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|safety_13 (r_prep) trial_16\NN\786195|,_53|dose_42|,_38|groups_27|and_11|in_51 (r_conj) efficacy_13\NN\5199286|,_47|blind_38|._115 (l_prep) in_24\IN\13603305|,_104|dose_93|,_89|groups_78|and_62|trial_51 (l_pobj) treatment_26\NN\654885|NONE_0 (l_prep) of_27\IN\0|the_14 (l_pobj) rhinitis_30\NN\14336539|NONE_0
D002744_D006255 NONE maleate_11\NN\2718811|NONE_0 (l_prep) for_14\IN\0|chlorpheniramine_37|and_12|placebo_8 (l_pobj) efficacy_15\NN\5199286|NONE_0 (l_prep) in_18\IN\13603305|and_11|safety_7 (l_pobj) treatment_20\NN\654885|NONE_0 (l_prep) of_21\IN\0|the_14|in_28 (l_pobj) rhinitis_24\NN\14336539|NONE_0
C020976_D013651 CID azelastine_16\NN\0|the_14|dose_5 (r_compound) group_17\NN\2137|only_33 (r_pobj) in_11\IN\13603305|drowsiness_87|were_47|significantly_32|over_18|._33 (r_prep) increased_6\VBN\169651|NONE_0 (l_nsubjpass) drowsiness_0\VB\14015731|were_40|significantly_55|over_69|in_87|._120 (l_conj) perception_4\NN\5926676|and_18
9214597
D004967_D009369 NONE estrogen_14\NN\14745635|-_8 (r_npadvmod) induced_16\VBN\1627355|NONE_0 (r_amod) rat_17\NN\2329401|pituitary_4 (r_nmod) tumors_19\NNS\14234074|NONE_0 (r_pobj) of_13\IN\0|the_16 (r_prep) development_12\NN\248977|NONE_0 (r_pobj) during_10\IN\0|its_13 (r_prep) receptor_9\NN\5225602|vascular_43|endothelial_34|growth_22|and_8 (r_conj) factor_6\NN\7326557|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) expression_1\NN\4679549|NONE_0 (r_pobj) over_0\IN\5867413|may_135|angiogenesis_172|._184 (r_prep) mediate_21\VB\761713|NONE_0 (l_dobj) angiogenesis_26\NN\13489037|over_172|may_37|._12 (l_compound) tumor_25\NN\14234074|initiated_10
D004967_D009369 NONE estrogen_22\NN\14745635|-_8 (r_npadvmod) initiated_24\VBN\1617192|tumor_10 (r_amod) angiogenesis_26\NN\13489037|over_172|may_37|._12 (l_compound) tumor_25\NN\14234074|initiated_10
D004967_D009369 NONE estrogens_0\NNP\14745635|can_86|angiogenesis_103|in_116|._152 (l_relcl) associated_5\VBN\628491|,_18|,_57 (l_prep) with_6\IN\0|which_27|have_21|been_16 (l_pobj) types_8\NNS\5839024|NONE_0 (l_prep) of_9\IN\0|several_14 (l_pobj) cancers_13\NNS\14239425|NONE_0
D004967_D009369 NONE estrogens_0\NNP\14745635|can_86|angiogenesis_103|in_116|._152 (r_nsubj) induce_16\VB\1627355|NONE_0 (l_dobj) angiogenesis_18\NN\13489037|estrogens_103|can_17|in_13|._49 (l_compound) tumor_17\NN\14234074|NONE_0
D004967_D009369 NONE estrogen_9\NN\14745635|NONE_0 (r_compound) carcinogenesis_10\NN\0|NONE_0 (r_pobj) during_8\IN\0|details_41|,_2|,_30|still_36|unknown_42|._49 (r_prep) are_12\VBP\13600404|NONE_0 (l_nsubj) details_2\NNS\6634376|,_39|during_41|,_71|still_77|unknown_83|._90 (l_prep) of_3\IN\0|the_24|mechanistic_20|induction_22 (l_pobj) angiogenesis_5\NN\13489037|NONE_0 (l_compound) tumor_4\NN\14234074|NONE_0
D004967_D009369 NONE estrogen_5\NN\14745635|NONE_0 (r_pobj) of_4\IN\0|the_9 (r_prep) role_3\NN\719494|to_17|in_17 (r_dobj) elucidate_1\VB\939277|,_102|density_108|was_133|using_146 (l_prep) in_6\IN\13603305|to_34|role_17 (l_pobj) regulation_8\NN\6652242|NONE_0 (l_prep) of_9\IN\0|the_15|in_22 (l_pobj) angiogenesis_11\NN\13489037|NONE_0 (l_compound) tumor_10\NN\14234074|NONE_0
D004967_D009369 NONE estrogen_27\NN\14745635|NONE_0 (r_pobj) of_26\IN\0|the_15 (r_prep) regulation_25\NN\6652242|NONE_0 (r_pobj) of_23\IN\0|the_17|initial_13 (r_prep) step_22\NN\168237|NONE_0 (r_pobj) in_19\IN\13603305|that_83|over_78|may_27|role_5 (r_prep) play_15\VB\7007684|findings_77|induced_73|._120 (r_ccomp) suggest_2\VBP\1010118|NONE_0 (l_ccomp) induced_28\VBN\1627355|findings_150|play_73|._47 (l_dobj) angiogenesis_30\NN\13489037|in_13 (l_compound) tumor_29\NN\14234074|NONE_0
D004967_D010911 NONE estrogen_14\NN\14745635|-_8 (r_npadvmod) induced_16\VBN\1627355|NONE_0 (r_amod) rat_17\NN\2329401|pituitary_4 (r_nmod) tumors_19\NNS\14234074|NONE_0
D004967_D010911 NONE estrogen_22\NN\14745635|-_8 (r_npadvmod) initiated_24\VBN\1617192|tumor_10 (r_amod) angiogenesis_26\NN\13489037|over_172|may_37|._12 (r_dobj) mediate_21\VB\761713|NONE_0 (l_prep) over_0\IN\5867413|may_135|angiogenesis_172|._184 (l_pobj) expression_1\NN\4679549|NONE_0 (l_prep) of_2\IN\0|NONE_0 (l_pobj) factor_6\NN\7326557|NONE_0 (l_conj) receptor_9\NN\5225602|vascular_43|endothelial_34|growth_22|and_8 (l_prep) during_10\IN\0|its_13 (l_pobj) development_12\NN\248977|NONE_0 (l_prep) of_13\IN\0|the_16 (l_pobj) tumors_19\NNS\14234074|NONE_0
D004967_D063646 NONE estrogen_9\NN\14745635|NONE_0 (r_compound) carcinogenesis_10\NN\0|NONE_0
15893386
D015742_D008305 NONE propofol_5\JJ\0|NONE_0 (r_amod) infusion_6\NN\14589223|NONE_0 (r_pobj) with_4\IN\0|anesthesia_38|was_27|uneventfully_13|were_44|._101 (r_prep) continued_2\VBN\2367363|NONE_0 (l_advcl) were_10\VBD\0|anesthesia_82|was_71|uneventfully_57|with_44|._57 (l_acomp) available_11\JJ\0|while_26|facilities_16 (l_xcomp) detect_13\VB\2163746|NONE_0 (l_conj) treat_15\VB\7570720|to_14|and_4 (l_dobj) hyperthermia_17\NN\14034177|NONE_0
D013390_D014313 CID succinylcholine_0\NN\3800001|-_15 (r_npadvmod) induced_2\VBN\1627355|masseter_8|muscle_17|during_33|._88 (r_amod) rigidity_5\NN\5023233|NONE_0
D013390_D014313 CID succinylcholine_17\NN\3800001|(_16|sch_17|)_20|during_37 (r_nmod) administration_21\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|here_75|,_71|we_69|case_55|._138 (r_prep) describe_3\VBP\1001294|NONE_0 (l_dobj) case_5\NN\7283608|here_20|,_16|we_14|after_55|._193 (l_prep) of_6\IN\0|a_7 (l_pobj) rigidity_10\NN\5023233|NONE_0
D013390_D014313 CID succinylcholine_17\NN\3800001|(_16|sch_17|)_20|during_37 (r_nmod) administration_21\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|here_75|,_71|we_69|case_55|._138 (r_prep) describe_3\VBP\1001294|NONE_0 (l_dobj) case_5\NN\7283608|here_20|,_16|we_14|after_55|._193 (l_prep) of_6\IN\0|a_7 (l_pobj) rigidity_10\NN\5023233|NONE_0 (l_appos) jaw_12\NN\5269901|severe_33|masseter_26|muscle_17|(_1|)_12 (l_prep) of_13\IN\0|NONE_0 (l_pobj) steel_14\NN\14586769|NONE_0
D013390_D014313 CID sch_19\NNP\0|succinylcholine_17|(_1|)_3|during_20 (r_nmod) administration_21\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|here_75|,_71|we_69|case_55|._138 (r_prep) describe_3\VBP\1001294|NONE_0 (l_dobj) case_5\NN\7283608|here_20|,_16|we_14|after_55|._193 (l_prep) of_6\IN\0|a_7 (l_pobj) rigidity_10\NN\5023233|NONE_0
D013390_D014313 CID sch_19\NNP\0|succinylcholine_17|(_1|)_3|during_20 (r_nmod) administration_21\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|here_75|,_71|we_69|case_55|._138 (r_prep) describe_3\VBP\1001294|NONE_0 (l_dobj) case_5\NN\7283608|here_20|,_16|we_14|after_55|._193 (l_prep) of_6\IN\0|a_7 (l_pobj) rigidity_10\NN\5023233|NONE_0 (l_appos) jaw_12\NN\5269901|severe_33|masseter_26|muscle_17|(_1|)_12 (l_prep) of_13\IN\0|NONE_0 (l_pobj) steel_14\NN\14586769|NONE_0
3461217
D013739_D011471 NONE testosterone_21\NN\14747587|nitroso_25|-_18|n_17|-_16|and_4 (r_conj) methylurea_19\NN\0|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treatments_11\NNS\654885|NONE_0 (r_pobj) by_10\IN\0|of_55|._58 (r_prep) production_0\NN\30358|NONE_0 (l_prep) of_1\IN\0|by_55|._113 (l_pobj) cancer_4\NN\14239425|NONE_0
D043343_D009369 NONE tp_6\NNP\0|in_13|,_2|as_9|,_37|with_39|._98 (r_nsubj) acted_7\VBD\0|NONE_0 (l_prep) as_8\IN\14622893|in_22|,_11|tp_9|,_28|with_30|._89 (l_pobj) agent_12\NN\7347|NONE_0 (l_compound) enhancement_11\NN\248977|a_8 (l_compound) tumor_10\NN\14234074|NONE_0
D043343_D011471 CID propionate_45\NN\0|(_33|:_29|5_20|)_19|and_17 (r_conj) cas_35\NN\14625458|nitroso_22|-_15|n_14|-_13 (r_appos) methylurea_33\NN\0|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) treatments_25\NNS\654885|NONE_0 (r_pobj) following_24\VBG\8180190|rats_62|pas_5 (r_prep) developed_15\VBD\1753788|%_37 (l_dobj) pas_22\FW\285557|rats_57|following_5 (l_nmod) adenocarcinomas_20\NNS\14242337|large_25|,_20|palpable_18|prostate_9|(_16|)_20
D043343_D011471 CID propionate_45\NN\0|(_33|:_29|5_20|)_19|and_17 (r_conj) cas_35\NN\14625458|nitroso_22|-_15|n_14|-_13 (r_appos) methylurea_33\NN\0|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) treatments_25\NNS\654885|NONE_0 (r_pobj) following_24\VBG\8180190|rats_62|pas_5 (r_prep) developed_15\VBD\1753788|%_37 (l_dobj) pas_22\FW\285557|rats_57|following_5
D043343_D011471 CID tp_19\NNP\0|only_10 (r_pobj) with_18\IN\0|when_18 (r_prep) treated_16\VBN\2376958|within_75|,_50|rat_41|pa_8|._20 (r_advcl) developed_10\VBD\1753788|NONE_0 (l_dobj) pa_14\NNP\10080869|within_67|,_42|rat_33|treated_8|._28
D043343_D011471 CID tp_6\NNP\0|in_13|,_2|as_9|,_37|with_39|._98 (r_nsubj) acted_7\VBD\0|NONE_0 (l_prep) with_14\IN\0|in_52|,_41|tp_39|as_30|,_2|._59 (l_pobj) emphasis_16\NN\14434681|NONE_0 (l_prep) on_17\IN\0|primary_17 (l_pobj) development_19\NN\248977|NONE_0 (l_prep) of_20\IN\0|the_16 (l_pobj) cancer_22\NN\14239425|NONE_0
D008770_D011471 CID methylurea_19\NN\0|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treatments_11\NNS\654885|NONE_0 (r_pobj) by_10\IN\0|of_55|._58 (r_prep) production_0\NN\30358|NONE_0 (l_prep) of_1\IN\0|by_55|._113 (l_pobj) cancer_4\NN\14239425|NONE_0
D008770_D011471 CID methylurea_33\NN\0|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) treatments_25\NNS\654885|NONE_0 (r_pobj) following_24\VBG\8180190|rats_62|pas_5 (r_prep) developed_15\VBD\1753788|%_37 (l_dobj) pas_22\FW\285557|rats_57|following_5 (l_nmod) adenocarcinomas_20\NNS\14242337|large_25|,_20|palpable_18|prostate_9|(_16|)_20
D008770_D011471 CID methylurea_33\NN\0|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) treatments_25\NNS\654885|NONE_0 (r_pobj) following_24\VBG\8180190|rats_62|pas_5 (r_prep) developed_15\VBD\1753788|%_37 (l_dobj) pas_22\FW\285557|rats_57|following_5
8251368
D017311_D013684 CID amlodipine_6\NN\0|one_39|later_19|,_24|with_26|._59 (r_dobj) commenced_1\VBD\0|NONE_0 (l_prep) with_11\IN\0|one_65|amlodipine_26|later_7|,_2|._33 (l_pobj) recurrence_12\NN\7342049|NONE_0 (l_prep) of_13\IN\0|NONE_0 (l_pobj) telangiectasia_14\NN\0|NONE_0
D009543_D013684 CID nifedipine_1\RB\2938514|-_10 (r_advmod) induced_3\VBN\1627355|facial_8 (r_amod) telangiectasia_5\NN\0|._14
D009543_D013684 CID nifedipine_4\NN\2938514|adalat_12 (r_dobj) starting_3\VBG\457382|months_13 (r_pcomp) after_2\IN\0|,_34|patients_40|telangiectasia_83|._137 (r_prep) developed_11\VBD\1753788|NONE_0 (l_dobj) telangiectasia_14\NN\0|after_83|,_49|patients_43|._54
D009543_D013684 CID adalat_6\NNP\0|nifedipine_12 (r_oprd) starting_3\VBG\457382|months_13 (r_pcomp) after_2\IN\0|,_34|patients_40|telangiectasia_83|._137 (r_prep) developed_11\VBD\1753788|NONE_0 (l_dobj) telangiectasia_14\NN\0|after_83|,_49|patients_43|._54
17019386
D008353_D009362 NONE mannitol_2\NN\3214670|:_2 (r_appos) methods_0\NNS\5616786|was_41|as_58|had_86|._186 (r_nsubjpass) administered_14\VBN\2436349|NONE_0 (l_parataxis) had_22\VBD\0|methods_86|was_45|as_28|._100 (l_dobj) glioma_24\NN\14236743|(_19|ten_18|before_69 (l_conj) metastases_28\NNS\13533470|malignant_30|,_14|)_30
D008353_D009362 NONE mannitol_8\NN\3214670|NONE_0 (r_pobj) of_7\IN\0|patients_31|plasma_22 (r_prep) concentrations_6\NNS\4916342|in_45|higher_32|except_72|._131 (l_compound) patients_4\NNS\9898892|plasma_9|of_31 (l_nmod) meningioma_1\NN\14235200|NONE_0 (l_conj) metastases_3\NNS\13533470|and_4
D008353_D004487 NONE mannitol_13\NN\3214670|that_32|after_22|,_2|may_9|through_18|near_42|,_54|reversing_56 (r_nsubj) leak_15\VB\9304465|the_75|of_63|._157 (l_advcl) reversing_23\VBG\109660|that_88|after_78|,_58|mannitol_56|may_47|through_38|near_14|,_2 (l_conj) aggravating_34\VBG\126264|gradient_10|,_2 (l_dobj) edema_36\NN\14315192|and_6|promoting_10
D008353_D005910 NONE mannitol_2\NN\3214670|NONE_0 (r_pobj) of_1\IN\0|into_12 (r_prep) passage_0\NN\199130|:_49|cause_63|._90 (r_nsubj) gliomas_7\NNS\14236743|NONE_0
D008353_D005910 NONE mannitol_2\NN\3214670|:_2 (r_appos) methods_0\NNS\5616786|was_41|as_58|had_86|._186 (r_nsubjpass) administered_14\VBN\2436349|NONE_0 (l_parataxis) had_22\VBD\0|methods_86|was_45|as_28|._100 (l_dobj) glioma_24\NN\14236743|(_19|ten_18|before_69
D008353_D005910 NONE mannitol_5\NN\3214670|in_24 (r_amod) concentrations_6\NNS\4916342|in_34|,_11|higher_49|mean_72|._87 (r_nsubj) were_10\VBD\0|NONE_0 (l_prep) in_0\IN\13603305|,_23|concentrations_34|higher_83|mean_106|._121 (l_pobj) patients_3\NNS\9898892|NONE_0 (l_compound) glioma_2\NN\14236743|most_5
D008353_D005910 NONE mannitol_13\NN\3214670|that_32|after_22|,_2|may_9|through_18|near_42|,_54|reversing_56 (r_nsubj) leak_15\VB\9304465|the_75|of_63|._157 (l_prep) near_20\IN\1849221|that_74|after_64|,_44|mannitol_42|may_33|through_24|,_12|reversing_14 (l_pobj) gliomas_21\NNS\14236743|NONE_0
D008353_D019586 CID mannitol_5\NN\3214670|NONE_0 (r_pobj) of_4\IN\0|widespread_15|reduce_15 (r_prep) use_3\NN\407535|:_13|continues_85|._146 (l_acl) reduce_7\VB\441445|widespread_30|of_15 (l_dobj) edema_9\NN\14315192|to_16 (l_conj) icp_13\NNP\0|brain_31|and_19
D008353_D008579 NONE mannitol_2\NN\3214670|:_2 (r_appos) methods_0\NNS\5616786|was_41|as_58|had_86|._186 (r_nsubjpass) administered_14\VBN\2436349|NONE_0 (l_parataxis) had_22\VBD\0|methods_86|was_45|as_28|._100 (l_dobj) glioma_24\NN\14236743|(_19|ten_18|before_69 (l_conj) metastases_28\NNS\13533470|malignant_30|,_14|)_30 (l_conj) meningioma_31\NN\14235200|seven_32|brain_26|and_9
D008353_D008579 NONE mannitol_8\NN\3214670|NONE_0 (r_pobj) of_7\IN\0|patients_31|plasma_22 (r_prep) concentrations_6\NNS\4916342|in_45|higher_32|except_72|._131 (l_compound) patients_4\NNS\9898892|plasma_9|of_31 (l_nmod) meningioma_1\NN\14235200|NONE_0
D008353_D001929 NONE mannitol_5\NN\3214670|NONE_0 (r_pobj) of_4\IN\0|widespread_15|reduce_15 (r_prep) use_3\NN\407535|:_13|continues_85|._146 (l_acl) reduce_7\VB\441445|widespread_30|of_15 (l_dobj) edema_9\NN\14315192|to_16
D008353_D001932 NONE mannitol_5\NN\3214670|NONE_0 (r_pobj) of_4\IN\0|widespread_15|reduce_15 (r_prep) use_3\NN\407535|:_13|continues_85|._146 (l_acl) reduce_7\VB\441445|widespread_30|of_15 (l_dobj) edema_9\NN\14315192|to_16 (l_conj) icp_13\NNP\0|brain_31|and_19 (l_prep) in_14\IN\13603305|lower_19|elevated_13 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_compound) tumor_16\NN\14234074|NONE_0
D008353_D001932 NONE mannitol_14\NN\3214670|NONE_0 (r_pobj) of_13\IN\0|the_21|possible_17|into_12 (r_prep) passage_12\NN\199130|to_25|after_35|to_56 (r_dobj) research_9\VB\633864|as_46|we_14|._104 (l_prep) to_20\IN\0|to_81|passage_56|after_21 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_compound) tumor_23\NN\14234074|21_9
9209318
D015215_D009190 CID azidothymidine_5\NN\0|NONE_0 (r_pcomp) with_4\IN\0|lifetime_27|of_8|azt_21 (r_prep) treatment_1\NN\654885|myelodysplasia_53|._67 (r_nsubj) produces_9\VBZ\7555863|NONE_0 (l_dobj) myelodysplasia_10\NN\0|treatment_53|._14
D015215_D009190 CID azt_7\NNP\3834836|lifetime_48|of_29|with_21 (r_appos) treatment_1\NN\654885|myelodysplasia_53|._67 (r_nsubj) produces_9\VBZ\7555863|NONE_0 (l_dobj) myelodysplasia_10\NN\0|treatment_53|._14
D015215_D009190 CID azt_2\NNP\3834836|NONE_0 (r_compound) incorporation_3\NN\1237415|may_14|have_18|hemopoiesis_46 (r_nsubj) induced_6\VBN\1627355|above_43|._148 (l_dobj) hemopoiesis_9\NN\13526110|incorporation_46|may_32|have_28 (l_prep) in_10\IN\13603305|an_27|ineffective_24 (l_pobj) cells_15\NNS\3080309|NONE_0 (l_relcl) known_19\VBN\0|the_53|primitive_49|progenitor_27|,_11 (l_xcomp) seen_22\VBN\2106506|which_21|is_15 (l_prep) in_24\IN\13603305|to_20|be_17|commonly_9 (l_pobj) syndrome_27\NN\5870365|NONE_0
D015215_D000748 CID azt_0\NNP\3834836|has_4|anemia_29|._77 (r_nsubj) induced_2\VBN\1627355|NONE_0 (l_dobj) anemia_5\NN\14189204|azt_29|has_25|._48
D015215_D000748 CID azt_12\NNP\3834836|NONE_0 (r_compound) therapy_13\NN\657604|long_14 (r_appos) term_11\NN\6286395|NONE_0 (r_pobj) on_9\IN\0|a_37|macrocytic_35|in_17 (r_prep) anemia_5\NN\14189204|azt_29|has_25|._48
D015215_D000163 NONE azt_0\NNP\3834836|has_4|anemia_29|._77 (r_nsubj) induced_2\VBN\1627355|NONE_0 (l_dobj) anemia_5\NN\14189204|azt_29|has_25|._48 (l_prep) in_6\IN\13603305|a_20|macrocytic_18|on_17 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_compound) aids_7\NNP\13974317|NONE_0
D015215_D000163 NONE azt_12\NNP\3834836|NONE_0 (r_compound) therapy_13\NN\657604|long_14 (r_appos) term_11\NN\6286395|NONE_0 (r_pobj) on_9\IN\0|a_37|macrocytic_35|in_17 (r_prep) anemia_5\NN\14189204|azt_29|has_25|._48 (l_prep) in_6\IN\13603305|a_20|macrocytic_18|on_17 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_compound) aids_7\NNP\13974317|NONE_0
8514073
D003975_D010146 NONE diazepam_18\NN\2830852|the_4 (r_compound) group_19\NN\2137|NONE_0 (r_pobj) in_16\IN\13603305|NONE_0 (r_prep) patients_15\NNS\9898892|NONE_0 (r_pobj) of_14\IN\0|35_15|(_11|22_10|)_2 (r_prep) %_8\NN\0|NONE_0 (r_pobj) in_6\IN\13603305|pain_36|compared_52|._122 (r_prep) occurred_5\VBD\0|NONE_0 (l_nsubj) pain_0\NN\14299637|in_36|compared_88|._158
D000431_D014652 NONE alcohol_19\NN\7881800|,_11|and_13|pain_17 (r_compound) use_20\NN\407535|dwell_34|of_23|,_10 (r_conj) time_14\NN\7308889|intravenous_33|catheter_21|,_8 (r_conj) site_11\NN\8673395|nonsteroidal_62|inflammatory_44|drug_31|,_23 (r_conj) use_7\NN\407535|,_38 (r_appos) smoking_0\NN\831191|effect_153|._200 (r_nsubj) had_27\VBD\0|NONE_0 (l_dobj) effect_29\NN\34213|smoking_153|._47 (l_prep) on_30\IN\0|no_10 (l_pobj) incidence_32\NN\13821570|NONE_0 (l_prep) of_33\IN\0|the_14 (l_pobj) complications_35\NNS\1073995|NONE_0
D008874_D010146 NONE midazolam_32\JJ\2830852|the_4 (r_amod) group_33\NN\2137|NONE_0 (r_pobj) in_30\IN\13603305|7_22|(_19|patients_10|)_2|0.001_28 (r_prep) %_23\NN\0|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) compared_20\VBN\644583|pain_88|in_52|._70 (r_prep) occurred_5\VBD\0|NONE_0 (l_nsubj) pain_0\NN\14299637|in_36|compared_88|._158
D000431_D010146 NONE alcohol_19\NN\7881800|,_11|and_13|pain_17 (r_compound) use_20\NN\407535|dwell_34|of_23|,_10 (l_conj) pain_23\NN\14299637|alcohol_17|,_6|and_4
D008874_D014652 CID midazolam_3\FW\2830852|NONE_0 (r_pobj) of_2\IN\0|venous_21|._28 (r_prep) complications_1\NNS\1073995|NONE_0
D008874_D014652 CID midazolam_11\DT\2830852|NONE_0 (r_pobj) with_10\IN\0|complications_29|are_15 (r_prep) associated_9\VBN\628491|although_68|studies_54|have_46 (l_nsubjpass) complications_7\NNS\1073995|are_14|with_29
D008874_D014652 CID midazolam_14\NN\2830852|or_3 (r_conj) diazepam_12\NN\2830852|NONE_0 (r_pobj) of_11\IN\0|intravenous_22|in_25 (r_prep) injection_10\NN\320852|NONE_0 (r_pobj) after_8\IN\0|we_65|prospectively_62|incidence_34|._134 (r_prep) evaluated_2\VBD\670261|NONE_0 (l_dobj) incidence_4\NN\13821570|we_31|prospectively_28|after_34|._168 (l_prep) of_5\IN\0|the_14 (l_pobj) complications_7\NNS\1073995|NONE_0
D008874_D014652 CID midazolam_17\NNP\2830852|NONE_0 (r_pobj) with_16\IN\0|0.001_39 (r_prep) than_15\IN\0|(_20|of_16|)_2 (r_prep) 22_10\CD\13745420|overall_64|,_57|complications_48|frequent_24|._69 (r_npadvmod) were_4\VBD\0|NONE_0 (l_nsubj) complications_3\NNS\1073995|overall_16|,_9|frequent_24|22_48|._117
D003975_D014652 CID diazepam_5\NN\2830852|NONE_0 (r_pobj) versus_4\FW\0|NONE_0 (r_prep) midazolam_3\FW\2830852|NONE_0 (r_pobj) of_2\IN\0|venous_21|._28 (r_prep) complications_1\NNS\1073995|NONE_0
D003975_D014652 CID diazepam_14\NN\2830852|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) than_12\IN\0|NONE_0 (r_prep) midazolam_11\DT\2830852|NONE_0 (r_pobj) with_10\IN\0|complications_29|are_15 (r_prep) associated_9\VBN\628491|although_68|studies_54|have_46 (l_nsubjpass) complications_7\NNS\1073995|are_14|with_29
D003975_D014652 CID diazepam_12\NN\2830852|NONE_0 (r_pobj) of_11\IN\0|intravenous_22|in_25 (r_prep) injection_10\NN\320852|NONE_0 (r_pobj) after_8\IN\0|we_65|prospectively_62|incidence_34|._134 (r_prep) evaluated_2\VBD\670261|NONE_0 (l_dobj) incidence_4\NN\13821570|we_31|prospectively_28|after_34|._168 (l_prep) of_5\IN\0|the_14 (l_pobj) complications_7\NNS\1073995|NONE_0
D003975_D014652 CID diazepam_8\NN\2830852|NONE_0 (r_pobj) with_7\IN\0|more_14 (r_prep) frequent_6\JJ\2556126|overall_40|,_33|complications_24|22_24|._93 (r_acomp) were_4\VBD\0|NONE_0 (l_nsubj) complications_3\NNS\1073995|overall_16|,_9|frequent_24|22_48|._117
6892185
D002122_D015878 NONE chloride_4\NN\14818238|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|into_36|upon_102|)_147|,_148|fighting_150|injected_310 (r_nsubj) injected_5\VBD\81072|similarly_292|was_302|._318 (l_advcl) fighting_26\VBG\958896|effect_150|into_114|upon_48|)_3|,_2|injected_160 (l_conj) mydriasis_43\NN\365995|attack_69|,_2
D002122_D015878 NONE chloride_24\NN\14818238|NONE_0 (r_pobj) by_22\IN\0|on_129|,_112|mydriasis_110|were_31|not_26|significantly_22|._19 (r_agent) changed_21\VBN\0|NONE_0 (l_nsubjpass) mydriasis_5\NN\365995|on_19|,_2|were_79|not_84|significantly_88|by_110|._129
D002122_D015878 NONE chloride_5\NN\14818238|that_13|can_9|"_13|"_24|vocalization_26|from_52|caused_142 (r_nsubj) dissociate_8\VB\2431320|it_42|apparent_36|._159 (l_prep) from_13\IN\0|that_65|chloride_52|can_43|"_39|"_28|vocalization_26|caused_90 (l_pobj) phenomena_17\NNS\29677|NONE_0 (l_prep) as_19\IN\14622893|autonomic_35 (l_pobj) mydriasis_20\NN\365995|such_8
D002217_D004830 CID carbachol_53\NN\0|NONE_0 (r_pobj) by_52\IN\0|NONE_0 (r_agent) produced_51\VBN\1617192|tonic_18 (r_acl) convulsions_50\NNS\14081375|and_17
D002217_D004830 CID carbachol_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) evoked_13\VBN\1617192|,_38|tremor_36 (r_acl) mydriasis_5\NN\365995|on_19|,_2|were_79|not_84|significantly_88|by_110|._129 (l_conj) tremor_7\NN\345926|,_2|evoked_36 (l_conj) convulsions_12\NNS\14081375|and_17
D002217_D004830 CID carbachol_30\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) caused_28\VBN\1617192|that_155|chloride_142|can_133|"_129|"_118|vocalization_116|from_90 (r_acl) dissociate_8\VB\2431320|it_42|apparent_36|._159 (l_prep) from_13\IN\0|that_65|chloride_52|can_43|"_39|"_28|vocalization_26|caused_90 (l_pobj) phenomena_17\NNS\29677|NONE_0 (l_prep) as_19\IN\14622893|autonomic_35 (l_pobj) mydriasis_20\NN\365995|such_8 (l_conj) tremor_22\NN\345926|,_2 (l_conj) convulsions_27\NNS\14081375|and_17
D002122_D014202 NONE chloride_4\NN\14818238|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|into_36|upon_102|)_147|,_148|fighting_150|injected_310 (r_nsubj) injected_5\VBD\81072|similarly_292|was_302|._318 (l_advcl) fighting_26\VBG\958896|effect_150|into_114|upon_48|)_3|,_2|injected_160 (l_conj) mydriasis_43\NN\365995|attack_69|,_2 (l_conj) tremor_45\NN\345926|,_2
D002122_D014202 NONE chloride_24\NN\14818238|NONE_0 (r_pobj) by_22\IN\0|on_129|,_112|mydriasis_110|were_31|not_26|significantly_22|._19 (r_agent) changed_21\VBN\0|NONE_0 (l_nsubjpass) mydriasis_5\NN\365995|on_19|,_2|were_79|not_84|significantly_88|by_110|._129 (l_conj) tremor_7\NN\345926|,_2|evoked_36
D002122_D014202 NONE chloride_5\NN\14818238|that_13|can_9|"_13|"_24|vocalization_26|from_52|caused_142 (r_nsubj) dissociate_8\VB\2431320|it_42|apparent_36|._159 (l_prep) from_13\IN\0|that_65|chloride_52|can_43|"_39|"_28|vocalization_26|caused_90 (l_pobj) phenomena_17\NNS\29677|NONE_0 (l_prep) as_19\IN\14622893|autonomic_35 (l_pobj) mydriasis_20\NN\365995|such_8 (l_conj) tremor_22\NN\345926|,_2
D010830_D015878 CID eserine_55\NN\0|and_4 (r_conj) carbachol_53\NN\0|NONE_0 (r_pobj) by_52\IN\0|NONE_0 (r_agent) produced_51\VBN\1617192|tonic_18 (r_acl) convulsions_50\NNS\14081375|and_17 (r_conj) tremor_45\NN\345926|,_2 (r_conj) mydriasis_43\NN\365995|attack_69|,_2
D010830_D015878 CID eserine_17\NN\0|and_4 (r_conj) carbachol_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) evoked_13\VBN\1617192|,_38|tremor_36 (r_acl) mydriasis_5\NN\365995|on_19|,_2|were_79|not_84|significantly_88|by_110|._129
D010830_D015878 CID eserine_32\NN\0|and_4 (r_conj) carbachol_30\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) caused_28\VBN\1617192|that_155|chloride_142|can_133|"_129|"_118|vocalization_116|from_90 (r_acl) dissociate_8\VB\2431320|it_42|apparent_36|._159 (l_prep) from_13\IN\0|that_65|chloride_52|can_43|"_39|"_28|vocalization_26|caused_90 (l_pobj) phenomena_17\NNS\29677|NONE_0 (l_prep) as_19\IN\14622893|autonomic_35 (l_pobj) mydriasis_20\NN\365995|such_8
D010830_D014202 CID eserine_55\NN\0|and_4 (r_conj) carbachol_53\NN\0|NONE_0 (r_pobj) by_52\IN\0|NONE_0 (r_agent) produced_51\VBN\1617192|tonic_18 (r_acl) convulsions_50\NNS\14081375|and_17 (r_conj) tremor_45\NN\345926|,_2
D010830_D014202 CID eserine_17\NN\0|and_4 (r_conj) carbachol_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) evoked_13\VBN\1617192|,_38|tremor_36 (r_acl) mydriasis_5\NN\365995|on_19|,_2|were_79|not_84|significantly_88|by_110|._129 (l_conj) tremor_7\NN\345926|,_2|evoked_36
D010830_D014202 CID eserine_32\NN\0|and_4 (r_conj) carbachol_30\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) caused_28\VBN\1617192|that_155|chloride_142|can_133|"_129|"_118|vocalization_116|from_90 (r_acl) dissociate_8\VB\2431320|it_42|apparent_36|._159 (l_prep) from_13\IN\0|that_65|chloride_52|can_43|"_39|"_28|vocalization_26|caused_90 (l_pobj) phenomena_17\NNS\29677|NONE_0 (l_prep) as_19\IN\14622893|autonomic_35 (l_pobj) mydriasis_20\NN\365995|such_8 (l_conj) tremor_22\NN\345926|,_2
D002217_D015878 CID carbachol_53\NN\0|NONE_0 (r_pobj) by_52\IN\0|NONE_0 (r_agent) produced_51\VBN\1617192|tonic_18 (r_acl) convulsions_50\NNS\14081375|and_17 (r_conj) tremor_45\NN\345926|,_2 (r_conj) mydriasis_43\NN\365995|attack_69|,_2
D002217_D015878 CID carbachol_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) evoked_13\VBN\1617192|,_38|tremor_36 (r_acl) mydriasis_5\NN\365995|on_19|,_2|were_79|not_84|significantly_88|by_110|._129
D002217_D015878 CID carbachol_30\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) caused_28\VBN\1617192|that_155|chloride_142|can_133|"_129|"_118|vocalization_116|from_90 (r_acl) dissociate_8\VB\2431320|it_42|apparent_36|._159 (l_prep) from_13\IN\0|that_65|chloride_52|can_43|"_39|"_28|vocalization_26|caused_90 (l_pobj) phenomena_17\NNS\29677|NONE_0 (l_prep) as_19\IN\14622893|autonomic_35 (l_pobj) mydriasis_20\NN\365995|such_8
D002217_D014202 CID carbachol_53\NN\0|NONE_0 (r_pobj) by_52\IN\0|NONE_0 (r_agent) produced_51\VBN\1617192|tonic_18 (r_acl) convulsions_50\NNS\14081375|and_17 (r_conj) tremor_45\NN\345926|,_2
D002217_D014202 CID carbachol_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) evoked_13\VBN\1617192|,_38|tremor_36 (r_acl) mydriasis_5\NN\365995|on_19|,_2|were_79|not_84|significantly_88|by_110|._129 (l_conj) tremor_7\NN\345926|,_2|evoked_36
D002217_D014202 CID carbachol_30\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) caused_28\VBN\1617192|that_155|chloride_142|can_133|"_129|"_118|vocalization_116|from_90 (r_acl) dissociate_8\VB\2431320|it_42|apparent_36|._159 (l_prep) from_13\IN\0|that_65|chloride_52|can_43|"_39|"_28|vocalization_26|caused_90 (l_pobj) phenomena_17\NNS\29677|NONE_0 (l_prep) as_19\IN\14622893|autonomic_35 (l_pobj) mydriasis_20\NN\365995|such_8 (l_conj) tremor_22\NN\345926|,_2
D002122_D004830 NONE chloride_4\NN\14818238|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|into_36|upon_102|)_147|,_148|fighting_150|injected_310 (r_nsubj) injected_5\VBD\81072|similarly_292|was_302|._318 (l_advcl) fighting_26\VBG\958896|effect_150|into_114|upon_48|)_3|,_2|injected_160 (l_conj) mydriasis_43\NN\365995|attack_69|,_2 (l_conj) tremor_45\NN\345926|,_2 (l_conj) convulsions_50\NNS\14081375|and_17
D002122_D004830 NONE chloride_24\NN\14818238|NONE_0 (r_pobj) by_22\IN\0|on_129|,_112|mydriasis_110|were_31|not_26|significantly_22|._19 (r_agent) changed_21\VBN\0|NONE_0 (l_nsubjpass) mydriasis_5\NN\365995|on_19|,_2|were_79|not_84|significantly_88|by_110|._129 (l_conj) tremor_7\NN\345926|,_2|evoked_36 (l_conj) convulsions_12\NNS\14081375|and_17
D002122_D004830 NONE chloride_5\NN\14818238|that_13|can_9|"_13|"_24|vocalization_26|from_52|caused_142 (r_nsubj) dissociate_8\VB\2431320|it_42|apparent_36|._159 (l_prep) from_13\IN\0|that_65|chloride_52|can_43|"_39|"_28|vocalization_26|caused_90 (l_pobj) phenomena_17\NNS\29677|NONE_0 (l_prep) as_19\IN\14622893|autonomic_35 (l_pobj) mydriasis_20\NN\365995|such_8 (l_conj) tremor_22\NN\345926|,_2 (l_conj) convulsions_27\NNS\14081375|and_17
D010830_D004830 CID eserine_55\NN\0|and_4 (r_conj) carbachol_53\NN\0|NONE_0 (r_pobj) by_52\IN\0|NONE_0 (r_agent) produced_51\VBN\1617192|tonic_18 (r_acl) convulsions_50\NNS\14081375|and_17
D010830_D004830 CID eserine_17\NN\0|and_4 (r_conj) carbachol_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) evoked_13\VBN\1617192|,_38|tremor_36 (r_acl) mydriasis_5\NN\365995|on_19|,_2|were_79|not_84|significantly_88|by_110|._129 (l_conj) tremor_7\NN\345926|,_2|evoked_36 (l_conj) convulsions_12\NNS\14081375|and_17
D010830_D004830 CID eserine_32\NN\0|and_4 (r_conj) carbachol_30\NN\0|NONE_0 (r_pobj) by_29\IN\0|NONE_0 (r_agent) caused_28\VBN\1617192|that_155|chloride_142|can_133|"_129|"_118|vocalization_116|from_90 (r_acl) dissociate_8\VB\2431320|it_42|apparent_36|._159 (l_prep) from_13\IN\0|that_65|chloride_52|can_43|"_39|"_28|vocalization_26|caused_90 (l_pobj) phenomena_17\NNS\29677|NONE_0 (l_prep) as_19\IN\14622893|autonomic_35 (l_pobj) mydriasis_20\NN\365995|such_8 (l_conj) tremor_22\NN\345926|,_2 (l_conj) convulsions_27\NNS\14081375|and_17
11337188
D010068_D011693 NONE oxacillin_9\NN\3910417|NONE_0 (r_pobj) with_8\IN\0|who_16|was_12|for_15|because_28 (r_prep) treated_7\VBN\2376958|a_26|old_16 (r_relcl) man_4\NN\9605289|failure_109|._178 (r_nsubj) developed_19\VBD\1753788|NONE_0 (l_dobj) failure_21\NN\66216|man_109|._69 (l_appos) lesions_29\NNS\14204950|renal_56|and_42|diffuse_38|,_31
D010068_D051437 CID oxacillin_9\NN\3910417|NONE_0 (r_pobj) with_8\IN\0|who_16|was_12|for_15|because_28 (r_prep) treated_7\VBN\2376958|a_26|old_16 (r_relcl) man_4\NN\9605289|failure_109|._178 (r_nsubj) developed_19\VBD\1753788|NONE_0 (l_dobj) failure_21\NN\66216|man_109|._69
D010068_D013203 NONE oxacillin_9\NN\3910417|NONE_0 (r_pobj) with_8\IN\0|who_16|was_12|for_15|because_28 (r_prep) treated_7\VBN\2376958|a_26|old_16 (l_prep) because_13\IN\0|who_44|was_40|with_28|for_13 (l_pobj) bacteremia_17\NN\14204950|of_25
D010068_D018366 CID oxacillin_5\NN\3910417|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) associated_3\VBN\628491|cutaneous_38|leucocytoclastic_28|._25 (r_acl) vasculitis_2\NN\14336539|NONE_0
D010068_D018366 CID oxacillin_0\NNP\3910417|should_10|be_17|among_29|._87 (r_nsubjpass) included_3\VBN\0|NONE_0 (l_prep) among_4\IN\0|oxacillin_29|should_19|be_12|._58 (l_pobj) drugs_6\NNS\14778436|NONE_0 (l_relcl) cause_9\VB\7323922|the_19 (l_dobj) vasculitis_11\NN\14336539|that_32|can_27
D010068_D016470 NONE oxacillin_9\NN\3910417|NONE_0 (r_pobj) with_8\IN\0|who_16|was_12|for_15|because_28 (r_prep) treated_7\VBN\2376958|a_26|old_16 (l_prep) because_13\IN\0|who_44|was_40|with_28|for_13 (l_pobj) bacteremia_17\NN\14204950|of_25
6111982
D011433_D001145 NONE propranolol_6\NN\0|NONE_0 (l_conj) pindolol_8\NN\2832168|and_4 (l_xcomp) inhibiting_9\VBG\2510337|NONE_0 (l_dobj) arrhythmia_12\NN\14103288|in_11
D010042_D001145 CID ouabain_11\JJ\0|the_4 (r_compound) arrhythmia_12\NN\14103288|in_11
D010869_D001145 NONE pindolol_8\NN\2832168|and_4 (l_xcomp) inhibiting_9\VBG\2510337|NONE_0 (l_dobj) arrhythmia_12\NN\14103288|in_11
10533019
D004110_D013746 CID diltiazem_6\NN\2938514|-_9 (r_npadvmod) induced_8\VBN\1627355|threatening_22|with_15 (r_amod) tetany_9\NN\14304060|NONE_0
D004110_D013746 CID diltiazem_16\NN\2938514|NONE_0 (r_pobj) of_14\IN\0|the_13 (r_prep) infusion_13\NN\14589223|NONE_0 (r_pobj) after_11\IN\0|who_52|tetany_38|with_31 (r_prep) developed_5\VBD\1753788|a_14 (l_dobj) tetany_6\NN\14304060|who_14|with_7|after_38
D004110_D013746 CID diltiazem_17\NN\2938514|NONE_0 (r_pobj) of_15\IN\0|the_19 (r_prep) administration_14\NN\1133281|that_47|tetany_25|may_18|and_40|be_70 (r_dobj) accompany_12\VB\0|NONE_0 (l_nsubj) tetany_10\NN\14304060|that_22|may_7|administration_25|and_65|be_95
D004110_D012131 NONE diltiazem_16\NN\2938514|NONE_0 (r_pobj) of_14\IN\0|the_13 (r_prep) infusion_13\NN\14589223|NONE_0 (r_pobj) after_11\IN\0|who_52|tetany_38|with_31 (r_prep) developed_5\VBD\1753788|a_14 (l_prep) with_7\IN\0|who_21|tetany_7|after_31 (l_pobj) arrest_10\NN\88481|NONE_0
D002122_D013746 NONE chloride_12\NN\14818238|NONE_0 (r_pobj) with_10\IN\0|threatening_37|induced_15 (r_prep) tetany_9\NN\14304060|NONE_0
D002122_D013746 NONE chloride_4\NN\14818238|NONE_0 (r_pobj) of_2\IN\0|the_19 (r_prep) administration_1\NN\1133281|rapidly_35|tetany_66|,_117|averting_119|._198 (r_nsubj) resolved_6\VBD\352826|NONE_0 (l_dobj) tetany_10\NN\14304060|administration_66|rapidly_31|,_51|averting_53|._132
D002122_D013746 NONE chloride_21\NN\14818238|that_13|may_9|remedy_38 (r_nsubj) be_23\VB\14625458|that_117|tetany_95|may_88|administration_70|and_30 (r_conj) accompany_12\VB\0|NONE_0 (l_nsubj) tetany_10\NN\14304060|that_22|may_7|administration_25|and_65|be_95
14982270
D011433_D006980 NONE propranolol_21\NN\0|methimazole_28|(_16|tid_9|)_6|and_4 (l_prep) for_27\IN\0|tid_5 (l_pobj) treatment_28\NN\654885|NONE_0 (l_prep) of_29\IN\0|NONE_0 (l_pobj) hyperthyroidism_30\NN\14059928|NONE_0
D008713_D011537 CID methimazole_14\NN\0|(_12|tid_19|)_22|and_24|propranolol_28 (r_dobj) receiving_13\VBG\2210855|NONE_0 (r_pcomp) after_12\IN\0|month_6 (r_prep) itching_9\NN\5723210|woman_30|jaundice_13|and_4|._116
D011433_D007565 NONE propranolol_21\NN\0|methimazole_28|(_16|tid_9|)_6|and_4 (r_conj) receiving_13\VBG\2210855|NONE_0 (r_pcomp) after_12\IN\0|month_6 (r_prep) itching_9\NN\5723210|woman_30|jaundice_13|and_4|._116 (r_conj) had_5\VBD\0|NONE_0 (l_dobj) jaundice_7\NN\14299637|woman_17|and_9|itching_13|._129
D008713_D002779 NONE methimazole_0\NN\0|-_11 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) cholestasis_3\NN\14052403|was_12|,_25|and_27|propranolol_31
D011433_D002779 NONE propranolol_8\NN\0|cholestasis_31|was_19|,_6|and_4 (r_conj) diagnosed_5\VBN\644583|was_35|._46 (l_nsubjpass) cholestasis_3\NN\14052403|was_12|,_25|and_27|propranolol_31
D008713_D041781 CID methimazole_0\NN\0|-_11 (r_npadvmod) induced_2\VBN\1627355|cholestatic_8|._28 (r_amod) jaundice_4\NN\14299637|NONE_0
D008713_D007565 NONE methimazole_14\NN\0|(_12|tid_19|)_22|and_24|propranolol_28 (r_dobj) receiving_13\VBG\2210855|NONE_0 (r_pcomp) after_12\IN\0|month_6 (r_prep) itching_9\NN\5723210|woman_30|jaundice_13|and_4|._116 (r_conj) had_5\VBD\0|NONE_0 (l_dobj) jaundice_7\NN\14299637|woman_17|and_9|itching_13|._129
D008713_D006980 NONE methimazole_14\NN\0|(_12|tid_19|)_22|and_24|propranolol_28 (r_dobj) receiving_13\VBG\2210855|NONE_0 (l_conj) propranolol_21\NN\0|methimazole_28|(_16|tid_9|)_6|and_4 (l_prep) for_27\IN\0|tid_5 (l_pobj) treatment_28\NN\654885|NONE_0 (l_prep) of_29\IN\0|NONE_0 (l_pobj) hyperthyroidism_30\NN\14059928|NONE_0
D011433_D011537 NONE propranolol_21\NN\0|methimazole_28|(_16|tid_9|)_6|and_4 (r_conj) receiving_13\VBG\2210855|NONE_0 (r_pcomp) after_12\IN\0|month_6 (r_prep) itching_9\NN\5723210|woman_30|jaundice_13|and_4|._116
8638876
D011374_D012640 NONE progesterone_26\NN\14747338|NONE_0 (r_pobj) of_25\IN\0|parenteral_15 (r_prep) use_24\NN\407535|days_22 (r_pobj) after_22\IN\0|hemiparesis_33 (r_prep) left_16\VBD\8621598|woman_47|headache_31|,_2|._88 (l_dobj) hemiparesis_17\NN\0|after_33 (l_conj) seizure_19\NN\14081375|and_4
D011374_D014839 NONE progesterone_26\NN\14747338|NONE_0 (r_pobj) of_25\IN\0|parenteral_15 (r_prep) use_24\NN\407535|days_22 (r_pobj) after_22\IN\0|hemiparesis_33 (r_prep) left_16\VBD\8621598|woman_47|headache_31|,_2|._88 (r_conj) developed_9\VBD\1753788|NONE_0 (l_dobj) headache_10\NN\5829480|woman_16|,_29|left_31|._119 (l_conj) nausea_12\NN\14299637|,_2 (l_conj) vomiting_14\NN\116687|and_4
D011374_D009325 NONE progesterone_26\NN\14747338|NONE_0 (r_pobj) of_25\IN\0|parenteral_15 (r_prep) use_24\NN\407535|days_22 (r_pobj) after_22\IN\0|hemiparesis_33 (r_prep) left_16\VBD\8621598|woman_47|headache_31|,_2|._88 (r_conj) developed_9\VBD\1753788|NONE_0 (l_dobj) headache_10\NN\5829480|woman_16|,_29|left_31|._119 (l_conj) nausea_12\NN\14299637|,_2
D011374_D002341 CID progesterone_13\NN\14747338|and_4 (r_conj) estradiol_11\NN\14749794|NONE_0 (r_pobj) of_10\IN\0|the_8|and_30|dm_49 (r_prep) use_9\NN\407535|that_9|thrombogenicity_75 (r_nsubj) increased_18\VBD\169651|in_101|,_89|authors_83|._123 (l_dobj) thrombogenicity_20\NN\0|that_84|use_75 (l_relcl) provided_23\VBD\2199590|vascular_32|,_8 (l_dobj) denominator_26\NN\13733167|which_24 (l_prep) for_27\IN\0|a_21|common_19 (l_pobj) thrombosis_28\NN\14100769|NONE_0 (l_prep) of_29\IN\0|NONE_0 (l_pobj) ica_32\NNP\0|NONE_0 (l_conj) sinus_36\NN\5248181|both_28|the_23|and_15
D004958_D009325 NONE estradiol_28\NN\14749794|and_4 (r_conj) progesterone_26\NN\14747338|NONE_0 (r_pobj) of_25\IN\0|parenteral_15 (r_prep) use_24\NN\407535|days_22 (r_pobj) after_22\IN\0|hemiparesis_33 (r_prep) left_16\VBD\8621598|woman_47|headache_31|,_2|._88 (r_conj) developed_9\VBD\1753788|NONE_0 (l_dobj) headache_10\NN\5829480|woman_16|,_29|left_31|._119 (l_conj) nausea_12\NN\14299637|,_2
D011374_D003920 NONE progesterone_13\NN\14747338|and_4 (r_conj) estradiol_11\NN\14749794|NONE_0 (r_pobj) of_10\IN\0|the_8|and_30|dm_49 (r_prep) use_9\NN\407535|that_9|thrombogenicity_75 (l_conj) dm_17\NNP\14117805|the_57|of_49|and_19
D004958_D010291 NONE estradiol_28\NN\14749794|and_4 (r_conj) progesterone_26\NN\14747338|NONE_0 (r_pobj) of_25\IN\0|parenteral_15 (r_prep) use_24\NN\407535|days_22 (r_pobj) after_22\IN\0|hemiparesis_33 (r_prep) left_16\VBD\8621598|woman_47|headache_31|,_2|._88 (l_dobj) hemiparesis_17\NN\0|after_33
D004958_D006261 NONE estradiol_28\NN\14749794|and_4 (r_conj) progesterone_26\NN\14747338|NONE_0 (r_pobj) of_25\IN\0|parenteral_15 (r_prep) use_24\NN\407535|days_22 (r_pobj) after_22\IN\0|hemiparesis_33 (r_prep) left_16\VBD\8621598|woman_47|headache_31|,_2|._88 (r_conj) developed_9\VBD\1753788|NONE_0 (l_dobj) headache_10\NN\5829480|woman_16|,_29|left_31|._119
D011374_D006261 NONE progesterone_26\NN\14747338|NONE_0 (r_pobj) of_25\IN\0|parenteral_15 (r_prep) use_24\NN\407535|days_22 (r_pobj) after_22\IN\0|hemiparesis_33 (r_prep) left_16\VBD\8621598|woman_47|headache_31|,_2|._88 (r_conj) developed_9\VBD\1753788|NONE_0 (l_dobj) headache_10\NN\5829480|woman_16|,_29|left_31|._119
D004958_D002341 CID estradiol_11\NN\14749794|NONE_0 (r_pobj) of_10\IN\0|the_8|and_30|dm_49 (r_prep) use_9\NN\407535|that_9|thrombogenicity_75 (r_nsubj) increased_18\VBD\169651|in_101|,_89|authors_83|._123 (l_dobj) thrombogenicity_20\NN\0|that_84|use_75 (l_relcl) provided_23\VBD\2199590|vascular_32|,_8 (l_dobj) denominator_26\NN\13733167|which_24 (l_prep) for_27\IN\0|a_21|common_19 (l_pobj) thrombosis_28\NN\14100769|NONE_0 (l_prep) of_29\IN\0|NONE_0 (l_pobj) ica_32\NNP\0|NONE_0 (l_conj) sinus_36\NN\5248181|both_28|the_23|and_15
D004958_D014839 NONE estradiol_28\NN\14749794|and_4 (r_conj) progesterone_26\NN\14747338|NONE_0 (r_pobj) of_25\IN\0|parenteral_15 (r_prep) use_24\NN\407535|days_22 (r_pobj) after_22\IN\0|hemiparesis_33 (r_prep) left_16\VBD\8621598|woman_47|headache_31|,_2|._88 (r_conj) developed_9\VBD\1753788|NONE_0 (l_dobj) headache_10\NN\5829480|woman_16|,_29|left_31|._119 (l_conj) nausea_12\NN\14299637|,_2 (l_conj) vomiting_14\NN\116687|and_4
D011374_D010291 NONE progesterone_26\NN\14747338|NONE_0 (r_pobj) of_25\IN\0|parenteral_15 (r_prep) use_24\NN\407535|days_22 (r_pobj) after_22\IN\0|hemiparesis_33 (r_prep) left_16\VBD\8621598|woman_47|headache_31|,_2|._88 (l_dobj) hemiparesis_17\NN\0|after_33
D004958_D003920 NONE estradiol_11\NN\14749794|NONE_0 (r_pobj) of_10\IN\0|the_8|and_30|dm_49 (r_prep) use_9\NN\407535|that_9|thrombogenicity_75 (l_conj) dm_17\NNP\14117805|the_57|of_49|and_19
D011374_D012851 CID progesterone_13\NN\14747338|and_4 (r_conj) estradiol_11\NN\14749794|NONE_0 (r_pobj) of_10\IN\0|the_8|and_30|dm_49 (r_prep) use_9\NN\407535|that_9|thrombogenicity_75 (r_nsubj) increased_18\VBD\169651|in_101|,_89|authors_83|._123 (l_dobj) thrombogenicity_20\NN\0|that_84|use_75 (l_relcl) provided_23\VBD\2199590|vascular_32|,_8 (l_dobj) denominator_26\NN\13733167|which_24 (l_prep) for_27\IN\0|a_21|common_19 (l_pobj) thrombosis_28\NN\14100769|NONE_0 (l_prep) of_29\IN\0|NONE_0 (l_pobj) ica_32\NNP\0|NONE_0 (l_conj) sinus_36\NN\5248181|both_28|the_23|and_15
D004958_D012851 CID estradiol_11\NN\14749794|NONE_0 (r_pobj) of_10\IN\0|the_8|and_30|dm_49 (r_prep) use_9\NN\407535|that_9|thrombogenicity_75 (r_nsubj) increased_18\VBD\169651|in_101|,_89|authors_83|._123 (l_dobj) thrombogenicity_20\NN\0|that_84|use_75 (l_relcl) provided_23\VBD\2199590|vascular_32|,_8 (l_dobj) denominator_26\NN\13733167|which_24 (l_prep) for_27\IN\0|a_21|common_19 (l_pobj) thrombosis_28\NN\14100769|NONE_0 (l_prep) of_29\IN\0|NONE_0 (l_pobj) ica_32\NNP\0|NONE_0 (l_conj) sinus_36\NN\5248181|both_28|the_23|and_15
D004958_D012640 NONE estradiol_28\NN\14749794|and_4 (r_conj) progesterone_26\NN\14747338|NONE_0 (r_pobj) of_25\IN\0|parenteral_15 (r_prep) use_24\NN\407535|days_22 (r_pobj) after_22\IN\0|hemiparesis_33 (r_prep) left_16\VBD\8621598|woman_47|headache_31|,_2|._88 (l_dobj) hemiparesis_17\NN\0|after_33 (l_conj) seizure_19\NN\14081375|and_4
6732043
D000728_D020181 CID androgen_12\JJ\14745635|exogenous_10 (r_compound) administration_13\NN\1133281|NONE_0 (r_pobj) by_10\IN\0|a_8 (r_prep) woman_9\NN\9605289|NONE_0 (r_pobj) in_7\IN\13603305|the_37|apnea_15 (r_prep) syndrome_6\NN\5870365|NONE_0
D000728_D020181 CID androgens_36\NNS\14745635|while_35|being_29 (r_dobj) administered_34\VBN\2436349|who_91|had_87|changes_64 (r_advcl) developed_22\VBN\1753788|a_26|old_18 (l_dobj) changes_24\NNS\7283608|who_27|had_23|administered_64 (l_conj) syndrome_27\NN\5870365|physical_25|and_8 (l_prep) of_28\IN\0|the_13 (l_pobj) apnea_31\NN\14299637|NONE_0
D000728_D020181 CID androgen_3\NN\14745635|produced_9|of_27|abated_59 (r_nmod) symptoms_5\NNS\5823932|NONE_0 (l_prep) of_6\IN\0|androgen_27|produced_18|abated_32 (l_pobj) apnea_9\NN\14299637|NONE_0
D000728_D020181 CID androgen_15\NN\14745635|NONE_0 (r_compound) therapy_16\NN\657604|NONE_0 (r_pobj) of_14\IN\0|a_23|possible_21|side_12 (r_prep) effect_13\NN\34213|development_87|must_35|be_30|._26 (r_oprd) considered_9\VBN\689344|NONE_0 (l_nsubjpass) development_0\NN\248977|must_52|be_57|effect_87|._113 (l_prep) of_1\IN\0|NONE_0 (l_pobj) syndrome_6\NN\5870365|NONE_0
D000728_D012891 NONE androgens_7\NNS\14745635|NONE_0 (r_pobj) of_6\IN\0|a_7 (r_prep) role_5\NN\719494|reports_23|have_15|in_18|._52 (r_dobj) favored_3\VBN\2397637|NONE_0 (l_prep) in_8\IN\13603305|reports_41|have_33|role_18|._34 (l_pobj) pathogenesis_10\NN\13533470|NONE_0 (l_prep) of_11\IN\0|the_17 (l_pobj) apnea_13\NN\14299637|NONE_0
15814210
D003907_D009422 CID dexamethasone_19\NN\2721538|in_24 (r_compound) treatment_20\NN\654885|NONE_0 (r_pobj) after_18\IN\0|minor_106|neurological_100|,_76|development_64|at_27|._62 (r_prep) dysfunction_2\NN\14204950|NONE_0
D003907_D009422 CID dexamethasone_19\NN\2721538|in_22 (r_compound) therapy_20\NN\657604|NONE_0 (r_pobj) after_18\IN\0|to_89|dysfunction_60 (r_prep) assess_7\VB\5220461|objective_31|._145 (l_dobj) dysfunction_10\NN\14204950|to_29|after_60
D003907_D009422 CID dexamethasone_1\NN\2721538|NONE_0 (r_compound) treatment_2\NN\654885|NONE_0 (r_pobj) after_0\IN\0|,_29|children_31|rate_56|._95 (r_prep) showed_5\VBD\2137132|NONE_0 (l_dobj) rate_8\NN\13815152|after_56|,_27|children_25|._39 (l_prep) of_9\IN\0|a_14|higher_12 (l_pobj) dysfunctions_12\NNS\14204950|NONE_0
6153967
D004737_D012640 CID enflurane_4\NN\3299929|in_16|,_2|in_59|._95 (r_nsubj) resulted_10\VBD\2633881|NONE_0 (l_prep) in_11\IN\13603305|in_75|,_61|enflurane_59|._36 (l_pobj) seizures_15\NNS\14081375|NONE_0
D004737_D012640 CID enflurane_6\NN\3299929|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) activated_4\VBN\1641914|foci_20|and_4|ablated_39|and_47|are_64 (r_conj) delineated_2\VBN\2137132|NONE_0 (l_conj) are_13\VBP\13600404|foci_84|and_68|activated_64|ablated_25|and_17 (l_acomp) free_17\JJ\7942152|patients_25|now_12|._4 (l_npadvmod) seizure_15\NN\14081375|-_7
D004737_D004827 NONE enflurane_6\NN\3299929|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) activated_4\VBN\1641914|foci_20|and_4|ablated_39|and_47|are_64 (r_conj) delineated_2\VBN\2137132|NONE_0 (l_nsubj) foci_1\NN\5704266|and_16|activated_20|ablated_59|and_67|are_84 (l_amod) epileptic_0\JJ\10595647|NONE_0
D004737_D004827 NONE enflurane_5\NN\3299929|on_19|,_2|may_10|be_23|._138 (r_nsubj) prove_7\VB\2604760|NONE_0 (l_xcomp) be_9\VB\14625458|on_42|,_25|enflurane_23|may_13|._115 (l_attr) activator_14\NN\19613|to_25 (l_prep) of_15\IN\0|a_29|safe_27|fast_22|acting_17|during_18 (l_pobj) foci_17\VBD\5704266|NONE_0 (l_amod) epileptic_16\JJ\10595647|NONE_0
17574447
D010634_D004827 NONE pb_15\NNP\14625458|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|a_27|long_25|of_12 (r_acl) history_10\NN\15120823|NONE_0 (l_prep) of_11\IN\0|a_15|long_13|treated_12 (l_pobj) epilepsy_12\NN\14085708|NONE_0
D010634_D006323 NONE pb_15\NNP\14625458|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|a_27|long_25|of_12 (r_acl) history_10\NN\15120823|NONE_0 (r_pobj) with_7\IN\0|here_37|we_32|of_22|:_65|one_67|._140 (r_prep) report_2\VBP\6470073|NONE_0 (l_appos) one_20\CD\13741022|here_104|we_99|of_89|with_67|:_2|._73 (l_prep) as_21\IN\14622893|,_32|other_38 (l_pobj) consequence_22\NN\34213|NONE_0 (l_prep) of_23\IN\0|NONE_0 (l_pobj) arrest_25\NN\88481|NONE_0
D010634_D056487 NONE pb_15\NNP\14625458|-_2 (r_npadvmod) related_17\VBN\628491|asymptomatic_8|chronic_21|enzyme_37 (r_amod) dysfunction_22\NN\14204950|NONE_0
D010634_-1 NONE phenobarbital_8\JJ\2792049|term_5|:_21|report_34 (r_amod) therapy_9\NN\657604|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) related_3\VBN\628491|and_16|cholangitis_12|._77 (r_acl) hepatonecrosis_0\NNP\0|NONE_0
D010634_D008107 CID phenobarbital_0\NNP\2792049|reputation_25|,_46|and_48|believed_67 (r_nsubj) has_4\VBZ\13888491|NONE_0 (l_conj) believed_14\VBN\686447|phenobarbital_67|reputation_42|,_21|and_19 (l_ccomp) indicate_26\VB\952524|it_90|is_87|commonly_84|._72 (l_conj) predict_28\VB\916909|that_78|increases_62|do_19|not_16|or_3 (l_dobj) development_30\NN\248977|NONE_0 (l_prep) of_31\IN\0|the_16 (l_pobj) disease_35\NN\14061805|NONE_0
D010634_D008107 CID pb_2\NNP\14625458|(_1|)_2 (r_appos) phenobarbital_0\NNP\2792049|reputation_25|,_46|and_48|believed_67 (r_nsubj) has_4\VBZ\13888491|NONE_0 (l_conj) believed_14\VBN\686447|phenobarbital_67|reputation_42|,_21|and_19 (l_ccomp) indicate_26\VB\952524|it_90|is_87|commonly_84|._72 (l_conj) predict_28\VB\916909|that_78|increases_62|do_19|not_16|or_3 (l_dobj) development_30\NN\248977|NONE_0 (l_prep) of_31\IN\0|the_16 (l_pobj) disease_35\NN\14061805|NONE_0
D010634_D008107 CID pb_16\NNP\14625458|-_2 (r_npadvmod) related_18\VBN\628491|in_18 (r_amod) increases_19\NNS\13576355|that_16|do_43|not_46|or_59|predict_62 (r_nsubj) indicate_26\VB\952524|it_90|is_87|commonly_84|._72 (l_conj) predict_28\VB\916909|that_78|increases_62|do_19|not_16|or_3 (l_dobj) development_30\NN\248977|NONE_0 (l_prep) of_31\IN\0|the_16 (l_pobj) disease_35\NN\14061805|NONE_0
D010634_D008107 CID pb_4\NNP\14625458|that_5|may_3|be_7|with_21 (r_nsubjpass) associated_7\VBN\628491|findings_35|._97 (l_prep) with_8\IN\0|that_26|pb_21|may_18|be_14 (l_pobj) damage_11\NN\7296428|NONE_0
D010634_D001996 NONE pb_15\NNP\14625458|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|a_27|long_25|of_12 (r_acl) history_10\NN\15120823|NONE_0 (r_pobj) with_7\IN\0|here_37|we_32|of_22|:_65|one_67|._140 (r_prep) report_2\VBP\6470073|NONE_0 (l_appos) one_20\CD\13741022|here_104|we_99|of_89|with_67|:_2|._73 (l_appos) other_28\JJ\0|as_38|,_6 (l_prep) of_29\IN\0|the_10 (l_pobj) bronchopneumonia_31\NN\14147627|NONE_0
D010634_D002761 CID phenobarbital_8\JJ\2792049|term_5|:_21|report_34 (r_amod) therapy_9\NN\657604|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) related_3\VBN\628491|and_16|cholangitis_12|._77 (r_acl) hepatonecrosis_0\NNP\0|NONE_0 (l_conj) cholangitis_2\NN\14336539|and_4|related_12|._89
2220369
C015173_D020246 CID epinephrine_6\NN\14807929|central_46|vein_38|and_22|._11 (r_conj) thrombosis_2\NN\14100769|NONE_0
C015173_D020246 CID epinephrine_28\NN\14807929|NONE_0 (r_pobj) with_26\IN\0|having_34|medication_11 (r_prep) started_23\VBN\0|NONE_0 (r_pcomp) after_21\IN\0|who_63|thrombosis_37|in_26|day_4 (r_prep) acquired_11\VBD\0|an_26|old_15 (l_dobj) thrombosis_14\NN\14100769|who_26|in_11|day_33|after_37
C015173_D005901 NONE epinephrine_28\NN\14807929|NONE_0 (l_prep) for_29\IN\0|dipivalyl_22 (l_pobj) glaucoma_31\NN\14252864|NONE_0
17366349
C092292_D009459 CID ziprasidone_5\NN\0|NONE_0 (r_pobj) by_4\IN\0|syndrome_17|._45 (r_prep) induced_3\VBN\1627355|NONE_0 (l_nsubj) syndrome_2\NN\5870365|by_17|._62
C092292_D009459 CID ziprasidone_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|the_8 (r_prep) use_14\NN\407535|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) associated_11\VBN\628491|neuroleptic_37|malignant_25|nms_5 (r_acl) syndrome_7\NN\5870365|NONE_0
C092292_D009459 CID ziprasidone_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|the_8 (r_prep) use_14\NN\407535|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) associated_11\VBN\628491|neuroleptic_37|malignant_25|nms_5 (r_acl) syndrome_7\NN\5870365|NONE_0 (l_appos) nms_9\NNP\13649268|neuroleptic_32|malignant_20|associated_5
C092292_D009459 CID ziprasidone_14\NN\0|NONE_0 (r_pobj) like_13\IN\5839024|nms_34|,_31|atypical_29|antipsychotic_20 (r_prep) drugs_12\NNS\14778436|NONE_0 (l_nmod) nms_8\NNP\13649268|,_3|atypical_5|antipsychotic_14|like_34
C092292_D009459 CID ziprasidone_34\NNP\0|NONE_0 (r_pobj) of_31\IN\0|an_18|day_9 (r_prep) dose_30\NN\3740161|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) treatment_24\NN\654885|NONE_0 (r_pobj) of_23\IN\0|2_7 (r_prep) days_22\NNS\15140892|NONE_0 (r_pobj) after_20\IN\0|who_40|signs_26 (r_prep) developed_14\VBD\1753788|NONE_0 (l_dobj) signs_15\NNS\6643763|who_14|after_26 (l_prep) of_18\IN\0|and_13|symptoms_9 (l_pobj) nms_19\NNP\13649268|NONE_0
C092292_D009459 CID ziprasidone_3\NNP\0|NONE_0 (r_xcomp) due_1\IN\5174653|NONE_0 (r_amod) nms_0\NNP\13649268|in_32|._49
C092292_D012559 NONE ziprasidone_34\NNP\0|NONE_0 (r_pobj) of_31\IN\0|an_18|day_9 (r_prep) dose_30\NN\3740161|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) treatment_24\NN\654885|NONE_0 (r_pobj) of_23\IN\0|2_7 (r_prep) days_22\NNS\15140892|NONE_0 (r_pobj) after_20\IN\0|who_40|signs_26 (r_prep) developed_14\VBD\1753788|NONE_0 (r_relcl) schizophrenia_12\NN\14398067|NONE_0
19370593
D004967_D001943 NONE oestrogen_3\NN\14745635|term_5 (r_nmod) ht_6\NNP\0|significantly_3|risk_31|after_96|,_166|but_168|increase_194|._228 (r_nsubj) increased_8\VBD\169651|NONE_0 (l_conj) increase_42\VB\13576355|ht_194|significantly_191|risk_163|after_98|,_28|but_26|._34 (l_dobj) risk_44\NN\14541044|did_35|not_31|significantly_27 (l_prep) of_45\IN\0|the_9 (l_pobj) cancer_47\NN\14239425|NONE_0
D004967_D020521 CID oestrogen_3\NN\14745635|term_5 (r_nmod) ht_6\NNP\0|significantly_3|risk_31|after_96|,_166|but_168|increase_194|._228 (r_nsubj) increased_8\VBD\169651|NONE_0 (l_dobj) risk_10\NN\14541044|ht_31|significantly_28|after_65|,_135|but_137|increase_163|._197 (l_prep) of_11\IN\0|the_9 (l_pobj) embolism_15\NN\15269513|NONE_0 (l_appos) disease_20\NN\14061805|venous_48|thrombo_41|-_34|,_25|(_8 (l_nmod) stroke_17\NN\556313|gallbladder_11
D004967_D005705 CID oestrogen_3\NN\14745635|term_5 (r_nmod) ht_6\NNP\0|significantly_3|risk_31|after_96|,_166|but_168|increase_194|._228 (r_nsubj) increased_8\VBD\169651|NONE_0 (l_dobj) risk_10\NN\14541044|ht_31|significantly_28|after_65|,_135|but_137|increase_163|._197 (l_prep) of_11\IN\0|the_9 (l_pobj) embolism_15\NN\15269513|NONE_0 (l_appos) disease_20\NN\14061805|venous_48|thrombo_41|-_34|,_25|(_8
D004967_D054556 CID oestrogen_3\NN\14745635|term_5 (r_nmod) ht_6\NNP\0|significantly_3|risk_31|after_96|,_166|but_168|increase_194|._228 (r_nsubj) increased_8\VBD\169651|NONE_0 (l_dobj) risk_10\NN\14541044|ht_31|significantly_28|after_65|,_135|but_137|increase_163|._197 (l_prep) of_11\IN\0|the_9 (l_pobj) embolism_15\NN\15269513|NONE_0
2466960
D005472_D009369 NONE 5-fu_11\CD\0|for_14 (r_compound) infusion_12\NN\14589223|NONE_0 (l_prep) for_13\IN\0|5-fu_14 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|NONE_0 (l_pobj) tumors_17\NNS\14234074|NONE_0
D005472_D003324 NONE 5-fu_3\CD\0|NONE_0 (r_compound) infusion_4\NN\14589223|that_10|is_9|with_23 (r_nsubjpass) associated_6\VBN\628491|we_34|._150 (l_prep) with_7\IN\0|that_33|infusion_23|is_14 (l_pobj) increase_10\NN\13576355|NONE_0 (l_prep) among_21\IN\0|a_91|significant_89|in_68|,_15 (l_pobj) patients_22\NNS\9898892|particularly_19 (l_prep) with_23\IN\0|NONE_0 (l_pobj) disease_26\NN\14061805|NONE_0
D005472_D066126 NONE fluorouracil_11\NN\2722166|(_13|5-fu_14|)_18 (r_nmod) therapy_15\NN\657604|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|cardiac_17 (r_acl) toxicity_8\NN\13576101|NONE_0
D005472_D066126 NONE 5-fu_13\CD\0|fluorouracil_14|(_1|)_4 (r_nmod) therapy_15\NN\657604|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|cardiac_17 (r_acl) toxicity_8\NN\13576101|NONE_0
D005472_D000787 CID 5-fu_12\CD\0|NONE_0 (r_nummod) infusion_13\NN\14589223|NONE_0 (r_pobj) during_11\IN\0|were_40|:_31|patient_20|angina_8|(_1|)_20|._21 (r_prep) had_8\VBD\0|NONE_0 (l_ccomp) were_2\VBD\0|:_9|patient_20|angina_32|(_39|during_40|)_60|._61 (l_nsubj) episodes_1\NNS\7283608|rare_14 (l_compound) anginal_0\JJ\0|NONE_0
D005472_D000787 CID 5-fu_12\CD\0|NONE_0 (r_nummod) infusion_13\NN\14589223|NONE_0 (r_pobj) during_11\IN\0|were_40|:_31|patient_20|angina_8|(_1|)_20|._21 (r_prep) had_8\VBD\0|NONE_0 (l_dobj) angina_9\NN\14171682|were_32|:_23|patient_12|(_7|during_8|)_28|._29
D005472_D007511 CID 5-fu_11\CD\0|for_14 (r_compound) infusion_12\NN\14589223|NONE_0 (r_dobj) undergoing_10\VBG\109660|25_12 (r_acl) patients_9\NNS\9898892|NONE_0 (r_pobj) on_7\IN\0|continuous_37|ecg_15 (r_prep) monitoring_6\NN\879759|we_53|prospectively_50|in_81|._136 (r_dobj) performed_2\VBD\0|NONE_0 (l_prep) in_18\IN\13603305|we_134|prospectively_131|monitoring_81|._55 (l_pobj) order_19\NN\7168131|NONE_0 (l_acl) assess_21\VB\5220461|NONE_0 (l_dobj) incidence_23\NN\13821570|to_14 (l_prep) of_24\IN\0|the_14 (l_pobj) changes_27\NNS\7283608|NONE_0 (l_compound) st_26\NNP\0|NONE_0 (l_amod) ischemic_25\JJ\0|NONE_0
D005472_D007511 CID 5-fu_15\CD\0|v_14|during_30 (r_nummod) infusion_16\NN\14589223|NONE_0 (r_pobj) to_14\IN\0|0.02_11 (r_prep) prior_13\RB\10675876|incidence_70 (r_advmod) was_9\VBD\0|;_96|duration_102|+/-_134|before_171|v_183|during_226|._255 (l_nsubj) incidence_1\NN\13821570|prior_70 (l_prep) of_2\IN\0|the_14 (l_pobj) episodes_4\NNS\7283608|NONE_0 (l_amod) ischemic_3\JJ\0|per_18|per_30
D005472_D007511 CID 5-fu_22\CD\0|(_14|p_15|)_31 (r_nummod) infusion_23\NN\14589223|NONE_0 (r_pobj) during_21\IN\0|5-fu_30|v_16 (r_prep) infusion_16\NN\14589223|NONE_0 (r_pobj) to_14\IN\0|0.02_11 (r_prep) prior_13\RB\10675876|incidence_70 (r_advmod) was_9\VBD\0|;_96|duration_102|+/-_134|before_171|v_183|during_226|._255 (l_nsubj) incidence_1\NN\13821570|prior_70 (l_prep) of_2\IN\0|the_14 (l_pobj) episodes_4\NNS\7283608|NONE_0 (l_amod) ischemic_3\JJ\0|per_18|per_30
D005472_D007511 CID 5-fu_46\CD\0|NONE_0 (r_pobj) before_45\IN\0|was_171|;_75|duration_69|+/-_37|v_12|during_55|._84 (r_prep) was_36\VBD\0|NONE_0 (l_ccomp) was_9\VBD\0|;_96|duration_102|+/-_134|before_171|v_183|during_226|._255 (l_nsubj) incidence_1\NN\13821570|prior_70 (l_prep) of_2\IN\0|the_14 (l_pobj) episodes_4\NNS\7283608|NONE_0 (l_amod) ischemic_3\JJ\0|per_18|per_30
D005472_D007511 CID 5-fu_57\CD\0|NONE_0 (r_pobj) during_56\IN\0|was_226|;_130|duration_124|+/-_92|before_55|v_43|._29 (r_prep) was_36\VBD\0|NONE_0 (l_ccomp) was_9\VBD\0|;_96|duration_102|+/-_134|before_171|v_183|during_226|._255 (l_nsubj) incidence_1\NN\13821570|prior_70 (l_prep) of_2\IN\0|the_14 (l_pobj) episodes_4\NNS\7283608|NONE_0 (l_amod) ischemic_3\JJ\0|per_18|per_30
D005472_D007511 CID 5-fu_3\CD\0|NONE_0 (r_compound) infusion_4\NN\14589223|that_10|is_9|with_23 (r_nsubjpass) associated_6\VBN\628491|we_34|._150 (l_prep) with_7\IN\0|that_33|infusion_23|is_14 (l_pobj) increase_10\NN\13576355|NONE_0 (l_prep) in_11\IN\13603305|a_23|significant_21|,_53|among_68 (l_pobj) deviation_15\NN\7337390|NONE_0 (l_amod) suggestive_16\JJ\0|silent_28|segment_18 (l_prep) of_17\IN\0|NONE_0 (l_pobj) ischemia_18\NN\14195315|NONE_0
12448656
D013792_D002292 NONE thalidomide_5\NN\4166841|NONE_0 (r_pobj) of_4\IN\0|a_17|phase_15|ii_9|in_15|._58 (r_prep) study_3\NN\635850|NONE_0 (l_prep) in_6\IN\13603305|a_32|phase_30|ii_24|of_15|._43 (l_pobj) carcinoma_11\NN\14239918|NONE_0
D013792_D002292 NONE thalidomide_9\NN\4166841|NONE_0 (r_pobj) of_8\IN\0|the_26|and_13|activity_9 (r_prep) toxicity_5\NN\13576101|to_16|in_37 (r_dobj) evaluate_3\VB\670261|:_5|._212 (l_prep) in_10\IN\13603305|to_53|toxicity_37 (l_pobj) patients_11\NNS\9898892|and_52|measure_59 (l_prep) with_12\IN\0|NONE_0 (l_pobj) cancer_17\NN\14239425|NONE_0
D013792_D002292 NONE thalidomide_11\NN\4166841|NONE_0 (r_pobj) of_10\IN\0|NONE_0 (r_prep) activity_9\NN\30358|NONE_0 (r_pobj) of_8\IN\0|a_12|low_10|in_27 (r_prep) level_7\NN\4916342|NONE_0 (l_prep) in_12\IN\13603305|a_39|low_37|of_27 (l_pobj) carcinoma_15\NN\14239918|NONE_0
D013792_D002292 NONE thalidomide_10\NN\4166841|NONE_0 (l_prep) for_11\IN\0|NONE_0 (l_pobj) carcinoma_14\NN\14239918|NONE_0
D013792_D064420 NONE thalidomide_9\NN\4166841|NONE_0 (r_pobj) of_8\IN\0|the_26|and_13|activity_9 (r_prep) toxicity_5\NN\13576101|to_16|in_37
6942642
D011188_D007008 NONE potassium_13\NN\14625458|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) depletion_10\NN\351638|and_4 (r_conj) hypokalemia_8\NN\14299637|that_30|thiazide_25
D049971_D001145 NONE thiazide_0\NNP\3214670|,_18|hypokalemia_20|._55 (r_compound) diuretics_1\NNS\3247620|NONE_0 (l_conj) hypokalemia_3\JJ\14299637|thiazide_20|,_2|._35 (l_conj) arrhythmias_6\NNS\14103288|and_12
D006852_C563897 NONE hydrochlorothiazide_18\NN\4423288|NONE_0 (r_pobj) with_17\IN\0|moderate_32|diastolic_23 (r_prep) hypertension_16\NN\14057371|NONE_0
D006852_C563897 NONE hctc_20\NNP\0|administered_6 (r_appos) hydrochlorothiazide_18\NN\4423288|NONE_0 (r_pobj) with_17\IN\0|moderate_32|diastolic_23 (r_prep) hypertension_16\NN\14057371|NONE_0
D049971_D007008 NONE thiazide_0\NNP\3214670|,_18|hypokalemia_20|._55 (r_compound) diuretics_1\NNS\3247620|NONE_0 (l_conj) hypokalemia_3\JJ\14299637|thiazide_20|,_2|._35
D049971_D007008 NONE thiazide_9\NN\3214670|chronic_8 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) of_7\IN\0|a_45|encountered_34|metabolic_22 (r_prep) consequence_6\NN\34213|hypokalemia_48|._39 (r_attr) is_1\VBZ\0|NONE_0 (l_nsubj) hypokalemia_0\NNP\14299637|consequence_48|._87
D049971_D007008 NONE thiazide_5\JJ\3214670|that_5|hypokalemia_25 (r_csubj) cause_7\VBP\7323922|in_47|we_33|._49 (l_dobj) hypokalemia_8\NN\14299637|that_30|thiazide_25
2598570
D013496_D021501 CID suprofen_9\NN\0|NONE_0 (r_pobj) from_8\IN\0|the_50|of_33|._13 (r_prep) epidemiology_1\NN\6043075|NONE_0 (l_prep) of_2\IN\0|the_17|from_33|._46 (l_pobj) syndrome_7\NN\5870365|NONE_0 (l_compound) pain_6\NN\14299637|flank_6
D007052_D007674 NONE ibuprofen_15\NNP\3828465|other_35|analgesic_29|(_12|)_9 (r_appos) agents_12\NNS\7347|NONE_0 (r_pobj) of_9\IN\0|concurrent_15 (r_prep) use_8\NN\407535|young_22|,_13|,_52|disease_72 (r_appos) age_5\NN\4916342|factors_23|._238 (l_conj) disease_20\NN\14061805|young_94|,_85|use_72|,_20
D007052_D006073 NONE ibuprofen_15\NNP\3828465|other_35|analgesic_29|(_12|)_9 (r_appos) agents_12\NNS\7347|NONE_0 (r_pobj) of_9\IN\0|concurrent_15 (r_prep) use_8\NN\407535|young_22|,_13|,_52|disease_72 (r_appos) age_5\NN\4916342|factors_23|._238 (l_conj) disease_20\NN\14061805|young_94|,_85|use_72|,_20 (l_conj) history_29\NN\15120823|preexisting_57|renal_45|,_32|history_28|,_4|,_15|increase_26|,_46|increase_57 (l_prep) of_30\IN\0|a_10 (l_pobj) gout_31\NN\14186541|NONE_0
D000431_D006255 NONE alcohol_83\NN\7881800|to_7 (r_dobj) use_82\VB\407535|were_320|;_154|to_152|in_137|;_9|and_7|._64 (r_conj) participate_47\VB\2367363|NONE_0 (l_ccomp) were_2\VBD\0|;_166|to_168|in_183|;_311|and_313|use_320|._384 (l_conj) suffer_24\VB\2110220|patients_90|likely_71 (l_prep) from_25\IN\0|NONE_0 (l_pobj) fever_27\NN\14299637|NONE_0
D007052_D007669 NONE ibuprofen_15\NNP\3828465|other_35|analgesic_29|(_12|)_9 (r_appos) agents_12\NNS\7347|NONE_0 (r_pobj) of_9\IN\0|concurrent_15 (r_prep) use_8\NN\407535|young_22|,_13|,_52|disease_72 (r_appos) age_5\NN\4916342|factors_23|._238 (l_conj) disease_20\NN\14061805|young_94|,_85|use_72|,_20 (l_conj) history_23\NN\15120823|preexisting_29|renal_17|,_4|,_24|history_28|,_43|increase_54|,_74|increase_85 (l_prep) of_24\IN\0|a_10 (l_pobj) stones_26\NNS\19128|NONE_0
D000431_D001249 NONE alcohol_83\NN\7881800|to_7 (r_dobj) use_82\VB\407535|were_320|;_154|to_152|in_137|;_9|and_7|._64 (r_conj) participate_47\VB\2367363|NONE_0 (l_ccomp) were_2\VBD\0|;_166|to_168|in_183|;_311|and_313|use_320|._384 (l_conj) suffer_24\VB\2110220|patients_90|likely_71 (l_prep) from_25\IN\0|NONE_0 (l_pobj) fever_27\NN\14299637|NONE_0 (l_conj) asthma_29\NN\14145095|hay_14|and_4|(_7|ratio_13
458486
D063325_D010300 NONE tiapride_0\NNP\0|NONE_0 (l_appos) movements_18\NNS\191142|,_119|._60 (l_prep) in_19\IN\13603305|derivative_103|peak_32|dose_27|involuntary_22 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|16_12 (l_pobj) disease_26\NN\14061805|NONE_0
D008787_D010300 NONE metoclopramide_9\NN\0|NONE_0 (r_pobj) to_8\IN\0|closely_16 (r_prep) related_7\JJ\628491|a_43|substituted_41|benzamide_29|,_25 (r_acl) derivative_5\JJ\5802185|peak_71|dose_76|involuntary_81|in_103 (r_amod) movements_18\NNS\191142|,_119|._60 (l_prep) in_19\IN\13603305|derivative_103|peak_32|dose_27|involuntary_22 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|16_12 (l_pobj) disease_26\NN\14061805|NONE_0
D007980_D004409 CID levodopa_2\NN\14604959|-_8 (r_npadvmod) induced_4\VBN\1627355|involuntary_8 (r_amod) movements_6\NNS\191142|NONE_0
D007980_D004409 CID levodopa_12\NN\14604959|-_8 (r_npadvmod) induced_14\VBN\1627355|reduced_17 (r_amod) peak_15\NN\13758296|derivative_71|dose_5|involuntary_10|in_32 (r_nmod) movements_18\NNS\191142|,_119|._60
D007980_D004409 CID levodopa_8\RB\14604959|-_8 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) dyskinesias_11\NNS\14084880|that_22|are_12|by_23
C037689_D004409 NONE benzamide_4\RB\0|a_14|substituted_12|related_29|,_54 (r_amod) derivative_5\JJ\5802185|peak_71|dose_76|involuntary_81|in_103 (r_amod) movements_18\NNS\191142|,_119|._60
C037689_D010300 NONE benzamide_4\RB\0|a_14|substituted_12|related_29|,_54 (r_amod) derivative_5\JJ\5802185|peak_71|dose_76|involuntary_81|in_103 (r_amod) movements_18\NNS\191142|,_119|._60 (l_prep) in_19\IN\13603305|derivative_103|peak_32|dose_27|involuntary_22 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|16_12 (l_pobj) disease_26\NN\14061805|NONE_0
D063325_D004421 NONE tiapride_0\NNP\0|effect_16|induced_35|._91 (r_nsubj) had_1\VBD\0|NONE_0 (l_advcl) induced_7\VBN\1627355|tiapride_35|effect_19|._56 (l_prep) of_10\IN\0|levodopa_31|-_23|morning_8 (l_pobj) dystonia_17\NN\0|NONE_0
D008787_D004409 NONE metoclopramide_9\NN\0|NONE_0 (r_pobj) to_8\IN\0|closely_16 (r_prep) related_7\JJ\628491|a_43|substituted_41|benzamide_29|,_25 (r_acl) derivative_5\JJ\5802185|peak_71|dose_76|involuntary_81|in_103 (r_amod) movements_18\NNS\191142|,_119|._60
D007980_D004421 NONE levodopa_5\NN\14604959|-_8|morning_23|of_31 (r_npadvmod) induced_7\VBN\1627355|tiapride_35|effect_19|._56 (l_prep) of_10\IN\0|levodopa_31|-_23|morning_8 (l_pobj) dystonia_17\NN\0|NONE_0
D004298_D004409 NONE dopamine_21\NN\14807737|NONE_0 (r_compound) receptors_22\NNS\5225602|NONE_0 (r_pobj) of_20\IN\0|a_17|separate_15 (r_prep) group_19\NN\2137|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) overstimulation_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|that_45|dyskinesias_23|are_11 (r_agent) caused_13\VBN\1617192|the_49 (l_nsubjpass) dyskinesias_11\NNS\14084880|that_22|are_12|by_23
D063325_D004409 NONE tiapride_0\NNP\0|NONE_0 (l_prep) in_1\IN\13603305|._41 (l_pobj) movements_6\NNS\191142|NONE_0
D063325_D004409 NONE tiapride_0\NNP\0|NONE_0 (l_appos) movements_18\NNS\191142|,_119|._60
D007980_D010300 NONE levodopa_12\NN\14604959|-_8 (r_npadvmod) induced_14\VBN\1627355|reduced_17 (r_amod) peak_15\NN\13758296|derivative_71|dose_5|involuntary_10|in_32 (r_nmod) movements_18\NNS\191142|,_119|._60 (l_prep) in_19\IN\13603305|derivative_103|peak_32|dose_27|involuntary_22 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|16_12 (l_pobj) disease_26\NN\14061805|NONE_0
17786501
D004221_D000437 NONE disulfiram_15\NN\3740161|NONE_0 (r_pobj) of_14\IN\0|chronic_12|for_14 (r_prep) use_13\NN\407535|NONE_0 (l_prep) for_16\IN\0|chronic_26|of_14 (l_pobj) management_19\NN\1123598|NONE_0 (l_compound) dependence_18\NN\24720|alcohol_8
D004221_D000437 NONE disulfiram_4\NN\3740161|he_19|had_16|been_12|for_11|._59 (r_dobj) taking_3\VBG\37396|NONE_0 (l_prep) for_5\IN\0|he_30|had_27|been_23|disulfiram_11|._48 (l_pobj) dependence_7\NN\24720|NONE_0
D004221_D009901 NONE disulfiram_0\NNP\3740161|-_10 (r_npadvmod) induced_2\VBN\1627355|transient_8|and_24|neuropathy_39 (r_amod) optic_4\JJ\5299178|:_31|a_33|case_35|._46 (l_conj) neuropathy_7\NN\14204950|induced_39|transient_31|and_15
D004221_D009901 NONE disulfiram_15\NN\3740161|NONE_0 (r_pobj) of_14\IN\0|chronic_12|for_14 (r_prep) use_13\NN\407535|NONE_0 (r_pobj) after_11\IN\0|to_52|case_40 (r_prep) report_3\VB\6470073|:_5|._114 (l_dobj) case_5\NN\7283608|to_12|after_40 (l_prep) of_6\IN\0|a_7 (l_pobj) optic_7\JJ\5299178|NONE_0 (l_conj) neuropathy_10\NN\14204950|and_15
D004221_D010523 NONE disulfiram_0\NNP\3740161|-_10 (r_npadvmod) induced_2\VBN\1627355|transient_8|and_24|neuropathy_39 (r_amod) optic_4\JJ\5299178|:_31|a_33|case_35|._46 (l_conj) neuropathy_7\NN\14204950|induced_39|transient_31|and_15
D004221_D010523 NONE disulfiram_15\NN\3740161|NONE_0 (r_pobj) of_14\IN\0|chronic_12|for_14 (r_prep) use_13\NN\407535|NONE_0 (r_pobj) after_11\IN\0|to_52|case_40 (r_prep) report_3\VB\6470073|:_5|._114 (l_dobj) case_5\NN\7283608|to_12|after_40 (l_prep) of_6\IN\0|a_7 (l_pobj) optic_7\JJ\5299178|NONE_0 (l_conj) neuropathy_10\NN\14204950|and_15
3961813
C025541_D020258 NONE totp_6\NNP\0|hr_9 (r_pobj) after_5\IN\0|esterase_26 (r_prep) activities_2\NNS\30358|%_52|given_89|._122 (l_compound) esterase_1\NN\0|after_26 (l_amod) neurotoxic_0\JJ\0|NONE_0
D003345_D009422 NONE corticosterone_9\NN\14752057|NONE_0 (l_prep) on_10\IN\0|dietary_23 (l_pobj) neuropathy_15\NN\14204950|NONE_0
D003345_D009422 NONE corticosterone_13\NN\14752057|NONE_0 (r_pobj) of_12\IN\0|low_50|(_31|less_30|)_2 (r_prep) concentrations_2\NNS\4916342|although_13|effects_79|signs_169|._211 (r_nsubj) had_14\VBD\0|NONE_0 (l_dobj) effects_16\NNS\13245626|although_92|concentrations_79|signs_90|._132 (l_prep) on_17\IN\0|beneficial_19 (l_pobj) neuropathy_21\NN\14204950|NONE_0
D007531_D009422 CID dfp_39\NNP\0|either_15|or_3 (r_conj) totp_37\NNP\0|NONE_0 (r_pobj) given_35\VBN\5892096|exacerbated_39|clinical_27|in_12 (r_acl) signs_32\NNS\6643763|although_182|concentrations_169|effects_90|._42 (r_dobj) had_14\VBD\0|NONE_0 (l_dobj) effects_16\NNS\13245626|although_92|concentrations_79|signs_90|._132 (l_prep) on_17\IN\0|beneficial_19 (l_pobj) neuropathy_21\NN\14204950|NONE_0
C025541_D009410 CID totp_16\NNP\0|NONE_0 (r_pobj) given_15\VBN\5892096|fibers_79|also_67|evident_62|._17 (r_prep) were_3\VBD\0|NONE_0 (l_nsubj) fibers_2\NNS\14580897|also_12|evident_17|given_79|._96
D010755_D020258 NONE organophosphorous_21\JJ\0|NONE_0 (r_amod) compounds_22\NNS\5869584|not_28 (r_dobj) given_20\VBN\5892096|activities_89|%_37|._33 (r_prep) were_9\VBD\0|NONE_0 (l_nsubj) activities_2\NNS\30358|%_52|given_89|._122 (l_compound) esterase_1\NN\0|after_26 (l_amod) neurotoxic_0\JJ\0|NONE_0
D007531_D009410 CID dfp_18\NNP\0|or_3 (r_conj) totp_16\NNP\0|NONE_0 (r_pobj) given_15\VBN\5892096|fibers_79|also_67|evident_62|._17 (r_prep) were_3\VBD\0|NONE_0 (l_nsubj) fibers_2\NNS\14580897|also_12|evident_17|given_79|._96
C025541_D009422 CID totp_18\NNP\0|-_4 (r_npadvmod) induced_20\VBN\1627355|,_18|greater_20 (r_amod) neuropathy_21\NN\14204950|NONE_0
C025541_D009422 CID totp_37\NNP\0|NONE_0 (r_pobj) given_35\VBN\5892096|exacerbated_39|clinical_27|in_12 (r_acl) signs_32\NNS\6643763|although_182|concentrations_169|effects_90|._42 (r_dobj) had_14\VBD\0|NONE_0 (l_dobj) effects_16\NNS\13245626|although_92|concentrations_79|signs_90|._132 (l_prep) on_17\IN\0|beneficial_19 (l_pobj) neuropathy_21\NN\14204950|NONE_0
D010755_D009422 NONE organophosphorus_11\NN\0|-_16 (r_npadvmod) induced_13\VBN\1627355|delayed_8|in_27 (r_amod) neuropathy_15\NN\14204950|NONE_0
D007531_D020258 NONE dfp_8\NNP\0|or_3 (r_conj) totp_6\NNP\0|hr_9 (r_pobj) after_5\IN\0|esterase_26 (r_prep) activities_2\NNS\30358|%_52|given_89|._122 (l_compound) esterase_1\NN\0|after_26 (l_amod) neurotoxic_0\JJ\0|NONE_0
1504402
D007741_D004342 CID dilevalol_7\NN\0|-_9 (r_npadvmod) associated_9\VBN\628491|NONE_0 (r_amod) hepatitis_10\NN\14127211|NONE_0 (r_pobj) for_6\IN\0|a_12 (r_prep) mechanism_5\NN\13446390|NONE_0 (r_pobj) as_3\IN\14622893|hypersensitivity_33|immune_16|._49 (r_prep) reaction_2\NN\13446390|NONE_0 (l_nmod) hypersensitivity_0\NN\14531772|immune_17|as_33|._82
D007741_D056486 CID dilevalol_7\NN\0|-_9 (r_npadvmod) associated_9\VBN\628491|NONE_0 (r_amod) hepatitis_10\NN\14127211|NONE_0
D007741_D056486 CID dilevalol_7\VB\0|to_35|reactivity_14 (l_conj) serum_10\VB\5397468|to_20|and_7 (l_prep) in_19\IN\13603305|to_71|containing_62 (l_pobj) case_21\NN\7283608|NONE_0 (l_prep) of_22\IN\0|a_7 (l_pobj) injury_27\NN\14052046|NONE_0
D007741_D056486 CID dilevalol_15\JJ\0|putative_17|ex_8|vivo_5|or_19|metabolites_22 (r_compound) antigens_16\NNS\20090|NONE_0 (r_dobj) containing_11\VBG\2632940|to_9|in_62 (r_xcomp) serum_10\VB\5397468|to_20|and_7 (l_prep) in_19\IN\13603305|to_71|containing_62 (l_pobj) case_21\NN\7283608|NONE_0 (l_prep) of_22\IN\0|a_7 (l_pobj) injury_27\NN\14052046|NONE_0
D007741_D056486 CID dilevalol_23\NN\0|-_9 (r_npadvmod) induced_25\VBN\1627355|liver_8 (r_amod) injury_27\NN\14052046|NONE_0
D007741_D056486 CID dilevalol_10\NN\0|-_9 (r_npadvmod) induced_12\VBN\1627355|liver_8 (r_amod) injury_14\NN\14052046|NONE_0
D007741_D056486 CID dilevalol_16\JJ\0|ex_17|prepared_9 (r_compound) antigens_17\NNS\20090|NONE_0 (r_dobj) containing_11\VBG\2632940|NONE_0 (r_acl) sera_10\NN\5397468|NONE_0 (r_pobj) to_9\IN\0|lymphocyte_25 (r_prep) sensitization_8\NN\14531772|NONE_0 (r_pobj) of_6\IN\0|the_14 (r_prep) detection_5\NN\5708432|methodology_29|,_92|suggesting_94|._182 (r_dobj) allowed_3\VBD\0|NONE_0 (l_advcl) suggesting_19\VBG\1010118|methodology_123|detection_94|,_2|._88 (l_dobj) involvement_21\NN\1080366|NONE_0 (l_prep) of_22\IN\0|the_16 (l_pobj) mechanism_25\NN\13446390|NONE_0 (l_prep) in_26\IN\13603305|an_25|immunologic_22 (l_pobj) injury_31\NN\14052046|NONE_0
D007741_D056486 CID dilevalol_27\NN\0|-_9 (r_npadvmod) induced_29\VBN\1627355|liver_8 (r_amod) injury_31\NN\14052046|NONE_0
12760988
D003907_D063806 NONE dexamethasone_18\NN\2721538|or_3 (r_conj) saline_16\NN\14849367|NONE_0 (r_pobj) with_15\IN\0|before_29 (r_prep) pretreated_14\VBN\0|64_12 (r_acl) patients_13\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|incidence_76|was_15|._95 (r_prep) determined_10\VBN\0|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_61|in_76|._171 (l_prep) of_4\IN\0|the_27|and_13|severity_9 (l_pobj) myalgia_8\NN\14322699|NONE_0
D003907_D063806 NONE dexamethasone_18\NN\2721538|the_4 (r_compound) group_19\NN\2137|NONE_0 (r_pobj) in_16\IN\13603305|15_12 (r_prep) patients_15\NNS\9898892|of_47|compared_58|,_103|and_105|reported_128 (r_nsubj) complained_20\VBD\0|the_55|two_51|:_41 (r_acl) groups_12\NNS\2137|NONE_0 (r_pobj) between_9\IN\0|incidence_63|did_29|not_25|significantly_14 (r_prep) differ_7\VB\0|NONE_0 (l_nsubj) incidence_0\NN\13821570|did_34|not_38|significantly_49|between_63 (l_conj) severity_2\NN\5036394|and_4 (l_prep) of_3\IN\0|NONE_0 (l_pobj) myalgia_4\NN\14322699|NONE_0
D003907_D063806 NONE dexamethasone_18\NN\2721538|the_4 (r_compound) group_19\NN\2137|NONE_0 (r_pobj) in_16\IN\13603305|15_12 (r_prep) patients_15\NNS\9898892|of_47|compared_58|,_103|and_105|reported_128 (r_nsubj) complained_20\VBD\0|the_55|two_51|:_41 (l_prep) of_21\IN\0|patients_47|compared_11|,_56|and_58|reported_81 (l_pobj) myalgia_22\NN\14322699|NONE_0
D003907_D063806 NONE dexamethasone_18\NN\2721538|the_4 (r_compound) group_19\NN\2137|NONE_0 (r_pobj) in_16\IN\13603305|15_12 (r_prep) patients_15\NNS\9898892|of_47|compared_58|,_103|and_105|reported_128 (r_nsubj) complained_20\VBD\0|the_55|two_51|:_41 (l_conj) reported_36\VBN\831651|patients_128|of_81|compared_70|,_25|and_23 (l_nsubjpass) myalgia_34\NN\14322699|was_8|by_21|._88
D003907_D010149 NONE dexamethasone_4\NN\2721538|NONE_0 (r_pobj) of_3\IN\0|NONE_0 (r_prep) administration_2\NN\1133281|:_2|before_32 (r_appos) implications_0\NNS\5774614|not_73|effective_77|._179 (r_nsubj) was_7\VBD\0|NONE_0 (l_acomp) effective_9\JJ\0|implications_77|not_4|._102 (l_prep) in_10\IN\13603305|NONE_0 (l_pcomp) decreasing_11\VBG\169651|NONE_0 (l_dobj) incidence_13\NN\13821570|NONE_0 (l_conj) severity_16\NN\5036394|the_21|or_7 (l_prep) of_17\IN\0|the_13 (l_pobj) myalgia_22\NN\14322699|NONE_0
D003907_D010149 NONE dexamethasone_2\NN\2721538|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) pretreatment_0\NN\0|not_35|justified_39|._103 (r_nsubj) is_3\VBZ\0|NONE_0 (l_acomp) justified_5\VBN\1012073|pretreatment_39|not_4|._64 (l_xcomp) prevent_7\VB\0|NONE_0 (l_dobj) myalgia_9\NN\14322699|to_25|after_8
D013390_D010149 CID succinylcholine_3\NN\3800001|NONE_0 (r_pobj) after_2\IN\0|postoperative_22|:_21|evidence_26|._61 (r_prep) myalgia_1\NN\14322699|NONE_0
D013390_D010149 CID succinylcholine_6\NN\3800001|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|a_21|common_19|side_12 (r_acl) effect_3\NN\34213|myalgia_56|._63 (r_nsubj) is_7\VBZ\0|NONE_0 (l_attr) myalgia_9\NN\14322699|effect_56|._7
D013390_D010149 CID succinylcholine_6\NN\3800001|NONE_0 (r_pobj) before_5\IN\0|:_34|administration_32 (r_punct) implications_0\NNS\5774614|not_73|effective_77|._179 (r_nsubj) was_7\VBD\0|NONE_0 (l_acomp) effective_9\JJ\0|implications_77|not_4|._102 (l_prep) in_10\IN\13603305|NONE_0 (l_pcomp) decreasing_11\VBG\169651|NONE_0 (l_dobj) incidence_13\NN\13821570|NONE_0 (l_conj) severity_16\NN\5036394|the_21|or_7 (l_prep) of_17\IN\0|the_13 (l_pobj) myalgia_22\NN\14322699|NONE_0
D013390_D010149 CID succinylcholine_18\NN\3800001|-_15 (r_npadvmod) induced_20\VBN\1627355|postoperative_8 (r_amod) myalgia_22\NN\14322699|NONE_0
D013390_D010149 CID succinylcholine_11\NN\3800001|NONE_0 (r_pobj) after_10\IN\0|to_33|myalgia_8 (r_prep) prevent_7\VB\0|NONE_0 (l_dobj) myalgia_9\NN\14322699|to_25|after_8
D013390_D063806 CID succinylcholine_5\NN\3800001|-_15 (r_npadvmod) associated_7\VBN\628491|NONE_0 (r_amod) myalgia_8\NN\14322699|NONE_0
D013390_D063806 CID succinylcholine_20\NN\3800001|NONE_0 (r_pobj) before_19\IN\0|with_29 (r_prep) pretreated_14\VBN\0|64_12 (r_acl) patients_13\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|incidence_76|was_15|._95 (r_prep) determined_10\VBN\0|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_61|in_76|._171 (l_prep) of_4\IN\0|the_27|and_13|severity_9 (l_pobj) myalgia_8\NN\14322699|NONE_0
D013390_D063806 CID succinylcholine_12\NN\3800001|-_15 (r_npadvmod) associated_14\VBN\628491|NONE_0 (r_amod) myalgia_15\NN\14322699|NONE_0
11827497
D006493_D013921 CID heparin_3\NN\2718259|-_7 (r_npadvmod) induced_5\VBN\1627355|onset_14|._24 (r_amod) thrombocytopenia_6\NN\14189204|NONE_0
D006493_D013921 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_3\NN\14189204|after_39|._111
D006493_D013921 CID heparin_10\JJ\2718259|,_16|with_18 (r_compound) exposure_11\NN\5042871|days_19 (r_pobj) after_9\IN\0|thrombocytopenia_39|._72 (r_prep) presents_4\VBZ\28270|NONE_0 (l_nsubj) thrombocytopenia_3\NN\14189204|after_39|._111
D006493_D013921 CID heparin_5\NN\2718259|-_7 (r_npadvmod) induced_7\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_8\NN\14189204|NONE_0
D006493_D013921 CID heparin_16\NN\2718259|-_7 (r_npadvmod) induced_18\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_19\NN\14189204|NONE_0
D006493_D013921 CID heparin_9\NN\2718259|-_7 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_12\NN\14189204|in_24|apparent_24|on_33
D006493_D013921 CID heparin_9\JJ\2718259|NONE_0 (r_compound) exposure_10\NN\5042871|that_26|had_21 (r_dobj) included_8\VBN\0|NONE_0 (r_relcl) hospitalizations_5\NNS\15113229|NONE_0 (r_pobj) after_4\IN\0|:_21|patients_19|home_5|--_57|in_59|,_72|with_74|--_109|return_119|._192 (r_prep) went_2\VBD\0|NONE_0 (l_prep) with_16\IN\0|:_95|patients_93|home_79|after_74|--_17|in_15|,_2|--_35|return_45|._118 (l_pobj) thrombocytopenia_18\NN\14189204|NONE_0
D006493_D013921 CID heparin_3\NN\2718259|-_7 (r_npadvmod) induced_5\VBN\1627355|onset_14 (r_amod) thrombocytopenia_6\NN\14189204|is_17|increasingly_20|being_33|._49
D006493_D013921 CID heparin_8\NN\2718259|-_7 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_11\NN\14189204|avoid_68|,_43|physicians_41|must_30|returns_58
D006493_D013921 CID heparin_27\VBN\2718259|alternative_32|,_6|not_4 (r_appos) anticoagulants_24\NNS\3740161|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) therapy_21\NN\657604|consider_113|;_2|,_52|should_54|be_61|._73 (r_nsubjpass) initiated_31\VBN\1617192|NONE_0 (l_ccomp) consider_7\VB\689344|;_111|therapy_113|,_165|should_167|be_174|._186 (l_dobj) thrombocytopenia_11\NN\14189204|avoid_68|,_43|physicians_41|must_30|returns_58
D006493_D001157 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_3\NN\14189204|after_39|._111 (r_nsubj) presents_4\VBZ\28270|NONE_0 (l_prep) after_9\IN\0|thrombocytopenia_39|._72 (l_pobj) exposure_11\NN\5042871|days_19 (l_prep) with_13\IN\0|heparin_18|,_2 (l_conj) without_15\IN\0|or_3 (l_pobj) thromboemboli_19\NN\0|NONE_0
D006493_D001157 CID heparin_10\JJ\2718259|,_16|with_18 (r_compound) exposure_11\NN\5042871|days_19 (l_prep) with_13\IN\0|heparin_18|,_2 (l_conj) without_15\IN\0|or_3 (l_pobj) thromboemboli_19\NN\0|NONE_0
D006493_D054556 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_3\NN\14189204|after_39|._111 (r_nsubj) presents_4\VBZ\28270|NONE_0 (l_prep) after_9\IN\0|thrombocytopenia_39|._72 (l_pobj) exposure_11\NN\5042871|days_19 (l_prep) with_13\IN\0|heparin_18|,_2 (l_conj) without_15\IN\0|or_3 (l_pobj) thromboemboli_19\NN\0|NONE_0
D006493_D054556 CID heparin_10\JJ\2718259|,_16|with_18 (r_compound) exposure_11\NN\5042871|days_19 (l_prep) with_13\IN\0|heparin_18|,_2 (l_conj) without_15\IN\0|or_3 (l_pobj) thromboemboli_19\NN\0|NONE_0
D006493_D013923 NONE heparin_9\NN\2718259|-_7 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_12\NN\14189204|in_24|apparent_24|on_33 (r_nsubj) became_13\VBD\146138|a_57|3-year_55 (l_prep) on_15\IN\0|in_57|thrombocytopenia_33|apparent_9 (l_pobj) presentation_17\NN\1027379|NONE_0 (l_prep) with_18\IN\0|delayed_21 (l_pobj) complications_20\NNS\1073995|NONE_0 (l_compound) thromboembolic_19\JJ\0|NONE_0
D006493_D013923 NONE heparin_13\NN\2718259|-_7 (r_npadvmod) induced_15\VBN\1627355|platelet_8|tests_35 (r_nmod) factor_17\NN\7326557|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) results_11\NNS\34213|platelet_66|,_51|onset_49|,_2 (r_appos) counts_3\VBZ\13582013|:_11|._130 (l_appos) onset_5\NN\7325190|platelet_17|,_2|,_47|results_49 (l_prep) of_6\IN\0|NONE_0 (l_pobj) thromboembolism_9\NN\14100769|NONE_0
D006493_D013923 NONE heparin_9\JJ\2718259|NONE_0 (r_compound) exposure_10\NN\5042871|that_26|had_21 (r_dobj) included_8\VBN\0|NONE_0 (r_relcl) hospitalizations_5\NNS\15113229|NONE_0 (r_pobj) after_4\IN\0|:_21|patients_19|home_5|--_57|in_59|,_72|with_74|--_109|return_119|._192 (r_prep) went_2\VBD\0|NONE_0 (l_advcl) return_23\VB\6479665|:_140|patients_138|home_124|after_119|--_62|in_60|,_47|with_45|--_10|._73 (l_prep) with_33\IN\0|only_48|to_43|to_33 (l_pobj) complications_35\NNS\1073995|NONE_0 (l_compound) thromboembolic_34\JJ\0|NONE_0
D006493_D013923 NONE heparin_8\NN\2718259|-_7 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_11\NN\14189204|avoid_68|,_43|physicians_41|must_30|returns_58 (r_dobj) consider_7\VB\689344|;_111|therapy_113|,_165|should_167|be_174|._186 (l_advcl) returns_17\NNS\6479665|avoid_126|,_101|physicians_99|must_88|thrombocytopenia_58 (l_prep) with_18\IN\0|whenever_49|a_40|hospitalized_29|patient_16 (l_pobj) thromboembolism_19\NN\14100769|NONE_0
D006493_D013923 NONE heparin_27\VBN\2718259|alternative_32|,_6|not_4 (r_appos) anticoagulants_24\NNS\3740161|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) therapy_21\NN\657604|consider_113|;_2|,_52|should_54|be_61|._73 (r_nsubjpass) initiated_31\VBN\1617192|NONE_0 (l_ccomp) consider_7\VB\689344|;_111|therapy_113|,_165|should_167|be_174|._186 (l_advcl) returns_17\NNS\6479665|avoid_126|,_101|physicians_99|must_88|thrombocytopenia_58 (l_prep) with_18\IN\0|whenever_49|a_40|hospitalized_29|patient_16 (l_pobj) thromboembolism_19\NN\14100769|NONE_0
1355091
D009638_D001919 CID noradrenaline_33\NN\14807929|the_175|pressor_171|and_153|bradycardia_149|micrograms_92|kg-1_81|i.v._76|)_72|,_71|abbott-53693_49|kg-1_16|,_6|and_4 (r_conj) responses_2\NNS\11410625|were_212|in_228|with_245|._291 (l_conj) bradycardia_4\NNS\14110674|the_26|pressor_22|and_4|micrograms_57|kg-1_68|i.v._73|)_77|,_78|abbott-53693_100|kg-1_133|,_143|and_145|noradrenaline_149
D009638_D001919 CID noradrenaline_7\NN\14807929|-_13 (r_npadvmod) induced_9\VBN\1627355|the_18|pressor_8|in_23 (r_amod) effect_11\NN\34213|that_51 (r_dobj) accompanied_5\VBD\0|the_21 (r_relcl) bradycardia_3\NN\14110674|furthermore_17|,_6|similar_81|despite_133
C014282_D001919 CID cirazoline_9\NN\0|NONE_0 (r_pobj) to_5\IN\0|NONE_0 (r_prep) bradycardia_4\NNS\14110674|the_26|pressor_22|and_4|micrograms_57|kg-1_68|i.v._73|)_77|,_78|abbott-53693_100|kg-1_133|,_143|and_145|noradrenaline_149
C014282_D001919 CID cirazoline_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|bradycardia_20 (r_prep) effects_5\NNS\13245626|both_33|the_28|and_16 (l_amod) bradycardia_4\NN\14110674|of_20
D015016_D007024 NONE rauwolscine_33\JJ\0|NONE_0 (r_pobj) with_32\IN\0|NONE_0 (r_prep) treated_31\VBN\2376958|the_8 (r_acl) shr_30\NN\0|not_11 (r_pobj) in_28\IN\13603305|however_118|,_111|tilt_97|hypotension_72|,_10|but_8|._62 (r_conj) induced_7\VBN\1627355|NONE_0 (l_dobj) hypotension_9\NN\14057371|however_46|,_39|tilt_25|,_62|but_64|in_72|._134
D011224_D006973 NONE prazosin_9\NN\2698769|-_8 (r_npadvmod) pretreated_11\VBN\0|NONE_0 (r_amod) conscious_12\JJ\0|hypertensive_24 (r_amod) rats_15\NNS\2329401|NONE_0 (l_amod) hypertensive_14\JJ\10405694|conscious_24
D011224_D006973 NONE prazosin_7\NN\2698769|chronic_8 (r_compound) treatment_8\NN\654885|whether_25|function_42|for_51 (r_nsubj) alters_9\VBZ\0|to_47 (l_prep) for_14\IN\0|whether_76|treatment_51|function_9 (l_pobj) control_16\NN\5190804|NONE_0 (l_prep) in_21\IN\13603305|orthostatic_47|of_27 (l_pobj) rats_25\NNS\2329401|NONE_0 (l_amod) hypertensive_24\JJ\10405694|conscious_24|(_18|shr_19|)_22
D011224_D001919 NONE prazosin_51\NN\2698769|chronic_8 (r_compound) pretreatment_52\NN\0|NONE_0 (r_pobj) without_49\IN\0|and_4 (r_conj) with_47\IN\0|responses_245|were_33|in_17|._46 (r_prep) determined_43\VBN\0|NONE_0 (l_nsubjpass) responses_2\NNS\11410625|were_212|in_228|with_245|._291 (l_conj) bradycardia_4\NNS\14110674|the_26|pressor_22|and_4|micrograms_57|kg-1_68|i.v._73|)_77|,_78|abbott-53693_100|kg-1_133|,_143|and_145|noradrenaline_149
D011224_D001919 NONE prazosin_12\NN\2698769|NONE_0 (r_pobj) in_10\IN\13603305|pressor_61|were_15|treated_20|compared_43|._80 (r_prep) abolished_9\VBN\0|NONE_0 (l_nsubjpass) pressor_2\NN\9190918|were_46|in_61|treated_81|compared_104|._141 (l_conj) effects_5\NNS\13245626|both_33|the_28|and_16 (l_amod) bradycardia_4\NN\14110674|of_20
D011224_D001919 NONE prazosin_28\NN\2698769|chronic_8 (r_compound) treatment_29\NN\654885|NONE_0 (r_pobj) with_26\IN\0|NONE_0 (r_prep) shr_25\NNP\0|NONE_0 (r_pobj) in_24\IN\13603305|than_39 (r_prep) greater_23\JJR\0|bradycardia_16|._74 (r_acomp) was_22\VBD\0|on_124|,_107|effects_93|similar_64|,_35|but_33 (l_nsubj) bradycardia_21\NN\14110674|greater_16|._90
D011224_D001919 NONE prazosin_20\NN\2698769|chronic_8 (r_compound) treatment_21\NN\654885|NONE_0 (r_pobj) without_18\IN\0|and_4 (r_conj) with_16\IN\0|NONE_0 (r_prep) similar_15\JJ\0|furthermore_98|,_87|bradycardia_81|despite_52 (r_acomp) was_14\VBD\0|NONE_0 (l_nsubj) bradycardia_3\NN\14110674|furthermore_17|,_6|similar_81|despite_133
D011224_D007024 CID prazosin_9\NN\2698769|-_8 (r_npadvmod) pretreated_11\VBN\0|NONE_0 (r_amod) conscious_12\JJ\0|hypertensive_24 (r_amod) rats_15\NNS\2329401|NONE_0 (r_pobj) in_7\IN\13603305|alpha_30|2-adrenoceptor_24 (r_prep) blockade_6\NN\952963|NONE_0 (r_pobj) following_3\VBG\8180190|hypotension_19|._112 (r_prep) occurs_2\VBZ\0|NONE_0 (l_nsubj) hypotension_1\NN\14057371|following_19|._131
D011224_D007024 CID prazosin_15\NN\2698769|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|orthostatic_35|in_11 (r_acl) hypotension_9\NN\14057371|however_46|,_39|tilt_25|,_62|but_64|in_72|._134
D011224_D007024 CID prazosin_22\NN\2698769|NONE_0 (r_pobj) of_21\IN\0|acute_13 (r_prep) dosing_20\NN\515154|NONE_0 (r_pobj) after_18\IN\0|or_3 (r_conj) to_16\IN\0|either_13 (r_prep) prior_15\RB\10675876|when_22 (r_advmod) performed_13\VBN\0|tilts_65|did_45|not_41|hypotension_17|._78 (r_advcl) produce_9\VB\7555863|NONE_0 (l_dobj) hypotension_11\NN\14057371|tilts_48|did_28|not_24|performed_17|._95
C056299_D001919 CID abbott-53693_22\NNP\0|the_126|pressor_122|and_104|bradycardia_100|micrograms_43|kg-1_32|i.v._27|)_23|,_22|kg-1_33|,_43|and_45|noradrenaline_49 (r_appos) responses_2\NNS\11410625|were_212|in_228|with_245|._291 (l_conj) bradycardia_4\NNS\14110674|the_26|pressor_22|and_4|micrograms_57|kg-1_68|i.v._73|)_77|,_78|abbott-53693_100|kg-1_133|,_143|and_145|noradrenaline_149
C056299_D001919 CID abbott-53693_9\NNP\0|NONE_0 (r_pobj) of_8\IN\0|the_20|pressor_16 (r_prep) effects_7\NNS\13245626|on_31|,_14|similar_29|,_58|but_60|was_93 (r_nsubj) were_10\VBD\0|NONE_0 (l_conj) was_22\VBD\0|on_124|,_107|effects_93|similar_64|,_35|but_33 (l_nsubj) bradycardia_21\NN\14110674|greater_16|._90
15579441
D011692_D000860 CID aminonucleoside_15\NN\0|-_15 (r_advmod) induced_17\VBN\1627355|nephrotic_8|and_27|hypoxia_51 (r_amod) syndrome_19\NN\5870365|the_48 (r_appos) puromycin_14\NNS\0|NONE_0 (r_pobj) in_12\IN\13603305|to_37|hypoxia_8 (r_prep) identify_8\VB\699815|NONE_0 (l_dobj) hypoxia_11\NN\14035298|to_29|in_8
D011692_D000860 CID aminonucleoside_15\NN\0|-_15 (r_advmod) induced_17\VBN\1627355|nephrotic_8|and_27|hypoxia_51 (r_amod) syndrome_19\NN\5870365|the_48 (l_conj) hypoxia_24\NN\14035298|induced_51|nephrotic_43|and_24
D011692_D000860 CID aminonucleoside_21\NN\0|puromycin_10 (r_compound) model_22\NN\5888929|and_6|2.6-fold_10 (r_pobj) in_18\IN\13603305|2.2-fold_20|at_11|,_90|showed_143 (r_prep) reaching_13\VBG\331950|expression_92|throughout_35|,_2|._242 (r_advcl) increased_7\VBD\169651|NONE_0 (l_nsubj) expression_0\NN\4679549|throughout_57|,_90|reaching_92|._334 (l_prep) of_1\IN\0|NONE_0 (l_pobj) transgene_6\NN\5436752|NONE_0 (l_amod) responsive_5\JJ\0|the_12 (l_npadvmod) hypoxia_3\NN\14035298|-_7
D011692_D009404 CID aminonucleoside_15\NN\0|-_15 (r_advmod) induced_17\VBN\1627355|nephrotic_8|and_27|hypoxia_51 (r_amod) syndrome_19\NN\5870365|the_48
8988571
D003042_D064420 NONE cocaine_4\NN\3492717|NONE_0 (r_compound) use_5\NN\407535|NONE_0 (r_dobj) following_3\VBG\8180190|fatal_23|excited_17 (r_acl) delirium_2\NN\14391660|:_30|findings_46|evidence_67|._110 (r_dep) provide_9\VBP\2199590|NONE_0 (l_dobj) evidence_11\NN\5816287|delirium_67|:_37|findings_21|._43 (l_prep) for_12\IN\0|new_13 (l_pobj) mechanisms_13\NNS\13446390|NONE_0 (l_prep) of_14\IN\0|NONE_0 (l_pobj) toxicity_16\NN\13576101|NONE_0
D003042_D064420 NONE cocaine_15\NN\3492717|NONE_0 (r_compound) toxicity_16\NN\13576101|NONE_0
D003042_D003645 CID cocaine_11\NN\3492717|chronic_8 (r_compound) use_12\NN\407535|that_21|function_26|and_35 (r_nsubj) disrupts_13\VBZ\362348|the_40 (r_acl) hypothesis_8\NN\7162194|NONE_0 (r_pobj) with_6\IN\0|most_16 (r_prep) consistent_5\JJ\0|findings_18|,_90|precipitate_134|._226 (r_acomp) are_3\VBP\13600404|NONE_0 (l_advcl) precipitate_26\VB\15046900|findings_152|consistent_134|,_44|._92 (l_dobj) agitation_27\NN\14373582|coupled_49|,_18|may_16 (l_conj) delirium_29\NN\14391660|,_2 (l_conj) thermoregulation_32\NN\0|,_11 (l_conj) rhabdomyolysis_34\NN\0|aberrant_27|,_2 (l_conj) death_38\NN\7296428|,_13|and_11
D003042_D003645 CID cocaine_22\NN\3492717|recent_7 (r_compound) use_23\NN\407535|NONE_0 (r_pobj) with_20\IN\0|when_13 (r_prep) coupled_19\VBN\1295275|,_31|may_33|agitation_49 (r_advcl) precipitate_26\VB\15046900|findings_152|consistent_134|,_44|._92 (l_dobj) agitation_27\NN\14373582|coupled_49|,_18|may_16 (l_conj) delirium_29\NN\14391660|,_2 (l_conj) thermoregulation_32\NN\0|,_11 (l_conj) rhabdomyolysis_34\NN\0|aberrant_27|,_2 (l_conj) death_38\NN\7296428|,_13|and_11
D003042_D062787 NONE cocaine_5\NN\3492717|-_7 (r_npadvmod) related_7\VBN\628491|all_12|in_15 (r_amod) deaths_8\NNS\7296428|NONE_0 (r_pobj) of_3\IN\0|a_11 (r_prep) registry_2\NN\6502378|NONE_0 (r_pobj) from_0\IN\0|,_69|from_71|,_85|edds_90|were_95|with_109|._181 (r_prep) compared_23\VBN\644583|NONE_0 (l_prep) with_24\IN\0|from_109|,_40|from_38|,_24|edds_19|were_14|._72 (l_pobj) victims_26\NNS\9630641|NONE_0 (l_prep) of_27\IN\0|125_12|without_31 (l_pobj) overdose_30\NN\84738|NONE_0
D003042_D062787 NONE cocaine_29\NN\3492717|accidental_11 (r_compound) overdose_30\NN\84738|NONE_0
C005618_D003693 NONE benzoylecgonine_6\NN\0|and_4 (r_conj) cocaine_4\NN\3492717|NONE_0 (r_pobj) of_3\IN\0|in_31|were_53 (r_prep) concentrations_2\NNS\4916342|edds_9|._102 (r_dobj) had_1\VBD\0|NONE_0 (l_nsubj) edds_0\NNS\6702458|concentrations_9|._111
D003042_D012206 CID cocaine_11\NN\3492717|chronic_8 (r_compound) use_12\NN\407535|that_21|function_26|and_35 (r_nsubj) disrupts_13\VBZ\362348|the_40 (r_acl) hypothesis_8\NN\7162194|NONE_0 (r_pobj) with_6\IN\0|most_16 (r_prep) consistent_5\JJ\0|findings_18|,_90|precipitate_134|._226 (r_acomp) are_3\VBP\13600404|NONE_0 (l_advcl) precipitate_26\VB\15046900|findings_152|consistent_134|,_44|._92 (l_dobj) agitation_27\NN\14373582|coupled_49|,_18|may_16 (l_conj) delirium_29\NN\14391660|,_2 (l_conj) thermoregulation_32\NN\0|,_11 (l_conj) rhabdomyolysis_34\NN\0|aberrant_27|,_2
D003042_D012206 CID cocaine_22\NN\3492717|recent_7 (r_compound) use_23\NN\407535|NONE_0 (r_pobj) with_20\IN\0|when_13 (r_prep) coupled_19\VBN\1295275|,_31|may_33|agitation_49 (r_advcl) precipitate_26\VB\15046900|findings_152|consistent_134|,_44|._92 (l_dobj) agitation_27\NN\14373582|coupled_49|,_18|may_16 (l_conj) delirium_29\NN\14391660|,_2 (l_conj) thermoregulation_32\NN\0|,_11 (l_conj) rhabdomyolysis_34\NN\0|aberrant_27|,_2
D003042_D003693 CID cocaine_4\NN\3492717|NONE_0 (r_compound) use_5\NN\407535|NONE_0 (r_dobj) following_3\VBG\8180190|fatal_23|excited_17 (r_acl) delirium_2\NN\14391660|:_30|findings_46|evidence_67|._110
D003042_D003693 CID cocaine_15\NN\3492717|NONE_0 (r_compound) toxicity_16\NN\13576101|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) mechanisms_13\NNS\13446390|NONE_0 (r_pobj) for_12\IN\0|new_13 (r_prep) evidence_11\NN\5816287|delirium_67|:_37|findings_21|._43 (r_dobj) provide_9\VBP\2199590|NONE_0 (l_dep) delirium_2\NN\14391660|:_30|findings_46|evidence_67|._110
D003042_D003693 CID cocaine_7\NN\3492717|-_7 (r_npadvmod) induced_9\VBN\1627355|excited_8|(_25|edds_26|between_56 (r_amod) delirium_11\NN\14391660|NONE_0
D003042_D003693 CID cocaine_7\NN\3492717|-_7 (r_npadvmod) induced_9\VBN\1627355|excited_8|(_25|edds_26|between_56 (r_amod) delirium_11\NN\14391660|NONE_0 (l_appos) edds_13\NNP\6702458|induced_26|excited_18|(_1|between_30
D003042_D003693 CID cocaine_5\NN\3492717|-_7 (r_npadvmod) related_7\VBN\628491|all_12|in_15 (r_amod) deaths_8\NNS\7296428|NONE_0 (r_pobj) of_3\IN\0|a_11 (r_prep) registry_2\NN\6502378|NONE_0 (r_pobj) from_0\IN\0|,_69|from_71|,_85|edds_90|were_95|with_109|._181 (r_prep) compared_23\VBN\644583|NONE_0 (l_nsubjpass) edds_21\NNS\6702458|from_90|,_21|from_19|,_5|were_5|with_19|._91
D003042_D003693 CID cocaine_5\NN\3492717|-_7 (r_npadvmod) related_7\VBN\628491|all_12|in_15 (r_amod) deaths_8\NNS\7296428|NONE_0 (r_pobj) of_3\IN\0|a_11 (r_prep) registry_2\NN\6502378|NONE_0 (r_pobj) from_0\IN\0|,_69|from_71|,_85|edds_90|were_95|with_109|._181 (r_prep) compared_23\VBN\644583|NONE_0 (l_prep) with_24\IN\0|from_109|,_40|from_38|,_24|edds_19|were_14|._72 (l_pobj) victims_26\NNS\9630641|NONE_0 (l_prep) without_31\IN\0|125_43|of_31 (l_pobj) delirium_33\NN\14391660|NONE_0
D003042_D003693 CID cocaine_29\NN\3492717|accidental_11 (r_compound) overdose_30\NN\84738|NONE_0 (r_pobj) of_27\IN\0|125_12|without_31 (r_prep) victims_26\NNS\9630641|NONE_0 (r_pobj) with_24\IN\0|from_109|,_40|from_38|,_24|edds_19|were_14|._72 (r_prep) compared_23\VBN\644583|NONE_0 (l_nsubjpass) edds_21\NNS\6702458|from_90|,_21|from_19|,_5|were_5|with_19|._91
D003042_D003693 CID cocaine_29\NN\3492717|accidental_11 (r_compound) overdose_30\NN\84738|NONE_0 (r_pobj) of_27\IN\0|125_12|without_31 (r_prep) victims_26\NNS\9630641|NONE_0 (l_prep) without_31\IN\0|125_43|of_31 (l_pobj) delirium_33\NN\14391660|NONE_0
D003042_D003693 CID cocaine_4\NN\3492717|NONE_0 (r_pobj) of_3\IN\0|in_31|were_53 (r_prep) concentrations_2\NNS\4916342|edds_9|._102 (r_dobj) had_1\VBD\0|NONE_0 (l_nsubj) edds_0\NNS\6702458|concentrations_9|._111
D003042_D003693 CID cocaine_11\NN\3492717|chronic_8 (r_compound) use_12\NN\407535|that_21|function_26|and_35 (r_nsubj) disrupts_13\VBZ\362348|the_40 (r_acl) hypothesis_8\NN\7162194|NONE_0 (r_pobj) with_6\IN\0|most_16 (r_prep) consistent_5\JJ\0|findings_18|,_90|precipitate_134|._226 (r_acomp) are_3\VBP\13600404|NONE_0 (l_advcl) precipitate_26\VB\15046900|findings_152|consistent_134|,_44|._92 (l_dobj) agitation_27\NN\14373582|coupled_49|,_18|may_16 (l_conj) delirium_29\NN\14391660|,_2
D003042_D003693 CID cocaine_22\NN\3492717|recent_7 (r_compound) use_23\NN\407535|NONE_0 (r_pobj) with_20\IN\0|when_13 (r_prep) coupled_19\VBN\1295275|,_31|may_33|agitation_49 (r_advcl) precipitate_26\VB\15046900|findings_152|consistent_134|,_44|._92 (l_dobj) agitation_27\NN\14373582|coupled_49|,_18|may_16 (l_conj) delirium_29\NN\14391660|,_2
D003042_D011595 NONE cocaine_11\NN\3492717|chronic_8 (r_compound) use_12\NN\407535|that_21|function_26|and_35 (r_nsubj) disrupts_13\VBZ\362348|the_40 (r_acl) hypothesis_8\NN\7162194|NONE_0 (r_pobj) with_6\IN\0|most_16 (r_prep) consistent_5\JJ\0|findings_18|,_90|precipitate_134|._226 (r_acomp) are_3\VBP\13600404|NONE_0 (l_advcl) precipitate_26\VB\15046900|findings_152|consistent_134|,_44|._92 (l_dobj) agitation_27\NN\14373582|coupled_49|,_18|may_16
D003042_D011595 NONE cocaine_22\NN\3492717|recent_7 (r_compound) use_23\NN\407535|NONE_0 (r_pobj) with_20\IN\0|when_13 (r_prep) coupled_19\VBN\1295275|,_31|may_33|agitation_49 (r_advcl) precipitate_26\VB\15046900|findings_152|consistent_134|,_44|._92 (l_dobj) agitation_27\NN\14373582|coupled_49|,_18|may_16
3934126
D000617_D006311 NONE aminoglycoside_18\NN\0|NONE_0 (r_dobj) receiving_16\VBG\2210855|NONE_0 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) to_14\IN\0|occurred_102|;_47|nephrotoxicity_45|were_14|._55 (r_prep) confined_13\VBN\2510337|NONE_0 (l_nsubjpass) nephrotoxicity_9\NN\0|occurred_57|;_2|were_31|to_45|._100 (l_conj) ototoxicity_11\NN\0|and_4
D014640_D006311 CID vancomycin_20\NNP\2716866|an_23|plus_5 (r_appos) aminoglycoside_18\NN\0|NONE_0 (r_dobj) receiving_16\VBG\2210855|NONE_0 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) to_14\IN\0|occurred_102|;_47|nephrotoxicity_45|were_14|._55 (r_prep) confined_13\VBN\2510337|NONE_0 (l_nsubjpass) nephrotoxicity_9\NN\0|occurred_57|;_2|were_31|to_45|._100 (l_conj) ototoxicity_11\NN\0|and_4
D014640_D007674 NONE vancomycin_20\NNP\2716866|an_23|plus_5 (r_appos) aminoglycoside_18\NN\0|NONE_0 (r_dobj) receiving_16\VBG\2210855|NONE_0 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) to_14\IN\0|occurred_102|;_47|nephrotoxicity_45|were_14|._55 (r_prep) confined_13\VBN\2510337|NONE_0 (l_nsubjpass) nephrotoxicity_9\NN\0|occurred_57|;_2|were_31|to_45|._100
D000617_D007674 NONE aminoglycoside_18\NN\0|NONE_0 (r_dobj) receiving_16\VBG\2210855|NONE_0 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) to_14\IN\0|occurred_102|;_47|nephrotoxicity_45|were_14|._55 (r_prep) confined_13\VBN\2510337|NONE_0 (l_nsubjpass) nephrotoxicity_9\NN\0|occurred_57|;_2|were_31|to_45|._100
D014640_D013924 CID vancomycin_20\NNP\2716866|an_23|plus_5 (r_appos) aminoglycoside_18\NN\0|NONE_0 (r_dobj) receiving_16\VBG\2210855|NONE_0 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) to_14\IN\0|occurred_102|;_47|nephrotoxicity_45|were_14|._55 (r_prep) confined_13\VBN\2510337|NONE_0 (l_ccomp) occurred_1\VBD\0|;_55|nephrotoxicity_57|were_88|to_102|._157 (l_nsubj) thrombophlebitis_0\NNP\14352890|with_31
D014640_D007239 NONE vancomycin_0\NNP\2716866|curative_15|._67 (r_nsubj) was_1\VBD\0|NONE_0 (l_acomp) curative_2\JJ\3740161|vancomycin_15|._52 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) %_5\NN\0|NONE_0 (l_prep) of_6\IN\0|95_4 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|43_12 (l_pobj) infection_11\NN\14052046|NONE_0
D014640_D007239 NONE vancomycin_3\NNP\2716866|that_5|,_10|administered_12|,_38|therapy_68 (r_nsubj) constitutes_8\VBZ\0|we_57|._81 (l_dobj) therapy_12\NN\657604|that_73|vancomycin_68|,_58|administered_56|,_30 (l_prep) for_13\IN\0|safe_24|,_20|effective_18 (l_pobj) infections_14\NNS\14052046|NONE_0
D000617_D013924 NONE aminoglycoside_18\NN\0|NONE_0 (r_dobj) receiving_16\VBG\2210855|NONE_0 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) to_14\IN\0|occurred_102|;_47|nephrotoxicity_45|were_14|._55 (r_prep) confined_13\VBN\2510337|NONE_0 (l_ccomp) occurred_1\VBD\0|;_55|nephrotoxicity_57|were_88|to_102|._157 (l_nsubj) thrombophlebitis_0\NNP\14352890|with_31
16844102
D003676_D009422 NONE dfo_7\NNP\0|alpha_13|-_8|and_4 (r_conj) tc_5\NNP\14625458|that_11|damage_46|by_53 (r_nsubj) ameliorate_8\VB\126264|this_36|._85 (l_dobj) damage_14\NN\7296428|that_57|tc_46|by_7
D008694_D020258 NONE methamphetamine_8\NN\2704153|-_15 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) neurotoxicity_11\NN\0|NONE_0
D008694_D020258 NONE methamphetamine_0\NN\2704153|is_56|associated_74|._130 (l_appos) neurotoxicity_4\NN\0|NONE_0
D008694_D020258 NONE ma)-induced_2\VBN\0|dopaminergic_12 (r_amod) neurotoxicity_4\NN\0|NONE_0
D008694_D020258 NONE ma_34\NNP\10332385|-_2 (r_npadvmod) induced_36\VBN\1627355|the_7 (r_amod) neurotoxicity_37\NN\0|NONE_0
D003676_D005334 NONE dfo_4\NNP\0|alpha_13|-_8|and_4 (r_conj) tc_2\NNP\14625458|hyperthermia_37|as_58|alterations_65|._102 (r_nsubj) attenuated_5\VBD\224901|NONE_0 (l_dobj) hyperthermia_10\NN\14034177|tc_37|as_21|alterations_28|._65
D024502_D009422 NONE tc_5\NNP\14625458|that_11|damage_46|by_53 (r_nsubj) ameliorate_8\VB\126264|this_36|._85 (l_dobj) damage_14\NN\7296428|that_57|tc_46|by_7
D024502_D020258 NONE tocopherol_4\NN\14724645|NONE_0 (l_conj) deferoxamine_6\NN\0|alpha_21|-_16|and_4 (l_prep) on_7\IN\0|NONE_0 (l_pobj) neurotoxicity_11\NN\0|NONE_0
D024502_D020258 NONE tocopherol_8\NN\14724645|NONE_0 (r_pobj) of_5\IN\0|the_11|on_114 (r_prep) effect_4\NN\34213|study_19|._152 (l_prep) on_32\IN\0|the_125|of_114 (l_pobj) neurotoxicity_37\NN\0|NONE_0
D024502_D020258 NONE tc_12\NNP\14625458|alpha_24|-_19|(_7|)_2|,_3|scavenger_7|,_67|chelator_77|,_85 (r_appos) tocopherol_8\NN\14724645|NONE_0 (r_pobj) of_5\IN\0|the_11|on_114 (r_prep) effect_4\NN\34213|study_19|._152 (l_prep) on_32\IN\0|the_125|of_114 (l_pobj) neurotoxicity_37\NN\0|NONE_0
D008694_D005334 CID ma_7\NNP\10332385|-_2 (r_npadvmod) induced_9\VBN\1627355|the_7 (r_amod) hyperthermia_10\NN\14034177|tc_37|as_21|alterations_28|._65
D010100_D020258 NONE oxygen_19\NN\14622893|reactive_9 (r_compound) species_20\NNS\7992450|NONE_0 (r_pobj) of_17\IN\0|a_12|,_26|and_28|dfo_46 (r_prep) scavenger_16\NN\14779550|alpha_31|-_26|(_14|tc_7|)_5|,_4|,_60|chelator_70|,_78 (r_appos) tocopherol_8\NN\14724645|NONE_0 (r_pobj) of_5\IN\0|the_11|on_114 (r_prep) effect_4\NN\34213|study_19|._152 (l_prep) on_32\IN\0|the_125|of_114 (l_pobj) neurotoxicity_37\NN\0|NONE_0
D007501_D020258 NONE iron_29\NN\14625458|an_3 (r_compound) chelator_30\NN\0|alpha_101|-_96|(_84|tc_77|)_75|,_74|scavenger_70|,_10|,_8 (r_appos) tocopherol_8\NN\14724645|NONE_0 (r_pobj) of_5\IN\0|the_11|on_114 (r_prep) effect_4\NN\34213|study_19|._152 (l_prep) on_32\IN\0|the_125|of_114 (l_pobj) neurotoxicity_37\NN\0|NONE_0
D024502_D005334 NONE tc_2\NNP\14625458|hyperthermia_37|as_58|alterations_65|._102 (r_nsubj) attenuated_5\VBD\224901|NONE_0 (l_dobj) hyperthermia_10\NN\14034177|tc_37|as_21|alterations_28|._65
D003676_D020258 NONE deferoxamine_6\NN\0|alpha_21|-_16|and_4 (l_prep) on_7\IN\0|NONE_0 (l_pobj) neurotoxicity_11\NN\0|NONE_0
D003676_D020258 NONE deferoxamine_23\NN\0|(_13|)_17 (r_nmod) dfo_25\NNP\0|a_58|of_46|,_20|and_18 (r_conj) scavenger_16\NN\14779550|alpha_31|-_26|(_14|tc_7|)_5|,_4|,_60|chelator_70|,_78 (r_appos) tocopherol_8\NN\14724645|NONE_0 (r_pobj) of_5\IN\0|the_11|on_114 (r_prep) effect_4\NN\34213|study_19|._152 (l_prep) on_32\IN\0|the_125|of_114 (l_pobj) neurotoxicity_37\NN\0|NONE_0
D003676_D020258 NONE dfo_25\NNP\0|a_58|of_46|,_20|and_18 (r_conj) scavenger_16\NN\14779550|alpha_31|-_26|(_14|tc_7|)_5|,_4|,_60|chelator_70|,_78 (r_appos) tocopherol_8\NN\14724645|NONE_0 (r_pobj) of_5\IN\0|the_11|on_114 (r_prep) effect_4\NN\34213|study_19|._152 (l_prep) on_32\IN\0|the_125|of_114 (l_pobj) neurotoxicity_37\NN\0|NONE_0
D008694_D009422 CID ma_10\NNP\10332385|-_2 (r_npadvmod) induced_12\VBN\1627355|the_7|neuronal_8 (r_amod) damage_14\NN\7296428|that_57|tc_46|by_7
15867025
D006514_D012409 NONE antigen_42\NN\20090|-_7 (r_npadvmod) positive_44\JJ\6321702|b_18|surface_16|,_16|immunity_26 (r_amod) mothers_45\NNS\10399491|NONE_0 (r_pobj) to_38\IN\0|who_14|were_10|to_128 (r_prep) born_37\VBN\0|NONE_0 (r_relcl) infants_34\NNS\9918248|NONE_0 (r_pobj) to_33\IN\0|of_31 (r_prep) administration_27\NN\1133281|administration_69|to_16|,_2 (r_conj) dose_22\NN\3740161|prenatal_96|for_77|,_50 (r_conj) screening_8\NN\6887726|assessment_47|was_36|on_27|:_11|._333 (l_prep) for_9\IN\0|prenatal_19|,_27|dose_77 (l_pobj) b_11\NNP\1355326|NONE_0 (l_conj) rubella_13\NN\14123044|hepatitis_16|and_4
D006514_D012409 NONE antigen_42\NN\20090|-_7 (r_npadvmod) positive_44\JJ\6321702|b_18|surface_16|,_16|immunity_26 (r_amod) mothers_45\NNS\10399491|NONE_0 (l_conj) immunity_48\NN\13920835|b_44|surface_42|positive_26|,_10 (l_compound) rubella_47\NN\14123044|,_16|and_18|administration_22
D006514_D012409 NONE antigen_42\NN\20090|-_7 (r_npadvmod) positive_44\JJ\6321702|b_18|surface_16|,_16|immunity_26 (r_amod) mothers_45\NNS\10399491|NONE_0 (l_conj) immunity_48\NN\13920835|b_44|surface_42|positive_26|,_10 (l_conj) administration_51\NN\1133281|rubella_22|,_6|and_4 (l_prep) of_52\IN\0|NONE_0 (l_pobj) vaccine_58\NN\3562739|NONE_0 (l_compound) rubella_57\NN\14123044|in_23
D006514_D012409 NONE antigen_42\NN\20090|-_7 (r_npadvmod) positive_44\JJ\6321702|b_18|surface_16|,_16|immunity_26 (r_amod) mothers_45\NNS\10399491|NONE_0 (r_pobj) to_38\IN\0|who_14|were_10|to_128 (r_prep) born_37\VBN\0|NONE_0 (l_prep) to_59\TO\0|who_142|were_138|to_128 (l_pobj) women_62\NNS\9605289|NONE_0 (l_compound) rubella_60\VB\14123044|nonimmune_8
D006514_D006509 CID antigen_42\NN\20090|-_7 (r_npadvmod) positive_44\JJ\6321702|b_18|surface_16|,_16|immunity_26 (r_amod) mothers_45\NNS\10399491|NONE_0 (r_pobj) to_38\IN\0|who_14|were_10|to_128 (r_prep) born_37\VBN\0|NONE_0 (r_relcl) infants_34\NNS\9918248|NONE_0 (r_pobj) to_33\IN\0|of_31 (r_prep) administration_27\NN\1133281|administration_69|to_16|,_2 (r_conj) dose_22\NN\3740161|prenatal_96|for_77|,_50 (r_conj) screening_8\NN\6887726|assessment_47|was_36|on_27|:_11|._333 (l_prep) for_9\IN\0|prenatal_19|,_27|dose_77 (l_pobj) b_11\NNP\1355326|NONE_0
D006514_D006509 CID antigen_42\NN\20090|-_7 (r_npadvmod) positive_44\JJ\6321702|b_18|surface_16|,_16|immunity_26 (r_amod) mothers_45\NNS\10399491|NONE_0 (r_pobj) to_38\IN\0|who_14|were_10|to_128 (r_prep) born_37\VBN\0|NONE_0 (r_relcl) infants_34\NNS\9918248|NONE_0 (r_pobj) to_33\IN\0|of_31 (r_prep) administration_27\NN\1133281|administration_69|to_16|,_2 (r_conj) dose_22\NN\3740161|prenatal_96|for_77|,_50 (l_nsubj) administration_15\NN\1133281|to_53|,_67|administration_69 (l_prep) of_16\IN\0|NONE_0 (l_pobj) birth_21\NN\15265518|NONE_0 (l_compound) vaccine_20\NN\3562739|the_16 (l_compound) b_19\NNP\1355326|NONE_0
D006514_D006509 CID antigen_42\NN\20090|-_7 (r_npadvmod) positive_44\JJ\6321702|b_18|surface_16|,_16|immunity_26 (r_amod) mothers_45\NNS\10399491|NONE_0 (r_pobj) to_38\IN\0|who_14|were_10|to_128 (r_prep) born_37\VBN\0|NONE_0 (r_relcl) infants_34\NNS\9918248|NONE_0 (r_pobj) to_33\IN\0|of_31 (r_prep) administration_27\NN\1133281|administration_69|to_16|,_2 (l_prep) of_28\IN\0|to_31 (l_pobj) globulin_32\NN\14736972|NONE_0 (l_compound) b_30\NNP\1355326|immune_2
D006514_D006509 CID antigen_9\NN\20090|-_7 (r_npadvmod) positive_11\JJ\6321702|b_18|surface_16 (r_amod) mothers_12\NNS\10399491|NONE_0 (r_pobj) to_5\IN\0|who_14|were_10 (r_prep) born_4\VBN\0|all_21 (r_relcl) infants_1\NNS\9918248|also_70|globulin_103|._111 (r_nsubj) received_14\VBD\2210855|NONE_0 (l_dobj) globulin_18\NN\14736972|infants_103|also_33|._8 (l_compound) b_16\NN\1355326|immune_2
16471092
C099041_D053201 NONE tolterodine_14\JJ\0|NONE_0 (r_amod) treatment_15\NN\654885|NONE_0 (r_pobj) after_13\IN\0|urinary_83|and_66|quality_62|._27 (r_prep) symptoms_1\NNS\5823932|NONE_0 (l_conj) quality_3\NN\24264|urinary_21|and_4|after_62|._89 (l_prep) of_4\IN\0|NONE_0 (l_pobj) changes_6\NNS\7283608|NONE_0 (l_prep) with_10\IN\0|life_27|in_14 (l_pobj) bladder_12\NN\5515670|NONE_0
C099041_D053201 NONE tolterodine_22\JJ\0|NONE_0 (r_amod) treatment_23\NN\654885|NONE_0 (r_pobj) after_21\IN\0|to_102|symptoms_81 (r_prep) study_3\VB\635850|:_5|._126 (l_dobj) symptoms_6\NNS\5823932|to_21|after_81 (l_conj) quality_8\NN\24264|the_25|urinary_21|and_4 (l_prep) of_9\IN\0|NONE_0 (l_pobj) changes_11\NNS\7283608|NONE_0 (l_prep) with_15\IN\0|life_27|in_14 (l_pobj) bladder_17\NN\5515670|NONE_0
C099041_D053201 NONE tolterodine_22\JJ\0|NONE_0 (r_amod) treatment_23\NN\654885|NONE_0 (r_pobj) after_21\IN\0|to_102|symptoms_81 (r_prep) study_3\VB\635850|:_5|._126 (l_dobj) symptoms_6\NNS\5823932|to_21|after_81 (l_conj) quality_8\NN\24264|the_25|urinary_21|and_4 (l_prep) of_9\IN\0|NONE_0 (l_pobj) changes_11\NNS\7283608|NONE_0 (l_prep) with_15\IN\0|life_27|in_14 (l_pobj) bladder_17\NN\5515670|NONE_0 (l_appos) oab_19\NNP\0|overactive_20|(_1|)_3
C099041_D053201 NONE tolterodine_0\NNP\0|was_12|well_16|and_31|improved_47 (r_nsubjpass) tolerated_3\VBN\802318|NONE_0 (l_conj) improved_7\VBD\126264|tolterodine_47|was_35|well_31|and_16 (l_dobj) quality_9\NN\24264|effects_21|._38 (l_prep) with_15\IN\0|the_34|of_22|in_14 (l_pobj) oab_16\NNP\0|NONE_0
15974569
D005557_D006930 NONE formalin_17\NN\14589223|-_8 (r_npadvmod) induced_19\VBN\1627355|paw_8 (r_amod) licking_21\NN\7291312|NONE_0 (r_pobj) of_16\IN\0|,_31|hyperalgesia_61 (r_prep) reversal_15\NN\199130|three_22|of_9|:_2 (l_conj) hyperalgesia_27\NN\0|of_61|,_30
D005557_D006930 NONE formalin_17\NN\14589223|-_8 (r_npadvmod) induced_19\VBN\1627355|paw_8 (r_amod) licking_21\NN\7291312|NONE_0 (r_pobj) of_16\IN\0|,_31|hyperalgesia_61 (r_prep) reversal_15\NN\199130|three_22|of_9|:_2 (l_conj) hyperalgesia_27\NN\0|of_61|,_30 (l_conj) hyperalgesia_34\NN\0|induced_63|thermal_55|,_35|and_33
D002211_D006930 CID capsaicin_30\NN\15032661|-_9 (r_npadvmod) induced_32\VBN\1627355|mechanical_8 (r_amod) hyperalgesia_34\NN\0|induced_63|thermal_55|,_35|and_33 (r_conj) hyperalgesia_27\NN\0|of_61|,_30
D002211_D006930 CID capsaicin_30\NN\15032661|-_9 (r_npadvmod) induced_32\VBN\1627355|mechanical_8 (r_amod) hyperalgesia_34\NN\0|induced_63|thermal_55|,_35|and_33
D002351_D006930 CID carrageenan_23\NN\14898470|-_11 (r_npadvmod) induced_25\VBN\1627355|thermal_8|,_28|and_30|hyperalgesia_63 (r_amod) hyperalgesia_27\NN\0|of_61|,_30
D002351_D006930 CID carrageenan_23\NN\14898470|-_11 (r_npadvmod) induced_25\VBN\1627355|thermal_8|,_28|and_30|hyperalgesia_63 (r_amod) hyperalgesia_27\NN\0|of_61|,_30 (l_conj) hyperalgesia_34\NN\0|induced_63|thermal_55|,_35|and_33
D002351_D010146 NONE carrageenan_23\NN\14898470|-_11 (r_npadvmod) induced_25\VBN\1627355|thermal_8|,_28|and_30|hyperalgesia_63 (r_amod) hyperalgesia_27\NN\0|of_61|,_30 (r_conj) reversal_15\NN\199130|three_22|of_9|:_2 (r_appos) models_11\NNS\5888929|NONE_0 (l_prep) of_12\IN\0|three_13|:_7|reversal_9 (l_pobj) pain_13\NN\14299637|NONE_0
D007608_D010146 NONE kainate_7\NN\0|potent_27|glur5_6|receptor_8 (r_compound) antagonists_9\NNS\7846|in_20 (r_compound) actives_10\NNS\14779550|NONE_0 (l_prep) in_11\IN\13603305|antagonists_20 (l_pobj) models_14\NNS\5888929|NONE_0 (l_prep) of_15\IN\0|three_20|animal_14 (l_pobj) pain_16\NN\14299637|NONE_0
D005557_D010146 NONE formalin_17\NN\14589223|-_8 (r_npadvmod) induced_19\VBN\1627355|paw_8 (r_amod) licking_21\NN\7291312|NONE_0 (r_pobj) of_16\IN\0|,_31|hyperalgesia_61 (r_prep) reversal_15\NN\199130|three_22|of_9|:_2 (r_appos) models_11\NNS\5888929|NONE_0 (l_prep) of_12\IN\0|three_13|:_7|reversal_9 (l_pobj) pain_13\NN\14299637|NONE_0
D002211_D010146 NONE capsaicin_30\NN\15032661|-_9 (r_npadvmod) induced_32\VBN\1627355|mechanical_8 (r_amod) hyperalgesia_34\NN\0|induced_63|thermal_55|,_35|and_33 (r_conj) hyperalgesia_27\NN\0|of_61|,_30 (r_conj) reversal_15\NN\199130|three_22|of_9|:_2 (r_appos) models_11\NNS\5888929|NONE_0 (l_prep) of_12\IN\0|three_13|:_7|reversal_9 (l_pobj) pain_13\NN\14299637|NONE_0
6504332
D010634_D004409 CID phenobarbital_0\NN\2792049|-_13 (r_npadvmod) induced_2\VBN\1627355|in_19|._53 (r_amod) dyskinesia_3\NN\14084880|NONE_0
D010634_D004409 CID phenobarbital_15\JJ\2792049|for_22 (r_amod) therapy_16\NN\657604|NONE_0 (r_dobj) starting_14\VBG\457382|soon_11 (r_pcomp) after_13\IN\0|child_67|dyskinesia_16|._49 (r_prep) developed_9\VBD\1753788|NONE_0 (l_dobj) dyskinesia_11\JJ\14084880|child_51|after_16|._65
D010634_D004409 CID phenobarbital_4\JJ\2792049|NONE_0 (r_pobj) with_3\IN\0|repeat_17 (r_prep) challenge_2\NN\13927383|NONE_0 (r_pobj) on_0\IN\0|,_38|dyskinesia_44|._63 (r_prep) recurred_8\VBD\339934|NONE_0 (l_nsubj) dyskinesia_7\NN\14084880|on_44|,_6|._19
D010634_D009069 NONE phenobarbital_0\NN\2792049|should_14|be_21|to_30|._99 (r_nsubjpass) added_3\VBN\156601|NONE_0 (l_prep) to_4\IN\0|phenobarbital_30|should_16|be_9|._69 (l_pobj) list_6\NN\6637824|NONE_0 (l_prep) of_7\IN\0|the_9 (l_pobj) drugs_9\NNS\14778436|NONE_0 (l_relcl) cause_12\VB\7323922|anticonvulsant_30 (l_dobj) disorders_14\NNS\14034177|that_24|can_19
D010634_D012640 NONE phenobarbital_15\JJ\2792049|for_22 (r_amod) therapy_16\NN\657604|NONE_0 (l_prep) for_17\IN\0|phenobarbital_22 (l_pobj) seizures_18\NNS\14081375|NONE_0
D010634_D009422 NONE phenobarbital_0\NN\2792049|-_13 (r_npadvmod) induced_2\VBN\1627355|in_19|._53 (r_amod) dyskinesia_3\NN\14084880|NONE_0 (l_prep) in_4\IN\13603305|induced_19|._34 (l_pobj) child_9\NN\9622049|NONE_0 (l_amod) impaired_8\VBN\258857|a_17
D010634_D009422 NONE phenobarbital_15\JJ\2792049|for_22 (r_amod) therapy_16\NN\657604|NONE_0 (r_dobj) starting_14\VBG\457382|soon_11 (r_pcomp) after_13\IN\0|child_67|dyskinesia_16|._49 (r_prep) developed_9\VBD\1753788|NONE_0 (l_nsubj) child_4\NN\9622049|dyskinesia_51|after_67|._116 (l_prep) with_5\IN\0|a_19|old_10 (l_pobj) impairment_8\NN\7296428|NONE_0
18356633
D000583_D007674 CID amikacin_3\JJ\0|in_24 (r_amod) nephrotoxicity_4\NN\0|NONE_0
D000583_D007674 CID amikacin_2\RB\0|-_8 (r_npadvmod) associated_4\VBN\628491|NONE_0 (r_amod) nephrotoxicity_5\NN\0|to_32|in_15
D000583_D007674 CID amikacin_17\JJ\0|NONE_0 (r_prep) via_16\IN\0|of_12 (r_prep) evaluation_13\NN\874067|serum_21|and_4 (r_conj) creatinine_11\NN\0|NONE_0 (r_pobj) in_9\IN\13603305|an_12 (r_prep) increase_8\NN\13576355|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) means_5\NNS\44150|NONE_0 (r_pobj) by_4\IN\0|the_33|of_18 (r_prep) occurrence_1\NN\29378|were_160|._173 (l_prep) of_2\IN\0|the_15|by_18 (l_pobj) nephrotoxicity_3\NN\0|NONE_0
D000617_D009369 NONE aminoglycoside_17\NN\0|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) treatment_14\NN\654885|that_14 (r_dobj) required_13\VBD\0|a_38|oncologic_24 (r_relcl) disorder_11\NN\14034177|NONE_0
D000583_D009503 NONE amikacin_0\NNP\0|aminoglycoside_15|._150 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) aminoglycoside_3\NN\0|amikacin_15|._135 (l_acl) used_5\VBN\0|an_27 (l_xcomp) provide_7\VB\2199590|commonly_17 (l_dobj) treatment_13\NN\654885|to_42 (l_prep) for_14\IN\0|empirical_41|double_31|negative_19 (l_pobj) neutropenia_16\NN\14196405|NONE_0
D003404_D007674 NONE creatinine_11\NN\0|NONE_0 (r_pobj) in_9\IN\13603305|an_12 (r_prep) increase_8\NN\13576355|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) means_5\NNS\44150|NONE_0 (r_pobj) by_4\IN\0|the_33|of_18 (r_prep) occurrence_1\NN\29378|were_160|._173 (l_prep) of_2\IN\0|the_15|by_18 (l_pobj) nephrotoxicity_3\NN\0|NONE_0
D000583_D007239 NONE amikacin_0\NNP\0|aminoglycoside_15|._150 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) aminoglycoside_3\NN\0|amikacin_15|._135 (l_acl) used_5\VBN\0|an_27 (l_xcomp) provide_7\VB\2199590|commonly_17 (l_dobj) treatment_13\NN\654885|to_42 (l_prep) for_14\IN\0|empirical_41|double_31|negative_19 (l_pobj) neutropenia_16\NN\14196405|NONE_0 (l_conj) infections_20\NNS\14052046|febrile_40|and_20
D000617_D007239 NONE aminoglycoside_3\NN\0|amikacin_15|._135 (l_acl) used_5\VBN\0|an_27 (l_xcomp) provide_7\VB\2199590|commonly_17 (l_dobj) treatment_13\NN\654885|to_42 (l_prep) for_14\IN\0|empirical_41|double_31|negative_19 (l_pobj) neutropenia_16\NN\14196405|NONE_0 (l_conj) infections_20\NNS\14052046|febrile_40|and_20
D000617_D006402 NONE aminoglycoside_17\NN\0|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) treatment_14\NN\654885|that_14 (r_dobj) required_13\VBD\0|a_38|oncologic_24 (r_relcl) disorder_11\NN\14034177|NONE_0
D000583_D006402 NONE amikacin_27\JJ\0|NONE_0 (r_pobj) to_20\IN\0|patients_138|were_16|._52 (r_prep) randomized_19\VBN\278117|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_122|to_138|._190 (l_prep) with_2\IN\0|forty_15 (l_pobj) diagnosis_4\NN\152018|NONE_0 (l_amod) consistent_5\JJ\0|a_12 (l_prep) with_6\IN\0|NONE_0 (l_pobj) disorder_11\NN\14034177|NONE_0
D000617_D009503 NONE aminoglycoside_3\NN\0|amikacin_15|._135 (l_acl) used_5\VBN\0|an_27 (l_xcomp) provide_7\VB\2199590|commonly_17 (l_dobj) treatment_13\NN\654885|to_42 (l_prep) for_14\IN\0|empirical_41|double_31|negative_19 (l_pobj) neutropenia_16\NN\14196405|NONE_0
D000583_D009369 NONE amikacin_27\JJ\0|NONE_0 (r_pobj) to_20\IN\0|patients_138|were_16|._52 (r_prep) randomized_19\VBN\278117|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_122|to_138|._190 (l_prep) with_2\IN\0|forty_15 (l_pobj) diagnosis_4\NN\152018|NONE_0 (l_amod) consistent_5\JJ\0|a_12 (l_prep) with_6\IN\0|NONE_0 (l_pobj) disorder_11\NN\14034177|NONE_0
1564236
D013793_D023921 NONE thallium-201_18\JJ\0|emission_27 (r_amod) tomography_23\NN\900375|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) correlation_16\NN\13841213|relation_119|with_80|:_2|._63 (r_appos) observed_4\VBN\2163746|NONE_0 (l_prep) with_5\IN\0|relation_39|:_78|correlation_80|._143 (l_pobj) contrast_7\NN\13854649|NONE_0 (l_prep) to_9\IN\0|myocardial_37|echocardiography_17 (l_pobj) severity_11\NN\5036394|NONE_0 (l_prep) of_12\IN\0|the_13 (l_pobj) stenosis_14\NN\14204950|NONE_0
D004176_D023921 NONE dipyridamole_1\NN\0|-_12 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (r_amod) hyperemia_4\NN\14320394|NONE_0 (r_pobj) during_0\IN\0|,_37|12_39|area_104|by_126|._154 (r_prep) had_16\VBD\0|NONE_0 (l_nsubj) 12_6\CD\13745420|during_39|,_2|area_65|by_87|._115 (l_prep) of_7\IN\0|NONE_0 (l_pobj) dogs_10\NNS\2083346|NONE_0 (l_prep) with_11\IN\0|the_12|16_8 (l_pobj) stenosis_15\NN\14204950|NONE_0
D004176_D006940 CID dipyridamole_1\NN\0|-_12 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (r_amod) hyperemia_4\NN\14320394|NONE_0
D004176_D006940 CID dipyridamole_24\NN\0|-_12 (r_npadvmod) induced_26\VBN\1627355|NONE_0 (r_amod) hyperemia_27\NN\14320394|NONE_0
D004176_D006940 CID dipyridamole_11\NN\0|-_12 (r_npadvmod) induced_13\VBN\1627355|NONE_0 (r_amod) hyperemia_14\NN\14320394|NONE_0
9305828
D010862_D012640 NONE pilocarpine_1\NN\14712692|model_19|is_37|by_54|._162 (r_nsubjpass) characterized_9\VBN\609683|NONE_0 (l_agent) by_10\IN\0|pilocarpine_54|model_35|is_17|._108 (l_pobj) period_13\NN\13575869|NONE_0 (l_acl) followed_17\VBN\1835496|an_38|acute_35|of_22 (l_agent) by_18\IN\0|NONE_0 (l_pobj) seizures_21\NNS\14081375|NONE_0
D010862_D012640 NONE pilo_3\NNP\0|(_1|)_4|of_12 (r_nmod) model_5\NN\5888929|pilocarpine_19|is_18|by_35|._143 (r_nsubjpass) characterized_9\VBN\609683|NONE_0 (l_agent) by_10\IN\0|pilocarpine_54|model_35|is_17|._108 (l_pobj) period_13\NN\13575869|NONE_0 (l_acl) followed_17\VBN\1835496|an_38|acute_35|of_22 (l_agent) by_18\IN\0|NONE_0 (l_pobj) seizures_21\NNS\14081375|NONE_0
D010862_D004827 NONE pilocarpine_1\NN\14712692|model_19|is_37|by_54|._162 (r_nsubjpass) characterized_9\VBN\609683|NONE_0 (l_nsubjpass) model_5\NN\5888929|pilocarpine_19|is_18|by_35|._143 (l_prep) of_6\IN\0|(_13|pilo_12|)_8 (l_pobj) epilepsy_7\NN\14085708|NONE_0
D010862_D004827 NONE pilo_3\NNP\0|(_1|)_4|of_12 (r_nmod) model_5\NN\5888929|pilocarpine_19|is_18|by_35|._143 (l_prep) of_6\IN\0|(_13|pilo_12|)_8 (l_pobj) epilepsy_7\NN\14085708|NONE_0
D010862_D013226 NONE pilocarpine_1\NN\14712692|model_19|is_37|by_54|._162 (r_nsubjpass) characterized_9\VBN\609683|NONE_0 (l_agent) by_10\IN\0|pilocarpine_54|model_35|is_17|._108 (l_pobj) period_13\NN\13575869|NONE_0 (l_prep) of_14\IN\0|an_16|acute_13|followed_22 (l_pobj) epilepticus_16\NN\0|NONE_0
D010862_D013226 NONE pilo_3\NNP\0|(_1|)_4|of_12 (r_nmod) model_5\NN\5888929|pilocarpine_19|is_18|by_35|._143 (r_nsubjpass) characterized_9\VBN\609683|NONE_0 (l_agent) by_10\IN\0|pilocarpine_54|model_35|is_17|._108 (l_pobj) period_13\NN\13575869|NONE_0 (l_prep) of_14\IN\0|an_16|acute_13|followed_22 (l_pobj) epilepticus_16\NN\0|NONE_0
D010862_D004833 CID pilocarpine_6\NN\14712692|the_4|of_18 (r_amod) model_7\NN\5888929|NONE_0 (l_prep) of_8\IN\0|the_22|pilocarpine_18 (l_pobj) epilepsy_11\NN\14085708|NONE_0
D010862_D004833 CID pilo_30\NNP\0|the_4|of_11 (r_amod) model_31\NN\5888929|NONE_0 (l_prep) of_32\IN\0|the_15|pilo_11 (l_pobj) tle_33\NNP\0|NONE_0
D010862_D001930 NONE pilocarpine_1\NN\14712692|model_19|is_37|by_54|._162 (r_nsubjpass) characterized_9\VBN\609683|NONE_0 (l_agent) by_10\IN\0|pilocarpine_54|model_35|is_17|._108 (l_pobj) period_13\NN\13575869|NONE_0 (l_acl) followed_17\VBN\1835496|an_38|acute_35|of_22 (l_agent) by_18\IN\0|NONE_0 (l_pobj) seizures_21\NNS\14081375|NONE_0 (l_conj) damage_25\NN\7296428|spontaneous_49|recurrent_37|and_18
D010862_D001930 NONE pilo_3\NNP\0|(_1|)_4|of_12 (r_nmod) model_5\NN\5888929|pilocarpine_19|is_18|by_35|._143 (r_nsubjpass) characterized_9\VBN\609683|NONE_0 (l_agent) by_10\IN\0|pilocarpine_54|model_35|is_17|._108 (l_pobj) period_13\NN\13575869|NONE_0 (l_acl) followed_17\VBN\1835496|an_38|acute_35|of_22 (l_agent) by_18\IN\0|NONE_0 (l_pobj) seizures_21\NNS\14081375|NONE_0 (l_conj) damage_25\NN\7296428|spontaneous_49|recurrent_37|and_18
7791169
D016595_D010146 NONE misoprostol_2\NNP\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) addition_0\NN\3081021|can_24|impairment_48|without_59|._89 (r_nsubj) minimize_4\VB\441445|NONE_0 (l_prep) without_8\IN\0|addition_59|can_35|impairment_11|._30 (l_pcomp) affecting_9\VBG\126264|NONE_0 (l_dobj) control_11\NN\5190804|NONE_0 (l_compound) pain_10\NN\14299637|NONE_0
D016595_D007674 NONE misoprostol_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|protective_18 (r_prep) effect_1\NN\34213|dysfunction_52|._83 (r_nsubj) induced_6\VBD\1627355|NONE_0 (l_dobj) dysfunction_8\NN\14204950|effect_52|._31
D016595_D007674 NONE misoprostol_2\NNP\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) addition_0\NN\3081021|can_24|impairment_48|without_59|._89 (r_nsubj) minimize_4\VB\441445|NONE_0 (l_dobj) impairment_7\NN\7296428|addition_48|can_24|without_11|._41
D007213_D007674 CID indomethacin_5\NN\3828465|NONE_0 (r_pobj) on_4\IN\0|NONE_0 (r_prep) misoprostol_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|protective_18 (r_prep) effect_1\NN\34213|dysfunction_52|._83 (r_nsubj) induced_6\VBD\1627355|NONE_0 (l_dobj) dysfunction_8\NN\14204950|effect_52|._31
D007213_D007674 CID indomethacin_8\NN\3828465|related_13|renal_21 (r_nmod) dysfunction_11\NN\14204950|NONE_0
2021202
D007530_D007022 CID isoflurane_6\RB\3570838|-_10 (r_npadvmod) induced_8\VBN\1627355|prolonged_21|in_20 (r_amod) hypotension_9\NN\14057371|NONE_0
D007530_D007022 CID isoflurane_3\RB\3570838|-_10 (r_npadvmod) induced_5\VBN\1627355|on_20 (r_amod) hypotension_6\NN\14057371|NONE_0
D007530_D007022 CID isoflurane_11\NN\3570838|the_4|inspired_11 (r_amod) concentration_13\NN\4916342|maintain_17 (r_dobj) increasing_9\VBG\169651|NONE_0 (r_pcomp) by_8\IN\0|hypotension_47|was_35|for_23|mmhg_105|._109 (r_prep) induced_2\VBN\1627355|NONE_0 (l_nsubjpass) hypotension_0\NNP\14057371|was_12|for_24|by_47|mmhg_152|._156
D007530_D007022 CID isoflurane_9\RB\3570838|-_10 (r_npadvmod) induced_11\VBN\1627355|and_20 (r_amod) hypotension_12\NN\14057371|NONE_0
17285209
D000809_D000799 NONE angiotensin_3\NN\4522421|-_11 (r_npadvmod) converting_5\VBG\126264|(_18|ace_19|)_22|and_24|blocker_49 (r_amod) enzyme_6\NN\14723628|NONE_0 (r_pobj) of_2\IN\0|the_16 (r_prep) recognition_1\NN\13932421|(_84|angioedema_101|challenge_126|._212 (r_nsubj) constitutes_19\VBZ\0|NONE_0 (l_nsubj) angioedema_18\NN\14316714|recognition_101|(_17|challenge_25|._111
D000809_D000799 NONE angiotensin_11\NN\4522421|receptor_12 (r_compound) blocker_13\NN\10101634|converting_49|(_31|ace_30|)_27|and_25 (r_conj) enzyme_6\NN\14723628|NONE_0 (r_pobj) of_2\IN\0|the_16 (r_prep) recognition_1\NN\13932421|(_84|angioedema_101|challenge_126|._212 (r_nsubj) constitutes_19\VBZ\0|NONE_0 (l_nsubj) angioedema_18\NN\14316714|recognition_101|(_17|challenge_25|._111
D000809_D007410 NONE angiotensin_3\NN\4522421|-_11 (r_npadvmod) converting_5\VBG\126264|(_18|ace_19|)_22|and_24|blocker_49 (r_amod) enzyme_6\NN\14723628|NONE_0 (r_pobj) of_2\IN\0|the_16 (r_prep) recognition_1\NN\13932421|(_84|angioedema_101|challenge_126|._212 (r_nsubj) constitutes_19\VBZ\0|NONE_0 (l_nsubj) angioedema_18\NN\14316714|recognition_101|(_17|challenge_25|._111
D000809_D007410 NONE angiotensin_11\NN\4522421|receptor_12 (r_compound) blocker_13\NN\10101634|converting_49|(_31|ace_30|)_27|and_25 (r_conj) enzyme_6\NN\14723628|NONE_0 (r_pobj) of_2\IN\0|the_16 (r_prep) recognition_1\NN\13932421|(_84|angioedema_101|challenge_126|._212 (r_nsubj) constitutes_19\VBZ\0|NONE_0 (l_nsubj) angioedema_18\NN\14316714|recognition_101|(_17|challenge_25|._111
C044946_D006973 NONE benazapril_28\NN\0|10/5_11 (r_compound) mg._30\CD\0|a_49|combination_47|of_30|/_17 (r_appos) pill_24\NN\4424218|NONE_0 (r_pobj) on_21\IN\0|who_16|was_12 (r_prep) started_20\VBN\0|a_81|45-year_79|old_71|american_59|with_43|,_10 (r_relcl) female_12\NN\15388|NONE_0 (l_prep) with_13\IN\0|a_38|45-year_36|old_28|american_16|,_33|started_43 (l_pobj) hypertension_16\NN\14057371|NONE_0
D017311_D006973 NONE amlodipine_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|a_19|combination_17|/_13|mg._30 (r_prep) pill_24\NN\4424218|NONE_0 (r_pobj) on_21\IN\0|who_16|was_12 (r_prep) started_20\VBN\0|a_81|45-year_79|old_71|american_59|with_43|,_10 (r_relcl) female_12\NN\15388|NONE_0 (l_prep) with_13\IN\0|a_38|45-year_36|old_28|american_16|,_33|started_43 (l_pobj) hypertension_16\NN\14057371|NONE_0
7752389
D011453_D053201 NONE prostanoids_0\NNS\0|may_12|,_15|via_17|,_43|to_56|._153 (r_nsubj) contribute_8\VBP\126264|NONE_0 (l_prep) to_9\IN\0|prostanoids_56|may_44|,_41|via_39|,_13|._97 (l_pobj) urge_11\VB\23773|NONE_0 (l_conj) hyperactivity_14\NN\14052403|both_22|and_12|seen_14
D015232_D053201 CID e2-induced_1\JJ\0|prostaglandin_14|bladder_11|in_33|?_86 (r_amod) hyperactivity_3\NN\14052403|NONE_0
D015320_D053201 NONE tachykinins_12\NNS\0|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) involvement_10\NN\1080366|normal_24|,_18|conscious_16|:_2 (r_appos) rats_8\NNS\2329401|NONE_0 (r_pobj) in_4\IN\13603305|prostaglandin_47|e2-induced_33|bladder_22|?_53 (r_prep) hyperactivity_3\NN\14052403|NONE_0
D015320_D053201 NONE tachykinins_6\NNS\0|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) release_4\NN\3748886|NONE_0 (r_pobj) via_3\IN\0|prostanoids_17|may_5|,_2|,_26|to_39|._136 (r_prep) contribute_8\VBP\126264|NONE_0 (l_prep) to_9\IN\0|prostanoids_56|may_44|,_41|via_39|,_13|._97 (l_pobj) urge_11\VB\23773|NONE_0 (l_conj) hyperactivity_14\NN\14052403|both_22|and_12|seen_14
12907924
D008774_D000544 NONE methylphenidate_18\NN\4320126|NONE_0 (r_pobj) on_17\IN\0|man_82|was_12|._18 (r_prep) started_16\VBN\0|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_70|on_82|._100 (l_prep) with_5\IN\0|an_19|old_8 (l_pobj) depression_9\NN\14373582|NONE_0 (l_conj) disease_14\NN\14061805|resistant_43|and_22
D008774_D009771 CID methylphenidate_0\NNP\4320126|-_15 (r_npadvmod) induced_2\VBN\1627355|compulsive_18|in_38|._55 (r_amod) symptoms_6\NNS\5823932|NONE_0
D008774_D009771 CID methylphenidate_12\NN\4320126|when_5|was_16|by_29 (r_nsubjpass) replaced_14\VBN\1631072|over_44 (r_advcl) diminished_7\VBN\169651|behavior_20|but_4|._78 (r_conj) ensued_5\VBD\2633881|NONE_0 (l_nsubj) behavior_4\NN\407535|but_16|diminished_20|._98
D016666_D009771 NONE fluvoxamine_16\NN\0|NONE_0 (r_pobj) by_15\IN\0|when_34|methylphenidate_29|was_13 (r_agent) replaced_14\VBN\1631072|over_44 (r_advcl) diminished_7\VBN\169651|behavior_20|but_4|._78 (r_conj) ensued_5\VBD\2633881|NONE_0 (l_nsubj) behavior_4\NN\407535|but_16|diminished_20|._98
D008774_D061218 NONE methylphenidate_18\NN\4320126|NONE_0 (r_pobj) on_17\IN\0|man_82|was_12|._18 (r_prep) started_16\VBN\0|NONE_0 (l_nsubjpass) man_4\NN\9605289|was_70|on_82|._100 (l_prep) with_5\IN\0|an_19|old_8 (l_pobj) depression_9\NN\14373582|NONE_0
8643973
D017239_D010051 NONE paclitaxel_0\NNP\0|NONE_0 (l_acl) combined_1\VBD\2630189|._80 (l_prep) in_4\IN\13603305|with_17 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) of_10\IN\0|the_25|line_15 (l_pobj) cancer_13\NN\14239425|NONE_0
D017239_D010051 NONE paclitaxel_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|the_27|maximum_23|tolerated_15|taxol_15 (r_prep) dose_10\NN\3740161|to_35|given_72 (r_dobj) determine_6\VB\0|in_22|i_11|escalated_251 (l_prep) given_26\VBN\5892096|to_107|dose_72 (l_prep) as_27\IN\14622893|NONE_0 (l_pobj) infusion_30\NN\14589223|NONE_0 (l_acl) administered_35\VBN\2436349|a_50|3-hour_48|in_32 (l_prep) to_39\IN\0|days_5 (l_pobj) women_40\NNS\9605289|NONE_0 (l_prep) with_41\IN\0|NONE_0 (l_pobj) cancer_44\NN\14239425|NONE_0
D017239_D010051 NONE taxol_14\NNP\0|the_42|maximum_38|tolerated_30|of_15 (r_appos) dose_10\NN\3740161|to_35|given_72 (r_dobj) determine_6\VB\0|in_22|i_11|escalated_251 (l_prep) given_26\VBN\5892096|to_107|dose_72 (l_prep) as_27\IN\14622893|NONE_0 (l_pobj) infusion_30\NN\14589223|NONE_0 (l_acl) administered_35\VBN\2436349|a_50|3-hour_48|in_32 (l_prep) to_39\IN\0|days_5 (l_pobj) women_40\NNS\9605289|NONE_0 (l_prep) with_41\IN\0|NONE_0 (l_pobj) cancer_44\NN\14239425|NONE_0
D017239_D010051 NONE paclitaxel_46\NN\0|NONE_0 (r_compound) doses_47\NNS\3740161|were_6|follows_24|level_33|._114 (r_nsubjpass) escalated_49\VBN\153263|in_273|i_262|determine_251 (r_conj) study_4\VBP\635850|NONE_0 (l_xcomp) determine_6\VB\0|in_22|i_11|escalated_251 (l_prep) given_26\VBN\5892096|to_107|dose_72 (l_prep) as_27\IN\14622893|NONE_0 (l_pobj) infusion_30\NN\14589223|NONE_0 (l_acl) administered_35\VBN\2436349|a_50|3-hour_48|in_32 (l_prep) to_39\IN\0|days_5 (l_pobj) women_40\NNS\9605289|NONE_0 (l_prep) with_41\IN\0|NONE_0 (l_pobj) cancer_44\NN\14239425|NONE_0
D016190_D010051 NONE carboplatin_3\NN\0|NONE_0 (r_pobj) with_2\IN\0|in_17 (r_prep) combined_1\VBD\2630189|._80 (l_prep) in_4\IN\13603305|with_17 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) of_10\IN\0|the_25|line_15 (l_pobj) cancer_13\NN\14239425|NONE_0
D016190_D010051 NONE carboplatin_34\NN\0|NONE_0 (r_pobj) with_33\IN\0|NONE_0 (r_prep) combination_32\NN\7951464|NONE_0 (r_pobj) in_31\IN\13603305|a_18|3-hour_16|administered_32 (r_prep) infusion_30\NN\14589223|NONE_0 (l_acl) administered_35\VBN\2436349|a_50|3-hour_48|in_32 (l_prep) to_39\IN\0|days_5 (l_pobj) women_40\NNS\9605289|NONE_0 (l_prep) with_41\IN\0|NONE_0 (l_pobj) cancer_44\NN\14239425|NONE_0
11912119
D007980_D004409 CID levodopa_3\RB\14604959|-_8 (r_npadvmod) induced_5\VBN\1627355|in_20 (r_amod) dyskinesias_6\NNS\14084880|force_36|and_21|._34
D007980_D004409 CID levodopa_18\NN\14604959|NONE_0 (r_compound) therapy_19\NN\657604|NONE_0 (r_pobj) of_17\IN\0|motor_20 (r_prep) complications_16\NNS\1073995|NONE_0 (r_pobj) to_14\IN\0|its_17 (r_prep) relationship_13\NN\31921|parkinson_28|and_8 (r_conj) disease_10\NN\14061805|NONE_0 (r_pobj) in_7\IN\13603305|we_43|coordination_25|,_86|to_101|._138 (r_prep) assessed_1\VBD\670261|NONE_0 (l_prep) to_22\IN\0|we_144|coordination_126|in_101|,_15|._37 (l_pobj) dyskinesias_26\NNS\14084880|particularly_33
D007980_D004409 CID levodopa_18\NN\14604959|NONE_0 (r_compound) therapy_19\NN\657604|NONE_0 (r_pobj) of_17\IN\0|motor_20 (r_prep) complications_16\NNS\1073995|NONE_0 (r_pobj) to_14\IN\0|its_17 (r_prep) relationship_13\NN\31921|parkinson_28|and_8 (r_conj) disease_10\NN\14061805|NONE_0 (r_pobj) in_7\IN\13603305|we_43|coordination_25|,_86|to_101|._138 (r_prep) assessed_1\VBD\670261|NONE_0 (l_prep) to_22\IN\0|we_144|coordination_126|in_101|,_15|._37 (l_pobj) dyskinesias_26\NNS\14084880|particularly_33 (l_appos) lid_28\NNP\5313679|induced_21|(_1|)_3
D007980_D004409 CID levodopa_23\VB\14604959|-_8 (r_npadvmod) induced_25\VBN\1627355|(_20|lid_21|)_24 (r_amod) dyskinesias_26\NNS\14084880|particularly_33
D007980_D004409 CID levodopa_23\VB\14604959|-_8 (r_npadvmod) induced_25\VBN\1627355|(_20|lid_21|)_24 (r_amod) dyskinesias_26\NNS\14084880|particularly_33 (l_appos) lid_28\NNP\5313679|induced_21|(_1|)_3
D007980_D004409 CID levodopa_23\NN\14604959|-_8 (r_npadvmod) induced_25\VBN\1627355|(_20|lid_43 (r_amod) dyskinesias_26\NNS\14084880|NONE_0 (r_pobj) without_22\IN\0|disease_27|)_6|and_4 (r_conj) with_9\IN\0|we_54|groups_39|._151 (l_pobj) disease_13\NN\14061805|)_21|and_23|without_27 (l_conj) lid_15\NNP\5313679|(_23|parkinson_22|+_2|,_3|n_5|23_9
D007980_D004409 CID levodopa_23\NN\14604959|-_8 (r_npadvmod) induced_25\VBN\1627355|(_20|lid_43 (r_amod) dyskinesias_26\NNS\14084880|NONE_0
D007980_D004409 CID levodopa_23\NN\14604959|-_8 (r_npadvmod) induced_25\VBN\1627355|(_20|lid_43 (r_amod) dyskinesias_26\NNS\14084880|NONE_0 (l_appos) lid_32\NNP\5313679|induced_43|(_23
D007980_D004409 CID levodopa_28\RB\14604959|score_133|were_25|._8 (r_dobj) assessed_24\VBN\670261|NONE_0 (l_nsubjpass) score_2\NN\5736149|were_108|levodopa_133|._141 (l_prep) of_3\IN\0|the_16|motor_12 (l_pobj) scale_10\NNP\7260623|NONE_0 (l_appos) score_14\NN\5736149|parkinson_47|rating_27|,_15 (l_compound) dyskinesia_13\JJ\14084880|a_2|and_17|force_21|in_27
D007980_D004409 CID levodopa_21\NN\14604959|NONE_0 (r_pobj) by_20\IN\0|in_120|,_92|force_86|was_28|significantly_24|)_29|._30 (r_agent) increased_19\VBN\169651|NONE_0 (l_prep) in_0\IN\13603305|,_28|force_34|was_92|significantly_96|by_120|)_149|._150 (l_pobj) disease_3\NN\14061805|NONE_0 (l_conj) lid_5\NNP\5313679|parkinson_22|+_2
D007980_D010300 NONE levodopa_3\RB\14604959|-_8 (r_npadvmod) induced_5\VBN\1627355|in_20 (r_amod) dyskinesias_6\NNS\14084880|force_36|and_21|._34 (l_prep) in_7\IN\13603305|induced_20 (l_pobj) disease_10\NN\14061805|NONE_0
D007980_D010300 NONE levodopa_18\NN\14604959|NONE_0 (r_compound) therapy_19\NN\657604|NONE_0 (r_pobj) of_17\IN\0|motor_20 (r_prep) complications_16\NNS\1073995|NONE_0 (r_pobj) to_14\IN\0|its_17 (r_prep) relationship_13\NN\31921|parkinson_28|and_8 (r_conj) disease_10\NN\14061805|NONE_0
D007980_D010300 NONE levodopa_23\VB\14604959|-_8 (r_npadvmod) induced_25\VBN\1627355|(_20|lid_21|)_24 (r_amod) dyskinesias_26\NNS\14084880|particularly_33 (r_pobj) to_22\IN\0|we_144|coordination_126|in_101|,_15|._37 (r_prep) assessed_1\VBD\670261|NONE_0 (l_prep) in_7\IN\13603305|we_43|coordination_25|,_86|to_101|._138 (l_pobj) disease_10\NN\14061805|NONE_0
D007980_D010300 NONE levodopa_23\NN\14604959|-_8 (r_npadvmod) induced_25\VBN\1627355|(_20|lid_43 (r_amod) dyskinesias_26\NNS\14084880|NONE_0 (r_pobj) without_22\IN\0|disease_27|)_6|and_4 (r_conj) with_9\IN\0|we_54|groups_39|._151 (r_prep) studied_1\VBD\0|NONE_0 (l_dobj) groups_3\NNS\2137|we_15|with_39|._190 (l_prep) of_4\IN\0|two_11 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_compound) disease_7\NN\14061805|parkinson_12
D007980_D010300 NONE levodopa_23\NN\14604959|-_8 (r_npadvmod) induced_25\VBN\1627355|(_20|lid_43 (r_amod) dyskinesias_26\NNS\14084880|NONE_0 (r_pobj) without_22\IN\0|disease_27|)_6|and_4 (r_conj) with_9\IN\0|we_54|groups_39|._151 (l_pobj) disease_13\NN\14061805|)_21|and_23|without_27
D007980_D010300 NONE levodopa_23\NN\14604959|-_8 (r_npadvmod) induced_25\VBN\1627355|(_20|lid_43 (r_amod) dyskinesias_26\NNS\14084880|NONE_0 (l_appos) lid_32\NNP\5313679|induced_43|(_23 (l_compound) disease_30\NN\14061805|parkinson_12|-_8|,_13|n_15|10_19|)_21|,_22|and_24|controls_48
D007980_D010300 NONE levodopa_28\RB\14604959|score_133|were_25|._8 (r_dobj) assessed_24\VBN\670261|NONE_0 (l_nsubjpass) score_2\NN\5736149|were_108|levodopa_133|._141 (l_prep) of_3\IN\0|the_16|motor_12 (l_pobj) scale_10\NNP\7260623|NONE_0 (l_compound) rating_9\NNP\5733583|parkinson_20|,_12|score_27 (l_compound) disease_8\NNP\14061805|NONE_0
D007980_D010300 NONE levodopa_21\NN\14604959|NONE_0 (r_pobj) by_20\IN\0|in_120|,_92|force_86|was_28|significantly_24|)_29|._30 (r_agent) increased_19\VBN\169651|NONE_0 (l_prep) in_0\IN\13603305|,_28|force_34|was_92|significantly_96|by_120|)_149|._150 (l_pobj) disease_3\NN\14061805|NONE_0
3108839
D016685_D013274 NONE c_29\NN\13714184|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) treatment_26\NN\654885|while_9 (r_pobj) on_25\IN\0|we_160|course_135|in_102|and_30|died_34|._57 (r_advcl) describe_1\VBP\1001294|NONE_0 (l_prep) in_8\IN\13603305|we_58|course_33|on_102|and_132|died_136|._159 (l_pobj) man_14\NN\9605289|NONE_0 (l_prep) with_15\IN\0|a_16|65_14|old_8|developed_32 (l_pobj) adenocarcinoma_17\NN\14242337|NONE_0
D016685_D000743 NONE c_15\NN\13714184|mitomycin_10 (r_compound) treatment_16\NN\654885|NONE_0 (r_pobj) with_13\IN\0|and_27 (r_prep) associated_12\VBN\628491|progressive_26|renal_14 (r_acl) failure_11\NN\66216|and_22 (r_conj) thrombocytopenia_7\JJ\14189204|microangiopathic_35|hemolytic_18|,_2 (r_conj) anemia_5\NN\14189204|NONE_0
D016685_D011654 NONE c_14\NN\13714184|mitomycin_10 (r_compound) treatment_15\NN\654885|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) start_11\NN\7290905|NONE_0 (r_pobj) after_10\IN\0|failure_40|usually_32|mth_4|and_37|is_55 (r_prep) develops_4\VBZ\1753788|NONE_0 (l_conj) is_19\VBZ\0|failure_95|usually_87|mth_59|after_55|and_18 (l_attr) %_22\NN\0|mortality_29|._39 (l_prep) from_23\IN\0|60_4 (l_pobj) failure_25\NN\66216|NONE_0 (l_conj) edema_28\NN\14315192|renal_27|or_13
D016685_D011654 NONE c_29\NN\13714184|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) treatment_26\NN\654885|while_9 (r_pobj) on_25\IN\0|we_160|course_135|in_102|and_30|died_34|._57 (r_advcl) describe_1\VBP\1001294|NONE_0 (l_conj) died_31\VBD\146138|we_194|course_169|in_136|on_34|and_4|._23 (l_prep) in_32\IN\13603305|NONE_0 (l_pobj) edema_34\NN\14315192|NONE_0
D016685_D006463 CID c_1\NNP\13714184|syndrome_30|._38 (r_nsubj) associated_2\VBD\628491|NONE_0 (l_dobj) syndrome_5\NN\5870365|c_30|._8
D016685_D006463 CID c_1\NNP\13714184|syndrome_30 (r_nsubj) associated_2\VBD\628491|condition_79|._122 (l_dobj) syndrome_5\NNP\5870365|c_30
D016685_D006463 CID c_1\NNP\13714184|syndrome_30 (r_nsubj) associated_2\VBD\628491|condition_79|._122 (l_dobj) syndrome_5\NNP\5870365|c_30 (l_appos) hus_7\NNP\0|hemolytic_27|uremic_17|)_3
D016685_D051437 CID c_15\NN\13714184|mitomycin_10 (r_compound) treatment_16\NN\654885|NONE_0 (r_pobj) with_13\IN\0|and_27 (r_prep) associated_12\VBN\628491|progressive_26|renal_14 (r_acl) failure_11\NN\66216|and_22
D016685_D051437 CID c_14\NN\13714184|mitomycin_10 (r_compound) treatment_15\NN\654885|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) start_11\NN\7290905|NONE_0 (r_pobj) after_10\IN\0|failure_40|usually_32|mth_4|and_37|is_55 (r_prep) develops_4\VBZ\1753788|NONE_0 (l_nsubj) failure_2\NN\66216|usually_8|mth_36|after_40|and_77|is_95
D016685_D051437 CID c_14\NN\13714184|mitomycin_10 (r_compound) treatment_15\NN\654885|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) start_11\NN\7290905|NONE_0 (r_pobj) after_10\IN\0|failure_40|usually_32|mth_4|and_37|is_55 (r_prep) develops_4\VBZ\1753788|NONE_0 (l_conj) is_19\VBZ\0|failure_95|usually_87|mth_59|after_55|and_18 (l_attr) %_22\NN\0|mortality_29|._39 (l_prep) from_23\IN\0|60_4 (l_pobj) failure_25\NN\66216|NONE_0
D016685_D051437 CID c_29\NN\13714184|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) treatment_26\NN\654885|while_9 (r_pobj) on_25\IN\0|we_160|course_135|in_102|and_30|died_34|._57 (r_advcl) describe_1\VBP\1001294|NONE_0 (l_prep) in_8\IN\13603305|we_58|course_33|on_102|and_132|died_136|._159 (l_pobj) man_14\NN\9605289|NONE_0 (l_relcl) developed_19\VBD\1753788|a_48|65_46|old_40|with_32 (l_dobj) failure_21\NN\66216|who_20|and_8|thrombocytopenia_12
D016685_D013921 NONE c_15\NN\13714184|mitomycin_10 (r_compound) treatment_16\NN\654885|NONE_0 (r_pobj) with_13\IN\0|and_27 (r_prep) associated_12\VBN\628491|progressive_26|renal_14 (r_acl) failure_11\NN\66216|and_22 (r_conj) thrombocytopenia_7\JJ\14189204|microangiopathic_35|hemolytic_18|,_2
D016685_D013921 NONE c_29\NN\13714184|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) treatment_26\NN\654885|while_9 (r_pobj) on_25\IN\0|we_160|course_135|in_102|and_30|died_34|._57 (r_advcl) describe_1\VBP\1001294|NONE_0 (l_prep) in_8\IN\13603305|we_58|course_33|on_102|and_132|died_136|._159 (l_pobj) man_14\NN\9605289|NONE_0 (l_relcl) developed_19\VBD\1753788|a_48|65_46|old_40|with_32 (l_conj) thrombocytopenia_23\NN\14189204|who_32|failure_12|and_4
17682013
D008727_D002544 NONE methotrexate_21\NN\2722166|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) recipients_18\NNS\9764201|commonly_12 (r_pobj) in_17\IN\13603305|leukoencephalopathy_123|has_68|been_64|as_49|,_16|._65 (r_prep) described_8\VBN\1001294|NONE_0 (l_nsubjpass) leukoencephalopathy_2\JJ\0|has_55|been_59|as_74|,_107|in_123|._188 (l_acl) mimicking_3\VBG\1742886|a_32|transient_30 (l_dobj) accident_5\NN\7314427|NONE_0
D008727_D056784 CID methotrexate_21\NN\2722166|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) recipients_18\NNS\9764201|commonly_12 (r_pobj) in_17\IN\13603305|leukoencephalopathy_123|has_68|been_64|as_49|,_16|._65 (r_prep) described_8\VBN\1001294|NONE_0 (l_nsubjpass) leukoencephalopathy_2\JJ\0|has_55|been_59|as_74|,_107|in_123|._188
D008727_D056784 CID methotrexate_12\NNP\2722166|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) treated_10\VBN\2376958|NONE_0 (r_acl) patients_9\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|toxic_26 (r_prep) leukoencephalopathy_7\JJ\0|NONE_0
C017367_D056784 CID carmofur_23\NN\0|:_153|we_151|reports_134|5-fluorouracil_34|and_19|._26 (r_conj) identified_2\VBD\699815|NONE_0 (l_dobj) reports_4\NNS\6470073|:_19|we_17|5-fluorouracil_100|and_115|carmofur_134|._160 (l_prep) of_5\IN\0|27_11 (l_pobj) leukoencephalopathy_7\JJ\0|NONE_0
D005472_D056784 CID 5-fluorouracil_19\CD\0|:_119|we_117|reports_100|and_15|carmofur_34|._60 (r_punct) identified_2\VBD\699815|NONE_0 (l_dobj) reports_4\NNS\6470073|:_19|we_17|5-fluorouracil_100|and_115|carmofur_134|._160 (l_prep) of_5\IN\0|27_11 (l_pobj) leukoencephalopathy_7\JJ\0|NONE_0
C110904_D056784 CID capecitabine_26\NN\0|its_29|derivative_25|,_6|and_4 (r_conj) carmofur_23\NN\0|:_153|we_151|reports_134|5-fluorouracil_34|and_19|._26 (r_conj) identified_2\VBD\699815|NONE_0 (l_dobj) reports_4\NNS\6470073|:_19|we_17|5-fluorouracil_100|and_115|carmofur_134|._160 (l_prep) of_5\IN\0|27_11 (l_pobj) leukoencephalopathy_7\JJ\0|NONE_0
D008727_D007938 NONE methotrexate_21\NN\2722166|NONE_0 (l_prep) for_22\IN\0|intrathecal_25 (l_pobj) leukaemia_24\NN\14239918|NONE_0
6216862
D010396_D006527 NONE penicillamine_32\NN\3740161|NONE_0 (r_pobj) with_31\IN\0|NONE_0 (r_prep) treated_30\VBN\2376958|with_26 (r_acl) patients_26\NNS\9898892|not_7 (r_pobj) in_25\IN\13603305|which_88|has_82|been_78|as_64|but_8 (r_conj) reported_11\VBN\831651|elastosis_48|perforans_38|,_17 (l_prep) as_12\IN\14622893|which_24|has_18|been_14|but_56|in_64 (l_pobj) effect_16\NN\34213|NONE_0 (l_prep) in_17\IN\13603305|a_19|rare_17|side_12 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) disease_22\NN\14061805|NONE_0
D010396_D017285 CID penicillamine_20\NN\3740161|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) of_19\IN\0|in_25 (r_prep) complications_18\NNS\1073995|NONE_0 (r_pobj) as_17\IN\14622893|rashes_109|have_23|all_18|been_14|._79 (r_prep) recorded_16\VBN\2225492|NONE_0 (l_nsubjpass) rashes_1\NNS\14321469|have_86|all_91|been_95|as_109|._188 (l_conj) proteinuria_3\NN\14299637|skin_13|,_2 (l_conj) erythematosus_7\NN\0|,_17 (l_conj) polymyositis_9\NN\14350292|systemic_30|lupus_21|,_2
D010396_D005076 CID penicillamine_20\NN\3740161|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) of_19\IN\0|in_25 (r_prep) complications_18\NNS\1073995|NONE_0 (r_pobj) as_17\IN\14622893|rashes_109|have_23|all_18|been_14|._79 (r_prep) recorded_16\VBN\2225492|NONE_0 (l_nsubjpass) rashes_1\NNS\14321469|have_86|all_91|been_95|as_109|._188
D010396_D001172 NONE penicillamine_4\NN\3740161|NONE_0 (r_compound) therapy_5\NN\657604|NONE_0 (r_pobj) of_3\IN\0|multiple_22|side_13|in_25|._65 (r_prep) effects_2\NNS\13245626|NONE_0 (l_prep) in_6\IN\13603305|multiple_47|side_38|of_25|._40 (l_pobj) patient_8\NN\9898892|NONE_0 (l_prep) with_9\IN\0|one_12 (l_pobj) arthritis_11\NN\14171682|NONE_0
D010396_D001172 NONE penicillamine_20\NN\3740161|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) of_19\IN\0|in_25 (r_prep) complications_18\NNS\1073995|NONE_0 (l_prep) in_22\IN\13603305|of_25 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_prep) with_24\IN\0|NONE_0 (l_pobj) arthritis_26\NN\14171682|NONE_0
D010396_D001172 NONE penicillamine_32\NN\3740161|NONE_0 (r_pobj) with_31\IN\0|NONE_0 (r_prep) treated_30\VBN\2376958|with_26 (r_acl) patients_26\NNS\9898892|not_7 (l_prep) with_27\IN\0|treated_26 (l_pobj) arthritis_29\NN\14171682|NONE_0
D010396_D012871 NONE penicillamine_32\NN\3740161|NONE_0 (r_pobj) with_31\IN\0|NONE_0 (r_prep) treated_30\VBN\2376958|with_26 (r_acl) patients_26\NNS\9898892|not_7 (r_pobj) in_25\IN\13603305|which_88|has_82|been_78|as_64|but_8 (r_conj) reported_11\VBN\831651|elastosis_48|perforans_38|,_17 (r_relcl) serpiginosa_6\NN\0|lesion_37|._165 (r_dobj) resembled_3\VBD\2657219|NONE_0 (l_nsubj) lesion_2\NN\14204950|serpiginosa_37|._202
D010396_D011507 CID penicillamine_20\NN\3740161|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) of_19\IN\0|in_25 (r_prep) complications_18\NNS\1073995|NONE_0 (r_pobj) as_17\IN\14622893|rashes_109|have_23|all_18|been_14|._79 (r_prep) recorded_16\VBN\2225492|NONE_0 (l_nsubjpass) rashes_1\NNS\14321469|have_86|all_91|been_95|as_109|._188 (l_conj) proteinuria_3\NN\14299637|skin_13|,_2
D010396_D008180 CID penicillamine_20\NN\3740161|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) of_19\IN\0|in_25 (r_prep) complications_18\NNS\1073995|NONE_0 (r_pobj) as_17\IN\14622893|rashes_109|have_23|all_18|been_14|._79 (r_prep) recorded_16\VBN\2225492|NONE_0 (l_nsubjpass) rashes_1\NNS\14321469|have_86|all_91|been_95|as_109|._188 (l_conj) proteinuria_3\NN\14299637|skin_13|,_2 (l_conj) erythematosus_7\NN\0|,_17
D010396_C536202 NONE penicillamine_32\NN\3740161|NONE_0 (r_pobj) with_31\IN\0|NONE_0 (r_prep) treated_30\VBN\2376958|with_26 (r_acl) patients_26\NNS\9898892|not_7 (r_pobj) in_25\IN\13603305|which_88|has_82|been_78|as_64|but_8 (r_conj) reported_11\VBN\831651|elastosis_48|perforans_38|,_17 (r_relcl) serpiginosa_6\NN\0|lesion_37|._165
D010396_D009157 CID penicillamine_20\NN\3740161|NONE_0 (r_compound) therapy_21\NN\657604|NONE_0 (r_pobj) of_19\IN\0|in_25 (r_prep) complications_18\NNS\1073995|NONE_0 (r_pobj) as_17\IN\14622893|rashes_109|have_23|all_18|been_14|._79 (r_prep) recorded_16\VBN\2225492|NONE_0 (l_nsubjpass) rashes_1\NNS\14321469|have_86|all_91|been_95|as_109|._188 (l_conj) proteinuria_3\NN\14299637|skin_13|,_2 (l_conj) erythematosus_7\NN\0|,_17 (l_conj) polymyositis_9\NN\14350292|systemic_30|lupus_21|,_2 (l_conj) gravis_12\NN\0|and_15|myasthenia_11
9636837
D016190_D010523 CID cbdca_5\NNP\0|intensity_13|and_33|association_41 (r_nmod) schedules_9\NNS\5898568|NONE_0 (r_pobj) of_4\IN\0|the_8 (r_prep) use_3\NN\407535|however_13|,_6|may_108|concern_123|._196 (r_nsubj) cause_20\VB\7323922|NONE_0 (l_dobj) concern_22\NN\5682950|however_136|,_129|use_123|may_15|._73 (l_prep) about_23\IN\0|some_13 (l_pobj) safety_25\NN\13920835|NONE_0 (l_prep) with_26\IN\0|its_11 (l_pobj) respect_27\NN\5817845|NONE_0 (l_prep) to_28\IN\0|NONE_0 (l_pobj) damage_32\NN\7296428|NONE_0
D016190_D010523 CID cbdca_0\JJ\0|NONE_0 (r_compound) administration_1\NN\1133281|neurotoxicity_49|._62 (r_nsubj) induced_2\VBD\1627355|NONE_0 (l_dobj) neurotoxicity_7\NN\0|administration_49|._13
D016190_D020258 NONE carboplatin_4\NN\0|(_25|cbdca_26|)_31 (r_poss) advantages_6\NNS\5154517|NONE_0 (r_pobj) of_3\IN\0|the_18|most_14|over_36 (r_prep) striking_2\JJ\7283608|)_65|rate_91|._117 (r_nsubj) is_15\VBZ\0|NONE_0 (l_attr) rate_19\NN\13815152|striking_91|)_26|._26 (l_prep) of_20\IN\0|its_26|reduced_13 (l_pobj) effects_22\NNS\13245626|NONE_0 (l_amod) neurotoxic_21\JJ\0|NONE_0
D016190_D020258 NONE cbdca_8\NNP\0|carboplatin_26|(_1|)_5 (r_appos) advantages_6\NNS\5154517|NONE_0 (r_pobj) of_3\IN\0|the_18|most_14|over_36 (r_prep) striking_2\JJ\7283608|)_65|rate_91|._117 (r_nsubj) is_15\VBZ\0|NONE_0 (l_attr) rate_19\NN\13815152|striking_91|)_26|._26 (l_prep) of_20\IN\0|its_26|reduced_13 (l_pobj) effects_22\NNS\13245626|NONE_0 (l_amod) neurotoxic_21\JJ\0|NONE_0
D016190_D020258 NONE cbdca_5\NNP\0|intensity_13|and_33|association_41 (r_nmod) schedules_9\NNS\5898568|NONE_0 (l_conj) association_12\NN\8008335|cbdca_41|intensity_28|and_8 (l_prep) with_13\IN\0|the_16|in_28 (l_pobj) drugs_16\NNS\14778436|NONE_0 (l_amod) neurotoxic_15\JJ\0|other_6
D016190_D020258 NONE cbdca_0\NNP\0|neurotoxic_9|in_20|,_32|and_34|are_82 (r_nsubj) is_1\VBZ\0|NONE_0 (l_acomp) neurotoxic_2\JJ\0|cbdca_9|in_11|,_23|and_25|are_73
D016190_D020258 NONE cbdca_0\NNP\0|neurotoxic_9|in_20|,_32|and_34|are_82 (r_nsubj) is_1\VBZ\0|NONE_0 (l_conj) are_15\VBP\13600404|cbdca_82|neurotoxic_73|in_62|,_50|and_48 (l_ccomp) is_26\VBZ\0|type_95|similar_40|._80 (l_ccomp) induced_31\VBN\1627355|that_42|it_37|probable_31 (l_nsubjpass) neurotoxicity_29\NN\0|that_5|is_14|in_25|by_42
D002945_D020258 NONE cisplatin_11\NN\0|(_10 (r_nmod) cddp_13\NNP\0|NONE_0 (r_pobj) over_10\IN\5867413|the_54|most_50|of_36 (r_prep) striking_2\JJ\7283608|)_65|rate_91|._117 (r_nsubj) is_15\VBZ\0|NONE_0 (l_attr) rate_19\NN\13815152|striking_91|)_26|._26 (l_prep) of_20\IN\0|its_26|reduced_13 (l_pobj) effects_22\NNS\13245626|NONE_0 (l_amod) neurotoxic_21\JJ\0|NONE_0
D002945_D020258 NONE cddp_13\NNP\0|NONE_0 (r_pobj) over_10\IN\5867413|the_54|most_50|of_36 (r_prep) striking_2\JJ\7283608|)_65|rate_91|._117 (r_nsubj) is_15\VBZ\0|NONE_0 (l_attr) rate_19\NN\13815152|striking_91|)_26|._26 (l_prep) of_20\IN\0|its_26|reduced_13 (l_pobj) effects_22\NNS\13245626|NONE_0 (l_amod) neurotoxic_21\JJ\0|NONE_0
D002945_D020258 NONE cddp_23\NNP\0|NONE_0 (r_pobj) by_22\IN\0|NONE_0 (r_agent) caused_21\VBN\1617192|NONE_0 (r_acl) those_20\DT\0|NONE_0 (r_pobj) to_19\IN\0|closely_16 (r_prep) similar_18\JJ\0|type_55|is_40|._120 (r_acomp) are_15\VBP\13600404|cbdca_82|neurotoxic_73|in_62|,_50|and_48 (r_conj) is_1\VBZ\0|NONE_0 (l_acomp) neurotoxic_2\JJ\0|cbdca_9|in_11|,_23|and_25|are_73
D002945_D020258 NONE cddp_23\NNP\0|NONE_0 (r_pobj) by_22\IN\0|NONE_0 (r_agent) caused_21\VBN\1617192|NONE_0 (r_acl) those_20\DT\0|NONE_0 (r_pobj) to_19\IN\0|closely_16 (r_prep) similar_18\JJ\0|type_55|is_40|._120 (r_acomp) are_15\VBP\13600404|cbdca_82|neurotoxic_73|in_62|,_50|and_48 (l_ccomp) is_26\VBZ\0|type_95|similar_40|._80 (l_ccomp) induced_31\VBN\1627355|that_42|it_37|probable_31 (l_nsubjpass) neurotoxicity_29\NN\0|that_5|is_14|in_25|by_42
1728915
D002220_D062787 NONE carbamazepine_12\NN\0|a_10|massive_8 (r_compound) overdose_13\NN\84738|NONE_0
D002220_D001523 NONE carbamazepine_1\NN\0|because_8|is_14|widely_17|in_29 (r_nsubjpass) used_4\VBN\0|,_67|recognition_73|implications_122|._179 (l_prep) in_5\IN\13603305|because_37|carbamazepine_29|is_15|widely_12 (l_pobj) treatment_7\NN\654885|NONE_0 (l_prep) of_8\IN\0|the_14 (l_pobj) conditions_13\NNS\14512817|NONE_0 (l_amod) neurologic_10\JJ\0|many_5 (l_conj) psychiatric_12\JJ\0|and_4
D002220_D013616 CID carbamazepine_12\NN\0|a_10|massive_8 (r_compound) overdose_13\NN\84738|NONE_0 (r_pobj) of_9\IN\0|the_12 (r_prep) setting_8\NN\8567235|NONE_0 (r_pobj) in_6\IN\13603305|group_35|tachycardias_13|._50 (r_prep) developed_3\VBD\1753788|NONE_0 (l_dobj) tachycardias_5\NNS\14110674|group_22|in_13|._63
D002220_D001919 CID carbamazepine_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|a_61|with_51|,_2|,_24 (r_acl) patient_1\NN\9898892|review_118|._157 (l_prep) with_2\IN\0|a_10|,_49|induced_51|,_75 (l_pobj) bradycardia_4\NNP\14110674|NONE_0
D002220_D001919 CID carbamazepine_28\NN\0|therapeutic_33|serum_14 (r_compound) levels_30\NNS\4916342|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) associated_21\VBN\628491|group_150|exclusively_127|._82 (r_advcl) consisted_3\VBD\2603699|NONE_0 (l_advmod) exclusively_5\RB\0|group_23|associated_127|._209 (l_prep) of_6\IN\0|almost_19 (l_pobj) women_8\NNS\9605289|NONE_0 (l_relcl) developed_10\VBD\1753788|elderly_18|,_92 (l_dobj) bradyarrhythmias_15\NNS\0|who_43
D002220_D054537 CID carbamazepine_11\NN\0|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|a_61|with_51|,_2|,_24 (r_acl) patient_1\NN\9898892|review_118|._157 (l_prep) with_2\IN\0|a_10|,_49|induced_51|,_75 (l_pobj) bradycardia_4\NNP\14110674|NONE_0 (l_conj) block_7\NN\21939|sinus_39|and_21
D002220_D054537 CID carbamazepine_28\NN\0|therapeutic_33|serum_14 (r_compound) levels_30\NNS\4916342|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) associated_21\VBN\628491|group_150|exclusively_127|._82 (r_advcl) consisted_3\VBD\2603699|NONE_0 (l_advmod) exclusively_5\RB\0|group_23|associated_127|._209 (l_prep) of_6\IN\0|almost_19 (l_pobj) women_8\NNS\9605289|NONE_0 (l_relcl) developed_10\VBD\1753788|elderly_18|,_92 (l_dobj) bradyarrhythmias_15\NNS\0|who_43 (l_conj) delay_19\NN\15271008|threatening_60|or_31
D002220_D006331 NONE carbamazepine_0\NNP\0|-_13 (r_npadvmod) induced_2\VBN\1627355|cardiac_8|._27 (r_amod) dysfunction_4\NN\14204950|NONE_0
D002220_D006331 NONE carbamazepine_11\NN\0|-_13 (r_npadvmod) associated_13\VBN\628491|cardiac_11 (r_amod) dysfunction_15\NN\14204950|NONE_0
6323692
D009020_D000699 NONE morphine_11\NN\2707683|nh4ac_28 (r_appos) pretreatment_9\NN\0|both_41|(_26|mg/kg_22|i.p._16|)_12|and_10 (r_conj) verapamil_1\NN\2938514|and_78|incoordination_108|and_123|antagonized_127|,_173|and_175|affected_207 (r_nsubj) analgesia-_12\JJ\0|NONE_0
D014700_D000699 NONE verapamil_1\NN\2938514|and_78|incoordination_108|and_123|antagonized_127|,_173|and_175|affected_207 (r_nsubj) analgesia-_12\JJ\0|NONE_0
D014700_D000699 NONE verapamil_29\NN\2938514|action_44|._62 (r_nsubj) affected_32\VBD\126264|verapamil_207|and_129|incoordination_99|and_84|antagonized_80|,_34|and_32 (r_conj) analgesia-_12\JJ\0|NONE_0
D002118_D022124 NONE calcium_7\NN\14625458|a_2|blocking_16|enhances_38 (r_compound) channel_8\NN\6251781|hyperammonemia_32 (r_dobj) exerts_5\VBZ\1158872|data_33|._135 (l_nsubj) hyperammonemia_4\NN\0|channel_32
D000079_D003866 NONE acetaldehyde_18\NN\14584765|NONE_0 (r_pobj) by_17\IN\0|independent_34|catecholamine_22 (r_prep) release_16\NN\3748886|was_24|not_28|by_40|._48 (r_nsubjpass) blocked_21\VBN\1476483|addition_138|depression_98|,_72|but_70 (r_conj) reversed_4\VBD\109660|NONE_0 (l_dobj) depression_6\NN\14373582|addition_40|,_26|but_28|blocked_98
D003975_D000699 NONE diazepam_14\NN\2830852|-_8 (r_npadvmod) induced_16\VBN\1627355|muscular_8 (r_amod) incoordination_18\NN\5648247|verapamil_108|and_30|and_15|antagonized_19|,_65|and_67|affected_99 (r_conj) analgesia-_12\JJ\0|NONE_0
D002395_D003866 NONE catecholamine_15\NN\5407119|independent_12|by_22 (r_compound) release_16\NN\3748886|was_24|not_28|by_40|._48 (r_nsubjpass) blocked_21\VBN\1476483|addition_138|depression_98|,_72|but_70 (r_conj) reversed_4\VBD\109660|NONE_0 (l_dobj) depression_6\NN\14373582|addition_40|,_26|but_28|blocked_98
C018824_D003866 NONE nh4ac_23\NNPS\0|NONE_0 (r_pobj) by_22\IN\0|release_40|was_16|not_12|._8 (r_agent) blocked_21\VBN\1476483|addition_138|depression_98|,_72|but_70 (r_conj) reversed_4\VBD\109660|NONE_0 (l_dobj) depression_6\NN\14373582|addition_40|,_26|but_28|blocked_98
D014700_D001259 NONE verapamil_1\NN\2938514|and_78|incoordination_108|and_123|antagonized_127|,_173|and_175|affected_207 (r_nsubj) analgesia-_12\JJ\0|NONE_0 (l_conj) incoordination_18\NN\5648247|verapamil_108|and_30|and_15|antagonized_19|,_65|and_67|affected_99
D014700_D001259 NONE verapamil_29\NN\2938514|action_44|._62 (r_nsubj) affected_32\VBD\126264|verapamil_207|and_129|incoordination_99|and_84|antagonized_80|,_34|and_32 (r_conj) analgesia-_12\JJ\0|NONE_0 (l_conj) incoordination_18\NN\5648247|verapamil_108|and_30|and_15|antagonized_19|,_65|and_67|affected_99
D010433_D000699 NONE metrazol_37\NN\3740161|NONE_0 (r_pobj) of_36\IN\0|the_22|convulsant_18 (r_prep) action_35\NN\30358|verapamil_44|._18 (r_dobj) affected_32\VBD\126264|verapamil_207|and_129|incoordination_99|and_84|antagonized_80|,_34|and_32 (r_conj) analgesia-_12\JJ\0|NONE_0
D000661_D000699 NONE amphetamine_21\NN\3248958|-_11 (r_npadvmod) induced_23\VBN\1627355|motor_8 (r_amod) activity_25\NN\30358|NONE_0 (r_dobj) antagonized_20\VBN\1787955|verapamil_127|and_49|incoordination_19|and_4|,_46|and_48|affected_80 (r_conj) analgesia-_12\JJ\0|NONE_0
D010433_D001259 NONE metrazol_37\NN\3740161|NONE_0 (r_pobj) of_36\IN\0|the_22|convulsant_18 (r_prep) action_35\NN\30358|verapamil_44|._18 (r_dobj) affected_32\VBD\126264|verapamil_207|and_129|incoordination_99|and_84|antagonized_80|,_34|and_32 (r_conj) analgesia-_12\JJ\0|NONE_0 (l_conj) incoordination_18\NN\5648247|verapamil_108|and_30|and_15|antagonized_19|,_65|and_67|affected_99
C018824_D000699 NONE nh4ac_8\NNP\0|morphine_28 (r_nmod) pretreatment_9\NN\0|both_41|(_26|mg/kg_22|i.p._16|)_12|and_10 (r_conj) verapamil_1\NN\2938514|and_78|incoordination_108|and_123|antagonized_127|,_173|and_175|affected_207 (r_nsubj) analgesia-_12\JJ\0|NONE_0
C018824_D000699 NONE nh4ac_31\NNP\0|neither_22|nor_4 (r_conj) verapamil_29\NN\2938514|action_44|._62 (r_nsubj) affected_32\VBD\126264|verapamil_207|and_129|incoordination_99|and_84|antagonized_80|,_34|and_32 (r_conj) analgesia-_12\JJ\0|NONE_0
C018824_D001259 CID acetate_3\NN\15010703|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) pretreatment_0\NN\0|approximately_60|time_86|._239 (r_nsubj) doubled_15\VBD\247390|NONE_0 (l_npadvmod) time_17\NN\7308889|pretreatment_86|approximately_26|._153 (l_relcl) remained_22\VBD\2604760|the_31 (l_conj) incoordination_31\NN\5648247|mice_64|on_50|and_33|had_54
C018824_D001259 CID nh4ac_5\NNP\0|ammonium_18|(_7|s.c._18|)_22 (r_appos) acetate_3\NN\15010703|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) pretreatment_0\NN\0|approximately_60|time_86|._239 (r_nsubj) doubled_15\VBD\247390|NONE_0 (l_npadvmod) time_17\NN\7308889|pretreatment_86|approximately_26|._153 (l_relcl) remained_22\VBD\2604760|the_31 (l_conj) incoordination_31\NN\5648247|mice_64|on_50|and_33|had_54
C018824_D001259 CID nh4ac_36\NNP\0|alone_16 (r_compound) treatment_37\NN\654885|effect_23 (r_nsubj) had_39\VBD\0|mice_118|on_104|and_87|incoordination_54 (r_conj) remained_22\VBD\2604760|the_31 (l_conj) incoordination_31\NN\5648247|mice_64|on_50|and_33|had_54
C018824_D001259 CID nh4ac_8\NNP\0|morphine_28 (r_nmod) pretreatment_9\NN\0|both_41|(_26|mg/kg_22|i.p._16|)_12|and_10 (r_conj) verapamil_1\NN\2938514|and_78|incoordination_108|and_123|antagonized_127|,_173|and_175|affected_207 (r_nsubj) analgesia-_12\JJ\0|NONE_0 (l_conj) incoordination_18\NN\5648247|verapamil_108|and_30|and_15|antagonized_19|,_65|and_67|affected_99
C018824_D001259 CID nh4ac_31\NNP\0|neither_22|nor_4 (r_conj) verapamil_29\NN\2938514|action_44|._62 (r_nsubj) affected_32\VBD\126264|verapamil_207|and_129|incoordination_99|and_84|antagonized_80|,_34|and_32 (r_conj) analgesia-_12\JJ\0|NONE_0 (l_conj) incoordination_18\NN\5648247|verapamil_108|and_30|and_15|antagonized_19|,_65|and_67|affected_99
D009020_D001259 NONE morphine_18\NN\2707683|-_8 (r_npadvmod) treated_20\VBN\2376958|NONE_0 (r_amod) mice_21\NNS\2329401|on_14|and_31|incoordination_64|had_118 (r_nsubj) remained_22\VBD\2604760|the_31 (l_conj) incoordination_31\NN\5648247|mice_64|on_50|and_33|had_54
D009020_D001259 NONE morphine_11\NN\2707683|nh4ac_28 (r_appos) pretreatment_9\NN\0|both_41|(_26|mg/kg_22|i.p._16|)_12|and_10 (r_conj) verapamil_1\NN\2938514|and_78|incoordination_108|and_123|antagonized_127|,_173|and_175|affected_207 (r_nsubj) analgesia-_12\JJ\0|NONE_0 (l_conj) incoordination_18\NN\5648247|verapamil_108|and_30|and_15|antagonized_19|,_65|and_67|affected_99
D000661_D001259 NONE amphetamine_21\NN\3248958|-_11 (r_npadvmod) induced_23\VBN\1627355|motor_8 (r_amod) activity_25\NN\30358|NONE_0 (r_dobj) antagonized_20\VBN\1787955|verapamil_127|and_49|incoordination_19|and_4|,_46|and_48|affected_80 (r_conj) analgesia-_12\JJ\0|NONE_0 (l_conj) incoordination_18\NN\5648247|verapamil_108|and_30|and_15|antagonized_19|,_65|and_67|affected_99
D003975_D001259 CID diazepam_33\NN\2830852|NONE_0 (r_pobj) by_32\IN\0|increased_34|muscular_24|,_11|but_13 (r_prep) incoordination_31\NN\5648247|mice_64|on_50|and_33|had_54
D003975_D001259 CID diazepam_14\NN\2830852|-_8 (r_npadvmod) induced_16\VBN\1627355|muscular_8 (r_amod) incoordination_18\NN\5648247|verapamil_108|and_30|and_15|antagonized_19|,_65|and_67|affected_99
D002118_D003866 NONE calcium_3\NN\14625458|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) addition_0\NN\3081021|depression_40|,_66|but_68|blocked_138 (r_nsubj) reversed_4\VBD\109660|NONE_0 (l_dobj) depression_6\NN\14373582|addition_40|,_26|but_28|blocked_98
D002118_D003866 NONE calcium_12\NN\14625458|-_7 (r_npadvmod) independent_14\JJ\9619824|catecholamine_12|by_34 (r_amod) release_16\NN\3748886|was_24|not_28|by_40|._48 (r_nsubjpass) blocked_21\VBN\1476483|addition_138|depression_98|,_72|but_70 (r_conj) reversed_4\VBD\109660|NONE_0 (l_dobj) depression_6\NN\14373582|addition_40|,_26|but_28|blocked_98
7072798
D002701_D001855 NONE chloramphenicol_13\NN\2716866|NONE_0 (r_pobj) with_12\IN\0|topical_18|for_21 (r_prep) treatment_11\NN\654885|NONE_0 (r_pobj) after_9\IN\0|the_43|second_39|of_25 (r_prep) report_4\NN\6470073|this_20|,_98|reported_171|._179 (r_attr) was_1\VBD\0|NONE_0 (l_advcl) reported_29\VBN\831651|this_191|report_171|,_73|._8 (l_nsubjpass) cases_20\NNS\7283608|although_13|have_43|also_48|been_53 (l_prep) of_21\IN\0|two_10 (l_pobj) hypoplasia_25\NN\14365950|NONE_0
D002701_D002386 NONE chloramphenicol_22\NN\2716866|NONE_0 (r_pobj) with_21\IN\0|topical_16 (r_prep) therapy_20\NN\657604|NONE_0 (r_dobj) beginning_18\VBG\7283608|extraction_15|and_4 (r_conj) undergoing_14\VBG\109660|months_13 (l_dobj) extraction_16\NN\13518963|and_11|beginning_15 (l_compound) cataract_15\NN\14252864|NONE_0
D002701_D005128 NONE chloramphenicol_11\NN\2716866|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) associated_7\VBN\628491|ocular_16 (r_acl) toxicity_6\NN\13576101|NONE_0
D002701_D000741 CID chloramphenicol_8\NN\2716866|NONE_0 (r_pobj) of_6\IN\0|topical_23 (r_prep) administration_5\NN\1133281|NONE_0 (r_pobj) following_3\VBG\8180190|fatal_22|aplastic_16|._62 (r_prep) anemia_2\NN\14189204|NONE_0
D002701_D000741 CID chloramphenicol_22\NN\2716866|NONE_0 (r_pobj) with_21\IN\0|topical_16 (r_prep) therapy_20\NN\657604|NONE_0 (r_dobj) beginning_18\VBG\7283608|extraction_15|and_4 (r_conj) undergoing_14\VBG\109660|months_13 (r_pcomp) after_13\IN\0|woman_51|of_40|._87 (r_prep) died_5\VBD\146138|NONE_0 (l_prep) of_6\IN\0|woman_11|after_40|._127 (l_pobj) anemia_8\NN\14189204|NONE_0
D002701_D000741 CID chloramphenicol_13\NN\2716866|an_29|idiosyncratic_26 (r_acl) response_11\NN\11410625|NONE_0 (r_pobj) with_8\IN\0|pattern_46|was_15|._49 (r_prep) associated_7\VBN\628491|NONE_0 (l_nsubjpass) pattern_1\NN\5726345|was_31|with_46|._95 (l_prep) of_2\IN\0|the_12 (l_pobj) anemia_5\NN\14189204|NONE_0
D002701_D000741 CID chloramphenicol_13\NN\2716866|NONE_0 (r_pobj) with_12\IN\0|topical_18|for_21 (r_prep) treatment_11\NN\654885|NONE_0 (r_pobj) after_9\IN\0|the_43|second_39|of_25 (r_prep) report_4\NN\6470073|this_20|,_98|reported_171|._179 (l_prep) of_5\IN\0|the_18|second_14|after_25 (l_pobj) anemia_8\NN\14189204|NONE_0
8441146
D010396_D000741 CID penicillamine_19\NN\3740161|one_15|and_6|in_14 (r_conj) case_15\NN\7283608|NONE_0 (r_pobj) in_13\IN\13603305|which_25|was_19|by_8 (r_prep) caused_10\VBN\1617192|severe_33|aplastic_26 (r_relcl) anemia_7\NN\14189204|to_25
D006046_D000741 CID gold_12\NN\13371489|NONE_0 (r_pobj) by_11\IN\0|which_17|was_11|in_8 (r_agent) caused_10\VBN\1617192|severe_33|aplastic_26 (r_relcl) anemia_7\NN\14189204|to_25
8911359
D003520_D014523 NONE cyclophosphamide_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|the_39|,_27|treatment_25 (r_prep) etiology_7\NN\7326557|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) knowledge_4\NN\23100|we_10|cancer_94|._100 (r_dobj) gained_3\VBD\2238085|:_5 (l_dobj) cancer_16\NN\14239425|we_104|knowledge_94|._6
D003520_D001749 CID cyclophosphamide_0\NN\0|associated_17|bladder_28|--_42|disease_64|._93 (r_nmod) cancer_3\NN\14239425|NONE_0
D003520_D001749 CID cyclophosphamide_17\NN\0|cancer_36 (r_pobj) with_16\IN\0|the_61|medical_57|of_41|age_14 (l_pobj) cancer_20\NN\14239425|cyclophosphamide_36
D003520_D001749 CID cyclophosphamide_0\NN\0|associated_17|bladder_28 (r_nmod) tumor_3\NN\14234074|disease_23|._30
10193809
D011692_D011507 CID aminonucleoside_1\NN\0|NONE_0 (r_amod) puromycin_0\NNP\0|was_32|to_49|induce_75|._93 (r_nsubjpass) administered_6\VBN\2436349|NONE_0 (l_advcl) induce_12\VB\1627355|puromycin_75|was_43|to_26|._18 (l_dobj) proteinuria_13\NN\14299637|to_10
D011692_D011507 CID pan_3\NNP\3101986|NONE_0 (r_appos) aminonucleoside_1\NN\0|NONE_0 (r_amod) puromycin_0\NNP\0|was_32|to_49|induce_75|._93 (r_nsubjpass) administered_6\VBN\2436349|NONE_0 (l_advcl) induce_12\VB\1627355|puromycin_75|was_43|to_26|._18 (l_dobj) proteinuria_13\NN\14299637|to_10
3780814
D010634_D011230 NONE pb_22\NNP\14625458|when_5|was_3|simultaneously_13|with_28|for_37 (r_nsubjpass) given_24\VBN\5892096|after_137|,_107|number_101|was_38|significantly_34|._47 (r_advcl) reduced_20\VBN\441445|NONE_0 (l_nsubjpass) number_8\NN\5107765|after_36|,_6|was_63|significantly_67|given_101|._148 (l_conj) size_11\NN\5090441|the_19|and_8 (l_prep) of_12\IN\0|the_9 (l_pcomp) induced_13\VBN\1627355|NONE_0 (l_dobj) foci_17\NN\5704266|NONE_0
D010634_D063646 NONE phenobarbital_5\JJ\2792049|NONE_0 (r_pobj) of_4\IN\0|carcinogenic_20|given_17|._72 (r_prep) action_3\NN\30358|NONE_0 (l_amod) carcinogenic_2\JJ\0|of_20|given_37|._92
D010634_D063646 NONE phenobarbital_13\JJ\2792049|NONE_0 (r_pobj) of_12\IN\0|the_11|on_54 (r_prep) effect_11\NN\34213|to_17|administered_90 (l_prep) on_25\IN\0|the_65|of_54 (l_pobj) carcinogenesis_26\NN\0|NONE_0
D010634_D063646 NONE pb_15\NNP\14625458|(_1|)_34 (r_appos) phenobarbital_13\JJ\2792049|NONE_0 (r_pobj) of_12\IN\0|the_11|on_54 (r_prep) effect_11\NN\34213|to_17|administered_90 (l_prep) on_25\IN\0|the_65|of_54 (l_pobj) carcinogenesis_26\NN\0|NONE_0
D010634_D063646 NONE pb_15\NNP\14625458|+_2 (r_conj) den_13\NNP\8580803|NONE_0 (r_pobj) by_12\IN\0|den_13|or_3 (r_conj) by_8\IN\0|rats_26|were_13|during_28|according_52|._102 (r_agent) treated_7\VBN\2376958|NONE_0 (l_prep) according_23\VBG\2657219|rats_78|were_65|by_52|during_24|._50 (l_prep) to_24\IN\0|NONE_0 (l_pobj) schedule_26\NN\5898568|NONE_0 (l_prep) for_27\IN\0|our_13 (l_pobj) hepatocarcinogenesis_28\NN\0|NONE_0
D010634_D063646 NONE pb_4\NNP\14625458|that_5|effect_100|given_112 (l_relcl) promotes_7\VBZ\2556126|,_8|,_65 (l_dobj) carcinogenesis_8\NN\0|which_15|administered_20
D004052_D011230 CID den_27\NNP\8580803|NONE_0 (r_pobj) with_26\IN\0|when_33|pb_28|was_25|simultaneously_15|for_9 (r_prep) given_24\VBN\5892096|after_137|,_107|number_101|was_38|significantly_34|._47 (r_advcl) reduced_20\VBN\441445|NONE_0 (l_nsubjpass) number_8\NN\5107765|after_36|,_6|was_63|significantly_67|given_101|._148 (l_conj) size_11\NN\5090441|the_19|and_8 (l_prep) of_12\IN\0|the_9 (l_pcomp) induced_13\VBN\1627355|NONE_0 (l_dobj) foci_17\NN\5704266|NONE_0
D004052_D009369 NONE den_1\NNP\8580803|rats_17 (r_nsubj) treated_4\VBN\2376958|in_12|,_12|survival_18|prolonged_31|and_41|decreased_65 (r_ccomp) was_9\VBD\0|NONE_0 (l_conj) decreased_15\VBD\169651|in_77|treated_65|,_53|survival_47|prolonged_34|and_24 (l_nsubj) incidence_14\NN\13821570|as_20|._70 (l_compound) tumor_13\NN\14234074|the_4
D004052_D009369 NONE den_23\NNP\8580803|NONE_0 (r_pobj) by_22\IN\0|alone_7 (r_agent) obtained_21\VBN\2210855|the_12 (r_acl) results_20\NNS\34213|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) compared_17\VBN\644583|NONE_0 (r_prep) as_16\IN\14622893|incidence_20|._50 (r_prep) decreased_15\VBD\169651|in_77|treated_65|,_53|survival_47|prolonged_34|and_24 (l_nsubj) incidence_14\NN\13821570|as_20|._70 (l_compound) tumor_13\NN\14234074|the_4
D004052_D063646 NONE diethylnitrosamine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|simultaneously_15 (r_prep) given_6\VBN\5892096|carcinogenic_37|of_17|._55 (r_prep) action_3\NN\30358|NONE_0 (l_amod) carcinogenic_2\JJ\0|of_20|given_37|._92
D004052_D063646 NONE diethylnitrosamine_33\JJ\0|NONE_0 (r_pobj) with_32\IN\0|when_39|it_34|is_31|simultaneously_15 (r_prep) administered_30\VBN\2436349|to_107|effect_90 (r_advcl) elucidate_9\VB\939277|NONE_0 (l_dobj) effect_11\NN\34213|to_17|administered_90 (l_prep) on_25\IN\0|the_65|of_54 (l_pobj) carcinogenesis_26\NN\0|NONE_0
D004052_D063646 NONE den_35\NNP\8580803|work_191|has_186|been_182|in_169|._18 (r_parataxis) planned_5\VBN\708538|NONE_0 (l_prep) in_6\IN\13603305|work_22|has_17|been_13|den_169|._187 (l_pobj) order_7\NN\7168131|NONE_0 (l_acl) elucidate_9\VB\939277|NONE_0 (l_dobj) effect_11\NN\34213|to_17|administered_90 (l_prep) on_25\IN\0|the_65|of_54 (l_pobj) carcinogenesis_26\NN\0|NONE_0
D004052_D063646 NONE den_9\NNP\8580803|or_10|by_13 (r_pobj) by_8\IN\0|rats_26|were_13|during_28|according_52|._102 (r_agent) treated_7\VBN\2376958|NONE_0 (l_prep) according_23\VBG\2657219|rats_78|were_65|by_52|during_24|._50 (l_prep) to_24\IN\0|NONE_0 (l_pobj) schedule_26\NN\5898568|NONE_0 (l_prep) for_27\IN\0|our_13 (l_pobj) hepatocarcinogenesis_28\NN\0|NONE_0
D004052_D063646 NONE den_13\NNP\8580803|NONE_0 (r_pobj) by_12\IN\0|den_13|or_3 (r_conj) by_8\IN\0|rats_26|were_13|during_28|according_52|._102 (r_agent) treated_7\VBN\2376958|NONE_0 (l_prep) according_23\VBG\2657219|rats_78|were_65|by_52|during_24|._50 (l_prep) to_24\IN\0|NONE_0 (l_pobj) schedule_26\NN\5898568|NONE_0 (l_prep) for_27\IN\0|our_13 (l_pobj) hepatocarcinogenesis_28\NN\0|NONE_0
D004052_D063646 NONE den_13\NNP\8580803|the_4 (r_compound) treatment_14\NN\654885|NONE_0 (r_pobj) after_11\IN\0|when_18 (r_prep) administered_10\VBN\2436349|which_35|carcinogenesis_20 (r_advcl) promotes_7\VBZ\2556126|,_8|,_65 (l_dobj) carcinogenesis_8\NN\0|which_15|administered_20
D004052_D063646 NONE den_24\NNP\8580803|NONE_0 (r_pobj) with_23\IN\0|when_26|simultaneously_15 (r_prep) given_21\VBN\5892096|that_117|pb_112|effect_12 (r_advcl) reduces_16\VBZ\441445|it_98|is_95|._64 (l_nsubj) pb_4\NNP\14625458|that_5|effect_100|given_112 (l_relcl) promotes_7\VBZ\2556126|,_8|,_65 (l_dobj) carcinogenesis_8\NN\0|which_15|administered_20
D010634_D009369 NONE pb_3\NNP\14625458|+_2 (r_conj) den_1\NNP\8580803|rats_17 (r_nsubj) treated_4\VBN\2376958|in_12|,_12|survival_18|prolonged_31|and_41|decreased_65 (r_ccomp) was_9\VBD\0|NONE_0 (l_conj) decreased_15\VBD\169651|in_77|treated_65|,_53|survival_47|prolonged_34|and_24 (l_nsubj) incidence_14\NN\13821570|as_20|._70 (l_compound) tumor_13\NN\14234074|the_4
20683499
C029036_D008569 NONE crocin_3\NNS\0|NONE_0 (l_prep) in_4\IN\13603305|in_20|,_9|._139 (l_pobj) impairment_14\NN\7296428|NONE_0
C029036_D007859 NONE crocin_3\NNS\0|NONE_0 (l_prep) in_4\IN\13603305|in_20|,_9|._139 (l_pobj) impairment_14\NN\7296428|NONE_0
D013311_D008569 NONE stz_17\NNP\0|-_3 (r_npadvmod) injected_19\VBN\81072|treated_12|in_15 (r_amod) group_20\NN\2137|NONE_0 (r_pobj) in_15\IN\13603305|dose_67|attenuated_42|learning_31 (r_prep) impairment_14\NN\7296428|NONE_0
D013311_D000544 CID streptozocin_11\NNS\0|-_12 (r_npadvmod) induced_13\VBN\1627355|of_14 (r_amod) model_14\NN\5888929|NONE_0 (l_prep) of_15\IN\0|induced_14 (l_pobj) disease_19\NN\14061805|NONE_0
D013311_D000544 CID streptozocin_20\NNP\0|the_95|of_84 (r_appos) effect_6\NN\34213|in_26|,_6|was_123|._139 (l_prep) of_7\IN\0|the_11|streptozocin_84 (l_pobj) crocins_8\NNS\0|NONE_0 (l_prep) on_9\IN\0|NONE_0 (l_pobj) disease_13\NN\14061805|NONE_0
D013311_D000544 CID stz_22\NNP\0|(_20|icv_19|)_16 (r_appos) streptozocin_20\NNP\0|the_95|of_84 (r_appos) effect_6\NN\34213|in_26|,_6|was_123|._139 (l_prep) of_7\IN\0|the_11|streptozocin_84 (l_pobj) crocins_8\NNS\0|NONE_0 (l_prep) on_9\IN\0|NONE_0 (l_pobj) disease_13\NN\14061805|NONE_0
D013311_D000544 CID stz_10\NNP\0|-_3 (r_compound) icv_12\NN\0|NONE_0 (r_pobj) with_9\IN\0|in_50|,_21|rats_19|were_14|bilaterally_13|)_33|in_35 (r_prep) injected_8\VBN\81072|,_73|application_93|was_105|._117 (l_prep) in_0\IN\13603305|,_29|rats_31|were_36|with_50|bilaterally_63|)_83|in_85 (l_pobj) groups_4\NNS\2137|NONE_0 (l_compound) disease_3\NN\14061805|alzheimer_12
D013311_D000544 CID stz_28\NNP\0|-_3 (r_compound) icv_30\NN\0|a_14|similar_12 (r_compound) application_31\NN\947128|injected_93|,_20|was_12|._24 (r_nsubjpass) repeated_33\VBN\952524|NONE_0 (l_ccomp) injected_8\VBN\81072|,_73|application_93|was_105|._117 (l_prep) in_0\IN\13603305|,_29|rats_31|were_36|with_50|bilaterally_63|)_83|in_85 (l_pobj) groups_4\NNS\2137|NONE_0 (l_compound) disease_3\NN\14061805|alzheimer_12
D013311_D000544 CID stz_20\NNP\0|-_3 (r_compound) icv_22\NN\0|NONE_0 (r_pobj) by_19\IN\0|in_11 (r_agent) caused_18\VBN\1617192|the_23|cognitive_19 (l_prep) in_23\IN\13603305|by_11 (l_pobj) rats_24\NNS\2329401|NONE_0 (l_conj) potential_27\NN\14481929|and_8 (l_prep) in_28\IN\13603305|its_14 (l_pobj) treatment_30\NN\654885|NONE_0 (l_prep) of_31\IN\0|the_14 (l_pobj) diseases_33\NNS\14061805|NONE_0 (l_prep) as_35\IN\14622893|neurodegenerative_32 (l_pobj) disease_38\NN\14061805|such_20
C029036_D000544 NONE crocin_9\NNS\0|sativus_12|,_2 (l_prep) on_10\IN\0|NONE_0 (l_pobj) model_14\NN\5888929|NONE_0 (l_prep) of_15\IN\0|induced_14 (l_pobj) disease_19\NN\14061805|NONE_0
C029036_D000544 NONE crocins_8\NNS\0|NONE_0 (l_prep) on_9\IN\0|NONE_0 (l_pobj) disease_13\NN\14061805|NONE_0
C029036_D000544 NONE crocin_8\NNS\0|NONE_0 (r_pobj) of_7\IN\0|the_18|(_10|mg/kg_14|)_19|in_21 (r_prep) effectiveness_6\NN\5190804|therefore_41|,_32|results_24|._192 (l_prep) in_13\IN\13603305|the_39|of_21|(_11|mg/kg_7|)_2 (l_pcomp) antagonizing_14\VBG\1787955|NONE_0 (l_dobj) deficits_17\NNS\5113133|NONE_0 (l_acl) caused_18\VBN\1617192|the_23|cognitive_19 (l_prep) in_23\IN\13603305|by_11 (l_pobj) rats_24\NNS\2329401|NONE_0 (l_conj) potential_27\NN\14481929|and_8 (l_prep) in_28\IN\13603305|its_14 (l_pobj) treatment_30\NN\654885|NONE_0 (l_prep) of_31\IN\0|the_14 (l_pobj) diseases_33\NNS\14061805|NONE_0 (l_prep) as_35\IN\14622893|neurodegenerative_32 (l_pobj) disease_38\NN\14061805|such_20
D013311_D019636 NONE stz_20\NNP\0|-_3 (r_compound) icv_22\NN\0|NONE_0 (r_pobj) by_19\IN\0|in_11 (r_agent) caused_18\VBN\1617192|the_23|cognitive_19 (l_prep) in_23\IN\13603305|by_11 (l_pobj) rats_24\NNS\2329401|NONE_0 (l_conj) potential_27\NN\14481929|and_8 (l_prep) in_28\IN\13603305|its_14 (l_pobj) treatment_30\NN\654885|NONE_0 (l_prep) of_31\IN\0|the_14 (l_pobj) diseases_33\NNS\14061805|NONE_0
D013311_D003072 CID stz_20\NNP\0|-_3 (r_compound) icv_22\NN\0|NONE_0 (r_pobj) by_19\IN\0|in_11 (r_agent) caused_18\VBN\1617192|the_23|cognitive_19 (r_acl) deficits_17\NNS\5113133|NONE_0
C029036_D019636 NONE crocin_8\NNS\0|NONE_0 (r_pobj) of_7\IN\0|the_18|(_10|mg/kg_14|)_19|in_21 (r_prep) effectiveness_6\NN\5190804|therefore_41|,_32|results_24|._192 (l_prep) in_13\IN\13603305|the_39|of_21|(_11|mg/kg_7|)_2 (l_pcomp) antagonizing_14\VBG\1787955|NONE_0 (l_dobj) deficits_17\NNS\5113133|NONE_0 (l_acl) caused_18\VBN\1617192|the_23|cognitive_19 (l_prep) in_23\IN\13603305|by_11 (l_pobj) rats_24\NNS\2329401|NONE_0 (l_conj) potential_27\NN\14481929|and_8 (l_prep) in_28\IN\13603305|its_14 (l_pobj) treatment_30\NN\654885|NONE_0 (l_prep) of_31\IN\0|the_14 (l_pobj) diseases_33\NNS\14061805|NONE_0
D013311_D007859 NONE stz_17\NNP\0|-_3 (r_npadvmod) injected_19\VBN\81072|treated_12|in_15 (r_amod) group_20\NN\2137|NONE_0 (r_pobj) in_15\IN\13603305|dose_67|attenuated_42|learning_31 (r_prep) impairment_14\NN\7296428|NONE_0
C029036_D003072 NONE crocin_8\NNS\0|NONE_0 (r_pobj) of_7\IN\0|the_18|(_10|mg/kg_14|)_19|in_21 (r_prep) effectiveness_6\NN\5190804|therefore_41|,_32|results_24|._192 (l_prep) in_13\IN\13603305|the_39|of_21|(_11|mg/kg_7|)_2 (l_pcomp) antagonizing_14\VBG\1787955|NONE_0 (l_dobj) deficits_17\NNS\5113133|NONE_0
19674115
D011718_D033461 NONE pyrazinamide_0\NNP\0|can_13|effects_30|._100 (r_nsubj) have_2\VB\7846|NONE_0 (l_dobj) effects_4\NNS\13245626|pyrazinamide_30|can_17|._70 (l_prep) as_6\IN\14622893|adverse_21 (l_pobj) toxicity_8\NN\13576101|such_16 (l_conj) disorders_13\NNS\14034177|hepatic_45|,_29 (l_nmod) hyperuricemia_10\NN\0|NONE_0
D011718_D000857 CID pyrazinamide_4\NN\0|NONE_0 (r_pobj) by_3\IN\0|dysosmia_17|._15 (r_agent) induced_2\VBN\1627355|NONE_0 (l_nsubj) dysosmia_1\NN\14052403|by_17|._32
D011718_D000857 CID pyrazinamide_10\VB\0|NONE_0 (r_xcomp) related_8\VBN\628491|reversible_30|olfactory_19 (r_acl) disorder_7\NN\14034177|NONE_0
D011718_D000857 CID pyrazinamide_4\JJ\0|NONE_0 (r_compound) withdrawal_5\NN\7206096|completely_30 (r_pobj) after_3\IN\0|dysosmia_32|and_30|recurred_34|._64 (r_prep) disappeared_1\VBD\0|NONE_0 (l_nsubj) dysosmia_0\NNP\14052403|after_32|and_62|recurred_66|._96
D011718_D056486 NONE pyrazinamide_0\NNP\0|can_13|effects_30|._100 (r_nsubj) have_2\VB\7846|NONE_0 (l_dobj) effects_4\NNS\13245626|pyrazinamide_30|can_17|._70 (l_prep) as_6\IN\14622893|adverse_21 (l_pobj) toxicity_8\NN\13576101|such_16
19944736
D018021_D012640 CID licl_4\NNP\0|NONE_0 (r_pobj) in_3\IN\13603305|NONE_0 (r_prep) administered_2\VBN\2436349|,_2|rats_33|,_37 (r_acl) tacrine_0\NNP\0|seizures_78|and_87|delayed_91|._117 (r_nsubj) induces_10\VBZ\1627355|NONE_0 (l_dobj) seizures_12\NNS\14081375|tacrine_78|and_9|delayed_13|._39
D013619_D004827 NONE tacrine_5\NN\0|-_7 (r_npadvmod) loaded_7\VBN\452512|NONE_0 (r_amod) nanoparticles_8\NNS\0|NONE_0 (r_pobj) with_4\IN\0|animals_16 (r_prep) treated_3\VBN\2376958|outcome_60|._208 (r_csubj) showed_9\VBD\2137132|NONE_0 (l_dobj) outcome_12\NN\7291312|treated_60|._148 (l_prep) of_13\IN\0|an_19|earlier_16|with_47 (l_pobj) symptoms_16\NNS\5823932|NONE_0 (l_appos) onset_20\NN\7325190|cns_37|adverse_33|,_17|,_5 (l_amod) epileptic_19\JJ\10595647|i.e._5
D013619_D004827 NONE tacrine_22\NN\0|-_7 (r_compound) lithium_24\NN\14625458|the_12|of_14|in_26 (r_compound) model_25\NN\5888929|NONE_0 (l_prep) of_26\IN\0|the_26|lithium_14|in_12 (l_pobj) epilepsy_27\NN\14085708|NONE_0
D008094_D004827 NONE lithium_24\NN\14625458|the_12|of_14|in_26 (r_compound) model_25\NN\5888929|NONE_0 (l_prep) of_26\IN\0|the_26|lithium_14|in_12 (l_pobj) epilepsy_27\NN\14085708|NONE_0
D013619_D001930 CID tacrine_0\NNP\0|seizures_78|and_87|delayed_91|._117 (r_nsubj) induces_10\VBZ\1627355|NONE_0 (l_conj) delayed_14\VBD\439958|tacrine_91|seizures_13|and_4|._26 (l_dobj) damage_16\NN\7296428|NONE_0
D013619_D001930 CID tacrine_3\NN\0|-_7 (r_npadvmod) loaded_5\VBN\452512|nanoparticles_7 (r_amod) administration_7\NN\1133281|in_42|,_31|damage_23|,_102|solution_121|._163 (r_nsubj) induced_8\VBD\1627355|NONE_0 (l_dobj) damage_9\NN\7296428|in_65|,_54|administration_23|,_79|solution_98|._140 (l_prep) of_10\IN\0|in_50 (l_pobj) cells_12\NNS\3080309|NONE_0
D013619_D001930 CID tacrine_29\NN\0|NONE_0 (r_pobj) of_28\IN\0|while_26|the_20|saline_16|%_21 (r_prep) solution_27\NN\14586258|in_163|,_152|administration_121|damage_98|,_19|._42 (r_advcl) induced_8\VBD\1627355|NONE_0 (l_dobj) damage_9\NN\7296428|in_65|,_54|administration_23|,_79|solution_98|._140 (l_prep) of_10\IN\0|in_50 (l_pobj) cells_12\NNS\3080309|NONE_0
D018021_D001930 CID licl_4\NNP\0|NONE_0 (r_pobj) in_3\IN\13603305|NONE_0 (r_prep) administered_2\VBN\2436349|,_2|rats_33|,_37 (r_acl) tacrine_0\NNP\0|seizures_78|and_87|delayed_91|._117 (r_nsubj) induces_10\VBZ\1627355|NONE_0 (l_conj) delayed_14\VBD\439958|tacrine_91|seizures_13|and_4|._26 (l_dobj) damage_16\NN\7296428|NONE_0
D013619_D012640 CID tacrine_0\NNP\0|seizures_78|and_87|delayed_91|._117 (r_nsubj) induces_10\VBZ\1627355|NONE_0 (l_dobj) seizures_12\NNS\14081375|tacrine_78|and_9|delayed_13|._39
1141447
D008094_D003919 CID lithium_7\NN\14625458|-_7 (r_npadvmod) induced_9\VBN\1627355|diabetes_8 (r_amod) insipidus_11\NN\0|NONE_0
D008094_D003919 CID lithium_3\NN\14625458|-_7 (r_npadvmod) induced_5\VBN\1627355|diabetes_8 (r_amod) insipidus_7\NN\0|NONE_0
8686832
D000431_D010146 NONE alcohol_27\NN\7881800|a_7|high_5|,_14|be_28 (r_compound) intake_28\NN\13440063|NONE_0 (r_pobj) to_24\IN\0|NONE_0 (r_prep) admitted_23\VBD\822367|NONE_0 (r_acl) pain_22\NN\14299637|NONE_0 (r_pobj) without_21\IN\0|and_35|seven_31 (r_prep) pain_10\NN\14299637|NONE_0
D000431_D010146 NONE alcohol_27\NN\7881800|a_7|high_5|,_14|be_28 (r_compound) intake_28\NN\13440063|NONE_0 (r_pobj) to_24\IN\0|NONE_0 (r_prep) admitted_23\VBD\822367|NONE_0 (r_acl) pain_22\NN\14299637|NONE_0
D008012_D001416 CID lignocaine_11\NN\0|NONE_0 (r_dobj) involving_7\VBG\2676054|spinal_19 (r_acl) anaesthesia_6\NN\14034177|NONE_0 (r_pobj) after_4\IN\0|back_10 (r_prep) pain_3\NN\14299637|and_9|._64
D008012_D001416 CID lignocaine_14\NN\0|NONE_0 (r_pobj) of_10\IN\0|the_20|intrathecal_16 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) with_6\IN\0|leg_35|is_14|._52 (r_prep) associated_5\VBN\628491|NONE_0 (l_nsubjpass) leg_0\NNP\5560244|is_21|with_35|._87 (l_conj) pain_3\NN\14299637|and/or_12|back_5
11185967
D000431_D019969 NONE alcohol_8\NN\7881800|-_7 (r_npadvmod) related_10\VBN\628491|seizure_8 (r_amod) disorder_12\NN\14034177|underlying_43|or_27 (r_conj) drug_6\NN\14778436|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) history_3\NN\15120823|patient_22|,_2|,_62 (r_appos) demographics_1\NNS\6021499|time_88|from_93|,_180|results_182|recorded_259|._295 (r_nsubj) estimated_14\VBN\637259|NONE_0 (l_prep) from_16\IN\0|demographics_93|time_5|,_87|results_89|recorded_166|._202 (l_prep) to_18\IN\0|seizure_8 (l_pobj) collection_20\NN\31264|NONE_0 (l_conj) history_22\NN\15120823|sample_19|,_2 (l_conj) suspicion_24\NN\5916739|or_3 (l_prep) of_25\IN\0|NONE_0 (l_pobj) cocaine_26\NN\3492717|NONE_0 (l_conj) abuse_29\NN\418025|or_15
D000431_D012640 NONE alcohol_8\NN\7881800|-_7 (r_npadvmod) related_10\VBN\628491|seizure_8 (r_amod) disorder_12\NN\14034177|underlying_43|or_27 (l_compound) seizure_11\NN\14081375|related_8
D000431_D012640 NONE alcohol_8\NN\7881800|-_7 (r_npadvmod) related_10\VBN\628491|seizure_8 (r_amod) disorder_12\NN\14034177|underlying_43|or_27 (r_conj) drug_6\NN\14778436|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) history_3\NN\15120823|patient_22|,_2|,_62 (r_appos) demographics_1\NNS\6021499|time_88|from_93|,_180|results_182|recorded_259|._295 (r_nsubj) estimated_14\VBN\637259|NONE_0 (l_prep) from_16\IN\0|demographics_93|time_5|,_87|results_89|recorded_166|._202 (l_pobj) seizure_17\NN\14081375|to_8
D000431_D019970 NONE alcohol_8\NN\7881800|-_7 (r_npadvmod) related_10\VBN\628491|seizure_8 (r_amod) disorder_12\NN\14034177|underlying_43|or_27 (r_conj) drug_6\NN\14778436|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) history_3\NN\15120823|patient_22|,_2|,_62 (r_appos) demographics_1\NNS\6021499|time_88|from_93|,_180|results_182|recorded_259|._295 (r_nsubj) estimated_14\VBN\637259|NONE_0 (l_prep) from_16\IN\0|demographics_93|time_5|,_87|results_89|recorded_166|._202 (l_prep) to_18\IN\0|seizure_8 (l_pobj) collection_20\NN\31264|NONE_0 (l_conj) history_22\NN\15120823|sample_19|,_2 (l_conj) suspicion_24\NN\5916739|or_3 (l_prep) of_25\IN\0|NONE_0 (l_pobj) cocaine_26\NN\3492717|NONE_0 (l_conj) abuse_29\NN\418025|or_15
D003042_D012640 NONE cocaine_16\NN\3492717|NONE_0 (l_prep) in_19\IN\13603305|or_15|amphetamine_12 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_compound) seizure_23\NN\14081375|emergency_21
D003042_D012640 NONE cocaine_9\NN\3492717|NONE_0 (l_prep) in_12\IN\13603305|and_17|amphetamines_13 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_compound) seizure_14\NN\14081375|NONE_0
D000661_D012640 NONE amphetamine_18\NN\3248958|or_3|in_12 (r_conj) cocaine_16\NN\3492717|NONE_0 (l_prep) in_19\IN\13603305|or_15|amphetamine_12 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_compound) seizure_23\NN\14081375|emergency_21
D000662_D012640 NONE amphetamines_11\NNS\3248958|and_4|in_13 (r_conj) cocaine_9\NN\3492717|NONE_0 (l_prep) in_12\IN\13603305|and_17|amphetamines_13 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_compound) seizure_14\NN\14081375|NONE_0
9564988
D064704_D012852 NONE levofloxacin_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|label_17|for_16|._72 (r_prep) assessment_3\NN\5732756|NONE_0 (l_prep) for_6\IN\0|label_33|of_16|._56 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14|in_29 (l_pobj) sinusitis_12\NN\14336539|NONE_0
D064704_D012852 NONE levofloxacin_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_24|and_11|safety_7 (r_prep) efficacy_3\NN\5199286|to_16|daily_56|in_81|._141 (r_dobj) evaluate_1\VB\670261|NONE_0 (l_prep) in_20\IN\13603305|to_97|efficacy_81|daily_25|._60 (l_pcomp) treating_21\VBG\2376958|NONE_0 (l_prep) with_24\IN\0|outpatients_12 (l_pobj) sinusitis_27\NN\14336539|NONE_0
D064704_D012852 NONE levofloxacin_7\VBZ\0|results_36|is_31|._95 (r_ccomp) indicate_5\VBP\952524|NONE_0 (l_ccomp) is_12\VBZ\0|results_67|levofloxacin_31|._64 (l_attr) treatment_17\NN\654885|NONE_0 (l_prep) for_18\IN\0|an_32|effective_29 (l_pobj) sinusitis_21\NN\14336539|NONE_0
10565806
C076029_D001714 CID olanzapine_6\NN\0|NONE_0 (r_pobj) by_5\IN\0|hypomania_32|._13 (r_prep) induced_4\VBN\1627355|NONE_0 (l_nsubj) hypomania_0\NNP\0|by_32|._45
C076029_D001714 CID olanzapine_28\JJ\0|NONE_0 (r_compound) treatment_29\NN\654885|NONE_0 (r_pobj) of_27\IN\0|the_17 (r_prep) introduction_26\NN\235435|shortly_18 (r_pobj) after_24\IN\0|who_32|hypomania_18 (r_prep) developed_21\VBD\1753788|a_58|specified_42|psychotic_32|iv_8 (l_dobj) hypomania_22\NN\0|who_14|after_18
C076029_D011618 NONE olanzapine_28\JJ\0|NONE_0 (r_compound) treatment_29\NN\654885|NONE_0 (r_pobj) of_27\IN\0|the_17 (r_prep) introduction_26\NN\235435|shortly_18 (r_pobj) after_24\IN\0|who_32|hypomania_18 (r_prep) developed_21\VBD\1753788|a_58|specified_42|psychotic_32|iv_8 (r_relcl) disorder_14\NN\14034177|NONE_0
9672273
D013629_D014652 CID tamoxifen_20\NN\2714883|NONE_0 (r_pobj) on_19\IN\0|NONE_0 (r_prep) women_18\NNS\9605289|NONE_0 (r_pobj) among_17\IN\0|vascular_42|and_26|hypertriglyceridaemia_22 (r_prep) events_14\NNS\23100|NONE_0
D013629_D016889 NONE tamoxifen_0\NNP\2714883|agent_41|,_63|associated_90|._143 (r_nsubj) is_1\VBZ\0|NONE_0 (l_advcl) associated_15\VBN\628491|tamoxifen_90|agent_49|,_27|._53 (l_prep) with_16\IN\0|although_36|drug_23|may_18|be_14 (l_pobj) development_18\NN\248977|NONE_0 (l_prep) of_19\IN\0|the_16 (l_pobj) cancer_21\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_5\NN\2714883|NONE_0 (r_pobj) with_4\IN\0|of_17|:_14|findings_28|._98 (r_prep) prevention_0\NN\1073995|NONE_0 (l_prep) of_1\IN\0|with_17|:_31|findings_45|._115 (l_pobj) cancer_3\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_0\NNP\2714883|agent_41|,_63|associated_90|._143 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agent_5\NN\7347|tamoxifen_41|,_22|associated_49|._102 (l_prep) in_6\IN\13603305|a_34|candidate_32|chemopreventive_22 (l_pobj) cancer_8\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_18\NN\2714883|NONE_0 (r_pobj) of_17\IN\0|a_52|blind_43|controlled_29|,_19|randomised_17|in_13|(_22|in_30|)_38|have_52 (r_prep) trial_16\NN\786195|in_75|,_59|we_57|._107 (l_relcl) have_29\VB\7846|a_104|blind_95|controlled_81|,_71|randomised_69|of_52|in_39|(_30|in_22|)_14 (l_dobj) cancer_31\NN\14239425|who_24|did_20|not_16|and_7|had_19
D013629_D001943 NONE tamoxifen_17\NN\2714883|(_10|19_11|)_13 (r_nmod) arms_21\NNS\3575240|the_42|(_30|cases_26|)_21|and_19 (r_conj) placebo_11\NN\3740161|NONE_0 (r_pobj) between_9\IN\0|cancer_17 (r_prep) frequency_8\NN\15286249|NONE_0 (l_compound) cancer_7\NN\14239425|between_17
D013629_D001943 NONE tamoxifen_12\NN\2714883|NONE_0 (r_dobj) receiving_11\VBG\2210855|used_29 (r_acl) women_10\NNS\9605289|NONE_0 (r_pobj) among_9\IN\0|a_55|significant_39|of_17|:_90|among_92 (r_prep) reduction_5\NN\351485|there_37 (l_prep) of_6\IN\0|a_38|significant_22|among_17|:_107|among_109 (l_pobj) cancer_8\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_12\NN\2714883|NONE_0 (r_dobj) receiving_11\VBG\2210855|used_29 (r_acl) women_10\NNS\9605289|NONE_0 (r_pobj) among_9\IN\0|a_55|significant_39|of_17|:_90|among_92 (r_prep) reduction_5\NN\351485|there_37 (r_attr) is_1\VBZ\0|,_206|we_208|cases_223|compared_246|._307 (r_ccomp) found_36\VBD\13279262|NONE_0 (l_dobj) cases_38\NNS\7283608|is_223|,_17|we_15|compared_23|._84 (l_prep) of_39\IN\0|eight_12 (l_pobj) cancer_41\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_51\NN\2714883|NONE_0 (r_pobj) to_50\IN\0|NONE_0 (r_prep) allocated_49\VBN\2228698|362_10 (r_acl) women_48\NNS\9605289|NONE_0 (r_pobj) among_46\IN\0|one_9 (r_prep) case_45\NN\7283608|NONE_0 (r_pobj) with_43\IN\0|NONE_0 (r_prep) compared_42\VBN\644583|is_246|,_40|we_38|cases_23|._61 (r_prep) found_36\VBD\13279262|NONE_0 (l_ccomp) is_1\VBZ\0|,_206|we_208|cases_223|compared_246|._307 (l_attr) reduction_5\NN\351485|there_37 (l_prep) of_6\IN\0|a_38|significant_22|among_17|:_107|among_109 (l_pobj) cancer_8\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_51\NN\2714883|NONE_0 (r_pobj) to_50\IN\0|NONE_0 (r_prep) allocated_49\VBN\2228698|362_10 (r_acl) women_48\NNS\9605289|NONE_0 (r_pobj) among_46\IN\0|one_9 (r_prep) case_45\NN\7283608|NONE_0 (r_pobj) with_43\IN\0|NONE_0 (r_prep) compared_42\VBN\644583|is_246|,_40|we_38|cases_23|._61 (r_prep) found_36\VBD\13279262|NONE_0 (l_dobj) cases_38\NNS\7283608|is_223|,_17|we_15|compared_23|._84 (l_prep) of_39\IN\0|eight_12 (l_pobj) cancer_41\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_29\NN\2714883|NONE_0 (r_pobj) of_28\IN\0|the_34|postulated_30|protective_19 (r_prep) effects_27\NNS\13245626|has_105|,_92|in_90|,_28|not_25|apparent_33|._41 (r_nsubj) are_30\VBP\13600404|NONE_0 (l_prep) in_8\IN\13603305|has_15|,_2|,_62|effects_90|not_115|apparent_123|._131 (l_prep) at_13\IN\14622893|cohort_16 (l_pobj) risk_19\NN\14541044|NONE_0 (l_prep) of_20\IN\0|low_19 (l_pobj) cancer_22\NN\14239425|NONE_0
D013629_D015228 CID tamoxifen_20\NN\2714883|NONE_0 (r_pobj) on_19\IN\0|NONE_0 (r_prep) women_18\NNS\9605289|NONE_0 (r_pobj) among_17\IN\0|vascular_42|and_26|hypertriglyceridaemia_22 (r_prep) events_14\NNS\23100|NONE_0 (l_conj) hypertriglyceridaemia_16\NN\0|vascular_20|and_4|among_22
11077455
D020888_D014786 CID vigabatrin_16\NN\0|-_10 (r_npadvmod) attributed_18\VBN\670261|field_18 (r_amod) constriction_21\NN\5071027|NONE_0
D020888_D014786 CID vigabatrin_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|to_17|be_14 (r_prep) associated_7\VBN\628491|constriction_27 (r_xcomp) thought_4\NN\5809192|has_41|been_45|._58 (l_nsubj) constriction_3\NN\5071027|associated_27
D020888_D014786 CID vigabatrin_15\NN\0|-_10 (r_npadvmod) attributed_17\VBN\670261|known_17|field_18 (r_amod) loss_20\NN\13252973|NONE_0
D020888_D014786 CID vigabatrin_9\NN\0|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) with_8\IN\0|to_17|be_14 (r_prep) associated_7\VBN\628491|constriction_27|._34 (r_xcomp) appears_4\VBZ\2604760|NONE_0 (l_nsubj) constriction_3\NN\5071027|associated_27|._61
1423339
D011433_D064420 NONE propranolol_4\JJ\0|NONE_0 (r_amod) toxicity_5\NN\13576101|NONE_0
D011433_D064420 NONE propranolol_14\JJ\0|NONE_0 (r_amod) toxicity_15\NN\13576101|NONE_0
D011433_D003704 NONE propranolol_14\JJ\0|NONE_0 (r_amod) toxicity_15\NN\13576101|NONE_0 (r_pobj) of_13\IN\0|a_9 (r_prep) result_12\NN\34213|NONE_0 (r_pobj) as_10\IN\14622893|woman_52|dementia_9|._35 (r_prep) developed_3\VBD\1753788|NONE_0 (l_dobj) dementia_9\NN\14395018|woman_43|as_9|._44
D011433_D000647 CID propranolol_4\JJ\0|NONE_0 (r_amod) toxicity_5\NN\13576101|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|amnestic_18|:_36|report_45|._51 (r_acl) syndrome_1\NN\5870365|NONE_0
D011433_D000544 NONE propranolol_14\JJ\0|NONE_0 (r_amod) toxicity_15\NN\13576101|NONE_0 (r_pobj) of_13\IN\0|a_9 (r_prep) result_12\NN\34213|NONE_0 (r_pobj) as_10\IN\14622893|woman_52|dementia_9|._35 (r_prep) developed_3\VBD\1753788|NONE_0 (l_dobj) dementia_9\NN\14395018|woman_43|as_9|._44 (l_amod) like_7\JJ\5839024|an_13|subacute_5 (l_npadvmod) alzheimer_5\NNP\0|-_9
7710775
D001241_D007511 NONE acetylsalicylate_4\VBP\0|NONE_0 (l_prep) before_7\IN\0|of_75|,_15|other_21|._58 (l_pobj) ischemia_8\NN\14195315|intravenously_33|immediately_19
D008315_D007022 NONE malondialdehyde_23\NN\0|NONE_0 (r_pobj) in_19\IN\13603305|although_9|higher_55 (r_prep) was_24\VBD\0|of_153|/_82|intravenously_77|during_63|,_48|._24 (r_advcl) min_13\NN\15154774|NONE_0 (l_prep) of_0\IN\0|/_71|intravenously_76|during_90|,_105|was_153|._177 (l_pobj) drug_3\NN\14778436|NONE_0 (l_amod) hypotensive_2\JJ\10405694|the_4|nitroprusside_17
D009705_D002545 NONE nucleosides_9\NNS\14887305|dependence_54|,_6|and_4|._58 (l_prep) during_10\IN\0|NONE_0 (l_pobj) ischemia_13\NN\14195315|NONE_0
-1_D007511 NONE oxypurines_10\NNS\0|NONE_0 (r_pobj) of_8\IN\0|a_26|dependent_19 (r_prep) increase_7\NN\13576355|during_34|,_19|was_46|._58 (r_nsubjpass) observed_14\VBN\2163746|NONE_0 (l_prep) during_0\IN\0|,_15|increase_34|was_80|._92 (l_pobj) ischemia_1\NN\14195315|NONE_0
-1_D007511 NONE oxypurines_10\NNS\0|,_2 (r_conj) malondialdehyde_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_18 (r_prep) determination_6\NN\43195|that_9|,_81|may_83|be_87|monitor_98 (r_nsubjpass) used_20\VBN\0|data_113|._88 (l_xcomp) monitor_22\VB\10676877|that_107|determination_98|,_17|may_15|be_11 (l_dobj) alterations_25\NNS\7283608|to_25 (l_acl) occurring_28\VBG\0|the_37|metabolic_33|of_11 (l_prep) during_29\IN\0|NONE_0 (l_pobj) phenomena_31\NNS\29677|NONE_0 (l_amod) ischemic_30\JJ\0|NONE_0
D008315_D007511 NONE malondialdehyde_1\NN\0|after_114|,_137|resulting_139|._242 (r_nsubj) increased_23\VBD\169651|NONE_0 (l_prep) after_24\IN\0|malondialdehyde_114|,_23|resulting_25|._128 (l_pobj) min_26\NN\15154774|NONE_0 (l_prep) of_27\IN\0|5_6 (l_pobj) ischemia_28\NN\14195315|NONE_0
D008315_D007511 NONE malondialdehyde_23\NN\0|NONE_0 (r_pobj) in_19\IN\13603305|although_9|higher_55 (r_prep) was_24\VBD\0|of_153|/_82|intravenously_77|during_63|,_48|._24 (r_advcl) min_13\NN\15154774|NONE_0 (l_prep) during_15\IN\0|of_90|/_19|intravenously_14|,_15|was_63|._87 (l_pobj) ischemia_16\NN\14195315|NONE_0
D008315_D007511 NONE malondialdehyde_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_18 (r_prep) determination_6\NN\43195|that_9|,_81|may_83|be_87|monitor_98 (r_nsubjpass) used_20\VBN\0|data_113|._88 (l_xcomp) monitor_22\VB\10676877|that_107|determination_98|,_17|may_15|be_11 (l_dobj) alterations_25\NNS\7283608|to_25 (l_acl) occurring_28\VBG\0|the_37|metabolic_33|of_11 (l_prep) during_29\IN\0|NONE_0 (l_pobj) phenomena_31\NNS\29677|NONE_0 (l_amod) ischemic_30\JJ\0|NONE_0
-1_D002545 NONE oxypurines_6\NNS\0|NONE_0 (l_conj) nucleosides_9\NNS\14887305|dependence_54|,_6|and_4|._58 (l_prep) during_10\IN\0|NONE_0 (l_pobj) ischemia_13\NN\14195315|NONE_0
D008315_D002545 CID malondialdehyde_4\NN\0|NONE_0 (r_pobj) of_2\IN\0|time_16 (r_prep) dependence_1\NN\24720|,_48|and_50|nucleosides_54|._112 (r_nsubj) oxypurines_6\NNS\0|NONE_0 (l_conj) nucleosides_9\NNS\14887305|dependence_54|,_6|and_4|._58 (l_prep) during_10\IN\0|NONE_0 (l_pobj) ischemia_13\NN\14195315|NONE_0
D009599_D007511 NONE nitroprusside_4\NN\0|the_21|hypotensive_17 (r_acl) drug_3\NN\14778436|NONE_0 (r_pobj) of_0\IN\0|/_71|intravenously_76|during_90|,_105|was_153|._177 (r_prep) min_13\NN\15154774|NONE_0 (l_prep) during_15\IN\0|of_90|/_19|intravenously_14|,_15|was_63|._87 (l_pobj) ischemia_16\NN\14195315|NONE_0
D009705_D007511 NONE nucleosides_12\NNS\14887305|plasma_22|and_4 (r_conj) oxypurines_10\NNS\0|NONE_0 (r_pobj) of_8\IN\0|a_26|dependent_19 (r_prep) increase_7\NN\13576355|during_34|,_19|was_46|._58 (r_nsubjpass) observed_14\VBN\2163746|NONE_0 (l_prep) during_0\IN\0|,_15|increase_34|was_80|._92 (l_pobj) ischemia_1\NN\14195315|NONE_0
D009705_D007511 NONE nucleosides_13\NNS\14887305|,_6|and_4 (r_conj) oxypurines_10\NNS\0|,_2 (r_conj) malondialdehyde_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_18 (r_prep) determination_6\NN\43195|that_9|,_81|may_83|be_87|monitor_98 (r_nsubjpass) used_20\VBN\0|data_113|._88 (l_xcomp) monitor_22\VB\10676877|that_107|determination_98|,_17|may_15|be_11 (l_dobj) alterations_25\NNS\7283608|to_25 (l_acl) occurring_28\VBG\0|the_37|metabolic_33|of_11 (l_prep) during_29\IN\0|NONE_0 (l_pobj) phenomena_31\NNS\29677|NONE_0 (l_amod) ischemic_30\JJ\0|NONE_0
D009599_D007022 NONE nitroprusside_4\NN\0|the_21|hypotensive_17 (r_acl) drug_3\NN\14778436|NONE_0 (l_amod) hypotensive_2\JJ\10405694|the_4|nitroprusside_17
8888541
D012701_D011595 NONE serotonin_3\NN\14807737|5ht1a_10 (r_nmod) receptors_5\NNS\5225602|NONE_0 (r_pobj) of_2\IN\0|excessive_22 (r_prep) stimulation_1\NN\242808|syndrome_50|._173 (r_nsubj) causes_6\VBZ\7323922|NONE_0 (l_dobj) syndrome_8\NN\5870365|stimulation_50|._123 (l_prep) of_9\IN\0|a_11 (l_pobj) excess_11\NN\5119367|NONE_0 (l_relcl) consists_13\VBZ\2603699|serotonin_22 (l_prep) of_14\IN\0|that_14 (l_pcomp) shivering_15\VBG\14299637|NONE_0 (l_conj) rigidity_18\NN\5023233|,_9 (l_conj) salivation_20\NN\13553916|muscle_17|,_2 (l_conj) confusion_22\NN\13972797|,_2 (l_conj) agitation_24\NN\14373582|,_2
D012701_D011595 NONE serotonin_10\NN\14807737|consists_22 (r_compound) excess_11\NN\5119367|NONE_0 (l_relcl) consists_13\VBZ\2603699|serotonin_22 (l_prep) of_14\IN\0|that_14 (l_pcomp) shivering_15\VBG\14299637|NONE_0 (l_conj) rigidity_18\NN\5023233|,_9 (l_conj) salivation_20\NN\13553916|muscle_17|,_2 (l_conj) confusion_22\NN\13972797|,_2 (l_conj) agitation_24\NN\14373582|,_2
D014191_D003866 NONE tranylcypromine_22\NN\3783017|who_15|was_11 (l_prep) for_23\IN\0|NONE_0 (l_pobj) depression_24\NN\14373582|NONE_0
D012701_D012798 NONE serotonin_3\NN\14807737|5ht1a_10 (r_nmod) receptors_5\NNS\5225602|NONE_0 (r_pobj) of_2\IN\0|excessive_22 (r_prep) stimulation_1\NN\242808|syndrome_50|._173 (r_nsubj) causes_6\VBZ\7323922|NONE_0 (l_dobj) syndrome_8\NN\5870365|stimulation_50|._123 (l_prep) of_9\IN\0|a_11 (l_pobj) excess_11\NN\5119367|NONE_0 (l_relcl) consists_13\VBZ\2603699|serotonin_22 (l_prep) of_14\IN\0|that_14 (l_pcomp) shivering_15\VBG\14299637|NONE_0 (l_conj) rigidity_18\NN\5023233|,_9 (l_conj) salivation_20\NN\13553916|muscle_17|,_2
D012701_D012798 NONE serotonin_10\NN\14807737|consists_22 (r_compound) excess_11\NN\5119367|NONE_0 (l_relcl) consists_13\VBZ\2603699|serotonin_22 (l_prep) of_14\IN\0|that_14 (l_pcomp) shivering_15\VBG\14299637|NONE_0 (l_conj) rigidity_18\NN\5023233|,_9 (l_conj) salivation_20\NN\13553916|muscle_17|,_2
C047426_D020230 CID venlafaxine_3\NNP\0|-_11 (r_compound) tranylcypromine_5\NN\3783017|NONE_0 (r_compound) interaction_6\NN\37396|NONE_0 (r_pobj) from_2\IN\0|serotonin_19|._44 (r_prep) syndrome_1\NN\5870365|NONE_0
C047426_D020230 CID venlafaxine_3\NNP\0|-_11 (r_compound) maoi_5\NNP\2718811|a_14|resulted_22 (r_compound) interaction_6\NN\37396|we_29|._116 (l_relcl) resulted_8\VBD\2633881|a_36|maoi_22 (l_prep) in_9\IN\13603305|that_14|in_26 (l_pobj) syndrome_12\NN\5870365|NONE_0
D012701_D005334 NONE serotonin_3\NN\14807737|5ht1a_10 (r_nmod) receptors_5\NNS\5225602|NONE_0 (r_pobj) of_2\IN\0|excessive_22 (r_prep) stimulation_1\NN\242808|syndrome_50|._173 (r_nsubj) causes_6\VBZ\7323922|NONE_0 (l_dobj) syndrome_8\NN\5870365|stimulation_50|._123 (l_prep) of_9\IN\0|a_11 (l_pobj) excess_11\NN\5119367|NONE_0 (l_relcl) consists_13\VBZ\2603699|serotonin_22 (l_prep) of_14\IN\0|that_14 (l_pcomp) shivering_15\VBG\14299637|NONE_0 (l_conj) rigidity_18\NN\5023233|,_9 (l_conj) salivation_20\NN\13553916|muscle_17|,_2 (l_conj) confusion_22\NN\13972797|,_2 (l_conj) agitation_24\NN\14373582|,_2 (l_conj) hyperthermia_26\NN\14034177|and_4
D012701_D005334 NONE serotonin_10\NN\14807737|consists_22 (r_compound) excess_11\NN\5119367|NONE_0 (l_relcl) consists_13\VBZ\2603699|serotonin_22 (l_prep) of_14\IN\0|that_14 (l_pcomp) shivering_15\VBG\14299637|NONE_0 (l_conj) rigidity_18\NN\5023233|,_9 (l_conj) salivation_20\NN\13553916|muscle_17|,_2 (l_conj) confusion_22\NN\13972797|,_2 (l_conj) agitation_24\NN\14373582|,_2 (l_conj) hyperthermia_26\NN\14034177|and_4
D012701_D003221 NONE serotonin_3\NN\14807737|5ht1a_10 (r_nmod) receptors_5\NNS\5225602|NONE_0 (r_pobj) of_2\IN\0|excessive_22 (r_prep) stimulation_1\NN\242808|syndrome_50|._173 (r_nsubj) causes_6\VBZ\7323922|NONE_0 (l_dobj) syndrome_8\NN\5870365|stimulation_50|._123 (l_prep) of_9\IN\0|a_11 (l_pobj) excess_11\NN\5119367|NONE_0 (l_relcl) consists_13\VBZ\2603699|serotonin_22 (l_prep) of_14\IN\0|that_14 (l_pcomp) shivering_15\VBG\14299637|NONE_0 (l_conj) rigidity_18\NN\5023233|,_9 (l_conj) salivation_20\NN\13553916|muscle_17|,_2 (l_conj) confusion_22\NN\13972797|,_2
D012701_D003221 NONE serotonin_10\NN\14807737|consists_22 (r_compound) excess_11\NN\5119367|NONE_0 (l_relcl) consists_13\VBZ\2603699|serotonin_22 (l_prep) of_14\IN\0|that_14 (l_pcomp) shivering_15\VBG\14299637|NONE_0 (l_conj) rigidity_18\NN\5023233|,_9 (l_conj) salivation_20\NN\13553916|muscle_17|,_2 (l_conj) confusion_22\NN\13972797|,_2
D012701_D009127 NONE serotonin_3\NN\14807737|5ht1a_10 (r_nmod) receptors_5\NNS\5225602|NONE_0 (r_pobj) of_2\IN\0|excessive_22 (r_prep) stimulation_1\NN\242808|syndrome_50|._173 (r_nsubj) causes_6\VBZ\7323922|NONE_0 (l_dobj) syndrome_8\NN\5870365|stimulation_50|._123 (l_prep) of_9\IN\0|a_11 (l_pobj) excess_11\NN\5119367|NONE_0 (l_relcl) consists_13\VBZ\2603699|serotonin_22 (l_prep) of_14\IN\0|that_14 (l_pcomp) shivering_15\VBG\14299637|NONE_0 (l_conj) rigidity_18\NN\5023233|,_9
D012701_D009127 NONE serotonin_10\NN\14807737|consists_22 (r_compound) excess_11\NN\5119367|NONE_0 (l_relcl) consists_13\VBZ\2603699|serotonin_22 (l_prep) of_14\IN\0|that_14 (l_pcomp) shivering_15\VBG\14299637|NONE_0 (l_conj) rigidity_18\NN\5023233|,_9
C047426_D003866 NONE venlafaxine_3\NNP\0|-_11 (r_compound) maoi_5\NNP\2718811|a_14|resulted_22 (r_compound) interaction_6\NN\37396|we_29|._116 (l_relcl) resulted_8\VBD\2633881|a_36|maoi_22 (l_prep) in_13\IN\13603305|that_40|in_26 (l_pobj) male_18\NN\15388|NONE_0 (l_relcl) taking_21\VBG\37396|a_24|old_17 (l_dobj) tranylcypromine_22\NN\3783017|who_15|was_11 (l_prep) for_23\IN\0|NONE_0 (l_pobj) depression_24\NN\14373582|NONE_0
D003975_D009127 NONE diazepam_4\NN\2830852|NONE_0 (r_pobj) of_3\IN\0|180_7|i.v._12 (r_prep) mg_2\NN\13717155|NONE_0 (r_pobj) after_0\IN\0|he_30|tremulous_42|._90 (r_prep) remained_7\VBD\2604760|NONE_0 (l_acomp) tremulous_8\JJ\0|after_42|he_12|._48 (l_prep) with_9\IN\0|NONE_0 (l_pobj) rigidity_11\NN\5023233|NONE_0
D014191_D020230 CID tranylcypromine_5\NN\3783017|NONE_0 (r_compound) interaction_6\NN\37396|NONE_0 (r_pobj) from_2\IN\0|serotonin_19|._44 (r_prep) syndrome_1\NN\5870365|NONE_0
D014191_D020230 CID tranylcypromine_22\NN\3783017|who_15|was_11 (r_dobj) taking_21\VBG\37396|a_24|old_17 (r_relcl) male_18\NN\15388|NONE_0 (r_pobj) in_13\IN\13603305|that_40|in_26 (r_prep) resulted_8\VBD\2633881|a_36|maoi_22 (l_prep) in_9\IN\13603305|that_14|in_26 (l_pobj) syndrome_12\NN\5870365|NONE_0
7282516
D004317_D009202 CID doxorubicin_9\NN\2716866|NONE_0 (r_compound) cardiomyopathy_10\NN\14103288|NONE_0
D004317_D009202 CID doxorubicin_10\NN\2716866|NONE_0 (l_nsubj) cm_3\NNP\13649268|dxr_49|)_52 (l_amod) cardiomyopathy_1\NN\14103288|the_4|(_15|)_18|produced_20
D004317_D009202 CID doxorubicin_10\NN\2716866|NONE_0 (l_nsubj) cm_3\NNP\13649268|dxr_49|)_52
D004317_D009202 CID dxr_12\NN\0|cm_49|)_3 (r_appos) doxorubicin_10\NN\2716866|NONE_0 (l_nsubj) cm_3\NNP\13649268|dxr_49|)_52 (l_amod) cardiomyopathy_1\NN\14103288|the_4|(_15|)_18|produced_20
D004317_D009202 CID dxr_12\NN\0|cm_49|)_3 (r_appos) doxorubicin_10\NN\2716866|NONE_0 (l_nsubj) cm_3\NNP\13649268|dxr_49|)_52
D004317_D009202 CID adriamycin_1\NNP\0|(_1|)_10|opportunity_30|._142 (r_nsubj) provides_3\VBZ\2199590|NONE_0 (l_dobj) opportunity_6\NN\14481929|(_31|adriamycin_30|)_20|._112 (l_acl) analyze_8\VB\0|a_24|unique_22 (l_dobj) relationships_16\NNS\31921|to_46 (l_prep) during_17\IN\0|effect_44 (l_pobj) development_18\NN\248977|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) disease_21\NN\14061805|NONE_0
D004317_D009202 CID dxr_1\NNP\0|-_3 (r_compound) cm_3\NNP\13649268|myocardial_3
D004317_D009202 CID dxr_1\NNP\0|-_3 (r_compound) cm_3\NNP\13649268|myocardial_3 (r_nmod) damage_5\NN\7296428|NONE_0
D004317_D009202 CID dxr_15\NNP\0|NONE_0 (r_compound) dose_16\NN\3740161|cytotoxic_22|(_5|)_4 (r_appos) insult_13\NN\6714976|NONE_0 (r_pobj) of_11\IN\0|the_11 (r_prep) degree_10\NN\4916342|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) proportional_7\JJ\5855125|in_31|preserved_87|._206 (r_acomp) is_6\VBZ\0|NONE_0 (l_prep) in_0\IN\13603305|proportional_31|preserved_118|._237 (l_pobj) damage_5\NN\7296428|NONE_0 (l_nmod) cm_3\NNP\13649268|myocardial_3
D004317_D009202 CID dxr_15\NNP\0|NONE_0 (r_compound) dose_16\NN\3740161|cytotoxic_22|(_5|)_4 (r_appos) insult_13\NN\6714976|NONE_0 (r_pobj) of_11\IN\0|the_11 (r_prep) degree_10\NN\4916342|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) proportional_7\JJ\5855125|in_31|preserved_87|._206 (r_acomp) is_6\VBZ\0|NONE_0 (l_prep) in_0\IN\13603305|proportional_31|preserved_118|._237 (l_pobj) damage_5\NN\7296428|NONE_0
11838826
C047047_D011605 NONE cabergoline_55\NN\0|NONE_0 (r_pobj) with_54\IN\0|males_242|were_13|dose_23|)_49|._50 (r_prep) treated_53\VBN\2376958|NONE_0 (l_nsubjpass) males_1\NNS\15388|were_229|with_242|dose_265|)_291|._292 (l_prep) with_9\IN\0|four_28|(_17|age_16|)_2|,_105|with_107|(_169|ml_182|)_203|,_204 (l_pobj) disorder_22\NN\14034177|NONE_0 (l_conj) psychoses_24\NNS\14380140|diagnostic_91|edition_29|bipolar_20|or_3
D018967_D001714 NONE risperidone_27\NN\0|-_11 (r_npadvmod) induced_29\VBN\1627355|in_19 (r_amod) elevations_30\NNS\7445480|NONE_0 (r_pobj) with_26\IN\0|four_135|(_124|age_123|)_109|with_107|,_2|(_62|ml_75|)_96|,_97 (r_prep) males_1\NNS\15388|were_229|with_242|dose_265|)_291|._292 (l_prep) with_9\IN\0|four_28|(_17|age_16|)_2|,_105|with_107|(_169|ml_182|)_203|,_204 (l_pobj) disorder_22\NN\14034177|NONE_0
D018967_D001523 NONE risperidone_27\NN\0|-_11 (r_npadvmod) induced_29\VBN\1627355|in_19 (r_amod) elevations_30\NNS\7445480|NONE_0 (r_pobj) with_26\IN\0|four_135|(_124|age_123|)_109|with_107|,_2|(_62|ml_75|)_96|,_97 (r_prep) males_1\NNS\15388|were_229|with_242|dose_265|)_291|._292 (l_prep) with_9\IN\0|four_28|(_17|age_16|)_2|,_105|with_107|(_169|ml_182|)_203|,_204 (l_pobj) disorder_22\NN\14034177|NONE_0 (l_amod) diagnostic_10\NNP\0|edition_62|bipolar_71|or_88|psychoses_91 (l_conj) manual_13\NNP\6421301|and_16 (l_prep) of_14\IN\0|statistical_19 (l_pobj) disorders_16\NNPS\14034177|NONE_0
C047047_D001714 NONE cabergoline_55\NN\0|NONE_0 (r_pobj) with_54\IN\0|males_242|were_13|dose_23|)_49|._50 (r_prep) treated_53\VBN\2376958|NONE_0 (l_nsubjpass) males_1\NNS\15388|were_229|with_242|dose_265|)_291|._292 (l_prep) with_9\IN\0|four_28|(_17|age_16|)_2|,_105|with_107|(_169|ml_182|)_203|,_204 (l_pobj) disorder_22\NN\14034177|NONE_0
C047047_D006966 NONE cabergoline_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|induced_27 (r_prep) hyperprolactinemia_9\NN\0|NONE_0
C047047_D006966 NONE cabergoline_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) treated_14\VBN\2376958|induced_27 (r_acl) hyperprolactinemia_13\NN\0|NONE_0
C047047_D006966 NONE cabergoline_0\NNP\0|may_12|useful_19|for_26 (r_nsubj) be_2\VB\14625458|;_78|however_80|,_87|research_97|is_106|._115 (l_prep) for_4\IN\0|cabergoline_26|may_14|useful_7 (l_pobj) treatment_6\NN\654885|NONE_0 (l_prep) of_7\IN\0|the_14|in_42 (l_pobj) hyperprolactinemia_11\NN\0|NONE_0
D004298_D006966 NONE dopamine_8\NN\14807737|a_2|in_17 (r_compound) agonist_9\NN\0|NONE_0 (r_pobj) with_6\IN\0|induced_27 (r_prep) hyperprolactinemia_5\NN\0|NONE_0
D018967_D006966 CID risperidone_2\NN\0|-_11 (r_npadvmod) induced_4\VBN\1627355|with_27 (r_amod) hyperprolactinemia_5\NN\0|NONE_0
D018967_D006966 CID risperidone_0\NNP\0|is_92|with_106|._152 (r_nsubjpass) associated_16\VBN\628491|NONE_0 (l_prep) with_17\IN\0|risperidone_106|is_14|._46 (l_pobj) hyperprolactinemia_18\NN\0|NONE_0
D018967_D006966 CID risperidone_6\NN\0|-_11 (r_npadvmod) induced_8\VBN\1627355|with_27 (r_amod) hyperprolactinemia_9\NN\0|NONE_0
D018967_D006966 CID risperidone_10\NN\0|-_11 (r_npadvmod) induced_12\VBN\1627355|treated_27 (r_amod) hyperprolactinemia_13\NN\0|NONE_0
D018967_D006966 CID risperidone_8\NN\0|-_11 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) hyperprolactinemia_11\NN\0|NONE_0
D018967_D011605 NONE risperidone_27\NN\0|-_11 (r_npadvmod) induced_29\VBN\1627355|in_19 (r_amod) elevations_30\NNS\7445480|NONE_0 (r_pobj) with_26\IN\0|four_135|(_124|age_123|)_109|with_107|,_2|(_62|ml_75|)_96|,_97 (r_prep) males_1\NNS\15388|were_229|with_242|dose_265|)_291|._292 (l_prep) with_9\IN\0|four_28|(_17|age_16|)_2|,_105|with_107|(_169|ml_182|)_203|,_204 (l_pobj) disorder_22\NN\14034177|NONE_0 (l_conj) psychoses_24\NNS\14380140|diagnostic_91|edition_29|bipolar_20|or_3
C047047_D001523 NONE cabergoline_55\NN\0|NONE_0 (r_pobj) with_54\IN\0|males_242|were_13|dose_23|)_49|._50 (r_prep) treated_53\VBN\2376958|NONE_0 (l_nsubjpass) males_1\NNS\15388|were_229|with_242|dose_265|)_291|._292 (l_prep) with_9\IN\0|four_28|(_17|age_16|)_2|,_105|with_107|(_169|ml_182|)_203|,_204 (l_pobj) disorder_22\NN\14034177|NONE_0 (l_amod) diagnostic_10\NNP\0|edition_62|bipolar_71|or_88|psychoses_91 (l_conj) manual_13\NNP\6421301|and_16 (l_prep) of_14\IN\0|statistical_19 (l_pobj) disorders_16\NNPS\14034177|NONE_0
16192988
D008694_D001523 CID methamphetamine_0\NN\2704153|alterations_23|._129 (r_nsubj) causes_1\VBZ\7323922|NONE_0 (l_dobj) alterations_2\NNS\7283608|methamphetamine_23|._106 (l_relcl) display_16\VBP\6879180|in_62 (l_dobj) aggressiveness_18\NN\4835724|that_23
D008694_D001523 CID methamphetamine_18\NN\2704153|NONE_0 (r_pobj) in_17\IN\13603305|NONE_0 (r_prep) common_16\JJ\8673395|NONE_0 (r_acomp) are_15\VBP\13600404|behaviors_89|have_79|been_74|in_60|,_6|and_4|._44 (r_conj) reported_4\VBN\831651|NONE_0 (l_nsubjpass) behaviors_1\NNS\407535|have_10|been_15|in_29|,_83|and_85|are_89|._133
D008694_D001523 CID methamphetamine_18\NN\2704153|NONE_0 (r_pobj) in_17\IN\13603305|NONE_0 (r_prep) common_16\JJ\8673395|NONE_0 (r_acomp) are_15\VBP\13600404|behaviors_89|have_79|been_74|in_60|,_6|and_4|._44 (r_conj) reported_4\VBN\831651|NONE_0 (l_prep) in_5\IN\13603305|behaviors_29|have_19|been_14|,_54|and_56|are_60|._104 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_relcl) suffer_8\VBP\2110220|NONE_0 (l_prep) from_9\IN\0|who_11 (l_pobj) disorders_12\NNS\14034177|NONE_0
D008694_D001523 CID meth_20\NN\2704153|NONE_0 (r_nmod) abusers_22\NNS\9633969|(_7 (r_appos) methamphetamine_18\NN\2704153|NONE_0 (r_pobj) in_17\IN\13603305|NONE_0 (r_prep) common_16\JJ\8673395|NONE_0 (r_acomp) are_15\VBP\13600404|behaviors_89|have_79|been_74|in_60|,_6|and_4|._44 (r_conj) reported_4\VBN\831651|NONE_0 (l_nsubjpass) behaviors_1\NNS\407535|have_10|been_15|in_29|,_83|and_85|are_89|._133
D008694_D001523 CID meth_20\NN\2704153|NONE_0 (r_nmod) abusers_22\NNS\9633969|(_7 (r_appos) methamphetamine_18\NN\2704153|NONE_0 (r_pobj) in_17\IN\13603305|NONE_0 (r_prep) common_16\JJ\8673395|NONE_0 (r_acomp) are_15\VBP\13600404|behaviors_89|have_79|been_74|in_60|,_6|and_4|._44 (r_conj) reported_4\VBN\831651|NONE_0 (l_prep) in_5\IN\13603305|behaviors_29|have_19|been_14|,_54|and_56|are_60|._104 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_relcl) suffer_8\VBP\2110220|NONE_0 (l_prep) from_9\IN\0|who_11 (l_pobj) disorders_12\NNS\14034177|NONE_0
D008694_D001523 CID meth_13\NNP\2704153|NONE_0 (r_pobj) of_12\IN\0|multiple_37|(_28|single_19|)_13 (r_prep) injections_11\NNS\320852|that_31|significantly_19|aggressiveness_43 (r_nsubj) increased_15\VBD\169651|herein_82|,_76|we_74|._42 (l_dobj) aggressiveness_16\NN\4835724|that_74|injections_43|significantly_24
D008694_D001523 CID meth_8\NNP\2704153|-_4 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) hyperactivity_11\NN\14052403|NONE_0 (r_pobj) to_7\IN\0|NONE_0 (r_prep) secondary_6\JJ\8426461|increase_35|not_4|._39 (r_acomp) was_4\VBD\0|NONE_0 (l_nsubj) increase_1\NN\13576355|not_31|secondary_35|._74 (l_prep) in_2\IN\13603305|this_14 (l_pobj) aggressiveness_3\NN\4835724|NONE_0
D008694_D006948 NONE meth_8\NNP\2704153|-_4 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) hyperactivity_11\NN\14052403|NONE_0
1732442
D004317_D009202 CID adriamycin_8\NNS\0|-_10 (r_npadvmod) induced_10\VBN\1627355|with_23 (r_amod) cardiomyopathy_11\NN\14103288|NONE_0
D004317_D009202 CID adriamycin_5\NNS\0|-_10 (r_amod) induced_7\VBN\1627355|NONE_0 (r_amod) cardiomyopathy_8\NN\14103288|NONE_0
D004317_D009202 CID adriamycin_5\NNS\0|-_10 (r_amod) induced_7\VBN\1627355|NONE_0 (r_amod) cardiomyopathy_8\NN\14103288|NONE_0 (r_pobj) of_4\IN\0|a_12|rat_10 (r_prep) model_3\NN\5888929|NONE_0 (r_dobj) using_0\VBG\418025|,_54|we_56|hypothesis_70|._205 (r_advcl) tested_11\VBD\670261|NONE_0 (l_dobj) hypothesis_13\NN\7162194|using_70|,_16|we_14|._135 (l_acl) appear_21\VB\2604760|the_68 (l_conj) exacerbated_24\VBN\126264|that_67|activity_27|may_18|and_7 (l_advmod) dependently_27\RB\0|be_20 (l_prep) in_28\IN\13603305|dose_17|-_13 (l_pobj) cardiomyopathy_30\NN\14103288|NONE_0
D004317_D009202 CID adriamycin_29\FW\0|NONE_0 (r_amod) cardiomyopathy_30\NN\14103288|NONE_0 (r_pobj) in_28\IN\13603305|dose_17|-_13 (r_prep) dependently_27\RB\0|be_20 (r_advmod) exacerbated_24\VBN\126264|that_67|activity_27|may_18|and_7 (r_conj) appear_21\VB\2604760|the_68 (r_acl) hypothesis_13\NN\7162194|using_70|,_16|we_14|._135 (r_dobj) tested_11\VBD\670261|NONE_0 (l_advcl) using_0\VBG\418025|,_54|we_56|hypothesis_70|._205 (l_dobj) model_3\NN\5888929|NONE_0 (l_prep) of_4\IN\0|a_12|rat_10 (l_pobj) cardiomyopathy_8\NN\14103288|NONE_0
D004317_D009202 CID adriamycin_29\FW\0|NONE_0 (r_amod) cardiomyopathy_30\NN\14103288|NONE_0
D004317_D009202 CID adriamycin_34\NNS\0|-_10 (r_amod) induced_36\VBN\1627355|NONE_0 (r_amod) cardiomyopathy_37\NN\14103288|NONE_0 (r_pobj) of_33\IN\0|NONE_0 (r_prep) detection_32\NN\5708432|NONE_0 (r_pobj) for_31\IN\0|a_16|useful_14 (r_prep) method_30\NN\5616786|that_39|scintigraphy_29|may_16 (r_attr) be_27\VB\14625458|appearance_186|._69 (r_ccomp) indicates_22\VBZ\952524|NONE_0 (l_nsubj) appearance_1\NN\4723816|be_186|._255 (l_prep) of_2\IN\0|the_15 (l_pobj) activity_7\NN\30358|NONE_0 (l_prep) in_8\IN\13603305|impaired_44|cardiac_35|neuron_16 (l_pobj) presence_10\NN\13954253|NONE_0 (l_prep) of_11\IN\0|the_13 (l_pobj) impairment_14\NN\7296428|NONE_0
D004317_D009202 CID adriamycin_34\NNS\0|-_10 (r_amod) induced_36\VBN\1627355|NONE_0 (r_amod) cardiomyopathy_37\NN\14103288|NONE_0
D004317_C536522 NONE adriamycin_16\JJ\0|NONE_0 (r_amod) treatment_17\NN\654885|NONE_0 (r_pobj) of_15\IN\0|the_13 (r_prep) duration_14\NN\15113229|NONE_0 (r_pobj) to_12\IN\0|NONE_0 (r_prep) relation_11\NN\2137|NONE_0 (r_pobj) in_10\IN\13603305|degree_65|was_13|mg/kg_55|._74 (r_prep) analyzed_9\VBN\0|NONE_0 (l_nsubjpass) degree_1\NN\4916342|was_52|in_65|mg/kg_120|._139 (l_prep) of_2\IN\0|the_11 (l_pobj) degeneration_4\NN\29677|NONE_0 (l_prep) of_5\IN\0|vacuolar_22 (l_pobj) cells_7\NNS\3080309|NONE_0
D004317_C536522 NONE adriamycin_34\NNS\0|-_10 (r_amod) induced_36\VBN\1627355|NONE_0 (r_amod) cardiomyopathy_37\NN\14103288|NONE_0 (r_pobj) of_33\IN\0|NONE_0 (r_prep) detection_32\NN\5708432|NONE_0 (r_pobj) for_31\IN\0|a_16|useful_14 (r_prep) method_30\NN\5616786|that_39|scintigraphy_29|may_16 (r_attr) be_27\VB\14625458|appearance_186|._69 (r_ccomp) indicates_22\VBZ\952524|NONE_0 (l_nsubj) appearance_1\NN\4723816|be_186|._255 (l_prep) of_2\IN\0|the_15 (l_pobj) activity_7\NN\30358|NONE_0 (l_prep) in_8\IN\13603305|impaired_44|cardiac_35|neuron_16 (l_pobj) presence_10\NN\13954253|NONE_0 (l_prep) of_11\IN\0|the_13 (l_pobj) impairment_14\NN\7296428|NONE_0 (l_appos) degeneration_20\NN\29677|slight_58|myocardial_51|(_29|)_12
D019797_C536522 NONE mibg_24\NNP\0|NONE_0 (r_compound) scintigraphy_25\NN\0|that_10|may_13|method_29 (r_nsubj) be_27\VB\14625458|appearance_186|._69 (r_ccomp) indicates_22\VBZ\952524|NONE_0 (l_nsubj) appearance_1\NN\4723816|be_186|._255 (l_prep) of_2\IN\0|the_15 (l_pobj) activity_7\NN\30358|NONE_0 (l_prep) in_8\IN\13603305|impaired_44|cardiac_35|neuron_16 (l_pobj) presence_10\NN\13954253|NONE_0 (l_prep) of_11\IN\0|the_13 (l_pobj) impairment_14\NN\7296428|NONE_0 (l_appos) degeneration_20\NN\29677|slight_58|myocardial_51|(_29|)_12
D019797_D009202 NONE iodine-125-metaiodobenzylguanidine_13\NNP\0|NONE_0 (r_pcomp) with_12\IN\0|induced_23 (r_prep) cardiomyopathy_11\NN\14103288|NONE_0
D019797_D009202 NONE mibg_24\NNP\0|NONE_0 (r_compound) scintigraphy_25\NN\0|that_10|may_13|method_29 (r_nsubj) be_27\VB\14625458|appearance_186|._69 (r_ccomp) indicates_22\VBZ\952524|NONE_0 (l_nsubj) appearance_1\NN\4723816|be_186|._255 (l_prep) of_2\IN\0|the_15 (l_pobj) activity_7\NN\30358|NONE_0 (l_prep) in_8\IN\13603305|impaired_44|cardiac_35|neuron_16 (l_pobj) presence_10\NN\13954253|NONE_0 (l_prep) of_11\IN\0|the_13 (l_pobj) impairment_14\NN\7296428|NONE_0
D019797_D009202 NONE mibg_24\NNP\0|NONE_0 (r_compound) scintigraphy_25\NN\0|that_10|may_13|method_29 (r_nsubj) be_27\VB\14625458|appearance_186|._69 (l_attr) method_30\NN\5616786|that_39|scintigraphy_29|may_16 (l_prep) for_31\IN\0|a_16|useful_14 (l_pobj) detection_32\NN\5708432|NONE_0 (l_prep) of_33\IN\0|NONE_0 (l_pobj) cardiomyopathy_37\NN\14103288|NONE_0
11890511
33969
D011352_D001008 NONE procyclindine_17\JJ\0|NONE_0 (r_compound) treatment_18\NN\654885|NONE_0 (r_pobj) during_16\IN\0|their_16 (r_prep) condition_15\NN\24720|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) compared_12\VBN\644583|however_87|,_80|benztropine_78|increase_31|,_58|and_60|treated_125 (r_prep) had_5\VBD\0|NONE_0 (l_conj) treated_28\VBN\2376958|however_212|,_205|benztropine_203|increase_156|compared_125|,_67|and_65 (l_nsubj) anxiety_23\NN\14373582|than_23|patients_50|._58
D011352_D010302 NONE procyclidine_18\NN\3800001|NONE_0 (r_pobj) as_17\IN\14622893|as_15 (r_prep) efficacious_16\JJ\0|,_27|drug_61 (r_acomp) were_14\VBD\0|ethopropazine_106|were_76|be_62|and_4|._73 (r_conj) found_4\VBN\13279262|NONE_0 (l_xcomp) be_6\VB\14625458|ethopropazine_44|were_14|and_58|were_62|._135 (l_acomp) effective_8\JJ\0|to_14 (l_prep) in_9\IN\13603305|equally_18 (l_pcomp) controlling_10\VBG\0|NONE_0 (l_dobj) symptoms_12\NNS\5823932|NONE_0
C084820_D003866 NONE ethopropazine_27\NN\0|NONE_0 (r_pobj) than_26\IN\0|anxiety_23|patients_27|._35 (r_mark) treated_28\VBN\2376958|however_212|,_205|benztropine_203|increase_156|compared_125|,_67|and_65 (l_nsubj) anxiety_23\NN\14373582|than_23|patients_50|._58 (l_conj) depression_25\NN\14373582|more_17|and_4
C017610_D010302 CID enanthate_18\NN\0|NONE_0 (r_amod) fluphenazine_17\JJ\3713736|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|to_48|in_33 (r_advcl) benztropine_9\VB\0|in_60|was_16|._110 (l_prep) in_10\IN\13603305|to_15|induced_33 (l_pobj) treatment_12\NN\654885|NONE_0 (l_prep) of_13\IN\0|the_14 (l_pobj) parkinsonism_14\NN\14085708|NONE_0
C084820_D004409 NONE ethopropazine_27\NN\0|NONE_0 (r_pobj) than_26\IN\0|anxiety_23|patients_27|._35 (r_mark) treated_28\VBN\2376958|however_212|,_205|benztropine_203|increase_156|compared_125|,_67|and_65 (r_conj) had_5\VBD\0|NONE_0 (l_dobj) increase_8\NN\13576355|however_56|,_49|benztropine_47|compared_31|,_89|and_91|treated_156 (l_prep) in_9\IN\13603305|a_23|significant_21 (l_pobj) dyskinesia_11\JJ\14084880|NONE_0
C084820_D001008 NONE ethopropazine_27\NN\0|NONE_0 (r_pobj) than_26\IN\0|anxiety_23|patients_27|._35 (r_mark) treated_28\VBN\2376958|however_212|,_205|benztropine_203|increase_156|compared_125|,_67|and_65 (l_nsubj) anxiety_23\NN\14373582|than_23|patients_50|._58
D001590_D010302 NONE benztropine_2\NN\0|and_4|._47 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) parkinsonism_7\NN\14085708|NONE_0
D001590_D010302 NONE benztropine_9\VB\0|in_60|was_16|._110 (l_prep) in_10\IN\13603305|to_15|induced_33 (l_pobj) treatment_12\NN\654885|NONE_0 (l_prep) of_13\IN\0|the_14 (l_pobj) parkinsonism_14\NN\14085708|NONE_0
D001590_D010302 NONE benztropine_2\NN\0|and_4 (r_conj) ethopropazine_0\NN\0|were_30|be_44|and_102|were_106|._179 (r_nsubjpass) found_4\VBN\13279262|NONE_0 (l_xcomp) be_6\VB\14625458|ethopropazine_44|were_14|and_58|were_62|._135 (l_acomp) effective_8\JJ\0|to_14 (l_prep) in_9\IN\13603305|equally_18 (l_pcomp) controlling_10\VBG\0|NONE_0 (l_dobj) symptoms_12\NNS\5823932|NONE_0
D001590_D010302 NONE benztropine_3\NN\0|that_5|not_15|drug_39|,_115|because_117 (r_nsubj) is_4\VBZ\0|this_31|._170 (l_attr) drug_8\NN\14778436|that_44|benztropine_39|not_24|,_76|because_78 (l_prep) in_11\IN\13603305|the_35|anticholinergic_31|of_10 (l_pobj) treatment_13\NN\654885|NONE_0 (l_prep) of_14\IN\0|the_14 (l_pobj) symptoms_19\NNS\5823932|NONE_0
C084820_D012559 NONE ethopropazine_5\NN\0|NONE_0 (r_pobj) in_0\IN\13603305|was_44|benztropine_60|._170 (r_prep) compared_7\VBN\644583|NONE_0 (l_xcomp) benztropine_9\VB\0|in_60|was_16|._110 (l_advcl) induced_15\VBN\1627355|to_48|in_33 (l_agent) by_16\IN\0|NONE_0 (l_pobj) fluphenazine_17\JJ\3713736|NONE_0 (l_amod) enanthate_18\NN\0|NONE_0 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) outpatients_22\NNS\10405694|NONE_0 (l_amod) schizophrenic_21\JJ\10490141|60_3
D011352_D003866 NONE procyclindine_17\JJ\0|NONE_0 (r_compound) treatment_18\NN\654885|NONE_0 (r_pobj) during_16\IN\0|their_16 (r_prep) condition_15\NN\24720|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) compared_12\VBN\644583|however_87|,_80|benztropine_78|increase_31|,_58|and_60|treated_125 (r_prep) had_5\VBD\0|NONE_0 (l_conj) treated_28\VBN\2376958|however_212|,_205|benztropine_203|increase_156|compared_125|,_67|and_65 (l_nsubj) anxiety_23\NN\14373582|than_23|patients_50|._58 (l_conj) depression_25\NN\14373582|more_17|and_4
D011352_D004409 NONE procyclindine_17\JJ\0|NONE_0 (r_compound) treatment_18\NN\654885|NONE_0 (r_pobj) during_16\IN\0|their_16 (r_prep) condition_15\NN\24720|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_prep) compared_12\VBN\644583|however_87|,_80|benztropine_78|increase_31|,_58|and_60|treated_125 (r_prep) had_5\VBD\0|NONE_0 (l_dobj) increase_8\NN\13576355|however_56|,_49|benztropine_47|compared_31|,_89|and_91|treated_156 (l_prep) in_9\IN\13603305|a_23|significant_21 (l_pobj) dyskinesia_11\JJ\14084880|NONE_0
C017610_D012559 NONE enanthate_18\NN\0|NONE_0 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) outpatients_22\NNS\10405694|NONE_0 (l_amod) schizophrenic_21\JJ\10490141|60_3
D001590_D004409 CID benztropine_2\NN\0|however_9|,_2|increase_47|compared_78|,_136|and_138|treated_203 (r_nsubj) had_5\VBD\0|NONE_0 (l_dobj) increase_8\NN\13576355|however_56|,_49|benztropine_47|compared_31|,_89|and_91|treated_156 (l_prep) in_9\IN\13603305|a_23|significant_21 (l_pobj) dyskinesia_11\JJ\14084880|NONE_0
C084820_D010302 NONE ethopropazine_0\NN\0|NONE_0 (l_conj) benztropine_2\NN\0|and_4|._47 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) parkinsonism_7\NN\14085708|NONE_0
C084820_D010302 NONE ethopropazine_5\NN\0|NONE_0 (r_pobj) in_0\IN\13603305|was_44|benztropine_60|._170 (r_prep) compared_7\VBN\644583|NONE_0 (l_xcomp) benztropine_9\VB\0|in_60|was_16|._110 (l_prep) in_10\IN\13603305|to_15|induced_33 (l_pobj) treatment_12\NN\654885|NONE_0 (l_prep) of_13\IN\0|the_14 (l_pobj) parkinsonism_14\NN\14085708|NONE_0
C084820_D010302 NONE ethopropazine_0\NN\0|were_30|be_44|and_102|were_106|._179 (r_nsubjpass) found_4\VBN\13279262|NONE_0 (l_xcomp) be_6\VB\14625458|ethopropazine_44|were_14|and_58|were_62|._135 (l_acomp) effective_8\JJ\0|to_14 (l_prep) in_9\IN\13603305|equally_18 (l_pcomp) controlling_10\VBG\0|NONE_0 (l_dobj) symptoms_12\NNS\5823932|NONE_0
D001590_D001008 CID benztropine_2\NN\0|however_9|,_2|increase_47|compared_78|,_136|and_138|treated_203 (r_nsubj) had_5\VBD\0|NONE_0 (l_conj) treated_28\VBN\2376958|however_212|,_205|benztropine_203|increase_156|compared_125|,_67|and_65 (l_nsubj) anxiety_23\NN\14373582|than_23|patients_50|._58
D001590_D012559 NONE benztropine_9\VB\0|in_60|was_16|._110 (l_advcl) induced_15\VBN\1627355|to_48|in_33 (l_agent) by_16\IN\0|NONE_0 (l_pobj) fluphenazine_17\JJ\3713736|NONE_0 (l_amod) enanthate_18\NN\0|NONE_0 (l_prep) in_19\IN\13603305|NONE_0 (l_pobj) outpatients_22\NNS\10405694|NONE_0 (l_amod) schizophrenic_21\JJ\10490141|60_3
D001590_D003866 CID benztropine_2\NN\0|however_9|,_2|increase_47|compared_78|,_136|and_138|treated_203 (r_nsubj) had_5\VBD\0|NONE_0 (l_conj) treated_28\VBN\2376958|however_212|,_205|benztropine_203|increase_156|compared_125|,_67|and_65 (l_nsubj) anxiety_23\NN\14373582|than_23|patients_50|._58 (l_conj) depression_25\NN\14373582|more_17|and_4
591536
D006493_D001791 NONE heparin_8\VBN\2718259|-_7 (r_npadvmod) induced_10\VBN\1627355|platelet_8 (r_amod) aggregation_12\NN\31264|factor_81|._11
D006493_D013921 CID heparin_6\JJ\2718259|systemic_9 (r_compound) therapy_7\NN\657604|NONE_0 (r_dobj) receiving_4\VBG\2210855|NONE_0 (r_acl) patients_3\NNS\9898892|NONE_0 (r_pobj) in_2\IN\13603305|arterial_25|:_46|complication_50|._111 (r_prep) thromboembolism_1\NN\14100769|NONE_0 (l_appos) complication_10\NN\1073995|arterial_75|in_50|:_4|._61 (l_acl) associated_11\VBN\628491|a_15 (l_prep) with_12\IN\0|NONE_0 (l_pobj) thrombocytopenia_16\NN\14189204|NONE_0
D006493_D013921 CID heparin_13\NN\2718259|-_7 (r_npadvmod) induced_15\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_16\NN\14189204|NONE_0
D006493_D013921 CID heparin_24\JJ\2718259|NONE_0 (r_compound) therapy_25\NN\657604|NONE_0 (r_pobj) of_23\IN\0|the_15 (r_prep) initiation_22\NN\7450842|days_15 (r_pobj) after_20\IN\0|NONE_0 (r_prep) occurring_15\VBG\0|thrombi_29 (r_pcomp) by_7\IN\0|arterial_19|,_117|preceded_119 (r_prep) occlusion_6\NN\14081375|characteristic_41|._241 (l_acl) preceded_27\VBN\0|arterial_138|by_119|,_2 (l_agent) by_28\IN\0|NONE_0 (l_pobj) thrombocytopenia_30\NN\14189204|NONE_0
D006493_D013921 CID heparin_8\VBN\2718259|-_7 (r_npadvmod) induced_10\VBN\1627355|platelet_8 (r_amod) aggregation_12\NN\31264|factor_81|._11 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) factor_2\NN\7326557|aggregation_81|._92 (l_acl) relating_3\VBG\628491|the_18|common_14 (l_dobj) thromboembolism_4\NN\14100769|NONE_0 (l_conj) thrombocytopenia_6\NN\14189204|and_4
D006493_D001157 CID heparin_24\JJ\2718259|NONE_0 (r_compound) therapy_25\NN\657604|NONE_0 (r_pobj) of_23\IN\0|the_15 (r_prep) initiation_22\NN\7450842|days_15 (r_pobj) after_20\IN\0|NONE_0 (r_prep) occurring_15\VBG\0|thrombi_29 (r_pcomp) by_7\IN\0|arterial_19|,_117|preceded_119 (r_prep) occlusion_6\NN\14081375|characteristic_41|._241
D006493_D013923 NONE heparin_6\JJ\2718259|systemic_9 (r_compound) therapy_7\NN\657604|NONE_0 (r_dobj) receiving_4\VBG\2210855|NONE_0 (r_acl) patients_3\NNS\9898892|NONE_0 (r_pobj) in_2\IN\13603305|arterial_25|:_46|complication_50|._111 (r_prep) thromboembolism_1\NN\14100769|NONE_0
D006493_D013923 NONE heparin_13\NN\2718259|-_7 (r_npadvmod) induced_15\VBN\1627355|NONE_0 (r_amod) thrombocytopenia_16\NN\14189204|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) associated_11\VBN\628491|a_15 (r_acl) complication_10\NN\1073995|arterial_75|in_50|:_4|._61 (r_appos) thromboembolism_1\NN\14100769|NONE_0
D006493_D013923 NONE heparin_8\JJ\2718259|systemic_9 (r_compound) therapy_9\NN\657604|NONE_0 (r_pobj) of_6\IN\0|a_26|recognized_24 (r_prep) complication_5\NN\1073995|thromboembolism_32|._40 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) thromboembolism_1\NN\14100769|complication_32|._72
D006493_D013923 NONE heparin_8\VBN\2718259|-_7 (r_npadvmod) induced_10\VBN\1627355|platelet_8 (r_amod) aggregation_12\NN\31264|factor_81|._11 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) factor_2\NN\7326557|aggregation_81|._92 (l_acl) relating_3\VBG\628491|the_18|common_14 (l_dobj) thromboembolism_4\NN\14100769|NONE_0
D006493_D013927 NONE heparin_24\JJ\2718259|NONE_0 (r_compound) therapy_25\NN\657604|NONE_0 (r_pobj) of_23\IN\0|the_15 (r_prep) initiation_22\NN\7450842|days_15 (r_pobj) after_20\IN\0|NONE_0 (r_prep) occurring_15\VBG\0|thrombi_29 (r_pcomp) by_7\IN\0|arterial_19|,_117|preceded_119 (l_pobj) thrombi_11\NN\5402091|occurring_29
D006493_D007511 NONE heparin_24\JJ\2718259|NONE_0 (r_compound) therapy_25\NN\657604|NONE_0 (r_pobj) of_23\IN\0|the_15 (r_prep) initiation_22\NN\7450842|days_15 (r_pobj) after_20\IN\0|NONE_0 (r_prep) occurring_15\VBG\0|thrombi_29 (r_pcomp) by_7\IN\0|arterial_19|,_117|preceded_119 (l_pobj) thrombi_11\NN\5402091|occurring_29 (l_prep) with_12\IN\0|fibrin_15 (l_pobj) ischemia_14\NN\14195315|NONE_0
133615
D003276_D013923 NONE contraceptive_6\NN\3183080|oral_5 (r_amod) therapy_7\NN\657604|NONE_0 (r_pobj) of_4\IN\0|thromboembolic_39|in_30|:_97|report_107|._133 (r_prep) complications_3\NNS\1073995|NONE_0 (l_amod) thromboembolic_0\JJ\0|of_39|in_69|:_136|report_146|._172
D003276_D001778 CID contraceptive_6\NN\3183080|oral_5 (r_amod) therapy_7\NN\657604|NONE_0 (r_pobj) of_4\IN\0|thromboembolic_39|in_30|:_97|report_107|._133 (r_prep) complications_3\NNS\1073995|NONE_0 (l_prep) in_8\IN\13603305|thromboembolic_69|of_30|:_67|report_77|._103 (l_pobj) relationship_9\NN\31921|NONE_0 (l_prep) to_10\IN\0|NONE_0 (l_pobj) levels_12\NNS\4916342|NONE_0 (l_prep) of_13\IN\0|pretreatment_20 (l_pobj) factors_16\NNS\7326557|NONE_0 (l_compound) coagulation_15\NN\13518963|NONE_0
19944333
C471405_D003329 CID sorafenib_0\NNP\0|-_9|infarction_35|due_46|._74 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_prep) due_6\IN\5174653|sorafenib_46|-_37|infarction_11|._28 (l_pobj) spasm_10\NN\14299637|to_19
C471405_D003329 CID sorafenib_6\NN\0|-_9 (r_npadvmod) induced_8\VBN\1627355|coronary_8|artery_17 (r_amod) spasm_11\NN\14299637|NONE_0
D020108_D060050 NONE nicorandil_3\NN\0|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) addition_0\NN\3081021|symptoms_40|and_49|maintained_53|._84 (r_nsubj) reduced_4\VBD\441445|NONE_0 (l_conj) maintained_8\VBD\0|addition_53|symptoms_13|and_4|._31 (l_dobj) status_11\NN\24720|NONE_0 (l_compound) angina_10\NN\14171682|NONE_0
C471405_D009203 NONE sorafenib_0\NNP\0|-_9|infarction_35|due_46|._74 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) infarction_5\NN\14204950|sorafenib_35|-_26|due_11|._39
16174948
D003042_D013345 CID cocaine_6\NN\3492717|-_7 (r_npadvmod) associated_8\VBN\628491|subarachnoid_11 (r_amod) hemorrhage_10\NN\14285662|NONE_0
D003042_D013345 CID cocaine_12\NN\3492717|-_7 (r_npadvmod) associated_14\VBN\628491|subarachnoid_11|sah_36|underwent_45 (r_amod) hemorrhage_16\NN\14285662|NONE_0
D003042_D013345 CID cocaine_12\NN\3492717|-_7 (r_npadvmod) associated_14\VBN\628491|subarachnoid_11|sah_36|underwent_45 (r_amod) hemorrhage_16\NN\14285662|NONE_0 (l_appos) sah_18\NNP\0|associated_36|subarachnoid_25|underwent_9
D003042_D013345 CID cocaine_25\NN\3492717|NONE_0 (r_compound) use_26\NN\407535|shortly_22 (r_pobj) after_24\IN\0|who_34|angiography_20 (r_prep) underwent_21\VBD\109660|associated_45|subarachnoid_34|sah_9 (r_relcl) hemorrhage_16\NN\14285662|NONE_0
D003042_D013345 CID cocaine_25\NN\3492717|NONE_0 (r_compound) use_26\NN\407535|shortly_22 (r_pobj) after_24\IN\0|who_34|angiography_20 (r_prep) underwent_21\VBD\109660|associated_45|subarachnoid_34|sah_9 (r_relcl) hemorrhage_16\NN\14285662|NONE_0 (l_appos) sah_18\NNP\0|associated_36|subarachnoid_25|underwent_9
D003042_D013345 CID cocaine_14\NN\3492717|NONE_0 (r_pobj) for_13\IN\0|positive_26|urine_17 (r_prep) toxicology_12\NN\6054892|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) those_8\DT\0|NONE_0 (r_dobj) identified_7\VBD\699815|we_50|patients_38|retrospectively_20|and_4|._78 (r_conj) screened_1\VBD\2533282|NONE_0 (l_dobj) patients_2\NNS\9898892|we_12|retrospectively_18|and_34|identified_38|._116 (l_prep) with_3\IN\0|NONE_0 (l_pobj) sah_4\NNP\0|NONE_0
D003042_D013345 CID cocaine_31\NN\3492717|NONE_0 (r_compound) use_32\NN\407535|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) associated_29\VBN\628491|aneurysmal_15 (r_acl) sah_28\NNP\0|NONE_0
D003042_D014657 NONE cocaine_0\NN\3492717|NONE_0 (r_compound) use_1\NN\407535|has_4|been_8|with_24|._108 (r_nsubjpass) associated_4\VBN\628491|NONE_0 (l_prep) with_5\IN\0|use_24|has_20|been_16|._84 (l_pobj) complications_7\NNS\1073995|NONE_0 (l_prep) including_9\VBG\0|neurovascular_29|,_2 (l_pobj) vasoconstriction_11\NN\1149911|NONE_0 (l_conj) vasculitis_13\NN\14336539|arterial_30|and_4
D003042_D014657 NONE cocaine_31\NN\3492717|NONE_0 (r_compound) use_32\NN\407535|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) associated_29\VBN\628491|aneurysmal_15 (r_acl) sah_28\NNP\0|NONE_0 (r_pobj) after_26\IN\0|who_26|angiography_12 (r_prep) underwent_24\VBD\109660|NONE_0 (r_relcl) patients_22\NNS\9898892|NONE_0 (r_pobj) in_21\IN\13603305|evidence_137|could_15|be_9|._86 (r_prep) found_20\VBN\13279262|NONE_0 (l_nsubjpass) evidence_2\NN\5816287|could_122|be_128|in_137|._223 (l_prep) for_3\IN\0|no_25|quantitative_22 (l_pobj) narrowing_4\VBG\5064037|NONE_0 (l_prep) of_5\IN\0|NONE_0 (l_pobj) arteries_8\NNS\5417975|NONE_0 (l_conj) evidence_12\NN\5816287|large_52|cerebral_46|or_28 (l_prep) for_13\IN\0|qualitative_34|angiographic_22 (l_pobj) narrowing_15\NN\5064037|NONE_0 (l_conj) vasculitis_17\NN\14336539|distal_20|or_3
D003042_D017542 CID cocaine_31\NN\3492717|NONE_0 (r_compound) use_32\NN\407535|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) associated_29\VBN\628491|aneurysmal_15 (r_acl) sah_28\NNP\0|NONE_0 (l_amod) aneurysmal_27\NN\0|associated_15
D003042_D013901 NONE cocaine_0\NN\3492717|NONE_0 (r_compound) use_1\NN\407535|has_4|been_8|with_24|._108 (r_nsubjpass) associated_4\VBN\628491|NONE_0 (l_prep) with_5\IN\0|use_24|has_20|been_16|._84 (l_pobj) complications_7\NNS\1073995|NONE_0
8267029
D010396_D001172 NONE penicillamine_0\NN\3740161|-_13|glomerulonephritis_42|in_61|._99 (r_nsubj) induced_2\VBN\1627355|NONE_0 (l_prep) in_6\IN\13603305|penicillamine_61|-_48|glomerulonephritis_19|._38 (l_pobj) patient_8\NN\9898892|NONE_0 (l_prep) with_9\IN\0|a_10 (l_pobj) arthritis_11\NN\14171682|NONE_0
D010396_D001172 NONE penicillamine_21\NN\3740161|(_14|day_22|)_25 (r_nmod) treatment_28\NN\654885|NONE_0 (r_pobj) of_18\IN\0|5_9 (r_prep) months_17\NNS\15113229|NONE_0 (r_pobj) after_15\IN\0|woman_88|glomerulonephritis_26|._56 (r_prep) presented_8\VBD\2137132|NONE_0 (l_nsubj) woman_4\NN\9605289|glomerulonephritis_62|after_88|._144 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) arthritis_7\NN\14171682|NONE_0
D010396_D005921 CID penicillamine_0\NN\3740161|-_13|glomerulonephritis_42|in_61|._99 (r_nsubj) induced_2\VBN\1627355|NONE_0 (l_dobj) glomerulonephritis_5\NN\14113798|penicillamine_42|-_29|in_19|._57
D010396_D005921 CID penicillamine_21\NN\3740161|(_14|day_22|)_25 (r_nmod) treatment_28\NN\654885|NONE_0 (r_pobj) of_18\IN\0|5_9 (r_prep) months_17\NNS\15113229|NONE_0 (r_pobj) after_15\IN\0|woman_88|glomerulonephritis_26|._56 (r_prep) presented_8\VBD\2137132|NONE_0 (l_dobj) glomerulonephritis_11\NN\14113798|woman_62|after_26|._82
D010396_D005921 CID penicillamine_21\NN\3740161|(_14|day_22|)_25 (r_nmod) treatment_28\NN\654885|NONE_0 (r_pobj) of_18\IN\0|5_9 (r_prep) months_17\NNS\15113229|NONE_0 (r_pobj) after_15\IN\0|woman_88|glomerulonephritis_26|._56 (r_prep) presented_8\VBD\2137132|NONE_0 (l_dobj) glomerulonephritis_11\NN\14113798|woman_62|after_26|._82 (l_appos) rpgn_13\NNP\0|progressive_32
D010396_D005921 CID penicillamine_11\NN\3740161|NONE_0 (r_compound) treatment_12\NN\654885|NONE_0 (r_pobj) of_8\IN\0|the_11 (r_prep) course_7\NN\883297|NONE_0 (r_pobj) in_5\IN\13603305|this_22|new_17|of_8 (r_prep) case_2\NN\7283608|need_71|._186 (l_prep) of_3\IN\0|this_14|new_9|in_8 (l_pobj) rpgn_4\NNP\0|NONE_0
D010396_D011507 NONE penicillamine_11\NN\3740161|NONE_0 (r_compound) treatment_12\NN\654885|NONE_0 (r_pobj) of_8\IN\0|the_11 (r_prep) course_7\NN\883297|NONE_0 (r_pobj) in_5\IN\13603305|this_22|new_17|of_8 (r_prep) case_2\NN\7283608|need_71|._186 (r_nsubj) emphasizes_13\VBZ\943837|NONE_0 (l_dobj) need_15\NN\13920835|case_71|._115 (l_prep) for_16\IN\0|the_9 (l_pobj) monitoring_18\NN\879759|NONE_0 (l_prep) of_19\IN\0|frequent_20 (l_pobj) function_21\NN\13783581|NONE_0 (l_conj) evaluation_23\NN\874067|renal_19|and_4 (l_prep) of_24\IN\0|NONE_0 (l_pobj) sediment_26\NN\20827|NONE_0 (l_conj) proteinuria_28\NN\14299637|urinary_21|and_4|in_12
2435991
D004837_D001145 CID adrenaline_10\RB\14807929|-_10 (r_npadvmod) induced_12\VBN\1627355|,_17|and_15 (r_conj) digitalis-_7\NN\0|stage_26|coronary_20|,_2 (r_conj) ligation-_5\JJ\0|canine_46|ventricular_53 (r_nmod) arrhythmias_15\NNS\14103288|NONE_0
D004837_D001145 CID adrenaline_10\RB\14807929|-_10 (r_npadvmod) induced_12\VBN\1627355|,_17|and_15 (r_conj) digitalis-_7\NN\0|stage_26|coronary_20|,_2 (r_conj) ligation-_5\JJ\0|canine_46|ventricular_53 (r_nmod) arrhythmias_15\NNS\14103288|NONE_0 (r_dobj) using_0\VBG\418025|,_101|effects_118|were_141|and_155|determined_232 (r_advcl) examined_22\VBN\0|NONE_0 (l_conj) determined_34\VBN\0|using_232|,_131|effects_114|were_91|and_77 (l_nsubjpass) concentration_28\NN\4916342|was_40|._54 (l_prep) for_29\IN\0|the_43|minimum_39|effective_31|plasma_21 (l_pobj) model_32\NN\5888929|NONE_0 (l_compound) arrhythmia_31\NN\14103288|each_5
D004837_D001145 CID adrenaline_27\NN\14807929|,_6|and_4 (r_conj) digitalis_24\NN\15059939|48-h_24|coronary_19|,_2 (r_conj) ligation_22\NN\149084|24-h_38|coronary_33|,_16 (r_appos) ligation_18\NN\149084|NONE_0 (r_pobj) by_15\IN\0|concentrations_39 (r_agent) induced_14\VBN\1627355|cibenzoline_108|arrhythmias_77|,_66|and_64|were_85|._268 (r_conj) suppressed_1\VBD\2510337|NONE_0 (l_dobj) arrhythmias_4\NNS\14103288|cibenzoline_31|,_11|and_13|induced_77|were_162|._345
D004837_D001145 CID adrenaline_27\NN\14807929|,_6|and_4 (r_conj) digitalis_24\NN\15059939|48-h_24|coronary_19|,_2 (r_conj) ligation_22\NN\149084|24-h_38|coronary_33|,_16 (r_appos) ligation_18\NN\149084|NONE_0 (r_pobj) by_15\IN\0|concentrations_39 (r_agent) induced_14\VBN\1627355|cibenzoline_108|arrhythmias_77|,_66|and_64|were_85|._268 (l_nsubj) concentrations_11\NNS\4916342|by_39 (l_prep) for_12\IN\0|the_44|minimum_40|effective_32|plasma_22 (l_pobj) arrhythmias_13\NNS\14103288|NONE_0
D004837_D001145 CID adrenaline_3\NN\14807929|-_10 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) arrhythmia_6\NN\14103288|NONE_0
D004837_D001145 CID adrenaline_3\NN\14807929|-_10 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) arrhythmia_6\NN\14103288|NONE_0 (r_pobj) for_2\IN\0|the_18 (r_prep) concentration_1\NN\4916342|higher_66|._118 (r_nsubj) was_7\VBD\0|NONE_0 (l_acomp) higher_9\JJR\0|concentration_66|._52 (l_prep) than_10\IN\0|significantly_21 (l_pobj) those_11\DT\0|NONE_0 (l_prep) for_12\IN\0|NONE_0 (l_pobj) types_15\NNS\5839024|NONE_0 (l_prep) of_16\IN\0|the_16|other_12 (l_pobj) arrhythmias_17\NNS\14103288|NONE_0
C032151_D007022 NONE cibenzoline_1\NN\0|because_8|effects_64|and_72|found_80|given_111 (r_nsubj) had_2\VBD\0|,_141|usefulness_156|is_167|._178 (l_dobj) effects_10\NNS\13245626|because_72|cibenzoline_64|and_8|found_16|given_47 (l_nmod) node_8\NN\13870805|depressive_5 (l_amod) hypotensive_5\JJ\10405694|only_10|weak_5
D004071_D001145 CID digitalis-_7\NN\0|stage_26|coronary_20|,_2 (r_conj) ligation-_5\JJ\0|canine_46|ventricular_53 (r_nmod) arrhythmias_15\NNS\14103288|NONE_0
D004071_D001145 CID digitalis-_7\NN\0|stage_26|coronary_20|,_2 (r_conj) ligation-_5\JJ\0|canine_46|ventricular_53 (r_nmod) arrhythmias_15\NNS\14103288|NONE_0 (r_dobj) using_0\VBG\418025|,_101|effects_118|were_141|and_155|determined_232 (r_advcl) examined_22\VBN\0|NONE_0 (l_conj) determined_34\VBN\0|using_232|,_131|effects_114|were_91|and_77 (l_nsubjpass) concentration_28\NN\4916342|was_40|._54 (l_prep) for_29\IN\0|the_43|minimum_39|effective_31|plasma_21 (l_pobj) model_32\NN\5888929|NONE_0 (l_compound) arrhythmia_31\NN\14103288|each_5
D004071_D001145 CID digitalis_24\NN\15059939|48-h_24|coronary_19|,_2 (r_conj) ligation_22\NN\149084|24-h_38|coronary_33|,_16 (r_appos) ligation_18\NN\149084|NONE_0 (r_pobj) by_15\IN\0|concentrations_39 (r_agent) induced_14\VBN\1627355|cibenzoline_108|arrhythmias_77|,_66|and_64|were_85|._268 (r_conj) suppressed_1\VBD\2510337|NONE_0 (l_dobj) arrhythmias_4\NNS\14103288|cibenzoline_31|,_11|and_13|induced_77|were_162|._345
D004071_D001145 CID digitalis_24\NN\15059939|48-h_24|coronary_19|,_2 (r_conj) ligation_22\NN\149084|24-h_38|coronary_33|,_16 (r_appos) ligation_18\NN\149084|NONE_0 (r_pobj) by_15\IN\0|concentrations_39 (r_agent) induced_14\VBN\1627355|cibenzoline_108|arrhythmias_77|,_66|and_64|were_85|._268 (l_nsubj) concentrations_11\NNS\4916342|by_39 (l_prep) for_12\IN\0|the_44|minimum_40|effective_32|plasma_22 (l_pobj) arrhythmias_13\NNS\14103288|NONE_0
C032151_D003866 NONE cibenzoline_1\NN\0|because_8|effects_64|and_72|found_80|given_111 (r_nsubj) had_2\VBD\0|,_141|usefulness_156|is_167|._178 (l_dobj) effects_10\NNS\13245626|because_72|cibenzoline_64|and_8|found_16|given_47 (l_amod) depressive_9\JJ\10595647|node_5
C032151_D001145 NONE cibenzoline_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|antiarrhythmic_37|plasma_22|on_15|._48 (r_prep) concentrations_2\NNS\4916342|NONE_0 (l_prep) on_5\IN\0|antiarrhythmic_52|plasma_37|of_15|._33 (l_pobj) arrhythmias_8\NNS\14103288|NONE_0
C032151_D001145 NONE cibenzoline_20\NN\0|NONE_0 (r_pobj) of_19\IN\0|antiarrhythmic_23 (r_prep) effects_18\NNS\13245626|using_118|,_17|were_23|and_37|determined_114 (r_nsubjpass) examined_22\VBN\0|NONE_0 (l_advcl) using_0\VBG\418025|,_101|effects_118|were_141|and_155|determined_232 (l_dobj) arrhythmias_15\NNS\14103288|NONE_0
C032151_D001145 NONE cibenzoline_20\NN\0|NONE_0 (r_pobj) of_19\IN\0|antiarrhythmic_23 (r_prep) effects_18\NNS\13245626|using_118|,_17|were_23|and_37|determined_114 (r_nsubjpass) examined_22\VBN\0|NONE_0 (l_conj) determined_34\VBN\0|using_232|,_131|effects_114|were_91|and_77 (l_nsubjpass) concentration_28\NN\4916342|was_40|._54 (l_prep) for_29\IN\0|the_43|minimum_39|effective_31|plasma_21 (l_pobj) model_32\NN\5888929|NONE_0 (l_compound) arrhythmia_31\NN\14103288|each_5
C032151_D001145 NONE cibenzoline_0\NNP\0|arrhythmias_31|,_42|and_44|induced_108|were_193|._376 (r_nsubj) suppressed_1\VBD\2510337|NONE_0 (l_dobj) arrhythmias_4\NNS\14103288|cibenzoline_31|,_11|and_13|induced_77|were_162|._345
C032151_D001145 NONE cibenzoline_0\NNP\0|arrhythmias_31|,_42|and_44|induced_108|were_193|._376 (r_nsubj) suppressed_1\VBD\2510337|NONE_0 (l_conj) induced_14\VBN\1627355|cibenzoline_108|arrhythmias_77|,_66|and_64|were_85|._268 (l_nsubj) concentrations_11\NNS\4916342|by_39 (l_prep) for_12\IN\0|the_44|minimum_40|effective_32|plasma_22 (l_pobj) arrhythmias_13\NNS\14103288|NONE_0
C032151_D001145 NONE cibenzoline_1\NN\0|because_8|effects_64|and_72|found_80|given_111 (r_nsubj) had_2\VBD\0|,_141|usefulness_156|is_167|._178 (l_advcl) given_19\VBN\5892096|because_119|cibenzoline_111|effects_47|and_39|found_31 (l_prep) to_20\IN\0|when_11 (l_pobj) dogs_24\NNS\2083346|NONE_0 (l_compound) arrhythmia_23\NN\14103288|coronary_18
7102237
D012601_D001049 NONE scopolamine_4\NN\14712692|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) premedicated_2\VBN\0|NONE_0 (r_acl) patients_1\NNS\9898892|NONE_0 (r_pobj) in_0\IN\13603305|)_97|,_98|effect_119|mg/kg_144|slower_167|found_278|,_306|but_308|,_311|occurred_329|._388 (r_prep) was_28\VBD\0|NONE_0 (l_advcl) occurred_57\VBD\0|in_329|)_232|,_231|effect_210|mg/kg_185|slower_162|found_51|,_23|but_21|,_18|._59 (l_nsubj) apnoea_56\NN\0|although_9|often_21|in_27
D009567_D001049 NONE nitrazepam_11\NN\2830852|5_5|evening_15 (r_amod) mg_10\IN\13717155|+_15|morphine_13|(_4|+_3 (r_conj) scopolamine_4\NN\14712692|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) premedicated_2\VBN\0|NONE_0 (r_acl) patients_1\NNS\9898892|NONE_0 (r_pobj) in_0\IN\13603305|)_97|,_98|effect_119|mg/kg_144|slower_167|found_278|,_306|but_308|,_311|occurred_329|._388 (r_prep) was_28\VBD\0|NONE_0 (l_advcl) occurred_57\VBD\0|in_329|)_232|,_231|effect_210|mg/kg_185|slower_162|found_51|,_23|but_21|,_18|._59 (l_nsubj) apnoea_56\NN\0|although_9|often_21|in_27
D009020_D001049 NONE morphine_6\NN\2707683|+_2|(_9|+_10|mg_13 (r_conj) scopolamine_4\NN\14712692|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) premedicated_2\VBN\0|NONE_0 (r_acl) patients_1\NNS\9898892|NONE_0 (r_pobj) in_0\IN\13603305|)_97|,_98|effect_119|mg/kg_144|slower_167|found_278|,_306|but_308|,_311|occurred_329|._388 (r_prep) was_28\VBD\0|NONE_0 (l_advcl) occurred_57\VBD\0|in_329|)_232|,_231|effect_210|mg/kg_185|slower_162|found_51|,_23|but_21|,_18|._59 (l_nsubj) apnoea_56\NN\0|although_9|often_21|in_27
D008874_D001049 CID midazolam_24\JJ\2830852|NONE_0 (r_pobj) of_23\IN\0|the_26|inducing_16 (r_prep) effect_22\NN\34213|in_119|)_22|,_21|mg/kg_25|slower_48|found_159|,_187|but_189|,_192|occurred_210|._269 (r_nsubj) was_28\VBD\0|NONE_0 (l_advcl) occurred_57\VBD\0|in_329|)_232|,_231|effect_210|mg/kg_185|slower_162|found_51|,_23|but_21|,_18|._59 (l_nsubj) apnoea_56\NN\0|although_9|often_21|in_27
D008874_D001049 CID midazolam_50\JJ\2830852|the_4 (r_amod) group_51\NN\2137|NONE_0 (r_pobj) in_48\IN\13603305|sequelae_20|were_11 (r_prep) found_47\VBN\13279262|in_278|)_181|,_180|effect_159|mg/kg_134|slower_111|,_28|but_30|,_33|occurred_51|._110 (r_conj) was_28\VBD\0|NONE_0 (l_advcl) occurred_57\VBD\0|in_329|)_232|,_231|effect_210|mg/kg_185|slower_162|found_51|,_23|but_21|,_18|._59 (l_nsubj) apnoea_56\NN\0|although_9|often_21|in_27
D008874_D001049 CID midazolam_62\JJ\2830852|the_4|lasted_19 (r_amod) group_63\NN\2137|NONE_0 (r_pobj) in_60\IN\13603305|although_36|apnoea_27|often_6 (r_prep) occurred_57\VBD\0|in_329|)_232|,_231|effect_210|mg/kg_185|slower_162|found_51|,_23|but_21|,_18|._59 (l_nsubj) apnoea_56\NN\0|although_9|often_21|in_27
D013874_D001049 CID thiopentone_36\NN\0|NONE_0 (r_pobj) of_35\IN\0|NONE_0 (r_prep) that_34\DT\0|NONE_0 (r_pobj) than_33\IN\0|NONE_0 (r_prep) onset_32\NN\7325190|NONE_0 (r_pobj) in_31\IN\13603305|clearly_15 (r_prep) slower_30\JJR\0|in_167|)_70|,_69|effect_48|mg/kg_23|found_111|,_139|but_141|,_144|occurred_162|._221 (r_acomp) was_28\VBD\0|NONE_0 (l_advcl) occurred_57\VBD\0|in_329|)_232|,_231|effect_210|mg/kg_185|slower_162|found_51|,_23|but_21|,_18|._59 (l_nsubj) apnoea_56\NN\0|although_9|often_21|in_27
2051906
D001379_D017285 NONE azathioprine_30\NN\3740161|NONE_0 (r_amod) therapy_31\NN\657604|NONE_0 (r_pobj) of_29\IN\0|NONE_0 (r_prep) initiation_28\NN\7450842|months_13 (r_pobj) after_27\IN\0|patient_158|features_40|._40 (r_prep) developed_17\VBD\1753788|NONE_0 (l_nsubj) patient_4\NN\9898892|features_118|after_158|._198 (l_prep) with_6\IN\0|a_23|old_13|,_2 (l_pobj) polymyositis_8\NN\14350292|and_13|without_17
D001379_D002779 CID azathioprine_7\JJ\3740161|NONE_0 (r_amod) therapy_8\NN\657604|NONE_0 (r_pobj) following_6\VBG\8180190|reversible_45|with_22|._30 (r_prep) cholestasis_1\NN\14052403|NONE_0
D001379_D002779 CID azathioprine_7\JJ\3740161|NONE_0 (r_amod) therapy_8\NN\657604|NONE_0 (r_pobj) following_6\VBG\8180190|reversible_45|with_22|._30 (r_prep) cholestasis_1\NN\14052403|NONE_0 (l_prep) with_2\IN\0|reversible_23|following_22|._52 (l_pobj) injury_5\NN\14052046|NONE_0
D001379_D002779 CID azathioprine_30\NN\3740161|NONE_0 (r_amod) therapy_31\NN\657604|NONE_0 (r_pobj) of_29\IN\0|NONE_0 (r_prep) initiation_28\NN\7450842|months_13 (r_pobj) after_27\IN\0|patient_158|features_40|._40 (r_prep) developed_17\VBD\1753788|NONE_0 (l_dobj) features_21\NNS\5849040|patient_118|after_40|._80 (l_prep) of_22\IN\0|clinical_34 (l_pobj) cholestasis_24\NN\14052403|NONE_0
D001379_D002779 CID azathioprine_12\RB\3740161|-_12 (r_advmod) induced_14\VBN\1627355|reversible_24|associated_20 (r_amod) cholestasis_15\NN\14052403|NONE_0
D001379_D002779 CID azathioprine_12\RB\3740161|-_12 (r_advmod) induced_14\VBN\1627355|reversible_24|associated_20 (r_amod) cholestasis_15\NN\14052403|NONE_0 (l_acl) associated_16\VBN\628491|reversible_44|induced_20 (l_prep) with_17\IN\0|NONE_0 (l_pobj) evidence_19\NN\5816287|NONE_0 (l_prep) of_20\IN\0|histological_22 (l_pobj) injury_23\NN\14052046|NONE_0
D001379_D008107 NONE azathioprine_30\NN\3740161|NONE_0 (r_amod) therapy_31\NN\657604|NONE_0 (r_pobj) of_29\IN\0|NONE_0 (r_prep) initiation_28\NN\7450842|months_13 (r_pobj) after_27\IN\0|patient_158|features_40|._40 (r_prep) developed_17\VBD\1753788|NONE_0 (l_nsubj) patient_4\NN\9898892|features_118|after_158|._198 (l_prep) with_6\IN\0|a_23|old_13|,_2 (l_conj) without_10\IN\0|polymyositis_17|and_4 (l_pobj) evidence_12\NN\5816287|NONE_0 (l_prep) of_13\IN\0|previous_18 (l_pobj) disease_15\NN\14061805|NONE_0
803783
D010121_D001247 NONE oxytocin_0\NN\5407119|during_24 (r_compound) administration_1\NN\1133281|is_53|carried_84|._323 (r_nsubjpass) advocated_8\VBN\875394|NONE_0 (l_advcl) carried_14\VBN\1850315|administration_84|is_31|._239 (l_conj) instructed_33\VBD\831651|only_132|if_127|it_124|can_121|be_117|out_106|under_102|,_50|aware_48|and_4 (l_xcomp) watch_35\VB\4437953|NONE_0 (l_conj) report_39\VB\6470073|to_26|diuresis_13|and_4 (l_dobj) signs_42\NNS\6643763|NONE_0 (l_prep) as_46\IN\14622893|such_33|early_28|of_16 (l_pobj) asthenia_47\NNP\14547643|NONE_0
D010121_D001523 NONE oxytocin_0\NN\5407119|during_24 (r_compound) administration_1\NN\1133281|is_53|carried_84|._323 (r_nsubjpass) advocated_8\VBN\875394|NONE_0 (l_advcl) carried_14\VBN\1850315|administration_84|is_31|._239 (l_conj) instructed_33\VBD\831651|only_132|if_127|it_124|can_121|be_117|out_106|under_102|,_50|aware_48|and_4 (l_xcomp) watch_35\VB\4437953|NONE_0 (l_conj) report_39\VB\6470073|to_26|diuresis_13|and_4 (l_dobj) signs_42\NNS\6643763|NONE_0 (l_prep) as_46\IN\14622893|such_33|early_28|of_16 (l_pobj) asthenia_47\NNP\14547643|NONE_0 (l_conj) irritability_50\NN\7552087|,_11
D010121_D000031 NONE oxytocin_4\NN\5407119|NONE_0 (r_compound) administration_5\NN\1133281|NONE_0 (r_pobj) with_3\IN\0|during_29 (r_prep) associated_2\VBN\628491|water_19|._70 (l_prep) during_6\IN\0|with_29 (l_pobj) abortion_10\NN\209943|NONE_0
D010121_D000031 NONE oxytocin_8\NN\5407119|NONE_0 (r_compound) administration_9\NN\1133281|NONE_0 (r_pobj) with_7\IN\0|during_29 (r_prep) connection_6\NN\31921|NONE_0 (l_prep) during_10\IN\0|with_29 (l_pobj) abortions_14\NNS\209943|NONE_0
D010121_D000031 NONE oxytocin_0\NN\5407119|during_24 (r_compound) administration_1\NN\1133281|is_53|carried_84|._323 (l_prep) during_2\IN\0|oxytocin_24 (l_pobj) abortions_6\NNS\209943|NONE_0
D010121_D014869 CID oxytocin_4\NN\5407119|NONE_0 (r_compound) administration_5\NN\1133281|NONE_0 (r_pobj) with_3\IN\0|during_29 (r_prep) associated_2\VBN\628491|water_19|._70 (r_acl) intoxication_1\NN\14034177|NONE_0
D010121_D014869 CID oxytocin_8\NN\5407119|NONE_0 (r_compound) administration_9\NN\1133281|NONE_0 (r_pobj) with_7\IN\0|during_29 (r_prep) connection_6\NN\31921|NONE_0 (r_pobj) in_5\IN\13603305|water_19 (r_prep) intoxication_4\NN\14034177|NONE_0
D010121_D014869 CID oxytocin_0\NN\5407119|during_24 (r_compound) administration_1\NN\1133281|is_53|carried_84|._323 (r_nsubjpass) advocated_8\VBN\875394|NONE_0 (l_advcl) carried_14\VBN\1850315|administration_84|is_31|._239 (l_advcl) aware_25\JJ\0|only_84|if_79|it_76|can_73|be_69|out_58|under_54|,_2|and_44|instructed_48 (l_prep) of_26\IN\0|NONE_0 (l_pobj) symptoms_28\NNS\5823932|NONE_0 (l_prep) of_29\IN\0|the_13 (l_pobj) intoxication_31\NN\14034177|NONE_0
D010121_D006261 NONE oxytocin_0\NN\5407119|during_24 (r_compound) administration_1\NN\1133281|is_53|carried_84|._323 (r_nsubjpass) advocated_8\VBN\875394|NONE_0 (l_advcl) carried_14\VBN\1850315|administration_84|is_31|._239 (l_conj) instructed_33\VBD\831651|only_132|if_127|it_124|can_121|be_117|out_106|under_102|,_50|aware_48|and_4 (l_xcomp) watch_35\VB\4437953|NONE_0 (l_conj) report_39\VB\6470073|to_26|diuresis_13|and_4 (l_dobj) signs_42\NNS\6643763|NONE_0 (l_prep) as_46\IN\14622893|such_33|early_28|of_16 (l_pobj) asthenia_47\NNP\14547643|NONE_0 (l_conj) irritability_50\NN\7552087|,_11 (l_conj) headaches_53\NNS\5829480|muscular_26|,_5|or_3
3001299
D008094_D007037 CID lithium_22\NN\14625458|NONE_0 (r_compound) treatment_23\NN\654885|NONE_0 (r_pobj) during_21\IN\0|the_74|of_58 (r_prep) development_13\NN\248977|NONE_0 (l_prep) of_14\IN\0|the_16|during_58 (l_pobj) insipidus_18\NN\0|NONE_0 (l_conj) hypothyroidism_20\NN\14059928|both_40|nephrogenic_35|diabetes_23|and_4
D008094_D007037 CID lithium_9\NN\14625458|while_23|they_17|were_12 (r_dobj) taking_8\VBG\37396|hypothyroidism_59|in_34|._14 (r_advcl) developed_1\VBD\1753788|NONE_0 (l_nsubj) hypothyroidism_0\NN\14059928|in_25|taking_59|._73
D008094_D018500 NONE lithium_22\NN\14625458|NONE_0 (r_compound) treatment_23\NN\654885|NONE_0 (r_pobj) during_21\IN\0|the_74|of_58 (r_prep) development_13\NN\248977|NONE_0 (l_prep) of_14\IN\0|the_16|during_58 (l_pobj) insipidus_18\NN\0|NONE_0
1711760
D010656_D006973 CID phenylephrine_4\NN\2682038|-_13 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) hypertension_7\NN\14057371|that_27|h_26|aggravate_48|,_84
D007530_D006973 NONE isoflurane_1\JJ\3570838|NONE_0 (r_amod) anesthesia_2\NN\14034177|NONE_0 (r_pobj) under_0\IN\0|,_27|mca_33|was_75|._87 (r_prep) occluded_12\VBN\2451370|NONE_0 (l_nsubjpass) mca_5\NNP\0|under_33|,_6|was_42|._54 (l_prep) of_6\IN\0|the_8 (l_pobj) rats_10\NNS\2329401|14_30 (l_amod) hypertensive_9\JJ\10405694|NONE_0
C009591_D009410 NONE 2,3,5-triphenyltetrazolium_8\CD\0|NONE_0 (r_nummod) staining_9\VBG\275424|NONE_0 (r_pobj) by_7\IN\0|extent_41|was_15|._38 (r_agent) determined_6\VBN\0|NONE_0 (l_nsubjpass) extent_1\NN\13939892|was_26|by_41|._79 (l_prep) of_2\IN\0|the_11 (l_pobj) injury_4\NN\14052046|NONE_0
D010656_D009410 NONE phenylephrine_4\NN\2682038|-_13 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) hypertension_7\NN\14057371|that_27|h_26|aggravate_48|,_84 (r_nsubj) instituted_8\VBD\1641914|data_54|._206 (l_advcl) aggravate_15\VB\126264|that_75|hypertension_48|h_22|,_36 (l_dobj) edema_16\NN\14315192|after_30|mcao_24|does_19|not_14 (l_acl) improves_24\VBZ\126264|in_30 (l_conj) reduces_37\VBZ\441445|that_79|it_74|edema_62|,_14|and_12 (l_dobj) area_39\NN\8630985|that_20|it_15 (l_prep) of_40\IN\0|the_9 (l_pobj) dysfunction_43\NN\14204950|NONE_0
D010656_D007511 NONE phenylephrine_4\NN\2682038|-_13 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) hypertension_7\NN\14057371|that_27|h_26|aggravate_48|,_84 (r_nsubj) instituted_8\VBD\1641914|data_54|._206 (l_advcl) aggravate_15\VB\126264|that_75|hypertension_48|h_22|,_36 (l_dobj) edema_16\NN\14315192|after_30|mcao_24|does_19|not_14 (l_prep) in_17\IN\13603305|improves_30 (l_pobj) core_20\NN\7996689|NONE_0 (l_amod) ischemic_19\JJ\0|the_4
D010656_D007511 NONE phenylephrine_4\NN\2682038|-_13 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) hypertension_7\NN\14057371|that_27|h_26|aggravate_48|,_84 (r_nsubj) instituted_8\VBD\1641914|data_54|._206 (l_advcl) aggravate_15\VB\126264|that_75|hypertension_48|h_22|,_36 (l_dobj) edema_16\NN\14315192|after_30|mcao_24|does_19|not_14 (l_acl) improves_24\VBZ\126264|in_30 (l_dobj) edema_25\NN\14315192|that_17|it_12|,_48|and_50|reduces_62 (l_prep) in_26\IN\13603305|NONE_0 (l_pobj) periphery_28\NN\13903079|NONE_0 (l_prep) of_29\IN\0|the_14 (l_pobj) territory_32\NN\8630985|NONE_0 (l_amod) ischemic_31\JJ\0|the_4
D010656_D020244 NONE phenylephrine_4\NN\2682038|-_13 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) hypertension_7\NN\14057371|that_27|h_26|aggravate_48|,_84 (r_nsubj) instituted_8\VBD\1641914|data_54|._206 (l_advcl) aggravate_15\VB\126264|that_75|hypertension_48|h_22|,_36 (l_nsubj) mcao_12\NNP\0|after_6|does_5|not_10|edema_24
D010656_D004487 NONE phenylephrine_4\NN\2682038|-_13 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) hypertension_7\NN\14057371|that_27|h_26|aggravate_48|,_84 (r_nsubj) instituted_8\VBD\1641914|data_54|._206 (l_advcl) aggravate_15\VB\126264|that_75|hypertension_48|h_22|,_36 (l_dobj) edema_16\NN\14315192|after_30|mcao_24|does_19|not_14
D010656_D004487 NONE phenylephrine_4\NN\2682038|-_13 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) hypertension_7\NN\14057371|that_27|h_26|aggravate_48|,_84 (r_nsubj) instituted_8\VBD\1641914|data_54|._206 (l_advcl) aggravate_15\VB\126264|that_75|hypertension_48|h_22|,_36 (l_dobj) edema_16\NN\14315192|after_30|mcao_24|does_19|not_14 (l_acl) improves_24\VBZ\126264|in_30 (l_dobj) edema_25\NN\14315192|that_17|it_12|,_48|and_50|reduces_62
20735774
D000082_D056486 NONE paracetamol_9\NN\0|-_11 (r_npadvmod) induced_11\VBN\1627355|acute_8|liver_14 (r_amod) injury_14\NN\14052046|NONE_0
D000082_D056486 NONE paracetamol_16\RB\0|-_11 (r_npadvmod) induced_18\VBN\1627355|whose_18|liver_8 (r_amod) injury_20\NN\14052046|had_7|failure_33
D000082_D017114 CID paracetamol_10\NN\0|-_11 (r_npadvmod) induced_12\VBN\1627355|acute_8|liver_14 (r_amod) failure_15\NN\66216|NONE_0
D000082_D017114 CID paracetamol_8\NN\0|-_11 (r_npadvmod) induced_10\VBN\1627355|acute_8|liver_14 (r_amod) failure_13\NN\66216|NONE_0
D000082_D017114 CID paracetamol_5\NN\0|whether_8|-_11 (r_advmod) induced_7\VBN\1627355|failure_20|mortality_48 (r_nmod) increases_11\VBZ\13576355|to_59 (l_nsubj) failure_10\NN\66216|induced_20|mortality_28
D000082_D017114 CID paracetamol_16\RB\0|-_11 (r_npadvmod) induced_18\VBN\1627355|whose_18|liver_8 (r_amod) injury_20\NN\14052046|had_7|failure_33 (r_nsubj) caused_22\VBN\1617192|the_60|101_56 (l_dobj) failure_26\NN\66216|injury_33|had_26
D000082_D017114 CID paracetamol_16\RB\0|-_11 (r_npadvmod) induced_18\VBN\1627355|whose_18|liver_8 (r_amod) injury_20\NN\14052046|had_7|failure_33 (r_nsubj) caused_22\VBN\1617192|the_60|101_56 (r_relcl) patients_14\NNS\9898892|NONE_0 (r_pobj) for_11\IN\0|slightly_16 (r_prep) higher_10\JJR\0|on_55|,_45|rates_20|,_157|but_159|was_179 (r_acomp) were_8\VBD\0|NONE_0 (l_conj) was_46\VBD\0|on_234|,_224|rates_199|higher_179|,_22|but_20 (l_conj) died_58\VBD\146138|association_71|dependent_51|,_42|and_40 (l_nsubj) survivors_53\NNS\9630641|of_38|,_54|were_73|._101 (l_prep) of_54\IN\0|no_13 (l_pobj) failure_57\NN\66216|NONE_0
D000082_D017114 CID paracetamol_0\NNP\0|-_11 (r_npadvmod) induced_2\VBN\1627355|acute_8|liver_14 (r_amod) failure_5\NN\66216|did_8|not_12|mortality_33|._42
D000082_D008107 NONE paracetamol_16\RB\0|-_11 (r_npadvmod) induced_18\VBN\1627355|whose_18|liver_8 (r_amod) injury_20\NN\14052046|had_7|failure_33 (r_nsubj) caused_22\VBN\1617192|the_60|101_56 (r_relcl) patients_14\NNS\9898892|NONE_0 (r_pobj) for_11\IN\0|slightly_16 (r_prep) higher_10\JJR\0|on_55|,_45|rates_20|,_157|but_159|was_179 (r_acomp) were_8\VBD\0|NONE_0 (l_conj) was_46\VBD\0|on_234|,_224|rates_199|higher_179|,_22|but_20 (l_conj) died_58\VBD\146138|association_71|dependent_51|,_42|and_40 (l_prep) of_59\IN\0|survivors_38|,_16|were_35|._63 (l_pobj) disease_61\NN\14061805|NONE_0
20705401
D012701_D006948 NONE serotonin_1\NN\14807737|is_29|therapeutically_32|by_57|corrected_187|._250 (r_nsubjpass) targeted_9\VBN\1151110|NONE_0 (l_agent) by_10\IN\0|serotonin_57|is_28|therapeutically_25|corrected_130|._193 (l_pobj) antipsychotics_14\NNS\4470232|NONE_0 (l_prep) as_17\IN\14622893|several_47|generation_32|,_7 (l_pobj) clozapine_18\NN\3713736|such_8 (l_conj) hyperactivity_28\NN\14052403|and_42|olanzapine_38|,_28|and_26|induced_8
D012701_D006948 NONE 5-ht6_4\CD\0|6_3|(_1|)_5 (r_nummod) receptor_6\NN\5225602|the_24 (r_appos) serotonin_1\NN\14807737|is_29|therapeutically_32|by_57|corrected_187|._250 (r_nsubjpass) targeted_9\VBN\1151110|NONE_0 (l_agent) by_10\IN\0|serotonin_57|is_28|therapeutically_25|corrected_130|._193 (l_pobj) antipsychotics_14\NNS\4470232|NONE_0 (l_prep) as_17\IN\14622893|several_47|generation_32|,_7 (l_pobj) clozapine_18\NN\3713736|such_8 (l_conj) hyperactivity_28\NN\14052403|and_42|olanzapine_38|,_28|and_26|induced_8
D012701_D006948 NONE 5-ht6_39\CD\0|a_12|selective_10|receptor_6 (r_nummod) antagonist_41\NN\7846|NONE_0 (r_pobj) of_36\IN\0|the_8 (r_prep) use_35\NN\407535|NONE_0 (r_pobj) with_33\IN\0|is_13 (r_prep) corrected_32\VBN\138508|serotonin_187|is_158|therapeutically_155|by_130|._63 (r_conj) targeted_9\VBN\1151110|NONE_0 (l_agent) by_10\IN\0|serotonin_57|is_28|therapeutically_25|corrected_130|._193 (l_pobj) antipsychotics_14\NNS\4470232|NONE_0 (l_prep) as_17\IN\14622893|several_47|generation_32|,_7 (l_pobj) clozapine_18\NN\3713736|such_8 (l_conj) hyperactivity_28\NN\14052403|and_42|olanzapine_38|,_28|and_26|induced_8
D012701_D012559 NONE 5-ht6_20\CD\0|altered_8 (r_nummod) receptors_21\NNS\5225602|that_19|are_10|in_23 (r_nsubjpass) involved_23\VBN\2676054|evidence_51|._54 (r_ccomp) suggests_17\VBZ\1010118|models_97|were_90|reflect_71|,_25|and_23 (r_conj) considered_4\VBN\689344|NONE_0 (l_xcomp) reflect_6\VB\923793|models_26|were_19|,_46|and_48|suggests_71 (l_dobj) symptoms_9\NNS\5823932|to_24 (l_prep) of_10\IN\0|the_22|positive_18 (l_pobj) schizophrenia_11\NN\14398067|NONE_0
C076029_D006948 NONE olanzapine_20\NN\0|and_4|,_10|and_12|induced_30|hyperactivity_38 (r_conj) clozapine_18\NN\3713736|such_8 (l_conj) hyperactivity_28\NN\14052403|and_42|olanzapine_38|,_28|and_26|induced_8
D008694_D011605 CID methamphetamine_7\NN\2704153|-_15 (r_npadvmod) induced_9\VBN\1627355|in_18 (r_amod) psychosis_10\NN\14380140|NONE_0
D008694_D011605 CID methamphetamine_3\NN\2704153|NONE_0 (r_pobj) of_2\IN\0|the_13|psychosis_34 (r_prep) symptoms_1\NNS\5823932|similar_57|._104 (l_appos) psychosis_6\NN\14380140|the_47|of_34
D008694_D011605 CID meth)-induced_5\JJ\0|(_1 (r_amod) psychosis_6\NN\14380140|the_47|of_34
D008694_D011605 CID meth_17\NNP\2704153|-_4 (r_npadvmod) induced_19\VBN\1627355|NONE_0 (r_amod) psychosis_20\NN\14380140|NONE_0
D008694_D011605 CID meth_29\NN\2704153|-_4 (r_npadvmod) induced_31\VBN\1627355|(_10|197_9|psychosis_8|and_27|controls_35|)_43|in_45 (r_amod) patients_33\NNS\9898892|control_44 (l_compound) psychosis_32\NN\14380140|(_18|197_17|induced_8|and_19|controls_27|)_35|in_37
D008694_D011605 CID meth_4\NNP\2704153|-_4 (r_npadvmod) induced_6\VBN\1627355|psychosis_8|in_27 (r_amod) patients_8\NNS\9898892|NONE_0 (l_compound) psychosis_7\NN\14380140|induced_8|in_19
D008694_D011605 CID meth_32\NNP\2704153|-_4 (r_npadvmod) induced_34\VBN\1627355|psychosis_8 (r_amod) patients_36\NNS\9898892|an_151|between_136|,_8 (l_compound) psychosis_35\NN\14380140|induced_8
D008694_D011605 CID meth_10\NNP\2704153|-_4 (r_npadvmod) induced_12\VBN\1627355|in_18 (r_amod) psychosis_13\NN\14380140|NONE_0
D012701_D011605 NONE serotonin_0\NN\14807737|6_10|receptor_12 (r_nmod) gene_3\NN\8459252|is_5|with_19|._82 (r_nsubjpass) associated_5\VBN\628491|NONE_0 (l_prep) with_6\IN\0|gene_19|is_14|._63 (l_pobj) psychosis_10\NN\14380140|NONE_0
D012701_D011605 NONE 5-ht6_20\CD\0|altered_8 (r_nummod) receptors_21\NNS\5225602|that_19|are_10|in_23 (r_nsubjpass) involved_23\VBN\2676054|evidence_51|._54 (l_prep) in_24\IN\13603305|that_42|receptors_23|are_13 (l_pobj) pathophysiology_26\NN\0|NONE_0 (l_prep) of_27\IN\0|the_20 (l_pobj) disorders_29\NNS\14034177|NONE_0
D012701_D011605 NONE 5-ht6_11\CD\0|the_4|(_11|htr6_12|)_16|with_18 (r_nummod) gene_12\NN\8459252|NONE_0 (l_prep) with_16\IN\0|the_22|5-ht6_18|(_7|htr6_6|)_2 (l_pobj) psychosis_20\NN\14380140|NONE_0
D003024_D006948 NONE clozapine_18\NN\3713736|such_8 (l_conj) hyperactivity_28\NN\14052403|and_42|olanzapine_38|,_28|and_26|induced_8
D003913_D006948 NONE amphetamine_25\NN\3248958|d_2|-_1|-_11 (r_npadvmod) induced_27\VBN\1627355|and_34|olanzapine_30|,_20|and_18|hyperactivity_8 (r_conj) clozapine_18\NN\3713736|such_8 (l_conj) hyperactivity_28\NN\14052403|and_42|olanzapine_38|,_28|and_26|induced_8
D008694_D012563 NONE methamphetamine_3\NN\2704153|NONE_0 (r_pobj) of_2\IN\0|the_13|psychosis_34 (r_prep) symptoms_1\NNS\5823932|similar_57|._104 (r_nsubj) are_7\VBP\13600404|NONE_0 (l_acomp) similar_8\JJ\0|symptoms_57|._47 (l_prep) to_9\IN\0|NONE_0 (l_pobj) those_10\DT\0|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) schizophrenia_14\NN\14398067|NONE_0
D008694_D012563 NONE meth)-induced_5\JJ\0|(_1 (r_amod) psychosis_6\NN\14380140|the_47|of_34 (r_appos) symptoms_1\NNS\5823932|similar_57|._104 (r_nsubj) are_7\VBP\13600404|NONE_0 (l_acomp) similar_8\JJ\0|symptoms_57|._47 (l_prep) to_9\IN\0|NONE_0 (l_pobj) those_10\DT\0|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) schizophrenia_14\NN\14398067|NONE_0
14704468
C066440_D012640 NONE loreclezole_0\NNP\0|action_55|,_86|reducing_88|._138 (r_nsubj) exerted_5\VBD\1158872|NONE_0 (l_advcl) reducing_16\VBG\13447361|loreclezole_88|action_33|,_2|._50 (l_dobj) seizure_18\NN\14081375|NONE_0
18006530
D015742_D010146 CID propofol_9\NN\0|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) induction_4\NN\7450842|NONE_0 (r_pobj) during_3\IN\0|of_8|._65 (r_prep) reduction_0\NN\351485|NONE_0 (l_prep) of_1\IN\0|during_8|._73 (l_pobj) pain_2\NN\14299637|NONE_0
D015742_D010146 CID propofol_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|NONE_0 (r_prep) injection_2\NN\320852|NONE_0 (r_pobj) on_1\IN\0|NONE_0 (r_prep) pain_0\NN\14299637|unpleasant_33|._43
D015742_D010146 CID propofol_3\JJ\0|infusion_9 (r_amod) pain_5\NN\14299637|that_23|might_5|be_11|by_24
D015742_D010146 CID propofol_15\JJ\0|the_4|in_18 (r_amod) infusion_16\NN\14589223|NONE_0 (r_dobj) starting_13\VBG\457382|NONE_0 (r_pcomp) before_12\IN\0|remifentanil_13 (r_prep) infusing_10\VBG\606335|NONE_0 (r_pcomp) by_9\IN\0|that_47|pain_24|might_19|be_13 (r_prep) prevented_8\VBN\0|we_53|._158 (l_nsubjpass) pain_5\NN\14299637|that_23|might_5|be_11|by_24
D015742_D010146 CID propofol_15\NN\0|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) caused_13\VBN\1617192|NONE_0 (r_acl) pain_12\NN\14299637|was_24|using_38|._91
D015742_D010146 CID propofol_26\JJ\0|the_4 (r_amod) infusion_27\NN\14589223|NONE_0 (r_pobj) during_24\IN\0|scale_6 (r_prep) using_18\VBG\418025|pain_38|was_14|._53 (r_advcl) evaluated_17\VBN\670261|complications_94|were_80|during_66|,_34|and_32 (l_nsubjpass) pain_12\NN\14299637|was_24|using_38|._91
D015742_D010146 CID propofol_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|with_9 (r_prep) anaesthesia_3\NN\14034177|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) induction_1\NN\7450842|NONE_0 (r_pobj) during_0\IN\0|,_69|reduction_85|was_121|without_134|)_236|._237 (r_prep) achieved_19\VBN\2524171|NONE_0 (l_nsubjpass) reduction_13\NN\351485|during_85|,_16|was_36|without_49|)_151|._152 (l_prep) in_14\IN\13603305|a_24|significant_22 (l_pobj) pain_17\NN\14299637|NONE_0
D015742_D010146 CID propofol_15\JJ\0|infusion_9 (r_amod) pain_17\NN\14299637|NONE_0
C071741_D010146 NONE remifentanil_11\NN\0|controlled_24|and_4 (r_conj) propofol_9\NN\0|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) induction_4\NN\7450842|NONE_0 (r_pobj) during_3\IN\0|of_8|._65 (r_prep) reduction_0\NN\351485|NONE_0 (l_prep) of_1\IN\0|during_8|._73 (l_pobj) pain_2\NN\14299637|NONE_0
C071741_D010146 NONE remifentanil_11\NN\0|before_13 (r_dobj) infusing_10\VBG\606335|NONE_0 (r_pcomp) by_9\IN\0|that_47|pain_24|might_19|be_13 (r_prep) prevented_8\VBN\0|we_53|._158 (l_nsubjpass) pain_5\NN\14299637|that_23|might_5|be_11|by_24
C071741_D010146 NONE remifentanil_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|(_5|)_2 (r_prep) ce_23\NNP\14625458|the_31|site_20|prevent_23 (r_appos) concentration_21\NN\4916342|to_29 (l_relcl) prevent_28\VB\0|the_54|site_43|ce_23 (l_dobj) pain_30\NN\14299637|to_15|without_5
C071741_D010146 NONE remifentanil_0\NN\0|-_12 (r_npadvmod) related_2\VBN\628491|NONE_0 (r_amod) complications_3\NNS\1073995|were_14|during_28|,_60|and_62|evaluated_94 (r_nsubjpass) assessed_5\VBN\670261|NONE_0 (l_conj) evaluated_17\VBN\670261|complications_94|were_80|during_66|,_34|and_32 (l_nsubjpass) pain_12\NN\14299637|was_24|using_38|._91
C071741_D010146 NONE remifentanil_8\NN\0|the_4 (r_compound) infusion_9\NN\14589223|NONE_0 (r_pobj) during_6\IN\0|complications_28|were_14|,_32|and_34|evaluated_66 (r_prep) assessed_5\VBN\670261|NONE_0 (l_conj) evaluated_17\VBN\670261|complications_94|were_80|during_66|,_34|and_32 (l_nsubjpass) pain_12\NN\14299637|was_24|using_38|._91
C071741_D010146 NONE remifentanil_9\NN\0|and_4 (r_conj) propofol_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|with_9 (r_prep) anaesthesia_3\NN\14034177|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) induction_1\NN\7450842|NONE_0 (r_pobj) during_0\IN\0|,_69|reduction_85|was_121|without_134|)_236|._237 (r_prep) achieved_19\VBN\2524171|NONE_0 (l_nsubjpass) reduction_13\NN\351485|during_85|,_16|was_36|without_49|)_151|._152 (l_prep) in_14\IN\13603305|a_24|significant_22 (l_pobj) pain_17\NN\14299637|NONE_0
C071741_D010146 NONE remifentanil_27\NN\0|NONE_0 (r_pobj) of_26\IN\0|prior_21 (r_prep) administration_25\NN\1133281|NONE_0 (r_pobj) by_23\IN\0|significant_26|at_40 (r_prep) complications_22\NNS\1073995|NONE_0 (r_pobj) without_20\IN\0|during_134|,_65|reduction_49|was_13|)_102|._103 (r_prep) achieved_19\VBN\2524171|NONE_0 (l_nsubjpass) reduction_13\NN\351485|during_85|,_16|was_36|without_49|)_151|._152 (l_prep) in_14\IN\13603305|a_24|significant_22 (l_pobj) pain_17\NN\14299637|NONE_0
8045270
C061282_D002375 CID 21680_29\CD\0|(_6|micrograms_10|)_20 (r_nummod) cgs_28\NNP\13577934|an_35|adenosine_32|a2a_22|receptor_18|,_2 (r_appos) agonist_26\NN\0|NONE_0 (r_pobj) of_21\IN\0|intracerebroventricular_39 (r_prep) administration_20\NN\1133281|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) induced_17\VBN\1627355|the_25|cataleptic_21 (r_acl) responses_16\NNS\11410625|administration_94|significantly_41|,_123|in_125|._151 (l_amod) cataleptic_15\JJ\10490141|the_4|induced_21
D006220_D002375 CID haloperidol_7\NN\3713736|and_27|by_31 (r_pobj) by_6\IN\0|NONE_0 (r_agent) induced_5\VBN\1627355|the_14 (r_acl) catalepsy_4\NN\14023236|kf17837_25|also_17|._79
D000241_D002375 NONE adenosine_23\NN\14964367|an_3|a2a_10|receptor_14|,_30|cgs_32 (r_amod) agonist_26\NN\0|NONE_0 (r_pobj) of_21\IN\0|intracerebroventricular_39 (r_prep) administration_20\NN\1133281|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) induced_17\VBN\1627355|the_25|cataleptic_21 (r_acl) responses_16\NNS\11410625|administration_94|significantly_41|,_123|in_125|._151 (l_amod) cataleptic_15\JJ\10490141|the_4|induced_21
C081198_D010302 NONE kf17837_2\NN\0|furthermore_13|,_2|may_8|drug_24|._61 (r_nsubj) be_4\VB\14625458|NONE_0 (l_attr) drug_7\NN\14778436|furthermore_37|,_26|kf17837_24|may_16|._37 (l_prep) in_8\IN\13603305|a_14|useful_12 (l_pobj) treatment_10\NN\654885|NONE_0 (l_prep) of_11\IN\0|the_14 (l_pobj) parkinsonism_12\NN\14085708|NONE_0
C081198_D002375 NONE kf17837_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|oral_20|2.5_12 (r_prep) administration_1\NN\1133281|significantly_53|responses_94|,_217|in_219|._245 (r_nsubj) ameliorated_13\VBD\126264|NONE_0 (l_dobj) responses_16\NNS\11410625|administration_94|significantly_41|,_123|in_125|._151 (l_amod) cataleptic_15\JJ\10490141|the_4|induced_21
C081198_D002375 NONE kf17837_0\NN\0|also_8|catalepsy_25|._104 (r_nsubj) reduced_2\VBD\441445|NONE_0 (l_dobj) catalepsy_4\NN\14023236|kf17837_25|also_17|._79
D012110_D002375 CID reserpine_15\NN\2721160|NONE_0 (r_pobj) by_14\IN\0|haloperidol_31|and_4 (r_conj) by_6\IN\0|NONE_0 (r_agent) induced_5\VBN\1627355|the_14 (r_acl) catalepsy_4\NN\14023236|kf17837_25|also_17|._79
17344330
D008691_D008133 CID methadone_8\NN\3808564|NONE_0 (r_pobj) with_7\IN\0|for_15 (r_prep) treated_6\VBN\2376958|NONE_0 (r_acl) patients_5\NNS\9898892|NONE_0 (r_pobj) among_4\IN\0|and_20|prolongation_13|._85 (r_prep) syncope_0\NNP\7478169|NONE_0 (l_conj) prolongation_3\NN\1017987|and_7|among_13|._98
D008691_D008133 CID methadone_5\NN\3808564|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) treated_3\VBN\2376958|the_13 (r_acl) subjects_2\NNS\6598915|NONE_0 (r_pobj) among_0\IN\0|interval_83|._91 (r_prep) had_14\VBD\0|NONE_0 (l_dobj) interval_17\NN\33615|among_83|._8
D008691_D008133 CID methadone_0\NNP\3808564|is_10|with_24|._110 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_prep) with_3\IN\0|methadone_24|is_14|._86 (l_pobj) prolongation_5\NN\1017987|NONE_0
D003932_D016171 NONE heroin_1\NN\3492717|NONE_0 (r_compound) addicts_2\NNS\10059582|as_10|sometimes_8|using_30 (r_nsubj) faint_4\JJ\7478169|,_31|doctors_33|might_41|episodes_66|and_106|underestimate_118|,_179|and_181|caused_240 (r_advcl) attribute_12\VB\5835747|NONE_0 (l_conj) underestimate_24\VBP\5803379|faint_118|,_87|doctors_85|might_77|episodes_52|and_12|,_61|and_63|caused_122 (l_dobj) incidence_26\NN\13821570|thereby_26 (l_prep) of_27\IN\0|the_14|in_7 (l_pobj) tdp_28\NNP\0|NONE_0
D003932_D013575 NONE heroin_10\NN\3492717|in_18 (r_compound) dependence_11\NN\24720|NONE_0 (r_pobj) for_9\IN\0|with_15 (r_prep) treated_6\VBN\2376958|NONE_0 (r_acl) patients_5\NNS\9898892|NONE_0 (r_pobj) among_4\IN\0|and_20|prolongation_13|._85 (r_prep) syncope_0\NNP\7478169|NONE_0
D003932_D013575 NONE heroin_1\NN\3492717|NONE_0 (r_compound) addicts_2\NNS\10059582|as_10|sometimes_8|using_30 (r_nsubj) faint_4\JJ\7478169|,_31|doctors_33|might_41|episodes_66|and_106|underestimate_118|,_179|and_181|caused_240 (r_advcl) attribute_12\VB\5835747|NONE_0 (l_dobj) episodes_15\NNS\7283608|faint_66|,_35|doctors_33|might_25|and_40|underestimate_52|,_113|and_115|caused_174 (l_prep) of_16\IN\0|many_14 (l_pobj) syncope_17\NN\7478169|NONE_0
D003932_D013575 NONE heroin_15\NN\3492717|NONE_0 (r_compound) addicts_16\NNS\10059582|NONE_0 (r_pobj) of_14\IN\0|a_13 (r_prep) population_13\NN\7942152|NONE_0 (r_pobj) in_11\IN\13603305|NONE_0 (r_prep) syncope_10\NN\7478169|NONE_0
D008691_D013575 CID methadone_8\NN\3808564|NONE_0 (r_pobj) with_7\IN\0|for_15 (r_prep) treated_6\VBN\2376958|NONE_0 (r_acl) patients_5\NNS\9898892|NONE_0 (r_pobj) among_4\IN\0|and_20|prolongation_13|._85 (r_prep) syncope_0\NNP\7478169|NONE_0
D008691_D013575 CID methadone_53\NN\3808564|NONE_0 (r_pobj) of_52\IN\0|the_25|proarrhythmic_21 (r_prep) effect_51\NN\34213|NONE_0 (r_pobj) by_48\IN\0|mortality_53|may_24|,_21|in_19|,_12|be_10|._40 (r_agent) caused_47\VBN\1617192|faint_240|,_209|doctors_207|might_199|episodes_174|and_134|underestimate_122|,_61|and_59 (r_conj) attribute_12\VB\5835747|NONE_0 (l_dobj) episodes_15\NNS\7283608|faint_66|,_35|doctors_33|might_25|and_40|underestimate_52|,_113|and_115|caused_174 (l_prep) of_16\IN\0|many_14 (l_pobj) syncope_17\NN\7478169|NONE_0
D008691_D013575 CID methadone_9\NN\3808564|and_15|reporting_19 (r_compound) dose_10\NN\3740161|opioid_34|and_22|qt_18|,_16|and_14 (l_conj) reporting_12\NN\6681177|methadone_19|and_4 (l_prep) of_13\IN\0|NONE_0 (l_pobj) syncope_14\NN\7478169|NONE_0
D008691_D013575 CID methadone_4\NN\3808564|NONE_0 (r_compound) dose_5\NN\3740161|was_5|with_20|._80 (r_nsubjpass) associated_7\VBN\628491|NONE_0 (l_prep) with_8\IN\0|dose_20|was_15|._60 (l_pobj) ci_14\NNP\13635336|NONE_0 (l_appos) odds_21\NNS\4756635|a_39|%_30|1.1_25|to_21|)_15 (l_prep) for_22\IN\0|higher_12 (l_pobj) syncope_23\NN\7478169|NONE_0
D008691_D013575 CID methadone_0\NNP\3808564|is_10|with_24|._110 (r_nsubjpass) associated_2\VBN\628491|NONE_0 (l_prep) with_3\IN\0|methadone_24|is_14|._86 (l_pobj) prolongation_5\NN\1017987|NONE_0 (l_conj) reporting_8\NN\6681177|qt_27|and_11 (l_prep) of_9\IN\0|higher_17 (l_pobj) syncope_10\NN\7478169|NONE_0
D003932_D008133 NONE heroin_10\NN\3492717|in_18 (r_compound) dependence_11\NN\24720|NONE_0 (r_pobj) for_9\IN\0|with_15 (r_prep) treated_6\VBN\2376958|NONE_0 (r_acl) patients_5\NNS\9898892|NONE_0 (r_pobj) among_4\IN\0|and_20|prolongation_13|._85 (r_prep) syncope_0\NNP\7478169|NONE_0 (l_conj) prolongation_3\NN\1017987|and_7|among_13|._98
D003932_D008133 NONE heroin_15\NN\3492717|NONE_0 (r_compound) addicts_16\NNS\10059582|NONE_0 (r_pobj) of_14\IN\0|a_13 (r_prep) population_13\NN\7942152|NONE_0 (r_pobj) in_11\IN\13603305|NONE_0 (r_prep) syncope_10\NN\7478169|NONE_0 (r_pobj) of_9\IN\0|higher_17 (r_prep) reporting_8\NN\6681177|qt_27|and_11 (r_conj) prolongation_5\NN\1017987|NONE_0
D008691_D016171 NONE methadone_21\NN\3808564|NONE_0 (r_compound) users_22\NNS\7846|NONE_0 (r_pobj) in_20\IN\13603305|prolongation_103|has_18|been_14|._18 (r_prep) reported_19\VBN\831651|NONE_0 (l_nsubjpass) prolongation_0\NN\1017987|has_85|been_89|in_103|._121 (l_prep) of_1\IN\0|NONE_0 (l_pobj) interval_4\NN\33615|NONE_0 (l_prep) in_5\IN\13603305|the_16|qt_12 (l_pobj) ecg_7\NNP\7000195|NONE_0 (l_prep) of_8\IN\0|the_8 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) pointes_13\FW\831651|NONE_0
D008691_D016171 NONE methadone_21\NN\3808564|NONE_0 (r_compound) users_22\NNS\7846|NONE_0 (r_pobj) in_20\IN\13603305|prolongation_103|has_18|been_14|._18 (r_prep) reported_19\VBN\831651|NONE_0 (l_nsubjpass) prolongation_0\NN\1017987|has_85|been_89|in_103|._121 (l_prep) of_1\IN\0|NONE_0 (l_pobj) interval_4\NN\33615|NONE_0 (l_prep) in_5\IN\13603305|the_16|qt_12 (l_pobj) ecg_7\NNP\7000195|NONE_0 (l_prep) of_8\IN\0|the_8 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) pointes_13\FW\831651|NONE_0 (l_appos) tdp_15\NN\0|torsade_20|de_12|(_1|)_3
D008691_D016171 NONE methadone_53\NN\3808564|NONE_0 (r_pobj) of_52\IN\0|the_25|proarrhythmic_21 (r_prep) effect_51\NN\34213|NONE_0 (r_pobj) by_48\IN\0|mortality_53|may_24|,_21|in_19|,_12|be_10|._40 (r_agent) caused_47\VBN\1617192|faint_240|,_209|doctors_207|might_199|episodes_174|and_134|underestimate_122|,_61|and_59 (r_conj) attribute_12\VB\5835747|NONE_0 (l_conj) underestimate_24\VBP\5803379|faint_118|,_87|doctors_85|might_77|episodes_52|and_12|,_61|and_63|caused_122 (l_dobj) incidence_26\NN\13821570|thereby_26 (l_prep) of_27\IN\0|the_14|in_7 (l_pobj) tdp_28\NNP\0|NONE_0
9799166
D000661_D020521 CID amphetamine_4\NN\3248958|or_3 (r_conj) cocaine_2\NN\3492717|and_4 (r_conj) stroke_0\NN\556313|._37
D000661_D020521 CID amphetamine_5\NN\3248958|NONE_0 (r_compound) use_6\NN\407535|and_16 (r_conj) cocaine_3\NN\3492717|NONE_0 (r_pobj) of_2\IN\0|the_16|with_31 (r_prep) association_1\NN\8008335|is_80|on_103|._127 (l_prep) with_7\IN\0|the_47|of_31 (l_pobj) stroke_11\NN\556313|NONE_0
D000661_D020521 CID amphetamine_13\NN\3248958|and/or_7 (r_conj) cocaine_11\NN\3492717|NONE_0 (r_pobj) of_10\IN\0|NONE_0 (r_prep) use_9\NN\407535|and_4 (r_conj) stroke_7\NN\556313|NONE_0
D000661_D020521 CID amphetamine_15\NN\3248958|and/or_7 (r_conj) cocaine_13\NN\3492717|NONE_0 (r_dobj) using_12\VBG\418025|NONE_0 (r_pcomp) to_11\IN\0|who_13 (r_prep) admitted_10\VBD\822367|in_13 (r_relcl) stroke_6\NN\556313|NONE_0
D000661_D020521 CID amphetamine_5\NN\3248958|and/or_7 (r_conj) cocaine_3\NN\3492717|NONE_0 (r_pobj) of_2\IN\0|the_8 (r_prep) use_1\NN\407535|factor_51|._134 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) factor_10\NN\7326557|use_51|._83 (l_prep) for_11\IN\0|a_21|strong_19|risk_12 (l_pobj) stroke_12\NN\556313|NONE_0
D003042_D007511 NONE cocaine_3\NN\3492717|NONE_0 (r_pobj) of_2\IN\0|the_16|with_31 (r_prep) association_1\NN\8008335|is_80|on_103|._127 (l_prep) with_7\IN\0|the_47|of_31 (l_pobj) stroke_11\NN\556313|NONE_0 (l_amod) hemorrhagic_8\JJ\0|NONE_0 (l_conj) ischemic_10\JJ\0|and_4
D000661_D007511 NONE amphetamine_5\NN\3248958|NONE_0 (r_compound) use_6\NN\407535|and_16 (r_conj) cocaine_3\NN\3492717|NONE_0 (r_pobj) of_2\IN\0|the_16|with_31 (r_prep) association_1\NN\8008335|is_80|on_103|._127 (l_prep) with_7\IN\0|the_47|of_31 (l_pobj) stroke_11\NN\556313|NONE_0 (l_amod) hemorrhagic_8\JJ\0|NONE_0 (l_conj) ischemic_10\JJ\0|and_4
D003042_D020521 CID cocaine_2\NN\3492717|and_4 (r_conj) stroke_0\NN\556313|._37
D003042_D020521 CID cocaine_3\NN\3492717|NONE_0 (r_pobj) of_2\IN\0|the_16|with_31 (r_prep) association_1\NN\8008335|is_80|on_103|._127 (l_prep) with_7\IN\0|the_47|of_31 (l_pobj) stroke_11\NN\556313|NONE_0
D003042_D020521 CID cocaine_11\NN\3492717|NONE_0 (r_pobj) of_10\IN\0|NONE_0 (r_prep) use_9\NN\407535|and_4 (r_conj) stroke_7\NN\556313|NONE_0
D003042_D020521 CID cocaine_13\NN\3492717|NONE_0 (r_dobj) using_12\VBG\418025|NONE_0 (r_pcomp) to_11\IN\0|who_13 (r_prep) admitted_10\VBD\822367|in_13 (r_relcl) stroke_6\NN\556313|NONE_0
D003042_D020521 CID cocaine_3\NN\3492717|NONE_0 (r_pobj) of_2\IN\0|the_8 (r_prep) use_1\NN\407535|factor_51|._134 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) factor_10\NN\7326557|use_51|._83 (l_prep) for_11\IN\0|a_21|strong_19|risk_12 (l_pobj) stroke_12\NN\556313|NONE_0
11226639
D008550_D053608 CID melatonin_3\NN\5407119|NONE_0 (l_prep) on_4\IN\0|NONE_0 (l_pobj) narcosis_8\NN\5678932|NONE_0
D008550_D053608 CID melatonin_0\NNP\5407119|cycle_43|,_48|but_50|is_57 (r_nsubj) affects_1\VBZ\26192|NONE_0 (l_conj) is_11\VBZ\0|melatonin_57|cycle_14|,_9|but_7 (l_ccomp) influence_17\VB\5190804|it_31|not_25|clear_21|._31 (l_dobj) narcosis_21\NN\5678932|whether_38|it_30|may_27
D008550_D053608 CID melatonin_0\NNP\5407119|,_70|however_72|,_79|correlation_96|was_108|._117 (r_nsubjpass) found_20\VBN\13279262|NONE_0 (l_punct) ,_11\,\0|melatonin_70|however_2|,_9|correlation_26|was_38|._47 (l_punct) affected_4\VBN\126264|NONE_0 (l_prep) in_5\IN\13603305|treatment_19 (l_pobj) narcosis_10\NN\5678932|NONE_0
D008550_D053608 CID melatonin_7\NN\5407119|NONE_0 (r_pobj) of_6\IN\0|the_17|highest_13 (r_prep) dose_5\NN\3740161|in_25|,_14|increase_50|and_74|produced_78|and_138|reduction_144|._171 (r_nsubj) caused_12\VBD\1617192|NONE_0 (l_conj) produced_20\VBD\1617192|in_103|,_92|dose_78|increase_28|and_4|and_60|reduction_66|._93 (l_dobj) reduction_23\NN\351485|,_37 (l_prep) of_24\IN\0|a_22|sustained_20 (l_pobj) duration_26\NN\15113229|NONE_0 (l_prep) of_27\IN\0|the_13 (l_pobj) narcosis_28\NN\5678932|NONE_0
D008550_D053608 CID melatonin_0\NNP\5407119|duration_41|._111 (r_nsubj) influenced_5\VBD\137313|NONE_0 (l_dobj) duration_7\NN\15113229|melatonin_41|._70 (l_conj) latency_11\NN\15269513|the_25|but_12 (l_prep) of_12\IN\0|not_16|the_12 (l_pobj) narcosis_18\NN\5678932|NONE_0
D008550_D053608 CID melatonin_6\NN\5407119|NONE_0 (l_prep) on_7\IN\0|NONE_0 (l_pobj) narcosis_9\NN\5678932|NONE_0
D007649_D053608 CID ketamine-_13\NNS\0|NONE_0 (r_nmod) narcosis_18\NN\5678932|NONE_0
C032232_D053608 NONE barbiturate_5\NN\4166841|-_11 (r_npadvmod) induced_7\VBN\1627355|in_17 (r_amod) narcosis_8\NN\5678932|NONE_0
C032232_D053608 NONE barbiturate_9\NN\4166841|a_14|manner_7 (r_compound) narcosis_10\NN\5678932|NONE_0
C032232_D053608 NONE barbiturate_14\NN\4166841|NONE_0 (r_compound) narcosis_15\NN\5678932|NONE_0
C032232_D053608 NONE barbiturate_16\JJ\4166841|the_4|of_22 (r_compound) mechanism_17\NN\13446390|NONE_0 (r_pobj) for_14\IN\0|NONE_0 (r_prep) specific_13\JJ\5817396|to_6 (r_acomp) be_12\VB\14625458|thus_72|,_68|action_57|._51 (r_xcomp) seems_10\VBZ\2604760|NONE_0 (l_nsubj) action_4\NN\30358|thus_15|,_11|be_57|._108 (l_prep) of_5\IN\0|the_16|dual_12 (l_pobj) melatonin_6\NN\5407119|NONE_0 (l_prep) on_7\IN\0|NONE_0 (l_pobj) narcosis_9\NN\5678932|NONE_0
D003975_D053608 CID diazepam_15\NN\2830852|-_8 (r_npadvmod) induced_17\VBN\1627355|or_12 (r_conj) ketamine-_13\NNS\0|NONE_0 (r_nmod) narcosis_18\NN\5678932|NONE_0
2894433
D001569_D001919 NONE benzodiazepine_36\JJ\3771443|the_4|chloride_20|channel_29|macromolecular_37 (r_amod) complex_43\NN\5869584|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) associated_33\VBN\628491|NONE_0 (r_acl) sites_32\NNS\8673395|NONE_0 (r_pobj) to_31\IN\0|NONE_0 (r_prep) binding_30\VBG\4688246|NONE_0 (r_pcomp) by_29\IN\0|agent_31|channels_9 (r_prep) blocks_26\NNS\21939|(_10|)_124 (r_appos) picrotoxin_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|an_20|intravenous_17 (r_prep) dose_20\NN\3740161|NONE_0 (r_pobj) with_17\IN\0|of_8 (r_prep) pretreatment_14\NN\0|NONE_0 (r_pobj) by_13\IN\0|however_91|,_84|enhancement_69|was_16|._198 (r_agent) antagonized_12\VBN\1787955|NONE_0 (l_nsubjpass) enhancement_4\NN\248977|however_22|,_15|was_53|by_69|._267 (l_prep) of_5\IN\0|the_25|diazepam_21 (l_pobj) bradycardia_10\NN\14110674|NONE_0
D001569_D001919 NONE benzodiazepine_8\JJ\3771443|the_4|chloride_20|channel_29|macromolecular_37|within_60 (r_amod) complex_15\NN\5869584|NONE_0 (r_pobj) through_6\IN\0|that_19|diazepam_14|facilitate_109 (r_prep) acts_5\VBZ\0|data_28|._236 (l_advcl) facilitate_22\VB\2547586|that_128|diazepam_123|through_109 (l_dobj) bradycardia_24\NN\14110674|to_21
D005680_D001919 NONE gaba_38\NNP\14601829|-_1|-_4 (r_compound) chloride_40\NN\14818238|the_24|benzodiazepine_20|channel_9|macromolecular_17 (r_compound) complex_43\NN\5869584|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) associated_33\VBN\628491|NONE_0 (r_acl) sites_32\NNS\8673395|NONE_0 (r_pobj) to_31\IN\0|NONE_0 (r_prep) binding_30\VBG\4688246|NONE_0 (r_pcomp) by_29\IN\0|agent_31|channels_9 (r_prep) blocks_26\NNS\21939|(_10|)_124 (r_appos) picrotoxin_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|an_20|intravenous_17 (r_prep) dose_20\NN\3740161|NONE_0 (r_pobj) with_17\IN\0|of_8 (r_prep) pretreatment_14\NN\0|NONE_0 (r_pobj) by_13\IN\0|however_91|,_84|enhancement_69|was_16|._198 (r_agent) antagonized_12\VBN\1787955|NONE_0 (l_nsubjpass) enhancement_4\NN\248977|however_22|,_15|was_53|by_69|._267 (l_prep) of_5\IN\0|the_25|diazepam_21 (l_pobj) bradycardia_10\NN\14110674|NONE_0
D005680_D001919 NONE gaba_10\NNP\14601829|-_1|-_4 (r_compound) chloride_12\NN\14818238|the_24|benzodiazepine_20|channel_9|macromolecular_17|within_40 (r_compound) complex_15\NN\5869584|NONE_0 (r_pobj) through_6\IN\0|that_19|diazepam_14|facilitate_109 (r_prep) acts_5\VBZ\0|data_28|._236 (l_advcl) facilitate_22\VB\2547586|that_128|diazepam_123|through_109 (l_dobj) bradycardia_24\NN\14110674|to_21
D004837_D001919 CID adrenaline_12\NN\14807929|NONE_0 (r_pobj) of_11\IN\0|intravenous_21|(_14|micrograms_24|)_39 (r_prep) infusion_10\NN\14589223|NONE_0 (r_pobj) by_8\IN\0|also_46|,_42|bradycardia_33|was_21|in_8|._64 (r_agent) produced_5\VBN\1617192|NONE_0 (l_nsubjpass) bradycardia_3\NN\14110674|also_13|,_9|was_12|in_25|by_33|._97
D004837_D001919 CID adrenaline_14\NN\14807929|-_10 (r_npadvmod) induced_16\VBN\1627355|the_15|pressor_8 (r_amod) effect_18\NN\34213|NONE_0 (r_pobj) in_12\IN\13603305|no_10 (r_prep) change_11\NN\7283608|although_20 (r_dobj) causing_9\VBG\30358|intravenous_61|of_36|with_24|,_11 (r_advcl) pretreatment_1\NN\0|,_107|did_109|bradycardia_151|._162 (r_nsubj) enhance_21\VB\227165|NONE_0 (l_dobj) bradycardia_27\NN\14110674|pretreatment_151|,_44|did_42|._11
D004837_D001919 CID adrenaline_23\NN\14807929|-_10 (r_npadvmod) induced_25\VBN\1627355|the_15|reflex_8 (r_amod) bradycardia_27\NN\14110674|pretreatment_151|,_44|did_42|._11
D004837_D001919 CID adrenaline_6\NN\14807929|-_10 (r_npadvmod) induced_8\VBN\1627355|reflex_8 (r_amod) bradycardia_10\NN\14110674|NONE_0
D010852_D001919 NONE picrotoxin_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|an_20|intravenous_17 (r_prep) dose_20\NN\3740161|NONE_0 (r_pobj) with_17\IN\0|of_8 (r_prep) pretreatment_14\NN\0|NONE_0 (r_pobj) by_13\IN\0|however_91|,_84|enhancement_69|was_16|._198 (r_agent) antagonized_12\VBN\1787955|NONE_0 (l_nsubjpass) enhancement_4\NN\248977|however_22|,_15|was_53|by_69|._267 (l_prep) of_5\IN\0|the_25|diazepam_21 (l_pobj) bradycardia_10\NN\14110674|NONE_0
D002712_D001919 NONE chloride_27\NN\14818238|NONE_0 (r_compound) channels_28\NNS\6251781|agent_22|by_9 (r_dobj) blocks_26\NNS\21939|(_10|)_124 (r_appos) picrotoxin_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|an_20|intravenous_17 (r_prep) dose_20\NN\3740161|NONE_0 (r_pobj) with_17\IN\0|of_8 (r_prep) pretreatment_14\NN\0|NONE_0 (r_pobj) by_13\IN\0|however_91|,_84|enhancement_69|was_16|._198 (r_agent) antagonized_12\VBN\1787955|NONE_0 (l_nsubjpass) enhancement_4\NN\248977|however_22|,_15|was_53|by_69|._267 (l_prep) of_5\IN\0|the_25|diazepam_21 (l_pobj) bradycardia_10\NN\14110674|NONE_0
D002712_D001919 NONE chloride_40\NN\14818238|the_24|benzodiazepine_20|channel_9|macromolecular_17 (r_compound) complex_43\NN\5869584|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) associated_33\VBN\628491|NONE_0 (r_acl) sites_32\NNS\8673395|NONE_0 (r_pobj) to_31\IN\0|NONE_0 (r_prep) binding_30\VBG\4688246|NONE_0 (r_pcomp) by_29\IN\0|agent_31|channels_9 (r_prep) blocks_26\NNS\21939|(_10|)_124 (r_appos) picrotoxin_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|an_20|intravenous_17 (r_prep) dose_20\NN\3740161|NONE_0 (r_pobj) with_17\IN\0|of_8 (r_prep) pretreatment_14\NN\0|NONE_0 (r_pobj) by_13\IN\0|however_91|,_84|enhancement_69|was_16|._198 (r_agent) antagonized_12\VBN\1787955|NONE_0 (l_nsubjpass) enhancement_4\NN\248977|however_22|,_15|was_53|by_69|._267 (l_prep) of_5\IN\0|the_25|diazepam_21 (l_pobj) bradycardia_10\NN\14110674|NONE_0
D002712_D001919 NONE chloride_12\NN\14818238|the_24|benzodiazepine_20|channel_9|macromolecular_17|within_40 (r_compound) complex_15\NN\5869584|NONE_0 (r_pobj) through_6\IN\0|that_19|diazepam_14|facilitate_109 (r_prep) acts_5\VBZ\0|data_28|._236 (l_advcl) facilitate_22\VB\2547586|that_128|diazepam_123|through_109 (l_dobj) bradycardia_24\NN\14110674|to_21
D003975_D001919 CID diazepam_0\NNP\2830852|bradycardia_28|._57 (r_nsubj) facilitates_1\VBZ\2547586|NONE_0 (l_dobj) bradycardia_3\NN\14110674|diazepam_28|._29
D003975_D001919 CID diazepam_6\NN\2830852|NONE_0 (r_pobj) with_5\IN\0|intravenous_37|of_12|,_13|causing_24 (r_prep) pretreatment_1\NN\0|,_107|did_109|bradycardia_151|._162 (r_nsubj) enhance_21\VB\227165|NONE_0 (l_dobj) bradycardia_27\NN\14110674|pretreatment_151|,_44|did_42|._11
D003975_D001919 CID diazepam_3\NN\2830852|the_4|of_21 (r_compound) enhancement_4\NN\248977|however_22|,_15|was_53|by_69|._267 (l_prep) of_5\IN\0|the_25|diazepam_21 (l_pobj) bradycardia_10\NN\14110674|NONE_0
D003975_D001919 CID diazepam_4\NN\2830852|that_5|through_14|facilitate_123 (r_nsubj) acts_5\VBZ\0|data_28|._236 (l_advcl) facilitate_22\VB\2547586|that_128|diazepam_123|through_109 (l_dobj) bradycardia_24\NN\14110674|to_21
7905523
D015215_D015658 NONE zidovudine_15\NN\3834836|n_40|-_39|butyl_38|-_33|sc-48334_14|and_4 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|and_21 (l_pobj) infection_20\NN\14052046|NONE_0
C059896_D007153 NONE sc-48334_2\VBP\0|the_9|mean_5|state_16|trough_22|ml_61 (r_nmod) level_7\NN\4916342|below_40|._122 (r_nsubj) was_16\VBD\0|NONE_0 (l_prep) below_17\IN\0|level_40|._82 (l_pobj) concentration_22\NN\4916342|NONE_0 (l_prep) for_23\IN\0|the_38|vitro_31|inhibitory_25 (l_pobj) virus_26\NN\9312843|NONE_0 (l_compound) immunodeficiency_25\NN\13973990|human_6|(_23|hiv_24|)_27
C059896_D015658 NONE deoxynojirimycin_10\NNP\0|safety_43|cells_92|/_97|._101 (l_conj) zidovudine_15\NN\3834836|n_40|-_39|butyl_38|-_33|sc-48334_14|and_4 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|and_21 (l_pobj) infection_20\NN\14052046|NONE_0
C059896_D015658 NONE sc-48334_12\NNP\0|n_26|-_25|butyl_24|-_19|and_10|zidovudine_14 (r_appos) deoxynojirimycin_10\NNP\0|safety_43|cells_92|/_97|._101 (l_conj) zidovudine_15\NN\3834836|n_40|-_39|butyl_38|-_33|sc-48334_14|and_4 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|and_21 (l_pobj) infection_20\NN\14052046|NONE_0
19289093
D002809_D007022 CID sulfate_19\NN\15010703|an_28|oversulfated_25|elicit_37 (r_nmod) derivative_23\NN\5802185|NONE_0 (l_relcl) elicit_26\VB\1617192|an_65|oversulfated_62|sulfate_37 (l_dobj) response_29\NN\11410625|that_32|could_27|following_17 (l_amod) hypotensive_28\JJ\10405694|a_2|in_21
D006493_D007022 NONE heparin_8\JJ\2718259|NONE_0 (r_compound) products_9\NNS\3076708|NONE_0 (r_pobj) of_7\IN\0|commercial_16 (r_prep) lots_6\NNS\13757724|NONE_0 (r_pobj) of_4\IN\0|a_9 (r_prep) number_3\NN\5107765|recently_12|,_4|were_46|contaminated_63|._221 (r_nsubjpass) found_11\VBN\13279262|NONE_0 (l_xcomp) contaminated_14\VBN\1534147|recently_75|,_67|number_63|were_17|._158 (l_prep) with_15\IN\0|to_19|be_16 (l_pobj) derivative_23\NN\5802185|NONE_0 (l_relcl) elicit_26\VB\1617192|an_65|oversulfated_62|sulfate_37 (l_dobj) response_29\NN\11410625|that_32|could_27|following_17 (l_amod) hypotensive_28\JJ\10405694|a_2|in_21
D006493_D007022 NONE heparin_3\JJ\2718259|both_18|contaminated_13|and_17|derivative_48 (r_compound) products_4\NNS\3076708|NONE_0 (r_dobj) using_0\VBG\418025|,_82|we_84|produces_108|._151 (r_advcl) showed_12\VBD\2137132|NONE_0 (l_ccomp) produces_16\VBZ\7555863|using_108|,_26|we_24|._43 (l_dobj) hypotension_20\NN\14057371|that_38|oscs_29
12231232
C095756_D009127 NONE aida_0\NNP\0|rigidity_84|._92 (r_nsubj) diminished_9\VBD\169651|NONE_0 (l_dobj) rigidity_15\NN\5023233|aida_84|._8
D006220_D009127 CID haloperidol_0\NN\3713736|rigidity_58|._176 (r_nsubj) induced_6\VBD\1627355|NONE_0 (l_dobj) rigidity_11\NN\5023233|haloperidol_58|._118
D006220_D009127 CID haloperidol_11\NN\3713736|-_11 (r_npadvmod) induced_13\VBN\1627355|the_16|muscle_8 (r_amod) rigidity_15\NN\5023233|aida_84|._8
D006220_D010300 NONE haloperidol_0\NN\3713736|rigidity_58|._176 (r_nsubj) induced_6\VBD\1627355|NONE_0 (l_dobj) rigidity_11\NN\5023233|haloperidol_58|._118 (l_amod) parkinsonian_7\JJ\0|muscle_18|,_33|measured_35
871943
D013390_D001049 CID succinylcholine_6\NN\3800001|NONE_0 (r_compound) apnoea_7\NN\0|NONE_0
D013390_D001049 CID succinylcholine_10\NN\3800001|hours_12|after_6|have_16|been_21|by_34 (r_nsubjpass) treated_13\VBN\2376958|patients_105|apnoea_61|._58 (r_advcl) demonstrating_2\VBG\2137132|NONE_0 (l_dobj) apnoea_5\NN\0|patients_44|treated_61|._119
D013390_D001049 CID succinylcholine_6\NN\3800001|NONE_0 (r_compound) apnoea_7\NN\0|NONE_0
19692487
D015232_D011141 NONE )_29\-RRB-\0|NONE_0 (r_punct) pge(2_28\NNP\0|high_11|and_7|output_16 (r_appos) urine_27\NN\14853947|NONE_0 (r_pobj) of_25\IN\0|complete_18 (r_prep) blockade_24\NN\952963|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) accompanied_20\VBN\0|in_115|,_104|mpges-1_102|mice_90|resistant_72|,_2|._76 (r_advcl) were_6\VBD\0|NONE_0 (l_acomp) resistant_8\JJ\0|in_43|,_32|mpges-1_30|mice_18|,_70|accompanied_72|._148 (l_prep) to_9\IN\0|largely_18 (l_pobj) polyuria_13\NN\14113228|NONE_0
D015232_D011141 NONE )_5\-RRB-\0|mpges-1-derived_21 (r_punct) pge(2_4\NNP\0|that_21|polyuria_32|via_48 (r_nsubj) mediates_6\VBZ\761713|we_40|._84 (l_dobj) polyuria_10\NN\14113228|that_53|pge(2_32|via_16
D008094_D011141 NONE lithium_6\NN\14625458|-_7 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) polyuria_9\NN\14113228|NONE_0
D008094_D011141 NONE lithium_8\NN\14625458|-_7 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) polyuria_11\NN\14113228|NONE_0
D008094_D011141 NONE lithium_7\NN\14625458|-_7 (r_npadvmod) induced_9\VBN\1627355|in_17 (r_amod) polyuria_10\NN\14113228|to_26
D008094_D011141 NONE lithium_10\NN\14625458|-_7 (r_npadvmod) induced_12\VBN\1627355|and_17|urine_23 (r_amod) polyuria_13\NN\14113228|NONE_0
D008094_D011141 NONE lithium_7\NN\14625458|-_7 (r_npadvmod) induced_9\VBN\1627355|likely_17 (r_amod) polyuria_10\NN\14113228|that_53|pge(2_32|via_16
D011458_D011141 NONE e_17\NN\14724645|NONE_0 (r_appos) microsomal_15\JJ\0|NONE_0 (r_pobj) in_14\IN\13603305|mice_15 (r_prep) deficient_13\JJ\0|NONE_0 (r_pobj) in_11\IN\13603305|induced_17 (r_prep) polyuria_10\NN\14113228|to_26
2907585
-1_D002375 NONE piperazine_10\NN\4528630|novel_11|anxiolytic_11 (r_nmod) drugs_12\NNS\14778436|NONE_0 (r_pobj) by_6\IN\0|of_33|._41 (r_prep) reversal_0\NN\199130|NONE_0 (l_prep) of_1\IN\0|by_33|._74 (l_pobj) catalepsy_5\NN\14023236|NONE_0
-1_D002375 NONE piperazine_5\NN\4528630|of_21 (r_compound) analogues_6\NNS\4743605|NONE_0 (r_pobj) of_2\IN\0|a_9 (r_prep) series_1\NN\8456993|were_92|for_104|induced_145|._162 (r_nsubjpass) tested_14\VBN\670261|NONE_0 (l_conj) induced_21\VBN\1627355|series_145|were_53|for_41|._17 (l_dobj) catalepsy_22\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_11\NN\3713736|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|NONE_0 (r_acl) catalepsy_8\NN\14023236|drug_26|._32
D006220_D002375 CID haloperidol_20\NN\3713736|to_11 (r_dobj) reverse_19\VB\13854649|their_17 (r_acl) ability_17\NN\4723816|NONE_0 (r_pobj) for_15\IN\0|series_104|were_12|induced_41|._58 (r_prep) tested_14\VBN\670261|NONE_0 (l_conj) induced_21\VBN\1627355|series_145|were_53|for_41|._17 (l_dobj) catalepsy_22\NN\14023236|NONE_0
D002065_D002375 NONE buspirone_5\NN\3771443|the_27|novel_23|anxiolytic_17|,_2|,_9 (r_appos) drug_3\NN\14778436|catalepsy_26|._58 (r_nsubj) reverses_7\VBZ\13854649|NONE_0 (l_dobj) catalepsy_8\NN\14023236|drug_26|._32
D002065_D002375 NONE buspirone_8\NN\3771443|NONE_0 (r_pobj) of_7\IN\0|piperazine_21 (r_prep) analogues_6\NNS\4743605|NONE_0 (r_pobj) of_2\IN\0|a_9 (r_prep) series_1\NN\8456993|were_92|for_104|induced_145|._162 (r_nsubjpass) tested_14\VBN\670261|NONE_0 (l_conj) induced_21\VBN\1627355|series_145|were_53|for_41|._17 (l_dobj) catalepsy_22\NN\14023236|NONE_0
D058825_D002375 NONE agonists_12\NNS\0|and_34 (r_conj) buspirone_8\NN\3771443|NONE_0 (r_pobj) of_7\IN\0|piperazine_21 (r_prep) analogues_6\NNS\4743605|NONE_0 (r_pobj) of_2\IN\0|a_9 (r_prep) series_1\NN\8456993|were_92|for_104|induced_145|._162 (r_nsubjpass) tested_14\VBN\670261|NONE_0 (l_conj) induced_21\VBN\1627355|series_145|were_53|for_41|._17 (l_dobj) catalepsy_22\NN\14023236|NONE_0
D012701_D002375 NONE 5-hydroxytryptamine1a_6\CD\0|NONE_0 (r_compound) receptors_7\NNS\5225602|NONE_0 (r_pobj) for_5\IN\0|strong_16 (r_prep) affinity_4\NN\11426530|NONE_0 (r_pobj) with_2\IN\0|those_12 (r_prep) drugs_1\NNS\14778436|able_68|._93 (r_nsubj) were_8\VBD\0|NONE_0 (l_acomp) able_9\JJ\0|drugs_68|._25 (l_xcomp) reverse_11\VB\13854649|NONE_0 (l_dobj) catalepsy_12\NN\14023236|to_11
D012701_D002375 NONE 5-ht_5\CD\0|postsynaptic_13 (r_compound) receptors_6\NNS\5225602|NONE_0 (r_pobj) of_3\IN\0|NONE_0 (r_prep) inhibition_2\NN\1068773|however_9|,_2|neither_42|nor_60|potentiated_64|._170 (r_nsubj) inhibited_8\VBN\2510337|NONE_0 (l_conj) potentiated_10\VBN\229605|however_73|,_66|inhibition_64|neither_22|nor_4|._106 (l_dobj) reversal_11\NN\199130|and_22|leaves_26 (l_prep) of_12\IN\0|NONE_0 (l_pobj) catalepsy_13\NN\14023236|NONE_0
9098464
D005473_D062788 CID hydrochloride_13\NN\14817592|NONE_0 (r_pobj) by_11\IN\0|on_71 (r_agent) induced_10\VBN\1627355|the_34|of_22 (r_acl) effects_7\NNS\13245626|a_35|murine_33|of_20|:_6|._155 (r_appos) model_2\NN\5888929|NONE_0 (l_prep) of_3\IN\0|a_15|murine_13|:_14|effects_20|._175 (l_pobj) adenomyosis_4\NN\14204950|NONE_0
D005473_D062788 CID hydrochloride_13\NN\14817592|NONE_0 (r_pobj) by_11\IN\0|on_71 (r_agent) induced_10\VBN\1627355|the_34|of_22 (l_prep) on_21\IN\0|by_71 (l_pobj) induction_23\NN\7450842|NONE_0 (l_compound) adenomyosis_22\NN\14204950|in_22
D005473_D062788 CID fluoxetine_9\NN\4169152|whether_8|hyperprolactinemia_59 (r_nsubj) caused_16\VBD\1617192|to_75 (l_dobj) hyperprolactinemia_17\NN\0|whether_67|fluoxetine_59 (l_conj) effects_20\NNS\13245626|and_8 (l_prep) with_21\IN\0|its_12 (l_pobj) respect_22\NN\5817845|NONE_0 (l_prep) to_23\IN\0|NONE_0 (l_pobj) adenomyosis_24\NN\14204950|NONE_0
D005473_D062788 CID fluoxetine_14\NN\4169152|NONE_0 (r_dobj) receiving_13\VBG\2210855|the_23|noncastrated_19 (r_acl) group_12\NN\2137|all_28 (r_pobj) within_9\IN\0|studies_46|cases_26|._50 (r_prep) revealed_2\VBD\2137132|NONE_0 (l_dobj) cases_4\NNS\7283608|studies_20|within_26|._76 (l_prep) of_5\IN\0|11_9|,_14 (l_pobj) adenomyosis_6\NN\14204950|NONE_0
D005473_D006966 CID hydrochloride_13\NN\14817592|NONE_0 (r_pobj) by_11\IN\0|on_71 (r_agent) induced_10\VBN\1627355|the_34|of_22 (r_acl) effects_7\NNS\13245626|a_35|murine_33|of_20|:_6|._155 (l_prep) of_8\IN\0|the_12|induced_22 (l_pobj) hyperprolactinemia_9\NN\0|NONE_0
D005473_D006966 CID fluoxetine_9\NN\4169152|whether_8|hyperprolactinemia_59 (r_nsubj) caused_16\VBD\1617192|to_75 (l_dobj) hyperprolactinemia_17\NN\0|whether_67|fluoxetine_59
D005473_D006966 CID fluoxetine_0\NNP\4169152|was_44|to_54|for_76|produce_91|._117 (r_nsubjpass) given_8\VBN\5892096|NONE_0 (l_advcl) produce_17\VB\7555863|fluoxetine_91|was_47|to_37|for_15|._26 (l_dobj) hyperprolactinemia_18\NN\0|to_11
D012701_D062788 NONE serotonin_17\NN\14807737|a_12|selective_10|reuptake_10 (r_compound) inhibitor_19\NN\20090|fluoxetine_57|,_33|,_9 (r_appos) hydrochloride_13\NN\14817592|NONE_0 (r_pobj) by_11\IN\0|on_71 (r_agent) induced_10\VBN\1627355|the_34|of_22 (r_acl) effects_7\NNS\13245626|a_35|murine_33|of_20|:_6|._155 (r_appos) model_2\NN\5888929|NONE_0 (l_prep) of_3\IN\0|a_15|murine_13|:_14|effects_20|._175 (l_pobj) adenomyosis_4\NN\14204950|NONE_0
D012701_D062788 NONE serotonin_17\NN\14807737|a_12|selective_10|reuptake_10 (r_compound) inhibitor_19\NN\20090|fluoxetine_57|,_33|,_9 (r_appos) hydrochloride_13\NN\14817592|NONE_0 (r_pobj) by_11\IN\0|on_71 (r_agent) induced_10\VBN\1627355|the_34|of_22 (l_prep) on_21\IN\0|by_71 (l_pobj) induction_23\NN\7450842|NONE_0 (l_compound) adenomyosis_22\NN\14204950|in_22
D012701_D006966 NONE serotonin_17\NN\14807737|a_12|selective_10|reuptake_10 (r_compound) inhibitor_19\NN\20090|fluoxetine_57|,_33|,_9 (r_appos) hydrochloride_13\NN\14817592|NONE_0 (r_pobj) by_11\IN\0|on_71 (r_agent) induced_10\VBN\1627355|the_34|of_22 (r_acl) effects_7\NNS\13245626|a_35|murine_33|of_20|:_6|._155 (l_prep) of_8\IN\0|the_12|induced_22 (l_pobj) hyperprolactinemia_9\NN\0|NONE_0
D012701_D006966 NONE serotonin_3\NN\14807737|a_2|reuptake_10 (r_compound) inhibitor_5\NN\20090|,_23|,_9 (r_appos) fluoxetine_0\NNP\4169152|was_44|to_54|for_76|produce_91|._117 (r_nsubjpass) given_8\VBN\5892096|NONE_0 (l_advcl) produce_17\VB\7555863|fluoxetine_91|was_47|to_37|for_15|._26 (l_dobj) hyperprolactinemia_18\NN\0|to_11
28952
D011188_D007008 NONE potassium_1\NN\14625458|initial_8|and_15|hypokalaemia_19|:_108|influence_114|._153 (r_compound) loss_2\NN\13252973|NONE_0 (l_conj) hypokalaemia_4\NN\0|initial_27|potassium_19|and_4|:_89|influence_95|._134
D011188_D007008 NONE potassium_4\NN\14625458|the_12|initial_8|and_15|development_19|during_47 (r_compound) loss_5\NN\13252973|to_37 (l_conj) development_7\NN\248977|the_31|initial_27|potassium_19|and_4|during_28 (l_prep) of_8\IN\0|NONE_0 (l_pobj) hypokalaemia_9\NN\0|NONE_0
D011188_D007008 NONE potassium_4\NN\14625458|the_12|initial_8|and_15|development_19|during_47 (r_compound) loss_5\NN\13252973|to_37 (r_dobj) investigate_1\VB\644583|were_144|in_159|._265 (r_csubjpass) performed_22\VBN\0|NONE_0 (l_prep) in_23\IN\13603305|investigate_159|were_15|._106 (l_pobj) patients_25\NNS\9898892|NONE_0 (l_prep) with_26\IN\0|ten_13 (l_pobj) hypertension_28\NN\14057371|NONE_0 (l_relcl) shown_31\VBN\2137132|essential_31 (l_dobj) hypokalaemia_32\NN\0|who_14|had_10|under_13
D002752_D006973 NONE chlorthalidone_6\NN\3214670|in_30 (r_compound) administration_7\NN\1133281|NONE_0 (l_prep) in_8\IN\13603305|chlorthalidone_30 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) hypertension_12\NN\14057371|NONE_0
D012964_D007008 NONE sodium_18\NN\14625458|dietary_8 (r_compound) restriction_19\NN\5846054|NONE_0 (r_pobj) of_16\IN\0|the_14 (r_prep) influence_15\NN\5190804|initial_122|potassium_114|and_99|hypokalaemia_95|:_6|._39 (r_appos) loss_2\NN\13252973|NONE_0 (l_conj) hypokalaemia_4\NN\0|initial_27|potassium_19|and_4|:_89|influence_95|._134
D011188_D006973 NONE potassium_1\NN\14625458|initial_8|and_15|hypokalaemia_19|:_108|influence_114|._153 (r_compound) loss_2\NN\13252973|NONE_0 (l_conj) hypokalaemia_4\NN\0|initial_27|potassium_19|and_4|:_89|influence_95|._134 (l_prep) during_5\IN\0|NONE_0 (l_pobj) administration_7\NN\1133281|NONE_0 (l_prep) in_8\IN\13603305|chlorthalidone_30 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) hypertension_12\NN\14057371|NONE_0
D011188_D006973 NONE potassium_4\NN\14625458|the_12|initial_8|and_15|development_19|during_47 (r_compound) loss_5\NN\13252973|to_37 (r_dobj) investigate_1\VB\644583|were_144|in_159|._265 (r_csubjpass) performed_22\VBN\0|NONE_0 (l_prep) in_23\IN\13603305|investigate_159|were_15|._106 (l_pobj) patients_25\NNS\9898892|NONE_0 (l_prep) with_26\IN\0|ten_13 (l_pobj) hypertension_28\NN\14057371|NONE_0
D002752_D007008 CID chlorthalidone_6\NN\3214670|in_30 (r_compound) administration_7\NN\1133281|NONE_0 (r_pobj) during_5\IN\0|NONE_0 (r_prep) hypokalaemia_4\NN\0|initial_27|potassium_19|and_4|:_89|influence_95|._134
D012964_D006973 NONE sodium_18\NN\14625458|dietary_8 (r_compound) restriction_19\NN\5846054|NONE_0 (r_pobj) of_16\IN\0|the_14 (r_prep) influence_15\NN\5190804|initial_122|potassium_114|and_99|hypokalaemia_95|:_6|._39 (r_appos) loss_2\NN\13252973|NONE_0 (l_conj) hypokalaemia_4\NN\0|initial_27|potassium_19|and_4|:_89|influence_95|._134 (l_prep) during_5\IN\0|NONE_0 (l_pobj) administration_7\NN\1133281|NONE_0 (l_prep) in_8\IN\13603305|chlorthalidone_30 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) hypertension_12\NN\14057371|NONE_0
12042105
C052342_D053040 CID topiramate_0\NNP\0|-_10 (r_npadvmod) induced_2\VBN\1627355|._23 (r_amod) nephrolithiasis_3\NN\14115914|NONE_0
C052342_D053040 CID topiramate_7\RB\0|-_10 (r_npadvmod) induced_9\VBN\1627355|in_24 (r_amod) nephrolithiasis_10\NN\14115914|NONE_0
C052342_D004827 NONE topiramate_0\NNP\0|medication_49|._155 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) medication_6\NN\3247620|topiramate_49|._106 (l_relcl) becoming_9\VBG\146138|a_54|developed_43|antiepileptic_33 (l_prep) because_13\IN\0|that_40|is_35|prescribed_11 (l_pobj) efficacy_16\NN\5199286|of_7 (l_prep) in_17\IN\13603305|its_13 (l_pcomp) treating_18\VBG\2376958|NONE_0 (l_dobj) seizures_20\NNS\14081375|NONE_0
C020243_D053040 NONE phosphate_29\NN\15010703|NONE_0 (r_compound) nephrolithiasis_30\NN\14115914|NONE_0
15858223
D005978_D056486 NONE glutathione_11\NN\0|s_12|-_13|(_26|gst_33|)_36 (r_compound) transferase_14\NNP\14732946|NONE_0 (r_pobj) of_8\IN\0|serum_13 (r_prep) levels_7\NNS\4916342|and_54|by_58 (r_pobj) on_5\IN\0|NONE_0 (r_prep) based_4\VBN\0|toxicity_23|was_14|._85 (r_prep) evaluated_3\VBN\670261|NONE_0 (l_nsubjpass) toxicity_1\NN\13576101|was_9|based_23|._108
C075750_D009336 NONE 15-f(2t)-isop_18\CD\0|NONE_0 (r_pobj) of_17\IN\0|,_16|precedes_24 (r_prep) levels_16\NNS\4916342|NONE_0 (l_relcl) precedes_21\VBZ\0|of_24|,_8 (l_dobj) onset_23\NN\7325190|which_19 (l_prep) of_24\IN\0|the_10 (l_pobj) necrosis_25\NN\11444117|NONE_0
D014635_D005234 CID vpa_6\NNP\0|that_5|treatment_4|in_22|,_41|measured_46 (r_compound) results_8\NNS\34213|overall_52|,_45|findings_37|._156 (l_advcl) measured_14\VBN\697589|that_51|vpa_46|treatment_42|in_24|,_5 (l_agent) by_15\IN\0|as_12 (l_pobj) levels_16\NNS\4916342|NONE_0 (l_relcl) precedes_21\VBZ\0|of_24|,_8 (l_dobj) onset_23\NN\7325190|which_19 (l_prep) of_24\IN\0|the_10 (l_pobj) necrosis_25\NN\11444117|NONE_0 (l_conj) steatosis_27\NN\0|,_2
D014635_D056486 CID acid_14\NN\14818238|NONE_0 (r_compound) metabolite_15\NN\20090|valproic_14|in_18 (r_amod) levels_16\NNS\4916342|liver_45|,_31|and_29 (r_conj) toxicity_10\NN\13576101|peroxidation_31|,_8
D014635_D056486 CID vpa_9\NNP\0|-_3 (r_npadvmod) associated_11\VBN\628491|oxidative_11|and_28|hepatotoxicity_32|,_46 (r_amod) stress_13\NN\7083732|NONE_0 (l_conj) hepatotoxicity_15\NN\0|associated_32|oxidative_21|and_4|,_14
D014635_D056486 CID vpa_27\NNP\0|NONE_0 (r_pobj) with_26\IN\0|determine_159|rats_21|were_16|ip_3|daily_51|for_57|._84 (r_prep) treated_24\VBN\2376958|NONE_0 (l_advcl) determine_1\VB\0|rats_138|were_143|ip_156|with_159|daily_210|for_216|._243 (l_ccomp) was_4\VBD\0|to_27 (l_attr) relationship_7\NN\31921|whether_29|there_21 (l_prep) between_8\IN\0|a_24|temporal_22 (l_pobj) stress_13\NN\7083732|NONE_0 (l_conj) hepatotoxicity_15\NN\0|associated_32|oxidative_21|and_4|,_14
D014635_D009336 CID vpa_6\NNP\0|that_5|treatment_4|in_22|,_41|measured_46 (r_compound) results_8\NNS\34213|overall_52|,_45|findings_37|._156 (l_advcl) measured_14\VBN\697589|that_51|vpa_46|treatment_42|in_24|,_5 (l_agent) by_15\IN\0|as_12 (l_pobj) levels_16\NNS\4916342|NONE_0 (l_relcl) precedes_21\VBZ\0|of_24|,_8 (l_dobj) onset_23\NN\7325190|which_19 (l_prep) of_24\IN\0|the_10 (l_pobj) necrosis_25\NN\11444117|NONE_0
C075750_D005234 NONE 15-f(2t)-isop_18\CD\0|NONE_0 (r_pobj) of_17\IN\0|,_16|precedes_24 (r_prep) levels_16\NNS\4916342|NONE_0 (l_relcl) precedes_21\VBZ\0|of_24|,_8 (l_dobj) onset_23\NN\7325190|which_19 (l_prep) of_24\IN\0|the_10 (l_pobj) necrosis_25\NN\11444117|NONE_0 (l_conj) steatosis_27\NN\0|,_2
16820346
D013481_D006973 NONE superoxide_25\RB\14971519|plasma_7 (r_advmod) decreased_23\VBD\169651|atorva_96|hypertension_68|mmhg_42|,_38|vs._36|mmhg_20|)_6|and_4 (r_conj) reversed_1\VBN\109660|NONE_0 (l_dobj) hypertension_5\NN\14057371|atorva_28|mmhg_26|,_30|vs._32|mmhg_48|)_62|and_64|decreased_68
D003907_D006973 CID dexamethasone_4\NN\2721538|-_13 (r_npadvmod) induced_6\VBN\1627355|in_21 (r_amod) hypertension_7\NN\14057371|NONE_0
D003907_D006973 CID dexamethasone_11\NN\2721538|NONE_0 (l_appos) hypertension_14\NN\14057371|(_14
D003907_D006973 CID dex)-induced_13\VBN\0|,_25 (r_amod) hypertension_14\NN\14057371|(_14
D003907_D006973 CID dex_2\NN\0|-_3 (r_npadvmod) induced_4\VBN\1627355|+/-_26 (r_amod) hypertension_5\NN\14057371|atorva_28|mmhg_26|,_30|vs._32|mmhg_48|)_62|and_64|decreased_68
D003907_D006973 CID dexamethasone_6\NN\2721538|-_13 (r_npadvmod) induced_8\VBN\1627355|in_21 (r_amod) hypertension_9\NN\14057371|NONE_0
C065179_D006973 NONE atorvastatin_0\NNS\3676175|and_23|reversed_27|._81 (r_nsubj) prevented_1\VBD\0|NONE_0 (l_conj) reversed_3\VBD\109660|atorvastatin_27|and_4|._54 (l_dobj) hypertension_7\NN\14057371|NONE_0
C065179_D006973 NONE atorvastatin_6\NN\3676175|(_13|)_20 (r_nmod) atorva_8\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_24|antioxidant_20|on_25 (r_prep) effects_4\NNS\13245626|to_26 (l_prep) on_10\IN\0|the_49|antioxidant_45|of_25 (l_pobj) dexamethasone_11\NN\2721538|NONE_0 (l_appos) hypertension_14\NN\14057371|(_14
C065179_D006973 NONE atorva_8\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_24|antioxidant_20|on_25 (r_prep) effects_4\NNS\13245626|to_26 (l_prep) on_10\IN\0|the_49|antioxidant_45|of_25 (l_pobj) dexamethasone_11\NN\2721538|NONE_0 (l_appos) hypertension_14\NN\14057371|(_14
C065179_D006973 NONE atorva_25\NN\0|kg_13|tap_23 (r_nmod) water_34\NN\14618834|NONE_0 (r_pobj) with_24\IN\0|assess_142|rats_18|were_13|for_38|._49 (r_prep) treated_23\VBN\2376958|NONE_0 (l_advcl) assess_1\VB\5220461|rats_124|were_129|with_142|for_180|._191 (l_dobj) effects_4\NNS\13245626|to_26 (l_prep) on_10\IN\0|the_49|antioxidant_45|of_25 (l_pobj) dexamethasone_11\NN\2721538|NONE_0 (l_appos) hypertension_14\NN\14057371|(_14
C065179_D006973 NONE atorva_0\NN\0|hypertension_28|mmhg_54|,_58|vs._60|mmhg_76|)_90|and_92|decreased_96 (r_nsubj) reversed_1\VBN\109660|NONE_0 (l_dobj) hypertension_5\NN\14057371|atorva_28|mmhg_26|,_30|vs._32|mmhg_48|)_62|and_64|decreased_68
C065179_D006973 NONE atorvastatin_2\NN\3676175|thus_6|,_2|and_23|reversed_27|._81 (r_nsubj) prevented_3\VBN\0|NONE_0 (l_conj) reversed_5\VBN\109660|thus_33|,_29|atorvastatin_27|and_4|._54 (l_dobj) hypertension_9\NN\14057371|NONE_0
18674790
D004317_D009765 NONE doxorubicin_11\RB\2716866|-_11 (r_npadvmod) induced_13\VBN\1627355|NONE_0 (r_compound) cardiotoxicity_14\NN\0|NONE_0 (r_pobj) to_10\IN\0|highly_17 (r_prep) sensitive_9\JJ\10488309|rats_16|._47 (r_acomp) are_7\VBP\13600404|NONE_0 (l_nsubj) rats_6\NNS\2329401|sensitive_16|._63 (l_amod) obese_5\JJ\0|high_18|fat_13|fed_4
D004317_D009765 NONE doxorubicin_40\RB\2716866|-_11 (r_npadvmod) induced_42\VBN\1627355|NONE_0 (r_compound) cardiotoxicity_43\NN\0|NONE_0 (r_pobj) to_39\IN\0|whether_147|intervention_123|,_13 (r_prep) sensitizes_38\VBZ\126264|in_174|,_154|we_152|._48 (l_nsubj) intervention_10\NN\1239064|whether_24|,_110|to_123 (l_prep) by_11\IN\0|a_29|physiological_27 (l_pcomp) feeding_12\VBG\838098|NONE_0 (l_dobj) diet_17\NN\7560652|NONE_0 (l_relcl) induces_23\VBZ\1627355|%_29|high_27|fat_22|(_13|hfd_12|)_9|,_8 (l_dobj) obesity_24\NN\4999401|which_14|g_45
D004317_D009765 NONE doxorubicin_7\NN\2716866|(_6|mg_3|/_11|,_14|ip_16|)_18 (r_nmod) kg_9\NNS\13717155|a_32|ld(10_30|administered_8|._229 (r_appos) dose_3\NN\3740161|NONE_0 (l_acl) administered_13\VBN\2436349|a_40|ld(10_38|kg_8|._221 (l_prep) on_14\IN\0|NONE_0 (l_pobj) day_15\NN\15154774|NONE_0 (l_nummod) 43_16\CD\0|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) regimen_21\NN\5898568|NONE_0 (l_acl) led_22\VBD\3202760|the_24|hfd_20|feeding_16 (l_prep) to_23\IN\0|NONE_0 (l_pobj) cardiotoxicity_25\NN\0|NONE_0 (l_conj) dysfunction_28\NN\14204950|higher_31|,_10 (l_conj) peroxidation_31\NN\0|cardiac_27|,_8 (l_conj) mortality_36\NN\5054863|lipid_28|,_10|and_8 (l_prep) in_37\IN\13603305|%_12|in_23 (l_pobj) rats_43\NNS\2329401|NONE_0 (l_amod) obese_39\JJ\0|the_4|(_6|ob_7|)_9
D004317_D009765 NONE doxorubicin_7\NN\2716866|(_6|mg_3|/_11|,_14|ip_16|)_18 (r_nmod) kg_9\NNS\13717155|a_32|ld(10_30|administered_8|._229 (r_appos) dose_3\NN\3740161|NONE_0 (l_acl) administered_13\VBN\2436349|a_40|ld(10_38|kg_8|._221 (l_prep) on_14\IN\0|NONE_0 (l_pobj) day_15\NN\15154774|NONE_0 (l_nummod) 43_16\CD\0|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) regimen_21\NN\5898568|NONE_0 (l_acl) led_22\VBD\3202760|the_24|hfd_20|feeding_16 (l_prep) to_23\IN\0|NONE_0 (l_pobj) cardiotoxicity_25\NN\0|NONE_0 (l_conj) dysfunction_28\NN\14204950|higher_31|,_10 (l_conj) peroxidation_31\NN\0|cardiac_27|,_8 (l_conj) mortality_36\NN\5054863|lipid_28|,_10|and_8 (l_prep) in_37\IN\13603305|%_12|in_23 (l_pobj) rats_43\NNS\2329401|NONE_0 (l_nmod) ob_41\NNP\0|the_11|obese_7|(_1|)_2
D004317_D009765 NONE doxorubicin_0\NNP\2716866|NONE_0 (r_compound) toxicokinetics_1\NNS\0|NONE_0 (r_compound) studies_2\NNS\635850|change_20|._136 (r_nsubj) revealed_3\VBD\2137132|NONE_0 (l_dobj) change_5\NN\7283608|studies_20|._116 (l_conj) hearts_27\NNS\496167|no_113|in_103|in_35|)_9|and_7 (l_compound) ob_26\NNP\0|NONE_0
D004317_D009765 NONE doxorubicin_9\NN\2716866|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) accumulation_7\NN\13497135|NONE_0 (r_pobj) in_6\IN\13603305|no_10|in_68|)_94|and_96|hearts_103 (r_prep) change_5\NN\7283608|studies_20|._116 (l_conj) hearts_27\NNS\496167|no_113|in_103|in_35|)_9|and_7 (l_compound) ob_26\NNP\0|NONE_0
D004317_D009765 NONE doxorubicin_109\NN\2716866|NONE_0 (r_compound) administration_110\NN\1133281|NONE_0 (r_pobj) after_108\IN\0|decreased_24|adp_10 (r_prep) ratio_107\NN\13815152|NONE_0 (r_pobj) by_102\IN\0|NONE_0 (r_agent) accompanied_101\VBN\0|(_35|6_34|)_33|%_29|in_22 (r_acl) drop_96\NN\13899200|stress_377|kinase_20|,_14|and_12 (r_conj) decreased_82\VBD\169651|studies_389|sensitized_355|._161 (r_ccomp) revealed_2\VBD\2137132|NONE_0 (l_ccomp) sensitized_7\VBN\126264|studies_34|decreased_355|._516 (l_nsubjpass) rats_5\NNS\2329401|that_8|are_5|due_20 (l_compound) ob_4\NNP\0|NONE_0
D004317_D009765 NONE doxorubicin_109\NN\2716866|NONE_0 (r_compound) administration_110\NN\1133281|NONE_0 (r_pobj) after_108\IN\0|decreased_24|adp_10 (r_prep) ratio_107\NN\13815152|NONE_0 (r_pobj) by_102\IN\0|NONE_0 (r_agent) accompanied_101\VBN\0|(_35|6_34|)_33|%_29|in_22 (r_acl) drop_96\NN\13899200|stress_377|kinase_20|,_14|and_12 (r_conj) decreased_82\VBD\169651|studies_389|sensitized_355|._161 (l_nsubj) stress_16\NN\7083732|kinase_357|,_363|and_365|drop_377 (l_acl) activated_35\VBN\1641914|(_140|1_139|)_138|higher_136|oxyradical_129|leading_111 (l_dobj) oxidation_56\NN\13447361|downregulation_151|alpha_81 (l_appos) heart_64\NN\5919034|decreased_64|cardiac_54|acid_40|(_25|,_55|5_58|)_59 (l_prep) versus_67\IN\0|min_18|g_14|in_6|)_42 (l_pobj) heart_74\NN\5919034|NONE_0 (l_prep) in_75\IN\13603305|400.2+/-11.8_30|g_8 (l_pobj) ob_76\NNP\0|NONE_0
D004317_D009765 NONE doxorubicin_12\RB\2716866|-_11 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_15\NN\0|NONE_0 (r_pobj) to_11\IN\0|highly_18|by_38 (r_prep) sensitized_10\JJ\126264|in_49|,_36|rats_16|._187 (r_acomp) are_8\VBP\13600404|NONE_0 (l_nsubj) rats_7\NNS\2329401|in_33|,_20|sensitized_16|._203 (l_amod) obese_6\JJ\0|induced_8
D004317_D066126 NONE doxorubicin_11\RB\2716866|-_11 (r_npadvmod) induced_13\VBN\1627355|NONE_0 (r_compound) cardiotoxicity_14\NN\0|NONE_0
D004317_D066126 NONE doxorubicin_4\NN\2716866|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_prep) chemotherapy_2\NN\661091|often_7|,_2|is_41|due_52|._125 (r_nsubjpass) limited_9\VBN\4019101|NONE_0 (l_prep) due_10\IN\5174653|often_59|,_54|chemotherapy_52|is_11|._73 (l_pobj) life_12\NN\13954253|to_3 (l_acl) threatening_13\VBG\2603699|NONE_0 (l_dobj) cardiotoxicity_14\NN\0|during_27
D004317_D066126 NONE adriamycin_6\NNP\0|NONE_0 (r_punct) )_7\-RRB-\0|NONE_0 (r_punct) is_8\VBZ\0|often_48|,_43|chemotherapy_41|due_11|._84 (r_auxpass) limited_9\VBN\4019101|NONE_0 (l_prep) due_10\IN\5174653|often_59|,_54|chemotherapy_52|is_11|._73 (l_pobj) life_12\NN\13954253|to_3 (l_acl) threatening_13\VBG\2603699|NONE_0 (l_dobj) cardiotoxicity_14\NN\0|during_27
D004317_D066126 NONE doxorubicin_12\RB\2716866|-_11 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_15\NN\0|NONE_0
D004317_D066126 NONE doxorubicin_40\RB\2716866|-_11 (r_npadvmod) induced_42\VBN\1627355|NONE_0 (r_compound) cardiotoxicity_43\NN\0|NONE_0
D004317_D066126 NONE doxorubicin_7\NN\2716866|(_6|mg_3|/_11|,_14|ip_16|)_18 (r_nmod) kg_9\NNS\13717155|a_32|ld(10_30|administered_8|._229 (r_appos) dose_3\NN\3740161|NONE_0 (l_acl) administered_13\VBN\2436349|a_40|ld(10_38|kg_8|._221 (l_prep) on_14\IN\0|NONE_0 (l_pobj) day_15\NN\15154774|NONE_0 (l_nummod) 43_16\CD\0|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) regimen_21\NN\5898568|NONE_0 (l_acl) led_22\VBD\3202760|the_24|hfd_20|feeding_16 (l_prep) to_23\IN\0|NONE_0 (l_pobj) cardiotoxicity_25\NN\0|NONE_0
D004317_D066126 NONE doxorubicin_12\RB\2716866|-_11 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_15\NN\0|NONE_0
C010013_D009765 NONE doxorubicinol_11\NN\0|and_4 (r_conj) doxorubicin_9\NN\2716866|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) accumulation_7\NN\13497135|NONE_0 (r_pobj) in_6\IN\13603305|no_10|in_68|)_94|and_96|hearts_103 (r_prep) change_5\NN\7283608|studies_20|._116 (l_conj) hearts_27\NNS\496167|no_113|in_103|in_35|)_9|and_7 (l_compound) ob_26\NNP\0|NONE_0
D004317_D056486 NONE doxorubicin_7\NN\2716866|(_6|mg_3|/_11|,_14|ip_16|)_18 (r_nmod) kg_9\NNS\13717155|a_32|ld(10_30|administered_8|._229 (r_appos) dose_3\NN\3740161|NONE_0 (l_acl) administered_13\VBN\2436349|a_40|ld(10_38|kg_8|._221 (l_prep) on_14\IN\0|NONE_0 (l_pobj) day_15\NN\15154774|NONE_0 (l_nummod) 43_16\CD\0|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) regimen_21\NN\5898568|NONE_0 (l_acl) led_22\VBD\3202760|the_24|hfd_20|feeding_16 (l_prep) to_23\IN\0|NONE_0 (l_pobj) cardiotoxicity_25\NN\0|NONE_0 (l_conj) dysfunction_28\NN\14204950|higher_31|,_10 (l_conj) peroxidation_31\NN\0|cardiac_27|,_8 (l_conj) mortality_36\NN\5054863|lipid_28|,_10|and_8 (l_prep) in_44\IN\13603305|%_35|in_23 (l_pobj) absence_46\NN\14449405|NONE_0 (l_prep) of_47\IN\0|the_12 (l_pobj) toxicity_53\NN\13576101|NONE_0
D000255_D066126 NONE atp_21\NNP\14964590|cardiac_22|mitochondrial_14 (r_compound) generation_22\NN\7942152|substantially_55|,_10|increasing_12 (r_dobj) downregulating_18\VBG\0|NONE_0 (r_pcomp) by_16\IN\0|highly_56|to_38 (r_prep) sensitized_10\JJ\126264|in_49|,_36|rats_16|._187 (l_prep) to_11\IN\0|highly_18|by_38 (l_pobj) cardiotoxicity_15\NN\0|NONE_0
D004041_D066126 NONE fat_1\JJ\14938907|high_5|fed_9|obese_13 (r_amod) rats_6\NNS\2329401|sensitive_16|._63 (r_nsubj) are_7\VBP\13600404|NONE_0 (l_acomp) sensitive_9\JJ\10488309|rats_16|._47 (l_prep) to_10\IN\0|highly_17 (l_pobj) cardiotoxicity_14\NN\0|NONE_0
D004041_D066126 NONE fat_16\JJ\14938907|%_7|high_5|(_9|hfd_10|)_13|,_14|induces_22 (r_amod) diet_17\NN\7560652|NONE_0 (r_dobj) feeding_12\VBG\838098|NONE_0 (r_pcomp) by_11\IN\0|a_29|physiological_27 (r_prep) intervention_10\NN\1239064|whether_24|,_110|to_123 (r_nsubj) sensitizes_38\VBZ\126264|in_174|,_154|we_152|._48 (l_prep) to_39\IN\0|whether_147|intervention_123|,_13 (l_pobj) cardiotoxicity_43\NN\0|NONE_0
D004317_D007674 NONE doxorubicin_7\NN\2716866|(_6|mg_3|/_11|,_14|ip_16|)_18 (r_nmod) kg_9\NNS\13717155|a_32|ld(10_30|administered_8|._229 (r_appos) dose_3\NN\3740161|NONE_0 (l_acl) administered_13\VBN\2436349|a_40|ld(10_38|kg_8|._221 (l_prep) on_14\IN\0|NONE_0 (l_pobj) day_15\NN\15154774|NONE_0 (l_nummod) 43_16\CD\0|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) regimen_21\NN\5898568|NONE_0 (l_acl) led_22\VBD\3202760|the_24|hfd_20|feeding_16 (l_prep) to_23\IN\0|NONE_0 (l_pobj) cardiotoxicity_25\NN\0|NONE_0 (l_conj) dysfunction_28\NN\14204950|higher_31|,_10 (l_conj) peroxidation_31\NN\0|cardiac_27|,_8 (l_conj) mortality_36\NN\5054863|lipid_28|,_10|and_8 (l_prep) in_44\IN\13603305|%_35|in_23 (l_pobj) absence_46\NN\14449405|NONE_0 (l_prep) of_47\IN\0|the_12 (l_pobj) toxicity_53\NN\13576101|NONE_0
D000244_D009765 NONE adp_106\NNP\14964590|decreased_14|after_10 (r_compound) ratio_107\NN\13815152|NONE_0 (r_pobj) by_102\IN\0|NONE_0 (r_agent) accompanied_101\VBN\0|(_35|6_34|)_33|%_29|in_22 (r_acl) drop_96\NN\13899200|stress_377|kinase_20|,_14|and_12 (r_conj) decreased_82\VBD\169651|studies_389|sensitized_355|._161 (r_ccomp) revealed_2\VBD\2137132|NONE_0 (l_ccomp) sensitized_7\VBN\126264|studies_34|decreased_355|._516 (l_nsubjpass) rats_5\NNS\2329401|that_8|are_5|due_20 (l_compound) ob_4\NNP\0|NONE_0
D000244_D009765 NONE adp_106\NNP\14964590|decreased_14|after_10 (r_compound) ratio_107\NN\13815152|NONE_0 (r_pobj) by_102\IN\0|NONE_0 (r_agent) accompanied_101\VBN\0|(_35|6_34|)_33|%_29|in_22 (r_acl) drop_96\NN\13899200|stress_377|kinase_20|,_14|and_12 (r_conj) decreased_82\VBD\169651|studies_389|sensitized_355|._161 (l_nsubj) stress_16\NN\7083732|kinase_357|,_363|and_365|drop_377 (l_acl) activated_35\VBN\1641914|(_140|1_139|)_138|higher_136|oxyradical_129|leading_111 (l_dobj) oxidation_56\NN\13447361|downregulation_151|alpha_81 (l_appos) heart_64\NN\5919034|decreased_64|cardiac_54|acid_40|(_25|,_55|5_58|)_59 (l_prep) versus_67\IN\0|min_18|g_14|in_6|)_42 (l_pobj) heart_74\NN\5919034|NONE_0 (l_prep) in_75\IN\13603305|400.2+/-11.8_30|g_8 (l_pobj) ob_76\NNP\0|NONE_0
D004041_D009765 CID fat_1\JJ\14938907|high_5|fed_9|obese_13 (r_amod) rats_6\NNS\2329401|sensitive_16|._63 (l_amod) obese_5\JJ\0|high_18|fat_13|fed_4
D004041_D009765 CID fat_16\JJ\14938907|%_7|high_5|(_9|hfd_10|)_13|,_14|induces_22 (r_amod) diet_17\NN\7560652|NONE_0 (l_relcl) induces_23\VBZ\1627355|%_29|high_27|fat_22|(_13|hfd_12|)_9|,_8 (l_dobj) obesity_24\NN\4999401|which_14|g_45
D004317_D006331 CID doxorubicin_7\NN\2716866|(_6|mg_3|/_11|,_14|ip_16|)_18 (r_nmod) kg_9\NNS\13717155|a_32|ld(10_30|administered_8|._229 (r_appos) dose_3\NN\3740161|NONE_0 (l_acl) administered_13\VBN\2436349|a_40|ld(10_38|kg_8|._221 (l_prep) on_14\IN\0|NONE_0 (l_pobj) day_15\NN\15154774|NONE_0 (l_nummod) 43_16\CD\0|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) regimen_21\NN\5898568|NONE_0 (l_acl) led_22\VBD\3202760|the_24|hfd_20|feeding_16 (l_prep) to_23\IN\0|NONE_0 (l_pobj) cardiotoxicity_25\NN\0|NONE_0 (l_conj) dysfunction_28\NN\14204950|higher_31|,_10
D000255_D009765 NONE atp_99\NNP\14964590|cardiac_8 (r_compound) levels_100\NNS\4916342|NONE_0 (r_pobj) in_97\IN\13603305|(_13|6_12|)_11|%_7|accompanied_22 (r_prep) drop_96\NN\13899200|stress_377|kinase_20|,_14|and_12 (r_conj) decreased_82\VBD\169651|studies_389|sensitized_355|._161 (r_ccomp) revealed_2\VBD\2137132|NONE_0 (l_ccomp) sensitized_7\VBN\126264|studies_34|decreased_355|._516 (l_nsubjpass) rats_5\NNS\2329401|that_8|are_5|due_20 (l_compound) ob_4\NNP\0|NONE_0
D000255_D009765 NONE atp_99\NNP\14964590|cardiac_8 (r_compound) levels_100\NNS\4916342|NONE_0 (r_pobj) in_97\IN\13603305|(_13|6_12|)_11|%_7|accompanied_22 (r_prep) drop_96\NN\13899200|stress_377|kinase_20|,_14|and_12 (r_conj) decreased_82\VBD\169651|studies_389|sensitized_355|._161 (l_nsubj) stress_16\NN\7083732|kinase_357|,_363|and_365|drop_377 (l_acl) activated_35\VBN\1641914|(_140|1_139|)_138|higher_136|oxyradical_129|leading_111 (l_dobj) oxidation_56\NN\13447361|downregulation_151|alpha_81 (l_appos) heart_64\NN\5919034|decreased_64|cardiac_54|acid_40|(_25|,_55|5_58|)_59 (l_prep) versus_67\IN\0|min_18|g_14|in_6|)_42 (l_pobj) heart_74\NN\5919034|NONE_0 (l_prep) in_75\IN\13603305|400.2+/-11.8_30|g_8 (l_pobj) ob_76\NNP\0|NONE_0
D000255_D009765 NONE atp_104\NNP\14964590|/_3 (r_nmod) adp_106\NNP\14964590|decreased_14|after_10 (r_compound) ratio_107\NN\13815152|NONE_0 (r_pobj) by_102\IN\0|NONE_0 (r_agent) accompanied_101\VBN\0|(_35|6_34|)_33|%_29|in_22 (r_acl) drop_96\NN\13899200|stress_377|kinase_20|,_14|and_12 (r_conj) decreased_82\VBD\169651|studies_389|sensitized_355|._161 (r_ccomp) revealed_2\VBD\2137132|NONE_0 (l_ccomp) sensitized_7\VBN\126264|studies_34|decreased_355|._516 (l_nsubjpass) rats_5\NNS\2329401|that_8|are_5|due_20 (l_compound) ob_4\NNP\0|NONE_0
D000255_D009765 NONE atp_104\NNP\14964590|/_3 (r_nmod) adp_106\NNP\14964590|decreased_14|after_10 (r_compound) ratio_107\NN\13815152|NONE_0 (r_pobj) by_102\IN\0|NONE_0 (r_agent) accompanied_101\VBN\0|(_35|6_34|)_33|%_29|in_22 (r_acl) drop_96\NN\13899200|stress_377|kinase_20|,_14|and_12 (r_conj) decreased_82\VBD\169651|studies_389|sensitized_355|._161 (l_nsubj) stress_16\NN\7083732|kinase_357|,_363|and_365|drop_377 (l_acl) activated_35\VBN\1641914|(_140|1_139|)_138|higher_136|oxyradical_129|leading_111 (l_dobj) oxidation_56\NN\13447361|downregulation_151|alpha_81 (l_appos) heart_64\NN\5919034|decreased_64|cardiac_54|acid_40|(_25|,_55|5_58|)_59 (l_prep) versus_67\IN\0|min_18|g_14|in_6|)_42 (l_pobj) heart_74\NN\5919034|NONE_0 (l_prep) in_75\IN\13603305|400.2+/-11.8_30|g_8 (l_pobj) ob_76\NNP\0|NONE_0
D000255_D009765 NONE atp_21\NNP\14964590|cardiac_22|mitochondrial_14 (r_compound) generation_22\NN\7942152|substantially_55|,_10|increasing_12 (r_dobj) downregulating_18\VBG\0|NONE_0 (r_pcomp) by_16\IN\0|highly_56|to_38 (r_prep) sensitized_10\JJ\126264|in_49|,_36|rats_16|._187 (r_acomp) are_8\VBP\13600404|NONE_0 (l_nsubj) rats_7\NNS\2329401|in_33|,_20|sensitized_16|._203 (l_amod) obese_6\JJ\0|induced_8
D000249_D009765 NONE amp_84\NN\13633375|-_3 (r_compound) alpha2_86\NN\0|mitochondrial_18|protein_7 (r_compound) kinase_88\NN\14732946|stress_357|,_6|and_8|drop_20 (r_dobj) decreased_82\VBD\169651|studies_389|sensitized_355|._161 (r_ccomp) revealed_2\VBD\2137132|NONE_0 (l_ccomp) sensitized_7\VBN\126264|studies_34|decreased_355|._516 (l_nsubjpass) rats_5\NNS\2329401|that_8|are_5|due_20 (l_compound) ob_4\NNP\0|NONE_0
D000249_D009765 NONE amp_84\NN\13633375|-_3 (r_compound) alpha2_86\NN\0|mitochondrial_18|protein_7 (r_compound) kinase_88\NN\14732946|stress_357|,_6|and_8|drop_20 (r_dobj) decreased_82\VBD\169651|studies_389|sensitized_355|._161 (l_nsubj) stress_16\NN\7083732|kinase_357|,_363|and_365|drop_377 (l_acl) activated_35\VBN\1641914|(_140|1_139|)_138|higher_136|oxyradical_129|leading_111 (l_dobj) oxidation_56\NN\13447361|downregulation_151|alpha_81 (l_appos) heart_64\NN\5919034|decreased_64|cardiac_54|acid_40|(_25|,_55|5_58|)_59 (l_prep) versus_67\IN\0|min_18|g_14|in_6|)_42 (l_pobj) heart_74\NN\5919034|NONE_0 (l_prep) in_75\IN\13603305|400.2+/-11.8_30|g_8 (l_pobj) ob_76\NNP\0|NONE_0
8424298
D007530_D007022 CID isoflurane_8\NN\3570838|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) labetalol_6\NN\2721160|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) induced_4\VBN\1627355|deliberate_23 (r_acl) hypotension_3\NN\14057371|NONE_0
D007530_D007022 CID isoflurane_18\JJ\3570838|(_11|hypotensive_12 (r_amod) group_21\NN\2137|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) labetalol_16\NN\2721160|NONE_0 (r_pobj) by_15\IN\0|NONE_0 (r_agent) induced_14\VBN\1627355|deliberate_23 (r_acl) hypotension_13\NN\14057371|NONE_0
D007530_D007022 CID isoflurane_18\JJ\3570838|(_11|hypotensive_12 (r_amod) group_21\NN\2137|NONE_0 (l_amod) hypotensive_20\JJ\10405694|isoflurane_12|(_1
D007530_D007022 CID isoflurane_9\NN\3570838|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) labetalol_7\NN\2721160|NONE_0 (r_pobj) by_6\IN\0|that_25|hypotension_20 (r_prep) induced_5\VBN\1627355|results_34|has_37|._128 (l_nsubj) hypotension_4\NN\14057371|that_5|by_20
D007741_D007022 CID labetalol_6\NN\2721160|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) induced_4\VBN\1627355|deliberate_23 (r_acl) hypotension_3\NN\14057371|NONE_0
D007741_D007022 CID labetalol_16\NN\2721160|NONE_0 (r_pobj) by_15\IN\0|NONE_0 (r_agent) induced_14\VBN\1627355|deliberate_23 (r_acl) hypotension_13\NN\14057371|NONE_0
D007741_D007022 CID labetalol_16\NN\2721160|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) group_21\NN\2137|NONE_0 (l_amod) hypotensive_20\JJ\10405694|isoflurane_12|(_1
D007741_D007022 CID labetalol_7\NN\2721160|NONE_0 (r_pobj) by_6\IN\0|that_25|hypotension_20 (r_prep) induced_5\VBN\1627355|results_34|has_37|._128 (l_nsubj) hypotension_4\NN\14057371|that_5|by_20
9758264
D005492_D008180 CID acid_4\NN\14818238|NONE_0 (r_pobj) of_2\IN\0|epileptogenic_23 (r_prep) activity_1\NN\30358|after_23|sle_42|)_70 (r_nsubj) induces_7\VBZ\1627355|NONE_0 (l_dobj) sle_8\NNP\14229912|activity_42|after_19|)_28
D005492_D008180 CID acid_11\NN\14818238|(_7 (r_appos) sle_8\NNP\14229912|activity_42|after_19|)_28
D005492_D008180 CID acid_35\NN\14818238|NONE_0 (r_pobj) of_33\IN\0|the_34|therapeutic_30|(_13|>_12|)_2 (r_prep) dose_25\NN\3740161|damage_58|,_28|therefore_26|cluster_44|._63 (r_nsubj) triggered_36\VBD\1641914|NONE_0 (l_ccomp) damage_15\VB\7296428|,_30|therefore_32|dose_58|cluster_102|._121 (l_nsubj) disease_6\NN\14061805|could_38|barrier_67 (l_appos) lupus_12\NN\14219661|patient_52|autoimmune_42|(_23|)_5
D005492_D012640 CID acid_35\NN\14818238|NONE_0 (r_pobj) of_33\IN\0|the_34|therapeutic_30|(_13|>_12|)_2 (r_prep) dose_25\NN\3740161|damage_58|,_28|therefore_26|cluster_44|._63 (r_nsubj) triggered_36\VBD\1641914|NONE_0 (l_dobj) cluster_38\NN\7959269|damage_102|,_72|therefore_70|dose_44|._19 (l_prep) of_39\IN\0|a_10 (l_pobj) seizures_40\NNS\14081375|NONE_0
D005492_D001327 NONE acid_35\NN\14818238|NONE_0 (r_pobj) of_33\IN\0|the_34|therapeutic_30|(_13|>_12|)_2 (r_prep) dose_25\NN\3740161|damage_58|,_28|therefore_26|cluster_44|._63 (r_nsubj) triggered_36\VBD\1641914|NONE_0 (l_ccomp) damage_15\VB\7296428|,_30|therefore_32|dose_58|cluster_102|._121 (l_nsubj) disease_6\NN\14061805|could_38|barrier_67
D005492_D001327 NONE acid_9\NN\14818238|NONE_0 (r_pobj) of_7\IN\0|(_8|<_7|1_6|)_2 (r_prep) mg_5\NN\13717155|physiological_23|in_23|,_56|without_62|,_92 (r_appos) dose_1\NN\3740161|did_103|not_107|risk_124|._151 (l_prep) without_19\IN\0|physiological_85|mg_62|in_39|,_6|,_30 (l_pobj) disease_22\NN\14061805|all_27
D005492_D004827 NONE acid_4\NN\14818238|NONE_0 (r_pobj) of_2\IN\0|epileptogenic_23 (r_prep) activity_1\NN\30358|after_23|sle_42|)_70 (r_nsubj) induces_7\VBZ\1627355|NONE_0 (l_dobj) sle_8\NNP\14229912|activity_42|after_19|)_28 (l_appos) acid_11\NN\14818238|(_7 (l_conj) epilepsy_13\NN\14085708|folic_15|and_4
D005492_D004827 NONE acid_11\NN\14818238|(_7 (l_conj) epilepsy_13\NN\14085708|folic_15|and_4
D005492_D004827 NONE acid_6\NN\14818238|-_4 (r_npadvmod) containing_8\VBG\2632940|folic_11|multivitamin_11|in_40 (r_amod) supplementation_10\NN\5108947|NONE_0 (l_prep) in_11\IN\13603305|folic_51|containing_40|multivitamin_29 (l_pobj) women_13\NNS\9605289|NONE_0 (l_amod) epileptic_12\JJ\10595647|NONE_0
D005492_D004827 NONE acid_6\NN\14818238|-_4 (r_npadvmod) containing_8\VBG\2632940|folic_11|multivitamin_11|in_40 (r_amod) supplementation_10\NN\5108947|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) effect_3\NN\34213|to_13|before_80|in_108|._200 (r_dobj) study_1\VB\635850|NONE_0 (l_prep) in_18\IN\13603305|to_121|effect_108|before_28|._92 (l_pobj) order_19\NN\7168131|NONE_0 (l_acl) determine_21\VB\0|NONE_0 (l_dobj) rate_23\NN\13815152|to_17 (l_prep) of_24\IN\0|the_9 (l_pobj) defects_27\NNS\14462666|NONE_0 (l_conj) effects_33\NNS\13245626|structural_51|birth_40|and_26 (l_amod) related_31\VBN\628491|side_8 (l_npadvmod) epilepsy_29\NN\14085708|-_8
D005492_D004827 NONE acid_7\NN\14818238|NONE_0 (r_pobj) with_4\IN\0|60_19|epileptic_16|._162 (r_prep) women_3\NNS\9605289|NONE_0 (l_amod) epileptic_2\JJ\10595647|60_3|with_16|._178
D005492_D004827 NONE acid_7\NN\14818238|NONE_0 (l_appos) effects_21\NNS\13245626|periconceptional_117|folic_100|(_89|supplementation_56|,_41 (l_amod) related_19\VBN\628491|developed_19|side_8|during_21 (l_npadvmod) epilepsy_17\NN\14085708|-_8
D005492_D004827 NONE acid_14\NN\14818238|and_12 (r_conj) carbamazepine_10\NN\0|NONE_0 (r_pobj) by_9\IN\0|woman_31|was_25|continuously_13|._96 (r_agent) treated_7\VBN\2376958|NONE_0 (l_nsubjpass) woman_5\NN\9605289|was_6|continuously_18|by_31|._127 (l_amod) epileptic_4\JJ\10595647|this_17|old_4
D005492_D004827 NONE acid_35\NN\14818238|NONE_0 (r_pobj) of_33\IN\0|the_34|therapeutic_30|(_13|>_12|)_2 (r_prep) dose_25\NN\3740161|damage_58|,_28|therefore_26|cluster_44|._63 (r_nsubj) triggered_36\VBD\1641914|NONE_0 (l_ccomp) damage_15\VB\7296428|,_30|therefore_32|dose_58|cluster_102|._121 (l_nsubj) disease_6\NN\14061805|could_38|barrier_67 (l_poss) patient_3\NN\9898892|autoimmune_10|(_29|lupus_52|)_57 (l_amod) epileptic_1\JJ\10595647|the_4|pregnant_10|'s_26
D005492_D004827 NONE acid_9\NN\14818238|NONE_0 (r_pobj) of_7\IN\0|(_8|<_7|1_6|)_2 (r_prep) mg_5\NN\13717155|physiological_23|in_23|,_56|without_62|,_92 (r_appos) dose_1\NN\3740161|did_103|not_107|risk_124|._151 (l_prep) in_11\IN\13603305|physiological_46|mg_23|,_33|without_39|,_69 (l_pobj) women_16\NNS\9605289|both_33 (l_amod) epileptic_15\JJ\10595647|healthy_15|60_3
D005492_D004827 NONE acid_9\NN\14818238|NONE_0 (r_pobj) of_7\IN\0|(_8|<_7|1_6|)_2 (r_prep) mg_5\NN\13717155|physiological_23|in_23|,_56|without_62|,_92 (r_appos) dose_1\NN\3740161|did_103|not_107|risk_124|._151 (r_nsubj) increase_26\VB\13576355|NONE_0 (l_dobj) risk_28\NN\14541044|dose_124|did_21|not_17|._27 (l_prep) for_29\IN\0|the_9 (l_pobj) seizures_31\NNS\14081375|NONE_0
D002220_D004827 NONE carbamazepine_10\NN\0|NONE_0 (r_pobj) by_9\IN\0|woman_31|was_25|continuously_13|._96 (r_agent) treated_7\VBN\2376958|NONE_0 (l_nsubjpass) woman_5\NN\9605289|was_6|continuously_18|by_31|._127 (l_amod) epileptic_4\JJ\10595647|this_17|old_4
D005492_D000014 NONE acid_6\NN\14818238|-_4 (r_npadvmod) containing_8\VBG\2632940|folic_11|multivitamin_11|in_40 (r_amod) supplementation_10\NN\5108947|NONE_0 (r_pobj) of_4\IN\0|the_11 (r_prep) effect_3\NN\34213|to_13|before_80|in_108|._200 (r_dobj) study_1\VB\635850|NONE_0 (l_prep) in_18\IN\13603305|to_121|effect_108|before_28|._92 (l_pobj) order_19\NN\7168131|NONE_0 (l_acl) determine_21\VB\0|NONE_0 (l_dobj) rate_23\NN\13815152|to_17 (l_prep) of_24\IN\0|the_9 (l_pobj) defects_27\NNS\14462666|NONE_0
9875685
D014031_D064420 NONE tobramicyn_17\NN\0|NONE_0 (l_prep) on_18\IN\0|NONE_0 (l_pobj) concentrations_23\NNS\4916342|NONE_0 (l_conj) toxicity_25\NN\13576101|state_31|serum_25|and_4
D003404_D007674 NONE creatinine_2\NN\0|was_11|in_24|versus_49|,_77|without_79|._113 (r_nsubjpass) observed_4\VBN\2163746|NONE_0 (l_prep) without_20\IN\0|creatinine_79|was_68|in_55|versus_30|,_2|._34 (l_pobj) evidence_21\NN\5816287|NONE_0 (l_prep) of_22\IN\0|NONE_0 (l_pobj) nephrotoxicity_23\NN\0|NONE_0
20331935
D013739_D006966 NONE testosterone_1\NN\14747587|serum_6 (r_compound) concentration_2\NN\4916342|with_24|but_45|affected_57|._87 (r_nsubj) increased_3\VBD\169651|NONE_0 (l_conj) affected_10\VBN\126264|concentration_57|with_33|but_12|._30 (l_agent) by_11\IN\0|was_17|not_13 (l_pobj) hyperprolactinemia_12\NN\0|NONE_0
D018967_D050723 NONE risperidone_8\NN\0|after_6|were_22 (r_nsubjpass) started_12\VBN\0|fractures_55|3_44|,_7|and_9|occurred_18 (r_advcl) occurred_6\VBD\0|NONE_0 (l_nsubj) fractures_3\NNS\14285662|3_11|started_55|,_62|and_64|occurred_73
D018967_D006966 CID risperidone_12\NN\0|-_11 (r_npadvmod) induced_14\VBN\1627355|on_27 (r_amod) hyperprolactinemia_15\NN\0|NONE_0
D018967_D006966 CID risperidone_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treated_15\VBN\2376958|49_24|of_20 (r_acl) %_6\NN\0|NONE_0 (r_pobj) in_4\IN\13603305|NONE_0 (r_prep) present_3\JJ\28270|:_25|hyperprolactinemia_23|._83 (r_acomp) was_2\VBD\0|NONE_0 (l_nsubj) hyperprolactinemia_1\NNP\0|:_2|present_23|._106
D018967_D006966 CID risperidone_8\NN\0|after_6|were_22 (r_nsubjpass) started_12\VBN\0|fractures_55|3_44|,_7|and_9|occurred_18 (r_advcl) occurred_6\VBD\0|NONE_0 (l_conj) occurred_16\VBD\0|fractures_73|3_62|started_18|,_11|and_9 (l_prep) in_17\IN\13603305|none_14|._35 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) hyperprolactinemia_20\NN\0|NONE_0
D018967_D006966 CID risperidone_7\NN\0|-_11 (r_npadvmod) induced_9\VBN\1627355|and_27|treatment_36 (r_amod) hyperprolactinemia_10\NN\0|to_28|lower_41
16225977
C076029_D013981 NONE olanzapine_13\NN\0|,_2 (r_conj) risperidone_11\NN\0|such_8 (r_pobj) as_10\IN\14622893|atypical_29 (r_prep) antipsychotics_8\NNS\4470232|NONE_0 (r_pobj) by_6\IN\0|disorders_37|can_27|be_23|effectively_20|._74 (r_agent) treated_5\VBN\2376958|NONE_0 (l_nsubjpass) disorders_1\NNS\14034177|can_10|be_14|effectively_17|by_37|._111
C092292_D013981 NONE ziprasidone_15\NN\0|and_4 (r_conj) olanzapine_13\NN\0|,_2 (r_conj) risperidone_11\NN\0|such_8 (r_pobj) as_10\IN\14622893|atypical_29 (r_prep) antipsychotics_8\NNS\4470232|NONE_0 (r_pobj) by_6\IN\0|disorders_37|can_27|be_23|effectively_20|._74 (r_agent) treated_5\VBN\2376958|NONE_0 (l_nsubjpass) disorders_1\NNS\14034177|can_10|be_14|effectively_17|by_37|._111
C012052_D012559 NONE amisulpride_0\NNP\0|related_12|like_24|in_38|._68 (r_amod) symptoms_5\NNS\5823932|NONE_0 (l_prep) in_6\IN\13603305|amisulpride_38|related_26|like_14|._30 (l_pobj) schizophrenic_9\NN\10490141|NONE_0
C012052_D012559 NONE amisulpride_20\JJ\0|NONE_0 (r_amod) treatment_21\NN\654885|NONE_0 (r_pobj) of_19\IN\0|5_9 (r_prep) months_18\NNS\15113229|NONE_0 (r_pobj) after_16\IN\0|who_58|movements_10 (r_prep) developed_9\VBD\1753788|a_37|old_27|girl_23|mg_100 (r_relcl) schizophrenic_7\NN\10490141|we_30|._129
C012052_D020820 NONE amisulpride_20\JJ\0|NONE_0 (r_amod) treatment_21\NN\654885|NONE_0 (r_pobj) of_19\IN\0|5_9 (r_prep) months_18\NNS\15113229|NONE_0 (r_pobj) after_16\IN\0|who_58|movements_10 (r_prep) developed_9\VBD\1753788|a_37|old_27|girl_23|mg_100 (l_dobj) movements_15\NNS\191142|who_48|after_10
D003024_D013981 NONE clozapine_26\NN\3713736|or_3 (r_conj) quetiapine_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) during_21\IN\0|NONE_0 (r_prep) occurring_20\VBG\0|that_66|symptoms_47 (r_xcomp) show_8\VBP\429048|case_18 (l_dobj) symptoms_12\NNS\5823932|that_19|occurring_47
D003024_D013981 NONE clozapine_29\NN\3713736|,_2 (r_conj) quetiapine_27\NN\0|such_8 (r_pobj) as_26\IN\14622893|atypical_29 (r_prep) antipsychotics_24\NNS\4470232|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) during_20\IN\0|that_69|symptoms_55|might_46|in_34 (r_prep) occur_15\VB\0|with_82|,_52|patient_46|._131 (l_nsubj) symptoms_13\NNS\5823932|that_14|might_9|in_21|during_55
C069541_D013981 NONE quetiapine_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) during_21\IN\0|NONE_0 (r_prep) occurring_20\VBG\0|that_66|symptoms_47 (r_xcomp) show_8\VBP\429048|case_18 (l_dobj) symptoms_12\NNS\5823932|that_19|occurring_47
C069541_D013981 NONE quetiapine_27\NN\0|such_8 (r_pobj) as_26\IN\14622893|atypical_29 (r_prep) antipsychotics_24\NNS\4470232|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) during_20\IN\0|that_69|symptoms_55|might_46|in_34 (r_prep) occur_15\VB\0|with_82|,_52|patient_46|._131 (l_nsubj) symptoms_13\NNS\5823932|that_14|might_9|in_21|during_55
C012052_D013981 CID amisulpride_0\NNP\0|related_12|like_24|in_38|._68 (r_amod) symptoms_5\NNS\5823932|NONE_0
C012052_D013981 CID amisulpride_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|the_9|mg_27 (r_prep) dose_11\NN\3740161|completely_32|after_21|we_15 (r_dobj) reduced_9\VBD\441445|symptoms_38|._54 (r_advcl) resolved_5\VBN\352826|NONE_0 (l_nsubj) symptoms_4\NNS\5823932|reduced_38|._92
C012052_D013981 CID amisulpride_32\NN\0|,_5|or_3 (r_conj) clozapine_29\NN\3713736|,_2 (r_conj) quetiapine_27\NN\0|such_8 (r_pobj) as_26\IN\14622893|atypical_29 (r_prep) antipsychotics_24\NNS\4470232|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) during_20\IN\0|that_69|symptoms_55|might_46|in_34 (r_prep) occur_15\VB\0|with_82|,_52|patient_46|._131 (l_nsubj) symptoms_13\NNS\5823932|that_14|might_9|in_21|during_55
D018967_D013981 NONE risperidone_11\NN\0|such_8 (r_pobj) as_10\IN\14622893|atypical_29 (r_prep) antipsychotics_8\NNS\4470232|NONE_0 (r_pobj) by_6\IN\0|disorders_37|can_27|be_23|effectively_20|._74 (r_agent) treated_5\VBN\2376958|NONE_0 (l_nsubjpass) disorders_1\NNS\14034177|can_10|be_14|effectively_17|by_37|._111
6540303
D007649_D002389 CID ketamine_5\NN\3054098|NONE_0 (r_compound) catatonia_6\NN\14544672|NONE_0
D007649_D002389 CID ketamine_15\NN\3054098|-_8 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) catatonia_18\NN\14544672|NONE_0
D007649_D002389 CID ketamine_17\NN\3054098|NONE_0 (r_pobj) after_16\IN\0|in_99|,_71|pretreatment_69|duration_28|,_14|but_16|did_53 (r_prep) increased_8\VBD\169651|NONE_0 (l_dobj) duration_10\NN\15113229|in_71|,_43|pretreatment_41|after_28|,_42|but_44|did_81 (l_prep) of_11\IN\0|the_13 (l_pobj) catatonia_12\NNP\14544672|NONE_0
D007649_D002389 CID ketamine_15\NN\3054098|than_26 (r_compound) catatonia_16\NNP\14544672|NONE_0
D004298_D002389 CID dopamine_7\NN\14807737|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) pretreatment_5\NN\0|in_30|,_2|duration_41|after_69|,_83|but_85|did_122 (r_nsubj) increased_8\VBD\169651|NONE_0 (l_dobj) duration_10\NN\15113229|in_71|,_43|pretreatment_41|after_28|,_42|but_44|did_81 (l_prep) of_11\IN\0|the_13 (l_pobj) catatonia_12\NNP\14544672|NONE_0
D004298_D002389 CID dopamine_2\NN\14807737|furthermore_13|,_2|act_21|._136 (r_nsubj) appeared_3\VBD\2604760|NONE_0 (l_xcomp) act_5\VB\6479665|furthermore_34|,_23|dopamine_21|._115 (l_prep) on_6\IN\0|to_7 (l_pobj) systems_7\NNS\3575240|NONE_0 (l_acl) involved_10\JJ\2676054|NONE_0 (l_prep) with_11\IN\0|closely_17 (l_pobj) induction_13\NN\7450842|NONE_0 (l_prep) of_14\IN\0|the_14|on_43 (l_pobj) catatonia_16\NNP\14544672|NONE_0
D002395_D002389 NONE catecholamines_10\NNS\5407119|NONE_0 (r_pobj) of_9\IN\0|the_9|on_40 (r_prep) role_8\NN\719494|to_15|in_75 (l_prep) on_14\IN\0|the_49|of_40 (l_pobj) catatonia_18\NN\14544672|NONE_0
D009638_D002389 NONE norepinephrine_22\NN\14807929|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) pretreatment_20\NN\0|not_37|._40 (r_nsubj) did_23\VBD\0|in_152|,_124|pretreatment_122|duration_81|after_53|,_39|but_37 (r_conj) increased_8\VBD\169651|NONE_0 (l_dobj) duration_10\NN\15113229|in_71|,_43|pretreatment_41|after_28|,_42|but_44|did_81 (l_prep) of_11\IN\0|the_13 (l_pobj) catatonia_12\NNP\14544672|NONE_0
D000588_D002389 NONE amine_2\NN\14951377|on_19 (r_compound) pretreatment_3\NN\0|NONE_0 (l_prep) on_4\IN\0|amine_19 (l_pobj) catatonia_6\NN\14544672|NONE_0
6292680
D004317_D009202 CID doxorubicin_0\JJ\2716866|in_27|._66 (r_nsubj) cardiomyopathy_1\NN\14103288|NONE_0
D004317_D009202 CID doxorubicin_23\NN\2716866|NONE_0 (r_pobj) of_22\IN\0|conventional_20 (r_prep) dosage_21\NN\13576355|the_31|tumor_27|and_17 (r_conj) bed_18\NN\2821943|NONE_0 (r_pobj) to_15\IN\0|NONE_0 (r_prep) irradiation_14\NN\13920835|NONE_0 (r_pobj) after_13\IN\0|children_93|cardiomyopathy_15|._73 (r_prep) experienced_9\VBD\2108377|NONE_0 (l_dobj) cardiomyopathy_12\NN\14103288|children_78|after_15|._88
D004317_D009202 CID doxorubicin_30\NN\2716866|NONE_0 (r_pobj) of_29\IN\0|the_16|on_31 (r_prep) interaction_28\NN\37396|NONE_0 (r_pobj) to_26\IN\0|that_89|fields_74|portion_28 (r_prep) include_16\VBP\0|the_52 (r_acl) fact_8\NN\5816287|NONE_0 (r_pobj) to_6\IN\0|cardiomyopathy_32|is_17|1_3|)_2|._168 (r_prep) attributed_3\VBN\670261|NONE_0 (l_nsubjpass) cardiomyopathy_1\NN\14103288|is_15|1_29|)_30|to_32|._200
D018943_D009202 NONE anthracycline_11\NN\0|severe_7 (r_amod) cardiomyopathy_12\NN\14103288|children_78|after_15|._88
D004317_D009369 NONE doxorubicin_23\NN\2716866|NONE_0 (r_pobj) of_22\IN\0|conventional_20 (r_prep) dosage_21\NN\13576355|the_31|tumor_27|and_17 (r_conj) bed_18\NN\2821943|NONE_0 (l_compound) tumor_17\NN\14234074|the_4|and_10|dosage_27
D004317_D009396 NONE doxorubicin_0\JJ\2716866|in_27|._66 (r_nsubj) cardiomyopathy_1\NN\14103288|NONE_0 (l_prep) in_2\IN\13603305|doxorubicin_27|._39 (l_pobj) children_3\NNS\9622049|NONE_0 (l_prep) with_4\IN\0|NONE_0 (l_pobj) tumor_9\NN\14234074|NONE_0
D004317_D009396 NONE doxorubicin_23\NN\2716866|NONE_0 (r_pobj) of_22\IN\0|conventional_20 (r_prep) dosage_21\NN\13576355|the_31|tumor_27|and_17 (r_conj) bed_18\NN\2821943|NONE_0 (r_pobj) to_15\IN\0|NONE_0 (r_prep) irradiation_14\NN\13920835|NONE_0 (r_pobj) after_13\IN\0|children_93|cardiomyopathy_15|._73 (r_prep) experienced_9\VBD\2108377|NONE_0 (l_nsubj) children_1\NNS\9622049|cardiomyopathy_78|after_93|._166 (l_prep) with_2\IN\0|two_13 (l_pobj) tumor_4\NN\14234074|NONE_0
D004317_D009396 NONE doxorubicin_30\NN\2716866|NONE_0 (r_pobj) of_29\IN\0|the_16|on_31 (r_prep) interaction_28\NN\37396|NONE_0 (r_pobj) to_26\IN\0|that_89|fields_74|portion_28 (r_prep) include_16\VBP\0|the_52 (l_nsubj) fields_11\VBZ\0|that_15|portion_46|to_74 (l_prep) for_12\IN\0|radiation_17 (l_pobj) tumor_15\NN\14234074|NONE_0
D004317_D009396 NONE doxorubicin_4\NN\2716866|NONE_0 (r_compound) dosage_5\NN\13576355|that_17|be_7|sharply_10|in_29 (r_nsubjpass) restricted_8\VBN\235368|it_53|is_50|._96 (l_prep) in_9\IN\13603305|that_46|dosage_29|be_22|sharply_19 (l_pobj) children_10\NNS\9622049|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) tumor_13\NN\14234074|NONE_0
D018943_D009369 NONE anthracycline_11\NN\0|severe_7 (r_amod) cardiomyopathy_12\NN\14103288|children_78|after_15|._88 (r_dobj) experienced_9\VBD\2108377|NONE_0 (l_prep) after_13\IN\0|children_93|cardiomyopathy_15|._73 (l_pobj) irradiation_14\NN\13920835|NONE_0 (l_prep) to_15\IN\0|NONE_0 (l_pobj) bed_18\NN\2821943|NONE_0 (l_compound) tumor_17\NN\14234074|the_4|and_10|dosage_27
D018943_D009396 NONE anthracycline_11\NN\0|severe_7 (r_amod) cardiomyopathy_12\NN\14103288|children_78|after_15|._88 (r_dobj) experienced_9\VBD\2108377|NONE_0 (l_nsubj) children_1\NNS\9622049|cardiomyopathy_78|after_93|._166 (l_prep) with_2\IN\0|two_13 (l_pobj) tumor_4\NN\14234074|NONE_0
2826064
D013726_D007008 CID terbutaline_9\NN\0|-_11 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) hypokalemia_12\NN\14299637|NONE_0
D013726_D007008 CID terbutaline_4\JJ\0|higher_7|after_27 (r_compound) concentrations_5\NNS\4916342|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) spite_1\NN\7550369|NONE_0 (r_pobj) in_0\IN\13603305|,_75|hypokalemia_81|was_93|completely_104|by_127|._156 (r_prep) antagonized_15\VBN\1787955|NONE_0 (l_nsubjpass) hypokalemia_11\NN\14299637|in_81|,_6|was_12|completely_23|by_46|._75
D010096_D007008 NONE oxprenolol_8\NN\0|NONE_0 (r_pobj) by_7\IN\0|its_16 (r_prep) abolishment_6\NN\209943|mediated_29|and_8|._25 (r_conj) hypokalemia_3\NN\14299637|NONE_0
D010096_D007008 NONE oxprenolol_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_13 (r_prep) efficacy_4\NN\5199286|subsequently_33|we_20|in_23|,_55|with_66|._121 (r_dobj) investigated_2\VBD\644583|NONE_0 (l_prep) in_7\IN\13603305|subsequently_56|we_43|efficacy_23|,_32|with_43|._98 (l_pcomp) antagonizing_8\VBG\1787955|NONE_0 (l_dobj) hypokalemia_10\NN\14299637|NONE_0
D010096_D007008 NONE oxprenolol_7\NN\0|NONE_0 (r_amod) pretreatment_8\NN\0|NONE_0 (r_pobj) after_6\IN\0|higher_34|terbutaline_27 (r_prep) concentrations_5\NNS\4916342|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) spite_1\NN\7550369|NONE_0 (r_pobj) in_0\IN\13603305|,_75|hypokalemia_81|was_93|completely_104|by_127|._156 (r_prep) antagonized_15\VBN\1787955|NONE_0 (l_nsubjpass) hypokalemia_11\NN\14299637|in_81|,_6|was_12|completely_23|by_46|._75
9915601
D005680_D001919 NONE acid_29\NN\14818238|NONE_0 (r_pobj) of_24\IN\0|decreased_20 (r_prep) synthesis_23\NN\13446390|NONE_0 (r_pobj) to_21\IN\0|NONE_0 (r_prep) attributed_20\VBN\670261|an_15 (r_acl) interaction_19\NN\37396|high_135|of_124|hypotension_102|,_5|._85 (r_appos) doses_1\NNS\3740161|NONE_0 (l_appos) hypotension_5\NN\14057371|high_33|of_22|,_97|interaction_102|._187 (l_conj) change_10\VB\7283608|increase_49|induced_28|and_4 (l_prep) to_15\IN\0|tachycardia_12 (l_pobj) bradycardia_16\NNP\14110674|NONE_0
D005680_D001919 NONE gaba_31\NNP\14601829|brain_31|aminobutyric_19 (r_appos) acid_29\NN\14818238|NONE_0 (r_pobj) of_24\IN\0|decreased_20 (r_prep) synthesis_23\NN\13446390|NONE_0 (r_pobj) to_21\IN\0|NONE_0 (r_prep) attributed_20\VBN\670261|an_15 (r_acl) interaction_19\NN\37396|high_135|of_124|hypotension_102|,_5|._85 (r_appos) doses_1\NNS\3740161|NONE_0 (l_appos) hypotension_5\NN\14057371|high_33|of_22|,_97|interaction_102|._187 (l_conj) change_10\VB\7283608|increase_49|induced_28|and_4 (l_prep) to_15\IN\0|tachycardia_12 (l_pobj) bradycardia_16\NNP\14110674|NONE_0
D007538_D001919 CID isoniazid_12\NN\2716205|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) pretreated_10\VBD\0|NONE_0 (r_acl) rats_9\NNS\2329401|NONE_0 (r_pobj) in_8\IN\13603305|adrenoceptor_25 (r_prep) antagonists_7\NNS\7846|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|enhanced_21|._74 (r_acl) bradycardia_1\NNS\14110674|NONE_0
D007538_D001919 CID isoniazid_3\NN\2716205|NONE_0 (r_pobj) of_2\IN\0|high_11|hypotension_22|,_119|interaction_124|._209 (r_prep) doses_1\NNS\3740161|NONE_0 (l_appos) hypotension_5\NN\14057371|high_33|of_22|,_97|interaction_102|._187 (l_conj) change_10\VB\7283608|increase_49|induced_28|and_4 (l_prep) to_15\IN\0|tachycardia_12 (l_pobj) bradycardia_16\NNP\14110674|NONE_0
D007538_D001919 CID isoniazid_9\NN\2716205|NONE_0 (l_prep) of_10\IN\0|NONE_0 (l_pobj) bradycardia_11\NN\14110674|NONE_0
D007538_D001919 CID isoniazid_0\NNP\2716205|significantly_10|bradycardia_34|propranolol_52|,_97|as_107|,_125|but_127|after_135|._167 (r_nsubj) increased_2\VBD\169651|NONE_0 (l_acomp) bradycardia_3\NNP\14110674|isoniazid_34|significantly_24|propranolol_18|,_63|as_73|,_91|but_93|after_101|._133
D018738_D001919 NONE hexamethonium_22\NN\0|not_10 (r_pobj) after_21\IN\0|isoniazid_135|significantly_125|bradycardia_101|propranolol_83|,_38|as_28|,_10|but_8|._32 (r_conj) increased_2\VBD\169651|NONE_0 (l_acomp) bradycardia_3\NNP\14110674|isoniazid_34|significantly_24|propranolol_18|,_63|as_73|,_91|but_93|after_101|._133
D001262_D001919 NONE atenolol_11\NN\2832168|and_4 (r_conj) labetalol_9\JJ\2721160|,_2 (r_conj) pindolol_7\NN\2832168|after_19|,_2 (r_conj) propranolol_5\NN\0|isoniazid_52|significantly_42|bradycardia_18|,_45|as_55|,_73|but_75|after_83|._115 (r_advcl) increased_2\VBD\169651|NONE_0 (l_acomp) bradycardia_3\NNP\14110674|isoniazid_34|significantly_24|propranolol_18|,_63|as_73|,_91|but_93|after_101|._133
D003000_D001919 NONE clonidine_17\NN\2721160|NONE_0 (r_pobj) after_16\IN\0|as_11|well_8 (r_prep) as_15\IN\14622893|isoniazid_107|significantly_97|bradycardia_73|propranolol_55|,_10|,_18|but_20|after_28|._60 (r_cc) increased_2\VBD\169651|NONE_0 (l_acomp) bradycardia_3\NNP\14110674|isoniazid_34|significantly_24|propranolol_18|,_63|as_73|,_91|but_93|after_101|._133
D007538_D013610 NONE isoniazid_3\NN\2716205|NONE_0 (r_pobj) of_2\IN\0|high_11|hypotension_22|,_119|interaction_124|._209 (r_prep) doses_1\NNS\3740161|NONE_0 (l_appos) hypotension_5\NN\14057371|high_33|of_22|,_97|interaction_102|._187 (l_conj) change_10\VB\7283608|increase_49|induced_28|and_4 (l_dobj) tachycardia_14\NN\14110674|to_12
D007538_D007022 CID isoniazid_3\NN\2716205|NONE_0 (r_pobj) of_2\IN\0|high_11|hypotension_22|,_119|interaction_124|._209 (r_prep) doses_1\NNS\3740161|NONE_0 (l_appos) hypotension_5\NN\14057371|high_33|of_22|,_97|interaction_102|._187
D011433_D001919 NONE propranolol_5\NN\0|isoniazid_52|significantly_42|bradycardia_18|,_45|as_55|,_73|but_75|after_83|._115 (r_advcl) increased_2\VBD\169651|NONE_0 (l_acomp) bradycardia_3\NNP\14110674|isoniazid_34|significantly_24|propranolol_18|,_63|as_73|,_91|but_93|after_101|._133
D007741_D001919 NONE labetalol_9\JJ\2721160|,_2 (r_conj) pindolol_7\NN\2832168|after_19|,_2 (r_conj) propranolol_5\NN\0|isoniazid_52|significantly_42|bradycardia_18|,_45|as_55|,_73|but_75|after_83|._115 (r_advcl) increased_2\VBD\169651|NONE_0 (l_acomp) bradycardia_3\NNP\14110674|isoniazid_34|significantly_24|propranolol_18|,_63|as_73|,_91|but_93|after_101|._133
D010869_D001919 NONE pindolol_7\NN\2832168|after_19|,_2 (r_conj) propranolol_5\NN\0|isoniazid_52|significantly_42|bradycardia_18|,_45|as_55|,_73|but_75|after_83|._115 (r_advcl) increased_2\VBD\169651|NONE_0 (l_acomp) bradycardia_3\NNP\14110674|isoniazid_34|significantly_24|propranolol_18|,_63|as_73|,_91|but_93|after_101|._133
D014520_D001919 NONE urethane_26\NN\14850483|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) anaesthetised_22\VBN\84738|NONE_0 (r_acl) rats_21\NNS\2329401|NONE_0 (r_pobj) in_20\IN\13603305|in_131|,_111|enhancement_96|was_15|._46 (r_prep) determined_19\VBN\0|NONE_0 (l_nsubjpass) enhancement_7\NN\248977|in_35|,_15|was_81|in_96|._142 (l_prep) by_8\IN\0|the_25|possible_21|induced_28 (l_pobj) isoniazid_9\NN\2716205|NONE_0 (l_prep) of_10\IN\0|NONE_0 (l_pobj) bradycardia_11\NN\14110674|NONE_0
D005680_D007022 NONE acid_29\NN\14818238|NONE_0 (r_pobj) of_24\IN\0|decreased_20 (r_prep) synthesis_23\NN\13446390|NONE_0 (r_pobj) to_21\IN\0|NONE_0 (r_prep) attributed_20\VBN\670261|an_15 (r_acl) interaction_19\NN\37396|high_135|of_124|hypotension_102|,_5|._85 (r_appos) doses_1\NNS\3740161|NONE_0 (l_appos) hypotension_5\NN\14057371|high_33|of_22|,_97|interaction_102|._187
D005680_D007022 NONE gaba_31\NNP\14601829|brain_31|aminobutyric_19 (r_appos) acid_29\NN\14818238|NONE_0 (r_pobj) of_24\IN\0|decreased_20 (r_prep) synthesis_23\NN\13446390|NONE_0 (r_pobj) to_21\IN\0|NONE_0 (r_prep) attributed_20\VBN\670261|an_15 (r_acl) interaction_19\NN\37396|high_135|of_124|hypotension_102|,_5|._85 (r_appos) doses_1\NNS\3740161|NONE_0 (l_appos) hypotension_5\NN\14057371|high_33|of_22|,_97|interaction_102|._187
D002217_D001919 NONE carbachol_24\NN\0|or_3 (r_conj) hexamethonium_22\NN\0|not_10 (r_pobj) after_21\IN\0|isoniazid_135|significantly_125|bradycardia_101|propranolol_83|,_38|as_28|,_10|but_8|._32 (r_conj) increased_2\VBD\169651|NONE_0 (l_acomp) bradycardia_3\NNP\14110674|isoniazid_34|significantly_24|propranolol_18|,_63|as_73|,_91|but_93|after_101|._133
D002698_D001919 NONE chloralose_24\NN\0|-_10 (r_compound) urethane_26\NN\14850483|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) anaesthetised_22\VBN\84738|NONE_0 (r_acl) rats_21\NNS\2329401|NONE_0 (r_pobj) in_20\IN\13603305|in_131|,_111|enhancement_96|was_15|._46 (r_prep) determined_19\VBN\0|NONE_0 (l_nsubjpass) enhancement_7\NN\248977|in_35|,_15|was_81|in_96|._142 (l_prep) by_8\IN\0|the_25|possible_21|induced_28 (l_pobj) isoniazid_9\NN\2716205|NONE_0 (l_prep) of_10\IN\0|NONE_0 (l_pobj) bradycardia_11\NN\14110674|NONE_0
D005680_D013610 NONE acid_29\NN\14818238|NONE_0 (r_pobj) of_24\IN\0|decreased_20 (r_prep) synthesis_23\NN\13446390|NONE_0 (r_pobj) to_21\IN\0|NONE_0 (r_prep) attributed_20\VBN\670261|an_15 (r_acl) interaction_19\NN\37396|high_135|of_124|hypotension_102|,_5|._85 (r_appos) doses_1\NNS\3740161|NONE_0 (l_appos) hypotension_5\NN\14057371|high_33|of_22|,_97|interaction_102|._187 (l_conj) change_10\VB\7283608|increase_49|induced_28|and_4 (l_dobj) tachycardia_14\NN\14110674|to_12
D005680_D013610 NONE gaba_31\NNP\14601829|brain_31|aminobutyric_19 (r_appos) acid_29\NN\14818238|NONE_0 (r_pobj) of_24\IN\0|decreased_20 (r_prep) synthesis_23\NN\13446390|NONE_0 (r_pobj) to_21\IN\0|NONE_0 (r_prep) attributed_20\VBN\670261|an_15 (r_acl) interaction_19\NN\37396|high_135|of_124|hypotension_102|,_5|._85 (r_appos) doses_1\NNS\3740161|NONE_0 (l_appos) hypotension_5\NN\14057371|high_33|of_22|,_97|interaction_102|._187 (l_conj) change_10\VB\7283608|increase_49|induced_28|and_4 (l_dobj) tachycardia_14\NN\14110674|to_12
6496797
D014196_D006327 CID trazodone_8\NN\3829085|NONE_0 (r_pobj) of_7\IN\0|a_14|single_12 (r_prep) dose_6\NN\3740161|NONE_0 (r_pobj) following_3\VBG\8180190|complete_21|heart_12|._36 (r_prep) block_2\NN\21939|NONE_0
D014196_D006327 CID trazodone_9\NN\3829085|NONE_0 (r_pobj) of_8\IN\0|a_23|single_21|starting_14 (r_prep) dose_7\NN\3740161|NONE_0 (r_dobj) receiving_3\VBG\2210855|minutes_14 (r_pcomp) after_2\IN\0|,_51|patient_55|block_88|._93 (r_prep) developed_13\VBD\1753788|NONE_0 (l_dobj) block_16\NN\21939|after_88|,_37|patient_33|._5
7604176
D017035_D009220 CID pravastatin_11\NN\3676175|NONE_0 (r_pobj) of_10\IN\0|the_8 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|a_38|of_31|,_38|inhibitor_106 (r_acl) case_1\NN\7283608|,_151|is_153|._164 (l_prep) of_2\IN\0|a_7|associated_31|,_69|inhibitor_137 (l_pobj) myopathy_5\NNS\14204950|NONE_0
D017035_D009135 NONE pravastatin_0\NNP\3676175|-_11 (r_npadvmod) associated_2\VBN\628491|._19 (r_amod) myopathy_3\NN\14204950|NONE_0
D017035_D009135 NONE pravastatin_17\JJ\3676175|NONE_0 (r_amod) discontinuation_18\NN\209943|NONE_0 (r_pobj) after_16\IN\0|which_29|in_14 (r_prep) resolved_11\VBD\352826|the_22|lower_18 (r_relcl) limbs_9\NNS\5559908|NONE_0 (r_pobj) of_6\IN\0|acute_15 (r_prep) myopathy_5\NN\14204950|NONE_0
D017035_D009135 NONE pravastatin_11\RB\3676175|-_11 (r_npadvmod) associated_13\VBN\628491|NONE_0 (r_amod) myopathy_14\NNS\14204950|associated_55|,_25|could_9|entity_50|._56 (r_nsubj) represent_16\VB\2664769|NONE_0 (l_advcl) associated_6\VBN\628491|,_30|myopathy_55|could_64|entity_105|._111 (l_prep) with_7\IN\0|while_54|lovastatin_48|have_21|been_16 (l_pobj) myopathy_9\NNS\14204950|NONE_0
D017035_D009135 NONE pravastatin_11\RB\3676175|-_11 (r_npadvmod) associated_13\VBN\628491|NONE_0 (r_amod) myopathy_14\NNS\14204950|associated_55|,_25|could_9|entity_50|._56
D019821_D009135 NONE simvastatin_3\NN\3676175|and_4 (r_conj) lovastatin_1\NN\3676175|while_6|have_27|been_32|with_48 (r_nsubjpass) associated_6\VBN\628491|,_30|myopathy_55|could_64|entity_105|._111 (l_prep) with_7\IN\0|while_54|lovastatin_48|have_21|been_16 (l_pobj) myopathy_9\NNS\14204950|NONE_0
D019821_D009135 NONE simvastatin_3\NN\3676175|and_4 (r_conj) lovastatin_1\NN\3676175|while_6|have_27|been_32|with_48 (r_nsubjpass) associated_6\VBN\628491|,_30|myopathy_55|could_64|entity_105|._111 (r_advcl) represent_16\VB\2664769|NONE_0 (l_nsubj) myopathy_14\NNS\14204950|associated_55|,_25|could_9|entity_50|._56
D008148_D009135 NONE lovastatin_1\NN\3676175|while_6|have_27|been_32|with_48 (r_nsubjpass) associated_6\VBN\628491|,_30|myopathy_55|could_64|entity_105|._111 (l_prep) with_7\IN\0|while_54|lovastatin_48|have_21|been_16 (l_pobj) myopathy_9\NNS\14204950|NONE_0
D008148_D009135 NONE lovastatin_1\NN\3676175|while_6|have_27|been_32|with_48 (r_nsubjpass) associated_6\VBN\628491|,_30|myopathy_55|could_64|entity_105|._111 (r_advcl) represent_16\VB\2664769|NONE_0 (l_nsubj) myopathy_14\NNS\14204950|associated_55|,_25|could_9|entity_50|._56
D017035_D006937 NONE pravastatin_2\RB\3676175|he_11|day_19|because_24|._55 (r_dobj) assumed_1\VBD\719734|NONE_0 (l_prep) because_9\IN\0|he_35|pravastatin_24|day_5|._31 (l_pobj) hypercholesterolemia_11\NN\14299637|of_3
20466178
D016559_D003872 NONE tacrolimus_5\NN\0|topical_8 (r_compound) treatment_6\NN\654885|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|rosaceiform_23|._44 (r_acl) dermatitis_1\NN\14226056|NONE_0
D016559_D003872 NONE tacrolimus_19\NN\0|%_10 (r_compound) ointment_20\NN\4074482|while_37|for_9 (r_dobj) using_13\VBG\418025|who_54|eruptions_16 (r_advcl) developed_6\VBD\1753788|3_15 (l_dobj) eruptions_11\NNS\7307754|who_38|using_16 (l_compound) dermatitis_10\NN\14226056|like_5
D016559_D003872 NONE tacrolimus_7\NN\0|such_8 (r_pobj) as_6\IN\14622893|NONE_0 (r_prep) immunomodulators_4\NNS\0|NONE_0 (r_pobj) of_3\IN\0|continuous_23|topical_12 (r_prep) use_2\NN\407535|should_59|be_66|as_78|,_124|reported_160|._168 (r_nsubjpass) regarded_12\VBN\689344|NONE_0 (l_prep) as_13\IN\14622893|use_78|should_19|be_12|,_46|reported_82|._90 (l_pobj) cause_16\NN\7323922|NONE_0 (l_prep) of_17\IN\0|a_18|potential_16 (l_pobj) dermatitis_19\NN\14226056|NONE_0
C117268_D003872 CID pimecrolimus_9\NN\0|or_3 (r_conj) tacrolimus_7\NN\0|such_8 (r_pobj) as_6\IN\14622893|NONE_0 (r_prep) immunomodulators_4\NNS\0|NONE_0 (r_pobj) of_3\IN\0|continuous_23|topical_12 (r_prep) use_2\NN\407535|should_59|be_66|as_78|,_124|reported_160|._168 (r_nsubjpass) regarded_12\VBN\689344|NONE_0 (l_prep) as_13\IN\14622893|use_78|should_19|be_12|,_46|reported_82|._90 (l_pobj) cause_16\NN\7323922|NONE_0 (l_prep) of_17\IN\0|a_18|potential_16 (l_pobj) dermatitis_19\NN\14226056|NONE_0
D016559_D003875 NONE tacrolimus_19\NN\0|%_10 (r_compound) ointment_20\NN\4074482|while_37|for_9 (r_dobj) using_13\VBG\418025|who_54|eruptions_16 (r_advcl) developed_6\VBD\1753788|3_15 (l_dobj) eruptions_11\NNS\7307754|who_38|using_16
D016559_D005148 NONE tacrolimus_19\NN\0|%_10 (r_compound) ointment_20\NN\4074482|while_37|for_9 (r_dobj) using_13\VBG\418025|who_54|eruptions_16 (l_prep) for_21\IN\0|while_46|ointment_9 (l_pobj) dermatitis_23\NN\14226056|NONE_0
D016559_D012393 NONE tacrolimus_19\NN\0|%_10 (r_compound) ointment_20\NN\4074482|while_37|for_9 (r_dobj) using_13\VBG\418025|who_54|eruptions_16 (r_advcl) developed_6\VBD\1753788|3_15 (l_dobj) eruptions_11\NNS\7307754|who_38|using_16 (l_amod) like_9\JJ\5839024|dermatitis_5 (l_npadvmod) rosacea_7\NN\14222112|-_7
663266
D003974_D014693 NONE renografin_7\NNP\0|NONE_0 (r_pobj) with_6\IN\0|fibrillation_47|often_6|,_15|suggesting_17|._96 (r_prep) occurred_2\VBD\0|NONE_0 (l_nsubj) fibrillation_1\NN\14361664|often_41|with_47|,_62|suggesting_64|._143
C027278_D064420 NONE %_5\NN\0|the_29|of_16 (r_appos) toxicity_1\NN\13576101|was_27|with_40|%_63|into_96|._134
C027278_D064420 NONE %_13\NN\0|toxicity_63|was_36|with_23|into_33|._71 (r_npadvmod) compared_7\VBN\644583|NONE_0 (l_nsubjpass) toxicity_1\NN\13576101|was_27|with_40|%_63|into_96|._134
D003973_D014693 NONE diatrizoate_3\JJ\0|with_12 (r_pobj) from_2\IN\0|ventricular_25|._50 (r_prep) fibrillation_1\NN\14361664|NONE_0
D003974_D064420 NONE renografin_7\NNP\0|NONE_0 (r_pobj) with_6\IN\0|fibrillation_47|often_6|,_15|suggesting_17|._96 (r_prep) occurred_2\VBD\0|NONE_0 (l_advcl) suggesting_9\VBG\1010118|fibrillation_64|often_23|with_17|,_2|._79 (l_ccomp) contribute_13\VBP\126264|NONE_0 (l_prep) to_14\IN\0|that_33|agents_18|in_12 (l_pobj) toxicity_15\NN\13576101|NONE_0
15638391
D006220_D006966 CID haloperidol_16\NN\3713736|NONE_0 (r_pobj) by_15\IN\0|process_104|._14 (r_agent) induced_14\VBN\1627355|NONE_0 (l_nsubj) process_1\NN\407535|by_104|._118 (l_prep) of_2\IN\0|aging_14 (l_pobj) cells_4\NNS\3080309|NONE_0 (l_prep) of_5\IN\0|epithelial_17 (l_pobj) lobe_10\NN\5220461|NONE_0 (l_prep) in_11\IN\13603305|the_30|rat_26|prostate_22|lateral_13 (l_pobj) hyperprolactinemia_13\NN\0|NONE_0
D006220_D006966 CID haloperidol_15\NN\3713736|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|aim_69|examine_45|._124 (r_advcl) was_5\VBD\0|NONE_0 (l_xcomp) examine_7\VB\0|aim_24|induced_45|._169 (l_dobj) influence_9\NN\5190804|to_15|,_31 (l_prep) of_10\IN\0|the_14 (l_pobj) hyperprolactinemia_11\NN\0|NONE_0
D006220_D006966 CID hal_17\NNP\0|on_5 (r_appos) haloperidol_15\NN\3713736|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|aim_69|examine_45|._124 (r_advcl) was_5\VBD\0|NONE_0 (l_xcomp) examine_7\VB\0|aim_24|induced_45|._169 (l_dobj) influence_9\NN\5190804|to_15|,_31 (l_prep) of_10\IN\0|the_14 (l_pobj) hyperprolactinemia_11\NN\0|NONE_0
15266362
D004280_D004342 CID dobutamine_13\NN\0|that_68|hypersensitivity_59|was_15 (r_xcomp) related_11\VBN\628491|NONE_0 (l_nsubjpass) hypersensitivity_5\NN\14531772|that_9|was_44|dobutamine_59
D004280_D004802 CID dobutamine_13\NN\0|that_68|hypersensitivity_59|was_15 (r_xcomp) related_11\VBN\628491|NONE_0 (l_nsubjpass) hypersensitivity_5\NN\14531772|that_9|was_44|dobutamine_59 (l_amod) eosinophilic_7\JJ\0|the_22|(_1|)_12|myocarditis_14
D004280_D018754 NONE dobutamine_22\NN\0|and_20|drugs_30 (r_compound) infusion_23\NN\14589223|NONE_0 (r_pobj) with_21\IN\0|aggressively_13|assessed_53 (r_prep) managed_19\VBD\2524171|patient_96|was_44|with_31|and_4|._108 (r_conj) admitted_14\VBN\822367|NONE_0 (l_prep) with_15\IN\0|patient_65|was_13|and_27|managed_31|._139 (l_pobj) failure_17\NN\66216|NONE_0
D004280_D009205 CID dobutamine_13\NN\0|that_68|hypersensitivity_59|was_15 (r_xcomp) related_11\VBN\628491|NONE_0 (l_nsubjpass) hypersensitivity_5\NN\14531772|that_9|was_44|dobutamine_59 (l_amod) myocarditis_9\NN\14338942|the_36|(_15|eosinophilic_14|)_2
D004280_D002312 NONE dobutamine_22\NN\0|and_20|drugs_30 (r_compound) infusion_23\NN\14589223|NONE_0 (r_pobj) with_21\IN\0|aggressively_13|assessed_53 (r_prep) managed_19\VBD\2524171|patient_96|was_44|with_31|and_4|._108 (r_conj) admitted_14\VBN\822367|NONE_0 (l_nsubjpass) patient_5\NN\9898892|was_52|with_65|and_92|managed_96|._204 (l_acl) known_7\VBN\0|the_32|old_20|female_16|,_2|,_41 (l_xcomp) have_9\VB\7846|NONE_0 (l_dobj) cardiomyopathy_11\NN\14103288|to_21
2004015
D015215_D007239 NONE azt_28\NNP\3834836|-_3 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) anaemia_31\NN\14299637|if_15|due_11|,_14|in_16 (r_nsubj) is_32\VBZ\0|to_36 (r_ccomp) determine_26\VB\0|we_116|have_113|model_94|,_5|decreased_53|._138 (r_xcomp) used_2\VBN\0|NONE_0 (l_dobj) model_5\NN\5888929|we_22|have_19|,_89|determine_94|decreased_147|._232 (l_prep) of_6\IN\0|a_15|murine_13 (l_pobj) aids_7\NNP\13974317|NONE_0 (l_appos) infection_9\NN\14052046|,_2
D015215_C565469 NONE azidothymidine_8\NN\0|sensitivity_66|mice_39|._43 (r_advmod) treated_9\VBN\2376958|NONE_0 (l_dobj) mice_11\NNS\2329401|sensitivity_105|azidothymidine_39|._4 (l_amod) immunodeficient_10\JJ\0|NONE_0
D015215_D000163 NONE azt_28\NNP\3834836|-_3 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) anaemia_31\NN\14299637|if_15|due_11|,_14|in_16 (r_nsubj) is_32\VBZ\0|to_36 (r_ccomp) determine_26\VB\0|we_116|have_113|model_94|,_5|decreased_53|._138 (r_xcomp) used_2\VBN\0|NONE_0 (l_dobj) model_5\NN\5888929|we_22|have_19|,_89|determine_94|decreased_147|._232 (l_prep) of_6\IN\0|a_15|murine_13 (l_pobj) aids_7\NNP\13974317|NONE_0
D015215_D000740 CID 3'-azido-3'dideoxythymidine_4\NN\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|the_12 (r_acl) anaemia_1\NN\14299637|is_53|poorly_56|._73
D015215_D000740 CID azt_6\NNP\3834836|NONE_0 (r_appos) 3'-azido-3'dideoxythymidine_4\NN\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|the_12 (r_acl) anaemia_1\NN\14299637|is_53|poorly_56|._73
D015215_D000740 CID azt_28\NNP\3834836|-_3 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) anaemia_31\NN\14299637|if_15|due_11|,_14|in_16
D015215_D000740 CID azt_0\NNP\3834836|anaemia_13|in_21|,_35|in_37|._64 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) anaemia_2\NN\14299637|azt_13|in_8|,_22|in_24|._51
D015215_D000740 CID azt_15\NNP\3834836|NONE_0 (r_pobj) in_14\IN\13603305|marrow_13|bfu_6|-_3 (r_prep) e_13\NNP\14724645|NONE_0 (r_pobj) of_6\IN\0|the_11 (r_prep) number_5\NN\5107765|despite_25|,_6|mice_55 (r_nsubj) treated_16\VBD\2376958|up_23|to_26|over_39|observed_51|._113 (l_prep) despite_0\IN\7501545|,_19|number_25|mice_80 (l_pobj) anaemia_2\NN\14299637|NONE_0
D015215_D000740 CID azt_8\NNP\3834836|NONE_0 (r_pobj) in_7\IN\13603305|levels_23|treated_7|were_20|treated_113|._125 (r_prep) observed_6\VBD\2163746|NONE_0 (l_conj) were_11\VBD\0|levels_43|in_20|treated_13|treated_93|._105 (l_acomp) appropriate_12\JJ\2228698|NONE_0 (l_prep) for_13\IN\0|NONE_0 (l_pobj) degree_15\NN\4916342|NONE_0 (l_prep) of_16\IN\0|the_11|observed_11 (l_pobj) anaemia_17\NN\14299637|NONE_0
D015215_D000740 CID azt_17\NNP\3834836|mice_20|with_25 (r_nsubj) treated_20\VBD\2376958|numbers_105|were_31|._44 (l_prep) with_22\IN\0|azt_25|mice_5 (l_pobj) degrees_24\NNS\4916342|NONE_0 (l_prep) of_25\IN\0|similar_16 (l_pobj) anaemia_26\NN\14299637|NONE_0
D015215_D000740 CID azt_12\NNP\3834836|NONE_0 (r_pobj) in_11\IN\13603305|NONE_0 (r_prep) observed_10\VBN\2163746|the_22|of_11 (r_acl) degree_7\NN\4916342|NONE_0 (l_prep) of_8\IN\0|the_11|observed_11 (l_pobj) anaemia_9\NN\14299637|NONE_0
D015215_D000740 CID azt_0\NNP\3834836|-_3|anaemia_23|in_31|and_73|levels_87 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) anaemia_4\NN\14299637|azt_23|-_20|in_8|and_50|levels_64
D015215_D007938 NONE azt_28\NNP\3834836|-_3 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) anaemia_31\NN\14299637|if_15|due_11|,_14|in_16 (r_nsubj) is_32\VBZ\0|to_36 (r_ccomp) determine_26\VB\0|we_116|have_113|model_94|,_5|decreased_53|._138 (r_xcomp) used_2\VBN\0|NONE_0 (l_dobj) model_5\NN\5888929|we_22|have_19|,_89|determine_94|decreased_147|._232 (l_prep) of_6\IN\0|a_15|murine_13 (l_pobj) aids_7\NNP\13974317|NONE_0 (l_appos) infection_9\NN\14052046|,_2 (l_prep) of_10\IN\0|NONE_0 (l_pobj) mice_13\NNS\2329401|NONE_0 (l_prep) with_14\IN\0|female_20|c57bl/6_13 (l_pobj) leukaemia_19\NN\14239918|NONE_0
D015215_D045262 NONE azt_12\NNP\3834836|NONE_0 (r_pobj) in_11\IN\13603305|NONE_0 (r_prep) observed_10\VBN\2163746|the_22|of_11 (r_acl) degree_7\NN\4916342|NONE_0 (r_pobj) for_5\IN\0|NONE_0 (r_prep) inappropriate_4\JJ\0|however_29|,_22|reticulocytosis_20|treated_56|._77 (r_acomp) was_3\VBD\0|NONE_0 (l_nsubj) reticulocytosis_2\NN\0|however_9|,_2|inappropriate_20|treated_76|._97
C030299_D000740 NONE phenylhydrazine_22\NN\0|(_16|phz_17|)_20|mice_30 (r_npadvmod) treated_26\VBD\2376958|levels_136|in_113|treated_106|were_93|._12 (r_conj) observed_6\VBD\2163746|NONE_0 (l_conj) were_11\VBD\0|levels_43|in_20|treated_13|treated_93|._105 (l_acomp) appropriate_12\JJ\2228698|NONE_0 (l_prep) for_13\IN\0|NONE_0 (l_pobj) degree_15\NN\4916342|NONE_0 (l_prep) of_16\IN\0|the_11|observed_11 (l_pobj) anaemia_17\NN\14299637|NONE_0
C030299_D000740 NONE phz_24\NNP\0|phenylhydrazine_17|(_1|)_3|mice_13 (r_nsubj) treated_26\VBD\2376958|levels_136|in_113|treated_106|were_93|._12 (r_conj) observed_6\VBD\2163746|NONE_0 (l_conj) were_11\VBD\0|levels_43|in_20|treated_13|treated_93|._105 (l_acomp) appropriate_12\JJ\2228698|NONE_0 (l_prep) for_13\IN\0|NONE_0 (l_pobj) degree_15\NN\4916342|NONE_0 (l_prep) of_16\IN\0|the_11|observed_11 (l_pobj) anaemia_17\NN\14299637|NONE_0
C030299_D000740 NONE phz_19\NNP\0|and_4 (r_conj) azt_17\NNP\3834836|mice_20|with_25 (r_nsubj) treated_20\VBD\2376958|numbers_105|were_31|._44 (l_prep) with_22\IN\0|azt_25|mice_5 (l_pobj) degrees_24\NNS\4916342|NONE_0 (l_prep) of_25\IN\0|similar_16 (l_pobj) anaemia_26\NN\14299637|NONE_0
188339
D013256_D008113 NONE steroids_19\NNS\14727670|NONE_0 (r_dobj) using_16\VBG\418025|within_90|,_61|previously_59|tumors_37|have_30|been_25|in_15|._33 (r_advcl) seen_12\VBN\2106506|NONE_0 (l_nsubjpass) tumors_9\NNS\14234074|within_53|,_24|previously_22|have_7|been_12|in_22|using_37|._70
D003276_D008113 CID contraceptives_11\NNS\3183080|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) associated_8\VBN\628491|liver_13 (r_acl) tumors_7\NNS\14234074|NONE_0
D003276_D008113 CID contraceptive_18\JJ\3183080|oral_5 (r_amod) steroids_19\NNS\14727670|NONE_0 (r_dobj) using_16\VBG\418025|within_90|,_61|previously_59|tumors_37|have_30|been_25|in_15|._33 (r_advcl) seen_12\VBN\2106506|NONE_0 (l_nsubjpass) tumors_9\NNS\14234074|within_53|,_24|previously_22|have_7|been_12|in_22|using_37|._70
6293644
D006220_D002375 CID haloperidol_7\NN\3713736|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) catalepsy_10\NN\14023236|NONE_0
D001058_D006948 CID apomorphine_16\NN\3786417|-_11 (r_npadvmod) induced_18\VBN\1627355|NONE_0 (r_amod) hyperactivity_19\NN\14052403|NONE_0
D001058_D002375 NONE apomorphine_16\NN\3786417|-_11 (r_npadvmod) induced_18\VBN\1627355|NONE_0 (r_amod) hyperactivity_19\NN\14052403|NONE_0 (r_pobj) of_15\IN\0|a_21|partial_19 (r_prep) prevention_14\NN\1073995|a_62|of_47|and_14 (r_conj) potentiation_5\NN\13564910|NONE_0 (l_prep) of_6\IN\0|a_15|and_33|prevention_47 (l_pobj) catalepsy_10\NN\14023236|NONE_0
D006220_D006948 NONE haloperidol_7\NN\3713736|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) catalepsy_10\NN\14023236|NONE_0 (r_pobj) of_6\IN\0|a_15|and_33|prevention_47 (r_prep) potentiation_5\NN\13564910|NONE_0 (l_conj) prevention_14\NN\1073995|a_62|of_47|and_14 (l_prep) of_15\IN\0|a_21|partial_19 (l_pobj) hyperactivity_19\NN\14052403|NONE_0
11243580
D009569_D012640 NONE oxide_20\NN\14818238|methyl_31|(_18|name_15|)_11 (r_appos) ester_12\NN\14727670|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|,_121|were_123|on_141|._173 (r_nsubjpass) investigated_36\VBN\644583|NONE_0 (l_prep) on_37\IN\0|effects_141|,_20|were_18|._32 (l_pobj) convulsions_41\NNS\14081375|NONE_0
D009569_D012640 NONE no_22\NNP\7204911|)_2|synthase_4|and_23|arginine_29 (r_intj) inhibitor_25\NN\20090|a_29|nitric_27|(_14|,_24|precursor_31 (r_appos) oxide_20\NN\14818238|methyl_31|(_18|name_15|)_11 (r_appos) ester_12\NN\14727670|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|,_121|were_123|on_141|._173 (r_nsubjpass) investigated_36\VBN\644583|NONE_0 (l_prep) on_37\IN\0|effects_141|,_20|were_18|._32 (l_pobj) convulsions_41\NNS\14081375|NONE_0
D009569_D012640 NONE no_32\JJ\7204911|a_2 (r_det) precursor_33\NN\14580897|a_60|nitric_58|(_45|inhibitor_31|,_7 (r_appos) oxide_20\NN\14818238|methyl_31|(_18|name_15|)_11 (r_appos) ester_12\NN\14727670|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|,_121|were_123|on_141|._173 (r_nsubjpass) investigated_36\VBN\644583|NONE_0 (l_prep) on_37\IN\0|effects_141|,_20|were_18|._32 (l_pobj) convulsions_41\NNS\14081375|NONE_0
D009569_D012640 NONE no_5\DT\7204911|that_5|mediator_22 (r_nsubj) is_6\VBZ\0|results_28|may_20|._60 (l_attr) mediator_9\NN\10351874|that_27|no_22 (l_prep) in_10\IN\13603305|a_25|proconvulsant_23 (l_pobj) convulsions_14\NNS\14081375|NONE_0
D001120_D012640 NONE arginine_29\NN\14605787|no_29|)_27|synthase_25|and_6 (r_conj) inhibitor_25\NN\20090|a_29|nitric_27|(_14|,_24|precursor_31 (r_appos) oxide_20\NN\14818238|methyl_31|(_18|name_15|)_11 (r_appos) ester_12\NN\14727670|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|,_121|were_123|on_141|._173 (r_nsubjpass) investigated_36\VBN\644583|NONE_0 (l_prep) on_37\IN\0|effects_141|,_20|were_18|._32 (l_pobj) convulsions_41\NNS\14081375|NONE_0
D001120_D012640 NONE arginine_6\NN\14605787|the_6 (r_compound) treatment_7\NN\654885|in_28|,_17|incidence_24|._97 (r_nsubj) increased_8\VBD\169651|NONE_0 (l_dobj) incidence_10\NN\13821570|in_52|,_41|treatment_24|._73 (l_appos) convulsions_18\NNS\14081375|the_52|of_38|(_25|mg/kg_21|,_16
D019331_D012640 NONE ester_12\NN\14727670|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|,_121|were_123|on_141|._173 (r_nsubjpass) investigated_36\VBN\644583|NONE_0 (l_prep) on_37\IN\0|effects_141|,_20|were_18|._32 (l_pobj) convulsions_41\NNS\14081375|NONE_0
D019331_D012640 NONE name_16\NN\6284225|methyl_16|(_3|)_4|oxide_15 (r_appos) ester_12\NN\14727670|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|,_121|were_123|on_141|._173 (r_nsubjpass) investigated_36\VBN\644583|NONE_0 (l_prep) on_37\IN\0|effects_141|,_20|were_18|._32 (l_pobj) convulsions_41\NNS\14081375|NONE_0
D019331_D012640 NONE name_2\NNP\6284225|significantly_46|incidence_74|._127 (r_nsubj) decreased_16\VBD\169651|NONE_0 (l_dobj) incidence_18\NN\13821570|name_74|significantly_28|._53 (l_appos) convulsions_26\NNS\14081375|the_46|of_32
D003975_D012640 NONE diazepam_10\NN\2830852|l_29|-_28|mg/kg_17|i.p._10|)_6|and_4 (r_conj) name_2\NNP\6284225|significantly_46|incidence_74|._127 (r_nsubj) decreased_16\VBD\169651|NONE_0 (l_dobj) incidence_18\NN\13821570|name_74|significantly_28|._53 (l_appos) convulsions_26\NNS\14081375|the_46|of_32
D008012_D012640 CID lidocaine_6\NN\3681148|-_9 (r_npadvmod) induced_8\VBN\1627355|in_19 (r_amod) convulsion_9\NN\14081375|NONE_0
D008012_D012640 CID lidocaine_38\NN\3681148|-_9 (r_npadvmod) induced_40\VBN\1627355|NONE_0 (r_amod) convulsions_41\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine_20\NN\3681148|NONE_0 (r_pobj) of_19\IN\0|the_14|convulsions_32 (r_prep) incidence_18\NN\13821570|name_74|significantly_28|._53 (l_appos) convulsions_26\NNS\14081375|the_46|of_32
D008012_D012640 CID lidocaine_12\NN\3681148|NONE_0 (r_pobj) of_11\IN\0|the_14|(_13|mg/kg_17|,_22|convulsions_38 (r_prep) incidence_10\NN\13821570|in_52|,_41|treatment_24|._73 (l_appos) convulsions_18\NNS\14081375|the_52|of_38|(_25|mg/kg_21|,_16
D008012_D012640 CID lidocaine_11\NN\3681148|-_9 (r_npadvmod) induced_13\VBN\1627355|NONE_0 (r_amod) convulsions_14\NNS\14081375|NONE_0
326460
D001539_D007008 CID bendrofluazide_2\NN\0|-_14 (r_advmod) induced_4\VBN\1627355|NONE_0 (r_amod) hypokalemia_5\NN\14299637|NONE_0
D001539_D007008 CID bendrofluazide_17\NN\0|term_5|in_25 (r_amod) treatment_18\NN\654885|NONE_0 (r_pobj) of_13\IN\0|the_16 (r_prep) hypokalemia_12\NN\14299637|to_15
D013999_D007008 NONE timolol_7\NN\2832168|NONE_0 (r_pobj) by_6\IN\0|of_38|._10 (r_prep) amelioration_0\NN\248977|NONE_0 (l_prep) of_1\IN\0|by_38|._48 (l_pobj) hypokalemia_5\NN\14299637|NONE_0
D013999_D007008 NONE timolol_6\NN\2832168|the_35|beta_31|blocking_15|,_2|,_7 (r_appos) drug_4\NN\14778436|correct_25|and_115|was_152 (r_nsubj) tended_8\VBD\2604760|NONE_0 (l_xcomp) correct_10\VB\138508|drug_25|and_90|was_127 (l_dobj) hypokalemia_12\NN\14299637|to_15
17923537
D005446_D009798 CID acetonide_21\NN\0|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treated_17\VBN\2376958|with_13 (r_acl) patients_14\NNS\9898892|NONE_0 (r_pobj) in_13\IN\13603305|the_68|and_54|management_50|of_39 (r_prep) incidence_3\NN\13821570|to_14|._154 (l_prep) of_6\IN\0|the_29|and_15|management_11|in_39 (l_pobj) pressure_9\NN\11419404|NONE_0
D005446_D009798 CID fa_23\NNP\6868043|(_1|)_2|intravitreal_4 (r_nmod) implant_26\NN\4013729|the_45|fluocinolone_41 (r_appos) acetonide_21\NN\0|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treated_17\VBN\2376958|with_13 (r_acl) patients_14\NNS\9898892|NONE_0 (r_pobj) in_13\IN\13603305|the_68|and_54|management_50|of_39 (r_prep) incidence_3\NN\13821570|to_14|._154 (l_prep) of_6\IN\0|the_29|and_15|management_11|in_39 (l_pobj) pressure_9\NN\11419404|NONE_0
D005446_D014605 NONE acetonide_9\NN\0|fluocinolone_13 (r_compound) implants_10\NNS\4013729|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) treated_6\VBN\2376958|intraocular_46|in_25|._44 (r_acl) pressure_1\NN\11419404|NONE_0 (l_prep) in_2\IN\13603305|intraocular_21|treated_25|._69 (l_pobj) patients_3\NNS\9898892|NONE_0 (l_prep) with_4\IN\0|NONE_0 (l_pobj) uveitis_5\NN\14336539|NONE_0
D005446_D014605 NONE acetonide_21\NN\0|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treated_17\VBN\2376958|with_13 (r_acl) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|treated_13 (l_pobj) uveitis_16\NN\14336539|NONE_0
D005446_D014605 NONE fa_23\NNP\6868043|(_1|)_2|intravitreal_4 (r_nmod) implant_26\NN\4013729|the_45|fluocinolone_41 (r_appos) acetonide_21\NN\0|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) treated_17\VBN\2376958|with_13 (r_acl) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|treated_13 (l_pobj) uveitis_16\NN\14336539|NONE_0
14736955
D013481_D007674 NONE superoxide_41\JJ\14971519|and_22|activities_30 (r_amod) production_42\NN\30358|NONE_0 (r_pobj) with_40\IN\0|injury_33|was_26|positively_22|._101 (r_prep) correlated_39\VBN\2657219|among_237|were_188|inversely_183|with_162|activities_111 (r_conj) correlated_10\VBN\2657219|NONE_0 (l_prep) among_0\IN\0|were_49|inversely_54|with_75|activities_126|correlated_237 (l_pobj) injury_7\NN\14052046|animals_32
D013481_D007674 NONE superoxide_25\NN\14971519|NONE_0 (l_prep) in_26\IN\13603305|NONE_0 (l_pobj) lesions_31\NNS\14204950|NONE_0
C102006_D007674 NONE citrate_32\NN\14850483|NONE_0 (r_compound) synthase_33\NN\0|increased_18 (r_compound) activity_34\NN\30358|depressed_119|of_98|and_31 (r_conj) activities_15\NNS\30358|significant_54|glomerular_42|,_12 (r_appos) lesions_12\NNS\14204950|group_45|._136
D004317_D009401 CID doxorubicin_10\NN\2716866|NONE_0 (r_compound) nephrosis_11\NN\14304060|NONE_0
D004317_D007674 NONE doxorubicin_0\NNP\2716866|nephropathy_40|._124 (r_nsubj) induces_1\VBZ\1627355|NONE_0 (l_dobj) nephropathy_6\NN\14573196|doxorubicin_40|._84
D004317_D007674 NONE doxorubicin_0\NNP\2716866|nephropathy_40|._124 (r_nsubj) induces_1\VBZ\1627355|NONE_0 (l_dobj) nephropathy_6\NN\14573196|doxorubicin_40|._84 (l_acl) characterized_7\VBN\609683|a_32|perpetuating_25 (l_agent) by_8\IN\0|NONE_0 (l_pobj) lesions_16\NNS\14204950|NONE_0
D004317_D007674 NONE doxorubicin_27\RB\2716866|-_11 (r_npadvmod) induced_29\VBN\1627355|renal_8 (r_amod) lesions_31\NNS\14204950|NONE_0
20727411
-1_D011605 NONE ketamine_5\NN\3054098|NONE_0 (r_pobj) of_2\IN\0|neural_18 (r_prep) correlates_1\NNS\5857459|psychosis_33|during_43|._81 (r_nsubj) induced_6\VBD\1627355|NONE_0 (l_dobj) psychosis_7\NN\14380140|correlates_33|during_10|._48
D016202_D012559 NONE aspartate_8\NNP\0|the_29|glutamatergic_25|(_10|nmda_11|)_15 (r_nmod) receptor_12\NN\5225602|has_9|been_13|in_29|._68 (r_nsubjpass) implicated_15\VBN\2677097|NONE_0 (l_prep) in_16\IN\13603305|receptor_29|has_20|been_16|._39 (l_pobj) pathophysiology_18\NN\0|NONE_0 (l_prep) of_19\IN\0|the_20 (l_pobj) schizophrenia_20\NN\14398067|NONE_0
D016202_D012559 NONE nmda_10\NNP\0|the_40|glutamatergic_36|aspartate_11|(_1|)_4 (r_nmod) receptor_12\NN\5225602|has_9|been_13|in_29|._68 (r_nsubjpass) implicated_15\VBN\2677097|NONE_0 (l_prep) in_16\IN\13603305|receptor_29|has_20|been_16|._39 (l_pobj) pathophysiology_18\NN\0|NONE_0 (l_prep) of_19\IN\0|the_20 (l_pobj) schizophrenia_20\NN\14398067|NONE_0
D016202_D012559 NONE nmda_13\NNP\0|competitive_12|receptor_5 (r_compound) antagonist_15\NN\7846|the_34 (r_compound) ketamine_16\NN\3054098|NONE_0 (r_pobj) of_8\IN\0|a_21|subanesthetic_19 (r_prep) dose_7\NN\3740161|administered_52|,_18|to_68|._141 (r_nsubj) leads_17\VBZ\5155821|NONE_0 (l_prep) to_18\IN\0|administered_120|,_86|dose_68|._73 (l_pobj) symptoms_20\NNS\5823932|NONE_0 (l_amod) similar_21\JJ\0|psychopathological_28 (l_prep) to_22\IN\0|NONE_0 (l_pobj) those_23\DT\0|NONE_0 (l_acl) observed_24\VBN\2163746|NONE_0 (l_prep) in_25\IN\13603305|NONE_0 (l_pobj) schizophrenia_26\NN\14398067|NONE_0
D016202_D012559 NONE nmda_10\NNP\0|an_3|receptor_5|in_26 (r_compound) dysfunction_12\NN\14204950|NONE_0 (l_prep) in_13\IN\13603305|an_29|nmda_26|receptor_21 (l_pobj) pathophysiology_15\NN\0|NONE_0 (l_prep) of_16\IN\0|the_20 (l_pobj) schizophrenia_17\NN\14398067|NONE_0
D007649_D011605 CID ketamine_0\NN\3054098|psychosis_18|._48 (r_nsubj) elicited_1\VBD\1617192|NONE_0 (l_dobj) psychosis_2\NN\14380140|ketamine_18|._30
D007649_D012559 NONE ketamine_16\NN\3054098|NONE_0 (r_pobj) of_8\IN\0|a_21|subanesthetic_19 (r_prep) dose_7\NN\3740161|administered_52|,_18|to_68|._141 (r_nsubj) leads_17\VBZ\5155821|NONE_0 (l_prep) to_18\IN\0|administered_120|,_86|dose_68|._73 (l_pobj) symptoms_20\NNS\5823932|NONE_0 (l_amod) similar_21\JJ\0|psychopathological_28 (l_prep) to_22\IN\0|NONE_0 (l_pobj) those_23\DT\0|NONE_0 (l_acl) observed_24\VBN\2163746|NONE_0 (l_prep) in_25\IN\13603305|NONE_0 (l_pobj) schizophrenia_26\NN\14398067|NONE_0
D007649_D012559 NONE ketamine_5\NN\3054098|in_32|,_2|symptoms_30|,_49|supporting_51|._107 (r_nsubj) exacerbates_6\VBZ\126264|NONE_0 (l_prep) in_0\IN\13603305|,_30|ketamine_32|symptoms_62|,_81|supporting_83|._139 (l_pobj) patients_1\NNS\9898892|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) schizophrenia_3\NN\14398067|NONE_0
D007649_D012559 NONE ketamine_0\NN\3054098|changes_28|,_112|in_127|._164 (r_nsubj) induces_1\VBZ\1627355|NONE_0 (l_dobj) changes_3\NNS\7283608|ketamine_28|,_84|in_99|._136 (l_prep) in_4\IN\13603305|activation_19 (l_pobj) subjects_6\NNS\6598915|NONE_0 (l_amod) similar_7\JJ\0|healthy_17 (l_prep) to_8\IN\0|NONE_0 (l_pobj) those_9\DT\0|NONE_0 (l_acl) observed_10\VBN\2163746|NONE_0 (l_prep) in_11\IN\13603305|NONE_0 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) schizophrenia_14\NN\14398067|NONE_0
D007649_D018754 NONE ketamine_5\NN\3054098|in_32|,_2|symptoms_30|,_49|supporting_51|._107 (r_nsubj) exacerbates_6\VBZ\126264|NONE_0 (l_advcl) supporting_13\VBG\407535|in_83|,_53|ketamine_51|symptoms_21|,_2|._56 (l_dobj) hypothesis_15\NN\7162194|NONE_0 (l_prep) of_16\IN\0|the_15 (l_pobj) dysfunction_19\NN\14204950|NONE_0
3969369
D013739_D063646 NONE testosterone_3\NN\14747587|NONE_0 (r_pobj) of_2\IN\0|promotional_20|on_32|._90 (r_prep) effects_1\NNS\13245626|NONE_0 (l_prep) on_7\IN\0|promotional_52|of_32|._58 (l_pobj) carcinogenesis_9\NN\0|NONE_0
D013739_D011471 CID testosterone_6\NN\14747587|NONE_0 (r_pobj) with_5\IN\0|at_18|months_27 (r_prep) implanted_4\VBN\1421622|lw_9|,_2|,_43 (r_acl) rats_2\NNS\2329401|incidence_70|after_99 (r_nsubj) developed_12\VBD\1753788|:_86|%_90|had_92|tumors_112|,_118|and_120|%_126|._163 (l_dobj) incidence_15\NN\13821570|rats_70|after_29 (l_prep) of_16\IN\0|a_19|higher_17 (l_pobj) cancer_18\NN\14239425|NONE_0
D013739_D011471 CID testosterone_4\NN\14747587|-_12 (r_npadvmod) treated_6\VBN\2376958|that_18|lw_8|fed_26 (r_amod) rats_8\NNS\2329401|results_46|._142 (l_relcl) fed_11\VBN\10373801|that_44|treated_26|lw_18 (l_dobj) diet_14\NN\7560652|that_23|were_18 (l_relcl) supplemented_18\VBN\182406|the_25|same_21|,_12 (l_dobj) fat_26\NN\14938907|which_47|was_41|with_24 (l_conj) cancer_30\NN\14239425|%_26|,_21
D013739_D009369 NONE testosterone_6\NN\14747587|NONE_0 (r_pobj) with_5\IN\0|at_18|months_27 (r_prep) implanted_4\VBN\1421622|lw_9|,_2|,_43 (r_acl) rats_2\NNS\2329401|incidence_70|after_99 (r_nsubj) developed_12\VBD\1753788|:_86|%_90|had_92|tumors_112|,_118|and_120|%_126|._163 (r_ccomp) developed_30\VBN\1753788|NONE_0 (l_dobj) tumors_32\NNS\14234074|developed_112|:_26|%_22|had_20|,_6|and_8|%_14|._51
D013739_D009369 NONE testosterone_6\NN\14747587|NONE_0 (r_pobj) with_5\IN\0|at_18|months_27 (r_prep) implanted_4\VBN\1421622|lw_9|,_2|,_43 (r_acl) rats_2\NNS\2329401|incidence_70|after_99 (r_nsubj) developed_12\VBD\1753788|:_86|%_90|had_92|tumors_112|,_118|and_120|%_126|._163 (r_ccomp) developed_30\VBN\1753788|NONE_0 (l_conj) %_36\NN\0|developed_126|:_40|%_36|had_34|tumors_14|,_8|and_6|._37 (l_advcl) included_39\VBD\0|40_12 (l_dobj) tumors_41\NNS\14234074|when_29|it_24
D013739_D011472 CID testosterone_9\NN\14747587|NONE_0 (r_pobj) with_8\IN\0|developed_18 (r_prep) treated_7\VBN\2376958|rats_24|diet_15|l-485_10|and_4|._52 (l_advcl) developed_10\VBD\1753788|with_18 (l_dobj) prostatitis_12\NN\14336539|NONE_0
2339463
D015119_D008595 NONE acid_22\NN\14818238|prolonged_31|aminocaproic_13|for_13 (r_compound) therapy_23\NN\657604|NONE_0 (l_prep) for_24\IN\0|prolonged_44|aminocaproic_26|acid_13 (l_pobj) menorrhagia_25\NN\13513747|NONE_0
D015119_D020227 NONE acid_22\NN\14818238|prolonged_31|aminocaproic_13|for_13 (r_compound) therapy_23\NN\657604|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) associated_16\VBN\628491|transverse_28|sinus_17 (r_acl) thrombosis_15\NN\14100769|NONE_0
D015119_D020225 NONE acid_22\NN\14818238|prolonged_31|aminocaproic_13|for_13 (r_compound) therapy_23\NN\657604|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) associated_16\VBN\628491|transverse_28|sinus_17 (r_acl) thrombosis_15\NN\14100769|NONE_0
D015119_D012851 NONE acid_15\NN\14818238|NONE_0 (l_appos) thrombosis_19\NN\14100769|aminocaproic_34|,_17
D015119_D013923 NONE acid_15\NN\14818238|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) treatment_10\NN\654885|NONE_0 (r_pobj) during_9\IN\0|increased_59|risk_49|has_18|been_14 (r_prep) reported_8\VBN\831651|has_84|not_88|been_92|previously_97|._117 (l_nsubjpass) risk_2\NN\14541044|increased_10|has_31|been_35|during_49 (l_prep) of_3\IN\0|NONE_0 (l_pobj) disease_5\NN\14061805|NONE_0
8268147
D010396_D003882 NONE penicillamine_14\NN\3740161|NONE_0 (r_compound) treatment_15\NN\654885|NONE_0 (r_pobj) of_11\IN\0|the_29|autoimmune_25 (r_prep) complications_10\NNS\1073995|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) one_6\CD\13741022|NONE_0 (r_pobj) as_5\IN\14622893|dermatomyositis_28|can_12|,_67|but_69|remains_96 (r_prep) develop_4\VB\1753788|NONE_0 (l_nsubj) dermatomyositis_2\NN\14350292|can_16|as_28|,_95|but_97|remains_124
D010396_D003882 NONE penicillamine_4\NN\3740161|NONE_0 (r_compound) therapy_5\NN\657604|NONE_0 (r_dobj) receiving_1\VBG\2210855|NONE_0 (r_acl) patients_0\NNS\9898892|should_43|be_50|carefully_62|for_72|._153 (r_nsubjpass) followed_8\VBN\1835496|NONE_0 (l_prep) for_10\IN\0|patients_72|should_29|be_22|carefully_10|._81 (l_pobj) development_12\NN\248977|NONE_0 (l_prep) of_13\IN\0|the_16 (l_pobj) complications_15\NNS\1073995|NONE_0 (l_prep) like_16\IN\5839024|autoimmune_25 (l_pobj) dermatomyositis_19\NN\14350292|NONE_0
D010396_D017285 CID penicillamine_15\NN\3740161|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treated_11\VBN\2376958|primary_26|biliary_18 (r_acl) cirrhosis_10\NN\14116321|NONE_0 (r_pobj) with_7\IN\0|a_10 (r_prep) patient_6\NN\9898892|NONE_0 (r_pobj) in_4\IN\13603305|a_23|of_16|._72 (r_prep) case_1\NN\7283608|NONE_0 (l_prep) of_2\IN\0|a_7|in_16|._88 (l_pobj) polymyositis_3\NN\14350292|NONE_0
D010396_D017285 CID penicillamine_14\NN\3740161|NONE_0 (r_compound) treatment_15\NN\654885|NONE_0 (r_pobj) of_11\IN\0|the_29|autoimmune_25 (r_prep) complications_10\NNS\1073995|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) one_6\CD\13741022|NONE_0 (r_pobj) as_5\IN\14622893|dermatomyositis_28|can_12|,_67|but_69|remains_96 (r_prep) develop_4\VB\1753788|NONE_0 (l_nsubj) dermatomyositis_2\NN\14350292|can_16|as_28|,_95|but_97|remains_124 (l_nmod) polymyositis_0\NNP\14350292|/_12
D010396_D017285 CID penicillamine_16\NN\3740161|NONE_0 (r_compound) therapy_17\NN\657604|while_32 (r_dobj) receiving_13\VBG\2210855|who_33|polymyositis_19 (r_advcl) developed_10\VBD\1753788|primary_31|biliary_23|,_6 (l_dobj) polymyositis_11\NN\14350292|who_14|receiving_19
D010396_D017285 CID penicillamine_4\NN\3740161|NONE_0 (r_compound) therapy_5\NN\657604|NONE_0 (r_dobj) receiving_1\VBG\2210855|NONE_0 (r_acl) patients_0\NNS\9898892|should_43|be_50|carefully_62|for_72|._153 (r_nsubjpass) followed_8\VBN\1835496|NONE_0 (l_prep) for_10\IN\0|patients_72|should_29|be_22|carefully_10|._81 (l_pobj) development_12\NN\248977|NONE_0 (l_prep) of_13\IN\0|the_16 (l_pobj) complications_15\NNS\1073995|NONE_0 (l_prep) like_16\IN\5839024|autoimmune_25 (l_pobj) dermatomyositis_19\NN\14350292|NONE_0 (l_nmod) polymyositis_17\NN\14350292|/_12
D010396_D012216 NONE penicillamine_3\NN\3740161|although_11|has_14|been_18|for_28 (r_nsubjpass) used_6\VBN\0|,_36|toxicity_38|usefulness_58|._85 (l_prep) for_7\IN\0|although_39|penicillamine_28|has_14|been_10 (l_pobj) diseases_10\NNS\14061805|NONE_0
D010396_D008105 NONE penicillamine_15\NN\3740161|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treated_11\VBN\2376958|primary_26|biliary_18 (r_acl) cirrhosis_10\NN\14116321|NONE_0
D010396_D008105 NONE penicillamine_16\NN\3740161|NONE_0 (r_compound) therapy_17\NN\657604|while_32 (r_dobj) receiving_13\VBG\2210855|who_33|polymyositis_19 (r_advcl) developed_10\VBD\1753788|primary_31|biliary_23|,_6 (r_relcl) cirrhosis_7\NN\14116321|NONE_0
D010396_D064420 NONE penicillamine_3\NN\3740161|although_11|has_14|been_18|for_28 (r_nsubjpass) used_6\VBN\0|,_36|toxicity_38|usefulness_58|._85 (r_advcl) limits_13\VBZ\5123416|NONE_0 (l_nsubj) toxicity_12\NN\13576101|used_38|,_2|usefulness_20|._47
9165568
D018967_D001480 NONE risperidone_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|the_45|low_41|of_27 (r_prep) frequency_9\NN\15286249|to_18 (l_prep) of_10\IN\0|the_18|low_14|with_27 (l_pobj) symptoms_12\NNS\5823932|NONE_0
D004298_D009459 NONE dopamine_10\NN\14807737|d2_9|receptor_12|in_30 (r_compound) blockade_13\NN\952963|NONE_0 (r_pobj) of_9\IN\0|a_9 (r_prep) result_8\NN\34213|to_8 (r_attr) be_6\VB\14625458|syndrome_23|is_14|._81 (r_xcomp) thought_4\VBN\5809192|NONE_0 (l_nsubjpass) syndrome_2\NN\5870365|is_9|be_23|._104
D018967_D009459 CID risperidone_4\NN\0|NONE_0 (r_pobj) with_3\IN\0|neuroleptic_31|malignant_19|._16 (r_prep) syndrome_2\NN\5870365|NONE_0
D018967_D009459 CID risperidone_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) monotherapy_10\NN\0|NONE_0 (r_pobj) after_9\IN\0|woman_47|syndrome_9|._34 (r_prep) developed_5\VBD\1753788|NONE_0 (l_dobj) syndrome_8\NN\5870365|woman_38|after_9|._43
D018967_D009459 CID risperidone_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|that_62|protection_53 (r_prep) observed_9\VBN\2163746|it_64|ensure_35|._88 (r_ccomp) appears_1\VBZ\2604760|NONE_0 (l_conj) ensure_14\VB\0|it_99|observed_35|._53 (l_dobj) protection_15\NN\407535|does_16|not_11 (l_prep) from_16\IN\0|NONE_0 (l_pobj) syndrome_19\NN\5870365|NONE_0
20164825
D008687_D014652 NONE metformin_3\NN\2719105|can_10|apoptosis_23|induced_33|and_82|prevent_86|._143 (r_nsubj) diminish_5\VB\169651|NONE_0 (l_conj) prevent_15\VB\0|metformin_86|can_76|apoptosis_63|induced_53|and_4|._57 (l_dobj) dysfunction_17\NN\14204950|in_17
D005839_D058186 CID gentamicin_4\NN\2716866|-_10 (r_npadvmod) mediated_6\VBN\761713|acute_9|renal_15 (r_amod) failure_9\NN\66216|treatment_56|fully_46|._7
D005839_D007674 NONE gentamicin_3\NN\2716866|-_10 (r_npadvmod) induced_5\VBN\1627355|experimental_24 (r_amod) nephropathy_6\NN\14573196|metformin_51|by_12|._47
D005839_D007674 NONE gentamicin_12\NN\2716866|NONE_0 (r_amod) nephrotoxicity_13\NN\0|that_60|effects_43|can_22|and_15|improve_19
D008687_D007674 NONE metformin_0\NNP\2719105|nephropathy_51|by_63|._98 (r_nsubj) prevents_1\VBZ\0|NONE_0 (l_dobj) nephropathy_6\NN\14573196|metformin_51|by_12|._47
D008687_D007674 NONE metformin_11\NN\2719105|NONE_0 (r_pobj) by_10\IN\0|their_17 (r_prep) correction_9\NN\248977|vivo_45|of_32|and_10 (r_conj) markers_3\NNS\21939|NONE_0 (l_prep) of_4\IN\0|vivo_13|and_22|correction_32 (l_pobj) dysfunction_6\NN\14204950|NONE_0
D008687_D007674 NONE metformin_9\NN\2719105|NONE_0 (r_pobj) of_8\IN\0|pleiotropic_20 (r_prep) effects_7\NNS\13245626|that_17|can_21|nephrotoxicity_43|and_58|improve_62 (r_nsubj) lessen_11\VB\169651|thus_67|,_63|study_57|._70 (l_dobj) nephrotoxicity_13\NN\0|that_60|effects_43|can_22|and_15|improve_19
D005839_D064420 NONE gentamicin_14\NN\2716866|NONE_0 (r_amod) toxicity_15\NN\13576101|NONE_0
D008687_D058186 NONE metformin_0\NNP\2719105|NONE_0 (r_compound) treatment_1\NN\654885|fully_10|failure_56|._63 (r_nsubj) blocked_3\VBD\1476483|NONE_0 (l_dobj) failure_9\NN\66216|treatment_56|fully_46|._7
6728084
D000617_D007674 NONE aminoglycoside_3\NN\0|on_25 (r_compound) treatment_4\NN\654885|NONE_0 (r_pobj) of_2\IN\0|nephrotoxic_20|._74 (r_prep) effects_1\NNS\13245626|NONE_0 (l_amod) nephrotoxic_0\JJ\0|of_20|._94
D000617_D007674 NONE aminoglycosides_2\NNS\0|thus_6|,_2|may_16|as_24|._148 (r_nsubj) act_4\VB\6479665|NONE_0 (l_prep) as_5\IN\14622893|thus_30|,_26|aminoglycosides_24|may_8|._124 (l_pobj) nephrotoxicants_6\NNS\0|NONE_0 (l_prep) at_7\IN\14622893|NONE_0 (l_pobj) impairment_13\NN\7296428|NONE_0 (l_prep) of_14\IN\0|glomerular_52|inducing_20 (l_pobj) reabsorption_16\NN\13526110|NONE_0
625456
D002119_D006934 CID ate_24\VBN\0|carbon_7|-_1|-_3 (r_amod) sodium_26\NN\14625458|calcium_19|bicarbonate_7 (r_compound) powders_28\NNS\15046900|NONE_0 (r_pobj) of_20\IN\0|large_14 (r_prep) amounts_19\NNS\13329641|who_33|had_29|regularly_25|for_57 (r_dobj) consumed_17\VBN\1168468|NONE_0 (r_relcl) patients_13\NNS\9898892|NONE_0 (r_pobj) in_12\IN\13603305|case_79|two_46|are_13|._124 (r_prep) reported_11\VBN\831651|NONE_0 (l_nsubjpass) case_1\NN\7283608|two_33|are_66|in_79|._203 (l_prep) of_2\IN\0|one_9|and_24 (l_pobj) hypercalcaemia_4\NN\14299637|NONE_0
D017693_D006934 CID bicarbonate_27\NN\14798450|calcium_26|sodium_7 (r_compound) powders_28\NNS\15046900|NONE_0 (r_pobj) of_20\IN\0|large_14 (r_prep) amounts_19\NNS\13329641|who_33|had_29|regularly_25|for_57 (r_dobj) consumed_17\VBN\1168468|NONE_0 (r_relcl) patients_13\NNS\9898892|NONE_0 (r_pobj) in_12\IN\13603305|case_79|two_46|are_13|._124 (r_prep) reported_11\VBN\831651|NONE_0 (l_nsubjpass) case_1\NN\7283608|two_33|are_66|in_79|._203 (l_prep) of_2\IN\0|one_9|and_24 (l_pobj) hypercalcaemia_4\NN\14299637|NONE_0
D002119_D053040 CID ate_24\VBN\0|carbon_7|-_1|-_3 (r_amod) sodium_26\NN\14625458|calcium_19|bicarbonate_7 (r_compound) powders_28\NNS\15046900|NONE_0 (r_pobj) of_20\IN\0|large_14 (r_prep) amounts_19\NNS\13329641|who_33|had_29|regularly_25|for_57 (r_dobj) consumed_17\VBN\1168468|NONE_0 (r_relcl) patients_13\NNS\9898892|NONE_0 (r_pobj) in_12\IN\13603305|case_79|two_46|are_13|._124 (r_prep) reported_11\VBN\831651|NONE_0 (l_nsubjpass) two_6\CD\13741022|case_33|are_33|in_46|._170 (l_prep) of_7\IN\0|NONE_0 (l_pobj) nephrolithiasis_9\NN\14115914|NONE_0
D017693_D053040 CID bicarbonate_27\NN\14798450|calcium_26|sodium_7 (r_compound) powders_28\NNS\15046900|NONE_0 (r_pobj) of_20\IN\0|large_14 (r_prep) amounts_19\NNS\13329641|who_33|had_29|regularly_25|for_57 (r_dobj) consumed_17\VBN\1168468|NONE_0 (r_relcl) patients_13\NNS\9898892|NONE_0 (r_pobj) in_12\IN\13603305|case_79|two_46|are_13|._124 (r_prep) reported_11\VBN\831651|NONE_0 (l_nsubjpass) two_6\CD\13741022|case_33|are_33|in_46|._170 (l_prep) of_7\IN\0|NONE_0 (l_pobj) nephrolithiasis_9\NN\14115914|NONE_0
18363626
D010100_D001919 NONE oxygen_30\NN\14622893|NONE_0 (r_compound) saturations_31\NNS\13534954|adjusted_33|normal_24|and_11 (r_conj) range_28\NN\5123416|NONE_0 (r_pobj) of_23\IN\0|20_4 (r_prep) %_22\NN\0|NONE_0 (r_pobj) within_20\IN\0|associated_99|,_53|pressures_15|were_63|._81 (r_prep) were_19\VBD\0|NONE_0 (l_advcl) associated_4\VBN\628491|,_46|pressures_84|within_99|were_162|._180 (l_prep) with_5\IN\0|although_49|sedation_24|was_15 (l_pobj) incidence_9\NN\13821570|NONE_0 (l_prep) of_10\IN\0|a_16|%_12 (l_pobj) bradycardia_11\NN\14110674|NONE_0
D020927_D001919 CID dexmedetomidine_1\NN\0|NONE_0 (r_amod) sedation_2\NN\14034177|although_25|was_9|with_24 (r_nsubjpass) associated_4\VBN\628491|,_46|pressures_84|within_99|were_162|._180 (l_prep) with_5\IN\0|although_49|sedation_24|was_15 (l_pobj) incidence_9\NN\13821570|NONE_0 (l_prep) of_10\IN\0|a_16|%_12 (l_pobj) bradycardia_11\NN\14110674|NONE_0
1286498
D005442_D009325 CID flumazenil_11\JJ\0|the_4|and_17|pain_47 (r_compound) group_12\NN\2137|NONE_0 (r_pobj) in_9\IN\13603305|NONE_0 (r_prep) vomiting_8\VBG\116687|and_4 (r_conj) nausea_6\NN\14299637|effects_13|._99
D005442_D009325 CID flumazenil_11\JJ\0|the_4|and_17|pain_47 (r_compound) group_12\NN\2137|NONE_0 (l_conj) pain_19\NN\14299637|the_51|flumazenil_47|and_30 (l_nmod) nausea_14\NN\14299637|in_31
D005442_D010146 NONE flumazenil_11\JJ\0|the_4|and_17|pain_47 (r_compound) group_12\NN\2137|NONE_0 (l_conj) pain_19\NN\14299637|the_51|flumazenil_47|and_30
D005442_D014839 CID flumazenil_11\JJ\0|the_4|and_17|pain_47 (r_compound) group_12\NN\2137|NONE_0 (r_pobj) in_9\IN\13603305|NONE_0 (r_prep) vomiting_8\VBG\116687|and_4
8599504
D004329_D000799 CID droperidol_3\NN\0|NONE_0 (r_compound) administration_4\NN\1133281|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBD\628491|._41 (r_acl) angioedema_0\NNP\14316714|NONE_0
D004329_D000799 CID droperidol_39\NN\0|NONE_0 (r_pobj) of_38\IN\0|a_17|single_15|iv_8 (r_prep) dose_37\NN\3740161|NONE_0 (r_pobj) of_33\IN\0|the_19 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) of_30\IN\0|10_11 (r_prep) minutes_29\NNS\6502378|NONE_0 (r_pobj) within_27\IN\0|in_77|angioedema_69 (r_prep) developed_26\VBN\1753788|no_91|known_88|drug_82 (l_nsubj) angioedema_19\NN\14316714|in_8|within_69
D004329_D004487 NONE droperidol_39\NN\0|NONE_0 (r_pobj) of_38\IN\0|a_17|single_15|iv_8 (r_prep) dose_37\NN\3740161|NONE_0 (r_pobj) of_33\IN\0|the_19 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) of_30\IN\0|10_11 (r_prep) minutes_29\NNS\6502378|NONE_0 (r_pobj) within_27\IN\0|in_77|angioedema_69 (r_prep) developed_26\VBN\1753788|no_91|known_88|drug_82 (l_nsubj) angioedema_19\NN\14316714|in_8|within_69 (l_prep) with_20\IN\0|NONE_0 (l_pobj) swelling_23\NN\14315071|NONE_0
D004329_D004342 NONE droperidol_39\NN\0|NONE_0 (r_pobj) of_38\IN\0|a_17|single_15|iv_8 (r_prep) dose_37\NN\3740161|NONE_0 (r_pobj) of_33\IN\0|the_19 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) of_30\IN\0|10_11 (r_prep) minutes_29\NNS\6502378|NONE_0 (r_pobj) within_27\IN\0|in_77|angioedema_69 (r_prep) developed_26\VBN\1753788|no_91|known_88|drug_82 (r_relcl) allergies_16\NNS\14533203|NONE_0
D004329_D014060 NONE droperidol_39\NN\0|NONE_0 (r_pobj) of_38\IN\0|a_17|single_15|iv_8 (r_prep) dose_37\NN\3740161|NONE_0 (r_pobj) of_33\IN\0|the_19 (r_prep) administration_32\NN\1133281|NONE_0 (r_pobj) of_30\IN\0|10_11 (r_prep) minutes_29\NNS\6502378|NONE_0 (r_pobj) within_27\IN\0|in_77|angioedema_69 (r_prep) developed_26\VBN\1753788|no_91|known_88|drug_82 (l_nsubj) angioedema_19\NN\14316714|in_8|within_69 (l_prep) with_20\IN\0|NONE_0 (l_pobj) swelling_23\NN\14315071|NONE_0
9514561
D002211_D010146 CID capsaicin_5\NN\15032661|NONE_0 (r_pobj) by_4\IN\0|NONE_0 (r_agent) elicited_3\VBN\1617192|experimental_26|cranial_13|:_21|study_29|._34 (r_acl) pain_2\NN\14299637|NONE_0
D002211_D010146 CID capsaicin_4\NN\15032661|NONE_0 (r_pobj) of_3\IN\0|a_15|small_13 (r_prep) amount_2\NN\13329641|was_20|subcutaneously_37|in_52|evoke_77|._156 (r_nsubjpass) administered_6\VBN\2436349|NONE_0 (l_advcl) evoke_13\VB\1617192|amount_77|was_57|subcutaneously_40|in_25|._79 (l_dobj) sensation_17\NN\5708432|to_27 (l_amod) painful_16\JJ\0|a_10|burning_8|in_18
9848575
D004317_D009202 CID doxorubicin_15\RB\2716866|-_11 (r_npadvmod) induced_17\VBN\1627355|in_23 (r_amod) cardiomyopathy_18\NN\14103288|normal_37|and_24
D004317_D009202 CID doxorubicin_7\NN\2716866|NONE_0 (r_pobj) of_6\IN\0|six_12 (r_prep) courses_5\NNS\883297|which_24 (r_dobj) received_2\VBD\2210855|NONE_0 (r_relcl) animals_0\NNS\4475|electrocardiogram_72|decrease_105|,_179|show_269|._343 (r_nsubj) demonstrated_8\VBD\2137132|NONE_0 (l_dobj) decrease_16\NN\7296428|animals_105|electrocardiogram_33|,_74|show_164|._238 (l_prep) of_17\IN\0|NONE_0 (l_pobj) pressure_19\NN\11419404|NONE_0 (l_conj) cardiomyopathy_25\NN\14103288|blood_48|and_33
D004317_D009202 CID doxorubicin_22\NN\2716866|NONE_0 (r_pobj) of_21\IN\0|four_13|(_15|mg/kg_20|)_25 (r_prep) courses_20\NNS\883297|NONE_0 (r_pobj) by_18\IN\0|examine_109|was_20|in_8|._42 (r_agent) induced_15\VBN\1627355|NONE_0 (l_csubjpass) examine_1\VB\0|was_89|in_101|by_109|._151 (l_dobj) effect_6\NN\34213|to_48 (l_prep) of_7\IN\0|a_44|deteriorating_33|cardiotoxic_19 (l_pobj) cardiomyopathy_13\NN\14103288|NONE_0
D018943_D009202 NONE anthracycline_6\NN\0|a_18|novel_16|synthetic_10|(_25|sm-5887_26|)_33 (r_amod) derivative_7\JJ\5802185|NONE_0 (r_pobj) of_2\IN\0|chronic_16|on_56|._125 (r_prep) effects_1\NNS\13245626|NONE_0 (l_prep) on_11\IN\0|chronic_72|of_56|._69 (l_pobj) heart_13\NN\5919034|NONE_0 (l_conj) cardiomyopathy_18\NN\14103288|normal_37|and_24
D004317_D066126 NONE doxorubicin_28\NN\2716866|the_135|chronic_131|cardiotoxic_123|of_101|and_90|effect_61 (r_appos) potential_9\NN\14481929|to_39 (l_amod) cardiotoxic_8\JJ\0|the_12|chronic_8|of_22|and_33|effect_62|doxorubicin_123
D004317_D066126 NONE doxorubicin_28\NN\2716866|the_135|chronic_131|cardiotoxic_123|of_101|and_90|effect_61 (r_appos) potential_9\NN\14481929|to_39 (l_conj) effect_16\NN\34213|the_74|chronic_70|cardiotoxic_62|of_40|and_29|doxorubicin_61 (l_prep) on_19\IN\0|a_43|possible_41|deteriorating_32|of_11 (l_pobj) cardiotoxicity_23\NN\0|NONE_0
D004317_D066126 NONE doxorubicin_22\NN\2716866|NONE_0 (r_pobj) of_21\IN\0|four_13|(_15|mg/kg_20|)_25 (r_prep) courses_20\NNS\883297|NONE_0 (r_pobj) by_18\IN\0|examine_109|was_20|in_8|._42 (r_agent) induced_15\VBN\1627355|NONE_0 (l_csubjpass) examine_1\VB\0|was_89|in_101|by_109|._151 (l_dobj) effect_6\NN\34213|to_48 (l_amod) cardiotoxic_5\JJ\0|a_25|deteriorating_14|of_19
D004317_D066126 NONE doxorubicin_11\NN\2716866|the_15|additional_11 (r_compound) treatment_12\NN\654885|NONE_0 (r_pobj) by_8\IN\0|changes_22|were_14|._39 (r_agent) enhanced_7\VBN\227165|NONE_0 (l_nsubjpass) changes_5\NNS\7283608|were_8|by_22|._61 (l_amod) cardiotoxic_4\JJ\0|the_14|grade_6
D004317_D066126 NONE doxorubicin_16\RB\2716866|-_11 (r_npadvmod) induced_18\VBN\1627355|in_23 (r_amod) cardiotoxicity_19\NN\0|NONE_0 (r_pobj) on_15\IN\0|deteriorating_21 (r_prep) effect_14\NN\34213|chronic_41|and_18 (r_conj) cardiotoxicity_11\NN\0|NONE_0
D004317_D066126 NONE doxorubicin_16\RB\2716866|-_11 (r_npadvmod) induced_18\VBN\1627355|in_23 (r_amod) cardiotoxicity_19\NN\0|NONE_0
C055866_D009202 NONE sm-5887_9\NNP\0|a_44|novel_42|synthetic_36|anthracycline_26|(_1|)_7 (r_appos) derivative_7\JJ\5802185|NONE_0 (r_pobj) of_2\IN\0|chronic_16|on_56|._125 (r_prep) effects_1\NNS\13245626|NONE_0 (l_prep) on_11\IN\0|chronic_72|of_56|._69 (l_pobj) heart_13\NN\5919034|NONE_0 (l_conj) cardiomyopathy_18\NN\14103288|normal_37|and_24
C055866_D009202 NONE sm-5887_35\NNP\0|the_4 (r_compound) administration_36\NN\1133281|while_65|animals_59|did_15|not_19|changes_32 (r_nsubj) show_39\VB\429048|animals_269|electrocardiogram_197|decrease_164|,_90|._74 (r_advcl) demonstrated_8\VBD\2137132|NONE_0 (l_dobj) decrease_16\NN\7296428|animals_105|electrocardiogram_33|,_74|show_164|._238 (l_prep) of_17\IN\0|NONE_0 (l_pobj) pressure_19\NN\11419404|NONE_0 (l_conj) cardiomyopathy_25\NN\14103288|blood_48|and_33
C055866_D009202 NONE sm-5887_8\NNP\0|,_7|grade_13 (r_nmod) cardiomyopathy_13\NN\14103288|NONE_0
C055866_D009202 NONE sm-5887_5\NNP\0|the_4 (r_compound) treatment_6\NN\654885|on_29|,_14|did_10|not_14|grade_31|._54 (r_nsubj) progress_9\VB\250259|NONE_0 (l_dobj) grade_11\NN\7975026|on_60|,_45|treatment_31|did_21|not_17|._23 (l_prep) of_12\IN\0|the_10 (l_pobj) cardiomyopathy_13\NN\14103288|NONE_0
C055866_D066126 NONE sm-5887_11\NNP\0|NONE_0 (r_pobj) of_10\IN\0|the_34|chronic_30|cardiotoxic_22|and_11|effect_40|doxorubicin_101 (r_prep) potential_9\NN\14481929|to_39 (l_amod) cardiotoxic_8\JJ\0|the_12|chronic_8|of_22|and_33|effect_62|doxorubicin_123
C055866_D066126 NONE sm-5887_11\NNP\0|NONE_0 (r_pobj) of_10\IN\0|the_34|chronic_30|cardiotoxic_22|and_11|effect_40|doxorubicin_101 (r_prep) potential_9\NN\14481929|to_39 (l_conj) effect_16\NN\34213|the_74|chronic_70|cardiotoxic_62|of_40|and_29|doxorubicin_61 (l_prep) on_19\IN\0|a_43|possible_41|deteriorating_32|of_11 (l_pobj) cardiotoxicity_23\NN\0|NONE_0
C055866_D066126 NONE sm-5887_18\NNP\0|NONE_0 (r_pobj) of_17\IN\0|a_32|possible_30|deteriorating_21|on_11 (r_prep) effect_16\NN\34213|the_74|chronic_70|cardiotoxic_62|of_40|and_29|doxorubicin_61 (r_conj) potential_9\NN\14481929|to_39 (l_amod) cardiotoxic_8\JJ\0|the_12|chronic_8|of_22|and_33|effect_62|doxorubicin_123
C055866_D066126 NONE sm-5887_18\NNP\0|NONE_0 (r_pobj) of_17\IN\0|a_32|possible_30|deteriorating_21|on_11 (r_prep) effect_16\NN\34213|the_74|chronic_70|cardiotoxic_62|of_40|and_29|doxorubicin_61 (l_prep) on_19\IN\0|a_43|possible_41|deteriorating_32|of_11 (l_pobj) cardiotoxicity_23\NN\0|NONE_0
C055866_D066126 NONE sm-5887_8\NNP\0|,_7|grade_13 (r_nmod) cardiomyopathy_13\NN\14103288|NONE_0 (r_pobj) of_7\IN\0|a_44|deteriorating_33|cardiotoxic_19 (r_prep) effect_6\NN\34213|to_48 (l_amod) cardiotoxic_5\JJ\0|a_25|deteriorating_14|of_19
C055866_D066126 NONE sm-5887_3\NNP\0|in_15|,_2|does_8|not_13|potential_26|._132 (r_nsubj) have_6\VB\7846|NONE_0 (l_dobj) potential_8\NN\14481929|in_41|,_28|sm-5887_26|does_18|not_13|._106 (l_prep) of_9\IN\0|any_14 (l_pobj) cardiotoxicity_11\NN\0|NONE_0
C055866_D066126 NONE sm-5887_3\NNP\0|in_15|,_2|does_8|not_13|potential_26|._132 (r_nsubj) have_6\VB\7846|NONE_0 (l_dobj) potential_8\NN\14481929|in_41|,_28|sm-5887_26|does_18|not_13|._106 (l_prep) of_9\IN\0|any_14 (l_pobj) cardiotoxicity_11\NN\0|NONE_0 (l_conj) effect_14\NN\34213|chronic_41|and_18 (l_prep) on_15\IN\0|deteriorating_21 (l_pobj) cardiotoxicity_19\NN\0|NONE_0
11573852
D000666_D004830 NONE b_18\NNP\1355326|NONE_0 (r_pobj) of_16\IN\0|intravenous_21 (r_prep) infusion_15\NN\14589223|NONE_0 (r_pobj) during_13\IN\0|man_45|seizures_9|,_45|then_47|stopped_91|._146 (r_prep) experienced_8\VBD\2108377|NONE_0 (l_dobj) seizures_12\NNS\14081375|man_36|during_9|,_54|then_56|stopped_100|._155
D000666_D012640 CID b_1\NN\1355326|-_1 (r_npadvmod) induced_3\VBN\1627355|in_17|._39 (r_amod) seizures_4\NNS\14081375|NONE_0
D000666_D012640 CID b_16\NNP\1355326|NONE_0 (r_compound) infusion_17\NN\14589223|NONE_0 (r_pobj) following_14\VBG\8180190|a_66|of_59 (r_prep) case_3\NN\7283608|to_12|._97 (l_prep) of_4\IN\0|a_7|following_59 (l_pobj) episodes_6\NNS\7283608|NONE_0 (l_prep) of_7\IN\0|multiple_18|in_20 (l_pobj) activity_9\NN\30358|NONE_0 (l_compound) seizure_8\NN\14081375|NONE_0
D000666_D012640 CID b_18\NNP\1355326|NONE_0 (r_pobj) of_16\IN\0|intravenous_21 (r_prep) infusion_15\NN\14589223|NONE_0 (r_pobj) during_13\IN\0|man_45|seizures_9|,_45|then_47|stopped_91|._146 (r_prep) experienced_8\VBD\2108377|NONE_0 (l_conj) stopped_28\VBN\0|man_136|seizures_100|during_91|,_46|then_44|._55 (l_nsubjpass) seizures_23\NNS\14081375|was_25|and_37|decreased_65
D000666_D012640 CID b_15\NNP\1355326|amphotercin_12 (r_compound) administration_16\NN\1133281|only_26 (r_pobj) during_13\IN\0|NONE_0 (r_prep) occurred_11\VBD\0|despite_78|,_29|seizures_23|and_4|._49 (r_conj) persisted_9\VBD\118523|NONE_0 (l_nsubj) seizures_8\NNS\14081375|despite_55|,_6|and_19|occurred_23|._72
D000666_D012640 CID b_8\NNP\1355326|that_18|cause_10 (r_nsubj) was_9\VBD\0|course_47|._50 (l_attr) cause_11\NN\7323922|that_28|b_10 (l_prep) of_12\IN\0|the_10 (l_pobj) seizures_14\NNS\14081375|NONE_0
D000666_D012640 CID b_1\NNP\1355326|be_11|._48 (r_nsubj) seems_2\VBZ\2604760|NONE_0 (l_xcomp) be_4\VB\14625458|b_11|._37 (l_attr) cause_7\NN\7323922|to_19 (l_prep) of_8\IN\0|the_19|probable_15 (l_pobj) seizures_10\NNS\14081375|NONE_0
D000666_D012640 CID b_11\NNP\1355326|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) associated_8\VBN\628491|NONE_0 (r_acl) seizures_7\NNS\14081375|NONE_0
D000431_D012640 NONE alcohol_9\NN\7881800|as_23|withdrawal_26 (r_compound) intake_10\NN\13440063|a_36|of_26|;_10 (r_conj) history_4\NN\15120823|patient_14|cause_72|._86 (r_dobj) had_2\VBD\0|NONE_0 (l_conj) cause_17\VB\7323922|patient_86|history_72|._14 (l_dobj) seizures_18\NNS\14081375|can_15|also_11
D016049_D012640 NONE didanosine_0\NNP\2725367|also_11|potential_22|._53 (r_nsubj) has_2\VBZ\13888491|NONE_0 (l_dobj) potential_4\NN\14481929|didanosine_22|also_11|._31 (l_prep) for_5\IN\0|a_12 (l_pcomp) inducing_6\VBG\42311|NONE_0 (l_dobj) seizures_7\NNS\14081375|NONE_0
D000666_D000163 NONE b_1\NN\1355326|-_1 (r_npadvmod) induced_3\VBN\1627355|in_17|._39 (r_amod) seizures_4\NNS\14081375|NONE_0 (l_prep) in_5\IN\13603305|induced_17|._22 (l_pobj) patient_7\NN\9898892|NONE_0 (l_prep) with_8\IN\0|a_10 (l_pobj) aids_9\NNP\13974317|NONE_0
D000666_D000163 NONE b_16\NNP\1355326|NONE_0 (r_compound) infusion_17\NN\14589223|NONE_0 (r_pobj) following_14\VBG\8180190|a_66|of_59 (r_prep) case_3\NN\7283608|to_12|._97 (l_prep) of_4\IN\0|a_7|following_59 (l_pobj) episodes_6\NNS\7283608|NONE_0 (l_prep) in_10\IN\13603305|multiple_38|of_20 (l_pobj) patent_13\NN\6470073|NONE_0 (l_compound) aids_12\NNP\13974317|an_3
D000666_D000163 NONE b_8\NNP\1355326|that_18|cause_10 (r_nsubj) was_9\VBD\0|course_47|._50 (l_attr) cause_11\NN\7323922|that_28|b_10 (l_prep) of_12\IN\0|the_10 (l_pobj) seizures_14\NNS\14081375|NONE_0 (l_prep) in_15\IN\13603305|the_13 (l_pobj) patient_18\NN\9898892|NONE_0 (l_compound) aids_17\NNP\13974317|this_5
D000431_D000437 NONE alcohol_9\NN\7881800|as_23|withdrawal_26 (r_compound) intake_10\NN\13440063|a_36|of_26|;_10 (r_conj) history_4\NN\15120823|patient_14|cause_72|._86 (l_prep) of_5\IN\0|a_10|;_16|intake_26 (l_pobj) abuse_7\NN\418025|NONE_0
D008140_D012640 NONE lorazepam_5\NN\2830852|and_4 (r_conj) phenytoin_3\NN\3550533|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) administration_1\NN\1133281|NONE_0 (r_pobj) despite_0\IN\7501545|,_49|seizures_55|and_74|occurred_78|._127 (r_prep) persisted_9\VBD\118523|NONE_0 (l_nsubj) seizures_8\NNS\14081375|despite_55|,_6|and_19|occurred_23|._72
D010672_D012640 NONE phenytoin_3\NN\3550533|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) administration_1\NN\1133281|NONE_0 (r_pobj) despite_0\IN\7501545|,_49|seizures_55|and_74|occurred_78|._127 (r_prep) persisted_9\VBD\118523|NONE_0 (l_nsubj) seizures_8\NNS\14081375|despite_55|,_6|and_19|occurred_23|._72
8012887
D006493_D013927 CID heparin_7\NN\2718259|-_7 (r_npadvmod) induced_9\VBN\1627355|arterial_8 (r_amod) thrombosis_11\NN\14100769|NONE_0
D006493_D013927 CID heparin_6\NN\2718259|-_7 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) thrombosis_9\NN\14100769|NONE_0
D006493_D013927 CID heparin_14\JJ\2718259|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) patients_12\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|ancrod_84|has_77|been_73|successfully_63|for_50|induced_25|,_93|but_95|defined_178 (r_prep) used_3\VBN\0|NONE_0 (l_prep) for_5\IN\0|ancrod_34|has_27|been_23|successfully_13|in_50|induced_75|,_143|but_145|defined_228 (l_pobj) prophylaxis_6\NN\1077350|NONE_0 (l_prep) against_7\IN\0|NONE_0 (l_pobj) development_8\NN\248977|NONE_0 (l_prep) of_9\IN\0|NONE_0 (l_pobj) thrombosis_10\NN\14100769|NONE_0
D006493_D013927 CID heparin_14\JJ\2718259|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) patients_12\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|ancrod_84|has_77|been_73|successfully_63|for_50|induced_25|,_93|but_95|defined_178 (r_prep) used_3\VBN\0|NONE_0 (l_conj) defined_39\VBN\2604760|ancrod_262|has_255|been_251|successfully_241|for_228|in_178|induced_153|,_85|but_83 (l_auxpass) is_36\VBZ\0|not_3|well_7|._19 (l_nsubj) success_27\NN\7283608|NONE_0 (l_prep) in_28\IN\13603305|its_12 (l_pobj) patients_29\NNS\9898892|NONE_0 (l_relcl) developed_32\VBN\1753788|NONE_0 (l_dobj) syndrome_35\NN\5870365|who_34|have_30 (l_compound) thrombosis_34\NN\14100769|the_4
D006493_D013927 CID heparin_23\NN\2718259|NONE_0 (r_pobj) to_22\IN\0|brief_17 (r_prep) reexposure_21\NN\0|who_18 (r_dobj) require_19\VBP\0|platelet_25 (r_relcl) aggregation_17\NN\31264|NONE_0 (r_dobj) induced_15\VBN\1627355|ancrod_109|has_102|been_98|successfully_88|for_75|in_25|,_68|but_70|defined_153 (r_advcl) used_3\VBN\0|NONE_0 (l_prep) for_5\IN\0|ancrod_34|has_27|been_23|successfully_13|in_50|induced_75|,_143|but_145|defined_228 (l_pobj) prophylaxis_6\NN\1077350|NONE_0 (l_prep) against_7\IN\0|NONE_0 (l_pobj) development_8\NN\248977|NONE_0 (l_prep) of_9\IN\0|NONE_0 (l_pobj) thrombosis_10\NN\14100769|NONE_0
D006493_D013927 CID heparin_23\NN\2718259|NONE_0 (r_pobj) to_22\IN\0|brief_17 (r_prep) reexposure_21\NN\0|who_18 (r_dobj) require_19\VBP\0|platelet_25 (r_relcl) aggregation_17\NN\31264|NONE_0 (r_dobj) induced_15\VBN\1627355|ancrod_109|has_102|been_98|successfully_88|for_75|in_25|,_68|but_70|defined_153 (r_advcl) used_3\VBN\0|NONE_0 (l_conj) defined_39\VBN\2604760|ancrod_262|has_255|been_251|successfully_241|for_228|in_178|induced_153|,_85|but_83 (l_auxpass) is_36\VBZ\0|not_3|well_7|._19 (l_nsubj) success_27\NN\7283608|NONE_0 (l_prep) in_28\IN\13603305|its_12 (l_pobj) patients_29\NNS\9898892|NONE_0 (l_relcl) developed_32\VBN\1753788|NONE_0 (l_dobj) syndrome_35\NN\5870365|who_34|have_30 (l_compound) thrombosis_34\NN\14100769|the_4
D006493_D013927 CID heparin_14\NN\2718259|-_7 (r_npadvmod) induced_16\VBN\1627355|NONE_0 (r_amod) thrombosis_17\NN\14100769|NONE_0
D006493_D001791 NONE heparin_14\JJ\2718259|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) patients_12\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|ancrod_84|has_77|been_73|successfully_63|for_50|induced_25|,_93|but_95|defined_178 (r_prep) used_3\VBN\0|NONE_0 (l_advcl) induced_15\VBN\1627355|ancrod_109|has_102|been_98|successfully_88|for_75|in_25|,_68|but_70|defined_153 (l_dobj) aggregation_17\NN\31264|NONE_0
D006493_D001791 NONE heparin_23\NN\2718259|NONE_0 (r_pobj) to_22\IN\0|brief_17 (r_prep) reexposure_21\NN\0|who_18 (r_dobj) require_19\VBP\0|platelet_25 (r_relcl) aggregation_17\NN\31264|NONE_0
8766220
D017374_-1 NONE paroxetine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) association_5\NN\8008335|NONE_0 (r_pobj) in_4\IN\13603305|drug_19|was_14|and_31|dosulepine_35|._103 (r_prep) initiated_3\VBN\1617192|NONE_0 (l_conj) dosulepine_9\JJ\0|drug_54|was_49|in_35|and_4|._68 (l_prep) in_11\IN\13603305|hydrochloride_14 (l_pobj) patient_14\NN\9898892|NONE_0 (l_amod) tetraparetic_13\JJ\0|a_2|with_21
D014147_D006212 CID tramadol_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|term_12 (r_prep) intake_7\NN\13440063|NONE_0 (r_pobj) after_3\IN\0|and_19|hallucinations_15|combined_35|._64 (r_prep) nightmares_0\NNS\14411243|NONE_0 (l_conj) hallucinations_2\NNS\14376855|and_4|after_15|combined_50|._79
D014147_D006212 CID tramadol_25\NN\0|active_17|and_4 (r_conj) drugs_23\NNS\14778436|NONE_0 (r_pobj) of_19\IN\0|the_15 (r_prep) withdrawal_18\NN\7206096|NONE_0 (r_pobj) after_16\IN\0|that_18|only_13 (r_prep) stopped_15\VBD\0|NONE_0 (r_relcl) hallucinations_12\NNS\14376855|after_56|patient_18|._89
D004308_D059350 NONE hydrochloride_10\NN\14817592|in_14 (r_dobj) dosulepine_9\JJ\0|drug_54|was_49|in_35|and_4|._68 (l_prep) in_11\IN\13603305|hydrochloride_14 (l_pobj) patient_14\NN\9898892|NONE_0 (l_prep) with_15\IN\0|a_23|tetraparetic_21 (l_pobj) pain_17\NN\14299637|NONE_0
D004308_-1 NONE hydrochloride_10\NN\14817592|in_14 (r_dobj) dosulepine_9\JJ\0|drug_54|was_49|in_35|and_4|._68 (l_prep) in_11\IN\13603305|hydrochloride_14 (l_pobj) patient_14\NN\9898892|NONE_0 (l_amod) tetraparetic_13\JJ\0|a_2|with_21
D017374_D059350 NONE paroxetine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) association_5\NN\8008335|NONE_0 (r_pobj) in_4\IN\13603305|drug_19|was_14|and_31|dosulepine_35|._103 (r_prep) initiated_3\VBN\1617192|NONE_0 (l_conj) dosulepine_9\JJ\0|drug_54|was_49|in_35|and_4|._68 (l_prep) in_11\IN\13603305|hydrochloride_14 (l_pobj) patient_14\NN\9898892|NONE_0 (l_prep) with_15\IN\0|a_23|tetraparetic_21 (l_pobj) pain_17\NN\14299637|NONE_0
D014147_D010146 NONE tramadol_0\NNP\0|opioid_19|._152 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) opioid_4\NN\0|tramadol_19|._133 (l_prep) with_5\IN\0|a_14|weak_12 (l_pobj) effects_6\NNS\13245626|NONE_0 (l_relcl) used_14\VBN\0|on_57 (l_xcomp) treat_16\VB\7570720|that_16|is_11 (l_dobj) pain_18\NN\14299637|to_16
D014147_D010146 NONE tramadol_0\NNP\0|opioid_19|._152 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) opioid_4\NN\0|tramadol_19|._133 (l_prep) with_5\IN\0|a_14|weak_12 (l_pobj) effects_6\NNS\13245626|NONE_0 (l_relcl) used_14\VBN\0|on_57 (l_xcomp) treat_16\VB\7570720|that_16|is_11 (l_dobj) pain_18\NN\14299637|to_16 (l_conj) pain_23\NN\14299637|cancer_38|and_26
D014147_D009369 NONE tramadol_0\NNP\0|opioid_19|._152 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) opioid_4\NN\0|tramadol_19|._133 (l_prep) with_5\IN\0|a_14|weak_12 (l_pobj) effects_6\NNS\13245626|NONE_0 (l_relcl) used_14\VBN\0|on_57 (l_xcomp) treat_16\VB\7570720|that_16|is_11 (l_dobj) pain_18\NN\14299637|to_16 (l_compound) cancer_17\NN\14239425|and_12|pain_38
3088349
D000661_-1 NONE amphetamine_17\NN\3248958|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_prep) exhaustion_15\NN\14016361|NONE_0 (r_pobj) to_14\TO\0|rotation_106|susceptibility_43|._28 (r_prep) reflects_8\VBZ\923793|NONE_0 (l_nsubj) rotation_2\NN\331950|susceptibility_63|to_106|._134 (l_prep) following_3\VBG\8180190|transient_33|contralateral_23 (l_pobj) lesion_7\NN\14204950|NONE_0
D000661_D009069 CID amphetamine_17\NN\3248958|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_prep) exhaustion_15\NN\14016361|NONE_0 (r_pobj) to_14\TO\0|rotation_106|susceptibility_43|._28 (r_prep) reflects_8\VBZ\923793|NONE_0 (l_nsubj) rotation_2\NN\331950|susceptibility_63|to_106|._134
D000661_D009069 CID amphetamine_26\NN\3248958|-_11 (r_npadvmod) induced_28\VBN\1627355|rotational_8 (r_amod) behavior_30\NN\407535|NONE_0 (r_pobj) on_25\IN\0|in_146|we_76|effect_60|,_2|._42 (r_prep) examined_12\VBD\0|NONE_0 (l_prep) in_0\IN\13603305|we_70|effect_86|,_144|on_146|._188 (l_pobj) order_1\NN\7168131|NONE_0 (l_acl) clarify_3\VB\939277|NONE_0 (l_dobj) nature_5\NN\4723816|to_15 (l_prep) of_6\IN\0|the_11 (l_pobj) rotation_10\NN\331950|NONE_0
D000661_D009069 CID amphetamine_26\NN\3248958|-_11 (r_npadvmod) induced_28\VBN\1627355|rotational_8 (r_amod) behavior_30\NN\407535|NONE_0
D000661_D009069 CID amphetamine_10\NN\3248958|when_5|was_12|for_29 (r_nsubjpass) administered_12\VBN\2436349|degree_74|still_35|evident_29|,_55|indicating_57|._125 (r_advcl) was_6\VBD\0|NONE_0 (l_advcl) indicating_22\VBG\952524|degree_131|still_92|evident_86|administered_57|,_2|._68 (l_dobj) involvement_23\NN\1080366|NONE_0 (l_prep) of_24\IN\0|NONE_0 (l_pobj) cells_26\NNS\3080309|NONE_0 (l_prep) in_27\IN\13603305|spared_13 (l_pobj) rotation_30\NN\331950|NONE_0
D000661_D009069 CID amphetamine_16\NN\3248958|,_16|or_18|exercise_39 (r_compound) dose_17\NN\3740161|either_34|lesion_27|,_14 (r_conj) volume_14\NN\33615|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) irrespective_10\RB\0|the_30|of_17|(_5|and_4 (r_conj) duration_5\NN\15113229|NONE_0 (r_pobj) of_3\IN\0|NONE_0 (r_prep) regardless_2\RB\0|however_9|,_2|,_130|rotation_152|become_171|,_242|and_244|circled_257 (r_advmod) tended_31\VBD\2604760|NONE_0 (l_nsubj) rotation_30\NN\331950|however_161|,_154|regardless_152|,_22|become_19|,_90|and_92|circled_105
D000661_D009069 CID amphetamine_27\NN\3248958|-_11 (r_npadvmod) induced_29\VBN\1627355|NONE_0 (r_amod) rotation_30\NN\331950|however_161|,_154|regardless_152|,_22|become_19|,_90|and_92|circled_105
D000661_D009069 CID amphetamine_55\NN\3248958|further_8 (r_compound) injections_56\NNS\320852|NONE_0 (r_pobj) to_53\IN\0|NONE_0 (r_prep) response_52\NN\11410625|NONE_0 (r_pobj) in_51\IN\13603305|rats_41|ipsilaterally_28|to_14|._45 (r_prep) circled_46\VBD\1835496|however_266|,_259|regardless_257|,_127|rotation_105|become_86|,_15|and_13 (r_conj) tended_31\VBD\2604760|NONE_0 (l_nsubj) rotation_30\NN\331950|however_161|,_154|regardless_152|,_22|become_19|,_90|and_92|circled_105
D000661_D009069 CID amphetamine_4\NN\3248958|that_5|effect_32 (r_nsubj) has_5\VBZ\13888491|findings_34|._92 (l_dobj) effect_8\NN\34213|that_37|amphetamine_32 (l_prep) on_9\IN\0|an_23|irreversible_20 (l_pobj) pool_15\NN\3302121|NONE_0 (l_acl) contributing_16\VBG\126264|the_24|lesion_15|da_8 (l_prep) to_17\IN\0|NONE_0 (l_pobj) rotation_19\NN\331950|NONE_0
D016627_-1 NONE 6-ohda_2\CD\0|NONE_0 (r_pobj) following_0\VBG\8180190|lesion_39 (r_prep) induced_3\VBN\1627355|period_31|has_64|been_68|precede_85|._129 (l_dobj) lesion_5\NN\14204950|following_39
D016627_D009069 NONE 6-ohda_2\CD\0|NONE_0 (r_pobj) following_0\VBG\8180190|lesion_39 (r_prep) induced_3\VBN\1627355|period_31|has_64|been_68|precede_85|._129 (r_ccomp) reported_15\VBN\831651|NONE_0 (l_nsubjpass) period_9\NN\13575869|induced_31|has_33|been_37|precede_54|._98 (l_prep) of_10\IN\0|a_19|transient_17 (l_pobj) rotation_12\NN\331950|NONE_0
D016627_D009069 NONE 6-ohda_2\CD\0|NONE_0 (r_pobj) following_0\VBG\8180190|lesion_39 (r_prep) induced_3\VBN\1627355|period_31|has_64|been_68|precede_85|._129 (r_ccomp) reported_15\VBN\831651|NONE_0 (l_xcomp) precede_17\VB\0|induced_85|period_54|has_21|been_17|._44 (l_dobj) circling_21\NN\1835496|to_39
12739036
D003401_D008180 NONE creatine_5\NN\14601829|kinase_9|in_23 (r_compound) levels_7\NNS\4916342|NONE_0 (l_prep) in_8\IN\13603305|creatine_23|kinase_14 (l_pobj) erythematosus_11\NN\0|NONE_0
D003520_D007674 NONE cyclophosphamide_25\NN\0|and_4 (r_conj) azathioprine_23\NN\3740161|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) periods_19\NNS\13575869|NONE_0 (r_dobj) undergone_18\JJ\109660|since_102|,_92|she_90|had_86|been_82|from_67|with_27|and_4|._69 (r_conj) suffering_6\VBG\14322699|NONE_0 (l_prep) with_14\IN\0|since_75|,_65|she_63|had_59|been_55|from_40|and_23|undergone_27|._96 (l_pobj) involvement_16\NN\1080366|NONE_0
D001379_D007674 NONE azathioprine_23\NN\3740161|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) periods_19\NNS\13575869|NONE_0 (r_dobj) undergone_18\JJ\109660|since_102|,_92|she_90|had_86|been_82|from_67|with_27|and_4|._69 (r_conj) suffering_6\VBG\14322699|NONE_0 (l_prep) with_14\IN\0|since_75|,_65|she_63|had_59|been_55|from_40|and_23|undergone_27|._96 (l_pobj) involvement_16\NN\1080366|NONE_0
D013256_D009220 NONE steroids_10\NNS\14727670|NONE_0 (r_pobj) with_9\IN\0|patient_20|was_12|._13 (r_prep) treated_8\VBN\2376958|myositis_44|was_35|,_22|and_20 (r_conj) suspected_2\VBN\916909|NONE_0 (l_nsubjpass) myositis_0\NNP\14336539|was_9|,_22|and_24|treated_44
D002738_D009135 NONE chloroquine_15\NN\2721948|-_11 (r_advmod) induced_17\VBN\1627355|severe_19 (r_amod) myopathy_18\NN\14204950|NONE_0
D002738_D009135 NONE chloroquine_3\NN\2721948|-_11 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_compound) myopathy_6\NN\14204950|as_35|it_32
D003520_D008180 NONE cyclophosphamide_25\NN\0|and_4 (r_conj) azathioprine_23\NN\3740161|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) periods_19\NNS\13575869|NONE_0 (r_dobj) undergone_18\JJ\109660|since_102|,_92|she_90|had_86|been_82|from_67|with_27|and_4|._69 (r_conj) suffering_6\VBG\14322699|NONE_0 (l_prep) from_7\IN\0|since_35|,_25|she_23|had_19|been_15|with_40|and_63|undergone_67|._136 (l_pobj) erythematosus_10\NN\0|NONE_0
D003520_D008180 NONE cyclophosphamide_25\NN\0|and_4 (r_conj) azathioprine_23\NN\3740161|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) periods_19\NNS\13575869|NONE_0 (r_dobj) undergone_18\JJ\109660|since_102|,_92|she_90|had_86|been_82|from_67|with_27|and_4|._69 (r_conj) suffering_6\VBG\14322699|NONE_0 (l_prep) from_7\IN\0|since_35|,_25|she_23|had_19|been_15|with_40|and_63|undergone_67|._136 (l_pobj) erythematosus_10\NN\0|NONE_0 (l_appos) sle_12\NNP\14229912|systemic_30|lupus_21|(_1|)_3
D002738_D018771 NONE chloroquine_3\NN\2721948|(_12 (r_amod) cq_5\NNP\0|NONE_0 (r_pobj) with_2\IN\0|additional_19|)_20 (r_prep) therapy_1\NN\657604|was_30|because_42|._63 (r_nsubjpass) started_8\VBN\0|NONE_0 (l_prep) because_9\IN\0|therapy_42|was_12|._21 (l_pobj) arthralgia_11\NN\14322699|of_3
D002738_D018771 NONE cq_5\NNP\0|NONE_0 (r_pobj) with_2\IN\0|additional_19|)_20 (r_prep) therapy_1\NN\657604|was_30|because_42|._63 (r_nsubjpass) started_8\VBN\0|NONE_0 (l_prep) because_9\IN\0|therapy_42|was_12|._21 (l_pobj) arthralgia_11\NN\14322699|of_3
D001379_D008180 NONE azathioprine_23\NN\3740161|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) periods_19\NNS\13575869|NONE_0 (r_dobj) undergone_18\JJ\109660|since_102|,_92|she_90|had_86|been_82|from_67|with_27|and_4|._69 (r_conj) suffering_6\VBG\14322699|NONE_0 (l_prep) from_7\IN\0|since_35|,_25|she_23|had_19|been_15|with_40|and_63|undergone_67|._136 (l_pobj) erythematosus_10\NN\0|NONE_0
D001379_D008180 NONE azathioprine_23\NN\3740161|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) periods_19\NNS\13575869|NONE_0 (r_dobj) undergone_18\JJ\109660|since_102|,_92|she_90|had_86|been_82|from_67|with_27|and_4|._69 (r_conj) suffering_6\VBG\14322699|NONE_0 (l_prep) from_7\IN\0|since_35|,_25|she_23|had_19|been_15|with_40|and_63|undergone_67|._136 (l_pobj) erythematosus_10\NN\0|NONE_0 (l_appos) sle_12\NNP\14229912|systemic_30|lupus_21|(_1|)_3
3220106
D009538_D006948 CID nicotine_3\NN\14712692|-_8 (r_npadvmod) induced_5\VBN\1627355|locomotor_8|in_32 (r_amod) hyperactivity_7\NN\14052403|NONE_0
D009538_D006948 CID nicotine_10\NN\14712692|-_8 (r_npadvmod) treated_12\VBN\2376958|chronic_17 (r_amod) rats_13\NNS\2329401|NONE_0 (r_pobj) in_8\IN\13603305|induced_32|locomotor_24 (r_prep) hyperactivity_7\NN\14052403|NONE_0
D009538_D006948 CID nicotine_5\NN\14712692|-_8 (r_npadvmod) treated_7\VBN\2376958|chronic_17 (r_amod) rats_8\NNS\2329401|that_30|hyperactivity_23|in_37|initially_61|due_71|,_151 (r_nsubj) develop_9\VBP\1753788|results_51|followed_148|._213 (l_dobj) hyperactivity_11\NN\14052403|that_53|rats_23|in_14|initially_38|due_48|,_128
D009538_D006948 CID nicotine_15\NN\14712692|NONE_0 (r_pobj) to_14\IN\0|NONE_0 (r_prep) response_13\NN\11410625|NONE_0 (r_pobj) in_12\IN\13603305|that_67|rats_37|hyperactivity_14|initially_24|due_34|,_114 (r_prep) develop_9\VBP\1753788|results_51|followed_148|._213 (l_dobj) hyperactivity_11\NN\14052403|that_53|rats_23|in_14|initially_38|due_48|,_128
D004298_D006948 NONE da_28\NNP\10484858|NONE_0 (r_compound) concentration_29\NN\4916342|nicotinic_27|and_7 (r_conj) receptors_26\NNS\5225602|NONE_0 (r_pobj) of_24\IN\0|both_17|the_12 (r_prep) density_23\NN\4941325|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) increases_19\NNS\13576355|to_3 (r_pobj) due_17\JJ\5174653|that_101|rats_71|hyperactivity_48|in_34|initially_10|,_80 (r_prep) develop_9\VBP\1753788|results_51|followed_148|._213 (l_dobj) hyperactivity_11\NN\14052403|that_53|rats_23|in_14|initially_38|due_48|,_128
D004298_D006948 NONE da_34\NNP\10484858|receptor_3|in_29 (r_compound) supersensitivity_36\NN\0|NONE_0 (r_dobj) inducing_33\VBG\42311|NONE_0 (r_pcomp) by_32\IN\0|NONE_0 (r_agent) followed_31\VBN\1835496|results_199|develop_148|._65 (r_advcl) suggest_2\VBP\1010118|NONE_0 (l_ccomp) develop_9\VBP\1753788|results_51|followed_148|._213 (l_dobj) hyperactivity_11\NN\14052403|that_53|rats_23|in_14|initially_38|due_48|,_128
2790457
D003042_D012640 CID cocaine_11\NN\3492717|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) kindled_9\VBN\2764245|local_26|anesthetic_20 (r_acl) seizures_8\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_10\NN\3492717|-_7 (r_npadvmod) induced_12\VBN\1627355|both_28|and_12 (r_conj) lidocaine-_8\NN\0|NONE_0 (r_nmod) seizures_13\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_10\NN\3492717|-_7 (r_npadvmod) induced_12\VBN\1627355|both_28|and_12 (r_conj) lidocaine-_8\NN\0|NONE_0 (r_nmod) seizures_13\NNS\14081375|NONE_0 (r_pobj) of_6\IN\0|the_16 (r_prep) development_5\NN\248977|cbz_18|,_59|but_61|had_65|._131 (r_dobj) inhibited_3\VBD\2510337|NONE_0 (l_conj) had_16\VBD\0|cbz_83|development_65|,_6|but_4|._66 (l_dobj) effect_18\NN\34213|NONE_0 (l_prep) on_19\IN\0|little_14 (l_pobj) seizures_25\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_13\NN\3492717|-_7 (r_npadvmod) injected_15\VBN\81072|the_12 (r_amod) rats_16\NNS\2329401|NONE_0 (r_pobj) in_11\IN\13603305|related_18 (r_prep) mortality_10\NN\5054863|NONE_0 (l_amod) related_9\VBN\628491|in_18 (l_npadvmod) seizure_7\NN\14081375|-_7
D003042_D012640 CID cocaine_23\NN\3492717|-_7 (r_npadvmod) induced_25\VBN\1627355|completed_45|kindled_25 (r_amod) seizures_26\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_19\NN\3492717|-_7 (r_npadvmod) kindled_21\VBN\2764245|lidocaine-_22 (r_amod) seizures_22\NNS\14081375|NONE_0
D002220_D012640 NONE carbamazepine_1\NN\0|development_27|._100 (r_nsubj) inhibits_2\VBZ\2510337|NONE_0 (l_dobj) development_4\NN\248977|carbamazepine_27|._73 (l_prep) of_5\IN\0|the_16 (l_pobj) seizures_8\NNS\14081375|NONE_0
D002220_D012640 NONE carbamazepine_3\NN\0|NONE_0 (l_appos) treatment_7\NN\654885|NONE_0 (l_prep) on_8\IN\0|(_16|cbz_15|)_12 (l_pobj) seizures_13\NNS\14081375|NONE_0
D002220_D012640 NONE cbz_5\NNP\0|(_1|)_3|on_15 (r_nmod) treatment_7\NN\654885|NONE_0 (l_prep) on_8\IN\0|(_16|cbz_15|)_12 (l_pobj) seizures_13\NNS\14081375|NONE_0
D002220_D012640 NONE cbz_30\NNP\0|NONE_0 (r_compound) administration_31\NN\1133281|NONE_0 (r_pobj) of_29\IN\0|different_18 (r_prep) methods_28\NNS\5616786|NONE_0 (r_pobj) under_26\IN\0|stages_35|and_4 (r_conj) in_18\IN\13603305|effects_107|were_15|._93 (r_prep) evaluated_17\VBN\670261|NONE_0 (l_nsubjpass) effects_1\NNS\13245626|were_92|in_107|._200 (l_prep) of_2\IN\0|the_12 (l_pobj) carbamazepine_3\NN\0|NONE_0 (l_appos) treatment_7\NN\654885|NONE_0 (l_prep) on_8\IN\0|(_16|cbz_15|)_12 (l_pobj) seizures_13\NNS\14081375|NONE_0
D002220_D012640 NONE cbz_2\NN\0|development_18|,_77|but_79|had_83|._149 (r_nsubj) inhibited_3\VBD\2510337|NONE_0 (l_dobj) development_5\NN\248977|cbz_18|,_59|but_61|had_65|._131 (l_prep) of_6\IN\0|the_16 (l_pobj) seizures_13\NNS\14081375|NONE_0
D002220_D012640 NONE cbz_2\NN\0|development_18|,_77|but_79|had_83|._149 (r_nsubj) inhibited_3\VBD\2510337|NONE_0 (l_conj) had_16\VBD\0|cbz_83|development_65|,_6|but_4|._66 (l_dobj) effect_18\NN\34213|NONE_0 (l_prep) on_19\IN\0|little_14 (l_pobj) seizures_25\NNS\14081375|NONE_0
D002220_D012640 NONE cbz_1\NN\0|also_4|incidence_23|._90 (r_nsubj) decreased_3\VBD\169651|NONE_0 (l_dobj) incidence_5\NN\13821570|cbz_23|also_19|._67 (l_prep) of_6\IN\0|the_14 (l_pobj) mortality_10\NN\5054863|NONE_0 (l_amod) related_9\VBN\628491|in_18 (l_npadvmod) seizure_7\NN\14081375|-_7
D002220_D012640 NONE cbz_1\NN\0|effect_47|._118 (r_nsubj) had_13\VBD\0|NONE_0 (l_dobj) effect_15\NN\34213|cbz_47|._71 (l_prep) on_16\IN\0|no_10 (l_pobj) seizures_26\NNS\14081375|NONE_0
D002220_D012640 NONE cbz_4\NNP\0|NONE_0 (r_pobj) of_3\IN\0|repeated_24|i.p._15|)_16 (r_prep) injection_2\NN\320852|also_28|without_37|._112 (r_nsubj) was_10\VBD\0|NONE_0 (l_prep) without_11\IN\0|injection_37|also_9|._75 (l_pobj) effect_12\NN\34213|NONE_0 (l_prep) on_13\IN\0|NONE_0 (l_pobj) development_15\NN\248977|NONE_0 (l_prep) of_16\IN\0|the_16 (l_pobj) seizures_22\NNS\14081375|NONE_0
D002220_D012640 NONE cbz_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_25|differential_21|depending_7 (r_prep) effects_2\NNS\13245626|underlie_92|._172 (l_prep) depending_5\VBG\2604760|the_32|differential_28|of_7 (l_prep) upon_6\IN\0|NONE_0 (l_pobj) stage_7\NN\15113229|NONE_0 (l_prep) of_8\IN\0|NONE_0 (l_pobj) development_10\NN\248977|NONE_0 (l_compound) seizure_9\NN\14081375|NONE_0
D002220_D012640 NONE cbz_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_25|differential_21|depending_7 (r_prep) effects_2\NNS\13245626|underlie_92|._172 (r_nsubj) suggest_11\VBP\1010118|NONE_0 (l_ccomp) underlie_15\VBP\2604760|effects_92|._80 (l_dobj) development_17\NN\248977|that_38|mechanisms_24 (l_prep) versus_18\IN\0|the_16 (l_pobj) maintenance_19\NN\266806|NONE_0 (l_prep) of_20\IN\0|NONE_0 (l_pobj) seizures_25\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine_13\NN\3681148|and_4 (r_conj) cocaine_11\NN\3492717|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) kindled_9\VBN\2764245|local_26|anesthetic_20 (r_acl) seizures_8\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine-_8\NN\0|NONE_0 (r_nmod) seizures_13\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine-_8\NN\0|NONE_0 (r_nmod) seizures_13\NNS\14081375|NONE_0 (r_pobj) of_6\IN\0|the_16 (r_prep) development_5\NN\248977|cbz_18|,_59|but_61|had_65|._131 (r_dobj) inhibited_3\VBD\2510337|NONE_0 (l_conj) had_16\VBD\0|cbz_83|development_65|,_6|but_4|._66 (l_dobj) effect_18\NN\34213|NONE_0 (l_prep) on_19\IN\0|little_14 (l_pobj) seizures_25\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine_18\NN\3681148|-_9|or_18|acute_21 (r_npadvmod) kindled_20\VBN\2764245|completed_20|induced_25 (r_amod) seizures_26\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine-_17\NN\0|kindled_22 (r_nmod) seizures_22\NNS\14081375|NONE_0
16116131
D007980_D004409 CID levodopa_7\RB\14604959|-_8 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) dyskinesia_10\NN\14084880|NONE_0
D001058_D004409 NONE apomorphine_46\NN\3786417|continuous_11 (r_compound) infusion_47\NN\14589223|NONE_0 (r_pobj) by_44\IN\0|NONE_0 (r_agent) induced_43\VBN\1627355|a_19|dyskinetic_17 (r_acl) state_42\NN\8491826|NONE_0 (l_amod) dyskinetic_41\JJ\0|a_2|induced_17
D001058_D010300 NONE apomorphine_46\NN\3786417|continuous_11 (r_compound) infusion_47\NN\14589223|NONE_0 (r_pobj) by_44\IN\0|NONE_0 (r_agent) induced_43\VBN\1627355|a_19|dyskinetic_17 (r_acl) state_42\NN\8491826|NONE_0 (r_pobj) of_39\IN\0|a_15 (r_prep) modification_38\NN\191142|NONE_0 (r_pobj) in_36\IN\13603305|whether_50|modulation_42|may_11 (r_prep) result_35\VB\34213|using_222|,_70|authors_64|._89 (r_ccomp) investigated_28\VBN\644583|NONE_0 (l_advcl) using_0\VBG\418025|,_152|authors_158|result_222|._311 (l_parataxis) rtms_6\NN\0|stimulation_13 (l_prep) over_8\IN\5867413|(_7|)_2 (l_pobj) area_12\NN\8630985|NONE_0 (l_prep) in_16\IN\13603305|the_35|supplementary_31|motor_17|sma_5 (l_pobj) group_18\NN\2137|NONE_0 (l_prep) of_19\IN\0|a_8 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) disease_24\NN\14061805|NONE_0
9867728
D005277_D006349 NONE fenfluramine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|underwent_40 (r_prep) users_6\NNS\7846|NONE_0 (r_pobj) among_5\IN\0|valvular_23|heart_14 (r_prep) disease_4\NN\14061805|NONE_0
D005277_D006349 NONE fenfluramine_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) users_14\NNS\7846|NONE_0 (r_pobj) of_13\IN\0|38_4 (r_prep) %_12\NN\0|disease_60 (r_nsubj) had_19\VBD\0|because_124|surveys_85 (l_dobj) disease_21\NN\14061805|%_60
D005277_D006349 NONE fenfluramine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|underwent_39 (r_prep) users_11\NNS\7846|NONE_0 (r_pobj) among_10\IN\0|new_40|valvular_23 (r_prep) abnormalities_9\NNS\14034177|NONE_0
D005277_D006349 NONE fenfluramine_18\JJ\0|-_12 (r_compound) phentermine_20\NN\0|NONE_0 (r_dobj) receiving_17\VBG\2210855|two_44|(_31|%_27|]_3|)_2 (r_acl) patients_1\NNS\9898892|disease_100|._107 (r_nsubj) developed_21\VBD\1753788|NONE_0 (l_dobj) disease_24\NN\14061805|patients_100|._7
D010645_D006349 NONE phentermine_20\NN\0|NONE_0 (r_dobj) receiving_17\VBG\2210855|two_44|(_31|%_27|]_3|)_2 (r_acl) patients_1\NNS\9898892|disease_100|._107 (r_nsubj) developed_21\VBD\1753788|NONE_0 (l_dobj) disease_24\NN\14061805|patients_100|._7
D020372_D006349 NONE dexfenfluramine_10\NN\0|and_4 (r_conj) fenfluramine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|underwent_40 (r_prep) users_6\NNS\7846|NONE_0 (r_pobj) among_5\IN\0|valvular_23|heart_14 (r_prep) disease_4\NN\14061805|NONE_0
D020372_D006349 NONE dexfenfluramine_18\NN\0|and_4 (r_conj) fenfluramine_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|NONE_0 (r_prep) users_14\NNS\7846|NONE_0 (r_pobj) of_13\IN\0|38_4 (r_prep) %_12\NN\0|disease_60 (r_nsubj) had_19\VBD\0|because_124|surveys_85 (l_dobj) disease_21\NN\14061805|%_60
D020372_D006349 NONE dexfenfluramine_15\NN\0|or_3 (r_conj) fenfluramine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|underwent_39 (r_prep) users_11\NNS\7846|NONE_0 (r_pobj) among_10\IN\0|new_40|valvular_23 (r_prep) abnormalities_9\NNS\14034177|NONE_0
804391
D012293_D011507 CID rifampin_8\NN\2716205|NONE_0 (r_advmod) treated_9\VBN\2376958|with_17 (r_amod) patients_10\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|light_55|chain_49|and_31|immunity_9|._46 (r_prep) proteinuria_2\NN\14299637|NONE_0
D012293_D011507 CID rifampin_13\NN\2716205|NONE_0 (r_pobj) with_12\IN\0|patients_17 (r_prep) treated_11\VBN\2376958|proteinuria_55|was_43|in_33|._21 (r_advcl) found_4\VBN\13279262|NONE_0 (l_nsubjpass) proteinuria_2\NN\14299637|was_12|in_22|treated_55|._76
D012293_D014376 NONE rifampin_8\NN\2716205|NONE_0 (r_advmod) treated_9\VBN\2376958|with_17 (r_amod) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|treated_17 (l_pobj) tuberculosis_12\NN\14127211|NONE_0
D012293_D014376 NONE rifampin_13\NN\2716205|NONE_0 (r_pobj) with_12\IN\0|patients_17 (r_prep) treated_11\VBN\2376958|proteinuria_55|was_43|in_33|._21 (l_nsubj) patients_10\NNS\9898892|with_17 (l_compound) tuberculosis_9\NN\14127211|17_3
9523850
D008775_D063806 NONE methylprednisolone_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|in_22|:_126|trial_154|._159 (r_prep) value_0\NN\5856066|NONE_0 (l_prep) in_3\IN\13603305|of_22|:_104|trial_132|._137 (l_pobj) prevention_4\NN\1073995|NONE_0 (l_prep) of_5\IN\0|NONE_0 (l_pobj) syndrome_10\NN\5870365|NONE_0 (l_compound) myalgia_9\NN\14322699|the_15|associated_17
D008775_D063806 NONE mp_6\NNP\10249459|NONE_0 (r_pobj) of_5\IN\0|before_6 (r_prep) administration_4\NN\1133281|that_5|after_32|tdi_38|frequency_54 (r_nsubj) reduces_11\VBZ\441445|data_64|._69 (l_dobj) frequency_13\NN\15286249|that_59|administration_54|after_22|tdi_16 (l_prep) of_16\IN\0|the_27|and_13|severity_9 (l_pobj) syndrome_21\NN\5870365|NONE_0 (l_compound) myalgia_20\NN\14322699|the_15
D008775_D018771 NONE methylprednisolone_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|in_22|:_126|trial_154|._159 (r_prep) value_0\NN\5856066|NONE_0 (l_prep) in_3\IN\13603305|of_22|:_104|trial_132|._137 (l_pobj) prevention_4\NN\1073995|NONE_0 (l_prep) of_5\IN\0|NONE_0 (l_pobj) syndrome_10\NN\5870365|NONE_0 (l_compound) myalgia_9\NN\14322699|the_15|associated_17 (l_compound) arthralgia_7\JJ\14322699|-_10
D008775_D018771 NONE mp_6\NNP\10249459|NONE_0 (r_pobj) of_5\IN\0|before_6 (r_prep) administration_4\NN\1133281|that_5|after_32|tdi_38|frequency_54 (r_nsubj) reduces_11\VBZ\441445|data_64|._69 (l_dobj) frequency_13\NN\15286249|that_59|administration_54|after_22|tdi_16 (l_prep) of_16\IN\0|the_27|and_13|severity_9 (l_pobj) syndrome_21\NN\5870365|NONE_0 (l_compound) myalgia_20\NN\14322699|the_15 (l_compound) arthralgia_18\JJ\14322699|-_10
D007505_D018771 CID dextran_19\NN\0|NONE_0 (r_pobj) of_17\IN\0|the_24|total_20|dose_14 (r_prep) infusion_16\NN\14589223|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) associated_11\VBN\628491|the_32|myalgia_17 (r_acl) syndrome_10\NN\5870365|NONE_0 (l_compound) myalgia_9\NN\14322699|the_15|associated_17 (l_compound) arthralgia_7\JJ\14322699|-_10
D007505_D063806 NONE dextran_19\NN\0|NONE_0 (r_pobj) of_17\IN\0|the_24|total_20|dose_14 (r_prep) infusion_16\NN\14589223|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) associated_11\VBN\628491|the_32|myalgia_17 (r_acl) syndrome_10\NN\5870365|NONE_0 (l_compound) myalgia_9\NN\14322699|the_15|associated_17
2569282
D020927_D009123 NONE dexmedetomidine_7\NN\0|capable_27|._96 (r_nsubj) is_13\VBZ\0|NONE_0 (l_acomp) capable_14\JJ\0|dexmedetomidine_27|._69 (l_prep) of_15\IN\0|NONE_0 (l_pcomp) inducing_16\VBG\42311|NONE_0 (l_dobj) flaccidity_18\NN\4938228|NONE_0
D020927_D009123 NONE med_11\NNP\6700447|the_67|selective_56|alpha-2_46|agonist_27 (r_appos) dexmedetomidine_7\NN\0|capable_27|._96 (r_nsubj) is_13\VBZ\0|NONE_0 (l_acomp) capable_14\JJ\0|dexmedetomidine_27|._69 (l_prep) of_15\IN\0|NONE_0 (l_pcomp) inducing_16\VBG\42311|NONE_0 (l_dobj) flaccidity_18\NN\4938228|NONE_0
D015760_D009127 CID alfentanil_23\NN\0|dose_5|in_22 (r_compound) anesthesia_24\NN\14034177|NONE_0 (r_pobj) by_19\IN\0|NONE_0 (r_agent) caused_18\VBN\1617192|the_20|muscle_16 (r_acl) rigidity_17\NN\5023233|if_44|treatment_41
D015760_D009127 CID alfentanil_7\NN\0|-_10 (r_npadvmod) induced_9\VBN\1627355|muscle_8|in_24 (r_amod) rigidity_11\NN\5023233|in_55|,_44|med_40|._36
D020927_D009127 NONE dexmedetomidine_0\NNP\0|,_15|acting_17|,_61|rigidity_94|._113 (r_nsubj) prevents_8\VBZ\0|NONE_0 (l_dobj) rigidity_13\NN\5023233|dexmedetomidine_94|,_79|acting_77|,_33|._19
D020927_D009127 NONE med_13\NNP\6700447|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treatment_9\NN\654885|if_3|rigidity_41 (r_nsubj) prevents_14\VBZ\0|in_69|,_49|authors_43|._81 (l_dobj) rigidity_17\NN\5023233|if_44|treatment_41
D020927_D009127 NONE med_5\NNP\6700447|in_15|,_4|rigidity_40|._76 (r_nsubj) prevented_6\VBD\0|NONE_0 (l_dobj) rigidity_11\NN\5023233|in_55|,_44|med_40|._36
D020927_D018476 NONE med_6\NNP\6700447|the_16|dose_7 (r_compound) animals_7\NNS\4475|flaccid_13|,_30|and_32|lacked_36|._99 (r_nsubj) were_8\VBD\0|NONE_0 (l_acomp) flaccid_9\JJ\0|animals_13|,_17|and_19|lacked_23|._86 (l_conj) akinetic_11\JJ\0|,_2
D020927_D012021 NONE med_6\NNP\6700447|the_16|dose_7 (r_compound) animals_7\NNS\4475|flaccid_13|,_30|and_32|lacked_36|._99 (r_nsubj) were_8\VBD\0|NONE_0 (l_conj) lacked_14\VBD\0|animals_36|flaccid_23|,_6|and_4|._63 (l_dobj) response_17\NN\11410625|NONE_0 (l_compound) startle_16\JJ\863513|a_2|during_17
12481039
D012964_D012640 NONE sodium_1\NN\14625458|NONE_0 (r_compound) channel_2\NN\6251781|reduced_15|,_15|dependence_33|._148 (r_compound) density_3\NN\4941325|NONE_0 (l_appos) dependence_7\NN\24720|reduced_48|channel_33|,_18|._115 (l_conj) susceptibility_13\NN\13920835|altered_58|voltage_50|of_31|,_16|and_14 (l_prep) to_14\IN\0|increased_25 (l_pobj) seizures_15\NNS\14081375|NONE_0
D012964_D012640 NONE sodium_19\NN\14625458|NONE_0 (r_compound) channel_20\NN\6251781|beta_8 (r_compound) 2-subunits_22\NNS\0|mice_33 (r_dobj) lacking_18\VBG\0|NONE_0 (r_pcomp) in_16\IN\13603305|NONE_0 (r_prep) seizures_15\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_17\NN\14712692|-_11 (r_npadvmod) induced_19\VBN\1627355|NONE_0 (r_amod) seizures_20\NNS\14081375|NONE_0 (r_pobj) for_16\IN\0|NONE_0 (r_prep) threshold_15\NN\15265518|reduced_20|and_4 (r_conj) latency_13\NN\15269513|NONE_0 (r_pobj) by_11\IN\0|as_13 (r_agent) indicated_10\VBN\952524|mice_56|susceptibility_31|,_5|,_75|but_77|seemed_81|._122 (r_advcl) displayed_3\VBD\2137132|NONE_0 (l_dobj) susceptibility_5\NN\13920835|mice_25|,_26|indicated_31|,_106|but_108|seemed_112|._153 (l_prep) to_6\IN\0|increased_25 (l_pobj) seizures_7\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_17\NN\14712692|-_11 (r_npadvmod) induced_19\VBN\1627355|NONE_0 (r_amod) seizures_20\NNS\14081375|NONE_0
20195852
C038192_D003490 NONE iopromide_17\JJ\0|two_34|contrast_21|(_6|cm_5|,_2 (r_appos) media_12\NNS\3575240|NONE_0 (r_pobj) for_8\IN\0|the_21|of_7 (r_prep) incidence_5\NN\13821570|study_21|,_76|among_78|._232 (r_dobj) determined_3\VBD\0|NONE_0 (l_prep) among_21\IN\0|study_99|incidence_78|,_2|._154 (l_conj) compared_29\VBD\644583|patients_35|and_4 (l_dobj) rates_31\NNS\13308999|NONE_0 (l_prep) for_32\IN\0|the_10 (l_pobj) complication_34\NN\1073995|NONE_0 (l_prep) in_35\IN\13603305|this_18 (l_pobj) relation_36\NN\2137|NONE_0 (l_prep) to_37\IN\0|NONE_0 (l_pobj) type_39\NN\5839024|NONE_0 (l_conj) presence_46\NN\13954253|the_34|and_25|dosage_21|of_14|and_8 (l_prep) of_47\IN\0|the_13 (l_pobj) cyanosis_48\NN\14299637|NONE_0
D007472_D003490 NONE iohexol_19\NN\0|and_4 (r_conj) iopromide_17\JJ\0|two_34|contrast_21|(_6|cm_5|,_2 (r_appos) media_12\NNS\3575240|NONE_0 (r_pobj) for_8\IN\0|the_21|of_7 (r_prep) incidence_5\NN\13821570|study_21|,_76|among_78|._232 (r_dobj) determined_3\VBD\0|NONE_0 (l_prep) among_21\IN\0|study_99|incidence_78|,_2|._154 (l_conj) compared_29\VBD\644583|patients_35|and_4 (l_dobj) rates_31\NNS\13308999|NONE_0 (l_prep) for_32\IN\0|the_10 (l_pobj) complication_34\NN\1073995|NONE_0 (l_prep) in_35\IN\13603305|this_18 (l_pobj) relation_36\NN\2137|NONE_0 (l_prep) to_37\IN\0|NONE_0 (l_pobj) type_39\NN\5839024|NONE_0 (l_conj) presence_46\NN\13954253|the_34|and_25|dosage_21|of_14|and_8 (l_prep) of_47\IN\0|the_13 (l_pobj) cyanosis_48\NN\14299637|NONE_0
D007472_D007674 CID iohexol_19\NN\0|and_4 (r_conj) iopromide_17\JJ\0|two_34|contrast_21|(_6|cm_5|,_2 (r_appos) media_12\NNS\3575240|NONE_0 (r_pobj) for_8\IN\0|the_21|of_7 (r_prep) incidence_5\NN\13821570|study_21|,_76|among_78|._232 (l_prep) of_6\IN\0|the_14|for_7 (l_pobj) cin_7\NNP\0|NONE_0
C038192_D007674 CID iopromide_17\JJ\0|two_34|contrast_21|(_6|cm_5|,_2 (r_appos) media_12\NNS\3575240|NONE_0 (r_pobj) for_8\IN\0|the_21|of_7 (r_prep) incidence_5\NN\13821570|study_21|,_76|among_78|._232 (l_prep) of_6\IN\0|the_14|for_7 (l_pobj) cin_7\NNP\0|NONE_0
D003287_D007674 CID media_8\NNS\3575240|risk_59|by_6|._69 (r_dobj) contrast_7\NN\13854649|NONE_0 (l_nsubj) risk_0\NN\14541044|media_59|by_65|._128 (l_prep) of_1\IN\0|after_15 (l_pobj) nephropathy_2\NN\14573196|NONE_0
D003287_D007674 CID media_6\NNS\3575240|-_5 (r_npadvmod) induced_8\VBN\1627355|(_20|cin_21|in_26 (r_amod) nephropathy_9\NN\14573196|nonionic_32
D003287_D007674 CID media_6\NNS\3575240|-_5 (r_npadvmod) induced_8\VBN\1627355|(_20|cin_21|in_26 (r_amod) nephropathy_9\NN\14573196|nonionic_32 (l_appos) cin_11\NNP\0|induced_21|(_1|in_5
D003287_D007674 CID media_12\NNS\3575240|NONE_0 (r_pobj) for_8\IN\0|the_21|of_7 (r_prep) incidence_5\NN\13821570|study_21|,_76|among_78|._232 (l_prep) of_6\IN\0|the_14|for_7 (l_pobj) cin_7\NNP\0|NONE_0
D003287_D007674 CID cm_14\NNP\13649268|two_29|contrast_16|(_1|,_3|iopromide_5 (r_appos) media_12\NNS\3575240|NONE_0 (r_pobj) for_8\IN\0|the_21|of_7 (r_prep) incidence_5\NN\13821570|study_21|,_76|among_78|._232 (l_prep) of_6\IN\0|the_14|for_7 (l_pobj) cin_7\NNP\0|NONE_0
D003287_D007674 CID cm_43\NNP\13649268|NONE_0 (r_pobj) of_42\IN\0|the_20|and_11|dosage_7|and_6|presence_14 (r_prep) type_39\NN\5839024|NONE_0 (r_pobj) to_37\IN\0|NONE_0 (r_prep) relation_36\NN\2137|NONE_0 (r_pobj) in_35\IN\13603305|this_18 (r_prep) complication_34\NN\1073995|NONE_0 (r_pobj) for_32\IN\0|the_10 (r_prep) rates_31\NNS\13308999|NONE_0 (r_dobj) compared_29\VBD\644583|patients_35|and_4 (r_conj) among_21\IN\0|study_99|incidence_78|,_2|._154 (r_prep) determined_3\VBD\0|NONE_0 (l_dobj) incidence_5\NN\13821570|study_21|,_76|among_78|._232 (l_prep) of_6\IN\0|the_14|for_7 (l_pobj) cin_7\NNP\0|NONE_0
D003287_D007674 CID cm_17\NNP\13649268|NONE_0 (r_pobj) of_16\IN\0|the_18|proper_14 (r_prep) dosage_15\NN\13576355|who_24 (r_dobj) received_12\VBD\2210855|NONE_0 (r_relcl) those_10\DT\0|NONE_0 (r_pobj) among_9\IN\0|whereas_44|%_32 (r_prep) were_8\VBD\0|,_53|percentage_59|to_80|among_89|,_126|with_128|)_231|._232 (l_nsubj) %_2\NN\0|whereas_12|among_32 (l_prep) of_3\IN\0|33.3_6 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_prep) with_6\IN\0|the_13 (l_pobj) cin_7\NNP\0|NONE_0
D003287_D007674 CID cm_17\NNP\13649268|NONE_0 (r_pobj) of_16\IN\0|the_18|proper_14 (r_prep) dosage_15\NN\13576355|who_24 (r_dobj) received_12\VBD\2210855|NONE_0 (r_relcl) those_10\DT\0|NONE_0 (r_pobj) among_9\IN\0|whereas_44|%_32 (r_prep) were_8\VBD\0|,_53|percentage_59|to_80|among_89|,_126|with_128|)_231|._232 (r_advcl) increased_21\VBD\169651|NONE_0 (l_prep) with_32\IN\0|were_128|,_75|percentage_69|to_48|among_39|,_2|)_103|._104 (l_pobj) difference_35\NN\4723816|NONE_0 (l_prep) in_36\IN\13603305|a_25|significant_23 (l_pobj) incidence_38\NN\13821570|NONE_0 (l_prep) of_39\IN\0|the_14|related_7 (l_pobj) cin_40\NNP\0|NONE_0
D003287_D007674 CID cm_47\NNP\13649268|NONE_0 (r_pobj) of_46\IN\0|the_22|different_18 (r_prep) dosages_45\NNS\13576355|NONE_0 (r_pobj) to_42\IN\0|NONE_0 (r_prep) related_41\VBN\628491|the_21|of_7 (r_acl) incidence_38\NN\13821570|NONE_0 (r_pobj) in_36\IN\13603305|a_25|significant_23 (r_prep) difference_35\NN\4723816|NONE_0 (r_pobj) with_32\IN\0|were_128|,_75|percentage_69|to_48|among_39|,_2|)_103|._104 (r_prep) increased_21\VBD\169651|NONE_0 (l_advcl) were_8\VBD\0|,_53|percentage_59|to_80|among_89|,_126|with_128|)_231|._232 (l_nsubj) %_2\NN\0|whereas_12|among_32 (l_prep) of_3\IN\0|33.3_6 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_prep) with_6\IN\0|the_13 (l_pobj) cin_7\NNP\0|NONE_0
D003287_D007674 CID cm_47\NNP\13649268|NONE_0 (r_pobj) of_46\IN\0|the_22|different_18 (r_prep) dosages_45\NNS\13576355|NONE_0 (r_pobj) to_42\IN\0|NONE_0 (r_prep) related_41\VBN\628491|the_21|of_7 (r_acl) incidence_38\NN\13821570|NONE_0 (l_prep) of_39\IN\0|the_14|related_7 (l_pobj) cin_40\NNP\0|NONE_0
D003287_D007674 CID cm_13\NNP\13649268|NONE_0 (r_pobj) of_10\IN\0|the_9 (r_prep) type_9\NN\5839024|not_11|,_28|nor_30|on_34 (r_pobj) on_7\IN\0|dosage_15|but_8 (r_conj) on_3\IN\0|incidence_18|,_86|and_88|needed_144 (r_prep) depends_2\VBZ\2604760|NONE_0 (l_conj) needed_32\VBN\0|incidence_162|on_144|,_58|and_56 (l_advcl) is_26\VBZ\0|,_13|concern_20|is_28|for_38|._91 (l_nsubj) cin_24\NNP\0|although_9|usually_4|reversible_15
D003287_D003490 NONE media_12\NNS\3575240|NONE_0 (r_pobj) for_8\IN\0|the_21|of_7 (r_prep) incidence_5\NN\13821570|study_21|,_76|among_78|._232 (r_dobj) determined_3\VBD\0|NONE_0 (l_prep) among_21\IN\0|study_99|incidence_78|,_2|._154 (l_conj) compared_29\VBD\644583|patients_35|and_4 (l_dobj) rates_31\NNS\13308999|NONE_0 (l_prep) for_32\IN\0|the_10 (l_pobj) complication_34\NN\1073995|NONE_0 (l_prep) in_35\IN\13603305|this_18 (l_pobj) relation_36\NN\2137|NONE_0 (l_prep) to_37\IN\0|NONE_0 (l_pobj) type_39\NN\5839024|NONE_0 (l_conj) presence_46\NN\13954253|the_34|and_25|dosage_21|of_14|and_8 (l_prep) of_47\IN\0|the_13 (l_pobj) cyanosis_48\NN\14299637|NONE_0
D003287_D003490 NONE cm_14\NNP\13649268|two_29|contrast_16|(_1|,_3|iopromide_5 (r_appos) media_12\NNS\3575240|NONE_0 (r_pobj) for_8\IN\0|the_21|of_7 (r_prep) incidence_5\NN\13821570|study_21|,_76|among_78|._232 (r_dobj) determined_3\VBD\0|NONE_0 (l_prep) among_21\IN\0|study_99|incidence_78|,_2|._154 (l_conj) compared_29\VBD\644583|patients_35|and_4 (l_dobj) rates_31\NNS\13308999|NONE_0 (l_prep) for_32\IN\0|the_10 (l_pobj) complication_34\NN\1073995|NONE_0 (l_prep) in_35\IN\13603305|this_18 (l_pobj) relation_36\NN\2137|NONE_0 (l_prep) to_37\IN\0|NONE_0 (l_pobj) type_39\NN\5839024|NONE_0 (l_conj) presence_46\NN\13954253|the_34|and_25|dosage_21|of_14|and_8 (l_prep) of_47\IN\0|the_13 (l_pobj) cyanosis_48\NN\14299637|NONE_0
D003287_D003490 NONE cm_43\NNP\13649268|NONE_0 (r_pobj) of_42\IN\0|the_20|and_11|dosage_7|and_6|presence_14 (r_prep) type_39\NN\5839024|NONE_0 (l_conj) presence_46\NN\13954253|the_34|and_25|dosage_21|of_14|and_8 (l_prep) of_47\IN\0|the_13 (l_pobj) cyanosis_48\NN\14299637|NONE_0
D003287_D003490 NONE cm_13\NNP\13649268|NONE_0 (r_pobj) of_10\IN\0|the_9 (r_prep) type_9\NN\5839024|not_11|,_28|nor_30|on_34 (r_pobj) on_7\IN\0|dosage_15|but_8 (l_conj) on_16\IN\0|not_45|type_34|,_6|nor_4 (l_pobj) presence_18\NN\13954253|NONE_0 (l_prep) of_19\IN\0|the_13 (l_pobj) cyanosis_20\NN\14299637|NONE_0
15673851
D016202_D020760 NONE aspartate_10\NN\0|spinal_18 (r_compound) receptors_11\NNS\5225602|NONE_0 (r_pobj) of_2\IN\0|the_15 (r_prep) activation_1\NN\13561719|may_52|to_67|._190 (r_nsubj) contribute_13\VB\126264|NONE_0 (l_prep) to_14\IN\0|activation_67|may_15|._123 (l_pobj) degeneration_15\NN\29677|NONE_0 (l_acl) induced_20\VBN\1627355|of_24 (l_prep) after_24\IN\0|by_22 (l_pobj) interval_27\NN\33615|NONE_0 (l_prep) of_28\IN\0|a_24|noninjurious_22 (l_pobj) ischemia_31\NN\14195315|NONE_0
D016202_D020760 NONE nmda_15\NNP\0|receptor_5 (r_compound) activation_17\NN\13561719|NONE_0 (r_pobj) via_14\IN\0|cord_14 (r_prep) ischemia_13\NN\14195315|NONE_0
D016202_D020258 NONE nmda_15\NNP\0|receptor_5 (r_compound) activation_17\NN\13561719|NONE_0 (r_pobj) via_14\IN\0|cord_14 (r_prep) ischemia_13\NN\14195315|NONE_0 (r_pobj) of_10\IN\0|the_12 (r_prep) setting_9\NN\8567235|NONE_0 (r_pobj) in_7\IN\13603305|that_31|opioids_26|may_18|neurotoxic_11 (r_prep) be_5\VB\14625458|we_28|._81 (l_acomp) neurotoxic_6\JJ\0|that_20|opioids_15|may_7|in_11
D016202_D001157 NONE aspartate_20\NNP\0|(_10|nmda_11|)_15 (r_nmod) receptors_24\NNS\5225602|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) activation_12\NN\13561719|spinal_25|motor_18|and_4 (r_conj) neurons_10\NNS\5430628|NONE_0 (r_pobj) of_7\IN\0|the_17|after_80|following_105 (r_prep) degeneration_6\NN\29677|NONE_0 (l_prep) following_28\VBG\8180190|the_122|of_105|after_25 (l_pobj) interval_31\NN\33615|NONE_0 (l_prep) of_32\IN\0|a_24|noninjurious_22 (l_pobj) occlusion_34\NN\14081375|NONE_0
D016202_D001157 NONE nmda_22\NNP\0|aspartate_11|(_1|)_4 (r_nmod) receptors_24\NNS\5225602|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) activation_12\NN\13561719|spinal_25|motor_18|and_4 (r_conj) neurons_10\NNS\5430628|NONE_0 (r_pobj) of_7\IN\0|the_17|after_80|following_105 (r_prep) degeneration_6\NN\29677|NONE_0 (l_prep) following_28\VBG\8180190|the_122|of_105|after_25 (l_pobj) interval_31\NN\33615|NONE_0 (l_prep) of_32\IN\0|a_24|noninjurious_22 (l_pobj) occlusion_34\NN\14081375|NONE_0
D018698_D020336 NONE glutamate_15\NN\15010703|NONE_0 (r_pobj) in_13\IN\13603305|a_23|concomitant_21 (r_prep) increase_12\NN\13576355|NONE_0 (r_pobj) with_9\IN\0|that_45|morphine_37|paraparesis_12 (r_prep) induces_6\VBZ\1627355|data_31|._119 (l_dobj) paraparesis_8\NN\14558599|that_33|morphine_25|with_12
D016202_D020336 NONE nmda_21\NNP\0|receptor_5 (r_compound) activation_23\NN\13561719|NONE_0 (r_pobj) in_20\IN\13603305|which_18|is_12 (r_prep) involved_19\VBN\2676054|csf_24|,_11 (r_relcl) glutamate_15\NN\15010703|NONE_0 (r_pobj) in_13\IN\13603305|a_23|concomitant_21 (r_prep) increase_12\NN\13576355|NONE_0 (r_pobj) with_9\IN\0|that_45|morphine_37|paraparesis_12 (r_prep) induces_6\VBZ\1627355|data_31|._119 (l_dobj) paraparesis_8\NN\14558599|that_33|morphine_25|with_12
D009020_D020760 NONE morphine_23\NN\2707683|NONE_0 (r_pobj) by_21\IN\0|after_22 (r_agent) induced_20\VBN\1627355|of_24 (l_prep) after_24\IN\0|by_22 (l_pobj) interval_27\NN\33615|NONE_0 (l_prep) of_28\IN\0|a_24|noninjurious_22 (l_pobj) ischemia_31\NN\14195315|NONE_0
D016291_D020336 NONE mk-801_8\NNP\0|NONE_0 (r_punct) (_9\-LRB-\0|30_1|)_7|on_9 (r_punct) mug_11\NN\13756125|second_52|,_46|we_44|effect_24|._97 (l_prep) on_13\IN\0|(_9|30_8|)_2 (l_pobj) changes_16\NNS\7283608|NONE_0 (l_prep) after_21\IN\0|the_47|histopathologic_43|in_19 (l_pobj) paraparesis_26\NN\14558599|NONE_0
D016291_D020336 NONE mk-801_1\NNP\0|it_3|significantly_7|number_33|after_74|compared_117|._147 (r_punct) reduced_3\VBD\441445|NONE_0 (l_prep) after_13\IN\0|it_77|mk-801_74|significantly_67|number_41|compared_43|._73 (l_pobj) paraparesis_18\NN\14558599|NONE_0
D009020_D020336 CID morphine_22\NN\2707683|-_8 (r_npadvmod) induced_24\VBN\1627355|spastic_8 (r_amod) paraparesis_26\NN\14558599|NONE_0
D009020_D020336 CID morphine_14\NN\2707683|-_8 (r_npadvmod) induced_16\VBN\1627355|spastic_8 (r_amod) paraparesis_18\NN\14558599|NONE_0
D009020_D020336 CID morphine_5\NN\2707683|that_8|paraparesis_25|with_37 (r_nsubj) induces_6\VBZ\1627355|data_31|._119 (l_dobj) paraparesis_8\NN\14558599|that_33|morphine_25|with_12
D009020_D001157 NONE morphine_27\NN\2707683|NONE_0 (r_pobj) after_25\IN\0|the_97|of_80|following_25 (r_prep) degeneration_6\NN\29677|NONE_0 (l_prep) following_28\VBG\8180190|the_122|of_105|after_25 (l_pobj) interval_31\NN\33615|NONE_0 (l_prep) of_32\IN\0|a_24|noninjurious_22 (l_pobj) occlusion_34\NN\14081375|NONE_0
7647582
D014269_D056486 NONE trifluoroacetyl_11\JJ\0|NONE_0 (r_compound) adduct_12\NN\14818238|a_59|bound_49|biotransformation_43|(_17|)_6 (r_appos) product_9\NN\3076708|NONE_0 (r_pobj) to_3\IN\0|an_21|antibody_18 (r_prep) response_2\NN\11410625|has_79|been_83|on_97|._128 (r_nsubjpass) detected_16\VBN\2163746|NONE_0 (l_prep) on_17\IN\0|response_97|has_18|been_14|._31 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_compound) hepatitis_19\NN\14127211|halothane_10
D006221_D056486 CID halothane_25\NN\3570838|previous_21 (r_relcl) exposure_23\NN\5042871|NONE_0 (r_pobj) following_21\VBG\8180190|anesthetics_112|have_73|been_68|with_52|alone_10|._40 (r_agent) associated_10\VBN\628491|NONE_0 (l_prep) with_11\IN\0|anesthetics_60|have_21|been_16|alone_42|following_52|._92 (l_pobj) injury_17\NN\14052046|NONE_0
D006221_D056486 CID halothane_0\NNP\3570838|NONE_0 (r_compound) hepatitis_1\NN\14127211|involve_21|._56
D006221_D056486 CID halothane_18\NN\3570838|hepatitis_10 (r_amod) patients_20\NNS\9898892|NONE_0 (l_compound) hepatitis_19\NN\14127211|halothane_10
D006221_D056486 CID halothane_23\NN\3570838|NONE_0 (r_compound) hepatitis_24\NN\14127211|NONE_0
D006221_D056486 CID halothane_30\NN\3570838|supports_204|enflurane_140|could_112|condition_79|alone_23|._24 (r_advcl) produce_15\VB\7555863|NONE_0 (l_dobj) condition_18\NN\24720|supports_125|enflurane_61|could_33|alone_56|halothane_79|._103 (l_amod) similar_19\JJ\0|a_29|hypersensitivity_27 (l_prep) to_20\IN\0|NONE_0 (l_pobj) that_21\DT\0|NONE_0 (l_prep) of_22\IN\0|NONE_0 (l_pobj) hepatitis_24\NN\14127211|NONE_0
D004737_D004342 NONE enflurane_10\NN\3299929|NONE_0 (l_conj) isoflurane_12\RB\3570838|and_4 (l_prep) with_13\IN\0|NONE_0 (l_pobj) hypersensitivity_15\NN\14531772|NONE_0
D004737_D004342 NONE enflurane_11\NN\3299929|supports_64|could_28|condition_61|alone_117|halothane_140|._164 (r_nsubj) produce_15\VB\7555863|NONE_0 (l_dobj) condition_18\NN\24720|supports_125|enflurane_61|could_33|alone_56|halothane_79|._103 (l_compound) hypersensitivity_17\NN\14531772|a_2|similar_27
D007530_D056486 CID isoflurane_6\RB\3570838|and_4 (r_conj) enflurane_4\NN\3299929|two_29|halogenated_25|,_2|,_24 (r_conj) anesthetics_2\NNS\3247620|have_39|been_44|with_60|alone_102|following_112|._152 (r_nsubjpass) associated_10\VBN\628491|NONE_0 (l_prep) with_11\IN\0|anesthetics_60|have_21|been_16|alone_42|following_52|._92 (l_pobj) injury_17\NN\14052046|NONE_0
D007530_D056486 CID isoflurane_13\NN\3570838|by_26|and/or_7 (r_conj) enflurane_11\NN\3299929|supports_64|could_28|condition_61|alone_117|halothane_140|._164 (r_nsubj) produce_15\VB\7555863|NONE_0 (l_dobj) condition_18\NN\24720|supports_125|enflurane_61|could_33|alone_56|halothane_79|._103 (l_amod) similar_19\JJ\0|a_29|hypersensitivity_27 (l_prep) to_20\IN\0|NONE_0 (l_pobj) that_21\DT\0|NONE_0 (l_prep) of_22\IN\0|NONE_0 (l_pobj) hepatitis_24\NN\14127211|NONE_0
D007530_D004342 NONE isoflurane_12\RB\3570838|and_4 (l_prep) with_13\IN\0|NONE_0 (l_pobj) hypersensitivity_15\NN\14531772|NONE_0
D007530_D004342 NONE isoflurane_13\NN\3570838|by_26|and/or_7 (r_conj) enflurane_11\NN\3299929|supports_64|could_28|condition_61|alone_117|halothane_140|._164 (r_nsubj) produce_15\VB\7555863|NONE_0 (l_dobj) condition_18\NN\24720|supports_125|enflurane_61|could_33|alone_56|halothane_79|._103 (l_compound) hypersensitivity_17\NN\14531772|a_2|similar_27
D006221_D004342 NONE halothane_18\NN\3570838|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|the_21 (r_acl) hypersensitivity_15\NN\14531772|NONE_0
D006221_D004342 NONE halothane_23\NN\3570838|NONE_0 (r_compound) hepatitis_24\NN\14127211|NONE_0 (r_pobj) of_22\IN\0|NONE_0 (r_prep) that_21\DT\0|NONE_0 (r_pobj) to_20\IN\0|NONE_0 (r_prep) similar_19\JJ\0|a_29|hypersensitivity_27 (r_amod) condition_18\NN\24720|supports_125|enflurane_61|could_33|alone_56|halothane_79|._103 (l_compound) hypersensitivity_17\NN\14531772|a_2|similar_27
D006221_D004342 NONE halothane_30\NN\3570838|supports_204|enflurane_140|could_112|condition_79|alone_23|._24 (r_advcl) produce_15\VB\7555863|NONE_0 (l_dobj) condition_18\NN\24720|supports_125|enflurane_61|could_33|alone_56|halothane_79|._103 (l_compound) hypersensitivity_17\NN\14531772|a_2|similar_27
D004737_D056486 CID enflurane_4\NN\3299929|two_29|halogenated_25|,_2|,_24 (r_conj) anesthetics_2\NNS\3247620|have_39|been_44|with_60|alone_102|following_112|._152 (r_nsubjpass) associated_10\VBN\628491|NONE_0 (l_prep) with_11\IN\0|anesthetics_60|have_21|been_16|alone_42|following_52|._92 (l_pobj) injury_17\NN\14052046|NONE_0
D004737_D056486 CID enflurane_11\NN\3299929|supports_64|could_28|condition_61|alone_117|halothane_140|._164 (r_nsubj) produce_15\VB\7555863|NONE_0 (l_dobj) condition_18\NN\24720|supports_125|enflurane_61|could_33|alone_56|halothane_79|._103 (l_amod) similar_19\JJ\0|a_29|hypersensitivity_27 (l_prep) to_20\IN\0|NONE_0 (l_pobj) that_21\DT\0|NONE_0 (l_prep) of_22\IN\0|NONE_0 (l_pobj) hepatitis_24\NN\14127211|NONE_0
7059267
D002747_D003924 NONE chlorpropamide_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|woman_40 (r_prep) treated_10\VBN\2376958|neuropathy_58|._129 (l_nsubj) woman_4\NN\9605289|with_40 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) diabetes_9\NNS\14075199|NONE_0
D002747_D003924 NONE diabenese_14\NNP\0|(_1|)_9 (r_appos) chlorpropamide_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|woman_40 (r_prep) treated_10\VBN\2376958|neuropathy_58|._129 (l_nsubj) woman_4\NN\9605289|with_40 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) diabetes_9\NNS\14075199|NONE_0
D002747_D003924 NONE chlorpropamide_26\NN\0|NONE_0 (r_amod) therapy_27\NN\657604|NONE_0 (r_pobj) of_25\IN\0|NONE_0 (r_prep) discontinuation_24\NN\209943|NONE_0 (r_pobj) with_23\IN\0|that_14 (r_prep) resolved_22\VBD\352826|a_30|toxic_28|optic_22 (r_relcl) neuropathy_20\NN\14204950|treated_58|._71 (r_dobj) had_16\VBD\0|NONE_0 (l_csubj) treated_10\VBN\2376958|neuropathy_58|._129 (l_nsubj) woman_4\NN\9605289|with_40 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) diabetes_9\NNS\14075199|NONE_0
D002747_D009901 CID chlorpropamide_0\NN\0|-_14 (r_npadvmod) induced_2\VBN\1627355|optic_8|._24 (r_amod) neuropathy_4\NN\14204950|NONE_0
D002747_D009901 CID chlorpropamide_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|woman_40 (r_prep) treated_10\VBN\2376958|neuropathy_58|._129 (r_csubj) had_16\VBD\0|NONE_0 (l_dobj) neuropathy_20\NN\14204950|treated_58|._71
D002747_D009901 CID diabenese_14\NNP\0|(_1|)_9 (r_appos) chlorpropamide_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|woman_40 (r_prep) treated_10\VBN\2376958|neuropathy_58|._129 (r_csubj) had_16\VBD\0|NONE_0 (l_dobj) neuropathy_20\NN\14204950|treated_58|._71
D002747_D009901 CID chlorpropamide_26\NN\0|NONE_0 (r_amod) therapy_27\NN\657604|NONE_0 (r_pobj) of_25\IN\0|NONE_0 (r_prep) discontinuation_24\NN\209943|NONE_0 (r_pobj) with_23\IN\0|that_14 (r_prep) resolved_22\VBD\352826|a_30|toxic_28|optic_22 (r_relcl) neuropathy_20\NN\14204950|treated_58|._71
2528969
11208990
D000109_D007674 NONE acetylcholine_5\NN\14807558|NONE_0 (r_npadvmod) related_6\VBN\628491|iprk_37|and_18 (r_conj) phenylephrine_3\NN\2682038|the_9 (r_nmod) responses_7\NNS\11410625|NONE_0 (r_pobj) in_0\IN\13603305|impaired_81|._118 (r_prep) were_8\VBD\0|NONE_0 (l_acomp) impaired_10\VBN\258857|in_81|._37 (l_prep) in_11\IN\13603305|significantly_23 (l_pobj) group_16\NN\2137|NONE_0 (l_compound) nephropathy_15\NN\14573196|the_8
D004317_D009401 NONE adr_15\NNP\0|-_3 (r_npadvmod) induced_17\VBN\1627355|the_8 (r_amod) nephrosis_18\NN\14304060|NONE_0
D009569_D007674 NONE oxide_3\NN\14818238|NONE_0 (r_compound) production_4\NN\30358|NONE_0 (r_pobj) of_1\IN\0|and_27|apoptosis_31|._79 (r_prep) association_0\NN\8008335|NONE_0 (l_conj) apoptosis_6\NN\11486178|of_31|and_4|._48 (l_prep) in_7\IN\13603305|NONE_0 (l_pobj) model_9\NN\5888929|NONE_0 (l_prep) of_10\IN\0|a_8 (l_pobj) nephropathy_12\NN\14573196|NONE_0
D004317_D009395 NONE adr_9\NNP\0|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) treated_7\VBN\2376958|NONE_0 (r_acl) rats_6\NNS\2329401|NONE_0 (r_pobj) of_5\IN\0|the_12 (r_prep) kidneys_4\NNS\5333259|NONE_0 (r_pobj) of_2\IN\0|histopathological_30 (r_prep) examination_1\NN\633864|areas_67|._140 (r_nsubj) revealed_10\VBD\2137132|NONE_0 (l_dobj) areas_12\NNS\8630985|examination_67|._73 (l_prep) of_13\IN\0|focal_12 (l_pobj) proliferation_15\NN\13489037|NONE_0 (l_conj) inflammation_19\NN\14299637|mesangial_52|and_28
D009569_D009401 NONE no_5\UH\7204911|NONE_0 (r_intj) between_4\IN\0|NONE_0 (r_prep) interactions_3\NNS\37396|that_5|important_42|in_52 (r_nsubj) are_8\VBP\13600404|we_54|._62 (l_prep) in_10\IN\13603305|that_57|interactions_52|important_10 (l_pobj) pathogenesis_12\NN\13533470|NONE_0 (l_prep) of_13\IN\0|the_17 (l_pobj) nephrosis_18\NN\14304060|NONE_0
D010656_D007674 NONE phenylephrine_3\NN\2682038|the_9 (r_nmod) responses_7\NNS\11410625|NONE_0 (r_pobj) in_0\IN\13603305|impaired_81|._118 (r_prep) were_8\VBD\0|NONE_0 (l_acomp) impaired_10\VBN\258857|in_81|._37 (l_prep) in_11\IN\13603305|significantly_23 (l_pobj) group_16\NN\2137|NONE_0 (l_compound) nephropathy_15\NN\14573196|the_8
D004317_D007674 NONE adr_7\NNP\0|-_3 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) nephropathy_10\NN\14573196|NONE_0
D004317_D007674 NONE adr_8\NNP\0|-_3 (r_compound) nephropathy_10\NN\14573196|the_8|(_18|p_19|)_27
D004317_D007674 NONE adr_13\NNP\0|-_3 (r_compound) nephropathy_15\NN\14573196|the_8
D004317_D007674 NONE adr_4\NNP\0|-_3 (r_compound) nephropathy_6\NN\14573196|the_8
D009569_D009404 NONE no_6\DT\7204911|association_11 (r_intj) of_5\IN\0|the_9 (l_pobj) association_9\NN\8008335|no_11 (l_prep) with_10\IN\0|its_16 (l_pobj) apoptosis_11\NN\11486178|NONE_0 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) model_15\NN\5888929|NONE_0 (l_prep) of_16\IN\0|an_22|experimental_19|induced_22 (l_pobj) syndrome_18\NN\5870365|NONE_0
D009573_D007674 NONE nitrite_1\NN\14621446|urine_6 (r_compound) levels_2\NNS\4916342|were_7|significantly_12|in_36|._75 (r_nsubjpass) increased_5\VBN\169651|NONE_0 (l_prep) in_6\IN\13603305|levels_36|were_29|significantly_24|._39 (l_pobj) group_11\NN\2137|NONE_0 (l_compound) nephropathy_10\NN\14573196|the_8|(_18|p_19|)_27
D004317_D009404 CID adriamycin_25\NNS\0|NONE_0 (r_pobj) of_24\IN\0|a_19|single_17 (r_prep) injection_23\NN\320852|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|an_44|experimental_41|of_22 (r_acl) model_15\NN\5888929|NONE_0 (l_prep) of_16\IN\0|an_22|experimental_19|induced_22 (l_pobj) syndrome_18\NN\5870365|NONE_0
D004317_D009404 CID adr_27\NNP\0|(_1|)_3 (r_appos) adriamycin_25\NNS\0|NONE_0 (r_pobj) of_24\IN\0|a_19|single_17 (r_prep) injection_23\NN\320852|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|an_44|experimental_41|of_22 (r_acl) model_15\NN\5888929|NONE_0 (l_prep) of_16\IN\0|an_22|experimental_19|induced_22 (l_pobj) syndrome_18\NN\5870365|NONE_0
D004317_C537346 NONE adr_9\NNP\0|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) treated_7\VBN\2376958|NONE_0 (r_acl) rats_6\NNS\2329401|NONE_0 (r_pobj) of_5\IN\0|the_12 (r_prep) kidneys_4\NNS\5333259|NONE_0 (r_pobj) of_2\IN\0|histopathological_30 (r_prep) examination_1\NN\633864|areas_67|._140 (r_nsubj) revealed_10\VBD\2137132|NONE_0 (l_dobj) areas_12\NNS\8630985|examination_67|._73 (l_prep) of_13\IN\0|focal_12 (l_pobj) proliferation_15\NN\13489037|NONE_0
16634859
D000431_D006130 CID alcohol_9\NN\7881800|-_7 (r_npadvmod) related_11\VBN\628491|growth_14 (r_amod) impairment_14\NN\7296428|NONE_0
D000431_D006130 CID alcohol_1\NN\7881800|NONE_0 (r_compound) consumption_2\NN\13440063|any_12|postpregnancy_12|among_38 (r_compound) recognition_4\NN\13932421|in_46|._192 (r_nsubj) resulted_9\VBD\2633881|NONE_0 (l_prep) in_10\IN\13603305|recognition_46|._146 (l_pobj) growth_13\NN\13526110|NONE_0
D000431_D006130 CID alcohol_1\NN\7881800|NONE_0 (r_compound) consumption_2\NN\13440063|any_12|postpregnancy_12|among_38 (r_compound) recognition_4\NN\13932421|in_46|._192 (r_nsubj) resulted_9\VBD\2633881|NONE_0 (l_prep) in_10\IN\13603305|recognition_46|._146 (l_pobj) growth_13\NN\13526110|NONE_0 (l_conj) cranial_18\JJ\0|reduced_47|cerebellar_39|as_13 (l_acl) body_20\NN\19128|decreased_21 (l_dobj) growth_21\NN\13526110|to_8|in_7
16428827
D012601_D007859 NONE scopolamine_12\NN\14712692|-_11 (r_npadvmod) induced_14\VBN\1627355|of_20 (r_amod) impairments_15\NNS\7296428|NONE_0 (l_prep) of_16\IN\0|induced_20 (l_pobj) learning_17\NN\5701944|NONE_0 (l_conj) memory_19\NN\5926676|and_4
D012601_D000647 CID scopolamine_16\NN\14712692|-_11 (r_npadvmod) induced_18\VBN\1627355|NONE_0 (r_amod) amnesia_19\NN\5669934|to_31
D012601_D000647 CID scopolamine_22\NN\14712692|-_11 (r_npadvmod) induced_24\VBN\1627355|NONE_0 (r_amod) amnesia_25\NN\5669934|that_45|it_40|also_37
D000109_D000544 NONE acetylcholine_20\NN\14807558|(_14 (r_nmod) ach_22\NNS\0|NONE_0 (r_pobj) of_19\IN\0|the_25|enzymatic_21 (r_prep) production_18\NN\30358|NONE_0 (r_pobj) of_15\IN\0|an_16 (r_prep) augmentation_14\NN\7356676|NONE_0 (r_pobj) via_12\IN\0|which_40|transmission_13 (r_prep) enhances_9\VBZ\227165|(_24|chat_23|)_19|,_8|)_103 (r_relcl) activator_6\NN\19613|the_37|choline_33|,_121 (r_appos) acetyltransferase_2\NN\0|factor_164|._215 (r_nsubj) is_25\VBZ\0|NONE_0 (l_attr) factor_28\NN\7326557|acetyltransferase_164|._51 (l_prep) in_29\IN\13603305|an_20|important_17 (l_pobj) treatment_31\NN\654885|NONE_0 (l_prep) of_32\IN\0|the_14 (l_pobj) disease_35\NN\14061805|NONE_0
D000109_D000544 NONE acetylcholine_20\NN\14807558|(_14 (r_nmod) ach_22\NNS\0|NONE_0 (r_pobj) of_19\IN\0|the_25|enzymatic_21 (r_prep) production_18\NN\30358|NONE_0 (r_pobj) of_15\IN\0|an_16 (r_prep) augmentation_14\NN\7356676|NONE_0 (r_pobj) via_12\IN\0|which_40|transmission_13 (r_prep) enhances_9\VBZ\227165|(_24|chat_23|)_19|,_8|)_103 (r_relcl) activator_6\NN\19613|the_37|choline_33|,_121 (r_appos) acetyltransferase_2\NN\0|factor_164|._215 (r_nsubj) is_25\VBZ\0|NONE_0 (l_attr) factor_28\NN\7326557|acetyltransferase_164|._51 (l_prep) in_29\IN\13603305|an_20|important_17 (l_pobj) treatment_31\NN\654885|NONE_0 (l_prep) of_32\IN\0|the_14 (l_pobj) disease_35\NN\14061805|NONE_0 (l_appos) ad_37\NN\7247071|alzheimer_21|)_2
D000109_D000544 NONE ach_22\NNS\0|NONE_0 (r_pobj) of_19\IN\0|the_25|enzymatic_21 (r_prep) production_18\NN\30358|NONE_0 (r_pobj) of_15\IN\0|an_16 (r_prep) augmentation_14\NN\7356676|NONE_0 (r_pobj) via_12\IN\0|which_40|transmission_13 (r_prep) enhances_9\VBZ\227165|(_24|chat_23|)_19|,_8|)_103 (r_relcl) activator_6\NN\19613|the_37|choline_33|,_121 (r_appos) acetyltransferase_2\NN\0|factor_164|._215 (r_nsubj) is_25\VBZ\0|NONE_0 (l_attr) factor_28\NN\7326557|acetyltransferase_164|._51 (l_prep) in_29\IN\13603305|an_20|important_17 (l_pobj) treatment_31\NN\654885|NONE_0 (l_prep) of_32\IN\0|the_14 (l_pobj) disease_35\NN\14061805|NONE_0
D000109_D000544 NONE ach_22\NNS\0|NONE_0 (r_pobj) of_19\IN\0|the_25|enzymatic_21 (r_prep) production_18\NN\30358|NONE_0 (r_pobj) of_15\IN\0|an_16 (r_prep) augmentation_14\NN\7356676|NONE_0 (r_pobj) via_12\IN\0|which_40|transmission_13 (r_prep) enhances_9\VBZ\227165|(_24|chat_23|)_19|,_8|)_103 (r_relcl) activator_6\NN\19613|the_37|choline_33|,_121 (r_appos) acetyltransferase_2\NN\0|factor_164|._215 (r_nsubj) is_25\VBZ\0|NONE_0 (l_attr) factor_28\NN\7326557|acetyltransferase_164|._51 (l_prep) in_29\IN\13603305|an_20|important_17 (l_pobj) treatment_31\NN\654885|NONE_0 (l_prep) of_32\IN\0|the_14 (l_pobj) disease_35\NN\14061805|NONE_0 (l_appos) ad_37\NN\7247071|alzheimer_21|)_2
D000109_D000647 NONE acetylcholine_10\NN\14807558|NONE_0 (r_compound) biosynthesis_11\NN\13565379|NONE_0 (r_pobj) in_9\IN\13603305|a_7 (r_prep) role_8\NN\719494|that_27|daidzein_22|might_13|as_35|,_54|and_56|ameliorates_73 (r_dobj) play_6\VB\7007684|results_37|._119 (l_conj) ameliorates_21\VBZ\126264|that_100|daidzein_95|might_86|role_73|as_38|,_19|and_17 (l_dobj) amnesia_25\NN\5669934|that_45|it_40|also_37
C004742_D008569 NONE daidzein_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_12|from_12 (r_prep) effects_5\NNS\13245626|to_19 (l_prep) from_8\IN\0|the_24|of_12 (l_pobj) thunbergiana_10\NNS\0|NONE_0 (l_prep) on_11\IN\0|pueraria_22 (l_pobj) impairments_15\NNS\7296428|NONE_0 (l_prep) of_16\IN\0|induced_20 (l_pobj) learning_17\NN\5701944|NONE_0 (l_conj) memory_19\NN\5926676|and_4
D002794_D000647 NONE choline_2\NN\15090742|NONE_0 (r_compound) acetyltransferase_3\NN\0|daidzein_27|from_18|and_36|improves_40|._69 (r_dobj) activates_1\VBZ\1641914|NONE_0 (l_conj) improves_10\VBZ\126264|daidzein_67|acetyltransferase_40|from_22|and_4|._29 (l_dobj) amnesia_14\NN\5669934|NONE_0
D012601_D008569 NONE scopolamine_12\NN\14712692|-_11 (r_npadvmod) induced_14\VBN\1627355|of_20 (r_amod) impairments_15\NNS\7296428|NONE_0 (l_prep) of_16\IN\0|induced_20 (l_pobj) learning_17\NN\5701944|NONE_0 (l_conj) memory_19\NN\5926676|and_4
D002794_D000544 NONE choline_1\NN\15090742|the_4|activator_33|,_154 (r_compound) acetyltransferase_2\NN\0|factor_164|._215 (r_nsubj) is_25\VBZ\0|NONE_0 (l_attr) factor_28\NN\7326557|acetyltransferase_164|._51 (l_prep) in_29\IN\13603305|an_20|important_17 (l_pobj) treatment_31\NN\654885|NONE_0 (l_prep) of_32\IN\0|the_14 (l_pobj) disease_35\NN\14061805|NONE_0
D002794_D000544 NONE choline_1\NN\15090742|the_4|activator_33|,_154 (r_compound) acetyltransferase_2\NN\0|factor_164|._215 (r_nsubj) is_25\VBZ\0|NONE_0 (l_attr) factor_28\NN\7326557|acetyltransferase_164|._51 (l_prep) in_29\IN\13603305|an_20|important_17 (l_pobj) treatment_31\NN\654885|NONE_0 (l_prep) of_32\IN\0|the_14 (l_pobj) disease_35\NN\14061805|NONE_0 (l_appos) ad_37\NN\7247071|alzheimer_21|)_2
C004742_D000647 NONE daidzein_0\NNP\0|acetyltransferase_27|from_45|and_63|improves_67|._96 (r_nsubj) activates_1\VBZ\1641914|NONE_0 (l_conj) improves_10\VBZ\126264|daidzein_67|acetyltransferase_40|from_22|and_4|._29 (l_dobj) amnesia_14\NN\5669934|NONE_0
C004742_D000647 NONE daidzein_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|weight_28|to_36 (r_prep) administration_0\NN\1133281|was_59|significantly_69|reverse_86|,_121|according_123|._164 (r_nsubjpass) shown_12\VBN\2137132|NONE_0 (l_xcomp) reverse_15\VB\13854649|administration_86|was_27|significantly_17|,_35|according_37|._78 (l_dobj) amnesia_19\NN\5669934|to_31
C004742_D000647 NONE daidzein_4\NN\0|that_5|might_9|role_22|as_57|,_76|and_78|ameliorates_95 (r_nsubj) play_6\VB\7007684|results_37|._119 (l_conj) ameliorates_21\VBZ\126264|that_100|daidzein_95|might_86|role_73|as_38|,_19|and_17 (l_dobj) amnesia_25\NN\5669934|that_45|it_40|also_37
C004742_D007859 NONE daidzein_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_12|from_12 (r_prep) effects_5\NNS\13245626|to_19 (l_prep) from_8\IN\0|the_24|of_12 (l_pobj) thunbergiana_10\NNS\0|NONE_0 (l_prep) on_11\IN\0|pueraria_22 (l_pobj) impairments_15\NNS\7296428|NONE_0 (l_prep) of_16\IN\0|induced_20 (l_pobj) learning_17\NN\5701944|NONE_0 (l_conj) memory_19\NN\5926676|and_4
7910951
D003473_D009468 CID nmba_21\NNP\0|to_6 (r_pobj) due_17\IN\5174653|(_13|most_12|likely_33 (r_prep) likely_16\JJ\0|at_41 (r_parataxis) pathology_8\NN\6045562|to_3 (l_prep) at_9\IN\14622893|likely_41 (l_pobj) junction_13\NN\8664443|NONE_0
D000305_D009468 NONE corticosteroids_30\NNS\14745635|to_3 (r_pobj) due_28\IN\5174653|(_13|most_12|)_22 (r_prep) likely_27\JJ\0|(_46|most_45|due_33 (r_parataxis) likely_16\JJ\0|at_41 (r_parataxis) pathology_8\NN\6045562|to_3 (l_prep) at_9\IN\14622893|likely_41 (l_pobj) junction_13\NN\8664443|NONE_0
D003473_D018908 CID agents_9\NNS\7347|NONE_0 (r_pobj) of_5\IN\0|the_18|term_9 (r_prep) use_4\NN\407535|has_63|recently_67|been_76|as_92|,_131|been_199|._211 (r_nsubjpass) implicated_18\VBN\2677097|NONE_0 (l_prep) as_19\IN\14622893|use_92|has_29|recently_25|been_16|,_39|been_107|._119 (l_pobj) cause_21\NN\7323922|NONE_0 (l_prep) of_22\IN\0|a_8 (l_pobj) weakness_25\NN\14462666|NONE_0
D003473_D018908 CID nmba_13\NNP\0|neuromuscular_34|blocking_20|(_4|)_4 (r_appos) agents_9\NNS\7347|NONE_0 (r_pobj) of_5\IN\0|the_18|term_9 (r_prep) use_4\NN\407535|has_63|recently_67|been_76|as_92|,_131|been_199|._211 (r_nsubjpass) implicated_18\VBN\2677097|NONE_0 (l_prep) as_19\IN\14622893|use_92|has_29|recently_25|been_16|,_39|been_107|._119 (l_pobj) cause_21\NN\7323922|NONE_0 (l_prep) of_22\IN\0|a_8 (l_pobj) weakness_25\NN\14462666|NONE_0
D003473_D018908 CID nmbas_25\NNP\0|NONE_0 (r_pobj) of_22\IN\0|the_20 (r_prep) discontinuation_21\NN\209943|NONE_0 (r_pobj) following_19\VBG\8180190|prolonged_19 (r_prep) weakness_18\NN\14462666|who_24
D003473_D018908 CID nmba_21\NNP\0|to_6 (r_pobj) due_17\IN\5174653|(_13|most_12|likely_33 (r_prep) likely_16\JJ\0|at_41 (r_parataxis) pathology_8\NN\6045562|to_3 (r_pobj) due_6\JJ\5174653|weakness_30|._128 (r_acomp) is_5\VBZ\0|NONE_0 (l_nsubj) weakness_1\NN\14462666|due_30|._158
D000305_D018908 NONE corticosteroids_30\NNS\14745635|to_3 (r_pobj) due_28\IN\5174653|(_13|most_12|)_22 (r_prep) likely_27\JJ\0|(_46|most_45|due_33 (r_parataxis) likely_16\JJ\0|at_41 (r_parataxis) pathology_8\NN\6045562|to_3 (r_pobj) due_6\JJ\5174653|weakness_30|._128 (r_acomp) is_5\VBZ\0|NONE_0 (l_nsubj) weakness_1\NN\14462666|due_30|._158
D003473_D012131 NONE nmbas_25\NNP\0|NONE_0 (r_pobj) of_22\IN\0|the_20 (r_prep) discontinuation_21\NN\209943|NONE_0 (r_pobj) following_19\VBG\8180190|prolonged_19 (r_prep) weakness_18\NN\14462666|who_24 (r_dobj) developed_16\VBD\1753788|acute_36|respiratory_30 (r_relcl) insufficiency_14\NN\14462946|NONE_0
D003473_D010243 NONE agents_7\NNS\7347|nondepolarizing_39 (r_appos) neuromuscular_5\JJ\0|to_19 (r_pobj) due_2\IN\5174653|prolonged_20|._72 (r_prep) paralysis_1\NN\14557898|NONE_0
D000305_D010243 NONE corticosteroids_9\NNS\14745635|blocking_20|and_4 (r_conj) agents_7\NNS\7347|nondepolarizing_39 (r_appos) neuromuscular_5\JJ\0|to_19 (r_pobj) due_2\IN\5174653|prolonged_20|._72 (r_prep) paralysis_1\NN\14557898|NONE_0
7437994
6127992
D014700_D007022 CID verapamil_18\NN\2938514|blocking_30 (r_nmod) drugs_24\NNS\14778436|NONE_0 (r_pobj) with_17\IN\0|combined_17 (r_prep) therapy_16\NN\657604|NONE_0 (r_pobj) during_14\IN\0|NONE_0 (r_prep) bradycardia_13\NN\14110674|and_4 (r_conj) hypotension_11\NN\14057371|profound_26|cardiac_17|,_2
D014700_D001919 CID verapamil_18\NN\2938514|blocking_30 (r_nmod) drugs_24\NNS\14778436|NONE_0 (r_pobj) with_17\IN\0|combined_17 (r_prep) therapy_16\NN\657604|NONE_0 (r_pobj) during_14\IN\0|NONE_0 (r_prep) bradycardia_13\NN\14110674|and_4
D000319_D007022 CID drugs_24\NNS\14778436|NONE_0 (r_pobj) with_17\IN\0|combined_17 (r_prep) therapy_16\NN\657604|NONE_0 (r_pobj) during_14\IN\0|NONE_0 (r_prep) bradycardia_13\NN\14110674|and_4 (r_conj) hypotension_11\NN\14057371|profound_26|cardiac_17|,_2
D000319_D006333 CID drugs_24\NNS\14778436|NONE_0 (r_pobj) with_17\IN\0|combined_17 (r_prep) therapy_16\NN\657604|NONE_0 (r_pobj) during_14\IN\0|NONE_0 (r_prep) bradycardia_13\NN\14110674|and_4 (r_conj) hypotension_11\NN\14057371|profound_26|cardiac_17|,_2 (r_conj) failure_9\NN\66216|patients_65|._110
D014700_D006333 CID verapamil_18\NN\2938514|blocking_30 (r_nmod) drugs_24\NNS\14778436|NONE_0 (r_pobj) with_17\IN\0|combined_17 (r_prep) therapy_16\NN\657604|NONE_0 (r_pobj) during_14\IN\0|NONE_0 (r_prep) bradycardia_13\NN\14110674|and_4 (r_conj) hypotension_11\NN\14057371|profound_26|cardiac_17|,_2 (r_conj) failure_9\NN\66216|patients_65|._110
D000319_D017202 NONE drugs_24\NNS\14778436|NONE_0 (r_pobj) with_17\IN\0|combined_17 (r_prep) therapy_16\NN\657604|NONE_0 (r_pobj) during_14\IN\0|NONE_0 (r_prep) bradycardia_13\NN\14110674|and_4 (r_conj) hypotension_11\NN\14057371|profound_26|cardiac_17|,_2 (r_conj) failure_9\NN\66216|patients_65|._110 (r_dobj) developed_6\VBD\1753788|NONE_0 (l_nsubj) patients_1\NNS\9898892|failure_65|._175 (l_prep) with_2\IN\0|three_15 (l_pobj) disease_5\NN\14061805|NONE_0
D014700_D017202 NONE verapamil_18\NN\2938514|blocking_30 (r_nmod) drugs_24\NNS\14778436|NONE_0 (r_pobj) with_17\IN\0|combined_17 (r_prep) therapy_16\NN\657604|NONE_0 (r_pobj) during_14\IN\0|NONE_0 (r_prep) bradycardia_13\NN\14110674|and_4 (r_conj) hypotension_11\NN\14057371|profound_26|cardiac_17|,_2 (r_conj) failure_9\NN\66216|patients_65|._110 (r_dobj) developed_6\VBD\1753788|NONE_0 (l_nsubj) patients_1\NNS\9898892|failure_65|._175 (l_prep) with_2\IN\0|three_15 (l_pobj) disease_5\NN\14061805|NONE_0
D000319_D001919 CID drugs_24\NNS\14778436|NONE_0 (r_pobj) with_17\IN\0|combined_17 (r_prep) therapy_16\NN\657604|NONE_0 (r_pobj) during_14\IN\0|NONE_0 (r_prep) bradycardia_13\NN\14110674|and_4
15764424
D000661_D006948 CID amphetamine_2\NN\3248958|NONE_0 (r_compound) levels_3\NNS\4916342|or_15 (r_conj) methamphetamine_0\NN\2704153|were_38|to_51|._119 (r_nsubjpass) related_5\VBN\628491|NONE_0 (l_prep) to_6\IN\0|methamphetamine_51|were_13|._68 (l_pobj) scores_9\NNS\13757724|NONE_0 (l_conj) rating_14\NN\5733583|several_59|psychopathology_51|and_28 (l_compound) hyperkinesia_13\NN\0|the_11|global_7
D002395_D006948 NONE catecholamines_12\NNS\5407119|symptom_18|,_2 (l_conj) hyperkinesia_14\NN\0|and_4
D002395_D011605 NONE catecholamines_12\NNS\5407119|symptom_18|,_2 (r_conj) severity_10\NN\5036394|NONE_0 (r_pobj) to_8\IN\0|NONE_0 (r_prep) relationship_7\NN\31921|quantitative_49|drug_36|in_24|:_2|._65 (r_appos) levels_2\NNS\4916342|NONE_0 (l_prep) in_3\IN\13603305|quantitative_25|drug_12|:_22|relationship_24|._89 (l_pobj) psychosis_5\NN\14380140|NONE_0
D002395_D011605 NONE catecholamines_10\NNS\5407119|quantitative_36|stimulant_23|drug_13|,_2 (l_conj) symptoms_14\NNS\5823932|,_16|and_14
D002395_D011605 NONE catecholamines_10\NNS\5407119|quantitative_36|stimulant_23|drug_13|,_2 (r_conj) levels_8\NNS\4916342|NONE_0 (r_pobj) between_4\IN\0|the_17 (r_prep) relationship_3\NN\31921|to_15 (r_dobj) examine_1\VB\0|,_107|patients_118|were_224|,_240|and_242|collected_268 (r_advcl) interviewed_34\VBN\964694|NONE_0 (l_nsubjpass) patients_17\NNS\9898892|examine_118|,_11|were_106|,_122|and_124|collected_150 (l_prep) in_18\IN\13603305|nineteen_18 (l_pobj) service_22\NN\575741|NONE_0 (l_prep) with_23\IN\0|a_32|psychiatric_30|emergency_18 (l_pobj) diagnosis_25\NN\152018|NONE_0 (l_prep) of_26\IN\0|a_12 (l_pobj) psychosis_32\NN\14380140|NONE_0
D002395_D011605 NONE catecholamine_49\NN\5407119|stimulant_19|and_4 (r_conj) drug_47\NN\14778436|metabolite_23 (r_nmod) levels_51\NNS\4916342|NONE_0 (r_pobj) of_45\IN\0|quantitative_20 (r_prep) assays_44\NNS\5733583|NONE_0 (r_pobj) for_42\IN\0|plasma_32|were_15|._77 (r_prep) collected_41\VBN\2281093|examine_268|,_161|patients_150|were_44|,_28|and_26 (r_conj) interviewed_34\VBN\964694|NONE_0 (l_advcl) examine_1\VB\0|,_107|patients_118|were_224|,_240|and_242|collected_268 (l_dobj) relationship_3\NN\31921|to_15 (l_prep) between_4\IN\0|the_17 (l_pobj) levels_8\NNS\4916342|NONE_0 (l_conj) catecholamines_10\NNS\5407119|quantitative_36|stimulant_23|drug_13|,_2 (l_conj) symptoms_14\NNS\5823932|,_16|and_14
D002395_D011605 NONE catecholamine_49\NN\5407119|stimulant_19|and_4 (r_conj) drug_47\NN\14778436|metabolite_23 (r_nmod) levels_51\NNS\4916342|NONE_0 (r_pobj) of_45\IN\0|quantitative_20 (r_prep) assays_44\NNS\5733583|NONE_0 (r_pobj) for_42\IN\0|plasma_32|were_15|._77 (r_prep) collected_41\VBN\2281093|examine_268|,_161|patients_150|were_44|,_28|and_26 (r_conj) interviewed_34\VBN\964694|NONE_0 (l_nsubjpass) patients_17\NNS\9898892|examine_118|,_11|were_106|,_122|and_124|collected_150 (l_prep) in_18\IN\13603305|nineteen_18 (l_pobj) service_22\NN\575741|NONE_0 (l_prep) with_23\IN\0|a_32|psychiatric_30|emergency_18 (l_pobj) diagnosis_25\NN\152018|NONE_0 (l_prep) of_26\IN\0|a_12 (l_pobj) psychosis_32\NN\14380140|NONE_0
D003042_D001523 NONE cocaine_29\NN\3492717|or_3 (r_conj) amphetamine-_27\JJ\0|-_23 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) psychosis_32\NN\14380140|NONE_0 (r_pobj) of_26\IN\0|a_12 (r_prep) diagnosis_25\NN\152018|NONE_0 (r_pobj) with_23\IN\0|a_32|psychiatric_30|emergency_18 (r_prep) service_22\NN\575741|NONE_0 (l_amod) psychiatric_20\JJ\0|a_2|emergency_12|with_30
D000661_D001523 NONE amphetamine-_27\JJ\0|-_23 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) psychosis_32\NN\14380140|NONE_0 (r_pobj) of_26\IN\0|a_12 (r_prep) diagnosis_25\NN\152018|NONE_0 (r_pobj) with_23\IN\0|a_32|psychiatric_30|emergency_18 (r_prep) service_22\NN\575741|NONE_0 (l_amod) psychiatric_20\JJ\0|a_2|emergency_12|with_30
D003042_D011605 CID cocaine_29\NN\3492717|or_3 (r_conj) amphetamine-_27\JJ\0|-_23 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) psychosis_32\NN\14380140|NONE_0 (r_pobj) of_26\IN\0|a_12 (r_prep) diagnosis_25\NN\152018|NONE_0 (r_pobj) with_23\IN\0|a_32|psychiatric_30|emergency_18 (r_prep) service_22\NN\575741|NONE_0 (r_pobj) in_18\IN\13603305|nineteen_18 (r_prep) patients_17\NNS\9898892|examine_118|,_11|were_106|,_122|and_124|collected_150 (r_nsubjpass) interviewed_34\VBN\964694|NONE_0 (l_advcl) examine_1\VB\0|,_107|patients_118|were_224|,_240|and_242|collected_268 (l_dobj) relationship_3\NN\31921|to_15 (l_prep) between_4\IN\0|the_17 (l_pobj) levels_8\NNS\4916342|NONE_0 (l_conj) catecholamines_10\NNS\5407119|quantitative_36|stimulant_23|drug_13|,_2 (l_conj) symptoms_14\NNS\5823932|,_16|and_14
D003042_D011605 CID cocaine_29\NN\3492717|or_3 (r_conj) amphetamine-_27\JJ\0|-_23 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) psychosis_32\NN\14380140|NONE_0
D008694_D006948 CID methamphetamine_0\NN\2704153|were_38|to_51|._119 (r_nsubjpass) related_5\VBN\628491|NONE_0 (l_prep) to_6\IN\0|methamphetamine_51|were_13|._68 (l_pobj) scores_9\NNS\13757724|NONE_0 (l_conj) rating_14\NN\5733583|several_59|psychopathology_51|and_28 (l_compound) hyperkinesia_13\NN\0|the_11|global_7
D002395_D001523 NONE catecholamines_10\NNS\5407119|quantitative_36|stimulant_23|drug_13|,_2 (r_conj) levels_8\NNS\4916342|NONE_0 (r_pobj) between_4\IN\0|the_17 (r_prep) relationship_3\NN\31921|to_15 (r_dobj) examine_1\VB\0|,_107|patients_118|were_224|,_240|and_242|collected_268 (r_advcl) interviewed_34\VBN\964694|NONE_0 (l_nsubjpass) patients_17\NNS\9898892|examine_118|,_11|were_106|,_122|and_124|collected_150 (l_prep) in_18\IN\13603305|nineteen_18 (l_pobj) service_22\NN\575741|NONE_0 (l_amod) psychiatric_20\JJ\0|a_2|emergency_12|with_30
D002395_D001523 NONE catecholamine_49\NN\5407119|stimulant_19|and_4 (r_conj) drug_47\NN\14778436|metabolite_23 (r_nmod) levels_51\NNS\4916342|NONE_0 (r_pobj) of_45\IN\0|quantitative_20 (r_prep) assays_44\NNS\5733583|NONE_0 (r_pobj) for_42\IN\0|plasma_32|were_15|._77 (r_prep) collected_41\VBN\2281093|examine_268|,_161|patients_150|were_44|,_28|and_26 (r_conj) interviewed_34\VBN\964694|NONE_0 (l_nsubjpass) patients_17\NNS\9898892|examine_118|,_11|were_106|,_122|and_124|collected_150 (l_prep) in_18\IN\13603305|nineteen_18 (l_pobj) service_22\NN\575741|NONE_0 (l_amod) psychiatric_20\JJ\0|a_2|emergency_12|with_30
D000661_D011605 CID amphetamine-_27\JJ\0|-_23 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) psychosis_32\NN\14380140|NONE_0 (r_pobj) of_26\IN\0|a_12 (r_prep) diagnosis_25\NN\152018|NONE_0 (r_pobj) with_23\IN\0|a_32|psychiatric_30|emergency_18 (r_prep) service_22\NN\575741|NONE_0 (r_pobj) in_18\IN\13603305|nineteen_18 (r_prep) patients_17\NNS\9898892|examine_118|,_11|were_106|,_122|and_124|collected_150 (r_nsubjpass) interviewed_34\VBN\964694|NONE_0 (l_advcl) examine_1\VB\0|,_107|patients_118|were_224|,_240|and_242|collected_268 (l_dobj) relationship_3\NN\31921|to_15 (l_prep) between_4\IN\0|the_17 (l_pobj) levels_8\NNS\4916342|NONE_0 (l_conj) catecholamines_10\NNS\5407119|quantitative_36|stimulant_23|drug_13|,_2 (l_conj) symptoms_14\NNS\5823932|,_16|and_14
D000661_D011605 CID amphetamine-_27\JJ\0|-_23 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) psychosis_32\NN\14380140|NONE_0
2343592
C044650_D006259 NONE cilastatin_32\NN\0|NONE_0 (r_pobj) of_29\IN\0|maximum_14 (r_prep) doses_28\NNS\3740161|while_24 (r_dobj) receiving_26\VBG\2210855|evidence_51|seizures_15|._46 (r_advcl) developed_23\VBN\1753788|patients_115|trauma_40|and_33 (r_conj) head_15\NN\5225090|NONE_0 (l_dobj) trauma_16\NN\14052046|patients_75|and_7|developed_40
C044650_D012640 CID cilastatin_32\NN\0|NONE_0 (r_pobj) of_29\IN\0|maximum_14 (r_prep) doses_28\NNS\3740161|while_24 (r_dobj) receiving_26\VBG\2210855|evidence_51|seizures_15|._46 (r_advcl) developed_23\VBN\1753788|patients_115|trauma_40|and_33 (l_dobj) seizures_24\NNS\14081375|evidence_36|receiving_15|._61
C044650_D020521 NONE cilastatin_32\NN\0|NONE_0 (r_pobj) of_29\IN\0|maximum_14 (r_prep) doses_28\NNS\3740161|while_24 (r_dobj) receiving_26\VBG\2210855|evidence_51|seizures_15|._46 (r_advcl) developed_23\VBN\1753788|patients_115|trauma_40|and_33 (r_conj) head_15\NN\5225090|NONE_0 (l_nsubj) patients_2\NNS\9898892|trauma_75|and_82|developed_115 (l_prep) with_3\IN\0|two_21|elderly_17 (l_pobj) history_5\NN\15120823|NONE_0 (l_prep) of_6\IN\0|a_10 (l_pobj) accident_10\NN\7314427|NONE_0
C044650_D020521 NONE cilastatin_32\NN\0|NONE_0 (r_pobj) of_29\IN\0|maximum_14 (r_prep) doses_28\NNS\3740161|while_24 (r_dobj) receiving_26\VBG\2210855|evidence_51|seizures_15|._46 (r_advcl) developed_23\VBN\1753788|patients_115|trauma_40|and_33 (r_conj) head_15\NN\5225090|NONE_0 (l_nsubj) patients_2\NNS\9898892|trauma_75|and_82|developed_115 (l_prep) with_3\IN\0|two_21|elderly_17 (l_pobj) history_5\NN\15120823|NONE_0 (l_prep) of_6\IN\0|a_10 (l_pobj) accident_10\NN\7314427|NONE_0 (l_appos) cva_12\NNP\14081375|either_35|cerebral_28|vascular_19|(_1|or_5
D047090_D012640 NONE lactam_10\NN\0|other_11 (r_compound) antibiotics_11\NNS\2716205|NONE_0 (r_pobj) of_6\IN\0|maximum_14 (r_prep) doses_5\NNS\3740161|patients_30|had_21|without_39|._75 (r_dobj) received_3\VBN\2210855|NONE_0 (l_prep) without_12\IN\0|patients_69|had_60|doses_39|._36 (l_pobj) evidence_13\NN\5816287|NONE_0 (l_prep) of_14\IN\0|NONE_0 (l_pobj) activity_16\NN\30358|NONE_0 (l_compound) seizure_15\NN\14081375|NONE_0
C044650_D007674 NONE cilastatin_32\NN\0|NONE_0 (r_pobj) of_29\IN\0|maximum_14 (r_prep) doses_28\NNS\3740161|while_24 (r_dobj) receiving_26\VBG\2210855|evidence_51|seizures_15|._46 (r_advcl) developed_23\VBN\1753788|patients_115|trauma_40|and_33 (l_nsubj) evidence_19\NN\5816287|seizures_36|receiving_51|._97 (l_prep) of_20\IN\0|no_12 (l_pobj) disease_22\NN\14061805|NONE_0
D015378_D012640 NONE imipenem_3\NN\0|:_16|factors_37 (r_compound) therapy_4\NN\657604|NONE_0 (r_pobj) with_2\IN\0|seizure_17|._49 (r_prep) activity_1\NN\30358|NONE_0 (l_compound) seizure_0\NN\14081375|with_17|._66
D010672_D012640 NONE phenytoin_8\NN\3550533|NONE_0 (r_pobj) of_7\IN\0|therapeutic_18 (r_prep) doses_6\NNS\3740161|NONE_0 (r_pobj) with_4\IN\0|seizures_25|were_16|._35 (r_prep) controlled_3\VBN\0|NONE_0 (l_nsubjpass) seizures_1\NNS\14081375|were_9|with_25|._60
18161408
D002996_D013927 NONE cc_9\NN\13616054|NONE_0 (r_pobj) of_8\IN\0|a_34|rare_32 (r_prep) complication_7\NN\1073995|thrombosis_41|might_30|._18 (r_attr) be_2\VB\14625458|NONE_0 (l_nsubj) thrombosis_0\NN\14100769|might_11|complication_41|._59
D002996_D013923 CID cc_17\NN\13616054|NONE_0 (r_pobj) with_16\IN\0|ovulation_20 (r_prep) induction_15\NN\7450842|NONE_0 (r_pobj) after_13\IN\0|that_23|has_18|been_14 (r_prep) reported_12\VBN\831651|a_55|rare_53 (r_relcl) complication_8\NN\1073995|thromboembolism_47|._69 (r_attr) is_1\VBZ\0|NONE_0 (l_nsubj) thromboembolism_0\NN\14100769|complication_47|._116
D002996_D009203 CID citrate_7\NN\14850483|NONE_0 (r_pobj) with_5\IN\0|for_24 (r_prep) associated_4\VBN\628491|myocardial_35|in_13|:_58|report_67|._73 (r_acl) infarction_1\NN\14204950|NONE_0
D002996_D009203 CID cc_13\NN\13616054|NONE_0 (l_conj) infarction_16\NN\14204950|and_15
D002996_D002637 NONE cc_12\NN\13616054|woman_52|had_22|recently_18|for_3|and_27|presented_31|._56 (r_dobj) received_11\VBN\2210855|NONE_0 (l_conj) presented_17\VBD\2137132|woman_83|had_53|recently_49|cc_31|for_28|and_4|._25 (l_prep) with_18\IN\0|NONE_0 (l_pobj) pain_20\NN\14299637|NONE_0
16960342
D019259_D005355 NONE lamivudine_17\NN\3834836|NONE_0 (r_amod) monotherapy_18\NN\0|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treatment_15\NN\654885|NONE_0 (r_pobj) after_14\IN\0|sustained_99|clinical_89|of_68|._43 (r_prep) improvement_2\NN\7359599|NONE_0 (l_prep) of_3\IN\0|sustained_31|clinical_21|after_68|._111 (l_pobj) patient_5\NN\9898892|NONE_0 (l_prep) with_6\IN\0|a_10 (l_pobj) cirrhosis_13\NN\14116321|NONE_0
D019259_D005355 NONE lamivudine_3\NN\3834836|NONE_0 (r_pobj) of_2\IN\0|the_19|to_14 (r_prep) administration_1\NN\1133281|,_67|like_69|,_90|should_92|be_99|as_113|,_153|in_166|._232 (l_prep) to_4\IN\0|the_33|of_14 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_prep) with_6\IN\0|NONE_0 (l_pobj) cirrhosis_10\NN\14116321|NONE_0
D019259_D006509 NONE lamivudine_17\NN\3834836|NONE_0 (r_amod) monotherapy_18\NN\0|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treatment_15\NN\654885|NONE_0 (r_pobj) after_14\IN\0|sustained_99|clinical_89|of_68|._43 (r_prep) improvement_2\NN\7359599|NONE_0 (l_prep) of_3\IN\0|sustained_31|clinical_21|after_68|._111 (l_pobj) patient_5\NN\9898892|NONE_0 (l_prep) with_6\IN\0|a_10 (l_pobj) cirrhosis_13\NN\14116321|NONE_0 (l_amod) related_12\VBN\628491|decompensated_32 (l_npadvmod) virus_10\NN\9312843|-_5 (l_compound) b_9\NNP\1355326|NONE_0
3300918
D004876_D008881 CID ergot_6\NN\14276936|NONE_0 (r_pobj) of_5\IN\0|the_12 (r_prep) history_4\NN\15120823|NONE_0 (r_pobj) of_2\IN\0|a_13 (r_prep) discussion_1\NN\6252138|discovery_57|._198 (r_nsubj) includes_7\VBZ\0|NONE_0 (l_dobj) discovery_10\NN\30358|discussion_57|._141 (l_appos) epidemics_13\NNS\7435273|its_28|original_24|,_6 (l_relcl) caused_19\VBN\1617192|the_38|of_24 (l_prep) through_20\IN\0|that_19|it_14|has_11 (l_pobj) ages_22\NNS\4916342|NONE_0 (l_conj) role_28\NN\719494|the_34|and_25 (l_prep) in_29\IN\13603305|its_26|past_22 (l_pobj) management_31\NN\1123598|NONE_0 (l_prep) of_32\IN\0|the_15 (l_pobj) headache_34\NN\5829480|NONE_0
D004876_D008881 CID ergot_13\NN\14276936|NONE_0 (r_compound) preparations_14\NNS\407535|despite_86|,_8|play_25|,_62|persists_105|._113 (r_nsubj) continue_15\VBP\2367363|NONE_0 (l_xcomp) play_17\VB\7007684|despite_111|,_33|preparations_25|,_37|persists_80|._88 (l_dobj) role_20\NN\719494|to_16 (l_prep) in_21\IN\13603305|a_13|major_11 (l_pobj) therapy_23\NN\657604|NONE_0 (l_compound) migraine_22\NN\14326607|NONE_0
D002118_D004881 NONE calcium_4\NN\14625458|NONE_0 (r_compound) channel_5\NN\6251781|and_17|antagonists_37 (r_compound) blockers_6\NNS\10101634|NONE_0 (r_pobj) of_3\IN\0|the_11 (r_prep) advent_2\NN\48225|NONE_0 (r_pobj) despite_0\IN\7501545|,_78|preparations_86|play_111|,_148|persists_191|._199 (r_prep) continue_15\VBP\2367363|NONE_0 (l_advcl) persists_34\VBZ\118523|despite_191|,_113|preparations_105|play_80|,_43|._8 (l_nsubj) danger_28\NN\13920835|so_12|that_9 (l_prep) of_29\IN\0|the_11 (l_pobj) fire_33\NN\7283608|NONE_0
D004876_D004881 NONE ergot_13\NN\14276936|NONE_0 (r_compound) preparations_14\NNS\407535|despite_86|,_8|play_25|,_62|persists_105|._113 (r_nsubj) continue_15\VBP\2367363|NONE_0 (l_advcl) persists_34\VBZ\118523|despite_191|,_113|preparations_105|play_80|,_43|._8 (l_nsubj) danger_28\NN\13920835|so_12|that_9 (l_prep) of_29\IN\0|the_11 (l_pobj) fire_33\NN\7283608|NONE_0
D002118_D008881 NONE calcium_4\NN\14625458|NONE_0 (r_compound) channel_5\NN\6251781|and_17|antagonists_37 (r_compound) blockers_6\NNS\10101634|NONE_0 (r_pobj) of_3\IN\0|the_11 (r_prep) advent_2\NN\48225|NONE_0 (r_pobj) despite_0\IN\7501545|,_78|preparations_86|play_111|,_148|persists_191|._199 (r_prep) continue_15\VBP\2367363|NONE_0 (l_xcomp) play_17\VB\7007684|despite_111|,_33|preparations_25|,_37|persists_80|._88 (l_dobj) role_20\NN\719494|to_16 (l_prep) in_21\IN\13603305|a_13|major_11 (l_pobj) therapy_23\NN\657604|NONE_0 (l_compound) migraine_22\NN\14326607|NONE_0
D008784_D014652 CID methysergide_20\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_14|by_16 (r_prep) ingestion_18\NN\13440063|NONE_0 (r_pobj) to_16\IN\0|case_95|,_25|is_23|secondary_10|._55 (r_prep) described_14\VBN\1001294|NONE_0 (l_nsubjpass) case_2\NN\7283608|,_70|is_72|secondary_85|to_95|._150 (l_prep) of_3\IN\0|a_12|rare_10|,_19|with_30 (l_pobj) vasospasm_5\NN\0|NONE_0
D004876_D005734 NONE ergot_6\NN\14276936|NONE_0 (r_pobj) of_5\IN\0|the_12 (r_prep) history_4\NN\15120823|NONE_0 (r_pobj) of_2\IN\0|a_13 (r_prep) discussion_1\NN\6252138|discovery_57|._198 (r_nsubj) includes_7\VBZ\0|NONE_0 (l_dobj) discovery_10\NN\30358|discussion_57|._141 (l_appos) epidemics_13\NNS\7435273|its_28|original_24|,_6 (l_prep) of_14\IN\0|the_14|caused_24 (l_pobj) gangrene_15\NN\14204950|NONE_0
19642243
D014640_D051437 NONE vancomycin_8\NNP\2716866|NONE_0 (r_amod) therapy_9\NN\657604|NONE_0 (r_pobj) of_7\IN\0|a_19|prolonged_17|in_22 (r_prep) course_6\NN\883297|NONE_0 (r_pobj) after_3\IN\0|failure_18|._146 (r_prep) developed_2\VBD\1753788|NONE_0 (l_nsubj) failure_1\NN\66216|after_18|._164
D014640_D051437 NONE vancomycin_17\NNP\2716866|NONE_0 (r_pobj) of_16\IN\0|prolonged_25 (r_prep) administration_15\NN\1133281|NONE_0 (r_pobj) during_13\IN\0|that_51|tenofovir_46|may_36|risk_22 (r_prep) raise_7\VB\5108947|NONE_0 (l_dobj) risk_9\NN\14541044|that_29|tenofovir_24|may_14|during_22 (l_prep) of_10\IN\0|the_9 (l_pobj) failure_12\NN\66216|NONE_0
C418563_D051437 NONE fumarate_18\NN\0|who_40|were_36|as_9 (r_dobj) receiving_15\VBG\2210855|2_20 (r_relcl) patients_12\NNS\9898892|NONE_0 (r_pobj) in_10\IN\13603305|a_41|prolonged_39|of_22 (r_prep) course_6\NN\883297|NONE_0 (r_pobj) after_3\IN\0|failure_18|._146 (r_prep) developed_2\VBD\1753788|NONE_0 (l_nsubj) failure_1\NN\66216|after_18|._164
D014640_D007674 NONE vancomycin_0\NNP\2716866|NONE_0 (r_compound) nephrotoxicity_1\NN\0|infrequent_18|but_29|result_37|._90
D014640_D007674 NONE vancomycin_0\NNP\2716866|NONE_0 (r_compound) nephrotoxicity_1\NN\0|infrequent_18|but_29|result_37|._90 (r_nsubj) is_2\VBZ\0|NONE_0 (l_conj) result_6\VB\34213|nephrotoxicity_37|infrequent_19|but_8|._53 (l_prep) from_7\IN\0|may_11 (l_pobj) coadministration_8\NN\0|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) agent_12\NN\7347|NONE_0 (l_amod) nephrotoxic_11\JJ\0|a_2
D014640_D058186 CID vancomycin_12\NNP\2716866|prolonged_10 (r_amod) course_13\NN\883297|while_37|for_7 (r_dobj) receiving_10\VBG\2210855|acute_61|renal_55|in_41|._55 (r_advcl) failure_2\NN\66216|NONE_0
C096918_D005198 NONE tenofovir_0\NNP\0|has_10|been_14|in_30|because_93|._144 (r_nsubjpass) implicated_3\VBN\2677097|NONE_0 (l_prep) in_4\IN\13603305|tenofovir_30|has_20|been_16|because_63|._114 (l_pobj) development_6\NN\248977|NONE_0 (l_prep) of_7\IN\0|the_16 (l_pobj) syndrome_9\NN\5870365|NONE_0
D014640_D010019 NONE vancomycin_12\NNP\2716866|prolonged_10 (r_amod) course_13\NN\883297|while_37|for_7 (r_dobj) receiving_10\VBG\2210855|acute_61|renal_55|in_41|._55 (l_prep) for_14\IN\0|while_44|course_7 (l_pobj) osteomyelitis_15\NN\14351321|NONE_0
C096918_D058186 NONE tenofovir_8\NNS\0|NONE_0 (r_pobj) on_7\IN\0|with_10 (r_prep) patients_4\NNS\9898892|NONE_0 (r_pobj) in_3\IN\13603305|acute_20|renal_14|receiving_41|._96 (r_prep) failure_2\NN\66216|NONE_0
D014640_D000163 NONE vancomycin_12\NNP\2716866|prolonged_10 (r_amod) course_13\NN\883297|while_37|for_7 (r_dobj) receiving_10\VBG\2210855|acute_61|renal_55|in_41|._55 (r_advcl) failure_2\NN\66216|NONE_0 (l_prep) in_3\IN\13603305|acute_20|renal_14|receiving_41|._96 (l_pobj) patients_4\NNS\9898892|NONE_0 (l_prep) with_5\IN\0|on_10 (l_pobj) aids_6\NNP\13974317|NONE_0
C096918_D010019 NONE tenofovir_8\NNS\0|NONE_0 (r_pobj) on_7\IN\0|with_10 (r_prep) patients_4\NNS\9898892|NONE_0 (r_pobj) in_3\IN\13603305|acute_20|renal_14|receiving_41|._96 (r_prep) failure_2\NN\66216|NONE_0 (l_advcl) receiving_10\VBG\2210855|acute_61|renal_55|in_41|._55 (l_prep) for_14\IN\0|while_44|course_7 (l_pobj) osteomyelitis_15\NN\14351321|NONE_0
C096918_D000163 NONE tenofovir_8\NNS\0|NONE_0 (r_pobj) on_7\IN\0|with_10 (r_prep) patients_4\NNS\9898892|NONE_0 (l_prep) with_5\IN\0|on_10 (l_pobj) aids_6\NNP\13974317|NONE_0
C096918_D051437 NONE tenofovir_0\NNP\0|has_10|been_14|in_30|because_93|._144 (r_nsubjpass) implicated_3\VBN\2677097|NONE_0 (l_prep) in_4\IN\13603305|tenofovir_30|has_20|been_16|because_63|._114 (l_pobj) development_6\NN\248977|NONE_0 (l_prep) of_7\IN\0|the_16 (l_pobj) syndrome_9\NN\5870365|NONE_0 (l_conj) insufficiency_12\NN\14462946|fanconi_27|and_10
C096918_D051437 NONE tenofovir_5\NNS\0|that_5|may_10|risk_24|during_46 (r_nsubj) raise_7\VB\5108947|NONE_0 (l_dobj) risk_9\NN\14541044|that_29|tenofovir_24|may_14|during_22 (l_prep) of_10\IN\0|the_9 (l_pobj) failure_12\NN\66216|NONE_0
6454943
D002216_D011507 NONE captopril_2\NN\2673637|NONE_0 (r_pobj) of_1\IN\0|on_13 (r_prep) effect_0\NN\34213|-_55|proteinuria_64|in_76|._110 (r_nsubj) induced_10\VBN\1627355|NONE_0 (l_dobj) proteinuria_11\NN\14299637|effect_64|-_9|in_12|._46
D002216_D011507 NONE captopril_6\NN\2673637|in_20 (r_compound) treatment_7\NN\654885|NONE_0 (r_pobj) of_5\IN\0|a_14|side_12 (r_prep) effect_4\NN\34213|proteinuria_22|._54 (r_attr) is_1\VBZ\0|NONE_0 (l_nsubj) proteinuria_0\NNP\14299637|effect_22|._76
D002216_D011507 NONE captopril_3\NN\2673637|NONE_0 (r_pobj) of_2\IN\0|oral_20|at_13|for_26 (r_prep) administration_1\NN\1133281|aggravate_63|._104 (r_nsubj) failed_10\VBD\0|NONE_0 (l_xcomp) aggravate_12\VB\126264|administration_63|._41 (l_dobj) proteinuria_13\JJ\14299637|to_13
D002216_D011507 NONE captopril_2\NN\2673637|NONE_0 (r_compound) treatment_3\NN\654885|also_16|,_12|potentiate_20|._123 (r_nsubj) failed_4\VBD\0|NONE_0 (l_xcomp) potentiate_6\VB\229605|also_36|,_32|treatment_20|._103 (l_conj) facilitate_8\VB\2547586|to_17|or_3 (l_dobj) development_9\NN\248977|NONE_0 (l_prep) of_10\IN\0|NONE_0 (l_pobj) proteinuria_12\NN\14299637|NONE_0
D011692_D006973 NONE aminonucleoside_8\RB\0|existing_13 (r_punct) -_9\HYPH\0|effect_55|proteinuria_9|in_21|._55 (r_punct) induced_10\VBN\1627355|NONE_0 (l_prep) in_12\IN\13603305|effect_76|-_21|proteinuria_12|._34 (l_pobj) rats_15\NNS\2329401|NONE_0 (l_amod) hypertensive_14\JJ\10405694|NONE_0
D002216_D007674 NONE captopril_9\NN\2673637|NONE_0 (r_pobj) with_8\IN\0|the_27|same_23|renal_18 (r_prep) abnormality_7\NN\14034177|NONE_0
D002216_D006973 NONE captopril_2\NN\2673637|NONE_0 (r_pobj) of_1\IN\0|on_13 (r_prep) effect_0\NN\34213|-_55|proteinuria_64|in_76|._110 (r_nsubj) induced_10\VBN\1627355|NONE_0 (l_prep) in_12\IN\13603305|effect_76|-_21|proteinuria_12|._34 (l_pobj) rats_15\NNS\2329401|NONE_0 (l_amod) hypertensive_14\JJ\10405694|NONE_0
D002216_D006973 NONE captopril_6\NN\2673637|in_20 (r_compound) treatment_7\NN\654885|NONE_0 (l_prep) in_8\IN\13603305|captopril_20 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) hypertensive_9\JJ\10405694|NONE_0
D011692_D011507 CID aminonucleoside_8\RB\0|existing_13 (r_punct) -_9\HYPH\0|effect_55|proteinuria_9|in_21|._55 (r_punct) induced_10\VBN\1627355|NONE_0 (l_dobj) proteinuria_11\NN\14299637|effect_64|-_9|in_12|._46
D011692_D011507 CID aminonucleoside_16\NN\0|NONE_0 (r_amod) puromycin_15\NNS\0|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) invoked_13\VBN\1617192|massive_20 (r_acl) proteinuria_12\NN\14299637|NONE_0
10328196
D003907_D011565 NONE dexamethasone_15\NN\2721538|-_13 (r_npadvmod) induced_17\VBN\1627355|greater_37|or_17 (r_conj) spontaneous_13\JJ\0|did_52 (r_amod) apoptosis_18\NN\11486178|to_56 (r_oprd) exhibit_11\VB\6733939|NONE_0 (r_xcomp) tended_9\VBD\2604760|cells_35|._139 (r_ccomp) activated_0\VBN\1641914|NONE_0 (l_dobj) cells_4\NNS\3080309|tended_35|._174 (l_prep) from_5\IN\0|peripheral_25|t_8 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|NONE_0 (l_pobj) psoriasis_8\NN\14219661|NONE_0
D020123_D011565 NONE sirolimus_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) administration_3\NN\1133281|NONE_0 (r_dobj) following_2\VBG\8180190|systemic_18|(_38|rapamycin_48|)_57|for_59|:_72|association_74|._151 (r_prep) toxicity_1\NN\13576101|NONE_0 (l_prep) for_10\IN\0|systemic_77|following_59|(_21|rapamycin_11|)_2|:_13|association_15|._92 (l_pobj) psoriasis_11\NN\14219661|NONE_0
D020123_D011565 NONE rapamycin_8\VBZ\0|systemic_66|following_48|(_10|)_9|for_11|:_24|association_26|._103 (r_appos) toxicity_1\NN\13576101|NONE_0 (l_prep) for_10\IN\0|systemic_77|following_59|(_21|rapamycin_11|)_2|:_13|association_15|._92 (l_pobj) psoriasis_11\NN\14219661|NONE_0
D020123_D011565 NONE sirolimus_14\NN\0|lesional_10|skin_19 (r_nmod) cells_17\NNS\3080309|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treatment_11\NN\654885|NONE_0 (r_pobj) following_10\VBG\8180190|a_26|leak_14 (r_acl) syndrome_9\NN\5870365|after_62|individuals_54|and_69|analyzed_111|._146 (r_dobj) developed_5\VBD\1753788|NONE_0 (l_nsubj) individuals_2\NNS\7347|after_8|syndrome_54|and_123|analyzed_165|._200 (l_prep) with_3\IN\0|2_14 (l_pobj) psoriasis_4\NN\14219661|NONE_0
D020123_D011565 NONE sirolimus_8\NN\0|-_9 (r_npadvmod) induced_10\VBN\1627355|leak_18 (r_amod) syndrome_13\NN\5870365|NONE_0 (r_pobj) with_7\IN\0|1_10 (r_prep) patient_6\NN\9898892|NONE_0 (r_pobj) from_4\IN\0|a_25|keratome_23|skin_14 (r_prep) specimen_3\NN\5820620|increase_86|compared_137|._211 (r_nsubj) had_14\VBD\0|NONE_0 (l_prep) compared_28\VBN\644583|specimen_137|increase_51|._74 (l_prep) with_29\IN\0|NONE_0 (l_pobj) patient_35\NN\9898892|NONE_0 (l_prep) with_36\IN\0|an_40|unaffected_37|treated_16|(_15|%_18|)_19 (l_pobj) psoriasis_37\NN\14219661|NONE_0
D020123_D011565 NONE sirolimus_32\NN\0|-_9 (r_npadvmod) treated_34\VBN\2376958|an_24|unaffected_21|with_16|(_31|%_34|)_35 (r_amod) patient_35\NN\9898892|NONE_0 (l_prep) with_36\IN\0|an_40|unaffected_37|treated_16|(_15|%_18|)_19 (l_pobj) psoriasis_37\NN\14219661|NONE_0
D020123_D011565 NONE sirolimus_30\NN\0|NONE_0 (r_pobj) of_29\IN\0|the_13 (r_prep) presence_28\NN\13954253|particularly_20 (r_pobj) in_26\IN\13603305|than_38|cells_20|,_15 (r_prep) did_20\VBD\0|spontaneous_52 (r_advcl) apoptosis_18\NN\11486178|to_56 (r_oprd) exhibit_11\VB\6733939|NONE_0 (r_xcomp) tended_9\VBD\2604760|cells_35|._139 (r_ccomp) activated_0\VBN\1641914|NONE_0 (l_dobj) cells_4\NNS\3080309|tended_35|._174 (l_prep) from_5\IN\0|peripheral_25|t_8 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|NONE_0 (l_pobj) psoriasis_8\NN\14219661|NONE_0
D020123_D019559 CID sirolimus_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) administration_3\NN\1133281|NONE_0 (r_dobj) following_2\VBG\8180190|systemic_18|(_38|rapamycin_48|)_57|for_59|:_72|association_74|._151 (r_prep) toxicity_1\NN\13576101|NONE_0 (l_appos) association_13\NN\8008335|systemic_92|following_74|(_36|rapamycin_26|)_17|for_15|:_2|._77 (l_prep) of_14\IN\0|with_27 (l_pobj) syndrome_17\NN\5870365|NONE_0
D020123_D019559 CID rapamycin_8\VBZ\0|systemic_66|following_48|(_10|)_9|for_11|:_24|association_26|._103 (r_appos) toxicity_1\NN\13576101|NONE_0 (l_appos) association_13\NN\8008335|systemic_92|following_74|(_36|rapamycin_26|)_17|for_15|:_2|._77 (l_prep) of_14\IN\0|with_27 (l_pobj) syndrome_17\NN\5870365|NONE_0
D020123_D019559 CID sirolimus_14\NN\0|lesional_10|skin_19 (r_nmod) cells_17\NNS\3080309|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treatment_11\NN\654885|NONE_0 (r_pobj) following_10\VBG\8180190|a_26|leak_14 (r_acl) syndrome_9\NN\5870365|after_62|individuals_54|and_69|analyzed_111|._146
D020123_D019559 CID sirolimus_8\NN\0|-_9 (r_npadvmod) induced_10\VBN\1627355|leak_18 (r_amod) syndrome_13\NN\5870365|NONE_0
D020123_D019559 CID sirolimus_32\NN\0|-_9 (r_npadvmod) treated_34\VBN\2376958|an_24|unaffected_21|with_16|(_31|%_34|)_35 (r_amod) patient_35\NN\9898892|NONE_0 (r_pobj) with_29\IN\0|NONE_0 (r_prep) compared_28\VBN\644583|specimen_137|increase_51|._74 (r_prep) had_14\VBD\0|NONE_0 (l_nsubj) specimen_3\NN\5820620|increase_86|compared_137|._211 (l_prep) from_4\IN\0|a_25|keratome_23|skin_14 (l_pobj) patient_6\NN\9898892|NONE_0 (l_prep) with_7\IN\0|1_10 (l_pobj) syndrome_13\NN\5870365|NONE_0
D020123_D019559 CID sirolimus_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|severe_23|adverse_16 (r_prep) effects_2\NNS\13245626|fever_29|._71 (r_nsubj) include_5\VBP\0|NONE_0 (l_dobj) fever_6\NN\14299637|effects_29|._42 (l_conj) anemia_8\NN\14189204|,_2 (l_conj) syndrome_13\NN\5870365|,_21|and_19
D020123_D005334 NONE sirolimus_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|severe_23|adverse_16 (r_prep) effects_2\NNS\13245626|fever_29|._71 (r_nsubj) include_5\VBP\0|NONE_0 (l_dobj) fever_6\NN\14299637|effects_29|._42
D020123_D000740 NONE sirolimus_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|severe_23|adverse_16 (r_prep) effects_2\NNS\13245626|fever_29|._71 (r_nsubj) include_5\VBP\0|NONE_0 (l_dobj) fever_6\NN\14299637|effects_29|._42 (l_conj) anemia_8\NN\14189204|,_2
D020123_D064420 NONE sirolimus_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) administration_3\NN\1133281|NONE_0 (r_dobj) following_2\VBG\8180190|systemic_18|(_38|rapamycin_48|)_57|for_59|:_72|association_74|._151 (r_prep) toxicity_1\NN\13576101|NONE_0
D020123_D064420 NONE rapamycin_8\VBZ\0|systemic_66|following_48|(_10|)_9|for_11|:_24|association_26|._103 (r_appos) toxicity_1\NN\13576101|NONE_0
2716967
D009020_D009127 NONE morphine_21\NN\2707683|or_3 (r_conj) ketamine_19\NN\3054098|NONE_0 (r_pobj) of_18\IN\0|the_26|relative_22|in_24 (r_prep) predominance_17\NN\14441825|latency_98|,_25|._56 (r_dobj) reflected_14\VBD\923793|NONE_0 (l_nsubj) latency_0\NN\15269513|,_73|predominance_98|._154 (l_prep) to_1\IN\0|NONE_0 (l_pobj) loss_3\NN\13252973|NONE_0 (l_prep) of_4\IN\0|the_9 (l_pobj) reflex_6\NN\859001|NONE_0 (l_conj) rigidity_8\NN\5023233|righting_17|,_2
D009270_D002375 NONE naloxone_0\NN\3808977|effects_42|._49 (r_nsubj) inhibited_1\VBD\2510337|NONE_0 (l_dobj) effects_5\NNS\13245626|naloxone_42|._7 (l_amod) cataleptic_4\JJ\10490141|the_12|induced_8
D009270_D002375 NONE naloxone_36\NN\3808977|NONE_0 (r_pobj) for_35\IN\0|a_24|different_15 (r_prep) id50_34\NNP\0|of_42|and_23 (r_conj) asymmetry_24\NN\5062748|in_35|,_2 (r_conj) differences_16\NNS\4723816|the_23|induced_19|,_2 (r_conj) catalepsy_14\NN\14023236|NONE_0
D009020_D000699 NONE morphine_7\NN\2707683|both_18|and_4 (r_conj) ketamine_5\NN\3054098|that_10|analgesia_30 (r_nsubj) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30
D009020_D000699 NONE morphine_26\NN\2707683|NONE_0 (r_pobj) to_25\IN\0|produced_25|cross_16|-_11 (r_prep) tolerance_24\NN\5032565|studies_140|induced_87|,_21|induce_66 (r_dobj) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_ccomp) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30
D009020_D000699 NONE morphine_31\NN\2707683|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) pretreatment_29\NN\0|whereas_8|did_27|not_31|tolerance_48|but_70|augmented_81 (r_nsubj) induce_34\VB\1627355|studies_206|induced_153|tolerance_66|,_45 (r_advcl) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_ccomp) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30
D009020_D000699 NONE morphine_53\NN\2707683|NONE_0 (r_pobj) to_51\IN\0|demonstrated_312|;_35|augmentation_28|was_15|._33 (r_prep) attributed_50\VBN\670261|NONE_0 (l_ccomp) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_ccomp) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30
D007649_D000699 NONE ketamine_5\NN\3054098|that_10|analgesia_30 (r_nsubj) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30
D007649_D000699 NONE ketamine_20\NN\3054098|NONE_0 (r_pobj) with_19\IN\0|-_11 (r_prep) treatment_18\NN\654885|NONE_0 (r_nsubj) produced_21\VBD\1617192|cross_9|-_14|to_25 (r_amod) tolerance_24\NN\5032565|studies_140|induced_87|,_21|induce_66 (r_dobj) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_ccomp) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30
D007649_D000699 NONE ketamine_39\NN\3054098|NONE_0 (r_pobj) to_38\IN\0|cross_16|-_11 (r_prep) tolerance_37\NN\5032565|whereas_56|pretreatment_48|did_21|not_17|but_22|augmented_33 (r_dobj) induce_34\VB\1627355|studies_206|induced_153|tolerance_66|,_45 (r_advcl) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_ccomp) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30
D009270_D009127 NONE naloxone_36\NN\3808977|NONE_0 (r_pobj) for_35\IN\0|a_24|different_15 (r_prep) id50_34\NNP\0|of_42|and_23 (r_conj) asymmetry_24\NN\5062748|in_35|,_2 (r_conj) differences_16\NNS\4723816|the_23|induced_19|,_2 (l_prep) in_17\IN\13603305|,_33|asymmetry_35 (l_pobj) latency_18\NN\15269513|NONE_0 (l_conj) rigidity_20\NN\5023233|,_2
D007649_D002375 CID ketamine_5\NN\3054098|NONE_0 (r_pobj) of_4\IN\0|:_24|potentiation_26 (r_prep) combinations_3\NNS\7951464|NONE_0 (r_pobj) by_2\IN\0|catalepsy_18|._108 (r_agent) induced_1\VBN\1627355|NONE_0 (l_nsubj) catalepsy_0\NNP\14023236|by_18|._126
D007649_D002375 CID ketamine_5\NN\3054098|that_10|analgesia_30 (r_nsubj) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30 (l_conj) catalepsy_11\NN\14023236|and_4|in_10
D007649_D002375 CID ketamine_5\NN\3054098|that_10|analgesia_30 (r_nsubj) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (r_ccomp) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_advcl) induce_34\VB\1627355|studies_206|induced_153|tolerance_66|,_45 (l_conj) augmented_42\VBD\153263|whereas_89|pretreatment_81|did_54|not_50|tolerance_33|but_11 (l_dobj) response_45\NN\11410625|rather_32 (l_amod) cataleptic_44\JJ\10490141|the_4
D007649_D002375 CID ketamine_20\NN\3054098|NONE_0 (r_pobj) with_19\IN\0|-_11 (r_prep) treatment_18\NN\654885|NONE_0 (r_nsubj) produced_21\VBD\1617192|cross_9|-_14|to_25 (r_amod) tolerance_24\NN\5032565|studies_140|induced_87|,_21|induce_66 (r_dobj) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_ccomp) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30 (l_conj) catalepsy_11\NN\14023236|and_4|in_10
D007649_D002375 CID ketamine_20\NN\3054098|NONE_0 (r_pobj) with_19\IN\0|-_11 (r_prep) treatment_18\NN\654885|NONE_0 (r_nsubj) produced_21\VBD\1617192|cross_9|-_14|to_25 (r_amod) tolerance_24\NN\5032565|studies_140|induced_87|,_21|induce_66 (r_dobj) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_advcl) induce_34\VB\1627355|studies_206|induced_153|tolerance_66|,_45 (l_conj) augmented_42\VBD\153263|whereas_89|pretreatment_81|did_54|not_50|tolerance_33|but_11 (l_dobj) response_45\NN\11410625|rather_32 (l_amod) cataleptic_44\JJ\10490141|the_4
D007649_D002375 CID ketamine_39\NN\3054098|NONE_0 (r_pobj) to_38\IN\0|cross_16|-_11 (r_prep) tolerance_37\NN\5032565|whereas_56|pretreatment_48|did_21|not_17|but_22|augmented_33 (r_dobj) induce_34\VB\1627355|studies_206|induced_153|tolerance_66|,_45 (r_advcl) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_ccomp) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30 (l_conj) catalepsy_11\NN\14023236|and_4|in_10
D007649_D002375 CID ketamine_39\NN\3054098|NONE_0 (r_pobj) to_38\IN\0|cross_16|-_11 (r_prep) tolerance_37\NN\5032565|whereas_56|pretreatment_48|did_21|not_17|but_22|augmented_33 (r_dobj) induce_34\VB\1627355|studies_206|induced_153|tolerance_66|,_45 (l_conj) augmented_42\VBD\153263|whereas_89|pretreatment_81|did_54|not_50|tolerance_33|but_11 (l_dobj) response_45\NN\11410625|rather_32 (l_amod) cataleptic_44\JJ\10490141|the_4
D009020_D002375 CID morphine_7\NN\2707683|and_4 (r_conj) ketamine_5\NN\3054098|NONE_0 (r_pobj) of_4\IN\0|:_24|potentiation_26 (r_prep) combinations_3\NNS\7951464|NONE_0 (r_pobj) by_2\IN\0|catalepsy_18|._108 (r_agent) induced_1\VBN\1627355|NONE_0 (l_nsubj) catalepsy_0\NNP\14023236|by_18|._126
D009020_D002375 CID morphine_7\NN\2707683|both_18|and_4 (r_conj) ketamine_5\NN\3054098|that_10|analgesia_30 (r_nsubj) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30 (l_conj) catalepsy_11\NN\14023236|and_4|in_10
D009020_D002375 CID morphine_7\NN\2707683|both_18|and_4 (r_conj) ketamine_5\NN\3054098|that_10|analgesia_30 (r_nsubj) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (r_ccomp) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_advcl) induce_34\VB\1627355|studies_206|induced_153|tolerance_66|,_45 (l_conj) augmented_42\VBD\153263|whereas_89|pretreatment_81|did_54|not_50|tolerance_33|but_11 (l_dobj) response_45\NN\11410625|rather_32 (l_amod) cataleptic_44\JJ\10490141|the_4
D009020_D002375 CID morphine_26\NN\2707683|NONE_0 (r_pobj) to_25\IN\0|produced_25|cross_16|-_11 (r_prep) tolerance_24\NN\5032565|studies_140|induced_87|,_21|induce_66 (r_dobj) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_ccomp) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30 (l_conj) catalepsy_11\NN\14023236|and_4|in_10
D009020_D002375 CID morphine_26\NN\2707683|NONE_0 (r_pobj) to_25\IN\0|produced_25|cross_16|-_11 (r_prep) tolerance_24\NN\5032565|studies_140|induced_87|,_21|induce_66 (r_dobj) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_advcl) induce_34\VB\1627355|studies_206|induced_153|tolerance_66|,_45 (l_conj) augmented_42\VBD\153263|whereas_89|pretreatment_81|did_54|not_50|tolerance_33|but_11 (l_dobj) response_45\NN\11410625|rather_32 (l_amod) cataleptic_44\JJ\10490141|the_4
D009020_D002375 CID morphine_31\NN\2707683|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) pretreatment_29\NN\0|whereas_8|did_27|not_31|tolerance_48|but_70|augmented_81 (r_nsubj) induce_34\VB\1627355|studies_206|induced_153|tolerance_66|,_45 (r_advcl) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_ccomp) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30 (l_conj) catalepsy_11\NN\14023236|and_4|in_10
D009020_D002375 CID morphine_31\NN\2707683|NONE_0 (r_pobj) with_30\IN\0|NONE_0 (r_prep) pretreatment_29\NN\0|whereas_8|did_27|not_31|tolerance_48|but_70|augmented_81 (r_nsubj) induce_34\VB\1627355|studies_206|induced_153|tolerance_66|,_45 (l_conj) augmented_42\VBD\153263|whereas_89|pretreatment_81|did_54|not_50|tolerance_33|but_11 (l_dobj) response_45\NN\11410625|rather_32 (l_amod) cataleptic_44\JJ\10490141|the_4
D009020_D002375 CID morphine_53\NN\2707683|NONE_0 (r_pobj) to_51\IN\0|demonstrated_312|;_35|augmentation_28|was_15|._33 (r_prep) attributed_50\VBN\670261|NONE_0 (l_ccomp) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_ccomp) induced_8\VBN\1627355|studies_53|tolerance_87|,_108|induce_153 (l_dobj) analgesia_9\NN\14034177|that_40|ketamine_30 (l_conj) catalepsy_11\NN\14023236|and_4|in_10
D009020_D002375 CID morphine_53\NN\2707683|NONE_0 (r_pobj) to_51\IN\0|demonstrated_312|;_35|augmentation_28|was_15|._33 (r_prep) attributed_50\VBN\670261|NONE_0 (l_ccomp) demonstrated_2\VBD\2137132|;_277|augmentation_284|was_297|to_312|._345 (l_advcl) induce_34\VB\1627355|studies_206|induced_153|tolerance_66|,_45 (l_conj) augmented_42\VBD\153263|whereas_89|pretreatment_81|did_54|not_50|tolerance_33|but_11 (l_dobj) response_45\NN\11410625|rather_32 (l_amod) cataleptic_44\JJ\10490141|the_4
D007649_D009127 NONE ketamine_19\NN\3054098|NONE_0 (r_pobj) of_18\IN\0|the_26|relative_22|in_24 (r_prep) predominance_17\NN\14441825|latency_98|,_25|._56 (r_dobj) reflected_14\VBD\923793|NONE_0 (l_nsubj) latency_0\NN\15269513|,_73|predominance_98|._154 (l_prep) to_1\IN\0|NONE_0 (l_pobj) loss_3\NN\13252973|NONE_0 (l_prep) of_4\IN\0|the_9 (l_pobj) reflex_6\NN\859001|NONE_0 (l_conj) rigidity_8\NN\5023233|righting_17|,_2
11861791
D004317_D006333 CID doxorubicin_11\NN\2716866|-_11 (r_npadvmod) induced_13\VBN\1627355|heart_8 (r_amod) failure_15\NN\66216|NONE_0
D004317_D006331 NONE dox_36\NNP\0|NONE_0 (r_pobj) by_35\IN\0|NONE_0 (r_agent) induced_34\VBN\1627355|cardiac_20 (r_acl) dysfunction_33\NN\14204950|NONE_0
D004317_D005117 NONE dox_16\NNP\0|the_4 (r_compound) treatment_17\NN\654885|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) associated_13\VBN\628491|severe_29|cardiac_22 (r_acl) complications_12\NNS\1073995|NONE_0
D004317_D066126 NONE doxorubicin_12\NN\2716866|NONE_0 (r_pobj) of_11\IN\0|the_19 (r_prep) cardiotoxicity_10\NN\0|NONE_0
D004317_D066126 NONE dox_14\NNP\0|,_4|antibiotic_44 (r_appos) doxorubicin_12\NN\2716866|NONE_0 (r_pobj) of_11\IN\0|the_19 (r_prep) cardiotoxicity_10\NN\0|NONE_0
D004317_D066126 NONE dox_13\NNP\0|-_3 (r_npadvmod) induced_15\VBN\1627355|the_8 (r_amod) cardiotoxicity_16\NN\0|NONE_0
D004317_D066126 NONE dox_9\NNP\0|NONE_0 (r_pobj) of_8\IN\0|the_19 (r_prep) cardiotoxicity_7\NN\0|NONE_0
C434926_D006331 NONE pj34_19\NNP\0|NONE_0 (r_pobj) with_14\IN\0|pharmacological_27 (r_prep) inhibition_13\NN\1068773|genetic_36|or_19 (r_conj) deletion_10\NN\13508333|NONE_0 (r_pobj) by_8\IN\0|approach_32|,_2 (r_prep) using_0\VBG\418025|,_140|we_142|now_145|role_165|._234 (r_advcl) demonstrate_23\VBP\2137132|NONE_0 (l_dobj) role_25\NN\719494|using_165|,_25|we_23|now_20|._69 (l_prep) in_28\IN\13603305|the_17|of_8 (l_pobj) development_30\NN\248977|NONE_0 (l_prep) of_31\IN\0|the_16 (l_pobj) dysfunction_33\NN\14204950|NONE_0
C434926_D006331 NONE pj34_3\NNP\0|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) treatment_0\NN\654885|significantly_22|dysfunction_53|and_65|increased_69|._106 (r_nsubj) improved_5\VBD\126264|NONE_0 (l_dobj) dysfunction_7\NN\14204950|treatment_53|significantly_31|and_12|increased_16|._53
D018943_D066126 NONE anthracycline_21\NN\0|a_24|used_15|antitumor_10 (r_amod) antibiotic_22\NN\2716205|dox_44|,_40 (r_appos) doxorubicin_12\NN\2716866|NONE_0 (r_pobj) of_11\IN\0|the_19 (r_prep) cardiotoxicity_10\NN\0|NONE_0
D011064_D006333 NONE )_5\-RRB-\0|ribose_6 (r_punct) polymerase_6\NN\14732946|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) activation_0\NN\13561719|to_54|._105 (r_nsubj) contributes_7\VBZ\126264|NONE_0 (l_prep) to_8\IN\0|activation_54|._51 (l_pobj) development_9\NN\248977|NONE_0 (l_prep) of_10\IN\0|NONE_0 (l_pobj) failure_15\NN\66216|NONE_0
12109865
3131282
C009166_D013274 NONE acetate_6\NN\15010703|NONE_0 (r_pobj) of_4\IN\0|carcinogenic_20|on_19 (r_prep) effect_3\NN\34213|with_82|._111 (l_prep) on_7\IN\0|carcinogenic_39|of_19 (l_pobj) carcinogenesis_9\NN\0|NONE_0
C009166_D013274 NONE acetate_6\NN\15010703|NONE_0 (r_pobj) of_4\IN\0|the_31|potential_27|modifying_17|on_24 (r_prep) effect_3\NN\34213|(_59|tumorigenesis_89|was_103|._115 (r_nsubjpass) examined_19\VBN\0|NONE_0 (l_nsubjpass) tumorigenesis_17\NN\0|effect_89|(_30|was_14|._26
C009166_D013274 NONE ra_8\NNP\14625458|retinyl_17 (r_appos) acetate_6\NN\15010703|NONE_0 (r_pobj) of_4\IN\0|the_31|potential_27|modifying_17|on_24 (r_prep) effect_3\NN\34213|(_59|tumorigenesis_89|was_103|._115 (r_nsubjpass) examined_19\VBN\0|NONE_0 (l_nsubjpass) tumorigenesis_17\NN\0|effect_89|(_30|was_14|._26
C009166_D013274 NONE ra_27\NNP\14625458|incidence_50|to_122|from_159 (r_nsubj) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_dobj) incidence_37\NN\13821570|ra_50|to_72|from_109 (l_prep) of_38\IN\0|the_14|(_22|papilloma_37|)_60 (l_pobj) tumors_40\NNS\14234074|NONE_0
C009166_D013274 NONE ra_74\NNP\14625458|-_2 (r_npadvmod) free_76\JJ\7942152|NONE_0 (r_amod) water_77\NN\14618834|NONE_0 (r_dobj) given_73\VBN\5892096|the_10 (r_acl) group_72\NN\2137|NONE_0 (r_pobj) in_70\IN\13603305|%_33 (r_prep) from_59\IN\0|ra_159|incidence_109|to_37 (r_prep) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_dobj) incidence_37\NN\13821570|ra_50|to_72|from_109 (l_prep) of_38\IN\0|the_14|(_22|papilloma_37|)_60 (l_pobj) tumors_40\NNS\14234074|NONE_0
C009166_D013274 NONE ra_4\NNP\14625458|that_5|as_9|carcinogenesis_51 (r_nsubj) acted_5\VBD\0|findings_26|._73 (l_dobj) carcinogenesis_15\NN\0|that_56|ra_51|as_42
D002083_D063646 NONE hydroxyanisole_17\NN\0|NONE_0 (r_pobj) with_15\IN\0|effect_82|._29 (r_prep) induced_14\VBN\1627355|NONE_0 (l_nsubj) effect_3\NN\34213|with_82|._111 (l_amod) carcinogenic_2\JJ\0|of_20|on_39
D002083_D013274 CID hydroxyanisole_17\NN\0|NONE_0 (r_pobj) with_15\IN\0|effect_82|._29 (r_prep) induced_14\VBN\1627355|NONE_0 (l_nsubj) effect_3\NN\34213|with_82|._111 (l_prep) on_7\IN\0|carcinogenic_39|of_19 (l_pobj) carcinogenesis_9\NN\0|NONE_0
D002083_D013274 CID hydroxyanisole_12\NN\0|NONE_0 (r_pobj) on_10\IN\0|the_55|potential_51|modifying_41|of_24 (r_prep) effect_3\NN\34213|(_59|tumorigenesis_89|was_103|._115 (r_nsubjpass) examined_19\VBN\0|NONE_0 (l_nsubjpass) tumorigenesis_17\NN\0|effect_89|(_30|was_14|._26
D002083_D013274 CID bha)-induced_14\JJ\0|NONE_0 (r_amod) rat_15\NN\2329401|forestomach_4 (r_compound) tumorigenesis_17\NN\0|effect_89|(_30|was_14|._26
D002083_D013274 CID bha_5\NNP\0|NONE_0 (r_dobj) given_2\VBN\5892096|NONE_0 (r_acl) groups_1\NNS\2137|NONE_0 (r_pobj) in_0\IN\13603305|,_22|marked_33|changes_53|were_91|in_105|increased_184|._379 (r_prep) observed_16\VBN\2163746|NONE_0 (l_conj) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_dobj) incidence_37\NN\13821570|ra_50|to_72|from_109 (l_prep) of_38\IN\0|the_14|(_22|papilloma_37|)_60 (l_pobj) tumors_40\NNS\14234074|NONE_0
D002083_D013274 CID bha_13\NNP\0|the_4|forestomach_4|of_31 (r_compound) carcinogenesis_15\NN\0|that_56|ra_51|as_42
C009166_D063646 NONE acetate_6\NN\15010703|NONE_0 (r_pobj) of_4\IN\0|carcinogenic_20|on_19 (r_prep) effect_3\NN\34213|with_82|._111 (l_amod) carcinogenic_2\JJ\0|of_20|on_39
C009166_D017573 NONE ra_7\NNP\14625458|NONE_0 (r_punct) co_8\NNP\14954601|NONE_0 (r_punct) -_9\HYPH\0|NONE_0 (r_punct) administered_10\VBN\2436349|dose_18 (r_punct) at_11\IN\14622893|bha_24 (r_prep) given_2\VBN\5892096|NONE_0 (r_acl) rats_1\NNS\2329401|NONE_0 (r_pobj) in_0\IN\13603305|%_76|effect_112|._179 (r_prep) showed_23\VBD\2137132|NONE_0 (l_dobj) effect_29\NN\34213|in_112|%_36|._67 (l_prep) on_30\IN\0|a_34|dependent_27|enhancing_17 (l_pobj) development_32\NN\248977|NONE_0 (l_prep) of_33\IN\0|the_16 (l_pobj) hyperplasia_39\NN\14365950|NONE_0
D002083_D017573 NONE bha_5\NNP\0|at_24 (r_dobj) given_2\VBN\5892096|NONE_0 (r_acl) rats_1\NNS\2329401|NONE_0 (r_pobj) in_0\IN\13603305|%_76|effect_112|._179 (r_prep) showed_23\VBD\2137132|NONE_0 (l_dobj) effect_29\NN\34213|in_112|%_36|._67 (l_prep) on_30\IN\0|a_34|dependent_27|enhancing_17 (l_pobj) development_32\NN\248977|NONE_0 (l_prep) of_33\IN\0|the_16 (l_pobj) hyperplasia_39\NN\14365950|NONE_0
D002083_D017573 NONE bha_35\NNP\0|-_3 (r_npadvmod) induced_37\VBN\1627355|the_8|epithelial_8 (r_amod) hyperplasia_39\NN\14365950|NONE_0
C009166_D002277 NONE ra_27\NNP\14625458|incidence_50|to_122|from_159 (r_nsubj) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_dobj) incidence_37\NN\13821570|ra_50|to_72|from_109 (l_appos) papilloma_44\NN\14236226|the_51|of_37|(_15|)_23 (l_conj) carcinoma_46\NN\14239918|squamous_28|cell_19|and_4
C009166_D002277 NONE ra_27\NNP\14625458|incidence_50|to_122|from_159 (r_nsubj) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_prep) to_48\IN\0|ra_122|incidence_72|from_37 (l_pobj) %_50\NN\0|NONE_0 (l_appos) rats_55\NNS\2329401|60_13 (l_prep) with_56\IN\0|(_14|9/15_13|,_9|2_7|)_14 (l_pobj) carcinoma_57\NN\14239918|NONE_0
C009166_D002277 NONE ra_27\NNP\14625458|incidence_50|to_122|from_159 (r_nsubj) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_prep) from_59\IN\0|ra_159|incidence_109|to_37 (l_pobj) %_61\NN\0|in_33 (l_appos) rat_66\NN\2329401|15_15|(_11|3/20_10|,_6|)_18 (l_prep) with_67\IN\0|one_8 (l_pobj) carcinoma_68\NN\14239918|NONE_0
C009166_D002277 NONE ra_74\NNP\14625458|-_2 (r_npadvmod) free_76\JJ\7942152|NONE_0 (r_amod) water_77\NN\14618834|NONE_0 (r_dobj) given_73\VBN\5892096|the_10 (r_acl) group_72\NN\2137|NONE_0 (r_pobj) in_70\IN\13603305|%_33 (r_prep) from_59\IN\0|ra_159|incidence_109|to_37 (r_prep) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_dobj) incidence_37\NN\13821570|ra_50|to_72|from_109 (l_appos) papilloma_44\NN\14236226|the_51|of_37|(_15|)_23 (l_conj) carcinoma_46\NN\14239918|squamous_28|cell_19|and_4
C009166_D002277 NONE ra_74\NNP\14625458|-_2 (r_npadvmod) free_76\JJ\7942152|NONE_0 (r_amod) water_77\NN\14618834|NONE_0 (r_dobj) given_73\VBN\5892096|the_10 (r_acl) group_72\NN\2137|NONE_0 (r_pobj) in_70\IN\13603305|%_33 (r_prep) from_59\IN\0|ra_159|incidence_109|to_37 (r_prep) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_prep) to_48\IN\0|ra_122|incidence_72|from_37 (l_pobj) %_50\NN\0|NONE_0 (l_appos) rats_55\NNS\2329401|60_13 (l_prep) with_56\IN\0|(_14|9/15_13|,_9|2_7|)_14 (l_pobj) carcinoma_57\NN\14239918|NONE_0
C009166_D002277 NONE ra_74\NNP\14625458|-_2 (r_npadvmod) free_76\JJ\7942152|NONE_0 (r_amod) water_77\NN\14618834|NONE_0 (r_dobj) given_73\VBN\5892096|the_10 (r_acl) group_72\NN\2137|NONE_0 (r_pobj) in_70\IN\13603305|%_33 (r_prep) from_59\IN\0|ra_159|incidence_109|to_37 (l_pobj) %_61\NN\0|in_33 (l_appos) rat_66\NN\2329401|15_15|(_11|3/20_10|,_6|)_18 (l_prep) with_67\IN\0|one_8 (l_pobj) carcinoma_68\NN\14239918|NONE_0
C009166_D009369 NONE ra_17\NN\14625458|and_3|in_7 (r_pobj) with_14\IN\0|3_13|(_6|%_3|)_2 (r_prep) rats_9\NNS\2329401|NONE_0 (r_pobj) in_7\IN\13603305|tumors_37|were_13|._82 (r_prep) induced_6\VBN\1627355|NONE_0 (l_nsubjpass) tumors_0\NNS\14234074|were_24|in_37|._119
C009166_D009369 NONE ra_29\NNP\14625458|%_2|-_5 (r_compound) administration_32\NN\1133281|NONE_0 (r_punct) ._33\.\0|tumors_119|were_95|in_82 (r_punct) induced_6\VBN\1627355|NONE_0 (l_nsubjpass) tumors_0\NNS\14234074|were_24|in_37|._119
D002083_D002277 NONE bha_5\NNP\0|NONE_0 (r_dobj) given_2\VBN\5892096|NONE_0 (r_acl) groups_1\NNS\2137|NONE_0 (r_pobj) in_0\IN\13603305|,_22|marked_33|changes_53|were_91|in_105|increased_184|._379 (r_prep) observed_16\VBN\2163746|NONE_0 (l_conj) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_dobj) incidence_37\NN\13821570|ra_50|to_72|from_109 (l_appos) papilloma_44\NN\14236226|the_51|of_37|(_15|)_23 (l_conj) carcinoma_46\NN\14239918|squamous_28|cell_19|and_4
D002083_D002277 NONE bha_5\NNP\0|NONE_0 (r_dobj) given_2\VBN\5892096|NONE_0 (r_acl) groups_1\NNS\2137|NONE_0 (r_pobj) in_0\IN\13603305|,_22|marked_33|changes_53|were_91|in_105|increased_184|._379 (r_prep) observed_16\VBN\2163746|NONE_0 (l_conj) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_prep) to_48\IN\0|ra_122|incidence_72|from_37 (l_pobj) %_50\NN\0|NONE_0 (l_appos) rats_55\NNS\2329401|60_13 (l_prep) with_56\IN\0|(_14|9/15_13|,_9|2_7|)_14 (l_pobj) carcinoma_57\NN\14239918|NONE_0
D002083_D002277 NONE bha_5\NNP\0|NONE_0 (r_dobj) given_2\VBN\5892096|NONE_0 (r_acl) groups_1\NNS\2137|NONE_0 (r_pobj) in_0\IN\13603305|,_22|marked_33|changes_53|were_91|in_105|increased_184|._379 (r_prep) observed_16\VBN\2163746|NONE_0 (l_conj) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_prep) from_59\IN\0|ra_159|incidence_109|to_37 (l_pobj) %_61\NN\0|in_33 (l_appos) rat_66\NN\2329401|15_15|(_11|3/20_10|,_6|)_18 (l_prep) with_67\IN\0|one_8 (l_pobj) carcinoma_68\NN\14239918|NONE_0
D002083_D010212 NONE bha_5\NNP\0|NONE_0 (r_dobj) given_2\VBN\5892096|NONE_0 (r_acl) groups_1\NNS\2137|NONE_0 (r_pobj) in_0\IN\13603305|,_22|marked_33|changes_53|were_91|in_105|increased_184|._379 (r_prep) observed_16\VBN\2163746|NONE_0 (l_conj) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_dobj) incidence_37\NN\13821570|ra_50|to_72|from_109 (l_appos) papilloma_44\NN\14236226|the_51|of_37|(_15|)_23
C009166_D010212 NONE ra_27\NNP\14625458|incidence_50|to_122|from_159 (r_nsubj) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_dobj) incidence_37\NN\13821570|ra_50|to_72|from_109 (l_appos) papilloma_44\NN\14236226|the_51|of_37|(_15|)_23
C009166_D010212 NONE ra_74\NNP\14625458|-_2 (r_npadvmod) free_76\JJ\7942152|NONE_0 (r_amod) water_77\NN\14618834|NONE_0 (r_dobj) given_73\VBN\5892096|the_10 (r_acl) group_72\NN\2137|NONE_0 (r_pobj) in_70\IN\13603305|%_33 (r_prep) from_59\IN\0|ra_159|incidence_109|to_37 (r_prep) increased_35\VBD\169651|in_184|,_162|marked_151|changes_131|were_93|in_79|._195 (l_dobj) incidence_37\NN\13821570|ra_50|to_72|from_109 (l_appos) papilloma_44\NN\14236226|the_51|of_37|(_15|)_23
C009166_D010212 NONE ra_17\NN\14625458|and_3|in_7 (r_pobj) with_14\IN\0|3_13|(_6|%_3|)_2 (r_prep) rats_9\NNS\2329401|NONE_0 (r_pobj) in_7\IN\13603305|tumors_37|were_13|._82 (r_prep) induced_6\VBN\1627355|NONE_0 (l_nsubjpass) tumors_0\NNS\14234074|were_24|in_37|._119 (l_appos) papillomas_3\NNS\14236226|,_6|,_10
C009166_D010212 NONE ra_29\NNP\14625458|%_2|-_5 (r_compound) administration_32\NN\1133281|NONE_0 (r_punct) ._33\.\0|tumors_119|were_95|in_82 (r_punct) induced_6\VBN\1627355|NONE_0 (l_nsubjpass) tumors_0\NNS\14234074|were_24|in_37|._119 (l_appos) papillomas_3\NNS\14236226|,_6|,_10
19234905
D014635_D006423 NONE valproate_33\NNP\0|NONE_0 (r_pobj) with_32\IN\0|which_37|partly_31|within_15 (r_prep) improved_28\VBD\126264|one_84|movements_51|after_34 (r_advcl) developed_18\VBN\1753788|observed_98|:_74|one_72|hemianopsia_46|after_34|and_16|._130 (r_conj) had_8\VBD\0|NONE_0 (l_dobj) hemianopsia_12\NN\14552802|observed_52|:_28|one_26|after_12|and_30|developed_46|._176
D007980_D004409 CID levodopa_55\RB\14604959|-_8 (r_npadvmod) induced_57\VBN\1627355|NONE_0 (r_amod) dyskinesias_58\NNS\14084880|were_12|._25
8600333
C053519_D001859 NONE protocol_23\NN\6652242|NONE_0 (r_pobj) to_17\IN\0|NONE_0 (r_prep) according_16\VBG\2657219|who_17|were_13 (r_prep) treated_15\VBN\2376958|term_49|of_34 (r_relcl) survivors_8\NNS\9630641|NONE_0 (l_prep) of_9\IN\0|term_15|treated_34 (l_pobj) tumors_12\NNS\14234074|NONE_0
D004317_D066126 NONE doxorubicin_3\NN\2716866|-_11 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_compound) cardiotoxicity_6\NN\0|NONE_0
D004317_D001859 NONE doxorubicin_27\NN\2716866|NONE_0 (r_pobj) including_26\VBG\0|NONE_0 (r_prep) both_25\DT\0|rosen_28|t5_20|,_2 (r_appos) protocol_23\NN\6652242|NONE_0 (r_pobj) to_17\IN\0|NONE_0 (r_prep) according_16\VBG\2657219|who_17|were_13 (r_prep) treated_15\VBN\2376958|term_49|of_34 (r_relcl) survivors_8\NNS\9630641|NONE_0 (l_prep) of_9\IN\0|term_15|treated_34 (l_pobj) tumors_12\NNS\14234074|NONE_0
6308526
D009020_D007035 CID morphine_5\NN\2707683|pretreatment_51|significantly_22|analgesia_9|at_46|._124 (r_dobj) blocked_4\VBD\1476483|NONE_0 (l_npadvmod) analgesia_6\NN\14034177|pretreatment_60|significantly_31|morphine_9|at_37|._115 (l_conj) catalepsy_8\NN\14023236|,_2 (l_conj) hypothermia_10\VBN\14034177|and_4
D009020_D000699 NONE morphine_5\NN\2707683|pretreatment_51|significantly_22|analgesia_9|at_46|._124 (r_dobj) blocked_4\VBD\1476483|NONE_0 (l_npadvmod) analgesia_6\NN\14034177|pretreatment_60|significantly_31|morphine_9|at_37|._115
D009020_D012131 NONE morphine_6\NN\2707683|-_8 (r_npadvmod) induced_8\VBN\1627355|the_13|hypotension_8 (r_amod) depression_12\NN\14373582|moreover_95|,_87|naloxazone_85|significantly_74|,_10|was_49|._66
D009020_D012131 NONE morphine_15\NN\2707683|-_8 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) bradycardia_18\NN\14110674|whereas_25|affected_21 (r_nsubj) was_19\VBD\0|moreover_144|,_136|naloxazone_134|significantly_123|depression_49|,_39|._17 (r_advcl) attenuated_4\VBD\224901|NONE_0 (l_dobj) depression_12\NN\14373582|moreover_95|,_87|naloxazone_85|significantly_74|,_10|was_49|._66
D009020_D007022 CID morphine_6\NN\2707683|-_8 (r_npadvmod) induced_8\VBN\1627355|the_13|hypotension_8 (r_amod) depression_12\NN\14373582|moreover_95|,_87|naloxazone_85|significantly_74|,_10|was_49|._66 (l_nmod) hypotension_9\NN\14057371|the_21|induced_8
D009020_D007022 CID morphine_15\NN\2707683|-_8 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) bradycardia_18\NN\14110674|whereas_25|affected_21 (r_nsubj) was_19\VBD\0|moreover_144|,_136|naloxazone_134|significantly_123|depression_49|,_39|._17 (r_advcl) attenuated_4\VBD\224901|NONE_0 (l_dobj) depression_12\NN\14373582|moreover_95|,_87|naloxazone_85|significantly_74|,_10|was_49|._66 (l_nmod) hypotension_9\NN\14057371|the_21|induced_8
C024224_D007022 NONE naloxazone_2\NN\0|moreover_10|,_2|significantly_11|depression_85|,_95|was_134|._151 (r_nsubj) attenuated_4\VBD\224901|NONE_0 (l_dobj) depression_12\NN\14373582|moreover_95|,_87|naloxazone_85|significantly_74|,_10|was_49|._66 (l_nmod) hypotension_9\NN\14057371|the_21|induced_8
D009020_D002375 CID morphine_5\NN\2707683|pretreatment_51|significantly_22|analgesia_9|at_46|._124 (r_dobj) blocked_4\VBD\1476483|NONE_0 (l_npadvmod) analgesia_6\NN\14034177|pretreatment_60|significantly_31|morphine_9|at_37|._115 (l_conj) catalepsy_8\NN\14023236|,_2
C024224_D002375 NONE naloxazone_2\NN\0|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) pretreatment_0\NN\0|significantly_29|morphine_51|analgesia_60|at_97|._175 (r_nsubj) blocked_4\VBD\1476483|NONE_0 (l_npadvmod) analgesia_6\NN\14034177|pretreatment_60|significantly_31|morphine_9|at_37|._115 (l_conj) catalepsy_8\NN\14023236|,_2
C024224_D000699 NONE naloxazone_2\NN\0|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) pretreatment_0\NN\0|significantly_29|morphine_51|analgesia_60|at_97|._175 (r_nsubj) blocked_4\VBD\1476483|NONE_0 (l_npadvmod) analgesia_6\NN\14034177|pretreatment_60|significantly_31|morphine_9|at_37|._115
C024224_D007035 NONE naloxazone_2\NN\0|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) pretreatment_0\NN\0|significantly_29|morphine_51|analgesia_60|at_97|._175 (r_nsubj) blocked_4\VBD\1476483|NONE_0 (l_npadvmod) analgesia_6\NN\14034177|pretreatment_60|significantly_31|morphine_9|at_37|._115 (l_conj) catalepsy_8\NN\14023236|,_2 (l_conj) hypothermia_10\VBN\14034177|and_4
D009020_D001919 CID morphine_6\NN\2707683|-_8 (r_npadvmod) induced_8\VBN\1627355|the_13|hypotension_8 (r_amod) depression_12\NN\14373582|moreover_95|,_87|naloxazone_85|significantly_74|,_10|was_49|._66 (r_dobj) attenuated_4\VBD\224901|NONE_0 (l_advcl) was_19\VBD\0|moreover_144|,_136|naloxazone_134|significantly_123|depression_49|,_39|._17 (l_nsubj) bradycardia_18\NN\14110674|whereas_25|affected_21
D009020_D001919 CID morphine_15\NN\2707683|-_8 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) bradycardia_18\NN\14110674|whereas_25|affected_21
C024224_D001919 NONE naloxazone_2\NN\0|moreover_10|,_2|significantly_11|depression_85|,_95|was_134|._151 (r_nsubj) attenuated_4\VBD\224901|NONE_0 (l_advcl) was_19\VBD\0|moreover_144|,_136|naloxazone_134|significantly_123|depression_49|,_39|._17 (l_nsubj) bradycardia_18\NN\14110674|whereas_25|affected_21
C024224_D012131 NONE naloxazone_2\NN\0|moreover_10|,_2|significantly_11|depression_85|,_95|was_134|._151 (r_nsubj) attenuated_4\VBD\224901|NONE_0 (l_dobj) depression_12\NN\14373582|moreover_95|,_87|naloxazone_85|significantly_74|,_10|was_49|._66
9326871
D004917_D005759 CID erythromycin_7\NNP\2716866|NONE_0 (r_pobj) of_6\IN\0|the_24|effect_15 (r_prep) profile_5\NN\6999802|although_25|is_24 (r_nsubjpass) established_9\VBN\2426171|experience_127|is_164|still_167|being_173|._187 (r_advcl) recorded_35\VBN\2225492|NONE_0 (l_nsubjpass) experience_27\NN\5984287|established_127|is_37|still_40|being_46|._60 (l_prep) including_11\VBG\0|,_2|,_112|with_125 (l_pobj) gastroenteritis_12\JJ\14171682|NONE_0
D004917_D066126 NONE erythromycin_11\NNP\2716866|NONE_0 (r_pobj) of_10\IN\0|intravenous_36 (r_prep) administration_9\NN\1133281|NONE_0 (r_pobj) after_4\IN\0|cardiotoxicity_37|has_22|been_18|but_63|reported_82|._116 (r_prep) demonstrated_3\VBN\2137132|NONE_0 (l_nsubjpass) cardiotoxicity_0\NN\0|has_15|been_19|after_37|but_100|reported_119|._153
D017291_D001145 NONE clarithromycin_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|six_22|therapeutic_18 (r_prep) doses_12\NNS\3740161|NONE_0 (r_pobj) after_9\IN\0|that_14 (r_prep) occurred_8\VBD\0|ventricular_30 (r_relcl) dysrhythmias_6\NNS\0|NONE_0
D018942_D005759 NONE macrolides_31\NNS\0|NONE_0 (r_pobj) with_28\IN\0|,_127|including_125|,_13 (r_prep) experience_27\NN\5984287|established_127|is_37|still_40|being_46|._60 (l_prep) including_11\VBG\0|,_2|,_112|with_125 (l_pobj) gastroenteritis_12\JJ\14171682|NONE_0
D017291_D017180 CID clarithromycin_0\NN\0|-_14 (r_npadvmod) induced_2\VBN\1627355|ventricular_8|._31 (r_amod) tachycardia_4\NN\14110674|NONE_0
D018942_D066126 NONE macrolides_20\NNS\0|NONE_0 (r_pobj) with_17\IN\0|has_24|never_20|been_14 (r_prep) reported_16\VBN\831651|cardiotoxicity_119|has_104|been_100|after_82|but_19|._34 (r_conj) demonstrated_3\VBN\2137132|NONE_0 (l_nsubjpass) cardiotoxicity_0\NN\0|has_15|been_19|after_37|but_100|reported_119|._153
2594614
D002045_D007022 CID bupivacaine_5\NN\0|NONE_0 (r_pobj) of_1\IN\0|(_37|mg/kg_47|)_58|to_60 (r_prep) administration_0\NN\1133281|decrease_101|._224 (r_nsubj) elicited_16\VBD\1617192|NONE_0 (l_dobj) decrease_19\NN\7296428|administration_101|._123 (l_prep) of_20\IN\0|a_18|marked_16|(_75|in_76|)_113 (l_pobj) pressure_24\NN\11419404|NONE_0 (l_appos) mbp_26\NNP\0|mean_30|arterial_25|blood_16|(_1|leading_25 (l_conj) rate_30\NN\13815152|)_12|and_10 (l_punct) )_33\-RRB-\0|heart_14|(_3|hr_2
D002045_D007022 CID bupivacaine_23\NN\0|NONE_0 (r_compound) administration_24\NN\1133281|NONE_0 (r_pobj) before_22\IN\0|30_7|i.v._43|)_47 (r_prep) min_21\NN\15154774|intravenous_106|of_84|antagonist_35|,_5 (r_appos) injection_1\NN\320852|decrease_167|._189 (r_nsubj) suppressed_30\VBD\2510337|NONE_0 (l_dobj) decrease_33\NN\7296428|injection_167|._22 (l_prep) of_34\IN\0|both_18|the_13 (l_pobj) mbp_35\NNP\0|NONE_0 (l_conj) hr_37\NN\15154774|and_4
D002045_D007022 CID bupivacaine_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|when_55|bn_50|was_25|immediately_12|mg/kg_21 (r_prep) injected_9\VBN\81072|,_48|reversion_60|was_100|,_112|was_143|._158 (r_advcl) observed_29\VBN\2163746|NONE_0 (l_nsubjpass) reversion_20\NN\13286801|injected_60|,_12|was_40|,_52|was_83|._98 (l_prep) of_21\IN\0|a_20|partial_18 (l_pobj) decrease_23\NN\7296428|NONE_0 (l_prep) of_24\IN\0|the_13 (l_pobj) mbp_25\NNP\0|NONE_0 (l_conj) hr_27\NN\15154774|and_4
D002045_D002318 NONE bupivacaine_15\NN\0|-_11 (r_npadvmod) induced_17\VBN\1627355|cardiovascular_8|in_35 (r_amod) impairments_19\NNS\7296428|NONE_0
D002045_D002318 NONE bupivacaine_44\NN\0|-_11 (r_npadvmod) induced_46\VBN\1627355|cardiovascular_8 (r_amod) toxicity_48\NN\13576101|NONE_0
C045856_D002318 NONE 52021_12\CD\0|NONE_0 (r_nummod) bn_11\NNP\0|a_50|specific_48|activating_30|factor_19|,_2|,_8|on_10 (r_appos) antagonist_9\NN\7846|NONE_0 (l_prep) on_14\IN\0|a_60|specific_58|activating_40|factor_29|,_12|bn_10|,_2 (l_pobj) impairments_19\NNS\7296428|NONE_0
C045856_D002318 NONE 52021_5\CD\0|NONE_0 (r_nummod) bn_4\NNP\0|NONE_0 (r_pobj) of_3\IN\0|the_19 (r_prep) administration_2\NN\1133281|since_10|,_26|at_28|,_48|did_50|not_54|mbp_64|at_75 (r_nsubj) alter_14\VB\0|,_34|bulk_40|clearly_62|action_95|._196 (r_advcl) demonstrate_29\VBP\2137132|NONE_0 (l_dobj) action_32\NN\30358|alter_95|,_61|bulk_55|clearly_33|._101 (l_prep) against_43\IN\0|a_63|protective_61|of_43|,_32|antagonist_19|,_2 (l_pobj) toxicity_48\NN\13576101|NONE_0
C045856_D002318 NONE 52021_35\CD\0|NONE_0 (r_nummod) bn_34\NNP\0|NONE_0 (r_pobj) of_33\IN\0|a_20|protective_18|,_11|antagonist_24|,_41|against_43 (r_prep) action_32\NN\30358|alter_95|,_61|bulk_55|clearly_33|._101 (l_prep) against_43\IN\0|a_63|protective_61|of_43|,_32|antagonist_19|,_2 (l_pobj) toxicity_48\NN\13576101|NONE_0
C045856_D001919 NONE 52021_14\CD\0|(_20|paf_19|)_16|mg/kg_10|)_15 (r_appos) antagonist_12\NN\7846|intravenous_71|of_49|,_30|min_35 (r_appos) injection_1\NN\320852|decrease_167|._189 (r_nsubj) suppressed_30\VBD\2510337|NONE_0 (l_dobj) decrease_33\NN\7296428|injection_167|._22 (l_prep) of_34\IN\0|both_18|the_13 (l_pobj) mbp_35\NNP\0|NONE_0 (l_conj) hr_37\NN\15154774|and_4
C045856_D001919 NONE 52021_2\CD\0|mg/kg_10|i.v._16|)_20 (r_nummod) bn_1\NNP\0|when_5|was_25|immediately_38|after_50|mg/kg_71 (r_nsubjpass) injected_9\VBN\81072|,_48|reversion_60|was_100|,_112|was_143|._158 (r_advcl) observed_29\VBN\2163746|NONE_0 (l_nsubjpass) reversion_20\NN\13286801|injected_60|,_12|was_40|,_52|was_83|._98 (l_prep) of_21\IN\0|a_20|partial_18 (l_pobj) decrease_23\NN\7296428|NONE_0 (l_prep) of_24\IN\0|the_13 (l_pobj) mbp_25\NNP\0|NONE_0 (l_conj) hr_27\NN\15154774|and_4
D002045_D018376 NONE bupivacaine_16\NN\0|-_11 (r_npadvmod) induced_18\VBN\1627355|cardiovascular_8 (r_amod) alterations_20\NNS\7283608|NONE_0
D002045_D001919 CID bupivacaine_5\NN\0|NONE_0 (r_pobj) of_1\IN\0|(_37|mg/kg_47|)_58|to_60 (r_prep) administration_0\NN\1133281|decrease_101|._224 (r_nsubj) elicited_16\VBD\1617192|NONE_0 (l_dobj) decrease_19\NN\7296428|administration_101|._123 (l_prep) of_20\IN\0|a_18|marked_16|(_75|in_76|)_113 (l_pobj) pressure_24\NN\11419404|NONE_0 (l_appos) mbp_26\NNP\0|mean_30|arterial_25|blood_16|(_1|leading_25 (l_conj) rate_30\NN\13815152|)_12|and_10 (l_punct) )_33\-RRB-\0|heart_14|(_3|hr_2
D002045_D001919 CID bupivacaine_23\NN\0|NONE_0 (r_compound) administration_24\NN\1133281|NONE_0 (r_pobj) before_22\IN\0|30_7|i.v._43|)_47 (r_prep) min_21\NN\15154774|intravenous_106|of_84|antagonist_35|,_5 (r_appos) injection_1\NN\320852|decrease_167|._189 (r_nsubj) suppressed_30\VBD\2510337|NONE_0 (l_dobj) decrease_33\NN\7296428|injection_167|._22 (l_prep) of_34\IN\0|both_18|the_13 (l_pobj) mbp_35\NNP\0|NONE_0 (l_conj) hr_37\NN\15154774|and_4
D002045_D001919 CID bupivacaine_12\NN\0|NONE_0 (r_pobj) after_11\IN\0|when_55|bn_50|was_25|immediately_12|mg/kg_21 (r_prep) injected_9\VBN\81072|,_48|reversion_60|was_100|,_112|was_143|._158 (r_advcl) observed_29\VBN\2163746|NONE_0 (l_nsubjpass) reversion_20\NN\13286801|injected_60|,_12|was_40|,_52|was_83|._98 (l_prep) of_21\IN\0|a_20|partial_18 (l_pobj) decrease_23\NN\7296428|NONE_0 (l_prep) of_24\IN\0|the_13 (l_pobj) mbp_25\NNP\0|NONE_0 (l_conj) hr_27\NN\15154774|and_4
C045856_D007022 NONE 52021_14\CD\0|(_20|paf_19|)_16|mg/kg_10|)_15 (r_appos) antagonist_12\NN\7846|intravenous_71|of_49|,_30|min_35 (r_appos) injection_1\NN\320852|decrease_167|._189 (r_nsubj) suppressed_30\VBD\2510337|NONE_0 (l_dobj) decrease_33\NN\7296428|injection_167|._22 (l_prep) of_34\IN\0|both_18|the_13 (l_pobj) mbp_35\NNP\0|NONE_0 (l_conj) hr_37\NN\15154774|and_4
C045856_D007022 NONE 52021_2\CD\0|mg/kg_10|i.v._16|)_20 (r_nummod) bn_1\NNP\0|when_5|was_25|immediately_38|after_50|mg/kg_71 (r_nsubjpass) injected_9\VBN\81072|,_48|reversion_60|was_100|,_112|was_143|._158 (r_advcl) observed_29\VBN\2163746|NONE_0 (l_nsubjpass) reversion_20\NN\13286801|injected_60|,_12|was_40|,_52|was_83|._98 (l_prep) of_21\IN\0|a_20|partial_18 (l_pobj) decrease_23\NN\7296428|NONE_0 (l_prep) of_24\IN\0|the_13 (l_pobj) mbp_25\NNP\0|NONE_0 (l_conj) hr_27\NN\15154774|and_4
9061311
D010100_D017114 NONE oxygen_5\NN\14622893|radical_7|in_26|due_47 (r_nmod) production_7\NN\30358|in_37|,_17|was_60|with_73|._104 (l_prep) in_8\IN\13603305|oxygen_26|radical_19|due_21 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) alf_11\NNP\0|NONE_0
D013481_D001424 NONE superoxide_2\NN\14971519|peroxide_24 (r_amod) production_6\NN\30358|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) defects_0\NNS\14462666|may_55|be_59|in_73|._161 (r_nsubjpass) implicated_9\VBN\2677097|NONE_0 (l_prep) in_10\IN\13603305|defects_73|may_18|be_14|._88 (l_pobj) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|the_19|high_15 (l_pobj) infections_16\NNS\14052046|NONE_0
D006861_D001424 NONE peroxide_5\NN\14780040|superoxide_24 (r_compound) production_6\NN\30358|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) defects_0\NNS\14462666|may_55|be_59|in_73|._161 (r_nsubjpass) implicated_9\VBN\2677097|NONE_0 (l_prep) in_10\IN\13603305|defects_73|may_18|be_14|._88 (l_pobj) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|the_19|high_15 (l_pobj) infections_16\NNS\14052046|NONE_0
D009240_D017114 NONE phenylalanine_15\NN\14605787|(_14|)_19 (r_nmod) fmlp_17\NN\0|NONE_0 (r_pobj) with_8\IN\0|from_50 (r_prep) stimulated_7\VBN\137313|NONE_0 (l_prep) from_19\IN\0|with_50 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_compound) alf_23\NNP\0|a_13|further_11|18_3
D009240_D017114 NONE fmlp_17\NN\0|NONE_0 (r_pobj) with_8\IN\0|from_50 (r_prep) stimulated_7\VBN\137313|NONE_0 (l_prep) from_19\IN\0|with_50 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_compound) alf_23\NNP\0|a_13|further_11|18_3
D000082_D017114 CID paracetamol_14\JJ\0|NONE_0 (r_compound) overdose_15\NN\84738|to_15 (r_pobj) due_12\IN\5174653|oxygen_47|radical_40|in_21 (r_amod) production_7\NN\30358|in_37|,_17|was_60|with_73|._104 (l_prep) in_8\IN\13603305|oxygen_26|radical_19|due_21 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) alf_11\NNP\0|NONE_0
D000082_D017114 CID paracetamol_10\JJ\0|NONE_0 (r_compound) overdose_11\NN\84738|to_15 (r_pobj) due_8\IN\5174653|results_47|defect_14|,_27|complement_37|._140 (r_prep) demonstrate_2\VBP\2137132|NONE_0 (l_dobj) defect_5\NN\14462666|results_33|due_14|,_41|complement_51|._154 (l_prep) in_6\IN\13603305|a_20|neutrophil_18 (l_pobj) alf_7\NNP\0|NONE_0
D010100_D062787 NONE oxygen_5\NN\14622893|radical_7|in_26|due_47 (r_nmod) production_7\NN\30358|in_37|,_17|was_60|with_73|._104 (l_amod) due_12\IN\5174653|oxygen_47|radical_40|in_21 (l_pobj) overdose_15\NN\84738|to_15
D006861_D017114 NONE peroxide_4\NN\14780040|and_13 (r_conj) superoxide_1\NN\14971519|neutrophil_11|in_44|._80 (r_nmod) production_5\NN\30358|NONE_0 (l_prep) in_6\IN\13603305|neutrophil_55|superoxide_44|._36 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|NONE_0 (l_pobj) failure_11\NN\66216|NONE_0
D006861_D017114 NONE peroxide_5\NN\14780040|superoxide_24 (r_compound) production_6\NN\30358|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) defects_0\NNS\14462666|may_55|be_59|in_73|._161 (r_nsubjpass) implicated_9\VBN\2677097|NONE_0 (l_prep) in_10\IN\13603305|defects_73|may_18|be_14|._88 (l_pobj) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|the_19|high_15 (l_pobj) infections_16\NNS\14052046|NONE_0 (l_prep) in_17\IN\13603305|bacterial_21 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) failure_22\NN\66216|NONE_0
D006861_D017114 NONE peroxide_5\NN\14780040|superoxide_24 (r_compound) production_6\NN\30358|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) defects_0\NNS\14462666|may_55|be_59|in_73|._161 (r_nsubjpass) implicated_9\VBN\2677097|NONE_0 (l_prep) in_10\IN\13603305|defects_73|may_18|be_14|._88 (l_pobj) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|the_19|high_15 (l_pobj) infections_16\NNS\14052046|NONE_0 (l_prep) in_17\IN\13603305|bacterial_21 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) failure_22\NN\66216|NONE_0 (l_appos) alf_24\NNP\0|acute_21|liver_15|(_1|)_3
D006861_D017114 NONE peroxide_3\NN\14780040|NONE_0 (r_compound) production_4\NN\30358|and_22|by_11 (r_conj) superoxide_0\NN\14971519|with_74|opsonized_87|reduced_130|._183 (l_prep) by_5\IN\0|and_33|production_11 (l_pobj) neutrophils_7\NNS\5449959|NONE_0 (l_compound) alf_6\NNP\0|NONE_0
D006861_D017114 NONE peroxide_3\NN\14780040|NONE_0 (r_compound) production_4\NN\30358|and_22|by_11 (r_conj) superoxide_0\NN\14971519|with_74|opsonized_87|reduced_130|._183 (r_nsubj) stimulated_8\VBN\137313|NONE_0 (l_dobj) opsonized_11\VBN\126264|superoxide_87|with_13|reduced_43|._96 (l_prep) with_12\IN\0|NONE_0 (l_pobj) serum_14\NN\5397468|NONE_0 (l_compound) alf_13\NNP\0|NONE_0
D006861_D017114 NONE peroxide_3\NN\14780040|NONE_0 (r_compound) production_4\NN\30358|and_22|in_11 (r_conj) superoxide_0\NN\14971519|unaffected_155|compared_166|._199 (l_prep) in_5\IN\13603305|and_33|production_11 (l_pobj) neutrophils_6\NNS\5449959|NONE_0 (l_acl) stimulated_7\VBN\137313|NONE_0 (l_prep) from_19\IN\0|with_50 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_compound) alf_23\NNP\0|a_13|further_11|18_3
D013481_D017114 NONE superoxide_1\NN\14971519|neutrophil_11|in_44|._80 (r_nmod) production_5\NN\30358|NONE_0 (l_prep) in_6\IN\13603305|neutrophil_55|superoxide_44|._36 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_prep) with_8\IN\0|NONE_0 (l_pobj) failure_11\NN\66216|NONE_0
D013481_D017114 NONE superoxide_2\NN\14971519|peroxide_24 (r_amod) production_6\NN\30358|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) defects_0\NNS\14462666|may_55|be_59|in_73|._161 (r_nsubjpass) implicated_9\VBN\2677097|NONE_0 (l_prep) in_10\IN\13603305|defects_73|may_18|be_14|._88 (l_pobj) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|the_19|high_15 (l_pobj) infections_16\NNS\14052046|NONE_0 (l_prep) in_17\IN\13603305|bacterial_21 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) failure_22\NN\66216|NONE_0
D013481_D017114 NONE superoxide_2\NN\14971519|peroxide_24 (r_amod) production_6\NN\30358|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) defects_0\NNS\14462666|may_55|be_59|in_73|._161 (r_nsubjpass) implicated_9\VBN\2677097|NONE_0 (l_prep) in_10\IN\13603305|defects_73|may_18|be_14|._88 (l_pobj) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|the_19|high_15 (l_pobj) infections_16\NNS\14052046|NONE_0 (l_prep) in_17\IN\13603305|bacterial_21 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) failure_22\NN\66216|NONE_0 (l_appos) alf_24\NNP\0|acute_21|liver_15|(_1|)_3
D013481_D017114 NONE superoxide_0\NN\14971519|with_74|opsonized_87|reduced_130|._183 (l_prep) by_5\IN\0|and_33|production_11 (l_pobj) neutrophils_7\NNS\5449959|NONE_0 (l_compound) alf_6\NNP\0|NONE_0
D013481_D017114 NONE superoxide_0\NN\14971519|with_74|opsonized_87|reduced_130|._183 (r_nsubj) stimulated_8\VBN\137313|NONE_0 (l_dobj) opsonized_11\VBN\126264|superoxide_87|with_13|reduced_43|._96 (l_prep) with_12\IN\0|NONE_0 (l_pobj) serum_14\NN\5397468|NONE_0 (l_compound) alf_13\NNP\0|NONE_0
D013481_D017114 NONE superoxide_0\NN\14971519|unaffected_155|compared_166|._199 (l_prep) in_5\IN\13603305|and_33|production_11 (l_pobj) neutrophils_6\NNS\5449959|NONE_0 (l_acl) stimulated_7\VBN\137313|NONE_0 (l_prep) from_19\IN\0|with_50 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_compound) alf_23\NNP\0|a_13|further_11|18_3
D000082_D062787 NONE paracetamol_14\JJ\0|NONE_0 (r_compound) overdose_15\NN\84738|to_15
D000082_D062787 NONE paracetamol_10\JJ\0|NONE_0 (r_compound) overdose_11\NN\84738|to_15
18483878
D003520_D001745 NONE cyp_22\NNP\0|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) wt_20\NNP\0|NONE_0 (r_pobj) in_19\IN\13603305|that_14 (r_prep) observed_18\VBD\2163746|mice_80|,_50|mediators_35|are_25|above_11 (r_advcl) increased_15\VBN\169651|data_89|._44 (l_advcl) mice_7\NNS\2329401|,_30|mediators_45|are_55|above_69|observed_80 (l_prep) with_8\IN\0|that_22|in_17 (l_pobj) inflammation_10\NN\14299637|NONE_0
D003520_D003556 CID cyclophosphamide_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) mice_13\NNS\2329401|polypeptide_30|(_9|vip-/-_8|)_2|cystitis_41 (r_appos) knockout_9\NN\10787470|NONE_0 (l_appos) cystitis_18\NN\14566129|polypeptide_71|(_50|vip-/-_49|)_43|mice_41
D003520_D003556 CID cyp)-induced_17\VBN\0|NONE_0 (r_compound) cystitis_18\NN\14566129|polypeptide_71|(_50|vip-/-_49|)_43|mice_41
D003520_D003556 CID cyclophosphamide_14\NN\0|NONE_0 (r_pobj) after_13\IN\0|vip(-/-_100|function_62|cystitis_37|._45 (r_prep) altered_4\JJ\0|NONE_0 (l_dobj) cystitis_17\NN\14566129|vip(-/-_137|function_99|after_37|._8
D003520_D003556 CID cyp)-induced_16\VBN\0|(_1 (r_amod) cystitis_17\NN\14566129|vip(-/-_137|function_99|after_37|._8
D003520_D003556 CID cyp_32\NNP\0|-_3 (r_npadvmod) induced_34\VBN\1627355|(_17|mg/kg_22|;_27|i.p._29|;_33|h_38|)_39 (r_amod) cystitis_35\NN\14566129|NONE_0
19300240
D002395_D054549 NONE catecholamines_9\NNS\5407119|NONE_0 (r_pobj) of_7\IN\0|both_29|supraphysiologic_24|caused_58 (r_prep) levels_6\NNS\4916342|in_38|,_24|may_116|have_120|development_141|._159 (r_nsubj) contributed_24\VBN\126264|NONE_0 (l_dobj) development_26\NN\248977|in_179|,_165|levels_141|may_25|have_21|._18 (l_prep) of_27\IN\0|the_16 (l_pobj) abs_28\NN\14592610|NONE_0
D002395_D009369 NONE catecholamines_9\NNS\5407119|NONE_0 (r_pobj) of_7\IN\0|both_29|supraphysiologic_24|caused_58 (r_prep) levels_6\NNS\4916342|in_38|,_24|may_116|have_120|development_141|._159 (l_acl) caused_14\VBN\1617192|both_87|supraphysiologic_82|of_58 (l_agent) by_15\IN\0|NONE_0 (l_pobj) diagnosis_17\NN\152018|NONE_0 (l_compound) cancer_16\NN\14239425|as_25|chemotherapy_28
D005472_D015179 NONE fluorouracil_5\NN\2722166|NONE_0 (r_pobj) with_4\IN\0|she_34|chemotherapy_13|for_18|._50 (r_prep) underwent_1\VBD\109660|NONE_0 (l_prep) for_6\IN\0|she_52|chemotherapy_31|with_18|._32 (l_pobj) cancer_9\NN\14239425|NONE_0
D005472_D054549 CID flourouracil_1\NN\0|-_12 (r_npadvmod) induced_3\VBN\1627355|5_15|ballooning_15|:_34|report_43|._49 (r_amod) syndrome_6\NN\5870365|NONE_0
11078231
D000109_D023921 NONE acetylcholine_8\NN\14807558|NONE_0 (r_pobj) of_7\IN\0|intracoronary_24 (r_prep) injection_6\NN\320852|NONE_0 (r_pobj) by_4\IN\0|spasm_18|was_12|,_43|and_45|documented_87 (r_agent) induced_3\VBN\1627355|NONE_0 (l_conj) documented_17\VBN\1000214|spasm_105|was_99|by_87|,_44|and_42 (l_nsubjpass) stenosis_15\NN\14204950|was_9|on_24|._53
D004280_D003329 CID dobutamine_8\NN\0|NONE_0 (r_compound) stress_9\NN\7083732|NONE_0 (r_compound) echocardiography_10\RB\177127|NONE_0 (r_pobj) during_7\IN\0|coronary_22|artery_13 (r_prep) spasm_6\NN\14299637|to_19
D004280_D003329 CID dobutamine_19\NN\0|NONE_0 (r_pobj) by_18\IN\0|whether_61|ischemia_42|is_11 (r_agent) induced_17\VBN\1627355|to_64 (l_nsubjpass) ischemia_11\NN\14195315|whether_19|is_31|by_42 (l_amod) due_12\IN\5174653|myocardial_20 (l_pcomp) to_13\IN\0|NONE_0 (l_pobj) spasm_15\NN\14299637|NONE_0
D004280_D003329 CID dobutamine_4\NN\0|can_11|spasm_32|in_38 (r_nsubj) provoke_6\VB\1617192|findings_38|._68 (l_dobj) spasm_8\NN\14299637|dobutamine_32|can_21|in_6
D004280_D000788 CID dobutamine_4\NN\0|can_11|spasm_32|in_38 (r_nsubj) provoke_6\VB\1617192|findings_38|._68 (l_prep) in_9\IN\13603305|dobutamine_38|can_27|spasm_6 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|some_14 (l_pobj) angina_15\NN\14171682|NONE_0
D004280_D017202 NONE dobutamine_8\NN\0|NONE_0 (r_compound) stress_9\NN\7083732|NONE_0 (r_compound) echocardiography_10\RB\177127|NONE_0 (r_pobj) during_7\IN\0|coronary_22|artery_13 (r_prep) spasm_6\NN\14299637|to_19 (r_pobj) due_2\IN\5174653|myocardial_20|._70 (r_amod) ischemia_1\NN\14195315|NONE_0
D004280_D017202 NONE dobutamine_0\NNP\0|echocardiography_18 (r_nsubj) stress_1\NN\7083732|test_63|._91 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) test_12\NN\5798043|stress_63|._28 (l_prep) for_13\IN\0|a_35|useful_33|provocation_17 (l_pobj) ischemia_15\NN\14195315|NONE_0
D004280_D017202 NONE dobutamine_19\NN\0|NONE_0 (r_pobj) by_18\IN\0|whether_61|ischemia_42|is_11 (r_agent) induced_17\VBN\1627355|to_64 (l_nsubjpass) ischemia_11\NN\14195315|whether_19|is_31|by_42
9630698
D006220_D009127 CID haloperidol_5\NN\3713736|NONE_0 (r_pobj) by_4\IN\0|rigidity_21|was_12|)_30|._31 (r_agent) induced_3\VBN\1627355|NONE_0 (l_nsubjpass) rigidity_1\NN\5023233|was_9|by_21|)_51|._52
D006220_D009127 CID haloperidol_34\NN\3713736|-_11 (r_advmod) induced_36\VBN\1627355|both_21|the_16|muscle_8|(_24|mmg_25|)_28|and_30|activity_65 (r_amod) rigidity_38\NN\5023233|NONE_0
C066192_D009127 NONE acid_1\NN\14818238|in_63|,_116|into_118|,_157|decreased_159|._269 (r_nsubj) injected_12\VBN\81072|NONE_0 (l_conj) decreased_31\VBD\169651|acid_159|in_96|,_43|into_41|,_2|._110 (l_dobj) rigidity_38\NN\5023233|NONE_0
C066192_D009127 NONE 5,7-dcka_3\CD\0|5,7-dichlorokynurenic_28|)_8|,_9|antagonist_36|,_46 (r_appos) acid_1\NN\14818238|in_63|,_116|into_118|,_157|decreased_159|._269 (r_nsubj) injected_12\VBN\81072|NONE_0 (l_conj) decreased_31\VBD\169651|acid_159|in_96|,_43|into_41|,_2|._110 (l_dobj) rigidity_38\NN\5023233|NONE_0
D005998_D009127 NONE glycine_8\NN\14601829|NONE_0 (r_compound) site_9\NN\8673395|a_20|selective_18 (r_compound) antagonist_10\NN\7846|5,7-dichlorokynurenic_64|5,7-dcka_36|)_28|,_27|,_10 (r_appos) acid_1\NN\14818238|in_63|,_116|into_118|,_157|decreased_159|._269 (r_nsubj) injected_12\VBN\81072|NONE_0 (l_conj) decreased_31\VBD\169651|acid_159|in_96|,_43|into_41|,_2|._110 (l_dobj) rigidity_38\NN\5023233|NONE_0
12139551
D008787_D006323 CID metoclopramide_4\NN\0|intravenous_12|a_17|of_24|causing_70 (r_compound) case_7\NN\7283608|NONE_0 (r_pobj) after_2\IN\0|cardiac_15|._127 (r_prep) arrest_1\NN\88481|NONE_0
D008787_D006323 CID metoclopramide_4\NN\0|intravenous_12|a_17|of_24|causing_70 (r_compound) case_7\NN\7283608|NONE_0 (l_acl) causing_14\VBG\30358|intravenous_82|metoclopramide_70|a_53|of_46 (l_dobj) episodes_16\NNS\7283608|NONE_0 (l_prep) of_17\IN\0|five_14 (l_pobj) arrest_19\NN\88481|NONE_0
D008787_D006323 CID metoclopramide_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|five_25|repeated_20 (r_prep) injections_11\NNS\320852|NONE_0 (r_pobj) of_8\IN\0|intravenous_36|metoclopramide_24|a_7|causing_46 (r_prep) case_7\NN\7283608|NONE_0 (r_pobj) after_2\IN\0|cardiac_15|._127 (r_prep) arrest_1\NN\88481|NONE_0
D008787_D006323 CID metoclopramide_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|five_25|repeated_20 (r_prep) injections_11\NNS\320852|NONE_0 (r_pobj) of_8\IN\0|intravenous_36|metoclopramide_24|a_7|causing_46 (r_prep) case_7\NN\7283608|NONE_0 (l_acl) causing_14\VBG\30358|intravenous_82|metoclopramide_70|a_53|of_46 (l_dobj) episodes_16\NNS\7283608|NONE_0 (l_prep) of_17\IN\0|five_14 (l_pobj) arrest_19\NN\88481|NONE_0
D008787_D006323 CID metoclopramide_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|intravenous_22 (r_prep) injection_6\NN\320852|where_18|was_28|immediately_32|by_53|repeatedly_65 (r_nsubjpass) followed_11\VBN\1835496|a_72 (l_agent) by_12\IN\0|where_71|injection_53|was_25|immediately_21|repeatedly_12 (l_pobj) asystole_13\NN\14204950|NONE_0
D008787_D006323 CID metoclopramide_3\JJ\0|patient_17|mg_18|during_37|after_50 (r_dobj) received_2\VBD\2210855|,_138|it_140|clear_146|was_196|followed_223|._243 (r_ccomp) is_24\VBZ\0|NONE_0 (l_advcl) followed_37\VBN\1835496|received_223|,_85|it_83|clear_77|was_27|._20 (l_agent) by_38\IN\0|NONE_0 (l_pobj) asystole_39\NN\14204950|NONE_0
D008787_D006323 CID metoclopramide_30\NN\0|NONE_0 (r_pobj) of_29\IN\0|every_21 (r_prep) administration_28\NN\1133281|that_11|immediately_37|(_49|within_50|)_58 (r_nsubj) was_31\VBD\0|received_196|,_58|it_56|clear_50|followed_27|._47 (r_ccomp) is_24\VBZ\0|NONE_0 (l_advcl) followed_37\VBN\1835496|received_223|,_85|it_83|clear_77|was_27|._20 (l_agent) by_38\IN\0|NONE_0 (l_pobj) asystole_39\NN\14204950|NONE_0
D008787_D006323 CID metoclopramide_10\NN\0|NONE_0 (r_pobj) by_9\IN\0|NONE_0 (r_agent) caused_8\VBN\1617192|of_18 (r_acl) episodes_4\NNS\7283608|NONE_0 (l_prep) of_5\IN\0|caused_18 (l_pobj) arrest_7\NN\88481|NONE_0
11022397
D010862_D008569 NONE pilocarpine_10\NN\14712692|and_4 (r_conj) tropicamide_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) administration_6\NN\1133281|NONE_0 (r_pobj) after_5\IN\0|pupil_26|at_15 (r_prep) size_1\NN\5090441|;_71|induced_85|in_104|._118 (r_ccomp) impairment_15\NN\7296428|NONE_0 (l_prep) in_16\IN\13603305|size_104|;_33|induced_19|._14 (l_pobj) recall_18\NN\7185325|NONE_0
D014331_D008569 NONE tropicamide_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) administration_6\NN\1133281|NONE_0 (r_pobj) after_5\IN\0|pupil_26|at_15 (r_prep) size_1\NN\5090441|;_71|induced_85|in_104|._118 (r_ccomp) impairment_15\NN\7296428|NONE_0 (l_prep) in_16\IN\13603305|size_104|;_33|induced_19|._14 (l_pobj) recall_18\NN\7185325|NONE_0
D012601_D008569 CID scopolamine_12\NN\14712692|-_11 (r_npadvmod) induced_14\VBN\1627355|size_85|;_14|in_19|._33 (r_amod) impairment_15\NN\7296428|NONE_0 (l_prep) in_16\IN\13603305|size_104|;_33|induced_19|._14 (l_pobj) recall_18\NN\7185325|NONE_0
D012601_D008569 CID scopolamine_11\NN\14712692|-_11 (r_npadvmod) induced_13\VBN\1627355|greater_20|in_19 (r_amod) impairment_14\NN\7296428|compared_81|,_52|group_38|recall_19|after_49|)_79|._80 (r_dobj) had_9\VBD\0|NONE_0 (l_dobj) recall_17\NN\7185325|compared_100|,_71|group_57|impairment_19|after_30|)_60|._61
16047871
D014859_D012871 NONE warfarin_11\NN\2718259|for_9 (r_dobj) receiving_10\VBG\2210855|NONE_0 (r_pcomp) after_9\IN\0|that_15 (r_prep) developed_8\VBD\1753788|skin_20 (r_relcl) eruptions_6\NNS\7307754|NONE_0
D014859_D012871 NONE warfarin_21\NN\2718259|after_6|was_9 (r_nsubjpass) discontinued_23\VBN\0|in_35 (r_advcl) resolved_16\VBD\352826|lv_21|cutaneous_18 (r_acl) lesions_15\NNS\14204950|NONE_0 (r_dobj) confirming_12\VBG\0|results_62|available_25|,_2|._88 (r_advcl) were_6\VBD\0|NONE_0 (l_nsubj) results_1\NNS\34213|available_37|,_60|confirming_62|._150 (l_prep) of_2\IN\0|the_12 (l_pobj) biopsies_5\NNS\5739043|NONE_0 (l_compound) lesion_4\NN\14204950|NONE_0
D014859_D018366 CID warfarin_21\NN\2718259|after_6|was_9 (r_nsubjpass) discontinued_23\VBN\0|in_35 (r_advcl) resolved_16\VBD\352826|lv_21|cutaneous_18 (r_acl) lesions_15\NNS\14204950|NONE_0
D014859_C535509 NONE warfarin_0\NNP\2718259|-_8 (r_npadvmod) induced_2\VBN\1627355|leukocytoclastic_8|._35 (r_amod) vasculitis_4\NN\14336539|NONE_0
D014859_C535509 NONE warfarin_12\NN\2718259|probably_16|to_3 (r_pobj) due_10\JJ\5174653|4_39|with_28 (r_amod) patients_3\NNS\9898892|we_12|._52 (l_prep) with_4\IN\0|4_11|due_28 (l_pobj) lv_8\NNP\0|NONE_0
D014859_C535509 NONE warfarin_11\JJ\2718259|NONE_0 (r_compound) therapy_12\NN\657604|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) associated_9\VBN\628491|a_30|onset_23|adverse_17 (r_acl) reaction_8\NN\13446390|lv_31|may_28|._41 (r_attr) be_2\VB\14625458|NONE_0 (l_nsubj) lv_0\NNP\0|may_3|reaction_31|._72
16364460
D012601_D000647 CID scopolamine_10\NN\14712692|-_11 (r_npadvmod) induced_12\VBN\1627355|in_16 (r_amod) amnesia_13\NN\5669934|microinjection_93|._26
D012601_D000647 CID scopolamine_9\NN\14712692|(_12|muscarinic_13|cholinergic_24|antagonist)-induced_36|in_64 (r_nmod) amnesia_14\NN\5669934|NONE_0
D012601_D000647 CID scopolamine_16\NN\14712692|-_11 (r_npadvmod) induced_18\VBN\1627355|the_16 (r_amod) amnesia_19\NN\5669934|that_106|microinjection_101
D016713_D000647 NONE ritanserin_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|into_14 (r_prep) microinjection_0\NN\0|amnesia_93|._119 (r_nsubj) improves_9\VBZ\126264|NONE_0 (l_dobj) amnesia_13\NN\5669934|microinjection_93|._26
D016713_D000647 NONE ritanserin_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11|antagonist_21|on_33 (r_prep) effect_1\NN\34213|mwm_129|was_134|._150 (l_prep) on_8\IN\0|the_44|of_33|antagonist_12 (l_pobj) amnesia_14\NN\5669934|NONE_0
D016713_D000647 NONE ritanserin_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|into_14 (r_prep) microinjection_4\NN\0|that_5|amnesia_101 (r_nsubj) improves_14\VBZ\126264|findings_87|._40 (l_dobj) amnesia_19\NN\5669934|that_106|microinjection_101
16418614
D011441_D014424 NONE ptu_0\NNP\0|-_3 (r_npadvmod) associated_2\VBN\628491|in_22|._72 (r_amod) vasculitis_3\NN\14336539|NONE_0 (l_prep) in_4\IN\13603305|associated_22|._50 (l_pobj) girl_6\NN\10787470|NONE_0 (l_prep) with_7\IN\0|a_7 (l_pobj) syndrome_9\NNP\5870365|NONE_0
D011441_D006111 NONE ptu_0\NNP\0|-_3 (r_npadvmod) associated_2\VBN\628491|in_22|._72 (r_amod) vasculitis_3\NN\14336539|NONE_0 (l_prep) in_4\IN\13603305|associated_22|._50 (l_pobj) girl_6\NN\10787470|NONE_0 (l_prep) with_7\IN\0|a_7 (l_pobj) syndrome_9\NNP\5870365|NONE_0 (l_conj) disease_13\NN\14061805|turner_28|and_12
D011441_D014657 CID ptu_0\NNP\0|-_3 (r_npadvmod) associated_2\VBN\628491|in_22|._72 (r_amod) vasculitis_3\NN\14336539|NONE_0
D011441_D014657 CID propylthiouracil_3\NN\14727670|NONE_0 (r_pobj) of_2\IN\0|the_14 (r_prep) diagnosis_1\NN\152018|(_30|vasculitis_47|was_58|by_67|,_113|detection_119|._244 (r_nsubjpass) made_8\VBN\0|NONE_0 (l_nsubjpass) vasculitis_6\NN\14336539|diagnosis_47|(_17|was_11|by_20|,_66|detection_72|._197
D011441_D014657 CID ptu)-associated_5\VBN\0|NONE_0 (r_amod) vasculitis_6\NN\14336539|diagnosis_47|(_17|was_11|by_20|,_66|detection_72|._197
D011441_D014657 CID ptu_37\NNP\0|NONE_0 (r_pobj) of_36\IN\0|NONE_0 (r_prep) withdrawal_35\NN\7206096|NONE_0 (r_dobj) following_34\VBG\8180190|the_45|observed_41|clinical_32|of_12 (r_acl) resolution_31\NN\6470073|the_79|of_65|,_28|and_26 (r_conj) detection_17\NN\5708432|diagnosis_119|(_89|vasculitis_72|was_61|by_52|,_6|._125 (r_appos) made_8\VBN\0|NONE_0 (l_nsubjpass) vasculitis_6\NN\14336539|diagnosis_47|(_17|was_11|by_20|,_66|detection_72|._197
7263204
D000493_D000741 NONE allopurinol_14\NN\3740161|NONE_0 (r_pobj) than_13\IN\0|NONE_0 (r_prep) other_12\JJ\0|no_9 (r_amod) drugs_11\NNS\14778436|in_12|were_46 (r_nsubjpass) given_18\VBN\5892096|case_106|is_76|._5 (r_relcl) described_7\VBN\1001294|NONE_0 (l_nsubjpass) case_1\NN\7283608|is_30|given_106|._111 (l_prep) of_2\IN\0|a_7 (l_pobj) anemia_5\NN\14189204|NONE_0
D007213_D000741 CID indomethacin_5\NN\3828465|to_3 (r_pobj) due_3\IN\5174653|fatal_22|aplastic_16|--_19|lymphocyte_21|._61 (r_amod) anemia_2\NN\14189204|NONE_0
D007213_D000741 CID indomethacin_1\NN\3828465|although_9|has_13|been_17|as_33 (r_nsubjpass) implicated_4\VBN\2677097|,_93|role_99|has_104|not_108|been_112|definitely_117|._139 (l_prep) as_5\IN\14622893|although_42|indomethacin_33|has_20|been_16 (l_pobj) cause_8\NN\7323922|NONE_0 (l_prep) of_9\IN\0|a_17|possible_15 (l_pobj) anemia_11\NN\14189204|NONE_0
D007213_D000741 CID indomethacin_16\NN\3828465|and_4 (r_conj) allopurinol_14\NN\3740161|NONE_0 (r_pobj) than_13\IN\0|NONE_0 (r_prep) other_12\JJ\0|no_9 (r_amod) drugs_11\NNS\14778436|in_12|were_46 (r_nsubjpass) given_18\VBN\5892096|case_106|is_76|._5 (r_relcl) described_7\VBN\1001294|NONE_0 (l_nsubjpass) case_1\NN\7283608|is_30|given_106|._111 (l_prep) of_2\IN\0|a_7 (l_pobj) anemia_5\NN\14189204|NONE_0
D007213_D000741 CID indomethacin_6\NN\3828465|NONE_0 (r_pobj) with_5\IN\0|a_42|positive_40|transformation_20 (r_prep) test_4\NN\5798043|further_32|role_68|._137 (r_nsubj) substantiates_10\VBZ\0|NONE_0 (l_dobj) role_13\NN\719494|test_68|further_36|._69 (l_prep) in_17\IN\13603305|the_32|potential_28|of_13 (l_pcomp) causing_18\VBG\30358|NONE_0 (l_dobj) anemia_20\NN\14189204|in_7
9545159
D001393_D016171 CID azole_22\JJ\0|antifungal_6 (r_amod) agents_24\NNS\7347|or_20 (r_conj) erythromycin_20\NNP\2716866|NONE_0 (r_pobj) with_19\IN\0|concomitant_27 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|torsades_65|have_19|been_14|,_77|but_79|with_87|._115 (r_prep) reported_15\VBN\831651|NONE_0 (l_nsubjpass) torsades_5\NNS\0|have_46|been_51|after_65|,_142|but_144|with_152|._180 (l_dobj) pointes_7\FW\831651|prolongation_41
D001393_D008133 CID azole_22\JJ\0|antifungal_6 (r_amod) agents_24\NNS\7347|or_20 (r_conj) erythromycin_20\NNP\2716866|NONE_0 (r_pobj) with_19\IN\0|concomitant_27 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|torsades_65|have_19|been_14|,_77|but_79|with_87|._115 (r_prep) reported_15\VBN\831651|NONE_0 (l_nsubjpass) torsades_5\NNS\0|have_46|been_51|after_65|,_142|but_144|with_152|._180 (l_nsubj) prolongation_0\NN\1017987|pointes_41 (l_prep) of_1\IN\0|,_14 (l_pobj) interval_3\NN\33615|NONE_0
D004110_D008133 CID diltiazem_9\NN\2938514|NONE_0 (r_compound) interaction_10\NN\37396|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) related_5\VBN\628491|the_16|qt_12 (r_acl) interval_4\NN\33615|NONE_0
D004110_D005764 NONE diltiazem_20\NN\2938514|gastroesophageal_37|reflux_20|and_4|,_9|agent_14 (r_conj) disorder_18\NN\14034177|NONE_0
D004917_D008133 CID erythromycin_20\NNP\2716866|NONE_0 (r_pobj) with_19\IN\0|concomitant_27 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|torsades_65|have_19|been_14|,_77|but_79|with_87|._115 (r_prep) reported_15\VBN\831651|NONE_0 (l_nsubjpass) torsades_5\NNS\0|have_46|been_51|after_65|,_142|but_144|with_152|._180 (l_nsubj) prolongation_0\NN\1017987|pointes_41 (l_prep) of_1\IN\0|,_14 (l_pobj) interval_3\NN\33615|NONE_0
D020117_D006973 NONE cisapride_14\NN\0|who_15|was_11|for_10|,_107|for_109 (r_dobj) taking_13\VBG\37396|a_28|old_18 (l_prep) for_31\IN\0|who_124|was_120|cisapride_109|for_99|,_2 (l_pobj) hypertension_32\NN\14057371|NONE_0
D020117_D008133 CID cisapride_7\NN\0|-_9 (r_compound) diltiazem_9\NN\2938514|NONE_0 (r_compound) interaction_10\NN\37396|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) related_5\VBN\628491|the_16|qt_12 (r_acl) interval_4\NN\33615|NONE_0
D020117_D005764 NONE cisapride_14\NN\0|who_15|was_11|for_10|,_107|for_109 (r_dobj) taking_13\VBG\37396|a_28|old_18 (l_prep) for_15\IN\0|who_25|was_21|cisapride_10|,_97|for_99 (l_pobj) disorder_18\NN\14034177|NONE_0
D004110_D006973 NONE diltiazem_20\NN\2938514|gastroesophageal_37|reflux_20|and_4|,_9|agent_14 (r_conj) disorder_18\NN\14034177|NONE_0 (r_pobj) for_15\IN\0|who_25|was_21|cisapride_10|,_97|for_99 (r_prep) taking_13\VBG\37396|a_28|old_18 (l_prep) for_31\IN\0|who_124|was_120|cisapride_109|for_99|,_2 (l_pobj) hypertension_32\NN\14057371|NONE_0
D004917_D016171 CID erythromycin_20\NNP\2716866|NONE_0 (r_pobj) with_19\IN\0|concomitant_27 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|torsades_65|have_19|been_14|,_77|but_79|with_87|._115 (r_prep) reported_15\VBN\831651|NONE_0 (l_nsubjpass) torsades_5\NNS\0|have_46|been_51|after_65|,_142|but_144|with_152|._180 (l_dobj) pointes_7\FW\831651|prolongation_41
D001393_D016757 CID azole_22\JJ\0|antifungal_6 (r_amod) agents_24\NNS\7347|or_20 (r_conj) erythromycin_20\NNP\2716866|NONE_0 (r_pobj) with_19\IN\0|concomitant_27 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|torsades_65|have_19|been_14|,_77|but_79|with_87|._115 (r_prep) reported_15\VBN\831651|NONE_0 (l_nsubjpass) torsades_5\NNS\0|have_46|been_51|after_65|,_142|but_144|with_152|._180 (l_dobj) pointes_7\FW\831651|prolongation_41 (l_conj) death_12\NN\7296428|de_31|,_21|and_19
D020117_D015835 NONE cisapride_0\NNP\0|is_53|widely_56|for_74|._130 (r_nsubjpass) prescribed_13\VBN\748282|NONE_0 (l_prep) for_14\IN\0|cisapride_74|is_21|widely_18|._56 (l_pobj) treatment_16\NN\654885|NONE_0 (l_prep) of_17\IN\0|the_14 (l_pobj) disorders_20\NNS\14034177|NONE_0
D004917_D016757 CID erythromycin_20\NNP\2716866|NONE_0 (r_pobj) with_19\IN\0|concomitant_27 (r_prep) administration_18\NN\1133281|NONE_0 (r_pobj) after_16\IN\0|torsades_65|have_19|been_14|,_77|but_79|with_87|._115 (r_prep) reported_15\VBN\831651|NONE_0 (l_nsubjpass) torsades_5\NNS\0|have_46|been_51|after_65|,_142|but_144|with_152|._180 (l_dobj) pointes_7\FW\831651|prolongation_41 (l_conj) death_12\NN\7296428|de_31|,_21|and_19
2320800
D007069_D051437 NONE ifosfamide_34\NN\0|5_13 (r_pobj) after_28\IN\0|the_8 (r_prep) day_27\NN\15154774|woman_134|failure_25|,_6|._33 (r_npadvmod) developed_17\VBD\1753788|NONE_0 (l_dobj) failure_22\NN\66216|woman_109|,_19|day_25|._58
D007069_D001943 NONE ifosfamide_5\JJ\0|dose_5 (r_compound) chemotherapy_6\NN\661091|anuria_41|in_13|._71 (r_dobj) complicating_2\VBG\126264|NONE_0 (l_prep) in_7\IN\13603305|anuria_54|chemotherapy_13|._58 (l_pobj) patient_11\NN\9898892|NONE_0 (l_compound) cancer_10\NN\14239425|a_9|with_15
D007069_D001943 NONE ifosfamide_34\NN\0|5_13 (r_pobj) after_28\IN\0|the_8 (r_prep) day_27\NN\15154774|woman_134|failure_25|,_6|._33 (r_npadvmod) developed_17\VBD\1753788|NONE_0 (l_nsubj) woman_6\NN\9605289|failure_109|,_128|day_134|._167 (l_prep) with_7\IN\0|a_23|old_10|,_27|treated_40|,_62 (l_pobj) cancer_10\NN\14239425|NONE_0
D002945_D001002 NONE cisplatin_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|previously_19 (r_prep) treated_13\VBN\2376958|a_63|old_50|with_40|,_13|,_22 (r_acl) woman_6\NN\9605289|failure_109|,_128|day_134|._167 (r_nsubj) developed_17\VBD\1753788|NONE_0 (l_dobj) failure_22\NN\66216|woman_109|,_19|day_25|._58 (l_prep) with_23\IN\0|an_37|irreversible_34|lethal_21|renal_14 (l_pobj) anuria_24\NN\14061805|NONE_0
D002945_D001002 NONE cisplatin_20\NN\0|previous_9 (r_amod) chemotherapy_21\NN\661091|having_35|and_13|with_17 (r_dobj) received_18\VBN\2210855|in_20 (r_advcl) occurring_13\VBG\0|that_54|anuria_37|mainly_26|due_19|,_2 (r_advcl) was_7\VBD\0|we_44|strongly_41|._160 (l_nsubj) anuria_6\NN\14061805|that_17|mainly_11|due_18|,_35|occurring_37
D007069_D007022 NONE ifosfamide_11\NN\0|NONE_0 (r_xcomp) due_9\JJ\5174653|that_35|anuria_18|mainly_7|,_17|occurring_19 (r_acomp) was_7\VBD\0|we_44|strongly_41|._160 (l_advcl) occurring_13\VBG\0|that_54|anuria_37|mainly_26|due_19|,_2 (l_advcl) received_18\VBN\2210855|in_20 (l_prep) with_23\IN\0|having_52|chemotherapy_17|and_4 (l_pobj) perfusion_26\NN\320852|NONE_0 (l_prep) due_27\IN\5174653|poor_22|kidney_17 (l_pcomp) to_28\IN\0|NONE_0 (l_pobj) hypotension_30\NN\14057371|NONE_0
D002945_D007022 NONE cisplatin_20\NN\0|previous_9 (r_amod) chemotherapy_21\NN\661091|having_35|and_13|with_17 (r_dobj) received_18\VBN\2210855|in_20 (l_prep) with_23\IN\0|having_52|chemotherapy_17|and_4 (l_pobj) perfusion_26\NN\320852|NONE_0 (l_prep) due_27\IN\5174653|poor_22|kidney_17 (l_pcomp) to_28\IN\0|NONE_0 (l_pobj) hypotension_30\NN\14057371|NONE_0
D002945_D001943 NONE cisplatin_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|previously_19 (r_prep) treated_13\VBN\2376958|a_63|old_50|with_40|,_13|,_22 (r_acl) woman_6\NN\9605289|failure_109|,_128|day_134|._167 (l_prep) with_7\IN\0|a_23|old_10|,_27|treated_40|,_62 (l_pobj) cancer_10\NN\14239425|NONE_0
D002945_D051437 NONE cisplatin_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|previously_19 (r_prep) treated_13\VBN\2376958|a_63|old_50|with_40|,_13|,_22 (r_acl) woman_6\NN\9605289|failure_109|,_128|day_134|._167 (r_nsubj) developed_17\VBD\1753788|NONE_0 (l_dobj) failure_22\NN\66216|woman_109|,_19|day_25|._58
D007069_D001002 CID ifosfamide_5\JJ\0|dose_5 (r_compound) chemotherapy_6\NN\661091|anuria_41|in_13|._71 (r_dobj) complicating_2\VBG\126264|NONE_0 (l_nsubj) anuria_1\NN\14061805|chemotherapy_41|in_54|._112
D007069_D001002 CID ifosfamide_34\NN\0|5_13 (r_pobj) after_28\IN\0|the_8 (r_prep) day_27\NN\15154774|woman_134|failure_25|,_6|._33 (r_npadvmod) developed_17\VBD\1753788|NONE_0 (l_dobj) failure_22\NN\66216|woman_109|,_19|day_25|._58 (l_prep) with_23\IN\0|an_37|irreversible_34|lethal_21|renal_14 (l_pobj) anuria_24\NN\14061805|NONE_0
D007069_D001002 CID ifosfamide_11\NN\0|NONE_0 (r_xcomp) due_9\JJ\5174653|that_35|anuria_18|mainly_7|,_17|occurring_19 (r_acomp) was_7\VBD\0|we_44|strongly_41|._160 (l_nsubj) anuria_6\NN\14061805|that_17|mainly_11|due_18|,_35|occurring_37
D007069_D007674 CID ifosfamide_5\JJ\0|dose_5 (r_compound) chemotherapy_6\NN\661091|anuria_41|in_13|._71 (r_dobj) complicating_2\VBG\126264|NONE_0 (l_prep) in_7\IN\13603305|anuria_54|chemotherapy_13|._58 (l_pobj) patient_11\NN\9898892|NONE_0 (l_prep) with_12\IN\0|a_24|cancer_15 (l_pobj) function_16\NN\13783581|NONE_0
D007069_D007674 CID ifosfamide_0\NNP\0|drug_34|._70 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) drug_5\NN\14778436|ifosfamide_34|._36 (l_amod) nephrotoxic_4\JJ\0|a_8|known_6|with_17
D007069_D007674 CID ifosfamide_0\NNP\0|drug_34|._70 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) drug_5\NN\14778436|ifosfamide_34|._36 (l_prep) with_6\IN\0|a_25|known_23|nephrotoxic_17 (l_pobj) tubulopathies_8\NNS\0|NONE_0
D007069_D007674 CID ifosfamide_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|careful_12|in_14 (r_prep) use_3\NN\407535|we_21|._101 (l_prep) in_6\IN\13603305|careful_26|of_14 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_acl) pretreated_8\VBN\0|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) chemotherapy_11\NN\661091|NONE_0 (l_amod) nephrotoxic_10\JJ\0|and_25|perfusion_46
16586083
C109794_D002318 NONE peptide_10\NN\14724264|such_41 (r_pobj) as_3\IN\14622893|diagnostic_24 (r_prep) markers_1\NNS\21939|might_106|in_117|,_164|avoiding_171|._229 (r_nsubj) help_25\VB\407535|NONE_0 (l_advcl) avoiding_36\VBG\0|markers_171|might_65|in_54|,_7|._58 (l_dobj) occurrence_38\NN\29378|thus_18 (l_prep) of_39\IN\0|the_15 (l_pobj) toxicity_42\NN\13576101|NONE_0
C109794_D002318 NONE probnp_14\NNP\0|terminal_43|brain_30|natriuretic_24|(_4|)_6|or_8|protein_37 (r_appos) peptide_10\NN\14724264|such_41 (r_pobj) as_3\IN\14622893|diagnostic_24 (r_prep) markers_1\NNS\21939|might_106|in_117|,_164|avoiding_171|._229 (r_nsubj) help_25\VB\407535|NONE_0 (l_advcl) avoiding_36\VBG\0|markers_171|might_65|in_54|,_7|._58 (l_dobj) occurrence_38\NN\29378|thus_18 (l_prep) of_39\IN\0|the_15 (l_pobj) toxicity_42\NN\13576101|NONE_0
D016861_D006973 CID inhibitors_25\NNS\20090|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) during_21\IN\0|,_33|hypertension_31 (r_prep) stroke_15\NN\556313|myocardial_23|,_2 (l_conj) hypertension_17\NN\14057371|,_2|during_31
D016861_D006333 CID inhibitors_25\NNS\20090|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) during_21\IN\0|,_33|hypertension_31 (r_prep) stroke_15\NN\556313|myocardial_23|,_2 (l_conj) hypertension_17\NN\14057371|,_2|during_31 (l_conj) failure_20\NN\66216|and_10
D016861_D020521 CID inhibitors_25\NNS\20090|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) during_21\IN\0|,_33|hypertension_31 (r_prep) stroke_15\NN\556313|myocardial_23|,_2
D016861_D009203 CID inhibitors_25\NNS\20090|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) during_21\IN\0|,_33|hypertension_31 (r_prep) stroke_15\NN\556313|myocardial_23|,_2 (r_conj) infarction_13\NN\14204950|NONE_0
6615052
D006493_D013927 NONE heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|,_24|thrombosis_26|._52 (r_amod) thrombocytopenia_3\NN\14189204|NONE_0 (l_conj) thrombosis_5\NN\14100769|induced_26|,_2|._26
D006493_D013921 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|,_24|thrombosis_26|._52 (r_amod) thrombocytopenia_3\NN\14189204|NONE_0
D006493_D013921 CID heparin_6\NN\2718259|-_7 (r_npadvmod) induced_8\VBN\1627355|a_10 (r_amod) thrombocytopenia_9\NN\14189204|NONE_0
D006493_D013923 CID heparin_17\VBN\2718259|NONE_0 (r_dobj) receiving_16\VBG\2210855|NONE_0 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) in_14\IN\13603305|thromboembolic_22 (r_prep) events_13\NNS\23100|or_36|,_34|frequently_27|,_17 (l_compound) thromboembolic_12\JJ\0|in_22
D006493_D001791 NONE heparin_12\NN\2718259|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) resistance_10\NN\37396|,_21|and_23|added_92 (r_dobj) increased_9\VBN\169651|testing_47|has_39|count_7|,_2|._107 (r_conj) revealed_3\VBN\2137132|NONE_0 (l_dobj) count_7\NN\13582013|testing_40|has_32|,_5|increased_7|._114
D006493_D001791 NONE heparin_24\NN\2718259|aggregation_54|when_5|is_8 (r_nsubjpass) added_26\VBN\156601|resistance_92|,_71|and_69 (r_conj) increased_9\VBN\169651|testing_47|has_39|count_7|,_2|._107 (r_conj) revealed_3\VBN\2137132|NONE_0 (l_dobj) count_7\NN\13582013|testing_40|has_32|,_5|increased_7|._114
D006493_D001791 NONE heparin_15\JJ\2718259|while_31|patient_21|is_13|,_37|using_39 (l_appos) testing_19\NN\639556|,_23 (l_compound) aggregation_18\NN\31264|NONE_0
D006493_D006470 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|,_24|thrombosis_26|._52 (r_amod) thrombocytopenia_3\NN\14189204|NONE_0 (l_conj) thrombosis_5\NN\14100769|induced_26|,_2|._26 (l_conj) hemorrhage_8\NN\14285662|,_6|and_4
D006493_D006470 CID heparin_17\VBN\2718259|NONE_0 (r_dobj) receiving_16\VBG\2210855|NONE_0 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) in_14\IN\13603305|thromboembolic_22 (r_prep) events_13\NNS\23100|or_36|,_34|frequently_27|,_17 (r_appos) hemorrhage_6\NN\14285662|manifestations_40|._83
14648024
D014212_D015473 NONE acid_4\NN\14818238|-_4 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) erythema_7\NN\14227218|retinoic_22|in_17 (r_compound) nodosum_8\NN\0|._53 (l_prep) in_9\IN\13603305|retinoic_39|erythema_17 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) leukemia_14\NN\14239918|NONE_0
D014212_D015473 NONE acid_8\NN\14818238|NONE_0 (r_pobj) with_3\IN\0|for_37 (r_prep) associated_2\VBD\628491|erythema_17 (l_prep) for_12\IN\0|with_37 (l_pobj) leukemia_15\NN\14239918|NONE_0
D014212_D015473 NONE acid_8\NN\14818238|NONE_0 (r_pobj) with_3\IN\0|for_37 (r_prep) associated_2\VBD\628491|erythema_17 (l_prep) for_12\IN\0|with_37 (l_pobj) leukemia_15\NN\14239918|NONE_0 (l_appos) apl_17\NNP\0|acute_30|promyelocytic_24|(_1|)_3
D014212_D015473 NONE atra_10\NNP\0|all-_26|retinoic_15|(_1|)_4 (r_appos) acid_8\NN\14818238|NONE_0 (r_pobj) with_3\IN\0|for_37 (r_prep) associated_2\VBD\628491|erythema_17 (l_prep) for_12\IN\0|with_37 (l_pobj) leukemia_15\NN\14239918|NONE_0
D014212_D015473 NONE atra_10\NNP\0|all-_26|retinoic_15|(_1|)_4 (r_appos) acid_8\NN\14818238|NONE_0 (r_pobj) with_3\IN\0|for_37 (r_prep) associated_2\VBD\628491|erythema_17 (l_prep) for_12\IN\0|with_37 (l_pobj) leukemia_15\NN\14239918|NONE_0 (l_appos) apl_17\NNP\0|acute_30|promyelocytic_24|(_1|)_3
D014212_D015473 NONE atra_12\NNP\0|NONE_0 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) during_11\IN\0|who_31|nodosum_8 (r_prep) developed_8\VBD\1753788|classic_16 (r_relcl) apl_6\NNP\0|NONE_0
D014212_D010146 NONE atra_23\NNP\0|NONE_0 (r_compound) therapy_24\NN\657604|NONE_0 (r_pobj) after_22\IN\0|subsequent_117|multiple_106|painful_97|erythematous_89|over_68|,_2 (r_prep) nodules_6\NNS\5264913|and_45|._94 (l_amod) painful_4\JJ\0|subsequent_20|multiple_9|erythematous_8|over_29|,_95|after_97
D014212_D005334 CID atra_23\NNP\0|NONE_0 (r_compound) therapy_24\NN\657604|NONE_0 (r_pobj) after_22\IN\0|subsequent_117|multiple_106|painful_97|erythematous_89|over_68|,_2 (r_prep) nodules_6\NNS\5264913|and_45|._94 (r_conj) fever_0\NN\14299637|NONE_0
D013256_D004893 NONE steroid_5\NN\14727670|NONE_0 (r_pobj) of_4\IN\0|term_9 (r_prep) use_3\NN\407535|effective_23|in_33|._65 (r_nsubj) is_6\VBZ\0|NONE_0 (l_prep) in_9\IN\13603305|use_33|effective_10|._32 (l_pobj) nodosum_14\NN\0|NONE_0
D014212_D004893 CID acid_4\NN\14818238|-_4 (r_npadvmod) induced_6\VBN\1627355|NONE_0 (r_amod) erythema_7\NN\14227218|retinoic_22|in_17 (r_compound) nodosum_8\NN\0|._53
D014212_D004893 CID acid_8\NN\14818238|NONE_0 (r_pobj) with_3\IN\0|for_37 (r_prep) associated_2\VBD\628491|erythema_17 (r_acl) nodosum_1\NN\0|rare_103|._107
D014212_D004893 CID atra_10\NNP\0|all-_26|retinoic_15|(_1|)_4 (r_appos) acid_8\NN\14818238|NONE_0 (r_pobj) with_3\IN\0|for_37 (r_prep) associated_2\VBD\628491|erythema_17 (r_acl) nodosum_1\NN\0|rare_103|._107
D014212_D004893 CID atra_12\NNP\0|NONE_0 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) during_11\IN\0|who_31|nodosum_8 (r_prep) developed_8\VBD\1753788|classic_16 (l_dobj) nodosum_10\NN\0|who_23|during_8
D014212_D004893 CID atra_23\NNP\0|NONE_0 (r_compound) therapy_24\NN\657604|NONE_0 (r_pobj) after_22\IN\0|subsequent_117|multiple_106|painful_97|erythematous_89|over_68|,_2 (r_prep) nodules_6\NNS\5264913|and_45|._94
D014212_D004893 CID atra_0\NNP\0|be_15|._80 (r_nsubj) seemed_1\VBD\2604760|NONE_0 (l_xcomp) be_3\VB\14625458|atra_15|._65 (l_attr) etiology_7\NN\7326557|to_24 (l_prep) of_8\IN\0|the_27|possible_18 (l_pobj) nodosum_10\NN\0|NONE_0
D014212_D004893 CID atra_10\NNP\0|-_4 (r_npadvmod) induced_12\VBN\1627355|erythema_8 (r_amod) nodosum_14\NN\0|NONE_0
17490864
D000661_D006948 CID amphetamine_0\NN\3248958|-_11 (r_npadvmod) induced_2\VBN\1627355|locomotor_8 (r_amod) hyperactivity_4\NN\14052403|similar_18|._39
21418164
D008130_D015620 NONE ccnu_0\NNP\0|was_5|commonly_19|in_28|._138 (r_nsubjpass) used_2\VBN\0|NONE_0 (l_prep) in_5\IN\13603305|ccnu_28|was_23|commonly_9|._110 (l_pobj) treatment_7\NN\654885|NONE_0 (l_prep) of_8\IN\0|the_14 (l_pobj) lymphoma_9\NN\14239918|NONE_0 (l_conj) tumour_13\NN\14234074|,_12 (l_conj) tumour_16\NN\14234074|mast_24|cell_19|,_8 (l_conj) tumours_19\NNS\14234074|brain_26|,_14
D008130_D056486 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ\0|(_45 (r_nmod) ccnu_21\NNP\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|bearing_13 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) in_13\IN\13603305|haematological_63 (r_prep) toxicities_12\NNS\13576101|NONE_0
D008130_D056486 NONE ccnu_21\NNP\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|bearing_13 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) in_13\IN\13603305|haematological_63 (r_prep) toxicities_12\NNS\13576101|NONE_0
D008130_D064420 NONE ccnu_0\NNP\0|(_5|)_15|toxicity_17|._66 (r_npadvmod) lomustine_2\NN\2722458|NONE_0 (l_dobj) toxicity_4\NN\13576101|ccnu_17|(_12|)_2|._49
D008130_D064420 NONE lomustine_2\NN\2722458|NONE_0 (l_dobj) toxicity_4\NN\13576101|ccnu_17|(_12|)_2|._49
D008130_D064420 NONE ccnu_6\NNP\0|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) treated_4\VBN\2376958|the_13|206_9 (r_acl) dogs_3\NNS\2083346|NONE_0 (r_pobj) of_0\IN\0|,_33|185_35|criteria_57|._100 (r_prep) met_9\VBD\0|NONE_0 (l_dobj) criteria_12\NNS\13577171|of_57|,_24|185_22|._43 (l_prep) for_13\IN\0|the_23|inclusion_19 (l_pobj) class_17\NN\7951464|NONE_0 (l_prep) of_18\IN\0|one_10 (l_pobj) toxicity_19\NN\13576101|NONE_0
D008130_D064420 NONE ccnu_0\NN\0|-_4 (r_npadvmod) associated_2\VBN\628491|in_20 (r_amod) toxicity_3\NN\13576101|common_20|,_26|but_28|is_32|._63
D008130_D008223 NONE ccnu_0\NNP\0|was_5|commonly_19|in_28|._138 (r_nsubjpass) used_2\VBN\0|NONE_0 (l_prep) in_5\IN\13603305|ccnu_28|was_23|commonly_9|._110 (l_pobj) treatment_7\NN\654885|NONE_0 (l_prep) of_8\IN\0|the_14 (l_pobj) lymphoma_9\NN\14239918|NONE_0
D008130_D008223 NONE ccnu_0\NNP\0|was_5|commonly_19|in_28|._138 (r_nsubjpass) used_2\VBN\0|NONE_0 (l_prep) in_5\IN\13603305|ccnu_28|was_23|commonly_9|._110 (l_pobj) treatment_7\NN\654885|NONE_0 (l_prep) of_8\IN\0|the_14 (l_pobj) lymphoma_9\NN\14239918|NONE_0 (l_conj) tumour_13\NN\14234074|,_12 (l_conj) tumour_16\NN\14234074|mast_24|cell_19|,_8 (l_conj) tumours_19\NNS\14234074|brain_26|,_14 (l_conj) lymphoma_22\NN\14239918|histiocytic_40|and_20
D000409_D064420 NONE alanine_5\NN\14601829|elevated_9 (r_compound) transaminase_6\NN\15077571|(_13|alt_14 (r_nmod) concentration_10\NN\4916342|potential_65|renal_55|and_40 (r_conj) toxicity_2\NN\13576101|were_63|in_77|._117
D008130_D001932 NONE ccnu_0\NNP\0|was_5|commonly_19|in_28|._138 (r_nsubjpass) used_2\VBN\0|NONE_0 (l_prep) in_5\IN\13603305|ccnu_28|was_23|commonly_9|._110 (l_pobj) treatment_7\NN\654885|NONE_0 (l_prep) of_8\IN\0|the_14 (l_pobj) lymphoma_9\NN\14239918|NONE_0 (l_conj) tumour_13\NN\14234074|,_12 (l_conj) tumour_16\NN\14234074|mast_24|cell_19|,_8
D008130_D034801 NONE ccnu_0\NNP\0|was_5|commonly_19|in_28|._138 (r_nsubjpass) used_2\VBN\0|NONE_0 (l_prep) in_5\IN\13603305|ccnu_28|was_23|commonly_9|._110 (l_pobj) treatment_7\NN\654885|NONE_0 (l_prep) of_8\IN\0|the_14 (l_pobj) lymphoma_9\NN\14239918|NONE_0 (l_conj) tumour_13\NN\14234074|,_12
D008130_D007674 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ\0|(_45 (r_nmod) ccnu_21\NNP\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|bearing_13 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) in_13\IN\13603305|haematological_63 (r_prep) toxicities_12\NNS\13576101|NONE_0
D008130_D007674 NONE ccnu_21\NNP\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|bearing_13 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) in_13\IN\13603305|haematological_63 (r_prep) toxicities_12\NNS\13576101|NONE_0
D008130_D005767 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ\0|(_45 (r_nmod) ccnu_21\NNP\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|bearing_13 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) in_13\IN\13603305|haematological_63 (r_prep) toxicities_12\NNS\13576101|NONE_0
D008130_D005767 NONE ccnu_21\NNP\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|bearing_13 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) in_13\IN\13603305|haematological_63 (r_prep) toxicities_12\NNS\13576101|NONE_0
D008130_D006402 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ\0|(_45 (r_nmod) ccnu_21\NNP\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|bearing_13 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) in_13\IN\13603305|haematological_63 (r_prep) toxicities_12\NNS\13576101|NONE_0
D008130_D006402 NONE ccnu_21\NNP\0|NONE_0 (r_dobj) receiving_18\VBG\2210855|bearing_13 (r_acl) dogs_17\NNS\2083346|NONE_0 (r_pobj) in_13\IN\13603305|haematological_63 (r_prep) toxicities_12\NNS\13576101|NONE_0
9022662
D008774_D001289 NONE methylphenidate_14\NN\4320126|NONE_0 (r_pobj) with_13\IN\0|previously_19|without_21 (r_prep) treated_12\VBN\2376958|deficit_28 (r_acl) disorder_10\NN\14034177|NONE_0
D010389_D001289 NONE pemoline_0\NNP\0|derivative_27|._142 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) derivative_4\NN\5802185|pemoline_27|._115 (l_relcl) is_6\VBZ\0|an_31|oxazolidine_28 (l_conj) used_12\VBN\0|that_53|different_32|and_4 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) treatment_15\NN\654885|NONE_0 (l_prep) of_16\IN\0|the_14 (l_pobj) disorder_19\NN\14034177|NONE_0
D001569_D001264 NONE benzodiazepines_10\NNS\3771443|NONE_0 (r_pobj) of_8\IN\0|high_11 (r_prep) doses_7\NNS\3740161|gastrointestinal_42|and_9 (r_conj) decontamination_4\NN\391599|children_35|in_62|._115 (r_dobj) received_2\VBD\2210855|NONE_0 (l_prep) in_11\IN\13603305|children_97|decontamination_62|._53 (l_pobj) attempt_13\NN\407535|NONE_0 (l_acl) control_15\VB\5190804|an_14 (l_dobj) movements_18\NNS\191142|to_30 (l_compound) choreoathetoid_17\JJ\0|the_4
C064210_D001289 NONE oxazolidine_3\JJ\0|an_3|is_28 (r_compound) derivative_4\NN\5802185|pemoline_27|._115 (l_relcl) is_6\VBZ\0|an_31|oxazolidine_28 (l_conj) used_12\VBN\0|that_53|different_32|and_4 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) treatment_15\NN\654885|NONE_0 (l_prep) of_16\IN\0|the_14 (l_pobj) disorder_19\NN\14034177|NONE_0
D010389_D001264 CID pemoline_0\NNP\0|choreoathetosis_23 (r_nsubj) induced_1\VBD\1627355|:_29|case_31|and_43|review_47|of_54|._71 (l_dobj) choreoathetosis_3\NN\0|pemoline_23
D010389_D001264 CID pemoline_9\NN\0|NONE_0 (l_relcl) experienced_11\VBD\2108377|NONE_0 (l_dobj) choreoathetosis_13\NN\0|who_25
D010389_D001264 CID pemoline_12\NN\0|NONE_0 (r_compound) overdose_13\NN\84738|NONE_0 (r_pobj) after_11\IN\0|NONE_0 (r_prep) presenting_10\VBG\2137132|NONE_0 (r_acl) patients_9\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|possibility_61|should_21|be_14|._46 (r_prep) considered_7\VBN\689344|NONE_0 (l_nsubjpass) possibility_1\NN\5944958|should_40|be_47|in_61|._107 (l_prep) of_2\IN\0|the_16 (l_pobj) movements_4\NNS\191142|NONE_0 (l_compound) choreoathetoid_3\JJ\0|NONE_0
D010389_D062787 CID pemoline_12\NN\0|NONE_0 (r_compound) overdose_13\NN\84738|NONE_0
D001569_D002819 NONE benzodiazepines_10\NNS\3771443|NONE_0 (r_pobj) of_8\IN\0|high_11 (r_prep) doses_7\NNS\3740161|gastrointestinal_42|and_9 (r_conj) decontamination_4\NN\391599|children_35|in_62|._115 (r_dobj) received_2\VBD\2210855|NONE_0 (l_prep) in_11\IN\13603305|children_97|decontamination_62|._53 (l_pobj) attempt_13\NN\407535|NONE_0 (l_acl) control_15\VB\5190804|an_14 (l_dobj) movements_18\NNS\191142|to_30 (l_compound) choreoathetoid_17\JJ\0|the_4
D000662_D001289 NONE amphetamines_10\NNS\3248958|NONE_0 (r_pobj) from_9\IN\0|structurally_23 (r_prep) different_8\JJ\0|that_21|and_28|used_32 (r_acomp) is_6\VBZ\0|an_31|oxazolidine_28 (l_conj) used_12\VBN\0|that_53|different_32|and_4 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) treatment_15\NN\654885|NONE_0 (l_prep) of_16\IN\0|the_14 (l_pobj) disorder_19\NN\14034177|NONE_0
D010389_D009069 NONE pemoline_0\NNP\0|has_9|not_13|been_17|commonly_22|in_42|as_60|._98 (r_nsubjpass) associated_5\VBN\628491|NONE_0 (l_prep) as_9\IN\14622893|pemoline_60|has_51|not_47|been_43|commonly_38|in_18|._38 (l_pobj) cause_11\NN\7323922|NONE_0 (l_prep) of_12\IN\0|a_8 (l_pobj) disorders_15\NNS\14034177|NONE_0
D010389_D009069 NONE pemoline_0\NN\0|associated_9|movement_20 (r_nmod) disorder_3\NN\14034177|has_9|been_13|rarely_18|in_34|._68
D010389_D002819 CID pemoline_0\NNP\0|choreoathetosis_23 (r_nsubj) induced_1\VBD\1627355|:_29|case_31|and_43|review_47|of_54|._71 (l_dobj) choreoathetosis_3\NN\0|pemoline_23
D010389_D002819 CID pemoline_9\NN\0|NONE_0 (l_relcl) experienced_11\VBD\2108377|NONE_0 (l_dobj) choreoathetosis_13\NN\0|who_25
D010389_D002819 CID pemoline_12\NN\0|NONE_0 (r_compound) overdose_13\NN\84738|NONE_0 (r_pobj) after_11\IN\0|NONE_0 (r_prep) presenting_10\VBG\2137132|NONE_0 (r_acl) patients_9\NNS\9898892|NONE_0 (r_pobj) in_8\IN\13603305|possibility_61|should_21|be_14|._46 (r_prep) considered_7\VBN\689344|NONE_0 (l_nsubjpass) possibility_1\NN\5944958|should_40|be_47|in_61|._107 (l_prep) of_2\IN\0|the_16 (l_pobj) movements_4\NNS\191142|NONE_0 (l_compound) choreoathetoid_3\JJ\0|NONE_0
839274
D003276_D020518 CID contraceptives_14\NNS\3183080|NONE_0 (r_pobj) on_12\IN\0|focal_54|nodular_48|of_28 (r_prep) hyperplasia_5\NN\14365950|hepatic_35|and_18
D003276_D020518 CID contraceptives_18\NNS\3183080|NONE_0 (r_pobj) of_16\IN\0|the_8 (r_prep) use_15\NN\407535|NONE_0 (r_pobj) with_13\IN\0|presumably_22 (r_prep) associated_12\VBD\628491|of_40 (r_acl) one_6\CD\13741022|two_33|of_23|and_4 (l_prep) of_7\IN\0|associated_40 (l_pobj) hyperplasia_10\NN\14365950|NONE_0
D003276_D000236 CID contraceptives_14\NNS\3183080|NONE_0 (r_pobj) on_12\IN\0|focal_54|nodular_48|of_28 (r_prep) hyperplasia_5\NN\14365950|hepatic_35|and_18 (r_conj) adenomas_1\NNS\14236226|:_89|case_91|._103
D003276_D000236 CID contraceptives_18\NNS\3183080|NONE_0 (r_pobj) of_16\IN\0|the_8 (r_prep) use_15\NN\407535|NONE_0 (r_pobj) with_13\IN\0|presumably_22 (r_prep) associated_12\VBD\628491|of_40 (r_acl) one_6\CD\13741022|two_33|of_23|and_4 (r_conj) cases_1\NNS\7283608|,_119|are_121|._133 (l_prep) of_2\IN\0|two_10|and_19|one_23 (l_pobj) adenoma_4\NN\14236226|NONE_0
18177388
D000661_D054549 CID amphetamine_21\NN\3248958|NONE_0 (r_compound) use_22\NN\407535|NONE_0 (r_pobj) of_20\IN\0|the_12 (r_prep) setting_19\NN\8567235|NONE_0 (r_pobj) in_17\IN\13603305|a_14|young_12 (r_prep) woman_16\NN\9605289|NONE_0 (r_pobj) in_13\IN\13603305|reverse_99|syndrome_44|cardiomyopathy_16|)_2|._50 (r_prep) left_3\VBN\8621598|NONE_0 (l_dobj) syndrome_7\NN\5870365|reverse_55|cardiomyopathy_28|)_42|in_44|._94
D000661_D054549 CID amphetamine_21\NN\3248958|NONE_0 (r_compound) use_22\NN\407535|NONE_0 (r_pobj) of_20\IN\0|the_12 (r_prep) setting_19\NN\8567235|NONE_0 (r_pobj) in_17\IN\13603305|a_14|young_12 (r_prep) woman_16\NN\9605289|NONE_0 (r_pobj) in_13\IN\13603305|reverse_99|syndrome_44|cardiomyopathy_16|)_2|._50 (r_prep) left_3\VBN\8621598|NONE_0 (l_oprd) cardiomyopathy_11\NN\14103288|reverse_83|syndrome_28|)_14|in_16|._66
D000661_D054549 CID amphetamine_26\NN\3248958|NONE_0 (r_compound) use_27\NN\407535|NONE_0 (r_pobj) after_25\IN\0|NONE_0 (r_prep) occurring_24\VBG\0|this_53|rare_48|of_38 (r_acl) type_18\NN\5839024|NONE_0 (l_prep) of_19\IN\0|this_15|rare_10|occurring_38 (l_pobj) syndrome_23\NN\5870365|NONE_0
12851669
D016912_D054556 NONE levonorgestrel_42\NN\0|-_14 (r_npadvmod) containing_44\VBG\2632940|NONE_0 (r_amod) cocs_45\NNS\0|NONE_0 (r_pobj) on_41\IN\0|NONE_0 (r_prep) women_40\NNS\9605289|NONE_0 (r_pobj) among_39\IN\0|women_12 (r_prep) years_38\NNS\15144371|NONE_0 (r_pobj) per_34\IN\0|3.4_90|(_86|,_80|range_16|,_68|and_70|range_79 (r_prep) range_9\NN\5123416|risk_21|._228 (r_attr) was_6\VBD\0|NONE_0 (l_nsubj) risk_3\NN\14541044|range_21|._249 (l_prep) of_4\IN\0|the_32|corresponding_28|absolute_14 (l_pobj) vte_5\NNP\0|NONE_0
D003277_D054556 CID contraceptives_30\NNS\3183080|NONE_0 (r_pobj) on_27\IN\0|NONE_0 (r_prep) women_26\NNS\9605289|NONE_0 (r_pobj) among_25\IN\0|to_138|estimates_113|,_6|and_4|._50 (r_conj) achieve_1\VB\2524171|NONE_0 (l_dobj) estimates_4\NNS\5802185|to_25|,_107|and_109|among_113|._163 (l_prep) of_5\IN\0|absolute_24|risk_15 (l_pobj) thromboembolism_7\NN\14100769|NONE_0
D003277_D054556 CID contraceptives_30\NNS\3183080|NONE_0 (r_pobj) on_27\IN\0|NONE_0 (r_prep) women_26\NNS\9605289|NONE_0 (r_pobj) among_25\IN\0|to_138|estimates_113|,_6|and_4|._50 (r_conj) achieve_1\VB\2524171|NONE_0 (l_dobj) estimates_4\NNS\5802185|to_25|,_107|and_109|among_113|._163 (l_prep) of_5\IN\0|absolute_24|risk_15 (l_pobj) thromboembolism_7\NN\14100769|NONE_0 (l_appos) vte_9\NNP\0|venous_24|(_1|)_3|among_5
D003277_D054556 CID cocs_32\NNPS\0|combined_30|oral_21|(_1|)_4 (r_appos) contraceptives_30\NNS\3183080|NONE_0 (r_pobj) on_27\IN\0|NONE_0 (r_prep) women_26\NNS\9605289|NONE_0 (r_pobj) among_25\IN\0|to_138|estimates_113|,_6|and_4|._50 (r_conj) achieve_1\VB\2524171|NONE_0 (l_dobj) estimates_4\NNS\5802185|to_25|,_107|and_109|among_113|._163 (l_prep) of_5\IN\0|absolute_24|risk_15 (l_pobj) thromboembolism_7\NN\14100769|NONE_0
D003277_D054556 CID cocs_32\NNPS\0|combined_30|oral_21|(_1|)_4 (r_appos) contraceptives_30\NNS\3183080|NONE_0 (r_pobj) on_27\IN\0|NONE_0 (r_prep) women_26\NNS\9605289|NONE_0 (r_pobj) among_25\IN\0|to_138|estimates_113|,_6|and_4|._50 (r_conj) achieve_1\VB\2524171|NONE_0 (l_dobj) estimates_4\NNS\5802185|to_25|,_107|and_109|among_113|._163 (l_prep) of_5\IN\0|absolute_24|risk_15 (l_pobj) thromboembolism_7\NN\14100769|NONE_0 (l_appos) vte_9\NNP\0|venous_24|(_1|)_3|among_5
D003277_D054556 CID cocs_19\NNS\0|while_9 (r_pobj) on_18\IN\0|to_22|have_19|vte_10 (r_advcl) had_15\VBN\0|:_67|during_65|,_31|women_25|were_19|._21 (l_dobj) vte_16\NNP\0|to_12|have_9|on_10
D003277_D054556 CID cocs_24\NNS\0|NONE_0 (r_pobj) on_23\IN\0|the_10 (r_prep) women_22\NNS\9605289|NONE_0 (r_pobj) among_20\IN\0|women_12 (r_prep) years_19\NNS\15144371|NONE_0 (r_pobj) per_15\IN\0|3.8_5|)_2 (r_prep) 3.1_11\CD\0|,_55|4.2_57|(_61|,_67|3.2_69|)_76 (r_npadvmod) range_28\NN\5123416|3.4_74|(_70|,_64|per_16|,_84|and_86|range_95 (r_appos) range_9\NN\5123416|risk_21|._228 (r_attr) was_6\VBD\0|NONE_0 (l_nsubj) risk_3\NN\14541044|range_21|._249 (l_prep) of_4\IN\0|the_32|corresponding_28|absolute_14 (l_pobj) vte_5\NNP\0|NONE_0
D003277_D054556 CID cocs_45\NNS\0|NONE_0 (r_pobj) on_41\IN\0|NONE_0 (r_prep) women_40\NNS\9605289|NONE_0 (r_pobj) among_39\IN\0|women_12 (r_prep) years_38\NNS\15144371|NONE_0 (r_pobj) per_34\IN\0|3.4_90|(_86|,_80|range_16|,_68|and_70|range_79 (r_prep) range_9\NN\5123416|risk_21|._228 (r_attr) was_6\VBD\0|NONE_0 (l_nsubj) risk_3\NN\14541044|range_21|._249 (l_prep) of_4\IN\0|the_32|corresponding_28|absolute_14 (l_pobj) vte_5\NNP\0|NONE_0
D003277_D054556 CID cocs_12\NNS\0|NONE_0 (r_pobj) on_11\IN\0|danish_13 (r_prep) women_10\NNS\9605289|NONE_0 (r_pobj) among_8\IN\0|the_25|absolute_21|of_7 (r_prep) risk_5\NN\14541044|results_29|is_39|._83 (l_prep) of_6\IN\0|the_18|absolute_14|among_7 (l_pobj) vte_7\NNP\0|NONE_0
D017373_D054556 NONE acetate_12\NN\15010703|NONE_0 (r_pobj) on_9\IN\0|NONE_0 (r_prep) women_8\NNS\9605289|NONE_0 (r_pobj) in_7\IN\13603305|venous_23 (r_prep) thromboembolism_6\NN\14100769|NONE_0
D017373_D054556 NONE acetate_15\NN\15010703|NONE_0 (r_pobj) on_13\IN\0|NONE_0 (r_prep) women_12\NNS\9605289|NONE_0 (r_pobj) among_11\IN\0|venous_29|(_6|vte_5|)_2 (r_prep) thromboembolism_7\NN\14100769|NONE_0
D017373_D054556 NONE acetate_15\NN\15010703|NONE_0 (r_pobj) on_13\IN\0|NONE_0 (r_prep) women_12\NNS\9605289|NONE_0 (r_pobj) among_11\IN\0|venous_29|(_6|vte_5|)_2 (r_prep) thromboembolism_7\NN\14100769|NONE_0 (l_appos) vte_9\NNP\0|venous_24|(_1|)_3|among_5
D017373_D054556 NONE cpa_19\NNP\9761403|(_1|/_3|)_6 (r_nmod) ee_21\NNP\6125041|NONE_0 (r_appos) ethinylestradiol_17\NN\0|cyproterone_25|plus_5 (r_conj) acetate_15\NN\15010703|NONE_0 (r_pobj) on_13\IN\0|NONE_0 (r_prep) women_12\NNS\9605289|NONE_0 (r_pobj) among_11\IN\0|venous_29|(_6|vte_5|)_2 (r_prep) thromboembolism_7\NN\14100769|NONE_0
D017373_D054556 NONE cpa_19\NNP\9761403|(_1|/_3|)_6 (r_nmod) ee_21\NNP\6125041|NONE_0 (r_appos) ethinylestradiol_17\NN\0|cyproterone_25|plus_5 (r_conj) acetate_15\NN\15010703|NONE_0 (r_pobj) on_13\IN\0|NONE_0 (r_prep) women_12\NNS\9605289|NONE_0 (r_pobj) among_11\IN\0|venous_29|(_6|vte_5|)_2 (r_prep) thromboembolism_7\NN\14100769|NONE_0 (l_appos) vte_9\NNP\0|venous_24|(_1|)_3|among_5
D017373_D054556 NONE cpa_65\NNP\9761403|/_3 (r_nmod) ee_67\NNP\6125041|NONE_0 (r_pobj) on_64\IN\0|the_10 (r_prep) women_63\NNS\9605289|NONE_0 (r_pobj) among_61\IN\0|women_12 (r_prep) years_60\NNS\15144371|NONE_0 (r_pobj) per_56\IN\0|3.1_21|(_17|,_11|1.3_9|)_2 (r_prep) range_50\NN\5123416|3.4_169|(_165|,_159|range_95|per_79|,_11|and_9 (r_conj) range_9\NN\5123416|risk_21|._228 (r_attr) was_6\VBD\0|NONE_0 (l_nsubj) risk_3\NN\14541044|range_21|._249 (l_prep) of_4\IN\0|the_32|corresponding_28|absolute_14 (l_pobj) vte_5\NNP\0|NONE_0
D017373_D054556 NONE cpa_20\NNP\9761403|/_3 (r_nmod) ee_22\NNP\6125041|NONE_0 (r_dobj) taking_19\VBG\37396|NONE_0 (r_acl) women_18\NNS\9605289|NONE_0 (r_pobj) among_17\IN\0|NONE_0 (r_prep) that_16\DT\0|NONE_0 (r_pobj) to_15\IN\0|NONE_0 (r_prep) similar_14\JJ\0|NONE_0 (r_acomp) is_13\VBZ\0|results_68|risk_39|._44 (r_ccomp) suggest_2\VBP\1010118|NONE_0 (l_dobj) risk_5\NN\14541044|results_29|is_39|._83 (l_prep) of_6\IN\0|the_18|absolute_14|among_7 (l_pobj) vte_7\NNP\0|NONE_0
D004997_D054556 NONE ethinylestradiol_14\NN\0|combined_33|cyproterone_24|and_4 (r_conj) acetate_12\NN\15010703|NONE_0 (r_pobj) on_9\IN\0|NONE_0 (r_prep) women_8\NNS\9605289|NONE_0 (r_pobj) in_7\IN\13603305|venous_23 (r_prep) thromboembolism_6\NN\14100769|NONE_0
D004997_D054556 NONE ethinylestradiol_17\NN\0|cyproterone_25|plus_5 (r_conj) acetate_15\NN\15010703|NONE_0 (r_pobj) on_13\IN\0|NONE_0 (r_prep) women_12\NNS\9605289|NONE_0 (r_pobj) among_11\IN\0|venous_29|(_6|vte_5|)_2 (r_prep) thromboembolism_7\NN\14100769|NONE_0
D004997_D054556 NONE ethinylestradiol_17\NN\0|cyproterone_25|plus_5 (r_conj) acetate_15\NN\15010703|NONE_0 (r_pobj) on_13\IN\0|NONE_0 (r_prep) women_12\NNS\9605289|NONE_0 (r_pobj) among_11\IN\0|venous_29|(_6|vte_5|)_2 (r_prep) thromboembolism_7\NN\14100769|NONE_0 (l_appos) vte_9\NNP\0|venous_24|(_1|)_3|among_5
D004997_D054556 NONE ee_21\NNP\6125041|NONE_0 (r_appos) ethinylestradiol_17\NN\0|cyproterone_25|plus_5 (r_conj) acetate_15\NN\15010703|NONE_0 (r_pobj) on_13\IN\0|NONE_0 (r_prep) women_12\NNS\9605289|NONE_0 (r_pobj) among_11\IN\0|venous_29|(_6|vte_5|)_2 (r_prep) thromboembolism_7\NN\14100769|NONE_0
D004997_D054556 NONE ee_21\NNP\6125041|NONE_0 (r_appos) ethinylestradiol_17\NN\0|cyproterone_25|plus_5 (r_conj) acetate_15\NN\15010703|NONE_0 (r_pobj) on_13\IN\0|NONE_0 (r_prep) women_12\NNS\9605289|NONE_0 (r_pobj) among_11\IN\0|venous_29|(_6|vte_5|)_2 (r_prep) thromboembolism_7\NN\14100769|NONE_0 (l_appos) vte_9\NNP\0|venous_24|(_1|)_3|among_5
D004997_D054556 NONE ee_67\NNP\6125041|NONE_0 (r_pobj) on_64\IN\0|the_10 (r_prep) women_63\NNS\9605289|NONE_0 (r_pobj) among_61\IN\0|women_12 (r_prep) years_60\NNS\15144371|NONE_0 (r_pobj) per_56\IN\0|3.1_21|(_17|,_11|1.3_9|)_2 (r_prep) range_50\NN\5123416|3.4_169|(_165|,_159|range_95|per_79|,_11|and_9 (r_conj) range_9\NN\5123416|risk_21|._228 (r_attr) was_6\VBD\0|NONE_0 (l_nsubj) risk_3\NN\14541044|range_21|._249 (l_prep) of_4\IN\0|the_32|corresponding_28|absolute_14 (l_pobj) vte_5\NNP\0|NONE_0
D004997_D054556 NONE ee_22\NNP\6125041|NONE_0 (r_dobj) taking_19\VBG\37396|NONE_0 (r_acl) women_18\NNS\9605289|NONE_0 (r_pobj) among_17\IN\0|NONE_0 (r_prep) that_16\DT\0|NONE_0 (r_pobj) to_15\IN\0|NONE_0 (r_prep) similar_14\JJ\0|NONE_0 (r_acomp) is_13\VBZ\0|results_68|risk_39|._44 (r_ccomp) suggest_2\VBP\1010118|NONE_0 (l_dobj) risk_5\NN\14541044|results_29|is_39|._83 (l_prep) of_6\IN\0|the_18|absolute_14|among_7 (l_pobj) vte_7\NNP\0|NONE_0
3670965
D001241_D012202 CID aspirin_16\JJ\2707683|NONE_0 (r_compound) ingestion_17\NN\13440063|or_11 (r_conj) salicylates_14\NNS\3828465|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) association_12\NN\8008335|NONE_0 (r_pobj) of_11\IN\0|a_13|total_11 (r_prep) lack_10\NN\14449126|NONE_0 (r_pobj) despite_7\IN\7501545|syndrome_44|may_35|be_31|from_15|,_73|were_87|._156 (r_prep) disappearing_4\VBG\42757|NONE_0 (l_nsubj) syndrome_1\NN\5870365|may_9|be_13|from_29|despite_44|,_117|were_131|._200
D012459_D012202 NONE salicylates_14\NNS\3828465|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) association_12\NN\8008335|NONE_0 (r_pobj) of_11\IN\0|a_13|total_11 (r_prep) lack_10\NN\14449126|NONE_0 (r_pobj) despite_7\IN\7501545|syndrome_44|may_35|be_31|from_15|,_73|were_87|._156 (r_prep) disappearing_4\VBG\42757|NONE_0 (l_nsubj) syndrome_1\NN\5870365|may_9|be_13|from_29|despite_44|,_117|were_131|._200
10692744
D000086_D003221 NONE acetazolamide_4\NN\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|acute_16 (r_acl) confusion_1\NN\13972797|reaction_64|._106
D000086_D005862 CID acetazolamide_0\RB\0|-_13 (r_npadvmod) induced_2\VBN\1627355|gerstmann_8|._26 (r_amod) syndrome_4\NN\5870365|NONE_0
D000086_D005862 CID acetazolamide_5\NN\0|-_13 (r_npadvmod) induced_7\VBN\1627355|gerstmann_8 (r_amod) syndrome_9\NN\5870365|NONE_0
D000086_D007674 NONE acetazolamide_4\NN\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|acute_16 (r_acl) confusion_1\NN\13972797|reaction_64|._106 (r_nsubj) is_5\VBZ\0|NONE_0 (l_attr) reaction_11\NN\13446390|confusion_64|._42 (l_prep) in_12\IN\13603305|a_35|known_28|adverse_22|drug_14 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) impairment_16\NN\7296428|NONE_0
19940105
D006220_D002375 CID haloperidol_22\NN\3713736|-_11 (r_npadvmod) induced_24\VBN\1627355|in_18 (r_amod) catalepsy_25\NN\14023236|that_110|intrastriatal_87
D006220_D002375 CID haloperidol_8\NN\3713736|-_11 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) catalepsy_11\NN\14023236|NONE_0
D018698_D010300 NONE glutamate_1\NN\15010703|7_10|receptor_12 (r_nmod) subtype_4\NN\0|symptoms_24|in_33|._72 (r_nsubj) modulates_5\VBZ\1724459|NONE_0 (l_prep) in_8\IN\13603305|subtype_33|symptoms_9|._39 (l_pobj) models_10\NNS\5888929|NONE_0 (l_prep) of_11\IN\0|rodent_14 (l_pobj) disease_14\NN\14061805|NONE_0
D018698_D010300 NONE glutamate_1\NN\15010703|mglu_11 (r_nmod) receptors_5\NNS\5225602|transmission_28|and_71|represent_75|._168 (r_nsubj) modulate_6\VBP\1724459|NONE_0 (l_conj) represent_15\VBP\2664769|receptors_75|transmission_47|and_4|._93 (l_dobj) targets_18\NNS\7258332|NONE_0 (l_prep) for_19\IN\0|promising_30|therapeutic_20 (l_pobj) treatment_21\NN\654885|NONE_0 (l_prep) of_22\IN\0|symptomatic_22 (l_pobj) disease_25\NN\14061805|NONE_0
D018698_D010300 NONE glutamate_1\NN\15010703|mglu_11 (r_nmod) receptors_5\NNS\5225602|transmission_28|and_71|represent_75|._168 (r_nsubj) modulate_6\VBP\1724459|NONE_0 (l_conj) represent_15\VBP\2664769|receptors_75|transmission_47|and_4|._93 (l_dobj) targets_18\NNS\7258332|NONE_0 (l_prep) for_19\IN\0|promising_30|therapeutic_20 (l_pobj) treatment_21\NN\654885|NONE_0 (l_prep) of_22\IN\0|symptomatic_22 (l_pobj) disease_25\NN\14061805|NONE_0 (l_appos) pd_27\NNP\14625458|parkinson_21|(_1|)_2
C507346_D010300 NONE amn082_1\NNP\0|were_70|thus_75|in_87|._119 (r_nsubjpass) tested_15\VBN\670261|NONE_0 (l_prep) in_16\IN\13603305|amn082_87|were_17|thus_12|._32 (l_pobj) models_19\NNS\5888929|NONE_0 (l_prep) of_20\IN\0|different_24|rodent_14 (l_pobj) pd_21\NNP\14625458|NONE_0
C507346_D010300 NONE amn082_18\NNP\0|in_97|,_10|time_39|respond_47|._97 (r_nsubj) reverses_19\VBZ\13854649|NONE_0 (l_prep) in_0\IN\13603305|,_87|amn082_97|time_136|respond_144|._194 (l_pobj) task_4\NN\575741|NONE_0 (l_acl) used_6\VBN\0|a_29|complex_22 (l_xcomp) evaluate_8\VB\670261|commonly_17 (l_dobj) symptoms_11\NNS\5823932|to_27 (l_prep) of_12\IN\0|major_24|akinetic_18 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_compound) pd_13\NNP\14625458|NONE_0
C507346_D010300 NONE amn082_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|higher_13 (r_prep) doses_1\NNS\3740161|effect_47|._78 (r_nsubj) have_11\VBP\7846|NONE_0 (l_dobj) effect_13\NN\34213|doses_47|._31 (l_prep) on_14\IN\0|no_10 (l_pobj) models_17\NNS\5888929|NONE_0 (l_prep) of_18\IN\0|the_16|same_12 (l_pobj) pd_19\NNP\14625458|NONE_0
C507346_D002375 NONE amn082_20\NNP\0|NONE_0 (r_pobj) of_19\IN\0|(_19|0.1_18|nmol_6|)_2 (r_prep) administration_12\NN\1133281|NONE_0 (r_dobj) intrastriatal_11\JJ\0|that_23|catalepsy_87 (r_csubj) reverses_21\VBZ\13854649|here_95|,_91|we_89|._46 (l_dobj) catalepsy_25\NN\14023236|that_110|intrastriatal_87
C507346_D002375 NONE amn082_3\NNP\0|in_13|,_2|duration_19|._147 (r_nsubj) reduces_4\VBZ\441445|NONE_0 (l_dobj) duration_6\NN\15113229|in_32|,_21|amn082_19|._128 (l_prep) of_7\IN\0|the_13|in_33 (l_pobj) catalepsy_11\NN\14023236|NONE_0
C507346_D018476 NONE amn082_18\NNP\0|in_97|,_10|time_39|respond_47|._97 (r_nsubj) reverses_19\VBZ\13854649|NONE_0 (l_prep) in_0\IN\13603305|,_87|amn082_97|time_136|respond_144|._194 (l_pobj) task_4\NN\575741|NONE_0 (l_acl) used_6\VBN\0|a_29|complex_22 (l_xcomp) evaluate_8\VB\670261|commonly_17 (l_dobj) symptoms_11\NNS\5823932|to_27 (l_amod) akinetic_10\JJ\0|major_6|of_18
D016627_D010300 NONE 6-ohda_31\CD\0|-_6 (r_advmod) lesioned_33\VBN\0|bilateral_17 (r_amod) rats_34\NNS\2329401|NONE_0 (r_pobj) of_29\IN\0|a_6 (r_prep) cue_28\NN\7010821|NONE_0 (r_pobj) to_26\IN\0|to_11 (r_prep) respond_25\VB\2367363|in_144|,_57|amn082_47|time_8|._50 (r_xcomp) reverses_19\VBZ\13854649|NONE_0 (l_prep) in_0\IN\13603305|,_87|amn082_97|time_136|respond_144|._194 (l_pobj) task_4\NN\575741|NONE_0 (l_acl) used_6\VBN\0|a_29|complex_22 (l_xcomp) evaluate_8\VB\670261|commonly_17 (l_dobj) symptoms_11\NNS\5823932|to_27 (l_prep) of_12\IN\0|major_24|akinetic_18 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_compound) pd_13\NNP\14625458|NONE_0
D016627_D018476 NONE 6-ohda_31\CD\0|-_6 (r_advmod) lesioned_33\VBN\0|bilateral_17 (r_amod) rats_34\NNS\2329401|NONE_0 (r_pobj) of_29\IN\0|a_6 (r_prep) cue_28\NN\7010821|NONE_0 (r_pobj) to_26\IN\0|to_11 (r_prep) respond_25\VB\2367363|in_144|,_57|amn082_47|time_8|._50 (r_xcomp) reverses_19\VBZ\13854649|NONE_0 (l_prep) in_0\IN\13603305|,_87|amn082_97|time_136|respond_144|._194 (l_pobj) task_4\NN\575741|NONE_0 (l_acl) used_6\VBN\0|a_29|complex_22 (l_xcomp) evaluate_8\VB\670261|commonly_17 (l_dobj) symptoms_11\NNS\5823932|to_27 (l_amod) akinetic_10\JJ\0|major_6|of_18
2980315
C053571_D014693 NONE iopentol_14\NN\0|NONE_0 (r_pobj) after_13\IN\0|(_19|p_18|less_16|than_11|)_2 (r_prep) 0.05_11\CD\0|frequencies_78|lower_19|than_43|._70 (r_parataxis) were_4\VBD\0|NONE_0 (l_nsubj) frequencies_0\NNS\15286249|lower_59|0.05_78|than_121|._148 (l_prep) of_1\IN\0|NONE_0 (l_pobj) fibrillation_3\NN\14361664|NONE_0
D007472_D014693 NONE iohexol_20\NN\0|%_7|and_4 (r_conj) iopentol_14\NN\0|NONE_0 (r_pobj) after_13\IN\0|(_19|p_18|less_16|than_11|)_2 (r_prep) 0.05_11\CD\0|frequencies_78|lower_19|than_43|._70 (r_parataxis) were_4\VBD\0|NONE_0 (l_nsubj) frequencies_0\NNS\15286249|lower_59|0.05_78|than_121|._148 (l_prep) of_1\IN\0|NONE_0 (l_pobj) fibrillation_3\NN\14361664|NONE_0
D008794_D014693 CID metrizoate_27\NN\0|NONE_0 (r_pobj) after_26\IN\0|NONE_0 (r_prep) than_25\IN\0|frequencies_121|lower_62|0.05_43|._27 (r_prep) were_4\VBD\0|NONE_0 (l_nsubj) frequencies_0\NNS\15286249|lower_59|0.05_78|than_121|._148 (l_prep) of_1\IN\0|NONE_0 (l_pobj) fibrillation_3\NN\14361664|NONE_0
6433367
D011453_D012640 NONE prostaglandin_2\JJ\5414534|synthetase_14 (r_amod) inhibitors_4\NNS\20090|NONE_0 (r_pobj) of_1\IN\0|on_39|._84 (r_prep) effect_0\NN\34213|NONE_0 (l_prep) on_5\IN\0|of_39|._45 (l_pobj) convulsions_8\NNS\14081375|NONE_0
D011453_D012640 NONE prostaglandins_5\NNS\5414534|NONE_0 (r_pobj) of_4\IN\0|the_17 (r_prep) relationship_3\NN\31921|to_19|to_37 (r_dobj) investigate_1\VB\644583|,_73|effects_79|were_215|._229 (l_prep) to_9\TO\0|to_56|relationship_37 (l_pobj) induction_11\NN\7450842|NONE_0 (l_compound) seizure_10\NN\14081375|NONE_0
D011453_D012640 NONE prostaglandins_5\NNS\5414534|NONE_0 (r_pobj) of_4\IN\0|the_17 (r_prep) relationship_3\NN\31921|to_19|to_37 (r_dobj) investigate_1\VB\644583|,_73|effects_79|were_215|._229 (r_advcl) evaluated_37\VBN\670261|NONE_0 (l_nsubjpass) effects_14\NNS\13245626|investigate_79|,_6|were_136|._150 (l_prep) on_20\IN\0|the_44|of_32 (l_pobj) convulsions_21\NNS\14081375|NONE_0
D011453_D012640 NONE pgs_7\NNS\0|(_1|)_3 (r_appos) prostaglandins_5\NNS\5414534|NONE_0 (r_pobj) of_4\IN\0|the_17 (r_prep) relationship_3\NN\31921|to_19|to_37 (r_dobj) investigate_1\VB\644583|,_73|effects_79|were_215|._229 (l_prep) to_9\TO\0|to_56|relationship_37 (l_pobj) induction_11\NN\7450842|NONE_0 (l_compound) seizure_10\NN\14081375|NONE_0
D011453_D012640 NONE pgs_7\NNS\0|(_1|)_3 (r_appos) prostaglandins_5\NNS\5414534|NONE_0 (r_pobj) of_4\IN\0|the_17 (r_prep) relationship_3\NN\31921|to_19|to_37 (r_dobj) investigate_1\VB\644583|,_73|effects_79|were_215|._229 (r_advcl) evaluated_37\VBN\670261|NONE_0 (l_nsubjpass) effects_14\NNS\13245626|investigate_79|,_6|were_136|._150 (l_prep) on_20\IN\0|the_44|of_32 (l_pobj) convulsions_21\NNS\14081375|NONE_0
D011453_D012640 NONE pgs_4\NNS\0|that_5|are_4|in_17|,_86|but_88|picrotoxin-_96 (r_nsubjpass) involved_6\VBN\2676054|results_29|._150 (l_prep) in_7\IN\13603305|that_22|pgs_17|are_13|,_69|but_71|picrotoxin-_79 (l_pobj) fluorthyl-_12\NNS\0|NONE_0 (l_conj) convulsions_17\NNS\14081375|the_55|)_40|underlying_38|and_16
D011453_D012640 NONE pgs_4\NNS\0|that_5|are_4|in_17|,_86|but_88|picrotoxin-_96 (r_nsubjpass) involved_6\VBN\2676054|results_29|._150 (l_conj) picrotoxin-_21\XX\0|that_101|pgs_96|are_92|in_79|,_10|but_8 (l_pobj) convulsions_29\NNS\14081375|not_55|,_40|electroshock-_38
D010433_D012640 CID pentetrazol_28\NNP\0|(_12|)_16|,_17|electroshock_19 (r_nmod) ptz_30\NNP\0|,_15 (r_conj) picrotoxin_26\JJ\0|,_2 (r_conj) flurothyl_24\JJ\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) convulsions_21\NNS\14081375|NONE_0 (r_pobj) on_20\IN\0|the_44|of_32 (r_prep) effects_14\NNS\13245626|investigate_79|,_6|were_136|._150 (r_nsubjpass) evaluated_37\VBN\670261|NONE_0 (l_advcl) investigate_1\VB\644583|,_73|effects_79|were_215|._229 (l_prep) to_9\TO\0|to_56|relationship_37 (l_pobj) induction_11\NN\7450842|NONE_0 (l_compound) seizure_10\NN\14081375|NONE_0
D010433_D012640 CID pentetrazol_28\NNP\0|(_12|)_16|,_17|electroshock_19 (r_nmod) ptz_30\NNP\0|,_15 (r_conj) picrotoxin_26\JJ\0|,_2 (r_conj) flurothyl_24\JJ\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) convulsions_21\NNS\14081375|NONE_0
D010433_D012640 CID ptz_30\NNP\0|,_15 (r_conj) picrotoxin_26\JJ\0|,_2 (r_conj) flurothyl_24\JJ\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) convulsions_21\NNS\14081375|NONE_0 (r_pobj) on_20\IN\0|the_44|of_32 (r_prep) effects_14\NNS\13245626|investigate_79|,_6|were_136|._150 (r_nsubjpass) evaluated_37\VBN\670261|NONE_0 (l_advcl) investigate_1\VB\644583|,_73|effects_79|were_215|._229 (l_prep) to_9\TO\0|to_56|relationship_37 (l_pobj) induction_11\NN\7450842|NONE_0 (l_compound) seizure_10\NN\14081375|NONE_0
D010433_D012640 CID ptz_30\NNP\0|,_15 (r_conj) picrotoxin_26\JJ\0|,_2 (r_conj) flurothyl_24\JJ\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) convulsions_21\NNS\14081375|NONE_0
D010433_D012640 CID ptz_14\NNP\0|-_3 (r_npadvmod) induced_16\VBN\1627355|NONE_0 (r_amod) convulsions_17\NNS\14081375|the_55|)_40|underlying_38|and_16
D010433_D012640 CID ptz_14\NNP\0|-_3 (r_npadvmod) induced_16\VBN\1627355|NONE_0 (r_amod) convulsions_17\NNS\14081375|the_55|)_40|underlying_38|and_16 (r_conj) fluorthyl-_12\NNS\0|NONE_0 (r_pobj) in_7\IN\13603305|that_22|pgs_17|are_13|,_69|but_71|picrotoxin-_79 (r_prep) involved_6\VBN\2676054|results_29|._150 (l_conj) picrotoxin-_21\XX\0|that_101|pgs_96|are_92|in_79|,_10|but_8 (l_pobj) convulsions_29\NNS\14081375|not_55|,_40|electroshock-_38
D001640_D012640 CID bicuculline_35\NN\0|or_3 (r_conj) electroshock_33\NN\662681|pentetrazol_19|(_7|)_3|,_2 (r_conj) ptz_30\NNP\0|,_15 (r_conj) picrotoxin_26\JJ\0|,_2 (r_conj) flurothyl_24\JJ\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) convulsions_21\NNS\14081375|NONE_0 (r_pobj) on_20\IN\0|the_44|of_32 (r_prep) effects_14\NNS\13245626|investigate_79|,_6|were_136|._150 (r_nsubjpass) evaluated_37\VBN\670261|NONE_0 (l_advcl) investigate_1\VB\644583|,_73|effects_79|were_215|._229 (l_prep) to_9\TO\0|to_56|relationship_37 (l_pobj) induction_11\NN\7450842|NONE_0 (l_compound) seizure_10\NN\14081375|NONE_0
D001640_D012640 CID bicuculline_35\NN\0|or_3 (r_conj) electroshock_33\NN\662681|pentetrazol_19|(_7|)_3|,_2 (r_conj) ptz_30\NNP\0|,_15 (r_conj) picrotoxin_26\JJ\0|,_2 (r_conj) flurothyl_24\JJ\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) convulsions_21\NNS\14081375|NONE_0
D001640_D012640 CID bicuculline_26\NN\0|-_11 (r_advmod) induced_28\VBN\1627355|,_17|or_15 (r_conj) electroshock-_23\XX\0|not_17|,_2|convulsions_38 (r_conj) picrotoxin-_21\XX\0|that_101|pgs_96|are_92|in_79|,_10|but_8 (r_conj) involved_6\VBN\2676054|results_29|._150 (l_prep) in_7\IN\13603305|that_22|pgs_17|are_13|,_69|but_71|picrotoxin-_79 (l_pobj) fluorthyl-_12\NNS\0|NONE_0 (l_conj) convulsions_17\NNS\14081375|the_55|)_40|underlying_38|and_16
D001640_D012640 CID bicuculline_26\NN\0|-_11 (r_advmod) induced_28\VBN\1627355|,_17|or_15 (r_conj) electroshock-_23\XX\0|not_17|,_2|convulsions_38 (r_conj) picrotoxin-_21\XX\0|that_101|pgs_96|are_92|in_79|,_10|but_8 (l_pobj) convulsions_29\NNS\14081375|not_55|,_40|electroshock-_38
D010852_D012640 CID picrotoxin_26\JJ\0|,_2 (r_conj) flurothyl_24\JJ\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) convulsions_21\NNS\14081375|NONE_0 (r_pobj) on_20\IN\0|the_44|of_32 (r_prep) effects_14\NNS\13245626|investigate_79|,_6|were_136|._150 (r_nsubjpass) evaluated_37\VBN\670261|NONE_0 (l_advcl) investigate_1\VB\644583|,_73|effects_79|were_215|._229 (l_prep) to_9\TO\0|to_56|relationship_37 (l_pobj) induction_11\NN\7450842|NONE_0 (l_compound) seizure_10\NN\14081375|NONE_0
D010852_D012640 CID picrotoxin_26\JJ\0|,_2 (r_conj) flurothyl_24\JJ\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) convulsions_21\NNS\14081375|NONE_0
D010852_D012640 CID picrotoxin-_21\XX\0|that_101|pgs_96|are_92|in_79|,_10|but_8 (r_conj) involved_6\VBN\2676054|results_29|._150 (l_prep) in_7\IN\13603305|that_22|pgs_17|are_13|,_69|but_71|picrotoxin-_79 (l_pobj) fluorthyl-_12\NNS\0|NONE_0 (l_conj) convulsions_17\NNS\14081375|the_55|)_40|underlying_38|and_16
D010852_D012640 CID picrotoxin-_21\XX\0|that_101|pgs_96|are_92|in_79|,_10|but_8 (l_pobj) convulsions_29\NNS\14081375|not_55|,_40|electroshock-_38
D005481_D012640 CID flurothyl_24\JJ\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) convulsions_21\NNS\14081375|NONE_0 (r_pobj) on_20\IN\0|the_44|of_32 (r_prep) effects_14\NNS\13245626|investigate_79|,_6|were_136|._150 (r_nsubjpass) evaluated_37\VBN\670261|NONE_0 (l_advcl) investigate_1\VB\644583|,_73|effects_79|were_215|._229 (l_prep) to_9\TO\0|to_56|relationship_37 (l_pobj) induction_11\NN\7450842|NONE_0 (l_compound) seizure_10\NN\14081375|NONE_0
D005481_D012640 CID flurothyl_24\JJ\0|NONE_0 (r_pobj) by_23\IN\0|NONE_0 (r_agent) induced_22\VBN\1627355|NONE_0 (r_acl) convulsions_21\NNS\14081375|NONE_0
D005481_D012640 CID fluorthyl-_12\NNS\0|NONE_0 (l_conj) convulsions_17\NNS\14081375|the_55|)_40|underlying_38|and_16
D005481_D012640 CID fluorthyl-_12\NNS\0|NONE_0 (r_pobj) in_7\IN\13603305|that_22|pgs_17|are_13|,_69|but_71|picrotoxin-_79 (r_prep) involved_6\VBN\2676054|results_29|._150 (l_conj) picrotoxin-_21\XX\0|that_101|pgs_96|are_92|in_79|,_10|but_8 (l_pobj) convulsions_29\NNS\14081375|not_55|,_40|electroshock-_38
16600756
D011453_D053201 NONE prostaglandins_4\NNS\5414534|nerve_24|growth_18|and_4|in_15|._70 (r_conj) factor_2\NN\7326557|NONE_0 (l_prep) in_5\IN\13603305|nerve_39|growth_33|and_19|prostaglandins_15|._55 (l_pobj) urine_7\NN\14853947|NONE_0 (l_prep) of_8\IN\0|the_10 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|female_16 (l_pobj) bladder_13\NN\5515670|NONE_0
D011453_D053201 NONE pgs_7\NNS\0|urinary_16|and_4 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) women_9\NNS\9605289|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) oab_11\NNP\0|NONE_0
D011453_D053201 NONE pg_8\NNP\0|urinary_16|and_4 (r_conj) ngf_6\NNP\14734348|NONE_0 (r_pobj) between_4\IN\0|,_26|and_28|parameters_43 (r_prep) correlations_3\NNS\13841213|in_13|,_2|were_88|._101 (l_conj) parameters_12\NNS\5858936|between_43|,_17|and_15 (l_prep) in_13\IN\13603305|urodynamic_22 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|NONE_0 (l_pobj) oab_16\NNP\0|NONE_0
D011453_D053201 NONE pgs_2\NNS\0|and_4 (r_conj) ngf_0\NNP\14734348|roles_27|._86 (r_nsubj) have_3\VBP\7846|NONE_0 (l_dobj) roles_5\NNS\719494|ngf_27|._59 (l_prep) in_6\IN\13603305|important_16 (l_pobj) development_8\NN\248977|NONE_0 (l_prep) of_9\IN\0|the_16 (l_pobj) symptoms_11\NNS\5823932|NONE_0 (l_compound) oab_10\NNP\0|in_13
D011464_D053201 NONE pgi2_3\NNP\0|however_17|,_10|not_9|different_13|._61 (r_nsubj) was_4\VBD\0|NONE_0 (l_acomp) different_6\JJ\0|however_30|,_23|pgi2_13|not_4|._48 (l_prep) between_7\IN\0|NONE_0 (l_pobj) controls_8\NNS\5190804|NONE_0 (l_prep) with_11\IN\0|and_13|patients_9 (l_pobj) oab_12\NNP\0|NONE_0
D011464_D053201 NONE pgi2_5\NNP\0|and_4 (r_conj) pgf2alpha_3\NNP\0|urinary_13|,_2 (r_appos) ngf_1\NNP\14734348|did_24|not_28|with_42|._89 (r_nsubj) correlate_8\VB\5857459|NONE_0 (l_prep) with_9\IN\0|ngf_42|did_18|not_14|._47 (l_pobj) parameters_11\NNS\5858936|NONE_0 (l_prep) in_12\IN\13603305|urodynamic_22 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) oab_15\NNP\0|NONE_0
D015232_D053201 CID pge2_3\NNP\0|urinary_13|,_2 (r_conj) ngf_1\NNP\14734348|were_24|significantly_29|in_53|compared_74|)_105|._106 (r_nsubjpass) increased_8\VBN\169651|NONE_0 (l_prep) in_9\IN\13603305|ngf_53|were_29|significantly_24|compared_21|)_52|._53 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) oab_12\NNP\0|NONE_0
D015232_D053201 CID pge2_5\NNP\0|NONE_0 (l_compound) oab_3\NNP\0|urinary_4
D015237_D053201 CID pgf2alpha_5\NNP\0|and_4 (r_conj) pge2_3\NNP\0|urinary_13|,_2 (r_conj) ngf_1\NNP\14734348|were_24|significantly_29|in_53|compared_74|)_105|._106 (r_nsubjpass) increased_8\VBN\169651|NONE_0 (l_prep) in_9\IN\13603305|ngf_53|were_29|significantly_24|compared_21|)_52|._53 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) oab_12\NNP\0|NONE_0
D015237_D053201 CID pgf2alpha_3\NNP\0|urinary_13|,_2 (r_appos) ngf_1\NNP\14734348|did_24|not_28|with_42|._89 (r_nsubj) correlate_8\VB\5857459|NONE_0 (l_prep) with_9\IN\0|ngf_42|did_18|not_14|._47 (l_pobj) parameters_11\NNS\5858936|NONE_0 (l_prep) in_12\IN\13603305|urodynamic_22 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) oab_15\NNP\0|NONE_0
8410199
D010862_D012640 CID pilocarpine_14\NN\14712692|-_11 (r_npadvmod) induced_16\VBN\1627355|NONE_0 (r_amod) seizures_17\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_8\NN\14712692|NONE_0 (r_pobj) with_7\IN\0|rats_37|were_32|intraperitoneally_18|,_16|and_18|studied_52 (r_prep) injected_5\VBN\81072|NONE_0 (l_conj) studied_15\VBN\0|rats_89|were_84|intraperitoneally_70|with_52|,_36|and_34 (l_conj) intervals_27\NNS\33615|formation_60|was_50|histologically_38|at_23|,_13|and_11|._44 (l_prep) after_28\IN\0|week_15 (l_pobj) seizures_32\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_29\NN\14712692|-_11 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) seizures_32\NNS\14081375|NONE_0
D018698_D012640 NONE glutamate_2\NN\15010703|NONE_0 (r_compound) decarboxylase_3\NN\14732946|containing_19|in_38 (r_nmod) neurons_7\NNS\5430628|NONE_0 (r_pobj) of_1\IN\0|following_76|._114 (r_prep) loss_0\NN\13252973|NONE_0 (l_prep) following_13\VBG\8180190|of_76|._38 (l_pobj) seizures_17\NNS\14081375|NONE_0
D018698_D012640 NONE acid_10\NN\14818238|glutamic_9|(_19|neurons_41 (r_compound) decarboxylase_11\NN\14732946|if_17|vulnerable_86 (r_nsubj) are_26\VBP\13600404|to_112 (l_acomp) vulnerable_27\JJ\0|if_103|decarboxylase_86 (l_prep) to_28\IN\0|NONE_0 (l_pobj) damage_32\NN\7296428|NONE_0 (l_amod) induced_31\VBN\1627355|in_15 (l_npadvmod) seizure_29\NN\14081375|-_7
D018698_D012640 NONE acid_10\NN\14818238|glutamic_9|(_19|neurons_41 (r_compound) decarboxylase_11\NN\14732946|if_17|vulnerable_86 (r_nsubj) are_26\VBP\13600404|to_112 (l_acomp) vulnerable_27\JJ\0|if_103|decarboxylase_86 (l_prep) to_28\IN\0|NONE_0 (l_pobj) damage_32\NN\7296428|NONE_0 (l_prep) in_33\IN\13603305|induced_15 (l_pobj) model_35\NN\5888929|NONE_0 (l_prep) of_36\IN\0|a_8 (l_pobj) seizures_38\NNS\14081375|NONE_0
C028911_D009410 NONE violet_6\NN\12387633|cresyl_7|,_15|methods_39 (r_compound) staining_7\NN\275424|NONE_0 (l_conj) methods_11\NNS\5616786|cresyl_46|violet_39|,_24 (l_compound) degeneration_10\NN\29677|neuronal_9|,_20|and_22|localization_40
C028911_D009410 NONE violet_6\NN\12387633|cresyl_7|,_15|methods_39 (r_compound) staining_7\NN\275424|NONE_0 (r_pobj) including_4\VBG\0|additional_37|neuronanatomical_26|,_2|,_130 (r_prep) studies_2\NNS\635850|related_218|._287 (r_nsubj) suggested_22\VBD\1010118|NONE_0 (l_ccomp) related_36\VBN\628491|studies_218|._69 (l_prep) to_37\IN\0|that_75|decrease_66|was_12 (l_pobj) loss_39\NN\13252973|than_12|to_17
1636026
D014527_D007674 NONE acid_39\NN\14818238|NONE_0 (r_pobj) of_37\IN\0|5_8|mg_6|/_4 (r_prep) dl_36\NN\13616054|NONE_0 (r_pobj) of_32\IN\0|the_13 (r_prep) addition_31\NN\3081021|NONE_0 (r_pobj) without_29\IN\0|or_3 (r_conj) with_27\IN\0|free_12 (r_prep) buffer_26\NN\14818238|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) perfused_21\VBN\454868|the_38|recirculating_34|isolated_20|rat_11 (r_acl) kidney_20\NN\5333259|NONE_0 (r_pobj) in_15\IN\13603305|effects_60|mg_29|were_14|._124 (r_prep) compared_14\VBN\644583|NONE_0 (l_nsubjpass) effects_3\NNS\13245626|mg_31|were_46|in_60|._184 (l_amod) nephrotoxic_2\JJ\0|the_11|direct_7|of_20
D013496_D058186 CID suprofen_1\NN\0|although_9|has_9|been_13|with_29 (r_nsubjpass) associated_4\VBN\628491|,_83|mechanism_89|unclear_117|._124 (l_prep) with_5\IN\0|although_38|suprofen_29|has_20|been_16 (l_pobj) development_7\NN\248977|NONE_0 (l_prep) of_8\IN\0|the_16|in_23 (l_pobj) failure_11\NN\66216|NONE_0
D013496_D058186 CID suprofen_3\VB\0|in_12|,_2|declines_22|,_48|likely_55|._123 (r_nsubj) causes_4\VBZ\7323922|NONE_0 (l_dobj) declines_6\NNS\13458571|in_34|,_24|suprofen_22|,_26|likely_33|._101 (l_prep) in_7\IN\13603305|acute_15 (l_pobj) function_9\NN\13783581|NONE_0
D013496_D007674 NONE suprofen_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) mg_10\NN\13717155|effects_31|were_15|in_29|._153 (r_nsubjpass) compared_14\VBN\644583|NONE_0 (l_nsubjpass) effects_3\NNS\13245626|mg_31|were_46|in_60|._184 (l_amod) nephrotoxic_2\JJ\0|the_11|direct_7|of_20
D014527_D058186 NONE acid_21\NN\14818238|NONE_0 (r_pobj) of_19\IN\0|the_28|intrarenal_24 (r_prep) distribution_18\NN\5726596|directly_33 (r_dobj) altering_15\VBG\692130|NONE_0 (r_pcomp) by_13\IN\0|most_12 (r_prep) likely_12\JJ\0|in_67|,_57|suprofen_55|declines_33|,_7|._68 (r_advcl) causes_4\VBZ\7323922|NONE_0 (l_dobj) declines_6\NNS\13458571|in_34|,_24|suprofen_22|,_26|likely_33|._101 (l_prep) in_7\IN\13603305|acute_15 (l_pobj) function_9\NN\13783581|NONE_0
6637851
D000638_D064420 NONE amiodarone_10\NN\2715941|dose_5 (r_compound) therapy_11\NN\657604|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) toxicity_5\NN\13576101|term_18|and_4|for_41|._96
D000638_D064420 NONE amiodarone_4\NN\2715941|although_20|effective_21|in_31 (r_nsubj) is_5\VBZ\0|,_106|it_108|toxicity_130|._171 (r_advcl) causes_25\VBZ\7323922|NONE_0 (l_dobj) toxicity_27\NN\13576101|is_130|,_24|it_22|._41
D000638_D006323 NONE amiodarone_0\NNP\2715941|was_11|to_28|._203 (r_nsubjpass) administered_2\VBN\2436349|NONE_0 (l_prep) to_3\IN\0|amiodarone_28|was_17|._175 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_conj) arrest_24\NN\88481|154_96|sustained_75|118_18|or_13
D000638_D014693 NONE amiodarone_10\NN\2715941|dose_5 (r_compound) therapy_11\NN\657604|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) toxicity_5\NN\13576101|term_18|and_4|for_41|._96 (r_conj) efficacy_3\NN\5199286|NONE_0 (l_prep) for_12\IN\0|term_59|and_45|toxicity_41|._55 (l_pobj) tachycardia_14\NN\14110674|NONE_0 (l_conj) fibrillation_17\NN\14361664|ventricular_39|or_15
D000638_D014693 NONE amiodarone_9\NN\2715941|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) treatment_7\NN\654885|percent_30|and_26|had_30|._176 (r_dobj) continued_6\VBD\2367363|NONE_0 (l_conj) had_11\VBD\0|percent_60|treatment_30|and_4|._146 (l_dobj) recurrence_13\NN\7342049|NONE_0 (l_prep) of_14\IN\0|no_14|over_51 (l_pobj) vt_16\NNP\0|NONE_0 (l_conj) fibrillation_19\NN\14361664|symptomatic_30|or_15|(_13|vf_14|)_16
D000638_D014693 NONE amiodarone_9\NN\2715941|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) treatment_7\NN\654885|percent_30|and_26|had_30|._176 (r_dobj) continued_6\VBD\2367363|NONE_0 (l_conj) had_11\VBD\0|percent_60|treatment_30|and_4|._146 (l_dobj) recurrence_13\NN\7342049|NONE_0 (l_prep) of_14\IN\0|no_14|over_51 (l_pobj) vt_16\NNP\0|NONE_0 (l_appos) vf_21\NNP\0|symptomatic_44|or_29|fibrillation_14|(_1|)_2
D000638_D014693 NONE amiodarone_4\NN\2715941|although_20|effective_21|in_31 (r_nsubj) is_5\VBZ\0|,_106|it_108|toxicity_130|._171 (l_prep) in_8\IN\13603305|although_51|amiodarone_31|effective_10 (l_pobj) treatment_13\NN\654885|NONE_0 (l_prep) of_14\IN\0|the_24|term_15 (l_pobj) vt_15\NNP\0|NONE_0 (l_conj) refractory_18\NN\3673767|or_6 (l_compound) vf_17\NNP\0|to_14
D000638_D014693 NONE amiodarone_31\NN\2715941|NONE_0 (r_pobj) with_30\IN\0|however_159|,_152|adjusted_133|,_60|%_56|can_28|be_24|successfully_21|._15 (r_prep) managed_29\VBN\2524171|NONE_0 (l_nsubjpass) %_19\NN\0|however_103|,_96|adjusted_77|,_4|can_28|be_32|successfully_35|with_56|._71 (l_prep) of_20\IN\0|75_4 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|NONE_0 (l_pobj) vt_23\NNP\0|NONE_0 (l_conj) vf_25\NNP\0|or_3
D000638_D017180 NONE amiodarone_10\NN\2715941|dose_5 (r_compound) therapy_11\NN\657604|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) toxicity_5\NN\13576101|term_18|and_4|for_41|._96 (r_conj) efficacy_3\NN\5199286|NONE_0 (l_prep) for_12\IN\0|term_59|and_45|toxicity_41|._55 (l_pobj) tachycardia_14\NN\14110674|NONE_0
D000638_D017180 NONE amiodarone_0\NNP\2715941|was_11|to_28|._203 (r_nsubjpass) administered_2\VBN\2436349|NONE_0 (l_prep) to_3\IN\0|amiodarone_28|was_17|._175 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_relcl) sustained_8\VBN\2679899|154_21|118_57|or_62|arrest_75 (l_dobj) tachycardia_12\NN\14110674|who_43|had_39|,_26
D000638_D017180 NONE amiodarone_0\NNP\2715941|was_11|to_28|._203 (r_nsubjpass) administered_2\VBN\2436349|NONE_0 (l_prep) to_3\IN\0|amiodarone_28|was_17|._175 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_relcl) sustained_8\VBN\2679899|154_21|118_57|or_62|arrest_75 (l_dobj) tachycardia_12\NN\14110674|who_43|had_39|,_26 (l_appos) vt_14\NNP\0|symptomatic_37|ventricular_25|(_1|)_2
D000638_D017180 NONE amiodarone_9\NN\2715941|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) treatment_7\NN\654885|percent_30|and_26|had_30|._176 (r_dobj) continued_6\VBD\2367363|NONE_0 (l_conj) had_11\VBD\0|percent_60|treatment_30|and_4|._146 (l_dobj) recurrence_13\NN\7342049|NONE_0 (l_prep) of_14\IN\0|no_14|over_51 (l_pobj) vt_16\NNP\0|NONE_0
D000638_D017180 NONE amiodarone_17\NN\2715941|NONE_0 (r_pobj) by_15\IN\0|were_26|successfully_21 (r_agent) managed_14\VBN\2524171|percent_78|recurrence_39|and_22|._106 (r_conj) had_5\VBD\0|NONE_0 (l_dobj) recurrence_8\NN\7342049|percent_39|and_17|managed_39|._145 (l_prep) of_9\IN\0|a_22|nonfatal_20 (l_pobj) vt_10\NNP\0|NONE_0
D000638_D017180 NONE amiodarone_4\NN\2715941|although_20|effective_21|in_31 (r_nsubj) is_5\VBZ\0|,_106|it_108|toxicity_130|._171 (l_prep) in_8\IN\13603305|although_51|amiodarone_31|effective_10 (l_pobj) treatment_13\NN\654885|NONE_0 (l_prep) of_14\IN\0|the_24|term_15 (l_pobj) vt_15\NNP\0|NONE_0
D000638_D017180 NONE amiodarone_31\NN\2715941|NONE_0 (r_pobj) with_30\IN\0|however_159|,_152|adjusted_133|,_60|%_56|can_28|be_24|successfully_21|._15 (r_prep) managed_29\VBN\2524171|NONE_0 (l_nsubjpass) %_19\NN\0|however_103|,_96|adjusted_77|,_4|can_28|be_32|successfully_35|with_56|._71 (l_prep) of_20\IN\0|75_4 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|NONE_0 (l_pobj) vt_23\NNP\0|NONE_0
12734532
D010665_D009202 NONE ppa_7\NNP\0|NONE_0 (r_pobj) of_6\IN\0|the_10|with_7 (r_prep) abuse_5\NN\418025|reports_24|have_16|,_35|involved_65|._73 (l_prep) with_8\IN\0|the_17|of_7 (l_pobj) injury_10\NN\14052046|NONE_0
D010665_D009202 NONE dexatrim_7\NNP\0|ppa)-induced_10|myocardial_23|in_41 (r_nmod) injury_11\NN\14052046|NONE_0
D010665_D009202 NONE ppa)-induced_9\VBN\0|dexatrim_10|myocardial_13|in_31 (r_amod) injury_11\NN\14052046|NONE_0
D010665_D009202 NONE ppa_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_18|7_14|other_12|related_7 (r_prep) cases_8\NNS\7283608|in_35|,_24|we_22|._69 (l_acl) related_11\VBN\628491|the_25|7_21|other_19|of_7 (l_dobj) injury_13\NN\14052046|NONE_0
D010665_D009203 CID dexatrim_3\NNP\0|case_13|:_2|._66 (l_prep) as_7\IN\14622893|(_22|phenylpropanolamine_21|)_2 (l_pobj) cause_9\NN\7323922|NONE_0 (l_prep) of_10\IN\0|a_8 (l_pobj) infarction_12\NN\14204950|NONE_0
D010665_D009203 CID phenylpropanolamine_5\NNP\2682038|(_1|)_19|as_21 (r_appos) dexatrim_3\NNP\0|case_13|:_2|._66 (l_prep) as_7\IN\14622893|(_22|phenylpropanolamine_21|)_2 (l_pobj) cause_9\NN\7323922|NONE_0 (l_prep) of_10\IN\0|a_8 (l_pobj) infarction_12\NN\14204950|NONE_0
D010665_D062787 NONE ppa_7\NNP\0|NONE_0 (r_pobj) of_6\IN\0|the_10|with_7 (r_prep) abuse_5\NN\418025|reports_24|have_16|,_35|involved_65|._73 (r_dobj) linked_3\VBN\628491|NONE_0 (l_advcl) involved_16\VBN\2676054|reports_89|have_81|abuse_65|,_30|._8 (l_nsubjpass) overdose_14\NN\84738|especially_16|when_5|is_9
3535719
D014031_D064420 NONE tobramycin_7\JJ\2716866|NONE_0 (l_nsubj) efficacy_1\NN\5199286|in_51|._71 (l_conj) toxicity_3\NN\13576101|relative_22|and_4
D009428_D007239 NONE sulfate_9\NN\15010703|NONE_0 (r_pobj) of_7\IN\0|the_24|and_11|safety_7 (r_prep) efficacy_4\NN\5199286|we_30|prospectively_27|in_64|._169 (r_dobj) compared_2\VBD\644583|NONE_0 (l_prep) in_13\IN\13603305|we_94|prospectively_91|efficacy_64|._105 (l_pobj) conjunction_14\NN\5048123|NONE_0 (l_prep) in_18\IN\13603305|with_25 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|118_31|immunocompromised_27 (l_pobj) infections_25\NNS\14052046|NONE_0
D010878_D006311 CID piperacillin_12\VB\3910033|42_18|and_4 (r_conj) netilmicin_10\NNS\0|NONE_0 (r_pobj) of_8\IN\0|four_12|(_7|9.5_6|)_2 (r_prep) %_6\NN\0|and_37|in_41 (r_pobj) in_2\IN\13603305|ototoxicity_21|._115 (r_prep) occurred_1\VBD\0|NONE_0 (l_nsubj) ototoxicity_0\NN\0|in_21|._136
D010878_D006311 CID piperacillin_24\NN\3910033|-_12 (r_npadvmod) treated_26\VBN\2376958|NONE_0 (r_amod) patients_27\NNS\9898892|54_39|and_25 (r_conj) tobramycin_22\NNS\2716866|NONE_0 (r_pobj) of_20\IN\0|12_9|(_6|22_5|)_2 (r_prep) %_18\NN\0|NONE_0 (r_pobj) in_14\IN\13603305|%_41|and_4 (r_conj) in_2\IN\13603305|ototoxicity_21|._115 (r_prep) occurred_1\VBD\0|NONE_0 (l_nsubj) ototoxicity_0\NN\0|in_21|._136
D014031_D006311 CID tobramycin_22\NNS\2716866|NONE_0 (r_pobj) of_20\IN\0|12_9|(_6|22_5|)_2 (r_prep) %_18\NN\0|NONE_0 (r_pobj) in_14\IN\13603305|%_41|and_4 (r_conj) in_2\IN\13603305|ototoxicity_21|._115 (r_prep) occurred_1\VBD\0|NONE_0 (l_nsubj) ototoxicity_0\NN\0|in_21|._136
D014031_D006311 CID tobramycin_18\NNS\2716866|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) than_16\IN\0|often_33|with_16 (r_prep) reversible_13\JJ\3419014|less_27|and_15 (r_conj) severe_9\JJ\0|that_52|ototoxicity_21 (r_acomp) was_7\VBD\0|we_55|._78 (l_nsubj) ototoxicity_6\NN\0|that_31|severe_21
D009428_D006311 CID netilmicin_10\NNS\0|NONE_0 (r_pobj) of_8\IN\0|four_12|(_7|9.5_6|)_2 (r_prep) %_6\NN\0|and_37|in_41 (r_pobj) in_2\IN\13603305|ototoxicity_21|._115 (r_prep) occurred_1\VBD\0|NONE_0 (l_nsubj) ototoxicity_0\NN\0|in_21|._136
D009428_D006311 CID netilmicin_15\NNS\0|NONE_0 (r_pobj) with_14\IN\0|often_17|than_16 (r_prep) reversible_13\JJ\3419014|less_27|and_15 (r_conj) severe_9\JJ\0|that_52|ototoxicity_21 (r_acomp) was_7\VBD\0|we_55|._78 (l_nsubj) ototoxicity_6\NN\0|that_31|severe_21
D009428_D007674 CID netilmicin_10\NNS\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) treated_8\VBN\2376958|NONE_0 (r_acl) patients_7\NNS\9898892|NONE_0 (r_pobj) in_6\IN\13603305|a_21|similar_19|(_51|%_54|)_62 (r_prep) proportion_5\NN\13824815|NONE_0 (r_pobj) in_2\IN\13603305|nephrotoxicity_24|._87 (r_prep) occurred_1\VBD\0|NONE_0 (l_nsubj) nephrotoxicity_0\NN\0|in_24|._111
D000617_D006311 NONE aminoglycoside_3\NN\0|-_14 (r_npadvmod) associated_5\VBN\628491|NONE_0 (r_amod) ototoxicity_6\NN\0|that_31|severe_21
D010878_D007239 NONE sodium_17\NN\14625458|NONE_0 (r_pobj) with_15\IN\0|in_25 (r_prep) conjunction_14\NN\5048123|NONE_0 (l_prep) in_18\IN\13603305|with_25 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|118_31|immunocompromised_27 (l_pobj) infections_25\NNS\14052046|NONE_0
D014031_D007674 CID tobramycin_12\JJ\2716866|and_4 (r_conj) netilmicin_10\NNS\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) treated_8\VBN\2376958|NONE_0 (r_acl) patients_7\NNS\9898892|NONE_0 (r_pobj) in_6\IN\13603305|a_21|similar_19|(_51|%_54|)_62 (r_prep) proportion_5\NN\13824815|NONE_0 (r_pobj) in_2\IN\13603305|nephrotoxicity_24|._87 (r_prep) occurred_1\VBD\0|NONE_0 (l_nsubj) nephrotoxicity_0\NN\0|in_24|._111
D009428_D064420 NONE netilmicin_5\NNS\0|NONE_0 (r_pobj) of_4\IN\0|and_14 (r_prep) toxicity_3\NN\13576101|relative_22|and_4
D014031_D007239 NONE sulfate_12\NN\15010703|netilmicin_33|or_14 (r_conj) sulfate_9\NN\15010703|NONE_0 (r_pobj) of_7\IN\0|the_24|and_11|safety_7 (r_prep) efficacy_4\NN\5199286|we_30|prospectively_27|in_64|._169 (r_dobj) compared_2\VBD\644583|NONE_0 (l_prep) in_13\IN\13603305|we_94|prospectively_91|efficacy_64|._105 (l_pobj) conjunction_14\NN\5048123|NONE_0 (l_prep) in_18\IN\13603305|with_25 (l_pobj) patients_21\NNS\9898892|NONE_0 (l_prep) with_22\IN\0|118_31|immunocompromised_27 (l_pobj) infections_25\NNS\14052046|NONE_0
6115999
D011433_D003316 NONE propranolol_10\NN\0|the_4 (r_amod) group_11\NN\2137|NONE_0 (r_pobj) in_8\IN\13603305|to_17|have_14 (r_prep) occurred_7\VBN\0|disease_25|is_17|._33 (r_xcomp) known_4\VBN\0|NONE_0 (l_nsubjpass) disease_2\NN\14061805|is_8|occurred_25|._58
D011433_D011928 CID propranolol_37\NN\0|NONE_0 (r_dobj) taking_36\VBG\37396|and_10|women_6 (r_acl) men_33\NNS\8208016|NONE_0 (r_pobj) in_32\IN\13603305|raynaud_34|and_13|dyspnoea_9 (r_prep) phenomenon_29\NN\29677|impaired_117|glucose_108|in_90|,_58|associated_56|,_16|and_14
D001539_D007172 CID bendrofluazide_6\JJ\0|and_25|impotence_29 (r_amod) treatment_7\NN\654885|NONE_0 (l_conj) impotence_9\NN\4723816|bendrofluazide_29|and_4
D001539_D007172 CID bendrofluazide_6\JJ\0|and_25|impotence_29 (r_amod) treatment_7\NN\654885|NONE_0 (r_pobj) between_5\IN\0|an_15 (r_prep) association_4\NN\8008335|results_16|,_58|and_60|occurred_79 (r_dobj) show_2\VBP\429048|NONE_0 (l_conj) occurred_14\VBD\0|results_95|association_79|,_21|and_19 (l_nsubj) impotence_12\NN\4723816|also_10|frequently_29|in_40|._100
D001539_D006973 NONE bendrofluazide_3\VB\0|adverse_21|._69 (l_conj) propranolol_5\NN\0|to_22|and_4 (l_prep) for_6\IN\0|NONE_0 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) hypertension_11\NN\14057371|NONE_0
D001539_D006973 NONE bendrofluazide_21\NN\0|four_23|treatment_18|:_2 (r_amod) groups_19\NNS\2137|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) one_15\CD\13741022|NONE_0 (r_pobj) to_14\IN\0|participants_106|are_23|randomly_19|._100 (r_prep) allocated_13\VBN\2228698|NONE_0 (l_nsubjpass) participants_0\NNS\9816771|are_83|randomly_87|to_106|._206 (l_prep) in_1\IN\13603305|NONE_0 (l_pobj) trial_7\NN\786195|NONE_0 (l_prep) for_8\IN\0|the_45|council_24|treatment_16 (l_pobj) hypertension_10\NN\14057371|NONE_0
D001539_D018149 CID bendrofluazide_23\NN\0|NONE_0 (r_amod) treatment_24\NN\654885|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) associated_21\VBN\628491|impaired_61|glucose_52|in_34|,_2|,_40|and_42|phenomenon_56 (r_acl) tolerance_11\NN\5032565|NONE_0
D001539_D004417 NONE bendrofluazide_23\NN\0|NONE_0 (r_amod) treatment_24\NN\654885|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) associated_21\VBN\628491|impaired_61|glucose_52|in_34|,_2|,_40|and_42|phenomenon_56 (r_acl) tolerance_11\NN\5032565|NONE_0 (l_conj) phenomenon_29\NN\29677|impaired_117|glucose_108|in_90|,_58|associated_56|,_16|and_14 (l_conj) dyspnoea_31\NN\14299637|raynaud_25|and_4|in_9
D001539_D011928 NONE bendrofluazide_23\NN\0|NONE_0 (r_amod) treatment_24\NN\654885|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) associated_21\VBN\628491|impaired_61|glucose_52|in_34|,_2|,_40|and_42|phenomenon_56 (r_acl) tolerance_11\NN\5032565|NONE_0 (l_conj) phenomenon_29\NN\29677|impaired_117|glucose_108|in_90|,_58|associated_56|,_16|and_14
D011433_D004417 CID propranolol_37\NN\0|NONE_0 (r_dobj) taking_36\VBG\37396|and_10|women_6 (r_acl) men_33\NNS\8208016|NONE_0 (r_pobj) in_32\IN\13603305|raynaud_34|and_13|dyspnoea_9 (r_prep) phenomenon_29\NN\29677|impaired_117|glucose_108|in_90|,_58|associated_56|,_16|and_14 (l_conj) dyspnoea_31\NN\14299637|raynaud_25|and_4|in_9
D011433_D007172 CID propranolol_20\RB\0|than_12 (r_dobj) taking_19\VBG\37396|NONE_0 (r_acl) patients_18\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|impotence_40|also_30|frequently_11|._60 (r_prep) occurred_14\VBD\0|results_95|association_79|,_21|and_19 (r_conj) show_2\VBP\429048|NONE_0 (l_dobj) association_4\NN\8008335|results_16|,_58|and_60|occurred_79 (l_prep) between_5\IN\0|an_15 (l_pobj) treatment_7\NN\654885|NONE_0 (l_conj) impotence_9\NN\4723816|bendrofluazide_29|and_4
D011433_D007172 CID propranolol_20\RB\0|than_12 (r_dobj) taking_19\VBG\37396|NONE_0 (r_acl) patients_18\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|impotence_40|also_30|frequently_11|._60 (r_prep) occurred_14\VBD\0|results_95|association_79|,_21|and_19 (l_nsubj) impotence_12\NN\4723816|also_10|frequently_29|in_40|._100
D011433_D006973 NONE propranolol_5\NN\0|to_22|and_4 (l_prep) for_6\IN\0|NONE_0 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) hypertension_11\NN\14057371|NONE_0
D011433_D006973 NONE propranolol_23\NN\0|,_2 (r_conj) bendrofluazide_21\NN\0|four_23|treatment_18|:_2 (r_amod) groups_19\NNS\2137|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) one_15\CD\13741022|NONE_0 (r_pobj) to_14\IN\0|participants_106|are_23|randomly_19|._100 (r_prep) allocated_13\VBN\2228698|NONE_0 (l_nsubjpass) participants_0\NNS\9816771|are_83|randomly_87|to_106|._206 (l_prep) in_1\IN\13603305|NONE_0 (l_pobj) trial_7\NN\786195|NONE_0 (l_prep) for_8\IN\0|the_45|council_24|treatment_16 (l_pobj) hypertension_10\NN\14057371|NONE_0
D001539_D006073 CID bendrofluazide_23\NN\0|NONE_0 (r_amod) treatment_24\NN\654885|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) associated_21\VBN\628491|impaired_61|glucose_52|in_34|,_2|,_40|and_42|phenomenon_56 (r_acl) tolerance_11\NN\5032565|NONE_0 (l_prep) in_12\IN\13603305|impaired_27|glucose_18|,_32|associated_34|,_74|and_76|phenomenon_90 (l_pobj) men_13\NNS\8208016|NONE_0 (l_conj) women_15\NNS\9605289|and_4|in_15 (l_conj) gout_17\NN\14186541|and_4
D011433_D018149 NONE propranolol_37\NN\0|NONE_0 (r_dobj) taking_36\VBG\37396|and_10|women_6 (r_acl) men_33\NNS\8208016|NONE_0 (r_pobj) in_32\IN\13603305|raynaud_34|and_13|dyspnoea_9 (r_prep) phenomenon_29\NN\29677|impaired_117|glucose_108|in_90|,_58|associated_56|,_16|and_14 (r_conj) tolerance_11\NN\5032565|NONE_0
D011433_D006073 NONE propranolol_37\NN\0|NONE_0 (r_dobj) taking_36\VBG\37396|and_10|women_6 (r_acl) men_33\NNS\8208016|NONE_0 (r_pobj) in_32\IN\13603305|raynaud_34|and_13|dyspnoea_9 (r_prep) phenomenon_29\NN\29677|impaired_117|glucose_108|in_90|,_58|associated_56|,_16|and_14 (r_conj) tolerance_11\NN\5032565|NONE_0 (l_prep) in_12\IN\13603305|impaired_27|glucose_18|,_32|associated_34|,_74|and_76|phenomenon_90 (l_pobj) men_13\NNS\8208016|NONE_0 (l_conj) women_15\NNS\9605289|and_4|in_15 (l_conj) gout_17\NN\14186541|and_4
11847945
D007530_D056486 CID isoflurane_6\RB\3570838|NONE_0 (r_pobj) to_5\IN\0|NONE_0 (r_prep) exposure_4\NN\5042871|NONE_0 (r_pobj) after_3\IN\0|acute_28|cholestatic_22|._28 (r_prep) hepatitis_2\NN\14127211|NONE_0
D007530_D056486 CID isoflurane_14\RB\3570838|NONE_0 (r_pobj) to_10\IN\0|NONE_0 (r_prep) exposure_9\NN\5042871|NONE_0 (r_pobj) following_8\VBG\8180190|a_38|of_31 (r_prep) case_3\NN\7283608|to_12|._96 (l_prep) of_4\IN\0|a_7|following_31 (l_pobj) hepatitis_7\NN\14127211|NONE_0
D007530_D056486 CID isoflurane_0\NNP\3570838|,_37|can_39|hepatitis_68|._77 (r_nsubj) cause_8\VB\7323922|NONE_0 (l_dobj) hepatitis_11\NN\14127211|isoflurane_68|,_31|can_29|._9
D004177_D000699 NONE dipyrone_7\NN\0|NONE_0 (l_prep) for_8\IN\0|NONE_0 (l_pobj) analgesia_9\NN\14034177|NONE_0
D007530_D002779 CID isoflurane_6\RB\3570838|NONE_0 (r_pobj) to_5\IN\0|NONE_0 (r_prep) exposure_4\NN\5042871|NONE_0 (r_pobj) after_3\IN\0|acute_28|cholestatic_22|._28 (r_prep) hepatitis_2\NN\14127211|NONE_0
D007530_D002779 CID isoflurane_14\RB\3570838|NONE_0 (r_pobj) to_10\IN\0|NONE_0 (r_prep) exposure_9\NN\5042871|NONE_0 (r_pobj) following_8\VBG\8180190|a_38|of_31 (r_prep) case_3\NN\7283608|to_12|._96 (l_prep) of_4\IN\0|a_7|following_31 (l_pobj) hepatitis_7\NN\14127211|NONE_0
D007530_D002779 CID isoflurane_0\NNP\3570838|,_37|can_39|hepatitis_68|._77 (r_nsubj) cause_8\VB\7323922|NONE_0 (l_dobj) hepatitis_11\NN\14127211|isoflurane_68|,_31|can_29|._9
12013711
D018967_D001480 NONE risperidone_26\NN\0|NONE_0 (r_pobj) with_25\IN\0|patients_139|were_26|successfully_21|._16 (r_prep) treated_24\VBN\2376958|NONE_0 (l_nsubjpass) patients_2\NNS\9898892|were_113|successfully_118|with_139|._155 (l_relcl) had_5\VBD\0|two_32|schizophrenic_28|,_6|,_97 (l_conj) developed_16\VBN\1753788|who_60|history_44|and_23 (l_dobj) eps_17\NNP\0|who_29|had_25|previously_21|with_4
D008238_D010468 NONE lsd_16\NNP\3097890|NONE_0 (r_compound) abuse_17\NN\418025|NONE_0 (r_pobj) of_15\IN\0|a_15|past_13 (r_prep) history_14\NN\15120823|NONE_0 (r_pobj) with_11\IN\0|associated_75|,_65|benign_63|transient_56|visual_46|in_26|._32 (r_prep) disturbances_7\NNS\407535|NONE_0
D008238_D010468 NONE lsd_14\NNP\3097890|prior_6 (r_compound) consumption_15\NN\13440063|NONE_0 (r_pobj) to_12\IN\0|NONE_0 (r_prep) related_11\VBN\628491|"_13|"_2 (r_acl) flashbacks_9\NNS\6401328|NONE_0 (r_pobj) as_7\IN\14622893|previously_23 (r_prep) experienced_6\VBN\2108377|visual_31 (r_acl) disturbances_4\NNS\407535|imagery_25|._84
D018967_D012559 NONE risperidone_0\NNP\0|-_11 (r_npadvmod) associated_2\VBN\628491|,_10|benign_12|transient_19|visual_29|in_49|with_75|._107 (r_amod) disturbances_7\NNS\407535|NONE_0 (l_prep) in_8\IN\13603305|associated_49|,_39|benign_37|transient_30|visual_20|with_26|._58 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) schizophrenic_9\JJ\10490141|NONE_0
D018967_D012559 NONE risperidone_26\NN\0|NONE_0 (r_pobj) with_25\IN\0|patients_139|were_26|successfully_21|._16 (r_prep) treated_24\VBN\2376958|NONE_0 (l_nsubjpass) patients_2\NNS\9898892|were_113|successfully_118|with_139|._155 (l_amod) schizophrenic_1\JJ\10490141|two_4|,_22|had_28|,_125
D008238_D001480 NONE lsd_10\NNP\3097890|NONE_0 (r_compound) abuse_11\NN\418025|NONE_0 (r_pobj) of_9\IN\0|a_16|prior_14 (r_prep) history_8\NN\15120823|who_16|and_21|developed_44 (r_dobj) had_5\VBD\0|two_32|schizophrenic_28|,_6|,_97 (l_conj) developed_16\VBN\1753788|who_60|history_44|and_23 (l_dobj) eps_17\NNP\0|who_29|had_25|previously_21|with_4
D008238_D012559 NONE lsd_16\NNP\3097890|NONE_0 (r_compound) abuse_17\NN\418025|NONE_0 (r_pobj) of_15\IN\0|a_15|past_13 (r_prep) history_14\NN\15120823|NONE_0 (r_pobj) with_11\IN\0|associated_75|,_65|benign_63|transient_56|visual_46|in_26|._32 (r_prep) disturbances_7\NNS\407535|NONE_0 (l_prep) in_8\IN\13603305|associated_49|,_39|benign_37|transient_30|visual_20|with_26|._58 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) schizophrenic_9\JJ\10490141|NONE_0
D008238_D012559 NONE lsd_10\NNP\3097890|NONE_0 (r_compound) abuse_11\NN\418025|NONE_0 (r_pobj) of_9\IN\0|a_16|prior_14 (r_prep) history_8\NN\15120823|who_16|and_21|developed_44 (r_dobj) had_5\VBD\0|two_32|schizophrenic_28|,_6|,_97 (r_relcl) patients_2\NNS\9898892|were_113|successfully_118|with_139|._155 (l_amod) schizophrenic_1\JJ\10490141|two_4|,_22|had_28|,_125
D018967_D010468 CID risperidone_0\NNP\0|-_11 (r_npadvmod) associated_2\VBN\628491|,_10|benign_12|transient_19|visual_29|in_49|with_75|._107 (r_amod) disturbances_7\NNS\407535|NONE_0
D018967_D010468 CID risperidone_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treatment_15\NN\654885|NONE_0 (r_dobj) starting_14\VBG\457382|NONE_0 (r_pcomp) after_13\IN\0|which_27|immediately_12 (r_prep) appeared_11\VBD\2604760|transient_37|visual_27|,_8 (r_relcl) disturbances_8\NNS\407535|NONE_0
D018967_D010468 CID risperidone_0\NNP\0|NONE_0 (r_compound) administration_1\NN\1133281|was_15|and_29|wore_67 (r_nsubjpass) continued_3\VBN\2367363|NONE_0 (l_conj) wore_9\VBD\0|administration_67|was_52|and_38 (l_nsubj) disturbances_7\NNS\407535|gradually_13|off_28|._31
19923525
D009553_D008569 NONE nimodipine_0\NNP\0|impairment_27|._95 (r_nsubj) prevents_1\VBZ\0|NONE_0 (l_dobj) impairment_3\NN\7296428|nimodipine_27|._68
D002118_D007022 NONE calcium_13\NN\14625458|NONE_0 (r_compound) homeostasis_14\NN\13934900|NONE_0 (r_pobj) of_12\IN\0|the_17|during_23 (r_prep) preservation_11\NN\817680|NONE_0 (l_prep) during_15\IN\0|the_40|of_23 (l_pobj) hypotension_16\NN\14057371|NONE_0
D005996_D008569 CID nitroglycerin_6\NN\15015501|-_13 (r_npadvmod) induced_8\VBN\1627355|in_20 (r_amod) hypotension_9\NN\14057371|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) caused_4\VBN\1617192|memory_18 (r_acl) impairment_3\NN\7296428|nimodipine_27|._68
D009553_D007022 NONE nimodipine_0\NNP\0|impairment_27|._95 (r_nsubj) prevents_1\VBZ\0|NONE_0 (l_dobj) impairment_3\NN\7296428|nimodipine_27|._68 (l_acl) caused_4\VBN\1617192|memory_18 (l_agent) by_5\IN\0|NONE_0 (l_pobj) hypotension_9\NN\14057371|NONE_0
D009553_D007022 NONE nimodipine_5\NN\0|at_31 (r_nsubj) administered_9\VBN\2436349|the_38 (r_acl) hypothesis_3\NN\7162194|we_14 (r_dobj) tested_1\VBD\670261|(_88|hypotension_102|would_114|memory_151|._157 (r_ccomp) preserve_19\VB\14514039|NONE_0 (l_nsubj) hypotension_17\NN\14057371|tested_102|(_14|would_12|memory_49|._55
D009553_D007022 NONE nimo_7\NNP\0|that_17|(_1|)_4 (r_appos) nimodipine_5\NN\0|at_31 (r_nsubj) administered_9\VBN\2436349|the_38 (r_acl) hypothesis_3\NN\7162194|we_14 (r_dobj) tested_1\VBD\670261|(_88|hypotension_102|would_114|memory_151|._157 (r_ccomp) preserve_19\VB\14514039|NONE_0 (l_nsubj) hypotension_17\NN\14057371|tested_102|(_14|would_12|memory_49|._55
D009553_D007022 NONE nimo_27\NN\0|+_2 (r_conj) ntg_25\NNP\0|,_2 (r_appos) saline_23\NN\14849367|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) injected_21\VBN\81072|NONE_0 (r_acl) those_20\DT\0|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) compared_18\VBN\644583|decrease_41|,_52|or_54|delayed_57 (r_prep) showed_5\VBD\2137132|mice_39|to_24|._192 (r_conj) subjected_1\VBN\137313|NONE_0 (l_prep) to_2\IN\0|mice_15|showed_24|._216 (l_pobj) episodes_4\NNS\7283608|NONE_0 (l_amod) hypotensive_3\JJ\10405694|NONE_0
D009553_D007022 NONE nimo_0\NN\0|disruption_20|but_82|improve_94|._139 (r_advmod) attenuated_1\VBD\224901|NONE_0 (l_conj) improve_17\VB\126264|nimo_94|disruption_74|but_12|._45 (l_prep) in_19\IN\13603305|did_24|not_20|latency_8 (l_pobj) absence_21\NN\14449405|NONE_0 (l_prep) of_22\IN\0|the_12 (l_pobj) hypotension_23\NN\14057371|NONE_0
D009553_D007022 NONE nimo_4\NNP\0|NONE_0 (r_pobj) of_3\IN\0|the_20|observed_16 (r_prep) effect_2\NN\34213|may_15|have_19|attributable_29|,_103|were_119|._174 (r_nsubj) been_7\VBN\0|NONE_0 (l_acomp) attributable_8\JJ\0|effect_29|may_14|have_10|,_74|were_90|._145 (l_prep) to_9\IN\0|NONE_0 (l_pobj) preservation_11\NN\817680|NONE_0 (l_prep) during_15\IN\0|the_40|of_23 (l_pobj) hypotension_16\NN\14057371|NONE_0
D005996_D007022 CID nitroglycerin_6\NN\15015501|-_13 (r_npadvmod) induced_8\VBN\1627355|in_20 (r_amod) hypotension_9\NN\14057371|NONE_0
D005996_D007022 CID nitroglycerin_14\NN\15015501|NONE_0 (r_pobj) of_13\IN\0|the_10 (r_prep) onset_12\NN\7325190|NONE_0 (r_pobj) at_10\IN\14622893|nimodipine_31 (r_prep) administered_9\VBN\2436349|the_38 (r_acl) hypothesis_3\NN\7162194|we_14 (r_dobj) tested_1\VBD\670261|(_88|hypotension_102|would_114|memory_151|._157 (r_ccomp) preserve_19\VB\14514039|NONE_0 (l_nsubj) hypotension_17\NN\14057371|tested_102|(_14|would_12|memory_49|._55
D005996_D007022 CID ntg)-induced_16\JJ\0|NONE_0 (r_amod) hypotension_17\NN\14057371|tested_102|(_14|would_12|memory_49|._55
D005996_D007022 CID ntg_25\NNP\0|,_2 (r_appos) saline_23\NN\14849367|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) injected_21\VBN\81072|NONE_0 (r_acl) those_20\DT\0|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) compared_18\VBN\644583|decrease_41|,_52|or_54|delayed_57 (r_prep) showed_5\VBD\2137132|mice_39|to_24|._192 (r_conj) subjected_1\VBN\137313|NONE_0 (l_prep) to_2\IN\0|mice_15|showed_24|._216 (l_pobj) episodes_4\NNS\7283608|NONE_0 (l_amod) hypotensive_3\JJ\10405694|NONE_0
D005996_D007022 CID ntg_31\NNP\0|respectively_52|)_64 (r_dobj) delayed_30\VBN\439958|decrease_98|compared_57|,_5|or_3 (r_conj) showed_5\VBD\2137132|mice_39|to_24|._192 (r_conj) subjected_1\VBN\137313|NONE_0 (l_prep) to_2\IN\0|mice_15|showed_24|._216 (l_pobj) episodes_4\NNS\7283608|NONE_0 (l_amod) hypotensive_3\JJ\10405694|NONE_0
D005996_D007022 CID ntg_9\NNP\0|NONE_0 (r_pobj) of_8\IN\0|the_14 (r_prep) injection_7\NN\320852|in_32|,_6|after_29|impairment_67|,_117|had_155|._168 (r_nsubj) produced_13\VBD\1617192|NONE_0 (l_conj) had_30\VBD\0|in_187|,_161|injection_155|after_126|impairment_88|,_38|._13 (l_advcl) delayed_27\VBN\439958|effect_35 (l_dobj) hypotension_29\NN\14057371|whereas_24
D005996_D007022 CID ntg_13\NNP\0|NONE_0 (r_pobj) by_12\IN\0|NONE_0 (r_agent) caused_11\VBN\1617192|term_12 (r_acl) memory_10\NN\5926676|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) consolidation_5\NN\7373803|NONE_0 (r_pobj) in_4\IN\13603305|the_15 (r_prep) disruption_3\NN\1066163|nimo_20|but_62|improve_74|._119 (r_dobj) attenuated_1\VBD\224901|NONE_0 (l_conj) improve_17\VB\126264|nimo_94|disruption_74|but_12|._45 (l_prep) in_19\IN\13603305|did_24|not_20|latency_8 (l_pobj) absence_21\NN\14449405|NONE_0 (l_prep) of_22\IN\0|the_12 (l_pobj) hypotension_23\NN\14057371|NONE_0
6436733
D000641_D006970 CID ammonia_0\NN\14940386|higher_18|in_25|)_155|,_156|were_185|._212 (r_nsubj) was_4\VBD\0|NONE_0 (l_prep) in_6\IN\13603305|ammonia_25|higher_7|)_130|,_131|were_160|._187 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_relcl) complained_14\VBD\0|NONE_0 (l_prep) of_15\IN\0|who_43|,_40|during_38|,_13|than_27 (l_pobj) drowsiness_16\NN\14015731|NONE_0
D000641_D006970 CID nh3_2\NNP\0|NONE_0 (r_appos) ammonia_0\NN\14940386|higher_18|in_25|)_155|,_156|were_185|._212 (r_nsubj) was_4\VBD\0|NONE_0 (l_prep) in_6\IN\13603305|ammonia_25|higher_7|)_130|,_131|were_160|._187 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_relcl) complained_14\VBD\0|NONE_0 (l_prep) of_15\IN\0|who_43|,_40|during_38|,_13|than_27 (l_pobj) drowsiness_16\NN\14015731|NONE_0
D014635_D006970 CID vpa_35\NNP\0|plasma_4 (r_compound) levels_37\NNS\4916342|although_20|similar_12 (r_nsubj) were_38\VBD\0|ammonia_185|higher_167|in_160|)_30|,_29|._27 (r_advcl) was_4\VBD\0|NONE_0 (l_prep) in_6\IN\13603305|ammonia_25|higher_7|)_130|,_131|were_160|._187 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_relcl) complained_14\VBD\0|NONE_0 (l_prep) of_15\IN\0|who_43|,_40|during_38|,_13|than_27 (l_pobj) drowsiness_16\NN\14015731|NONE_0
D014635_D004827 NONE acid_1\NN\14818238|was_11|to_21|._107 (r_nsubjpass) given_6\VBN\5892096|NONE_0 (l_dative) to_7\IN\0|acid_21|was_10|._86 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) epileptic_9\JJ\10595647|24_3|treated_42
D014635_D004827 NONE vpa_3\NNP\0|valproic_15|(_1|)_3 (r_appos) acid_1\NN\14818238|was_11|to_21|._107 (r_nsubjpass) given_6\VBN\5892096|NONE_0 (l_dative) to_7\IN\0|acid_21|was_10|._86 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_amod) epileptic_9\JJ\10595647|24_3|treated_42
20533999
D004298_D020258 NONE dopamine_0\NN\14807737|not_12|essential_16|._86 (r_nsubj) is_1\VBZ\0|NONE_0 (l_acomp) essential_3\JJ\2452|dopamine_16|not_4|._70 (l_prep) for_4\IN\0|NONE_0 (l_pobj) development_6\NN\248977|NONE_0 (l_prep) of_7\IN\0|the_16 (l_pobj) neurotoxicity_11\NN\0|NONE_0
D004298_D020258 NONE da_29\NNP\10484858|induced_8 (r_compound) neurotoxicity_30\NN\0|NONE_0
D004298_D020258 NONE da_13\NN\10484858|NONE_0 (r_pobj) in_11\IN\13603305|NONE_0 (r_prep) deficient_10\JJ\0|to_6 (r_acomp) be_9\VB\14625458|that_36|mice_31|genetically_26|develop_25 (r_xcomp) engineered_7\VBN\1639714|further_39|,_32|we_30|._119 (l_conj) develop_14\VBP\1753788|that_61|mice_56|genetically_51|be_25 (l_dobj) neurotoxicity_16\NN\0|,_13|long_18
D004298_D020258 NONE da_7\NNP\10484858|that_5|not_6|essential_10|and_83|suggest_87 (r_nsubj) is_8\VBZ\0|taken_51|,_37|findings_29|._160 (l_acomp) essential_10\JJ\2452|that_15|da_10|not_4|and_73|suggest_77 (l_prep) for_11\IN\0|NONE_0 (l_pobj) development_13\NN\248977|NONE_0 (l_prep) of_14\IN\0|the_16 (l_pobj) neurotoxicity_19\NN\0|NONE_0
D004298_D020258 NONE da_26\JJ\10484858|NONE_0 (r_pobj) of_25\IN\0|NONE_0 (r_prep) independent_24\JJ\9619824|NONE_0 (r_amod) mechanisms_23\NNS\13446390|that_5|investigation_50 (r_nsubj) warrant_27\NN\6552984|NONE_0 (r_ccomp) suggest_21\VBP\1010118|that_92|da_87|not_81|essential_77|and_4 (r_conj) is_8\VBZ\0|taken_51|,_37|findings_29|._160 (l_acomp) essential_10\JJ\2452|that_15|da_10|not_4|and_73|suggest_77 (l_prep) for_11\IN\0|NONE_0 (l_pobj) development_13\NN\248977|NONE_0 (l_prep) of_14\IN\0|the_16 (l_pobj) neurotoxicity_19\NN\0|NONE_0
D004298_D009461 NONE da_13\NNP\10484858|unilateral_17 (r_compound) deficits_14\NNS\5113133|to_28 (r_dobj) have_10\VB\7846|that_36|mice_31|genetically_26|develop_34 (r_xcomp) engineered_8\VBN\1639714|in_50|,_39|we_37|._150 (l_conj) develop_15\VBP\1753788|that_70|mice_65|genetically_60|have_34 (l_dobj) deficits_20\NNS\5113133|NONE_0
D019805_D020258 NONE tyrosine_24\NN\14601829|NONE_0 (l_prep) on_25\IN\0|para_14|-_10 (l_pobj) neurotoxicity_30\NN\0|NONE_0
D008694_D020258 CID methamphetamine_8\NN\2704153|-_15 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) neurotoxicity_11\NN\0|NONE_0
D008694_D020258 CID meth_26\NNP\2704153|-_4 (r_npadvmod) induced_28\VBN\1627355|da_8 (r_amod) neurotoxicity_30\NN\0|NONE_0
D008694_D020258 CID meth_15\NNP\2704153|NONE_0 (r_compound) neurotoxicity_16\NN\0|,_13|long_18
D008694_D020258 CID meth_25\NNP\2704153|NONE_0 (r_pobj) of_24\IN\0|the_20|thermic_16 (r_prep) effects_23\NNS\13245626|as_15|are_16 (r_nsubjpass) preserved_27\VBN\2681795|as_43 (r_advcl) long_19\RB\1825237|neurotoxicity_18|,_5 (r_advmod) develop_14\VBP\1753788|that_61|mice_56|genetically_51|be_25 (l_dobj) neurotoxicity_16\NN\0|,_13|long_18
D008694_D020258 CID meth_15\NNP\2704153|-_4 (r_npadvmod) induced_17\VBN\1627355|dopaminergic_8 (r_amod) neurotoxicity_19\NN\0|NONE_0
D007980_D020258 NONE dihydroxyphenylalanine_11\NN\14601829|NONE_0 (r_pobj) of_8\IN\0|the_30|reported_17|reverse_31 (r_prep) ability_7\NN\4723816|that_27|is_132|also_135|by_151 (l_acl) reverse_13\VB\13854649|the_61|reported_48|of_31 (l_dobj) effect_16\NN\34213|to_26 (l_prep) of_17\IN\0|the_22|protective_18 (l_pobj) tyrosine_24\NN\14601829|NONE_0 (l_prep) on_25\IN\0|para_14|-_10 (l_pobj) neurotoxicity_30\NN\0|NONE_0
D008694_D009461 NONE meth_16\NN\2704153|-_4 (r_npadvmod) induced_18\VBN\1627355|dopaminergic_8|are_35 (r_amod) deficits_20\NNS\5113133|NONE_0
D004298_D064420 NONE dopamine_5\NN\14807737|that_5|methamphetamine_23|decrease_149 (r_nsubj) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_dobj) methamphetamine_10\NN\2704153|that_28|dopamine_23|decrease_126 (l_acl) meth)-induced_12\JJ\0|(_1|,_52 (l_dobj) toxicity_13\NN\13576101|brain_12
D004298_D064420 NONE dopamine_5\NN\14807737|that_5|methamphetamine_23|decrease_149 (r_nsubj) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_advcl) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (l_dobj) toxicity_27\NN\13576101|because_64|drugs_56|,_8|enhance_59
D004298_D064420 NONE dopamine_5\NN\14807737|that_5|methamphetamine_23|decrease_149 (r_nsubj) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_advcl) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (l_advcl) enhance_35\VB\227165|because_123|drugs_115|toxicity_59|,_51 (l_dobj) toxicity_36\NN\13576101|whereas_57|drugs_49
D004298_D064420 NONE da_7\NNP\10484858|NONE_0 (r_appos) dopamine_5\NN\14807737|that_5|methamphetamine_23|decrease_149 (r_nsubj) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_dobj) methamphetamine_10\NN\2704153|that_28|dopamine_23|decrease_126 (l_acl) meth)-induced_12\JJ\0|(_1|,_52 (l_dobj) toxicity_13\NN\13576101|brain_12
D004298_D064420 NONE da_7\NNP\10484858|NONE_0 (r_appos) dopamine_5\NN\14807737|that_5|methamphetamine_23|decrease_149 (r_nsubj) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_advcl) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (l_dobj) toxicity_27\NN\13576101|because_64|drugs_56|,_8|enhance_59
D004298_D064420 NONE da_7\NNP\10484858|NONE_0 (r_appos) dopamine_5\NN\14807737|that_5|methamphetamine_23|decrease_149 (r_nsubj) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_advcl) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (l_advcl) enhance_35\VB\227165|because_123|drugs_115|toxicity_59|,_51 (l_dobj) toxicity_36\NN\13576101|whereas_57|drugs_49
D004298_D064420 NONE da_24\NNP\10484858|NONE_0 (r_compound) neurotransmission_25\NN\0|NONE_0 (r_pobj) with_23\IN\0|that_15 (r_prep) interfere_22\VBP\2451370|NONE_0 (r_relcl) drugs_20\NNS\14778436|because_8|toxicity_56|,_64|enhance_115 (r_nsubj) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (r_advcl) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_dobj) methamphetamine_10\NN\2704153|that_28|dopamine_23|decrease_126 (l_acl) meth)-induced_12\JJ\0|(_1|,_52 (l_dobj) toxicity_13\NN\13576101|brain_12
D004298_D064420 NONE da_24\NNP\10484858|NONE_0 (r_compound) neurotransmission_25\NN\0|NONE_0 (r_pobj) with_23\IN\0|that_15 (r_prep) interfere_22\VBP\2451370|NONE_0 (r_relcl) drugs_20\NNS\14778436|because_8|toxicity_56|,_64|enhance_115 (r_nsubj) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (l_dobj) toxicity_27\NN\13576101|because_64|drugs_56|,_8|enhance_59
D004298_D064420 NONE da_24\NNP\10484858|NONE_0 (r_compound) neurotransmission_25\NN\0|NONE_0 (r_pobj) with_23\IN\0|that_15 (r_prep) interfere_22\VBP\2451370|NONE_0 (r_relcl) drugs_20\NNS\14778436|because_8|toxicity_56|,_64|enhance_115 (r_nsubj) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (l_advcl) enhance_35\VB\227165|because_123|drugs_115|toxicity_59|,_51 (l_dobj) toxicity_36\NN\13576101|whereas_57|drugs_49
D004298_D064420 NONE da_33\NNP\10484858|NONE_0 (r_compound) neurotransmission_34\NN\0|that_17 (r_dobj) increase_32\VBP\13576355|NONE_0 (r_relcl) drugs_30\NNS\14778436|whereas_8|toxicity_49 (r_nsubj) enhance_35\VB\227165|because_123|drugs_115|toxicity_59|,_51 (r_advcl) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (r_advcl) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_dobj) methamphetamine_10\NN\2704153|that_28|dopamine_23|decrease_126 (l_acl) meth)-induced_12\JJ\0|(_1|,_52 (l_dobj) toxicity_13\NN\13576101|brain_12
D004298_D064420 NONE da_33\NNP\10484858|NONE_0 (r_compound) neurotransmission_34\NN\0|that_17 (r_dobj) increase_32\VBP\13576355|NONE_0 (r_relcl) drugs_30\NNS\14778436|whereas_8|toxicity_49 (r_nsubj) enhance_35\VB\227165|because_123|drugs_115|toxicity_59|,_51 (r_advcl) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (l_dobj) toxicity_27\NN\13576101|because_64|drugs_56|,_8|enhance_59
D004298_D064420 NONE da_33\NNP\10484858|NONE_0 (r_compound) neurotransmission_34\NN\0|that_17 (r_dobj) increase_32\VBP\13576355|NONE_0 (r_relcl) drugs_30\NNS\14778436|whereas_8|toxicity_49 (r_nsubj) enhance_35\VB\227165|because_123|drugs_115|toxicity_59|,_51 (l_dobj) toxicity_36\NN\13576101|whereas_57|drugs_49
D008694_D064420 NONE methamphetamine_10\NN\2704153|that_28|dopamine_23|decrease_126 (l_acl) meth)-induced_12\JJ\0|(_1|,_52 (l_dobj) toxicity_13\NN\13576101|brain_12
D008694_D064420 NONE methamphetamine_10\NN\2704153|that_28|dopamine_23|decrease_126 (r_dobj) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_advcl) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (l_dobj) toxicity_27\NN\13576101|because_64|drugs_56|,_8|enhance_59
D008694_D064420 NONE methamphetamine_10\NN\2704153|that_28|dopamine_23|decrease_126 (r_dobj) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_advcl) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (l_advcl) enhance_35\VB\227165|because_123|drugs_115|toxicity_59|,_51 (l_dobj) toxicity_36\NN\13576101|whereas_57|drugs_49
D008694_D064420 NONE meth)-induced_12\JJ\0|(_1|,_52 (l_dobj) toxicity_13\NN\13576101|brain_12
D008694_D064420 NONE meth)-induced_12\JJ\0|(_1|,_52 (r_acl) methamphetamine_10\NN\2704153|that_28|dopamine_23|decrease_126 (r_dobj) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_advcl) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (l_dobj) toxicity_27\NN\13576101|because_64|drugs_56|,_8|enhance_59
D008694_D064420 NONE meth)-induced_12\JJ\0|(_1|,_52 (r_acl) methamphetamine_10\NN\2704153|that_28|dopamine_23|decrease_126 (r_dobj) mediates_9\VBZ\761713|it_41|is_38|widely_35|._219 (l_advcl) decrease_26\NN\7296428|that_154|dopamine_149|methamphetamine_126 (l_advcl) enhance_35\VB\227165|because_123|drugs_115|toxicity_59|,_51 (l_dobj) toxicity_36\NN\13576101|whereas_57|drugs_49
15517007
D018943_D006331 NONE anthracyclines_8\NNS\0|or_3 (r_conj) cyclophosphamide_6\NN\0|when_5|are_56|in_65|,_116|for_118|,_129|patients_150 (r_nsubjpass) used_13\VBN\0|however_94|,_87|caution_85|is_77|._98 (l_prep) in_14\IN\13603305|when_70|cyclophosphamide_65|are_9|,_51|for_53|,_64|patients_85 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) damage_21\NN\7296428|NONE_0
D008942_D012595 NONE mitoxantrone_11\NN\0|such_8 (r_pobj) as_10\IN\14622893|NONE_0 (r_prep) anthracyclines_8\NNS\0|or_3 (r_conj) cyclophosphamide_6\NN\0|when_5|are_56|in_65|,_116|for_118|,_129|patients_150 (r_nsubjpass) used_13\VBN\0|however_94|,_87|caution_85|is_77|._98 (l_dobj) patients_28\NNS\9898892|when_155|cyclophosphamide_150|are_94|in_85|,_34|for_32|,_21 (l_compound) sclerosis_27\NN\14204950|systemic_9
D003520_D006331 CID cyclophosphamide_6\NN\0|when_5|are_56|in_65|,_116|for_118|,_129|patients_150 (r_nsubjpass) used_13\VBN\0|however_94|,_87|caution_85|is_77|._98 (l_prep) in_14\IN\13603305|when_70|cyclophosphamide_65|are_9|,_51|for_53|,_64|patients_85 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) damage_21\NN\7296428|NONE_0
D018943_D012595 NONE anthracyclines_8\NNS\0|or_3 (r_conj) cyclophosphamide_6\NN\0|when_5|are_56|in_65|,_116|for_118|,_129|patients_150 (r_nsubjpass) used_13\VBN\0|however_94|,_87|caution_85|is_77|._98 (l_dobj) patients_28\NNS\9898892|when_155|cyclophosphamide_150|are_94|in_85|,_34|for_32|,_21 (l_compound) sclerosis_27\NN\14204950|systemic_9
D008942_D006331 CID mitoxantrone_11\NN\0|such_8 (r_pobj) as_10\IN\14622893|NONE_0 (r_prep) anthracyclines_8\NNS\0|or_3 (r_conj) cyclophosphamide_6\NN\0|when_5|are_56|in_65|,_116|for_118|,_129|patients_150 (r_nsubjpass) used_13\VBN\0|however_94|,_87|caution_85|is_77|._98 (l_prep) in_14\IN\13603305|when_70|cyclophosphamide_65|are_9|,_51|for_53|,_64|patients_85 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) damage_21\NN\7296428|NONE_0
D003520_D012595 NONE cyclophosphamide_6\NN\0|when_5|are_56|in_65|,_116|for_118|,_129|patients_150 (r_nsubjpass) used_13\VBN\0|however_94|,_87|caution_85|is_77|._98 (l_dobj) patients_28\NNS\9898892|when_155|cyclophosphamide_150|are_94|in_85|,_34|for_32|,_21 (l_compound) sclerosis_27\NN\14204950|systemic_9
16157917
C047781_C562694 NONE lamotrigine_0\NNP\0|NONE_0 (l_acl) associated_1\VBD\628491|._86 (l_prep) with_2\IN\0|NONE_0 (l_pobj) exacerbation_3\NN\374224|NONE_0 (l_prep) in_8\IN\13603305|or_21|myoclonus_10 (l_pobj) epilepsies_11\NNS\14085708|NONE_0
C047781_C562694 NONE lamotrigine_11\NNP\0|NONE_0 (r_pobj) with_10\IN\0|patients_62|experienced_23|._93 (r_prep) treated_9\VBN\2376958|NONE_0 (l_nsubj) patients_1\NNS\9898892|with_62|experienced_85|._155 (l_prep) with_2\IN\0|five_14 (l_pobj) epilepsies_5\NNS\14085708|NONE_0
C047781_C562694 NONE lamotrigine_11\NNP\0|NONE_0 (r_pobj) with_10\IN\0|patients_62|experienced_23|._93 (r_prep) treated_9\VBN\2376958|NONE_0 (l_nsubj) patients_1\NNS\9898892|with_62|experienced_85|._155 (l_prep) with_2\IN\0|five_14 (l_pobj) epilepsies_5\NNS\14085708|NONE_0 (l_appos) ige_7\NNP\15030481|idiopathic_35|generalized_24|(_1|)_3
C047781_C562694 NONE ltg_13\NNP\0|(_1|)_3 (r_appos) lamotrigine_11\NNP\0|NONE_0 (r_pobj) with_10\IN\0|patients_62|experienced_23|._93 (r_prep) treated_9\VBN\2376958|NONE_0 (l_nsubj) patients_1\NNS\9898892|with_62|experienced_85|._155 (l_prep) with_2\IN\0|five_14 (l_pobj) epilepsies_5\NNS\14085708|NONE_0
C047781_C562694 NONE ltg_13\NNP\0|(_1|)_3 (r_appos) lamotrigine_11\NNP\0|NONE_0 (r_pobj) with_10\IN\0|patients_62|experienced_23|._93 (r_prep) treated_9\VBN\2376958|NONE_0 (l_nsubj) patients_1\NNS\9898892|with_62|experienced_85|._155 (l_prep) with_2\IN\0|five_14 (l_pobj) epilepsies_5\NNS\14085708|NONE_0 (l_appos) ige_7\NNP\15030481|idiopathic_35|generalized_24|(_1|)_3
C047781_D009207 CID lamotrigine_0\NNP\0|NONE_0 (l_acl) associated_1\VBD\628491|._86 (l_prep) with_2\IN\0|NONE_0 (l_pobj) exacerbation_3\NN\374224|NONE_0 (l_conj) myoclonus_7\NN\14360459|or_11|in_10
C047781_D009207 CID lamotrigine_11\NNP\0|NONE_0 (r_pobj) with_10\IN\0|patients_62|experienced_23|._93 (r_prep) treated_9\VBN\2376958|NONE_0 (l_advcl) experienced_15\VBD\2108377|patients_85|with_23|._70 (l_dobj) exacerbation_16\NN\374224|NONE_0 (l_conj) appearance_20\NN\4723816|or_11 (l_prep) of_21\IN\0|de_19|novo_16 (l_pobj) jerks_23\NNS\10322238|NONE_0
C047781_D009207 CID lamotrigine_11\NNP\0|NONE_0 (r_pobj) with_10\IN\0|patients_62|experienced_23|._93 (r_prep) treated_9\VBN\2376958|NONE_0 (l_advcl) experienced_15\VBD\2108377|patients_85|with_23|._70 (l_dobj) exacerbation_16\NN\374224|NONE_0 (l_conj) appearance_20\NN\4723816|or_11 (l_prep) of_21\IN\0|de_19|novo_16 (l_pobj) jerks_23\NNS\10322238|NONE_0 (l_appos) mj_25\NNP\0|myoclonic_17|(_1|)_2
C047781_D009207 CID ltg_13\NNP\0|(_1|)_3 (r_appos) lamotrigine_11\NNP\0|NONE_0 (r_pobj) with_10\IN\0|patients_62|experienced_23|._93 (r_prep) treated_9\VBN\2376958|NONE_0 (l_advcl) experienced_15\VBD\2108377|patients_85|with_23|._70 (l_dobj) exacerbation_16\NN\374224|NONE_0 (l_conj) appearance_20\NN\4723816|or_11 (l_prep) of_21\IN\0|de_19|novo_16 (l_pobj) jerks_23\NNS\10322238|NONE_0
C047781_D009207 CID ltg_13\NNP\0|(_1|)_3 (r_appos) lamotrigine_11\NNP\0|NONE_0 (r_pobj) with_10\IN\0|patients_62|experienced_23|._93 (r_prep) treated_9\VBN\2376958|NONE_0 (l_advcl) experienced_15\VBD\2108377|patients_85|with_23|._70 (l_dobj) exacerbation_16\NN\374224|NONE_0 (l_conj) appearance_20\NN\4723816|or_11 (l_prep) of_21\IN\0|de_19|novo_16 (l_pobj) jerks_23\NNS\10322238|NONE_0 (l_appos) mj_25\NNP\0|myoclonic_17|(_1|)_2
C047781_D009207 CID ltg_4\NNP\0|in_19|,_2|mj_16|in_19|._85 (r_nsubj) exacerbated_5\VBD\126264|NONE_0 (l_dobj) mj_6\NNP\0|in_35|,_18|ltg_16|in_3|._69
C047781_D009207 CID ltg_3\NNP\0|NONE_0 (r_compound) dose_4\NN\3740161|when_9|was_5|by_19 (r_nsubjpass) decreased_6\VBN\169651|mj_33|._22 (r_advcl) disappeared_1\VBD\0|NONE_0 (l_nsubj) mj_0\NNP\0|decreased_33|._55
C047781_D009207 CID ltg_4\NNP\0|in_17|,_2|mj_16|in_19|,_54|with_56|._115 (r_nsubj) exacerbated_5\VBD\126264|NONE_0 (l_dobj) mj_6\NNP\0|in_33|,_18|ltg_16|in_3|,_38|with_40|._99
C047781_D009207 CID ltg_4\NNP\0|in_17|,_2|mj_16|in_19|,_54|with_56|._115 (r_nsubj) exacerbated_5\VBD\126264|NONE_0 (l_prep) with_15\IN\0|in_73|,_58|ltg_56|mj_40|in_37|,_2|._59 (l_pobj) status_17\NN\24720|NONE_0
C047781_D009207 CID ltg_22\NNP\0|NONE_0 (r_compound) withdrawal_23\NN\7206096|NONE_0 (r_pobj) after_21\IN\0|that_17|only_12 (r_prep) ceased_20\VBD\0|myoclonic_27 (r_relcl) status_17\NN\24720|NONE_0 (r_pobj) with_15\IN\0|in_73|,_58|ltg_56|mj_40|in_37|,_2|._59 (r_prep) exacerbated_5\VBD\126264|NONE_0 (l_dobj) mj_6\NNP\0|in_33|,_18|ltg_16|in_3|,_38|with_40|._99
C047781_D009207 CID ltg_22\NNP\0|NONE_0 (r_compound) withdrawal_23\NN\7206096|NONE_0 (r_pobj) after_21\IN\0|that_17|only_12 (r_prep) ceased_20\VBD\0|myoclonic_27 (r_relcl) status_17\NN\24720|NONE_0
12911170
D002939_D000744 NONE ciprofloxacin_0\NNP\2716866|-_13|nephritis_41|._82 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) nephritis_5\NN\14113228|ciprofloxacin_41|-_28|._41 (l_conj) anemia_9\NN\14189204|acute_54|interstitial_48|and_25
D002939_D000744 NONE ciprofloxacin_9\NNS\2716866|-_13 (r_npadvmod) induced_11\VBN\1627355|interstitial_8|and_31|anemia_56 (r_amod) nephritis_13\NN\14113228|NONE_0 (l_conj) anemia_17\NN\14189204|induced_56|interstitial_48|and_25
D002939_D000743 CID ciprofloxacin_0\NNP\2716866|has_14|been_18|with_34|._113 (r_nsubjpass) associated_3\VBN\628491|NONE_0 (l_prep) with_4\IN\0|ciprofloxacin_34|has_20|been_16|._79 (l_pobj) effects_7\NNS\13245626|NONE_0 (l_prep) including_8\VBG\0|several_21|side_13 (l_pobj) nephritis_10\NN\14113228|NONE_0 (l_conj) anemia_13\NN\14189204|interstitial_37|and_14
D002939_D009395 CID ciprofloxacin_0\NNP\2716866|-_13|nephritis_41|._82 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) nephritis_5\NN\14113228|ciprofloxacin_41|-_28|._41
D002939_D009395 CID ciprofloxacin_0\NNP\2716866|has_14|been_18|with_34|._113 (r_nsubjpass) associated_3\VBN\628491|NONE_0 (l_prep) with_4\IN\0|ciprofloxacin_34|has_20|been_16|._79 (l_pobj) effects_7\NNS\13245626|NONE_0 (l_prep) including_8\VBG\0|several_21|side_13 (l_pobj) nephritis_10\NN\14113228|NONE_0
D002939_D009395 CID ciprofloxacin_9\NNS\2716866|-_13 (r_npadvmod) induced_11\VBN\1627355|interstitial_8|and_31|anemia_56 (r_amod) nephritis_13\NN\14113228|NONE_0
D013256_D000743 NONE steroid_10\NN\14727670|NONE_0 (r_compound) therapy_11\NN\657604|NONE_0 (r_pobj) of_9\IN\0|NONE_0 (r_prep) initiation_8\NN\7450842|the_13|and_4 (r_conj) drug_6\NN\14778436|NONE_0 (r_dobj) stopping_4\VBG\3323703|NONE_0 (r_pcomp) after_3\IN\0|anemia_16|._57 (r_prep) improved_2\VBD\126264|NONE_0 (l_nsubj) anemia_1\NN\14189204|after_16|._73
2886572
D004837_D006973 CID epinephrine_7\NN\14807929|-_11 (r_npadvmod) induced_9\VBN\1627355|hypertensive_8 (r_amod) rats_11\NNS\2329401|NONE_0 (l_amod) hypertensive_10\JJ\10405694|induced_8
2322844
D015232_D006930 CID e2_1\NNP\0|effect_25|,_63|but_65|lasted_80 (r_nsubj) showed_2\VBD\2137132|NONE_0 (l_dobj) effect_5\NN\34213|e2_25|,_38|but_40|lasted_55 (l_amod) hyperalgesic_4\JJ\0|a_2|at_20
D015232_D006930 CID e2-induced_3\NNP\0|prostaglandin_14 (r_amod) hyperalgesia_4\NN\0|conversely_37|,_27|was_13|by_25|but_69|by_77|._106
D015232_D006930 CID e2_9\NNP\0|both_40|prostaglandin_35|and_18 (r_conj) d2_6\NN\0|that_24|hyperalgesia_30|,_61|but_63|in_67 (r_nsubj) exert_10\VBP\1158872|results_68|._60 (l_dobj) hyperalgesia_11\NN\0|that_54|d2_30|,_31|but_33|in_37
C053876_D006930 NONE ah6809_28\NN\0|not_7 (r_pobj) by_27\IN\0|effect_135|was_108|by_96|but_8|._47 (r_agent) blocked_7\VBN\1476483|NONE_0 (l_nsubjpass) effect_2\NN\34213|was_27|by_39|but_127|by_135|._182 (l_amod) hyperalgesic_1\JJ\0|the_4|of_20
C053876_D006930 NONE ah6809_8\NN\0|NONE_0 (r_pobj) by_7\IN\0|conversely_62|,_52|hyperalgesia_25|was_12|but_44|by_52|._81 (r_agent) blocked_6\VBN\1476483|NONE_0 (l_nsubjpass) hyperalgesia_4\NN\0|conversely_37|,_27|was_13|by_25|but_69|by_77|._106
D011453_D006930 NONE pg_10\NN\0|NONE_0 (r_pobj) of_8\IN\0|to_8 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) at_6\IN\14622893|a_22|hyperalgesic_20 (r_prep) effect_5\NN\34213|e2_25|,_38|but_40|lasted_55 (l_amod) hyperalgesic_4\JJ\0|a_2|at_20
D015237_D010146 NONE alpha_2\NN\6828818|effect_17|._41 (r_nsubj) had_3\VBD\0|NONE_0 (l_dobj) effect_5\NN\34213|alpha_17|._24 (l_prep) on_6\IN\0|little_14 (l_pobj) responses_8\NNS\11410625|NONE_0 (l_compound) pain_7\NN\14299637|NONE_0
D019342_D010146 NONE acid_21\NN\14818238|hot_21|and_11 (r_conj) plate_18\NN\2797881|writhing_22 (r_dobj) using_16\VBG\418025|NONE_0 (r_pcomp) by_15\IN\0|effects_107|were_15|._49 (r_prep) evaluated_14\VBN\670261|NONE_0 (l_nsubjpass) effects_1\NNS\13245626|were_92|by_107|._156 (l_prep) on_7\IN\0|the_60|of_48 (l_pobj) responses_9\NNS\11410625|NONE_0 (l_compound) pain_8\NN\14299637|in_15
D011453_D010146 NONE prostaglandins_6\NNS\5414534|NONE_0 (r_pobj) of_5\IN\0|intrathecal_27 (r_prep) administration_4\NN\1133281|NONE_0 (r_pobj) of_2\IN\0|the_12|on_48 (r_prep) effects_1\NNS\13245626|were_92|by_107|._156 (l_prep) on_7\IN\0|the_60|of_48 (l_pobj) responses_9\NNS\11410625|NONE_0 (l_compound) pain_8\NN\14299637|in_15
D015230_D006930 CID d2_1\NN\0|action_39|during_77|._117 (r_nsubj) had_10\VBD\0|NONE_0 (l_dobj) action_13\NN\30358|d2_39|during_38|._78 (l_amod) hyperalgesic_12\JJ\0|a_2|on_20
D015230_D006930 CID d2_32\NN\0|NONE_0 (r_pobj) of_30\IN\0|NONE_0 (r_prep) that_29\DT\0|NONE_0 (r_pobj) than_28\IN\0|shorter_19|(_11|30_8|)_2 (r_prep) min_26\NN\15154774|effect_28|._34 (r_dobj) lasted_20\VBD\2704349|e2_80|effect_55|,_17|but_15 (r_conj) showed_2\VBD\2137132|NONE_0 (l_dobj) effect_5\NN\34213|e2_25|,_38|but_40|lasted_55 (l_amod) hyperalgesic_4\JJ\0|a_2|at_20
D015230_D006930 CID d2_5\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_24|hyperalgesic_20 (r_prep) effect_2\NN\34213|was_27|by_39|but_127|by_135|._182 (l_amod) hyperalgesic_1\JJ\0|the_4|of_20
D015230_D006930 CID d2_6\NN\0|that_24|hyperalgesia_30|,_61|but_63|in_67 (r_nsubj) exert_10\VBP\1158872|results_68|._60 (l_dobj) hyperalgesia_11\NN\0|that_54|d2_30|,_31|but_33|in_37
6150641
D002927_D006402 NONE cimetidine_5\NN\14778019|NONE_0 (r_pobj) of_4\IN\0|high_11 (r_prep) doses_3\NNS\3740161|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) treatment_0\NN\654885|was_130|not_134|with_149|,_232|but_234|associated_261 (r_nsubjpass) associated_32\VBN\628491|NONE_0 (l_prep) with_33\IN\0|treatment_149|was_19|not_15|,_83|but_85|associated_112 (l_pobj) toxicity_37\NN\13576101|NONE_0
D002927_D006402 NONE cimetidine_60\NN\14778019|NONE_0 (r_compound) therapy_61\NN\657604|NONE_0 (r_pobj) with_59\IN\0|than_10 (r_prep) seen_58\VBN\2106506|a_50|lower_34|creatinine_22 (r_advcl) level_56\NN\4916342|NONE_0 (r_pobj) with_50\IN\0|therapy_23|was_15|._83 (r_prep) associated_49\VBN\628491|treatment_261|was_131|not_127|with_112|,_29|but_27 (r_conj) associated_32\VBN\628491|NONE_0 (l_prep) with_33\IN\0|treatment_149|was_19|not_15|,_83|but_85|associated_112 (l_pobj) toxicity_37\NN\13576101|NONE_0
D002927_D007172 CID cimetidine_12\NN\14778019|while_13|and_11|disappeared_42 (r_dobj) taking_11\VBG\37396|percent_65|changes_27|._103 (r_advcl) developed_5\VBD\1753788|NONE_0 (l_dobj) changes_7\NNS\7283608|percent_38|taking_27|._130 (l_conj) impotence_9\NN\4723816|breast_18|or_3
D002927_D007172 CID cimetidine_21\NN\14778019|when_5|was_11|by_24 (r_nsubjpass) replaced_23\VBN\1631072|in_59|changes_40 (r_advcl) disappeared_19\VBD\0|while_55|cimetidine_42|and_31 (r_conj) taking_11\VBG\37396|percent_65|changes_27|._103 (r_advcl) developed_5\VBD\1753788|NONE_0 (l_dobj) changes_7\NNS\7283608|percent_38|taking_27|._130 (l_conj) impotence_9\NN\4723816|breast_18|or_3
D002927_D056486 NONE cimetidine_5\NN\14778019|NONE_0 (r_pobj) of_4\IN\0|high_11 (r_prep) doses_3\NNS\3740161|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) treatment_0\NN\654885|was_130|not_134|with_149|,_232|but_234|associated_261 (r_nsubjpass) associated_32\VBN\628491|NONE_0 (l_prep) with_33\IN\0|treatment_149|was_19|not_15|,_83|but_85|associated_112 (l_pobj) toxicity_37\NN\13576101|NONE_0
D002927_D056486 NONE cimetidine_60\NN\14778019|NONE_0 (r_compound) therapy_61\NN\657604|NONE_0 (r_pobj) with_59\IN\0|than_10 (r_prep) seen_58\VBN\2106506|a_50|lower_34|creatinine_22 (r_advcl) level_56\NN\4916342|NONE_0 (r_pobj) with_50\IN\0|therapy_23|was_15|._83 (r_prep) associated_49\VBN\628491|treatment_261|was_131|not_127|with_112|,_29|but_27 (r_conj) associated_32\VBN\628491|NONE_0 (l_prep) with_33\IN\0|treatment_149|was_19|not_15|,_83|but_85|associated_112 (l_pobj) toxicity_37\NN\13576101|NONE_0
D003404_D006402 NONE creatinine_55\NN\0|a_28|lower_12|seen_22 (r_compound) level_56\NN\4916342|NONE_0 (r_pobj) with_50\IN\0|therapy_23|was_15|._83 (r_prep) associated_49\VBN\628491|treatment_261|was_131|not_127|with_112|,_29|but_27 (r_conj) associated_32\VBN\628491|NONE_0 (l_prep) with_33\IN\0|treatment_149|was_19|not_15|,_83|but_85|associated_112 (l_pobj) toxicity_37\NN\13576101|NONE_0
D003404_D056486 NONE creatinine_55\NN\0|a_28|lower_12|seen_22 (r_compound) level_56\NN\4916342|NONE_0 (r_pobj) with_50\IN\0|therapy_23|was_15|._83 (r_prep) associated_49\VBN\628491|treatment_261|was_131|not_127|with_112|,_29|but_27 (r_conj) associated_32\VBN\628491|NONE_0 (l_prep) with_33\IN\0|treatment_149|was_19|not_15|,_83|but_85|associated_112 (l_pobj) toxicity_37\NN\13576101|NONE_0
D011899_D056486 NONE ranitidine_18\NN\14778019|,_16|months_11|)_5|or_3 (r_conj) median_12\NN\6021761|(_19|months_8|;_2 (r_conj) cimetidine_5\NN\14778019|NONE_0 (r_pobj) of_4\IN\0|high_11 (r_prep) doses_3\NNS\3740161|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) treatment_0\NN\654885|was_130|not_134|with_149|,_232|but_234|associated_261 (r_nsubjpass) associated_32\VBN\628491|NONE_0 (l_prep) with_33\IN\0|treatment_149|was_19|not_15|,_83|but_85|associated_112 (l_pobj) toxicity_37\NN\13576101|NONE_0
D011899_D056486 NONE ranitidine_46\NN\14778019|NONE_0 (r_compound) therapy_47\NN\657604|was_8|with_23|._106 (r_nsubjpass) associated_49\VBN\628491|treatment_261|was_131|not_127|with_112|,_29|but_27 (r_conj) associated_32\VBN\628491|NONE_0 (l_prep) with_33\IN\0|treatment_149|was_19|not_15|,_83|but_85|associated_112 (l_pobj) toxicity_37\NN\13576101|NONE_0
D011899_D007172 NONE ranitidine_25\NN\14778019|NONE_0 (r_pobj) by_24\IN\0|when_29|cimetidine_24|was_13 (r_agent) replaced_23\VBN\1631072|in_59|changes_40 (r_advcl) disappeared_19\VBD\0|while_55|cimetidine_42|and_31 (r_conj) taking_11\VBG\37396|percent_65|changes_27|._103 (r_advcl) developed_5\VBD\1753788|NONE_0 (l_dobj) changes_7\NNS\7283608|percent_38|taking_27|._130 (l_conj) impotence_9\NN\4723816|breast_18|or_3
D011899_D006402 NONE ranitidine_18\NN\14778019|,_16|months_11|)_5|or_3 (r_conj) median_12\NN\6021761|(_19|months_8|;_2 (r_conj) cimetidine_5\NN\14778019|NONE_0 (r_pobj) of_4\IN\0|high_11 (r_prep) doses_3\NNS\3740161|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) treatment_0\NN\654885|was_130|not_134|with_149|,_232|but_234|associated_261 (r_nsubjpass) associated_32\VBN\628491|NONE_0 (l_prep) with_33\IN\0|treatment_149|was_19|not_15|,_83|but_85|associated_112 (l_pobj) toxicity_37\NN\13576101|NONE_0
D011899_D006402 NONE ranitidine_46\NN\14778019|NONE_0 (r_compound) therapy_47\NN\657604|was_8|with_23|._106 (r_nsubjpass) associated_49\VBN\628491|treatment_261|was_131|not_127|with_112|,_29|but_27 (r_conj) associated_32\VBN\628491|NONE_0 (l_prep) with_33\IN\0|treatment_149|was_19|not_15|,_83|but_85|associated_112 (l_pobj) toxicity_37\NN\13576101|NONE_0
15075188
D011692_D001201 CID pan_4\NNP\3101986|NONE_0 (r_compound) treatment_5\NN\654885|after_18|,_6|proteinuria_30 (r_nsubj) induced_6\VBD\1627355|,_48|excretion_75|._107 (r_advcl) decreased_12\VBD\169651|NONE_0 (l_dobj) excretion_15\NN\13466586|induced_75|,_27|._32 (l_conj) ascites_19\NNS\14204950|sodium_32|,_16|and_14
D012964_D001201 NONE sodium_14\NN\14625458|,_16|and_18|ascites_32 (r_compound) excretion_15\NN\13466586|induced_75|,_27|._32 (l_conj) ascites_19\NNS\14204950|sodium_32|,_16|and_14
D012964_D004487 NONE sodium_6\NN\14625458|and_17|edema_33 (r_compound) retention_7\NN\809465|NONE_0 (l_conj) edema_10\NN\14315192|sodium_33|and_16
D012964_D009404 NONE sodium_6\NN\14625458|and_17|edema_33 (r_compound) retention_7\NN\809465|NONE_0 (r_pobj) by_5\IN\0|syndrome_30|is_21|often_18|._41 (r_agent) accompanied_4\VBN\0|NONE_0 (l_nsubjpass) syndrome_1\NN\5870365|is_9|often_12|by_30|._71
D012964_D009404 NONE sodium_34\NN\14625458|the_4|associated_17 (r_compound) retention_35\NN\809465|NONE_0 (l_acl) associated_36\VBN\628491|the_21|sodium_17 (l_prep) with_37\IN\0|NONE_0 (l_pobj) syndrome_42\NN\5870365|NONE_0
D011692_D034141 CID pan_4\NNP\3101986|NONE_0 (r_compound) treatment_5\NN\654885|after_18|,_6|proteinuria_30 (r_nsubj) induced_6\VBD\1627355|,_48|excretion_75|._107 (l_dobj) proteinuria_8\NN\14299637|after_48|,_36|treatment_30 (l_appos) hypoalbuminemia_10\NN\0|significant_25|,_2
D012964_D011507 NONE sodium_14\NN\14625458|,_16|and_18|ascites_32 (r_compound) excretion_15\NN\13466586|induced_75|,_27|._32 (r_dobj) decreased_12\VBD\169651|NONE_0 (l_advcl) induced_6\VBD\1627355|,_48|excretion_75|._107 (l_dobj) proteinuria_8\NN\14299637|after_48|,_36|treatment_30
D012964_D034141 NONE sodium_14\NN\14625458|,_16|and_18|ascites_32 (r_compound) excretion_15\NN\13466586|induced_75|,_27|._32 (r_dobj) decreased_12\VBD\169651|NONE_0 (l_advcl) induced_6\VBD\1627355|,_48|excretion_75|._107 (l_dobj) proteinuria_8\NN\14299637|after_48|,_36|treatment_30 (l_appos) hypoalbuminemia_10\NN\0|significant_25|,_2
D011692_D009404 CID aminonucleoside_11\RB\0|-_15 (r_advmod) induced_13\VBN\1627355|puromycin_26|nephrotic_8|in_27 (r_amod) syndrome_15\NN\5870365|NONE_0
D011692_D009404 CID pan_38\NNP\3101986|-_3 (r_npadvmod) induced_40\VBN\1627355|nephrotic_8 (r_amod) syndrome_42\NN\5870365|NONE_0
D011692_D011507 CID pan_4\NNP\3101986|NONE_0 (r_compound) treatment_5\NN\654885|after_18|,_6|proteinuria_30 (r_nsubj) induced_6\VBD\1627355|,_48|excretion_75|._107 (l_dobj) proteinuria_8\NN\14299637|after_48|,_36|treatment_30
16006300
C019248_D006934 NONE pamidronate_0\JJ\0|NONE_0 (r_compound) treatment_1\NN\654885|is_10|with_24|,_63|in_70|._112 (r_nsubjpass) associated_3\VBN\628491|NONE_0 (l_prep) in_11\IN\13603305|treatment_70|is_60|with_46|,_7|._42 (l_pobj) cases_12\NNS\7283608|even_8 (l_prep) of_13\IN\0|NONE_0 (l_pobj) hypercalcemia_16\NN\14299637|NONE_0
D002118_D006934 NONE calcium_18\NN\14625458|(_17|>_8|and_25|review_29 (r_dobj) corrected_16\VBN\138508|we_98|data_60|._100 (r_parataxis) report_1\VBP\6470073|NONE_0 (l_dobj) data_6\NNS\7951464|we_38|corrected_60|._160 (l_prep) in_7\IN\13603305|the_33|clinical_29 (l_pobj) patients_9\NNS\9898892|NONE_0 (l_relcl) presented_11\VBD\2137132|3_15 (l_prep) with_12\IN\0|who_14 (l_pobj) hypercalcemia_14\NN\14299637|NONE_0
D002118_D006934 NONE calcium_18\NN\14625458|(_17|>_8|and_25|review_29 (r_dobj) corrected_16\VBN\138508|we_98|data_60|._100 (l_conj) review_28\VB\5733583|(_46|calcium_29|>_21|and_4 (l_dobj) literature_31\NN\6362953|NONE_0 (l_prep) on_32\IN\0|the_25|pertinent_21 (l_pobj) syndrome_36\NN\5870365|NONE_0
D002119_D064420 NONE carbonate_1\NN\15010703|:_18|syndrome_44|._100 (r_compound) toxicity_2\NN\13576101|NONE_0
C019248_D006996 CID pamidronate_10\JJ\0|NONE_0 (l_relcl) caused_22\VBD\1617192|patients_125|intravenously_50|mg_25|,_8|._26 (l_dobj) hypocalcemia_24\NN\14299637|which_20
C019248_D006996 CID pamidronate_0\JJ\0|NONE_0 (r_compound) treatment_1\NN\654885|is_10|with_24|,_63|in_70|._112 (r_nsubjpass) associated_3\VBN\628491|NONE_0 (l_prep) with_4\IN\0|treatment_24|is_14|,_39|in_46|._88 (l_pobj) risk_6\NN\14541044|NONE_0 (l_prep) for_7\IN\0|considerable_18 (l_pobj) hypocalcemia_8\NN\14299637|NONE_0
D002119_D006934 CID carbonate_1\NN\15010703|:_18|syndrome_44|._100 (r_compound) toxicity_2\NN\13576101|NONE_0 (l_appos) syndrome_9\NN\5870365|carbonate_44|:_26|._56
D002119_D006934 CID carbonate_6\NN\15010703|-_9 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) hypercalcemia_9\NN\14299637|NONE_0
D002119_D006934 CID carbonate_6\NN\15010703|-_9 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) hypercalcemia_9\NN\14299637|NONE_0 (r_pobj) with_4\IN\0|3_11 (r_prep) patients_3\NNS\9898892|to_14|and_54|gain_58|._129 (r_dobj) describe_1\VB\1001294|NONE_0 (l_conj) gain_11\VB\13576355|to_72|patients_58|and_4|._71 (l_dobj) insights_12\NNS\5710020|NONE_0 (l_prep) into_13\IN\0|NONE_0 (l_pobj) cause_15\NN\7323922|NONE_0 (l_prep) of_18\IN\0|the_25|and_15|management_11 (l_pobj) syndrome_23\NN\5870365|NONE_0
D002119_D006934 CID carbonate_23\NN\15010703|NONE_0 (r_pobj) of_19\IN\0|small_14|in_37 (r_prep) amounts_18\NNS\13329641|NONE_0 (r_pobj) by_16\IN\0|can_20|be_16 (r_agent) precipitated_15\VBN\1642924|syndrome_71|may_62|cause_46|and_11|._89 (r_conj) be_5\VB\14625458|NONE_0 (l_nsubj) syndrome_3\NN\5870365|may_9|cause_25|and_60|precipitated_71|._160
D002119_D006934 CID carbonate_23\NN\15010703|NONE_0 (r_pobj) of_19\IN\0|small_14|in_37 (r_prep) amounts_18\NNS\13329641|NONE_0 (r_pobj) by_16\IN\0|can_20|be_16 (r_agent) precipitated_15\VBN\1642924|syndrome_71|may_62|cause_46|and_11|._89 (r_conj) be_5\VB\14625458|NONE_0 (l_attr) cause_8\NN\7323922|syndrome_25|may_16|and_35|precipitated_46|._135 (l_prep) of_9\IN\0|a_15|common_13 (l_pobj) hypercalcemia_11\NN\14299637|NONE_0
D002118_D006996 NONE calcium_7\NN\14625458|the_17|higher_13|received_23 (r_compound) concentrations_8\NNS\4916342|NONE_0 (r_pobj) with_3\IN\0|the_15|2_11 (r_prep) patients_2\NNS\9898892|intravenously_75|mg_100|,_117|caused_125|._151 (r_nsubj) pamidronate_10\JJ\0|NONE_0 (l_relcl) caused_22\VBD\1617192|patients_125|intravenously_50|mg_25|,_8|._26 (l_dobj) hypocalcemia_24\NN\14299637|which_20
C097949_D000471 NONE d_27\JJ\15089472|NONE_0 (r_compound) concentrations_28\NNS\4916342|related_45|,_30|and_28 (r_conj) peptide_23\NN\14724264|low_43|parathyroid_39|(_19|pth_18|)_15|,_14 (r_conj) hormone_15\NN\5404728|relative_50|metabolic_41|,_22|and_20 (r_conj) alkalosis_10\NN\14204950|acute_46|renal_40|,_21
C097949_D058186 NONE d_27\JJ\15089472|NONE_0 (r_compound) concentrations_28\NNS\4916342|related_45|,_30|and_28 (r_conj) peptide_23\NN\14724264|low_43|parathyroid_39|(_19|pth_18|)_15|,_14 (r_conj) hormone_15\NN\5404728|relative_50|metabolic_41|,_22|and_20 (r_conj) alkalosis_10\NN\14204950|acute_46|renal_40|,_21 (r_conj) insufficiency_6\NN\14462946|patients_25|._143
3115150
D015760_D009127 CID alfentanil_3\NN\0|-_10 (r_npadvmod) induced_5\VBN\1627355|muscle_8 (r_amod) rigidity_7\NN\5023233|pretreatment_48|._8
D015760_D009127 CID alfentanil_29\NN\0|pretreatment_194|significantly_104|rigidity_68|._10 (r_advcl) attenuated_14\VBD\224901|NONE_0 (l_dobj) rigidity_17\NN\5023233|pretreatment_126|significantly_36|alfentanil_68|._78
D015760_D009127 CID alfentanil_15\NNS\0|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) produced_13\VBN\1617192|the_13 (r_acl) rigidity_12\NN\5023233|to_31|significantly_28
D015760_D009127 CID alfentanil_19\NNS\0|NONE_0 (r_pobj) by_18\IN\0|despite_106|,_75|animals_73 (r_agent) followed_17\VBN\1835496|motionless_28|._133 (l_prep) despite_0\IN\7501545|,_31|animals_33|by_106 (l_pobj) absence_2\NN\14449405|NONE_0 (l_prep) of_3\IN\0|the_12 (l_pobj) rigidity_4\NN\5023233|NONE_0
D015760_D009127 CID alfentanil_35\NN\0|alone_11 (r_advmod) receiving_34\VBG\2210855|NONE_0 (r_acl) animals_33\NNS\4475|than_10 (r_nsubj) were_32\VBD\0|less_41|to_25 (r_advcl) responsive_27\JJ\0|,_20|,_11|and_9 (r_conj) flaccid_23\JJ\0|NONE_0 (r_conj) motionless_21\JJ\0|followed_28|._105 (r_acomp) were_20\VBD\0|NONE_0 (l_csubj) followed_17\VBN\1835496|motionless_28|._133 (l_prep) despite_0\IN\7501545|,_31|animals_33|by_106 (l_pobj) absence_2\NN\14449405|NONE_0 (l_prep) of_3\IN\0|the_12 (l_pobj) rigidity_4\NN\5023233|NONE_0
D007650_D009127 NONE ketanserin_0\JJ\0|NONE_0 (r_compound) pretreatment_1\NN\0|rigidity_48|._56 (r_nsubj) reverses_2\VBZ\13854649|NONE_0 (l_dobj) rigidity_7\NN\5023233|pretreatment_48|._8
D007650_D009127 NONE ketanserin_3\NN\0|NONE_0 (r_pobj) with_2\IN\0|systemic_22|,_15|antagonist_65|,_75 (r_prep) pretreatment_1\NN\0|significantly_90|rigidity_126|alfentanil_194|._204 (r_nsubj) attenuated_14\VBD\224901|NONE_0 (l_dobj) rigidity_17\NN\5023233|pretreatment_126|significantly_36|alfentanil_68|._78
D007650_D009127 NONE ketanserin_9\JJ\0|that_14 (r_dobj) received_8\VBD\2210855|mg/kg_39 (r_relcl) animals_6\NNS\4475|despite_33|,_2|by_73 (r_nsubj) followed_17\VBN\1835496|motionless_28|._133 (l_prep) despite_0\IN\7501545|,_31|animals_33|by_106 (l_pobj) absence_2\NN\14449405|NONE_0 (l_prep) of_3\IN\0|the_12 (l_pobj) rigidity_4\NN\5023233|NONE_0
D012701_D002318 NONE serotonin_3\NN\14807737|NONE_0 (r_compound) antagonists_4\NNS\7846|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) pretreatment_0\NN\0|may_47|useful_65|,_110|be_142|._249 (r_nsubj) be_6\VB\14625458|NONE_0 (l_advcl) be_20\VB\14625458|pretreatment_142|may_95|useful_77|,_32|._107 (l_xcomp) assess_23\VB\5220461|although_46|studies_29|will_21|necessary_13 (l_dobj) interaction_25\NN\37396|to_14 (l_prep) of_26\IN\0|the_16 (l_pobj) cns_29\NNP\5237227|NONE_0 (l_conj) cardiovascular_31\JJ\0|enhanced_14|,_2 (l_conj) depression_35\NN\14373582|,_18|and_16
D002707_D009127 NONE chlordiazepoxide_0\VB\2830852|influence_65|._110 (r_nsubj) failed_7\VBD\0|NONE_0 (l_xcomp) influence_10\VB\5190804|chlordiazepoxide_65|._45 (l_dobj) rigidity_12\NN\5023233|to_31|significantly_28
D012701_D009127 NONE serotonin_9\NN\14807737|a_29|specific_16|receptor_10 (r_compound) antagonist_11\NN\7846|systemic_87|with_65|,_50|,_10 (r_appos) pretreatment_1\NN\0|significantly_90|rigidity_126|alfentanil_194|._204 (r_nsubj) attenuated_14\VBD\224901|NONE_0 (l_dobj) rigidity_17\NN\5023233|pretreatment_126|significantly_36|alfentanil_68|._78
D012701_D009127 NONE serotonin_3\NN\14807737|NONE_0 (r_compound) antagonists_4\NNS\7846|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) pretreatment_0\NN\0|may_47|useful_65|,_110|be_142|._249 (r_nsubj) be_6\VB\14625458|NONE_0 (l_acomp) useful_8\JJ\0|pretreatment_65|may_18|,_45|be_77|._184 (l_prep) in_9\IN\13603305|clinically_18 (l_pcomp) attenuating_10\VBG\224901|NONE_0 (l_dobj) rigidity_14\NN\5023233|NONE_0
D012701_D012131 NONE serotonin_3\NN\14807737|NONE_0 (r_compound) antagonists_4\NNS\7846|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) pretreatment_0\NN\0|may_47|useful_65|,_110|be_142|._249 (r_nsubj) be_6\VB\14625458|NONE_0 (l_advcl) be_20\VB\14625458|pretreatment_142|may_95|useful_77|,_32|._107 (l_xcomp) assess_23\VB\5220461|although_46|studies_29|will_21|necessary_13 (l_dobj) interaction_25\NN\37396|to_14 (l_prep) of_26\IN\0|the_16 (l_pobj) cns_29\NNP\5237227|NONE_0 (l_conj) cardiovascular_31\JJ\0|enhanced_14|,_2 (l_conj) depression_35\NN\14373582|,_18|and_16
18513945
D010121_D007022 CID oxytocin_0\NN\5407119|uterotonic_28|._128 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) uterotonic_5\NN\0|oxytocin_28|._100 (l_relcl) cause_8\VB\7323922|a_36|used_25 (l_dobj) hypotension_13\NN\14057371|that_42|can_37|,_11|given_31
D010121_D007022 CID oxytocin_0\NN\5407119|-_8 (r_npadvmod) induced_2\VBN\1627355|at_20 (r_amod) hypotension_3\NN\14057371|may_33|be_37|incorrectly_40|to_63|._76
D010121_D007022 CID oxytocin_4\NN\5407119|NONE_0 (r_pobj) to_3\IN\0|NONE_0 (r_prep) response_2\NN\11410625|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) hypotension_0\NN\14057371|was_36|with_51|._174
D010121_D020521 NONE oxytocin_4\NN\5407119|NONE_0 (r_pobj) to_3\IN\0|NONE_0 (r_prep) response_2\NN\11410625|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) hypotension_0\NN\14057371|was_36|with_51|._174 (r_nsubjpass) associated_6\VBN\628491|NONE_0 (l_prep) with_7\IN\0|hypotension_51|was_15|._123 (l_pobj) decrease_9\NN\7296428|NONE_0 (l_conj) increase_17\NN\13576355|a_62|in_51|and_19 (l_prep) in_18\IN\13603305|a_24|compensatory_22 (l_pobj) volume_20\NN\33615|NONE_0 (l_compound) stroke_19\NN\556313|,_13|rate_21
D010121_D006473 NONE oxytocin_0\NN\5407119|-_8 (r_npadvmod) induced_2\VBN\1627355|at_20 (r_amod) hypotension_3\NN\14057371|may_33|be_37|incorrectly_40|to_63|._76 (r_nsubjpass) attributed_10\VBN\670261|NONE_0 (l_prep) to_11\IN\0|hypotension_63|may_30|be_26|incorrectly_23|._13 (l_pobj) loss_13\NN\13252973|NONE_0
2722224
D006854_D006973 CID hydrocortisone_0\NNP\14751417|-_14|hypertension_23|:_45|responsiveness_55|._94 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) hypertension_3\NN\14057371|hydrocortisone_23|-_9|:_22|responsiveness_32|._71
D006854_D006973 CID hydrocortisone_7\NN\14751417|NONE_0 (r_pobj) with_6\IN\0|blood_15 (r_prep) pressure_5\NN\11419404|NONE_0
D006854_D016534 NONE hydrocortisone_7\NN\14751417|NONE_0 (r_pobj) with_6\IN\0|blood_15 (r_prep) pressure_5\NN\11419404|NONE_0 (r_dobj) resting_3\VBG\2604760|NONE_0 (r_pcomp) in_2\IN\13603305|the_9 (r_prep) rise_1\NN\7324673|is_51|with_65|._140 (r_nsubjpass) associated_9\VBN\628491|NONE_0 (l_prep) with_10\IN\0|rise_65|is_14|._75 (l_pobj) output_14\NN\4007894|NONE_0
16720068
D000525_D014202 NONE alprazolam_7\NN\2830852|NONE_0 (r_compound) treatment_8\NN\654885|and_15 (r_conj) paroxetine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_13|10th_9 (r_prep) day_3\NN\15154774|NONE_0 (r_pobj) on_0\IN\0|,_54|patient_60|retardation_97|._165 (r_prep) exhibited_12\VBD\2632167|NONE_0 (l_dobj) retardation_15\NN\7296428|on_97|,_43|patient_37|._68 (l_conj) disorientation_17\NN\5896733|marked_32|psychomotor_25|,_2 (l_conj) rigidity_22\NN\5023233|,_20|and_18 (l_prep) with_23\IN\0|severe_23|muscle_16 (l_pobj) tremors_24\NNS\345926|NONE_0
D000525_D009127 NONE alprazolam_7\NN\2830852|NONE_0 (r_compound) treatment_8\NN\654885|and_15 (r_conj) paroxetine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_13|10th_9 (r_prep) day_3\NN\15154774|NONE_0 (r_pobj) on_0\IN\0|,_54|patient_60|retardation_97|._165 (r_prep) exhibited_12\VBD\2632167|NONE_0 (l_dobj) retardation_15\NN\7296428|on_97|,_43|patient_37|._68 (l_conj) disorientation_17\NN\5896733|marked_32|psychomotor_25|,_2 (l_conj) rigidity_22\NN\5023233|,_20|and_18
D017374_D009127 NONE paroxetine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_13|10th_9 (r_prep) day_3\NN\15154774|NONE_0 (r_pobj) on_0\IN\0|,_54|patient_60|retardation_97|._165 (r_prep) exhibited_12\VBD\2632167|NONE_0 (l_dobj) retardation_15\NN\7296428|on_97|,_43|patient_37|._68 (l_conj) disorientation_17\NN\5896733|marked_32|psychomotor_25|,_2 (l_conj) rigidity_22\NN\5023233|,_20|and_18
D017374_D009459 CID paroxetine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|concomitant_22 (r_prep) treatment_7\NN\654885|NONE_0 (r_pobj) to_5\IN\0|NONE_0 (r_prep) related_4\VBN\628491|possible_40|neuroleptic_31|malignant_19|._63 (r_acl) syndrome_3\NN\5870365|NONE_0
D017374_D009459 CID paroxetine_24\NN\0|NONE_0 (r_pobj) after_22\IN\0|that_33|symptoms_19|can_10 (r_prep) occur_21\VB\0|thus_46 (r_ccomp) demonstrating_14\VBG\2137132|patient_78|with_60|,_7|._97 (r_advcl) presented_2\VBN\2137132|NONE_0 (l_prep) with_3\IN\0|patient_18|,_53|demonstrating_60|._157 (l_pobj) symptoms_4\NNS\5823932|NONE_0 (l_prep) of_5\IN\0|NONE_0 (l_pobj) syndrome_8\NN\5870365|NONE_0
D017374_D009459 CID paroxetine_24\NN\0|NONE_0 (r_pobj) after_22\IN\0|that_33|symptoms_19|can_10 (r_prep) occur_21\VB\0|thus_46 (r_ccomp) demonstrating_14\VBG\2137132|patient_78|with_60|,_7|._97 (r_advcl) presented_2\VBN\2137132|NONE_0 (l_prep) with_3\IN\0|patient_18|,_53|demonstrating_60|._157 (l_pobj) symptoms_4\NNS\5823932|NONE_0 (l_prep) of_5\IN\0|NONE_0 (l_pobj) syndrome_8\NN\5870365|NONE_0 (l_appos) nms_10\NNP\13649268|neuroleptic_32|malignant_20
D017374_D009459 CID paroxetine_24\NN\0|NONE_0 (r_pobj) after_22\IN\0|that_33|symptoms_19|can_10 (r_prep) occur_21\VB\0|thus_46 (l_nsubj) symptoms_19\NNS\5823932|that_14|can_9|after_19 (l_amod) like_18\JJ\5839024|NONE_0 (l_npadvmod) nms_16\NNP\13649268|-_3
D000525_D009459 CID alprazolam_11\NN\2830852|and_4 (r_conj) paroxetine_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|concomitant_22 (r_prep) treatment_7\NN\654885|NONE_0 (r_pobj) to_5\IN\0|NONE_0 (r_prep) related_4\VBN\628491|possible_40|neuroleptic_31|malignant_19|._63 (r_acl) syndrome_3\NN\5870365|NONE_0
D000525_D009459 CID alprazolam_26\NN\2830852|NONE_0 (r_compound) treatment_27\NN\654885|combined_35|and_15 (r_conj) paroxetine_24\NN\0|NONE_0 (r_pobj) after_22\IN\0|that_33|symptoms_19|can_10 (r_prep) occur_21\VB\0|thus_46 (r_ccomp) demonstrating_14\VBG\2137132|patient_78|with_60|,_7|._97 (r_advcl) presented_2\VBN\2137132|NONE_0 (l_prep) with_3\IN\0|patient_18|,_53|demonstrating_60|._157 (l_pobj) symptoms_4\NNS\5823932|NONE_0 (l_prep) of_5\IN\0|NONE_0 (l_pobj) syndrome_8\NN\5870365|NONE_0
D000525_D009459 CID alprazolam_26\NN\2830852|NONE_0 (r_compound) treatment_27\NN\654885|combined_35|and_15 (r_conj) paroxetine_24\NN\0|NONE_0 (r_pobj) after_22\IN\0|that_33|symptoms_19|can_10 (r_prep) occur_21\VB\0|thus_46 (r_ccomp) demonstrating_14\VBG\2137132|patient_78|with_60|,_7|._97 (r_advcl) presented_2\VBN\2137132|NONE_0 (l_prep) with_3\IN\0|patient_18|,_53|demonstrating_60|._157 (l_pobj) symptoms_4\NNS\5823932|NONE_0 (l_prep) of_5\IN\0|NONE_0 (l_pobj) syndrome_8\NN\5870365|NONE_0 (l_appos) nms_10\NNP\13649268|neuroleptic_32|malignant_20
D000525_D009459 CID alprazolam_26\NN\2830852|NONE_0 (r_compound) treatment_27\NN\654885|combined_35|and_15 (r_conj) paroxetine_24\NN\0|NONE_0 (r_pobj) after_22\IN\0|that_33|symptoms_19|can_10 (r_prep) occur_21\VB\0|thus_46 (l_nsubj) symptoms_19\NNS\5823932|that_14|can_9|after_19 (l_amod) like_18\JJ\5839024|NONE_0 (l_npadvmod) nms_16\NNP\13649268|-_3
D017374_D011596 NONE paroxetine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_13|10th_9 (r_prep) day_3\NN\15154774|NONE_0 (r_pobj) on_0\IN\0|,_54|patient_60|retardation_97|._165 (r_prep) exhibited_12\VBD\2632167|NONE_0 (l_dobj) retardation_15\NN\7296428|on_97|,_43|patient_37|._68
D017374_D014202 NONE paroxetine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_13|10th_9 (r_prep) day_3\NN\15154774|NONE_0 (r_pobj) on_0\IN\0|,_54|patient_60|retardation_97|._165 (r_prep) exhibited_12\VBD\2632167|NONE_0 (l_dobj) retardation_15\NN\7296428|on_97|,_43|patient_37|._68 (l_conj) disorientation_17\NN\5896733|marked_32|psychomotor_25|,_2 (l_conj) rigidity_22\NN\5023233|,_20|and_18 (l_prep) with_23\IN\0|severe_23|muscle_16 (l_pobj) tremors_24\NNS\345926|NONE_0
D000525_D011596 NONE alprazolam_7\NN\2830852|NONE_0 (r_compound) treatment_8\NN\654885|and_15 (r_conj) paroxetine_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_13|10th_9 (r_prep) day_3\NN\15154774|NONE_0 (r_pobj) on_0\IN\0|,_54|patient_60|retardation_97|._165 (r_prep) exhibited_12\VBD\2632167|NONE_0 (l_dobj) retardation_15\NN\7296428|on_97|,_43|patient_37|._68
19721134
D010862_D001145 NONE pilocarpine_9\NN\14712692|NONE_0 (r_pobj) of_8\IN\0|the_12 (r_prep) effects_7\NNS\13245626|to_16|and_23|explore_27 (r_dobj) evaluate_5\VB\670261|study_22|was_16|._161 (l_conj) explore_11\VB\789138|to_43|effects_27|and_4 (l_conj) using_17\VBG\418025|mechanism_11|,_2 (l_dobj) rat_22\NN\2329401|NONE_0 (l_conj) models_30\NNS\5888929|both_69|induced_54|and_42 (l_compound) arrhythmia_29\NN\14103288|induced_19
D010862_D001145 NONE pilocarpine_5\NN\14712692|that_5|delayed_26|of_40 (r_amod) onset_8\NN\7325190|data_51 (l_prep) of_9\IN\0|that_45|pilocarpine_40|delayed_14 (l_pobj) arrhythmias_10\NNS\14103288|NONE_0
D010862_D001145 NONE pilocarpine_5\NN\14712692|that_5|delayed_26|of_40 (r_amod) onset_8\NN\7325190|data_51 (r_dobj) showed_3\VBD\2137132|,_66|course_87|,_137|score_158|._231 (r_ccomp) decreased_12\VBD\169651|NONE_0 (l_npadvmod) score_24\NN\5736149|showed_158|,_92|course_71|,_21|._73 (l_compound) arrhythmia_23\NN\14103288|reduced_8|,_16|and_18|increased_22
D010862_D001145 NONE pilocarpine_5\NN\14712692|that_5|delayed_26|of_40 (r_amod) onset_8\NN\7325190|data_51 (r_dobj) showed_3\VBD\2137132|,_66|course_87|,_137|score_158|._231 (r_ccomp) decreased_12\VBD\169651|NONE_0 (l_npadvmod) score_24\NN\5736149|showed_158|,_92|course_71|,_21|._73 (l_conj) increased_27\VBD\169651|reduced_30|arrhythmia_22|,_6|and_4 (l_dobj) time_30\NN\7308889|NONE_0 (l_prep) of_31\IN\0|the_18|survival_14 (l_pobj) rats_33\NNS\2329401|NONE_0 (l_amod) arrhythmic_32\JJ\0|and_16|pigs_27
D010862_D001145 NONE pilocarpine_4\NN\14712692|that_5|actions_36 (r_nsubj) produced_5\VBD\1617192|data_30|._210 (l_dobj) actions_7\NNS\30358|that_41|pilocarpine_36 (l_prep) on_8\IN\0|antiarrhythmic_23 (l_pobj) models_14\NNS\5888929|NONE_0 (l_nmod) rat_10\NN\2329401|pig_15|induced_26 (l_amod) arrhythmic_9\JJ\0|and_15
D010042_D001145 CID ouabain_24\NN\0|-_7 (r_npadvmod) induced_26\VBN\1627355|arrhythmia_19 (r_amod) models_30\NNS\5888929|both_69|induced_54|and_42 (l_compound) arrhythmia_29\NN\14103288|induced_19
D010042_D001145 CID ouabain_19\RB\0|or_3 (r_conj) aconitine_17\NN\0|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|rat_26|pig_11 (r_acl) models_14\NNS\5888929|NONE_0 (l_nmod) rat_10\NN\2329401|pig_15|induced_26 (l_amod) arrhythmic_9\JJ\0|and_15
D010862_D014693 NONE pilocarpine_5\NN\14712692|that_5|delayed_26|of_40 (r_amod) onset_8\NN\7325190|data_51 (r_dobj) showed_3\VBD\2137132|,_66|course_87|,_137|score_158|._231 (r_ccomp) decreased_12\VBD\169651|NONE_0 (l_dobj) course_15\NN\883297|showed_87|,_21|,_50|score_71|._144 (l_prep) of_16\IN\0|the_16|time_12 (l_pobj) tachycardia_18\NN\14110674|NONE_0 (l_conj) fibrillation_20\NN\14361664|ventricular_28|and_4
D010862_D017180 NONE pilocarpine_5\NN\14712692|that_5|delayed_26|of_40 (r_amod) onset_8\NN\7325190|data_51 (r_dobj) showed_3\VBD\2137132|,_66|course_87|,_137|score_158|._231 (r_ccomp) decreased_12\VBD\169651|NONE_0 (l_dobj) course_15\NN\883297|showed_87|,_21|,_50|score_71|._144 (l_prep) of_16\IN\0|the_16|time_12 (l_pobj) tachycardia_18\NN\14110674|NONE_0 (l_conj) fibrillation_20\NN\14361664|ventricular_28|and_4
D000157_D001145 CID aconitine_19\NN\0|-_9 (r_npadvmod) induced_21\VBN\1627355|both_15|and_12|models_54 (r_amod) rat_22\NN\2329401|NONE_0 (l_conj) models_30\NNS\5888929|both_69|induced_54|and_42 (l_compound) arrhythmia_29\NN\14103288|induced_19
D000157_D001145 CID aconitine_17\NN\0|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|rat_26|pig_11 (r_acl) models_14\NNS\5888929|NONE_0 (l_nmod) rat_10\NN\2329401|pig_15|induced_26 (l_amod) arrhythmic_9\JJ\0|and_15
D002118_D001145 NONE ca(2_34\NNP\0|NONE_0 (r_pobj) of_33\IN\0|the_16 (r_prep) improvement_32\NN\7359599|NONE_0 (r_pobj) to_30\IN\0|mechanism_25|may_15|be_11 (r_prep) related_29\VBN\628491|the_45 (r_relcl) cardiac_23\JJ\0|NONE_0 (r_dobj) stimulating_21\VBG\137313|NONE_0 (r_pcomp) via_20\IN\0|NONE_0 (r_prep) ouabain_19\RB\0|or_3 (r_conj) aconitine_17\NN\0|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|rat_26|pig_11 (r_acl) models_14\NNS\5888929|NONE_0 (l_nmod) rat_10\NN\2329401|pig_15|induced_26 (l_amod) arrhythmic_9\JJ\0|and_15
21294084
D010406_D004827 NONE penicillin_12\NN\2716866|-_11 (r_npadvmod) induced_14\VBN\1627355|epilepsy_8|in_23 (r_amod) model_16\NN\5888929|NONE_0 (r_pobj) in_11\IN\13603305|cortical_30|epileptic_21 (r_prep) discharges_10\NNS\7283608|NONE_0 (l_amod) epileptic_9\JJ\10595647|cortical_9|in_21
D010406_D004827 NONE penicillin_12\NN\2716866|-_11 (r_npadvmod) induced_14\VBN\1627355|epilepsy_8|in_23 (r_amod) model_16\NN\5888929|NONE_0 (l_compound) epilepsy_15\NN\14085708|induced_8|in_15
D010406_D004827 NONE penicillin_17\NN\2716866|-_10 (r_npadvmod) induced_19\VBN\1627355|epilepsy_8 (r_amod) model_21\NN\5888929|NONE_0 (r_pobj) in_16\IN\13603305|cortical_28|epileptic_19 (r_prep) activity_15\NN\30358|NONE_0 (l_amod) epileptic_14\JJ\10595647|cortical_9|in_19
D010406_D004827 NONE penicillin_17\NN\2716866|-_10 (r_npadvmod) induced_19\VBN\1627355|epilepsy_8 (r_amod) model_21\NN\5888929|NONE_0 (l_compound) epilepsy_20\NN\14085708|induced_8
D010406_D004827 NONE penicillin_7\NN\2716866|-_10 (r_npadvmod) induced_9\VBN\1627355|the_21|acute_17|cortical_8|epileptic_17|independent_36 (r_amod) activity_12\NN\30358|dbs_63|._44 (l_amod) epileptic_11\JJ\10595647|the_38|acute_34|induced_17|cortical_9|independent_19
14742097
D020280_D020018 CID sertraline_8\NN\4169152|either_19|,_2 (r_conj) fluoxetine_6\NN\4169152|NONE_0 (r_dobj) receiving_4\VBG\2210855|nineteen_38|dysfunctional_20 (r_acl) women_3\NNS\9605289|in_74|._261 (l_amod) dysfunctional_2\JJ\0|nineteen_18|receiving_20
D004809_D020018 NONE ephedrine_10\NN\14712692|NONE_0 (r_pobj) of_9\IN\0|a_50|randomized_48|,_38|controlled_28|,_18|crossover_16|for_13|._55 (r_prep) study_8\NN\635850|NONE_0 (l_prep) for_11\IN\0|a_63|randomized_61|,_51|controlled_41|,_31|crossover_29|of_13|._42 (l_pobj) dysfunction_17\NN\14204950|NONE_0
D004809_D020018 NONE ephedrine_9\NN\14712692|whether_8|,_104|effects_121 (r_nsubj) has_28\VBZ\13888491|to_127 (l_dobj) effects_30\NNS\13245626|whether_129|ephedrine_121|,_17 (l_prep) in_31\IN\13603305|beneficial_19 (l_pcomp) reversing_32\VBG\109660|NONE_0 (l_dobj) dysfunction_37\NN\14204950|NONE_0
D004809_D020018 NONE ephedrine_35\NN\14712692|NONE_0 (r_pobj) of_34\IN\0|the_12|mg_17|on_21 (r_prep) effects_33\NNS\13245626|NONE_0 (r_pobj) of_31\IN\0|an_66|week_57|,_53|blind_44|,_39|controlled_29|,_19|cross_17 (r_prep) study_30\NN\635850|NONE_0 (r_pobj) in_13\IN\13603305|women_74|._187 (r_prep) participated_12\VBD\2367363|NONE_0 (l_nsubj) women_3\NNS\9605289|in_74|._261 (l_amod) dysfunctional_2\JJ\0|nineteen_18|receiving_20
D005473_D020018 CID fluoxetine_6\NN\4169152|NONE_0 (r_dobj) receiving_4\VBG\2210855|nineteen_38|dysfunctional_20 (r_acl) women_3\NNS\9605289|in_74|._261 (l_amod) dysfunctional_2\JJ\0|nineteen_18|receiving_20
D017374_D020018 CID paroxetine_11\NN\0|,_5|or_3 (r_conj) sertraline_8\NN\4169152|either_19|,_2 (r_conj) fluoxetine_6\NN\4169152|NONE_0 (r_dobj) receiving_4\VBG\2210855|nineteen_38|dysfunctional_20 (r_acl) women_3\NNS\9605289|in_74|._261 (l_amod) dysfunctional_2\JJ\0|nineteen_18|receiving_20
11868798
D013148_D009503 NONE spironolactone_9\NN\2721160|NONE_0 (r_pobj) of_8\IN\0|the_12|reduce_21 (r_prep) ability_7\NN\4723816|to_14 (l_acl) reduce_11\VB\441445|the_33|of_21 (l_conj) prevent_16\VB\0|to_40|requirements_20|and_7 (l_dobj) hypokalemia_17\NN\14299637|to_11 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_amod) neutropenic_19\JJ\0|on_21
D013148_D009503 NONE spironolactone_4\NN\2721160|that_5|can_15|requirements_36|and_49|prevent_53 (r_nsubj) reduce_6\VB\441445|study_37|._129 (l_conj) prevent_10\VBP\0|that_58|spironolactone_53|can_38|requirements_17|and_4 (l_prep) by_12\IN\0|hypokalemia_12 (l_pcomp) reducing_13\VBG\13447361|NONE_0 (l_dobj) loss_16\NN\13252973|NONE_0 (l_prep) in_17\IN\13603305|urinary_23|potassium_15 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_amod) neutropenic_18\JJ\0|on_21
D011188_D007008 NONE potassium_12\NN\14625458|NONE_0 (r_compound) requirements_13\NNS\1129920|to_20|and_13|prevent_20 (r_dobj) reduce_11\VB\441445|the_33|of_21 (l_conj) prevent_16\VB\0|to_40|requirements_20|and_7 (l_dobj) hypokalemia_17\NN\14299637|to_11
D011188_D007008 NONE potassium_7\NN\14625458|NONE_0 (r_compound) requirements_8\NNS\1129920|that_41|spironolactone_36|can_21|and_13|prevent_17 (r_dobj) reduce_6\VB\441445|study_37|._129 (l_conj) prevent_10\VBP\0|that_58|spironolactone_53|can_38|requirements_17|and_4 (l_dobj) hypokalemia_11\NN\14299637|by_12
D011188_D007008 NONE potassium_15\NN\14625458|urinary_8|in_15 (r_compound) loss_16\NN\13252973|NONE_0 (r_dobj) reducing_13\VBG\13447361|NONE_0 (r_pcomp) by_12\IN\0|hypokalemia_12 (r_prep) prevent_10\VBP\0|that_58|spironolactone_53|can_38|requirements_17|and_4 (l_dobj) hypokalemia_11\NN\14299637|by_12
D013148_D007008 NONE spironolactone_0\NNP\2721160|:_14|it_19|drug_30|?_110 (r_npadvmod) is_2\VBZ\0|NONE_0 (l_attr) drug_6\NN\14778436|spironolactone_30|:_16|it_11|?_80 (l_prep) for_7\IN\0|a_13|novel_11 (l_pobj) prevention_9\NN\1073995|NONE_0 (l_prep) of_10\IN\0|the_15 (l_pobj) hypokalemia_15\NN\14299637|NONE_0
D013148_D007008 NONE spironolactone_9\NN\2721160|NONE_0 (r_pobj) of_8\IN\0|the_12|reduce_21 (r_prep) ability_7\NN\4723816|to_14 (l_acl) reduce_11\VB\441445|the_33|of_21 (l_conj) prevent_16\VB\0|to_40|requirements_20|and_7 (l_dobj) hypokalemia_17\NN\14299637|to_11
D013148_D007008 NONE spironolactone_4\NN\2721160|that_5|can_15|requirements_36|and_49|prevent_53 (r_nsubj) reduce_6\VB\441445|study_37|._129 (l_conj) prevent_10\VBP\0|that_58|spironolactone_53|can_38|requirements_17|and_4 (l_dobj) hypokalemia_11\NN\14299637|by_12
D000666_D009369 NONE b_12\NN\1355326|-_1 (r_npadvmod) related_14\VBN\628491|in_20 (r_amod) hypokalemia_15\NN\14299637|NONE_0 (l_prep) in_16\IN\13603305|related_20 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_compound) cancer_17\NN\14239425|NONE_0
D000666_D009503 NONE amb_22\JJ\0|NONE_0 (r_compound) treatment_23\NN\654885|NONE_0 (r_pobj) on_21\IN\0|neutropenic_21 (r_prep) patients_20\NNS\9898892|NONE_0 (l_amod) neutropenic_19\JJ\0|on_21
D000666_D009503 NONE amb_21\JJ\0|NONE_0 (r_compound) treatment_22\NN\654885|NONE_0 (r_pobj) on_20\IN\0|neutropenic_21 (r_prep) patients_19\NNS\9898892|NONE_0 (l_amod) neutropenic_18\JJ\0|on_21
D013148_D006402 NONE spironolactone_21\NN\2721160|either_45|intravenous_38|alone_22|or_16|amb_13 (r_conj) amb_15\VB\0|to_30|twice_48|daily_54|developing_65 (r_dobj) receive_12\VB\2210855|in_82|patients_65|were_19|._141 (r_xcomp) randomized_10\VBN\278117|NONE_0 (l_nsubjpass) patients_4\NNS\9898892|in_17|were_46|receive_65|._206 (l_prep) with_5\IN\0|26_12 (l_pobj) disorders_8\NNS\14034177|NONE_0
D013148_D009369 NONE spironolactone_0\NNP\2721160|:_14|it_19|drug_30|?_110 (r_npadvmod) is_2\VBZ\0|NONE_0 (l_attr) drug_6\NN\14778436|spironolactone_30|:_16|it_11|?_80 (l_prep) for_7\IN\0|a_13|novel_11 (l_pobj) prevention_9\NN\1073995|NONE_0 (l_prep) of_10\IN\0|the_15 (l_pobj) hypokalemia_15\NN\14299637|NONE_0 (l_prep) in_16\IN\13603305|related_20 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_compound) cancer_17\NN\14239425|NONE_0
D000666_D007674 NONE b_9\NNP\1355326|NONE_0 (r_pobj) of_7\IN\0|the_25|major_21|adverse_15 (r_prep) effect_6\NN\34213|:_38|nephrotoxicity_36|,_30|limiting_38|._76 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) nephrotoxicity_1\NN\0|:_2|effect_36|,_66|limiting_74|._112
D000666_D007674 NONE amb_11\NNP\0|amphotericin_16 (r_appos) b_9\NNP\1355326|NONE_0 (r_pobj) of_7\IN\0|the_25|major_21|adverse_15 (r_prep) effect_6\NN\34213|:_38|nephrotoxicity_36|,_30|limiting_38|._76 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) nephrotoxicity_1\NN\0|:_2|effect_36|,_66|limiting_74|._112
D000666_D064420 NONE amb._24\NNP\0|NONE_0 (r_compound) potassium_25\NN\14625458|NONE_0 (r_compound) depletion_26\NN\351638|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) of_21\IN\0|a_29|major_27|side_12 (r_prep) effect_20\NN\34213|that_30 (r_attr) is_15\VBZ\0|the_36|profound_32|potassium_23 (r_relcl) wasting_13\VBG\14547643|NONE_0 (r_pobj) for_9\IN\0|NONE_0 (r_prep) responsible_8\JJ\0|to_6 (r_acomp) be_7\VB\14625458|toxicity_18|potentiates_135 (r_xcomp) seems_5\VBZ\2604760|NONE_0 (l_nsubj) toxicity_4\NN\13576101|be_18|potentiates_153
D000666_D064420 NONE amb._24\NNP\0|NONE_0 (r_compound) potassium_25\NN\14625458|NONE_0 (r_compound) depletion_26\NN\351638|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) of_21\IN\0|a_29|major_27|side_12 (r_prep) effect_20\NN\34213|that_30 (r_attr) is_15\VBZ\0|the_36|profound_32|potassium_23 (r_relcl) wasting_13\VBG\14547643|NONE_0 (r_pobj) for_9\IN\0|NONE_0 (r_prep) responsible_8\JJ\0|to_6 (r_acomp) be_7\VB\14625458|toxicity_18|potentiates_135 (r_xcomp) seems_5\VBZ\2604760|NONE_0 (l_conj) potentiates_28\VBZ\229605|toxicity_153|be_135 (l_dobj) toxicity_31\NN\13576101|also_29
D000666_D064420 NONE amb._33\NN\0|NONE_0 (r_pobj) of_32\IN\0|the_21|tubular_17 (r_prep) toxicity_31\NN\13576101|also_29 (r_dobj) potentiates_28\VBZ\229605|toxicity_153|be_135 (r_conj) seems_5\VBZ\2604760|NONE_0 (l_nsubj) toxicity_4\NN\13576101|be_18|potentiates_153
D000666_D064420 NONE amb._33\NN\0|NONE_0 (r_pobj) of_32\IN\0|the_21|tubular_17 (r_prep) toxicity_31\NN\13576101|also_29
D000666_D007008 CID b_12\NN\1355326|-_1 (r_npadvmod) related_14\VBN\628491|in_20 (r_amod) hypokalemia_15\NN\14299637|NONE_0
D000666_D007008 CID amb_22\JJ\0|NONE_0 (r_compound) treatment_23\NN\654885|NONE_0 (r_pobj) on_21\IN\0|neutropenic_21 (r_prep) patients_20\NNS\9898892|NONE_0 (r_pobj) in_18\IN\13603305|NONE_0 (r_prep) hypokalemia_17\NN\14299637|to_11
D000666_D007008 CID amb_21\JJ\0|NONE_0 (r_compound) treatment_22\NN\654885|NONE_0 (r_pobj) on_20\IN\0|neutropenic_21 (r_prep) patients_19\NNS\9898892|NONE_0 (r_pobj) in_17\IN\13603305|urinary_23|potassium_15 (r_prep) loss_16\NN\13252973|NONE_0 (r_dobj) reducing_13\VBG\13447361|NONE_0 (r_pcomp) by_12\IN\0|hypokalemia_12 (r_prep) prevent_10\VBP\0|that_58|spironolactone_53|can_38|requirements_17|and_4 (l_dobj) hypokalemia_11\NN\14299637|by_12
D000666_D006402 NONE amb_15\VB\0|to_30|twice_48|daily_54|developing_65 (r_dobj) receive_12\VB\2210855|in_82|patients_65|were_19|._141 (r_xcomp) randomized_10\VBN\278117|NONE_0 (l_nsubjpass) patients_4\NNS\9898892|in_17|were_46|receive_65|._206 (l_prep) with_5\IN\0|26_12 (l_pobj) disorders_8\NNS\14034177|NONE_0
D000666_D006402 NONE amb_18\JJ\0|either_32|intravenous_25|alone_9|or_3|spironolactone_13 (r_conj) amb_15\VB\0|to_30|twice_48|daily_54|developing_65 (r_dobj) receive_12\VB\2210855|in_82|patients_65|were_19|._141 (r_xcomp) randomized_10\VBN\278117|NONE_0 (l_nsubjpass) patients_4\NNS\9898892|in_17|were_46|receive_65|._206 (l_prep) with_5\IN\0|26_12 (l_pobj) disorders_8\NNS\14034177|NONE_0
D011188_D009503 NONE potassium_12\NN\14625458|NONE_0 (r_compound) requirements_13\NNS\1129920|to_20|and_13|prevent_20 (r_dobj) reduce_11\VB\441445|the_33|of_21 (l_conj) prevent_16\VB\0|to_40|requirements_20|and_7 (l_dobj) hypokalemia_17\NN\14299637|to_11 (l_prep) in_18\IN\13603305|NONE_0 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_amod) neutropenic_19\JJ\0|on_21
D011188_D009503 NONE potassium_7\NN\14625458|NONE_0 (r_compound) requirements_8\NNS\1129920|that_41|spironolactone_36|can_21|and_13|prevent_17 (r_dobj) reduce_6\VB\441445|study_37|._129 (l_conj) prevent_10\VBP\0|that_58|spironolactone_53|can_38|requirements_17|and_4 (l_prep) by_12\IN\0|hypokalemia_12 (l_pcomp) reducing_13\VBG\13447361|NONE_0 (l_dobj) loss_16\NN\13252973|NONE_0 (l_prep) in_17\IN\13603305|urinary_23|potassium_15 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_amod) neutropenic_18\JJ\0|on_21
D011188_D009503 NONE potassium_15\NN\14625458|urinary_8|in_15 (r_compound) loss_16\NN\13252973|NONE_0 (l_prep) in_17\IN\13603305|urinary_23|potassium_15 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_amod) neutropenic_18\JJ\0|on_21
D000666_D009181 NONE amb_15\VB\0|to_30|twice_48|daily_54|developing_65 (r_dobj) receive_12\VB\2210855|in_82|patients_65|were_19|._141 (l_advcl) developing_27\VBG\13541167|to_95|amb_65|twice_17|daily_11 (l_dobj) infection_33\NN\14052046|when_45
D000666_D009181 NONE amb_18\JJ\0|either_32|intravenous_25|alone_9|or_3|spironolactone_13 (r_conj) amb_15\VB\0|to_30|twice_48|daily_54|developing_65 (r_dobj) receive_12\VB\2210855|in_82|patients_65|were_19|._141 (l_advcl) developing_27\VBG\13541167|to_95|amb_65|twice_17|daily_11 (l_dobj) infection_33\NN\14052046|when_45
D013148_D009181 NONE spironolactone_21\NN\2721160|either_45|intravenous_38|alone_22|or_16|amb_13 (r_conj) amb_15\VB\0|to_30|twice_48|daily_54|developing_65 (r_dobj) receive_12\VB\2210855|in_82|patients_65|were_19|._141 (l_advcl) developing_27\VBG\13541167|to_95|amb_65|twice_17|daily_11 (l_dobj) infection_33\NN\14052046|when_45
D011188_D064420 NONE potassium_12\NN\14625458|the_13|profound_9|is_23 (r_compound) wasting_13\VBG\14547643|NONE_0 (r_pobj) for_9\IN\0|NONE_0 (r_prep) responsible_8\JJ\0|to_6 (r_acomp) be_7\VB\14625458|toxicity_18|potentiates_135 (r_xcomp) seems_5\VBZ\2604760|NONE_0 (l_nsubj) toxicity_4\NN\13576101|be_18|potentiates_153
D011188_D064420 NONE potassium_12\NN\14625458|the_13|profound_9|is_23 (r_compound) wasting_13\VBG\14547643|NONE_0 (r_pobj) for_9\IN\0|NONE_0 (r_prep) responsible_8\JJ\0|to_6 (r_acomp) be_7\VB\14625458|toxicity_18|potentiates_135 (r_xcomp) seems_5\VBZ\2604760|NONE_0 (l_conj) potentiates_28\VBZ\229605|toxicity_153|be_135 (l_dobj) toxicity_31\NN\13576101|also_29
D011188_D064420 NONE potassium_25\NN\14625458|NONE_0 (r_compound) depletion_26\NN\351638|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) of_21\IN\0|a_29|major_27|side_12 (r_prep) effect_20\NN\34213|that_30 (r_attr) is_15\VBZ\0|the_36|profound_32|potassium_23 (r_relcl) wasting_13\VBG\14547643|NONE_0 (r_pobj) for_9\IN\0|NONE_0 (r_prep) responsible_8\JJ\0|to_6 (r_acomp) be_7\VB\14625458|toxicity_18|potentiates_135 (r_xcomp) seems_5\VBZ\2604760|NONE_0 (l_nsubj) toxicity_4\NN\13576101|be_18|potentiates_153
D011188_D064420 NONE potassium_25\NN\14625458|NONE_0 (r_compound) depletion_26\NN\351638|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) of_21\IN\0|a_29|major_27|side_12 (r_prep) effect_20\NN\34213|that_30 (r_attr) is_15\VBZ\0|the_36|profound_32|potassium_23 (r_relcl) wasting_13\VBG\14547643|NONE_0 (r_pobj) for_9\IN\0|NONE_0 (r_prep) responsible_8\JJ\0|to_6 (r_acomp) be_7\VB\14625458|toxicity_18|potentiates_135 (r_xcomp) seems_5\VBZ\2604760|NONE_0 (l_conj) potentiates_28\VBZ\229605|toxicity_153|be_135 (l_dobj) toxicity_31\NN\13576101|also_29
12549952
D016642_D017114 CID bupropion_5\NN\0|NONE_0 (r_pobj) with_3\IN\0|acute_20|liver_14|._49 (r_prep) failure_2\NN\66216|NONE_0
D016642_D017114 CID bupropion_9\NN\0|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|of_18 (r_acl) evidence_4\NN\5816287|is_14 (r_dobj) increasing_3\VBG\169651|,_58|this_60|case_78|._225 (r_advcl) is_12\VBZ\0|NONE_0 (l_attr) case_15\NN\7283608|increasing_78|,_20|this_18|._147 (l_relcl) resulted_21\VBN\2633881|the_43|first_39|of_28 (l_prep) from_22\IN\0|that_25|could_20|have_14|on_64 (l_pobj) failure_25\NN\66216|NONE_0
D016642_D017114 CID bupropion_30\NN\0|NONE_0 (r_dobj) receiving_29\VBG\2210855|a_10 (r_acl) patient_28\JJ\9898892|NONE_0 (r_pobj) in_26\IN\13603305|acute_20|liver_14 (r_prep) failure_25\NN\66216|NONE_0
D016642_D017114 CID bupropion_13\NN\0|NONE_0 (r_pobj) by_12\IN\0|NONE_0 (r_agent) induced_11\VBN\1627355|acute_19|liver_13 (r_acl) insult_10\NN\6714976|NONE_0
D016642_D056486 CID bupropion_3\NN\0|that_5|hepatotoxicity_18|in_33 (r_nsubj) induced_4\VBD\1627355|the_30 (l_dobj) hepatotoxicity_5\NN\0|that_23|bupropion_18|in_15
D016642_D056486 CID bupropion_9\NN\0|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|of_18 (r_acl) evidence_4\NN\5816287|is_14 (l_prep) of_5\IN\0|induced_18 (l_pobj) hepatotoxicity_6\NN\0|NONE_0
D016642_D056486 CID bupropion_30\NN\0|NONE_0 (r_dobj) receiving_29\VBG\2210855|a_10 (r_acl) patient_28\JJ\9898892|NONE_0 (r_pobj) in_26\IN\13603305|acute_20|liver_14 (r_prep) failure_25\NN\66216|NONE_0 (r_pobj) from_22\IN\0|that_25|could_20|have_14|on_64 (r_prep) resulted_21\VBN\2633881|the_43|first_39|of_28 (r_relcl) case_15\NN\7283608|increasing_78|,_20|this_18|._147 (r_attr) is_12\VBZ\0|NONE_0 (l_advcl) increasing_3\VBG\169651|,_58|this_60|case_78|._225 (l_dobj) evidence_4\NN\5816287|is_14 (l_prep) of_5\IN\0|induced_18 (l_pobj) hepatotoxicity_6\NN\0|NONE_0
D016642_D056486 CID bupropion_13\NN\0|NONE_0 (l_acl) given_14\VBN\5892096|NONE_0 (l_prep) with_16\IN\0|concurrently_13 (l_pobj) drugs_19\NNS\14778436|NONE_0 (l_amod) hepatotoxic_18\JJ\0|other_6
D002231_D017093 NONE carbimazole_16\NN\0|and_4 (r_conj) bupropion_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|concurrent_15 (r_prep) use_12\NN\407535|NONE_0 (r_pobj) with_10\IN\0|possibly_20 (r_prep) associated_9\VBN\628491|fatal_29|liver_23 (r_acl) failure_7\NN\66216|NONE_0
D011433_D006980 NONE propranolol_17\NN\0|man_76|had_38|been_34|with_21|and_4|._32 (r_conj) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) man_5\NN\9605289|had_38|been_42|with_55|and_72|propranolol_76|._108 (l_prep) with_6\IN\0|a_26|old_16|chinese_12 (l_pobj) history_8\NN\15120823|NONE_0 (l_prep) of_9\IN\0|a_10 (l_pobj) hyperthyroidism_10\NN\14059928|NONE_0
D002231_D017114 CID carbimazole_7\NN\0|NONE_0 (r_compound) therapy_8\NN\657604|concurrent_37|and_16 (r_conj) bupropion_5\NN\0|NONE_0 (r_pobj) with_3\IN\0|acute_20|liver_14|._49 (r_prep) failure_2\NN\66216|NONE_0
D002231_D017114 CID carbimazole_36\NN\0|NONE_0 (r_pobj) with_35\IN\0|concomitant_22 (r_prep) treatment_34\NN\654885|while_21 (r_pobj) on_32\IN\0|that_89|could_84|have_78|from_64 (r_prep) resulted_21\VBN\2633881|the_43|first_39|of_28 (l_prep) from_22\IN\0|that_25|could_20|have_14|on_64 (l_pobj) failure_25\NN\66216|NONE_0
D002231_D006980 NONE carbimazole_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|man_55|had_17|been_13|and_17|propranolol_21|._53 (r_prep) treated_13\VBN\2376958|NONE_0 (l_nsubjpass) man_5\NN\9605289|had_38|been_42|with_55|and_72|propranolol_76|._108 (l_prep) with_6\IN\0|a_26|old_16|chinese_12 (l_pobj) history_8\NN\15120823|NONE_0 (l_prep) of_9\IN\0|a_10 (l_pobj) hyperthyroidism_10\NN\14059928|NONE_0
D016642_D017093 NONE bupropion_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|concurrent_15 (r_prep) use_12\NN\407535|NONE_0 (r_pobj) with_10\IN\0|possibly_20 (r_prep) associated_9\VBN\628491|fatal_29|liver_23 (r_acl) failure_7\NN\66216|NONE_0
D002231_D056486 CID carbimazole_36\NN\0|NONE_0 (r_pobj) with_35\IN\0|concomitant_22 (r_prep) treatment_34\NN\654885|while_21 (r_pobj) on_32\IN\0|that_89|could_84|have_78|from_64 (r_prep) resulted_21\VBN\2633881|the_43|first_39|of_28 (r_relcl) case_15\NN\7283608|increasing_78|,_20|this_18|._147 (r_attr) is_12\VBZ\0|NONE_0 (l_advcl) increasing_3\VBG\169651|,_58|this_60|case_78|._225 (l_dobj) evidence_4\NN\5816287|is_14 (l_prep) of_5\IN\0|induced_18 (l_pobj) hepatotoxicity_6\NN\0|NONE_0
7197363
D011814_D009069 CID quipazine_15\NN\0|-_9 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) head_18\NN\5225090|in_14 (r_compound) twitches_19\NNS\14360459|induced_50|and_27
D011814_D009069 CID quipazine_31\NN\0|NONE_0 (r_pobj) of_28\IN\0|NONE_0 (r_prep) completing_27\VBG\352826|NONE_0 (r_pcomp) after_26\IN\0|hr_3 (r_prep) increased_22\VBN\169651|(_42|after_29|)_5|or_3 (r_conj) reduced_13\VBN\441445|hr_61|aggressiveness_20|,_6|and_4|twitches_116|._124 (r_conj) increased_6\VBD\169651|NONE_0 (l_conj) twitches_35\NNS\14360459|hr_177|aggressiveness_136|,_122|and_120|reduced_116|._8
D001058_D009069 NONE apomorphine_10\NN\3786417|-_11 (r_npadvmod) induced_12\VBN\1627355|and_23|twitches_50 (r_amod) aggressiveness_13\NN\4835724|NONE_0 (l_conj) twitches_19\NNS\14360459|induced_50|and_27
D001058_D009069 NONE apomorphine_7\NN\3786417|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) aggressiveness_10\NN\4835724|hr_41|,_14|and_16|reduced_20|twitches_136|._144 (r_dobj) increased_6\VBD\169651|NONE_0 (l_conj) twitches_35\NNS\14360459|hr_177|aggressiveness_136|,_122|and_120|reduced_116|._8
D011814_D012892 NONE quipazine_15\NN\0|-_9 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) head_18\NN\5225090|in_14 (r_compound) twitches_19\NNS\14360459|induced_50|and_27 (r_conj) aggressiveness_13\NN\4835724|NONE_0 (r_pobj) on_9\IN\0|the_44|of_32 (r_prep) effects_1\NNS\13245626|were_122|._137 (l_prep) of_2\IN\0|the_12|on_32 (l_pobj) deprivation_5\NN\14493145|NONE_0
D011814_D012892 NONE quipazine_15\NN\0|-_9 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) head_18\NN\5225090|in_14 (r_compound) twitches_19\NNS\14360459|induced_50|and_27 (r_conj) aggressiveness_13\NN\4835724|NONE_0 (r_pobj) on_9\IN\0|the_44|of_32 (r_prep) effects_1\NNS\13245626|were_122|._137 (l_prep) of_2\IN\0|the_12|on_32 (l_pobj) deprivation_5\NN\14493145|NONE_0 (l_appos) remd_7\NNP\0|rem_23|sleep_19|(_1|)_4
D011814_D012892 NONE quipazine_31\NN\0|NONE_0 (r_pobj) of_28\IN\0|NONE_0 (r_prep) completing_27\VBG\352826|NONE_0 (r_pcomp) after_26\IN\0|hr_3 (r_prep) increased_22\VBN\169651|(_42|after_29|)_5|or_3 (r_conj) reduced_13\VBN\441445|hr_61|aggressiveness_20|,_6|and_4|twitches_116|._124 (r_conj) increased_6\VBD\169651|NONE_0 (l_nsubj) hr_3\NN\15154774|aggressiveness_41|,_55|and_57|reduced_61|twitches_177|._185 (l_prep) of_4\IN\0|eight_9 (l_pobj) remd_5\NNP\0|NONE_0
D011814_D012892 NONE quipazine_31\NN\0|NONE_0 (r_pobj) of_28\IN\0|NONE_0 (r_prep) completing_27\VBG\352826|NONE_0 (r_pcomp) after_26\IN\0|hr_3 (r_prep) increased_22\VBN\169651|(_42|after_29|)_5|or_3 (r_conj) reduced_13\VBN\441445|hr_61|aggressiveness_20|,_6|and_4|twitches_116|._124 (l_prep) after_16\IN\0|(_13|)_24|or_26|increased_29 (l_pcomp) completing_17\VBG\352826|immediately_18 (l_prep) of_18\IN\0|NONE_0 (l_pobj) remd_19\NNP\0|NONE_0
D011814_D012892 NONE quipazine_31\NN\0|NONE_0 (l_nmod) remd_29\NNP\0|)_4|-_15
D011814_D001523 NONE quipazine_15\NN\0|-_9 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) head_18\NN\5225090|in_14 (r_compound) twitches_19\NNS\14360459|induced_50|and_27 (r_conj) aggressiveness_13\NN\4835724|NONE_0
D011814_D001523 NONE quipazine_31\NN\0|NONE_0 (r_pobj) of_28\IN\0|NONE_0 (r_prep) completing_27\VBG\352826|NONE_0 (r_pcomp) after_26\IN\0|hr_3 (r_prep) increased_22\VBN\169651|(_42|after_29|)_5|or_3 (r_conj) reduced_13\VBN\441445|hr_61|aggressiveness_20|,_6|and_4|twitches_116|._124 (r_conj) increased_6\VBD\169651|NONE_0 (l_dobj) aggressiveness_10\NN\4835724|hr_41|,_14|and_16|reduced_20|twitches_136|._144
D001058_D001523 CID apomorphine_10\NN\3786417|-_11 (r_npadvmod) induced_12\VBN\1627355|and_23|twitches_50 (r_amod) aggressiveness_13\NN\4835724|NONE_0
D001058_D001523 CID apomorphine_7\NN\3786417|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) aggressiveness_10\NN\4835724|hr_41|,_14|and_16|reduced_20|twitches_136|._144
D001058_D012892 NONE apomorphine_10\NN\3786417|-_11 (r_npadvmod) induced_12\VBN\1627355|and_23|twitches_50 (r_amod) aggressiveness_13\NN\4835724|NONE_0 (r_pobj) on_9\IN\0|the_44|of_32 (r_prep) effects_1\NNS\13245626|were_122|._137 (l_prep) of_2\IN\0|the_12|on_32 (l_pobj) deprivation_5\NN\14493145|NONE_0
D001058_D012892 NONE apomorphine_10\NN\3786417|-_11 (r_npadvmod) induced_12\VBN\1627355|and_23|twitches_50 (r_amod) aggressiveness_13\NN\4835724|NONE_0 (r_pobj) on_9\IN\0|the_44|of_32 (r_prep) effects_1\NNS\13245626|were_122|._137 (l_prep) of_2\IN\0|the_12|on_32 (l_pobj) deprivation_5\NN\14493145|NONE_0 (l_appos) remd_7\NNP\0|rem_23|sleep_19|(_1|)_4
D001058_D012892 NONE apomorphine_7\NN\3786417|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) aggressiveness_10\NN\4835724|hr_41|,_14|and_16|reduced_20|twitches_136|._144 (r_dobj) increased_6\VBD\169651|NONE_0 (l_nsubj) hr_3\NN\15154774|aggressiveness_41|,_55|and_57|reduced_61|twitches_177|._185 (l_prep) of_4\IN\0|eight_9 (l_pobj) remd_5\NNP\0|NONE_0
D001058_D012892 NONE apomorphine_7\NN\3786417|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) aggressiveness_10\NN\4835724|hr_41|,_14|and_16|reduced_20|twitches_136|._144 (r_dobj) increased_6\VBD\169651|NONE_0 (l_conj) reduced_13\VBN\441445|hr_61|aggressiveness_20|,_6|and_4|twitches_116|._124 (l_prep) after_16\IN\0|(_13|)_24|or_26|increased_29 (l_pcomp) completing_17\VBG\352826|immediately_18 (l_prep) of_18\IN\0|NONE_0 (l_pobj) remd_19\NNP\0|NONE_0
D001058_D012892 NONE apomorphine_7\NN\3786417|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) aggressiveness_10\NN\4835724|hr_41|,_14|and_16|reduced_20|twitches_136|._144 (r_dobj) increased_6\VBD\169651|NONE_0 (l_conj) reduced_13\VBN\441445|hr_61|aggressiveness_20|,_6|and_4|twitches_116|._124 (l_conj) increased_22\VBN\169651|(_42|after_29|)_5|or_3 (l_prep) after_26\IN\0|hr_3 (l_pcomp) completing_27\VBG\352826|NONE_0 (l_prep) of_28\IN\0|NONE_0 (l_pobj) quipazine_31\NN\0|NONE_0 (l_nmod) remd_29\NNP\0|)_4|-_15
8665051
D013256_D009336 NONE steroid_18\NN\14727670|the_4 (r_compound) groups_19\NNS\2137|NONE_0 (r_pobj) in_16\IN\13603305|iib_18|fiber_14|and_22|atrophy_54 (r_prep) atrophy_15\NN\14299637|atpase_91|,_76|revealed_110|._169 (r_dobj) showed_11\VBD\2137132|NONE_0 (l_advcl) revealed_32\VBD\2137132|atpase_201|atrophy_110|,_34|._59 (l_dobj) pattern_36\NN\5726345|whereas_59|examinations_40 (l_prep) with_37\IN\0|a_26|normal_24|muscular_17 (l_pobj) absence_38\NN\14449405|NONE_0 (l_prep) of_39\IN\0|NONE_0 (l_pobj) necrosis_40\NN\11444117|NONE_0
D013256_D009336 NONE steroids_14\NNS\14727670|NONE_0 (r_pobj) of_13\IN\0|massive_14 (r_prep) doses_12\NNS\3740161|NONE_0 (r_pobj) with_10\IN\0|(_25|1_24|)_23|term_15 (r_prep) treatment_9\NN\654885|that_20|wasting_84 (r_nsubj) induced_15\VBD\1627355|we_73 (r_ccomp) conclude_1\VBP\628491|;_120|2_123|types_131|atrophy_180|,_187|resulting_189 (r_ccomp) induced_30\VBD\1627355|;_113|3_116|steroid_127|necrosis_149 (r_ccomp) caused_51\VBD\1617192|;_22|(_24|atrophy_37|was_45|not_49|by_60|alone_93|._98 (l_dobj) necrosis_53\NN\11444117|induced_149|;_36|3_33|steroid_22
D013256_D009336 NONE steroids_29\NNS\14727670|NONE_0 (r_pobj) of_28\IN\0|both_11 (r_prep) types_27\NNS\5839024|conclude_131|;_11|2_8|atrophy_49|,_56|resulting_58 (r_nsubj) induced_30\VBD\1627355|;_113|3_116|steroid_127|necrosis_149 (r_ccomp) caused_51\VBD\1617192|;_22|(_24|atrophy_37|was_45|not_49|by_60|alone_93|._98 (l_dobj) necrosis_53\NN\11444117|induced_149|;_36|3_33|steroid_22
D013256_D009336 NONE steroid_50\NN\14727670|induced_127|;_14|3_11|necrosis_22 (r_nsubj) caused_51\VBD\1617192|;_22|(_24|atrophy_37|was_45|not_49|by_60|alone_93|._98 (l_dobj) necrosis_53\NN\11444117|induced_149|;_36|3_33|steroid_22
D013256_D013746 NONE steroid_8\NN\14727670|both_5 (r_compound) groups_9\NNS\2137|NONE_0 (r_pobj) in_6\IN\13603305|time_19|was_14|,_22|and_24|was_49 (r_prep) prolonged_5\VBN\317700|NONE_0 (l_conj) was_16\VBD\0|time_68|was_63|in_49|,_27|and_25 (l_advcl) were_24\VBD\0|tension_52|longer_40|with_33|,_27|._12 (l_nsubj) tensions_23\NNS\14375890|whereas_16|similar_14 (l_compound) tetanic_22\JJ\0|NONE_0
D013256_D009133 NONE steroid_18\NN\14727670|the_4 (r_compound) groups_19\NNS\2137|NONE_0 (r_pobj) in_16\IN\13603305|iib_18|fiber_14|and_22|atrophy_54 (r_prep) atrophy_15\NN\14299637|atpase_91|,_76|revealed_110|._169
D013256_D009133 NONE steroid_18\NN\14727670|the_4 (r_compound) groups_19\NNS\2137|NONE_0 (r_pobj) in_16\IN\13603305|iib_18|fiber_14|and_22|atrophy_54 (r_prep) atrophy_15\NN\14299637|atpase_91|,_76|revealed_110|._169 (l_conj) atrophy_25\NN\14299637|iib_72|fiber_68|in_54|and_32
D013256_D009133 NONE steroids_14\NNS\14727670|NONE_0 (r_pobj) of_13\IN\0|massive_14 (r_prep) doses_12\NNS\3740161|NONE_0 (r_pobj) with_10\IN\0|(_25|1_24|)_23|term_15 (r_prep) treatment_9\NN\654885|that_20|wasting_84 (r_nsubj) induced_15\VBD\1627355|we_73 (r_ccomp) conclude_1\VBP\628491|;_120|2_123|types_131|atrophy_180|,_187|resulting_189 (r_ccomp) induced_30\VBD\1627355|;_113|3_116|steroid_127|necrosis_149 (r_ccomp) caused_51\VBD\1617192|;_22|(_24|atrophy_37|was_45|not_49|by_60|alone_93|._98 (r_ccomp) caused_63\VBN\1617192|NONE_0 (l_nsubjpass) atrophy_60\NN\14299637|caused_37|;_15|(_13|was_8|not_12|by_23|alone_56|._61
D013256_D009133 NONE steroids_29\NNS\14727670|NONE_0 (r_pobj) of_28\IN\0|both_11 (r_prep) types_27\NNS\5839024|conclude_131|;_11|2_8|atrophy_49|,_56|resulting_58 (r_nsubj) induced_30\VBD\1627355|;_113|3_116|steroid_127|necrosis_149 (r_ccomp) caused_51\VBD\1617192|;_22|(_24|atrophy_37|was_45|not_49|by_60|alone_93|._98 (r_ccomp) caused_63\VBN\1617192|NONE_0 (l_nsubjpass) atrophy_60\NN\14299637|caused_37|;_15|(_13|was_8|not_12|by_23|alone_56|._61
D013256_D009133 NONE steroid_50\NN\14727670|induced_127|;_14|3_11|necrosis_22 (r_nsubj) caused_51\VBD\1617192|;_22|(_24|atrophy_37|was_45|not_49|by_60|alone_93|._98 (r_ccomp) caused_63\VBN\1617192|NONE_0 (l_nsubjpass) atrophy_60\NN\14299637|caused_37|;_15|(_13|was_8|not_12|by_23|alone_56|._61
D014221_D000855 CID triamcinolone_24\NN\14751417|m_7|,_5|or_3 (r_conj) methylprednisolone_18\NN\0|saline_12|(_5|)_3|,_2 (r_appos) c_15\NNP\13714184|NONE_0 (r_pobj) of_12\IN\0|daily_16 (r_prep) injection_11\NN\320852|to_17 (r_dobj) receive_9\VB\2210855|therefore_50|,_41|rats_31|were_26|randomly_21|d_93|,_122|measured_124|,_152|showed_154|._269 (r_xcomp) assigned_7\VBN\2475922|NONE_0 (l_conj) showed_46\VBD\2137132|therefore_204|,_195|rats_185|were_180|randomly_175|receive_154|d_61|,_32|measured_30|,_2|._115 (l_dobj) reduction_49\NN\351485|respectively_81|)_93 (l_prep) of_50\IN\0|a_24|significant_22|in_15 (l_pobj) intake_52\NN\13440063|NONE_0
D014221_D000855 CID t_26\NNP\14999913|NONE_0 (r_appos) triamcinolone_24\NN\14751417|m_7|,_5|or_3 (r_conj) methylprednisolone_18\NN\0|saline_12|(_5|)_3|,_2 (r_appos) c_15\NNP\13714184|NONE_0 (r_pobj) of_12\IN\0|daily_16 (r_prep) injection_11\NN\320852|to_17 (r_dobj) receive_9\VB\2210855|therefore_50|,_41|rats_31|were_26|randomly_21|d_93|,_122|measured_124|,_152|showed_154|._269 (r_xcomp) assigned_7\VBN\2475922|NONE_0 (l_conj) showed_46\VBD\2137132|therefore_204|,_195|rats_185|were_180|randomly_175|receive_154|d_61|,_32|measured_30|,_2|._115 (l_dobj) reduction_49\NN\351485|respectively_81|)_93 (l_prep) of_50\IN\0|a_24|significant_22|in_15 (l_pobj) intake_52\NN\13440063|NONE_0
D014221_D000855 CID t_67\NNP\14999913|and_4|,_1 (r_conj) m_65\NNP\13649268|NONE_0 (r_pobj) in_64\IN\13603305|NONE_0 (r_prep) %_63\NN\0|the_39|treated_27|(_12|-50_11 (r_appos) groups_58\NNS\2137|NONE_0 (r_pobj) in_53\IN\13603305|a_39|significant_37|of_15 (r_prep) reduction_49\NN\351485|respectively_81|)_93 (l_prep) of_50\IN\0|a_24|significant_22|in_15 (l_pobj) intake_52\NN\13440063|NONE_0
D008775_D000855 CID methylprednisolone_18\NN\0|saline_12|(_5|)_3|,_2 (r_appos) c_15\NNP\13714184|NONE_0 (r_pobj) of_12\IN\0|daily_16 (r_prep) injection_11\NN\320852|to_17 (r_dobj) receive_9\VB\2210855|therefore_50|,_41|rats_31|were_26|randomly_21|d_93|,_122|measured_124|,_152|showed_154|._269 (r_xcomp) assigned_7\VBN\2475922|NONE_0 (l_conj) showed_46\VBD\2137132|therefore_204|,_195|rats_185|were_180|randomly_175|receive_154|d_61|,_32|measured_30|,_2|._115 (l_dobj) reduction_49\NN\351485|respectively_81|)_93 (l_prep) of_50\IN\0|a_24|significant_22|in_15 (l_pobj) intake_52\NN\13440063|NONE_0
D008775_D000855 CID m_20\NNP\13649268|,_2|or_4|triamcinolone_7 (r_appos) methylprednisolone_18\NN\0|saline_12|(_5|)_3|,_2 (r_appos) c_15\NNP\13714184|NONE_0 (r_pobj) of_12\IN\0|daily_16 (r_prep) injection_11\NN\320852|to_17 (r_dobj) receive_9\VB\2210855|therefore_50|,_41|rats_31|were_26|randomly_21|d_93|,_122|measured_124|,_152|showed_154|._269 (r_xcomp) assigned_7\VBN\2475922|NONE_0 (l_conj) showed_46\VBD\2137132|therefore_204|,_195|rats_185|were_180|randomly_175|receive_154|d_61|,_32|measured_30|,_2|._115 (l_dobj) reduction_49\NN\351485|respectively_81|)_93 (l_prep) of_50\IN\0|a_24|significant_22|in_15 (l_pobj) intake_52\NN\13440063|NONE_0
D008775_D000855 CID m_65\NNP\13649268|NONE_0 (r_pobj) in_64\IN\13603305|NONE_0 (r_prep) %_63\NN\0|the_39|treated_27|(_12|-50_11 (r_appos) groups_58\NNS\2137|NONE_0 (r_pobj) in_53\IN\13603305|a_39|significant_37|of_15 (r_prep) reduction_49\NN\351485|respectively_81|)_93 (l_prep) of_50\IN\0|a_24|significant_22|in_15 (l_pobj) intake_52\NN\13440063|NONE_0
D013256_D001284 NONE steroids_14\NNS\14727670|NONE_0 (r_pobj) of_13\IN\0|massive_14 (r_prep) doses_12\NNS\3740161|NONE_0 (r_pobj) with_10\IN\0|(_25|1_24|)_23|term_15 (r_prep) treatment_9\NN\654885|that_20|wasting_84 (r_nsubj) induced_15\VBD\1627355|we_73 (r_ccomp) conclude_1\VBP\628491|;_120|2_123|types_131|atrophy_180|,_187|resulting_189 (r_ccomp) induced_30\VBD\1627355|;_113|3_116|steroid_127|necrosis_149 (l_dobj) atrophy_34\NN\14299637|conclude_180|;_60|2_57|types_49|,_7|resulting_9
D013256_D001284 NONE steroids_29\NNS\14727670|NONE_0 (r_pobj) of_28\IN\0|both_11 (r_prep) types_27\NNS\5839024|conclude_131|;_11|2_8|atrophy_49|,_56|resulting_58 (r_nsubj) induced_30\VBD\1627355|;_113|3_116|steroid_127|necrosis_149 (l_dobj) atrophy_34\NN\14299637|conclude_180|;_60|2_57|types_49|,_7|resulting_9
D013256_D001284 NONE steroid_50\NN\14727670|induced_127|;_14|3_11|necrosis_22 (r_nsubj) caused_51\VBD\1617192|;_22|(_24|atrophy_37|was_45|not_49|by_60|alone_93|._98 (l_ccomp) induced_30\VBD\1627355|;_113|3_116|steroid_127|necrosis_149 (l_dobj) atrophy_34\NN\14299637|conclude_180|;_60|2_57|types_49|,_7|resulting_9
D014221_D009133 CID t_27\NNP\14999913|NONE_0 (r_pobj) with_26\IN\0|also_36|iia_12 (r_prep) atrophy_25\NN\14299637|iib_72|fiber_68|in_54|and_32 (r_conj) atrophy_15\NN\14299637|atpase_91|,_76|revealed_110|._169
D014221_D009133 CID t_27\NNP\14999913|NONE_0 (r_pobj) with_26\IN\0|also_36|iia_12 (r_prep) atrophy_25\NN\14299637|iib_72|fiber_68|in_54|and_32
D014221_D009133 CID t_18\NNP\14999913|,_2 (r_conj) c_16\NNP\13714184|18_9|(_1|)_12 (r_appos) rats_14\NNS\2329401|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) performed_11\VBN\0|a_23|fed_16|(_12|pf_11|)_9|,_2|,_35 (r_acl) study_9\NN\635850|finally_25|,_18|was_71|._143 (r_nsubj) showed_24\VBD\2137132|NONE_0 (l_ccomp) was_28\VBD\0|finally_96|,_89|study_71|._72 (l_nsubj) atrophy_27\NN\14299637|that_12|pronounced_30
D014221_D009133 CID t_37\NNP\14999913|-_1 (r_npadvmod) treated_39\VBN\2376958|NONE_0 (r_amod) animals_40\NNS\4475|NONE_0 (r_pobj) in_36\IN\13603305|NONE_0 (r_prep) than_35\IN\0|less_30|in_14 (r_prep) pronounced_31\VBN\0|that_42|atrophy_30 (r_acomp) was_28\VBD\0|finally_96|,_89|study_71|._72 (l_nsubj) atrophy_27\NN\14299637|that_12|pronounced_30
D013256_D000855 NONE steroid_55\NN\14727670|-_7 (r_npadvmod) treated_57\VBN\2376958|the_12|(_15|-50_16|%_27 (r_amod) groups_58\NNS\2137|NONE_0 (r_pobj) in_53\IN\13603305|a_39|significant_37|of_15 (r_prep) reduction_49\NN\351485|respectively_81|)_93 (l_prep) of_50\IN\0|a_24|significant_22|in_15 (l_pobj) intake_52\NN\13440063|NONE_0
D008775_D013746 NONE m_19\NNP\13649268|NONE_0 (r_pobj) with_18\IN\0|tension_19|longer_7|,_6|were_33|._45 (r_prep) was_16\VBD\0|time_68|was_63|in_49|,_27|and_25 (l_advcl) were_24\VBD\0|tension_52|longer_40|with_33|,_27|._12 (l_nsubj) tensions_23\NNS\14375890|whereas_16|similar_14 (l_compound) tetanic_22\JJ\0|NONE_0
D014221_D009336 NONE t_27\NNP\14999913|NONE_0 (r_pobj) with_26\IN\0|also_36|iia_12 (r_prep) atrophy_25\NN\14299637|iib_72|fiber_68|in_54|and_32 (r_conj) atrophy_15\NN\14299637|atpase_91|,_76|revealed_110|._169 (r_dobj) showed_11\VBD\2137132|NONE_0 (l_advcl) revealed_32\VBD\2137132|atpase_201|atrophy_110|,_34|._59 (l_dobj) pattern_36\NN\5726345|whereas_59|examinations_40 (l_prep) with_37\IN\0|a_26|normal_24|muscular_17 (l_pobj) absence_38\NN\14449405|NONE_0 (l_prep) of_39\IN\0|NONE_0 (l_pobj) necrosis_40\NN\11444117|NONE_0
D000305_D009135 NONE corticosteroids_17\NNS\14745635|NONE_0 (r_pobj) of_16\IN\0|massive_14 (r_prep) doses_15\NNS\3740161|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) treated_12\VBN\2376958|NONE_0 (r_acl) patients_11\NNS\9898892|NONE_0 (r_pobj) in_10\IN\13603305|that_30|myopathy_19|may_10 (r_prep) occur_9\VB\0|reports_43|have_35|._63 (l_nsubj) myopathy_7\NN\14204950|that_11|may_9|in_19
2709684
D005839_D058186 CID gentamicin_41\NN\2716866|-_10 (r_npadvmod) induced_43\VBN\1627355|acute_8|renal_14|arf_29 (r_amod) failure_46\NN\66216|NONE_0
D005839_D058186 CID gentamicin_41\NN\2716866|-_10 (r_npadvmod) induced_43\VBN\1627355|acute_8|renal_14|arf_29 (r_amod) failure_46\NN\66216|NONE_0 (l_appos) arf_48\NNP\0|induced_29|acute_21|renal_15
D005839_D058186 CID gentamicin_8\NN\2716866|-_10|(_15|decrease_24|,_52|p_54 (r_compound) arf_10\NNP\0|in_42|,_31|p_29|did_27|not_23|less_45|;_60|day_104|._149
D013311_D003920 CID streptozotocin_3\NNS\0|-_14 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) diabetes_6\NN\14075199|dm_19 (r_compound) mellitus_7\NN\0|NONE_0
D013311_D003920 CID streptozotocin_3\NNS\0|-_14 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) diabetes_6\NN\14075199|dm_19 (r_compound) mellitus_7\NN\0|NONE_0 (l_appos) dm_9\NNP\14117805|diabetes_19
D010695_D006029 NONE phlorizin_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) glycosuria_3\NN\14299637|does_11|not_16|nephrotoxicity_39|._61
D010695_D006029 NONE p_13\NN\14622893|the_4|treated_2 (r_nmod) animals_15\NNS\4475|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) that_10\DT\0|NONE_0 (r_pobj) to_9\IN\0|NONE_0 (r_prep) degree_8\NN\4916342|NONE_0 (r_pobj) in_7\IN\13603305|NONE_0 (r_prep) similar_6\JJ\0|mild_17|(_1|)_50 (r_amod) glycosuria_4\NN\14299637|NONE_0
D010695_D006029 NONE p_4\NN\14622893|in_12|i_3|,_2|glycosuria_32|and_68|ccr_141 (r_nsubj) induced_5\VBD\1627355|NONE_0 (l_dobj) glycosuria_10\NN\14299637|in_44|i_35|,_34|p_32|and_36|ccr_109
D005839_D007674 NONE gentamicin_7\NN\2716866|in_26 (r_compound) nephrotoxicity_8\NN\0|glycosuria_39|does_28|not_23|._22
D005839_D007674 NONE gentamicin_3\NN\2716866|NONE_0 (r_amod) nephrotoxicity_4\NN\0|NONE_0
D005839_D007674 NONE gentamicin_11\NN\2716866|NONE_0 (r_pobj) of_10\IN\0|nephrotoxic_41|(_23|body_13|)_2 (r_prep) doses_1\NNS\3740161|were_43|during_57|to_92|to_120|._125 (l_amod) nephrotoxic_0\JJ\0|(_18|body_28|)_39|of_41
D013311_D006029 NONE streptozotocin_3\NNS\0|-_14 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) diabetes_6\NN\14075199|dm_19 (r_compound) mellitus_7\NN\0|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) rats_1\NNS\2329401|because_8|diuresis_75 (r_nsubj) have_11\VBP\7846|,_58|we_60|have_63|be_100|._183 (l_dobj) diuresis_15\NN\14299637|because_83|rats_75 (l_appos) glycosuria_17\NN\14299637|a_24|solute_17|(_1|)_28
D005839_D009956 NONE gentamicin_8\NN\2716866|-_10|(_15|decrease_24|,_52|p_54 (r_compound) arf_10\NNP\0|in_42|,_31|p_29|did_27|not_23|less_45|;_60|day_104|._149 (r_dobj) prevent_7\VB\0|NONE_0 (l_conj) day_34\NN\15154774|in_146|,_135|p_133|did_131|not_127|arf_104|less_59|;_44|._45 (l_conj) score_39\NN\5736149|micrograms_37|/_27|;_23|and_21 (l_compound) necrosis_38\NN\11444117|tubular_8|,_14|0.1_24|)_27
D005947_D003920 NONE glucose_21\NN\14710501|tubular_8|with_21 (r_compound) reabsorption_22\NN\13526110|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) blockage_18\NN\14034177|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|diabetic_43|with_29 (r_acl) rats_11\NNS\2329401|NONE_0 (l_amod) diabetic_10\JJ\10595647|with_14|induced_43
D010695_D007674 NONE phlorizin_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) glycosuria_3\NN\14299637|does_11|not_16|nephrotoxicity_39|._61 (r_nsubj) prevent_6\VB\0|NONE_0 (l_dobj) nephrotoxicity_8\NN\0|glycosuria_39|does_28|not_23|._22
D010695_D007674 NONE phlorizin_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|tubular_29|glucose_21 (r_prep) reabsorption_22\NN\13526110|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) blockage_18\NN\14034177|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|diabetic_43|with_29 (r_acl) rats_11\NNS\2329401|NONE_0 (r_pobj) in_7\IN\13603305|protection_54|was_12|._120 (r_prep) studied_6\VBN\0|NONE_0 (l_nsubjpass) protection_1\NN\407535|was_42|in_54|._174 (l_prep) from_2\IN\0|the_15 (l_pobj) nephrotoxicity_4\NN\0|NONE_0
D010695_D007674 NONE p_26\NN\14622893|(_1|)_1 (r_appos) phlorizin_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|tubular_29|glucose_21 (r_prep) reabsorption_22\NN\13526110|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) blockage_18\NN\14034177|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|diabetic_43|with_29 (r_acl) rats_11\NNS\2329401|NONE_0 (r_pobj) in_7\IN\13603305|protection_54|was_12|._120 (r_prep) studied_6\VBN\0|NONE_0 (l_nsubjpass) protection_1\NN\407535|was_42|in_54|._174 (l_prep) from_2\IN\0|the_15 (l_pobj) nephrotoxicity_4\NN\0|NONE_0
D010695_D007674 NONE p_4\NN\14622893|in_12|i_3|,_2|glycosuria_32|and_68|ccr_141 (r_nsubj) induced_5\VBD\1627355|NONE_0 (l_conj) ccr_33\IN\0|in_153|i_144|,_143|p_141|glycosuria_109|and_73 (l_nsubj) evidence_27\NN\5816287|baseline_31|min_59|score_118|._142 (l_prep) of_28\IN\0|no_38|functional_35 (l_pobj) dysfunction_30\NN\14204950|NONE_0
D010695_D003920 NONE phlorizin_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|tubular_29|glucose_21 (r_prep) reabsorption_22\NN\13526110|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) blockage_18\NN\14034177|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|diabetic_43|with_29 (r_acl) rats_11\NNS\2329401|NONE_0 (l_amod) diabetic_10\JJ\10595647|with_14|induced_43
D010695_D003920 NONE p_26\NN\14622893|(_1|)_1 (r_appos) phlorizin_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|tubular_29|glucose_21 (r_prep) reabsorption_22\NN\13526110|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) blockage_18\NN\14034177|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|diabetic_43|with_29 (r_acl) rats_11\NNS\2329401|NONE_0 (l_amod) diabetic_10\JJ\10595647|with_14|induced_43
D010695_D003920 NONE p_13\NN\14622893|the_4|treated_2 (r_nmod) animals_15\NNS\4475|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) that_10\DT\0|NONE_0 (r_pobj) to_9\IN\0|NONE_0 (r_prep) degree_8\NN\4916342|NONE_0 (r_pobj) in_7\IN\13603305|NONE_0 (r_prep) similar_6\JJ\0|mild_17|(_1|)_50 (r_amod) glycosuria_4\NN\14299637|NONE_0 (r_pobj) with_2\IN\0|dm_8 (r_prep) rats_1\NNS\2329401|were_79|also_84|._96 (l_compound) dm_0\NNP\14117805|with_8
D010695_D003920 NONE p_3\NN\14622893|group_9|p_18|for_33|;_44|ii_52 (r_nsubj) received_6\VBD\2210855|NONE_0 (l_conj) ii_19\NNP\13741022|group_61|p_52|p_34|for_19|;_8 (l_conj) iii_27\NNP\13741022|group_33|(_24|p_23|;_8 (l_acl) gentamicin_29\NN\2716866|group_11|(_1|._53 (l_conj) iv_34\NNP\13741022|alone_17|)_12|and_10 (l_appos) dm_37\NNP\14117805|group_15
D010695_D003920 NONE p_7\NN\14622893|group_27|p_18|for_15|;_26|ii_34 (r_dobj) received_6\VBD\2210855|NONE_0 (l_conj) ii_19\NNP\13741022|group_61|p_52|p_34|for_19|;_8 (l_conj) iii_27\NNP\13741022|group_33|(_24|p_23|;_8 (l_acl) gentamicin_29\NN\2716866|group_11|(_1|._53 (l_conj) iv_34\NNP\13741022|alone_17|)_12|and_10 (l_appos) dm_37\NNP\14117805|group_15
D010695_D003920 NONE p_21\NN\14622893|group_10|(_1|;_15|iii_23 (r_appos) ii_19\NNP\13741022|group_61|p_52|p_34|for_19|;_8 (l_conj) iii_27\NNP\13741022|group_33|(_24|p_23|;_8 (l_acl) gentamicin_29\NN\2716866|group_11|(_1|._53 (l_conj) iv_34\NNP\13741022|alone_17|)_12|and_10 (l_appos) dm_37\NNP\14117805|group_15
D010695_D058186 NONE p_4\NN\14622893|in_13|,_2|did_2|not_6|arf_29|less_74|;_89|day_133|._178 (r_nsubj) prevent_7\VB\0|NONE_0 (l_dobj) arf_10\NNP\0|in_42|,_31|p_29|did_27|not_23|less_45|;_60|day_104|._149
D010695_D058186 NONE p_21\NN\14622893|gentamicin_54|-_44|(_39|decrease_30|,_2 (r_appos) arf_10\NNP\0|in_42|,_31|p_29|did_27|not_23|less_45|;_60|day_104|._149
D005839_D006029 NONE gentamicin_7\NN\2716866|in_26 (r_compound) nephrotoxicity_8\NN\0|glycosuria_39|does_28|not_23|._22 (r_dobj) prevent_6\VB\0|NONE_0 (l_nsubj) glycosuria_3\NN\14299637|does_11|not_16|nephrotoxicity_39|._61
D005839_D006029 NONE gentamicin_41\NN\2716866|-_10 (r_npadvmod) induced_43\VBN\1627355|acute_8|renal_14|arf_29 (r_amod) failure_46\NN\66216|NONE_0 (r_pobj) to_40\IN\0|their_17 (r_prep) resistance_39\NN\37396|NONE_0 (r_pobj) for_37\IN\0|NONE_0 (r_prep) responsible_36\JJ\0|that_25|this_20|may_15|in_11 (r_acomp) be_35\VB\14625458|have_100|,_42|we_40|have_37|._83 (r_ccomp) suggested_29\VBN\1010118|NONE_0 (l_advcl) have_11\VBP\7846|,_58|we_60|have_63|be_100|._183 (l_dobj) diuresis_15\NN\14299637|because_83|rats_75 (l_appos) glycosuria_17\NN\14299637|a_24|solute_17|(_1|)_28
D005839_D003920 NONE gentamicin_41\NN\2716866|-_10 (r_npadvmod) induced_43\VBN\1627355|acute_8|renal_14|arf_29 (r_amod) failure_46\NN\66216|NONE_0 (r_pobj) to_40\IN\0|their_17 (r_prep) resistance_39\NN\37396|NONE_0 (r_pobj) for_37\IN\0|NONE_0 (r_prep) responsible_36\JJ\0|that_25|this_20|may_15|in_11 (r_acomp) be_35\VB\14625458|have_100|,_42|we_40|have_37|._83 (r_ccomp) suggested_29\VBN\1010118|NONE_0 (l_advcl) have_11\VBP\7846|,_58|we_60|have_63|be_100|._183 (l_nsubj) rats_1\NNS\2329401|because_8|diuresis_75 (l_prep) with_2\IN\0|NONE_0 (l_pobj) mellitus_7\NN\0|NONE_0
D005839_D003920 NONE gentamicin_41\NN\2716866|-_10 (r_npadvmod) induced_43\VBN\1627355|acute_8|renal_14|arf_29 (r_amod) failure_46\NN\66216|NONE_0 (r_pobj) to_40\IN\0|their_17 (r_prep) resistance_39\NN\37396|NONE_0 (r_pobj) for_37\IN\0|NONE_0 (r_prep) responsible_36\JJ\0|that_25|this_20|may_15|in_11 (r_acomp) be_35\VB\14625458|have_100|,_42|we_40|have_37|._83 (r_ccomp) suggested_29\VBN\1010118|NONE_0 (l_advcl) have_11\VBP\7846|,_58|we_60|have_63|be_100|._183 (l_nsubj) rats_1\NNS\2329401|because_8|diuresis_75 (l_prep) with_2\IN\0|NONE_0 (l_pobj) mellitus_7\NN\0|NONE_0 (l_appos) dm_9\NNP\14117805|diabetes_19
D005839_D003920 NONE gentamicin_3\NN\2716866|NONE_0 (r_amod) nephrotoxicity_4\NN\0|NONE_0 (r_pobj) from_2\IN\0|the_15 (r_prep) protection_1\NN\407535|was_42|in_54|._174 (r_nsubjpass) studied_6\VBN\0|NONE_0 (l_prep) in_7\IN\13603305|protection_54|was_12|._120 (l_pobj) rats_11\NNS\2329401|NONE_0 (l_amod) diabetic_10\JJ\10595647|with_14|induced_43
D005839_D003920 NONE gentamicin_23\NN\2716866|+_2|)_10 (r_conj) p_21\NN\14622893|group_10|(_1|;_15|iii_23 (r_appos) ii_19\NNP\13741022|group_61|p_52|p_34|for_19|;_8 (l_conj) iii_27\NNP\13741022|group_33|(_24|p_23|;_8 (l_acl) gentamicin_29\NN\2716866|group_11|(_1|._53 (l_conj) iv_34\NNP\13741022|alone_17|)_12|and_10 (l_appos) dm_37\NNP\14117805|group_15
D005839_D003920 NONE gentamicin_29\NN\2716866|group_11|(_1|._53 (l_conj) iv_34\NNP\13741022|alone_17|)_12|and_10 (l_appos) dm_37\NNP\14117805|group_15
D005839_D003920 NONE gentamicin_39\NN\2716866|(_11|mild_10|+_2|)_10 (r_conj) dm_37\NNP\14117805|group_15
D013311_D058186 NONE streptozotocin_3\NNS\0|-_14 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) diabetes_6\NN\14075199|dm_19 (r_compound) mellitus_7\NN\0|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) rats_1\NNS\2329401|because_8|diuresis_75 (r_nsubj) have_11\VBP\7846|,_58|we_60|have_63|be_100|._183 (r_advcl) suggested_29\VBN\1010118|NONE_0 (l_ccomp) be_35\VB\14625458|have_100|,_42|we_40|have_37|._83 (l_acomp) responsible_36\JJ\0|that_25|this_20|may_15|in_11 (l_prep) for_37\IN\0|NONE_0 (l_pobj) resistance_39\NN\37396|NONE_0 (l_prep) to_40\IN\0|their_17 (l_pobj) failure_46\NN\66216|NONE_0
D013311_D058186 NONE streptozotocin_3\NNS\0|-_14 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) diabetes_6\NN\14075199|dm_19 (r_compound) mellitus_7\NN\0|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) rats_1\NNS\2329401|because_8|diuresis_75 (r_nsubj) have_11\VBP\7846|,_58|we_60|have_63|be_100|._183 (r_advcl) suggested_29\VBN\1010118|NONE_0 (l_ccomp) be_35\VB\14625458|have_100|,_42|we_40|have_37|._83 (l_acomp) responsible_36\JJ\0|that_25|this_20|may_15|in_11 (l_prep) for_37\IN\0|NONE_0 (l_pobj) resistance_39\NN\37396|NONE_0 (l_prep) to_40\IN\0|their_17 (l_pobj) failure_46\NN\66216|NONE_0 (l_appos) arf_48\NNP\0|induced_29|acute_21|renal_15
D010695_D009956 NONE p_4\NN\14622893|in_12|i_3|,_2|glycosuria_32|and_68|ccr_141 (r_nsubj) induced_5\VBD\1627355|NONE_0 (l_conj) ccr_33\IN\0|in_153|i_144|,_143|p_141|glycosuria_109|and_73 (l_dobj) score_49\NN\5736149|evidence_118|baseline_87|min_59|._24 (l_compound) necrosis_48\NN\11444117|(_9|tubular_8|[_15|maximum_16|4_24|]_25|,_26|zero_28|)_32
D010695_D009956 NONE p_4\NN\14622893|in_13|,_2|did_2|not_6|arf_29|less_74|;_89|day_133|._178 (r_nsubj) prevent_7\VB\0|NONE_0 (l_conj) day_34\NN\15154774|in_146|,_135|p_133|did_131|not_127|arf_104|less_59|;_44|._45 (l_conj) score_39\NN\5736149|micrograms_37|/_27|;_23|and_21 (l_compound) necrosis_38\NN\11444117|tubular_8|,_14|0.1_24|)_27
D010695_D009956 NONE p_21\NN\14622893|gentamicin_54|-_44|(_39|decrease_30|,_2 (r_appos) arf_10\NNP\0|in_42|,_31|p_29|did_27|not_23|less_45|;_60|day_104|._149 (r_dobj) prevent_7\VB\0|NONE_0 (l_conj) day_34\NN\15154774|in_146|,_135|p_133|did_131|not_127|arf_104|less_59|;_44|._45 (l_conj) score_39\NN\5736149|micrograms_37|/_27|;_23|and_21 (l_compound) necrosis_38\NN\11444117|tubular_8|,_14|0.1_24|)_27
D005947_D007674 NONE glucose_21\NN\14710501|tubular_8|with_21 (r_compound) reabsorption_22\NN\13526110|NONE_0 (r_pobj) of_19\IN\0|NONE_0 (r_prep) blockage_18\NN\14034177|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|diabetic_43|with_29 (r_acl) rats_11\NNS\2329401|NONE_0 (r_pobj) in_7\IN\13603305|protection_54|was_12|._120 (r_prep) studied_6\VBN\0|NONE_0 (l_nsubjpass) protection_1\NN\407535|was_42|in_54|._174 (l_prep) from_2\IN\0|the_15 (l_pobj) nephrotoxicity_4\NN\0|NONE_0
15531665
D001205_D050197 NONE c_12\NN\13714184|NONE_0 (r_pobj) of_10\IN\0|a_14|high_12|in_13 (r_prep) intake_9\NN\13440063|that_12|might_40|atherosclerosis_54 (r_nsubj) promote_17\VB\2556126|to_73 (l_dobj) atherosclerosis_18\NN\14108324|that_66|intake_54|might_14
D005492_D002318 NONE folate_21\NN\15090742|,_6|vitamin_8|,_17|and_19|carotene_28 (r_nmod) e_24\NN\14724645|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) intakes_19\NNS\13440063|of_17|,_6|and_4 (r_conj) duration_14\NN\15113229|of_29|used_6 (r_conj) type_8\NN\5839024|risk_14|,_2 (r_appos) factors_6\NNS\7326557|NONE_0 (l_compound) risk_5\NN\14541044|,_12|type_14 (l_compound) disease_4\NN\14061805|NONE_0
D005492_D002318 NONE folate_21\NN\15090742|,_6|vitamin_8|,_17|and_19|carotene_28 (r_nmod) e_24\NN\14724645|NONE_0 (l_conj) carotene_29\NN\15090379|folate_28|,_22|vitamin_20|,_11|and_9 (l_appos) risks_34\NNS\14541044|beta_37|-_33|,_24 (l_prep) of_35\IN\0|the_28|adjusted_24|relative_15 (l_pobj) mortality_39\NN\5054863|NONE_0 (l_compound) disease_38\NN\14061805|total_21|cardiovascular_15
D014810_D002318 NONE e_24\NN\14724645|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) intakes_19\NNS\13440063|of_17|,_6|and_4 (r_conj) duration_14\NN\15113229|of_29|used_6 (r_conj) type_8\NN\5839024|risk_14|,_2 (r_appos) factors_6\NNS\7326557|NONE_0 (l_compound) risk_5\NN\14541044|,_12|type_14 (l_compound) disease_4\NN\14061805|NONE_0
D014810_D002318 NONE e_24\NN\14724645|NONE_0 (l_conj) carotene_29\NN\15090379|folate_28|,_22|vitamin_20|,_11|and_9 (l_appos) risks_34\NNS\14541044|beta_37|-_33|,_24 (l_prep) of_35\IN\0|the_28|adjusted_24|relative_15 (l_pobj) mortality_39\NN\5054863|NONE_0 (l_compound) disease_38\NN\14061805|total_21|cardiovascular_15
D019207_D003920 NONE carotene_29\NN\15090379|folate_28|,_22|vitamin_20|,_11|and_9 (r_conj) e_24\NN\14724645|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) intakes_19\NNS\13440063|of_17|,_6|and_4 (r_conj) duration_14\NN\15113229|of_29|used_6 (r_conj) type_8\NN\5839024|risk_14|,_2 (l_prep) of_9\IN\0|used_23|duration_29 (l_pobj) medication_11\NN\3247620|NONE_0 (l_compound) diabetes_10\NN\14075199|NONE_0
D019207_D003920 NONE carotene_29\NN\15090379|folate_28|,_22|vitamin_20|,_11|and_9 (r_conj) e_24\NN\14724645|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) intakes_19\NNS\13440063|of_17|,_6|and_4 (r_conj) duration_14\NN\15113229|of_29|used_6 (l_prep) of_15\IN\0|,_11|and_13|intakes_17 (l_pobj) diabetes_16\NNS\14075199|NONE_0
D019207_D002318 NONE carotene_29\NN\15090379|folate_28|,_22|vitamin_20|,_11|and_9 (r_conj) e_24\NN\14724645|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) intakes_19\NNS\13440063|of_17|,_6|and_4 (r_conj) duration_14\NN\15113229|of_29|used_6 (r_conj) type_8\NN\5839024|risk_14|,_2 (r_appos) factors_6\NNS\7326557|NONE_0 (l_compound) risk_5\NN\14541044|,_12|type_14 (l_compound) disease_4\NN\14061805|NONE_0
D019207_D002318 NONE carotene_29\NN\15090379|folate_28|,_22|vitamin_20|,_11|and_9 (l_appos) risks_34\NNS\14541044|beta_37|-_33|,_24 (l_prep) of_35\IN\0|the_28|adjusted_24|relative_15 (l_pobj) mortality_39\NN\5054863|NONE_0 (l_compound) disease_38\NN\14061805|total_21|cardiovascular_15
D001205_D003324 NONE c_6\NN\13714184|and_9|mortality_13|from_23 (r_compound) intake_7\NN\13440063|NONE_0 (r_pobj) between_4\IN\0|the_13 (r_prep) relation_3\NN\2137|we_15|)_90|,_91|disease_109|._216 (r_dobj) studied_1\VBD\0|NONE_0 (l_dep) disease_22\NN\14061805|we_124|relation_109|)_19|,_18|._107
D001205_D002318 CID c_3\NN\13714184|does_26|risk_34|?_61 (r_nsubj) increase_4\VB\13576355|NONE_0 (l_dobj) risk_7\NN\14541044|does_60|c_34|?_27 (l_compound) disease_6\NN\14061805|in_13
D001205_D002318 CID c_10\NN\13714184|and_9|mortality_13|from_23 (r_compound) intake_11\NN\13440063|NONE_0 (l_prep) from_14\IN\0|c_23|and_14|mortality_10 (l_pobj) disease_16\NN\14061805|NONE_0
D001205_D002318 CID c_6\NN\13714184|and_9|mortality_13|from_23 (r_compound) intake_7\NN\13440063|NONE_0 (l_prep) from_10\IN\0|c_23|and_14|mortality_10 (l_pobj) disease_13\NN\14061805|NONE_0
D001205_D002318 CID c_63\NN\13714184|total_14|from_9 (r_compound) intake_64\NN\13440063|NONE_0 (r_pobj) of_60\IN\0|NONE_0 (r_prep) quintiles_59\NNS\0|NONE_0 (r_pobj) across_58\IN\0|,_50|0.97_48|,_44|1.11_42|(_21|p_20 (r_prep) 1.0_41\CD\0|after_242|adjustment_236|._121 (r_attr) were_40\VBD\0|NONE_0 (l_nsubj) adjustment_1\NN\7357388|after_6|1.0_236|._357 (l_prep) for_2\IN\0|NONE_0 (l_pobj) factors_6\NNS\7326557|NONE_0 (l_compound) risk_5\NN\14541044|,_12|type_14 (l_compound) disease_4\NN\14061805|NONE_0
D001205_D002318 CID c_63\NN\13714184|total_14|from_9 (r_compound) intake_64\NN\13440063|NONE_0 (r_pobj) of_60\IN\0|NONE_0 (r_prep) quintiles_59\NNS\0|NONE_0 (r_pobj) across_58\IN\0|,_50|0.97_48|,_44|1.11_42|(_21|p_20 (r_prep) 1.0_41\CD\0|after_242|adjustment_236|._121 (r_attr) were_40\VBD\0|NONE_0 (l_nsubj) adjustment_1\NN\7357388|after_6|1.0_236|._357 (l_prep) for_2\IN\0|NONE_0 (l_pobj) factors_6\NNS\7326557|NONE_0 (l_appos) type_8\NN\5839024|risk_14|,_2 (l_conj) duration_14\NN\15113229|of_29|used_6 (l_conj) intakes_19\NNS\13440063|of_17|,_6|and_4 (l_prep) of_20\IN\0|NONE_0 (l_pobj) e_24\NN\14724645|NONE_0 (l_conj) carotene_29\NN\15090379|folate_28|,_22|vitamin_20|,_11|and_9 (l_appos) risks_34\NNS\14541044|beta_37|-_33|,_24 (l_prep) of_35\IN\0|the_28|adjusted_24|relative_15 (l_pobj) mortality_39\NN\5054863|NONE_0 (l_compound) disease_38\NN\14061805|total_21|cardiovascular_15
D001205_D002318 CID c_1\NN\13714184|NONE_0 (r_compound) intake_2\NN\13440063|unrelated_11|._101 (r_nsubj) was_3\VBD\0|NONE_0 (l_acomp) unrelated_4\JJ\0|intake_11|._90 (l_prep) to_5\IN\0|NONE_0 (l_pobj) mortality_6\NN\5054863|NONE_0 (l_prep) from_7\IN\0|in_28 (l_pobj) disease_9\NN\14061805|NONE_0
D001205_D002318 CID c_3\NN\13714184|a_15|high_13|from_9 (r_compound) intake_4\NN\13440063|is_24|with_38|._134 (r_nsubjpass) associated_8\VBN\628491|NONE_0 (l_prep) with_9\IN\0|intake_38|is_14|._96 (l_pobj) risk_12\NN\14541044|NONE_0 (l_prep) of_13\IN\0|an_18|increased_15 (l_pobj) mortality_16\NN\5054863|NONE_0 (l_compound) disease_15\NN\14061805|cardiovascular_15|in_18
D005492_D003920 NONE folate_21\NN\15090742|,_6|vitamin_8|,_17|and_19|carotene_28 (r_nmod) e_24\NN\14724645|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) intakes_19\NNS\13440063|of_17|,_6|and_4 (r_conj) duration_14\NN\15113229|of_29|used_6 (r_conj) type_8\NN\5839024|risk_14|,_2 (l_prep) of_9\IN\0|used_23|duration_29 (l_pobj) medication_11\NN\3247620|NONE_0 (l_compound) diabetes_10\NN\14075199|NONE_0
D005492_D003920 NONE folate_21\NN\15090742|,_6|vitamin_8|,_17|and_19|carotene_28 (r_nmod) e_24\NN\14724645|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) intakes_19\NNS\13440063|of_17|,_6|and_4 (r_conj) duration_14\NN\15113229|of_29|used_6 (l_prep) of_15\IN\0|,_11|and_13|intakes_17 (l_pobj) diabetes_16\NNS\14075199|NONE_0
D001205_D020521 NONE c_6\NN\13714184|and_9|mortality_13|from_23 (r_compound) intake_7\NN\13440063|NONE_0 (r_pobj) between_4\IN\0|the_13 (r_prep) relation_3\NN\2137|we_15|)_90|,_91|disease_109|._216 (r_dobj) studied_1\VBD\0|NONE_0 (l_dep) disease_22\NN\14061805|we_124|relation_109|)_19|,_18|._107 (l_conj) stroke_30\NN\556313|coronary_39|artery_30|n_14|175_10|,_6|and_4
D014810_D003920 NONE e_24\NN\14724645|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) intakes_19\NNS\13440063|of_17|,_6|and_4 (r_conj) duration_14\NN\15113229|of_29|used_6 (r_conj) type_8\NN\5839024|risk_14|,_2 (l_prep) of_9\IN\0|used_23|duration_29 (l_pobj) medication_11\NN\3247620|NONE_0 (l_compound) diabetes_10\NN\14075199|NONE_0
D014810_D003920 NONE e_24\NN\14724645|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) intakes_19\NNS\13440063|of_17|,_6|and_4 (r_conj) duration_14\NN\15113229|of_29|used_6 (l_prep) of_15\IN\0|,_11|and_13|intakes_17 (l_pobj) diabetes_16\NNS\14075199|NONE_0
D001205_D003920 NONE c_3\NN\13714184|does_26|risk_34|?_61 (r_nsubj) increase_4\VB\13576355|NONE_0 (l_dobj) risk_7\NN\14541044|does_60|c_34|?_27 (l_prep) in_8\IN\13603305|disease_13 (l_pobj) women_9\NNS\9605289|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) diabetes_11\NNS\14075199|NONE_0
D001205_D003920 NONE c_12\NN\13714184|NONE_0 (r_pobj) of_10\IN\0|a_14|high_12|in_13 (r_prep) intake_9\NN\13440063|that_12|might_40|atherosclerosis_54 (l_prep) in_13\IN\13603305|a_27|high_25|of_13 (l_pobj) persons_15\NNS\7347|NONE_0 (l_amod) diabetic_14\JJ\10595647|NONE_0
D001205_D003920 NONE c_6\NN\13714184|and_9|mortality_13|from_23 (r_compound) intake_7\NN\13440063|NONE_0 (r_pobj) between_4\IN\0|the_13 (r_prep) relation_3\NN\2137|we_15|)_90|,_91|disease_109|._216 (r_dobj) studied_1\VBD\0|NONE_0 (l_dep) disease_22\NN\14061805|we_124|relation_109|)_19|,_18|._107 (l_conj) stroke_30\NN\556313|coronary_39|artery_30|n_14|175_10|,_6|and_4 (l_prep) in_36\IN\13603305|(_9|n_8|57_4|)_2 (l_pobj) women_39\NNS\9605289|NONE_0 (l_relcl) reported_41\VBD\831651|1923_30|postmenopausal_25 (l_xcomp) being_42\VBG\24720|who_13 (l_acomp) diabetic_43\JJ\10595647|NONE_0
D001205_D003920 NONE c_63\NN\13714184|total_14|from_9 (r_compound) intake_64\NN\13440063|NONE_0 (r_pobj) of_60\IN\0|NONE_0 (r_prep) quintiles_59\NNS\0|NONE_0 (r_pobj) across_58\IN\0|,_50|0.97_48|,_44|1.11_42|(_21|p_20 (r_prep) 1.0_41\CD\0|after_242|adjustment_236|._121 (r_attr) were_40\VBD\0|NONE_0 (l_nsubj) adjustment_1\NN\7357388|after_6|1.0_236|._357 (l_prep) for_2\IN\0|NONE_0 (l_pobj) factors_6\NNS\7326557|NONE_0 (l_appos) type_8\NN\5839024|risk_14|,_2 (l_prep) of_9\IN\0|used_23|duration_29 (l_pobj) medication_11\NN\3247620|NONE_0 (l_compound) diabetes_10\NN\14075199|NONE_0
D001205_D003920 NONE c_63\NN\13714184|total_14|from_9 (r_compound) intake_64\NN\13440063|NONE_0 (r_pobj) of_60\IN\0|NONE_0 (r_prep) quintiles_59\NNS\0|NONE_0 (r_pobj) across_58\IN\0|,_50|0.97_48|,_44|1.11_42|(_21|p_20 (r_prep) 1.0_41\CD\0|after_242|adjustment_236|._121 (r_attr) were_40\VBD\0|NONE_0 (l_nsubj) adjustment_1\NN\7357388|after_6|1.0_236|._357 (l_prep) for_2\IN\0|NONE_0 (l_pobj) factors_6\NNS\7326557|NONE_0 (l_appos) type_8\NN\5839024|risk_14|,_2 (l_conj) duration_14\NN\15113229|of_29|used_6 (l_prep) of_15\IN\0|,_11|and_13|intakes_17 (l_pobj) diabetes_16\NNS\14075199|NONE_0
D001205_D003920 NONE c_3\NN\13714184|a_15|high_13|from_9 (r_compound) intake_4\NN\13440063|is_24|with_38|._134 (r_nsubjpass) associated_8\VBN\628491|NONE_0 (l_prep) with_9\IN\0|intake_38|is_14|._96 (l_pobj) risk_12\NN\14541044|NONE_0 (l_prep) of_13\IN\0|an_18|increased_15 (l_pobj) mortality_16\NN\5054863|NONE_0 (l_prep) in_17\IN\13603305|cardiovascular_33|disease_18 (l_pobj) women_19\NNS\9605289|NONE_0 (l_prep) with_20\IN\0|postmenopausal_21 (l_pobj) diabetes_21\NNS\14075199|NONE_0
16563323
D005045_D011537 NONE etomidate_10\NN\0|NONE_0 (l_prep) without_12\IN\0|pretreatment_87|after_26|induction_10|._65 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_prep) as_16\IN\14622893|side_18 (l_pobj) sedation_17\NN\14034177|such_8 (l_conj) apnea_19\NN\14299637|,_2 (l_conj) nausea_21\NN\14299637|,_2 (l_conj) pruritus_24\NN\5723563|,_5|or_3
C071741_D001049 NONE remifentanil_2\NN\0|NONE_0 (r_pobj) with_1\IN\0|myoclonus_38 (r_prep) pretreatment_0\NN\0|after_61|induction_77|without_87|._152 (r_nsubj) etomidate_10\NN\0|NONE_0 (l_prep) without_12\IN\0|pretreatment_87|after_26|induction_10|._65 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_prep) as_16\IN\14622893|side_18 (l_pobj) sedation_17\NN\14034177|such_8 (l_conj) apnea_19\NN\14299637|,_2
D005045_D001049 NONE etomidate_10\NN\0|NONE_0 (l_prep) without_12\IN\0|pretreatment_87|after_26|induction_10|._65 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_prep) as_16\IN\14622893|side_18 (l_pobj) sedation_17\NN\14034177|such_8 (l_conj) apnea_19\NN\14299637|,_2
C071741_D011537 NONE remifentanil_2\NN\0|NONE_0 (r_pobj) with_1\IN\0|myoclonus_38 (r_prep) pretreatment_0\NN\0|after_61|induction_77|without_87|._152 (r_nsubj) etomidate_10\NN\0|NONE_0 (l_prep) without_12\IN\0|pretreatment_87|after_26|induction_10|._65 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_prep) as_16\IN\14622893|side_18 (l_pobj) sedation_17\NN\14034177|such_8 (l_conj) apnea_19\NN\14299637|,_2 (l_conj) nausea_21\NN\14299637|,_2 (l_conj) pruritus_24\NN\5723563|,_5|or_3
C071741_D009325 NONE remifentanil_2\NN\0|NONE_0 (r_pobj) with_1\IN\0|myoclonus_38 (r_prep) pretreatment_0\NN\0|after_61|induction_77|without_87|._152 (r_nsubj) etomidate_10\NN\0|NONE_0 (l_prep) without_12\IN\0|pretreatment_87|after_26|induction_10|._65 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_prep) as_16\IN\14622893|side_18 (l_pobj) sedation_17\NN\14034177|such_8 (l_conj) apnea_19\NN\14299637|,_2 (l_conj) nausea_21\NN\14299637|,_2
D005045_D009325 NONE etomidate_10\NN\0|NONE_0 (l_prep) without_12\IN\0|pretreatment_87|after_26|induction_10|._65 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_prep) as_16\IN\14622893|side_18 (l_pobj) sedation_17\NN\14034177|such_8 (l_conj) apnea_19\NN\14299637|,_2 (l_conj) nausea_21\NN\14299637|,_2
D005045_D009207 CID etomidate_5\NN\0|pretreatment_37|myoclonus_16|._9 (r_advcl) reduces_2\VBZ\441445|NONE_0 (l_dobj) myoclonus_3\NN\14360459|pretreatment_21|etomidate_16|._25
D005045_D009207 CID etomidate_32\NN\0|NONE_0 (r_pobj) with_31\IN\0|NONE_0 (r_prep) induction_30\NN\7450842|NONE_0 (r_amod) anesthesia_29\NN\14034177|NONE_0 (r_pobj) after_28\IN\0|the_51|of_40|on_30 (r_prep) effect_20\NN\34213|with_38|and_8 (l_prep) on_23\IN\0|the_21|of_10|after_30 (l_pobj) incidence_25\NN\13821570|NONE_0 (l_prep) of_26\IN\0|the_14 (l_pobj) myoclonus_27\NN\14360459|NONE_0
D005045_D009207 CID etomidate_16\NN\0|in_110|,_90|patients_83|were_74|with_58|._24 (r_advcl) associated_8\VBN\628491|NONE_0 (l_prep) with_9\IN\0|in_52|,_32|patients_25|were_16|etomidate_58|._82 (l_pobj) incidence_12\NN\13821570|NONE_0 (l_prep) of_13\IN\0|increased_20 (l_pobj) myoclonus_14\NN\14360459|NONE_0
D005045_D009207 CID etomidate_10\NN\0|NONE_0 (l_nsubj) pretreatment_0\NN\0|after_61|induction_77|without_87|._152 (l_appos) myoclonus_8\NN\14360459|with_38
D005045_D009207 CID etomidate_9\NN\0|experience_61|incidence_40|._24 (r_advcl) increased_2\VBD\169651|NONE_0 (l_dobj) incidence_3\NN\13821570|experience_21|etomidate_40|._64 (l_prep) of_4\IN\0|NONE_0 (l_pobj) myoclonus_5\NN\14360459|NONE_0
C071741_D009207 NONE remifentanil_0\NNP\0|NONE_0 (r_compound) pretreatment_1\NN\0|myoclonus_21|etomidate_37|._46 (r_nsubj) reduces_2\VBZ\441445|NONE_0 (l_dobj) myoclonus_3\NN\14360459|pretreatment_21|etomidate_16|._25
C071741_D009207 NONE remifentanil_13\NN\0|1_13|microg_15|/_21 (r_nmod) kg_17\NNS\13717155|NONE_0 (r_pobj) with_12\IN\0|and_30|effect_38 (r_prep) pretreatment_11\NN\0|NONE_0 (l_conj) effect_20\NN\34213|with_38|and_8 (l_prep) on_23\IN\0|the_21|of_10|after_30 (l_pobj) incidence_25\NN\13821570|NONE_0 (l_prep) of_26\IN\0|the_14 (l_pobj) myoclonus_27\NN\14360459|NONE_0
C071741_D009207 NONE remifentanil_9\NN\0|the_4|(_19|%_23|)_24 (r_compound) group_10\NN\2137|NONE_0 (r_pobj) in_7\IN\13603305|significantly_20|than_33 (r_prep) lower_6\JJR\2831724|incidence_41|(_71|p_72|._82 (r_acomp) was_4\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|lower_41|(_112|p_113|._123 (l_prep) of_2\IN\0|the_14 (l_pobj) myoclonus_3\NN\14360459|NONE_0
C071741_D009207 NONE remifentanil_2\NN\0|NONE_0 (r_pobj) with_1\IN\0|myoclonus_38 (r_prep) pretreatment_0\NN\0|after_61|induction_77|without_87|._152 (l_appos) myoclonus_8\NN\14360459|with_38
16584858
C009591_D017202 NONE chloride_10\NN\14818238|ttc_10|used_20 (r_nmod) test_14\NN\5798043|NONE_0 (l_acl) used_15\VBN\0|chloride_20|ttc_10 (l_prep) for_16\IN\0|NONE_0 (l_pobj) assay_20\NN\5733583|NONE_0 (l_prep) of_21\IN\0|macroscopic_33|mapping_14 (l_pobj) myocardium_24\NN\5389939|NONE_0
C009591_D017202 NONE ttc_12\NNP\0|chloride_10|used_10 (r_nmod) test_14\NN\5798043|NONE_0 (l_acl) used_15\VBN\0|chloride_20|ttc_10 (l_prep) for_16\IN\0|NONE_0 (l_pobj) assay_20\NN\5733583|NONE_0 (l_prep) of_21\IN\0|macroscopic_33|mapping_14 (l_pobj) myocardium_24\NN\5389939|NONE_0
D007501_D009202 NONE iron_58\NN\14625458|reduced_15|binding_5 (r_nmod) capacity_60\NN\5202497|uric_48|acid_43|and_32 (r_conj) level_54\NN\4916342|caused_190|,_22|._46 (r_dobj) increased_51\VBN\169651|NONE_0 (l_ccomp) caused_20\VBD\1617192|,_168|level_190|._236 (l_dobj) damage_22\NN\7296428|injection_106|creatine_109
C013592_D017202 NONE mangiferin_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_20|protective_16 (r_prep) role_2\NN\719494|was_19|by_32|._145 (r_nsubjpass) analyzed_6\VBN\0|NONE_0 (l_agent) by_7\IN\0|role_32|was_13|._113 (l_pobj) test_14\NN\5798043|NONE_0 (l_acl) used_15\VBN\0|chloride_20|ttc_10 (l_prep) for_16\IN\0|NONE_0 (l_pobj) assay_20\NN\5733583|NONE_0 (l_prep) of_21\IN\0|macroscopic_33|mapping_14 (l_pobj) myocardium_24\NN\5389939|NONE_0
C013592_D009203 NONE mangiferin_2\NN\0|NONE_0 (l_prep) on_3\IN\0|NONE_0 (l_pobj) alterations_5\NNS\7283608|NONE_0 (l_prep) in_9\IN\13603305|biochemical_47|and_23|status_7 (l_pobj) infarction_14\NN\14204950|NONE_0
C013592_D009203 NONE mangiferin_3\NN\0|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) pretreatment_1\NN\0|NONE_0 (r_pobj) upon_0\IN\0|(_34|weight_50|in_67|given_99|protected_146|._217 (r_prep) suspended_9\VBN\1481360|NONE_0 (l_prep) given_17\VBN\5892096|upon_99|(_65|weight_49|in_32|protected_47|._118 (l_prep) to_22\IN\0|intraperitoneally_30|for_12 (l_pobj) rats_24\NNS\2329401|NONE_0 (l_compound) mi_23\NNP\14207561|NONE_0
C013592_D009203 NONE mangiferin_16\JJ\0|NONE_0 (r_compound) administration_17\NN\1133281|NONE_0 (r_pobj) upon_15\IN\0|tissue_89|significantly_14|compared_34|._66 (r_prep) rose_13\VBD\13112664|NONE_0 (l_prep) compared_19\VBN\644583|tissue_123|significantly_48|upon_34|._32 (l_prep) to_20\IN\0|as_12 (l_pobj) rats_25\NNS\2329401|NONE_0 (l_compound) mi_24\NNP\14207561|induced_8
C013592_D009203 NONE mangiferin_8\NN\0|that_5|effect_31|due_62 (r_nsubj) exerts_9\VBZ\1158872|from_55|it_32|is_29|._150 (l_dobj) effect_12\NN\34213|that_36|mangiferin_31|due_31 (l_prep) against_13\IN\0|a_20|beneficial_18 (l_pobj) mi_17\NNP\14207561|NONE_0
D014527_D009202 NONE acid_53\NN\14818238|uric_5|and_11|capacity_43 (r_compound) level_54\NN\4916342|caused_190|,_22|._46 (r_dobj) increased_51\VBN\169651|NONE_0 (l_ccomp) caused_20\VBD\1617192|,_168|level_190|._236 (l_dobj) damage_22\NN\7296428|injection_106|creatine_109
C013592_D006331 NONE mangiferin_8\NN\0|that_5|effect_31|due_62 (r_nsubj) exerts_9\VBZ\1158872|from_55|it_32|is_29|._150 (l_prep) due_18\IN\5174653|that_67|mangiferin_62|effect_31 (l_pcomp) to_19\IN\0|NONE_0 (l_pobj) potential_22\NN\14481929|NONE_0 (l_relcl) regulated_25\VBD\296178|its_33|antioxidant_29|,_8 (l_prep) against_30\IN\0|which_43|system_7 (l_pobj) damage_32\NN\7296428|NONE_0
D001205_D009203 NONE c_31\NN\13714184|,_10 (r_conj) cerruloplasmin_28\NN\0|such_8 (r_pobj) as_27\IN\14622893|enzymic_26|levels_56 (r_prep) antioxidants_25\NNS\14724436|superoxide_130|,_110|catalase_108|,_14 (r_appos) dismutase_8\NN\0|such_19 (r_pobj) as_6\IN\14622893|antioxidant_25 (r_prep) enzymes_4\NNS\14723628|heart_25 (r_dobj) tissue_2\NN\5220461|were_246|in_259|._269 (r_nsubjpass) altered_39\VBN\0|NONE_0 (l_prep) in_40\IN\13603305|tissue_259|were_13|._10 (l_pobj) rats_42\NNS\2329401|NONE_0 (l_compound) mi_41\NNP\14207561|NONE_0
D019344_D009202 NONE lactate_36\NN\14850483|(_22|ldh_23|)_26 (r_compound) dehydrogenase_37\NN\0|NONE_0 (r_pobj) of_34\IN\0|the_23|increased_19 (r_prep) activity_33\NN\30358|NONE_0 (r_pobj) by_30\IN\0|which_21|was_15|and_63 (r_agent) determined_29\VBN\0|rat_21|,_12 (r_relcl) heart_25\NN\5919034|NONE_0 (r_pobj) in_23\IN\13603305|myocardial_18 (r_prep) damage_22\NN\7296428|injection_106|creatine_109
D005978_D009203 NONE glutathione_12\NN\0|,_22|transferase_36 (r_compound) peroxidase_13\NN\14971234|,_14 (r_conj) catalase_10\NNP\14732946|superoxide_22|,_2|,_94|antioxidants_108 (r_conj) dismutase_8\NN\0|such_19 (r_pobj) as_6\IN\14622893|antioxidant_25 (r_prep) enzymes_4\NNS\14723628|heart_25 (r_dobj) tissue_2\NN\5220461|were_246|in_259|._269 (r_nsubjpass) altered_39\VBN\0|NONE_0 (l_prep) in_40\IN\13603305|tissue_259|were_13|._10 (l_pobj) rats_42\NNS\2329401|NONE_0 (l_compound) mi_41\NNP\14207561|NONE_0
D005978_D009203 NONE glutathione_15\NN\0|and_24|activities_50 (r_compound) transferase_16\NN\14732946|glutathione_36|,_14 (r_conj) peroxidase_13\NN\14971234|,_14 (r_conj) catalase_10\NNP\14732946|superoxide_22|,_2|,_94|antioxidants_108 (r_conj) dismutase_8\NN\0|such_19 (r_pobj) as_6\IN\14622893|antioxidant_25 (r_prep) enzymes_4\NNS\14723628|heart_25 (r_dobj) tissue_2\NN\5220461|were_246|in_259|._269 (r_nsubjpass) altered_39\VBN\0|NONE_0 (l_prep) in_40\IN\13603305|tissue_259|were_13|._10 (l_pobj) rats_42\NNS\2329401|NONE_0 (l_compound) mi_41\NNP\14207561|NONE_0
D005978_D009203 NONE glutathione_18\NN\0|NONE_0 (r_compound) reductase_19\NN\14732946|NONE_0 (r_compound) activities_20\NNS\30358|glutathione_50|and_26 (r_conj) transferase_16\NN\14732946|glutathione_36|,_14 (r_conj) peroxidase_13\NN\14971234|,_14 (r_conj) catalase_10\NNP\14732946|superoxide_22|,_2|,_94|antioxidants_108 (r_conj) dismutase_8\NN\0|such_19 (r_pobj) as_6\IN\14622893|antioxidant_25 (r_prep) enzymes_4\NNS\14723628|heart_25 (r_dobj) tissue_2\NN\5220461|were_246|in_259|._269 (r_nsubjpass) altered_39\VBN\0|NONE_0 (l_prep) in_40\IN\13603305|tissue_259|were_13|._10 (l_pobj) rats_42\NNS\2329401|NONE_0 (l_compound) mi_41\NNP\14207561|NONE_0
D005978_D009203 NONE glutathione_36\NN\0|vitamin_14|and_4 (r_conj) e_34\NN\14724645|vitamin_19|,_10 (r_conj) c_31\NN\13714184|,_10 (r_conj) cerruloplasmin_28\NN\0|such_8 (r_pobj) as_27\IN\14622893|enzymic_26|levels_56 (r_prep) antioxidants_25\NNS\14724436|superoxide_130|,_110|catalase_108|,_14 (r_appos) dismutase_8\NN\0|such_19 (r_pobj) as_6\IN\14622893|antioxidant_25 (r_prep) enzymes_4\NNS\14723628|heart_25 (r_dobj) tissue_2\NN\5220461|were_246|in_259|._269 (r_nsubjpass) altered_39\VBN\0|NONE_0 (l_prep) in_40\IN\13603305|tissue_259|were_13|._10 (l_pobj) rats_42\NNS\2329401|NONE_0 (l_compound) mi_41\NNP\14207561|NONE_0
D007545_D009202 NONE isph_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|subcutaneous_23|to_47 (r_prep) injection_1\NN\320852|damage_106|creatine_215 (r_nsubj) caused_20\VBD\1617192|,_168|level_190|._236 (l_dobj) damage_22\NN\7296428|injection_106|creatine_109
D003401_D009202 NONE creatine_42\NN\14601829|injection_215|damage_109 (r_conj) caused_20\VBD\1617192|,_168|level_190|._236 (l_dobj) damage_22\NN\7296428|injection_106|creatine_109
D014810_D009203 NONE e_34\NN\14724645|vitamin_19|,_10 (r_conj) c_31\NN\13714184|,_10 (r_conj) cerruloplasmin_28\NN\0|such_8 (r_pobj) as_27\IN\14622893|enzymic_26|levels_56 (r_prep) antioxidants_25\NNS\14724436|superoxide_130|,_110|catalase_108|,_14 (r_appos) dismutase_8\NN\0|such_19 (r_pobj) as_6\IN\14622893|antioxidant_25 (r_prep) enzymes_4\NNS\14723628|heart_25 (r_dobj) tissue_2\NN\5220461|were_246|in_259|._269 (r_nsubjpass) altered_39\VBN\0|NONE_0 (l_prep) in_40\IN\13603305|tissue_259|were_13|._10 (l_pobj) rats_42\NNS\2329401|NONE_0 (l_compound) mi_41\NNP\14207561|NONE_0
D004121_D009203 NONE sulphoxide_15\RB\0|NONE_0 (r_pobj) of_13\IN\0|2_5|)_22 (r_prep) ml_12\NNS\13616054|NONE_0 (r_pobj) in_10\IN\13603305|upon_67|(_33|weight_17|given_32|protected_79|._150 (r_prep) suspended_9\VBN\1481360|NONE_0 (l_prep) given_17\VBN\5892096|upon_99|(_65|weight_49|in_32|protected_47|._118 (l_prep) to_22\IN\0|intraperitoneally_30|for_12 (l_pobj) rats_24\NNS\2329401|NONE_0 (l_compound) mi_23\NNP\14207561|NONE_0
D013481_D009203 NONE superoxide_7\JJ\14971519|,_20|catalase_22|,_116|antioxidants_130 (r_amod) dismutase_8\NN\0|such_19 (r_pobj) as_6\IN\14622893|antioxidant_25 (r_prep) enzymes_4\NNS\14723628|heart_25 (r_dobj) tissue_2\NN\5220461|were_246|in_259|._269 (r_nsubjpass) altered_39\VBN\0|NONE_0 (l_prep) in_40\IN\13603305|tissue_259|were_13|._10 (l_pobj) rats_42\NNS\2329401|NONE_0 (l_compound) mi_41\NNP\14207561|NONE_0
D007545_D006331 NONE isph_14\NNP\0|-_4 (r_npadvmod) induced_16\VBN\1627355|NONE_0 (r_amod) mi_17\NNP\14207561|NONE_0 (r_pobj) against_13\IN\0|a_20|beneficial_18 (r_prep) effect_12\NN\34213|that_36|mangiferin_31|due_31 (r_dobj) exerts_9\VBZ\1158872|from_55|it_32|is_29|._150 (l_prep) due_18\IN\5174653|that_67|mangiferin_62|effect_31 (l_pcomp) to_19\IN\0|NONE_0 (l_pobj) potential_22\NN\14481929|NONE_0 (l_relcl) regulated_25\VBD\296178|its_33|antioxidant_29|,_8 (l_prep) against_30\IN\0|which_43|system_7 (l_pobj) damage_32\NN\7296428|NONE_0
D007545_D009203 CID isoproterenol_10\NN\3740161|-_13 (r_npadvmod) induced_12\VBN\1627355|myocardial_8|in_30 (r_amod) infarction_14\NN\14204950|NONE_0
D007545_D009203 CID isoproterenol_5\NN\3740161|NONE_0 (r_pobj) on_4\IN\0|(_17|isph)-induced_18|myocardial_32|(_54|mi_55|)_57|in_59|through_67 (r_prep) infarction_9\NN\14204950|(_60|)_46|,_45|._59
D007545_D009203 CID isoproterenol_5\NN\3740161|NONE_0 (r_pobj) on_4\IN\0|(_17|isph)-induced_18|myocardial_32|(_54|mi_55|)_57|in_59|through_67 (r_prep) infarction_9\NN\14204950|(_60|)_46|,_45|._59 (l_appos) mi_11\NNP\14207561|on_55|(_38|isph)-induced_37|myocardial_23|(_1|)_2|in_4|through_12
D007545_D009203 CID isph)-induced_7\JJ\0|on_18|(_1|myocardial_14|(_36|mi_37|)_39|in_41|through_49 (r_amod) infarction_9\NN\14204950|(_60|)_46|,_45|._59
D007545_D009203 CID isph)-induced_7\JJ\0|on_18|(_1|myocardial_14|(_36|mi_37|)_39|in_41|through_49 (r_amod) infarction_9\NN\14204950|(_60|)_46|,_45|._59 (l_appos) mi_11\NNP\14207561|on_55|(_38|isph)-induced_37|myocardial_23|(_1|)_2|in_4|through_12
D007545_D009203 CID isph_21\NNP\0|-_4 (r_npadvmod) induced_23\VBN\1627355|mi_8 (r_amod) rats_25\NNS\2329401|NONE_0 (l_compound) mi_24\NNP\14207561|induced_8
D007545_D009203 CID isph_14\NNP\0|-_4 (r_npadvmod) induced_16\VBN\1627355|NONE_0 (r_amod) mi_17\NNP\14207561|NONE_0
2004
D000639_D002037 CID elavil_5\NNP\4482543|nortriptyline_19 (r_conj) aventyl_0\NNP\0|each_51|produced_56|left_65|branch_77|in_90|._112 (r_nsubj) block_14\NN\21939|NONE_0
D000639_D002037 CID amitriptyline_7\FW\4482543|NONE_0 (r_appos) elavil_5\NNP\4482543|nortriptyline_19 (r_conj) aventyl_0\NNP\0|each_51|produced_56|left_65|branch_77|in_90|._112 (r_nsubj) block_14\NN\21939|NONE_0
D013881_D017180 CID mellaril_8\NNP\3713736|receiving_25|,_2|be_36|was_107|._139 (r_nsubj) appeared_12\VBD\2604760|NONE_0 (l_xcomp) be_14\VB\14625458|receiving_61|,_38|mellaril_36|was_71|._103 (l_acomp) responsible_15\JJ\0|to_6 (l_prep) for_16\IN\0|NONE_0 (l_pobj) cases_18\NNS\7283608|NONE_0 (l_prep) of_19\IN\0|five_11|,_26 (l_pobj) tachycardia_21\NN\14110674|NONE_0
D013881_D017180 CID thioridazine_10\NNP\3713736|)_12 (r_appos) mellaril_8\NNP\3713736|receiving_25|,_2|be_36|was_107|._139 (r_nsubj) appeared_12\VBD\2604760|NONE_0 (l_xcomp) be_14\VB\14625458|receiving_61|,_38|mellaril_36|was_71|._103 (l_acomp) responsible_15\JJ\0|to_6 (l_prep) for_16\IN\0|NONE_0 (l_pobj) cases_18\NNS\7283608|NONE_0 (l_prep) of_19\IN\0|five_11|,_26 (l_pobj) tachycardia_21\NN\14110674|NONE_0
D010640_D005117 NONE phenothiazines_16\NNS\14771088|NONE_0 (r_dobj) receiving_15\VBG\2210855|NONE_0 (r_acl) patients_14\NNS\9898892|NONE_0 (r_pobj) to_13\IN\0|cardiac_22 (r_prep) complications_12\NNS\1073995|NONE_0
D008012_D001145 NONE lidocaine_8\NN\3681148|NONE_0 (r_pobj) of_7\IN\0|intravenous_27 (r_prep) administration_6\NN\1133281|and_28 (r_pobj) to_4\IN\0|arrhythmias_22|direct_50 (r_prep) responded_3\VBD\2367363|;_89|pacing_103|was_110|in_123|._226 (l_nsubj) arrhythmias_2\NNS\14103288|to_22|direct_72
D011433_D001145 NONE propranolol_27\NN\0|NONE_0 (r_pobj) of_26\IN\0|some_46|and_31|administration_15|combined_15 (r_prep) instances_22\NNS\7283608|NONE_0 (r_pobj) in_20\IN\13603305|responded_123|;_34|pacing_20|was_13|._103 (r_prep) required_19\VBN\0|NONE_0 (l_ccomp) responded_3\VBD\2367363|;_89|pacing_103|was_110|in_123|._226 (l_nsubj) arrhythmias_2\NNS\14103288|to_22|direct_72
D002746_D013617 NONE thorazine_7\NN\3713736|NONE_0 (r_dobj) receiving_6\VBG\2210855|one_12 (r_acl) patient_5\NN\9898892|NONE_0 (r_pobj) in_3\IN\13603305|tachycardia_22|._51 (r_prep) developed_2\VBN\1753788|NONE_0 (l_nsubj) tachycardia_1\NN\14110674|in_22|._73
D002746_D013617 NONE chlorpromazine_9\NN\3713736|NONE_0 (r_appos) thorazine_7\NN\3713736|NONE_0 (r_dobj) receiving_6\VBG\2210855|one_12 (r_acl) patient_5\NN\9898892|NONE_0 (r_pobj) in_3\IN\13603305|tachycardia_22|._51 (r_prep) developed_2\VBN\1753788|NONE_0 (l_nsubj) tachycardia_1\NN\14110674|in_22|._73
D009661_D002037 CID aventyl_0\NNP\0|each_51|produced_56|left_65|branch_77|in_90|._112 (r_nsubj) block_14\NN\21939|NONE_0
D009661_D002037 CID nortriptyline_2\NN\4482543|elavil_19 (r_appos) aventyl_0\NNP\0|each_51|produced_56|left_65|branch_77|in_90|._112 (r_nsubj) block_14\NN\21939|NONE_0
12745515
D016642_D012892 NONE bupropion_9\NN\0|sleep_40|and_22 (r_conj) deprivation_4\NN\14493145|NONE_0
D016642_D012892 NONE bupropion_12\NN\0|release_8|and_14|deprivation_24 (r_compound) use_13\NN\407535|NONE_0 (l_conj) deprivation_16\NN\14493145|release_32|bupropion_24|and_10
D016642_D012892 NONE bupropion_11\NN\0|-_9 (r_npadvmod) associated_13\VBN\628491|NONE_0 (r_amod) seizures_14\NNS\14081375|NONE_0 (r_pobj) of_10\IN\0|the_9 (r_prep) risk_9\NN\14541044|NONE_0 (r_pobj) to_7\IN\0|that_31|deprivation_20|may_8 (r_prep) add_6\VB\14304060|we_38|._48 (l_nsubj) deprivation_4\NN\14493145|that_11|may_12|to_20
D016642_D012640 CID bupropion_9\NN\0|sleep_40|and_22 (r_conj) deprivation_4\NN\14493145|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|._65 (r_acl) seizure_0\NN\14081375|NONE_0
D016642_D012640 CID bupropion_12\NN\0|release_8|and_14|deprivation_24 (r_compound) use_13\NN\407535|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) associated_7\VBN\628491|a_22|generalized_20 (r_acl) seizure_6\NN\14081375|report_31|._77
D016642_D012640 CID bupropion_4\NN\0|NONE_0 (r_compound) use_5\NN\407535|NONE_0 (r_pobj) of_3\IN\0|5_8 (r_prep) weeks_2\NNS\15113229|NONE_0 (r_pobj) after_0\IN\0|,_30|subject_36|seizure_83|after_91|._162 (r_prep) experienced_9\VBD\2108377|NONE_0 (l_dobj) seizure_14\NN\14081375|after_83|,_53|subject_47|after_8|._79
D016642_D012640 CID bupropion_11\NN\0|-_9 (r_npadvmod) associated_13\VBN\628491|NONE_0 (r_amod) seizures_14\NNS\14081375|NONE_0
3708922
D000666_D007674 NONE b_24\NN\1355326|(_38|at_37|)_17|,_16|,_18|used_41|,_74 (r_conj) gentamicin_16\NN\2716866|such_8 (r_pobj) as_15\IN\14622893|a_30|nephrotoxic_28|,_7 (r_prep) potential_12\NN\14481929|NONE_0 (l_amod) nephrotoxic_11\JJ\0|a_2|,_21|as_28
D000666_D064420 NONE b_24\NN\1355326|(_38|at_37|)_17|,_16|,_18|used_41|,_74 (r_conj) gentamicin_16\NN\2716866|such_8 (r_pobj) as_15\IN\14622893|a_30|nephrotoxic_28|,_7 (r_prep) potential_12\NN\14481929|NONE_0 (r_pobj) with_9\IN\0|the_70|combined_66|of_42|drugs_6 (r_prep) administration_2\NN\1133281|did_220|not_224|csa_242|induced_246|._279 (r_nsubj) aggravate_38\VB\126264|NONE_0 (l_ccomp) induced_41\VBN\1627355|administration_246|did_26|not_22|csa_4|._33 (l_dobj) toxicity_42\NN\13576101|NONE_0
D007654_D007674 NONE ketoconazole_26\NN\0|amphothericin_20|and_4 (r_conj) b_24\NN\1355326|(_38|at_37|)_17|,_16|,_18|used_41|,_74 (r_conj) gentamicin_16\NN\2716866|such_8 (r_pobj) as_15\IN\14622893|a_30|nephrotoxic_28|,_7 (r_prep) potential_12\NN\14481929|NONE_0 (l_amod) nephrotoxic_11\JJ\0|a_2|,_21|as_28
D016572_D064420 NONE csa_4\NNP\0|NONE_0 (r_pobj) of_3\IN\0|the_28|combined_24|drugs_36|with_42 (r_prep) administration_2\NN\1133281|did_220|not_224|csa_242|induced_246|._279 (r_nsubj) aggravate_38\VB\126264|NONE_0 (l_ccomp) induced_41\VBN\1627355|administration_246|did_26|not_22|csa_4|._33 (l_dobj) toxicity_42\NN\13576101|NONE_0
D016572_D064420 NONE csa_40\NNP\0|administration_242|did_22|not_18|induced_4|._37 (r_dobj) aggravate_38\VB\126264|NONE_0 (l_ccomp) induced_41\VBN\1627355|administration_246|did_26|not_22|csa_4|._33 (l_dobj) toxicity_42\NN\13576101|NONE_0
D007654_D064420 NONE ketoconazole_26\NN\0|amphothericin_20|and_4 (r_conj) b_24\NN\1355326|(_38|at_37|)_17|,_16|,_18|used_41|,_74 (r_conj) gentamicin_16\NN\2716866|such_8 (r_pobj) as_15\IN\14622893|a_30|nephrotoxic_28|,_7 (r_prep) potential_12\NN\14481929|NONE_0 (r_pobj) with_9\IN\0|the_70|combined_66|of_42|drugs_6 (r_prep) administration_2\NN\1133281|did_220|not_224|csa_242|induced_246|._279 (r_nsubj) aggravate_38\VB\126264|NONE_0 (l_ccomp) induced_41\VBN\1627355|administration_246|did_26|not_22|csa_4|._33 (l_dobj) toxicity_42\NN\13576101|NONE_0
D005839_D007674 NONE gentamicin_16\NN\2716866|such_8 (r_pobj) as_15\IN\14622893|a_30|nephrotoxic_28|,_7 (r_prep) potential_12\NN\14481929|NONE_0 (l_amod) nephrotoxic_11\JJ\0|a_2|,_21|as_28
D005839_D007674 NONE gentamicin_0\NNP\2716866|,_25|however_27|,_34|nephrotoxicity_50|._64 (r_nsubj) increased_7\VBD\169651|NONE_0 (l_dobj) nephrotoxicity_9\NN\0|gentamicin_50|,_25|however_23|,_16|._14
D016572_D007674 CID cyclosporine_1\NN\0|experimental_13|:_27|risk_29|._61 (r_compound) nephrotoxicity_2\NN\0|NONE_0
D016572_D007674 CID cyclosporine_3\NN\0|or_25|in_28 (r_pobj) of_2\IN\0|the_9 (l_conj) in_9\IN\13603305|cyclosporine_28|or_3 (l_pobj) combination_10\NN\7951464|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) chemotherapeutics_13\NNS\0|NONE_0 (l_prep) in_14\IN\13603305|various_26 (l_pobj) development_16\NN\248977|NONE_0 (l_prep) of_17\IN\0|the_16 (l_pobj) toxicity_19\NN\13576101|NONE_0
D016572_D007674 CID csa_5\NNP\0|NONE_0 (r_appos) cyclosporine_3\NN\0|or_25|in_28 (r_pobj) of_2\IN\0|the_9 (l_conj) in_9\IN\13603305|cyclosporine_28|or_3 (l_pobj) combination_10\NN\7951464|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) chemotherapeutics_13\NNS\0|NONE_0 (l_prep) in_14\IN\13603305|various_26 (l_pobj) development_16\NN\248977|NONE_0 (l_prep) of_17\IN\0|the_16 (l_pobj) toxicity_19\NN\13576101|NONE_0
D016572_D007674 CID csa_4\NNP\0|NONE_0 (r_pobj) of_3\IN\0|the_28|combined_24|drugs_36|with_42 (r_prep) administration_2\NN\1133281|did_220|not_224|csa_242|induced_246|._279 (l_prep) with_9\IN\0|the_70|combined_66|of_42|drugs_6 (l_pobj) potential_12\NN\14481929|NONE_0 (l_amod) nephrotoxic_11\JJ\0|a_2|,_21|as_28
D016572_D007674 CID csa_40\NNP\0|administration_242|did_22|not_18|induced_4|._37 (r_dobj) aggravate_38\VB\126264|NONE_0 (l_nsubj) administration_2\NN\1133281|did_220|not_224|csa_242|induced_246|._279 (l_prep) with_9\IN\0|the_70|combined_66|of_42|drugs_6 (l_pobj) potential_12\NN\14481929|NONE_0 (l_amod) nephrotoxic_11\JJ\0|a_2|,_21|as_28
D016572_D007674 CID csa_8\NNP\0|NONE_0 (r_compound) nephrotoxicity_9\NN\0|gentamicin_50|,_25|however_23|,_16|._14
D016572_D007674 CID csa_6\NNP\0|NONE_0 (r_pobj) by_5\IN\0|NONE_0 (r_agent) induced_4\VBN\1627355|the_19 (r_acl) nephrotoxicity_3\NN\0|thus_10|,_6|mechanism_59|._68
D005839_D064420 NONE gentamicin_16\NN\2716866|such_8 (r_pobj) as_15\IN\14622893|a_30|nephrotoxic_28|,_7 (r_prep) potential_12\NN\14481929|NONE_0 (r_pobj) with_9\IN\0|the_70|combined_66|of_42|drugs_6 (r_prep) administration_2\NN\1133281|did_220|not_224|csa_242|induced_246|._279 (r_nsubj) aggravate_38\VB\126264|NONE_0 (l_ccomp) induced_41\VBN\1627355|administration_246|did_26|not_22|csa_4|._33 (l_dobj) toxicity_42\NN\13576101|NONE_0
15266215
C406224_D001168 NONE valdecoxib_6\NNS\3124700|NONE_0 (l_prep) versus_7\IN\0|the_51|cyclooxygenase-2_47|specific_30|inhibitor_21 (l_pobj) agents_10\NNS\7347|NONE_0 (l_conj) placebo_12\NN\3740161|nonsteroidal_41|antiinflammatory_28|and_4 (l_prep) on_13\IN\0|NONE_0 (l_pobj) events_16\NNS\23100|NONE_0 (l_prep) in_17\IN\13603305|cardiovascular_33|thrombotic_18 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) arthritis_20\NN\14171682|NONE_0
D009288_D013927 NONE naproxen_46\NN\3828465|tid_8|,_5|or_3|and_21|data_33 (r_conj) ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (r_npadvmod) nsaid_33\NNP\2721538|incidence_198|was_77|by_62|,_15|._190 (r_appos) determined_19\VBN\0|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_121|by_136|,_183|nsaid_198|._388 (l_prep) of_2\IN\0|the_14 (l_pobj) events_5\NNS\23100|NONE_0 (l_amod) thrombotic_4\JJ\0|cardiovascular_15|(_18|thrombotic_81|)_91
D009288_D013927 NONE naproxen_46\NN\3828465|tid_8|,_5|or_3|and_21|data_33 (r_conj) ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (r_npadvmod) nsaid_33\NNP\2721538|incidence_198|was_77|by_62|,_15|._190 (r_appos) determined_19\VBN\0|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_121|by_136|,_183|nsaid_198|._388 (l_prep) of_2\IN\0|the_14 (l_pobj) events_5\NNS\23100|NONE_0 (l_appos) thrombotic_16\JJ\0|cardiovascular_96|thrombotic_81|(_63|)_10
D009288_D010003 NONE naproxen_46\NN\3828465|tid_8|,_5|or_3|and_21|data_33 (r_conj) ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (l_conj) data_53\NNS\7951464|tid_41|,_38|or_36|naproxen_33|and_12 (l_prep) from_54\IN\0|placebo_13 (l_pobj) trials_61\NNS\786195|NONE_0 (l_nmod) osteoarthritis_57\NN\14186541|arthritis_30|were_52
D007052_D010003 NONE ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (l_conj) data_53\NNS\7951464|tid_41|,_38|or_36|naproxen_33|and_12 (l_prep) from_54\IN\0|placebo_13 (l_pobj) trials_61\NNS\786195|NONE_0 (l_nmod) osteoarthritis_57\NN\14186541|arthritis_30|were_52
C406224_D010003 NONE valdecoxib_6\NNS\3124700|NONE_0 (r_pobj) for_5\IN\0|cardiovascular_26|event_11|,_14|inhibitor_37 (r_prep) data_4\NNS\7951464|we_34|._181 (l_appos) inhibitor_11\NN\20090|cardiovascular_63|event_48|for_37|,_23 (l_prep) in_12\IN\13603305|a_31|new_29|cox-2-specific_25|treated_76 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|8000_14 (l_pobj) osteoarthritis_17\NN\14186541|NONE_0
C406224_D010003 NONE valdecoxib_23\NNS\3124700|NONE_0 (r_dobj) analyzing_21\VBG\0|NONE_0 (r_pcomp) by_20\IN\0|incidence_136|was_15|,_47|nsaid_62|._252 (r_prep) determined_19\VBN\0|NONE_0 (l_appos) nsaid_33\NNP\2721538|incidence_198|was_77|by_62|,_15|._190 (l_npadvmod) ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (l_conj) data_53\NNS\7951464|tid_41|,_38|or_36|naproxen_33|and_12 (l_prep) from_54\IN\0|placebo_13 (l_pobj) trials_61\NNS\786195|NONE_0 (l_nmod) osteoarthritis_57\NN\14186541|arthritis_30|were_52
C406224_D010003 NONE valdecoxib_24\NN\3124700|NONE_0 (r_compound) doses_25\NNS\3740161|short-_128|term_104|with_89 (r_conj) treatment_5\NN\654885|was_105|not_109|with_124|._297 (r_nsubjpass) associated_28\VBN\628491|NONE_0 (l_prep) with_29\IN\0|treatment_124|was_19|not_15|._173 (l_pobj) incidence_32\NN\13821570|NONE_0 (l_prep) of_33\IN\0|an_23|increased_20 (l_pobj) events_35\NNS\23100|NONE_0 (l_amod) relative_36\JJ\7846|thrombotic_18 (l_prep) to_37\IN\0|NONE_0 (l_pobj) nsaids_39\NNPS\2721538|NONE_0 (l_prep) in_42\IN\13603305|nonselective_31|or_11|placebo_8|in_52 (l_pobj) patients_47\NNS\9898892|NONE_0 (l_nmod) osteoarthritis_43\NN\14186541|arthritis_30
D004008_D013927 NONE diclofenac_35\NN\0|mg_14|,_20 (r_nmod) bid_38\NN\7160883|nonselective_37|(_18|ibuprofen_5 (r_appos) nsaid_33\NNP\2721538|incidence_198|was_77|by_62|,_15|._190 (r_appos) determined_19\VBN\0|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_121|by_136|,_183|nsaid_198|._388 (l_prep) of_2\IN\0|the_14 (l_pobj) events_5\NNS\23100|NONE_0 (l_amod) thrombotic_4\JJ\0|cardiovascular_15|(_18|thrombotic_81|)_91
D004008_D013927 NONE diclofenac_35\NN\0|mg_14|,_20 (r_nmod) bid_38\NN\7160883|nonselective_37|(_18|ibuprofen_5 (r_appos) nsaid_33\NNP\2721538|incidence_198|was_77|by_62|,_15|._190 (r_appos) determined_19\VBN\0|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_121|by_136|,_183|nsaid_198|._388 (l_prep) of_2\IN\0|the_14 (l_pobj) events_5\NNS\23100|NONE_0 (l_appos) thrombotic_16\JJ\0|cardiovascular_96|thrombotic_81|(_63|)_10
D004008_D001172 NONE diclofenac_35\NN\0|mg_14|,_20 (r_nmod) bid_38\NN\7160883|nonselective_37|(_18|ibuprofen_5 (r_appos) nsaid_33\NNP\2721538|incidence_198|was_77|by_62|,_15|._190 (l_npadvmod) ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (l_conj) data_53\NNS\7951464|tid_41|,_38|or_36|naproxen_33|and_12 (l_prep) from_54\IN\0|placebo_13 (l_pobj) trials_61\NNS\786195|NONE_0 (l_compound) arthritis_60\NN\14171682|osteoarthritis_30|were_22
C406224_D001172 NONE valdecoxib_6\NNS\3124700|NONE_0 (r_pobj) for_5\IN\0|cardiovascular_26|event_11|,_14|inhibitor_37 (r_prep) data_4\NNS\7951464|we_34|._181 (l_appos) inhibitor_11\NN\20090|cardiovascular_63|event_48|for_37|,_23 (l_prep) in_12\IN\13603305|a_31|new_29|cox-2-specific_25|treated_76 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|8000_14 (l_pobj) osteoarthritis_17\NN\14186541|NONE_0 (l_conj) arthritis_20\NN\14171682|and_15
C406224_D001172 NONE valdecoxib_23\NNS\3124700|NONE_0 (r_dobj) analyzing_21\VBG\0|NONE_0 (r_pcomp) by_20\IN\0|incidence_136|was_15|,_47|nsaid_62|._252 (r_prep) determined_19\VBN\0|NONE_0 (l_appos) nsaid_33\NNP\2721538|incidence_198|was_77|by_62|,_15|._190 (l_npadvmod) ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (l_conj) data_53\NNS\7951464|tid_41|,_38|or_36|naproxen_33|and_12 (l_prep) from_54\IN\0|placebo_13 (l_pobj) trials_61\NNS\786195|NONE_0 (l_compound) arthritis_60\NN\14171682|osteoarthritis_30|were_22
C406224_D001172 NONE valdecoxib_24\NN\3124700|NONE_0 (r_compound) doses_25\NNS\3740161|short-_128|term_104|with_89 (r_conj) treatment_5\NN\654885|was_105|not_109|with_124|._297 (r_nsubjpass) associated_28\VBN\628491|NONE_0 (l_prep) with_29\IN\0|treatment_124|was_19|not_15|._173 (l_pobj) incidence_32\NN\13821570|NONE_0 (l_prep) of_33\IN\0|an_23|increased_20 (l_pobj) events_35\NNS\23100|NONE_0 (l_amod) relative_36\JJ\7846|thrombotic_18 (l_prep) to_37\IN\0|NONE_0 (l_pobj) nsaids_39\NNPS\2721538|NONE_0 (l_prep) in_42\IN\13603305|nonselective_31|or_11|placebo_8|in_52 (l_pobj) patients_47\NNS\9898892|NONE_0 (l_compound) arthritis_46\NN\14171682|osteoarthritis_30
C406224_D013927 NONE valdecoxib_6\NNS\3124700|NONE_0 (l_prep) versus_7\IN\0|the_51|cyclooxygenase-2_47|specific_30|inhibitor_21 (l_pobj) agents_10\NNS\7347|NONE_0 (l_conj) placebo_12\NN\3740161|nonsteroidal_41|antiinflammatory_28|and_4 (l_prep) on_13\IN\0|NONE_0 (l_pobj) events_16\NNS\23100|NONE_0 (l_amod) thrombotic_15\JJ\0|cardiovascular_15|in_18
C406224_D013927 NONE valdecoxib_23\NNS\3124700|NONE_0 (r_dobj) analyzing_21\VBG\0|NONE_0 (r_pcomp) by_20\IN\0|incidence_136|was_15|,_47|nsaid_62|._252 (r_prep) determined_19\VBN\0|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_121|by_136|,_183|nsaid_198|._388 (l_prep) of_2\IN\0|the_14 (l_pobj) events_5\NNS\23100|NONE_0 (l_amod) thrombotic_4\JJ\0|cardiovascular_15|(_18|thrombotic_81|)_91
C406224_D013927 NONE valdecoxib_23\NNS\3124700|NONE_0 (r_dobj) analyzing_21\VBG\0|NONE_0 (r_pcomp) by_20\IN\0|incidence_136|was_15|,_47|nsaid_62|._252 (r_prep) determined_19\VBN\0|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_121|by_136|,_183|nsaid_198|._388 (l_prep) of_2\IN\0|the_14 (l_pobj) events_5\NNS\23100|NONE_0 (l_appos) thrombotic_16\JJ\0|cardiovascular_96|thrombotic_81|(_63|)_10
C406224_D013927 NONE valdecoxib_12\NNS\3124700|NONE_0 (r_pobj) for_11\IN\0|NONE_0 (r_prep) similar_10\JJ\0|incidences_37|._43 (r_acomp) were_9\VBD\0|NONE_0 (l_nsubj) incidences_5\NNS\13821570|similar_37|._80 (l_prep) of_6\IN\0|crude_39|adjusted_20 (l_pobj) events_8\NNS\23100|NONE_0 (l_amod) thrombotic_7\JJ\0|NONE_0
C406224_D013927 NONE valdecoxib_11\NN\3124700|each_5 (r_compound) dose_12\NN\3740161|NONE_0 (r_pobj) for_9\IN\0|NONE_0 (r_prep) similar_8\JJ\0|risk_43|also_5|._32 (r_acomp) was_6\VBD\0|NONE_0 (l_nsubj) risk_1\NN\14541044|also_38|similar_43|._75 (l_prep) of_2\IN\0|the_9 (l_pobj) events_5\NNS\23100|NONE_0 (l_amod) thrombotic_4\JJ\0|serious_8
C406224_D013927 NONE valdecoxib_23\NN\3124700|,_15|%_10|;_2 (r_conj) placebo_15\NN\3740161|of_12|(_1|)_70 (r_appos) nonusers_11\NNS\0|NONE_0 (r_pobj) than_10\IN\0|aspirin_14 (r_prep) users_9\NNS\7846|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) users_6\NNS\7846|NONE_0 (r_pobj) for_5\IN\0|risk_29|higher_7|._124 (r_prep) was_2\VBD\0|NONE_0 (l_nsubj) risk_1\NN\14541044|higher_22|for_29|._153 (l_amod) thrombotic_0\JJ\0|NONE_0
C406224_D013927 NONE valdecoxib_24\NN\3124700|NONE_0 (r_compound) doses_25\NNS\3740161|short-_128|term_104|with_89 (r_conj) treatment_5\NN\654885|was_105|not_109|with_124|._297 (r_nsubjpass) associated_28\VBN\628491|NONE_0 (l_prep) with_29\IN\0|treatment_124|was_19|not_15|._173 (l_pobj) incidence_32\NN\13821570|NONE_0 (l_prep) of_33\IN\0|an_23|increased_20 (l_pobj) events_35\NNS\23100|NONE_0 (l_amod) thrombotic_34\JJ\0|relative_18
D007052_D013927 NONE ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (r_npadvmod) nsaid_33\NNP\2721538|incidence_198|was_77|by_62|,_15|._190 (r_appos) determined_19\VBN\0|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_121|by_136|,_183|nsaid_198|._388 (l_prep) of_2\IN\0|the_14 (l_pobj) events_5\NNS\23100|NONE_0 (l_amod) thrombotic_4\JJ\0|cardiovascular_15|(_18|thrombotic_81|)_91
D007052_D013927 NONE ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (r_npadvmod) nsaid_33\NNP\2721538|incidence_198|was_77|by_62|,_15|._190 (r_appos) determined_19\VBN\0|NONE_0 (l_nsubjpass) incidence_1\NN\13821570|was_121|by_136|,_183|nsaid_198|._388 (l_prep) of_2\IN\0|the_14 (l_pobj) events_5\NNS\23100|NONE_0 (l_appos) thrombotic_16\JJ\0|cardiovascular_96|thrombotic_81|(_63|)_10
D001241_D013927 CID aspirin_8\NN\2707683|than_14 (r_compound) users_9\NNS\7846|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) users_6\NNS\7846|NONE_0 (r_pobj) for_5\IN\0|risk_29|higher_7|._124 (r_prep) was_2\VBD\0|NONE_0 (l_nsubj) risk_1\NN\14541044|higher_22|for_29|._153 (l_amod) thrombotic_0\JJ\0|NONE_0
D001241_D013927 CID aspirin_13\NN\2707683|NONE_0 (r_pobj) of_12\IN\0|(_11|placebo_12|)_82 (r_prep) nonusers_11\NNS\0|NONE_0 (r_pobj) than_10\IN\0|aspirin_14 (r_prep) users_9\NNS\7846|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) users_6\NNS\7846|NONE_0 (r_pobj) for_5\IN\0|risk_29|higher_7|._124 (r_prep) was_2\VBD\0|NONE_0 (l_nsubj) risk_1\NN\14541044|higher_22|for_29|._153 (l_amod) thrombotic_0\JJ\0|NONE_0
D009288_D001172 NONE naproxen_46\NN\3828465|tid_8|,_5|or_3|and_21|data_33 (r_conj) ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (l_conj) data_53\NNS\7951464|tid_41|,_38|or_36|naproxen_33|and_12 (l_prep) from_54\IN\0|placebo_13 (l_pobj) trials_61\NNS\786195|NONE_0 (l_compound) arthritis_60\NN\14171682|osteoarthritis_30|were_22
D007052_D001172 NONE ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (l_conj) data_53\NNS\7951464|tid_41|,_38|or_36|naproxen_33|and_12 (l_prep) from_54\IN\0|placebo_13 (l_pobj) trials_61\NNS\786195|NONE_0 (l_compound) arthritis_60\NN\14171682|osteoarthritis_30|were_22
D004008_D010003 NONE diclofenac_35\NN\0|mg_14|,_20 (r_nmod) bid_38\NN\7160883|nonselective_37|(_18|ibuprofen_5 (r_appos) nsaid_33\NNP\2721538|incidence_198|was_77|by_62|,_15|._190 (l_npadvmod) ibuprofen_40\VBD\3828465|nonselective_42|(_23|bid_5 (l_conj) data_53\NNS\7951464|tid_41|,_38|or_36|naproxen_33|and_12 (l_prep) from_54\IN\0|placebo_13 (l_pobj) trials_61\NNS\786195|NONE_0 (l_nmod) osteoarthritis_57\NN\14186541|arthritis_30|were_52
3311455
D016572_D007674 CID cyclosporine_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|term_13 (r_prep) therapy_15\NN\657604|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) secondary_10\JJ\8426461|chronic_23 (r_amod) nephrotoxicity_9\NN\0|NONE_0
D016572_D007674 CID cyclosporine_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|even_25|these_20|lower_14 (r_prep) dosages_6\NNS\13576355|that_22|can_24|nephrotoxicity_42|required_123 (r_nsubj) cause_10\VB\7323922|we_59|._148 (l_dobj) nephrotoxicity_12\NN\0|that_64|dosages_42|can_18|required_81
20635749
D000638_D009230 CID amiodarone_6\NN\2715941|presenting_11 (r_pobj) on_5\IN\0|severe_40|failure_16|:_44|report_53|._59 (l_pcomp) presenting_7\VBG\2137132|amiodarone_11 (l_prep) with_8\IN\0|NONE_0 (l_pobj) coma_10\NN\5678932|NONE_0
D000638_D009230 CID amiodarone_10\NN\2715941|-_10 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) hypothyroidism_13\NN\14059928|NONE_0 (r_pobj) to_9\IN\0|secondary_10|in_37 (r_prep) coma_7\NN\5678932|this_34|report_19|._107
D000638_D009230 CID amiodarone_19\NN\2715941|term_5 (r_compound) therapy_20\NN\657604|NONE_0 (r_pobj) during_16\IN\0|one_33|case_29|of_17 (r_prep) report_12\NN\6470073|to_70|there_18|._59 (l_prep) of_13\IN\0|one_16|case_12|during_17 (l_pobj) coma_15\NN\5678932|NONE_0
D000638_D003128 CID amiodarone_6\NN\2715941|presenting_11 (r_pobj) on_5\IN\0|severe_40|failure_16|:_44|report_53|._59 (l_pcomp) presenting_7\VBG\2137132|amiodarone_11 (l_prep) with_8\IN\0|NONE_0 (l_pobj) coma_10\NN\5678932|NONE_0
D000638_D003128 CID amiodarone_10\NN\2715941|-_10 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) hypothyroidism_13\NN\14059928|NONE_0 (r_pobj) to_9\IN\0|secondary_10|in_37 (r_prep) coma_7\NN\5678932|this_34|report_19|._107
D000638_D003128 CID amiodarone_19\NN\2715941|term_5 (r_compound) therapy_20\NN\657604|NONE_0 (r_pobj) during_16\IN\0|one_33|case_29|of_17 (r_prep) report_12\NN\6470073|to_70|there_18|._59 (l_prep) of_13\IN\0|one_16|case_12|during_17 (l_pobj) coma_15\NN\5678932|NONE_0
D000638_D006333 NONE amiodarone_6\NN\2715941|presenting_11 (r_pobj) on_5\IN\0|severe_40|failure_16|:_44|report_53|._59 (r_prep) patient_4\NN\9898892|NONE_0 (l_compound) failure_3\NN\66216|severe_24|on_16|:_60|report_69|._75
D000638_D006333 NONE amiodarone_10\NN\2715941|-_10 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) hypothyroidism_13\NN\14059928|NONE_0 (r_pobj) to_9\IN\0|secondary_10|in_37 (r_prep) coma_7\NN\5678932|this_34|report_19|._107 (l_prep) in_14\IN\13603305|secondary_47|to_37 (l_pobj) patient_16\NN\9898892|NONE_0 (l_prep) with_17\IN\0|a_10 (l_pobj) failure_21\NN\66216|NONE_0
D000638_D006333 NONE amiodarone_10\NN\2715941|-_10 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) hypothyroidism_13\NN\14059928|NONE_0 (r_pobj) to_9\IN\0|secondary_10|in_37 (r_prep) coma_7\NN\5678932|this_34|report_19|._107 (l_prep) in_14\IN\13603305|secondary_47|to_37 (l_pobj) patient_16\NN\9898892|NONE_0 (l_prep) with_17\IN\0|a_10 (l_pobj) failure_21\NN\66216|NONE_0 (l_appos) chf_23\NNP\0|severe_33|heart_15
D000638_D006333 NONE amiodarone_4\NN\2715941|NONE_0 (r_pobj) on_3\IN\0|with_9 (r_prep) patients_0\NNS\9898892|may_32|morbidity_51|,_94|and_96|deserve_109|._178 (l_prep) with_1\IN\0|on_9 (l_pobj) chf_2\NNP\0|NONE_0
D000638_D006333 NONE amiodarone_13\NN\2715941|NONE_0 (l_prep) among_14\IN\0|NONE_0 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_compound) chf_15\NNP\0|NONE_0
D000638_D007037 CID amiodarone_10\NN\2715941|-_10 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) hypothyroidism_13\NN\14059928|NONE_0
D000638_D007037 CID amiodarone_4\NN\2715941|NONE_0 (r_pobj) on_3\IN\0|with_9 (r_prep) patients_0\NNS\9898892|may_32|morbidity_51|,_94|and_96|deserve_109|._178 (r_nsubj) suffer_6\VB\2110220|NONE_0 (l_dobj) morbidity_8\NN\13826959|patients_51|may_19|,_43|and_45|deserve_58|._127 (l_prep) from_11\IN\0|serious_32|and_14|mortality_10 (l_pobj) hypothyroidism_12\NN\14059928|NONE_0
17042884
C069541_D017109 NONE quetiapine_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|akathisia_11|,_2 (r_prep) including_10\VBG\0|to_43|symptoms_16|,_2 (l_pobj) akathisia_11\NN\0|,_9|with_11
C069541_D017109 NONE quetiapine_16\NN\0|(_23|%_28|)_29 (r_amod) monotherapy_17\NN\0|NONE_0 (r_pobj) with_15\IN\0|no_13|than_36 (r_prep) different_14\JJ\0|incidence_69|._71 (r_acomp) was_12\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|different_69|._140 (l_prep) including_9\VBG\0|the_45|of_31|,_2|,_19 (l_pobj) akathisia_10\NN\0|NONE_0
C069541_D017109 NONE quetiapine_9\NN\0|(_23|%_27|)_28|and_30|placebo_34 (r_amod) monotherapy_10\NN\0|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) similar_7\JJ\0|and_4 (r_conj) low_5\JJ\14520518|incidence_27|,_69|and_71|with_75|._123 (r_acomp) was_4\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|low_27|,_96|and_98|with_102|._150 (l_prep) of_2\IN\0|the_14 (l_pobj) akathisia_3\NN\0|NONE_0
C069541_D017109 NONE qtp_24\NNP\0|NONE_0 (r_pobj) with_23\IN\0|incidence_102|low_75|,_6|and_4|._48 (r_conj) was_4\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|low_27|,_96|and_98|with_102|._150 (l_prep) of_2\IN\0|the_14 (l_pobj) akathisia_3\NN\0|NONE_0
C069541_D017109 NONE quetiapine_41\NN\0|NONE_0 (r_pcomp) than_40\IN\0|,_78|(_69|%_64|)_51|,_50|and_48|syndrome_29 (r_prep) tremor_21\NN\345926|haloperidol_99|incidence_56|._91 (r_npadvmod) induced_1\VBD\1627355|NONE_0 (l_dobj) incidence_5\NN\13821570|haloperidol_43|tremor_56|._147 (l_appos) 0.001_9\CD\0|a_38|higher_22 (l_prep) of_11\IN\0|(_12|p_11|<_9|)_2 (l_pobj) akathisia_12\NN\0|NONE_0
C069541_D017109 NONE quetiapine_13\NN\0|NONE_0 (r_amod) therapy_14\NN\657604|in_77|,_61|incidence_55|with_16|similar_11|._39 (r_nsubj) is_15\VBZ\0|NONE_0 (l_nsubj) incidence_5\NN\13821570|in_22|,_6|with_39|therapy_55|similar_66|._94 (l_prep) including_9\VBG\0|the_22|of_8|,_2|,_19 (l_pobj) akathisia_10\NN\0|NONE_0
D006220_D017109 CID haloperidol_0\NNP\3713736|incidence_43|tremor_99|._190 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_dobj) incidence_5\NN\13821570|haloperidol_43|tremor_56|._147 (l_appos) 0.001_9\CD\0|a_38|higher_22 (l_prep) of_11\IN\0|(_12|p_11|<_9|)_2 (l_pobj) akathisia_12\NN\0|NONE_0
D006220_D014202 CID haloperidol_0\NNP\3713736|incidence_43|tremor_99|._190 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_npadvmod) tremor_21\NN\345926|haloperidol_99|incidence_56|._91
C069541_D014202 NONE quetiapine_20\NN\0|NONE_0 (r_pobj) than_19\IN\0|a_62|higher_46|0.05_24|(_8|%_3|)_2|(_16|%_20|)_21 (r_prep) incidence_7\NN\13821570|NONE_0 (l_appos) 0.05_11\CD\0|a_38|higher_22|(_16|%_21|)_22|than_24|(_40|%_44|)_45 (l_prep) of_13\IN\0|(_11|p_10|<_8|)_2 (l_pobj) tremor_14\NN\345926|NONE_0
C069541_D014202 NONE quetiapine_20\NN\0|NONE_0 (r_pobj) than_19\IN\0|a_62|higher_46|0.05_24|(_8|%_3|)_2|(_16|%_20|)_21 (r_prep) incidence_7\NN\13821570|NONE_0 (r_pobj) with_3\IN\0|lithium_23|was_15 (r_prep) associated_2\VBN\628491|;_100|tremor_113|may_165|have_169|to_186|._254 (r_ccomp) contributed_40\VBN\126264|NONE_0 (l_nsubj) tremor_27\NN\345926|associated_113|;_13|may_52|have_56|to_73|._141
C069541_D014202 NONE quetiapine_20\NN\0|NONE_0 (r_pobj) than_19\IN\0|a_62|higher_46|0.05_24|(_8|%_3|)_2|(_16|%_20|)_21 (r_prep) incidence_7\NN\13821570|NONE_0 (r_pobj) with_3\IN\0|lithium_23|was_15 (r_prep) associated_2\VBN\628491|;_100|tremor_113|may_165|have_169|to_186|._254 (r_ccomp) contributed_40\VBN\126264|NONE_0 (l_prep) to_41\IN\0|associated_186|;_86|tremor_73|may_21|have_17|._68 (l_pobj) rate_44\NN\13815152|NONE_0 (l_prep) of_45\IN\0|the_18|elevated_14|in_10 (l_pobj) tremor_46\NN\345926|NONE_0
C069541_D014202 NONE quetiapine_41\NN\0|NONE_0 (r_pcomp) than_40\IN\0|,_78|(_69|%_64|)_51|,_50|and_48|syndrome_29 (r_prep) tremor_21\NN\345926|haloperidol_99|incidence_56|._91
D006220_D001480 CID haloperidol_13\NN\3713736|NONE_0 (r_pobj) with_12\IN\0|whereas_39 (r_prep) treated_11\VBN\2376958|NONE_0 (r_acl) patients_10\NNS\9898892|NONE_0 (r_pobj) of_9\IN\0|59.6_6 (r_prep) %_8\NN\0|NONE_0 (r_pobj) in_6\IN\13603305|events_31|)_122 (r_prep) occurred_5\VBD\0|NONE_0 (l_nsubj) events_1\NNS\23100|in_31|)_153 (l_acl) related_2\VBN\628491|adverse_15 (l_prep) to_3\IN\0|NONE_0 (l_pobj) eps_4\NNP\0|NONE_0
D006220_D001480 CID haloperidol_0\NNP\3713736|incidence_43|tremor_99|._190 (r_nsubj) induced_1\VBD\1627355|NONE_0 (l_npadvmod) tremor_21\NN\345926|haloperidol_99|incidence_56|._91 (l_conj) syndrome_32\NN\5870365|,_49|(_40|%_35|)_22|,_21|and_19|than_29
C069541_D001480 NONE quetiapine_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|level_49|of_33|._68 (r_prep) incidence_3\NN\13821570|NONE_0 (l_prep) of_4\IN\0|level_16|with_33|._101 (l_pobj) symptoms_6\NNS\5823932|NONE_0
C069541_D001480 NONE quetiapine_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|level_49|of_33|._68 (r_prep) incidence_3\NN\13821570|NONE_0 (l_prep) of_4\IN\0|level_16|with_33|._101 (l_pobj) symptoms_6\NNS\5823932|NONE_0 (l_appos) eps_8\NNP\0|extrapyramidal_25
C069541_D001480 NONE quetiapine_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|akathisia_11|,_2 (r_prep) including_10\VBG\0|to_43|symptoms_16|,_2 (r_prep) evaluate_3\VB\670261|:_5|._107 (l_dobj) symptoms_5\NNS\5823932|to_27|,_14|including_16
C069541_D001480 NONE quetiapine_14\NN\0|NONE_0 (r_pobj) with_13\IN\0|akathisia_11|,_2 (r_prep) including_10\VBG\0|to_43|symptoms_16|,_2 (r_prep) evaluate_3\VB\670261|:_5|._107 (l_dobj) symptoms_5\NNS\5823932|to_27|,_14|including_16 (l_appos) eps_7\NNP\0|extrapyramidal_25
C069541_D001480 NONE quetiapine_16\NN\0|(_23|%_28|)_29 (r_amod) monotherapy_17\NN\0|NONE_0 (r_pobj) with_15\IN\0|no_13|than_36 (r_prep) different_14\JJ\0|incidence_69|._71 (r_acomp) was_12\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|different_69|._140 (l_prep) of_2\IN\0|the_14|,_29|including_31|,_50 (l_pobj) events_7\NNS\23100|NONE_0 (l_amod) related_5\VBN\628491|adverse_8 (l_npadvmod) eps_3\NNP\0|-_3
C069541_D001480 NONE qtp_8\NNP\0|NONE_0 (r_pobj) with_7\IN\0|related_23|adverse_15 (r_prep) events_6\NNS\23100|similarly_31|,_22|different_41|._81 (l_amod) related_4\VBN\628491|adverse_8|with_23 (l_npadvmod) eps_2\NNP\0|-_3
C069541_D001480 NONE quetiapine_41\NN\0|NONE_0 (r_pcomp) than_40\IN\0|,_78|(_69|%_64|)_51|,_50|and_48|syndrome_29 (r_prep) tremor_21\NN\345926|haloperidol_99|incidence_56|._91 (l_conj) syndrome_32\NN\5870365|,_49|(_40|%_35|)_22|,_21|and_19|than_29
C069541_D001480 NONE quetiapine_13\NN\0|NONE_0 (r_amod) therapy_14\NN\657604|in_77|,_61|incidence_55|with_16|similar_11|._39 (r_nsubj) is_15\VBZ\0|NONE_0 (l_nsubj) incidence_5\NN\13821570|in_22|,_6|with_39|therapy_55|similar_66|._94 (l_prep) of_6\IN\0|the_14|,_6|including_8|,_27 (l_pobj) eps_7\NNP\0|NONE_0
C069541_D001714 NONE quetiapine_11\NN\0|NONE_0 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) studies_14\NNS\635850|NONE_0 (l_prep) of_15\IN\0|controlled_19 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) mania_19\NN\9180259|NONE_0
C069541_D001714 NONE quetiapine_14\NN\0|NONE_0 (l_prep) in_15\IN\13603305|NONE_0 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) mania_19\NN\9180259|NONE_0
C069541_D001714 NONE quetiapine_13\NN\0|NONE_0 (r_amod) therapy_14\NN\657604|in_77|,_61|incidence_55|with_16|similar_11|._39 (r_nsubj) is_15\VBZ\0|NONE_0 (l_prep) in_0\IN\13603305|,_16|incidence_22|with_61|therapy_77|similar_88|._116 (l_pobj) mania_2\NN\9180259|NONE_0
D008094_D001480 CID li_10\NNP\14625458|/_2|(_7|%_12|)_13 (r_nmod) dvp_12\NNP\0|+_5 (r_conj) qtp_8\NNP\0|NONE_0 (r_pobj) with_7\IN\0|related_23|adverse_15 (r_prep) events_6\NNS\23100|similarly_31|,_22|different_41|._81 (l_amod) related_4\VBN\628491|adverse_8|with_23 (l_npadvmod) eps_2\NNP\0|-_3
D008094_D001480 CID li_24\NNP\14625458|/_2|(_7|%_12|)_13 (r_nmod) dvp_26\NNP\0|+_5 (r_conj) pbo_22\NNP\0|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) than_20\IN\0|no_13 (r_prep) different_19\JJ\0|similarly_72|,_63|events_41|._40 (r_acomp) were_17\VBD\0|NONE_0 (l_nsubj) events_6\NNS\23100|similarly_31|,_22|different_41|._81 (l_amod) related_4\VBN\628491|adverse_8|with_23 (l_npadvmod) eps_2\NNP\0|-_3
D008094_D001480 CID lithium_28\NN\14625458|NONE_0 (r_pobj) with_27\IN\0|NONE_0 (r_prep) treated_26\VBN\2376958|NONE_0 (r_acl) patients_25\NNS\9898892|NONE_0 (r_pobj) of_24\IN\0|26.5_6 (r_prep) %_23\NN\0|NONE_0 (r_pobj) whereas_21\IN\0|with_39 (r_prep) treated_11\VBN\2376958|NONE_0 (r_acl) patients_10\NNS\9898892|NONE_0 (r_pobj) of_9\IN\0|59.6_6 (r_prep) %_8\NN\0|NONE_0 (r_pobj) in_6\IN\13603305|events_31|)_122 (r_prep) occurred_5\VBD\0|NONE_0 (l_nsubj) events_1\NNS\23100|in_31|)_153 (l_acl) related_2\VBN\628491|adverse_15 (l_prep) to_3\IN\0|NONE_0 (l_pobj) eps_4\NNP\0|NONE_0
D008094_D017109 NONE li_26\NNP\14625458|/_2|(_7|%_11|)_12|and_14|pbo_18 (r_nmod) dvp_28\NNP\0|+_5 (r_conj) qtp_24\NNP\0|NONE_0 (r_pobj) with_23\IN\0|incidence_102|low_75|,_6|and_4|._48 (r_conj) was_4\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|low_27|,_96|and_98|with_102|._150 (l_prep) of_2\IN\0|the_14 (l_pobj) akathisia_3\NN\0|NONE_0
D008094_D017109 NONE li_36\NNP\14625458|/_2 (r_compound) dvp_38\NNP\0|+_5|(_4|%_8|)_9 (r_conj) pbo_34\NNP\0|li_18|/_16|(_11|%_7|)_6|and_4 (r_conj) dvp_28\NNP\0|+_5 (r_conj) qtp_24\NNP\0|NONE_0 (r_pobj) with_23\IN\0|incidence_102|low_75|,_6|and_4|._48 (r_conj) was_4\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|low_27|,_96|and_98|with_102|._150 (l_prep) of_2\IN\0|the_14 (l_pobj) akathisia_3\NN\0|NONE_0
D008094_D014202 CID lithium_0\NN\14625458|was_8|with_23 (r_nsubjpass) associated_2\VBN\628491|;_100|tremor_113|may_165|have_169|to_186|._254 (l_prep) with_3\IN\0|lithium_23|was_15 (l_pobj) incidence_7\NN\13821570|NONE_0 (l_appos) 0.05_11\CD\0|a_38|higher_22|(_16|%_21|)_22|than_24|(_40|%_44|)_45 (l_prep) of_13\IN\0|(_11|p_10|<_8|)_2 (l_pobj) tremor_14\NN\345926|NONE_0
D008094_D014202 CID lithium_0\NN\14625458|was_8|with_23 (r_nsubjpass) associated_2\VBN\628491|;_100|tremor_113|may_165|have_169|to_186|._254 (r_ccomp) contributed_40\VBN\126264|NONE_0 (l_nsubj) tremor_27\NN\345926|associated_113|;_13|may_52|have_56|to_73|._141
D008094_D014202 CID lithium_0\NN\14625458|was_8|with_23 (r_nsubjpass) associated_2\VBN\628491|;_100|tremor_113|may_165|have_169|to_186|._254 (r_ccomp) contributed_40\VBN\126264|NONE_0 (l_prep) to_41\IN\0|associated_186|;_86|tremor_73|may_21|have_17|._68 (l_pobj) rate_44\NN\13815152|NONE_0 (l_prep) of_45\IN\0|the_18|elevated_14|in_10 (l_pobj) tremor_46\NN\345926|NONE_0
D008094_D014202 CID lithium_36\NN\14625458|NONE_0 (r_pobj) of_35\IN\0|a_23|known_21|adverse_15 (r_prep) effect_34\NN\34213|which_25 (r_attr) is_30\VBZ\0|cerebellar_25|,_8|,_36 (r_relcl) tremor_27\NN\345926|associated_113|;_13|may_52|have_56|to_73|._141 (r_nsubj) contributed_40\VBN\126264|NONE_0 (l_ccomp) associated_2\VBN\628491|;_100|tremor_113|may_165|have_169|to_186|._254 (l_prep) with_3\IN\0|lithium_23|was_15 (l_pobj) incidence_7\NN\13821570|NONE_0 (l_appos) 0.05_11\CD\0|a_38|higher_22|(_16|%_21|)_22|than_24|(_40|%_44|)_45 (l_prep) of_13\IN\0|(_11|p_10|<_8|)_2 (l_pobj) tremor_14\NN\345926|NONE_0
D008094_D014202 CID lithium_36\NN\14625458|NONE_0 (r_pobj) of_35\IN\0|a_23|known_21|adverse_15 (r_prep) effect_34\NN\34213|which_25 (r_attr) is_30\VBZ\0|cerebellar_25|,_8|,_36 (r_relcl) tremor_27\NN\345926|associated_113|;_13|may_52|have_56|to_73|._141
D008094_D014202 CID lithium_36\NN\14625458|NONE_0 (r_pobj) of_35\IN\0|a_23|known_21|adverse_15 (r_prep) effect_34\NN\34213|which_25 (r_attr) is_30\VBZ\0|cerebellar_25|,_8|,_36 (r_relcl) tremor_27\NN\345926|associated_113|;_13|may_52|have_56|to_73|._141 (r_nsubj) contributed_40\VBN\126264|NONE_0 (l_prep) to_41\IN\0|associated_186|;_86|tremor_73|may_21|have_17|._68 (l_pobj) rate_44\NN\13815152|NONE_0 (l_prep) of_45\IN\0|the_18|elevated_14|in_10 (l_pobj) tremor_46\NN\345926|NONE_0
D008094_D014202 CID lithium_50\NN\14625458|NONE_0 (r_compound) therapy_51\NN\657604|NONE_0 (r_dobj) receiving_49\VBG\2210855|NONE_0 (r_acl) patients_48\NNS\9898892|NONE_0 (r_pobj) in_47\IN\13603305|the_28|elevated_24|of_10 (r_prep) rate_44\NN\13815152|NONE_0 (r_pobj) to_41\IN\0|associated_186|;_86|tremor_73|may_21|have_17|._68 (r_prep) contributed_40\VBN\126264|NONE_0 (l_ccomp) associated_2\VBN\628491|;_100|tremor_113|may_165|have_169|to_186|._254 (l_prep) with_3\IN\0|lithium_23|was_15 (l_pobj) incidence_7\NN\13821570|NONE_0 (l_appos) 0.05_11\CD\0|a_38|higher_22|(_16|%_21|)_22|than_24|(_40|%_44|)_45 (l_prep) of_13\IN\0|(_11|p_10|<_8|)_2 (l_pobj) tremor_14\NN\345926|NONE_0
D008094_D014202 CID lithium_50\NN\14625458|NONE_0 (r_compound) therapy_51\NN\657604|NONE_0 (r_dobj) receiving_49\VBG\2210855|NONE_0 (r_acl) patients_48\NNS\9898892|NONE_0 (r_pobj) in_47\IN\13603305|the_28|elevated_24|of_10 (r_prep) rate_44\NN\13815152|NONE_0 (r_pobj) to_41\IN\0|associated_186|;_86|tremor_73|may_21|have_17|._68 (r_prep) contributed_40\VBN\126264|NONE_0 (l_nsubj) tremor_27\NN\345926|associated_113|;_13|may_52|have_56|to_73|._141
D008094_D014202 CID lithium_50\NN\14625458|NONE_0 (r_compound) therapy_51\NN\657604|NONE_0 (r_dobj) receiving_49\VBG\2210855|NONE_0 (r_acl) patients_48\NNS\9898892|NONE_0 (r_pobj) in_47\IN\13603305|the_28|elevated_24|of_10 (r_prep) rate_44\NN\13815152|NONE_0 (l_prep) of_45\IN\0|the_18|elevated_14|in_10 (l_pobj) tremor_46\NN\345926|NONE_0
D014635_D001480 NONE dvp_12\NNP\0|+_5 (r_conj) qtp_8\NNP\0|NONE_0 (r_pobj) with_7\IN\0|related_23|adverse_15 (r_prep) events_6\NNS\23100|similarly_31|,_22|different_41|._81 (l_amod) related_4\VBN\628491|adverse_8|with_23 (l_npadvmod) eps_2\NNP\0|-_3
D014635_D001480 NONE dvp_26\NNP\0|+_5 (r_conj) pbo_22\NNP\0|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) than_20\IN\0|no_13 (r_prep) different_19\JJ\0|similarly_72|,_63|events_41|._40 (r_acomp) were_17\VBD\0|NONE_0 (l_nsubj) events_6\NNS\23100|similarly_31|,_22|different_41|._81 (l_amod) related_4\VBN\628491|adverse_8|with_23 (l_npadvmod) eps_2\NNP\0|-_3
D014635_D017109 NONE dvp_28\NNP\0|+_5 (r_conj) qtp_24\NNP\0|NONE_0 (r_pobj) with_23\IN\0|incidence_102|low_75|,_6|and_4|._48 (r_conj) was_4\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|low_27|,_96|and_98|with_102|._150 (l_prep) of_2\IN\0|the_14 (l_pobj) akathisia_3\NN\0|NONE_0
D014635_D017109 NONE dvp_38\NNP\0|+_5|(_4|%_8|)_9 (r_conj) pbo_34\NNP\0|li_18|/_16|(_11|%_7|)_6|and_4 (r_conj) dvp_28\NNP\0|+_5 (r_conj) qtp_24\NNP\0|NONE_0 (r_pobj) with_23\IN\0|incidence_102|low_75|,_6|and_4|._48 (r_conj) was_4\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|low_27|,_96|and_98|with_102|._150 (l_prep) of_2\IN\0|the_14 (l_pobj) akathisia_3\NN\0|NONE_0
85485
D001556_D006528 CID hexachloride_15\NN\0|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|in_59|._37 (r_acl) changes_0\NNS\7283608|NONE_0 (l_prep) in_1\IN\13603305|induced_59|._96 (l_pobj) peroxisomes_2\NNS\0|NONE_0 (l_prep) in_3\IN\13603305|NONE_0 (l_pobj) liver_5\NN\5298729|NONE_0 (l_conj) hepatoma_7\NN\14242337|preneoplastic_24|and_4
D001556_D006528 CID hexachloride_17\NN\0|NONE_0 (r_pobj) by_11\IN\0|peroxisomes_86|in_8|examined_43|._96 (r_prep) induced_8\VBN\1627355|NONE_0 (l_nsubj) peroxisomes_0\NNS\0|in_78|by_86|examined_129|._182 (l_prep) in_1\IN\13603305|NONE_0 (l_pobj) hepatomas_2\NNS\14242337|lesions_47
D001556_D017093 NONE hexachloride_17\NN\0|NONE_0 (r_pobj) by_11\IN\0|peroxisomes_86|in_8|examined_43|._96 (r_prep) induced_8\VBN\1627355|NONE_0 (l_nsubj) peroxisomes_0\NNS\0|in_78|by_86|examined_129|._182 (l_prep) in_1\IN\13603305|NONE_0 (l_pobj) lesions_7\NNS\14204950|hepatomas_47
C012282_D009369 NONE chlorophenoxyisobutyrate_31\NN\0|-_9 (r_appos) alpha_27\NN\6828818|NONE_0 (r_appos) ethyl_25\NN\14617189|NONE_0 (r_pobj) to_24\IN\0|were_116|,_34|cells_22|did_16|not_12|with_42|._75 (r_prep) respond_23\VB\2367363|NONE_0 (l_advcl) were_5\VBD\0|,_82|cells_94|did_100|not_104|to_116|with_158|._191 (l_attr) tumors_9\NNS\14234074|although_56|most_47|and_7|contained_11
C012282_D009369 NONE chlorophenoxyisobutyrate_31\NN\0|-_9 (r_appos) alpha_27\NN\6828818|NONE_0 (r_appos) ethyl_25\NN\14617189|NONE_0 (r_pobj) to_24\IN\0|were_116|,_34|cells_22|did_16|not_12|with_42|._75 (r_prep) respond_23\VB\2367363|NONE_0 (l_nsubj) cells_20\NNS\3080309|were_94|,_12|did_6|not_10|to_22|with_64|._97 (l_compound) tumor_19\NN\14234074|the_4
C012282_D006528 NONE chlorophenoxyisobutyrate_31\NN\0|-_9 (r_appos) alpha_27\NN\6828818|NONE_0 (r_appos) ethyl_25\NN\14617189|NONE_0 (r_pobj) to_24\IN\0|were_116|,_34|cells_22|did_16|not_12|with_42|._75 (r_prep) respond_23\VB\2367363|NONE_0 (l_advcl) were_5\VBD\0|,_82|cells_94|did_100|not_104|to_116|with_158|._191 (l_nsubj) most_1\JJS\0|although_9|tumors_47|and_54|contained_58 (l_prep) of_2\IN\0|NONE_0 (l_pobj) hepatomas_4\NNS\14242337|NONE_0
14975762
D004317_D006333 CID doxorubicin_11\RB\2716866|-_11 (r_compound) induced_13\VBN\1627355|NONE_0 (r_pobj) from_10\IN\0|p300_31|protects_26|cardiac_17 (r_prep) myocytes_9\NNS\0|NONE_0 (r_pobj) of_5\IN\0|that_20 (r_prep) overexpression_4\NN\0|and_84|reduces_88 (r_nsubj) apoptosis_14\NN\11486178|findings_100|._77 (l_conj) reduces_16\VBZ\441445|overexpression_88|and_4 (l_dobj) extent_18\NN\13939892|NONE_0 (l_prep) of_19\IN\0|the_11 (l_pobj) failure_22\NN\66216|NONE_0
D004317_D009369 NONE doxorubicin_0\NNP\2716866|agent_29 (r_nsubj) is_1\VBZ\0|._108 (l_attr) agent_6\NN\7347|doxorubicin_29 (l_compound) tumor_5\NN\14234074|an_8|represses_17
15930398
D015742_D000647 CID propofol_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|procedural_20 (r_prep) sedation_10\NN\14034177|NONE_0 (r_pobj) during_8\IN\0|the_37|and_27|persistence_23|of_11 (r_prep) onset_3\NN\7325190|NONE_0 (l_prep) of_6\IN\0|the_26|and_16|persistence_12|during_11 (l_pobj) amnesia_7\NN\5669934|NONE_0
18201582
C084178_D006973 NONE telmisartan_32\NN\0|monotherapy_45 (r_pobj) of_31\IN\0|a_25|dose_17|with_77 (r_prep) combination_30\NN\7951464|NONE_0 (l_prep) with_41\IN\0|a_102|dose_94|of_77 (l_pobj) hypertension_44\NN\14057371|NONE_0
C084178_D006973 NONE telmisartan_23\NNP\0|NONE_0 (r_pobj) of_22\IN\0|a_35|new_33|dose_23|(_6|fdc_5|)_2 (r_prep) combination_18\NN\7951464|NONE_0 (r_pobj) of_12\IN\0|the_30|and_17|tolerability_13 (r_prep) efficacy_9\NN\5199286|to_16|mg_82|+_85|amlodipine_87 (r_dobj) evaluate_7\VB\670261|aim_25|._219 (l_conj) amlodipine_27\NN\0|to_103|efficacy_87|mg_5|+_2 (l_prep) compared_33\VBN\644583|mg_9|)_2 (l_prep) with_34\IN\0|NONE_0 (l_pobj) amlodipine_35\NN\0|NONE_0 (l_appos) monotherapy_37\NN\0|NONE_0 (l_prep) in_41\IN\13603305|5-mg_21|a_3 (l_pobj) patients_44\NNS\9898892|NONE_0 (l_prep) with_45\IN\0|adult_22|indian_16 (l_pobj) hypertension_48\NN\14057371|NONE_0
D017311_D006973 NONE amlodipine_34\NN\0|and_4|versus_11 (r_conj) telmisartan_32\NN\0|monotherapy_45 (r_pobj) of_31\IN\0|a_25|dose_17|with_77 (r_prep) combination_30\NN\7951464|NONE_0 (l_prep) with_41\IN\0|a_102|dose_94|of_77 (l_pobj) hypertension_44\NN\14057371|NONE_0
D017311_D006973 NONE amlodipine_36\NN\0|NONE_0 (r_pobj) versus_35\IN\0|and_15|amlodipine_11 (r_prep) telmisartan_32\NN\0|monotherapy_45 (r_pobj) of_31\IN\0|a_25|dose_17|with_77 (r_prep) combination_30\NN\7951464|NONE_0 (l_prep) with_41\IN\0|a_102|dose_94|of_77 (l_pobj) hypertension_44\NN\14057371|NONE_0
D017311_D006973 NONE amlodipine_27\NN\0|to_103|efficacy_87|mg_5|+_2 (l_prep) compared_33\VBN\644583|mg_9|)_2 (l_prep) with_34\IN\0|NONE_0 (l_pobj) amlodipine_35\NN\0|NONE_0 (l_appos) monotherapy_37\NN\0|NONE_0 (l_prep) in_41\IN\13603305|5-mg_21|a_3 (l_pobj) patients_44\NNS\9898892|NONE_0 (l_prep) with_45\IN\0|adult_22|indian_16 (l_pobj) hypertension_48\NN\14057371|NONE_0
D017311_D006973 NONE amlodipine_35\NN\0|NONE_0 (l_appos) monotherapy_37\NN\0|NONE_0 (l_prep) in_41\IN\13603305|5-mg_21|a_3 (l_pobj) patients_44\NNS\9898892|NONE_0 (l_prep) with_45\IN\0|adult_22|indian_16 (l_pobj) hypertension_48\NN\14057371|NONE_0
19917396
D016559_D006332 CID tacrolimus_5\NNS\0|NONE_0 (r_pobj) by_4\IN\0|NONE_0 (r_agent) induced_3\VBN\1627355|reversible_34|myocardial_23 (r_acl) hypertrophy_2\NN\14365950|:_75|case_77|._88
D016559_D006332 CID tacrolimus_8\NNS\0|NONE_0 (r_pobj) by_7\IN\0|NONE_0 (r_agent) induced_6\VBN\1627355|transient_33|myocardial_23 (r_acl) hypertrophy_5\NN\14365950|herein_40|we_33|._61
D016559_D006332 CID tacrolimus_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_25|target_21 (r_prep) concentration_8\NN\4916342|NONE_0 (r_dobj) reducing_5\VBG\13447361|NONE_0 (r_pcomp) upon_4\IN\0|hypertrophy_32|completely_20|and_53|recur_65|._126 (r_prep) resolved_3\VBN\352826|NONE_0 (l_nsubj) hypertrophy_1\NN\14365950|completely_12|upon_32|and_85|recur_97|._158
D016559_D006332 CID tacrolimus_5\NN\0|that_5|hypertrophy_41 (r_nsubj) induces_6\VBZ\1627355|thus_34|,_30|we_28|._41 (l_dobj) hypertrophy_9\NN\14365950|that_46|tacrolimus_41
10074612
D008775_D007022 CID methylprednisolone_11\NN\0|NONE_0 (r_pobj) after_6\IN\0|NONE_0 (r_prep) asystole_5\NN\14204950|,_6|and_4 (r_conj) bradycardia_2\NNP\14110674|,_2|._95 (r_conj) hypotension_0\NN\14057371|NONE_0
D008775_D007022 CID methylprednisolone_18\NN\0|NONE_0 (r_pobj) of_14\IN\0|intravenous_27|in_32 (r_prep) administration_13\NN\1133281|NONE_0 (r_pobj) after_11\IN\0|NONE_0 (r_prep) asystole_10\NN\14204950|,_6|and_4 (r_conj) bradycardia_7\NNP\14110674|,_2 (r_conj) hypotension_5\NN\14057371|NONE_0
D008775_D003645 NONE methylprednisolone_16\NN\0|NONE_0 (r_pobj) of_14\IN\0|a_12|high_10 (r_prep) dose_13\NN\3740161|NONE_0 (r_pobj) after_10\IN\0|study_62|mechanisms_27|._58 (r_prep) reviews_2\VBZ\5733583|NONE_0 (l_dobj) mechanisms_6\NNS\13446390|study_35|after_27|._85 (l_prep) of_7\IN\0|the_32|current_28|proposed_20 (l_pobj) death_9\NN\7296428|NONE_0
D008775_D003645 NONE ivmp_18\NN\0|intravenous_32 (r_appos) methylprednisolone_16\NN\0|NONE_0 (r_pobj) of_14\IN\0|a_12|high_10 (r_prep) dose_13\NN\3740161|NONE_0 (r_pobj) after_10\IN\0|study_62|mechanisms_27|._58 (r_prep) reviews_2\VBZ\5733583|NONE_0 (l_dobj) mechanisms_6\NNS\13446390|study_35|after_27|._85 (l_prep) of_7\IN\0|the_32|current_28|proposed_20 (l_pobj) death_9\NN\7296428|NONE_0
D008775_D006323 CID methylprednisolone_11\NN\0|NONE_0 (r_pobj) after_6\IN\0|NONE_0 (r_prep) asystole_5\NN\14204950|,_6|and_4
D008775_D006323 CID methylprednisolone_18\NN\0|NONE_0 (r_pobj) of_14\IN\0|intravenous_27|in_32 (r_prep) administration_13\NN\1133281|NONE_0 (r_pobj) after_11\IN\0|NONE_0 (r_prep) asystole_10\NN\14204950|,_6|and_4
D008775_D001919 CID methylprednisolone_11\NN\0|NONE_0 (r_pobj) after_6\IN\0|NONE_0 (r_prep) asystole_5\NN\14204950|,_6|and_4 (r_conj) bradycardia_2\NNP\14110674|,_2|._95
D008775_D001919 CID methylprednisolone_18\NN\0|NONE_0 (r_pobj) of_14\IN\0|intravenous_27|in_32 (r_prep) administration_13\NN\1133281|NONE_0 (r_pobj) after_11\IN\0|NONE_0 (r_prep) asystole_10\NN\14204950|,_6|and_4 (r_conj) bradycardia_7\NNP\14110674|,_2
11704023
D013999_D005901 NONE timolol_6\NN\2832168|NONE_0 (l_prep) on_9\IN\0|aqueous_51|ophthalmic_32|with_13 (l_pobj) response_14\NN\11410625|NONE_0 (l_prep) in_15\IN\13603305|the_32|24-hour_28|rate_14 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) on_17\IN\0|NONE_0 (l_pobj) treatment_18\NN\654885|NONE_0 (l_prep) for_19\IN\0|NONE_0 (l_pobj) glaucoma_20\NN\14252864|NONE_0
D013999_D005901 NONE timolol_11\NN\2832168|the_36|of_25|,_15 (l_conj) suspension_21\NN\14586258|%_56|aqueous_54|(_38|solution_29|)_21|and_19 (l_relcl) forms_23\VBZ\6286395|a_31|%_26|timolol_24 (l_prep) on_26\IN\0|that_17|gel_4 (l_pobj) application_27\NN\947128|NONE_0 (l_prep) on_35\IN\0|to_36 (l_pobj) rate_39\NN\13815152|NONE_0 (l_prep) in_40\IN\13603305|the_23|24-hour_19|heart_11 (l_pobj) patients_41\NNS\9898892|NONE_0 (l_acl) treated_44\VBN\2376958|NONE_0 (l_prep) for_45\IN\0|currently_24|being_14|quantify_16 (l_pobj) glaucoma_46\NN\14252864|NONE_0
D013999_D005901 NONE timolol_13\NN\2832168|NONE_0 (r_compound) solution_14\NN\14586258|%_27|aqueous_25|(_9|)_8|and_10|suspension_29 (r_appos) timolol_11\NN\2832168|the_36|of_25|,_15 (l_conj) suspension_21\NN\14586258|%_56|aqueous_54|(_38|solution_29|)_21|and_19 (l_relcl) forms_23\VBZ\6286395|a_31|%_26|timolol_24 (l_prep) on_26\IN\0|that_17|gel_4 (l_pobj) application_27\NN\947128|NONE_0 (l_prep) on_35\IN\0|to_36 (l_pobj) rate_39\NN\13815152|NONE_0 (l_prep) in_40\IN\13603305|the_23|24-hour_19|heart_11 (l_pobj) patients_41\NNS\9898892|NONE_0 (l_acl) treated_44\VBN\2376958|NONE_0 (l_prep) for_45\IN\0|currently_24|being_14|quantify_16 (l_pobj) glaucoma_46\NN\14252864|NONE_0
D013999_D005901 NONE timolol_20\NN\2832168|a_7|%_2|forms_24 (r_compound) suspension_21\NN\14586258|%_56|aqueous_54|(_38|solution_29|)_21|and_19 (l_relcl) forms_23\VBZ\6286395|a_31|%_26|timolol_24 (l_prep) on_26\IN\0|that_17|gel_4 (l_pobj) application_27\NN\947128|NONE_0 (l_prep) on_35\IN\0|to_36 (l_pobj) rate_39\NN\13815152|NONE_0 (l_prep) in_40\IN\13603305|the_23|24-hour_19|heart_11 (l_pobj) patients_41\NNS\9898892|NONE_0 (l_acl) treated_44\VBN\2376958|NONE_0 (l_prep) for_45\IN\0|currently_24|being_14|quantify_16 (l_pobj) glaucoma_46\NN\14252864|NONE_0
D013999_D005901 NONE timolol_32\NN\2832168|(_1|)_14 (r_compound) gellan_33\NN\0|the_25 (r_appos) conjunctiva_30\NN\5327134|NONE_0 (r_pobj) to_28\IN\0|on_36 (r_prep) application_27\NN\947128|NONE_0 (l_prep) on_35\IN\0|to_36 (l_pobj) rate_39\NN\13815152|NONE_0 (l_prep) in_40\IN\13603305|the_23|24-hour_19|heart_11 (l_pobj) patients_41\NNS\9898892|NONE_0 (l_acl) treated_44\VBN\2376958|NONE_0 (l_prep) for_45\IN\0|currently_24|being_14|quantify_16 (l_pobj) glaucoma_46\NN\14252864|NONE_0
D013999_D009798 NONE timolol_56\NN\2832168|(_17|morning_18|)_50|,_51|or_53|gellan_64 (r_compound) solution_57\NN\14586258|over_112|in_107|to_81|)_11|,_10 (r_conj) crossed_32\VBN\2050132|patients_128|were_20|and_4|._233 (r_conj) randomized_30\VBN\278117|NONE_0 (l_nsubjpass) patients_4\NNS\9898892|were_108|and_124|crossed_128|._361 (l_prep) with_5\IN\0|three_25|caucasian_19 (l_pobj) glaucoma_10\NN\14252864|NONE_0 (l_conj) hypertension_13\NN\14057371|primary_38|angle_25|or_10
D013999_D009798 NONE timolol_68\NN\2832168|(_15|morning_16|)_64 (r_compound) gellan_69\NN\0|timolol_64|(_47|morning_46|)_14|,_13|or_11 (r_conj) solution_57\NN\14586258|over_112|in_107|to_81|)_11|,_10 (r_conj) crossed_32\VBN\2050132|patients_128|were_20|and_4|._233 (r_conj) randomized_30\VBN\278117|NONE_0 (l_nsubjpass) patients_4\NNS\9898892|were_108|and_124|crossed_128|._361 (l_prep) with_5\IN\0|three_25|caucasian_19 (l_pobj) glaucoma_10\NN\14252864|NONE_0 (l_conj) hypertension_13\NN\14057371|primary_38|angle_25|or_10
D013999_D005902 NONE timolol_56\NN\2832168|(_17|morning_18|)_50|,_51|or_53|gellan_64 (r_compound) solution_57\NN\14586258|over_112|in_107|to_81|)_11|,_10 (r_conj) crossed_32\VBN\2050132|patients_128|were_20|and_4|._233 (r_conj) randomized_30\VBN\278117|NONE_0 (l_nsubjpass) patients_4\NNS\9898892|were_108|and_124|crossed_128|._361 (l_prep) with_5\IN\0|three_25|caucasian_19 (l_pobj) glaucoma_10\NN\14252864|NONE_0
D013999_D005902 NONE timolol_68\NN\2832168|(_15|morning_16|)_64 (r_compound) gellan_69\NN\0|timolol_64|(_47|morning_46|)_14|,_13|or_11 (r_conj) solution_57\NN\14586258|over_112|in_107|to_81|)_11|,_10 (r_conj) crossed_32\VBN\2050132|patients_128|were_20|and_4|._233 (r_conj) randomized_30\VBN\278117|NONE_0 (l_nsubjpass) patients_4\NNS\9898892|were_108|and_124|crossed_128|._361 (l_prep) with_5\IN\0|three_25|caucasian_19 (l_pobj) glaucoma_10\NN\14252864|NONE_0
19135948
C107135_D009190 NONE everolimus_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|a_14|in_29|with_67 (r_prep) combination_4\NN\7951464|NONE_0 (l_prep) with_19\IN\0|a_81|of_67|in_38 (l_pobj) syndrome_22\NN\5870365|NONE_0
C107135_D009190 NONE everolimus_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|a_14|in_29|with_67 (r_prep) combination_4\NN\7951464|NONE_0 (l_prep) with_19\IN\0|a_81|of_67|in_38 (l_pobj) syndrome_22\NN\5870365|NONE_0 (l_appos) leukemia_33\NN\14239918|either_63|myelodysplastic_56|undergoing_22 (l_nmod) mds_24\NNP\14622893|(_1|myeloid_22|(_39|aml_40|)_50
D016559_D006504 CID tacrolimus_10\NN\0|and_4 (r_conj) everolimus_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|graft_38|disease_20 (r_prep) prophylaxis_6\VBN\1077350|is_43|with_57|and_114|microangiopathy_118|._161 (r_nsubjpass) associated_12\VBN\628491|NONE_0 (l_prep) with_13\IN\0|prophylaxis_57|is_14|and_57|microangiopathy_61|._104 (l_pobj) incidence_16\NN\13821570|NONE_0 (l_prep) of_17\IN\0|a_17|high_15 (l_pobj) syndrome_20\NN\5870365|NONE_0
C107135_D015470 NONE everolimus_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|a_14|in_29|with_67 (r_prep) combination_4\NN\7951464|NONE_0 (l_prep) with_19\IN\0|a_81|of_67|in_38 (l_pobj) syndrome_22\NN\5870365|NONE_0 (l_appos) leukemia_33\NN\14239918|either_63|myelodysplastic_56|undergoing_22
C107135_D015470 NONE everolimus_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|a_14|in_29|with_67 (r_prep) combination_4\NN\7951464|NONE_0 (l_prep) with_19\IN\0|a_81|of_67|in_38 (l_pobj) syndrome_22\NN\5870365|NONE_0 (l_appos) leukemia_33\NN\14239918|either_63|myelodysplastic_56|undergoing_22 (l_appos) aml_35\NNP\0|(_41|mds_40|myeloid_18|(_1|)_10
D016559_D006086 NONE tacrolimus_10\NN\0|and_4 (r_conj) everolimus_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|graft_38|disease_20 (r_prep) prophylaxis_6\VBN\1077350|is_43|with_57|and_114|microangiopathy_118|._161 (l_compound) disease_5\NN\14061805|graft_18|with_20
D016559_D015470 NONE tacrolimus_8\NN\0|and_4 (r_conj) everolimus_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|a_14|in_29|with_67 (r_prep) combination_4\NN\7951464|NONE_0 (l_prep) with_19\IN\0|a_81|of_67|in_38 (l_pobj) syndrome_22\NN\5870365|NONE_0 (l_appos) leukemia_33\NN\14239918|either_63|myelodysplastic_56|undergoing_22
D016559_D015470 NONE tacrolimus_8\NN\0|and_4 (r_conj) everolimus_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|a_14|in_29|with_67 (r_prep) combination_4\NN\7951464|NONE_0 (l_prep) with_19\IN\0|a_81|of_67|in_38 (l_pobj) syndrome_22\NN\5870365|NONE_0 (l_appos) leukemia_33\NN\14239918|either_63|myelodysplastic_56|undergoing_22 (l_appos) aml_35\NNP\0|(_41|mds_40|myeloid_18|(_1|)_10
C107135_D006504 CID everolimus_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|graft_38|disease_20 (r_prep) prophylaxis_6\VBN\1077350|is_43|with_57|and_114|microangiopathy_118|._161 (r_nsubjpass) associated_12\VBN\628491|NONE_0 (l_prep) with_13\IN\0|prophylaxis_57|is_14|and_57|microangiopathy_61|._104 (l_pobj) incidence_16\NN\13821570|NONE_0 (l_prep) of_17\IN\0|a_17|high_15 (l_pobj) syndrome_20\NN\5870365|NONE_0
D008727_D006086 NONE methotrexate_5\NNP\2722166|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) combined_3\VBN\2630189|a_24|calcineurin_22 (r_acl) inhibitor_2\NN\20090|prophylaxis_53|._165 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) prophylaxis_9\NN\1077350|inhibitor_53|._112 (l_prep) for_10\IN\0|the_25|standard_21|after_37 (l_pobj) disease_16\NN\14061805|NONE_0
D008727_D006086 NONE methotrexate_5\NNP\2722166|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) combined_3\VBN\2630189|a_24|calcineurin_22 (r_acl) inhibitor_2\NN\20090|prophylaxis_53|._165 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) prophylaxis_9\NN\1077350|inhibitor_53|._112 (l_prep) for_10\IN\0|the_25|standard_21|after_37 (l_pobj) disease_16\NN\14061805|NONE_0 (l_appos) gvhd_18\NNP\0|graft_27|(_1|)_4
D016559_D009190 NONE tacrolimus_8\NN\0|and_4 (r_conj) everolimus_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|a_14|in_29|with_67 (r_prep) combination_4\NN\7951464|NONE_0 (l_prep) with_19\IN\0|a_81|of_67|in_38 (l_pobj) syndrome_22\NN\5870365|NONE_0
D016559_D009190 NONE tacrolimus_8\NN\0|and_4 (r_conj) everolimus_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|a_14|in_29|with_67 (r_prep) combination_4\NN\7951464|NONE_0 (l_prep) with_19\IN\0|a_81|of_67|in_38 (l_pobj) syndrome_22\NN\5870365|NONE_0 (l_appos) leukemia_33\NN\14239918|either_63|myelodysplastic_56|undergoing_22 (l_nmod) mds_24\NNP\14622893|(_1|myeloid_22|(_39|aml_40|)_50
C107135_D006086 NONE everolimus_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|graft_38|disease_20 (r_prep) prophylaxis_6\VBN\1077350|is_43|with_57|and_114|microangiopathy_118|._161 (l_compound) disease_5\NN\14061805|graft_18|with_20
D016559_D014652 CID tacrolimus_10\NN\0|and_4 (r_conj) everolimus_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|graft_38|disease_20 (r_prep) prophylaxis_6\VBN\1077350|is_43|with_57|and_114|microangiopathy_118|._161 (r_nsubjpass) associated_12\VBN\628491|NONE_0 (l_conj) microangiopathy_22\NN\0|prophylaxis_118|is_75|with_61|and_4|._43
C107135_D014652 CID everolimus_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|graft_38|disease_20 (r_prep) prophylaxis_6\VBN\1077350|is_43|with_57|and_114|microangiopathy_118|._161 (r_nsubjpass) associated_12\VBN\628491|NONE_0 (l_conj) microangiopathy_22\NN\0|prophylaxis_118|is_75|with_61|and_4|._43
10091616
D007980_D004409 CID levodopa_2\NN\14604959|-_8 (r_npadvmod) induced_4\VBN\1627355|by_20 (r_amod) dyskinesias_5\NNS\14084880|NONE_0
D001058_D004409 CID apomorphine_69\NN\3786417|NONE_0 (r_pobj) of_68\IN\0|an_25|effective_22|single_12 (r_prep) dose_67\NN\3740161|NONE_0 (r_pobj) of_63\IN\0|NONE_0 (r_prep) administration_62\NN\1133281|NONE_0 (r_pobj) following_61\VBG\8180190|the_38|of_24 (r_prep) worsening_55\VBG\13457378|NONE_0 (r_pobj) on_53\IN\0|)_8 (r_prep) tasks_52\NNS\575741|aloud_7 (r_dobj) speaking_49\VBG\7109847|to_165|role_149|,_2 (r_dep) evaluate_16\VB\670261|patients_94|were_31|in_17|._292 (r_advcl) included_11\VBN\0|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_63|in_77|evaluate_94|._386 (l_relcl) had_3\VBD\0|ten_17 (l_prep) with_7\IN\0|who_28|disease_8 (l_pcomp) disabling_8\VBG\126264|NONE_0 (l_dobj) dyskinesia_9\NN\14084880|NONE_0
D001058_D004409 CID apomorphine_69\NN\3786417|NONE_0 (r_pobj) of_68\IN\0|an_25|effective_22|single_12 (r_prep) dose_67\NN\3740161|NONE_0 (r_pobj) of_63\IN\0|NONE_0 (r_prep) administration_62\NN\1133281|NONE_0 (r_pobj) following_61\VBG\8180190|the_38|of_24 (r_prep) worsening_55\VBG\13457378|NONE_0 (l_prep) of_56\IN\0|the_14|following_24 (l_pobj) dyskinesia_60\JJ\14084880|NONE_0
D001058_D010300 NONE apomorphine_69\NN\3786417|NONE_0 (r_pobj) of_68\IN\0|an_25|effective_22|single_12 (r_prep) dose_67\NN\3740161|NONE_0 (r_pobj) of_63\IN\0|NONE_0 (r_prep) administration_62\NN\1133281|NONE_0 (r_pobj) following_61\VBG\8180190|the_38|of_24 (r_prep) worsening_55\VBG\13457378|NONE_0 (r_pobj) on_53\IN\0|)_8 (r_prep) tasks_52\NNS\575741|aloud_7 (r_dobj) speaking_49\VBG\7109847|to_165|role_149|,_2 (r_dep) evaluate_16\VB\670261|patients_94|were_31|in_17|._292 (r_advcl) included_11\VBN\0|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_63|in_77|evaluate_94|._386 (l_relcl) had_3\VBD\0|ten_17 (l_dobj) disease_6\NN\14061805|who_20|with_8
950631
D010396_D007674 CID penicillamine_2\NN\3740161|-_13 (r_npadvmod) induced_4\VBN\1627355|glomerular_8 (r_amod) disease_6\NN\14061805|NONE_0
D010396_D001172 NONE penicillamine_18\NN\3740161|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) treatment_14\NN\654885|NONE_0 (r_pobj) of_13\IN\0|12_10 (r_prep) months_12\NNS\15113229|NONE_0 (r_pobj) after_8\IN\0|patients_63|proteinuria_12|._57 (r_prep) developed_5\VBD\1753788|NONE_0 (l_nsubj) patients_1\NNS\9898892|proteinuria_51|after_63|._120 (l_prep) with_2\IN\0|four_14 (l_pobj) arthritis_4\NN\14171682|NONE_0
D010396_D011507 CID penicillamine_18\NN\3740161|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) treatment_14\NN\654885|NONE_0 (r_pobj) of_13\IN\0|12_10 (r_prep) months_12\NNS\15113229|NONE_0 (r_pobj) after_8\IN\0|patients_63|proteinuria_12|._57 (r_prep) developed_5\VBD\1753788|NONE_0 (l_dobj) proteinuria_7\NN\14299637|patients_51|after_12|._69
7803371
D003915_D003072 CID dextromethorphan_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|term_11 (r_prep) abuse_6\NN\418025|NONE_0 (r_pobj) from_2\IN\0|cognitive_24|:_40|report_49|._55 (r_prep) deterioration_1\NN\14560612|NONE_0
D003915_D003072 CID dm_13\NN\14117805|NONE_0 (r_pobj) of_12\IN\0|prolonged_14 (r_prep) use_11\NN\407535|NONE_0 (r_pobj) from_9\IN\0|NONE_0 (r_prep) resulting_8\VBG\2633881|cognitive_24 (r_acl) deterioration_7\NN\14560612|NONE_0
9105126
D013256_D018658 CID steroid_9\NN\14727670|term_5 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|postinfarction_41|ventricular_26|septal_14|._41 (r_acl) defect_3\NN\14462666|NONE_0
D013256_D018658 CID steroid_13\NN\14727670|term_5 (r_compound) therapy_14\NN\657604|NONE_0 (r_pobj) on_9\IN\0|NONE_0 (r_prep) patients_8\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|postinfarction_42|ventricular_27|septal_15 (r_prep) rupture_6\NN\14285662|NONE_0
D013256_D018658 CID steroid_4\NN\14727670|and_16|rupture_53 (r_compound) therapy_5\NN\657604|NONE_0 (l_conj) rupture_10\NN\14285662|steroid_53|and_37
15276120
D014859_D006470 CID warfarin_3\RB\2718259|-_8 (r_npadvmod) associated_5\VBN\628491|NONE_0 (r_amod) hemorrhage_6\NN\14285662|NONE_0
D014859_D006470 CID warfarin_4\RB\2718259|-_8 (r_npadvmod) related_6\VBN\628491|at_17 (r_amod) bleeding_7\NN\14285662|NONE_0
11694026
D000082_D014581 NONE paracetamol_4\NN\0|and_4 (r_conj) nimesulide_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|in_30|._81 (r_prep) tolerability_0\DT\0|NONE_0 (l_prep) in_5\IN\13603305|of_30|._51 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|NONE_0 (l_pobj) angioedema_13\NN\14316714|NONE_0 (l_nmod) urticaria_11\NN\14533203|NONE_0
D000082_D014581 NONE paracetamol_11\NN\0|and_4 (r_conj) nimesulide_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|and_16|reliability_12 (r_prep) tolerability_5\NN\0|in_30|we_16|in_59|._173 (r_dobj) investigated_4\VBD\644583|NONE_0 (l_prep) in_12\IN\13603305|in_89|we_75|tolerability_59|._114 (l_pobj) number_16\NN\5107765|NONE_0 (l_prep) of_17\IN\0|a_20|large_13 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) history_25\NN\15120823|NONE_0 (l_prep) of_26\IN\0|an_37|exclusive_34|documented_19 (l_pobj) angioedema_32\NN\14316714|NONE_0 (l_nmod) urticaria_30\NN\14533203|/_9
D000082_D014581 NONE paracetamol_12\NNP\0|or_3 (r_conj) nimesulide_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|a_53|controlled_36|oral_25|challenge_20 (r_prep) procedure_8\NN\407535|was_41|to_53|with_69|._121 (r_nsubjpass) applied_14\VBN\0|NONE_0 (l_prep) with_18\IN\0|procedure_69|was_28|to_16|._52 (l_pobj) history_20\NN\15120823|NONE_0 (l_prep) of_21\IN\0|a_10 (l_pobj) angioedema_27\NN\14316714|NONE_0 (l_nmod) urticaria_25\NN\14533203|/_9
D000082_D014581 NONE paracetamol_12\NN\0|and_4 (r_conj) nimesulide_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_22|good_18|in_30 (r_prep) tolerability_8\NN\0|taken_45|,_31|results_25|._108 (l_prep) in_13\IN\13603305|the_52|good_48|of_30 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_relcl) experienced_16\VBD\2108377|NONE_0 (l_dobj) angioedema_19\NNP\14316714|who_26 (l_nmod) urticaria_17\NN\14533203|caused_21
D000894_D014581 NONE nsaid_8\NNP\2721538|-_5 (r_npadvmod) induced_10\VBN\1627355|/_17 (r_amod) urticaria_11\NN\14533203|NONE_0
D000894_D014581 NONE nsaid_27\NNP\2721538|-_5 (r_npadvmod) induced_29\VBN\1627355|NONE_0 (r_amod) urticaria_30\NN\14533203|/_9
D000894_D014581 NONE nsaid_22\NNP\2721538|-_5 (r_npadvmod) induced_24\VBN\1627355|NONE_0 (r_amod) urticaria_25\NN\14533203|/_9
D000894_D014581 NONE nsaid_21\NNP\2721538|-_5 (r_npadvmod) induced_23\VBN\1627355|/_17 (r_amod) urticaria_24\NN\14533203|or_21|angioedema_24|alone_35|(_41 (r_nmod) angioedema_26\NN\14316714|NONE_0 (r_pobj) of_20\IN\0|an_11|with_59 (r_prep) history_19\NN\15120823|NONE_0 (r_pobj) with_17\IN\0|NONE_0 (r_prep) subjects_16\NNS\6598915|NONE_0 (r_pobj) of_15\IN\0|11.8_6 (r_prep) %_14\NN\0|a_39|of_29|and_8 (r_conj) history_8\NN\15120823|NONE_0 (l_prep) of_9\IN\0|a_10|and_21|%_29 (l_pobj) urticaria_11\NN\14533203|NONE_0
D000894_D014581 NONE nsaid_21\NNP\2721538|-_5 (r_npadvmod) induced_23\VBN\1627355|/_17 (r_amod) urticaria_24\NN\14533203|or_21|angioedema_24|alone_35|(_41
D000894_D014581 NONE nsaid_21\NNP\2721538|-_5 (r_npadvmod) induced_23\VBN\1627355|/_17 (r_amod) urticaria_24\NN\14533203|or_21|angioedema_24|alone_35|(_41 (r_nmod) angioedema_26\NN\14316714|NONE_0 (r_pobj) of_20\IN\0|an_11|with_59 (r_prep) history_19\NN\15120823|NONE_0 (l_prep) with_31\IN\0|an_70|of_59 (l_conj) without_33\IN\0|or_3 (l_pobj) urticaria_35\NN\14533203|NONE_0
D000894_D014581 NONE nsaids_22\NNS\2721538|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) caused_20\VBN\1617192|urticaria_21 (r_acl) angioedema_19\NNP\14316714|who_26 (l_nmod) urticaria_17\NN\14533203|caused_21
D000894_D014581 NONE nsaid_29\NNP\2721538|-_5 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) angioedema_32\NN\14316714|NONE_0 (r_pobj) of_28\IN\0|a_10 (r_prep) history_27\NN\15120823|NONE_0 (r_pobj) by_25\IN\0|however_140|,_133|risk_127|is_77|statistically_74|by_50|and_16|,_13|all_5|,_2|._40 (r_prep) increased_13\VBN\169651|NONE_0 (l_agent) by_14\IN\0|however_90|,_83|risk_77|is_27|statistically_24|and_34|,_37|all_45|,_48|by_50|._90 (l_pobj) history_16\NN\15120823|NONE_0 (l_prep) of_17\IN\0|a_10 (l_pobj) urticaria_19\NN\14533203|NONE_0
D000082_D000799 CID paracetamol_4\NN\0|and_4 (r_conj) nimesulide_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|in_30|._81 (r_prep) tolerability_0\DT\0|NONE_0 (l_prep) in_5\IN\13603305|of_30|._51 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|NONE_0 (l_pobj) angioedema_13\NN\14316714|NONE_0
D000082_D000799 CID paracetamol_11\NN\0|and_4 (r_conj) nimesulide_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|and_16|reliability_12 (r_prep) tolerability_5\NN\0|in_30|we_16|in_59|._173 (r_dobj) investigated_4\VBD\644583|NONE_0 (l_prep) in_12\IN\13603305|in_89|we_75|tolerability_59|._114 (l_pobj) number_16\NN\5107765|NONE_0 (l_prep) of_17\IN\0|a_20|large_13 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) history_25\NN\15120823|NONE_0 (l_prep) of_26\IN\0|an_37|exclusive_34|documented_19 (l_pobj) angioedema_32\NN\14316714|NONE_0
D000082_D000799 CID paracetamol_12\NNP\0|or_3 (r_conj) nimesulide_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|a_53|controlled_36|oral_25|challenge_20 (r_prep) procedure_8\NN\407535|was_41|to_53|with_69|._121 (r_nsubjpass) applied_14\VBN\0|NONE_0 (l_prep) with_18\IN\0|procedure_69|was_28|to_16|._52 (l_pobj) history_20\NN\15120823|NONE_0 (l_prep) of_21\IN\0|a_10 (l_pobj) angioedema_27\NN\14316714|NONE_0
D000082_D000799 CID paracetamol_12\NN\0|and_4 (r_conj) nimesulide_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_22|good_18|in_30 (r_prep) tolerability_8\NN\0|taken_45|,_31|results_25|._108 (l_prep) in_13\IN\13603305|the_52|good_48|of_30 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_relcl) experienced_16\VBD\2108377|NONE_0 (l_dobj) angioedema_19\NNP\14316714|who_26
C012655_D000799 CID nimesulide_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|in_30|._81 (r_prep) tolerability_0\DT\0|NONE_0 (l_prep) in_5\IN\13603305|of_30|._51 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|NONE_0 (l_pobj) angioedema_13\NN\14316714|NONE_0
C012655_D000799 CID nimesulide_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|and_16|reliability_12 (r_prep) tolerability_5\NN\0|in_30|we_16|in_59|._173 (r_dobj) investigated_4\VBD\644583|NONE_0 (l_prep) in_12\IN\13603305|in_89|we_75|tolerability_59|._114 (l_pobj) number_16\NN\5107765|NONE_0 (l_prep) of_17\IN\0|a_20|large_13 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) history_25\NN\15120823|NONE_0 (l_prep) of_26\IN\0|an_37|exclusive_34|documented_19 (l_pobj) angioedema_32\NN\14316714|NONE_0
C012655_D000799 CID nimesulide_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|a_53|controlled_36|oral_25|challenge_20 (r_prep) procedure_8\NN\407535|was_41|to_53|with_69|._121 (r_nsubjpass) applied_14\VBN\0|NONE_0 (l_prep) with_18\IN\0|procedure_69|was_28|to_16|._52 (l_pobj) history_20\NN\15120823|NONE_0 (l_prep) of_21\IN\0|a_10 (l_pobj) angioedema_27\NN\14316714|NONE_0
C012655_D000799 CID nimesulide_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_22|good_18|in_30 (r_prep) tolerability_8\NN\0|taken_45|,_31|results_25|._108 (l_prep) in_13\IN\13603305|the_52|good_48|of_30 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_relcl) experienced_16\VBD\2108377|NONE_0 (l_dobj) angioedema_19\NNP\14316714|who_26
C012655_D014581 NONE nimesulide_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|in_30|._81 (r_prep) tolerability_0\DT\0|NONE_0 (l_prep) in_5\IN\13603305|of_30|._51 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|NONE_0 (l_pobj) angioedema_13\NN\14316714|NONE_0 (l_nmod) urticaria_11\NN\14533203|NONE_0
C012655_D014581 NONE nimesulide_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|and_16|reliability_12 (r_prep) tolerability_5\NN\0|in_30|we_16|in_59|._173 (r_dobj) investigated_4\VBD\644583|NONE_0 (l_prep) in_12\IN\13603305|in_89|we_75|tolerability_59|._114 (l_pobj) number_16\NN\5107765|NONE_0 (l_prep) of_17\IN\0|a_20|large_13 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) history_25\NN\15120823|NONE_0 (l_prep) of_26\IN\0|an_37|exclusive_34|documented_19 (l_pobj) angioedema_32\NN\14316714|NONE_0 (l_nmod) urticaria_30\NN\14533203|/_9
C012655_D014581 NONE nimesulide_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|a_53|controlled_36|oral_25|challenge_20 (r_prep) procedure_8\NN\407535|was_41|to_53|with_69|._121 (r_nsubjpass) applied_14\VBN\0|NONE_0 (l_prep) with_18\IN\0|procedure_69|was_28|to_16|._52 (l_pobj) history_20\NN\15120823|NONE_0 (l_prep) of_21\IN\0|a_10 (l_pobj) angioedema_27\NN\14316714|NONE_0 (l_nmod) urticaria_25\NN\14533203|/_9
C012655_D014581 NONE nimesulide_10\NN\0|NONE_0 (r_pobj) of_9\IN\0|the_22|good_18|in_30 (r_prep) tolerability_8\NN\0|taken_45|,_31|results_25|._108 (l_prep) in_13\IN\13603305|the_52|good_48|of_30 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_relcl) experienced_16\VBD\2108377|NONE_0 (l_dobj) angioedema_19\NNP\14316714|who_26 (l_nmod) urticaria_17\NN\14533203|caused_21
D000894_D000799 CID nsaid_8\NNP\2721538|-_5 (r_npadvmod) induced_10\VBN\1627355|/_17 (r_amod) urticaria_11\NN\14533203|NONE_0 (r_nmod) angioedema_13\NN\14316714|NONE_0
D000894_D000799 CID nsaid_27\NNP\2721538|-_5 (r_npadvmod) induced_29\VBN\1627355|NONE_0 (r_amod) urticaria_30\NN\14533203|/_9 (r_nmod) angioedema_32\NN\14316714|NONE_0
D000894_D000799 CID nsaid_22\NNP\2721538|-_5 (r_npadvmod) induced_24\VBN\1627355|NONE_0 (r_amod) urticaria_25\NN\14533203|/_9 (r_nmod) angioedema_27\NN\14316714|NONE_0
D000894_D000799 CID nsaid_21\NNP\2721538|-_5 (r_npadvmod) induced_23\VBN\1627355|/_17 (r_amod) urticaria_24\NN\14533203|or_21|angioedema_24|alone_35|(_41 (r_nmod) angioedema_26\NN\14316714|NONE_0
D000894_D000799 CID nsaid_21\NNP\2721538|-_5 (r_npadvmod) induced_23\VBN\1627355|/_17 (r_amod) urticaria_24\NN\14533203|or_21|angioedema_24|alone_35|(_41 (r_nmod) angioedema_26\NN\14316714|NONE_0 (l_conj) angioedema_28\NN\14316714|urticaria_24|or_3|alone_11|(_17
D000894_D000799 CID nsaids_22\NNS\2721538|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) caused_20\VBN\1617192|urticaria_21 (r_acl) angioedema_19\NNP\14316714|who_26
D000894_D000799 CID nsaid_29\NNP\2721538|-_5 (r_npadvmod) induced_31\VBN\1627355|NONE_0 (r_amod) angioedema_32\NN\14316714|NONE_0
19707748
D064704_D012640 CID levofloxacin_3\NNS\0|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|:_28|presentation_35|._69 (r_acl) seizures_0\NNS\14081375|NONE_0
D064704_D012640 CID levofloxacin_15\NNS\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treatment_13\NN\654885|and_28|discuss_35 (r_dobj) initiating_12\VBG\1617192|shortly_14|as_168 (r_pcomp) after_11\IN\0|who_31|seizures_17 (r_prep) developed_8\VBD\1753788|a_14|,_218|of_220 (l_dobj) seizures_9\NNS\14081375|who_14|after_17
D064704_D012640 CID levofloxacin_15\NNS\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treatment_13\NN\654885|and_28|discuss_35 (r_dobj) initiating_12\VBG\1617192|shortly_14|as_168 (r_pcomp) after_11\IN\0|who_31|seizures_17 (r_prep) developed_8\VBD\1753788|a_14|,_218|of_220 (r_relcl) patient_6\NN\9898892|NONE_0 (l_prep) of_47\IN\0|a_234|developed_220|,_2 (l_pobj) seizures_51\NNS\14081375|NONE_0
D064704_D012640 CID levofloxacin_48\NN\0|-_12 (r_npadvmod) induced_50\VBN\1627355|NONE_0 (r_amod) seizures_51\NNS\14081375|NONE_0 (r_pobj) of_47\IN\0|a_234|developed_220|,_2 (r_prep) patient_6\NN\9898892|NONE_0 (l_relcl) developed_8\VBD\1753788|a_14|,_218|of_220 (l_dobj) seizures_9\NNS\14081375|who_14|after_17
D064704_D012640 CID levofloxacin_48\NN\0|-_12 (r_npadvmod) induced_50\VBN\1627355|NONE_0 (r_amod) seizures_51\NNS\14081375|NONE_0
D064704_D012640 CID levofloxacin_3\NN\0|-_12 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) seizures_6\NNS\14081375|NONE_0
15811908
C037689_D010673 NONE benzamide_14\JJ\0|substituted_12 (r_amod) drugs_15\NNS\14778436|NONE_0 (r_pobj) of_12\IN\0|the_8 (r_prep) use_11\NN\407535|NONE_0 (r_pobj) with_9\IN\0|symptoms_50|are_21|often_17|,_43|but_45|is_74 (r_prep) associated_8\VBN\628491|NONE_0 (l_nsubjpass) symptoms_3\NNS\5823932|are_29|often_33|with_50|,_93|but_95|is_124 (l_prep) of_4\IN\0|induced_17 (l_pobj) pheochromocytoma_5\NN\14235200|NONE_0
D063325_D006973 CID tiapride_21\NN\0|NONE_0 (r_compound) therapy_22\NN\657604|and_13 (r_conj) amisulpride_19\NN\0|the_28|hypertensive_24|and_4 (r_conj) crisis_17\NN\14411243|NONE_0 (l_amod) hypertensive_16\JJ\10405694|the_4|and_20|amisulpride_24
D063325_D006973 CID tiapride_16\NN\0|-_8 (r_npadvmod) induced_18\VBN\1627355|hypertensive_8 (r_amod) crisis_20\NN\14411243|and_34 (l_amod) hypertensive_19\JJ\10405694|induced_8
D063325_D010673 NONE tiapride_5\NN\0|and_4 (r_conj) amisulpride_3\NN\0|NONE_0 (r_pobj) by_2\IN\0|pheochromocytoma_26|._27 (r_prep) unmasked_1\VBD\853195|NONE_0 (l_nsubj) pheochromocytoma_0\NNP\14235200|by_26|._53
D063325_D010673 NONE tiapride_13\NN\0|and_4 (r_conj) amisulpride_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treated_9\VBN\2376958|a_10 (r_acl) patient_8\NN\9898892|NONE_0 (r_pobj) in_6\IN\13603305|the_34|of_20 (r_prep) unmasking_3\NN\7215377|to_16|._80 (l_prep) of_4\IN\0|the_14|in_20 (l_pobj) pheochromocytoma_5\NN\14235200|NONE_0
D063325_D010673 NONE tiapride_16\NN\0|-_8 (r_npadvmod) induced_18\VBN\1627355|hypertensive_8 (r_amod) crisis_20\NN\14411243|and_34 (r_conj) amisulpride-_14\JJ\0|NONE_0 (r_pobj) of_13\IN\0|the_24|first_20|reported_14|in_57 (r_prep) case_12\NN\7283608|as_49|,_29|this_27|._96 (l_prep) in_21\IN\13603305|the_81|first_77|reported_71|of_57 (l_pobj) patient_23\NN\9898892|NONE_0 (l_prep) with_24\IN\0|a_10 (l_pobj) pheochromocytoma_25\NN\14235200|NONE_0
C012052_D014839 CID amisulpride_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_16|first_12 (r_prep) doses_19\NNS\3740161|hours_22 (r_pobj) after_16\IN\0|NONE_0 (r_prep) vomiting_13\NN\116687|man_58|hypertension_38|and_4
C012052_D006261 CID amisulpride_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_16|first_12 (r_prep) doses_19\NNS\3740161|hours_22 (r_pobj) after_16\IN\0|NONE_0 (r_prep) vomiting_13\NN\116687|man_58|hypertension_38|and_4 (r_conj) developed_6\VBD\1753788|NONE_0 (l_dobj) hypertension_8\NN\14057371|man_20|and_34|vomiting_38 (l_prep) with_9\IN\0|acute_19 (l_pobj) headache_11\NN\5829480|NONE_0
C012052_D010673 NONE amisulpride_3\NN\0|NONE_0 (r_pobj) by_2\IN\0|pheochromocytoma_26|._27 (r_prep) unmasked_1\VBD\853195|NONE_0 (l_nsubj) pheochromocytoma_0\NNP\14235200|by_26|._53
C012052_D010673 NONE amisulpride_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treated_9\VBN\2376958|a_10 (r_acl) patient_8\NN\9898892|NONE_0 (r_pobj) in_6\IN\13603305|the_34|of_20 (r_prep) unmasking_3\NN\7215377|to_16|._80 (l_prep) of_4\IN\0|the_14|in_20 (l_pobj) pheochromocytoma_5\NN\14235200|NONE_0
C012052_D010673 NONE amisulpride-_14\JJ\0|NONE_0 (r_pobj) of_13\IN\0|the_24|first_20|reported_14|in_57 (r_prep) case_12\NN\7283608|as_49|,_29|this_27|._96 (l_prep) in_21\IN\13603305|the_81|first_77|reported_71|of_57 (l_pobj) patient_23\NN\9898892|NONE_0 (l_prep) with_24\IN\0|a_10 (l_pobj) pheochromocytoma_25\NN\14235200|NONE_0
C012052_D006973 CID amisulpride_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|the_16|first_12 (r_prep) doses_19\NNS\3740161|hours_22 (r_pobj) after_16\IN\0|NONE_0 (r_prep) vomiting_13\NN\116687|man_58|hypertension_38|and_4 (r_conj) developed_6\VBD\1753788|NONE_0 (l_dobj) hypertension_8\NN\14057371|man_20|and_34|vomiting_38
C012052_D006973 CID amisulpride_19\NN\0|the_28|hypertensive_24|and_4 (r_conj) crisis_17\NN\14411243|NONE_0 (l_amod) hypertensive_16\JJ\10405694|the_4|and_20|amisulpride_24
C012052_D006973 CID amisulpride-_14\JJ\0|NONE_0 (l_conj) crisis_20\NN\14411243|and_34 (l_amod) hypertensive_19\JJ\10405694|induced_8
19719056
D002351_D010146 CID carrageenan_17\NN\14898470|-_11 (r_npadvmod) induced_19\VBN\1627355|rat_8|paw_12|edema_16|,_27 (r_amod) model_23\NN\5888929|)_40|and_38 (r_conj) mice_14\NNS\2329401|(_1 (r_appos) model_12\NN\5888929|respectively_58 (r_attr) writhing_11\VBG\1831531|NONE_0
D019342_D010146 NONE acid_9\NN\14818238|NONE_0 (r_dobj) using_7\VBG\418025|activities_28|were_17|induced_18|._105 (r_advcl) ascertained_6\VBN\0|NONE_0 (l_conj) induced_10\VBD\1627355|activities_46|were_35|using_18|._87 (l_xcomp) writhing_11\VBG\1831531|NONE_0
D019342_D004487 NONE acid_9\NN\14818238|NONE_0 (r_dobj) using_7\VBG\418025|activities_28|were_17|induced_18|._105 (r_advcl) ascertained_6\VBN\0|NONE_0 (l_conj) induced_10\VBD\1627355|activities_46|were_35|using_18|._87 (l_xcomp) writhing_11\VBG\1831531|NONE_0 (l_attr) model_12\NN\5888929|respectively_58 (l_appos) mice_14\NNS\2329401|(_1 (l_conj) model_23\NN\5888929|)_40|and_38 (l_compound) edema_22\NN\14315192|induced_16|rat_8|paw_4|,_11
D002351_D004487 CID carrageenan_17\NN\14898470|-_11 (r_npadvmod) induced_19\VBN\1627355|rat_8|paw_12|edema_16|,_27 (r_amod) model_23\NN\5888929|)_40|and_38 (l_compound) edema_22\NN\14315192|induced_16|rat_8|paw_4|,_11
7707116
D015474_D064420 NONE ra_24\NNP\14625458|NONE_0 (r_pobj) of_21\IN\0|,_23|and_21|pharmacokinetics_17|administered_10 (r_prep) toxicities_17\NNS\13576101|the_36|tolerated_24|(_7|mtd_6|)_3|,_2|following_115
D015474_D064420 NONE ra_6\NNP\14625458|after_10|was_3 (r_nsubjpass) discontinued_8\VBN\0|toxicities_37|._12 (r_advcl) resolved_2\VBD\352826|NONE_0 (l_nsubj) toxicities_1\NNS\13576101|discontinued_37|._49
D015474_D009447 NONE acid_7\NN\14818238|NONE_0 (r_pobj) of_3\IN\0|in_24|following_55 (r_prep) trial_2\NN\786195|phase_8|._98 (l_prep) in_8\IN\13603305|of_24|following_31 (l_pobj) children_9\NNS\9622049|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) neuroblastoma_11\NN\14239425|NONE_0
D015474_D009447 NONE acid_11\NN\14818238|NONE_0 (r_pobj) with_7\IN\0|neuroblastoma_25|cell_11 (r_prep) lines_6\NNS\8426461|NONE_0 (l_compound) neuroblastoma_4\NN\14239425|cell_14|with_25
D015474_D009447 NONE ra_15\NNP\14625458|retinoic_19 (r_appos) acid_11\NN\14818238|NONE_0 (r_pobj) with_7\IN\0|neuroblastoma_25|cell_11 (r_prep) lines_6\NNS\8426461|NONE_0 (l_compound) neuroblastoma_4\NN\14239425|cell_14|with_25
D015474_D009447 NONE ra_3\NNP\14625458|since_10|has_3|responses_29 (r_nsubj) demonstrated_5\VBN\2137132|,_57|it_59|may_62|effective_69|._124 (l_dobj) responses_7\NNS\11410625|since_39|ra_29|has_26 (l_prep) in_8\IN\13603305|clinical_19 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_compound) neuroblastoma_9\NN\14239425|NONE_0
D015474_D009447 NONE ra_24\NNP\14625458|NONE_0 (r_pobj) of_21\IN\0|,_23|and_21|pharmacokinetics_17|administered_10 (r_prep) toxicities_17\NNS\13576101|the_36|tolerated_24|(_7|mtd_6|)_3|,_2|following_115 (l_acl) administered_25\VBD\2436349|,_33|and_31|pharmacokinetics_27|of_10 (l_prep) on_26\IN\0|NONE_0 (l_pobj) schedule_29\NN\5898568|NONE_0 (l_prep) in_30\IN\13603305|an_25|intermittent_22 (l_pobj) children_31\NNS\9622049|NONE_0 (l_prep) with_32\IN\0|NONE_0 (l_pobj) neuroblastoma_33\NN\14239425|NONE_0
D015474_D006934 CID ra_13\NNP\14625458|serum_10 (r_compound) levels_14\NNS\4916342|NONE_0 (r_pobj) by_9\IN\0|may_17|be_13 (r_agent) predicted_8\VBN\916909|dlt_39|hypercalcemia_26|,_13|and_11|._32 (r_conj) included_2\VBD\0|NONE_0 (l_dobj) hypercalcemia_3\NN\14299637|dlt_13|,_13|and_15|predicted_26|._58
11858397
D008787_D002037 NONE metoclopramide_5\NN\0|NONE_0 (r_pobj) by_4\IN\0|in_18|with_38 (r_agent) induced_3\VBN\1627355|torsade_19|de_11|._96 (l_prep) with_10\IN\0|by_38|in_20 (l_pobj) block_16\NN\21939|NONE_0
D008787_D002037 NONE metoclopramide_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|intravenous_36 (r_prep) administration_24\NN\1133281|NONE_0 (r_pobj) after_20\IN\0|who_33|pointes_8 (r_prep) developed_16\VBD\1753788|a_75|old_65|with_55 (r_relcl) woman_7\NN\9605289|NONE_0 (l_prep) with_8\IN\0|a_20|old_10|developed_55 (l_pobj) block_14\NN\21939|NONE_0
D020117_D016171 CID cisapride_8\RB\0|when_5|were_27|simultaneously_38 (r_nsubjpass) given_12\VBN\5892096|patient_79|also_71|pointes_45|._20 (r_advcl) developed_3\VBD\1753788|NONE_0 (l_dobj) pointes_6\FW\831651|patient_34|also_26|given_45|._65
D008787_D016171 CID metoclopramide_5\NN\0|NONE_0 (r_pobj) by_4\IN\0|in_18|with_38 (r_agent) induced_3\VBN\1627355|torsade_19|de_11|._96 (r_acl) pointes_2\NNS\831651|NONE_0
D008787_D016171 CID metoclopramide_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|intravenous_36 (r_prep) administration_24\NN\1133281|NONE_0 (r_pobj) after_20\IN\0|who_33|pointes_8 (r_prep) developed_16\VBD\1753788|a_75|old_65|with_55 (l_dobj) pointes_19\NNS\831651|who_25|after_8
D008787_D016171 CID metoclopramide_6\NN\0|that_5|pointes_35|clinically_43 (r_nsubj) provokes_7\VBZ\1617192|the_44|first_40 (l_dobj) pointes_10\FW\831651|that_40|metoclopramide_35|clinically_8
D008787_D016171 CID metoclopramide_0\NNP\0|should_15|be_22|cautiously_30|in_41|._86 (r_nsubjpass) used_3\VBN\0|NONE_0 (l_prep) in_5\IN\13603305|metoclopramide_41|should_26|be_19|cautiously_11|._45 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|NONE_0 (l_pobj) risk_9\NN\14541044|NONE_0 (l_prep) of_10\IN\0|a_7 (l_pobj) pointes_13\FW\831651|NONE_0
D004917_D016171 CID erythromycin_10\NNP\2716866|and_4 (r_conj) cisapride_8\RB\0|when_5|were_27|simultaneously_38 (r_nsubjpass) given_12\VBN\5892096|patient_79|also_71|pointes_45|._20 (r_advcl) developed_3\VBD\1753788|NONE_0 (l_dobj) pointes_6\FW\831651|patient_34|also_26|given_45|._65
7007443
D000082_D017114 CID paracetamol_26\JJ\0|NONE_0 (r_compound) overdose_27\NN\84738|NONE_0 (r_pobj) after_25\IN\0|who_39|failure_8 (r_prep) survived_21\VBD\0|NONE_0 (l_dobj) failure_24\NN\66216|who_31|after_8
D000082_D017114 CID paracetamol_26\JJ\0|NONE_0 (r_compound) overdose_27\NN\84738|NONE_0 (r_pobj) after_25\IN\0|who_39|failure_8 (r_prep) survived_21\VBD\0|NONE_0 (r_relcl) those_19\DT\0|NONE_0 (r_pobj) in_18\IN\13603305|nearly_16 (r_prep) fourfold_17\RB\0|who_20|and_11 (r_conj) died_14\VBD\146138|NONE_0 (r_relcl) patients_12\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|activity_37|was_28|tenfold_8|,_115|increased_141|._253 (r_prep) increased_8\VBN\169651|NONE_0 (l_advcl) increased_32\VBN\169651|activity_178|was_169|tenfold_149|in_141|,_26|._112 (l_prep) in_34\IN\13603305|whereas_42|activities_34|were_23|equally_8|survived_86 (l_pobj) patients_35\NNS\9898892|NONE_0 (l_prep) with_36\IN\0|NONE_0 (l_pobj) failure_39\NN\66216|NONE_0
D000082_D006525 NONE paracetamol_26\JJ\0|NONE_0 (r_compound) overdose_27\NN\84738|NONE_0 (r_pobj) after_25\IN\0|who_39|failure_8 (r_prep) survived_21\VBD\0|NONE_0 (r_relcl) those_19\DT\0|NONE_0 (r_pobj) in_18\IN\13603305|nearly_16 (r_prep) fourfold_17\RB\0|who_20|and_11 (r_conj) died_14\VBD\146138|NONE_0 (r_relcl) patients_12\NNS\9898892|NONE_0 (r_pobj) in_11\IN\13603305|activity_37|was_28|tenfold_8|,_115|increased_141|._253 (r_prep) increased_8\VBN\169651|NONE_0 (l_advcl) increased_32\VBN\169651|activity_178|was_169|tenfold_149|in_141|,_26|._112 (l_prep) in_34\IN\13603305|whereas_42|activities_34|were_23|equally_8|survived_86 (l_pobj) patients_35\NNS\9898892|NONE_0 (l_prep) with_36\IN\0|NONE_0 (l_pobj) failure_39\NN\66216|NONE_0 (l_amod) due_40\IN\5174653|fulminant_26|hepatic_16 (l_pcomp) to_41\IN\0|NONE_0 (l_pobj) hepatitis_43\NN\14127211|NONE_0
D000082_D062787 NONE paracetamol_26\JJ\0|NONE_0 (r_compound) overdose_27\NN\84738|NONE_0
3653576
C001335_D007674 NONE hcbd_4\NNP\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) produced_2\VBN\1617192|tubular_15 (r_acl) damage_1\NN\7296428|was_31|quantitatively_54|from_87|._125 (r_nsubjpass) discriminated_8\VBN\650353|NONE_0 (l_prep) from_13\IN\0|damage_87|was_56|quantitatively_33|._38 (l_pobj) damage_15\NN\7296428|NONE_0
C004504_D058186 CID 2-bromoethylamine_36\NN\0|NONE_0 (r_punct) ._42\.\0|produced_137|pan_47|,_43|and_41 (r_punct) puromycin_29\NNS\0|NONE_0 (l_ccomp) produced_20\VBN\1617192|pan_90|,_94|and_96|._137 (l_nsubjpass) models_2\NNS\5888929|were_93|by_107|,_159 (l_prep) of_3\IN\0|acute_26|experimental_20 (l_pobj) damage_5\NN\7296428|NONE_0
C004504_D058186 CID bea_38\NNP\0|,_4|respectively_6 (r_nmod) 2-bromoethylamine_36\NN\0|NONE_0 (r_punct) ._42\.\0|produced_137|pan_47|,_43|and_41 (r_punct) puromycin_29\NNS\0|NONE_0 (l_ccomp) produced_20\VBN\1617192|pan_90|,_94|and_96|._137 (l_nsubjpass) models_2\NNS\5888929|were_93|by_107|,_159 (l_prep) of_3\IN\0|acute_26|experimental_20 (l_pobj) damage_5\NN\7296428|NONE_0
C004504_D007674 NONE bea_6\NNP\0|or_3 (r_conj) hcbd_4\NNP\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) produced_2\VBN\1617192|tubular_15 (r_acl) damage_1\NN\7296428|was_31|quantitatively_54|from_87|._125 (r_nsubjpass) discriminated_8\VBN\650353|NONE_0 (l_prep) from_13\IN\0|damage_87|was_56|quantitatively_33|._38 (l_pobj) damage_15\NN\7296428|NONE_0
D011692_D058186 CID aminonucleoside_30\NN\0|(_16|)_20 (r_nmod) pan_32\NNP\3101986|produced_90|,_4|and_6|._47 (r_npadvmod) puromycin_29\NNS\0|NONE_0 (l_ccomp) produced_20\VBN\1617192|pan_90|,_94|and_96|._137 (l_nsubjpass) models_2\NNS\5888929|were_93|by_107|,_159 (l_prep) of_3\IN\0|acute_26|experimental_20 (l_pobj) damage_5\NN\7296428|NONE_0
D011692_D058186 CID pan_32\NNP\3101986|produced_90|,_4|and_6|._47 (r_npadvmod) puromycin_29\NNS\0|NONE_0 (l_ccomp) produced_20\VBN\1617192|pan_90|,_94|and_96|._137 (l_nsubjpass) models_2\NNS\5888929|were_93|by_107|,_159 (l_prep) of_3\IN\0|acute_26|experimental_20 (l_pobj) damage_5\NN\7296428|NONE_0
C001335_D058186 CID hexachloro-1:3-butadiene_24\,\0|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) administration_22\NN\1133281|NONE_0 (r_pobj) by_21\IN\0|models_107|were_14|,_52 (r_agent) produced_20\VBN\1617192|pan_90|,_94|and_96|._137 (l_nsubjpass) models_2\NNS\5888929|were_93|by_107|,_159 (l_prep) of_3\IN\0|acute_26|experimental_20 (l_pobj) damage_5\NN\7296428|NONE_0
C001335_D058186 CID hcbd_26\NNP\0|(_1|)_4 (r_appos) hexachloro-1:3-butadiene_24\,\0|NONE_0 (r_pobj) of_23\IN\0|NONE_0 (r_prep) administration_22\NN\1133281|NONE_0 (r_pobj) by_21\IN\0|models_107|were_14|,_52 (r_agent) produced_20\VBN\1617192|pan_90|,_94|and_96|._137 (l_nsubjpass) models_2\NNS\5888929|were_93|by_107|,_159 (l_prep) of_3\IN\0|acute_26|experimental_20 (l_pobj) damage_5\NN\7296428|NONE_0
D011692_D007674 NONE pan_18\NNP\3101986|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) produced_16\VBN\1617192|glomerular_18 (r_acl) damage_15\NN\7296428|NONE_0
3084782
D008625_D003872 CID tiopronin_12\NNP\0|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_pcomp) due_10\IN\5174653|association_60|has_48|been_44|between_33|,_79|and_81|between_85|._136 (r_prep) found_5\VBN\13279262|NONE_0 (l_prep) between_6\IN\0|association_27|has_15|been_11|due_33|,_112|and_114|between_118|._169 (l_pobj) nephritis_7\NN\14113228|NONE_0 (l_conj) dermatitis_9\NN\14226056|and_4
D008625_D003872 CID tiopronin_12\NNP\0|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_pcomp) due_10\IN\5174653|association_60|has_48|been_44|between_33|,_79|and_81|between_85|._136 (r_prep) found_5\VBN\13279262|NONE_0 (l_prep) between_28\IN\0|association_145|has_133|been_129|between_118|due_85|,_6|and_4|._51 (l_pobj) dermatitis_29\NN\14226056|due_11
D006046_D009393 NONE gold_32\NN\13371489|and_18|b35_22 (r_compound) thiosulphate_33\NN\0|to_8 (r_pobj) due_30\IN\5174653|dermatitis_11 (r_prep) between_28\IN\0|association_145|has_133|been_129|between_118|due_85|,_6|and_4|._51 (r_prep) found_5\VBN\13279262|NONE_0 (l_prep) between_6\IN\0|association_27|has_15|been_11|due_33|,_112|and_114|between_118|._169 (l_pobj) nephritis_7\NN\14113228|NONE_0
-1_D009393 NONE thiosulphate_33\NN\0|to_8 (r_pobj) due_30\IN\5174653|dermatitis_11 (r_prep) between_28\IN\0|association_145|has_133|been_129|between_118|due_85|,_6|and_4|._51 (r_prep) found_5\VBN\13279262|NONE_0 (l_prep) between_6\IN\0|association_27|has_15|been_11|due_33|,_112|and_114|between_118|._169 (l_pobj) nephritis_7\NN\14113228|NONE_0
D006046_D003872 CID gold_32\NN\13371489|and_18|b35_22 (r_compound) thiosulphate_33\NN\0|to_8 (r_pobj) due_30\IN\5174653|dermatitis_11 (r_prep) between_28\IN\0|association_145|has_133|been_129|between_118|due_85|,_6|and_4|._51 (r_prep) found_5\VBN\13279262|NONE_0 (l_prep) between_6\IN\0|association_27|has_15|been_11|due_33|,_112|and_114|between_118|._169 (l_pobj) nephritis_7\NN\14113228|NONE_0 (l_conj) dermatitis_9\NN\14226056|and_4
D006046_D003872 CID gold_32\NN\13371489|and_18|b35_22 (r_compound) thiosulphate_33\NN\0|to_8 (r_pobj) due_30\IN\5174653|dermatitis_11 (r_prep) between_28\IN\0|association_145|has_133|been_129|between_118|due_85|,_6|and_4|._51 (l_pobj) dermatitis_29\NN\14226056|due_11
D008625_D009393 CID tiopronin_12\NNP\0|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_pcomp) due_10\IN\5174653|association_60|has_48|been_44|between_33|,_79|and_81|between_85|._136 (r_prep) found_5\VBN\13279262|NONE_0 (l_prep) between_6\IN\0|association_27|has_15|been_11|due_33|,_112|and_114|between_118|._169 (l_pobj) nephritis_7\NN\14113228|NONE_0
D008625_D009393 CID tiopronin_17\NNP\0|NONE_0 (r_npadvmod) related_18\VBN\628491|the_14|nephritis_8 (r_amod) group_20\NN\2137|NONE_0 (l_compound) nephritis_19\NN\14113228|the_22|related_8
D008625_D001172 NONE tiopronin_17\NNP\0|NONE_0 (r_npadvmod) related_18\VBN\628491|the_14|nephritis_8 (r_amod) group_20\NN\2137|NONE_0 (r_pobj) for_15\IN\0|NONE_0 (r_prep) except_14\IN\807461|with_8 (r_prep) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|except_8 (l_pobj) ra_13\NNP\14625458|NONE_0
D010396_D003872 NONE penicillamine_17\NN\3740161|(_5|)_27|and_29|class_33|b35-cw4_50 (r_appos) tiopronin_12\NNP\0|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_pcomp) due_10\IN\5174653|association_60|has_48|been_44|between_33|,_79|and_81|between_85|._136 (r_prep) found_5\VBN\13279262|NONE_0 (l_prep) between_6\IN\0|association_27|has_15|been_11|due_33|,_112|and_114|between_118|._169 (l_pobj) nephritis_7\NN\14113228|NONE_0 (l_conj) dermatitis_9\NN\14226056|and_4
D010396_D003872 NONE penicillamine_17\NN\3740161|(_5|)_27|and_29|class_33|b35-cw4_50 (r_appos) tiopronin_12\NNP\0|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_pcomp) due_10\IN\5174653|association_60|has_48|been_44|between_33|,_79|and_81|between_85|._136 (r_prep) found_5\VBN\13279262|NONE_0 (l_prep) between_28\IN\0|association_145|has_133|been_129|between_118|due_85|,_6|and_4|._51 (l_pobj) dermatitis_29\NN\14226056|due_11
D010396_D009393 NONE penicillamine_17\NN\3740161|(_5|)_27|and_29|class_33|b35-cw4_50 (r_appos) tiopronin_12\NNP\0|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_pcomp) due_10\IN\5174653|association_60|has_48|been_44|between_33|,_79|and_81|between_85|._136 (r_prep) found_5\VBN\13279262|NONE_0 (l_prep) between_6\IN\0|association_27|has_15|been_11|due_33|,_112|and_114|between_118|._169 (l_pobj) nephritis_7\NN\14113228|NONE_0
-1_D003872 NONE thiosulphate_33\NN\0|to_8 (r_pobj) due_30\IN\5174653|dermatitis_11 (r_prep) between_28\IN\0|association_145|has_133|been_129|between_118|due_85|,_6|and_4|._51 (r_prep) found_5\VBN\13279262|NONE_0 (l_prep) between_6\IN\0|association_27|has_15|been_11|due_33|,_112|and_114|between_118|._169 (l_pobj) nephritis_7\NN\14113228|NONE_0 (l_conj) dermatitis_9\NN\14226056|and_4
-1_D003872 NONE thiosulphate_33\NN\0|to_8 (r_pobj) due_30\IN\5174653|dermatitis_11 (r_prep) between_28\IN\0|association_145|has_133|been_129|between_118|due_85|,_6|and_4|._51 (l_pobj) dermatitis_29\NN\14226056|due_11
3703509
D011241_D011141 NONE prednisone_5\NN\2721538|NONE_0 (r_pobj) to_3\IN\0|short_15 (r_prep) exposure_2\NN\5042871|NONE_0 (r_pobj) following_0\VBG\8180190|,_43|boys_50|lethargy_65|,_73|increasing_75|._134 (r_prep) developed_9\VBD\1753788|NONE_0 (l_advcl) increasing_12\VBG\169651|following_75|,_32|boys_25|lethargy_10|,_2|._59 (l_dobj) somnolence_13\NN\14015731|NONE_0 (l_conj) polydipsia_15\NN\14040660|,_2 (l_conj) polyphagia_17\NN\0|,_2 (l_conj) polyuria_20\NN\14113228|,_6|and_4
D019344_D007662 NONE lactate_13\NN\14850483|a_14|known_12 (r_compound) level_14\NN\4916342|NONE_0 (r_pobj) without_9\IN\0|in_19 (r_prep) present_4\JJ\28270|acidosis_13|was_63|._87 (l_prep) in_5\IN\13603305|without_19 (l_pobj) one_6\CD\13741022|NONE_0 (l_conj) ketosis_8\NN\14299637|and_4
D011241_D006963 NONE prednisone_5\NN\2721538|NONE_0 (r_pobj) to_3\IN\0|short_15 (r_prep) exposure_2\NN\5042871|NONE_0 (r_pobj) following_0\VBG\8180190|,_43|boys_50|lethargy_65|,_73|increasing_75|._134 (r_prep) developed_9\VBD\1753788|NONE_0 (l_advcl) increasing_12\VBG\169651|following_75|,_32|boys_25|lethargy_10|,_2|._59 (l_dobj) somnolence_13\NN\14015731|NONE_0 (l_conj) polydipsia_15\NN\14040660|,_2 (l_conj) polyphagia_17\NN\0|,_2
D011241_D053609 NONE prednisone_5\NN\2721538|NONE_0 (r_pobj) to_3\IN\0|short_15 (r_prep) exposure_2\NN\5042871|NONE_0 (r_pobj) following_0\VBG\8180190|,_43|boys_50|lethargy_65|,_73|increasing_75|._134 (r_prep) developed_9\VBD\1753788|NONE_0 (l_dobj) lethargy_10\NN\14014621|following_65|,_22|boys_15|,_8|increasing_10|._69
D011241_D059606 NONE prednisone_5\NN\2721538|NONE_0 (r_pobj) to_3\IN\0|short_15 (r_prep) exposure_2\NN\5042871|NONE_0 (r_pobj) following_0\VBG\8180190|,_43|boys_50|lethargy_65|,_73|increasing_75|._134 (r_prep) developed_9\VBD\1753788|NONE_0 (l_advcl) increasing_12\VBG\169651|following_75|,_32|boys_25|lethargy_10|,_2|._59 (l_dobj) somnolence_13\NN\14015731|NONE_0 (l_conj) polydipsia_15\NN\14040660|,_2
D011241_D006970 NONE prednisone_5\NN\2721538|NONE_0 (r_pobj) to_3\IN\0|short_15 (r_prep) exposure_2\NN\5042871|NONE_0 (r_pobj) following_0\VBG\8180190|,_43|boys_50|lethargy_65|,_73|increasing_75|._134 (r_prep) developed_9\VBD\1753788|NONE_0 (l_advcl) increasing_12\VBG\169651|following_75|,_32|boys_25|lethargy_10|,_2|._59 (l_dobj) somnolence_13\NN\14015731|NONE_0
D019344_D000140 NONE lactate_13\NN\14850483|a_14|known_12 (r_compound) level_14\NN\4916342|NONE_0 (r_pobj) without_9\IN\0|in_19 (r_prep) present_4\JJ\28270|acidosis_13|was_63|._87 (r_acomp) was_3\VBD\0|NONE_0 (l_nsubj) acidosis_2\NN\14204950|present_13|was_76|._100
1687392
D015647_D002375 NONE 38393_5\CD\0|3_19|d-1_16|agonist_12|or_6|agonist_13 (r_nummod) skf_4\NNP\0|NONE_0 (r_nmod) quinpirole_9\NN\0|catalepsy_25|._82 (r_nsubj) decreased_10\VBD\169651|NONE_0 (l_dobj) catalepsy_12\NN\14023236|quinpirole_25|._57
D015647_D002375 NONE 38393_3\CD\0|NONE_0 (r_nummod) skf_2\NNP\0|NONE_0 (r_pobj) of_1\IN\0|with_13 (r_prep) combination_0\NN\7951464|did_41|not_45|potentiated_55|._129 (r_nsubj) cause_8\VB\7323922|NONE_0 (l_ccomp) potentiated_9\VBN\229605|combination_55|did_14|not_10|._74 (l_dobj) effect_11\NN\34213|NONE_0 (l_prep) on_12\IN\0|inhibitory_18|induced_13 (l_pobj) catalepsy_13\NN\14023236|NONE_0
D005476_D002375 CID fluphenazine_2\NN\3713736|sulpiride_57|catalepsy_75|._84 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) catalepsy_13\NN\14023236|fluphenazine_75|sulpiride_18|._9
D005476_D002375 CID fluphenazine_15\NN\3713736|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|the_14 (r_acl) catalepsy_12\NN\14023236|quinpirole_25|._57
C534628_D002375 CID 23390_7\CD\0|d-1_19|antagonist_15|or_6 (r_nummod) sch_6\NNP\0|dopamine_49|antagonist_40|,_17 (r_appos) fluphenazine_2\NN\3713736|sulpiride_57|catalepsy_75|._84 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) catalepsy_13\NN\14023236|fluphenazine_75|sulpiride_18|._9
C534628_D002375 CID 23390_3\CD\0|NONE_0 (r_nummod) sch_2\NNP\0|NONE_0 (r_pobj) of_1\IN\0|with_13 (r_prep) combination_0\NN\7951464|did_40|not_44|potentiation_65|._77 (r_nsubj) induce_8\VB\1627355|NONE_0 (l_dobj) potentiation_10\NN\13564910|combination_65|did_25|not_21|._12 (l_compound) catalepsy_9\NN\14023236|NONE_0
C534628_D002375 CID 23390_18\CD\0|or_6|sulpiride_9 (r_nummod) sch_17\NNP\0|,_2 (r_appos) fluphenazine_15\NN\3713736|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|the_14 (r_acl) catalepsy_12\NN\14023236|quinpirole_25|._57
D019257_D002375 NONE quinpirole_9\NN\0|catalepsy_25|._82 (r_nsubj) decreased_10\VBD\169651|NONE_0 (l_dobj) catalepsy_12\NN\14023236|quinpirole_25|._57
D019257_D002375 NONE quinpirole_5\NN\0|NONE_0 (r_pobj) with_4\IN\0|of_13 (r_prep) combination_0\NN\7951464|did_41|not_45|potentiated_55|._129 (r_nsubj) cause_8\VB\7323922|NONE_0 (l_ccomp) potentiated_9\VBN\229605|combination_55|did_14|not_10|._74 (l_dobj) effect_11\NN\34213|NONE_0 (l_prep) on_12\IN\0|inhibitory_18|induced_13 (l_pobj) catalepsy_13\NN\14023236|NONE_0
D004298_D002375 NONE dopamine_6\NN\14807737|both_17 (r_compound) receptors_7\NNS\5225602|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) blockade_0\NN\952963|may_48|catalepsy_59|in_69|._76 (r_nsubj) induce_9\VB\1627355|NONE_0 (l_dobj) catalepsy_10\NN\14023236|blockade_59|may_11|in_10|._17
D004298_D002375 NONE dopamine_4\NN\14807737|NONE_0 (r_compound) antagonists_5\NNS\7846|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|the_14 (r_acl) catalepsy_1\NN\14023236|has_42|been_46|and_58|determined_119
D004298_D002375 NONE dopamine_4\NN\14807737|NONE_0 (r_compound) antagonists_5\NNS\7846|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|the_14 (r_acl) catalepsy_1\NN\14023236|has_42|been_46|and_58|determined_119 (r_nsubjpass) tested_8\VBN\670261|NONE_0 (l_conj) determined_18\VBN\0|catalepsy_119|has_77|been_73|and_61 (l_nsubjpass) subtypes_13\NNS\0|was_31|._45 (l_acl) involved_14\VBN\2676054|the_31|possible_27|dopamine_18 (l_prep) in_15\IN\13603305|NONE_0 (l_pobj) catalepsy_16\NN\14023236|NONE_0
D004298_D002375 NONE dopamine_12\NN\14807737|the_13|possible_9|involved_18 (r_compound) subtypes_13\NNS\0|was_31|._45 (r_nsubjpass) determined_18\VBN\0|catalepsy_119|has_77|been_73|and_61 (r_conj) tested_8\VBN\670261|NONE_0 (l_nsubjpass) catalepsy_1\NN\14023236|has_42|been_46|and_58|determined_119
D004298_D002375 NONE dopamine_12\NN\14807737|the_13|possible_9|involved_18 (r_compound) subtypes_13\NNS\0|was_31|._45 (l_acl) involved_14\VBN\2676054|the_31|possible_27|dopamine_18 (l_prep) in_15\IN\13603305|NONE_0 (l_pobj) catalepsy_16\NN\14023236|NONE_0
D004298_D002375 NONE dopamine_0\NN\14807737|antagonist_9|,_32|sch_49 (r_compound) fluphenazine_2\NN\3713736|sulpiride_57|catalepsy_75|._84 (r_nsubj) induced_12\VBD\1627355|NONE_0 (l_dobj) catalepsy_13\NN\14023236|fluphenazine_75|sulpiride_18|._9
D004298_D002375 NONE dopamine_16\NN\14807737|NONE_0 (r_compound) antagonists_17\NNS\7846|NONE_0 (r_pobj) by_15\IN\0|NONE_0 (r_agent) induced_14\VBN\1627355|inhibitory_31|on_13 (r_acl) effect_11\NN\34213|NONE_0 (l_prep) on_12\IN\0|inhibitory_18|induced_13 (l_pobj) catalepsy_13\NN\14023236|NONE_0
D013469_D002375 CID sulpiride_11\NN\0|fluphenazine_57|catalepsy_18|._27 (r_npadvmod) induced_12\VBD\1627355|NONE_0 (l_dobj) catalepsy_13\NN\14023236|fluphenazine_75|sulpiride_18|._9
D013469_D002375 CID sulpiride_5\NN\0|NONE_0 (r_pobj) with_4\IN\0|of_13 (r_prep) combination_0\NN\7951464|did_40|not_44|potentiation_65|._77 (r_nsubj) induce_8\VB\1627355|NONE_0 (l_dobj) potentiation_10\NN\13564910|combination_65|did_25|not_21|._12 (l_compound) catalepsy_9\NN\14023236|NONE_0
D013469_D002375 CID sulpiride_20\NN\0|23390_9|or_3 (r_conj) sch_17\NNP\0|,_2 (r_appos) fluphenazine_15\NN\3713736|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|the_14 (r_acl) catalepsy_12\NN\14023236|quinpirole_25|._57
4090988
D000082_D008113 CID paracetamol_2\NN\0|NONE_0 (l_prep) of_3\IN\0|in_29 (l_pobj) tumours_7\NNS\14234074|NONE_0
D000082_D008113 CID paracetamol_8\NN\0|-_11 (r_npadvmod) treated_10\VBN\2376958|NONE_0 (r_amod) rats_11\NNS\2329401|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) livers_6\NNS\5298729|NONE_0 (r_pobj) of_4\IN\0|an_29|microscope_17 (r_prep) study_3\NN\635850|changes_73|._185 (r_nsubj) revealed_12\VBD\2137132|NONE_0 (l_dobj) changes_14\NNS\7283608|study_73|._112 (l_relcl) resemble_19\VBP\2657219|ultrastructural_48|in_24 (l_dobj) those_20\DT\0|that_14 (l_relcl) result_22\NN\34213|NONE_0 (l_prep) from_23\IN\0|that_12 (l_pobj) exposure_24\NN\5042871|NONE_0 (l_prep) to_25\IN\0|NONE_0 (l_pobj) variety_27\NN\7951464|NONE_0 (l_prep) of_28\IN\0|a_10 (l_pobj) hepatocarcinogens_30\NNS\0|NONE_0
D000082_D009369 NONE paracetamol_12\JJ\0|NONE_0 (r_compound) feeding_13\NN\838098|NONE_0 (r_dobj) following_11\VBG\8180190|yield_51|also_11|._29 (r_prep) arose_10\VBD\2623529|NONE_0 (l_nsubj) yield_2\NN\913705|also_40|following_51|._80 (l_prep) of_3\IN\0|a_12|low_10|at_11 (l_pobj) tumours_4\NNS\14234074|NONE_0
D000082_D001749 CID paracetamol_2\NN\0|NONE_0 (l_prep) of_3\IN\0|in_29 (l_pobj) tumours_7\NNS\14234074|NONE_0
D000082_D001749 CID paracetamol_11\RB\0|-_11 (r_npadvmod) treated_13\VBN\2376958|all_16 (r_amod) groups_14\NNS\2137|NONE_0 (r_pobj) in_9\IN\13603305|papillomas_67|,_33|and_35|bore_50 (r_prep) developed_8\VBN\1753788|NONE_0 (l_conj) bore_19\VBD\9631463|papillomas_117|in_50|,_17|and_15 (l_dobj) carcinomas_21\NNS\14239918|rats_18|._10
D000082_D006965 CID paracetamol_7\NN\0|-_11 (r_npadvmod) treated_9\VBN\2376958|NONE_0 (r_amod) rats_10\NNS\2329401|NONE_0 (r_pobj) of_6\IN\0|25_4 (r_prep) %_5\NN\0|additionally_22|,_10|hyperplasia_40|._140 (r_nsubj) developed_11\VBD\1753788|NONE_0 (l_dobj) hyperplasia_12\NN\14365950|additionally_62|,_50|%_40|._100
D000082_D001744 NONE paracetamol_7\NN\0|-_11 (r_npadvmod) treated_9\VBN\2376958|NONE_0 (r_amod) rats_10\NNS\2329401|NONE_0 (r_pobj) of_6\IN\0|25_4 (r_prep) %_5\NN\0|additionally_22|,_10|hyperplasia_40|._140 (r_nsubj) developed_11\VBD\1753788|NONE_0 (l_dobj) hyperplasia_12\NN\14365950|additionally_62|,_50|%_40|._100 (l_prep) of_13\IN\0|NONE_0 (l_pobj) epithelium_16\NN\5267548|NONE_0 (l_relcl) was_19\VBD\0|the_30|bladder_26|,_8 (l_acomp) coincident_21\JJ\0|which_14|not_4 (l_prep) with_22\IN\0|NONE_0 (l_pobj) presence_24\NN\13954253|NONE_0 (l_prep) of_25\IN\0|the_13 (l_pobj) calculi_27\NNS\9416076|NONE_0
D000082_D010212 NONE paracetamol_11\RB\0|-_11 (r_npadvmod) treated_13\VBN\2376958|all_16 (r_amod) groups_14\NNS\2137|NONE_0 (r_pobj) in_9\IN\13603305|papillomas_67|,_33|and_35|bore_50 (r_prep) developed_8\VBN\1753788|NONE_0 (l_nsubj) papillomas_0\NNP\14236226|in_67|,_100|and_102|bore_117
11524350
C037663_D012640 CID ropivacaine_6\VBP\0|and_4 (r_conj) levobupivacaine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_21|cumulative_17 (r_prep) doses_2\NNS\3740161|seizures_55|similar_69|and_77|were_81|._118 (r_nsubj) were_10\VBD\0|NONE_0 (l_nsubj) seizures_9\NNS\14081375|doses_55|similar_14|and_22|were_26|._63
D002045_D064420 NONE bupivacaine-_5\DT\0|NONE_0 (r_nmod) rats_13\NNS\2329401|NONE_0 (r_pobj) in_4\IN\13603305|systemic_36|and_18|resuscitation_14|._62 (r_prep) toxicity_1\NN\13576101|NONE_0
D002045_D064420 NONE bupivacaine_6\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_22|systemic_18|,_14|levobupivacaine_16 (r_prep) toxicity_4\NN\13576101|we_25|._78
D002045_D064420 NONE bupivacaine_15\NN\0|and_4 (r_conj) ropivacaine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) that_11\DT\0|NONE_0 (r_pobj) between_10\IN\0|NONE_0 (r_prep) intermediate_9\JJ\14806838|that_49|toxicity_31|administered_62 (r_acomp) is_8\VBZ\0|we_58 (l_nsubj) toxicity_5\NN\13576101|that_18|intermediate_31|administered_93
D002045_D064420 NONE bupivacaine_40\NN\0|NONE_0 (r_pobj) by_39\IN\0|NONE_0 (r_agent) induced_38\VBN\1627355|NONE_0 (r_acl) that_37\DT\0|NONE_0 (r_pobj) than_36\IN\0|more_30|to_13 (r_prep) susceptible_33\JJ\0|to_11 (r_acomp) be_31\VB\14625458|arrest_18|._84 (r_xcomp) appears_29\VBZ\2604760|when_79|at_61|and_44 (r_conj) administered_17\VBN\2436349|that_111|toxicity_93|intermediate_62 (r_advcl) is_8\VBZ\0|we_58 (l_nsubj) toxicity_5\NN\13576101|that_18|intermediate_31|administered_93
C476513_D001145 CID levobupivacaine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_21|cumulative_17|produced_24 (r_prep) doses_2\NNS\3740161|smaller_70|,_121|but_123|were_132 (l_relcl) produced_6\VBD\1617192|the_45|cumulative_41|of_24 (l_dobj) dysrhythmias_7\NNS\0|that_14
D002045_D012640 NONE bupivacaine_18\NN\0|NONE_0 (r_pobj) of_17\IN\0|NONE_0 (r_prep) those_16\DT\0|NONE_0 (r_pobj) than_15\IN\0|NONE_0 (r_prep) larger_14\JJR\0|NONE_0 (r_acomp) were_13\VBD\0|doses_81|seizures_26|similar_12|and_4|._37 (r_conj) were_10\VBD\0|NONE_0 (l_nsubj) seizures_9\NNS\14081375|doses_55|similar_14|and_22|were_26|._63
C476513_D006323 CID levobupivacaine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_21|cumulative_17|produced_24 (r_prep) doses_2\NNS\3740161|smaller_70|,_121|but_123|were_132 (l_relcl) produced_6\VBD\1617192|the_45|cumulative_41|of_24 (l_dobj) dysrhythmias_7\NNS\0|that_14 (l_conj) asystole_9\NN\14204950|and_4
C476513_D006323 CID levobupivacaine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_22|systemic_18 (r_prep) toxicity_5\NN\13576101|that_18|intermediate_31|administered_93 (r_nsubj) is_8\VBZ\0|we_58 (l_advcl) administered_17\VBN\2436349|that_111|toxicity_93|intermediate_62 (l_conj) appears_29\VBZ\2604760|when_79|at_61|and_44 (l_nsubj) arrest_28\NN\88481|be_18|._102
C476513_D006323 CID levobupivacaine_42\NN\0|or_3 (r_conj) bupivacaine_40\NN\0|NONE_0 (r_pobj) by_39\IN\0|NONE_0 (r_agent) induced_38\VBN\1627355|NONE_0 (r_acl) that_37\DT\0|NONE_0 (r_pobj) than_36\IN\0|more_30|to_13 (r_prep) susceptible_33\JJ\0|to_11 (r_acomp) be_31\VB\14625458|arrest_18|._84 (r_xcomp) appears_29\VBZ\2604760|when_79|at_61|and_44 (l_nsubj) arrest_28\NN\88481|be_18|._102
D002045_D001145 NONE bupivacaine_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|NONE_0 (r_prep) those_24\DT\0|NONE_0 (r_pobj) than_23\IN\0|NONE_0 (r_prep) larger_22\JJR\0|they_10|._32 (r_acomp) were_21\VBD\0|doses_132|smaller_62|,_11|but_9 (r_conj) were_10\VBD\0|NONE_0 (l_nsubj) doses_2\NNS\3740161|smaller_70|,_121|but_123|were_132 (l_relcl) produced_6\VBD\1617192|the_45|cumulative_41|of_24 (l_dobj) dysrhythmias_7\NNS\0|that_14
C476513_D064420 NONE levobupivacaine-_7\JJ\0|,_2 (r_conj) bupivacaine-_5\DT\0|NONE_0 (r_nmod) rats_13\NNS\2329401|NONE_0 (r_pobj) in_4\IN\13603305|systemic_36|and_18|resuscitation_14|._62 (r_prep) toxicity_1\NN\13576101|NONE_0
C476513_D064420 NONE levobupivacaine_8\NN\0|the_38|systemic_34|of_16|,_2 (r_conj) toxicity_4\NN\13576101|we_25|._78
C476513_D064420 NONE levobupivacaine_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_22|systemic_18 (r_prep) toxicity_5\NN\13576101|that_18|intermediate_31|administered_93
C476513_D064420 NONE levobupivacaine_42\NN\0|or_3 (r_conj) bupivacaine_40\NN\0|NONE_0 (r_pobj) by_39\IN\0|NONE_0 (r_agent) induced_38\VBN\1627355|NONE_0 (r_acl) that_37\DT\0|NONE_0 (r_pobj) than_36\IN\0|more_30|to_13 (r_prep) susceptible_33\JJ\0|to_11 (r_acomp) be_31\VB\14625458|arrest_18|._84 (r_xcomp) appears_29\VBZ\2604760|when_79|at_61|and_44 (r_conj) administered_17\VBN\2436349|that_111|toxicity_93|intermediate_62 (r_advcl) is_8\VBZ\0|we_58 (l_nsubj) toxicity_5\NN\13576101|that_18|intermediate_31|administered_93
C476513_D012640 CID levobupivacaine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_21|cumulative_17 (r_prep) doses_2\NNS\3740161|seizures_55|similar_69|and_77|were_81|._118 (r_nsubj) were_10\VBD\0|NONE_0 (l_nsubj) seizures_9\NNS\14081375|doses_55|similar_14|and_22|were_26|._63
C037663_D064420 NONE ropivacaine_10\NN\0|-_11 (r_npadvmod) infused_12\VBN\606335|,_17|or_15 (r_conj) levobupivacaine-_7\JJ\0|,_2 (r_conj) bupivacaine-_5\DT\0|NONE_0 (r_nmod) rats_13\NNS\2329401|NONE_0 (r_pobj) in_4\IN\13603305|systemic_36|and_18|resuscitation_14|._62 (r_prep) toxicity_1\NN\13576101|NONE_0
C037663_D064420 NONE ropivacaine_11\NN\0|,_6|and_4 (r_conj) levobupivacaine_8\NN\0|the_38|systemic_34|of_16|,_2 (r_conj) toxicity_4\NN\13576101|we_25|._78
C037663_D064420 NONE ropivacaine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) that_11\DT\0|NONE_0 (r_pobj) between_10\IN\0|NONE_0 (r_prep) intermediate_9\JJ\14806838|that_49|toxicity_31|administered_62 (r_acomp) is_8\VBZ\0|we_58 (l_nsubj) toxicity_5\NN\13576101|that_18|intermediate_31|administered_93
C037663_D064420 NONE ropivacaine_24\NN\0|-_11 (r_npadvmod) induced_26\VBN\1627355|that_17|cardiac_8 (r_amod) arrest_28\NN\88481|be_18|._102 (r_nsubj) appears_29\VBZ\2604760|when_79|at_61|and_44 (r_conj) administered_17\VBN\2436349|that_111|toxicity_93|intermediate_62 (r_advcl) is_8\VBZ\0|we_58 (l_nsubj) toxicity_5\NN\13576101|that_18|intermediate_31|administered_93
C037663_D006323 CID ropivacaine_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|the_24|corresponding_20 (r_prep) doses_15\NNS\3740161|NONE_0 (r_pobj) than_12\IN\0|NONE_0 (r_prep) smaller_11\JJR\0|doses_70|,_51|but_53|were_62 (r_acomp) were_10\VBD\0|NONE_0 (l_nsubj) doses_2\NNS\3740161|smaller_70|,_121|but_123|were_132 (l_relcl) produced_6\VBD\1617192|the_45|cumulative_41|of_24 (l_dobj) dysrhythmias_7\NNS\0|that_14 (l_conj) asystole_9\NN\14204950|and_4
C037663_D006323 CID ropivacaine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) that_11\DT\0|NONE_0 (r_pobj) between_10\IN\0|NONE_0 (r_prep) intermediate_9\JJ\14806838|that_49|toxicity_31|administered_62 (r_acomp) is_8\VBZ\0|we_58 (l_advcl) administered_17\VBN\2436349|that_111|toxicity_93|intermediate_62 (l_conj) appears_29\VBZ\2604760|when_79|at_61|and_44 (l_nsubj) arrest_28\NN\88481|be_18|._102
C037663_D006323 CID ropivacaine_24\NN\0|-_11 (r_npadvmod) induced_26\VBN\1627355|that_17|cardiac_8 (r_amod) arrest_28\NN\88481|be_18|._102
C037663_D001145 CID ropivacaine_17\NN\0|NONE_0 (r_pobj) of_16\IN\0|the_24|corresponding_20 (r_prep) doses_15\NNS\3740161|NONE_0 (r_pobj) than_12\IN\0|NONE_0 (r_prep) smaller_11\JJR\0|doses_70|,_51|but_53|were_62 (r_acomp) were_10\VBD\0|NONE_0 (l_nsubj) doses_2\NNS\3740161|smaller_70|,_121|but_123|were_132 (l_relcl) produced_6\VBD\1617192|the_45|cumulative_41|of_24 (l_dobj) dysrhythmias_7\NNS\0|that_14
D002045_D006323 NONE bupivacaine_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|NONE_0 (r_prep) those_24\DT\0|NONE_0 (r_pobj) than_23\IN\0|NONE_0 (r_prep) larger_22\JJR\0|they_10|._32 (r_acomp) were_21\VBD\0|doses_132|smaller_62|,_11|but_9 (r_conj) were_10\VBD\0|NONE_0 (l_nsubj) doses_2\NNS\3740161|smaller_70|,_121|but_123|were_132 (l_relcl) produced_6\VBD\1617192|the_45|cumulative_41|of_24 (l_dobj) dysrhythmias_7\NNS\0|that_14 (l_conj) asystole_9\NN\14204950|and_4
D002045_D006323 NONE bupivacaine_15\NN\0|and_4 (r_conj) ropivacaine_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) that_11\DT\0|NONE_0 (r_pobj) between_10\IN\0|NONE_0 (r_prep) intermediate_9\JJ\14806838|that_49|toxicity_31|administered_62 (r_acomp) is_8\VBZ\0|we_58 (l_advcl) administered_17\VBN\2436349|that_111|toxicity_93|intermediate_62 (l_conj) appears_29\VBZ\2604760|when_79|at_61|and_44 (l_nsubj) arrest_28\NN\88481|be_18|._102
D002045_D006323 NONE bupivacaine_40\NN\0|NONE_0 (r_pobj) by_39\IN\0|NONE_0 (r_agent) induced_38\VBN\1627355|NONE_0 (r_acl) that_37\DT\0|NONE_0 (r_pobj) than_36\IN\0|more_30|to_13 (r_prep) susceptible_33\JJ\0|to_11 (r_acomp) be_31\VB\14625458|arrest_18|._84 (r_xcomp) appears_29\VBZ\2604760|when_79|at_61|and_44 (l_nsubj) arrest_28\NN\88481|be_18|._102
8106150
D016291_D004409 NONE mk-801_15\NNP\0|NONE_0 (r_punct) ,_16\,\0|drugs_88|markedly_2|movements_34|but_44|at_48|._102 (r_punct) reduced_18\VBD\441445|NONE_0 (l_dobj) movements_21\NNS\191142|drugs_122|,_34|markedly_32|but_10|at_14|._68 (l_amod) dyskinetic_20\JJ\0|the_4
D015632_D004409 NONE mptp_12\NNP\0|-_4 (r_npadvmod) treated_14\VBN\2376958|NONE_0 (r_amod) monkeys_15\NNS\2469914|NONE_0 (r_pobj) in_11\IN\13603305|induced_20 (r_prep) dyskinesias_10\NNS\14084880|NONE_0
D010830_D004409 NONE physostigmine_6\NN\14712692|,_2 (r_conj) clonidine_4\NN\2721160|NONE_0 (r_pobj) including_3\VBG\0|several_15|,_2 (r_prep) drugs_1\NNS\14778436|,_88|markedly_90|movements_122|but_132|at_136|._190 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_dobj) movements_21\NNS\191142|drugs_122|,_34|markedly_32|but_10|at_14|._68 (l_amod) dyskinetic_20\JJ\0|the_4
D008614_D004409 NONE meperidine_4\RB\3808564|and_4 (r_conj) yohimbine_2\NN\0|however_9|,_2|predominantly_33|movements_62|._71 (r_nsubj) reduced_5\VBN\441445|NONE_0 (l_dobj) movements_9\NNS\191142|however_71|,_64|yohimbine_62|predominantly_29|._9 (l_amod) dyskinetic_8\JJ\0|the_4
D003000_D020734 NONE clonidine_4\NN\2721160|NONE_0 (r_pobj) including_3\VBG\0|several_15|,_2 (r_prep) drugs_1\NNS\14778436|,_88|markedly_90|movements_122|but_132|at_136|._190 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_conj) at_23\IN\14622893|drugs_136|,_48|markedly_46|movements_14|but_4|._54 (l_pobj) cost_25\NN\13275288|NONE_0 (l_prep) of_26\IN\0|the_9 (l_pobj) return_28\NN\6479665|NONE_0 (l_prep) of_29\IN\0|a_9 (l_pobj) symptomatology_31\NN\0|NONE_0 (l_amod) parkinsonian_30\JJ\0|NONE_0
D001418_D004409 NONE baclofen_0\NNP\0|also_13|useful_18|._81 (r_nsubj) was_1\VBD\0|NONE_0 (l_acomp) useful_3\JJ\0|baclofen_18|also_5|._63 (l_prep) against_7\IN\0|in_14 (l_pobj) form_11\NN\6286395|NONE_0 (l_prep) of_12\IN\0|a_21|dystonic_14 (l_pobj) dyskinesia_13\NN\14084880|NONE_0
D001418_D020821 NONE baclofen_0\NNP\0|also_13|useful_18|._81 (r_nsubj) was_1\VBD\0|NONE_0 (l_acomp) useful_3\JJ\0|baclofen_18|also_5|._63 (l_prep) against_7\IN\0|in_14 (l_pobj) form_11\NN\6286395|NONE_0 (l_amod) dystonic_10\JJ\0|a_7|of_14
D001285_D002819 NONE atropine_0\NNP\14712692|movements_32|into_42|._53 (r_nsubj) converted_1\VBD\126264|NONE_0 (l_prep) into_5\IN\0|atropine_42|movements_10|._11 (l_pobj) chorea_6\NN\14253124|NONE_0
D011433_D004409 NONE propranolol_12\NN\0|,_10|5-mdot_8 (r_conj) methysergide_8\NN\0|,_2 (r_conj) physostigmine_6\NN\14712692|,_2 (r_conj) clonidine_4\NN\2721160|NONE_0 (r_pobj) including_3\VBG\0|several_15|,_2 (r_prep) drugs_1\NNS\14778436|,_88|markedly_90|movements_122|but_132|at_136|._190 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_dobj) movements_21\NNS\191142|drugs_122|,_34|markedly_32|but_10|at_14|._68 (l_amod) dyskinetic_20\JJ\0|the_4
D016291_D020734 NONE mk-801_15\NNP\0|NONE_0 (r_punct) ,_16\,\0|drugs_88|markedly_2|movements_34|but_44|at_48|._102 (r_punct) reduced_18\VBD\441445|NONE_0 (l_conj) at_23\IN\14622893|drugs_136|,_48|markedly_46|movements_14|but_4|._54 (l_pobj) cost_25\NN\13275288|NONE_0 (l_prep) of_26\IN\0|the_9 (l_pobj) return_28\NN\6479665|NONE_0 (l_prep) of_29\IN\0|a_9 (l_pobj) symptomatology_31\NN\0|NONE_0 (l_amod) parkinsonian_30\JJ\0|NONE_0
D008784_D020734 NONE methysergide_8\NN\0|,_2 (r_conj) physostigmine_6\NN\14712692|,_2 (r_conj) clonidine_4\NN\2721160|NONE_0 (r_pobj) including_3\VBG\0|several_15|,_2 (r_prep) drugs_1\NNS\14778436|,_88|markedly_90|movements_122|but_132|at_136|._190 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_conj) at_23\IN\14622893|drugs_136|,_48|markedly_46|movements_14|but_4|._54 (l_pobj) cost_25\NN\13275288|NONE_0 (l_prep) of_26\IN\0|the_9 (l_pobj) return_28\NN\6479665|NONE_0 (l_prep) of_29\IN\0|a_9 (l_pobj) symptomatology_31\NN\0|NONE_0 (l_amod) parkinsonian_30\JJ\0|NONE_0
D008784_D004409 NONE methysergide_8\NN\0|,_2 (r_conj) physostigmine_6\NN\14712692|,_2 (r_conj) clonidine_4\NN\2721160|NONE_0 (r_pobj) including_3\VBG\0|several_15|,_2 (r_prep) drugs_1\NNS\14778436|,_88|markedly_90|movements_122|but_132|at_136|._190 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_dobj) movements_21\NNS\191142|drugs_122|,_34|markedly_32|but_10|at_14|._68 (l_amod) dyskinetic_20\JJ\0|the_4
D007980_D004409 NONE dopa_7\NN\14601829|-_4 (r_npadvmod) induced_9\VBN\1627355|in_20 (r_amod) dyskinesias_10\NNS\14084880|NONE_0
D007980_D004409 NONE dopa_19\NNP\14601829|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) combination_15\NN\7951464|NONE_0 (r_pobj) in_14\IN\13603305|series_92|were_17|then_12|see_30|._79 (r_prep) tested_13\VBN\670261|NONE_0 (l_advcl) see_21\VB\8647945|series_122|were_47|then_42|in_30|._49 (l_ccomp) modified_28\VBN\109660|to_44 (l_nsubjpass) movements_25\NNS\191142|if_18|would_10|be_16 (l_amod) dyskinetic_24\JJ\0|the_4
D003000_D004409 NONE clonidine_4\NN\2721160|NONE_0 (r_pobj) including_3\VBG\0|several_15|,_2 (r_prep) drugs_1\NNS\14778436|,_88|markedly_90|movements_122|but_132|at_136|._190 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_dobj) movements_21\NNS\191142|drugs_122|,_34|markedly_32|but_10|at_14|._68 (l_amod) dyskinetic_20\JJ\0|the_4
D011433_D020734 NONE propranolol_12\NN\0|,_10|5-mdot_8 (r_conj) methysergide_8\NN\0|,_2 (r_conj) physostigmine_6\NN\14712692|,_2 (r_conj) clonidine_4\NN\2721160|NONE_0 (r_pobj) including_3\VBG\0|several_15|,_2 (r_prep) drugs_1\NNS\14778436|,_88|markedly_90|movements_122|but_132|at_136|._190 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_conj) at_23\IN\14622893|drugs_136|,_48|markedly_46|movements_14|but_4|._54 (l_pobj) cost_25\NN\13275288|NONE_0 (l_prep) of_26\IN\0|the_9 (l_pobj) return_28\NN\6479665|NONE_0 (l_prep) of_29\IN\0|a_9 (l_pobj) symptomatology_31\NN\0|NONE_0 (l_amod) parkinsonian_30\JJ\0|NONE_0
-1_D020734 NONE 5-mdot_10\CD\0|,_2|propranolol_8 (r_conj) methysergide_8\NN\0|,_2 (r_conj) physostigmine_6\NN\14712692|,_2 (r_conj) clonidine_4\NN\2721160|NONE_0 (r_pobj) including_3\VBG\0|several_15|,_2 (r_prep) drugs_1\NNS\14778436|,_88|markedly_90|movements_122|but_132|at_136|._190 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_conj) at_23\IN\14622893|drugs_136|,_48|markedly_46|movements_14|but_4|._54 (l_pobj) cost_25\NN\13275288|NONE_0 (l_prep) of_26\IN\0|the_9 (l_pobj) return_28\NN\6479665|NONE_0 (l_prep) of_29\IN\0|a_9 (l_pobj) symptomatology_31\NN\0|NONE_0 (l_amod) parkinsonian_30\JJ\0|NONE_0
D015632_D020734 CID mptp_11\NNP\0|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) parkinsonian_7\NN\0|group_35|was_13|._32
D001285_D020821 NONE atropine_0\NNP\14712692|movements_32|into_42|._53 (r_nsubj) converted_1\VBD\126264|NONE_0 (l_dobj) movements_4\NNS\191142|atropine_32|into_10|._21 (l_amod) dystonic_3\JJ\0|the_4
D015016_D004409 NONE yohimbine_2\NN\0|however_9|,_2|predominantly_33|movements_62|._71 (r_nsubj) reduced_5\VBN\441445|NONE_0 (l_dobj) movements_9\NNS\191142|however_71|,_64|yohimbine_62|predominantly_29|._9 (l_amod) dyskinetic_8\JJ\0|the_4
-1_D004409 NONE 5-mdot_10\CD\0|,_2|propranolol_8 (r_conj) methysergide_8\NN\0|,_2 (r_conj) physostigmine_6\NN\14712692|,_2 (r_conj) clonidine_4\NN\2721160|NONE_0 (r_pobj) including_3\VBG\0|several_15|,_2 (r_prep) drugs_1\NNS\14778436|,_88|markedly_90|movements_122|but_132|at_136|._190 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_dobj) movements_21\NNS\191142|drugs_122|,_34|markedly_32|but_10|at_14|._68 (l_amod) dyskinetic_20\JJ\0|the_4
D004298_D004409 NONE dopamine_10\NN\14807737|NONE_0 (r_pobj) than_9\IN\0|NONE_0 (r_prep) other_8\JJ\0|NONE_0 (r_amod) neurotransmitters_7\NNS\14807410|NONE_0 (r_pobj) on_6\IN\0|primarily_10 (r_prep) acting_4\VBG\407535|NONE_0 (r_acl) agents_3\NNS\7347|NONE_0 (r_pobj) of_2\IN\0|a_9 (r_prep) series_1\NN\8456993|were_75|then_80|in_92|see_122|._171 (r_nsubjpass) tested_13\VBN\670261|NONE_0 (l_advcl) see_21\VB\8647945|series_122|were_47|then_42|in_30|._49 (l_ccomp) modified_28\VBN\109660|to_44 (l_nsubjpass) movements_25\NNS\191142|if_18|would_10|be_16 (l_amod) dyskinetic_24\JJ\0|the_4
D010830_D020734 NONE physostigmine_6\NN\14712692|,_2 (r_conj) clonidine_4\NN\2721160|NONE_0 (r_pobj) including_3\VBG\0|several_15|,_2 (r_prep) drugs_1\NNS\14778436|,_88|markedly_90|movements_122|but_132|at_136|._190 (r_nsubj) reduced_18\VBD\441445|NONE_0 (l_conj) at_23\IN\14622893|drugs_136|,_48|markedly_46|movements_14|but_4|._54 (l_pobj) cost_25\NN\13275288|NONE_0 (l_prep) of_26\IN\0|the_9 (l_pobj) return_28\NN\6479665|NONE_0 (l_prep) of_29\IN\0|a_9 (l_pobj) symptomatology_31\NN\0|NONE_0 (l_amod) parkinsonian_30\JJ\0|NONE_0
3431591
C031662_D064420 NONE 3717_1\CD\0|,_4|acid_37|,_41 (r_nummod) cb_0\NN\0|inhibitor_65|._179 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) inhibitor_11\NN\20090|cb_65|._114 (l_relcl) mediated_21\VBN\761713|a_77|binding_69|of_51 (l_nsubjpass) cytotoxicity_19\NN\13583478|is_13|through_32
C031662_D064420 NONE acid_4\NN\14818238|3717_37|,_33|,_4 (r_appos) cb_0\NN\0|inhibitor_65|._179 (r_nsubj) is_6\VBZ\0|NONE_0 (l_attr) inhibitor_11\NN\20090|cb_65|._114 (l_relcl) mediated_21\VBN\761713|a_77|binding_69|of_51 (l_nsubjpass) cytotoxicity_19\NN\13583478|is_13|through_32
C031662_D064420 NONE 3717_28\CD\0|,_4 (r_nummod) cb_27\NNP\0|NONE_0 (r_pobj) than_26\IN\0|more_12 (r_prep) potent_25\JJ\0|,_30|87-_28|,_25|119-_23 (r_amod) 26-_17\NNPS\0|as_85|respectively_54|,_66|and_68|be_104 (r_attr) are_16\VBP\13600404|NONE_0 (l_conj) be_39\VB\14625458|as_189|26-_104|respectively_50|,_38|and_36 (l_attr) determinant_42\NN\5686481|formation_42|may_32|,_29|therefore_27|,_18|._35 (l_prep) of_43\IN\0|an_25|important_22 (l_pobj) cytotoxicity_46\NN\13583478|NONE_0
C031662_D064420 NONE 3717_45\CD\0|cb_3 (r_nummod) cytotoxicity_46\NN\13583478|NONE_0
C031662_D010051 NONE 3717_6\CD\0|NONE_0 (r_nummod) cb_5\NNP\0|NONE_0 (r_pobj) with_4\IN\0|early_23|clinical_17 (r_prep) studies_3\NNS\635850|NONE_0 (r_pobj) in_0\IN\13603305|,_38|activity_40|has_49|been_53|in_63|._123 (r_prep) seen_11\VBN\2106506|NONE_0 (l_prep) in_12\IN\13603305|in_63|,_25|activity_23|has_14|been_10|._60 (l_pobj) cancer_14\NN\14239425|NONE_0 (l_conj) cancer_17\NN\14239425|breast_23|,_10
C031662_D001943 NONE 3717_6\CD\0|NONE_0 (r_nummod) cb_5\NNP\0|NONE_0 (r_pobj) with_4\IN\0|early_23|clinical_17 (r_prep) studies_3\NNS\635850|NONE_0 (r_pobj) in_0\IN\13603305|,_38|activity_40|has_49|been_53|in_63|._123 (r_prep) seen_11\VBN\2106506|NONE_0 (l_prep) in_12\IN\13603305|in_63|,_25|activity_23|has_14|been_10|._60 (l_pobj) cancer_14\NN\14239425|NONE_0
C031662_D008654 NONE 3717_6\CD\0|NONE_0 (r_nummod) cb_5\NNP\0|NONE_0 (r_pobj) with_4\IN\0|early_23|clinical_17 (r_prep) studies_3\NNS\635850|NONE_0 (r_pobj) in_0\IN\13603305|,_38|activity_40|has_49|been_53|in_63|._123 (r_prep) seen_11\VBN\2106506|NONE_0 (l_prep) in_12\IN\13603305|in_63|,_25|activity_23|has_14|been_10|._60 (l_pobj) cancer_14\NN\14239425|NONE_0 (l_conj) cancer_17\NN\14239425|breast_23|,_10 (l_conj) hepatoma_19\NN\14242337|ovarian_16|,_2 (l_conj) mesothelioma_22\NN\14242337|,_6|and_4
C031662_D006528 NONE 3717_6\CD\0|NONE_0 (r_nummod) cb_5\NNP\0|NONE_0 (r_pobj) with_4\IN\0|early_23|clinical_17 (r_prep) studies_3\NNS\635850|NONE_0 (r_pobj) in_0\IN\13603305|,_38|activity_40|has_49|been_53|in_63|._123 (r_prep) seen_11\VBN\2106506|NONE_0 (l_prep) in_12\IN\13603305|in_63|,_25|activity_23|has_14|been_10|._60 (l_pobj) cancer_14\NN\14239425|NONE_0 (l_conj) cancer_17\NN\14239425|breast_23|,_10 (l_conj) hepatoma_19\NN\14242337|ovarian_16|,_2
18589141
D006493_D013927 NONE sodium_2\NN\14625458|is_52|in_60|at_87|prevent_114|._160 (r_nsubjpass) used_16\VBN\0|NONE_0 (l_xcomp) prevent_24\VB\0|sodium_114|is_62|in_54|at_27|._46 (l_dobj) thrombosis_25\NN\14100769|to_11|after_11
D006493_D013927 NONE ufh_4\NNP\0|unfractionated_31|heparin_16|(_1|)_3|or_5|heparin_29 (r_appos) sodium_2\NN\14625458|is_52|in_60|at_87|prevent_114|._160 (r_nsubjpass) used_16\VBN\0|NONE_0 (l_xcomp) prevent_24\VB\0|sodium_114|is_62|in_54|at_27|._46 (l_dobj) thrombosis_25\NN\14100769|to_11|after_11
D006493_D013921 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|after_25|._52 (r_amod) thrombocytopenia_3\NN\14189204|NONE_0
D006493_D013921 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|hit_26 (r_amod) thrombocytopenia_3\NN\14189204|reaction_53|,_72|resulting_74|decreases_102|._128
D006493_D013921 CID heparin_0\NNP\2718259|-_7 (r_npadvmod) induced_2\VBN\1627355|hit_26 (r_amod) thrombocytopenia_3\NN\14189204|reaction_53|,_72|resulting_74|decreases_102|._128 (l_appos) hit_5\NNP\36762|induced_26
D006493_D013921 CID heparin_15\NN\2718259|NONE_0 (r_pobj) to_14\IN\0|an_36|adverse_33|mediated_18 (r_prep) reaction_13\NN\13446390|thrombocytopenia_53|,_19|resulting_21|decreases_49|._75 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) thrombocytopenia_3\NN\14189204|reaction_53|,_72|resulting_74|decreases_102|._128
D006493_D013921 CID heparin_15\NN\2718259|NONE_0 (r_pobj) to_14\IN\0|an_36|adverse_33|mediated_18 (r_prep) reaction_13\NN\13446390|thrombocytopenia_53|,_19|resulting_21|decreases_49|._75 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) thrombocytopenia_3\NN\14189204|reaction_53|,_72|resulting_74|decreases_102|._128 (l_appos) hit_5\NNP\36762|induced_26
D006493_D013921 CID 4/heparin_10\NN\0|-_9 (r_nummod) reactive_12\JJ\0|NONE_0 (r_amod) antibody_13\NN\14728724|(_9|antibody_14|)_22|in_35 (r_nmod) positivity_18\NN\13856574|the_114|of_98|after_91 (r_conj) frequencies_1\NNS\15286249|,_154|however_156|,_163|unknown_169|._176 (l_prep) of_2\IN\0|the_16|after_7|positivity_98 (l_pobj) hit_3\NN\36762|NONE_0
D006493_D013921 CID 4/heparin_10\NN\0|-_9 (r_nummod) reactive_12\JJ\0|NONE_0 (r_amod) antibody_13\NN\14728724|(_9|antibody_14|)_22|in_35 (r_nmod) positivity_18\NN\13856574|the_114|of_98|after_91 (l_nmod) antibody_16\NN\14728724|antibody_14|(_5|)_8|in_21 (l_nmod) hit_15\NNP\36762|NONE_0
D006493_D013921 CID ufh_7\NN\0|-_3 (r_npadvmod) related_9\VBN\628491|NONE_0 (r_amod) hit_10\NN\36762|none_52|._3
D006493_D001791 NONE heparin_1\NN\2718259|-_7 (r_npadvmod) induced_3\VBN\1627355|the_12|aggregation_17 (r_amod) test_6\NN\5798043|negative_9|in_18|._35 (l_compound) aggregation_5\NN\31264|the_29|induced_17
D006495_D013927 NONE heparin_11\NN\2718259|unfractionated_60|heparin_45|(_30|ufh_29|)_26|or_24 (r_conj) sodium_2\NN\14625458|is_52|in_60|at_87|prevent_114|._160 (r_nsubjpass) used_16\VBN\0|NONE_0 (l_xcomp) prevent_24\VB\0|sodium_114|is_62|in_54|at_27|._46 (l_dobj) thrombosis_25\NN\14100769|to_11|after_11
7337133
D000082_D017093 CID acetaminophen_9\NN\2707683|NONE_0 (r_compound) overdose_10\NN\84738|NONE_0 (r_pobj) in_8\IN\13603305|fulminant_26|hepatic_16 (r_prep) failure_7\NN\66216|NONE_0
D000082_D017093 CID acetaminophen_6\RB\2707683|-_13 (r_advmod) induced_8\VBN\1627355|fatal_20|fulminant_8|hepatic_18 (r_amod) failure_11\NN\66216|NONE_0
D000082_D001929 CID acetaminophen_9\NN\2707683|NONE_0 (r_compound) overdose_10\NN\84738|NONE_0 (r_pobj) in_8\IN\13603305|fulminant_26|hepatic_16 (r_prep) failure_7\NN\66216|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) associated_3\VBN\628491|massive_23|cerebral_15|:_67|role_78|._107 (r_acl) edema_2\NN\14315192|NONE_0
D000082_D001929 CID acetaminophen_6\RB\2707683|-_13 (r_advmod) induced_8\VBN\1627355|fatal_20|fulminant_8|hepatic_18 (r_amod) failure_11\NN\66216|NONE_0 (r_pobj) with_4\IN\0|a_10 (r_prep) patient_3\NN\9898892|we_13|,_66|with_68|._155 (r_dobj) present_1\VBP\28270|NONE_0 (l_prep) with_13\IN\0|we_81|patient_68|,_2|._87 (l_pobj) signs_14\NNS\6643763|NONE_0 (l_prep) of_17\IN\0|and_13|symptoms_9 (l_pobj) edema_19\NN\14315192|NONE_0
D000082_D062787 NONE acetaminophen_9\NN\2707683|NONE_0 (r_compound) overdose_10\NN\84738|NONE_0
10539815
D004232_D003920 NONE diuretic_49\JJ\3247620|,_2 (r_conj) antiplatelet_47\JJ\0|NONE_0 (r_pobj) of_46\IN\0|NONE_0 (r_prep) use_45\NN\407535|,_6|and_4 (r_conj) diabetes_42\NNS\14075199|,_2
D004232_D003920 NONE diuretic_14\JJ\3247620|,_16|and_18|diabetes_22 (r_amod) therapy_15\NN\657604|older_20|,_11 (l_conj) diabetes_18\NNS\14075199|diuretic_22|,_6|and_4
D004656_D018487 NONE enalapril_26\NN\2673637|NONE_0 (r_pobj) of_25\IN\0|a_53|randomized_51|,_41|blind_32|,_27|controlled_17|for_13 (r_prep) trial_24\NN\786195|left_85|ventricular_80|(_56|solvd_55|)_50|,_49 (r_appos) dysfunction_9\NNP\14204950|NONE_0
D003404_D051437 NONE creatinine_10\NN\0|NONE_0 (r_pobj) in_8\IN\13603305|a_7 (r_prep) rise_7\NN\7324673|NONE_0 (r_pobj) as_5\IN\14622893|function_21|was_12|>_30|/=0.5_31 (r_prep) defined_4\VBN\2604760|NONE_0 (l_nsubjpass) function_2\NN\13783581|was_9|as_21|>_51|/=0.5_52
D003404_D003920 NONE creatinine_25\NN\0|ejection_28|,_11 (r_conj) fraction_22\NN\14806838|,_20|,_71|history_73 (r_conj) age_18\NN\4916342|NONE_0 (l_appos) history_38\NN\15120823|,_93|fraction_73|,_2 (l_prep) of_39\IN\0|NONE_0 (l_pobj) hypertension_40\NN\14057371|NONE_0 (l_conj) diabetes_42\NNS\14075199|,_2
D004656_D051437 CID enalapril_4\NN\2673637|NONE_0 (r_pobj) to_3\IN\0|randomly_18 (r_prep) assigned_2\VBN\2475922|NONE_0 (r_acl) patients_0\NNS\9898892|likelihood_58|._120 (r_nsubj) had_5\VBD\0|NONE_0 (l_dobj) likelihood_10\NN\4756172|patients_58|._62 (l_prep) of_11\IN\0|a_25|greater_19 (l_pobj) function_14\NN\13783581|NONE_0
D004656_D051437 CID enalapril_9\NN\2673637|NONE_0 (r_compound) groups_10\NNS\2137|both_31|the_26|and_14|age_13 (r_conj) placebo_7\NN\3740161|NONE_0 (r_pobj) in_4\IN\13603305|by_26|,_2|were_83|with_99|,_128|were_188|._207 (r_prep) associated_20\VBN\628491|NONE_0 (l_prep) with_21\IN\0|by_125|,_101|in_99|were_16|,_29|were_89|._108 (l_pobj) function_24\NN\13783581|NONE_0
D004656_D051437 CID enalapril_23\JJ\2673637|the_4|ratio_33 (r_compound) group_24\NN\2137|NONE_0 (r_pobj) in_21\IN\13603305|significantly_22|so_3|,_68|interval_85 (r_prep) more_19\RBR\0|age_112|was_108|with_93|,_20|but_18 (r_conj) associated_3\VBN\628491|NONE_0 (l_prep) with_4\IN\0|age_19|was_15|,_73|but_75|more_93 (l_pobj) risk_7\NN\14541044|NONE_0 (l_prep) of_8\IN\0|a_15|greater_13 (l_pcomp) developing_9\VBG\13541167|NONE_0 (l_dobj) function_12\NN\13783581|NONE_0
D004656_D051437 CID enalapril_26\NN\2673637|(_1|:_9|risk_11|[_22|rr_23|]_25|years_39 (r_dep) ratio_29\NN\13815152|the_37|enalapril_33 (r_appos) group_24\NN\2137|NONE_0 (r_pobj) in_21\IN\13603305|significantly_22|so_3|,_68|interval_85 (r_prep) more_19\RBR\0|age_112|was_108|with_93|,_20|but_18 (r_conj) associated_3\VBN\628491|NONE_0 (l_prep) with_4\IN\0|age_19|was_15|,_73|but_75|more_93 (l_pobj) risk_7\NN\14541044|NONE_0 (l_prep) of_8\IN\0|a_15|greater_13 (l_pcomp) developing_9\VBG\13541167|NONE_0 (l_dobj) function_12\NN\13783581|NONE_0
D004656_D051437 CID enalapril_15\JJ\2673637|the_4|(_16|%_28|)_42 (r_compound) group_16\NN\2137|NONE_0 (r_pobj) in_13\IN\13603305|decreased_25|renal_15 (r_prep) function_12\NN\13783581|NONE_0
D004656_D051437 CID enalapril_0\NNP\2673637|NONE_0 (r_compound) use_1\NN\407535|increase_17|._86 (r_nsubj) caused_2\VBD\1617192|NONE_0 (l_dobj) increase_6\NN\13576355|use_17|._69 (l_prep) in_7\IN\13603305|a_15|%_11 (l_pobj) risk_9\NN\14541044|NONE_0 (l_prep) of_10\IN\0|the_9 (l_pobj) function_13\NN\13783581|NONE_0
D004656_D051437 CID enalapril_23\JJ\2673637|the_4 (r_compound) group_24\NN\2137|NONE_0 (r_pobj) in_21\IN\13603305|risk_17|was_12|compared_23|._54 (r_prep) reduced_20\VBN\441445|diabetes_111|was_102|with_87|,_20|but_18 (r_conj) associated_2\VBN\628491|NONE_0 (l_prep) with_3\IN\0|diabetes_24|was_15|,_67|but_69|reduced_87 (l_pobj) risk_6\NN\14541044|NONE_0 (l_prep) of_7\IN\0|an_18|increased_15 (l_pobj) impairment_9\NN\7296428|NONE_0
D004232_D051437 CID diuretic_14\JJ\3247620|,_16|and_18|diabetes_22 (r_amod) therapy_15\NN\657604|older_20|,_11 (r_conj) age_12\NN\4916342|both_44|the_39|and_27|groups_13 (r_conj) placebo_7\NN\3740161|NONE_0 (r_pobj) in_4\IN\13603305|by_26|,_2|were_83|with_99|,_128|were_188|._207 (r_prep) associated_20\VBN\628491|NONE_0 (l_prep) with_21\IN\0|by_125|,_101|in_99|were_16|,_29|were_89|._108 (l_pobj) function_24\NN\13783581|NONE_0
D004232_D051437 CID diuretic_0\JJ\3247620|NONE_0 (r_compound) therapy_1\NN\657604|was_8|likewise_12|with_32|._184 (r_nsubjpass) associated_4\VBN\628491|NONE_0 (l_prep) with_5\IN\0|therapy_32|was_24|likewise_20|._152 (l_pobj) risk_8\NN\14541044|NONE_0 (l_prep) of_9\IN\0|a_15|greater_13|than_79 (l_pobj) function_12\NN\13783581|NONE_0
D004656_D006333 NONE enalapril_26\NN\2673637|NONE_0 (r_pobj) of_25\IN\0|a_53|randomized_51|,_41|blind_32|,_27|controlled_17|for_13 (r_prep) trial_24\NN\786195|left_85|ventricular_80|(_56|solvd_55|)_50|,_49 (l_prep) for_27\IN\0|a_66|randomized_64|,_54|blind_45|,_40|controlled_30|of_13 (l_pobj) treatment_29\NN\654885|NONE_0 (l_prep) of_30\IN\0|the_14 (l_pobj) chf_31\NNP\0|NONE_0
D004656_D006333 NONE enalapril_0\NNP\2673637|NONE_0 (r_compound) use_1\NN\407535|increase_17|._86 (r_nsubj) caused_2\VBD\1617192|NONE_0 (l_dobj) increase_6\NN\13576355|use_17|._69 (l_prep) in_7\IN\13603305|a_15|%_11 (l_pobj) risk_9\NN\14541044|NONE_0 (l_prep) of_10\IN\0|the_9 (l_pobj) function_13\NN\13783581|NONE_0 (l_prep) in_14\IN\13603305|decreased_25|renal_15 (l_pobj) patients_15\NNS\9898892|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) chf_17\NNP\0|NONE_0
D004656_D006333 NONE enalapril_23\JJ\2673637|the_4 (r_compound) group_24\NN\2137|NONE_0 (r_pobj) in_21\IN\13603305|risk_17|was_12|compared_23|._54 (r_prep) reduced_20\VBN\441445|diabetes_111|was_102|with_87|,_20|but_18 (r_conj) associated_2\VBN\628491|NONE_0 (l_prep) with_3\IN\0|diabetes_24|was_15|,_67|but_69|reduced_87 (l_pobj) risk_6\NN\14541044|NONE_0 (l_prep) of_7\IN\0|an_18|increased_15 (l_pobj) impairment_9\NN\7296428|NONE_0 (l_prep) in_10\IN\13603305|renal_17 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|all_13 (l_pobj) chf_14\NNP\0|NONE_0
D003404_D006973 NONE creatinine_25\NN\0|ejection_28|,_11 (r_conj) fraction_22\NN\14806838|,_20|,_71|history_73 (r_conj) age_18\NN\4916342|NONE_0 (l_appos) history_38\NN\15120823|,_93|fraction_73|,_2 (l_prep) of_39\IN\0|NONE_0 (l_pobj) hypertension_40\NN\14057371|NONE_0
D000809_D051437 NONE angiotensin_11\NN\4522421|-_11 (r_npadvmod) converting_13\VBG\126264|NONE_0 (r_amod) enzyme_14\NN\14723628|inhibitor_7 (r_compound) therapy_16\NN\657604|NONE_0 (r_pobj) during_10\IN\0|with_19 (r_prep) patients_6\NNS\9898892|NONE_0 (r_pobj) in_5\IN\13603305|decreased_25|renal_15 (r_prep) function_4\NN\13783581|NONE_0
D000809_D051437 NONE angiotensin_1\NN\4522421|-_11 (r_npadvmod) converting_3\VBG\126264|NONE_0 (r_amod) enzyme_4\NN\14723628|inhibitor_7 (r_compound) therapy_6\NN\657604|although_49|rates_26|in_32 (r_nsubj) reduces_7\VBZ\441445|,_71|it_73|may_76|also_80|function_107|._115 (r_advcl) cause_23\VB\7323922|NONE_0 (l_dobj) function_26\NN\13783581|reduces_107|,_36|it_34|may_31|also_27|._8
D000809_D051437 NONE angiotensin_17\NN\4522421|-_11 (r_npadvmod) converting_19\VBG\126264|NONE_0 (r_amod) enzyme_20\NN\14723628|inhibitor_7 (r_compound) therapy_22\NN\657604|who_59|are_55 (r_dobj) prescribed_16\VBN\748282|NONE_0 (r_relcl) chf_13\NNP\0|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) patients_11\NNS\9898892|NONE_0 (r_pobj) in_10\IN\13603305|in_18 (r_prep) reduction_6\NN\351485|NONE_0 (l_prep) in_7\IN\13603305|in_18 (l_pobj) function_9\NN\13783581|NONE_0
D000809_D018487 NONE angiotensin_11\NN\4522421|-_11 (r_npadvmod) converting_13\VBG\126264|NONE_0 (r_amod) enzyme_14\NN\14723628|inhibitor_7 (r_compound) therapy_16\NN\657604|NONE_0 (r_pobj) during_10\IN\0|with_19 (r_prep) patients_6\NNS\9898892|NONE_0 (r_pobj) in_5\IN\13603305|decreased_25|renal_15 (r_prep) function_4\NN\13783581|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) predictors_0\NNS\10756433|:_124|from_134 (r_dep) results_18\NNS\34213|NONE_0 (l_prep) from_19\IN\0|predictors_134|:_10 (l_pobj) studies_21\NNS\635850|NONE_0 (l_prep) of_22\IN\0|the_12 (l_pobj) dysfunction_25\NN\14204950|NONE_0
D004232_D006973 NONE diuretic_49\JJ\3247620|,_2 (r_conj) antiplatelet_47\JJ\0|NONE_0 (r_pobj) of_46\IN\0|NONE_0 (r_prep) use_45\NN\407535|,_6|and_4 (r_conj) diabetes_42\NNS\14075199|,_2 (r_conj) hypertension_40\NN\14057371|NONE_0
D004656_D003920 NONE enalapril_9\NN\2673637|NONE_0 (r_compound) groups_10\NNS\2137|both_31|the_26|and_14|age_13 (r_conj) placebo_7\NN\3740161|NONE_0 (l_conj) age_12\NN\4916342|both_44|the_39|and_27|groups_13 (l_conj) therapy_15\NN\657604|older_20|,_11 (l_conj) diabetes_18\NNS\14075199|diuretic_22|,_6|and_4
D004656_D003920 NONE enalapril_2\NN\2673637|conversely_12|,_2|effect_40|rr_48|._150 (r_nsubj) had_3\VBD\0|NONE_0 (l_npadvmod) rr_9\NN\0|conversely_60|,_50|enalapril_48|effect_8|._102 (l_nummod) 1.33_10\CD\0|(_4 (l_prep) compared_19\VBN\644583|NONE_0 (l_prep) with_20\IN\0|,_29 (l_pobj) placebo_21\NN\3740161|NONE_0 (l_appos) ci_28\NNP\13635336|(_14 (l_prep) in_33\IN\13603305|rr_27|,_20|%_16|2.44_6|)_2 (l_pobj) patients_34\NNS\9898892|NONE_0 (l_prep) with_35\IN\0|NONE_0 (l_pobj) diabetes_36\NNS\14075199|NONE_0
D004656_D003920 NONE enalapril_23\JJ\2673637|the_4 (r_compound) group_24\NN\2137|NONE_0 (r_pobj) in_21\IN\13603305|risk_17|was_12|compared_23|._54 (r_prep) reduced_20\VBN\441445|diabetes_111|was_102|with_87|,_20|but_18 (r_conj) associated_2\VBN\628491|NONE_0 (l_nsubjpass) diabetes_0\NN\14075199|was_9|with_24|,_91|but_93|reduced_111
D000809_D006333 NONE angiotensin_11\NN\4522421|-_11 (r_npadvmod) converting_13\VBG\126264|NONE_0 (r_amod) enzyme_14\NN\14723628|inhibitor_7 (r_compound) therapy_16\NN\657604|NONE_0 (r_pobj) during_10\IN\0|with_19 (r_prep) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|during_19 (l_pobj) failure_9\NN\66216|NONE_0
D000809_D006333 NONE angiotensin_1\NN\4522421|-_11 (r_npadvmod) converting_3\VBG\126264|NONE_0 (r_amod) enzyme_4\NN\14723628|inhibitor_7 (r_compound) therapy_6\NN\657604|although_49|rates_26|in_32 (r_nsubj) reduces_7\VBZ\441445|,_71|it_73|may_76|also_80|function_107|._115 (l_prep) in_10\IN\13603305|although_81|therapy_32|rates_6 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) failure_15\NN\66216|NONE_0
D000809_D006333 NONE angiotensin_1\NN\4522421|-_11 (r_npadvmod) converting_3\VBG\126264|NONE_0 (r_amod) enzyme_4\NN\14723628|inhibitor_7 (r_compound) therapy_6\NN\657604|although_49|rates_26|in_32 (r_nsubj) reduces_7\VBZ\441445|,_71|it_73|may_76|also_80|function_107|._115 (l_prep) in_10\IN\13603305|although_81|therapy_32|rates_6 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) failure_15\NN\66216|NONE_0 (l_appos) chf_17\NNP\0|congestive_26|heart_15
D000809_D006333 NONE angiotensin_17\NN\4522421|-_11 (r_npadvmod) converting_19\VBG\126264|NONE_0 (r_amod) enzyme_20\NN\14723628|inhibitor_7 (r_compound) therapy_22\NN\657604|who_59|are_55 (r_dobj) prescribed_16\VBN\748282|NONE_0 (r_relcl) chf_13\NNP\0|NONE_0
18441470
D008094_D012804 CID lithium_14\NN\14625458|NONE_0 (r_pobj) of_13\IN\0|the_35|adverse_31|cardiovascular_23 (r_prep) effects_12\NNS\13245626|NONE_0 (r_pobj) among_8\IN\0|dysfunction_46|has_34|been_30|frequently_11|._51 (r_prep) reported_5\VBN\831651|NONE_0 (l_nsubjpass) dysfunction_2\NN\14204950|has_12|been_16|frequently_35|among_46|._97
D008094_D013575 NONE lithium_17\NN\14625458|NONE_0 (r_compound) therapy_18\NN\657604|NONE_0 (r_pobj) to_16\IN\0|in_100|,_81|block_48|secondary_10|,_18|necessitating_20|._66 (r_prep) developed_14\VBD\1753788|NONE_0 (l_nsubj) block_10\NN\21939|in_52|,_33|secondary_38|to_48|,_66|necessitating_68|._114 (l_prep) with_11\IN\0|complete_37|atrioventricular_28|(_11|av_10|)_8 (l_pobj) attacks_13\NNS\955060|NONE_0
D008094_D013575 NONE lithium_1\NN\14625458|NONE_0 (r_compound) levels_2\NNS\4916342|under_16|during_54|._81 (r_nsubj) remained_3\VBD\2604760|NONE_0 (l_prep) during_10\IN\0|levels_54|under_38|._27 (l_pobj) attacks_13\NNS\955060|NONE_0
D008094_D054537 CID lithium_5\NN\14625458|NONE_0 (r_compound) therapy_6\NN\657604|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) secondary_3\JJ\8426461|complete_32|atrioventricular_23|._28 (r_amod) block_2\NN\21939|NONE_0
D008094_D054537 CID lithium_17\NN\14625458|NONE_0 (r_compound) therapy_18\NN\657604|NONE_0 (r_pobj) to_16\IN\0|in_100|,_81|block_48|secondary_10|,_18|necessitating_20|._66 (r_prep) developed_14\VBD\1753788|NONE_0 (l_nsubj) block_10\NN\21939|in_52|,_33|secondary_38|to_48|,_66|necessitating_68|._114
3973521
11230490
D003520_D001943 NONE cyclophosphamide_12\NN\0|encapsulated_29|and_4 (r_conj) doxorubicin_10\NN\2716866|NONE_0 (r_pobj) of_6\IN\0|preserved_29|antitumor_19 (r_prep) efficacy_5\NN\5199286|reduced_47|and_24|compared_67|._189 (r_conj) cardiotoxicity_1\NN\0|NONE_0 (l_prep) compared_13\VBN\644583|reduced_114|and_91|efficacy_67|._122 (l_prep) in_19\IN\13603305|with_51 (l_pobj) trial_24\NN\786195|NONE_0 (l_prep) of_25\IN\0|a_32|randomized_30|,_20|multicenter_18 (l_pobj) cancer_28\NN\14239425|NONE_0
D003520_D001943 NONE cyclophosphamide_18\NN\0|conventional_29|and_4 (r_conj) doxorubicin_16\NN\2716866|NONE_0 (r_pobj) with_14\IN\0|in_51 (r_prep) compared_13\VBN\644583|reduced_114|and_91|efficacy_67|._122 (l_prep) in_19\IN\13603305|with_51 (l_pobj) trial_24\NN\786195|NONE_0 (l_prep) of_25\IN\0|a_32|randomized_30|,_20|multicenter_18 (l_pobj) cancer_28\NN\14239425|NONE_0
D003520_D001943 NONE cyclophosphamide_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) combination_22\NN\7951464|NONE_0 (r_pobj) in_21\IN\13603305|the_55|liposome_51|,_35|corporation_28|)_2 (r_prep) company_12\NNP\8053576|determine_74|;_15|significantly_79|cardiotoxicity_113|providing_134|._231 (r_nsubj) reduces_26\VBZ\441445|NONE_0 (l_advcl) providing_30\VBG\2199590|determine_208|;_149|company_134|significantly_55|cardiotoxicity_21|._97 (l_prep) in_34\IN\13603305|while_46|efficacy_9 (l_pobj) treatment_38\NN\654885|NONE_0 (l_prep) of_39\IN\0|line_15 (l_pobj) cancer_42\NN\14239425|NONE_0
D003520_D001943 NONE cyclophosphamide_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) combination_22\NN\7951464|NONE_0 (r_pobj) in_21\IN\13603305|the_55|liposome_51|,_35|corporation_28|)_2 (r_prep) company_12\NNP\8053576|determine_74|;_15|significantly_79|cardiotoxicity_113|providing_134|._231 (r_nsubj) reduces_26\VBZ\441445|NONE_0 (l_advcl) providing_30\VBG\2199590|determine_208|;_149|company_134|significantly_55|cardiotoxicity_21|._97 (l_prep) in_34\IN\13603305|while_46|efficacy_9 (l_pobj) treatment_38\NN\654885|NONE_0 (l_prep) of_39\IN\0|line_15 (l_pobj) cancer_42\NN\14239425|NONE_0 (l_appos) mbc_44\NNP\0|metastatic_26|breast_15
D003520_D001943 NONE cyclophosphamide_46\NN\0|NONE_0 (r_pobj) of_45\IN\0|with_17|)_2 (r_prep) combination_38\NN\7951464|NONE_0 (r_pobj) in_37\IN\13603305|to_76|m(2_52|doxorubicin_17|,_2|,_55|weeks_65 (r_prep) receive_18\VB\2210855|patients_86|were_19|._194 (r_xcomp) randomized_16\VBN\278117|NONE_0 (l_nsubjpass) patients_5\NNS\9898892|were_67|receive_86|._280 (l_prep) with_6\IN\0|seven_15|and_9|chemotherapy_22 (l_pobj) mbc_7\NNP\0|NONE_0
D003520_D001943 NONE cyclophosphamide_26\NN\0|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) combination_24\NN\7951464|NONE_0 (r_pobj) in_23\IN\13603305|when_10|as_37 (r_prep) used_22\VBN\0|efficacy_15|,_7 (l_prep) as_27\IN\14622893|when_47|in_37 (l_pobj) therapy_31\NN\657604|NONE_0 (l_prep) for_32\IN\0|line_13 (l_pobj) mbc_33\NNP\0|NONE_0
D003520_D064420 NONE cyclophosphamide_46\NN\0|NONE_0 (r_pobj) of_45\IN\0|with_17|)_2 (r_prep) combination_38\NN\7951464|NONE_0 (r_pobj) in_37\IN\13603305|to_76|m(2_52|doxorubicin_17|,_2|,_55|weeks_65 (r_prep) receive_18\VB\2210855|patients_86|were_19|._194 (l_npadvmod) weeks_53\NNS\15113229|to_141|m(2_117|doxorubicin_82|,_67|in_65|,_10 (l_prep) until_54\IN\0|every_14|3_8 (l_pobj) progression_56\NN\8457976|NONE_0 (l_conj) toxicity_59\NN\13576101|disease_36|or_16
D003520_D009503 CID cyclophosphamide_26\NN\0|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) combination_24\NN\7951464|NONE_0 (r_pobj) in_23\IN\13603305|when_10|as_37 (r_prep) used_22\VBN\0|efficacy_15|,_7 (r_advcl) provides_16\VBZ\2199590|myocet_122|index_90|by_69|neutropenia_16|and_4|._116 (r_conj) improves_1\VBZ\126264|NONE_0 (l_dobj) neutropenia_14\NN\14196405|myocet_106|index_74|by_53|and_12|provides_16|._132
D004317_D066126 NONE doxorubicin_10\NN\2716866|NONE_0 (r_pobj) of_6\IN\0|preserved_29|antitumor_19 (r_prep) efficacy_5\NN\5199286|reduced_47|and_24|compared_67|._189 (r_conj) cardiotoxicity_1\NN\0|NONE_0
D004317_D066126 NONE doxorubicin_16\NN\2716866|NONE_0 (r_pobj) with_14\IN\0|in_51 (r_prep) compared_13\VBN\644583|reduced_114|and_91|efficacy_67|._122 (r_prep) cardiotoxicity_1\NN\0|NONE_0
D004317_D066126 NONE myocet_3\NNP\0|whether_8|encapsulated_17 (r_nmod) doxorubicin_8\NN\2716866|to_51 (r_dobj) determine_1\VB\0|;_59|company_74|significantly_153|cardiotoxicity_187|providing_208|._305 (r_advcl) reduces_26\VBZ\441445|NONE_0 (l_dobj) cardiotoxicity_28\NN\0|determine_187|;_128|company_113|significantly_34|providing_21|._118
D004317_D066126 NONE doxorubicin_8\NN\2716866|to_51 (r_dobj) determine_1\VB\0|;_59|company_74|significantly_153|cardiotoxicity_187|providing_208|._305 (r_advcl) reduces_26\VBZ\441445|NONE_0 (l_dobj) cardiotoxicity_28\NN\0|determine_187|;_128|company_113|significantly_34|providing_21|._118
D004317_D066126 NONE doxorubicin_27\NN\2716866|NONE_0 (r_compound) cardiotoxicity_28\NN\0|determine_187|;_128|company_113|significantly_34|providing_21|._118
D004317_D066126 NONE myocet_0\NNP\0|index_32|by_53|neutropenia_106|and_118|provides_122|._238 (r_nsubj) improves_1\VBZ\126264|NONE_0 (l_prep) by_7\IN\0|myocet_53|index_21|neutropenia_53|and_65|provides_69|._185 (l_pcomp) reducing_9\VBG\13447361|NONE_0 (l_dobj) cardiotoxicity_10\NN\0|significantly_23
D004317_D066126 NONE doxorubicin_6\NN\2716866|NONE_0 (r_pobj) of_5\IN\0|the_22|therapeutic_18 (r_prep) index_4\NN\13850304|myocet_32|by_21|neutropenia_74|and_86|provides_90|._206 (r_dobj) improves_1\VBZ\126264|NONE_0 (l_prep) by_7\IN\0|myocet_53|index_21|neutropenia_53|and_65|provides_69|._185 (l_pcomp) reducing_9\VBG\13447361|NONE_0 (l_dobj) cardiotoxicity_10\NN\0|significantly_23
D004317_D001943 NONE doxorubicin_10\NN\2716866|NONE_0 (r_pobj) of_6\IN\0|preserved_29|antitumor_19 (r_prep) efficacy_5\NN\5199286|reduced_47|and_24|compared_67|._189 (r_conj) cardiotoxicity_1\NN\0|NONE_0 (l_prep) compared_13\VBN\644583|reduced_114|and_91|efficacy_67|._122 (l_prep) in_19\IN\13603305|with_51 (l_pobj) trial_24\NN\786195|NONE_0 (l_prep) of_25\IN\0|a_32|randomized_30|,_20|multicenter_18 (l_pobj) cancer_28\NN\14239425|NONE_0
D004317_D001943 NONE doxorubicin_16\NN\2716866|NONE_0 (r_pobj) with_14\IN\0|in_51 (r_prep) compared_13\VBN\644583|reduced_114|and_91|efficacy_67|._122 (l_prep) in_19\IN\13603305|with_51 (l_pobj) trial_24\NN\786195|NONE_0 (l_prep) of_25\IN\0|a_32|randomized_30|,_20|multicenter_18 (l_pobj) cancer_28\NN\14239425|NONE_0
D004317_D001943 NONE myocet_3\NNP\0|whether_8|encapsulated_17 (r_nmod) doxorubicin_8\NN\2716866|to_51 (r_dobj) determine_1\VB\0|;_59|company_74|significantly_153|cardiotoxicity_187|providing_208|._305 (r_advcl) reduces_26\VBZ\441445|NONE_0 (l_advcl) providing_30\VBG\2199590|determine_208|;_149|company_134|significantly_55|cardiotoxicity_21|._97 (l_prep) in_34\IN\13603305|while_46|efficacy_9 (l_pobj) treatment_38\NN\654885|NONE_0 (l_prep) of_39\IN\0|line_15 (l_pobj) cancer_42\NN\14239425|NONE_0
D004317_D001943 NONE myocet_3\NNP\0|whether_8|encapsulated_17 (r_nmod) doxorubicin_8\NN\2716866|to_51 (r_dobj) determine_1\VB\0|;_59|company_74|significantly_153|cardiotoxicity_187|providing_208|._305 (r_advcl) reduces_26\VBZ\441445|NONE_0 (l_advcl) providing_30\VBG\2199590|determine_208|;_149|company_134|significantly_55|cardiotoxicity_21|._97 (l_prep) in_34\IN\13603305|while_46|efficacy_9 (l_pobj) treatment_38\NN\654885|NONE_0 (l_prep) of_39\IN\0|line_15 (l_pobj) cancer_42\NN\14239425|NONE_0 (l_appos) mbc_44\NNP\0|metastatic_26|breast_15
D004317_D001943 NONE doxorubicin_8\NN\2716866|to_51 (r_dobj) determine_1\VB\0|;_59|company_74|significantly_153|cardiotoxicity_187|providing_208|._305 (r_advcl) reduces_26\VBZ\441445|NONE_0 (l_advcl) providing_30\VBG\2199590|determine_208|;_149|company_134|significantly_55|cardiotoxicity_21|._97 (l_prep) in_34\IN\13603305|while_46|efficacy_9 (l_pobj) treatment_38\NN\654885|NONE_0 (l_prep) of_39\IN\0|line_15 (l_pobj) cancer_42\NN\14239425|NONE_0
D004317_D001943 NONE doxorubicin_8\NN\2716866|to_51 (r_dobj) determine_1\VB\0|;_59|company_74|significantly_153|cardiotoxicity_187|providing_208|._305 (r_advcl) reduces_26\VBZ\441445|NONE_0 (l_advcl) providing_30\VBG\2199590|determine_208|;_149|company_134|significantly_55|cardiotoxicity_21|._97 (l_prep) in_34\IN\13603305|while_46|efficacy_9 (l_pobj) treatment_38\NN\654885|NONE_0 (l_prep) of_39\IN\0|line_15 (l_pobj) cancer_42\NN\14239425|NONE_0 (l_appos) mbc_44\NNP\0|metastatic_26|breast_15
D004317_D001943 NONE doxorubicin_27\NN\2716866|NONE_0 (r_compound) cardiotoxicity_28\NN\0|determine_187|;_128|company_113|significantly_34|providing_21|._118 (r_dobj) reduces_26\VBZ\441445|NONE_0 (l_advcl) providing_30\VBG\2199590|determine_208|;_149|company_134|significantly_55|cardiotoxicity_21|._97 (l_prep) in_34\IN\13603305|while_46|efficacy_9 (l_pobj) treatment_38\NN\654885|NONE_0 (l_prep) of_39\IN\0|line_15 (l_pobj) cancer_42\NN\14239425|NONE_0
D004317_D001943 NONE doxorubicin_27\NN\2716866|NONE_0 (r_compound) cardiotoxicity_28\NN\0|determine_187|;_128|company_113|significantly_34|providing_21|._118 (r_dobj) reduces_26\VBZ\441445|NONE_0 (l_advcl) providing_30\VBG\2199590|determine_208|;_149|company_134|significantly_55|cardiotoxicity_21|._97 (l_prep) in_34\IN\13603305|while_46|efficacy_9 (l_pobj) treatment_38\NN\654885|NONE_0 (l_prep) of_39\IN\0|line_15 (l_pobj) cancer_42\NN\14239425|NONE_0 (l_appos) mbc_44\NNP\0|metastatic_26|breast_15
D004317_D001943 NONE myocet_26\NNP\0|(_7|)_9 (r_nmod) m_28\NNP\13649268|NONE_0 (r_pobj) of_25\IN\0|either_18|60_11|mg_8|/_6|)_2|or_14 (r_prep) m(2_23\NN\0|to_24|doxorubicin_35|,_50|in_52|,_107|weeks_117 (r_dobj) receive_18\VB\2210855|patients_86|were_19|._194 (r_xcomp) randomized_16\VBN\278117|NONE_0 (l_nsubjpass) patients_5\NNS\9898892|were_67|receive_86|._280 (l_prep) with_6\IN\0|seven_15|and_9|chemotherapy_22 (l_pobj) mbc_7\NNP\0|NONE_0
D004317_D001943 NONE doxorubicin_32\NN\2716866|to_59|m(2_35|,_15|in_17|,_72|weeks_82 (r_dobj) receive_18\VB\2210855|patients_86|were_19|._194 (r_xcomp) randomized_16\VBN\278117|NONE_0 (l_nsubjpass) patients_5\NNS\9898892|were_67|receive_86|._280 (l_prep) with_6\IN\0|seven_15|and_9|chemotherapy_22 (l_pobj) mbc_7\NNP\0|NONE_0
D004317_D001943 NONE myocet_0\NNP\0|index_32|by_53|neutropenia_106|and_118|provides_122|._238 (r_nsubj) improves_1\VBZ\126264|NONE_0 (l_conj) provides_16\VBZ\2199590|myocet_122|index_90|by_69|neutropenia_16|and_4|._116 (l_advcl) used_22\VBN\0|efficacy_15|,_7 (l_prep) as_27\IN\14622893|when_47|in_37 (l_pobj) therapy_31\NN\657604|NONE_0 (l_prep) for_32\IN\0|line_13 (l_pobj) mbc_33\NNP\0|NONE_0
D004317_D001943 NONE doxorubicin_6\NN\2716866|NONE_0 (r_pobj) of_5\IN\0|the_22|therapeutic_18 (r_prep) index_4\NN\13850304|myocet_32|by_21|neutropenia_74|and_86|provides_90|._206 (r_dobj) improves_1\VBZ\126264|NONE_0 (l_conj) provides_16\VBZ\2199590|myocet_122|index_90|by_69|neutropenia_16|and_4|._116 (l_advcl) used_22\VBN\0|efficacy_15|,_7 (l_prep) as_27\IN\14622893|when_47|in_37 (l_pobj) therapy_31\NN\657604|NONE_0 (l_prep) for_32\IN\0|line_13 (l_pobj) mbc_33\NNP\0|NONE_0
D004317_D009503 CID myocet_0\NNP\0|index_32|by_53|neutropenia_106|and_118|provides_122|._238 (r_nsubj) improves_1\VBZ\126264|NONE_0 (l_dobj) neutropenia_14\NN\14196405|myocet_106|index_74|by_53|and_12|provides_16|._132
D004317_D009503 CID doxorubicin_6\NN\2716866|NONE_0 (r_pobj) of_5\IN\0|the_22|therapeutic_18 (r_prep) index_4\NN\13850304|myocet_32|by_21|neutropenia_74|and_86|provides_90|._206 (r_dobj) improves_1\VBZ\126264|NONE_0 (l_dobj) neutropenia_14\NN\14196405|myocet_106|index_74|by_53|and_12|provides_16|._132
D003520_D066126 NONE cyclophosphamide_12\NN\0|encapsulated_29|and_4 (r_conj) doxorubicin_10\NN\2716866|NONE_0 (r_pobj) of_6\IN\0|preserved_29|antitumor_19 (r_prep) efficacy_5\NN\5199286|reduced_47|and_24|compared_67|._189 (r_conj) cardiotoxicity_1\NN\0|NONE_0
D003520_D066126 NONE cyclophosphamide_18\NN\0|conventional_29|and_4 (r_conj) doxorubicin_16\NN\2716866|NONE_0 (r_pobj) with_14\IN\0|in_51 (r_prep) compared_13\VBN\644583|reduced_114|and_91|efficacy_67|._122 (r_prep) cardiotoxicity_1\NN\0|NONE_0
D003520_D066126 NONE cyclophosphamide_24\NN\0|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) combination_22\NN\7951464|NONE_0 (r_pobj) in_21\IN\13603305|the_55|liposome_51|,_35|corporation_28|)_2 (r_prep) company_12\NNP\8053576|determine_74|;_15|significantly_79|cardiotoxicity_113|providing_134|._231 (r_nsubj) reduces_26\VBZ\441445|NONE_0 (l_dobj) cardiotoxicity_28\NN\0|determine_187|;_128|company_113|significantly_34|providing_21|._118
D003520_D066126 NONE cyclophosphamide_26\NN\0|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) combination_24\NN\7951464|NONE_0 (r_pobj) in_23\IN\13603305|when_10|as_37 (r_prep) used_22\VBN\0|efficacy_15|,_7 (r_advcl) provides_16\VBZ\2199590|myocet_122|index_90|by_69|neutropenia_16|and_4|._116 (r_conj) improves_1\VBZ\126264|NONE_0 (l_prep) by_7\IN\0|myocet_53|index_21|neutropenia_53|and_65|provides_69|._185 (l_pcomp) reducing_9\VBG\13447361|NONE_0 (l_dobj) cardiotoxicity_10\NN\0|significantly_23
D004317_D064420 NONE myocet_26\NNP\0|(_7|)_9 (r_nmod) m_28\NNP\13649268|NONE_0 (r_pobj) of_25\IN\0|either_18|60_11|mg_8|/_6|)_2|or_14 (r_prep) m(2_23\NN\0|to_24|doxorubicin_35|,_50|in_52|,_107|weeks_117 (r_dobj) receive_18\VB\2210855|patients_86|were_19|._194 (l_npadvmod) weeks_53\NNS\15113229|to_141|m(2_117|doxorubicin_82|,_67|in_65|,_10 (l_prep) until_54\IN\0|every_14|3_8 (l_pobj) progression_56\NN\8457976|NONE_0 (l_conj) toxicity_59\NN\13576101|disease_36|or_16
D004317_D064420 NONE doxorubicin_32\NN\2716866|to_59|m(2_35|,_15|in_17|,_72|weeks_82 (r_dobj) receive_18\VB\2210855|patients_86|were_19|._194 (l_npadvmod) weeks_53\NNS\15113229|to_141|m(2_117|doxorubicin_82|,_67|in_65|,_10 (l_prep) until_54\IN\0|every_14|3_8 (l_pobj) progression_56\NN\8457976|NONE_0 (l_conj) toxicity_59\NN\13576101|disease_36|or_16
11467664
D008687_D056486 NONE metformin_12\NN\2719105|NONE_0 (r_pobj) of_11\IN\0|the_15 (r_prep) initiation_10\NN\7450842|wk_13 (r_pobj) after_8\IN\0|the_31|of_21 (r_prep) onset_2\NN\7325190|NONE_0 (r_pobj) given_0\VBN\5892096|,_70|we_72|represents_98 (r_prep) believe_15\VBP\686447|,_83|case_100|._113 (l_ccomp) represents_19\VBZ\2664769|given_98|,_28|we_26 (l_dobj) example_21\NN\5816287|that_29|case_19 (l_prep) of_22\IN\0|an_11 (l_pobj) hepatotoxicity_26\NN\0|NONE_0
D008687_D056486 NONE metformin_23\NN\2719105|-_9 (r_npadvmod) associated_25\VBN\628491|NONE_0 (r_amod) hepatotoxicity_26\NN\0|NONE_0
D008687_D041781 CID metformin_7\NN\2719105|NONE_0 (r_pobj) of_6\IN\0|the_8 (r_prep) use_5\NN\407535|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|cholestatic_21|._36 (r_acl) jaundice_1\NN\14299637|NONE_0
D008687_D041781 CID hydrochloride_15\NN\14817592|NONE_0 (r_pobj) with_13\IN\0|NONE_0 (r_prep) treatment_12\NN\654885|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) initiation_10\NN\7450842|shortly_14 (r_pobj) after_9\IN\0|who_43|jaundice_17 (r_prep) developed_5\VBD\1753788|a_14 (l_dobj) jaundice_7\NN\14299637|who_26|after_17
D008687_D007565 NONE hydrochloride_1\NN\14817592|was_14|,_30|and_32|resolved_59 (r_nsubjpass) discontinued_3\VBN\0|NONE_0 (l_conj) resolved_10\VBN\352826|hydrochloride_59|was_45|,_29|and_27 (l_nsubj) jaundice_9\NN\14299637|slowly_18|over_25|._56
D008687_D007565 NONE metformin_12\NN\2719105|NONE_0 (r_pobj) of_11\IN\0|the_15 (r_prep) initiation_10\NN\7450842|wk_13 (r_pobj) after_8\IN\0|the_31|of_21 (r_prep) onset_2\NN\7325190|NONE_0 (l_prep) of_3\IN\0|the_10|after_21 (l_pobj) jaundice_5\NN\14299637|NONE_0
D008687_D007565 NONE metformin_23\NN\2719105|-_9 (r_npadvmod) associated_25\VBN\628491|NONE_0 (r_amod) hepatotoxicity_26\NN\0|NONE_0 (r_pobj) of_22\IN\0|an_11 (r_prep) example_21\NN\5816287|that_29|case_19 (r_dobj) represents_19\VBZ\2664769|given_98|,_28|we_26 (r_ccomp) believe_15\VBP\686447|,_83|case_100|._113 (l_prep) given_0\VBN\5892096|,_70|we_72|represents_98 (l_pobj) onset_2\NN\7325190|NONE_0 (l_prep) of_3\IN\0|the_10|after_21 (l_pobj) jaundice_5\NN\14299637|NONE_0
19319147
D014859_D006470 NONE warfarin_12\RB\2718259|-_8 (r_npadvmod) associated_14\VBN\628491|intracerebral_11 (r_amod) hemorrhage_16\NN\14285662|NONE_0 (r_pobj) of_11\IN\0|a_14|mouse_12 (r_prep) model_10\NN\5888929|NONE_0 (r_pobj) in_7\IN\13603305|reversal_54|volume_7|._64 (r_prep) reduces_4\VBZ\441445|NONE_0 (l_dobj) volume_6\NN\33615|reversal_47|in_7|._71 (l_compound) hemorrhage_5\NN\14285662|NONE_0
C025667_D002543 NONE pcc_5\NNP\0|to_4|treatment_29|in_49 (r_nsubj) be_7\VB\14625458|NONE_0 (l_attr) treatment_11\NN\654885|pcc_29|to_25|in_20 (l_prep) for_12\IN\0|an_29|effective_26|acute_16 (l_pobj) ich_15\NNP\0|NONE_0
D014859_D002543 CID warfarin_12\RB\2718259|-_8 (r_npadvmod) associated_14\VBN\628491|intracerebral_11 (r_amod) hemorrhage_16\NN\14285662|NONE_0
D014859_D002543 CID warfarin_0\NNP\2718259|-_8 (r_npadvmod) associated_2\VBN\628491|intracerebral_11|ich_39|)_42 (r_amod) hemorrhage_4\NN\14285662|type_31|._45
D014859_D002543 CID warfarin_0\NNP\2718259|-_8 (r_npadvmod) associated_2\VBN\628491|intracerebral_11|ich_39|)_42 (r_amod) hemorrhage_4\NN\14285662|type_31|._45 (l_appos) ich_8\NNP\0|associated_39|intracerebral_28|)_3
D014859_D020521 NONE warfarin_0\NNP\2718259|-_8 (r_npadvmod) associated_2\VBN\628491|intracerebral_11|ich_39|)_42 (r_amod) hemorrhage_4\NN\14285662|type_31|._45 (r_nsubj) is_10\VBZ\0|NONE_0 (l_attr) type_13\NN\5839024|hemorrhage_31|._14 (l_prep) of_14\IN\0|a_14|severe_12 (l_pobj) stroke_15\NN\556313|NONE_0
2557556
D009020_D006930 NONE morphine_0\NNP\2707683|did_9|not_13|,_16|however_18|,_25|hyperalgesia_37|._99 (r_nsubj) alter_6\VB\0|NONE_0 (l_dobj) hyperalgesia_8\NN\0|morphine_37|did_28|not_24|,_21|however_19|,_12|._62
D015232_D006930 CID e2-induced_23\VBN\0|prostaglandin_14 (r_amod) hyperalgesia_24\NN\0|NONE_0
D015124_D006930 CID monophosphate_14\NN\0|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|the_17 (r_acl) hyperalgesia_8\NN\0|morphine_37|did_28|not_24|,_21|however_19|,_12|._62
4069770
D005839_D058186 CID gentamicin_18\NN\2716866|NONE_0 (r_pobj) with_17\IN\0|day_25|and_30|penicillin_34 (r_prep) therapy_16\NN\657604|NONE_0 (r_pobj) after_15\IN\0|who_32|of_23 (r_prep) died_10\VBD\146138|a_21|premature_19 (l_prep) of_11\IN\0|who_9|after_23 (l_pobj) failure_14\NN\66216|NONE_0
D005839_D007674 NONE gentamicin_0\NNP\2716866|in_23|._35 (r_amod) nephropathy_1\NN\14573196|NONE_0
D010406_D058186 NONE penicillin_28\NN\2716866|with_34|day_9|and_4 (r_conj) therapy_16\NN\657604|NONE_0 (r_pobj) after_15\IN\0|who_32|of_23 (r_prep) died_10\VBD\146138|a_21|premature_19 (l_prep) of_11\IN\0|who_9|after_23 (l_pobj) failure_14\NN\66216|NONE_0
D005839_D001002 NONE gentamicin_2\NN\2716866|the_10|serum_6 (r_compound) concentration_3\NN\4916342|had_14|levels_32|developed_51|._60 (r_nsubj) reached_5\VBN\0|NONE_0 (l_advcl) developed_10\VBD\1753788|concentration_51|had_37|levels_19|._9 (l_nsubj) anuria_9\NN\14061805|when_5
2840807
D000324_D004421 CID acth_10\NNP\5407119|neuropeptide_18|)_4|of_18 (r_nmod) stimulation_12\NN\242808|NONE_0 (r_pobj) after_5\IN\0|a_25|like_14|._67 (r_prep) syndrome_4\NN\5870365|NONE_0 (l_amod) like_3\JJ\5839024|a_11|after_14|._81 (l_npadvmod) dystonia_1\NN\0|-_8
D009074_D004421 CID msh_8\NNP\5407119|(_1|/_3 (r_nmod) acth_10\NNP\5407119|neuropeptide_18|)_4|of_18 (r_nmod) stimulation_12\NN\242808|NONE_0 (r_pobj) after_5\IN\0|a_25|like_14|._67 (r_prep) syndrome_4\NN\5870365|NONE_0 (l_amod) like_3\JJ\5839024|a_11|after_14|._81 (l_npadvmod) dystonia_1\NN\0|-_8
D000324_D009069 NONE acth_20\NNP\5407119|n_5|-_6 (r_compound) terminal_23\NN\4306080|the_11|at_19|resulted_34 (r_compound) fragments_24\NNS\9385911|NONE_0 (r_pobj) by_18\IN\0|(_35|a_34|)_33|receptors_26|were_16|;_73 (r_agent) stimulated_17\VBN\137313|however_72|,_65|it_63|not_57|certain_53|released_102|,_193|cause_206|._643 (r_ccomp) is_3\VBZ\0|NONE_0 (l_conj) cause_57\VB\7323922|however_278|,_271|it_269|not_263|certain_259|stimulated_206|released_104|,_13|._437 (l_ccomp) resulted_94\VBD\2633881|did_218|indeed_214 (l_nsubj) depression_62\NN\14373582|c_132|whether_135|inhibition_147|in_196|,_300 (l_relcl) resulted_74\VBD\2633881|the_89|term_80|at_64|(_38|described_26|)_7|;_54|targets_238 (l_prep) in_75\IN\13603305|that_14 (l_pobj) duration_78\NN\15113229|NONE_0 (l_prep) of_79\IN\0|the_18|long_14 (l_pobj) disorder_82\NN\14034177|NONE_0
D000324_D003866 NONE acth_20\NNP\5407119|n_5|-_6 (r_compound) terminal_23\NN\4306080|the_11|at_19|resulted_34 (r_compound) fragments_24\NNS\9385911|NONE_0 (r_pobj) by_18\IN\0|(_35|a_34|)_33|receptors_26|were_16|;_73 (r_agent) stimulated_17\VBN\137313|however_72|,_65|it_63|not_57|certain_53|released_102|,_193|cause_206|._643 (r_ccomp) is_3\VBZ\0|NONE_0 (l_conj) cause_57\VB\7323922|however_278|,_271|it_269|not_263|certain_259|stimulated_206|released_104|,_13|._437 (l_ccomp) resulted_94\VBD\2633881|did_218|indeed_214 (l_nsubj) depression_62\NN\14373582|c_132|whether_135|inhibition_147|in_196|,_300
2533791
D017325_D006509 NONE vaccine_25\NN\3562739|injections_41|._7 (r_dobj) derived_22\VBN\634472|infants_118|are_110|with_98|and_40 (r_conj) treated_3\VBN\2376958|NONE_0 (l_prep) with_4\IN\0|infants_20|are_12|and_58|derived_98 (l_pobj) injections_6\NNS\320852|NONE_0 (l_prep) of_7\IN\0|two_15 (l_pobj) globulin_11\NN\14736972|NONE_0 (l_compound) b_9\NNP\1355326|immune_2|hbig_19
18808529
D007545_D007022 NONE isoproterenol_3\NN\3740161|-_13 (r_npadvmod) induced_5\VBN\1627355|myocardial_8 (r_amod) damage_7\NN\7296428|NONE_0 (r_pobj) of_2\IN\0|the_14 (r_prep) mechanism_1\NN\13446390|unknown_56|,_63|but_65|is_168 (r_nsubj) is_8\VBZ\0|NONE_0 (l_conj) is_25\VBZ\0|mechanism_168|unknown_112|,_105|but_103 (l_nsubj) mismatch_13\NN\5695806|explanation_109|._171 (l_prep) vs._17\IN\0|a_28|of_17 (l_pobj) demand_18\NN\6513366|NONE_0 (l_prep) following_19\VBG\8180190|NONE_0 (l_pobj) hyperactivity_24\NN\14052403|NONE_0 (l_nmod) hypotension_21\NN\14057371|myocardial_16
D010100_D007022 NONE oxygen_15\NN\14622893|NONE_0 (r_compound) supply_16\NN\13576355|NONE_0 (r_pobj) of_14\IN\0|a_11|vs._17 (r_prep) mismatch_13\NN\5695806|explanation_109|._171 (l_prep) vs._17\IN\0|a_28|of_17 (l_pobj) demand_18\NN\6513366|NONE_0 (l_prep) following_19\VBG\8180190|NONE_0 (l_pobj) hyperactivity_24\NN\14052403|NONE_0 (l_nmod) hypotension_21\NN\14057371|myocardial_16
D010100_D009202 NONE oxygen_15\NN\14622893|NONE_0 (r_compound) supply_16\NN\13576355|NONE_0 (r_pobj) of_14\IN\0|a_11|vs._17 (r_prep) mismatch_13\NN\5695806|explanation_109|._171 (r_nsubj) is_25\VBZ\0|mechanism_168|unknown_112|,_105|but_103 (r_conj) is_8\VBZ\0|NONE_0 (l_nsubj) mechanism_1\NN\13446390|unknown_56|,_63|but_65|is_168 (l_prep) of_2\IN\0|the_14 (l_pobj) damage_7\NN\7296428|NONE_0
D010100_D009202 NONE oxygen_15\NN\14622893|NONE_0 (r_compound) supply_16\NN\13576355|NONE_0 (r_pobj) of_14\IN\0|a_11|vs._17 (r_prep) mismatch_13\NN\5695806|explanation_109|._171 (l_prep) vs._17\IN\0|a_28|of_17 (l_pobj) demand_18\NN\6513366|NONE_0 (l_prep) following_19\VBG\8180190|NONE_0 (l_pobj) hyperactivity_24\NN\14052403|NONE_0
D007545_D009202 CID isoproterenol_0\NN\3740161|loss_30|:_62|correlation_64|._98 (r_nsubj) induces_1\VBZ\1627355|NONE_0 (l_dobj) correlation_10\NN\13841213|isoproterenol_64|loss_34|:_2|._34 (l_prep) with_11\IN\0|NONE_0 (l_pobj) injury_13\NN\14052046|NONE_0
D007545_D009202 CID isoproterenol_3\NN\3740161|-_13 (r_npadvmod) induced_5\VBN\1627355|myocardial_8 (r_amod) damage_7\NN\7296428|NONE_0
D007545_D009202 CID isoproterenol_3\NN\3740161|-_13 (r_npadvmod) induced_5\VBN\1627355|myocardial_8 (r_amod) damage_7\NN\7296428|NONE_0 (r_pobj) of_2\IN\0|the_14 (r_prep) mechanism_1\NN\13446390|unknown_56|,_63|but_65|is_168 (r_nsubj) is_8\VBZ\0|NONE_0 (l_conj) is_25\VBZ\0|mechanism_168|unknown_112|,_105|but_103 (l_nsubj) mismatch_13\NN\5695806|explanation_109|._171 (l_prep) vs._17\IN\0|a_28|of_17 (l_pobj) demand_18\NN\6513366|NONE_0 (l_prep) following_19\VBG\8180190|NONE_0 (l_pobj) hyperactivity_24\NN\14052403|NONE_0
D007545_D007511 CID isoproterenol_29\NN\3740161|NONE_0 (r_pobj) by_28\IN\0|NONE_0 (r_agent) induced_27\VBN\1627355|the_128|severe_124|in_105 (r_acl) alterations_11\NNS\7283608|changes_57|._141 (r_dobj) explain_8\VBP\831651|NONE_0 (l_nsubj) changes_1\NNS\7283608|alterations_57|._198 (l_acl) related_3\VBN\628491|these_15|,_2|,_27 (l_prep) to_4\IN\0|NONE_0 (l_pobj) injury_6\NN\14052046|NONE_0
9952311
D004317_D009202 NONE adriamycin_7\NNS\0|-_10 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) cardiomyopathy_10\NN\14103288|NONE_0
D004317_D028361 CID adriamycin_7\NNS\0|-_10 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) cardiomyopathy_10\NN\14103288|NONE_0 (r_pobj) in_6\IN\13603305|structural_53|of_16|in_37|:_44|suppression_46|._100 (r_prep) impairment_3\NN\7296428|NONE_0 (l_prep) of_4\IN\0|structural_37|in_16|in_53|:_60|suppression_62|._116 (l_pobj) mitochondria_5\NN\5445668|NONE_0
D004317_D028361 CID adr_21\NNP\0|NONE_0 (r_pobj) of_20\IN\0|the_26|deteriorating_22|on_7 (r_prep) effects_19\NNS\13245626|that_23|impairment_90 (r_nsubj) involve_25\VBP\2676054|knowing_157|,_79|we_77|._58 (l_dobj) impairment_30\NN\7296428|that_113|effects_90
D004317_D009369 NONE adriamycin_3\NNS\0|NONE_0 (r_pobj) of_2\IN\0|the_8|in_20 (r_prep) use_1\NN\407535|has_47|been_51|due_64|._109 (l_prep) in_7\IN\13603305|the_28|of_20 (l_pobj) chemotherapy_9\NN\661091|NONE_0 (l_compound) cancer_8\NN\14239425|NONE_0
D004317_D009369 NONE adr_5\NNP\0|(_1|)_3 (r_appos) adriamycin_3\NNS\0|NONE_0 (r_pobj) of_2\IN\0|the_8|in_20 (r_prep) use_1\NN\407535|has_47|been_51|due_64|._109 (l_prep) in_7\IN\13603305|the_28|of_20 (l_pobj) chemotherapy_9\NN\661091|NONE_0 (l_compound) cancer_8\NN\14239425|NONE_0
D004317_D002318 NONE adriamycin_3\NNS\0|NONE_0 (r_pobj) of_2\IN\0|the_8|in_20 (r_prep) use_1\NN\407535|has_47|been_51|due_64|._109 (r_nsubjpass) limited_12\VBN\4019101|NONE_0 (l_prep) due_13\IN\5174653|use_64|has_17|been_13|._45 (l_pcomp) to_14\IN\0|NONE_0 (l_pobj) toxicity_18\NN\13576101|NONE_0
D004317_D002318 NONE adr_5\NNP\0|(_1|)_3 (r_appos) adriamycin_3\NNS\0|NONE_0 (r_pobj) of_2\IN\0|the_8|in_20 (r_prep) use_1\NN\407535|has_47|been_51|due_64|._109 (r_nsubjpass) limited_12\VBN\4019101|NONE_0 (l_prep) due_13\IN\5174653|use_64|has_17|been_13|._45 (l_pcomp) to_14\IN\0|NONE_0 (l_pobj) toxicity_18\NN\13576101|NONE_0
D004317_D001145 NONE adr_10\NNP\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) mice_8\NNS\2329401|NONE_0 (r_pobj) of_7\IN\0|1_13 (r_prep) treatment_6\NN\654885|that_8|arrhythmias_49|swelling_265 (r_nsubj) caused_11\VBD\1617192|results_53|._344 (l_dobj) arrhythmias_13\NNS\14103288|that_57|treatment_49|swelling_216
D004317_D004487 NONE adr_10\NNP\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) mice_8\NNS\2329401|NONE_0 (r_pobj) of_7\IN\0|1_13 (r_prep) treatment_6\NN\654885|that_8|arrhythmias_49|swelling_265 (r_nsubj) caused_11\VBD\1617192|results_53|._344 (l_ccomp) swelling_51\NN\14315071|that_273|treatment_265|arrhythmias_216
D004317_D001919 CID adr_10\NNP\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) mice_8\NNS\2329401|NONE_0 (r_pobj) of_7\IN\0|1_13 (r_prep) treatment_6\NN\654885|that_8|arrhythmias_49|swelling_265 (r_nsubj) caused_11\VBD\1617192|results_53|._344 (l_dobj) arrhythmias_13\NNS\14103288|that_57|treatment_49|swelling_216 (l_acl) characterized_14\VBN\609683|cardiovascular_27 (l_agent) by_15\IN\0|NONE_0 (l_pobj) bradycardia_16\NNP\14110674|NONE_0
10523326
D009569_D006973 NONE oxide_1\NN\14818238|NONE_0 (r_compound) synthase_2\NN\0|nitric_13|in_20|._62 (r_compound) expression_3\NN\4679549|NONE_0 (l_prep) in_4\IN\13603305|nitric_33|synthase_20|._42 (l_pobj) course_6\NN\883297|NONE_0 (l_prep) of_7\IN\0|the_11 (l_pobj) hypertension_11\NN\14057371|NONE_0
D009569_D006973 NONE no_15\DT\7204911|(_15|nox_16|)_19 (r_det) metabolites_16\NNS\20090|NONE_0 (r_pobj) of_14\IN\0|reduced_26|urinary_18 (r_prep) excretion_13\NN\13466586|we_75|recently_72|species_31|,_33|and_35|increased_39|._140 (r_dobj) showed_2\VBD\2137132|NONE_0 (l_conj) increased_22\VBD\169651|we_114|recently_111|species_70|excretion_39|,_6|and_4|._101 (l_dobj) sequestration_24\NN\1201021|NONE_0 (l_prep) as_25\IN\14622893|no_17 (l_pobj) nitrotyrosine_26\JJ\0|NONE_0 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) tissues_29\NNS\5220461|NONE_0 (l_prep) in_30\IN\13603305|various_16 (l_pobj) rats_31\NNS\2329401|NONE_0 (l_prep) with_32\IN\0|NONE_0 (l_pobj) hypertension_36\NN\14057371|NONE_0
D009569_D006973 NONE no_23\DT\7204911|as_17 (r_det) sequestration_24\NN\1201021|NONE_0 (l_prep) as_25\IN\14622893|no_17 (l_pobj) nitrotyrosine_26\JJ\0|NONE_0 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) tissues_29\NNS\5220461|NONE_0 (l_prep) in_30\IN\13603305|various_16 (l_pobj) rats_31\NNS\2329401|NONE_0 (l_prep) with_32\IN\0|NONE_0 (l_pobj) hypertension_36\NN\14057371|NONE_0
D009569_D006973 NONE no_25\DT\7204911|depressed_10 (r_det) synthase_26\NN\0|(_9|nos_10|)_13 (r_nmod) expression_30\NN\4679549|to_31 (r_pobj) due_22\IN\5174653|whether_79|reduction_67|,_11|in_9|,_2 (r_prep) is_17\VBZ\0|to_77 (l_nsubj) reduction_8\NN\351485|whether_12|,_56|in_58|,_65|due_67 (l_prep) in_12\IN\13603305|the_29|in_15 (l_pobj) hypertension_16\NN\14057371|NONE_0
D009569_D006973 NONE no_11\DT\7204911|mediated_9|,_15|inhibition_33 (r_compound) inactivation_12\NN\13518963|to_19 (l_appos) inhibition_17\NN\1068773|mediated_42|no_33|,_18 (l_conj) actions_25\NNS\30358|associated_63|of_41|,_26|and_24 (l_prep) of_26\IN\0|perhaps_28|stimulatory_20 (l_pobj) stress_29\NN\7083732|NONE_0 (l_acl) associated_30\VBN\628491|increased_23|shear_13 (l_prep) with_31\IN\0|NONE_0 (l_pobj) hypertension_32\NN\14057371|NONE_0
C002744_D006973 NONE nitrotyrosine_26\JJ\0|NONE_0 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) tissues_29\NNS\5220461|NONE_0 (l_prep) in_30\IN\13603305|various_16 (l_pobj) rats_31\NNS\2329401|NONE_0 (l_prep) with_32\IN\0|NONE_0 (l_pobj) hypertension_36\NN\14057371|NONE_0
D007854_D006973 CID lead_8\NN\5155821|-_4 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) hypertension_11\NN\14057371|NONE_0
D007854_D006973 CID lead_33\NN\5155821|-_4 (r_npadvmod) induced_35\VBN\1627355|NONE_0 (r_amod) hypertension_36\NN\14057371|NONE_0
D007854_D006973 CID lead_13\NN\5155821|-_4 (r_npadvmod) induced_15\VBN\1627355|NONE_0 (r_amod) hypertension_16\NN\14057371|NONE_0
D007854_D006973 CID lead_3\NN\5155821|-_4 (r_npadvmod) induced_5\VBN\1627355|in_21 (r_amod) hypertension_6\NN\14057371|in_28|,_15|was_27|with_42|._121
D007854_D006973 CID lead_14\NN\5155821|-_4 (r_npadvmod) associated_16\VBN\628491|of_22|,_37|and_39|actions_63 (r_amod) inhibition_17\NN\1068773|mediated_42|no_33|,_18 (l_conj) actions_25\NNS\30358|associated_63|of_41|,_26|and_24 (l_prep) of_26\IN\0|perhaps_28|stimulatory_20 (l_pobj) stress_29\NN\7083732|NONE_0 (l_acl) associated_30\VBN\628491|increased_23|shear_13 (l_prep) with_31\IN\0|NONE_0 (l_pobj) hypertension_32\NN\14057371|NONE_0
D010100_D006973 NONE oxygen_5\NN\14622893|elevated_18|reactive_9|(_15|ros_16|)_19|,_20 (r_compound) species_6\NNS\7992450|we_44|recently_41|excretion_31|,_64|and_66|increased_70|._171 (r_dobj) showed_2\VBD\2137132|NONE_0 (l_conj) increased_22\VBD\169651|we_114|recently_111|species_70|excretion_39|,_6|and_4|._101 (l_dobj) sequestration_24\NN\1201021|NONE_0 (l_prep) as_25\IN\14622893|no_17 (l_pobj) nitrotyrosine_26\JJ\0|NONE_0 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) tissues_29\NNS\5220461|NONE_0 (l_prep) in_30\IN\13603305|various_16 (l_pobj) rats_31\NNS\2329401|NONE_0 (l_prep) with_32\IN\0|NONE_0 (l_pobj) hypertension_36\NN\14057371|NONE_0
D014810_D006973 NONE e_1\NN\14724645|NONE_0 (r_compound) supplementation_2\NN\5108947|hypertension_28|,_40|lowered_42|._194 (r_nsubj) ameliorated_3\VBD\126264|NONE_0 (l_dobj) hypertension_4\NN\14057371|supplementation_28|,_12|lowered_14|._166
D008315_D006973 NONE mda_8\NNP\0|plasma_7 (r_compound) concentration_9\NN\4916342|,_13|and_15|raised_19|enos_109 (r_dobj) lowered_6\VBD\1850315|supplementation_42|hypertension_14|,_2|._152 (r_conj) ameliorated_3\VBD\126264|NONE_0 (l_dobj) hypertension_4\NN\14057371|supplementation_28|,_12|lowered_14|._166
1610717
D003042_D012640 CID cocaine_0\NN\3492717|-_7 (r_npadvmod) induced_2\VBN\1627355|brainstem_8|and_27|behavior_31|._39 (r_amod) seizures_4\NNS\14081375|NONE_0
783197
D010042_D006333 NONE ouabain_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_12|weight_29|)_35|on_37 (r_prep) effects_3\NNS\13245626|we_16|._198 (l_prep) on_12\IN\0|the_49|of_37|weight_8|)_2 (l_pobj) parameters_19\NNS\5858936|NONE_0 (l_prep) without_29\IN\0|volumetric_96|metabolic_80|in_59 (l_pobj) failure_33\NN\66216|NONE_0
D010042_D006333 NONE ouabain_26\JJ\0|NONE_0 (r_compound) administration_27\NN\1133281|NONE_0 (r_pobj) after_25\IN\0|is_42 (r_prep) falls_24\VBZ\11692265|we_153|left_38|._67 (r_conj) conclude_1\VBP\628491|NONE_0 (l_ccomp) left_18\VBD\8621598|we_115|falls_38|._105 (l_nsubj) patients_4\NNS\9898892|that_8|in_3|volume_126 (l_prep) with_5\IN\0|NONE_0 (l_pobj) disease_9\NN\14061805|NONE_0 (l_relcl) are_11\VBP\13600404|chronic_36|coronary_28|artery_19 (l_prep) in_13\IN\13603305|who_12|not_4 (l_pobj) failure_17\NN\66216|NONE_0
D010042_D003324 NONE ouabain_2\NN\0|NONE_0 (l_prep) on_3\IN\0|NONE_0 (l_pobj) supply_6\NN\13576355|NONE_0 (l_conj) demand_8\NN\6513366|myocardial_29|oxygen_18|and_4 (l_prep) in_9\IN\13603305|NONE_0 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) disease_15\NN\14061805|NONE_0
D010042_D003324 NONE ouabain_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_12|weight_29|)_35|on_37 (r_prep) effects_3\NNS\13245626|we_16|._198 (l_prep) on_12\IN\0|the_49|of_37|weight_8|)_2 (l_pobj) parameters_19\NNS\5858936|NONE_0 (l_prep) in_20\IN\13603305|volumetric_37|metabolic_21|without_59 (l_pobj) patients_22\NNS\9898892|NONE_0 (l_prep) with_23\IN\0|11_12 (l_pobj) disease_28\NN\14061805|NONE_0
D010042_D003324 NONE ouabain_26\JJ\0|NONE_0 (r_compound) administration_27\NN\1133281|NONE_0 (r_pobj) after_25\IN\0|is_42 (r_prep) falls_24\VBZ\11692265|we_153|left_38|._67 (r_conj) conclude_1\VBP\628491|NONE_0 (l_ccomp) left_18\VBD\8621598|we_115|falls_38|._105 (l_nsubj) patients_4\NNS\9898892|that_8|in_3|volume_126 (l_prep) with_5\IN\0|NONE_0 (l_pobj) disease_9\NN\14061805|NONE_0
D010100_D003324 NONE oxygen_5\NN\14622893|myocardial_11|and_14|demand_18 (r_compound) supply_6\NN\13576355|NONE_0 (l_conj) demand_8\NN\6513366|myocardial_29|oxygen_18|and_4 (l_prep) in_9\IN\13603305|NONE_0 (l_pobj) patients_10\NNS\9898892|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) disease_15\NN\14061805|NONE_0
D010100_D003324 NONE oxygen_7\NN\14622893|myocardial_11|and_14|demand_18 (r_compound) supply_8\NN\13576355|NONE_0 (r_pobj) on_5\IN\0|digitalis_21 (r_prep) glycosides_4\NNS\14727670|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|of_75|,_152|but_154|measured_172|._198 (r_nsubj) are_11\VBP\13600404|NONE_0 (l_prep) of_12\IN\0|effects_75|,_77|but_79|measured_97|._123 (l_pobj) interest_14\NN\5682570|NONE_0 (l_prep) in_15\IN\13603305|particular_20 (l_pobj) presence_17\NN\13954253|NONE_0 (l_prep) of_18\IN\0|the_13 (l_pobj) disease_22\NN\14061805|NONE_0
D004071_D003324 NONE glycosides_4\NNS\14727670|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|of_75|,_152|but_154|measured_172|._198 (r_nsubj) are_11\VBP\13600404|NONE_0 (l_prep) of_12\IN\0|effects_75|,_77|but_79|measured_97|._123 (l_pobj) interest_14\NN\5682570|NONE_0 (l_prep) in_15\IN\13603305|particular_20 (l_pobj) presence_17\NN\13954253|NONE_0 (l_prep) of_18\IN\0|the_13 (l_pobj) disease_22\NN\14061805|NONE_0
D010042_D002303 CID ouabain_26\JJ\0|NONE_0 (r_compound) administration_27\NN\1133281|NONE_0 (r_pobj) after_25\IN\0|is_42 (r_prep) falls_24\VBZ\11692265|we_153|left_38|._67
2893236
D018698_D012133 NONE glutamate_11\NN\15010703|respiratory_23|,_2 (r_conj) paralysis_9\NN\14557898|naloxone_48|control_40|._120
D005680_D012133 NONE gaba_0\NNP\14601829|in_17 (r_compound) involvement_1\NN\1080366|reversal_32|._88 (r_nsubj) induced_4\VBN\1627355|NONE_0 (l_dobj) reversal_5\NN\199130|involvement_32|._56 (l_prep) of_6\IN\0|NONE_0 (l_pobj) paralysis_8\NN\14557898|NONE_0
D005680_D012133 NONE gaba_13\NNP\14601829|and_4|levels_5 (r_conj) glutamate_11\NN\15010703|respiratory_23|,_2 (r_conj) paralysis_9\NN\14557898|naloxone_48|control_40|._120
D005680_D012133 NONE gaba_12\NNP\14601829|in_5 (r_dobj) involves_11\VBZ\2676054|naloxone_67|paralysis_37|and_4 (r_conj) reverses_4\VBZ\13854649|data_22|._85 (l_dobj) paralysis_6\NN\14557898|naloxone_30|and_33|involves_37
D005680_D012131 NONE gaba_12\NNP\14601829|NONE_0 (r_pobj) in_11\IN\13603305|further_17|and_8|decrease_12 (r_prep) increase_10\NN\13576355|NONE_0 (r_pobj) with_8\IN\0|mg/kg_51|,_46|i.v._44|produced_28|respiratory_19 (r_prep) arrest_7\NN\88481|without_94|._171
D018698_D012131 NONE glutamate_16\NN\15010703|NONE_0 (r_pobj) in_15\IN\13603305|again_13|in_19 (r_prep) decrease_14\NN\7296428|further_29|in_12|and_4 (r_conj) increase_10\NN\13576355|NONE_0 (r_pobj) with_8\IN\0|mg/kg_51|,_46|i.v._44|produced_28|respiratory_19 (r_prep) arrest_7\NN\88481|without_94|._171
D009270_D012133 NONE naloxone_3\NN\3808977|NONE_0 (r_pobj) in_2\IN\13603305|gaba_17 (r_prep) involvement_1\NN\1080366|reversal_32|._88 (r_nsubj) induced_4\VBN\1627355|NONE_0 (l_dobj) reversal_5\NN\199130|involvement_32|._56 (l_prep) of_6\IN\0|NONE_0 (l_pobj) paralysis_8\NN\14557898|NONE_0
D009270_D012133 NONE naloxone_3\NN\3808977|in_14|paralysis_30|._69 (r_nsubj) reversed_4\VBD\109660|NONE_0 (l_dobj) paralysis_6\NN\14557898|in_44|naloxone_30|._39
D009270_D012133 NONE naloxone_0\NN\3808977|paralysis_48|control_88|._168 (r_nsubj) reversed_7\VBD\109660|NONE_0 (l_dobj) paralysis_9\NN\14557898|naloxone_48|control_40|._120
D009270_D012133 NONE naloxone_3\NN\3808977|paralysis_30|and_63|involves_67 (r_nsubj) reverses_4\VBZ\13854649|data_22|._85 (l_dobj) paralysis_6\NN\14557898|naloxone_30|and_33|involves_37
D013874_D012133 CID thiopental_11\NN\2792049|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) produced_9\VBN\1617192|respiratory_22 (r_acl) paralysis_8\NN\14557898|NONE_0
D013874_D012133 CID thiopental_9\NN\2792049|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|respiratory_22 (r_acl) paralysis_6\NN\14557898|in_44|naloxone_30|._39
D013874_D012133 CID thiopental_9\NN\2792049|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) produced_7\VBN\1617192|respiratory_22 (r_acl) paralysis_6\NN\14557898|naloxone_30|and_33|involves_37
D000596_D012131 NONE acids_29\NNS\14818238|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) any_25\DT\0|NONE_0 (r_dobj) affecting_24\VBG\126264|NONE_0 (r_pcomp) without_23\IN\0|arrest_94|._77 (r_prep) stem_22\NN\6290637|NONE_0 (l_nsubj) arrest_7\NN\88481|without_94|._171
D013874_D012131 NONE thiopental_4\NN\2792049|NONE_0 (r_npadvmod) produced_5\VBD\1617192|mg/kg_23|,_18|i.v._16|respiratory_9|with_28 (r_amod) arrest_7\NN\88481|without_94|._171
8677458
D015080_D064420 NONE mesna_15\NN\0|along_6 (r_dobj) administering_14\VBG\2436349|NONE_0 (r_pcomp) by_13\IN\0|that_22|can_17|be_13 (r_agent) prevented_12\VBN\0|a_53|major_51|potential_45|of_26 (r_relcl) toxicity_6\NN\13576101|cystitis_30|._98
D007069_D006470 CID ifosfamide_7\RB\0|-_10 (r_advmod) induced_9\VBN\1627355|hemorrhagic_8 (r_amod) cystitis_11\NN\14566129|to_42
D007069_D006470 CID ifosfamide_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_27|major_25|potential_19|prevented_26 (r_prep) toxicity_6\NN\13576101|cystitis_30|._98 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) cystitis_1\NN\14566129|toxicity_30|._128
D015080_D003556 CID mesna_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|continuous_39|subcutaneous_28|prevent_12|._59 (r_prep) administration_2\NN\1133281|NONE_0 (l_relcl) prevent_6\VB\0|continuous_51|subcutaneous_40|of_12|._47 (l_dobj) cystitis_11\NN\14566129|to_42
D015080_D003556 CID mesna_15\NN\0|along_6 (r_dobj) administering_14\VBG\2436349|NONE_0 (r_pcomp) by_13\IN\0|that_22|can_17|be_13 (r_agent) prevented_12\VBN\0|a_53|major_51|potential_45|of_26 (r_relcl) toxicity_6\NN\13576101|cystitis_30|._98 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) cystitis_1\NN\14566129|toxicity_30|._128
D007069_D003556 CID ifosfamide_7\RB\0|-_10 (r_advmod) induced_9\VBN\1627355|hemorrhagic_8 (r_amod) cystitis_11\NN\14566129|to_42
D007069_D003556 CID ifosfamide_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_27|major_25|potential_19|prevented_26 (r_prep) toxicity_6\NN\13576101|cystitis_30|._98 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) cystitis_1\NN\14566129|toxicity_30|._128
D015080_D006470 CID mesna_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|continuous_39|subcutaneous_28|prevent_12|._59 (r_prep) administration_2\NN\1133281|NONE_0 (l_relcl) prevent_6\VB\0|continuous_51|subcutaneous_40|of_12|._47 (l_dobj) cystitis_11\NN\14566129|to_42
D015080_D006470 CID mesna_15\NN\0|along_6 (r_dobj) administering_14\VBG\2436349|NONE_0 (r_pcomp) by_13\IN\0|that_22|can_17|be_13 (r_agent) prevented_12\VBN\0|a_53|major_51|potential_45|of_26 (r_relcl) toxicity_6\NN\13576101|cystitis_30|._98 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) cystitis_1\NN\14566129|toxicity_30|._128
D007069_D064420 NONE ifosfamide_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_27|major_25|potential_19|prevented_26 (r_prep) toxicity_6\NN\13576101|cystitis_30|._98
D007069_D014839 NONE ifosfamide_33\RB\0|-_10 (r_advmod) induced_35\VBN\1627355|severe_18 (r_amod) emesis_36\NN\116687|who_42|and_7|is_11
D015080_D014839 NONE mesna_19\NN\0|inadequate_19|,_20|as_27 (r_compound) concentrations_20\NNS\4916342|NONE_0 (l_prep) as_23\IN\14622893|inadequate_46|mesna_27|,_7 (l_prep) in_24\IN\13603305|such_8 (l_pobj) patient_26\NN\9898892|NONE_0 (l_relcl) experiences_31\VBZ\5984287|a_32|taking_22 (l_dobj) emesis_36\NN\116687|who_42|and_7|is_11
D015080_D014839 NONE mesna_29\NN\0|NONE_0 (r_dobj) taking_27\VBG\37396|a_10|experiences_22 (r_acl) patient_26\NN\9898892|NONE_0 (l_relcl) experiences_31\VBZ\5984287|a_32|taking_22 (l_dobj) emesis_36\NN\116687|who_42|and_7|is_11
3411101
D011802_D056486 NONE quinidine_0\NN\2715941|may_43|responsible_50|._101 (r_nsubj) be_5\VB\14625458|NONE_0 (l_acomp) responsible_6\JJ\0|quinidine_50|may_7|._51 (l_prep) for_7\IN\0|NONE_0 (l_pobj) hepatitis_9\NN\14127211|NONE_0
C033457_D056486 CID phenylethylbarbiturate_1\NN\0|quinidine_10|-_22|hepatitis_41|in_51|._70 (r_npadvmod) induced_3\VBN\1627355|NONE_0 (l_dobj) hepatitis_5\NN\14127211|quinidine_51|phenylethylbarbiturate_41|-_19|in_10|._29
C033457_D056486 CID phenylethylbarbiturate_28\NN\0|NONE_0 (r_pobj) of_26\IN\0|a_25|1-month_23 (r_prep) administration_25\NN\1133281|NONE_0 (r_pobj) after_22\IN\0|by_67|during_44 (r_prep) affected_11\VBN\126264|a_30|old_20|laotian_16 (l_agent) by_12\IN\0|during_23|after_67 (l_pobj) hepatitis_14\NN\14127211|NONE_0
C033457_D056486 CID phenylethylbarbiturate_3\NN\0|itself_10|or_3 (r_conj) quinidine_0\NN\2715941|may_43|responsible_50|._101 (r_nsubj) be_5\VB\14625458|NONE_0 (l_acomp) responsible_6\JJ\0|quinidine_50|may_7|._51 (l_prep) for_7\IN\0|NONE_0 (l_pobj) hepatitis_9\NN\14127211|NONE_0
17943461
D015215_D002311 CID zidovudine_12\NNP\3834836|the_20|haart_16|;_41|azt_43 (r_appos) component_11\NN\5867413|whether_18|pathway_96|and_104|cause_108 (r_nsubj) triggers_18\VBZ\3659292|to_91 (l_conj) cause_28\VB\7323922|whether_126|component_108|pathway_12|and_4 (l_dobj) disruption_30\NN\1066163|NONE_0 (l_prep) in_31\IN\13603305|cytoskeletal_24 (l_pobj) model_34\NN\5888929|NONE_0 (l_prep) of_35\IN\0|a_15|murine_13 (l_pobj) dcm_36\NNP\0|NONE_0
D015215_D002311 CID 3'-azido-2',3'-deoxythymidine_14\CD\0|NONE_0 (r_appos) zidovudine_12\NNP\3834836|the_20|haart_16|;_41|azt_43 (r_appos) component_11\NN\5867413|whether_18|pathway_96|and_104|cause_108 (r_nsubj) triggers_18\VBZ\3659292|to_91 (l_conj) cause_28\VB\7323922|whether_126|component_108|pathway_12|and_4 (l_dobj) disruption_30\NN\1066163|NONE_0 (l_prep) in_31\IN\13603305|cytoskeletal_24 (l_pobj) model_34\NN\5888929|NONE_0 (l_prep) of_35\IN\0|a_15|murine_13 (l_pobj) dcm_36\NNP\0|NONE_0
D015215_D002311 CID azt_16\NNP\3834836|the_63|haart_59|zidovudine_43|;_2 (r_appos) component_11\NN\5867413|whether_18|pathway_96|and_104|cause_108 (r_nsubj) triggers_18\VBZ\3659292|to_91 (l_conj) cause_28\VB\7323922|whether_126|component_108|pathway_12|and_4 (l_dobj) disruption_30\NN\1066163|NONE_0 (l_prep) in_31\IN\13603305|cytoskeletal_24 (l_pobj) model_34\NN\5888929|NONE_0 (l_prep) of_35\IN\0|a_15|murine_13 (l_pobj) dcm_36\NNP\0|NONE_0
D015215_D002311 CID azt_69\NNP\3834836|NONE_0 (r_pobj) of_68\IN\0|different_25 (r_prep) concentrations_67\NNS\4916342|NONE_0 (r_dobj) containing_65\VBG\2632940|ad_11 (r_acl) libitum_64\NN\0|methods_348|:_329|in_327|mice_23|._80 (r_dobj) received_61\VBD\2210855|NONE_0 (l_prep) in_4\IN\13603305|methods_21|:_2|mice_304|libitum_327|._407 (l_pobj) order_5\NN\7168131|NONE_0 (l_acl) investigate_7\VB\644583|NONE_0 (l_ccomp) triggers_18\VBZ\3659292|to_91 (l_conj) cause_28\VB\7323922|whether_126|component_108|pathway_12|and_4 (l_dobj) disruption_30\NN\1066163|NONE_0 (l_prep) in_31\IN\13603305|cytoskeletal_24 (l_pobj) model_34\NN\5888929|NONE_0 (l_prep) of_35\IN\0|a_15|murine_13 (l_pobj) dcm_36\NNP\0|NONE_0
D015215_D002311 CID azt_3\NNP\3834836|-_3 (r_npadvmod) treated_5\VBN\2376958|NONE_0 (r_amod) fasl_6\NNPS\0|tg_5 (r_compound) mice_8\NNS\2329401|in_33|,_22|dilation_23|in_63|,_89|with_91|._152 (r_nsubj) developed_9\VBD\1753788|NONE_0 (l_dobj) dilation_11\NN\7138085|in_56|,_45|mice_23|in_40|,_66|with_68|._129
D015215_D009202 CID azt_7\NNP\3834836|-_3 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) cardiomyopathy_10\NN\14103288|NONE_0
11027904
D020910_D010146 NONE ketorolac_48\RB\3828465|analgesic_17 (r_nmod) agents_53\NNS\7347|by_271|was_178|,_166|before_159|._6 (r_conj) examined_23\VBN\0|NONE_0 (l_prep) by_0\IN\0|was_93|,_105|before_112|agents_271|._277 (l_pcomp) using_1\VBG\418025|NONE_0 (l_dobj) tolerance_13\NN\5032565|design_8|,_2 (l_prep) to_14\IN\0|NONE_0 (l_pobj) pain_21\NN\14299637|NONE_0
D008691_D010146 NONE methadone_3\NN\3808564|-_9 (r_npadvmod) maintained_5\VBN\0|opioid_11 (r_amod) abusers_7\NNS\9633969|NONE_0 (r_pobj) in_2\IN\13603305|pain_15|._38 (r_prep) responses_1\NNS\11410625|NONE_0 (l_compound) pain_0\NN\14299637|in_15|._53
D008691_D010146 NONE methadone_19\NN\3808564|-_9 (r_compound) maintenance_21\NN\266806|(_12|mm_13|)_15|(_27|n_28|60_32|)_34 (r_nmod) treatment_25\NN\654885|NONE_0 (r_pobj) in_18\IN\13603305|in_49 (r_prep) stabilized_17\VBD\126264|a_27|of_18 (r_acl) sample_13\NN\5820620|NONE_0 (r_pobj) in_11\IN\13603305|pain_38|and_23|response_9 (r_prep) tolerance_7\NN\5032565|to_17 (l_compound) pain_6\NN\14299637|and_15|response_29|in_38
D004091_D010146 NONE hydromorphone_38\NN\2707683|common_15 (r_parataxis) opioid_36\NN\0|NONE_0 (r_pobj) of_34\IN\0|therapeutic_18 (r_prep) doses_33\NNS\3740161|NONE_0 (r_pobj) of_31\IN\0|oral_20 (r_prep) administration_30\NN\1133281|NONE_0 (r_pobj) after_28\IN\0|both_16|and_4 (r_conj) before_26\IN\0|by_112|was_19|,_7|agents_159|._165 (r_advmod) examined_23\VBN\0|NONE_0 (l_prep) by_0\IN\0|was_93|,_105|before_112|agents_271|._277 (l_pcomp) using_1\VBG\418025|NONE_0 (l_dobj) tolerance_13\NN\5032565|design_8|,_2 (l_prep) to_14\IN\0|NONE_0 (l_pobj) pain_21\NN\14299637|NONE_0
D008691_D009293 NONE methadone_19\NN\3808564|-_9 (r_compound) maintenance_21\NN\266806|(_12|mm_13|)_15|(_27|n_28|60_32|)_34 (r_nmod) treatment_25\NN\654885|NONE_0 (r_pobj) in_18\IN\13603305|in_49 (r_prep) stabilized_17\VBD\126264|a_27|of_18 (r_acl) sample_13\NN\5820620|NONE_0 (l_prep) of_14\IN\0|a_9|stabilized_18 (l_pobj) addicts_16\NNS\10059582|NONE_0
11705128
D012254_D019698 NONE ribavirin_19\RB\2725367|and_13 (r_conj) interferon_15\NN\2725367|NONE_0 (r_pobj) with_14\IN\0|combination_20 (r_prep) therapy_13\NN\657604|NONE_0 (r_pobj) of_11\IN\0|increased_42|and_23|effectiveness_14 (r_prep) efficacy_6\NN\5199286|studies_36|have_28|compared_94|._182 (r_dobj) demonstrated_4\VBN\2137132|NONE_0 (l_prep) compared_20\VBN\644583|studies_130|have_122|efficacy_94|._88 (l_prep) with_21\IN\0|NONE_0 (l_pobj) monotherapy_25\NN\0|NONE_0 (l_prep) in_26\IN\13603305|alpha_18 (l_pobj) treatment_28\NN\654885|NONE_0 (l_prep) of_29\IN\0|the_14 (l_pobj) c_32\NNP\13714184|NONE_0
D012254_D019698 NONE ribavirin_19\RB\2725367|and_13 (r_conj) interferon_15\NN\2725367|NONE_0 (r_pobj) with_14\IN\0|combination_20 (r_prep) therapy_13\NN\657604|NONE_0 (r_pobj) of_11\IN\0|increased_42|and_23|effectiveness_14 (r_prep) efficacy_6\NN\5199286|studies_36|have_28|compared_94|._182 (r_dobj) demonstrated_4\VBN\2137132|NONE_0 (l_prep) compared_20\VBN\644583|studies_130|have_122|efficacy_94|._88 (l_prep) with_21\IN\0|NONE_0 (l_pobj) monotherapy_25\NN\0|NONE_0 (l_prep) in_26\IN\13603305|alpha_18 (l_pobj) treatment_28\NN\654885|NONE_0 (l_prep) of_29\IN\0|the_14 (l_pobj) c_32\NNP\13714184|NONE_0 (l_appos) chc_34\NNP\0|chronic_21|hepatitis_13|(_1|)_3
D012254_D000743 CID ribavirin_3\RB\2725367|-_9 (r_npadvmod) induced_5\VBN\1627355|hemolytic_8|in_25 (r_amod) anemia_7\NN\14189204|NONE_0
D012254_D000743 CID ribavirin_11\RB\2725367|associated_55|:_2|-_9|anemia_28|._41 (r_npadvmod) induced_13\VBN\1627355|NONE_0 (l_dobj) anemia_15\NN\14189204|associated_83|:_30|ribavirin_28|-_19|._13
D012254_D000743 CID ribavirin_11\RB\2725367|associated_55|:_2|-_9|anemia_28|._41 (r_npadvmod) induced_13\VBN\1627355|NONE_0 (l_dobj) anemia_15\NN\14189204|associated_83|:_30|ribavirin_28|-_19|._13 (l_appos) riha_17\NNP\0|hemolytic_18|(_1|)_4
D012254_D000743 CID ribavirin_14\JJ\2725367|the_4 (r_compound) dosage_15\NN\13576355|NONE_0 (r_pobj) of_12\IN\0|or_19|discontinuation_16 (r_prep) reduction_9\NN\351485|standard_43|._52 (r_attr) is_8\VBZ\0|NONE_0 (l_nsubj) standard_1\NN\13577171|reduction_43|._95 (l_prep) for_4\IN\0|the_21|of_8 (l_pobj) management_5\NN\1123598|NONE_0 (l_prep) of_6\IN\0|NONE_0 (l_pobj) riha_7\NNP\0|NONE_0
D012254_D000743 CID ribavirin_7\NN\2725367|NONE_0 (r_pobj) of_6\IN\0|the_17|optimal_13|and_13|incidence_21 (r_prep) dose_5\NN\3740161|NONE_0 (l_conj) incidence_10\NN\13821570|the_38|optimal_34|of_21|and_8 (l_prep) of_11\IN\0|the_14|in_8 (l_pobj) riha_12\NNP\0|NONE_0
D012254_D006526 NONE ribavirin_3\RB\2725367|-_9 (r_npadvmod) induced_5\VBN\1627355|hemolytic_8|in_25 (r_amod) anemia_7\NN\14189204|NONE_0 (l_prep) in_8\IN\13603305|induced_25|hemolytic_17 (l_pobj) treatment_10\NN\654885|NONE_0 (l_prep) of_11\IN\0|the_14 (l_pobj) c_13\NNP\13714184|NONE_0
D016898_D019698 NONE alpha_24\NN\6828818|in_18 (r_compound) monotherapy_25\NN\0|NONE_0 (l_prep) in_26\IN\13603305|alpha_18 (l_pobj) treatment_28\NN\654885|NONE_0 (l_prep) of_29\IN\0|the_14 (l_pobj) c_32\NNP\13714184|NONE_0
D016898_D019698 NONE alpha_24\NN\6828818|in_18 (r_compound) monotherapy_25\NN\0|NONE_0 (l_prep) in_26\IN\13603305|alpha_18 (l_pobj) treatment_28\NN\654885|NONE_0 (l_prep) of_29\IN\0|the_14 (l_pobj) c_32\NNP\13714184|NONE_0 (l_appos) chc_34\NNP\0|chronic_21|hepatitis_13|(_1|)_3
17975693
D002939_D001008 CID ciprofloxacin-_5\JJ\0|NONE_0 (r_nmod) rats_10\NNS\2329401|that_44|behaviour_20|in_30 (r_nsubj) showed_11\VBD\2137132|:_72|results_66|studied_77|._84 (l_dobj) behaviour_13\NN\14006945|that_64|rats_20|in_10
D009643_D001008 CID norfloxacin_7\NNS\0|-_11 (r_npadvmod) treated_9\VBN\2376958|and_16 (r_conj) ciprofloxacin-_5\JJ\0|NONE_0 (r_nmod) rats_10\NNS\2329401|that_44|behaviour_20|in_30 (r_nsubj) showed_11\VBD\2137132|:_72|results_66|studied_77|._84 (l_dobj) behaviour_13\NN\14006945|that_64|rats_20|in_10
18627295
D004317_D009202 CID doxorubicin_0\NNP\2716866|are_62|by_77|._118 (l_dobj) inflammation_4\NN\14299637|and_13|apoptosis_17 (l_amod) induced_3\VBN\1627355|NONE_0 (l_npadvmod) cardiomyopathy_1\NN\14103288|-_14
D004317_D009202 CID dox_17\NNP\0|NONE_0 (r_compound) cardiomyopathy_18\NN\14103288|NONE_0
D004317_D009202 CID dox_17\NNP\0|NONE_0 (r_compound) cardiomyopathy_18\NN\14103288|NONE_0 (r_pobj) of_16\IN\0|the_16 (r_prep) development_15\NN\248977|NONE_0 (r_pobj) during_13\IN\0|to_62|role_36|)_2 (r_prep) elucidate_1\VB\939277|,_103|we_105|mice_129|by_145|._242 (r_advcl) studied_21\VBD\0|NONE_0 (l_prep) by_29\IN\0|elucidate_145|,_42|we_40|mice_16|._97 (l_pcomp) investigating_30\VBG\575741|NONE_0 (l_conj) apoptosis_34\NN\11486178|inflammation_17|and_4 (l_prep) after_35\IN\0|NONE_0 (l_pobj) induction_36\NN\7450842|NONE_0 (l_prep) of_37\IN\0|NONE_0 (l_pobj) cardiomyopathy_41\NN\14103288|NONE_0
D004317_D009202 CID dox_38\NNP\0|-_3 (r_npadvmod) induced_40\VBN\1627355|NONE_0 (r_amod) cardiomyopathy_41\NN\14103288|NONE_0 (r_pobj) of_37\IN\0|NONE_0 (r_prep) induction_36\NN\7450842|NONE_0 (r_pobj) after_35\IN\0|NONE_0 (r_prep) apoptosis_34\NN\11486178|inflammation_17|and_4 (r_conj) investigating_30\VBG\575741|NONE_0 (r_pcomp) by_29\IN\0|elucidate_145|,_42|we_40|mice_16|._97 (r_prep) studied_21\VBD\0|NONE_0 (l_advcl) elucidate_1\VB\939277|,_103|we_105|mice_129|by_145|._242 (l_prep) during_13\IN\0|to_62|role_36|)_2 (l_pobj) development_15\NN\248977|NONE_0 (l_prep) of_16\IN\0|the_16 (l_pobj) cardiomyopathy_18\NN\14103288|NONE_0
D004317_D009202 CID dox_38\NNP\0|-_3 (r_npadvmod) induced_40\VBN\1627355|NONE_0 (r_amod) cardiomyopathy_41\NN\14103288|NONE_0
D004317_D009202 CID dox_8\NNP\0|NONE_0 (r_pobj) in_7\IN\13603305|that_24|b1r_19|detrimental_12|cardiomyopathy_7|mediates_33 (r_prep) is_5\VBZ\0|findings_26|._96 (l_acl) cardiomyopathy_9\NN\14103288|that_31|b1r_26|detrimental_19|in_7|mediates_26
D004317_D009202 CID dox_16\NNP\0|NONE_0 (r_compound) cardiomyopathy_17\NN\14103288|NONE_0
D004317_D007249 NONE doxorubicin_0\NNP\2716866|are_62|by_77|._118 (l_dobj) inflammation_4\NN\14299637|and_13|apoptosis_17
D004317_D007249 NONE dox_17\NNP\0|NONE_0 (r_compound) cardiomyopathy_18\NN\14103288|NONE_0 (r_pobj) of_16\IN\0|the_16 (r_prep) development_15\NN\248977|NONE_0 (r_pobj) during_13\IN\0|to_62|role_36|)_2 (r_prep) elucidate_1\VB\939277|,_103|we_105|mice_129|by_145|._242 (r_advcl) studied_21\VBD\0|NONE_0 (l_prep) by_29\IN\0|elucidate_145|,_42|we_40|mice_16|._97 (l_pcomp) investigating_30\VBG\575741|NONE_0 (l_dobj) inflammation_32\NN\14299637|and_13|apoptosis_17
D004317_D007249 NONE dox_38\NNP\0|-_3 (r_npadvmod) induced_40\VBN\1627355|NONE_0 (r_amod) cardiomyopathy_41\NN\14103288|NONE_0 (r_pobj) of_37\IN\0|NONE_0 (r_prep) induction_36\NN\7450842|NONE_0 (r_pobj) after_35\IN\0|NONE_0 (r_prep) apoptosis_34\NN\11486178|inflammation_17|and_4 (r_conj) investigating_30\VBG\575741|NONE_0 (l_dobj) inflammation_32\NN\14299637|and_13|apoptosis_17
D004317_D066126 NONE doxorubicin_5\NN\2716866|NONE_0 (r_pobj) of_2\IN\0|clinical_13 (r_prep) use_1\NN\407535|is_43|by_54|._132 (r_nsubjpass) limited_10\VBN\4019101|NONE_0 (l_agent) by_11\IN\0|use_54|is_11|._78 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_amod) cardiotoxic_13\JJ\0|its_4|,_19|attributed_31
D004317_D066126 NONE dox_7\NNP\0|the_31|anthracycline_27|)_3 (r_appos) doxorubicin_5\NN\2716866|NONE_0 (r_pobj) of_2\IN\0|clinical_13 (r_prep) use_1\NN\407535|is_43|by_54|._132 (r_nsubjpass) limited_10\VBN\4019101|NONE_0 (l_agent) by_11\IN\0|use_54|is_11|._78 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_amod) cardiotoxic_13\JJ\0|its_4|,_19|attributed_31
D004317_D006331 NONE dox_0\NN\0|NONE_0 (r_compound) control_1\NN\5190804|NONE_0 (r_compound) mice_2\NNS\2329401|dysfunction_20|._73 (r_nsubj) showed_3\VBD\2137132|NONE_0 (l_dobj) dysfunction_5\NN\14204950|mice_20|._53
D004317_D006331 NONE dox_1\NNP\0|b1r(-/-_4|)_11 (r_nmod) mice_4\NNS\2329401|NONE_0 (r_pobj) in_0\IN\13603305|,_20|dysfunction_30|was_42|compared_55|._198 (r_prep) improved_9\VBN\126264|NONE_0 (l_nsubjpass) dysfunction_7\NN\14204950|in_30|,_10|was_12|compared_25|._168
D004317_D006331 NONE dox_12\NNP\0|control_4|,_16|associated_28 (r_compound) mice_14\NNS\2329401|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) compared_10\VBN\644583|in_55|,_35|dysfunction_25|was_13|._143 (r_prep) improved_9\VBN\126264|NONE_0 (l_nsubjpass) dysfunction_7\NN\14204950|in_30|,_10|was_12|compared_25|._168
D018943_D066126 NONE anthracycline_4\NN\0|the_4|dox_27|)_30 (r_amod) doxorubicin_5\NN\2716866|NONE_0 (r_pobj) of_2\IN\0|clinical_13 (r_prep) use_1\NN\407535|is_43|by_54|._132 (r_nsubjpass) limited_10\VBN\4019101|NONE_0 (l_agent) by_11\IN\0|use_54|is_11|._78 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_amod) cardiotoxic_13\JJ\0|its_4|,_19|attributed_31
2564649
D011224_D009127 NONE prazosin_32\NN\2698769|NONE_0 (r_pobj) with_25\IN\0|prior_66|electrolytic_60|of_39 (r_prep) lesions_18\NNS\14204950|NONE_0 (r_pobj) by_15\IN\0|even_13 (r_agent) reduced_14\VBN\441445|rigidity_69|was_38|significantly_34|or_8|._122 (r_conj) antagonized_11\VBN\1787955|NONE_0 (l_nsubjpass) rigidity_4\NN\5023233|was_31|significantly_35|or_61|reduced_69|._191
D005283_D009127 CID fentanyl_8\NN\2707683|-_8 (r_npadvmod) induced_10\VBN\1627355|muscular_8|in_26 (r_amod) rigidity_12\NN\5023233|NONE_0
D005283_D009127 CID fentanyl_17\NN\2707683|dose_5 (r_compound) anesthesia_18\NN\14034177|NONE_0 (r_pobj) with_13\IN\0|that_19|is_14 (r_prep) associated_12\VBN\628491|a_33|known_26|side_20 (r_relcl) effect_9\NN\34213|whereas_47|rigidity_30 (r_attr) is_3\VBZ\0|,_81|paucity_85|with_115|)_156|._157 (l_nsubj) rigidity_2\NN\5023233|whereas_17|effect_30
D005283_D009127 CID fentanyl_10\NN\2707683|NONE_0 (r_pobj) by_9\IN\0|muscular_18 (r_prep) rigidity_8\NN\5023233|NONE_0
7542793
D016559_D007674 CID fk506_5\NNP\0|of_21|and_4|:_5|inhibition_7|._44 (r_conj) nephrotoxicity_0\NN\0|NONE_0
D016559_D007674 CID fk506_10\NNP\0|that_40|effects_19|is_6|likely_9|through_25 (r_nsubjpass) mediated_13\VBN\761713|results_72|._85 (l_nsubjpass) effects_6\NNS\13245626|that_21|fk506_19|is_25|likely_28|through_44 (l_amod) nephrotoxic_5\JJ\0|the_4|of_20|and_27
D016572_D064420 NONE csa_4\NNP\0|NONE_0 (l_conj) toxicity_7\NN\13576101|and_10
D018942_D006984 NONE macrolide_21\NN\0|not_16|the_12|related_8|immunosuppressant_10|(_38|mg/kg_41|)_46 (r_amod) rapamycin_23\NNS\0|(_66|fk506_65|;_60|mg/kg_56|,_50|but_48 (r_conj) fujimycine_9\NNP\0|50_14|)_6|and_4 (r_conj) mg/kg_6\NN\0|cyclosporin_23|csa_8|;_5|,_107 (r_appos) a_1\NNP\13649268|reduction_129|given_297|._314 (r_nsubj) caused_29\VBD\1617192|NONE_0 (l_dobj) reduction_31\NN\351485|a_129|given_168|._185 (l_prep) of_32\IN\0|a_12 (l_pobj) rate_35\NN\13815152|NONE_0 (l_appos) changes_38\NNS\7283608|glomerular_41|filtration_30|,_15 (l_conj) hypertrophy_45\NN\14365950|degenerative_57|of_36|,_6|and_4
D016572_D006984 NONE a_1\NNP\13649268|reduction_129|given_297|._314 (r_nsubj) caused_29\VBD\1617192|NONE_0 (l_dobj) reduction_31\NN\351485|a_129|given_168|._185 (l_prep) of_32\IN\0|a_12 (l_pobj) rate_35\NN\13815152|NONE_0 (l_appos) changes_38\NNS\7283608|glomerular_41|filtration_30|,_15 (l_conj) hypertrophy_45\NN\14365950|degenerative_57|of_36|,_6|and_4
D016572_D006984 NONE csa_3\NNP\0|cyclosporin_15|;_3|mg/kg_8|,_115 (r_appos) a_1\NNP\13649268|reduction_129|given_297|._314 (r_nsubj) caused_29\VBD\1617192|NONE_0 (l_dobj) reduction_31\NN\351485|a_129|given_168|._185 (l_prep) of_32\IN\0|a_12 (l_pobj) rate_35\NN\13815152|NONE_0 (l_appos) changes_38\NNS\7283608|glomerular_41|filtration_30|,_15 (l_conj) hypertrophy_45\NN\14365950|degenerative_57|of_36|,_6|and_4
D016572_D007674 CID a_3\NNP\13649268|NONE_0 (r_pobj) of_1\IN\0|and_17|fk506_21|:_26|inhibition_28|._65 (r_prep) nephrotoxicity_0\NN\0|NONE_0
D016572_D007674 CID csa_8\NNP\0|NONE_0 (r_pobj) of_7\IN\0|the_24|nephrotoxic_20|and_7 (r_prep) effects_6\NNS\13245626|that_21|fk506_19|is_25|likely_28|through_44 (l_amod) nephrotoxic_5\JJ\0|the_4|of_20|and_27
D016559_D064420 NONE fk506_6\NNP\0|NONE_0 (r_compound) toxicity_7\NN\13576101|and_10
D016559_D006984 NONE fujimycine_9\NNP\0|50_14|)_6|and_4 (r_conj) mg/kg_6\NN\0|cyclosporin_23|csa_8|;_5|,_107 (r_appos) a_1\NNP\13649268|reduction_129|given_297|._314 (r_nsubj) caused_29\VBD\1617192|NONE_0 (l_dobj) reduction_31\NN\351485|a_129|given_168|._185 (l_prep) of_32\IN\0|a_12 (l_pobj) rate_35\NN\13815152|NONE_0 (l_appos) changes_38\NNS\7283608|glomerular_41|filtration_30|,_15 (l_conj) hypertrophy_45\NN\14365950|degenerative_57|of_36|,_6|and_4
D016559_D006984 NONE fk506_11\NNP\0|(_1|;_5|mg/kg_9|,_15|but_17|rapamycin_65 (r_appos) fujimycine_9\NNP\0|50_14|)_6|and_4 (r_conj) mg/kg_6\NN\0|cyclosporin_23|csa_8|;_5|,_107 (r_appos) a_1\NNP\13649268|reduction_129|given_297|._314 (r_nsubj) caused_29\VBD\1617192|NONE_0 (l_dobj) reduction_31\NN\351485|a_129|given_168|._185 (l_prep) of_32\IN\0|a_12 (l_pobj) rate_35\NN\13815152|NONE_0 (l_appos) changes_38\NNS\7283608|glomerular_41|filtration_30|,_15 (l_conj) hypertrophy_45\NN\14365950|degenerative_57|of_36|,_6|and_4
D020123_D006984 NONE rapamycin_23\NNS\0|(_66|fk506_65|;_60|mg/kg_56|,_50|but_48 (r_conj) fujimycine_9\NNP\0|50_14|)_6|and_4 (r_conj) mg/kg_6\NN\0|cyclosporin_23|csa_8|;_5|,_107 (r_appos) a_1\NNP\13649268|reduction_129|given_297|._314 (r_nsubj) caused_29\VBD\1617192|NONE_0 (l_dobj) reduction_31\NN\351485|a_129|given_168|._185 (l_prep) of_32\IN\0|a_12 (l_pobj) rate_35\NN\13815152|NONE_0 (l_appos) changes_38\NNS\7283608|glomerular_41|filtration_30|,_15 (l_conj) hypertrophy_45\NN\14365950|degenerative_57|of_36|,_6|and_4
1300436
D003404_D058186 NONE creatinine_46\NN\0|NONE_0 (r_pobj) in_44\IN\13603305|a_7|from_20 (r_prep) rise_43\NN\7324673|NONE_0 (r_pobj) with_41\IN\0|were_219|significantly_89|in_62|,_2|,_77|occurred_95|)_161|._162 (r_prep) deteriorated_26\VBD\208836|NONE_0
D005665_D007674 NONE furosemide_4\NN\3214670|NONE_0 (r_pobj) of_3\IN\0|potential_29|deleterious_19|in_14|._42 (r_prep) effect_2\NN\34213|NONE_0 (l_prep) in_5\IN\13603305|potential_43|deleterious_33|of_14|._28 (l_pobj) nephropathy_7\NN\14573196|NONE_0
D005665_D007674 NONE furosemide_11\NN\3214670|NONE_0 (r_pobj) of_10\IN\0|the_13 (r_prep) efficacy_9\NN\5199286|to_17|in_23 (r_dobj) determine_7\VB\0|purpose_28|._117 (l_prep) in_12\IN\13603305|to_40|efficacy_23 (l_pobj) addition_13\NN\3081021|NONE_0 (l_prep) in_17\IN\13603305|to_22 (l_pobj) prevention_19\NN\1073995|NONE_0 (l_prep) of_20\IN\0|the_15 (l_pobj) nephropathy_22\NN\14573196|NONE_0
D005665_D007674 NONE furosemide_0\NNP\3214670|may_11|deleterious_18|in_30|._76 (r_nsubj) be_2\VB\14625458|NONE_0 (l_prep) in_4\IN\13603305|furosemide_30|may_19|deleterious_12|._46 (l_pobj) prevention_6\NN\1073995|NONE_0 (l_prep) of_7\IN\0|the_15 (l_pobj) nephropathy_9\NN\14573196|NONE_0
D005665_D015431 NONE furosemide_9\NN\3214670|-_10 (r_npadvmod) treated_11\VBN\2376958|the_15 (r_amod) group_12\NN\2137|NONE_0 (r_pobj) in_7\IN\13603305|weight_12 (r_prep) loss_6\NN\13252973|NONE_0
D005665_D051437 NONE furosemide_9\NN\3214670|-_10 (r_npadvmod) treated_11\VBN\2376958|the_15 (r_amod) group_12\NN\2137|NONE_0 (r_pobj) in_7\IN\13603305|weight_12 (r_prep) loss_6\NN\13252973|NONE_0 (r_pobj) with_4\IN\0|failure_23|was_15|._48 (r_prep) associated_3\VBN\628491|NONE_0 (l_nsubjpass) failure_1\NN\66216|was_8|with_23|._71
D005665_D058186 CID furosemide_32\NN\3214670|NONE_0 (r_pobj) with_31\IN\0|NONE_0 (r_prep) pretreated_30\VBN\0|the_10 (r_acl) group_29\NN\2137|NONE_0 (r_pobj) in_27\IN\13603305|were_157|significantly_27|,_60|with_62|,_139|occurred_157|)_223|._224 (r_prep) deteriorated_26\VBD\208836|NONE_0
12101159
D002118_D006323 NONE calcium_13\NN\14625458|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) resuscitation_8\NN\1047338|arrest_33|;_2|._48 (r_dep) delayed_0\VBN\439958|NONE_0 (l_dobj) arrest_3\NN\88481|;_31|resuscitation_33|._81 (l_amod) asystolic_1\JJ\0|cardiac_10|after_25
D002118_D006323 NONE calcium_13\NN\14625458|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) resuscitation_8\NN\1047338|arrest_33|;_2|._48 (r_dep) delayed_0\VBN\439958|NONE_0 (l_dobj) arrest_3\NN\88481|;_31|resuscitation_33|._81
D002118_D006323 NONE calcium_12\NN\14625458|aggressive_33|dose_17|intravenous_12|in_16 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) for_7\IN\0|a_7|,_81|with_96 (r_prep) role_6\NN\719494|there_11 (l_prep) with_20\IN\0|a_103|for_96|,_15 (l_pobj) onset_22\NN\7325190|particularly_22 (l_prep) of_23\IN\0|the_10 (l_pobj) asystole_24\NN\14204950|NONE_0
D004110_D062787 CID diltiazem_5\NN\2938514|NONE_0 (r_compound) overdose_6\NN\84738|NONE_0
D004110_D062787 CID diltiazem_15\NN\2938514|NONE_0 (r_pobj) of_14\IN\0|1.8_10 (r_prep) g_13\NN\13717155|NONE_0 (r_pobj) including_9\VBG\0|a_17|mixed_15 (r_prep) overdose_8\NN\84738|man_17|._96
D004110_D062787 CID diltiazem_16\NN\2938514|severe_7 (r_compound) overdose_17\NN\84738|NONE_0
D004110_D062787 CID diltiazem_11\NN\2938514|NONE_0 (r_compound) overdose_12\NN\84738|NONE_0
D000431_D062787 NONE alcohol_25\NN\7881800|isosorbide_24|,_6|and_4 (r_conj) nitrate_22\NN\14818238|,_13 (r_conj) aspirin_19\NN\2707683|,_2 (r_conj) paracetamol_17\JJ\0|,_2 (r_conj) diltiazem_15\NN\2938514|NONE_0 (r_pobj) of_14\IN\0|1.8_10 (r_prep) g_13\NN\13717155|NONE_0 (r_pobj) including_9\VBG\0|a_17|mixed_15 (r_prep) overdose_8\NN\84738|man_17|._96
D002118_D062787 NONE calcium_13\NN\14625458|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) resuscitation_8\NN\1047338|arrest_33|;_2|._48 (r_dep) delayed_0\VBN\439958|NONE_0 (l_dobj) arrest_3\NN\88481|;_31|resuscitation_33|._81 (l_prep) after_4\IN\0|asystolic_25|cardiac_15 (l_pobj) overdose_6\NN\84738|NONE_0
D002118_D062787 NONE calcium_12\NN\14625458|aggressive_33|dose_17|intravenous_12|in_16 (r_compound) therapy_13\NN\657604|NONE_0 (l_prep) in_14\IN\13603305|aggressive_49|dose_33|intravenous_28|calcium_16 (l_pobj) overdose_17\NN\84738|NONE_0
D004110_D006323 CID diltiazem_5\NN\2938514|NONE_0 (r_compound) overdose_6\NN\84738|NONE_0 (r_pobj) after_4\IN\0|asystolic_25|cardiac_15 (r_prep) arrest_3\NN\88481|;_31|resuscitation_33|._81 (l_amod) asystolic_1\JJ\0|cardiac_10|after_25
D004110_D006323 CID diltiazem_5\NN\2938514|NONE_0 (r_compound) overdose_6\NN\84738|NONE_0 (r_pobj) after_4\IN\0|asystolic_25|cardiac_15 (r_prep) arrest_3\NN\88481|;_31|resuscitation_33|._81
D004110_D006323 CID diltiazem_16\NN\2938514|severe_7 (r_compound) overdose_17\NN\84738|NONE_0 (r_pobj) in_14\IN\13603305|aggressive_49|dose_33|intravenous_28|calcium_16 (r_prep) therapy_13\NN\657604|NONE_0 (r_pobj) for_7\IN\0|a_7|,_81|with_96 (r_prep) role_6\NN\719494|there_11 (l_prep) with_20\IN\0|a_103|for_96|,_15 (l_pobj) onset_22\NN\7325190|particularly_22 (l_prep) of_23\IN\0|the_10 (l_pobj) asystole_24\NN\14204950|NONE_0
D004110_D006323 CID diltiazem_11\NN\2938514|NONE_0 (r_compound) overdose_12\NN\84738|NONE_0 (r_pobj) after_10\IN\0|of_18 (r_prep) cases_6\NNS\7283608|NONE_0 (l_prep) of_7\IN\0|after_18 (l_pobj) arrest_9\NN\88481|NONE_0
D009566_D062787 NONE nitrate_22\NN\14818238|,_13 (r_conj) aspirin_19\NN\2707683|,_2 (r_conj) paracetamol_17\JJ\0|,_2 (r_conj) diltiazem_15\NN\2938514|NONE_0 (r_pobj) of_14\IN\0|1.8_10 (r_prep) g_13\NN\13717155|NONE_0 (r_pobj) including_9\VBG\0|a_17|mixed_15 (r_prep) overdose_8\NN\84738|man_17|._96
D001241_D062787 NONE aspirin_19\NN\2707683|,_2 (r_conj) paracetamol_17\JJ\0|,_2 (r_conj) diltiazem_15\NN\2938514|NONE_0 (r_pobj) of_14\IN\0|1.8_10 (r_prep) g_13\NN\13717155|NONE_0 (r_pobj) including_9\VBG\0|a_17|mixed_15 (r_prep) overdose_8\NN\84738|man_17|._96
D007547_D062787 NONE isosorbide_21\JJ\3740161|,_18|and_20|alcohol_24 (r_compound) nitrate_22\NN\14818238|,_13 (r_conj) aspirin_19\NN\2707683|,_2 (r_conj) paracetamol_17\JJ\0|,_2 (r_conj) diltiazem_15\NN\2938514|NONE_0 (r_pobj) of_14\IN\0|1.8_10 (r_prep) g_13\NN\13717155|NONE_0 (r_pobj) including_9\VBG\0|a_17|mixed_15 (r_prep) overdose_8\NN\84738|man_17|._96
D000082_D062787 NONE paracetamol_17\JJ\0|,_2 (r_conj) diltiazem_15\NN\2938514|NONE_0 (r_pobj) of_14\IN\0|1.8_10 (r_prep) g_13\NN\13717155|NONE_0 (r_pobj) including_9\VBG\0|a_17|mixed_15 (r_prep) overdose_8\NN\84738|man_17|._96
11099450
D007980_D004409 CID levodopa_33\RB\14604959|-_8 (r_npadvmod) induced_35\VBN\1627355|(_20|lid_21|)_24 (r_amod) dyskinesias_36\NNS\14084880|parkinsonian_46|off_32|and_21
D007980_D004409 CID levodopa_33\RB\14604959|-_8 (r_npadvmod) induced_35\VBN\1627355|(_20|lid_21|)_24 (r_amod) dyskinesias_36\NNS\14084880|parkinsonian_46|off_32|and_21 (l_appos) lid_38\NNP\5313679|induced_21|(_1|)_3
D007980_D004409 CID levodopa_8\JJ\14604959|the_17|preoperative_13|of_24|and_39|responsiveness_56 (r_compound) responsiveness_9\NN\5652926|NONE_0 (r_pobj) between_5\IN\0|significant_34|positive_22|program_138 (r_prep) correlations_4\NNS\13841213|we_30|in_195|,_271|was_287|._333 (r_dobj) found_1\VBD\13279262|NONE_0 (l_advcl) was_45\VBD\0|we_317|correlations_287|in_92|,_16|._46 (l_attr) correlation_47\NN\13841213|whereas_21|there_13 (l_prep) with_48\IN\0|no_15 (l_pobj) improvement_50\NN\7359599|NONE_0 (l_prep) in_51\IN\13603305|the_16 (l_pobj) lid_52\NNP\5313679|NONE_0
D007980_D004409 CID levodopa_15\JJ\14604959|the_4|of_24 (r_compound) responsiveness_16\NN\5652926|the_73|preoperative_69|levodopa_56|of_32|and_17 (r_conj) responsiveness_9\NN\5652926|NONE_0 (r_pobj) between_5\IN\0|significant_34|positive_22|program_138 (r_prep) correlations_4\NNS\13841213|we_30|in_195|,_271|was_287|._333 (r_dobj) found_1\VBD\13279262|NONE_0 (l_advcl) was_45\VBD\0|we_317|correlations_287|in_92|,_16|._46 (l_attr) correlation_47\NN\13841213|whereas_21|there_13 (l_prep) with_48\IN\0|no_15 (l_pobj) improvement_50\NN\7359599|NONE_0 (l_prep) in_51\IN\13603305|the_16 (l_pobj) lid_52\NNP\5313679|NONE_0
D007980_D004409 CID levodopa_5\JJ\14604959|for_24 (r_compound) responsiveness_6\NN\5652926|NONE_0 (l_prep) for_7\IN\0|levodopa_24 (l_pobj) outcome_9\NN\7291312|NONE_0 (l_prep) of_10\IN\0|the_12 (l_pobj) signs_15\NNS\6643763|NONE_0 (l_conj) lid_17\NNP\5313679|parkinsonian_29|off_15|and_4
D007980_D004409 CID levodopa_5\JJ\14604959|for_24 (r_compound) responsiveness_6\NN\5652926|NONE_0 (l_prep) for_7\IN\0|levodopa_24 (l_pobj) outcome_9\NN\7291312|NONE_0 (l_prep) of_10\IN\0|the_12 (l_pobj) signs_15\NNS\6643763|NONE_0 (l_conj) lid_17\NNP\5313679|parkinsonian_29|off_15|and_4 (l_conj) correlations_21\NNS\13841213|and_18 (l_prep) of_22\IN\0|the_27|different_23 (l_pobj) volume_25\NN\33615|NONE_0 (l_prep) with_26\IN\0|ventral_22|lesion_14 (l_pobj) dyskinesias_27\NNS\14084880|NONE_0
D007980_D004409 CID levodopa_5\JJ\14604959|for_24 (r_compound) responsiveness_6\NN\5652926|NONE_0 (r_pobj) of_4\IN\0|the_34|differential_30|predictive_17 (r_prep) value_3\NN\5856066|be_259|._336 (r_nsubj) indicate_34\VBP\952524|NONE_0 (l_ccomp) be_42\VB\14625458|value_259|._77 (l_acomp) responsible_43\JJ\0|that_66|substrates_18|may_7 (l_prep) for_44\IN\0|NONE_0 (l_pobj) signs_52\NNS\6643763|generation_33 (l_conj) dyskinesias_54\NNS\14084880|off_15|and_4
D007980_D010300 NONE levodopa_33\RB\14604959|-_8 (r_npadvmod) induced_35\VBN\1627355|(_20|lid_21|)_24 (r_amod) dyskinesias_36\NNS\14084880|parkinsonian_46|off_32|and_21 (r_conj) signs_31\NNS\6643763|NONE_0 (l_poss) parkinsonian_27\NN\0|off_14|and_25|dyskinesias_46
D007980_D010300 NONE levodopa_5\JJ\14604959|for_24 (r_compound) responsiveness_6\NN\5652926|NONE_0 (l_prep) for_7\IN\0|levodopa_24 (l_pobj) outcome_9\NN\7291312|NONE_0 (l_prep) of_10\IN\0|the_12 (l_pobj) signs_15\NNS\6643763|NONE_0 (l_poss) parkinsonian_11\NN\0|off_14|and_25|lid_29
D007980_D010300 NONE levodopa_5\JJ\14604959|for_24 (r_compound) responsiveness_6\NN\5652926|NONE_0 (l_prep) for_7\IN\0|levodopa_24 (l_pobj) outcome_9\NN\7291312|NONE_0 (l_prep) of_10\IN\0|the_12 (l_pobj) signs_15\NNS\6643763|NONE_0 (l_conj) lid_17\NNP\5313679|parkinsonian_29|off_15|and_4 (l_conj) correlations_21\NNS\13841213|and_18 (l_prep) of_22\IN\0|the_27|different_23 (l_pobj) volume_25\NN\33615|NONE_0 (l_prep) with_26\IN\0|ventral_22|lesion_14 (l_pobj) dyskinesias_27\NNS\14084880|NONE_0 (l_conj) parkinsonian_29\NN\0|and_4|signs_19
D007980_D010300 NONE levodopa_5\JJ\14604959|for_24 (r_compound) responsiveness_6\NN\5652926|NONE_0 (r_pobj) of_4\IN\0|the_34|differential_30|predictive_17 (r_prep) value_3\NN\5856066|be_259|._336 (r_nsubj) indicate_34\VBP\952524|NONE_0 (l_ccomp) be_42\VB\14625458|value_259|._77 (l_acomp) responsible_43\JJ\0|that_66|substrates_18|may_7 (l_prep) for_44\IN\0|NONE_0 (l_pobj) generation_46\NN\7942152|signs_33 (l_prep) of_47\IN\0|the_15 (l_pobj) parkinsonian_48\NN\0|NONE_0
1079693
D002738_D012164 NONE chloroquine_2\NN\2721948|we_8|and_54|found_58|._126 (r_xcomp) used_1\VBD\0|NONE_0 (l_conj) found_11\VBD\13279262|we_66|chloroquine_58|and_4|._68 (l_dobj) case_14\NN\7283608|NONE_0 (l_prep) of_15\IN\0|one_9 (l_pobj) chorioretinopathy_16\JJ\0|NONE_0
D000305_D014605 NONE corticosteroids_27\NNS\14745635|NONE_0 (r_pobj) with_26\IN\0|intensive_28|topical_18 (r_prep) treatment_25\NN\654885|NONE_0 (r_pobj) of_22\IN\0|six_11 (r_prep) months_21\NNS\15113229|NONE_0 (r_pobj) to_17\IN\0|after_84|,_42|%_38|did_16|not_12|._90 (r_prep) respond_16\VB\2367363|NONE_0 (l_nsubj) %_9\NN\0|after_46|,_4|did_22|not_26|to_38|._128 (l_prep) of_10\IN\0|41_4 (l_pobj) cases_11\NNS\7283608|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) uveitis_13\NN\14336539|NONE_0
D000305_D002386 NONE corticosteroids_2\NNS\14745635|systemically_26 (r_dobj) administered_1\VBN\2436349|were_29|in_39 (r_csubjpass) used_4\VBN\0|;_23|number_39|was_81|._90 (r_ccomp) found_19\VBN\13279262|NONE_0 (l_nsubjpass) number_13\NN\5107765|used_39|;_16|was_42|._51 (l_prep) of_14\IN\0|a_21|significant_19 (l_pobj) cataracts_17\NNS\14252864|NONE_0
D006886_D012164 CID hydroxychloroquine_4\NN\2721538|or_3 (r_conj) chloroquine_2\NN\2721948|we_8|and_54|found_58|._126 (r_xcomp) used_1\VBD\0|NONE_0 (l_conj) found_11\VBD\13279262|we_66|chloroquine_58|and_4|._68 (l_dobj) case_14\NN\7283608|NONE_0 (l_prep) of_15\IN\0|one_9 (l_pobj) chorioretinopathy_16\JJ\0|NONE_0
11195262
D014635_D004830 NONE vpa_4\NNP\0|he_19|had_16|been_12|for_4|was_78|._94 (r_dobj) taking_3\VBG\37396|NONE_0 (l_prep) for_5\IN\0|he_23|had_20|been_16|vpa_4|was_74|._90 (l_pobj) treatment_6\NN\654885|NONE_0 (l_prep) of_7\IN\0|NONE_0 (l_pobj) convulsions_13\NNS\14081375|NONE_0
D014635_D007177 CID valproate_3\NN\0|NONE_0 (l_prep) to_4\IN\0|contribution_33|._66 (l_pobj) syndrome_6\NN\5870365|NONE_0 (l_prep) of_7\IN\0|the_13 (l_pobj) secretion_9\NN\13526110|NONE_0 (l_prep) of_10\IN\0|inappropriate_24 (l_pobj) hormone_12\NN\5404728|NONE_0
D014635_D007177 CID valproate_14\NN\0|the_58|of_49 (l_conj) developed_21\VBD\1753788|(_27|vpa_26|)_23|and_21 (l_dobj) syndrome_23\NN\5870365|who_31|subsequently_27 (l_prep) of_24\IN\0|the_13 (l_pobj) secretion_26\NN\13526110|NONE_0 (l_prep) of_27\IN\0|inappropriate_24 (l_pobj) hormone_29\NN\5404728|NONE_0
D014635_D007177 CID valproate_14\NN\0|the_58|of_49 (l_conj) developed_21\VBD\1753788|(_27|vpa_26|)_23|and_21 (l_dobj) syndrome_23\NN\5870365|who_31|subsequently_27 (l_prep) of_24\IN\0|the_13 (l_pobj) secretion_26\NN\13526110|NONE_0 (l_prep) of_27\IN\0|inappropriate_24 (l_pobj) hormone_29\NN\5404728|NONE_0 (l_appos) siadh_31\NNP\0|antidiuretic_22|(_1|)_5
D014635_D007177 CID vpa_16\NNP\0|(_1|)_3|and_5|developed_26 (r_npadvmod) valproate_14\NN\0|the_58|of_49 (l_conj) developed_21\VBD\1753788|(_27|vpa_26|)_23|and_21 (l_dobj) syndrome_23\NN\5870365|who_31|subsequently_27 (l_prep) of_24\IN\0|the_13 (l_pobj) secretion_26\NN\13526110|NONE_0 (l_prep) of_27\IN\0|inappropriate_24 (l_pobj) hormone_29\NN\5404728|NONE_0
D014635_D007177 CID vpa_16\NNP\0|(_1|)_3|and_5|developed_26 (r_npadvmod) valproate_14\NN\0|the_58|of_49 (l_conj) developed_21\VBD\1753788|(_27|vpa_26|)_23|and_21 (l_dobj) syndrome_23\NN\5870365|who_31|subsequently_27 (l_prep) of_24\IN\0|the_13 (l_pobj) secretion_26\NN\13526110|NONE_0 (l_prep) of_27\IN\0|inappropriate_24 (l_pobj) hormone_29\NN\5404728|NONE_0 (l_appos) siadh_31\NNP\0|antidiuretic_22|(_1|)_5
D014635_D007177 CID vpa_30\NNP\0|NONE_0 (r_pobj) of_29\IN\0|the_29|term_20 (r_prep) administration_28\NN\1133281|a_59|of_48|and_18 (r_conj) weakness_17\NN\14462666|NONE_0 (r_pobj) including_15\VBG\0|NONE_0 (r_prep) factors_14\NNS\7326557|NONE_0 (r_pobj) of_13\IN\0|a_14 (r_prep) combination_12\NN\7951464|NONE_0 (r_pobj) of_10\IN\0|the_11 (r_prep) result_9\NN\34213|episode_27|to_10 (r_attr) be_7\VB\14625458|we_37|._132 (l_nsubj) episode_3\NN\7283608|to_17|result_27 (l_prep) of_4\IN\0|this_13 (l_pobj) siadh_5\NNP\0|NONE_0
D014635_D002493 NONE vpa_30\NNP\0|NONE_0 (r_pobj) of_29\IN\0|the_29|term_20 (r_prep) administration_28\NN\1133281|a_59|of_48|and_18 (r_conj) weakness_17\NN\14462666|NONE_0 (l_prep) of_18\IN\0|a_11|and_30|administration_48 (l_pobj) system_22\NN\3575240|NONE_0
2334179
D010396_D011507 CID penicillamine_2\NN\3740161|syndrome_31|in_40 (r_nsubj) caused_3\VBD\1617192|;_92|none_94|insufficiency_115|._128 (l_prep) in_6\IN\13603305|penicillamine_40|syndrome_9 (l_pobj) patient_8\NN\9898892|NONE_0 (l_conj) proteinuria_12\NN\14299637|1_32|and_22
D010396_D012594 NONE penicillamine_2\NN\3740161|NONE_0 (l_prep) in_3\IN\13603305|d_16|-_15|._41 (l_pobj) treatment_5\NN\654885|NONE_0 (l_prep) of_6\IN\0|the_14 (l_pobj) scleroderma_8\NN\14187378|NONE_0
D010396_D012594 NONE penicillamine_17\NN\3740161|NONE_0 (r_pobj) with_14\IN\0|who_17|were_13 (r_prep) treated_13\VBN\2376958|11_66|with_54 (r_relcl) patients_4\NNS\9898892|NONE_0 (l_prep) with_5\IN\0|11_12|treated_54 (l_pobj) scleroderma_10\NN\14187378|NONE_0
D010396_D012594 NONE penicillamine_6\NN\3740161|that_7|may_14|effective_21 (r_nsubj) be_8\VB\14625458|data_38|._53 (l_acomp) effective_9\JJ\0|that_28|penicillamine_21|may_7 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) cases_12\NNS\7283608|NONE_0 (l_prep) of_13\IN\0|severe_13 (l_pobj) scleroderma_15\NN\14187378|NONE_0
D010396_D009404 CID penicillamine_2\NN\3740161|syndrome_31|in_40 (r_nsubj) caused_3\VBD\1617192|;_92|none_94|insufficiency_115|._128 (l_dobj) syndrome_5\NN\5870365|penicillamine_31|in_9
D010396_D051437 NONE penicillamine_2\NN\3740161|syndrome_31|in_40 (r_nsubj) caused_3\VBD\1617192|;_92|none_94|insufficiency_115|._128 (r_ccomp) developed_19\VBD\1753788|NONE_0 (l_dobj) insufficiency_21\NN\14462946|caused_115|;_23|none_21|._13
18657397
D010400_D004827 CID potassium_20\NN\14625458|into_10|recorded_87 (r_dobj) injecting_14\VBG\81072|NONE_0 (r_pcomp) by_13\IN\0|after_78|,_30|focus_18|was_12|._136 (r_prep) induced_12\VBN\1627355|NONE_0 (l_nsubjpass) focus_10\NN\5704266|after_60|,_12|was_6|by_18|._154 (l_amod) epileptic_9\JJ\10595647|NONE_0
D010406_D004827 NONE penicillin_5\NN\2716866|-_10 (r_npadvmod) induced_7\VBN\1627355|epileptiform_8|in_30 (r_amod) activity_9\NN\30358|NONE_0
D010406_D004827 NONE penicillin_0\NNP\2716866|NONE_0 (r_compound) model_1\NN\5888929|model_36|._63 (r_nsubj) is_2\VBZ\0|NONE_0 (l_attr) model_7\NN\5888929|model_36|._27 (l_prep) for_8\IN\0|a_33|used_24|experimental_19 (l_pobj) research_10\NN\633864|NONE_0 (l_compound) epilepsy_9\NN\14085708|NONE_0
D010406_D004827 NONE penicillin_13\NN\2716866|-_10 (r_npadvmod) induced_15\VBN\1627355|epileptiform_8 (r_amod) activity_17\NN\30358|NONE_0
D010406_D004827 NONE penicillin_7\NN\2716866|-_10 (r_npadvmod) induced_9\VBN\1627355|the_15|activity_21 (r_amod) periods_12\NNS\13575869|latent_63|and_49 (l_compound) activity_11\NN\30358|the_36|induced_21
9270571
D004298_D010300 NONE dopamine_4\NN\14807737|NONE_0 (r_pobj) of_3\IN\0|the_21|clinical_17|agonists_29 (r_prep) utility_2\NN\8186047|still_94|unclear_100|._107 (l_appos) agonists_10\NNS\0|the_50|clinical_46|of_29 (l_prep) in_11\IN\13603305|(_26|da_25|)_23|d1_21|receptor_18 (l_pobj) treatment_13\NN\654885|NONE_0 (l_prep) of_14\IN\0|the_14 (l_pobj) disease_17\NN\14061805|NONE_0
D004298_D010300 NONE dopamine_4\NN\14807737|NONE_0 (r_pobj) of_3\IN\0|the_21|clinical_17|agonists_29 (r_prep) utility_2\NN\8186047|still_94|unclear_100|._107 (l_appos) agonists_10\NNS\0|the_50|clinical_46|of_29 (l_prep) in_11\IN\13603305|(_26|da_25|)_23|d1_21|receptor_18 (l_pobj) treatment_13\NN\654885|NONE_0 (l_prep) of_14\IN\0|the_14 (l_pobj) disease_17\NN\14061805|NONE_0 (l_appos) pd_19\NNP\14625458|parkinson_21|(_1|)_2
D004298_D010300 NONE da_6\NNP\10484858|(_1|)_2|d1_4|receptor_7|in_25 (r_nmod) agonists_10\NNS\0|the_50|clinical_46|of_29 (l_prep) in_11\IN\13603305|(_26|da_25|)_23|d1_21|receptor_18 (l_pobj) treatment_13\NN\654885|NONE_0 (l_prep) of_14\IN\0|the_14 (l_pobj) disease_17\NN\14061805|NONE_0
D004298_D010300 NONE da_6\NNP\10484858|(_1|)_2|d1_4|receptor_7|in_25 (r_nmod) agonists_10\NNS\0|the_50|clinical_46|of_29 (l_prep) in_11\IN\13603305|(_26|da_25|)_23|d1_21|receptor_18 (l_pobj) treatment_13\NN\654885|NONE_0 (l_prep) of_14\IN\0|the_14 (l_pobj) disease_17\NN\14061805|NONE_0 (l_appos) pd_19\NNP\14625458|parkinson_21|(_1|)_2
D004298_D010300 NONE da_1\NNP\10484858|potent_7 (r_compound) d1_2\NN\0|receptor_3|with_19|a-86929_69 (r_compound) agents_4\NNS\7347|tools_135|._174 (r_nsubj) are_23\VBP\13600404|NONE_0 (l_attr) tools_26\NNS\3563967|agents_135|._39 (l_prep) in_27\IN\13603305|potential_28|therapeutic_18|and_6|merit_10 (l_pobj) pd_28\NNP\14625458|NONE_0
D007980_D004409 CID levodopa_20\RB\14604959|-_8 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) dyskinesias_23\NNS\14084880|we_183|therefore_180|study_128|evaluate_15|._323
D007980_D004409 CID levodopa_20\RB\14604959|-_8 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) dyskinesias_23\NNS\14084880|we_183|therefore_180|study_128|evaluate_15|._323 (r_dobj) conducted_2\VBD\2436349|NONE_0 (l_advcl) evaluate_25\VB\670261|we_198|therefore_195|study_143|dyskinesias_15|._308 (l_dobj) effects_30\NNS\13245626|to_41 (l_amod) locomotor_27\NN\0|the_4|on_33 (l_conj) dyskinetic_29\JJ\0|and_4
D007980_D004409 CID levodopa_14\NN\14604959|NONE_0 (r_pobj) as_13\IN\14622893|parkinsonism_13 (r_prep) alleviating_8\VBG\205885|NONE_0 (r_pcomp) in_7\IN\13603305|as_15 (r_prep) efficacious_6\JJ\0|administration_33|a-86929_15|,_78|but_80|was_84|._225 (r_acomp) was_4\VBD\0|NONE_0 (l_conj) was_19\VBD\0|administration_117|a-86929_99|efficacious_84|,_6|but_4|._141 (l_acomp) likely_21\JJ\0|NONE_0 (l_xcomp) reproduce_23\VB\1621555|less_15 (l_dobj) dyskinesias_28\NNS\14084880|to_34|than_29
D007980_D004409 CID levodopa_25\RB\14604959|-_8 (r_npadvmod) induced_27\VBN\1627355|the_13|in_20 (r_amod) dyskinesias_28\NNS\14084880|to_34|than_29
D007980_D004409 CID levodopa_40\NN\14604959|NONE_0 (r_pobj) of_39\IN\0|ly-171555_34 (r_prep) challenge_38\NN\13927383|NONE_0 (r_pobj) with_33\IN\0|NONE_0 (r_prep) than_32\IN\0|to_63|dyskinesias_29 (r_prep) reproduce_23\VB\1621555|less_15 (l_dobj) dyskinesias_28\NNS\14084880|to_34|than_29
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD\0|NONE_0 (r_pobj) in_10\IN\13603305|the_38|present_34|acute_26|response_15 (r_prep) study_9\NN\635850|we_55|therefore_52|dyskinesias_128|evaluate_143|._451 (r_dobj) conducted_2\VBD\2436349|NONE_0 (l_dobj) dyskinesias_23\NNS\14084880|we_183|therefore_180|study_128|evaluate_15|._323
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD\0|NONE_0 (r_pobj) in_10\IN\13603305|the_38|present_34|acute_26|response_15 (r_prep) study_9\NN\635850|we_55|therefore_52|dyskinesias_128|evaluate_143|._451 (r_dobj) conducted_2\VBD\2436349|NONE_0 (l_advcl) evaluate_25\VB\670261|we_198|therefore_195|study_143|dyskinesias_15|._308 (l_dobj) effects_30\NNS\13245626|to_41 (l_amod) locomotor_27\NN\0|the_4|on_33 (l_conj) dyskinetic_29\JJ\0|and_4
D015632_D004409 NONE mptp)-exposed_14\VBN\0|(_1|cynomolgus_14|primed_33 (r_amod) monkeys_16\NNS\2469914|four_76 (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD\0|NONE_0 (r_pobj) in_10\IN\13603305|the_38|present_34|acute_26|response_15 (r_prep) study_9\NN\635850|we_55|therefore_52|dyskinesias_128|evaluate_143|._451 (r_dobj) conducted_2\VBD\2436349|NONE_0 (l_dobj) dyskinesias_23\NNS\14084880|we_183|therefore_180|study_128|evaluate_15|._323
D015632_D004409 NONE mptp)-exposed_14\VBN\0|(_1|cynomolgus_14|primed_33 (r_amod) monkeys_16\NNS\2469914|four_76 (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD\0|NONE_0 (r_pobj) in_10\IN\13603305|the_38|present_34|acute_26|response_15 (r_prep) study_9\NN\635850|we_55|therefore_52|dyskinesias_128|evaluate_143|._451 (r_dobj) conducted_2\VBD\2436349|NONE_0 (l_advcl) evaluate_25\VB\670261|we_198|therefore_195|study_143|dyskinesias_15|._308 (l_dobj) effects_30\NNS\13245626|to_41 (l_amod) locomotor_27\NN\0|the_4|on_33 (l_conj) dyskinetic_29\JJ\0|and_4
D015632_D004409 NONE mptp_9\NNP\0|-_4 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) parkinsonism_12\NN\14085708|as_13 (r_dobj) alleviating_8\VBG\205885|NONE_0 (r_pcomp) in_7\IN\13603305|as_15 (r_prep) efficacious_6\JJ\0|administration_33|a-86929_15|,_78|but_80|was_84|._225 (r_acomp) was_4\VBD\0|NONE_0 (l_conj) was_19\VBD\0|administration_117|a-86929_99|efficacious_84|,_6|but_4|._141 (l_acomp) likely_21\JJ\0|NONE_0 (l_xcomp) reproduce_23\VB\1621555|less_15 (l_dobj) dyskinesias_28\NNS\14084880|to_34|than_29
C095427_D010300 NONE a-86929_13\NNS\0|d1_69|receptor_66|with_50 (r_punct) agents_4\NNS\7347|tools_135|._174 (r_nsubj) are_23\VBP\13600404|NONE_0 (l_attr) tools_26\NNS\3563967|agents_135|._39 (l_prep) in_27\IN\13603305|potential_28|therapeutic_18|and_6|merit_10 (l_pobj) pd_28\NNP\14625458|NONE_0
C095427_D020734 NONE a-86929_0\NNS\0|NONE_0 (l_dep) study_4\NN\635850|:_11|._45 (l_prep) in_5\IN\13603305|an_15|acute_12 (l_pobj) monkeys_10\NNS\2469914|NONE_0 (l_amod) parkinsonian_6\JJ\0|primed_22
C095427_D020734 NONE a-86929_3\NNS\0|administration_18|efficacious_15|,_93|but_95|was_99|._240 (r_punct) was_4\VBD\0|NONE_0 (l_acomp) efficacious_6\JJ\0|administration_33|a-86929_15|,_78|but_80|was_84|._225 (l_prep) in_7\IN\13603305|as_15 (l_pcomp) alleviating_8\VBG\205885|NONE_0 (l_dobj) parkinsonism_12\NN\14085708|as_13
C095427_D004409 NONE a-86929_44\NNS\0|)_114 (r_punct) ,_57\,\0|four_154|(_143|from_142|)_120|of_118|agonist_43 (r_punct) doses_35\NNS\3740161|NONE_0 (r_pobj) with_33\IN\0|NONE_0 (r_prep) challenge_32\NN\13927383|NONE_0 (r_pobj) on_31\IN\0|the_37|locomotor_33 (r_prep) effects_30\NNS\13245626|to_41 (r_dobj) evaluate_25\VB\670261|we_198|therefore_195|study_143|dyskinesias_15|._308 (r_advcl) conducted_2\VBD\2436349|NONE_0 (l_dobj) dyskinesias_23\NNS\14084880|we_183|therefore_180|study_128|evaluate_15|._323
C095427_D004409 NONE a-86929_44\NNS\0|)_114 (r_punct) ,_57\,\0|four_154|(_143|from_142|)_120|of_118|agonist_43 (r_punct) doses_35\NNS\3740161|NONE_0 (r_pobj) with_33\IN\0|NONE_0 (r_prep) challenge_32\NN\13927383|NONE_0 (r_pobj) on_31\IN\0|the_37|locomotor_33 (r_prep) effects_30\NNS\13245626|to_41 (l_amod) locomotor_27\NN\0|the_4|on_33 (l_conj) dyskinetic_29\JJ\0|and_4
C095427_D004409 NONE 10-diol_55\JJ\0|NONE_0 (r_punct) )_56\-RRB-\0|a-86929_114 (r_punct) ,_57\,\0|four_154|(_143|from_142|)_120|of_118|agonist_43 (r_punct) doses_35\NNS\3740161|NONE_0 (r_pobj) with_33\IN\0|NONE_0 (r_prep) challenge_32\NN\13927383|NONE_0 (r_pobj) on_31\IN\0|the_37|locomotor_33 (r_prep) effects_30\NNS\13245626|to_41 (r_dobj) evaluate_25\VB\670261|we_198|therefore_195|study_143|dyskinesias_15|._308 (r_advcl) conducted_2\VBD\2436349|NONE_0 (l_dobj) dyskinesias_23\NNS\14084880|we_183|therefore_180|study_128|evaluate_15|._323
C095427_D004409 NONE 10-diol_55\JJ\0|NONE_0 (r_punct) )_56\-RRB-\0|a-86929_114 (r_punct) ,_57\,\0|four_154|(_143|from_142|)_120|of_118|agonist_43 (r_punct) doses_35\NNS\3740161|NONE_0 (r_pobj) with_33\IN\0|NONE_0 (r_prep) challenge_32\NN\13927383|NONE_0 (r_pobj) on_31\IN\0|the_37|locomotor_33 (r_prep) effects_30\NNS\13245626|to_41 (l_amod) locomotor_27\NN\0|the_4|on_33 (l_conj) dyskinetic_29\JJ\0|and_4
C095427_D004409 NONE a-86929_3\NNS\0|administration_18|efficacious_15|,_93|but_95|was_99|._240 (r_punct) was_4\VBD\0|NONE_0 (l_conj) was_19\VBD\0|administration_117|a-86929_99|efficacious_84|,_6|but_4|._141 (l_acomp) likely_21\JJ\0|NONE_0 (l_xcomp) reproduce_23\VB\1621555|less_15 (l_dobj) dyskinesias_28\NNS\14084880|to_34|than_29
D007980_D020734 NONE levodopa_7\NN\14604959|-_8 (r_npadvmod) primed_9\VBN\406243|parkinsonian_22 (r_amod) monkeys_10\NNS\2469914|NONE_0 (l_amod) parkinsonian_6\JJ\0|primed_22
D007980_D020734 NONE levodopa_14\NN\14604959|NONE_0 (r_pobj) as_13\IN\14622893|parkinsonism_13 (r_prep) alleviating_8\VBG\205885|NONE_0 (l_dobj) parkinsonism_12\NN\14085708|as_13
D007980_D020734 NONE levodopa_25\RB\14604959|-_8 (r_npadvmod) induced_27\VBN\1627355|the_13|in_20 (r_amod) dyskinesias_28\NNS\14084880|to_34|than_29 (r_dobj) reproduce_23\VB\1621555|less_15 (r_xcomp) likely_21\JJ\0|NONE_0 (r_acomp) was_19\VBD\0|administration_117|a-86929_99|efficacious_84|,_6|but_4|._141 (r_conj) was_4\VBD\0|NONE_0 (l_acomp) efficacious_6\JJ\0|administration_33|a-86929_15|,_78|but_80|was_84|._225 (l_prep) in_7\IN\13603305|as_15 (l_pcomp) alleviating_8\VBG\205885|NONE_0 (l_dobj) parkinsonism_12\NN\14085708|as_13
D007980_D020734 NONE levodopa_40\NN\14604959|NONE_0 (r_pobj) of_39\IN\0|ly-171555_34 (r_prep) challenge_38\NN\13927383|NONE_0 (r_pobj) with_33\IN\0|NONE_0 (r_prep) than_32\IN\0|to_63|dyskinesias_29 (r_prep) reproduce_23\VB\1621555|less_15 (r_xcomp) likely_21\JJ\0|NONE_0 (r_acomp) was_19\VBD\0|administration_117|a-86929_99|efficacious_84|,_6|but_4|._141 (r_conj) was_4\VBD\0|NONE_0 (l_acomp) efficacious_6\JJ\0|administration_33|a-86929_15|,_78|but_80|was_84|._225 (l_prep) in_7\IN\13603305|as_15 (l_pcomp) alleviating_8\VBG\205885|NONE_0 (l_dobj) parkinsonism_12\NN\14085708|as_13
D015632_D020734 CID mptp_9\NNP\0|-_4 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) parkinsonism_12\NN\14085708|as_13
D004298_D004409 NONE da_62\NNP\10484858|a_21|selective_19|d1-like_3|receptor_11|with_28 (r_compound) agonist_65\NN\0|four_197|(_186|from_185|)_163|of_161|,_43 (r_appos) doses_35\NNS\3740161|NONE_0 (r_pobj) with_33\IN\0|NONE_0 (r_prep) challenge_32\NN\13927383|NONE_0 (r_pobj) on_31\IN\0|the_37|locomotor_33 (r_prep) effects_30\NNS\13245626|to_41 (r_dobj) evaluate_25\VB\670261|we_198|therefore_195|study_143|dyskinesias_15|._308 (r_advcl) conducted_2\VBD\2436349|NONE_0 (l_dobj) dyskinesias_23\NNS\14084880|we_183|therefore_180|study_128|evaluate_15|._323
D004298_D004409 NONE da_62\NNP\10484858|a_21|selective_19|d1-like_3|receptor_11|with_28 (r_compound) agonist_65\NN\0|four_197|(_186|from_185|)_163|of_161|,_43 (r_appos) doses_35\NNS\3740161|NONE_0 (r_pobj) with_33\IN\0|NONE_0 (r_prep) challenge_32\NN\13927383|NONE_0 (r_pobj) on_31\IN\0|the_37|locomotor_33 (r_prep) effects_30\NNS\13245626|to_41 (l_amod) locomotor_27\NN\0|the_4|on_33 (l_conj) dyskinetic_29\JJ\0|and_4
C416545_D020734 NONE ly-171555_16\NNP\0|and_4 (r_conj) levodopa_14\NN\14604959|NONE_0 (r_pobj) as_13\IN\14622893|parkinsonism_13 (r_prep) alleviating_8\VBG\205885|NONE_0 (l_dobj) parkinsonism_12\NN\14085708|as_13
C416545_D020734 NONE ly-171555_35\NNP\0|of_34 (r_amod) challenge_38\NN\13927383|NONE_0 (r_pobj) with_33\IN\0|NONE_0 (r_prep) than_32\IN\0|to_63|dyskinesias_29 (r_prep) reproduce_23\VB\1621555|less_15 (r_xcomp) likely_21\JJ\0|NONE_0 (r_acomp) was_19\VBD\0|administration_117|a-86929_99|efficacious_84|,_6|but_4|._141 (r_conj) was_4\VBD\0|NONE_0 (l_acomp) efficacious_6\JJ\0|administration_33|a-86929_15|,_78|but_80|was_84|._225 (l_prep) in_7\IN\13603305|as_15 (l_pcomp) alleviating_8\VBG\205885|NONE_0 (l_dobj) parkinsonism_12\NN\14085708|as_13
C416545_D004409 NONE ly-171555_16\NNP\0|and_4 (r_conj) levodopa_14\NN\14604959|NONE_0 (r_pobj) as_13\IN\14622893|parkinsonism_13 (r_prep) alleviating_8\VBG\205885|NONE_0 (r_pcomp) in_7\IN\13603305|as_15 (r_prep) efficacious_6\JJ\0|administration_33|a-86929_15|,_78|but_80|was_84|._225 (r_acomp) was_4\VBD\0|NONE_0 (l_conj) was_19\VBD\0|administration_117|a-86929_99|efficacious_84|,_6|but_4|._141 (l_acomp) likely_21\JJ\0|NONE_0 (l_xcomp) reproduce_23\VB\1621555|less_15 (l_dobj) dyskinesias_28\NNS\14084880|to_34|than_29
C416545_D004409 NONE ly-171555_35\NNP\0|of_34 (r_amod) challenge_38\NN\13927383|NONE_0 (r_pobj) with_33\IN\0|NONE_0 (r_prep) than_32\IN\0|to_63|dyskinesias_29 (r_prep) reproduce_23\VB\1621555|less_15 (l_dobj) dyskinesias_28\NNS\14084880|to_34|than_29
8305357
D003630_D000163 NONE daunorubicin_18\NN\0|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) safety_15\NN\13920835|the_17|and_4|in_45 (r_conj) efficacy_13\NN\5199286|to_14 (l_prep) in_22\IN\13603305|the_62|and_49|safety_45 (l_pobj) treatment_24\NN\654885|NONE_0 (l_prep) of_25\IN\0|the_14 (l_pobj) aids_26\NNP\13974317|NONE_0
D003630_D012514 NONE daunorubicin_1\NN\0|NONE_0 (l_dobj) sarcoma_6\NN\14239918|liposomal_44|in_21|._25
D003630_D012514 NONE daunorubicin_18\NN\0|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) safety_15\NN\13920835|the_17|and_4|in_45 (r_conj) efficacy_13\NN\5199286|to_14 (r_dobj) assess_11\VB\5220461|a_44|randomized_38|ii_21|clinical_18 (r_relcl) trial_9\NN\786195|we_45|related_103|._127 (r_dobj) report_1\VBP\6470073|NONE_0 (l_ccomp) related_27\VBD\628491|we_148|trial_103|._24 (l_dobj) sarcoma_30\NN\14239918|NONE_0
D003630_D012514 NONE daunorubicin_7\NN\0|in_40|,_12|agent_49|._91 (r_nsubj) was_8\VBD\0|NONE_0 (l_attr) agent_14\NN\7347|in_89|,_61|daunorubicin_49|._42 (l_prep) in_15\IN\13603305|an_38|effective_35 (l_pobj) treatment_17\NN\654885|NONE_0 (l_prep) of_18\IN\0|the_14 (l_pobj) sarcoma_21\NN\14239918|NONE_0
15985056
D003907_D006606 NONE dexamethasone_2\NN\2721538|(_1|)_36|,_37|benzodiazepines_39 (r_appos) corticosteroids_0\NNS\14745635|have_108|agents_131|._233 (r_nsubj) been_15\VBN\0|NONE_0 (l_attr) agents_18\NNS\7347|corticosteroids_131|have_23|._102 (l_acl) mentioned_19\VBD\730052|the_20|specific_16 (l_prep) as_25\IN\14622893|frequently_29|in_18 (l_pcomp) associated_27\VBN\628491|NONE_0 (l_prep) with_28\IN\0|being_17 (l_pobj) development_30\NN\248977|NONE_0 (l_prep) of_31\IN\0|the_16 (l_pobj) hiccups_32\NNS\863513|NONE_0
D017963_D006606 CID azithromycin_1\RB\2716205|-_12 (r_advmod) associated_3\VBN\628491|possible_22|._18 (r_amod) hiccups_4\NNS\863513|NONE_0
D017963_D006606 CID azithromycin_9\CD\2716205|NONE_0 (r_amod) therapy_10\NN\657604|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) associated_7\VBN\628491|persistent_19 (r_acl) hiccups_6\NNS\863513|NONE_0
D017963_D006606 CID azithromycin_11\RB\2716205|for_13 (r_advmod) beginning_10\VBG\7283608|NONE_0 (r_pcomp) after_9\IN\0|man_38|with_24|._61 (r_prep) presented_5\VBN\2137132|NONE_0 (l_prep) with_6\IN\0|man_14|after_24|._85 (l_pobj) hiccups_8\NNS\863513|NONE_0
D017963_D006606 CID azithromycin_2\NNP\2716205|NONE_0 (r_pobj) of_1\IN\0|and_16|therapy_20 (r_prep) discontinuation_0\NN\209943|finally_58|hiccups_75|._82 (r_nsubj) resolved_8\VBD\352826|NONE_0 (l_dobj) hiccups_9\NNS\863513|discontinuation_75|finally_17|._7
D017963_D006606 CID azithromycin_9\WP\2716205|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) mediated_7\VBN\761713|a_18|vagal_16 (r_acl) mechanism_6\NN\13446390|that_13|could_35|pathogenesis_48 (r_nsubj) be_11\VB\14625458|hypothesis_68|._45 (l_attr) pathogenesis_13\NN\13533470|that_61|mechanism_48|could_13 (l_prep) of_14\IN\0|the_17 (l_pobj) hiccups_15\NNS\863513|NONE_0
D008775_D006606 NONE methylprednisolone_4\NN\0|and_4 (r_conj) dexamethasone_2\NN\2721538|(_1|)_36|,_37|benzodiazepines_39 (r_appos) corticosteroids_0\NNS\14745635|have_108|agents_131|._233 (r_nsubj) been_15\VBN\0|NONE_0 (l_attr) agents_18\NNS\7347|corticosteroids_131|have_23|._102 (l_acl) mentioned_19\VBD\730052|the_20|specific_16 (l_prep) as_25\IN\14622893|frequently_29|in_18 (l_pcomp) associated_27\VBN\628491|NONE_0 (l_prep) with_28\IN\0|being_17 (l_pobj) development_30\NN\248977|NONE_0 (l_prep) of_31\IN\0|the_16 (l_pobj) hiccups_32\NNS\863513|NONE_0
D001569_D006606 NONE benzodiazepines_7\NNS\3771443|(_40|dexamethasone_39|)_3|,_2 (r_appos) corticosteroids_0\NNS\14745635|have_108|agents_131|._233 (r_nsubj) been_15\VBN\0|NONE_0 (l_attr) agents_18\NNS\7347|corticosteroids_131|have_23|._102 (l_acl) mentioned_19\VBD\730052|the_20|specific_16 (l_prep) as_25\IN\14622893|frequently_29|in_18 (l_pcomp) associated_27\VBN\628491|NONE_0 (l_prep) with_28\IN\0|being_17 (l_pobj) development_30\NN\248977|NONE_0 (l_prep) of_31\IN\0|the_16 (l_pobj) hiccups_32\NNS\863513|NONE_0
D001418_D006606 CID baclofen_6\NN\0|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) therapy_4\NN\657604|of_20|and_4 (r_conj) discontinuation_0\NN\209943|finally_58|hiccups_75|._82 (r_nsubj) resolved_8\VBD\352826|NONE_0 (l_dobj) hiccups_9\NNS\863513|discontinuation_75|finally_17|._7
D018942_D006606 NONE macrolide_12\NN\0|NONE_0 (r_amod) antimicrobials_13\NNS\14778436|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) related_10\VBN\628491|cases_49|have_19|been_14|._35 (r_oprd) reported_9\VBN\831651|NONE_0 (l_nsubjpass) cases_1\NNS\7283608|have_30|been_35|related_49|._84 (l_prep) of_2\IN\0|few_10 (l_pobj) hiccups_6\NNS\863513|NONE_0
D018942_D006606 NONE macrolides_36\NNS\0|NONE_0 (r_pobj) with_34\IN\0|this_14|and_22|absence_30 (r_prep) reaction_33\NN\13446390|NONE_0 (l_conj) absence_39\NN\14449405|this_44|with_30|and_8 (l_prep) of_40\IN\0|the_12 (l_pobj) explanation_43\NN\6722453|NONE_0 (l_prep) for_44\IN\0|any_28|alternative_24 (l_pobj) hiccups_45\NNS\863513|NONE_0
D018942_D006606 NONE macrolide_2\NN\0|NONE_0 (r_amod) antimicrobials_3\NNS\14778436|however_19|,_12|have_15|been_20|associated_40|explain_90|._133 (r_nsubjpass) reported_6\VBN\831651|NONE_0 (l_xcomp) associated_9\VBN\628491|however_59|,_52|antimicrobials_40|have_25|been_20|explain_50|._93 (l_prep) with_10\IN\0|to_17|be_14 (l_pobj) mechanism_14\NN\13446390|NONE_0 (l_nmod) hiccups_11\NNS\863513|vagal_12
D017963_D010612 NONE azithromycin_11\RB\2716205|for_13 (r_advmod) beginning_10\VBG\7283608|NONE_0 (l_prep) for_12\IN\0|azithromycin_13 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|the_14 (l_pobj) pharyngitis_16\NN\14171682|NONE_0
D008874_D006606 NONE midazolam_9\NN\2830852|(_1|anaesthesia_23 (r_appos) benzodiazepines_7\NNS\3771443|(_40|dexamethasone_39|)_3|,_2 (r_appos) corticosteroids_0\NNS\14745635|have_108|agents_131|._233 (r_nsubj) been_15\VBN\0|NONE_0 (l_attr) agents_18\NNS\7347|corticosteroids_131|have_23|._102 (l_acl) mentioned_19\VBD\730052|the_20|specific_16 (l_prep) as_25\IN\14622893|frequently_29|in_18 (l_pcomp) associated_27\VBN\628491|NONE_0 (l_prep) with_28\IN\0|being_17 (l_pobj) development_30\NN\248977|NONE_0 (l_prep) of_31\IN\0|the_16 (l_pobj) hiccups_32\NNS\863513|NONE_0
6794356
D008094_D001282 NONE lithium_18\NN\14625458|a_13|high_11 (r_compound) level_19\NN\4916342|heart_40|,_27|and_25 (r_conj) failure_12\NN\66216|atrial_33|,_19 (r_conj) flutter_8\JJ\331950|massive_40|tricuspid_32|,_9
D008094_D001282 NONE lithium_26\NN\14625458|NONE_0 (r_compound) compounds_27\NNS\5869584|NONE_0 (r_pobj) to_25\IN\0|in_21 (r_prep) exposed_24\VBN\2110927|NONE_0 (r_acl) infants_23\NNS\9918248|NONE_0 (r_pobj) among_22\IN\0|cardiac_16 (r_prep) disease_21\NN\14061805|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) patient_18\NN\9898892|11th_15|._107 (r_dobj) described_17\VBN\1001294|this_105|patient_87|,_15|and_13 (r_conj) is_1\VBZ\0|NONE_0 (l_attr) patient_4\NN\9898892|this_18|,_72|and_74|described_87 (l_relcl) manifest_7\VB\6479665|the_31|first_27 (l_dobj) regurgitation_9\NN\7406350|to_32|initially_29 (l_conj) flutter_12\NN\331950|tricuspid_35|and_11
D008094_D014262 NONE lithium_18\NN\14625458|a_13|high_11 (r_compound) level_19\NN\4916342|heart_40|,_27|and_25 (r_conj) failure_12\NN\66216|atrial_33|,_19 (r_conj) flutter_8\JJ\331950|massive_40|tricuspid_32|,_9 (r_conj) regurgitation_5\NN\7406350|NONE_0
D008094_D014262 NONE lithium_26\NN\14625458|NONE_0 (r_compound) compounds_27\NNS\5869584|NONE_0 (r_pobj) to_25\IN\0|in_21 (r_prep) exposed_24\VBN\2110927|NONE_0 (r_acl) infants_23\NNS\9918248|NONE_0 (r_pobj) among_22\IN\0|cardiac_16 (r_prep) disease_21\NN\14061805|NONE_0 (r_pobj) with_19\IN\0|NONE_0 (r_prep) patient_18\NN\9898892|11th_15|._107 (r_dobj) described_17\VBN\1001294|this_105|patient_87|,_15|and_13 (r_conj) is_1\VBZ\0|NONE_0 (l_attr) patient_4\NN\9898892|this_18|,_72|and_74|described_87 (l_relcl) manifest_7\VB\6479665|the_31|first_27 (l_dobj) regurgitation_9\NN\7406350|to_32|initially_29
D008094_D006331 NONE lithium_26\NN\14625458|NONE_0 (r_compound) compounds_27\NNS\5869584|NONE_0 (r_pobj) to_25\IN\0|in_21 (r_prep) exposed_24\VBN\2110927|NONE_0 (r_acl) infants_23\NNS\9918248|NONE_0 (r_pobj) among_22\IN\0|cardiac_16 (r_prep) disease_21\NN\14061805|NONE_0
D016651_D014262 NONE carbonate_5\NN\15010703|NONE_0 (r_compound) toxicity_6\NN\13576101|tricuspid_52|valve_42|and_22|in_9|._28 (r_conj) regurgitation_2\NN\7406350|NONE_0
D016651_D006331 NONE carbonate_1\NN\15010703|may_10|factor_19|in_26|taken_87|._115 (r_nsubj) be_3\VB\14625458|NONE_0 (l_prep) in_6\IN\13603305|carbonate_26|may_16|factor_7|taken_61|._89 (l_pobj) incidence_9\NN\13821570|NONE_0 (l_prep) of_10\IN\0|the_25|increasing_21 (l_pobj) disease_13\NN\14061805|NONE_0
D016651_D064420 NONE carbonate_5\NN\15010703|NONE_0 (r_compound) toxicity_6\NN\13576101|tricuspid_52|valve_42|and_22|in_9|._28
D008094_D006333 NONE lithium_18\NN\14625458|a_13|high_11 (r_compound) level_19\NN\4916342|heart_40|,_27|and_25 (r_conj) failure_12\NN\66216|atrial_33|,_19
11999899
D016291_D014202 NONE mk-801_16\NNP\0|reserpine_97|also_87|tremor_73|._2 (r_punct) produced_2\VBD\1617192|NONE_0 (l_dobj) tremor_3\NN\345926|reserpine_24|also_14|._71|mk-801_73
D016291_D014202 NONE mk-801_2\NNP\0|however_9|,_2|injection_7|increase_40|._84 (r_punct) produced_4\VBD\1617192|NONE_0 (l_dobj) increase_7\NN\13576355|however_49|,_42|mk-801_40|injection_33|._44 (l_prep) of_8\IN\0|a_23|significant_21|in_10 (l_pobj) tremor_9\NN\345926|NONE_0
D016291_D014202 NONE mk-801_17\NNP\0|on_97|,_80|reserpine_78|increases_60|compared_26|._2 (r_punct) induced_6\VBN\1627355|NONE_0 (l_dobj) increases_7\NNS\13576355|on_37|,_20|reserpine_18|compared_34|._58|mk-801_60 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) tremor_9\NN\345926|NONE_0
D016291_D014202 NONE mk-801_33\NNP\0|mg/kg_12|)_17 (r_punct) injection_38\NN\320852|90_10 (r_nsubj) min_40\NN\15154774|whereas_40|before_4|test_15|effects_33 (r_nsubj) reversed_44\VBD\109660|(_220|mg/kg_217|h_207|before_205|test_182|increases_168|,_108|as_98|increases_95|,_62|._33 (r_advcl) produced_13\VBD\1617192|with_58 (l_conj) increases_26\NNS\13576355|(_125|mg/kg_122|h_112|before_110|test_87|increases_73|,_13|as_3|,_33|reversed_95|._128 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) tremor_28\NN\345926|NONE_0
D012110_D004409 CID reserpine_0\NN\2721160|increases_76|._206 (r_nsubj) produced_15\VBD\1617192|NONE_0 (l_dobj) increases_16\NNS\13576355|reserpine_76|._130 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) dyskinesia_19\NN\14084880|NONE_0 (l_relcl) are_30\VBP\13600404|orofacial_75|,_55|protrusion_46|,_8 (l_attr) signs_31\NNS\6643763|which_10 (l_amod) indicative_32\JJ\13801424|NONE_0 (l_prep) of_33\IN\0|NONE_0 (l_pobj) dyskinesia_35\NN\14084880|NONE_0
D012110_D004409 CID reserpine_4\NN\2721160|that_5|movements_42 (r_nsubj) produces_5\VBZ\7555863|results_28|._162 (l_dobj) movements_9\NNS\191142|that_47|reserpine_42
D012110_D004409 CID reserpine_4\NN\2721160|that_5|movements_42 (r_nsubj) produces_5\VBZ\7555863|results_28|._162 (l_dobj) movements_9\NNS\191142|that_47|reserpine_42 (l_relcl) related_13\VBN\628491|different_44|,_12 (l_conj) considered_22\VBN\689344|which_59|are_53|to_41|and_11 (l_prep) as_23\IN\14622893|can_18|be_14 (l_pobj) signs_30\NNS\6643763|NONE_0 (l_compound) dsykinesia_29\NN\0|parkinsonian_30
D016202_D002375 NONE nmda_5\NNP\0|NONE_0 (r_pobj) by_4\IN\0|NONE_0 (r_agent) produced_3\VBN\1617192|the_27|glutamatergic_23 (r_acl) blockage_2\NN\14034177|can_26|signs_44|according_127|._158 (r_nsubj) restore_7\VB\1631072|NONE_0 (l_dobj) signs_9\NNS\6643763|blockage_44|can_18|according_83|._114 (l_prep) as_12\IN\14622893|these_18|,_7 (l_pobj) movements_15\NNS\191142|such_24 (l_conj) protrusions_18\NNS\13919685|vacuous_34|chewing_26|,_9 (l_conj) catalepsy_20\NN\14023236|tongue_20|,_2
D016291_D002375 NONE mk-801_16\NNP\0|reserpine_97|also_87|tremor_73|._2 (r_punct) produced_2\VBD\1617192|NONE_0 (l_dobj) tremor_3\NN\345926|reserpine_24|also_14|._71|mk-801_73 (l_conj) catalepsy_5\NN\14023236|and_4|,_9|are_17
D016291_D002375 NONE mk-801_17\NNP\0|on_97|,_80|reserpine_78|increases_60|compared_26|._2 (r_punct) induced_6\VBN\1627355|NONE_0 (l_dobj) increases_7\NNS\13576355|on_37|,_20|reserpine_18|compared_34|._58|mk-801_60 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) tremor_9\NN\345926|NONE_0 (l_conj) catalepsy_11\NN\14023236|and_4
D016291_D002375 NONE mk-801_33\NNP\0|mg/kg_12|)_17 (r_punct) injection_38\NN\320852|90_10 (r_nsubj) min_40\NN\15154774|whereas_40|before_4|test_15|effects_33 (r_nsubj) reversed_44\VBD\109660|(_220|mg/kg_217|h_207|before_205|test_182|increases_168|,_108|as_98|increases_95|,_62|._33 (r_advcl) produced_13\VBD\1617192|with_58 (l_conj) increases_26\NNS\13576355|(_125|mg/kg_122|h_112|before_110|test_87|increases_73|,_13|as_3|,_33|reversed_95|._128 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) tremor_28\NN\345926|NONE_0 (l_conj) catalepsy_30\NN\14023236|and_4
D012110_D014202 CID reserpine_0\NN\2721160|also_10|tremor_24|._95|mk-801_97 (r_nsubj) produced_2\VBD\1617192|NONE_0 (l_dobj) tremor_3\NN\345926|reserpine_24|also_14|._71|mk-801_73
D012110_D014202 CID reserpine_11\NN\2721160|-_9 (r_npadvmod) treated_13\VBN\2376958|NONE_0 (r_amod) mice_14\NNS\2329401|NONE_0 (r_pobj) in_10\IN\13603305|a_33|significant_31|of_10 (r_prep) increase_7\NN\13576355|however_49|,_42|mk-801_40|injection_33|._44 (l_prep) of_8\IN\0|a_23|significant_21|in_10 (l_pobj) tremor_9\NN\345926|NONE_0
D012110_D014202 CID reserpine_5\NN\2721160|on_19|,_2|increases_18|compared_52|._76|mk-801_78 (r_nsubj) induced_6\VBN\1627355|NONE_0 (l_dobj) increases_7\NNS\13576355|on_37|,_20|reserpine_18|compared_34|._58|mk-801_60 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) tremor_9\NN\345926|NONE_0
D012110_D014202 CID reserpine_12\NN\2721160|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|the_25|and_11|tremor_7 (r_acl) catalepsy_7\NN\14023236|(_42|administration_30|._41 (l_conj) tremor_9\NN\345926|the_18|and_4|induced_7
D012110_D014202 CID reserpine_2\NN\2721160|NONE_0 (r_pobj) with_1\IN\0|produced_58 (r_prep) pretreatment_0\NN\0|NONE_0 (l_acl) produced_13\VBD\1617192|with_58 (l_conj) increases_26\NNS\13576355|(_125|mg/kg_122|h_112|before_110|test_87|increases_73|,_13|as_3|,_33|reversed_95|._128 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) tremor_28\NN\345926|NONE_0
D012110_D014202 CID reserpine_48\NN\2721160|NONE_0 (r_pobj) of_47\IN\0|the_12 (r_prep) effects_46\NNS\13245626|whereas_73|min_33|before_29|test_18 (r_dobj) reversed_44\VBD\109660|(_220|mg/kg_217|h_207|before_205|test_182|increases_168|,_108|as_98|increases_95|,_62|._33 (r_advcl) produced_13\VBD\1617192|with_58 (l_conj) increases_26\NNS\13576355|(_125|mg/kg_122|h_112|before_110|test_87|increases_73|,_13|as_3|,_33|reversed_95|._128 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) tremor_28\NN\345926|NONE_0
D012110_D009069 NONE reserpine_0\NN\2721160|increases_76|._206 (r_nsubj) produced_15\VBD\1617192|NONE_0 (l_dobj) increases_16\NNS\13576355|reserpine_76|._130 (l_prep) in_17\IN\13603305|NONE_0 (l_pobj) dyskinesia_19\NN\14084880|NONE_0
D012110_D009069 NONE reserpine_0\NN\2721160|before_41|and_57|followed_61 (r_nsubj) administered_6\VBN\2436349|,_106|did_108|not_112|dyskinesia_129|in_140|._147 (r_ccomp) produce_29\VB\7555863|NONE_0 (l_dobj) dyskinesia_31\NN\14084880|administered_129|,_23|did_21|not_17|in_11|._18
D001058_D009069 NONE apomophine_15\JJ\0|min_35 (r_amod) injection_16\NN\320852|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) followed_13\VBN\1835496|reserpine_61|before_20|and_4 (r_conj) administered_6\VBN\2436349|,_106|did_108|not_112|dyskinesia_129|in_140|._147 (r_ccomp) produce_29\VB\7555863|NONE_0 (l_dobj) dyskinesia_31\NN\14084880|administered_129|,_23|did_21|not_17|in_11|._18
D016202_D014202 NONE nmda_5\NNP\0|NONE_0 (r_pobj) by_4\IN\0|NONE_0 (r_agent) produced_3\VBN\1617192|the_27|glutamatergic_23 (r_acl) blockage_2\NN\14034177|can_26|signs_44|according_127|._158 (r_nsubj) restore_7\VB\1631072|NONE_0 (l_dobj) signs_9\NNS\6643763|blockage_44|can_18|according_83|._114 (l_prep) as_12\IN\14622893|these_18|,_7 (l_pobj) movements_15\NNS\191142|such_24 (l_conj) protrusions_18\NNS\13919685|vacuous_34|chewing_26|,_9 (l_conj) catalepsy_20\NN\14023236|tongue_20|,_2 (l_conj) tremor_22\NN\345926|and_4
D016291_D010300 NONE mk-801_16\NNP\0|reserpine_97|also_87|tremor_73|._2 (r_punct) produced_2\VBD\1617192|NONE_0 (l_dobj) tremor_3\NN\345926|reserpine_24|also_14|._71|mk-801_73 (l_relcl) are_8\VBP\13600404|and_21|catalepsy_17|,_8 (l_attr) signs_9\NNS\6643763|which_10 (l_amod) suggestive_10\JJ\0|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) disease_14\NN\14061805|NONE_0
D012110_D010300 NONE reserpine_0\NN\2721160|also_10|tremor_24|._95|mk-801_97 (r_nsubj) produced_2\VBD\1617192|NONE_0 (l_dobj) tremor_3\NN\345926|reserpine_24|also_14|._71|mk-801_73 (l_relcl) are_8\VBP\13600404|and_21|catalepsy_17|,_8 (l_attr) signs_9\NNS\6643763|which_10 (l_amod) suggestive_10\JJ\0|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) disease_14\NN\14061805|NONE_0
D012110_D010300 NONE reserpine_4\NN\2721160|that_5|movements_42 (r_nsubj) produces_5\VBZ\7555863|results_28|._162 (l_dobj) movements_9\NNS\191142|that_47|reserpine_42 (l_relcl) related_13\VBN\628491|different_44|,_12 (l_conj) considered_22\VBN\689344|which_59|are_53|to_41|and_11 (l_prep) as_23\IN\14622893|can_18|be_14 (l_pobj) signs_30\NNS\6643763|NONE_0 (l_amod) parkinsonian_24\JJ\0|dsykinesia_30
D012110_D002375 CID reserpine_0\NN\2721160|also_10|tremor_24|._95|mk-801_97 (r_nsubj) produced_2\VBD\1617192|NONE_0 (l_dobj) tremor_3\NN\345926|reserpine_24|also_14|._71|mk-801_73 (l_conj) catalepsy_5\NN\14023236|and_4|,_9|are_17
D012110_D002375 CID reserpine_25\NN\2721160|NONE_0 (r_pobj) by_24\IN\0|NONE_0 (r_agent) induced_23\VBN\1627355|the_64|vacuous_60|chewing_52|,_35|protrusions_26 (r_acl) movements_17\NNS\191142|mg/kg_87|._64 (l_conj) protrusions_20\NNS\13919685|the_38|vacuous_34|chewing_26|,_9|induced_26 (l_conj) catalepsy_22\NN\14023236|tongue_23|and_4
D012110_D002375 CID reserpine_5\NN\2721160|on_19|,_2|increases_18|compared_52|._76|mk-801_78 (r_nsubj) induced_6\VBN\1627355|NONE_0 (l_dobj) increases_7\NNS\13576355|on_37|,_20|reserpine_18|compared_34|._58|mk-801_60 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) tremor_9\NN\345926|NONE_0 (l_conj) catalepsy_11\NN\14023236|and_4
D012110_D002375 CID reserpine_12\NN\2721160|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|the_25|and_11|tremor_7 (r_acl) catalepsy_7\NN\14023236|(_42|administration_30|._41
D012110_D002375 CID reserpine_2\NN\2721160|NONE_0 (r_pobj) with_1\IN\0|produced_58 (r_prep) pretreatment_0\NN\0|NONE_0 (l_acl) produced_13\VBD\1617192|with_58 (l_conj) increases_26\NNS\13576355|(_125|mg/kg_122|h_112|before_110|test_87|increases_73|,_13|as_3|,_33|reversed_95|._128 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) tremor_28\NN\345926|NONE_0 (l_conj) catalepsy_30\NN\14023236|and_4
D012110_D002375 CID reserpine_48\NN\2721160|NONE_0 (r_pobj) of_47\IN\0|the_12 (r_prep) effects_46\NNS\13245626|whereas_73|min_33|before_29|test_18 (r_dobj) reversed_44\VBD\109660|(_220|mg/kg_217|h_207|before_205|test_182|increases_168|,_108|as_98|increases_95|,_62|._33 (r_advcl) produced_13\VBD\1617192|with_58 (l_conj) increases_26\NNS\13576355|(_125|mg/kg_122|h_112|before_110|test_87|increases_73|,_13|as_3|,_33|reversed_95|._128 (l_prep) in_27\IN\13603305|NONE_0 (l_pobj) tremor_28\NN\345926|NONE_0 (l_conj) catalepsy_30\NN\14023236|and_4
9205462
D013629_D001943 NONE tamoxifen_9\NN\2714883|NONE_0 (r_pobj) with_8\IN\0|woman_18|was_12|for_15|._71 (r_prep) treated_7\VBN\2376958|NONE_0 (l_prep) for_10\IN\0|woman_33|was_27|with_15|._56 (l_pobj) carcinoma_18\NN\14239918|NONE_0
D013629_D017093 CID tamoxifen_2\NN\2714883|-_9 (r_npadvmod) induced_4\VBN\1627355|liver_8 (r_amod) dysfunction_6\NN\14204950|NONE_0
D013629_D017093 CID tamoxifen_20\NN\2714883|NONE_0 (r_compound) metabolism_21\NN\13526110|NONE_0 (r_pobj) in_19\IN\13603305|NONE_0 (r_prep) alterations_18\NNS\7283608|of_3 (r_pobj) because_16\IN\0|patients_101|may_51|at_44|._46 (r_prep) be_8\VB\14625458|NONE_0 (l_nsubj) patients_0\NNS\9898892|may_50|at_57|because_101|._147 (l_prep) with_1\IN\0|NONE_0 (l_pobj) dysfunction_6\NN\14204950|NONE_0
D013629_D009369 NONE tamoxifen_8\NN\2714883|and_14|tumors_30 (r_compound) use_9\NN\407535|NONE_0 (l_conj) tumors_12\NNS\14234074|tamoxifen_30|and_16
D013629_C537296 CID tamoxifen_9\NN\2714883|antecedent_11 (r_compound) use_10\NN\407535|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) associated_6\VBN\628491|the_10 (r_acl) ovary_5\NN\11675842|NONE_0
D004967_D001943 NONE estrogen_13\NN\14745635|stage_9|ii_3|positive_18|breast_27 (r_compound) carcinoma_18\NN\14239918|NONE_0
D013629_D006106 NONE tamoxifen_2\NN\2714883|-_9 (r_npadvmod) induced_4\VBN\1627355|liver_8 (r_amod) dysfunction_6\NN\14204950|NONE_0 (r_pobj) with_1\IN\0|NONE_0 (r_prep) patients_0\NNS\9898892|may_50|at_57|because_101|._147 (r_nsubj) be_8\VB\14625458|NONE_0 (l_prep) at_9\IN\14622893|patients_57|may_7|because_44|._90 (l_pobj) risk_11\NN\14541044|NONE_0 (l_prep) for_12\IN\0|increased_15 (l_pobj) tumors_15\NNS\14234074|NONE_0
D013629_D006106 NONE tamoxifen_20\NN\2714883|NONE_0 (r_compound) metabolism_21\NN\13526110|NONE_0 (r_pobj) in_19\IN\13603305|NONE_0 (r_prep) alterations_18\NNS\7283608|of_3 (r_pobj) because_16\IN\0|patients_101|may_51|at_44|._46 (r_prep) be_8\VB\14625458|NONE_0 (l_prep) at_9\IN\14622893|patients_57|may_7|because_44|._90 (l_pobj) risk_11\NN\14541044|NONE_0 (l_prep) for_12\IN\0|increased_15 (l_pobj) tumors_15\NNS\14234074|NONE_0
19105845
D016642_D012640 CID hydrochloride_8\NN\14817592|-_13 (r_npadvmod) induced_10\VBN\1627355|in_17 (r_amod) seizures_11\NNS\14081375|NONE_0
D016642_D012640 CID bupropion_15\NN\0|-_9 (r_npadvmod) induced_17\VBN\1627355|NONE_0 (r_amod) seizures_18\NNS\14081375|NONE_0
D016642_D012640 CID hcl_12\NNP\0|NONE_0 (r_pobj) of_10\IN\0|the_35|intraperitoneal_31|infusion_15 (r_prep) rates_9\NNS\13308999|mg/kg_27 (r_dobj) varying_5\VBG\0|NONE_0 (r_pcomp) of_4\IN\0|the_11|,_72|cd50_102 (r_prep) effect_3\NN\34213|we_20|,_114|on_116|._203 (l_appos) cd50_22\NNP\0|the_113|of_102|,_30 (l_amod) convulsive_18\JJ\0|a_8|dose_11|(_19|)_24
D016642_D012640 CID hcl_12\NNP\0|NONE_0 (r_pobj) of_10\IN\0|the_35|intraperitoneal_31|infusion_15 (r_prep) rates_9\NNS\13308999|mg/kg_27 (r_dobj) varying_5\VBG\0|NONE_0 (r_pcomp) of_4\IN\0|the_11|,_72|cd50_102 (r_prep) effect_3\NN\34213|we_20|,_114|on_116|._203 (r_dobj) investigated_1\VBD\644583|NONE_0 (l_prep) on_25\IN\0|we_136|effect_116|,_2|._87 (l_pobj) incidence_27\NN\13821570|NONE_0 (l_prep) of_30\IN\0|the_27|and_13|severity_9 (l_pobj) convulsions_34\NNS\14081375|NONE_0
D016642_D012640 CID bupropion_31\NN\0|-_9 (r_npadvmod) induced_33\VBN\1627355|in_20 (r_amod) convulsions_34\NNS\14081375|NONE_0 (r_pobj) of_30\IN\0|the_27|and_13|severity_9 (r_prep) incidence_27\NN\13821570|NONE_0 (r_pobj) on_25\IN\0|we_136|effect_116|,_2|._87 (r_prep) investigated_1\VBD\644583|NONE_0 (l_dobj) effect_3\NN\34213|we_20|,_114|on_116|._203 (l_appos) cd50_22\NNP\0|the_113|of_102|,_30 (l_amod) convulsive_18\JJ\0|a_8|dose_11|(_19|)_24
D016642_D012640 CID bupropion_31\NN\0|-_9 (r_npadvmod) induced_33\VBN\1627355|in_20 (r_amod) convulsions_34\NNS\14081375|NONE_0
D016642_D012640 CID hcl_9\NNP\0|:_57|results_51|mg/kg_8|by_14|induced_33|%_76|._108 (r_ccomp) showed_3\VBD\2137132|NONE_0 (l_advcl) induced_15\VBD\1627355|:_90|results_84|hcl_33|mg/kg_25|by_19|%_43|._75 (l_dobj) convulsions_16\NNS\14081375|NONE_0
D016642_D012640 CID hcl_27\NNP\0|NONE_0 (r_pobj) of_25\IN\0|the_21|infusion_14 (r_prep) time_24\NN\7308889|mg/kg_26 (r_dobj) increasing_20\VBG\169651|;_26|odds_24|=_13|0.974_11|)_6|and_4 (r_conj) ratio_15\NN\13815152|was_78|with_93|compared_166 (r_nsubjpass) associated_31\VBN\628491|analysis_153|was_116|._111 (l_prep) with_32\IN\0|ratio_93|was_15|compared_73 (l_pobj) odds_37\NNS\4756635|NONE_0 (l_prep) of_38\IN\0|a_19|%_15|reduced_13 (l_pobj) convulsions_39\NNS\14081375|NONE_0
D016642_D012640 CID bupropion_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|a_28|fixed_26|and_13|risk_21 (r_prep) dose_17\NN\3740161|NONE_0 (l_amod) fixed_14\JJ\205885|a_2|of_26|and_39|risk_47 (l_conj) convulsive_16\JJ\0|and_4
D016642_D012640 CID bupropion_19\NN\0|NONE_0 (r_pobj) of_18\IN\0|a_28|fixed_26|and_13|risk_21 (r_prep) dose_17\NN\3740161|NONE_0 (l_conj) risk_22\NN\14541044|a_49|fixed_47|of_21|and_8 (l_prep) of_23\IN\0|the_9 (l_pobj) convulsions_24\NNS\14081375|NONE_0
9067481
D002251_D064420 NONE tetrachloride-_48\NN\0|NONE_0 (l_appos) toxicity_55\NN\13576101|acetaminophen-_90|carbon_61|,_40
D000082_D066126 NONE acetaminophen_35\RB\2707683|ccl4_13|,_9|,_2 (l_conj) against_39\IN\0|and_22|galactosamine_18|and_4 (l_pobj) lethal_41\JJ\0|NONE_0 (l_conj) effect_47\NN\34213|the_40|(_29|and_28 (l_amod) cardiotoxic_45\JJ\0|)_11|of_20
D005688_D064420 NONE galactosamine_52\NN\0|-_13 (r_npadvmod) induced_54\VBN\1627355|and_18 (r_conj) chloroform-_50\JJ\0|NONE_0 (r_nmod) toxicity_55\NN\13576101|acetaminophen-_90|carbon_61|,_40
D004317_D066126 CID adriamycin_49\NNS\0|NONE_0 (r_amod) administration_50\NN\1133281|NONE_0 (r_pobj) of_48\IN\0|cardiotoxic_20|)_9 (r_prep) effect_47\NN\34213|the_40|(_29|and_28 (l_amod) cardiotoxic_45\JJ\0|)_11|of_20
C103872_D064420 NONE acid_35\NN\14818238|,_30 (l_conj) salt_38\NN\14818238|cholesteryloxybutyric_33|,_7 (l_prep) against_42\IN\0|tris_16|cse_5 (l_pobj) tetrachloride-_48\NN\0|NONE_0 (l_appos) toxicity_55\NN\13576101|acetaminophen-_90|carbon_61|,_40
D002725_D064420 NONE chloroform-_50\JJ\0|NONE_0 (r_nmod) toxicity_55\NN\13576101|acetaminophen-_90|carbon_61|,_40
D004317_D056486 NONE adriamycin_49\NNS\0|NONE_0 (r_amod) administration_50\NN\1133281|NONE_0 (r_pobj) of_48\IN\0|cardiotoxic_20|)_9 (r_prep) effect_47\NN\34213|the_40|(_29|and_28 (r_conj) lethal_41\JJ\0|NONE_0 (r_pobj) against_39\IN\0|and_22|galactosamine_18|and_4 (r_conj) acetaminophen_35\RB\2707683|ccl4_13|,_9|,_2 (r_conj) chcl3_33\NNP\0|NONE_0 (r_pobj) of_30\IN\0|the_24|hepatotoxic_20 (r_prep) effects_29\NNS\13245626|NONE_0 (l_amod) hepatotoxic_28\JJ\0|the_4|of_20
D004317_D064420 NONE adriamycin-_45\JJ\0|,_2|,_11 (r_conj) acetaminophen-_43\NN\0|carbon_29|,_50|toxicity_90 (r_nmod) tetrachloride-_48\NN\0|NONE_0 (l_appos) toxicity_55\NN\13576101|acetaminophen-_90|carbon_61|,_40
D002251_D066126 NONE ccl4_31\NNP\0|,_4|,_11|acetaminophen_13 (r_nmod) chcl3_33\NNP\0|NONE_0 (l_conj) acetaminophen_35\RB\2707683|ccl4_13|,_9|,_2 (l_conj) against_39\IN\0|and_22|galactosamine_18|and_4 (l_pobj) lethal_41\JJ\0|NONE_0 (l_conj) effect_47\NN\34213|the_40|(_29|and_28 (l_amod) cardiotoxic_45\JJ\0|)_11|of_20
D002725_D056486 CID chcl3_33\NNP\0|NONE_0 (r_pobj) of_30\IN\0|the_24|hepatotoxic_20 (r_prep) effects_29\NNS\13245626|NONE_0 (l_amod) hepatotoxic_28\JJ\0|the_4|of_20
D005688_D056486 CID galactosamine_37\NN\0|and_4|and_14|against_18 (r_conj) acetaminophen_35\RB\2707683|ccl4_13|,_9|,_2 (r_conj) chcl3_33\NNP\0|NONE_0 (r_pobj) of_30\IN\0|the_24|hepatotoxic_20 (r_prep) effects_29\NNS\13245626|NONE_0 (l_amod) hepatotoxic_28\JJ\0|the_4|of_20
D005688_D056486 CID galactosamine_30\NN\0|NONE_0 (r_amod) hepatotoxicity_31\NN\0|NONE_0
D000082_D064420 NONE acetaminophen-_43\NN\0|carbon_29|,_50|toxicity_90 (r_nmod) tetrachloride-_48\NN\0|NONE_0 (l_appos) toxicity_55\NN\13576101|acetaminophen-_90|carbon_61|,_40
D002725_D066126 NONE chcl3_33\NNP\0|NONE_0 (l_conj) acetaminophen_35\RB\2707683|ccl4_13|,_9|,_2 (l_conj) against_39\IN\0|and_22|galactosamine_18|and_4 (l_pobj) lethal_41\JJ\0|NONE_0 (l_conj) effect_47\NN\34213|the_40|(_29|and_28 (l_amod) cardiotoxic_45\JJ\0|)_11|of_20
D002251_D056486 CID tetrachloride_35\NN\14818238|the_34|hepatotoxic_30|of_10|ccl4_15 (r_advmod) effects_32\NNS\13245626|NONE_0 (l_amod) hepatotoxic_31\JJ\0|the_4|of_20|tetrachloride_30|ccl4_45
D002251_D056486 CID ccl4_37\NNP\0|the_49|hepatotoxic_45|of_25|tetrachloride_15 (r_appos) effects_32\NNS\13245626|NONE_0 (l_amod) hepatotoxic_31\JJ\0|the_4|of_20|tetrachloride_30|ccl4_45
D002251_D056486 CID ccl4_31\NNP\0|,_4|,_11|acetaminophen_13 (r_nmod) chcl3_33\NNP\0|NONE_0 (r_pobj) of_30\IN\0|the_24|hepatotoxic_20 (r_prep) effects_29\NNS\13245626|NONE_0 (l_amod) hepatotoxic_28\JJ\0|the_4|of_20
-1_D056486 NONE salt_17\NN\14818238|tris_5|(_5|cs_6|)_8 (r_nmod) administration_21\NN\1133281|cholesteryl_42|,_17 (r_conj) hemisuccinate_14\NN\0|stabilizer_48|of_26|,_14 (r_conj) rigidifier_9\NN\0|NONE_0 (r_pobj) as_5\IN\14622893|its_8 (r_prep) use_4\NN\407535|NONE_0 (r_pobj) to_2\IN\0|NONE_0 (r_prep) addition_1\NN\3081021|NONE_0 (r_pobj) in_0\IN\13603305|has_121|also_125|been_130|protect_144|._216 (r_prep) shown_25\VBN\2137132|NONE_0 (l_xcomp) protect_27\VB\1127795|in_144|has_23|also_19|been_14|._72 (l_prep) from_29\IN\0|to_16|rats_5 (l_pobj) effects_32\NNS\13245626|NONE_0 (l_amod) hepatotoxic_31\JJ\0|the_4|of_20|tetrachloride_30|ccl4_45
-1_D056486 NONE cs_19\NNP\14625458|tris_11|salt_6|(_1|)_2 (r_nmod) administration_21\NN\1133281|cholesteryl_42|,_17 (r_conj) hemisuccinate_14\NN\0|stabilizer_48|of_26|,_14 (r_conj) rigidifier_9\NN\0|NONE_0 (r_pobj) as_5\IN\14622893|its_8 (r_prep) use_4\NN\407535|NONE_0 (r_pobj) to_2\IN\0|NONE_0 (r_prep) addition_1\NN\3081021|NONE_0 (r_pobj) in_0\IN\13603305|has_121|also_125|been_130|protect_144|._216 (r_prep) shown_25\VBN\2137132|NONE_0 (l_xcomp) protect_27\VB\1127795|in_144|has_23|also_19|been_14|._72 (l_prep) from_29\IN\0|to_16|rats_5 (l_pobj) effects_32\NNS\13245626|NONE_0 (l_amod) hepatotoxic_31\JJ\0|the_4|of_20|tetrachloride_30|ccl4_45
-1_D056486 NONE cs_13\NNP\14625458|(_3|100mg_4|/_9|,_12|i.p._14|)_18 (r_nmod) kg_17\NNS\13717155|NONE_0 (r_pobj) of_12\IN\0|a_14|single_12 (r_prep) dose_11\NN\3740161|NONE_0 (r_pobj) with_8\IN\0|a_42|24-h_40|of_22 (r_prep) pretreatment_2\NN\0|,_76|in_87|._280 (r_nsubj) resulted_22\VBD\2633881|NONE_0 (l_prep) in_23\IN\13603305|pretreatment_87|,_11|._193 (l_pobj) protection_25\NN\407535|NONE_0 (l_prep) against_26\IN\0|significant_23 (l_pobj) effects_29\NNS\13245626|NONE_0 (l_amod) hepatotoxic_28\JJ\0|the_4|of_20
-1_D056486 NONE cs_3\NNP\14625458|NONE_0 (r_compound) protection_4\NN\407535|NONE_0 (r_pobj) of_2\IN\0|the_14 (r_prep) mechanism_1\NN\13446390|does_27|not_32|be_46|)_209|._210 (r_nsubj) appear_7\VB\2604760|NONE_0 (l_xcomp) be_9\VB\14625458|mechanism_46|does_19|not_14|)_163|._164 (l_acomp) dependent_10\JJ\9627906|to_6 (l_prep) on_11\IN\0|NONE_0 (l_pobj) inhibition_13\NN\1068773|NONE_0 (l_prep) to_17\IN\0|the_41|of_26 (l_pobj) in_23\IN\13603305|NONE_0 (l_pobj) light_24\NN\11421401|intermediate_17|(_4 (l_prep) of_25\IN\0|NONE_0 (l_pobj) protection_27\NN\407535|NONE_0 (l_acl) observed_28\VBN\2163746|the_15 (l_prep) against_29\IN\0|NONE_0 (l_pobj) hepatotoxicity_31\NN\0|NONE_0
-1_D064420 NONE cs_8\NNP\14625458|NONE_0 (r_compound) cytoprotection_9\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_14 (r_prep) mechanism_6\NN\13446390|NONE_0 (r_pobj) of_4\IN\0|our_18 (r_prep) understanding_3\NN\5804793|to_15 (r_dobj) further_1\VB\2554922|,_63|we_65|in_77|and_85|mice_89|._324 (r_advmod) examined_12\VBD\0|NONE_0 (l_conj) mice_16\NNS\2329401|further_89|,_26|we_24|in_12|and_4|._235 (l_dobj) abilities_19\NNS\4723816|NONE_0 (l_prep) of_20\IN\0|the_25|protective_21 (l_pobj) cs_21\NNP\14625458|NONE_0 (l_conj) form_28\NN\6286395|and_31 (l_prep) of_29\IN\0|the_32|hydrolyzable_24|ether_11 (l_pobj) cs_30\NNP\14625458|NONE_0 (l_conj) acid_35\NN\14818238|,_30 (l_conj) salt_38\NN\14818238|cholesteryloxybutyric_33|,_7 (l_prep) against_42\IN\0|tris_16|cse_5 (l_pobj) tetrachloride-_48\NN\0|NONE_0 (l_appos) toxicity_55\NN\13576101|acetaminophen-_90|carbon_61|,_40
-1_D064420 NONE cs_21\NNP\14625458|NONE_0 (l_conj) form_28\NN\6286395|and_31 (l_prep) of_29\IN\0|the_32|hydrolyzable_24|ether_11 (l_pobj) cs_30\NNP\14625458|NONE_0 (l_conj) acid_35\NN\14818238|,_30 (l_conj) salt_38\NN\14818238|cholesteryloxybutyric_33|,_7 (l_prep) against_42\IN\0|tris_16|cse_5 (l_pobj) tetrachloride-_48\NN\0|NONE_0 (l_appos) toxicity_55\NN\13576101|acetaminophen-_90|carbon_61|,_40
-1_D064420 NONE cs_30\NNP\14625458|NONE_0 (l_conj) acid_35\NN\14818238|,_30 (l_conj) salt_38\NN\14818238|cholesteryloxybutyric_33|,_7 (l_prep) against_42\IN\0|tris_16|cse_5 (l_pobj) tetrachloride-_48\NN\0|NONE_0 (l_appos) toxicity_55\NN\13576101|acetaminophen-_90|carbon_61|,_40
-1_D064420 NONE salt_38\NN\14818238|cholesteryloxybutyric_33|,_7 (l_prep) against_42\IN\0|tris_16|cse_5 (l_pobj) tetrachloride-_48\NN\0|NONE_0 (l_appos) toxicity_55\NN\13576101|acetaminophen-_90|carbon_61|,_40
-1_D064420 NONE cse_40\NNP\8342039|tris_11|against_5 (r_appos) salt_38\NN\14818238|cholesteryloxybutyric_33|,_7 (l_prep) against_42\IN\0|tris_16|cse_5 (l_pobj) tetrachloride-_48\NN\0|NONE_0 (l_appos) toxicity_55\NN\13576101|acetaminophen-_90|carbon_61|,_40
D000082_D056486 CID acetaminophen_35\RB\2707683|ccl4_13|,_9|,_2 (r_conj) chcl3_33\NNP\0|NONE_0 (r_pobj) of_30\IN\0|the_24|hepatotoxic_20 (r_prep) effects_29\NNS\13245626|NONE_0 (l_amod) hepatotoxic_28\JJ\0|the_4|of_20
C013440_D056486 NONE hemisuccinate_14\NN\0|stabilizer_48|of_26|,_14 (r_conj) rigidifier_9\NN\0|NONE_0 (r_pobj) as_5\IN\14622893|its_8 (r_prep) use_4\NN\407535|NONE_0 (r_pobj) to_2\IN\0|NONE_0 (r_prep) addition_1\NN\3081021|NONE_0 (r_pobj) in_0\IN\13603305|has_121|also_125|been_130|protect_144|._216 (r_prep) shown_25\VBN\2137132|NONE_0 (l_xcomp) protect_27\VB\1127795|in_144|has_23|also_19|been_14|._72 (l_prep) from_29\IN\0|to_16|rats_5 (l_pobj) effects_32\NNS\13245626|NONE_0 (l_amod) hepatotoxic_31\JJ\0|the_4|of_20|tetrachloride_30|ccl4_45
-1_D066126 NONE cs_13\NNP\14625458|(_3|100mg_4|/_9|,_12|i.p._14|)_18 (r_nmod) kg_17\NNS\13717155|NONE_0 (r_pobj) of_12\IN\0|a_14|single_12 (r_prep) dose_11\NN\3740161|NONE_0 (r_pobj) with_8\IN\0|a_42|24-h_40|of_22 (r_prep) pretreatment_2\NN\0|,_76|in_87|._280 (r_nsubj) resulted_22\VBD\2633881|NONE_0 (l_prep) in_23\IN\13603305|pretreatment_87|,_11|._193 (l_pobj) protection_25\NN\407535|NONE_0 (l_prep) against_26\IN\0|significant_23 (l_pobj) effects_29\NNS\13245626|NONE_0 (l_prep) of_30\IN\0|the_24|hepatotoxic_20 (l_pobj) chcl3_33\NNP\0|NONE_0 (l_conj) acetaminophen_35\RB\2707683|ccl4_13|,_9|,_2 (l_conj) against_39\IN\0|and_22|galactosamine_18|and_4 (l_pobj) lethal_41\JJ\0|NONE_0 (l_conj) effect_47\NN\34213|the_40|(_29|and_28 (l_amod) cardiotoxic_45\JJ\0|)_11|of_20
D005688_D066126 NONE galactosamine_37\NN\0|and_4|and_14|against_18 (r_conj) acetaminophen_35\RB\2707683|ccl4_13|,_9|,_2 (l_conj) against_39\IN\0|and_22|galactosamine_18|and_4 (l_pobj) lethal_41\JJ\0|NONE_0 (l_conj) effect_47\NN\34213|the_40|(_29|and_28 (l_amod) cardiotoxic_45\JJ\0|)_11|of_20
2422478
D012701_D006973 NONE serotonin_19\NN\14807737|the_15|midline_11|cell_10|in_21 (r_compound) group_21\NN\2137|NONE_0 (r_pobj) of_15\IN\0|the_9 (r_prep) area_14\NN\8630985|NONE_0 (r_pobj) into_12\IN\0|of_14 (r_prep) microinjection_9\NN\0|hypertensive_33|,_21|prone_12|,_2 (r_conj) rats_7\NNS\2329401|NONE_0 (l_amod) hypertensive_2\JJ\10405694|,_12|prone_21|,_31|microinjection_33
D012701_D006973 NONE serotonin_51\NN\14807737|the_4|5,7-dihydroxytryptamine_21 (r_compound) neurotoxin_52\NN\15034074|NONE_0 (r_pobj) by_49\IN\0|was_14|injected_62 (r_agent) abolished_48\VBN\0|in_252|hypotension_81|h_31|and_8|._106 (r_conj) caused_26\VBD\1617192|NONE_0 (l_prep) in_0\IN\13603305|hypotension_171|h_221|and_244|abolished_252|._358 (l_pobj) rats_7\NNS\2329401|NONE_0 (l_amod) hypertensive_2\JJ\10405694|,_12|prone_21|,_31|microinjection_33
D012701_D020521 NONE serotonin_19\NN\14807737|the_15|midline_11|cell_10|in_21 (r_compound) group_21\NN\2137|NONE_0 (r_pobj) of_15\IN\0|the_9 (r_prep) area_14\NN\8630985|NONE_0 (r_pobj) into_12\IN\0|of_14 (r_prep) microinjection_9\NN\0|hypertensive_33|,_21|prone_12|,_2 (r_conj) rats_7\NNS\2329401|NONE_0 (l_amod) prone_6\JJ\0|hypertensive_21|,_9|,_10|microinjection_12 (l_npadvmod) stroke_4\NN\556313|-_6
D012701_D020521 NONE serotonin_51\NN\14807737|the_4|5,7-dihydroxytryptamine_21 (r_compound) neurotoxin_52\NN\15034074|NONE_0 (r_pobj) by_49\IN\0|was_14|injected_62 (r_agent) abolished_48\VBN\0|in_252|hypotension_81|h_31|and_8|._106 (r_conj) caused_26\VBD\1617192|NONE_0 (l_prep) in_0\IN\13603305|hypotension_171|h_221|and_244|abolished_252|._358 (l_pobj) rats_7\NNS\2329401|NONE_0 (l_amod) prone_6\JJ\0|hypertensive_21|,_9|,_10|microinjection_12 (l_npadvmod) stroke_4\NN\556313|-_6
D015116_D020521 NONE 5,7-dihydroxytryptamine_53\CD\0|the_25|serotonin_21 (r_appos) neurotoxin_52\NN\15034074|NONE_0 (r_pobj) by_49\IN\0|was_14|injected_62 (r_agent) abolished_48\VBN\0|in_252|hypotension_81|h_31|and_8|._106 (r_conj) caused_26\VBD\1617192|NONE_0 (l_prep) in_0\IN\13603305|hypotension_171|h_221|and_244|abolished_252|._358 (l_pobj) rats_7\NNS\2329401|NONE_0 (l_amod) prone_6\JJ\0|hypertensive_21|,_9|,_10|microinjection_12 (l_npadvmod) stroke_4\NN\556313|-_6
D015116_D020521 NONE 5,7-dht_55\NNP\0|NONE_0 (r_appos) 5,7-dihydroxytryptamine_53\CD\0|the_25|serotonin_21 (r_appos) neurotoxin_52\NN\15034074|NONE_0 (r_pobj) by_49\IN\0|was_14|injected_62 (r_agent) abolished_48\VBN\0|in_252|hypotension_81|h_31|and_8|._106 (r_conj) caused_26\VBD\1617192|NONE_0 (l_prep) in_0\IN\13603305|hypotension_171|h_221|and_244|abolished_252|._358 (l_pobj) rats_7\NNS\2329401|NONE_0 (l_amod) prone_6\JJ\0|hypertensive_21|,_9|,_10|microinjection_12 (l_npadvmod) stroke_4\NN\556313|-_6
D008750_D007022 CID methyldopa_13\NN\2721160|NONE_0 (r_pobj) of_12\IN\0|hypotensive_19 (r_prep) effect_11\NN\34213|NONE_0 (l_amod) hypotensive_10\JJ\10405694|of_19
D008750_D007022 CID methyldopa_10\NN\2721160|NONE_0 (r_pobj) of_9\IN\0|onto_14 (r_prep) microinjection_8\NN\0|that_5|response_123 (r_nsubj) elicits_23\VBZ\1617192|experiments_148|have_117|._87 (l_dobj) response_26\NN\11410625|that_128|microinjection_123 (l_amod) hypotensive_25\JJ\10405694|a_2|mediated_21
D008750_D007022 CID methyldopa_11\NN\2721160|NONE_0 (r_pobj) of_10\IN\0|into_14 (r_prep) microinjection_9\NN\0|hypertensive_33|,_21|prone_12|,_2 (r_conj) rats_7\NNS\2329401|NONE_0 (r_pobj) in_0\IN\13603305|hypotension_171|h_221|and_244|abolished_252|._358 (r_prep) caused_26\VBD\1617192|NONE_0 (l_dobj) hypotension_29\NN\14057371|in_171|h_50|and_73|abolished_81|._187
D008750_D007022 CID methyldopa_14\NN\2721160|-_10 (r_npadvmod) induced_16\VBN\1627355|a_13 (r_amod) hypotension_17\NN\14057371|which_35|via_12
D008750_D007022 CID methyldopa_14\NN\2721160|-_10 (r_npadvmod) induced_16\VBN\1627355|a_13 (r_amod) hypotension_17\NN\14057371|which_35|via_12 (r_dobj) mediate_12\VBP\761713|the_33|ventrolateral_29|b3_15 (r_relcl) cells_10\NNS\3080309|NONE_0 (r_pobj) unlike_6\IN\0|that_6|,_2|,_107|cells_134|to_166|,_205|by_214 (r_prep) contribute_30\VB\126264|it_187|is_184|therefore_171|._208 (l_prep) to_31\IN\0|that_172|,_168|unlike_166|,_59|cells_32|,_39|by_48 (l_pobj) action_34\NN\30358|NONE_0 (l_amod) hypotensive_33\JJ\10405694|the_4|of_19
D008750_D007022 CID methyldopa_36\NN\2721160|NONE_0 (r_pobj) of_35\IN\0|the_23|hypotensive_19 (r_prep) action_34\NN\30358|NONE_0 (r_pobj) to_31\IN\0|that_172|,_168|unlike_166|,_59|cells_32|,_39|by_48 (r_prep) contribute_30\VB\126264|it_187|is_184|therefore_171|._208 (l_prep) unlike_6\IN\0|that_6|,_2|,_107|cells_134|to_166|,_205|by_214 (l_pobj) cells_10\NNS\3080309|NONE_0 (l_relcl) mediate_12\VBP\761713|the_33|ventrolateral_29|b3_15 (l_dobj) hypotension_17\NN\14057371|which_35|via_12
D008750_D007022 CID methyldopa_36\NN\2721160|NONE_0 (r_pobj) of_35\IN\0|the_23|hypotensive_19 (r_prep) action_34\NN\30358|NONE_0 (l_amod) hypotensive_33\JJ\10405694|the_4|of_19
D008750_D006973 NONE methyldopa_11\NN\2721160|NONE_0 (r_pobj) of_10\IN\0|into_14 (r_prep) microinjection_9\NN\0|hypertensive_33|,_21|prone_12|,_2 (r_conj) rats_7\NNS\2329401|NONE_0 (l_amod) hypertensive_2\JJ\10405694|,_12|prone_21|,_31|microinjection_33
D008750_D020521 NONE methyldopa_11\NN\2721160|NONE_0 (r_pobj) of_10\IN\0|into_14 (r_prep) microinjection_9\NN\0|hypertensive_33|,_21|prone_12|,_2 (r_conj) rats_7\NNS\2329401|NONE_0 (l_amod) prone_6\JJ\0|hypertensive_21|,_9|,_10|microinjection_12 (l_npadvmod) stroke_4\NN\556313|-_6
D015116_D006973 NONE 5,7-dihydroxytryptamine_53\CD\0|the_25|serotonin_21 (r_appos) neurotoxin_52\NN\15034074|NONE_0 (r_pobj) by_49\IN\0|was_14|injected_62 (r_agent) abolished_48\VBN\0|in_252|hypotension_81|h_31|and_8|._106 (r_conj) caused_26\VBD\1617192|NONE_0 (l_prep) in_0\IN\13603305|hypotension_171|h_221|and_244|abolished_252|._358 (l_pobj) rats_7\NNS\2329401|NONE_0 (l_amod) hypertensive_2\JJ\10405694|,_12|prone_21|,_31|microinjection_33
D015116_D006973 NONE 5,7-dht_55\NNP\0|NONE_0 (r_appos) 5,7-dihydroxytryptamine_53\CD\0|the_25|serotonin_21 (r_appos) neurotoxin_52\NN\15034074|NONE_0 (r_pobj) by_49\IN\0|was_14|injected_62 (r_agent) abolished_48\VBN\0|in_252|hypotension_81|h_31|and_8|._106 (r_conj) caused_26\VBD\1617192|NONE_0 (l_prep) in_0\IN\13603305|hypotension_171|h_221|and_244|abolished_252|._358 (l_pobj) rats_7\NNS\2329401|NONE_0 (l_amod) hypertensive_2\JJ\10405694|,_12|prone_21|,_31|microinjection_33
D012701_D007022 NONE serotonin_2\NN\14807737|in_17 (r_compound) nerves_3\NNS\14373582|are_22|in_35|._70 (r_nsubjpass) involved_8\VBN\2676054|NONE_0 (l_prep) in_9\IN\13603305|nerves_35|are_13|._35 (l_pobj) effect_11\NN\34213|NONE_0 (l_amod) hypotensive_10\JJ\10405694|of_19
D012701_D007022 NONE serotonin_18\NN\14807737|the_7 (r_compound) neurons_19\NNS\5430628|NONE_0 (r_pobj) of_15\IN\0|the_24|ventrolateral_20|in_28 (r_prep) cells_14\NNS\3080309|NONE_0 (r_pobj) onto_11\IN\0|of_14 (r_prep) microinjection_8\NN\0|that_5|response_123 (r_nsubj) elicits_23\VBZ\1617192|experiments_148|have_117|._87 (l_dobj) response_26\NN\11410625|that_128|microinjection_123 (l_amod) hypotensive_25\JJ\10405694|a_2|mediated_21
D012701_D007022 NONE serotonin_19\NN\14807737|the_15|midline_11|cell_10|in_21 (r_compound) group_21\NN\2137|NONE_0 (r_pobj) of_15\IN\0|the_9 (r_prep) area_14\NN\8630985|NONE_0 (r_pobj) into_12\IN\0|of_14 (r_prep) microinjection_9\NN\0|hypertensive_33|,_21|prone_12|,_2 (r_conj) rats_7\NNS\2329401|NONE_0 (r_pobj) in_0\IN\13603305|hypotension_171|h_221|and_244|abolished_252|._358 (r_prep) caused_26\VBD\1617192|NONE_0 (l_dobj) hypotension_29\NN\14057371|in_171|h_50|and_73|abolished_81|._187
D012701_D007022 NONE serotonin_51\NN\14807737|the_4|5,7-dihydroxytryptamine_21 (r_compound) neurotoxin_52\NN\15034074|NONE_0 (r_pobj) by_49\IN\0|was_14|injected_62 (r_agent) abolished_48\VBN\0|in_252|hypotension_81|h_31|and_8|._106 (r_conj) caused_26\VBD\1617192|NONE_0 (l_dobj) hypotension_29\NN\14057371|in_171|h_50|and_73|abolished_81|._187
D012701_D007022 NONE serotonin_15\NN\14807737|in_22 (r_compound) projections_16\NNS\5775081|only_26 (r_dobj) descending_14\VBG\1835496|NONE_0 (r_pcomp) of_12\IN\0|a_24|selective_17 (r_prep) lesion_11\NN\14204950|to_28 (r_dobj) produce_7\VB\7555863|intraspinal_36|of_14 (r_relcl) injection_3\NN\320852|however_21|,_14|did_116|not_120|hypotension_136|._147 (r_nsubj) affect_23\VB\26192|NONE_0 (l_dobj) hypotension_25\NN\14057371|however_157|,_150|injection_136|did_20|not_16|._11
D012701_D007022 NONE serotonin_24\NN\14807737|the_12|midline_8|b3_10|in_19 (r_compound) cells_26\NNS\3080309|that_140|,_136|unlike_134|,_27|to_32|,_71|by_80 (r_nsubj) contribute_30\VB\126264|it_187|is_184|therefore_171|._208 (l_prep) unlike_6\IN\0|that_6|,_2|,_107|cells_134|to_166|,_205|by_214 (l_pobj) cells_10\NNS\3080309|NONE_0 (l_relcl) mediate_12\VBP\761713|the_33|ventrolateral_29|b3_15 (l_dobj) hypotension_17\NN\14057371|which_35|via_12
D012701_D007022 NONE serotonin_24\NN\14807737|the_12|midline_8|b3_10|in_19 (r_compound) cells_26\NNS\3080309|that_140|,_136|unlike_134|,_27|to_32|,_71|by_80 (r_nsubj) contribute_30\VB\126264|it_187|is_184|therefore_171|._208 (l_prep) to_31\IN\0|that_172|,_168|unlike_166|,_59|cells_32|,_39|by_48 (l_pobj) action_34\NN\30358|NONE_0 (l_amod) hypotensive_33\JJ\10405694|the_4|of_19
D015116_D007022 NONE 5,7-dihydroxytryptamine_53\CD\0|the_25|serotonin_21 (r_appos) neurotoxin_52\NN\15034074|NONE_0 (r_pobj) by_49\IN\0|was_14|injected_62 (r_agent) abolished_48\VBN\0|in_252|hypotension_81|h_31|and_8|._106 (r_conj) caused_26\VBD\1617192|NONE_0 (l_dobj) hypotension_29\NN\14057371|in_171|h_50|and_73|abolished_81|._187
D015116_D007022 NONE 5,7-dht_55\NNP\0|NONE_0 (r_appos) 5,7-dihydroxytryptamine_53\CD\0|the_25|serotonin_21 (r_appos) neurotoxin_52\NN\15034074|NONE_0 (r_pobj) by_49\IN\0|was_14|injected_62 (r_agent) abolished_48\VBN\0|in_252|hypotension_81|h_31|and_8|._106 (r_conj) caused_26\VBD\1617192|NONE_0 (l_dobj) hypotension_29\NN\14057371|in_171|h_50|and_73|abolished_81|._187
D015116_D007022 NONE 5,7-dht_5\CD\0|NONE_0 (r_pobj) of_4\IN\0|intraspinal_22|produce_14 (r_prep) injection_3\NN\320852|however_21|,_14|did_116|not_120|hypotension_136|._147 (r_nsubj) affect_23\VB\26192|NONE_0 (l_dobj) hypotension_25\NN\14057371|however_157|,_150|injection_136|did_20|not_16|._11
7421734
D004967_D009369 NONE estrogens_4\NNS\14745635|NONE_0 (r_pobj) on_2\IN\0|young_12 (r_prep) women_1\NNS\9605289|after_51|therapy_64|may_72|also_76|have_81|risk_96|and_126|examined_140|._161 (r_nsubj) increased_14\VBN\169651|NONE_0 (l_nsubj) therapy_10\NN\657604|women_64|after_13|may_8|also_12|have_17|risk_32|and_62|examined_76|._97 (l_compound) cancer_9\NN\14239425|NONE_0
D004967_D016889 CID estrogens_16\NNS\14745635|treatment_13 (r_dobj) received_14\VBD\2210855|she_94|failure_78|,_6|and_4|._113 (l_npadvmod) treatment_19\NN\654885|estrogens_13 (l_acl) implicated_20\VBN\2677097|,_14|a_12 (l_prep) in_21\IN\13603305|NONE_0 (l_pobj) development_23\NN\248977|NONE_0 (l_prep) of_24\IN\0|the_16 (l_pobj) cancer_26\NN\14239425|NONE_0
D004967_D016889 CID estrogens_4\NNS\14745635|NONE_0 (r_pobj) on_2\IN\0|young_12 (r_prep) women_1\NNS\9605289|after_51|therapy_64|may_72|also_76|have_81|risk_96|and_126|examined_140|._161 (r_nsubj) increased_14\VBN\169651|NONE_0 (l_dobj) risk_15\NN\14541044|women_96|after_45|therapy_32|may_24|also_20|have_15|and_30|examined_44|._65 (l_prep) of_16\IN\0|NONE_0 (l_pobj) carcinoma_18\NN\14239918|NONE_0
D004967_D010049 NONE estrogens_16\NNS\14745635|treatment_13 (r_dobj) received_14\VBD\2210855|she_94|failure_78|,_6|and_4|._113 (r_conj) had_1\VBD\0|NONE_0 (l_dobj) failure_3\NN\66216|she_16|,_72|and_74|received_78|._191
D004967_D010049 NONE estrogens_4\NNS\14745635|NONE_0 (l_prep) for_5\IN\0|replacement_22 (l_pobj) failure_7\NN\66216|NONE_0
D004967_D006689 NONE estrogens_16\NNS\14745635|treatment_13 (r_dobj) received_14\VBD\2210855|she_94|failure_78|,_6|and_4|._113 (r_conj) had_1\VBD\0|NONE_0 (l_dobj) failure_3\NN\66216|she_16|,_72|and_74|received_78|._191 (l_prep) after_4\IN\0|ovarian_16 (l_pobj) irradiation_6\NN\13920835|NONE_0 (l_prep) for_9\IN\0|abdominal_39|and_17|chemotherapy_13 (l_pobj) disease_11\NN\14061805|NONE_0
7843916
D013256_D005901 NONE steroid_0\NN\14727670|NONE_0 (r_compound) treatment_1\NN\654885|in_19|._146 (r_nsubj) resulted_2\VBD\2633881|NONE_0 (l_prep) in_3\IN\13603305|treatment_19|._127 (l_pobj) changes_5\NNS\7283608|NONE_0 (l_prep) in_6\IN\13603305|morphologic_20 (l_pobj) meshwork_9\NN\3309808|NONE_0 (l_amod) similar_10\JJ\0|the_24|trabecular_20 (l_prep) to_11\IN\0|NONE_0 (l_pobj) those_12\DT\0|NONE_0 (l_acl) reported_13\VBN\831651|NONE_0 (l_prep) for_14\IN\0|NONE_0 (l_pobj) glaucoma_16\NN\14252864|NONE_0
D003907_D009798 CID dexamethasone_0\NN\2721538|-_13|hypertension_29|._74 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) hypertension_4\NN\14057371|dexamethasone_29|-_16|._45
D003907_D009798 CID dexamethasone_4\NN\2721538|-_13 (r_npadvmod) treated_6\VBN\2376958|the_18|hypertensive_8 (r_amod) eyes_8\NNS\5945642|in_52|,_41|had_5|beams_30|,_35|decreased_37|._308
D003907_D009798 CID dexamethasone_0\NN\2721538|of_24 (r_compound) treatment_1\NN\654885|to_57|._152 (r_nsubj) led_10\VBD\3202760|NONE_0 (l_prep) to_11\IN\0|treatment_57|._95 (l_pobj) generation_13\NN\7942152|NONE_0 (l_prep) of_14\IN\0|the_15|in_23 (l_pobj) hypertension_16\NN\14057371|NONE_0
D003907_D009798 CID dexamethasone_23\NN\2721538|-_13 (r_npadvmod) treated_25\VBN\2376958|the_18 (r_amod) eyes_26\NNS\5945642|NONE_0 (r_pobj) of_21\IN\0|30_4 (r_prep) %_20\NN\0|NONE_0 (r_pobj) in_17\IN\13603305|the_38|of_23 (r_prep) generation_13\NN\7942152|NONE_0 (l_prep) of_14\IN\0|the_15|in_23 (l_pobj) hypertension_16\NN\14057371|NONE_0
D013256_D005902 NONE steroid_0\NN\14727670|NONE_0 (r_compound) treatment_1\NN\654885|in_19|._146 (r_nsubj) resulted_2\VBD\2633881|NONE_0 (l_prep) in_3\IN\13603305|treatment_19|._127 (l_pobj) changes_5\NNS\7283608|NONE_0 (l_prep) in_6\IN\13603305|morphologic_20 (l_pobj) meshwork_9\NN\3309808|NONE_0 (l_amod) similar_10\JJ\0|the_24|trabecular_20 (l_prep) to_11\IN\0|NONE_0 (l_pobj) those_12\DT\0|NONE_0 (l_acl) reported_13\VBN\831651|NONE_0 (l_prep) for_14\IN\0|NONE_0 (l_pobj) glaucoma_16\NN\14252864|NONE_0 (l_conj) glaucoma_20\NN\14252864|corticosteroid_39|and_15
6415512
D002220_D004831 CID carbamazepine_10\NN\0|NONE_0 (r_compound) therapy_11\NN\657604|NONE_0 (r_pobj) of_9\IN\0|in_25 (r_prep) institution_8\NN\8008335|NONE_0 (r_dobj) following_7\VBG\8180190|myoclonic_40|._58 (r_prep) seizures_6\NNS\14081375|NONE_0
D002220_D004831 CID carbamazepine_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|children_38|,_31|had_33|._176 (r_prep) treated_9\VBN\2376958|NONE_0 (l_conj) had_15\VBD\0|children_71|with_33|,_2|._143 (l_dobj) reaction_19\NN\13446390|NONE_0 (l_acl) characterized_20\VBN\609683|an_27|acute_24|aberrant_18 (l_agent) by_21\IN\0|NONE_0 (l_pobj) onset_23\NN\7325190|NONE_0 (l_prep) of_24\IN\0|the_10 (l_pobj) absence_28\NN\14449405|NONE_0 (l_conj) seizures_35\NNS\14081375|myoclonic_56|,_47|atypical_45|and/or_28
D002220_D004832 CID carbamazepine_10\NN\0|NONE_0 (r_compound) therapy_11\NN\657604|NONE_0 (r_pobj) of_9\IN\0|in_25 (r_prep) institution_8\NN\8008335|NONE_0 (r_dobj) following_7\VBG\8180190|myoclonic_40|._58 (r_prep) seizures_6\NNS\14081375|NONE_0
D002220_D004832 CID carbamazepine_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|children_38|,_31|had_33|._176 (r_prep) treated_9\VBN\2376958|NONE_0 (l_conj) had_15\VBD\0|children_71|with_33|,_2|._143 (l_dobj) reaction_19\NN\13446390|NONE_0 (l_acl) characterized_20\VBN\609683|an_27|acute_24|aberrant_18 (l_agent) by_21\IN\0|NONE_0 (l_pobj) onset_23\NN\7325190|NONE_0 (l_prep) of_24\IN\0|the_10 (l_pobj) absence_28\NN\14449405|NONE_0 (l_conj) seizures_35\NNS\14081375|myoclonic_56|,_47|atypical_45|and/or_28
D002220_D012640 NONE carbamazepine_2\NN\0|when_9|was_14 (r_nsubjpass) discontinued_4\VBN\0|,_12|two_14|to_43|quickly_70 (r_advcl) returned_10\VBD\1835496|,_43|two_45|resolve_78|,_103|and_105|had_113 (r_ccomp) had_19\VBD\0|NONE_0 (l_ccomp) resolve_24\VBP\4616059|returned_78|,_35|two_33|,_25|and_27|had_35 (l_nsubj) seizures_23\NNS\14081375|in_17
D002220_D012640 NONE carbamazepine_2\NN\0|when_9|was_14 (r_nsubjpass) discontinued_4\VBN\0|,_12|two_14|to_43|quickly_70 (r_advcl) returned_10\VBD\1835496|,_43|two_45|resolve_78|,_103|and_105|had_113 (r_ccomp) had_19\VBD\0|NONE_0 (l_conj) had_33\VBD\0|returned_113|,_70|two_68|resolve_35|,_10|and_8 (l_ccomp) persist_36\VB\118523|one_21|._7 (l_nsubj) seizures_35\NNS\14081375|NONE_0
D002220_D004827 NONE carbamazepine_11\NN\0|NONE_0 (l_prep) for_12\IN\0|NONE_0 (l_pobj) epilepsy_13\NN\14085708|NONE_0
1969772
D004298_D007022 NONE dopamine-1_4\NNS\0|a_12|selective_10|receptor_17|causes_39 (r_punct) agonist_9\NN\0|fenoldopam_52|._150 (l_relcl) causes_11\VBZ\7323922|a_51|selective_49|dopamine-1_39|receptor_22 (l_conj) preserves_23\VBZ\7597145|that_81|vasodilatation_69|to_54|and_4 (l_prep) during_29\IN\0|flow_19 (l_pobj) hypotension_31\NN\14057371|NONE_0
D012964_D007022 NONE sodium_25\NN\14625458|induced_21|(_41|p_42|)_58 (r_amod) hypotension_29\NN\14057371|NONE_0 (r_pobj) during_24\IN\0|+/-_15|8_11 (r_prep) decreased_18\VBD\169651|flow_81|during_60|and_4|._94 (r_conj) increased_6\VBD\169651|NONE_0 (l_prep) during_7\IN\0|flow_21|and_56|decreased_60|._154 (l_pobj) hypotension_11\NN\14057371|NONE_0
D012964_D007022 NONE sodium_25\NN\14625458|induced_21|(_41|p_42|)_58 (r_amod) hypotension_29\NN\14057371|NONE_0
D018818_D007022 CID fenoldopam_9\NN\0|NONE_0 (r_pobj) with_8\IN\0|preservation_60|in_16|._23 (r_prep) induced_7\VBN\1627355|NONE_0 (l_nsubj) preservation_0\NN\817680|with_60|in_76|._83 (l_prep) during_5\IN\0|of_20 (l_pobj) hypotension_6\NN\14057371|NONE_0
D018818_D007022 CID fenoldopam_3\NN\0|the_20 (r_relcl) hypothesis_1\NN\7162194|could_27|be_33|induce_44|tested_105|._111 (r_nsubjpass) used_6\VBN\0|NONE_0 (l_xcomp) induce_8\VB\1627355|hypothesis_44|could_17|be_11|tested_61|._67 (l_dobj) hypotension_9\NN\14057371|to_10|and_12|preserve_16
D018818_D007022 CID fenoldopam_8\NN\0|-_10 (r_npadvmod) induced_10\VBN\1627355|11_20|+/-_23|7_27 (r_amod) hypotension_11\NN\14057371|NONE_0
D018818_D007022 CID fenoldopam_8\NN\0|-_10 (r_npadvmod) induced_10\VBN\1627355|11_20|+/-_23|7_27 (r_amod) hypotension_11\NN\14057371|NONE_0 (r_pobj) during_7\IN\0|flow_21|and_56|decreased_60|._154 (r_prep) increased_6\VBD\169651|NONE_0 (l_conj) decreased_18\VBD\169651|flow_81|during_60|and_4|._94 (l_prep) during_24\IN\0|+/-_15|8_11 (l_pobj) hypotension_29\NN\14057371|NONE_0
D009599_D007022 CID nitroprusside_26\RB\0|-_13 (r_advmod) induced_28\VBN\1627355|sodium_21|(_20|p_21|)_37 (r_amod) hypotension_29\NN\14057371|NONE_0 (r_pobj) during_24\IN\0|+/-_15|8_11 (r_prep) decreased_18\VBD\169651|flow_81|during_60|and_4|._94 (r_conj) increased_6\VBD\169651|NONE_0 (l_prep) during_7\IN\0|flow_21|and_56|decreased_60|._154 (l_pobj) hypotension_11\NN\14057371|NONE_0
D009599_D007022 CID nitroprusside_26\RB\0|-_13 (r_advmod) induced_28\VBN\1627355|sodium_21|(_20|p_21|)_37 (r_amod) hypotension_29\NN\14057371|NONE_0
D009599_D007022 CID nitroprusside_1\NN\0|vasodilator_55|._160 (r_nsubj) is_2\VBZ\0|NONE_0 (l_attr) vasodilator_10\NN\3198383|nitroprusside_55|._105 (l_relcl) produce_13\VB\7555863|arteriolar_43|venous_28 (l_prep) during_22\IN\0|that_67|can_62|redistribution_50 (l_pobj) hypotension_24\NN\14057371|NONE_0
3686155
D001971_D011605 CID bromocriptine_4\NN\0|NONE_0 (r_pobj) by_3\IN\0|psychosis_18|._16 (r_prep) induced_2\VBN\1627355|NONE_0 (l_nsubj) psychosis_1\NN\14380140|by_18|._34
D001971_D011605 CID bromocriptine_16\NN\0|having_16|for_14 (r_dobj) received_15\VBN\2210855|patients_87|were_44|with_34|,_9|._50 (r_advcl) seen_9\VBN\2106506|NONE_0 (l_prep) with_10\IN\0|patients_53|were_10|,_25|received_34|._84 (l_pobj) psychosis_12\NN\14380140|NONE_0
D001971_D011605 CID bromocriptine_0\NNP\0|has_34|been_38|with_54|._123 (r_nsubjpass) associated_7\VBN\628491|NONE_0 (l_prep) with_8\IN\0|bromocriptine_54|has_20|been_16|._69 (l_pobj) psychosis_9\NN\14380140|NONE_0
D001971_D011605 CID bromocriptine_4\NN\0|may_14|psychosis_24|given_44 (r_nsubj) cause_6\VB\7323922|cases_41|._44 (l_dobj) psychosis_7\NN\14380140|bromocriptine_24|may_10|given_20
D001971_D010300 NONE bromocriptine_0\NNP\0|has_34|been_38|with_54|._123 (r_nsubjpass) associated_7\VBN\628491|NONE_0 (l_prep) with_8\IN\0|bromocriptine_54|has_20|been_16|._69 (l_pobj) psychosis_9\NN\14380140|NONE_0 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_acl) receiving_12\VBG\2210855|NONE_0 (l_dobj) drug_14\NN\14778436|NONE_0 (l_prep) for_15\IN\0|the_9 (l_pobj) disease_18\NN\14061805|NONE_0
D001971_D001523 NONE bromocriptine_16\NN\0|having_16|for_14 (r_dobj) received_15\VBN\2210855|patients_87|were_44|with_34|,_9|._50 (r_advcl) seen_9\VBN\2106506|NONE_0 (l_nsubjpass) patients_2\NNS\9898892|were_43|with_53|,_78|received_87|._137 (l_prep) with_3\IN\0|two_26|multigravida_22 (l_pobj) history_7\NN\15120823|NONE_0 (l_amod) psychiatric_6\JJ\0|no_9|prior_6
D001971_D007775 NONE bromocriptine_16\NN\0|having_16|for_14 (r_dobj) received_15\VBN\2210855|patients_87|were_44|with_34|,_9|._50 (l_prep) for_17\IN\0|having_30|bromocriptine_14 (l_pobj) inhibition_18\NN\1068773|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) lactation_20\NN\15113229|NONE_0
3120485
982002
D012293_D058186 CID rifampicin_8\NNS\0|NONE_0 (r_pobj) of_7\IN\0|the_19 (r_prep) administration_6\NN\1133281|NONE_0 (r_pobj) to_4\IN\0|NONE_0 (r_prep) subsequent_3\JJ\0|acute_20|renal_14|._46 (r_amod) failure_2\NN\66216|NONE_0
D012293_D051437 NONE rifampicin_12\NNS\0|NONE_0 (r_pobj) of_11\IN\0|the_32|intermittent_28 (r_prep) administration_10\NN\1133281|NONE_0 (r_pobj) after_7\IN\0|patients_47|had_38|failure_8|._51 (r_prep) developed_3\VBN\1753788|NONE_0 (l_dobj) failure_6\NN\66216|patients_39|had_30|after_8|._59
3950060
D000583_D007674 CID amikacin_10\JJ\0|NONE_0 (r_dobj) receiving_9\VBG\2210855|NONE_0 (r_acl) patients_8\NNS\9898892|NONE_0 (r_pobj) in_7\IN\13603305|and_21|outcome_8 (r_prep) nephrotoxicity_3\NN\0|NONE_0
D000583_D007674 CID amikacin_6\JJ\0|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) treated_4\VBN\2376958|60_12 (r_acl) patients_3\NNS\9898892|NONE_0 (r_pobj) from_1\IN\0|NONE_0 (r_prep) data_0\NNS\7951464|were_44|for_58|._100 (r_nsubjpass) analyzed_8\VBN\0|NONE_0 (l_prep) for_9\IN\0|data_58|were_14|._42 (l_pobj) factors_10\NNS\7326557|NONE_0 (l_acl) associated_11\VBN\628491|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) nephrotoxicity_13\NN\0|NONE_0
16574713
D018817_D008569 CID mdma_12\NNP\3054098|moderate_9 (r_compound) users_13\NNS\7846|NONE_0 (r_pobj) in_10\IN\13603305|in_59|,_48|evidence_43|was_13|._22 (r_prep) observed_9\VBN\2163746|NONE_0 (l_nsubjpass) evidence_4\NN\5816287|in_16|,_5|was_30|in_43|._65 (l_prep) of_5\IN\0|no_12 (l_pobj) impairment_7\NN\7296428|NONE_0
D018817_D008569 CID mdma_4\NNP\3054098|NONE_0 (r_pobj) of_3\IN\0|the_8|in_8 (r_prep) use_2\NN\407535|while_10|use_118|may_134|to_143|._177 (l_prep) in_5\IN\13603305|the_16|of_8 (l_pobj) quantities_6\NNS\2137|NONE_0 (l_relcl) considered_10\VBN\689344|NONE_0 (l_oprd) associated_16\VBN\628491|that_41|may_36|be_32 (l_prep) with_17\IN\0|"_29|"_20|is_18|not_15 (l_pobj) functioning_20\VBG\29677|NONE_0
D018817_D008569 CID mdma_4\NNP\3054098|NONE_0 (r_pobj) of_3\IN\0|the_8|in_8 (r_prep) use_2\NN\407535|while_10|use_118|may_134|to_143|._177 (r_nsubj) lead_28\VB\5155821|NONE_0 (l_prep) to_29\IN\0|while_153|use_143|use_25|may_9|._34 (l_pobj) impairments_33\NNS\7296428|NONE_0
D018817_D008569 CID mdma_25\NNP\3054098|NONE_0 (r_compound) use_26\NN\407535|NONE_0 (r_pobj) of_24\IN\0|heavy_10 (r_prep) use_23\NN\407535|while_128|use_118|may_16|to_25|._59 (r_nsubj) lead_28\VB\5155821|NONE_0 (l_nsubj) use_2\NN\407535|while_10|use_118|may_134|to_143|._177 (l_prep) in_5\IN\13603305|the_16|of_8 (l_pobj) quantities_6\NNS\2137|NONE_0 (l_relcl) considered_10\VBN\689344|NONE_0 (l_oprd) associated_16\VBN\628491|that_41|may_36|be_32 (l_prep) with_17\IN\0|"_29|"_20|is_18|not_15 (l_pobj) functioning_20\VBG\29677|NONE_0
D018817_D008569 CID mdma_25\NNP\3054098|NONE_0 (r_compound) use_26\NN\407535|NONE_0 (r_pobj) of_24\IN\0|heavy_10 (r_prep) use_23\NN\407535|while_128|use_118|may_16|to_25|._59 (r_nsubj) lead_28\VB\5155821|NONE_0 (l_prep) to_29\IN\0|while_153|use_143|use_25|may_9|._34 (l_pobj) impairments_33\NNS\7296428|NONE_0
D012701_D020258 NONE serotonin_13\NN\14807737|to_16 (r_dobj) damage_11\VB\7296428|although_79|3,4-methylenedioxymethamphetamine_70|mdma_35|has_18|been_14 (r_xcomp) shown_9\VBN\2137132|,_77|little_79|is_86|about_95|._234 (r_advcl) known_26\VBN\0|NONE_0 (l_prep) about_27\IN\0|shown_95|,_18|little_16|is_9|._139 (l_pobj) consequences_32\NNS\34213|NONE_0 (l_prep) of_33\IN\0|the_27|term_18 (l_pobj) lesions_39\NNS\14204950|NONE_0
D012701_D020258 NONE 5-ht_15\CD\0|(_1|)_4|in_14|and_25|humans_38 (r_nmod) neurons_17\NNS\5430628|brain_23 (r_appos) serotonin_13\NN\14807737|to_16 (r_dobj) damage_11\VB\7296428|although_79|3,4-methylenedioxymethamphetamine_70|mdma_35|has_18|been_14 (r_xcomp) shown_9\VBN\2137132|,_77|little_79|is_86|about_95|._234 (r_advcl) known_26\VBN\0|NONE_0 (l_prep) about_27\IN\0|shown_95|,_18|little_16|is_9|._139 (l_pobj) consequences_32\NNS\34213|NONE_0 (l_prep) of_33\IN\0|the_27|term_18 (l_pobj) lesions_39\NNS\14204950|NONE_0
D012701_D020258 NONE 5-ht_37\CD\0|induced_8|neurotoxic_5|on_24 (r_nummod) lesions_39\NNS\14204950|NONE_0
D012701_D020258 NONE 5-ht_44\CD\0|in_9|is_5 (r_nsubjpass) involved_46\VBN\2676054|,_8|as_15 (r_relcl) functions_41\NNS\13783581|NONE_0 (r_pobj) on_40\IN\0|induced_32|5-ht_24|neurotoxic_19 (r_prep) lesions_39\NNS\14204950|NONE_0
D018817_D020258 NONE 3,4-methylenedioxymethamphetamine_1\CD\0|although_9|mdma_35|has_52|been_56|damage_70 (r_nsubjpass) shown_9\VBN\2137132|,_77|little_79|is_86|about_95|._234 (r_advcl) known_26\VBN\0|NONE_0 (l_prep) about_27\IN\0|shown_95|,_18|little_16|is_9|._139 (l_pobj) consequences_32\NNS\34213|NONE_0 (l_prep) of_33\IN\0|the_27|term_18 (l_pobj) lesions_39\NNS\14204950|NONE_0
D018817_D020258 NONE mdma_3\NNP\3054098|although_44|3,4-methylenedioxymethamphetamine_35|has_17|been_21|damage_35 (r_nsubjpass) shown_9\VBN\2137132|,_77|little_79|is_86|about_95|._234 (r_advcl) known_26\VBN\0|NONE_0 (l_prep) about_27\IN\0|shown_95|,_18|little_16|is_9|._139 (l_pobj) consequences_32\NNS\34213|NONE_0 (l_prep) of_33\IN\0|the_27|term_18 (l_pobj) lesions_39\NNS\14204950|NONE_0
D018817_D020258 NONE ecstasy_5\NN\13985818|(_9|or_3|)_7 (r_conj) mdma_3\NNP\3054098|although_44|3,4-methylenedioxymethamphetamine_35|has_17|been_21|damage_35 (r_nsubjpass) shown_9\VBN\2137132|,_77|little_79|is_86|about_95|._234 (r_advcl) known_26\VBN\0|NONE_0 (l_prep) about_27\IN\0|shown_95|,_18|little_16|is_9|._139 (l_pobj) consequences_32\NNS\34213|NONE_0 (l_prep) of_33\IN\0|the_27|term_18 (l_pobj) lesions_39\NNS\14204950|NONE_0
D018817_D020258 NONE mdma_34\NNP\3054098|-_4 (r_npadvmod) induced_36\VBN\1627355|5-ht_8|neurotoxic_13|on_32 (r_amod) lesions_39\NNS\14204950|NONE_0
4038130
D008619_D009135 CID mepivacaine_19\NN\0|NONE_0 (r_pobj) to_18\IN\0|NONE_0 (r_prep) exposure_17\NN\5042871|especially_17 (r_pobj) after_16\IN\0|in_90|,_62|damage_53|was_46|also_42|in_32|,_13|._60 (r_prep) seen_10\VBN\2106506|NONE_0 (l_prep) in_0\IN\13603305|,_28|damage_37|was_44|also_48|in_58|,_77|after_90|._150 (l_pobj) addition_1\NN\3081021|NONE_0 (l_prep) to_2\IN\0|NONE_0 (l_pobj) damage_4\NN\7296428|NONE_0
D008012_D009135 CID lidocaine_21\NN\3681148|and_4|plus_10|epinephrine_15 (r_conj) mepivacaine_19\NN\0|NONE_0 (r_pobj) to_18\IN\0|NONE_0 (r_prep) exposure_17\NN\5042871|especially_17 (r_pobj) after_16\IN\0|in_90|,_62|damage_53|was_46|also_42|in_32|,_13|._60 (r_prep) seen_10\VBN\2106506|NONE_0 (l_prep) in_0\IN\13603305|,_28|damage_37|was_44|also_48|in_58|,_77|after_90|._150 (l_pobj) addition_1\NN\3081021|NONE_0 (l_prep) to_2\IN\0|NONE_0 (l_pobj) damage_4\NN\7296428|NONE_0
D004837_D009135 NONE epinephrine_23\NN\14807929|and_19|lidocaine_15|plus_5 (r_conj) mepivacaine_19\NN\0|NONE_0 (r_pobj) to_18\IN\0|NONE_0 (r_prep) exposure_17\NN\5042871|especially_17 (r_pobj) after_16\IN\0|in_90|,_62|damage_53|was_46|also_42|in_32|,_13|._60 (r_prep) seen_10\VBN\2106506|NONE_0 (l_prep) in_0\IN\13603305|,_28|damage_37|was_44|also_48|in_58|,_77|after_90|._150 (l_pobj) addition_1\NN\3081021|NONE_0 (l_prep) to_2\IN\0|NONE_0 (l_pobj) damage_4\NN\7296428|NONE_0
8800187
D003891_D064420 NONE desipramine_8\JJ\4482543|in_21 (r_amod) toxicity_9\NN\13576101|NONE_0
D015761_D064420 NONE 4-aminopyridine_5\CD\0|on_24 (r_compound) therapy_6\NN\657604|calcium_37|and_20 (l_prep) on_7\IN\0|4-aminopyridine_24 (l_pobj) toxicity_9\NN\13576101|NONE_0
D002122_D007022 NONE cacl2_3\NNP\0|or_6 (r_pobj) of_2\IN\0|the_19 (r_prep) administration_1\NN\1133281|did_43|not_47|hypotension_92|._111 (r_nsubj) reverse_8\VB\13854649|NONE_0 (l_dobj) hypotension_13\NN\14057371|administration_92|did_49|not_45|._19
D003891_D001919 CID desipramine_6\NN\4482543|the_29|antidepressant_15 (r_compound) ip_7\NNP\5999797|rats_55|produce_6|._60 (r_dobj) received_2\VBD\2210855|NONE_0 (l_advcl) produce_9\VB\7555863|rats_61|ip_6|._54 (l_dobj) prolongation_13\NN\1017987|to_28|hypotension_17|,_6 (l_conj) bradycardia_16\NN\14110674|qrs_22|,_6|and_4
D002118_D007022 NONE calcium_7\NN\14625458|NONE_0 (r_compound) channel_8\NN\6251781|in_17 (r_compound) blockade_9\NN\952963|NONE_0 (l_prep) in_10\IN\13603305|channel_17 (l_pobj) hypotension_15\NN\14057371|NONE_0
D002118_D007022 NONE calcium_8\NN\14625458|NONE_0 (r_compound) channel_9\NN\6251781|in_19 (r_compound) inhibition_10\NN\1068773|NONE_0 (l_prep) in_11\IN\13603305|channel_19 (l_pobj) pathogenesis_13\NN\13533470|NONE_0 (l_prep) of_14\IN\0|the_17 (l_pobj) hypotension_19\NN\14057371|NONE_0
D015761_D007022 NONE 4-aminopyridine_5\NN\0|NONE_0 (r_punct) did_6\VBD\0|administration_43|not_4|hypotension_49|._68 (r_aux) reverse_8\VB\13854649|NONE_0 (l_dobj) hypotension_13\NN\14057371|administration_92|did_49|not_45|._19
D002122_D001145 CID cacl2_19\NNP\0|the_4 (r_compound) group_20\NN\2137|NONE_0 (r_pobj) in_17\IN\13603305|(_11|0.03_6|)_2 (r_prep) seizures_11\NNS\14081375|ventricular_40|0.004_11|and_4 (r_conj) arrhythmias_4\NNS\14103288|NONE_0
D002122_D002318 NONE cacl2_0\NNP\0|NONE_0 (r_compound) therapy_1\NN\657604|may_8|possibly_12|toxicity_75|._83 (r_nsubj) worsen_4\VB\146138|NONE_0 (l_dobj) toxicity_11\NN\13576101|therapy_75|may_67|possibly_63|._8
D002118_D062787 NONE calcium_14\NN\14625458|NONE_0 (r_compound) channel_15\NN\6251781|blocker_8 (r_compound) overdose_17\NN\84738|NONE_0
D002122_D002493 NONE cacl2_0\NNP\0|NONE_0 (r_compound) therapy_1\NN\657604|may_8|possibly_12|toxicity_75|._83 (r_nsubj) worsen_4\VB\146138|NONE_0 (l_dobj) toxicity_11\NN\13576101|therapy_75|may_67|possibly_63|._8
D017693_D007022 NONE nahco3_0\NNP\0|hypotension_32|._64 (r_nsubj) reversed_6\VBD\109660|NONE_0 (l_dobj) hypotension_7\NN\14057371|nahco3_32|._32
D002122_D012640 NONE cacl2_19\NNP\0|the_4 (r_compound) group_20\NN\2137|NONE_0 (r_pobj) in_17\IN\13603305|(_11|0.03_6|)_2 (r_prep) seizures_11\NNS\14081375|ventricular_40|0.004_11|and_4
D002122_D064420 NONE chloride_3\NN\14818238|NONE_0 (l_conj) therapy_6\NN\657604|calcium_37|and_20 (l_prep) on_7\IN\0|4-aminopyridine_24 (l_pobj) toxicity_9\NN\13576101|NONE_0
D003891_D007022 CID desipramine_6\NN\4482543|the_29|antidepressant_15 (r_compound) ip_7\NNP\5999797|rats_55|produce_6|._60 (r_dobj) received_2\VBD\2210855|NONE_0 (l_advcl) produce_9\VB\7555863|rats_61|ip_6|._54 (l_dobj) hypotension_10\NN\14057371|to_11|,_11|prolongation_17
8546130
D017291_D007676 NONE clarithromycin_0\NN\0|-_14 (r_npadvmod) associated_2\VBN\628491|visual_11|in_33|._117 (r_amod) hallucinations_4\NNS\14376855|NONE_0 (l_prep) in_5\IN\13603305|associated_33|visual_22|._84 (l_pobj) patient_7\NN\9898892|NONE_0 (l_prep) with_8\IN\0|a_10 (l_pobj) failure_11\NN\66216|NONE_0
D017291_D007676 NONE clarithromycin_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_23|high_10|in_18|in_51 (r_prep) dose_6\NN\3740161|NONE_0 (l_prep) in_9\IN\13603305|a_41|high_28|of_18|in_33 (l_pobj) face_10\NN\5225090|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) failure_14\NN\66216|NONE_0
D017291_D020258 NONE clarithromycin_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_23|high_10|in_18|in_51 (r_prep) dose_6\NN\3740161|NONE_0 (r_pobj) of_2\IN\0|the_16|,_111|with_113|,_150 (r_prep) combination_1\NN\7951464|may_164|have_168|appearance_189|._230 (r_nsubj) facilitated_28\VBN\2547586|NONE_0 (l_dobj) appearance_30\NN\4723816|combination_189|may_25|have_21|._41 (l_prep) of_31\IN\0|the_15 (l_pobj) effect_35\NN\34213|NONE_0 (l_amod) neurotoxic_33\JJ\0|this_5|side_11
D018942_D006212 NONE macrolide_13\NN\0|the_8|new_4|,_20|clarithromycin_22 (r_amod) antibiotic_14\NN\2716205|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) association_9\NN\8008335|NONE_0 (r_pobj) in_8\IN\13603305|NONE_0 (r_prep) occurring_7\VBG\0|visual_22 (r_acl) hallucinations_6\NNS\14376855|in_28|is_10|._89
D000535_D020258 NONE aluminum_23\NN\14625458|underlying_11 (r_compound) intoxication_24\NN\14034177|NONE_0 (r_pobj) with_21\IN\0|the_129|of_113|,_2|,_37 (r_prep) combination_1\NN\7951464|may_164|have_168|appearance_189|._230 (r_nsubj) facilitated_28\VBN\2547586|NONE_0 (l_dobj) appearance_30\NN\4723816|combination_189|may_25|have_21|._41 (l_prep) of_31\IN\0|the_15 (l_pobj) effect_35\NN\34213|NONE_0 (l_amod) neurotoxic_33\JJ\0|this_5|side_11
D017291_D006212 CID clarithromycin_0\NN\0|-_14 (r_npadvmod) associated_2\VBN\628491|visual_11|in_33|._117 (r_amod) hallucinations_4\NNS\14376855|NONE_0
D017291_D006212 CID clarithromycin_16\NN\0|the_30|new_26|macrolide_22|,_2 (r_appos) antibiotic_14\NN\2716205|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) association_9\NN\8008335|NONE_0 (r_pobj) in_8\IN\13603305|NONE_0 (r_prep) occurring_7\VBG\0|visual_22 (r_acl) hallucinations_6\NNS\14376855|in_28|is_10|._89
D000535_D007676 NONE aluminum_23\NN\14625458|underlying_11 (r_compound) intoxication_24\NN\14034177|NONE_0 (r_pobj) with_21\IN\0|the_129|of_113|,_2|,_37 (r_prep) combination_1\NN\7951464|may_164|have_168|appearance_189|._230 (l_prep) of_2\IN\0|the_16|,_111|with_113|,_150 (l_pobj) dose_6\NN\3740161|NONE_0 (l_prep) in_9\IN\13603305|a_41|high_28|of_18|in_33 (l_pobj) face_10\NN\5225090|NONE_0 (l_prep) of_11\IN\0|NONE_0 (l_pobj) failure_14\NN\66216|NONE_0
9121607
D016202_D012640 NONE aspartate_6\NNP\0|NONE_0 (l_appos) seizures_9\NNS\14081375|methyl_34|d_27|-_26|._16
D016202_D012640 NONE nmda)-induced_8\JJ\0|(_1|in_23 (r_amod) seizures_9\NNS\14081375|methyl_34|d_27|-_26|._16
D016202_D012640 NONE nmda_10\NNP\0|NONE_0 (r_pobj) in_9\IN\13603305|a_23|dependent_16|(_8|mg/kg_13 (r_prep) delay_8\NN\15271008|steroids_38|also_29|,_49|but_51|protect_74|._116 (r_dobj) caused_3\VBD\1617192|NONE_0 (l_conj) protect_22\VB\1127795|steroids_112|also_103|delay_74|,_25|but_23|._42 (l_prep) against_23\IN\0|did_27|not_23|completely_19 (l_pobj) seizures_25\NNS\14081375|NONE_0
D016202_D012640 NONE nmda_24\NNP\0|or_14|lethality_17 (r_compound) seizures_25\NNS\14081375|NONE_0
D007608_D013226 CID acid_7\NN\14818238|-_4 (r_npadvmod) induced_9\VBN\1627355|pilocarpine-_29|limbic_8|and_24|status_28 (r_amod) seizures_11\NNS\14081375|NONE_0 (r_pobj) against_3\IN\0|steroids_17|epilepticus_72|._91 (r_prep) protect_2\VBP\1127795|NONE_0 (l_advcl) epilepticus_14\NN\0|steroids_89|against_72|._19
D007608_D013226 CID acid_23\NN\14818238|-_4 (r_npadvmod) induced_25\VBN\1627355|kainic_12|limbic_8|and_24|epilepticus_35 (r_amod) seizures_27\NNS\14081375|NONE_0 (l_conj) epilepticus_30\NN\0|kainic_47|induced_35|limbic_27|and_11
D007608_D013226 CID acid_14\NN\14818238|-_4 (r_npadvmod) induced_16\VBN\1627355|pilocarpine-_29|and_17|status_21 (r_amod) seizures_17\NNS\14081375|NONE_0 (r_pobj) against_10\IN\0|NONE_0 (r_prep) protecting_9\VBG\1127795|NONE_0 (r_pcomp) in_8\IN\13603305|highly_17 (r_prep) effective_7\JJ\0|that_37|steroids_20|epilepticus_89|,_108|and_110|be_118 (r_acomp) are_5\VBP\13600404|we_38|._205 (l_advcl) epilepticus_20\NN\0|that_126|steroids_109|effective_89|,_19|and_21|be_29
D007608_D013226 CID acid_14\NN\14818238|-_4 (r_npadvmod) induced_16\VBN\1627355|pilocarpine-_29|and_17|status_21 (r_amod) seizures_17\NNS\14081375|NONE_0 (r_pobj) against_10\IN\0|NONE_0 (r_prep) protecting_9\VBG\1127795|NONE_0 (r_pcomp) in_8\IN\13603305|highly_17 (r_prep) effective_7\JJ\0|that_37|steroids_20|epilepticus_89|,_108|and_110|be_118 (r_acomp) are_5\VBP\13600404|we_38|._205 (l_conj) be_26\VB\14625458|that_155|steroids_138|effective_118|epilepticus_29|,_10|and_8 (l_advmod) epilepticus_37\NN\0|may_59|of_52|in_41
D013256_D012640 NONE steroids_1\NNS\14727670|against_17|epilepticus_89|._108 (r_nsubj) protect_2\VBP\1127795|NONE_0 (l_prep) against_3\IN\0|steroids_17|epilepticus_72|._91 (l_pobj) seizures_11\NNS\14081375|NONE_0
D013256_D012640 NONE steroids_0\NNS\14727670|effective_113|mg/kg_162|values_234|._263 (r_nsubj) were_19\VBD\0|NONE_0 (l_parataxis) mg/kg_28\NNS\0|steroids_162|effective_49|values_72|._101 (l_conj) s.c.)-induced_30\VBN\0|(_12|416_11|,_2 (l_dobj) seizures_33\NNS\14081375|NONE_0
D013256_D012640 NONE steroids_3\NNS\14727670|although_25|potent_32 (r_nsubj) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (l_acomp) potent_7\JJ\0|although_57|steroids_32 (l_advcl) clonazepam_11\NN\0|less_36 (l_prep) in_12\IN\13603305|than_35|the_30|benzodiazepine_26 (l_pcomp) protecting_13\VBG\1127795|NONE_0 (l_prep) against_14\IN\0|NONE_0 (l_pobj) seizures_16\NNS\14081375|NONE_0
D013256_D012640 NONE steroids_3\NNS\14727670|although_25|potent_32 (r_nsubj) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (r_advcl) had_26\VBD\0|NONE_0 (l_dobj) values_32\NNS\5941423|were_199|,_92|steroids_90|clonazepam_79|,_89|indicating_91|._165 (l_appos) td50_34\NNP\0|comparable_46|protective_25|index_14|(_1|)_64 (l_acl) divided_38\VBN\140123|for_21 (l_prep) for_41\IN\0|by_8 (l_pobj) protection_43\NN\407535|NONE_0 (l_compound) seizure_42\NN\14081375|NONE_0
D013256_D012640 NONE steroids_18\NNS\14727670|were_109|,_2|values_90|clonazepam_169|,_179|indicating_181|._255 (r_nsubj) had_26\VBD\0|NONE_0 (l_advcl) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (l_acomp) potent_7\JJ\0|although_57|steroids_32 (l_advcl) clonazepam_11\NN\0|less_36 (l_prep) in_12\IN\13603305|than_35|the_30|benzodiazepine_26 (l_pcomp) protecting_13\VBG\1127795|NONE_0 (l_prep) against_14\IN\0|NONE_0 (l_pobj) seizures_16\NNS\14081375|NONE_0
D013256_D012640 NONE steroids_18\NNS\14727670|were_109|,_2|values_90|clonazepam_169|,_179|indicating_181|._255 (r_nsubj) had_26\VBD\0|NONE_0 (l_dobj) values_32\NNS\5941423|were_199|,_92|steroids_90|clonazepam_79|,_89|indicating_91|._165 (l_appos) td50_34\NNP\0|comparable_46|protective_25|index_14|(_1|)_64 (l_acl) divided_38\VBN\140123|for_21 (l_prep) for_41\IN\0|by_8 (l_pobj) protection_43\NN\407535|NONE_0 (l_compound) seizure_42\NN\14081375|NONE_0
D013256_D012640 NONE steroids_52\NNS\14727670|that_22|may_9|toxicity_33 (r_nsubj) have_54\VB\7846|NONE_0 (r_ccomp) indicating_48\VBG\952524|were_290|,_183|steroids_181|values_91|clonazepam_12|,_2|._74 (r_advcl) had_26\VBD\0|NONE_0 (l_advcl) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (l_acomp) potent_7\JJ\0|although_57|steroids_32 (l_advcl) clonazepam_11\NN\0|less_36 (l_prep) in_12\IN\13603305|than_35|the_30|benzodiazepine_26 (l_pcomp) protecting_13\VBG\1127795|NONE_0 (l_prep) against_14\IN\0|NONE_0 (l_pobj) seizures_16\NNS\14081375|NONE_0
D013256_D012640 NONE steroids_52\NNS\14727670|that_22|may_9|toxicity_33 (r_nsubj) have_54\VB\7846|NONE_0 (r_ccomp) indicating_48\VBG\952524|were_290|,_183|steroids_181|values_91|clonazepam_12|,_2|._74 (r_advcl) had_26\VBD\0|NONE_0 (l_dobj) values_32\NNS\5941423|were_199|,_92|steroids_90|clonazepam_79|,_89|indicating_91|._165 (l_appos) td50_34\NNP\0|comparable_46|protective_25|index_14|(_1|)_64 (l_acl) divided_38\VBN\140123|for_21 (l_prep) for_41\IN\0|by_8 (l_pobj) protection_43\NN\407535|NONE_0 (l_compound) seizure_42\NN\14081375|NONE_0
D013256_D012640 NONE steroids_0\NNS\14727670|configurations_53|also_68|delay_99|,_176|but_178|protect_201|._229 (r_nsubj) produced_13\VBD\1617192|NONE_0 (l_dobj) delay_18\NN\15271008|steroids_99|configurations_46|also_31|,_77|but_79|protect_102|._130 (l_prep) in_19\IN\13603305|a_23|dependent_16|induced_32 (l_pobj) onset_21\NN\7325190|NONE_0 (l_prep) of_22\IN\0|the_10 (l_pobj) seizures_24\NNS\14081375|NONE_0
D013256_D012640 NONE steroids_0\NNS\14727670|configurations_53|also_68|delay_99|,_176|but_178|protect_201|._229 (r_nsubj) produced_13\VBD\1617192|NONE_0 (l_conj) protect_40\VB\1127795|steroids_201|configurations_148|also_133|delay_102|,_25|but_23|._28 (l_prep) against_41\IN\0|did_27|not_23|completely_19 (l_pobj) seizures_43\NNS\14081375|NONE_0
D013256_D012640 NONE steroid_8\NN\14727670|NONE_0 (r_pobj) of_6\IN\0|a_14|second_12 (r_prep) dose_5\NN\3740161|when_14|was_20 (r_nsubjpass) administered_10\VBN\2436349|however_47|,_40|1_13|after_18 (r_advcl) hr_12\NN\15154774|,_23|complete_25|from_45 (r_nmod) protection_19\NN\407535|was_79|._91 (l_prep) from_20\IN\0|hr_45|,_22|complete_20 (l_pobj) seizures_27\NNS\14081375|NONE_0
D013256_D012640 NONE steroids_1\NNS\14727670|also_9|delay_38|,_87|but_89|protect_112|._154 (r_nsubj) caused_3\VBD\1617192|NONE_0 (l_conj) protect_22\VB\1127795|steroids_112|also_103|delay_74|,_25|but_23|._42 (l_prep) against_23\IN\0|did_27|not_23|completely_19 (l_pobj) seizures_25\NNS\14081375|NONE_0
D013256_D012640 NONE steroids_4\NNS\14727670|that_17|effective_20|epilepticus_109|,_128|and_130|be_138 (r_nsubj) are_5\VBP\13600404|we_38|._205 (l_acomp) effective_7\JJ\0|that_37|steroids_20|epilepticus_89|,_108|and_110|be_118 (l_prep) in_8\IN\13603305|highly_17 (l_pcomp) protecting_9\VBG\1127795|NONE_0 (l_prep) against_10\IN\0|NONE_0 (l_pobj) seizures_17\NNS\14081375|NONE_0
D001569_D012640 NONE benzodiazepine_10\JJ\3771443|than_9|the_4|in_26 (r_amod) clonazepam_11\NN\0|less_36 (l_prep) in_12\IN\13603305|than_35|the_30|benzodiazepine_26 (l_pcomp) protecting_13\VBG\1127795|NONE_0 (l_prep) against_14\IN\0|NONE_0 (l_pobj) seizures_16\NNS\14081375|NONE_0
D001569_D012640 NONE benzodiazepine_10\JJ\3771443|than_9|the_4|in_26 (r_amod) clonazepam_11\NN\0|less_36 (r_advcl) potent_7\JJ\0|although_57|steroids_32 (r_acomp) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (r_advcl) had_26\VBD\0|NONE_0 (l_dobj) values_32\NNS\5941423|were_199|,_92|steroids_90|clonazepam_79|,_89|indicating_91|._165 (l_appos) td50_34\NNP\0|comparable_46|protective_25|index_14|(_1|)_64 (l_acl) divided_38\VBN\140123|for_21 (l_prep) for_41\IN\0|by_8 (l_pobj) protection_43\NN\407535|NONE_0 (l_compound) seizure_42\NN\14081375|NONE_0
D013256_D013226 NONE steroids_1\NNS\14727670|against_17|epilepticus_89|._108 (r_nsubj) protect_2\VBP\1127795|NONE_0 (l_advcl) epilepticus_14\NN\0|steroids_89|against_72|._19
D013256_D013226 NONE steroids_0\NNS\14727670|effective_113|mg/kg_162|values_234|._263 (r_nsubj) were_19\VBD\0|NONE_0 (l_npadvmod) values_39\NNS\5941423|steroids_234|effective_121|mg/kg_72|._29 (l_amod) epilepticus_36\NN\0|(_12|ed50_13|,_24|mg/kg_35|)_46
D013256_D013226 NONE steroid_8\NN\14727670|NONE_0 (r_pobj) of_6\IN\0|a_14|second_12 (r_prep) dose_5\NN\3740161|when_14|was_20 (r_nsubjpass) administered_10\VBN\2436349|however_47|,_40|1_13|after_18 (r_advcl) hr_12\NN\15154774|,_23|complete_25|from_45 (r_nmod) protection_19\NN\407535|was_79|._91 (l_prep) from_20\IN\0|hr_45|,_22|complete_20 (l_pobj) seizures_27\NNS\14081375|NONE_0 (l_conj) epilepticus_30\NN\0|kainic_47|induced_35|limbic_27|and_11
D013256_D013226 NONE steroids_4\NNS\14727670|that_17|effective_20|epilepticus_109|,_128|and_130|be_138 (r_nsubj) are_5\VBP\13600404|we_38|._205 (l_advcl) epilepticus_20\NN\0|that_126|steroids_109|effective_89|,_19|and_21|be_29
D013256_D013226 NONE steroids_4\NNS\14727670|that_17|effective_20|epilepticus_109|,_128|and_130|be_138 (r_nsubj) are_5\VBP\13600404|we_38|._205 (l_conj) be_26\VB\14625458|that_155|steroids_138|effective_118|epilepticus_29|,_10|and_8 (l_advmod) epilepticus_37\NN\0|may_59|of_52|in_41
D010862_D013226 CID pilocarpine-_4\NN\0|induced_29|limbic_37|and_53|status_57 (r_nmod) seizures_11\NNS\14081375|NONE_0 (r_pobj) against_3\IN\0|steroids_17|epilepticus_72|._91 (r_prep) protect_2\VBP\1127795|NONE_0 (l_advcl) epilepticus_14\NN\0|steroids_89|against_72|._19
D010862_D013226 CID pilocarpine_25\NN\14712692|NONE_0 (r_pobj) against_24\IN\0|NONE_0 (r_prep) protecting_23\VBG\1127795|NONE_0 (r_pcomp) in_22\IN\13603305|highly_17 (r_prep) effective_21\JJ\0|steroids_113|mg/kg_49|values_121|._150 (r_acomp) were_19\VBD\0|NONE_0 (l_npadvmod) values_39\NNS\5941423|steroids_234|effective_121|mg/kg_72|._29 (l_amod) epilepticus_36\NN\0|(_12|ed50_13|,_24|mg/kg_35|)_46
D010862_D013226 CID pilocarpine-_11\NN\0|induced_29|and_46|status_50 (r_nmod) seizures_17\NNS\14081375|NONE_0 (r_pobj) against_10\IN\0|NONE_0 (r_prep) protecting_9\VBG\1127795|NONE_0 (r_pcomp) in_8\IN\13603305|highly_17 (r_prep) effective_7\JJ\0|that_37|steroids_20|epilepticus_89|,_108|and_110|be_118 (r_acomp) are_5\VBP\13600404|we_38|._205 (l_advcl) epilepticus_20\NN\0|that_126|steroids_109|effective_89|,_19|and_21|be_29
D010862_D013226 CID pilocarpine-_11\NN\0|induced_29|and_46|status_50 (r_nmod) seizures_17\NNS\14081375|NONE_0 (r_pobj) against_10\IN\0|NONE_0 (r_prep) protecting_9\VBG\1127795|NONE_0 (r_pcomp) in_8\IN\13603305|highly_17 (r_prep) effective_7\JJ\0|that_37|steroids_20|epilepticus_89|,_108|and_110|be_118 (r_acomp) are_5\VBP\13600404|we_38|._205 (l_conj) be_26\VB\14625458|that_155|steroids_138|effective_118|epilepticus_29|,_10|and_8 (l_advmod) epilepticus_37\NN\0|may_59|of_52|in_41
D001569_D064420 NONE benzodiazepine_10\JJ\3771443|than_9|the_4|in_26 (r_amod) clonazepam_11\NN\0|less_36 (r_advcl) potent_7\JJ\0|although_57|steroids_32 (r_acomp) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (r_advcl) had_26\VBD\0|NONE_0 (l_advcl) indicating_48\VBG\952524|were_290|,_183|steroids_181|values_91|clonazepam_12|,_2|._74 (l_ccomp) have_54\VB\7846|NONE_0 (l_dobj) toxicity_57\NN\13576101|that_55|steroids_33|may_24
D013256_D064420 NONE steroids_3\NNS\14727670|although_25|potent_32 (r_nsubj) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (r_advcl) had_26\VBD\0|NONE_0 (l_advcl) indicating_48\VBG\952524|were_290|,_183|steroids_181|values_91|clonazepam_12|,_2|._74 (l_ccomp) have_54\VB\7846|NONE_0 (l_dobj) toxicity_57\NN\13576101|that_55|steroids_33|may_24
D013256_D064420 NONE steroids_18\NNS\14727670|were_109|,_2|values_90|clonazepam_169|,_179|indicating_181|._255 (r_nsubj) had_26\VBD\0|NONE_0 (l_advcl) indicating_48\VBG\952524|were_290|,_183|steroids_181|values_91|clonazepam_12|,_2|._74 (l_ccomp) have_54\VB\7846|NONE_0 (l_dobj) toxicity_57\NN\13576101|that_55|steroids_33|may_24
D013256_D064420 NONE steroids_52\NNS\14727670|that_22|may_9|toxicity_33 (r_nsubj) have_54\VB\7846|NONE_0 (l_dobj) toxicity_57\NN\13576101|that_55|steroids_33|may_24
D002998_D064420 NONE clonazepam_11\NN\0|less_36 (r_advcl) potent_7\JJ\0|although_57|steroids_32 (r_acomp) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (r_advcl) had_26\VBD\0|NONE_0 (l_advcl) indicating_48\VBG\952524|were_290|,_183|steroids_181|values_91|clonazepam_12|,_2|._74 (l_ccomp) have_54\VB\7846|NONE_0 (l_dobj) toxicity_57\NN\13576101|that_55|steroids_33|may_24
D002998_D064420 NONE clonazepam_46\NN\0|were_278|,_171|steroids_169|values_79|,_10|indicating_12|._86 (r_advcl) had_26\VBD\0|NONE_0 (l_advcl) indicating_48\VBG\952524|were_290|,_183|steroids_181|values_91|clonazepam_12|,_2|._74 (l_ccomp) have_54\VB\7846|NONE_0 (l_dobj) toxicity_57\NN\13576101|that_55|steroids_33|may_24
D002998_D012640 NONE clonazepam_11\NN\0|less_36 (l_prep) in_12\IN\13603305|than_35|the_30|benzodiazepine_26 (l_pcomp) protecting_13\VBG\1127795|NONE_0 (l_prep) against_14\IN\0|NONE_0 (l_pobj) seizures_16\NNS\14081375|NONE_0
D002998_D012640 NONE clonazepam_11\NN\0|less_36 (r_advcl) potent_7\JJ\0|although_57|steroids_32 (r_acomp) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (r_advcl) had_26\VBD\0|NONE_0 (l_dobj) values_32\NNS\5941423|were_199|,_92|steroids_90|clonazepam_79|,_89|indicating_91|._165 (l_appos) td50_34\NNP\0|comparable_46|protective_25|index_14|(_1|)_64 (l_acl) divided_38\VBN\140123|for_21 (l_prep) for_41\IN\0|by_8 (l_pobj) protection_43\NN\407535|NONE_0 (l_compound) seizure_42\NN\14081375|NONE_0
D002998_D012640 NONE clonazepam_46\NN\0|were_278|,_171|steroids_169|values_79|,_10|indicating_12|._86 (r_advcl) had_26\VBD\0|NONE_0 (l_advcl) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (l_acomp) potent_7\JJ\0|although_57|steroids_32 (l_advcl) clonazepam_11\NN\0|less_36 (l_prep) in_12\IN\13603305|than_35|the_30|benzodiazepine_26 (l_pcomp) protecting_13\VBG\1127795|NONE_0 (l_prep) against_14\IN\0|NONE_0 (l_pobj) seizures_16\NNS\14081375|NONE_0
D002998_D012640 NONE clonazepam_46\NN\0|were_278|,_171|steroids_169|values_79|,_10|indicating_12|._86 (r_advcl) had_26\VBD\0|NONE_0 (l_dobj) values_32\NNS\5941423|were_199|,_92|steroids_90|clonazepam_79|,_89|indicating_91|._165 (l_appos) td50_34\NNP\0|comparable_46|protective_25|index_14|(_1|)_64 (l_acl) divided_38\VBN\140123|for_21 (l_prep) for_41\IN\0|by_8 (l_pobj) protection_43\NN\407535|NONE_0 (l_compound) seizure_42\NN\14081375|NONE_0
D010862_D012640 CID pilocarpine-_4\NN\0|induced_29|limbic_37|and_53|status_57 (r_nmod) seizures_11\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_25\NN\14712692|NONE_0 (r_pobj) against_24\IN\0|NONE_0 (r_prep) protecting_23\VBG\1127795|NONE_0 (r_pcomp) in_22\IN\13603305|highly_17 (r_prep) effective_21\JJ\0|steroids_113|mg/kg_49|values_121|._150 (r_acomp) were_19\VBD\0|NONE_0 (l_parataxis) mg/kg_28\NNS\0|steroids_162|effective_49|values_72|._101 (l_conj) s.c.)-induced_30\VBN\0|(_12|416_11|,_2 (l_dobj) seizures_33\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_15\NN\14712692|NONE_0 (r_amod) seizures_16\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_15\NN\14712692|NONE_0 (r_amod) seizures_16\NNS\14081375|NONE_0 (r_pobj) against_14\IN\0|NONE_0 (r_prep) protecting_13\VBG\1127795|NONE_0 (r_pcomp) in_12\IN\13603305|than_35|the_30|benzodiazepine_26 (r_prep) clonazepam_11\NN\0|less_36 (r_advcl) potent_7\JJ\0|although_57|steroids_32 (r_acomp) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (r_advcl) had_26\VBD\0|NONE_0 (l_dobj) values_32\NNS\5941423|were_199|,_92|steroids_90|clonazepam_79|,_89|indicating_91|._165 (l_appos) td50_34\NNP\0|comparable_46|protective_25|index_14|(_1|)_64 (l_acl) divided_38\VBN\140123|for_21 (l_prep) for_41\IN\0|by_8 (l_pobj) protection_43\NN\407535|NONE_0 (l_compound) seizure_42\NN\14081375|NONE_0
D010862_D012640 CID pilocarpine-_11\NN\0|induced_29|and_46|status_50 (r_nmod) seizures_17\NNS\14081375|NONE_0
D007608_D012640 CID acid_7\NN\14818238|-_4 (r_npadvmod) induced_9\VBN\1627355|pilocarpine-_29|limbic_8|and_24|status_28 (r_amod) seizures_11\NNS\14081375|NONE_0
D007608_D012640 CID acid_28\NN\14818238|NONE_0 (r_pobj) by_26\IN\0|NONE_0 (r_agent) induced_25\VBN\1627355|a_55|dependent_48|in_32 (r_acl) delay_18\NN\15271008|steroids_99|configurations_46|also_31|,_77|but_79|protect_102|._130 (l_prep) in_19\IN\13603305|a_23|dependent_16|induced_32 (l_pobj) onset_21\NN\7325190|NONE_0 (l_prep) of_22\IN\0|the_10 (l_pobj) seizures_24\NNS\14081375|NONE_0
D007608_D012640 CID acid_28\NN\14818238|NONE_0 (r_pobj) by_26\IN\0|NONE_0 (r_agent) induced_25\VBN\1627355|a_55|dependent_48|in_32 (r_acl) delay_18\NN\15271008|steroids_99|configurations_46|also_31|,_77|but_79|protect_102|._130 (r_dobj) produced_13\VBD\1617192|NONE_0 (l_conj) protect_40\VB\1127795|steroids_201|configurations_148|also_133|delay_102|,_25|but_23|._28 (l_prep) against_41\IN\0|did_27|not_23|completely_19 (l_pobj) seizures_43\NNS\14081375|NONE_0
D007608_D012640 CID acid_23\NN\14818238|-_4 (r_npadvmod) induced_25\VBN\1627355|kainic_12|limbic_8|and_24|epilepticus_35 (r_amod) seizures_27\NNS\14081375|NONE_0
D007608_D012640 CID acid_14\NN\14818238|-_4 (r_npadvmod) induced_16\VBN\1627355|pilocarpine-_29|and_17|status_21 (r_amod) seizures_17\NNS\14081375|NONE_0
D010862_D064420 NONE pilocarpine_15\NN\14712692|NONE_0 (r_amod) seizures_16\NNS\14081375|NONE_0 (r_pobj) against_14\IN\0|NONE_0 (r_prep) protecting_13\VBG\1127795|NONE_0 (r_pcomp) in_12\IN\13603305|than_35|the_30|benzodiazepine_26 (r_prep) clonazepam_11\NN\0|less_36 (r_advcl) potent_7\JJ\0|although_57|steroids_32 (r_acomp) were_4\VBD\0|,_107|steroids_109|values_199|clonazepam_278|,_288|indicating_290|._364 (r_advcl) had_26\VBD\0|NONE_0 (l_advcl) indicating_48\VBG\952524|were_290|,_183|steroids_181|values_91|clonazepam_12|,_2|._74 (l_ccomp) have_54\VB\7846|NONE_0 (l_dobj) toxicity_57\NN\13576101|that_55|steroids_33|may_24
9226773
D008094_D018500 CID lithium_5\NN\14625458|NONE_0 (r_compound) therapy_6\NN\657604|NONE_0 (r_dobj) following_4\VBG\8180190|diabetes_19|._25 (r_prep) insipidus_3\NN\0|NONE_0
D008094_D018500 CID lithium_9\NN\14625458|-_7 (r_npadvmod) induced_11\VBN\1627355|diabetes_20 (r_amod) insipidus_14\NN\0|to_45
D008094_D018500 CID lithium_17\NN\14625458|NONE_0 (r_compound) therapy_18\NN\657604|had_8|been_12|._29 (r_nsubjpass) discontinued_21\VBN\0|years_124|previously_118|he_107|had_104|been_100|have_82|,_31|and_29 (r_conj) diagnosed_6\VBN\644583|NONE_0 (l_xcomp) have_8\VB\7846|years_42|previously_36|he_25|had_22|been_18|,_51|and_53|discontinued_82 (l_dobj) insipidus_14\NN\0|to_45
D008094_D018500 CID lithium_8\NN\14625458|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) cessation_6\NN\7365849|NONE_0 (r_pobj) despite_5\IN\7501545|NONE_0 (r_prep) polyuric_4\JJ\0|and_4 (r_conj) thirsty_2\JJ\0|he_12|showed_82|._209 (r_acomp) remained_1\VBD\2604760|NONE_0 (l_conj) showed_13\VBD\2137132|he_94|thirsty_82|._127 (l_ccomp) have_16\VB\7846|NONE_0 (l_prep) with_24\IN\0|him_67|to_63|thirst_34|,_2 (l_pobj) evidence_26\NN\5816287|NONE_0 (l_prep) of_27\IN\0|clear_15 (l_pobj) insipidus_30\NN\0|NONE_0
D008094_D018500 CID lithium_0\NN\14625458|insipidus_37 (r_nsubj) induced_1\VBD\1627355|is_39|be_56|._172 (l_dobj) insipidus_4\NN\0|lithium_37
D008094_D018500 CID lithium_24\NN\14625458|after_6|was_8 (r_nsubjpass) stopped_26\VBN\0|to_112|reversible_106 (r_advcl) be_8\VB\14625458|induced_56|is_17|._116 (r_xcomp) considered_6\VBN\689344|NONE_0 (l_csubjpass) induced_1\VBD\1627355|is_39|be_56|._172 (l_dobj) insipidus_4\NN\0|lithium_37
D008094_D018500 CID lithium_14\NN\14625458|-_7 (r_npadvmod) induced_16\VBN\1627355|diabetes_20 (r_amod) insipidus_19\NN\0|NONE_0
D008094_D011141 CID lithium_8\NN\14625458|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) cessation_6\NN\7365849|NONE_0 (r_pobj) despite_5\IN\7501545|NONE_0 (r_prep) polyuric_4\JJ\0|and_4
D008094_D011141 CID lithium_0\NN\14625458|insipidus_37 (r_nsubj) induced_1\VBD\1627355|is_39|be_56|._172 (r_csubjpass) considered_6\VBN\689344|NONE_0 (l_xcomp) be_8\VB\14625458|induced_56|is_17|._116 (l_acomp) reversible_9\JJ\3419014|to_6|stopped_106 (l_prep) on_10\IN\0|NONE_0 (l_pobj) cessation_11\NN\7365849|NONE_0 (l_prep) of_12\IN\0|persisted_24 (l_pobj) therapy_13\NN\657604|NONE_0 (l_conj) polyuria_15\NN\14113228|but_4
D008094_D011141 CID lithium_24\NN\14625458|after_6|was_8 (r_nsubjpass) stopped_26\VBN\0|to_112|reversible_106 (r_advcl) be_8\VB\14625458|induced_56|is_17|._116 (l_acomp) reversible_9\JJ\3419014|to_6|stopped_106 (l_prep) on_10\IN\0|NONE_0 (l_pobj) cessation_11\NN\7365849|NONE_0 (l_prep) of_12\IN\0|persisted_24 (l_pobj) therapy_13\NN\657604|NONE_0 (l_conj) polyuria_15\NN\14113228|but_4
D014667_D011141 NONE vasopressin_21\NN\5407119|NONE_0 (r_compound) secretion_22\NN\13526110|normal_44|osmoregulated_37|and_16 (r_conj) thirst_19\NN\14035298|him_33|to_29|,_32|with_34 (r_dobj) have_16\VB\7846|NONE_0 (r_ccomp) showed_13\VBD\2137132|he_94|thirsty_82|._127 (r_conj) remained_1\VBD\2604760|NONE_0 (l_acomp) thirsty_2\JJ\0|he_12|showed_82|._209 (l_conj) polyuric_4\JJ\0|and_4
D014667_D018500 NONE vasopressin_21\NN\5407119|NONE_0 (r_compound) secretion_22\NN\13526110|normal_44|osmoregulated_37|and_16 (r_conj) thirst_19\NN\14035298|him_33|to_29|,_32|with_34 (r_dobj) have_16\VB\7846|NONE_0 (l_prep) with_24\IN\0|him_67|to_63|thirst_34|,_2 (l_pobj) evidence_26\NN\5816287|NONE_0 (l_prep) of_27\IN\0|clear_15 (l_pobj) insipidus_30\NN\0|NONE_0
3780697
D005283_D009127 CID fentanyl_5\NN\2707683|NONE_0 (r_compound) administration_6\NN\1133281|NONE_0 (r_pobj) after_4\IN\0|operative_19|._29 (r_prep) rigidity_3\NN\5023233|NONE_0
D005283_D009127 CID fentanyl_29\NN\2707683|NONE_0 (r_pobj) of_28\IN\0|a_16|moderate_14 (r_prep) dose_27\NN\3740161|who_24 (r_dobj) received_24\VBD\2210855|an_23|elderly_20 (r_relcl) patient_22\NN\9898892|NONE_0 (r_pobj) in_19\IN\13603305|the_26|operative_17 (r_prep) period_18\NN\13575869|NONE_0 (r_pobj) in_13\IN\13603305|case_79|is_13|._91 (r_prep) described_12\VBN\1001294|NONE_0 (l_nsubjpass) case_1\NN\7283608|is_66|in_79|._170 (l_prep) of_2\IN\0|a_7 (l_pobj) rigidity_6\NN\5023233|NONE_0
D005283_D012131 NONE fentanyl_29\NN\2707683|NONE_0 (r_pobj) of_28\IN\0|a_16|moderate_14 (r_prep) dose_27\NN\3740161|who_24 (r_dobj) received_24\VBD\2210855|an_23|elderly_20 (r_relcl) patient_22\NN\9898892|NONE_0 (r_pobj) in_19\IN\13603305|the_26|operative_17 (r_prep) period_18\NN\13575869|NONE_0 (r_pobj) in_13\IN\13603305|case_79|is_13|._91 (r_prep) described_12\VBN\1001294|NONE_0 (l_nsubjpass) case_1\NN\7283608|is_66|in_79|._170 (l_prep) of_2\IN\0|a_7 (l_pobj) rigidity_6\NN\5023233|NONE_0 (l_acl) leading_7\VBG\4339291|abdominal_19 (l_prep) to_8\IN\0|NONE_0 (l_pobj) failure_10\NN\66216|NONE_0
19203554
D013256_D010996 NONE steroid_32\NN\14727670|NONE_0 (r_compound) therapy_33\NN\657604|resulted_143|,_23|we_21|,_7|rose_32|increased_65 (r_dobj) initiated_31\VBD\1617192|NONE_0 (l_advcl) resulted_5\VBD\2633881|,_120|we_122|therapy_143|,_150|rose_175|increased_208 (l_prep) in_6\IN\13603305|although_56|cessation_47 (l_pobj) improvements_7\NNS\7359599|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) fever_9\NN\14299637|NONE_0 (l_appos) eyes_12\NNS\5945642|,_6 (l_conj) pain_15\NN\14299637|red_16|,_8 (l_conj) titer_17\NN\5038593|chest_12|,_2 (l_prep) of_18\IN\0|NONE_0 (l_pobj) protein_22\NN\14944888|NONE_0 (l_prep) of_25\IN\0|reactive_28|and_11|volume_7 (l_pobj) effusions_28\NNS\6880249|NONE_0
D013256_D010996 NONE steroid_32\NN\14727670|NONE_0 (r_compound) therapy_33\NN\657604|resulted_143|,_23|we_21|,_7|rose_32|increased_65 (r_dobj) initiated_31\VBD\1617192|NONE_0 (l_conj) increased_45\VBD\169651|resulted_208|,_88|we_86|therapy_65|,_58|rose_33 (l_conj) remained_56\VBD\2604760|,_77|count_64|to_48|,_27|and_25 (l_nsubj) effusion_55\NN\6880249|._17
D013256_D010996 NONE steroid_3\NN\14727670|NONE_0 (r_compound) therapy_4\NN\657604|month_20 (r_pobj) after_2\IN\0|,_21|effusion_35|,_55|and_57|normalized_76 (r_prep) disappeared_9\VBD\0|NONE_0 (l_nsubj) effusion_8\NN\6880249|after_35|,_14|,_20|and_22|normalized_41
D012460_D005334 CID sulphasalazine_3\NN\0|NONE_0 (r_compound) treatment_4\NN\654885|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) cessation_1\NN\7365849|although_9|in_47 (r_nsubj) resulted_5\VBD\2633881|,_120|we_122|therapy_143|,_150|rose_175|increased_208 (l_prep) in_6\IN\13603305|although_56|cessation_47 (l_pobj) improvements_7\NNS\7359599|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) fever_9\NN\14299637|NONE_0
D012460_D005921 NONE sulphasalazine_10\JJ\0|NONE_0 (r_compound) treatment_11\NN\654885|NONE_0 (r_dobj) restarting_9\VBG\1857717|NONE_0 (r_pcomp) after_8\IN\0|proteinase_100|3-antineutrophil_89|cytoplasmic_72|glomerulonephritis_19|._41 (r_prep) antibody-(pr3-anca_3\NNS\0|NONE_0 (l_appos) glomerulonephritis_7\NN\14113798|proteinase_81|3-antineutrophil_70|cytoplasmic_53|after_19|._60
D012460_D005921 NONE sulphasalazine_4\NN\0|that_5|can_15|glomerulonephritis_56 (r_nsubj) induce_6\VB\1627355|case_38|._55 (l_dobj) glomerulonephritis_11\NN\14113798|that_61|sulphasalazine_56|can_41
D012460_D002637 NONE sulphasalazine_3\NN\0|NONE_0 (r_compound) treatment_4\NN\654885|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) cessation_1\NN\7365849|although_9|in_47 (r_nsubj) resulted_5\VBD\2633881|,_120|we_122|therapy_143|,_150|rose_175|increased_208 (l_prep) in_6\IN\13603305|although_56|cessation_47 (l_pobj) improvements_7\NNS\7359599|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) fever_9\NN\14299637|NONE_0 (l_appos) eyes_12\NNS\5945642|,_6 (l_conj) pain_15\NN\14299637|red_16|,_8
D013256_D005128 NONE steroid_32\NN\14727670|NONE_0 (r_compound) therapy_33\NN\657604|resulted_143|,_23|we_21|,_7|rose_32|increased_65 (r_dobj) initiated_31\VBD\1617192|NONE_0 (l_advcl) resulted_5\VBD\2633881|,_120|we_122|therapy_143|,_150|rose_175|increased_208 (l_prep) in_6\IN\13603305|although_56|cessation_47 (l_pobj) improvements_7\NNS\7359599|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) fever_9\NN\14299637|NONE_0 (l_appos) eyes_12\NNS\5945642|,_6
D012460_D004802 NONE sulphasalazine_22\JJ\0|NONE_0 (r_compound) treatment_23\NN\654885|NONE_0 (r_pobj) of_21\IN\0|NONE_0 (r_prep) restarting_20\VBG\1857717|NONE_0 (r_pcomp) after_19\IN\0|woman_107|eyes_63|._44 (r_prep) developed_8\VBD\1753788|NONE_0 (l_dobj) eyes_10\NNS\5945642|woman_44|after_63|._107 (l_conj) effusion_13\NN\6880249|red_18|,_10 (l_conj) eosinophilia_15\NN\14299637|pleural_18|,_2
D012460_D003093 NONE sulphasalazine_22\JJ\0|NONE_0 (r_compound) treatment_23\NN\654885|NONE_0 (r_pobj) of_21\IN\0|NONE_0 (r_prep) restarting_20\VBG\1857717|NONE_0 (r_pcomp) after_19\IN\0|woman_107|eyes_63|._44 (r_prep) developed_8\VBD\1753788|NONE_0 (l_nsubj) woman_4\NN\9605289|eyes_44|after_107|._151 (l_prep) with_5\IN\0|a_20|old_10 (l_pobj) colitis_7\NN\14336539|NONE_0
D012460_D001745 NONE sulphasalazine_22\JJ\0|NONE_0 (r_compound) treatment_23\NN\654885|NONE_0 (r_pobj) of_21\IN\0|NONE_0 (r_prep) restarting_20\VBG\1857717|NONE_0 (r_pcomp) after_19\IN\0|woman_107|eyes_63|._44 (r_prep) developed_8\VBD\1753788|NONE_0 (l_dobj) eyes_10\NNS\5945642|woman_44|after_63|._107 (l_conj) effusion_13\NN\6880249|red_18|,_10 (l_conj) eosinophilia_15\NN\14299637|pleural_18|,_2 (l_conj) abnormalities_18\NNS\14034177|and_12
D012460_D005128 NONE sulphasalazine_22\JJ\0|NONE_0 (r_compound) treatment_23\NN\654885|NONE_0 (r_pobj) of_21\IN\0|NONE_0 (r_prep) restarting_20\VBG\1857717|NONE_0 (r_pcomp) after_19\IN\0|woman_107|eyes_63|._44 (r_prep) developed_8\VBD\1753788|NONE_0 (l_dobj) eyes_10\NNS\5945642|woman_44|after_63|._107
D012460_D005128 NONE sulphasalazine_3\NN\0|NONE_0 (r_compound) treatment_4\NN\654885|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) cessation_1\NN\7365849|although_9|in_47 (r_nsubj) resulted_5\VBD\2633881|,_120|we_122|therapy_143|,_150|rose_175|increased_208 (l_prep) in_6\IN\13603305|although_56|cessation_47 (l_pobj) improvements_7\NNS\7359599|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) fever_9\NN\14299637|NONE_0 (l_appos) eyes_12\NNS\5945642|,_6
D013256_D005334 NONE steroid_32\NN\14727670|NONE_0 (r_compound) therapy_33\NN\657604|resulted_143|,_23|we_21|,_7|rose_32|increased_65 (r_dobj) initiated_31\VBD\1617192|NONE_0 (l_advcl) resulted_5\VBD\2633881|,_120|we_122|therapy_143|,_150|rose_175|increased_208 (l_prep) in_6\IN\13603305|although_56|cessation_47 (l_pobj) improvements_7\NNS\7359599|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) fever_9\NN\14299637|NONE_0
D012460_D010996 CID sulphasalazine_22\JJ\0|NONE_0 (r_compound) treatment_23\NN\654885|NONE_0 (r_pobj) of_21\IN\0|NONE_0 (r_prep) restarting_20\VBG\1857717|NONE_0 (r_pcomp) after_19\IN\0|woman_107|eyes_63|._44 (r_prep) developed_8\VBD\1753788|NONE_0 (l_dobj) eyes_10\NNS\5945642|woman_44|after_63|._107 (l_conj) effusion_13\NN\6880249|red_18|,_10
D012460_D010996 CID sulphasalazine_3\NN\0|NONE_0 (r_compound) treatment_4\NN\654885|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) cessation_1\NN\7365849|although_9|in_47 (r_nsubj) resulted_5\VBD\2633881|,_120|we_122|therapy_143|,_150|rose_175|increased_208 (l_prep) in_6\IN\13603305|although_56|cessation_47 (l_pobj) improvements_7\NNS\7359599|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) fever_9\NN\14299637|NONE_0 (l_appos) eyes_12\NNS\5945642|,_6 (l_conj) pain_15\NN\14299637|red_16|,_8 (l_conj) titer_17\NN\5038593|chest_12|,_2 (l_prep) of_18\IN\0|NONE_0 (l_pobj) protein_22\NN\14944888|NONE_0 (l_prep) of_25\IN\0|reactive_28|and_11|volume_7 (l_pobj) effusions_28\NNS\6880249|NONE_0
D012460_D010996 CID sulphasalazine_3\NN\0|NONE_0 (r_compound) treatment_4\NN\654885|NONE_0 (r_pobj) of_2\IN\0|NONE_0 (r_prep) cessation_1\NN\7365849|although_9|in_47 (r_nsubj) resulted_5\VBD\2633881|,_120|we_122|therapy_143|,_150|rose_175|increased_208 (r_advcl) initiated_31\VBD\1617192|NONE_0 (l_conj) increased_45\VBD\169651|resulted_208|,_88|we_86|therapy_65|,_58|rose_33 (l_conj) remained_56\VBD\2604760|,_77|count_64|to_48|,_27|and_25 (l_nsubj) effusion_55\NN\6880249|._17
D013256_D002637 NONE steroid_32\NN\14727670|NONE_0 (r_compound) therapy_33\NN\657604|resulted_143|,_23|we_21|,_7|rose_32|increased_65 (r_dobj) initiated_31\VBD\1617192|NONE_0 (l_advcl) resulted_5\VBD\2633881|,_120|we_122|therapy_143|,_150|rose_175|increased_208 (l_prep) in_6\IN\13603305|although_56|cessation_47 (l_pobj) improvements_7\NNS\7359599|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) fever_9\NN\14299637|NONE_0 (l_appos) eyes_12\NNS\5945642|,_6 (l_conj) pain_15\NN\14299637|red_16|,_8
12842176
D000431_D064420 NONE ethanol_35\NN\14708720|or_3 (r_conj) pb_33\NNP\14625458|inducible_14|p450_24 (r_nmod) isoenzymes_38\NNS\0|NONE_0 (r_pobj) by_32\IN\0|NONE_0 (r_agent) formed_31\VBN\1617192|its_16 (r_acl) metabolites_30\NNS\20090|per_14|or_7 (r_conj) lindane_25\NN\14919948|that_5|are_84|in_97 (r_nsubjpass) involved_40\VBN\2676054|NONE_0 (l_prep) in_41\IN\13603305|that_102|lindane_97|are_13 (l_pobj) toxicity_44\NN\13576101|NONE_0
D001556_D064420 NONE lindane_7\NN\14919948|NONE_0 (r_pobj) of_6\IN\0|the_29|p450-mediated_25 (r_prep) metabolism_5\NN\13526110|when_23|was_22|by_34 (r_nsubjpass) blocked_9\VBN\1476483|similarly_60|,_51|was_52|in_66|indicating_98|._242 (r_advcl) increased_17\VBN\169651|NONE_0 (l_advcl) indicating_23\VBG\952524|similarly_158|,_149|blocked_98|was_46|in_32|._144 (l_ccomp) involved_40\VBN\2676054|NONE_0 (l_prep) in_41\IN\13603305|that_102|lindane_97|are_13 (l_pobj) toxicity_44\NN\13576101|NONE_0
D001556_D064420 NONE lindane_22\NN\14919948|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) treated_20\VBN\2376958|NONE_0 (r_acl) animals_19\NNS\4475|NONE_0 (r_pobj) in_18\IN\13603305|similarly_126|,_117|blocked_66|was_14|indicating_32|._176 (r_prep) increased_17\VBN\169651|NONE_0 (l_advcl) indicating_23\VBG\952524|similarly_158|,_149|blocked_98|was_46|in_32|._144 (l_ccomp) involved_40\VBN\2676054|NONE_0 (l_prep) in_41\IN\13603305|that_102|lindane_97|are_13 (l_pobj) toxicity_44\NN\13576101|NONE_0
D001556_D064420 NONE lindane_25\NN\14919948|that_5|are_84|in_97 (r_nsubjpass) involved_40\VBN\2676054|NONE_0 (l_prep) in_41\IN\13603305|that_102|lindane_97|are_13 (l_pobj) toxicity_44\NN\13576101|NONE_0
D000431_D012640 NONE ethanol_46\NN\14708720|an_30|of_19|2b1/2b2_11|or_3|,_7|inducer_12 (r_conj) inducer_41\NN\14778436|(_9|pb_8|)_6|,_5 (r_appos) phenobarbital_35\JJ\2792049|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) pretreatment_33\NN\0|,_2 (r_conj) convulsions_31\NNS\14081375|that_156|produce_67
D000431_D012640 NONE ethanol_46\NN\14708720|an_30|of_19|2b1/2b2_11|or_3|,_7|inducer_12 (r_conj) inducer_41\NN\14778436|(_9|pb_8|)_6|,_5 (r_appos) phenobarbital_35\JJ\2792049|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) pretreatment_33\NN\0|,_2 (r_conj) convulsions_31\NNS\14081375|that_156|produce_67 (r_dobj) induced_30\VBN\1627355|studies_175|have_167|further_162 (r_ccomp) shown_4\VBN\2137132|,_294|significantly_296|incidence_324|induced_345|._364 (r_ccomp) increased_57\VBD\169651|NONE_0 (l_advcl) induced_62\VBN\1627355|shown_345|,_51|significantly_49|incidence_21|._19 (l_dobj) convulsions_63\NNS\14081375|NONE_0
D000431_D012640 NONE ethanol_35\NN\14708720|or_3 (r_conj) pb_33\NNP\14625458|inducible_14|p450_24 (r_nmod) isoenzymes_38\NNS\0|NONE_0 (r_pobj) by_32\IN\0|NONE_0 (r_agent) formed_31\VBN\1617192|its_16 (r_acl) metabolites_30\NNS\20090|per_14|or_7 (r_conj) lindane_25\NN\14919948|that_5|are_84|in_97 (r_nsubjpass) involved_40\VBN\2676054|NONE_0 (r_ccomp) indicating_23\VBG\952524|similarly_158|,_149|blocked_98|was_46|in_32|._144 (r_advcl) increased_17\VBN\169651|NONE_0 (l_advcl) blocked_9\VBN\1476483|similarly_60|,_51|was_52|in_66|indicating_98|._242 (l_agent) by_10\IN\0|when_57|metabolism_34|was_12 (l_pobj) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|chloride_19 (l_pobj) convulsions_15\NNS\14081375|NONE_0
C018021_D012640 NONE chloride_12\NN\14818238|of_19 (r_compound) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|chloride_19 (l_pobj) convulsions_15\NNS\14081375|NONE_0
D008748_D012640 NONE 3-methylcholanthrene_9\NN\0|mc_22 (r_pobj) of_8\IN\0|,_28|inducer_33 (r_prep) pretreatment_7\NN\0|while_6|,_68|did_70|not_74|effect_102 (r_nsubj) produce_21\VB\7555863|that_89|convulsions_67 (r_advcl) induced_30\VBN\1627355|studies_175|have_167|further_162 (l_dobj) convulsions_31\NNS\14081375|that_156|produce_67
D008748_D012640 NONE 3-methylcholanthrene_9\NN\0|mc_22 (r_pobj) of_8\IN\0|,_28|inducer_33 (r_prep) pretreatment_7\NN\0|while_6|,_68|did_70|not_74|effect_102 (r_nsubj) produce_21\VB\7555863|that_89|convulsions_67 (r_advcl) induced_30\VBN\1627355|studies_175|have_167|further_162 (r_ccomp) shown_4\VBN\2137132|,_294|significantly_296|incidence_324|induced_345|._364 (r_ccomp) increased_57\VBD\169651|NONE_0 (l_advcl) induced_62\VBN\1627355|shown_345|,_51|significantly_49|incidence_21|._19 (l_dobj) convulsions_63\NNS\14081375|NONE_0
D008748_D012640 NONE mc_11\NNP\15286249|3-methylcholanthrene_22 (r_pobj) of_8\IN\0|,_28|inducer_33 (r_prep) pretreatment_7\NN\0|while_6|,_68|did_70|not_74|effect_102 (r_nsubj) produce_21\VB\7555863|that_89|convulsions_67 (r_advcl) induced_30\VBN\1627355|studies_175|have_167|further_162 (l_dobj) convulsions_31\NNS\14081375|that_156|produce_67
D008748_D012640 NONE mc_11\NNP\15286249|3-methylcholanthrene_22 (r_pobj) of_8\IN\0|,_28|inducer_33 (r_prep) pretreatment_7\NN\0|while_6|,_68|did_70|not_74|effect_102 (r_nsubj) produce_21\VB\7555863|that_89|convulsions_67 (r_advcl) induced_30\VBN\1627355|studies_175|have_167|further_162 (r_ccomp) shown_4\VBN\2137132|,_294|significantly_296|incidence_324|induced_345|._364 (r_ccomp) increased_57\VBD\169651|NONE_0 (l_advcl) induced_62\VBN\1627355|shown_345|,_51|significantly_49|incidence_21|._19 (l_dobj) convulsions_63\NNS\14081375|NONE_0
D010634_D012640 NONE phenobarbital_35\JJ\2792049|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) pretreatment_33\NN\0|,_2 (r_conj) convulsions_31\NNS\14081375|that_156|produce_67
D010634_D012640 NONE phenobarbital_35\JJ\2792049|NONE_0 (r_pobj) with_34\IN\0|NONE_0 (r_prep) pretreatment_33\NN\0|,_2 (r_conj) convulsions_31\NNS\14081375|that_156|produce_67 (r_dobj) induced_30\VBN\1627355|studies_175|have_167|further_162 (r_ccomp) shown_4\VBN\2137132|,_294|significantly_296|incidence_324|induced_345|._364 (r_ccomp) increased_57\VBD\169651|NONE_0 (l_advcl) induced_62\VBN\1627355|shown_345|,_51|significantly_49|incidence_21|._19 (l_dobj) convulsions_63\NNS\14081375|NONE_0
D001556_D020258 NONE lindane_2\NN\14919948|NONE_0 (r_pobj) of_1\IN\0|NONE_0 (r_prep) effect_0\NN\34213|influence_60|neurotoxicity_108|._121 (r_nsubj) induced_16\VBN\1627355|NONE_0 (l_dobj) neurotoxicity_17\NN\0|effect_108|influence_48|._13
D001556_D020258 NONE lindane_15\NN\14919948|NONE_0 (r_pobj) in_14\IN\13603305|p450_16 (r_prep) modulation_13\NN\7044917|NONE_0 (r_pobj) of_11\IN\0|NONE_0 (r_prep) influence_10\NN\5190804|effect_60|neurotoxicity_48|._61 (r_nsubj) induced_16\VBN\1627355|NONE_0 (l_dobj) neurotoxicity_17\NN\0|effect_108|influence_48|._13
C018021_D064420 NONE chloride_12\NN\14818238|of_19 (r_compound) incidence_13\NN\13821570|NONE_0 (r_pobj) by_10\IN\0|when_57|metabolism_34|was_12 (r_agent) blocked_9\VBN\1476483|similarly_60|,_51|was_52|in_66|indicating_98|._242 (r_advcl) increased_17\VBN\169651|NONE_0 (l_advcl) indicating_23\VBG\952524|similarly_158|,_149|blocked_98|was_46|in_32|._144 (l_ccomp) involved_40\VBN\2676054|NONE_0 (l_prep) in_41\IN\13603305|that_102|lindane_97|are_13 (l_pobj) toxicity_44\NN\13576101|NONE_0
D001556_D012640 CID lindane_29\NN\14919948|NONE_0 (r_pobj) of_28\IN\0|the_14 (r_prep) incidence_27\NN\13821570|NONE_0 (r_pobj) in_25\IN\13603305|any_23|significant_19 (r_prep) effect_24\NN\34213|while_108|pretreatment_102|,_34|did_32|not_28 (r_dobj) produce_21\VB\7555863|that_89|convulsions_67 (r_advcl) induced_30\VBN\1627355|studies_175|have_167|further_162 (l_dobj) convulsions_31\NNS\14081375|that_156|produce_67
D001556_D012640 CID lindane_29\NN\14919948|NONE_0 (r_pobj) of_28\IN\0|the_14 (r_prep) incidence_27\NN\13821570|NONE_0 (r_pobj) in_25\IN\13603305|any_23|significant_19 (r_prep) effect_24\NN\34213|while_108|pretreatment_102|,_34|did_32|not_28 (r_dobj) produce_21\VB\7555863|that_89|convulsions_67 (r_advcl) induced_30\VBN\1627355|studies_175|have_167|further_162 (r_ccomp) shown_4\VBN\2137132|,_294|significantly_296|incidence_324|induced_345|._364 (r_ccomp) increased_57\VBD\169651|NONE_0 (l_advcl) induced_62\VBN\1627355|shown_345|,_51|significantly_49|incidence_21|._19 (l_dobj) convulsions_63\NNS\14081375|NONE_0
D001556_D012640 CID lindane_61\NN\14919948|NONE_0 (r_pobj) of_60\IN\0|the_14 (r_prep) incidence_59\NN\13821570|shown_324|,_30|significantly_28|induced_21|._40 (r_dobj) increased_57\VBD\169651|NONE_0 (l_ccomp) shown_4\VBN\2137132|,_294|significantly_296|incidence_324|induced_345|._364 (l_ccomp) induced_30\VBN\1627355|studies_175|have_167|further_162 (l_dobj) convulsions_31\NNS\14081375|that_156|produce_67
D001556_D012640 CID lindane_61\NN\14919948|NONE_0 (r_pobj) of_60\IN\0|the_14 (r_prep) incidence_59\NN\13821570|shown_324|,_30|significantly_28|induced_21|._40 (r_dobj) increased_57\VBD\169651|NONE_0 (l_advcl) induced_62\VBN\1627355|shown_345|,_51|significantly_49|incidence_21|._19 (l_dobj) convulsions_63\NNS\14081375|NONE_0
D001556_D012640 CID lindane_7\NN\14919948|NONE_0 (r_pobj) of_6\IN\0|the_29|p450-mediated_25 (r_prep) metabolism_5\NN\13526110|when_23|was_22|by_34 (r_nsubjpass) blocked_9\VBN\1476483|similarly_60|,_51|was_52|in_66|indicating_98|._242 (l_agent) by_10\IN\0|when_57|metabolism_34|was_12 (l_pobj) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|chloride_19 (l_pobj) convulsions_15\NNS\14081375|NONE_0
D001556_D012640 CID lindane_22\NN\14919948|NONE_0 (r_pobj) with_21\IN\0|NONE_0 (r_prep) treated_20\VBN\2376958|NONE_0 (r_acl) animals_19\NNS\4475|NONE_0 (r_pobj) in_18\IN\13603305|similarly_126|,_117|blocked_66|was_14|indicating_32|._176 (r_prep) increased_17\VBN\169651|NONE_0 (l_advcl) blocked_9\VBN\1476483|similarly_60|,_51|was_52|in_66|indicating_98|._242 (l_agent) by_10\IN\0|when_57|metabolism_34|was_12 (l_pobj) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|chloride_19 (l_pobj) convulsions_15\NNS\14081375|NONE_0
D001556_D012640 CID lindane_25\NN\14919948|that_5|are_84|in_97 (r_nsubjpass) involved_40\VBN\2676054|NONE_0 (r_ccomp) indicating_23\VBG\952524|similarly_158|,_149|blocked_98|was_46|in_32|._144 (r_advcl) increased_17\VBN\169651|NONE_0 (l_advcl) blocked_9\VBN\1476483|similarly_60|,_51|was_52|in_66|indicating_98|._242 (l_agent) by_10\IN\0|when_57|metabolism_34|was_12 (l_pobj) incidence_13\NN\13821570|NONE_0 (l_prep) of_14\IN\0|chloride_19 (l_pobj) convulsions_15\NNS\14081375|NONE_0
6699841
D012459_D007681 NONE salicylates_22\NNS\3828465|fenoprofen_30|,_12 (r_conj) calcium_18\NN\14625458|,_13 (r_conj) sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (r_nsubj) developed_27\VBD\1753788|NONE_0 (l_dobj) necrosis_30\NN\11444117|man_162|after_24|._61
D012459_D007681 NONE salicylates_22\NNS\3828465|fenoprofen_30|,_12 (r_conj) calcium_18\NN\14625458|,_13 (r_conj) sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (r_nsubj) developed_27\VBD\1753788|NONE_0 (l_dobj) necrosis_30\NN\11444117|man_162|after_24|._61 (l_appos) rpn_32\NNP\0|renal_26|papillary_20|(_1|)_3
D013467_D007681 NONE sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (r_nsubj) developed_27\VBD\1753788|NONE_0 (l_dobj) necrosis_30\NN\11444117|man_162|after_24|._61
D013467_D007681 NONE sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (r_nsubj) developed_27\VBD\1753788|NONE_0 (l_dobj) necrosis_30\NN\11444117|man_162|after_24|._61 (l_appos) rpn_32\NNP\0|renal_26|papillary_20|(_1|)_3
D013467_D007681 NONE sulindac_15\NN\3828465|NONE_0 (r_pobj) of_14\IN\0|possible_20 (r_prep) advantages_13\NNS\5154517|NONE_0 (r_dobj) discuss_11\VB\7466557|rpn_37|to_33|and_4 (r_conj) linking_4\VBG\628491|previous_17 (l_dobj) rpn_5\NNP\0|to_4|and_33|discuss_37
D009288_D001172 NONE naproxen_39\NN\3828465|NONE_0 (r_compound) therapy_40\NN\657604|NONE_0 (r_pobj) of_38\IN\0|NONE_0 (r_prep) institution_37\NN\8008335|months_13 (r_pobj) after_36\IN\0|man_186|necrosis_24|._37 (r_prep) developed_27\VBD\1753788|NONE_0 (l_nsubj) man_4\NN\9605289|necrosis_162|after_186|._223 (l_prep) with_5\IN\0|a_18|old_8|,_25|treated_51|,_130 (l_pobj) arthritis_7\NN\14171682|NONE_0
D006046_D001172 NONE gold_24\NN\13371489|NONE_0 (r_compound) salts_25\NNS\14818238|high_31|dose_26|and_9 (r_conj) salicylates_22\NNS\3828465|fenoprofen_30|,_12 (r_conj) calcium_18\NN\14625458|,_13 (r_conj) sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (l_prep) with_5\IN\0|a_18|old_8|,_25|treated_51|,_130 (l_pobj) arthritis_7\NN\14171682|NONE_0
D005279_D001172 NONE calcium_18\NN\14625458|,_13 (r_conj) sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (l_prep) with_5\IN\0|a_18|old_8|,_25|treated_51|,_130 (l_pobj) arthritis_7\NN\14171682|NONE_0
D005279_D007681 NONE calcium_18\NN\14625458|,_13 (r_conj) sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (r_nsubj) developed_27\VBD\1753788|NONE_0 (l_dobj) necrosis_30\NN\11444117|man_162|after_24|._61
D005279_D007681 NONE calcium_18\NN\14625458|,_13 (r_conj) sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (r_nsubj) developed_27\VBD\1753788|NONE_0 (l_dobj) necrosis_30\NN\11444117|man_162|after_24|._61 (l_appos) rpn_32\NNP\0|renal_26|papillary_20|(_1|)_3
D013467_D007674 NONE sulindac_15\NN\3828465|NONE_0 (l_prep) in_16\IN\13603305|NONE_0 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_relcl) experienced_20\VBN\2108377|NONE_0 (l_dobj) toxicity_22\NN\13576101|who_27|have_23
D009288_D007681 CID naproxen_5\NN\3828465|to_3 (r_pobj) due_3\IN\5174653|renal_25|papillary_19|._15 (r_prep) necrosis_2\NN\11444117|NONE_0
D009288_D007681 CID naproxen_39\NN\3828465|NONE_0 (r_compound) therapy_40\NN\657604|NONE_0 (r_pobj) of_38\IN\0|NONE_0 (r_prep) institution_37\NN\8008335|months_13 (r_pobj) after_36\IN\0|man_186|necrosis_24|._37 (r_prep) developed_27\VBD\1753788|NONE_0 (l_dobj) necrosis_30\NN\11444117|man_162|after_24|._61
D009288_D007681 CID naproxen_39\NN\3828465|NONE_0 (r_compound) therapy_40\NN\657604|NONE_0 (r_pobj) of_38\IN\0|NONE_0 (r_prep) institution_37\NN\8008335|months_13 (r_pobj) after_36\IN\0|man_186|necrosis_24|._37 (r_prep) developed_27\VBD\1753788|NONE_0 (l_dobj) necrosis_30\NN\11444117|man_162|after_24|._61 (l_appos) rpn_32\NNP\0|renal_26|papillary_20|(_1|)_3
D006046_D007681 NONE gold_24\NN\13371489|NONE_0 (r_compound) salts_25\NNS\14818238|high_31|dose_26|and_9 (r_conj) salicylates_22\NNS\3828465|fenoprofen_30|,_12 (r_conj) calcium_18\NN\14625458|,_13 (r_conj) sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (r_nsubj) developed_27\VBD\1753788|NONE_0 (l_dobj) necrosis_30\NN\11444117|man_162|after_24|._61
D006046_D007681 NONE gold_24\NN\13371489|NONE_0 (r_compound) salts_25\NNS\14818238|high_31|dose_26|and_9 (r_conj) salicylates_22\NNS\3828465|fenoprofen_30|,_12 (r_conj) calcium_18\NN\14625458|,_13 (r_conj) sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (r_nsubj) developed_27\VBD\1753788|NONE_0 (l_dobj) necrosis_30\NN\11444117|man_162|after_24|._61 (l_appos) rpn_32\NNP\0|renal_26|papillary_20|(_1|)_3
D013467_D001172 NONE sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (l_prep) with_5\IN\0|a_18|old_8|,_25|treated_51|,_130 (l_pobj) arthritis_7\NN\14171682|NONE_0
D012459_D001172 NONE salicylates_22\NNS\3828465|fenoprofen_30|,_12 (r_conj) calcium_18\NN\14625458|,_13 (r_conj) sulindac_15\NN\3828465|NONE_0 (r_pobj) with_14\IN\0|who_32|had_28|previously_24|been_13 (r_prep) treated_13\VBN\2376958|a_69|old_59|with_51|,_26|,_79 (r_relcl) man_4\NN\9605289|necrosis_162|after_186|._223 (l_prep) with_5\IN\0|a_18|old_8|,_25|treated_51|,_130 (l_pobj) arthritis_7\NN\14171682|NONE_0
1545575
D015080_D006470 NONE mesna_19\NN\0|NONE_0 (r_pobj) with_18\IN\0|a_38|feasibility_36|of_18|,_10|neutralizes_18 (r_prep) trial_15\NN\786195|in_93|,_29|we_27|._129 (l_relcl) neutralizes_22\VBZ\126264|a_56|feasibility_54|of_36|with_18|,_8 (l_dobj) metabolite_25\NN\20090|which_30 (l_relcl) causes_29\VBZ\7323922|the_48|hepatic_44|of_25 (l_dobj) cystitis_31\NN\14566129|that_24
D015080_D006470 NONE mesna_10\JJ\0|NONE_0 (r_amod) uroprophylaxis_11\NNS\0|who_19|before_15 (r_dobj) received_9\VBD\2210855|four_30|consecutive_25 (r_relcl) patients_7\NNS\9898892|in_37|,_26|cystitis_112|for_121|._141 (r_nsubj) had_17\VBD\0|NONE_0 (l_dobj) cystitis_20\NN\14566129|in_149|,_138|patients_112|for_9|._29
D003520_D006470 CID cyclophosphamide_11\NN\0|dose_5|administered_25 (r_compound) therapy_12\NN\657604|NONE_0 (r_pobj) of_7\IN\0|a_35|serious_21 (r_prep) complication_6\NN\1073995|cystitis_34|._98 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) cystitis_1\NN\14566129|complication_34|._132
D003520_D006470 CID cyclophosphamide_27\NN\0|NONE_0 (r_pobj) of_26\IN\0|the_23|hepatic_19|causes_25 (r_prep) metabolite_25\NN\20090|which_30 (l_relcl) causes_29\VBZ\7323922|the_48|hepatic_44|of_25 (l_dobj) cystitis_31\NN\14566129|that_24
D015080_D003556 NONE mesna_19\NN\0|NONE_0 (r_pobj) with_18\IN\0|a_38|feasibility_36|of_18|,_10|neutralizes_18 (r_prep) trial_15\NN\786195|in_93|,_29|we_27|._129 (l_relcl) neutralizes_22\VBZ\126264|a_56|feasibility_54|of_36|with_18|,_8 (l_dobj) metabolite_25\NN\20090|which_30 (l_relcl) causes_29\VBZ\7323922|the_48|hepatic_44|of_25 (l_dobj) cystitis_31\NN\14566129|that_24
D015080_D003556 NONE mesna_10\JJ\0|NONE_0 (r_amod) uroprophylaxis_11\NNS\0|who_19|before_15 (r_dobj) received_9\VBD\2210855|four_30|consecutive_25 (r_relcl) patients_7\NNS\9898892|in_37|,_26|cystitis_112|for_121|._141 (r_nsubj) had_17\VBD\0|NONE_0 (l_dobj) cystitis_20\NN\14566129|in_149|,_138|patients_112|for_9|._29
D003520_D003556 CID cyclophosphamide_11\NN\0|dose_5|administered_25 (r_compound) therapy_12\NN\657604|NONE_0 (r_pobj) of_7\IN\0|a_35|serious_21 (r_prep) complication_6\NN\1073995|cystitis_34|._98 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) cystitis_1\NN\14566129|complication_34|._132
D003520_D003556 CID cyclophosphamide_27\NN\0|NONE_0 (r_pobj) of_26\IN\0|the_23|hepatic_19|causes_25 (r_prep) metabolite_25\NN\20090|which_30 (l_relcl) causes_29\VBZ\7323922|the_48|hepatic_44|of_25 (l_dobj) cystitis_31\NN\14566129|that_24
12452237
D008012_D063806 NONE lidocaine_9\JJ\3681148|on_23 (r_compound) pretreatment_10\NN\0|NONE_0 (l_prep) on_11\IN\0|lidocaine_23 (l_pobj) reduction_12\NN\351485|NONE_0 (l_prep) of_13\IN\0|NONE_0 (l_pobj) myalgia_17\NN\14322699|NONE_0
D013390_D010149 CID succinylcholine_3\NN\3800001|can_21|lidocaine_17|induced_16|?_45 (r_dobj) reduce_2\VB\441445|NONE_0 (l_conj) induced_4\VBD\1627355|can_37|lidocaine_33|succinylcholine_16|?_29 (l_dobj) myalgia_6\NN\14322699|NONE_0
D013390_D010149 CID succinylcholine_4\NN\3800001|where_6|is_16 (r_nsubjpass) used_6\VBN\0|in_40|,_27|,_4|lidocaine_6|is_16|be_29|._104 (r_advcl) proven_10\VBN\2604760|NONE_0 (l_xcomp) be_12\VB\14625458|in_69|,_56|used_29|,_25|lidocaine_23|is_13|._75 (l_attr) agent_16\NN\7347|to_30 (l_prep) for_17\IN\0|the_30|useful_26|pretreatment_19 (l_pobj) reduction_19\NN\351485|NONE_0 (l_prep) of_20\IN\0|the_14 (l_pobj) myalgia_22\NN\14322699|NONE_0
D008012_D010149 NONE lidocaine_1\RB\3681148|can_4|succinylcholine_17|induced_33|?_62 (r_nsubj) reduce_2\VB\441445|NONE_0 (l_conj) induced_4\VBD\1627355|can_37|lidocaine_33|succinylcholine_16|?_29 (l_dobj) myalgia_6\NN\14322699|NONE_0
D008012_D010149 NONE lidocaine_8\NN\3681148|in_46|,_33|used_6|,_2|is_10|be_23|._98 (r_nsubjpass) proven_10\VBN\2604760|NONE_0 (l_xcomp) be_12\VB\14625458|in_69|,_56|used_29|,_25|lidocaine_23|is_13|._75 (l_attr) agent_16\NN\7347|to_30 (l_prep) for_17\IN\0|the_30|useful_26|pretreatment_19 (l_pobj) reduction_19\NN\351485|NONE_0 (l_prep) of_20\IN\0|the_14 (l_pobj) myalgia_22\NN\14322699|NONE_0
D013390_D063806 NONE succinylcholine_14\NN\3800001|-_15 (r_npadvmod) induced_16\VBN\1627355|in_16 (r_amod) myalgia_17\NN\14322699|NONE_0
16826348
D003561_D010523 CID arabinoside_8\NN\0|dose_14|cytosine_9|in_22 (r_amod) treatment_9\NN\654885|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) caused_2\VBN\1617192|peripheral_22|._91 (r_acl) neuropathy_1\NNS\14204950|NONE_0
D003561_D010523 CID arabinoside_14\NN\0|are_38|,_21|therapy_17|,_83|and_85|play_111 (r_nsubj) is_15\VBZ\0|NONE_0 (l_advcl) are_6\VBP\13600404|,_17|arabinoside_38|therapy_55|,_121|and_123|play_149 (l_nsubj) mechanisms_2\NNS\13446390|although_13|still_40|unclear_46 (l_prep) of_3\IN\0|the_15 (l_pobj) neuropathy_5\NN\14204950|NONE_0
D003561_D015470 NONE arabinoside_8\NN\0|dose_14|cytosine_9|in_22 (r_amod) treatment_9\NN\654885|NONE_0 (l_prep) in_10\IN\13603305|dose_36|cytosine_31|arabinoside_22 (l_pobj) patient_12\NN\9898892|NONE_0 (l_prep) with_13\IN\0|a_10 (l_pobj) leukemia_16\NN\14239918|NONE_0
D003561_D006987 NONE arabinoside_8\NN\0|NONE_0 (r_pobj) of_3\IN\0|the_17|first_13 (r_prep) course_2\NN\883297|in_50|,_72|but_74|complained_135 (r_nsubj) resulted_9\VBD\2633881|NONE_0 (l_conj) complained_28\VBD\0|course_135|in_85|,_63|but_61 (l_prep) of_29\IN\0|on_68|,_25|patient_19|in_12|._29 (l_pobj) numbness_30\NN\14299637|NONE_0
D008775_D006086 NONE methylprednisolone_38\NN\0|NONE_0 (r_pobj) to_37\IN\0|symptoms_32|subsequently_23|._21 (r_prep) responded_36\VBD\2367363|received_153|,_106|symptoms_100|,_83|with_81|,_32|and_30 (r_conj) worsened_19\VBD\146138|NONE_0 (l_prep) with_21\IN\0|received_72|,_25|symptoms_19|,_2|,_49|and_51|responded_81 (l_pobj) development_23\NN\248977|NONE_0 (l_prep) of_24\IN\0|the_16 (l_pobj) disease_30\NN\14061805|NONE_0
D003561_D064420 NONE arabinoside_10\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_36|central_32|system_16 (r_prep) toxicity_4\NN\13576101|is_43|well_46|,_61|but_63|reported_159
D003561_D064420 NONE arabinoside_10\NN\0|NONE_0 (r_pobj) of_5\IN\0|the_36|central_32|system_16 (r_prep) toxicity_4\NN\13576101|is_43|well_46|,_61|but_63|reported_159 (r_nsubjpass) recognized_13\VBN\686447|NONE_0 (l_conj) reported_29\VBN\831651|toxicity_159|is_116|well_113|,_98|but_96 (l_nsubjpass) toxicity_17\NN\13576101|has_66|been_70|infrequently_75|._96
D003561_D064420 NONE arabinoside_20\NN\0|NONE_0 (r_pobj) of_18\IN\0|the_13 (r_prep) toxicity_17\NN\13576101|has_66|been_70|infrequently_75|._96 (r_nsubjpass) reported_29\VBN\831651|toxicity_159|is_116|well_113|,_98|but_96 (r_conj) recognized_13\VBN\686447|NONE_0 (l_nsubjpass) toxicity_4\NN\13576101|is_43|well_46|,_61|but_63|reported_159
D003561_D064420 NONE arabinoside_20\NN\0|NONE_0 (r_pobj) of_18\IN\0|the_13 (r_prep) toxicity_17\NN\13576101|has_66|been_70|infrequently_75|._96
D008775_D009422 NONE methylprednisolone_38\NN\0|NONE_0 (r_pobj) to_37\IN\0|symptoms_32|subsequently_23|._21 (r_prep) responded_36\VBD\2367363|received_153|,_106|symptoms_100|,_83|with_81|,_32|and_30 (r_conj) worsened_19\VBD\146138|NONE_0 (l_ccomp) received_11\VBD\2210855|,_47|symptoms_53|,_70|with_72|,_121|and_123|responded_153 (l_ccomp) resolving_4\VBG\5781800|;_9|however_11|,_18|after_20|patient_30|transplantation_70 (l_nsubj) neuropathy_1\NN\14204950|was_11|gradually_15
3123611
D003276_D002819 CID contraception_4\NN\851994|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|._34 (r_acl) chorea_0\NNP\14253124|NONE_0
D003276_D002819 CID contraceptives_7\NNS\3183080|while_21 (r_dobj) receiving_5\VBG\2210855|patients_32|chorea_13|._29 (r_advcl) developed_2\VBD\1753788|NONE_0 (l_dobj) chorea_3\NN\14253124|patients_19|receiving_13|._42
D003276_D002819 CID contraception_12\NN\851994|NONE_0 (r_pobj) after_9\IN\0|patient_45|chorea_7|._34 (r_prep) had_3\VBD\0|NONE_0 (l_dobj) chorea_8\NN\14253124|patient_38|after_7|._41
D000661_D002819 CID amphetamine_5\NN\3248958|-_11 (r_npadvmod) induced_7\VBN\1627355|acute_18 (r_amod) chorea_8\NN\14253124|patient_38|after_7|._41
10411803
D015313_D000743 CID cefotetan_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|prophylactic_17|in_13 (r_prep) use_7\NN\407535|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|severe_31|immune_24|hemolytic_17|._85 (r_acl) anemia_3\NN\14189204|NONE_0
D015313_D000743 CID cefotetan_8\JJ\0|generation_38|,_13|,_9 (r_appos) cephalosporins_5\NNS\2716866|and_21 (r_conj) second-_0\NNP\0|are_67|increasingly_71|with_95|._147 (r_nsubjpass) associated_12\VBN\628491|NONE_0 (l_prep) with_13\IN\0|second-_95|are_28|increasingly_24|._52 (l_pobj) anemia_20\NN\14189204|NONE_0
D015313_D000743 CID cefotetan_9\NN\0|-_9 (r_npadvmod) induced_11\VBN\1627355|hemolytic_8 (r_amod) anemias_13\NNS\14189204|NONE_0
D015313_D000743 CID cefotetan_20\JJ\0|who_17|had_13|prophylactically_10|for_27 (r_dobj) received_19\VBN\2210855|NONE_0 (r_relcl) patients_16\NNS\9898892|NONE_0 (r_pobj) in_15\IN\13603305|that_68|10_63 (r_prep) were_14\VBD\0|we_74|._101 (l_nsubj) 10_3\CD\13745420|that_5|in_63 (l_prep) of_4\IN\0|NONE_0 (l_pobj) cases_7\NNS\7283608|NONE_0 (l_prep) of_8\IN\0|our_13|35_9 (l_pobj) anemias_13\NNS\14189204|NONE_0
D002511_D000743 NONE cephalosporins_5\NNS\2716866|and_21 (r_conj) second-_0\NNP\0|are_67|increasingly_71|with_95|._147 (r_nsubjpass) associated_12\VBN\628491|NONE_0 (l_prep) with_13\IN\0|second-_95|are_28|increasingly_24|._52 (l_pobj) anemia_20\NN\14189204|NONE_0
16596970
D010862_D012640 NONE pilocarpine_0\NNP\14712692|NONE_0 (r_amod) seizures_1\NNS\14081375|impairment_29|._75
D010862_D012640 NONE pilocarpine_0\NN\14712692|status_34|epilepticus_41 (r_nsubj) induced_4\VBN\1627355|;_26|epilepticus_35|in_63|,_104|had_123|._163 (r_ccomp) resulted_12\VBD\2633881|NONE_0 (l_prep) in_13\IN\13603305|induced_63|;_37|epilepticus_28|,_41|had_60|._100 (l_pobj) loss_16\NN\13252973|NONE_0 (l_conj) seizures_19\NNS\14081375|ca3_30|cell_26|and_16
D010862_D012640 NONE pilocarpine_0\NN\14712692|status_34|epilepticus_41 (r_nsubj) induced_4\VBN\1627355|;_26|epilepticus_35|in_63|,_104|had_123|._163 (r_ccomp) resulted_12\VBD\2633881|NONE_0 (l_advcl) had_24\VBD\0|induced_123|;_97|epilepticus_88|in_60|,_19|._40 (l_dobj) loss_27\NN\13252973|whereas_29|rats_17 (l_conj) seizures_30\NNS\14081375|no_28|cell_25|or_15
D010862_D001308 CID pilocarpine_0\NNP\14712692|NONE_0 (r_amod) seizures_1\NNS\14081375|impairment_29|._75 (r_nsubj) cause_2\IN\7323922|NONE_0 (l_dobj) impairment_6\NN\7296428|seizures_29|._46 (l_prep) in_7\IN\13603305|dependent_21 (l_pobj) discrimination_10\NN\1123598|NONE_0
D010862_D013226 CID pilocarpine_0\NN\14712692|status_34|epilepticus_41 (r_nsubj) induced_4\VBN\1627355|;_26|epilepticus_35|in_63|,_104|had_123|._163 (l_advmod) epilepticus_6\NN\0|pilocarpine_41|status_7
D010862_D013226 CID pilocarpine_0\NN\14712692|status_34|epilepticus_41 (r_nsubj) induced_4\VBN\1627355|;_26|epilepticus_35|in_63|,_104|had_123|._163 (r_ccomp) resulted_12\VBD\2633881|NONE_0 (l_nsubj) epilepticus_9\NN\0|induced_35|;_9|in_28|,_69|had_88|._128
2576810
D009627_D006948 CID nomifensine_4\NN\0|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) induced_2\VBN\1627355|the_18 (r_acl) hyperactivity_1\NN\14052403|unaffected_54|._79
D016666_D006948 CID fluvoxamine_4\NNP\0|NONE_0 (r_pobj) with_3\IN\0|a_21|repeated_19|(_17|daily_24|)_41 (r_prep) treatment_2\NN\654885|in_65|weaker_86|hyperactivity_118|._131 (r_nsubj) potentiated_12\VBN\229605|NONE_0 (l_dobj) hyperactivity_25\NN\14052403|treatment_118|in_53|weaker_32|._13
D016666_D006948 CID fluvoxamine_10\NN\0|NONE_0 (r_pobj) by_9\IN\0|NONE_0 (r_prep) unaffected_8\JJ\0|hyperactivity_54|._25 (r_acomp) remained_7\VBD\2604760|NONE_0 (l_nsubj) hyperactivity_1\NN\14052403|unaffected_54|._79
D000661_D006948 CID amphetamine_22\NN\3248958|-_11 (r_npadvmod) induced_24\VBN\1627355|the_16 (r_amod) hyperactivity_25\NN\14052403|treatment_118|in_53|weaker_32|._13
12091028
D003975_D006212 NONE diazepam_0\NNP\2830852|,_8|contraindicated_17|,_41|drug_84|._229 (r_nsubj) remains_7\VBZ\2684|NONE_0 (l_attr) drug_12\NN\14778436|diazepam_84|,_76|contraindicated_67|,_43|._145 (l_relcl) ketamine_14\NN\3054098|the_41|only_37|necessary_32|complementary_22 (l_advcl) buffers_17\VBZ\14818238|to_18 (l_conj) decreases_22\VBZ\7296428|as_46|it_43|response_13|and_4 (l_dobj) duration_24\NN\15113229|NONE_0 (l_prep) of_27\IN\0|the_27|and_14|intensity_10 (l_pobj) hallucinations_31\NNS\14376855|NONE_0
D007649_D006212 CID ketamine_14\NN\3054098|the_41|only_37|necessary_32|complementary_22 (l_advcl) buffers_17\VBZ\14818238|to_18 (l_conj) decreases_22\VBZ\7296428|as_46|it_43|response_13|and_4 (l_dobj) duration_24\NN\15113229|NONE_0 (l_prep) of_27\IN\0|the_27|and_14|intensity_10 (l_pobj) hallucinations_31\NNS\14376855|NONE_0
11245434
D016190_D000740 CID carboplatin_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|a_14|single_12|i.v._25|)_29|resulting_31 (r_prep) dose_6\NN\3740161|NONE_0 (r_dobj) using_3\VBG\418025|anemia_19|was_12|._126 (r_xcomp) induced_2\VBN\1627355|NONE_0 (l_nsubjpass) anemia_0\NN\14189204|was_7|using_19|._145
D016190_D000740 CID carboplatin_29\NN\0|NONE_0 (r_amod) application_30\NN\947128|NONE_0 (r_pobj) before_28\IN\0|7_7 (r_prep) days_27\NNS\15140892|NONE_0 (r_dobj) starting_25\VBG\457382|s.c._22|week_5 (r_advcl) administered_19\VBN\2436349|in_82|,_65|development_59|was_37|by_23|._81 (r_conj) prevented_10\VBN\0|NONE_0 (l_nsubjpass) development_6\NN\248977|in_23|,_6|was_22|by_36|administered_59|._140 (l_prep) of_7\IN\0|the_16 (l_pobj) anemia_8\NN\14189204|NONE_0
D003520_D064420 NONE cyclophosphamide_8\NN\0|in_30 (r_compound) cytotoxicity_9\NN\13583478|NONE_0
D003520_D064420 NONE cyclophosphamide_25\NN\0|NONE_0 (r_pobj) of_24\IN\0|the_17|in_20 (r_prep) cytotoxicity_23\NN\13583478|NONE_0
D003520_D064420 NONE cyclophosphamide_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|in_20 (r_prep) cytotoxicity_9\NN\13583478|that_41|anemia_15|,_42|increases_109
D010100_D064420 NONE oxygen_37\NN\14622893|an_12|improved_9|to_14 (r_compound) supply_38\NN\13576355|NONE_0 (r_pobj) of_34\IN\0|a_9 (r_prep) result_33\NN\34213|probably_14 (r_pobj) as_31\IN\14622893|whereas_101|correction_93|sensitivity_22|,_11 (r_prep) increases_26\VBZ\13576355|that_150|anemia_124|cytotoxicity_109|,_67 (r_advcl) reduces_8\VBZ\441445|results_49|._209 (l_dobj) cytotoxicity_9\NN\13583478|that_41|anemia_15|,_42|increases_109
D016190_D009369 NONE carboplatin_3\NN\0|NONE_0 (r_amod) treatment_4\NN\654885|days_23 (r_pobj) after_2\IN\0|,_27|tumors_29|were_60|s.c._75|onto_80|._105 (r_prep) implanted_16\VBN\1421622|NONE_0 (l_nsubjpass) tumors_6\NNS\14234074|after_29|,_2|were_31|s.c._46|onto_51|._76
D016190_D009369 NONE carboplatin_1\NN\0|NONE_0 (l_conj) influenced_5\VBN\137313|neither_41|nor_21|treatment_10|._35 (l_dobj) rate_8\NN\13815152|se_9 (l_compound) tumor_6\NN\14234074|growth_6
D010100_D000740 NONE oxygen_37\NN\14622893|an_12|improved_9|to_14 (r_compound) supply_38\NN\13576355|NONE_0 (r_pobj) of_34\IN\0|a_9 (r_prep) result_33\NN\34213|probably_14 (r_pobj) as_31\IN\14622893|whereas_101|correction_93|sensitivity_22|,_11 (r_prep) increases_26\VBZ\13576355|that_150|anemia_124|cytotoxicity_109|,_67 (r_advcl) reduces_8\VBZ\441445|results_49|._209 (l_nsubj) anemia_7\NN\14189204|that_26|cytotoxicity_15|,_57|increases_124
D010100_D000740 NONE oxygen_37\NN\14622893|an_12|improved_9|to_14 (r_compound) supply_38\NN\13576355|NONE_0 (r_pobj) of_34\IN\0|a_9 (r_prep) result_33\NN\34213|probably_14 (r_pobj) as_31\IN\14622893|whereas_101|correction_93|sensitivity_22|,_11 (r_prep) increases_26\VBZ\13576355|that_150|anemia_124|cytotoxicity_109|,_67 (l_nsubj) correction_16\NN\248977|whereas_8|sensitivity_71|,_82|as_93 (l_prep) of_17\IN\0|by_10 (l_pobj) anemia_18\NN\14189204|NONE_0
D010100_D009369 NONE oxygen_37\NN\14622893|an_12|improved_9|to_14 (r_compound) supply_38\NN\13576355|NONE_0 (r_pobj) of_34\IN\0|a_9 (r_prep) result_33\NN\34213|probably_14 (r_pobj) as_31\IN\14622893|whereas_101|correction_93|sensitivity_22|,_11 (r_prep) increases_26\VBZ\13576355|that_150|anemia_124|cytotoxicity_109|,_67 (r_advcl) reduces_8\VBZ\441445|results_49|._209 (l_dobj) cytotoxicity_9\NN\13583478|that_41|anemia_15|,_42|increases_109 (l_prep) in_12\IN\13603305|of_20 (l_pobj) tumors_13\NNS\14234074|NONE_0
D010100_D009369 NONE oxygen_37\NN\14622893|an_12|improved_9|to_14 (r_compound) supply_38\NN\13576355|NONE_0 (l_prep) to_39\IN\0|an_26|improved_23|oxygen_14 (l_pobj) tissue_41\NN\5220461|NONE_0 (l_compound) tumor_40\NN\14234074|NONE_0
D016190_D012509 NONE carboplatin_3\NN\0|NONE_0 (r_amod) treatment_4\NN\654885|days_23 (r_pobj) after_2\IN\0|,_27|tumors_29|were_60|s.c._75|onto_80|._105 (r_prep) implanted_16\VBN\1421622|NONE_0 (l_nsubjpass) tumors_6\NNS\14234074|after_29|,_2|were_31|s.c._46|onto_51|._76 (l_appos) sarcoma_10\NN\14239918|(_4|)_18
D003520_D009369 NONE cyclophosphamide_8\NN\0|in_30 (r_compound) cytotoxicity_9\NN\13583478|NONE_0 (l_prep) in_10\IN\13603305|cyclophosphamide_30 (l_pobj) tumors_12\NNS\14234074|NONE_0
D003520_D009369 NONE cyclophosphamide_25\NN\0|NONE_0 (r_pobj) of_24\IN\0|the_17|in_20 (r_prep) cytotoxicity_23\NN\13583478|NONE_0 (l_prep) in_26\IN\13603305|the_37|of_20 (l_pobj) tumors_29\NNS\14234074|NONE_0
D003520_D009369 NONE cyclophosphamide_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|a_14|single_12|(_20|mg/kg_24|)_34 (r_prep) dose_7\NN\3740161|NONE_0 (r_pobj) with_4\IN\0|when_25|tumors_20|were_13|after_62 (r_prep) treated_3\VBN\2376958|,_88|delay_99|was_146|._158 (l_nsubjpass) tumors_1\NNS\14234074|when_5|were_7|with_20|after_82
D003520_D009369 NONE cyclophosphamide_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|a_14|single_12|(_20|mg/kg_24|)_34 (r_prep) dose_7\NN\3740161|NONE_0 (r_pobj) with_4\IN\0|when_25|tumors_20|were_13|after_62 (r_prep) treated_3\VBN\2376958|,_88|delay_99|was_146|._158 (r_advcl) observed_31\VBN\2163746|NONE_0 (l_nsubjpass) delay_22\NN\15271008|treated_99|,_11|was_47|._59 (l_prep) with_23\IN\0|a_15|growth_13 (l_pobj) regrowth_26\NN\0|NONE_0 (l_prep) of_27\IN\0|a_22|subsequent_20 (l_pobj) tumors_29\NNS\14234074|NONE_0
D003520_D009369 NONE cyclophosphamide_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|in_20 (r_prep) cytotoxicity_9\NN\13583478|that_41|anemia_15|,_42|increases_109 (l_prep) in_12\IN\13603305|of_20 (l_pobj) tumors_13\NNS\14234074|NONE_0
D003520_D009369 NONE cyclophosphamide_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|in_20 (r_prep) cytotoxicity_9\NN\13583478|that_41|anemia_15|,_42|increases_109 (r_dobj) reduces_8\VBZ\441445|results_49|._209 (l_advcl) increases_26\VBZ\13576355|that_150|anemia_124|cytotoxicity_109|,_67 (l_prep) as_31\IN\14622893|whereas_101|correction_93|sensitivity_22|,_11 (l_pobj) result_33\NN\34213|probably_14 (l_prep) of_34\IN\0|a_9 (l_pobj) supply_38\NN\13576355|NONE_0 (l_prep) to_39\IN\0|an_26|improved_23|oxygen_14 (l_pobj) tissue_41\NN\5220461|NONE_0 (l_compound) tumor_40\NN\14234074|NONE_0
D003520_D000740 NONE cyclophosphamide_8\NN\0|in_30 (r_compound) cytotoxicity_9\NN\13583478|NONE_0 (r_pobj) in_7\IN\13603305|the_29|induced_18 (r_prep) reduction_6\NN\351485|erythropoietin_43|._56 (l_amod) induced_5\VBN\1627355|the_11|in_18 (l_npadvmod) anemia_3\NN\14189204|-_6
D003520_D000740 NONE cyclophosphamide_25\NN\0|NONE_0 (r_pobj) of_24\IN\0|the_17|in_20 (r_prep) cytotoxicity_23\NN\13583478|NONE_0 (r_pobj) on_21\IN\0|erythropoietin_34|(_19|rhuepo_18|)_12 (r_prep) treatment_20\NN\654885|NONE_0 (r_pobj) by_13\IN\0|the_32|of_21 (r_prep) impact_9\NN\7339329|to_15 (l_prep) of_10\IN\0|the_11|by_21 (l_pobj) prevention_12\NN\1073995|NONE_0 (l_compound) anemia_11\NN\14189204|NONE_0
D003520_D000740 NONE cyclophosphamide_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|in_20 (r_prep) cytotoxicity_9\NN\13583478|that_41|anemia_15|,_42|increases_109 (r_dobj) reduces_8\VBZ\441445|results_49|._209 (l_nsubj) anemia_7\NN\14189204|that_26|cytotoxicity_15|,_57|increases_124
D003520_D000740 NONE cyclophosphamide_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|in_20 (r_prep) cytotoxicity_9\NN\13583478|that_41|anemia_15|,_42|increases_109 (r_dobj) reduces_8\VBZ\441445|results_49|._209 (l_advcl) increases_26\VBZ\13576355|that_150|anemia_124|cytotoxicity_109|,_67 (l_nsubj) correction_16\NN\248977|whereas_8|sensitivity_71|,_82|as_93 (l_prep) of_17\IN\0|by_10 (l_pobj) anemia_18\NN\14189204|NONE_0
6203632
D007545_D006332 CID isoproterenol_2\NN\3740161|-_13 (r_npadvmod) induced_4\VBN\1627355|cardiac_8 (r_amod) hypertrophy_6\NN\14365950|NONE_0
D007545_D006332 CID isoproterenol_17\NN\3740161|NONE_0 (r_pobj) of_16\IN\0|daily_30|subcutaneous_24|iso_18|(_23|weight_39|)_45 (r_prep) injections_15\NNS\320852|NONE_0 (r_pobj) following_12\VBG\8180190|development_75|was_40|in_28|._86 (r_prep) studied_6\VBN\0|NONE_0 (l_nsubjpass) development_1\NN\248977|was_35|in_47|following_75|._161 (l_prep) of_2\IN\0|the_16 (l_pobj) hypertrophy_4\NN\14365950|NONE_0
D007545_D006332 CID iso_19\NN\0|daily_48|subcutaneous_42|of_18|(_5|weight_21|)_27 (r_appos) injections_15\NNS\320852|NONE_0 (r_pobj) following_12\VBG\8180190|development_75|was_40|in_28|._86 (r_prep) studied_6\VBN\0|NONE_0 (l_nsubjpass) development_1\NN\248977|was_35|in_47|following_75|._161 (l_prep) of_2\IN\0|the_16 (l_pobj) hypertrophy_4\NN\14365950|NONE_0
D007545_D006984 NONE iso_8\NN\0|NONE_0 (r_pobj) to_7\IN\0|the_22|adaptive_18 (r_prep) response_6\NN\11410625|that_18|phase_44 (r_nsubj) shows_9\VBZ\429048|data_48|._149 (l_dobj) phase_13\NN\15113229|that_62|response_44 (l_amod) hypertrophic_12\JJ\0|an_9|early_6|(_19|days_24|)_28|characterized_30
8607407
D002110_D006973 CID caffeine_5\NN\14712692|NONE_0 (r_pobj) with_4\IN\0|acute_32|pressure_20|in_14|._58 (r_prep) elevations_3\NNS\7445480|NONE_0 (l_prep) in_6\IN\13603305|acute_46|pressure_34|with_14|._44 (l_pobj) men_7\NNS\8208016|NONE_0 (l_prep) with_8\IN\0|NONE_0 (l_pobj) hypertension_11\NN\14057371|NONE_0
D002110_D006973 CID caffeine_5\NN\14712692|NONE_0 (r_pobj) of_4\IN\0|the_29|vasoconstrictive_25 (r_prep) actions_3\NNS\30358|whether_29|are_20|in_33 (r_nsubjpass) enhanced_7\VBN\227165|has_33|not_37|been_41|._58 (l_prep) in_8\IN\13603305|whether_62|actions_33|are_13 (l_pobj) persons_10\NNS\7347|NONE_0 (l_amod) hypertensive_9\JJ\10405694|NONE_0
D002110_D006973 CID caffeine_24\NN\14712692|NONE_0 (r_compound) ingestion_25\NN\13440063|NONE_0 (r_pobj) after_23\IN\0|consequently_165|,_153|exhibited_126|,_61|%_57|levels_7|._24 (r_prep) achieved_19\VBD\2524171|NONE_0 (l_dobj) levels_22\NNS\4916342|consequently_158|,_146|exhibited_119|,_54|%_50|after_7|._31 (l_amod) hypertensive_20\JJ\10405694|bp_13
D002110_D006973 CID caffeine_10\NN\14712692|NONE_0 (r_pobj) to_9\IN\0|exaggerated_22 (r_prep) responses_8\NNS\11410625|thus_50|,_46|in_44|,_14|:_26|selective_28|consistent_56|,_96|replicated_98|._182 (r_nsubj) were_11\VBD\0|NONE_0 (l_prep) in_2\IN\13603305|thus_6|,_2|,_30|responses_44|:_70|selective_72|consistent_100|,_140|replicated_142|._226 (l_pobj) men_5\NNS\8208016|NONE_0 (l_amod) hypertensive_4\JJ\10405694|borderline_11
D002110_D006973 CID caffeine_10\NN\14712692|NONE_0 (r_pobj) to_9\IN\0|exaggerated_22 (r_prep) responses_8\NNS\11410625|thus_50|,_46|in_44|,_14|:_26|selective_28|consistent_56|,_96|replicated_98|._182 (r_nsubj) were_11\VBD\0|NONE_0 (l_advcl) replicated_23\VBN\2035919|thus_148|,_144|in_142|,_112|responses_98|:_72|selective_70|consistent_42|,_2|._84 (l_conj) representative_29\NN\10351874|in_20|,_6|and_4 (l_prep) of_30\IN\0|NONE_0 (l_pobj) hypertensives_34\NNS\10405694|NONE_0
8473723
D016666_D012640 CID fluvoxamine_6\NN\0|combined_25 (r_compound) treatment_7\NN\654885|NONE_0 (r_pobj) by_2\IN\0|seizures_17|._49 (r_agent) induced_1\VBN\1627355|NONE_0 (l_nsubj) seizures_0\NNS\14081375|by_17|._66
D016666_D012640 CID fluvoxamine_8\NN\0|combined_25|induced_22 (r_nmod) seizures_12\NNS\14081375|NONE_0
D008728_D012640 CID levomepromazine_4\JJ\0|-_15 (r_amod) fluvoxamine_6\NN\0|combined_25 (r_compound) treatment_7\NN\654885|NONE_0 (r_pobj) by_2\IN\0|seizures_17|._49 (r_agent) induced_1\VBN\1627355|NONE_0 (l_nsubj) seizures_0\NNS\14081375|by_17|._66
D008728_D012640 CID levomepromazine_6\JJ\0|-_15 (r_amod) fluvoxamine_8\NN\0|combined_25|induced_22 (r_nmod) seizures_12\NNS\14081375|NONE_0
17194457
D012701_D001523 NONE 5-ht_16\CD\0|NONE_0 (r_pobj) with_13\IN\0|pubertal_19|aas_10 (r_prep) users_12\NNS\7846|that_18|may_28|prone_46 (r_nsubj) be_18\VB\14625458|based_92|,_73|it_71|can_68|be_64|._50 (l_acomp) prone_20\JJ\0|that_64|users_46|may_18 (l_xcomp) exhibit_22\VB\6733939|especially_20 (l_dobj) behavior_24\NN\407535|to_22
D013739_D001523 CID t_0\NNP\14999913|effect_15|but_70|preference_92|._117 (r_nsubj) had_2\VBD\0|NONE_0 (l_dobj) effect_4\NN\34213|t_15|but_55|preference_77|._102 (l_prep) on_5\IN\0|no_10 (l_pobj) locomotion_6\NN\4773351|NONE_0 (l_conj) irritability_8\NN\7552087|,_2
D013739_D001523 CID t_0\NNP\14999913|effect_15|but_70|preference_92|._117 (r_nsubj) had_2\VBD\0|NONE_0 (l_conj) preference_16\NN\7497473|t_92|effect_77|but_22|._25 (l_conj) aggression_18\NN\4657876|increased_33|partner_23|and_4
-1_D001523 NONE pcpa_3\NNP\0|NONE_0 (r_pobj) to_2\IN\0|chronic_17|alone_8 (r_prep) exposure_1\NN\5042871|significantly_23|activity_57|and_66|increased_70|but_93|had_97|._164 (r_nsubj) decreased_6\VBD\169651|NONE_0 (l_conj) increased_10\VBN\169651|exposure_70|significantly_47|activity_13|and_4|but_23|had_27|._94 (l_dobj) irritability_11\NN\7552087|NONE_0
-1_D001523 NONE pcpa_3\NNP\0|NONE_0 (r_pobj) to_2\IN\0|chronic_17|alone_8 (r_prep) exposure_1\NN\5042871|significantly_23|activity_57|and_66|increased_70|but_93|had_97|._164 (r_nsubj) decreased_6\VBD\169651|NONE_0 (l_conj) had_13\VBD\0|exposure_97|significantly_74|activity_40|and_31|increased_27|but_4|._67 (l_dobj) effect_15\NN\34213|NONE_0 (l_prep) on_16\IN\0|no_10 (l_pobj) behavior_18\NN\407535|NONE_0 (l_conj) preference_21\NN\7497473|sexual_25|,_10 (l_conj) aggression_24\NN\4657876|partner_23|,_5|or_3
20394767
C015068_D012021 CID mcpp_12\NNS\0|furthermore_78|,_67|yohimbine_65|startle_36|,_8|suppressed_5 (r_advcl) increased_3\VBN\169651|NONE_0 (l_dobj) startle_5\NN\863513|furthermore_42|,_31|yohimbine_29|,_28|mcpp_36|suppressed_41
C015068_D012021 CID mcpp_12\NNS\0|furthermore_78|,_67|yohimbine_65|startle_36|,_8|suppressed_5 (r_advcl) increased_3\VBN\169651|NONE_0 (l_conj) suppressed_13\VBD\2510337|furthermore_83|,_72|yohimbine_70|startle_41|,_13|mcpp_5 (l_dobj) startle_15\NN\863513|and_32|suppressed_40
C015068_D012021 CID mcpp_12\NNS\0|furthermore_78|,_67|yohimbine_65|startle_36|,_8|suppressed_5 (r_advcl) increased_3\VBN\169651|NONE_0 (l_conj) suppressed_13\VBD\2510337|furthermore_83|,_72|yohimbine_70|startle_41|,_13|mcpp_5 (l_conj) suppressed_24\VBD\2510337|startle_40|and_8 (l_dobj) startle_26\NN\863513|ptz_24|._18
D015016_D012021 CID yohimbine_2\NN\0|furthermore_13|,_2|startle_29|,_57|mcpp_65|suppressed_70 (r_nsubj) increased_3\VBN\169651|NONE_0 (l_dobj) startle_5\NN\863513|furthermore_42|,_31|yohimbine_29|,_28|mcpp_36|suppressed_41
D015016_D012021 CID yohimbine_2\NN\0|furthermore_13|,_2|startle_29|,_57|mcpp_65|suppressed_70 (r_nsubj) increased_3\VBN\169651|NONE_0 (l_conj) suppressed_13\VBD\2510337|furthermore_83|,_72|yohimbine_70|startle_41|,_13|mcpp_5 (l_dobj) startle_15\NN\863513|and_32|suppressed_40
D015016_D012021 CID yohimbine_2\NN\0|furthermore_13|,_2|startle_29|,_57|mcpp_65|suppressed_70 (r_nsubj) increased_3\VBN\169651|NONE_0 (l_conj) suppressed_13\VBD\2510337|furthermore_83|,_72|yohimbine_70|startle_41|,_13|mcpp_5 (l_conj) suppressed_24\VBD\2510337|startle_40|and_8 (l_dobj) startle_26\NN\863513|ptz_24|._18
D010433_D012021 CID ptz_23\NNP\0|startle_24|._42 (r_nsubj) suppressed_24\VBD\2510337|startle_40|and_8 (r_conj) suppressed_13\VBD\2510337|furthermore_83|,_72|yohimbine_70|startle_41|,_13|mcpp_5 (r_conj) increased_3\VBN\169651|NONE_0 (l_dobj) startle_5\NN\863513|furthermore_42|,_31|yohimbine_29|,_28|mcpp_36|suppressed_41
D010433_D012021 CID ptz_23\NNP\0|startle_24|._42 (r_nsubj) suppressed_24\VBD\2510337|startle_40|and_8 (r_conj) suppressed_13\VBD\2510337|furthermore_83|,_72|yohimbine_70|startle_41|,_13|mcpp_5 (l_dobj) startle_15\NN\863513|and_32|suppressed_40
D010433_D012021 CID ptz_23\NNP\0|startle_24|._42 (r_nsubj) suppressed_24\VBD\2510337|startle_40|and_8 (l_dobj) startle_26\NN\863513|ptz_24|._18
9228650
D012601_D000647 CID scopolamine_6\NN\14712692|-_11 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) amnesia_9\NN\5669934|and_24
D012601_D000647 CID scopolamine_7\NN\14712692|-_11 (r_npadvmod) induced_9\VBN\1627355|and_16|movement_32 (r_amod) amnesia_10\NN\5669934|effects_58|,_22|were_33|and_47|compared_51|._133
D012601_D000647 CID scopolamine_14\NN\14712692|NONE_0 (r_pobj) by_13\IN\0|in_32 (r_agent) induced_12\VBN\1627355|the_12 (r_acl) amnesia_11\NN\5669934|compounds_57|p.o._32|significantly_27|._91
D012601_D000647 CID scopolamine_17\NN\14712692|-_11 (r_npadvmod) induced_19\VBN\1627355|NONE_0 (r_amod) amnesia_20\NN\5669934|that_75|nik-247_70|but_8|affect_21
C049860_D000647 CID nik-247_2\NNP\0|NONE_0 (l_prep) on_3\IN\0|NONE_0 (l_pobj) cholinesterase_4\NN\14732946|NONE_0 (l_conj) amnesia_9\NN\5669934|and_24
C049860_D000647 CID nik-247_3\NNP\0|NONE_0 (r_pobj) of_2\IN\0|the_12 (r_prep) effects_1\NNS\13245626|,_36|amnesia_58|were_91|and_105|compared_109|._191 (r_nsubjpass) examined_15\VBN\0|NONE_0 (l_nsubjpass) amnesia_10\NN\5669934|effects_58|,_22|were_33|and_47|compared_51|._133
C049860_D000647 CID nik-247_4\NNP\0|that_5|amnesia_70|but_78|affect_91 (r_nsubj) improves_16\VBZ\126264|findings_63|._77 (l_dobj) amnesia_20\NN\5669934|that_75|nik-247_70|but_8|affect_21
C076946_D000647 CID e-2020_29\NNS\0|and_4 (r_conj) tacrine_27\NN\0|the_41|known_32|cholinesterase_26 (r_appos) inhibitors_26\NNS\20090|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) those_19\DT\0|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) compared_17\VBN\644583|effects_109|,_73|amnesia_51|were_18|and_4|._82 (r_conj) examined_15\VBN\0|NONE_0 (l_nsubjpass) amnesia_10\NN\5669934|effects_58|,_22|were_33|and_47|compared_51|._133
C049860_D000544 NONE nik-247_4\NNP\0|that_5|may_8|drug_24 (r_nsubj) be_6\VB\14625458|findings_34|._57 (l_attr) drug_9\NN\14778436|that_29|nik-247_24|may_16 (l_prep) for_10\IN\0|a_14|useful_12 (l_pobj) treatment_12\NN\654885|NONE_0 (l_prep) of_13\IN\0|the_14 (l_pobj) disease_16\NN\14061805|NONE_0
D013619_D000647 CID tacrine_27\NN\0|the_41|known_32|cholinesterase_26 (r_appos) inhibitors_26\NNS\20090|NONE_0 (r_pobj) of_20\IN\0|NONE_0 (r_prep) those_19\DT\0|NONE_0 (r_pobj) with_18\IN\0|NONE_0 (r_prep) compared_17\VBN\644583|effects_109|,_73|amnesia_51|were_18|and_4|._82 (r_conj) examined_15\VBN\0|NONE_0 (l_nsubjpass) amnesia_10\NN\5669934|effects_58|,_22|were_33|and_47|compared_51|._133
17702969
D005473_D006976 CID fluoxetine_3\NN\4169152|to_3|hypertension_35 (r_advmod) induces_4\VBZ\1627355|prenatal_32|._47 (l_dobj) hypertension_7\NN\14057371|to_38|fluoxetine_35
D005473_D006976 CID fluoxetine_4\NN\4169152|NONE_0 (r_amod) exposure_5\NN\5042871|that_16|prenatally_9|prevalence_34 (r_nsubj) increases_7\VBZ\13576355|data_49|._85 (l_dobj) prevalence_9\NN\4764412|that_50|exposure_34|prenatally_25 (l_prep) of_10\IN\0|the_15 (l_pobj) syndrome_14\NN\5870365|NONE_0
D005473_D006976 CID fluoxetine_20\NN\4169152|protective_11|in_18 (r_amod) effect_21\NN\34213|the_71|current_67|of_50 (r_appos) evidence_14\NN\5816287|NONE_0 (l_prep) of_15\IN\0|the_21|current_17|effect_50 (l_pobj) hypertension_18\NN\14057371|NONE_0
D005473_D006976 CID fluoxetine_5\NN\4169152|NONE_0 (r_amod) exposure_6\NN\5042871|compared_35|,_13|in_18|evidenced_53|and_166|by_170|._234 (r_nsubj) resulted_7\VBD\2633881|NONE_0 (l_prep) in_8\IN\13603305|compared_53|,_31|exposure_18|evidenced_35|and_148|by_152|._216 (l_pobj) hypertension_11\NN\14057371|NONE_0
D005473_D006976 CID fluoxetine_6\NN\4169152|in_20 (r_amod) exposure_7\NN\5042871|in_37|,_13|hypertension_36|as_66|._167 (r_nsubj) induces_10\VBZ\1627355|NONE_0 (l_dobj) hypertension_12\NN\14057371|in_73|,_49|exposure_36|as_30|._131
D005473_D005315 CID fluoxetine_3\NN\4169152|to_3|hypertension_35 (r_advmod) induces_4\VBZ\1627355|prenatal_32|._47 (l_dobj) hypertension_7\NN\14057371|to_38|fluoxetine_35
D005473_D005315 CID fluoxetine_5\NN\4169152|NONE_0 (r_amod) exposure_6\NN\5042871|compared_35|,_13|in_18|evidenced_53|and_166|by_170|._234 (r_nsubj) resulted_7\VBD\2633881|NONE_0 (l_prep) in_8\IN\13603305|compared_53|,_31|exposure_18|evidenced_35|and_148|by_152|._216 (l_pobj) hypertension_11\NN\14057371|NONE_0
17490790
D007501_D009410 NONE iron_6\NN\14625458|peripheral_11|and_14|loss_38 (r_compound) overload_7\NN\3679986|NONE_0 (r_pobj) between_4\IN\0|the_17 (r_prep) relationship_3\NN\31921|to_19 (r_dobj) demonstrate_1\VB\2137132|,_119|in_121|we_142|voltammetry_162|._435 (r_advcl) used_25\VBD\0|NONE_0 (l_dobj) voltammetry_28\NN\0|demonstrate_162|,_43|in_41|we_20|._273 (l_conj) immunohistochemistry_35\NN\791527|fast_51|cyclic_46|,_28 (l_conj) staining_40\NN\275424|tyrosine_60|hydroxylase_51|(_39|th_38|)_36|,_14 (l_conj) detection_49\NN\5708432|perls_81|iron_74|,_61|and_59|content_79 (l_acl) study_51\VB\635850|performance_63|liquid_51|electrochemical_29|and_47 (l_dobj) degeneration_53\NN\29677|to_13 (l_prep) of_54\IN\0|the_17 (l_pobj) neurons_56\NNS\5430628|NONE_0
D007501_D009410 NONE iron_39\NN\14625458|perls_7|,_13|and_15|detection_74|content_153 (r_compound) staining_40\NN\275424|tyrosine_60|hydroxylase_51|(_39|th_38|)_36|,_14 (l_conj) detection_49\NN\5708432|perls_81|iron_74|,_61|and_59|content_79 (l_acl) study_51\VB\635850|performance_63|liquid_51|electrochemical_29|and_47 (l_dobj) degeneration_53\NN\29677|to_13 (l_prep) of_54\IN\0|the_17 (l_pobj) neurons_56\NNS\5430628|NONE_0
D007501_D009410 NONE iron_59\NN\14625458|increased_10|in_13 (r_compound) content_60\NN\7951464|perls_160|iron_153|,_140|and_138|detection_79 (r_conj) staining_40\NN\275424|tyrosine_60|hydroxylase_51|(_39|th_38|)_36|,_14 (l_conj) detection_49\NN\5708432|perls_81|iron_74|,_61|and_59|content_79 (l_acl) study_51\VB\635850|performance_63|liquid_51|electrochemical_29|and_47 (l_dobj) degeneration_53\NN\29677|to_13 (l_prep) of_54\IN\0|the_17 (l_pobj) neurons_56\NNS\5430628|NONE_0
D007501_D009410 NONE iron_10\NN\14625458|the_4|in_11|,_20|causes_43 (r_compound) level_11\NN\4916342|that_51|dextran_30|can_22 (l_relcl) causes_19\VBZ\7323922|the_47|iron_43|in_32|,_23 (l_dobj) degeneration_21\NN\29677|where_32|iron_16 (l_prep) of_22\IN\0|the_17 (l_pobj) neurons_24\NNS\5430628|NONE_0
D007501_D009410 NONE iron_18\NN\14625458|where_16|degeneration_16 (r_nsubj) causes_19\VBZ\7323922|the_47|iron_43|in_32|,_23 (l_dobj) degeneration_21\NN\29677|where_32|iron_16 (l_prep) of_22\IN\0|the_17 (l_pobj) neurons_24\NNS\5430628|NONE_0
D014443_D009410 NONE tyrosine_30\NN\14601829|hydroxylase_9|(_21|th_22|)_24|,_46|staining_60 (r_det) immunohistochemistry_35\NN\791527|fast_51|cyclic_46|,_28 (l_conj) staining_40\NN\275424|tyrosine_60|hydroxylase_51|(_39|th_38|)_36|,_14 (l_conj) detection_49\NN\5708432|perls_81|iron_74|,_61|and_59|content_79 (l_acl) study_51\VB\635850|performance_63|liquid_51|electrochemical_29|and_47 (l_dobj) degeneration_53\NN\29677|to_13 (l_prep) of_54\IN\0|the_17 (l_pobj) neurons_56\NNS\5430628|NONE_0
D007501_D010300 NONE iron_0\NN\14625458|NONE_0 (r_compound) accumulation_1\NN\13497135|is_13|involved_33|._84 (r_nsubjpass) considered_3\VBN\689344|NONE_0 (l_xcomp) involved_6\VBN\2676054|accumulation_33|is_20|._51 (l_prep) in_7\IN\13603305|to_15|be_12 (l_pobj) pathogenesis_9\NN\13533470|NONE_0 (l_prep) of_10\IN\0|the_17 (l_pobj) disease_13\NN\14061805|NONE_0
D007505_D009410 CID dextran_2\NN\0|degeneration_16|._76 (r_nsubj) induced_3\VBD\1627355|NONE_0 (l_dobj) degeneration_4\NN\29677|dextran_16|._60 (l_prep) of_5\IN\0|NONE_0 (l_pobj) neurons_7\NNS\5430628|NONE_0
D007505_D009410 CID dextran_66\NN\0|iron_5|overloaded_8 (r_amod) animals_68\NNS\4475|NONE_0 (r_pobj) of_64\IN\0|the_7 (r_prep) sn_63\NN\14625458|NONE_0 (r_pobj) in_61\IN\13603305|increased_23|iron_13 (r_prep) content_60\NN\7951464|perls_160|iron_153|,_140|and_138|detection_79 (r_conj) staining_40\NN\275424|tyrosine_60|hydroxylase_51|(_39|th_38|)_36|,_14 (l_conj) detection_49\NN\5708432|perls_81|iron_74|,_61|and_59|content_79 (l_acl) study_51\VB\635850|performance_63|liquid_51|electrochemical_29|and_47 (l_dobj) degeneration_53\NN\29677|to_13 (l_prep) of_54\IN\0|the_17 (l_pobj) neurons_56\NNS\5430628|NONE_0
D007505_D009410 CID dextran_6\NN\0|that_21|can_8|level_30 (r_nsubj) increase_8\VB\13576355|results_49|._103 (l_dobj) level_11\NN\4916342|that_51|dextran_30|can_22 (l_relcl) causes_19\VBZ\7323922|the_47|iron_43|in_32|,_23 (l_dobj) degeneration_21\NN\29677|where_32|iron_16 (l_prep) of_22\IN\0|the_17 (l_pobj) neurons_24\NNS\5430628|NONE_0
11752998
D002211_D004342 NONE capsaicin_27\NN\15032661|-_9 (r_npadvmod) evoked_29\VBN\1617192|mechanical_7 (r_amod) hypersensitivity_31\NN\14531772|both_63|acute_58|noxious_52|and_32
D002211_D004342 NONE capsaicin_20\NN\15032661|peripheral_11 (r_compound) injection_21\NN\320852|NONE_0 (r_pobj) after_18\IN\0|to_43|sensitization_24 (r_prep) reflect_13\VB\923793|NONE_0 (r_xcomp) presumed_11\VBN\719734|results_80|inhibition_57|,_2|._88 (r_advcl) show_2\VBP\429048|NONE_0 (l_dobj) inhibition_4\NN\1068773|results_23|,_55|presumed_57|._145 (l_prep) by_5\IN\0|selective_21 (l_pobj) adenosine_7\NN\14964367|NONE_0 (l_prep) of_8\IN\0|intrathecal_22 (l_pobj) hypersensitivity_9\NN\14531772|NONE_0
D002211_D010146 NONE capsaicin_82\NN\15032661|intradermal_12 (r_compound) injection_83\NN\320852|NONE_0 (r_pobj) after_80\IN\0|acute_70|heat_64|and_51|areas_47 (r_prep) stimuli_72\NNS\5816287|NONE_0 (r_pobj) to_69\IN\0|NONE_0 (r_prep) response_68\NN\11410625|NONE_0 (r_pobj) in_67\IN\13603305|pain_13 (r_prep) ratings_66\NNS\5733583|were_131|._146 (l_compound) pain_65\NN\14299637|in_13
D002211_D010146 NONE capsaicin_22\NN\15032661|intradermal_12 (r_compound) injection_23\NN\320852|NONE_0 (r_pobj) from_20\IN\0|NONE_0 (r_prep) allodynia_19\NN\0|reduced_36|mechanical_28|and_4|for_47 (r_conj) hyperalgesia_17\NN\0|acute_69|noxious_63|thermal_55|but_23 (r_conj) stimulation_13\NN\242808|NONE_0 (r_pobj) to_7\IN\0|adenosine_44|effect_22 (r_prep) produced_1\VBD\1617192|NONE_0 (l_dobj) effect_3\NN\34213|adenosine_22|to_22 (l_prep) on_4\IN\0|no_10 (l_pobj) report_6\NN\6470073|NONE_0 (l_compound) pain_5\NN\14299637|NONE_0
D000241_D059787 NONE adenosine_4\NN\14964367|NONE_0 (r_pobj) of_2\IN\0|preclinical_20 (r_prep) studies_1\NNS\635850|be_48|and_115|suggests_206 (r_nsubj) suggest_5\VBP\1010118|NONE_0 (l_ccomp) be_8\VB\14625458|studies_48|and_67|suggests_158 (l_acomp) effective_9\JJ\0|it_10|may_7|,_62 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) treatment_12\NN\654885|NONE_0 (l_prep) of_13\IN\0|the_14 (l_pobj) pain_17\NN\14299637|NONE_0
D000241_D059787 NONE adenosine_33\NN\14964367|NONE_0 (r_pobj) of_32\IN\0|a_22|swedish_20 (r_prep) formulation_31\NN\14818238|NONE_0 (r_pobj) with_28\IN\0|and_13|patients_9 (r_prep) volunteers_25\NNS\10582746|NONE_0 (r_pobj) in_24\IN\13603305|preliminary_20 (r_prep) studies_23\NNS\635850|be_91|._169 (r_nsubj) suggests_34\VBZ\1010118|studies_206|be_158|and_91 (r_conj) suggest_5\VBP\1010118|NONE_0 (l_ccomp) be_8\VB\14625458|studies_48|and_67|suggests_158 (l_acomp) effective_9\JJ\0|it_10|may_7|,_62 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) treatment_12\NN\654885|NONE_0 (l_prep) of_13\IN\0|the_14 (l_pobj) pain_17\NN\14299637|NONE_0
D000241_D006930 NONE adenosine_34\NN\14964367|intrathecal_12|of_16|and_31|trial_70 (r_amod) doses_35\NNS\3740161|NONE_0 (r_pobj) with_32\IN\0|an_37|label_29|,_24|escalating_17|,_105 (r_prep) trial_31\NN\786195|two_43|:_33 (r_appos) trials_21\NNS\786195|NONE_0 (r_pobj) in_19\IN\13603305|following_136|,_29|volunteers_24|were_13|obtained_189 (r_prep) studied_18\VBN\0|NONE_0 (l_conj) obtained_59\VBN\2210855|following_325|,_218|volunteers_213|were_202|in_189 (l_conj) determined_85\VBN\0|fluid_194|was_188|for_175|,_147|and_145 (l_nsubjpass) ratings_66\NNS\5733583|were_131|._146 (l_prep) in_67\IN\13603305|pain_13 (l_pobj) response_68\NN\11410625|NONE_0 (l_prep) to_69\IN\0|NONE_0 (l_pobj) stimuli_72\NNS\5816287|NONE_0 (l_conj) areas_74\NNS\8630985|acute_23|heat_17|and_4|after_47 (l_prep) of_75\IN\0|NONE_0 (l_pobj) hyperalgesia_77\NN\0|NONE_0
D000241_D006930 NONE adenosine_34\NN\14964367|intrathecal_12|of_16|and_31|trial_70 (r_amod) doses_35\NNS\3740161|NONE_0 (r_pobj) with_32\IN\0|an_37|label_29|,_24|escalating_17|,_105 (r_prep) trial_31\NN\786195|two_43|:_33 (r_appos) trials_21\NNS\786195|NONE_0 (r_pobj) in_19\IN\13603305|following_136|,_29|volunteers_24|were_13|obtained_189 (r_prep) studied_18\VBN\0|NONE_0 (l_conj) obtained_59\VBN\2210855|following_325|,_218|volunteers_213|were_202|in_189 (l_conj) determined_85\VBN\0|fluid_194|was_188|for_175|,_147|and_145 (l_nsubjpass) ratings_66\NNS\5733583|were_131|._146 (l_prep) in_67\IN\13603305|pain_13 (l_pobj) response_68\NN\11410625|NONE_0 (l_prep) to_69\IN\0|NONE_0 (l_pobj) stimuli_72\NNS\5816287|NONE_0 (l_conj) areas_74\NNS\8630985|acute_23|heat_17|and_4|after_47 (l_prep) of_75\IN\0|NONE_0 (l_pobj) hyperalgesia_77\NN\0|NONE_0 (l_conj) allodynia_79\NN\0|mechanical_28|and_4
D000241_D006930 NONE adenosine_52\NN\14964367|NONE_0 (r_pobj) of_51\IN\0|a_41|blind_32|,_27|controlled_17 (r_prep) trial_50\NN\786195|intrathecal_82|adenosine_70|of_54|and_39 (r_conj) doses_35\NNS\3740161|NONE_0 (r_pobj) with_32\IN\0|an_37|label_29|,_24|escalating_17|,_105 (r_prep) trial_31\NN\786195|two_43|:_33 (r_appos) trials_21\NNS\786195|NONE_0 (r_pobj) in_19\IN\13603305|following_136|,_29|volunteers_24|were_13|obtained_189 (r_prep) studied_18\VBN\0|NONE_0 (l_conj) obtained_59\VBN\2210855|following_325|,_218|volunteers_213|were_202|in_189 (l_conj) determined_85\VBN\0|fluid_194|was_188|for_175|,_147|and_145 (l_nsubjpass) ratings_66\NNS\5733583|were_131|._146 (l_prep) in_67\IN\13603305|pain_13 (l_pobj) response_68\NN\11410625|NONE_0 (l_prep) to_69\IN\0|NONE_0 (l_pobj) stimuli_72\NNS\5816287|NONE_0 (l_conj) areas_74\NNS\8630985|acute_23|heat_17|and_4|after_47 (l_prep) of_75\IN\0|NONE_0 (l_pobj) hyperalgesia_77\NN\0|NONE_0
D000241_D006930 NONE adenosine_52\NN\14964367|NONE_0 (r_pobj) of_51\IN\0|a_41|blind_32|,_27|controlled_17 (r_prep) trial_50\NN\786195|intrathecal_82|adenosine_70|of_54|and_39 (r_conj) doses_35\NNS\3740161|NONE_0 (r_pobj) with_32\IN\0|an_37|label_29|,_24|escalating_17|,_105 (r_prep) trial_31\NN\786195|two_43|:_33 (r_appos) trials_21\NNS\786195|NONE_0 (r_pobj) in_19\IN\13603305|following_136|,_29|volunteers_24|were_13|obtained_189 (r_prep) studied_18\VBN\0|NONE_0 (l_conj) obtained_59\VBN\2210855|following_325|,_218|volunteers_213|were_202|in_189 (l_conj) determined_85\VBN\0|fluid_194|was_188|for_175|,_147|and_145 (l_nsubjpass) ratings_66\NNS\5733583|were_131|._146 (l_prep) in_67\IN\13603305|pain_13 (l_pobj) response_68\NN\11410625|NONE_0 (l_prep) to_69\IN\0|NONE_0 (l_pobj) stimuli_72\NNS\5816287|NONE_0 (l_conj) areas_74\NNS\8630985|acute_23|heat_17|and_4|after_47 (l_prep) of_75\IN\0|NONE_0 (l_pobj) hyperalgesia_77\NN\0|NONE_0 (l_conj) allodynia_79\NN\0|mechanical_28|and_4
D000241_D006930 NONE adenosine_0\NNP\14964367|effect_22|to_44 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_prep) to_7\IN\0|adenosine_44|effect_22 (l_pobj) stimulation_13\NN\242808|NONE_0 (l_conj) hyperalgesia_17\NN\0|acute_69|noxious_63|thermal_55|but_23
D000241_D006930 NONE adenosine_0\NNP\14964367|effect_22|to_44 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_prep) to_7\IN\0|adenosine_44|effect_22 (l_pobj) stimulation_13\NN\242808|NONE_0 (l_conj) hyperalgesia_17\NN\0|acute_69|noxious_63|thermal_55|but_23 (l_conj) allodynia_19\NN\0|reduced_36|mechanical_28|and_4|for_47
D000241_D009437 NONE adenosine_27\NN\14964367|NONE_0 (r_pobj) of_26\IN\0|prolonged_20|in_13 (r_prep) residence_25\NN\8491027|to_13 (r_pobj) due_22\JJ\5174653|not_4 (r_acomp) is_20\VBZ\0|effect_109|consistent_99|and_4|._69 (r_conj) is_5\VBZ\0|NONE_0 (l_acomp) consistent_6\JJ\0|effect_10|and_95|is_99|._168 (l_prep) with_7\IN\0|NONE_0 (l_pcomp) observed_9\VBN\2163746|NONE_0 (l_prep) in_10\IN\13603305|that_14 (l_pobj) reports_12\NNS\6470073|NONE_0 (l_prep) of_13\IN\0|preliminary_20 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_prep) with_15\IN\0|NONE_0 (l_pobj) pain_18\NN\14299637|NONE_0
D000241_D004342 NONE adenosine_4\NN\14964367|NONE_0 (r_pobj) of_2\IN\0|preclinical_20 (r_prep) studies_1\NNS\635850|be_48|and_115|suggests_206 (r_nsubj) suggest_5\VBP\1010118|NONE_0 (l_conj) suggests_34\VBZ\1010118|studies_206|be_158|and_91 (l_ccomp) be_37\VB\14625458|studies_91|._78 (l_acomp) effective_38\JJ\0|it_10|may_7|but_37|with_45 (l_prep) in_39\IN\13603305|NONE_0 (l_pobj) states_41\NNS\8491826|NONE_0 (l_compound) hypersensitivity_40\NN\14531772|NONE_0
D000241_D004342 NONE adenosine_33\NN\14964367|NONE_0 (r_pobj) of_32\IN\0|a_22|swedish_20 (r_prep) formulation_31\NN\14818238|NONE_0 (r_pobj) with_28\IN\0|and_13|patients_9 (r_prep) volunteers_25\NNS\10582746|NONE_0 (r_pobj) in_24\IN\13603305|preliminary_20 (r_prep) studies_23\NNS\635850|be_91|._169 (r_nsubj) suggests_34\VBZ\1010118|studies_206|be_158|and_91 (l_ccomp) be_37\VB\14625458|studies_91|._78 (l_acomp) effective_38\JJ\0|it_10|may_7|but_37|with_45 (l_prep) in_39\IN\13603305|NONE_0 (l_pobj) states_41\NNS\8491826|NONE_0 (l_compound) hypersensitivity_40\NN\14531772|NONE_0
D000241_D004342 NONE adenosine_15\NN\14964367|NONE_0 (r_pobj) of_14\IN\0|a_24|different_22 (r_prep) formulation_13\NN\14818238|NONE_0 (r_pobj) of_10\IN\0|NONE_0 (r_prep) efficacy_9\NN\5199286|NONE_0 (r_pobj) for_8\IN\0|to_10|,_71|using_73 (r_prep) screen_7\VB\4362025|purpose_29|._165 (l_advcl) using_21\VBG\418025|to_83|for_73|,_2 (l_dobj) stimulation_25\NN\242808|NONE_0 (l_conj) hypersensitivity_31\NN\14531772|both_63|acute_58|noxious_52|and_32
D000241_D004342 NONE adenosine_7\NN\14964367|NONE_0 (l_prep) of_8\IN\0|intrathecal_22 (l_pobj) hypersensitivity_9\NN\14531772|NONE_0
D000241_D059350 NONE adenosine_4\NN\14964367|NONE_0 (r_pobj) of_2\IN\0|preclinical_20 (r_prep) studies_1\NNS\635850|be_48|and_115|suggests_206 (r_nsubj) suggest_5\VBP\1010118|NONE_0 (l_ccomp) be_8\VB\14625458|studies_48|and_67|suggests_158 (l_acomp) effective_9\JJ\0|it_10|may_7|,_62 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) treatment_12\NN\654885|NONE_0 (l_prep) of_13\IN\0|the_14 (l_pobj) pain_17\NN\14299637|NONE_0
D000241_D059350 NONE adenosine_33\NN\14964367|NONE_0 (r_pobj) of_32\IN\0|a_22|swedish_20 (r_prep) formulation_31\NN\14818238|NONE_0 (r_pobj) with_28\IN\0|and_13|patients_9 (r_prep) volunteers_25\NNS\10582746|NONE_0 (r_pobj) in_24\IN\13603305|preliminary_20 (r_prep) studies_23\NNS\635850|be_91|._169 (r_nsubj) suggests_34\VBZ\1010118|studies_206|be_158|and_91 (r_conj) suggest_5\VBP\1010118|NONE_0 (l_ccomp) be_8\VB\14625458|studies_48|and_67|suggests_158 (l_acomp) effective_9\JJ\0|it_10|may_7|,_62 (l_prep) in_10\IN\13603305|NONE_0 (l_pobj) treatment_12\NN\654885|NONE_0 (l_prep) of_13\IN\0|the_14 (l_pobj) pain_17\NN\14299637|NONE_0
D000241_D010146 NONE adenosine_34\NN\14964367|intrathecal_12|of_16|and_31|trial_70 (r_amod) doses_35\NNS\3740161|NONE_0 (r_pobj) with_32\IN\0|an_37|label_29|,_24|escalating_17|,_105 (r_prep) trial_31\NN\786195|two_43|:_33 (r_appos) trials_21\NNS\786195|NONE_0 (r_pobj) in_19\IN\13603305|following_136|,_29|volunteers_24|were_13|obtained_189 (r_prep) studied_18\VBN\0|NONE_0 (l_conj) obtained_59\VBN\2210855|following_325|,_218|volunteers_213|were_202|in_189 (l_conj) determined_85\VBN\0|fluid_194|was_188|for_175|,_147|and_145 (l_nsubjpass) ratings_66\NNS\5733583|were_131|._146 (l_compound) pain_65\NN\14299637|in_13
D000241_D010146 NONE adenosine_52\NN\14964367|NONE_0 (r_pobj) of_51\IN\0|a_41|blind_32|,_27|controlled_17 (r_prep) trial_50\NN\786195|intrathecal_82|adenosine_70|of_54|and_39 (r_conj) doses_35\NNS\3740161|NONE_0 (r_pobj) with_32\IN\0|an_37|label_29|,_24|escalating_17|,_105 (r_prep) trial_31\NN\786195|two_43|:_33 (r_appos) trials_21\NNS\786195|NONE_0 (r_pobj) in_19\IN\13603305|following_136|,_29|volunteers_24|were_13|obtained_189 (r_prep) studied_18\VBN\0|NONE_0 (l_conj) obtained_59\VBN\2210855|following_325|,_218|volunteers_213|were_202|in_189 (l_conj) determined_85\VBN\0|fluid_194|was_188|for_175|,_147|and_145 (l_nsubjpass) ratings_66\NNS\5733583|were_131|._146 (l_compound) pain_65\NN\14299637|in_13
D000241_D010146 NONE adenosine_0\NNP\14964367|effect_22|to_44 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) effect_3\NN\34213|adenosine_22|to_22 (l_prep) on_4\IN\0|no_10 (l_pobj) report_6\NN\6470073|NONE_0 (l_compound) pain_5\NN\14299637|NONE_0
D002211_D006930 CID capsaicin_82\NN\15032661|intradermal_12 (r_compound) injection_83\NN\320852|NONE_0 (r_pobj) after_80\IN\0|acute_70|heat_64|and_51|areas_47 (r_prep) stimuli_72\NNS\5816287|NONE_0 (l_conj) areas_74\NNS\8630985|acute_23|heat_17|and_4|after_47 (l_prep) of_75\IN\0|NONE_0 (l_pobj) hyperalgesia_77\NN\0|NONE_0
D002211_D006930 CID capsaicin_82\NN\15032661|intradermal_12 (r_compound) injection_83\NN\320852|NONE_0 (r_pobj) after_80\IN\0|acute_70|heat_64|and_51|areas_47 (r_prep) stimuli_72\NNS\5816287|NONE_0 (l_conj) areas_74\NNS\8630985|acute_23|heat_17|and_4|after_47 (l_prep) of_75\IN\0|NONE_0 (l_pobj) hyperalgesia_77\NN\0|NONE_0 (l_conj) allodynia_79\NN\0|mechanical_28|and_4
D002211_D006930 CID capsaicin_22\NN\15032661|intradermal_12 (r_compound) injection_23\NN\320852|NONE_0 (r_pobj) from_20\IN\0|NONE_0 (r_prep) allodynia_19\NN\0|reduced_36|mechanical_28|and_4|for_47 (r_conj) hyperalgesia_17\NN\0|acute_69|noxious_63|thermal_55|but_23
D002211_D006930 CID capsaicin_22\NN\15032661|intradermal_12 (r_compound) injection_23\NN\320852|NONE_0 (r_pobj) from_20\IN\0|NONE_0 (r_prep) allodynia_19\NN\0|reduced_36|mechanical_28|and_4|for_47
11079278
D004280_D017202 CID dobutamine_10\NN\0|-_10 (r_npadvmod) induced_12\VBN\1627355|myocardial_8 (r_amod) ischemia_14\NN\14195315|NONE_0
D004280_D017202 CID dobutamine_1\NN\0|NONE_0 (r_pcomp) during_0\IN\0|,_32|metoprolol_34|or_56|eliminates_59|._101 (r_prep) attenuates_6\VBZ\224901|NONE_0 (l_conj) eliminates_8\VBZ\1619929|during_59|,_27|metoprolol_25|or_3|._42 (l_dobj) evidence_9\NN\5816287|NONE_0 (l_prep) of_10\IN\0|NONE_0 (l_pobj) ischemia_12\NN\14195315|NONE_0
D008790_D017202 NONE metoprolol_3\NN\2832168|NONE_0 (l_conj) metoprolol_6\NN\2832168|intravenous_38|or_15 (l_conj) glucagon_8\NN\5407119|intravenous_28|plus_5 (l_prep) on_9\IN\0|NONE_0 (l_pobj) ischemia_14\NN\14195315|NONE_0
D008790_D017202 NONE metoprolol_6\NN\2832168|intravenous_38|or_15 (l_conj) glucagon_8\NN\5407119|intravenous_28|plus_5 (l_prep) on_9\IN\0|NONE_0 (l_pobj) ischemia_14\NN\14195315|NONE_0
D008790_D017202 NONE metoprolol_5\FW\2832168|during_34|,_2|or_22|eliminates_25|._67 (r_nsubj) attenuates_6\VBZ\224901|NONE_0 (l_conj) eliminates_8\VBZ\1619929|during_59|,_27|metoprolol_25|or_3|._42 (l_dobj) evidence_9\NN\5816287|NONE_0 (l_prep) of_10\IN\0|NONE_0 (l_pobj) ischemia_12\NN\14195315|NONE_0
7416947
D004077_D020018 CID digoxin_13\NN\15060131|NONE_0 (r_pobj) of_12\IN\0|term_20 (r_prep) administration_11\NN\1133281|NONE_0 (r_pobj) on_7\IN\0|NONE_0 (r_prep) patients_6\NNS\9898892|NONE_0 (r_pobj) of_5\IN\0|sexual_19 (r_prep) dysfunction_4\NN\14204950|NONE_0
D004077_D012214 NONE digoxin_10\NN\15060131|NONE_0 (r_pobj) without_9\IN\0|the_29|study_25|(_1|)_15 (r_prep) group_7\NN\2137|NONE_0 (r_pobj) of_2\IN\0|the_13 (r_prep) patients_1\NNS\9898892|of_63|and_124|selected_142|._192 (r_nsubj) were_12\VBD\0|NONE_0 (l_conj) selected_29\VBN\697589|patients_142|of_79|and_18|._50 (l_prep) from_30\IN\0|were_23|randomly_18 (l_pobj) patients_35\NNS\9898892|NONE_0 (l_compound) disease_34\NN\14061805|the_20|rheumatic_16
19761039
D010936_D004409 NONE sinensis_7\NN\0|NONE_0 (r_pobj) of_4\IN\0|methanolic_19 (r_prep) extract_3\NN\14589223|NONE_0 (r_pobj) of_1\IN\0|(_48|mg/kg_57|)_62 (r_prep) effect_0\NN\34213|was_71|on_83|._154 (r_nsubjpass) studied_15\VBN\0|NONE_0 (l_prep) on_16\IN\0|effect_83|was_12|._71 (l_pobj) dyskinesia_21\JJ\14084880|NONE_0
D010936_D004409 NONE sinensis_10\NN\0|that_19|role_26 (r_nsubj) had_11\VBD\0|results_67|._89 (l_dobj) role_14\NN\719494|that_45|sinensis_26 (l_prep) against_15\IN\0|a_18|protective_16 (l_pobj) dyskinesia_20\JJ\14084880|NONE_0
D012110_D004409 CID reserpine_17\NN\2721160|-_9 (r_npadvmod) induced_19\VBN\1627355|orofacial_8|and_29|alterations_47 (r_amod) dyskinesia_21\JJ\14084880|NONE_0
D012110_D004409 CID reserpine_16\NN\2721160|-_9 (r_npadvmod) induced_18\VBN\1627355|orofacial_8|and_29|stress_43 (r_amod) dyskinesia_20\JJ\14084880|NONE_0
12852481
D001241_D005767 NONE asa_20\NNP\0|when_5|is_4|on_20 (r_nsubjpass) administered_22\VBN\2436349|to_78|results_67 (r_advcl) compare_7\VB\4744814|objectives_40|;_106|._386 (r_xcomp) were_5\VBD\0|NONE_0 (l_nsubj) objectives_0\NNS\5980875|compare_40|;_146|._426 (l_acl) compare_33\VB\4744814|of_140 (l_conj) test_50\VB\5798043|to_115|patterns_87|;_9|and_7 (l_dobj) hypothesis_52\NN\7162194|to_12 (l_acl) confounds_57\VBZ\2604760|the_55 (l_nsubj) toxicity_56\NN\13576101|that_31|detection_23|used_108
D001241_D005767 NONE asa_65\NNP\0|NONE_0 (r_pobj) with_64\IN\0|low_28|incidence_24 (r_prep) malformations_63\NNS\14213199|NONE_0 (r_pobj) of_60\IN\0|the_14 (r_prep) detection_59\NN\5708432|that_54|toxicity_23|used_85 (r_dobj) confounds_57\VBZ\2604760|the_55 (l_nsubj) toxicity_56\NN\13576101|that_31|detection_23|used_108
D001241_D000014 CID aspirin_0\NNP\2707683|(_8|acid_25|)_35|,_36|cyclooxygenase_54|,_86|induces_88|9_177|._226 (r_nsubj) acetylsalicylic_2\JJ\0|NONE_0 (l_conj) induces_17\VBZ\1627355|aspirin_88|(_80|acid_63|)_53|,_52|cyclooxygenase_34|,_2|9_89|._138 (l_dobj) anomalies_19\NNS\14501726|administered_15
D001241_D000014 CID acid_3\NN\14818238|aspirin_25|(_17|)_10|,_11|cyclooxygenase_29|,_61|induces_63|9_152|._201 (r_npadvmod) acetylsalicylic_2\JJ\0|NONE_0 (l_conj) induces_17\VBZ\1627355|aspirin_88|(_80|acid_63|)_53|,_52|cyclooxygenase_34|,_2|9_89|._138 (l_dobj) anomalies_19\NNS\14501726|administered_15
D001241_D000014 CID asa_5\NNP\0|NONE_0 (r_appos) acid_3\NN\14818238|aspirin_25|(_17|)_10|,_11|cyclooxygenase_29|,_61|induces_63|9_152|._201 (r_npadvmod) acetylsalicylic_2\JJ\0|NONE_0 (l_conj) induces_17\VBZ\1627355|aspirin_88|(_80|acid_63|)_53|,_52|cyclooxygenase_34|,_2|9_89|._138 (l_dobj) anomalies_19\NNS\14501726|administered_15
D001241_D000014 CID asa_20\NNP\0|when_5|is_4|on_20 (r_nsubjpass) administered_22\VBN\2436349|to_78|results_67 (r_advcl) compare_7\VB\4744814|objectives_40|;_106|._386 (r_xcomp) were_5\VBD\0|NONE_0 (l_nsubj) objectives_0\NNS\5980875|compare_40|;_146|._426 (l_acl) compare_33\VB\4744814|of_140 (l_conj) test_50\VB\5798043|to_115|patterns_87|;_9|and_7 (l_dobj) hypothesis_52\NN\7162194|to_12 (l_acl) confounds_57\VBZ\2604760|the_55 (l_dobj) detection_59\NN\5708432|that_54|toxicity_23|used_85 (l_prep) of_60\IN\0|the_14 (l_pobj) malformations_63\NNS\14213199|NONE_0
D001241_D000014 CID asa_65\NNP\0|NONE_0 (r_pobj) with_64\IN\0|low_28|incidence_24 (r_prep) malformations_63\NNS\14213199|NONE_0
D001241_D000014 CID asa_16\NNP\0|even_12|though_7|malformations_40 (r_nsubj) induces_17\VBZ\1627355|,_82|)_76|;_75|hence_73|,_68|study_54|on_40|,_18|._49 (r_advcl) focused_9\VBD\628491|NONE_0 (l_prep) on_10\IN\0|,_42|)_36|;_35|hence_33|,_28|study_14|,_22|induces_40|._89 (l_pobj) malformations_12\NNS\14213199|NONE_0
D001241_D000014 CID asa_16\NNP\0|even_12|though_7|malformations_40 (r_nsubj) induces_17\VBZ\1627355|,_82|)_76|;_75|hence_73|,_68|study_54|on_40|,_18|._49 (l_dobj) malformations_23\NNS\14213199|even_52|though_47|asa_40
D001241_D000014 CID asa_6\NNP\0|when_5|was_4|as_21 (r_nsubjpass) administered_8\VBN\2436349|variations_55|similar_21|gds_69|._81 (r_advcl) were_3\VBD\0|NONE_0 (l_nsubj) variations_0\NNS\7296428|similar_34|administered_55|gds_124|._136 (l_conj) malformations_2\NNS\14213199|and_4
D001241_D000014 CID asa_38\NNP\0|NONE_0 (r_pobj) with_37\IN\0|that_186|,_182|malformations_121|,_24|could_22|also_16|be_11 (r_prep) induced_36\VBN\1627355|it_198|also_191|evident_186|._40 (l_nsubjpass) malformations_17\NNS\14213199|that_65|,_61|,_97|could_99|also_105|be_110|with_121
19058474
D014859_D006470 NONE warfarin_26\NN\2718259|NONE_0 (r_pobj) of_25\IN\0|his_17|usual_13 (r_prep) dosage_24\NN\13576355|while_28 (r_dobj) maintaining_21\VBG\0|who_54|juice_26|for_20 (r_advcl) consumed_13\VBD\1168468|an_19|elderly_16 (r_relcl) man_11\NN\9605289|NONE_0 (r_pobj) in_8\IN\13603305|a_37|of_30 (r_prep) case_3\NN\7283608|we_12|._147 (l_prep) of_4\IN\0|a_7|in_30 (l_pobj) haemorrhage_7\NN\14285662|NONE_0
D014859_D010490 NONE warfarin_13\NN\2718259|NONE_0 (r_pobj) with_12\IN\0|possible_40|of_19 (r_prep) interaction_8\NN\37396|to_12 (r_pobj) due_5\IN\5174653|haemopericardium_50|._60 (r_prep) haemorrhage_4\NN\14285662|NONE_0 (l_nmod) haemopericardium_1\NN\0|due_50|._110
D014859_D006471 CID warfarin_13\NN\2718259|NONE_0 (r_pobj) with_12\IN\0|possible_40|of_19 (r_prep) interaction_8\NN\37396|to_12 (r_pobj) due_5\IN\5174653|haemopericardium_50|._60 (r_prep) haemorrhage_4\NN\14285662|NONE_0
11009181
D001058_D004409 NONE apomorphine_13\NN\3786417|continuous_24 (r_compound) infusions_14\NNS\14589223|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) monotherapy_9\NN\0|that_5|is_63|with_77 (r_nsubjpass) associated_16\VBN\628491|clinical_89 (l_prep) with_17\IN\0|that_82|monotherapy_77|is_14 (l_pobj) reductions_19\NNS\351485|NONE_0 (l_prep) of_20\IN\0|marked_18 (l_pobj) dyskinesias_25\NNS\14084880|NONE_0
D007980_D004409 CID levodopa_22\NN\14604959|-_8 (r_npadvmod) induced_24\VBN\1627355|preexisting_21 (r_amod) dyskinesias_25\NNS\14084880|NONE_0
D001058_D001523 NONE apomorphine_6\NN\3786417|subcutaneous_13 (r_compound) treatment_7\NN\654885|NONE_0 (r_pobj) of_4\IN\0|the_22|main_18|side_13 (r_prep) effects_3\NNS\13245626|are_46|to_58|,_92|play_141|._159 (r_nsubjpass) related_9\VBN\628491|NONE_0 (l_advcl) play_20\VBP\7007684|effects_141|are_95|to_83|,_49|._18 (l_nsubj) sedation_16\NN\14034177|whereas_8|role_53 (l_conj) complications_19\NNS\1073995|and_16 (l_amod) psychiatric_18\JJ\0|NONE_0
D001058_D010300 NONE apomorphine_0\NNP\3786417|NONE_0 (l_appos) therapy_4\NN\657604|:_19|._31 (l_prep) for_5\IN\0|an_25|underutilized_22 (l_pobj) disease_8\NN\14061805|NONE_0
D001058_D010300 NONE apomorphine_0\NNP\3786417|drug_39|._94 (r_nsubj) was_1\VBD\0|NONE_0 (l_attr) drug_5\NN\14778436|apomorphine_39|._55 (l_acl) used_7\VBN\0|the_33|first_29|dopaminergic_23 (l_xcomp) treat_9\VB\7570720|ever_13 (l_dobj) symptoms_10\NNS\5823932|to_9 (l_prep) of_11\IN\0|NONE_0 (l_pobj) disease_14\NN\14061805|NONE_0
D001058_D010300 NONE apomorphine_24\NN\3786417|NONE_0 (r_pobj) of_23\IN\0|subcutaneous_28 (r_prep) administration_22\NN\1133281|NONE_0 (r_pobj) by_20\IN\0|disease_8 (r_prep) treating_15\VBG\2376958|NONE_0 (l_dobj) disease_19\NN\14061805|by_8
D001058_D010300 NONE apomorphine_8\NN\3786417|subcutaneous_13|in_22 (r_compound) treatment_9\NN\654885|NONE_0 (l_prep) in_10\IN\13603305|subcutaneous_35|apomorphine_22 (l_pobj) disease_14\NN\14061805|NONE_0
15897593
D005047_D015431 CID etoposide_12\RB\0|and_4 (r_conj) daunorubicin_10\NN\0|NONE_0 (r_pobj) from_9\IN\0|nontoxic_71|of_56|in_32|and_40|antagonized_44 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (l_prep) of_2\IN\0|nontoxic_15|from_56|in_88|and_96|antagonized_100 (l_pobj) myelosuppression_5\NN\0|NONE_0 (l_conj) loss_8\NN\13252973|reduced_36|and_11
D005047_D015431 CID etoposide_12\RB\0|and_4 (r_conj) daunorubicin_10\NN\0|NONE_0 (r_pobj) from_9\IN\0|nontoxic_71|of_56|in_32|and_40|antagonized_44 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (r_nsubj) dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77 (l_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9
D018943_D066126 NONE anthracyclines_1\NNS\0|and_28|doxorubicin_32|are_81 (r_nsubj) daunorubicin_2\NN\0|;_147|however_149|,_156|myelosuppression_158|use_208|._211 (r_ccomp) limit_30\VBP\5123416|NONE_0 (l_nsubj) myelosuppression_26\NN\0|daunorubicin_158|;_11|however_9|,_2|use_50|._53 (l_conj) toxicity_29\NN\13576101|and_12
D018943_D066126 NONE anthracycline_9\NN\0|-_13 (r_advmod) induced_11\VBN\1627355|NONE_0 (r_amod) cardiotoxicity_12\NN\0|NONE_0
D003630_D064420 NONE daunorubicin_10\NN\0|NONE_0 (r_pobj) from_9\IN\0|nontoxic_71|of_56|in_32|and_40|antagonized_44 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (r_nsubj) dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77 (l_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9 (l_conj) cytotoxicity_39\NN\13583478|weight_30|,_19|nor_17
D005047_D006402 CID etoposide_33\VB\0|NONE_0 (r_pobj) to_32\TO\0|of_43 (r_prep) sensitivity_24\NN\5651971|investigated_14|was_115|in_130|._177 (r_nsubjpass) determined_42\VBN\0|NONE_0 (l_advcl) investigated_22\VBN\644583|sensitivity_14|was_129|in_144|._191 (l_nsubjpass) toxicity_8\NN\13576101|because_49|,_18|enhancers_103|was_113|:_129
D005047_D006402 CID etoposide_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|dexrazoxane_27 (r_prep) doses_11\NNS\3740161|NONE_0 (r_dobj) combining_7\VBG\7373277|brain_17 (r_acl) metastases_6\NNS\13533470|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) patients_3\NNS\9898892|NONE_0 (r_pobj) in_2\IN\13603305|clinical_16 (r_prep) trials_1\NNS\786195|ongoing_94|._177 (r_nsubj) is_14\VBZ\0|NONE_0 (l_acomp) ongoing_15\JJ\0|trials_94|._83 (l_prep) with_16\IN\0|NONE_0 (l_pobj) aim_18\NN\5980875|NONE_0 (l_prep) of_19\IN\0|the_8 (l_pcomp) improving_20\VBG\126264|NONE_0 (l_prep) without_22\IN\0|efficacy_9 (l_pcomp) aggravating_23\VBG\126264|NONE_0 (l_dobj) toxicity_25\NN\13576101|NONE_0
D064730_D006402 NONE dexrazoxane_12\NN\0|NONE_0 (r_pobj) of_11\IN\0|and_15 (r_prep) coadministration_10\NN\0|NONE_0 (r_pobj) following_9\VBG\8180190|the_25|hematologic_21 (r_prep) toxicity_8\NN\13576101|because_49|,_18|enhancers_103|was_113|:_129
D064730_D006402 NONE dexrazoxane_40\NN\0|NONE_0 (r_dobj) doxorubicin_38\NN\2716866|,_6|and_4 (r_conj) daunorubicin_35\NNS\0|,_2 (r_conj) etoposide_33\VB\0|NONE_0 (r_pobj) to_32\TO\0|of_43 (r_prep) sensitivity_24\NN\5651971|investigated_14|was_115|in_130|._177 (r_nsubjpass) determined_42\VBN\0|NONE_0 (l_advcl) investigated_22\VBN\644583|sensitivity_14|was_129|in_144|._191 (l_nsubjpass) toxicity_8\NN\13576101|because_49|,_18|enhancers_103|was_113|:_129
D064730_D006402 NONE dexrazoxane_8\NN\0|of_27 (r_nmod) doses_11\NNS\3740161|NONE_0 (r_dobj) combining_7\VBG\7373277|brain_17 (r_acl) metastases_6\NNS\13533470|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) patients_3\NNS\9898892|NONE_0 (r_pobj) in_2\IN\13603305|clinical_16 (r_prep) trials_1\NNS\786195|ongoing_94|._177 (r_nsubj) is_14\VBZ\0|NONE_0 (l_acomp) ongoing_15\JJ\0|trials_94|._83 (l_prep) with_16\IN\0|NONE_0 (l_pobj) aim_18\NN\5980875|NONE_0 (l_prep) of_19\IN\0|the_8 (l_pcomp) improving_20\VBG\126264|NONE_0 (l_prep) without_22\IN\0|efficacy_9 (l_pcomp) aggravating_23\VBG\126264|NONE_0 (l_dobj) toxicity_25\NN\13576101|NONE_0
D011034_D001855 NONE epipodophyllotoxin_7\NN\0|and_8 (r_conj) doxorubicin_4\NN\2716866|anthracyclines_32|and_4|are_49 (r_conj) daunorubicin_2\NN\0|;_147|however_149|,_156|myelosuppression_158|use_208|._211 (r_ccomp) limit_30\VBP\5123416|NONE_0 (l_nsubj) myelosuppression_26\NN\0|daunorubicin_158|;_11|however_9|,_2|use_50|._53
D011034_D066126 NONE epipodophyllotoxin_7\NN\0|and_8 (r_conj) doxorubicin_4\NN\2716866|anthracyclines_32|and_4|are_49 (r_conj) daunorubicin_2\NN\0|;_147|however_149|,_156|myelosuppression_158|use_208|._211 (r_ccomp) limit_30\VBP\5123416|NONE_0 (l_nsubj) myelosuppression_26\NN\0|daunorubicin_158|;_11|however_9|,_2|use_50|._53 (l_conj) toxicity_29\NN\13576101|and_12
D003630_D001855 NONE daunorubicin_13\NNS\0|and_4|but_13|doxorubicin_21 (r_conj) etoposide_11\NN\0|dexrazoxane_84|against_63|._46 (r_advmod) protects_1\VBZ\1127795|NONE_0 (l_prep) against_2\IN\0|dexrazoxane_21|etoposide_63|._109 (l_pobj) myelosuppression_3\NN\0|NONE_0
D003630_D001855 NONE daunorubicin_2\NN\0|;_147|however_149|,_156|myelosuppression_158|use_208|._211 (r_ccomp) limit_30\VBP\5123416|NONE_0 (l_nsubj) myelosuppression_26\NN\0|daunorubicin_158|;_11|however_9|,_2|use_50|._53
D003630_D001855 NONE daunorubicin_10\NN\0|NONE_0 (r_pobj) from_9\IN\0|nontoxic_71|of_56|in_32|and_40|antagonized_44 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (l_prep) of_2\IN\0|nontoxic_15|from_56|in_88|and_96|antagonized_100 (l_pobj) myelosuppression_5\NN\0|NONE_0
D003630_D001855 NONE daunorubicin_10\NN\0|NONE_0 (r_pobj) from_9\IN\0|nontoxic_71|of_56|in_32|and_40|antagonized_44 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (r_nsubj) dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77
D064730_D064420 NONE dexrazoxane_3\NN\0|NONE_0 (r_npadvmod) reduced_4\VBN\441445|and_25|loss_36 (r_amod) myelosuppression_5\NN\0|NONE_0 (r_pobj) of_2\IN\0|nontoxic_15|from_56|in_88|and_96|antagonized_100 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (r_nsubj) dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77 (l_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9 (l_conj) cytotoxicity_39\NN\13583478|weight_30|,_19|nor_17
D064730_D064420 NONE dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77 (l_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9 (l_conj) cytotoxicity_39\NN\13583478|weight_30|,_19|nor_17
D004317_D006402 CID doxorubicin_38\NN\2716866|,_6|and_4 (r_conj) daunorubicin_35\NNS\0|,_2 (r_conj) etoposide_33\VB\0|NONE_0 (r_pobj) to_32\TO\0|of_43 (r_prep) sensitivity_24\NN\5651971|investigated_14|was_115|in_130|._177 (r_nsubjpass) determined_42\VBN\0|NONE_0 (l_advcl) investigated_22\VBN\644583|sensitivity_14|was_129|in_144|._191 (l_nsubjpass) toxicity_8\NN\13576101|because_49|,_18|enhancers_103|was_113|:_129
D064730_D015431 NONE dexrazoxane_3\NN\0|NONE_0 (r_npadvmod) reduced_4\VBN\441445|and_25|loss_36 (r_amod) myelosuppression_5\NN\0|NONE_0 (l_conj) loss_8\NN\13252973|reduced_36|and_11
D064730_D015431 NONE dexrazoxane_3\NN\0|NONE_0 (r_npadvmod) reduced_4\VBN\441445|and_25|loss_36 (r_amod) myelosuppression_5\NN\0|NONE_0 (r_pobj) of_2\IN\0|nontoxic_15|from_56|in_88|and_96|antagonized_100 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (r_nsubj) dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77 (l_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9
D064730_D015431 NONE dexrazoxane_27\NN\0|NONE_0 (l_nsubj) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (l_prep) of_2\IN\0|nontoxic_15|from_56|in_88|and_96|antagonized_100 (l_pobj) myelosuppression_5\NN\0|NONE_0 (l_conj) loss_8\NN\13252973|reduced_36|and_11
D064730_D015431 NONE dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77 (l_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9
D064730_D066126 NONE dexrazoxane_0\NNP\0|is_23|for_38|._97 (r_nsubjpass) recommended_5\VBN\875394|NONE_0 (l_prep) for_6\IN\0|dexrazoxane_38|is_15|._59 (l_pobj) protection_7\NN\407535|NONE_0 (l_prep) against_8\IN\0|NONE_0 (l_pobj) cardiotoxicity_12\NN\0|NONE_0
D064730_D066126 NONE icrf-187_2\NN\0|NONE_0 (r_appos) dexrazoxane_0\NNP\0|is_23|for_38|._97 (r_nsubjpass) recommended_5\VBN\875394|NONE_0 (l_prep) for_6\IN\0|dexrazoxane_38|is_15|._59 (l_pobj) protection_7\NN\407535|NONE_0 (l_prep) against_8\IN\0|NONE_0 (l_pobj) cardiotoxicity_12\NN\0|NONE_0
D005047_D066126 NONE etoposide_8\NN\0|the_23 (r_appos) epipodophyllotoxin_7\NN\0|and_8 (r_conj) doxorubicin_4\NN\2716866|anthracyclines_32|and_4|are_49 (r_conj) daunorubicin_2\NN\0|;_147|however_149|,_156|myelosuppression_158|use_208|._211 (r_ccomp) limit_30\VBP\5123416|NONE_0 (l_nsubj) myelosuppression_26\NN\0|daunorubicin_158|;_11|however_9|,_2|use_50|._53 (l_conj) toxicity_29\NN\13576101|and_12
D004317_D066126 NONE doxorubicin_4\NN\2716866|anthracyclines_32|and_4|are_49 (r_conj) daunorubicin_2\NN\0|;_147|however_149|,_156|myelosuppression_158|use_208|._211 (r_ccomp) limit_30\VBP\5123416|NONE_0 (l_nsubj) myelosuppression_26\NN\0|daunorubicin_158|;_11|however_9|,_2|use_50|._53 (l_conj) toxicity_29\NN\13576101|and_12
D064730_D001855 NONE dexrazoxane_0\NNP\0|against_21|etoposide_84|._130 (r_nsubj) protects_1\VBZ\1127795|NONE_0 (l_prep) against_2\IN\0|dexrazoxane_21|etoposide_63|._109 (l_pobj) myelosuppression_3\NN\0|NONE_0
D064730_D001855 NONE dexrazoxane_3\NN\0|NONE_0 (r_npadvmod) reduced_4\VBN\441445|and_25|loss_36 (r_amod) myelosuppression_5\NN\0|NONE_0
D064730_D001855 NONE dexrazoxane_3\NN\0|NONE_0 (r_npadvmod) reduced_4\VBN\441445|and_25|loss_36 (r_amod) myelosuppression_5\NN\0|NONE_0 (r_pobj) of_2\IN\0|nontoxic_15|from_56|in_88|and_96|antagonized_100 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (r_nsubj) dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77
D064730_D001855 NONE dexrazoxane_27\NN\0|NONE_0 (l_nsubj) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (l_prep) of_2\IN\0|nontoxic_15|from_56|in_88|and_96|antagonized_100 (l_pobj) myelosuppression_5\NN\0|NONE_0
D064730_D001855 NONE dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77
D005047_D064420 NONE etoposide_12\RB\0|and_4 (r_conj) daunorubicin_10\NN\0|NONE_0 (r_pobj) from_9\IN\0|nontoxic_71|of_56|in_32|and_40|antagonized_44 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (r_nsubj) dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77 (l_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9 (l_conj) cytotoxicity_39\NN\13583478|weight_30|,_19|nor_17
D064730_D009362 NONE dexrazoxane_8\NN\0|of_27 (r_nmod) doses_11\NNS\3740161|NONE_0 (r_dobj) combining_7\VBG\7373277|brain_17 (r_acl) metastases_6\NNS\13533470|NONE_0
D005047_D001855 NONE etoposide_11\NN\0|dexrazoxane_84|against_63|._46 (r_advmod) protects_1\VBZ\1127795|NONE_0 (l_prep) against_2\IN\0|dexrazoxane_21|etoposide_63|._109 (l_pobj) myelosuppression_3\NN\0|NONE_0
D005047_D001855 NONE etoposide_8\NN\0|the_23 (r_appos) epipodophyllotoxin_7\NN\0|and_8 (r_conj) doxorubicin_4\NN\2716866|anthracyclines_32|and_4|are_49 (r_conj) daunorubicin_2\NN\0|;_147|however_149|,_156|myelosuppression_158|use_208|._211 (r_ccomp) limit_30\VBP\5123416|NONE_0 (l_nsubj) myelosuppression_26\NN\0|daunorubicin_158|;_11|however_9|,_2|use_50|._53
D005047_D001855 NONE etoposide_12\RB\0|and_4 (r_conj) daunorubicin_10\NN\0|NONE_0 (r_pobj) from_9\IN\0|nontoxic_71|of_56|in_32|and_40|antagonized_44 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (l_prep) of_2\IN\0|nontoxic_15|from_56|in_88|and_96|antagonized_100 (l_pobj) myelosuppression_5\NN\0|NONE_0
D005047_D001855 NONE etoposide_12\RB\0|and_4 (r_conj) daunorubicin_10\NN\0|NONE_0 (r_pobj) from_9\IN\0|nontoxic_71|of_56|in_32|and_40|antagonized_44 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (r_nsubj) dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77
D004317_D064420 NONE doxorubicin_41\NN\2716866|NONE_0 (r_pobj) from_40\IN\0|the_26|vitro_19 (r_prep) cytotoxicity_39\NN\13583478|weight_30|,_19|nor_17
D005047_D009362 NONE etoposide_13\NN\0|NONE_0 (r_pobj) of_12\IN\0|dexrazoxane_27 (r_prep) doses_11\NNS\3740161|NONE_0 (r_dobj) combining_7\VBG\7373277|brain_17 (r_acl) metastases_6\NNS\13533470|NONE_0
D004317_D015431 CID doxorubicin_41\NN\2716866|NONE_0 (r_pobj) from_40\IN\0|the_26|vitro_19 (r_prep) cytotoxicity_39\NN\13583478|weight_30|,_19|nor_17 (r_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9 (r_conj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77 (r_dobj) dexrazoxane_27\NN\0|NONE_0 (l_nsubj) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (l_prep) of_2\IN\0|nontoxic_15|from_56|in_88|and_96|antagonized_100 (l_pobj) myelosuppression_5\NN\0|NONE_0 (l_conj) loss_8\NN\13252973|reduced_36|and_11
D004317_D015431 CID doxorubicin_41\NN\2716866|NONE_0 (r_pobj) from_40\IN\0|the_26|vitro_19 (r_prep) cytotoxicity_39\NN\13583478|weight_30|,_19|nor_17 (r_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9
D018943_D001855 NONE anthracyclines_1\NNS\0|and_28|doxorubicin_32|are_81 (r_nsubj) daunorubicin_2\NN\0|;_147|however_149|,_156|myelosuppression_158|use_208|._211 (r_ccomp) limit_30\VBP\5123416|NONE_0 (l_nsubj) myelosuppression_26\NN\0|daunorubicin_158|;_11|however_9|,_2|use_50|._53
D003630_D006402 CID daunorubicin_35\NNS\0|,_2 (r_conj) etoposide_33\VB\0|NONE_0 (r_pobj) to_32\TO\0|of_43 (r_prep) sensitivity_24\NN\5651971|investigated_14|was_115|in_130|._177 (r_nsubjpass) determined_42\VBN\0|NONE_0 (l_advcl) investigated_22\VBN\644583|sensitivity_14|was_129|in_144|._191 (l_nsubjpass) toxicity_8\NN\13576101|because_49|,_18|enhancers_103|was_113|:_129
D003630_D066126 NONE daunorubicin_2\NN\0|;_147|however_149|,_156|myelosuppression_158|use_208|._211 (r_ccomp) limit_30\VBP\5123416|NONE_0 (l_nsubj) myelosuppression_26\NN\0|daunorubicin_158|;_11|however_9|,_2|use_50|._53 (l_conj) toxicity_29\NN\13576101|and_12
D004317_D001855 NONE doxorubicin_16\RB\2716866|and_25|daunorubicin_21|but_8 (r_conj) etoposide_11\NN\0|dexrazoxane_84|against_63|._46 (r_advmod) protects_1\VBZ\1127795|NONE_0 (l_prep) against_2\IN\0|dexrazoxane_21|etoposide_63|._109 (l_pobj) myelosuppression_3\NN\0|NONE_0
D004317_D001855 NONE doxorubicin_4\NN\2716866|anthracyclines_32|and_4|are_49 (r_conj) daunorubicin_2\NN\0|;_147|however_149|,_156|myelosuppression_158|use_208|._211 (r_ccomp) limit_30\VBP\5123416|NONE_0 (l_nsubj) myelosuppression_26\NN\0|daunorubicin_158|;_11|however_9|,_2|use_50|._53
D004317_D001855 NONE doxorubicin_41\NN\2716866|NONE_0 (r_pobj) from_40\IN\0|the_26|vitro_19 (r_prep) cytotoxicity_39\NN\13583478|weight_30|,_19|nor_17 (r_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9 (r_conj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77 (r_dobj) dexrazoxane_27\NN\0|NONE_0 (l_nsubj) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (l_prep) of_2\IN\0|nontoxic_15|from_56|in_88|and_96|antagonized_100 (l_pobj) myelosuppression_5\NN\0|NONE_0
D004317_D001855 NONE doxorubicin_41\NN\2716866|NONE_0 (r_pobj) from_40\IN\0|the_26|vitro_19 (r_prep) cytotoxicity_39\NN\13583478|weight_30|,_19|nor_17 (r_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9 (r_conj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77
D003630_D015431 CID daunorubicin_10\NN\0|NONE_0 (r_pobj) from_9\IN\0|nontoxic_71|of_56|in_32|and_40|antagonized_44 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (l_prep) of_2\IN\0|nontoxic_15|from_56|in_88|and_96|antagonized_100 (l_pobj) myelosuppression_5\NN\0|NONE_0 (l_conj) loss_8\NN\13252973|reduced_36|and_11
D003630_D015431 CID daunorubicin_10\NN\0|NONE_0 (r_pobj) from_9\IN\0|nontoxic_71|of_56|in_32|and_40|antagonized_44 (r_prep) doses_1\NNS\3740161|;_169|however_171|,_178|myelosuppression_208|._285 (r_nsubj) dexrazoxane_27\NN\0|NONE_0 (l_dobj) myelosuppression_30\NN\0|doses_208|;_39|however_37|,_30|._77 (l_conj) loss_33\NN\13252973|neither_41|reduced_33|,_9
1595783
D000638_D011014 CID amiodarone_0\NN\2715941|agent_42|._133 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agent_5\NN\7347|amiodarone_42|._91 (l_appos) being_19\VBG\24720|an_102|effective_99|antiarrhythmic_89|limited_51|,_23 (l_attr) pneumonitis_20\NN\14336539|the_27|problematic_18
D000638_D008171 NONE amiodarone_0\NN\2715941|pulmonary_11|._29 (r_amod) toxicity_2\NN\13576101|NONE_0
D000638_D008171 NONE amiodarone_4\NN\2715941|NONE_0 (r_pobj) of_3\IN\0|the_23|pulmonary_19 (r_prep) toxicity_2\NN\13576101|is_23|result_37|._169
D000638_D008171 NONE amiodarone_6\NN\2715941|-_10 (r_npadvmod) induced_8\VBN\1627355|pulmonary_8 (r_amod) toxicity_10\NN\13576101|NONE_0
D000638_D004342 NONE amiodarone_4\NN\2715941|NONE_0 (r_pobj) of_3\IN\0|the_23|pulmonary_19 (r_prep) toxicity_2\NN\13576101|is_23|result_37|._169 (r_nsubjpass) thought_6\VBN\5809192|NONE_0 (l_xcomp) result_8\VB\34213|toxicity_37|is_14|._132 (l_prep) from_9\IN\0|to_10 (l_pobj) injury_11\NN\14052046|NONE_0 (l_acl) related_12\VBN\628491|direct_14 (l_prep) to_13\IN\0|NONE_0 (l_pobj) accumulation_16\NN\13497135|NONE_0 (l_prep) of_17\IN\0|the_31|intracellular_27 (l_pobj) pneumonitis_25\NN\14336539|NONE_0
D000638_D000542 NONE amiodarone_4\NN\2715941|NONE_0 (r_pobj) of_3\IN\0|the_23|pulmonary_19 (r_prep) toxicity_2\NN\13576101|is_23|result_37|._169 (r_nsubjpass) thought_6\VBN\5809192|NONE_0 (l_xcomp) result_8\VB\34213|toxicity_37|is_14|._132 (l_prep) from_9\IN\0|to_10 (l_pobj) injury_11\NN\14052046|NONE_0 (l_acl) related_12\VBN\628491|direct_14 (l_prep) to_13\IN\0|NONE_0 (l_pobj) accumulation_16\NN\13497135|NONE_0 (l_prep) of_17\IN\0|the_31|intracellular_27 (l_pobj) pneumonitis_25\NN\14336539|NONE_0
3952818
D005472_D066126 NONE 5-fluorouracil_3\CD\0|NONE_0 (r_punct) ._4\.\0|cardiac_34|of_17 (r_punct) toxicity_1\NN\13576101|NONE_0
D005472_D066126 NONE 5-fu_14\CD\0|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_pcomp) due_12\JJ\5174653|that_55|spasm_41|may_35|cause_24|,_11|and_13|used_58 (r_prep) be_7\VB\14625458|data_37|._147 (l_attr) cause_9\NN\7323922|that_31|spasm_17|may_11|due_24|,_35|and_37|used_82 (l_prep) of_10\IN\0|the_10 (l_pobj) cardiotoxicity_11\NN\0|NONE_0
D005472_D066126 NONE 5-fu_14\CD\0|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_pcomp) due_12\JJ\5174653|that_55|spasm_41|may_35|cause_24|,_11|and_13|used_58 (r_prep) be_7\VB\14625458|data_37|._147 (l_conj) used_23\VBN\0|that_113|spasm_99|may_93|cause_82|due_58|,_47|and_45 (l_prep) in_24\IN\13603305|that_46|antagonists_33|may_21|probably_17|be_8 (l_pobj) prevention_26\NN\1073995|NONE_0 (l_prep) of_29\IN\0|the_28|or_13|treatment_10 (l_pobj) cardiotoxicity_31\NN\0|NONE_0
D005472_D066126 NONE 5-fu_30\CD\0|NONE_0 (r_compound) cardiotoxicity_31\NN\0|NONE_0 (r_pobj) of_29\IN\0|the_28|or_13|treatment_10 (r_prep) prevention_26\NN\1073995|NONE_0 (r_pobj) in_24\IN\13603305|that_46|antagonists_33|may_21|probably_17|be_8 (r_prep) used_23\VBN\0|that_113|spasm_99|may_93|cause_82|due_58|,_47|and_45 (r_conj) be_7\VB\14625458|data_37|._147 (l_attr) cause_9\NN\7323922|that_31|spasm_17|may_11|due_24|,_35|and_37|used_82 (l_prep) of_10\IN\0|the_10 (l_pobj) cardiotoxicity_11\NN\0|NONE_0
D005472_D066126 NONE 5-fu_30\CD\0|NONE_0 (r_compound) cardiotoxicity_31\NN\0|NONE_0
D009543_D000788 NONE nifedipine_19\NN\2938514|NONE_0 (r_pobj) with_18\IN\0|pain_23|promptly_18|._15 (r_prep) resolved_17\VBD\352826|evolution_87|similar_73|,_26|and_24 (r_conj) was_3\VBD\0|NONE_0 (l_acomp) similar_4\JJ\0|evolution_14|,_47|and_49|resolved_73 (l_prep) to_5\IN\0|NONE_0 (l_pobj) that_6\DT\0|NONE_0 (l_acl) observed_7\VBN\2163746|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) angina_11\NN\14171682|NONE_0
D005472_D002637 CID 5-fluorouracil_18\CD\0|(_15|5-fu_16|)_20 (r_punct) administration_22\NN\1133281|NONE_0 (r_pobj) after_17\IN\0|who_25|pain_5 (r_prep) presented_14\VBD\2137132|a_56|with_46 (l_dobj) pain_16\NN\14299637|who_20|after_5
D005472_D002637 CID 5-fu_20\CD\0|5-fluorouracil_16|(_1|)_4 (r_nmod) administration_22\NN\1133281|NONE_0 (r_pobj) after_17\IN\0|who_25|pain_5 (r_prep) presented_14\VBD\2137132|a_56|with_46 (l_dobj) pain_16\NN\14299637|who_20|after_5
D009543_D002637 NONE nifedipine_19\NN\2938514|NONE_0 (r_pobj) with_18\IN\0|pain_23|promptly_18|._15 (r_prep) resolved_17\VBD\352826|evolution_87|similar_73|,_26|and_24 (l_nsubj) pain_15\NN\14299637|promptly_5|with_23|._38
D005472_D009362 NONE 5-fluorouracil_18\CD\0|(_15|5-fu_16|)_20 (r_punct) administration_22\NN\1133281|NONE_0 (r_pobj) after_17\IN\0|who_25|pain_5 (r_prep) presented_14\VBD\2137132|a_56|with_46 (r_relcl) patient_6\NN\9898892|NONE_0 (l_prep) with_7\IN\0|a_10|presented_46 (l_pobj) carcinoma_9\NN\14239918|NONE_0 (l_conj) metastasis_12\NN\13533470|colon_26|and_10
D005472_D009362 NONE 5-fu_20\CD\0|5-fluorouracil_16|(_1|)_4 (r_nmod) administration_22\NN\1133281|NONE_0 (r_pobj) after_17\IN\0|who_25|pain_5 (r_prep) presented_14\VBD\2137132|a_56|with_46 (r_relcl) patient_6\NN\9898892|NONE_0 (l_prep) with_7\IN\0|a_10|presented_46 (l_pobj) carcinoma_9\NN\14239918|NONE_0 (l_conj) metastasis_12\NN\13533470|colon_26|and_10
D005472_D003329 NONE 5-fu_14\CD\0|NONE_0 (r_pobj) to_13\IN\0|NONE_0 (r_pcomp) due_12\JJ\5174653|that_55|spasm_41|may_35|cause_24|,_11|and_13|used_58 (r_prep) be_7\VB\14625458|data_37|._147 (l_nsubj) spasm_5\NN\14299637|that_14|may_6|cause_17|due_41|,_52|and_54|used_99
D005472_D003329 NONE 5-fu_30\CD\0|NONE_0 (r_compound) cardiotoxicity_31\NN\0|NONE_0 (r_pobj) of_29\IN\0|the_28|or_13|treatment_10 (r_prep) prevention_26\NN\1073995|NONE_0 (r_pobj) in_24\IN\13603305|that_46|antagonists_33|may_21|probably_17|be_8 (r_prep) used_23\VBN\0|that_113|spasm_99|may_93|cause_82|due_58|,_47|and_45 (r_conj) be_7\VB\14625458|data_37|._147 (l_nsubj) spasm_5\NN\14299637|that_14|may_6|cause_17|due_41|,_52|and_54|used_99
D005472_D003110 NONE 5-fluorouracil_18\CD\0|(_15|5-fu_16|)_20 (r_punct) administration_22\NN\1133281|NONE_0 (r_pobj) after_17\IN\0|who_25|pain_5 (r_prep) presented_14\VBD\2137132|a_56|with_46 (r_relcl) patient_6\NN\9898892|NONE_0 (l_prep) with_7\IN\0|a_10|presented_46 (l_pobj) carcinoma_9\NN\14239918|NONE_0
D005472_D003110 NONE 5-fu_20\CD\0|5-fluorouracil_16|(_1|)_4 (r_nmod) administration_22\NN\1133281|NONE_0 (r_pobj) after_17\IN\0|who_25|pain_5 (r_prep) presented_14\VBD\2137132|a_56|with_46 (r_relcl) patient_6\NN\9898892|NONE_0 (l_prep) with_7\IN\0|a_10|presented_46 (l_pobj) carcinoma_9\NN\14239918|NONE_0
D002118_D066126 NONE calcium_18\NN\14625458|NONE_0 (r_compound) antagonists_19\NNS\7846|that_13|may_12|probably_16|be_25|in_33 (r_nsubjpass) used_23\VBN\0|that_113|spasm_99|may_93|cause_82|due_58|,_47|and_45 (r_conj) be_7\VB\14625458|data_37|._147 (l_attr) cause_9\NN\7323922|that_31|spasm_17|may_11|due_24|,_35|and_37|used_82 (l_prep) of_10\IN\0|the_10 (l_pobj) cardiotoxicity_11\NN\0|NONE_0
D002118_D066126 NONE calcium_18\NN\14625458|NONE_0 (r_compound) antagonists_19\NNS\7846|that_13|may_12|probably_16|be_25|in_33 (r_nsubjpass) used_23\VBN\0|that_113|spasm_99|may_93|cause_82|due_58|,_47|and_45 (l_prep) in_24\IN\13603305|that_46|antagonists_33|may_21|probably_17|be_8 (l_pobj) prevention_26\NN\1073995|NONE_0 (l_prep) of_29\IN\0|the_28|or_13|treatment_10 (l_pobj) cardiotoxicity_31\NN\0|NONE_0
D002118_D003329 NONE calcium_18\NN\14625458|NONE_0 (r_compound) antagonists_19\NNS\7846|that_13|may_12|probably_16|be_25|in_33 (r_nsubjpass) used_23\VBN\0|that_113|spasm_99|may_93|cause_82|due_58|,_47|and_45 (r_conj) be_7\VB\14625458|data_37|._147 (l_nsubj) spasm_5\NN\14299637|that_14|may_6|cause_17|due_41|,_52|and_54|used_99
8475949
D008274_C537153 NONE magnesium_11\NN\14625458|serum_6|and_17|hypomagnesemia_21 (r_compound) levels_12\NNS\4916342|NONE_0 (l_conj) hypomagnesemia_14\NN\0|serum_27|magnesium_21|and_4
D008274_D008133 NONE magnesium_8\NN\14625458|early_6 (r_compound) supplementation_9\NN\5108947|observed_26|,_18|is_16|._28 (r_nsubjpass) advocated_11\VBN\875394|NONE_0 (l_advcl) observed_5\VBN\2163746|,_8|supplementation_26|is_42|._54 (l_nsubjpass) prolongation_3\NN\1017987|when_18|is_13
D008274_D016171 NONE magnesium_11\NN\14625458|serum_6|and_17|hypomagnesemia_21 (r_compound) levels_12\NNS\4916342|NONE_0 (r_pobj) to_9\IN\0|pointes_23|may_15|be_11|induce_65|._79 (r_prep) related_8\VBN\628491|NONE_0 (l_nsubjpass) pointes_5\FW\831651|may_8|be_12|to_23|induce_88|._102
D010419_D017180 NONE pentamidine_3\NN\0|NONE_0 (l_conj) tachycardia_7\NN\14110674|and_28
D010419_D017180 NONE isethionate_1\NN\0|has_12|been_16|with_32|._95 (r_nsubjpass) associated_4\VBN\628491|NONE_0 (l_prep) with_5\IN\0|isethionate_32|has_20|been_16|._63 (l_pobj) tachyarrhythmias_7\NNS\0|NONE_0
D010419_D016171 CID isethionate_1\NN\0|has_12|been_16|with_32|._95 (r_nsubjpass) associated_4\VBN\628491|NONE_0 (l_prep) with_5\IN\0|isethionate_32|has_20|been_16|._63 (l_pobj) tachyarrhythmias_7\NNS\0|NONE_0 (l_prep) including_9\VBG\0|ventricular_30|,_2 (l_pobj) pointes_12\FW\831651|NONE_0
D010419_D016171 CID pentamidine_0\NNP\0|-_11 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) torsade_3\NN\0|de_8 (r_nmod) pointes_5\FW\831651|may_8|be_12|to_23|induce_88|._102
D010419_D016171 CID pentamidine_13\NN\0|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treatment_11\NN\654885|NONE_0 (r_pobj) of_10\IN\0|10_8 (r_prep) days_9\NNS\15140892|NONE_0 (r_pobj) of_7\IN\0|an_11 (r_prep) average_6\NN\6021499|NONE_0 (r_pobj) after_4\IN\0|pointes_17|._57 (r_prep) occurred_3\VBD\0|NONE_0 (l_nsubj) pointes_2\NNS\831651|after_17|._74
D010419_D016171 CID pentamidine_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) discontinuation_12\NN\209943|possibly_17 (r_pobj) without_11\IN\0|when_32|early_16|,_11 (r_prep) recognized_7\VBN\686447|pointes_28|can_20|be_16|._65 (r_advcl) treated_5\VBN\2376958|NONE_0 (l_nsubjpass) pointes_2\FW\831651|can_8|be_12|recognized_28|._93
D010419_C537153 NONE pentamidine_0\NNP\0|-_11 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) torsade_3\NN\0|de_8 (r_nmod) pointes_5\FW\831651|may_8|be_12|to_23|induce_88|._102 (r_nsubjpass) related_8\VBN\628491|NONE_0 (l_prep) to_9\IN\0|pointes_23|may_15|be_11|induce_65|._79 (l_pobj) levels_12\NNS\4916342|NONE_0 (l_conj) hypomagnesemia_14\NN\0|serum_27|magnesium_21|and_4
11860495
D012601_D000647 CID scopolamine_21\NN\14712692|-_11 (r_npadvmod) induced_23\VBN\1627355|NONE_0 (r_amod) amnesia_24\NN\5669934|NONE_0
D012601_D000647 CID scopolamine_25\NN\14712692|-_11 (r_npadvmod) induced_27\VBN\1627355|NONE_0 (r_amod) amnesia_28\NN\5669934|NONE_0
D005680_D000647 NONE gaba(a)r_15\NNP\0|NONE_0 (r_compound) ligands_16\NNS\20090|and_13 (r_conj) nmdar_13\NNP\0|NONE_0 (r_pobj) of_12\IN\0|the_25|like_13 (r_prep) effects_11\NNS\13245626|to_28 (l_amod) like_10\JJ\5839024|the_12|of_13 (l_amod) amnesic_8\JJ\10158756|-_7
C018370_D000647 NONE sulphate_13\NN\15010703|NONE_0 (r_pobj) of_11\IN\0|the_25|amnesic_16|in_25 (r_prep) effects_10\NNS\13245626|structure_68|._70 (l_amod) amnesic_9\JJ\10158756|the_9|of_16|in_41
C018370_D000647 NONE pregs_2\NNP\0|moreover_10|,_2|able_9|._79 (r_nsubj) is_3\VBZ\0|NONE_0 (l_acomp) able_4\JJ\0|moreover_19|,_11|pregs_9|._70 (l_xcomp) reverse_6\VB\13854649|NONE_0 (l_dobj) effects_11\NNS\13245626|to_28 (l_amod) like_10\JJ\5839024|the_12|of_13 (l_amod) amnesic_8\JJ\10158756|-_7
C018370_D000647 NONE pregs_6\NNP\0|NONE_0 (r_pobj) of_5\IN\0|the_29|enhancing_18 (r_prep) effects_4\NNS\13245626|were_33|in_45|._121 (r_nsubjpass) tested_11\VBN\670261|NONE_0 (l_prep) in_12\IN\13603305|effects_45|were_12|._76 (l_pobj) task_16\NN\575741|NONE_0 (l_acl) using_17\VBG\418025|the_27|passive_23|avoidance_15 (l_dobj) model_19\NN\5888929|NONE_0 (l_prep) of_20\IN\0|the_10 (l_pobj) amnesia_24\NN\5669934|NONE_0
C018370_D000647 NONE pregs_10\NNP\0|NONE_0 (r_pobj) of_8\IN\0|the_12|be_20 (r_prep) ability_7\NN\4723816|NONE_0 (l_acl) be_12\VB\14625458|the_32|of_20 (l_attr) order_14\NN\7168131|to_9 (l_amod) effective_18\JJ\0|an_27|of_18 (l_prep) than_19\IN\0|more_15 (l_pobj) enantiomer_22\NN\14818238|NONE_0 (l_prep) in_23\IN\13603305|its_25|synthetic_21 (l_pcomp) reversing_24\VBG\109660|NONE_0 (l_dobj) amnesia_28\NN\5669934|NONE_0
D013256_D000647 NONE steroid_0\NN\14727670|and_18|properties_38 (r_compound) structure_1\NN\21939|effects_68|._138 (r_nsubj) determine_5\VBP\0|NONE_0 (l_dobj) effects_10\NNS\13245626|structure_68|._70 (l_amod) amnesic_9\JJ\10158756|the_9|of_16|in_41
2257294
C034753_D001855 NONE benzylacyclouridine_0\NN\0|suppression_59|without_71|._135 (r_nsubj) reverses_1\VBZ\13854649|NONE_0 (l_dobj) suppression_6\NN\13489037|benzylacyclouridine_59|without_12|._76
C034753_D001855 NONE bau_11\NNP\0|coadministered_63|,_2|toxicity_31|._39 (r_nsubj) reduced_12\VBD\441445|NONE_0 (l_dobj) toxicity_17\NN\13576101|coadministered_94|,_33|bau_31|._8
C034753_D064420 NONE benzylacyclouridine_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|the_12|effect_32 (r_prep) ability_12\NN\4723816|because_83|,_6|,_46|in_48|,_55|anemia_69|was_91|._103 (r_nsubjpass) assessed_31\VBN\670261|NONE_0 (l_prep) because_0\IN\0|,_77|ability_83|,_129|in_131|,_138|anemia_152|was_174|._186 (l_pobj) toxicities_4\NNS\13576101|of_16
C034753_D064420 NONE bau_16\NNP\0|(_1|)_3 (r_appos) benzylacyclouridine_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|the_12|effect_32 (r_prep) ability_12\NN\4723816|because_83|,_6|,_46|in_48|,_55|anemia_69|was_91|._103 (r_nsubjpass) assessed_31\VBN\670261|NONE_0 (l_prep) because_0\IN\0|,_77|ability_83|,_129|in_131|,_138|anemia_152|was_174|._186 (l_pobj) toxicities_4\NNS\13576101|of_16
D014529_D000740 NONE urd_8\NNP\0|chronic_8 (r_compound) administration_9\NN\1133281|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|the_24|clinical_20 (r_acl) toxicities_4\NNS\13576101|of_16 (r_pobj) because_0\IN\0|,_77|ability_83|,_129|in_131|,_138|anemia_152|was_174|._186 (r_prep) assessed_31\VBN\670261|NONE_0 (l_nsubjpass) anemia_27\NN\14189204|because_152|,_75|ability_69|,_23|in_21|,_14|was_22|._34
D014529_D064420 NONE urd_8\NNP\0|chronic_8 (r_compound) administration_9\NN\1133281|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|the_24|clinical_20 (r_acl) toxicities_4\NNS\13576101|of_16
D014529_D064420 NONE urd_3\NNP\0|NONE_0 (r_compound) catabolism_4\NN\13526110|agent_19|and_11|,_14|increases_25|._123 (r_dobj) inhibits_2\VBZ\2510337|NONE_0 (l_conj) increases_10\VBZ\13576355|agent_44|catabolism_25|and_14|,_11|._98 (l_prep) without_23\IN\0|in_79|,_72|concentration_49|in_28|,_2 (l_pobj) toxicity_27\NN\13576101|NONE_0
D014529_D064420 NONE urd_15\NNP\0|NONE_0 (r_pobj) of_14\IN\0|the_25|plasma_21 (r_prep) concentration_13\NN\4916342|in_30|,_23|in_21|,_47|without_49 (r_dobj) increases_10\VBZ\13576355|agent_44|catabolism_25|and_14|,_11|._98 (l_prep) without_23\IN\0|in_79|,_72|concentration_49|in_28|,_2 (l_pobj) toxicity_27\NN\13576101|NONE_0
D014529_D064420 NONE urd_24\NNP\0|-_3 (r_npadvmod) related_26\VBN\628491|NONE_0 (r_amod) toxicity_27\NN\13576101|NONE_0
C034753_-1 NONE bau_31\NNP\0|plus_11|(_4|mg/kg_9|,_14 (r_conj) azt_28\NNP\3834836|NONE_0 (r_pobj) of_27\IN\0|the_29|continued_25|orally_34 (r_prep) administration_26\NN\1133281|in_125|,_16|)_55|partially_57|anemia_88|p_174|,_190|increased_192|._257 (r_nsubj) reversed_39\VBD\109660|NONE_0 (l_conj) increased_67\VBN\169651|in_317|,_208|administration_192|)_137|partially_135|anemia_104|p_18|,_2|._65 (l_conj) improved_74\VBN\126264|cellularity_31|in_19|,_6|and_4 (l_dobj) megaloblastosis_75\NN\0|NONE_0
D014529_D007970 NONE urd_8\NNP\0|chronic_8 (r_compound) administration_9\NN\1133281|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) associated_5\VBN\628491|the_24|clinical_20 (r_acl) toxicities_4\NNS\13576101|of_16 (r_pobj) because_0\IN\0|,_77|ability_83|,_129|in_131|,_138|anemia_152|was_174|._186 (r_prep) assessed_31\VBN\670261|NONE_0 (l_nsubjpass) anemia_27\NN\14189204|because_152|,_75|ability_69|,_23|in_21|,_14|was_22|._34 (l_conj) leukopenia_29\NN\14189204|induced_19|and_4
D015215_D064420 NONE azt_24\NNP\3834836|-_3 (r_npadvmod) induced_26\VBN\1627355|and_15|leukopenia_19 (r_amod) anemia_27\NN\14189204|because_152|,_75|ability_69|,_23|in_21|,_14|was_22|._34 (r_nsubjpass) assessed_31\VBN\670261|NONE_0 (l_prep) because_0\IN\0|,_77|ability_83|,_129|in_131|,_138|anemia_152|was_174|._186 (l_pobj) toxicities_4\NNS\13576101|of_16
D015215_D001855 CID azidothymidine_2\RB\0|-_14 (r_advmod) induced_4\VBN\1627355|marrow_8 (r_amod) suppression_6\NN\13489037|benzylacyclouridine_59|without_12|._76
D015215_D001855 CID azt_3\NNP\3834836|NONE_0 (r_pobj) with_2\IN\0|when_20|from_9 (r_prep) coadministered_1\VBN\0|,_61|bau_63|toxicity_94|._102 (r_advcl) reduced_12\VBD\441445|NONE_0 (l_dobj) toxicity_17\NN\13576101|coadministered_94|,_33|bau_31|._8
D015215_D001855 CID azt_13\NNP\3834836|-_3 (r_npadvmod) induced_15\VBN\1627355|marrow_8 (r_amod) toxicity_17\NN\13576101|coadministered_94|,_33|bau_31|._8
D014529_D007153 NONE uridine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|increased_39|extracellular_29 (r_prep) concentrations_2\NNS\4916342|have_32|been_37|reduce_54|._234 (r_nsubjpass) reported_10\VBN\831651|NONE_0 (l_xcomp) reduce_12\VB\441445|concentrations_54|have_22|been_17|._180 (l_dobj) inhibition_20\NN\1068773|to_50|,_41|in_39 (l_prep) without_28\IN\0|(_74|azt)-induced_73|of_49 (l_pobj) impairment_29\NN\7296428|NONE_0 (l_prep) of_30\IN\0|NONE_0 (l_pobj) virus_34\NN\9312843|NONE_0 (l_compound) immunodeficiency_33\NN\13973990|its_14|antihuman_10|activity_29
D014529_D007153 NONE urd_6\NNP\0|NONE_0 (r_appos) uridine_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|increased_39|extracellular_29 (r_prep) concentrations_2\NNS\4916342|have_32|been_37|reduce_54|._234 (r_nsubjpass) reported_10\VBN\831651|NONE_0 (l_xcomp) reduce_12\VB\441445|concentrations_54|have_22|been_17|._180 (l_dobj) inhibition_20\NN\1068773|to_50|,_41|in_39 (l_prep) without_28\IN\0|(_74|azt)-induced_73|of_49 (l_pobj) impairment_29\NN\7296428|NONE_0 (l_prep) of_30\IN\0|NONE_0 (l_pobj) virus_34\NN\9312843|NONE_0 (l_compound) immunodeficiency_33\NN\13973990|its_14|antihuman_10|activity_29
D015215_D007970 CID azt_24\NNP\3834836|-_3 (r_npadvmod) induced_26\VBN\1627355|and_15|leukopenia_19 (r_amod) anemia_27\NN\14189204|because_152|,_75|ability_69|,_23|in_21|,_14|was_22|._34 (l_conj) leukopenia_29\NN\14189204|induced_19|and_4
D015215_D007970 CID azt_10\NNP\3834836|NONE_0 (r_pobj) of_9\IN\0|the_19 (r_prep) administration_8\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|for_29|(_59|ml_67|)_69 (r_prep) leukopenic_5\JJ\0|anemic_11|and_4
D015215_D007970 CID azt_10\NNP\3834836|NONE_0 (r_pobj) of_9\IN\0|the_19 (r_prep) administration_8\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|for_29|(_59|ml_67|)_69 (r_prep) leukopenic_5\JJ\0|anemic_11|and_4 (r_conj) rendered_2\VBD\120316|NONE_0 (r_acl) mice_1\NNS\2329401|NONE_0 (r_pobj) in_0\IN\13603305|,_109|administration_125|)_180|partially_182|anemia_213|p_299|,_315|increased_317|._382 (r_prep) reversed_39\VBD\109660|NONE_0 (l_dobj) anemia_43\NN\14189204|in_213|,_104|administration_88|)_33|partially_31|p_86|,_102|increased_104|._169 (l_conj) leukopenia_45\NN\14189204|induced_19|and_4|(_11|p_12|reticulocytes_51
D015215_D007970 CID azt_28\NNP\3834836|NONE_0 (r_pobj) of_27\IN\0|the_29|continued_25|orally_34 (r_prep) administration_26\NN\1133281|in_125|,_16|)_55|partially_57|anemia_88|p_174|,_190|increased_192|._257 (r_nsubj) reversed_39\VBD\109660|NONE_0 (l_prep) in_0\IN\13603305|,_109|administration_125|)_180|partially_182|anemia_213|p_299|,_315|increased_317|._382 (l_pobj) mice_1\NNS\2329401|NONE_0 (l_acl) rendered_2\VBD\120316|NONE_0 (l_conj) leukopenic_5\JJ\0|anemic_11|and_4
D015215_D007970 CID azt_28\NNP\3834836|NONE_0 (r_pobj) of_27\IN\0|the_29|continued_25|orally_34 (r_prep) administration_26\NN\1133281|in_125|,_16|)_55|partially_57|anemia_88|p_174|,_190|increased_192|._257 (r_nsubj) reversed_39\VBD\109660|NONE_0 (l_dobj) anemia_43\NN\14189204|in_213|,_104|administration_88|)_33|partially_31|p_86|,_102|increased_104|._169 (l_conj) leukopenia_45\NN\14189204|induced_19|and_4|(_11|p_12|reticulocytes_51
D015215_D007970 CID azt_40\NNP\3834836|-_3 (r_npadvmod) induced_42\VBN\1627355|and_15|leukopenia_19|(_30|p_31|reticulocytes_70 (r_amod) anemia_43\NN\14189204|in_213|,_104|administration_88|)_33|partially_31|p_86|,_102|increased_104|._169 (r_dobj) reversed_39\VBD\109660|NONE_0 (l_prep) in_0\IN\13603305|,_109|administration_125|)_180|partially_182|anemia_213|p_299|,_315|increased_317|._382 (l_pobj) mice_1\NNS\2329401|NONE_0 (l_acl) rendered_2\VBD\120316|NONE_0 (l_conj) leukopenic_5\JJ\0|anemic_11|and_4
D015215_D007970 CID azt_40\NNP\3834836|-_3 (r_npadvmod) induced_42\VBN\1627355|and_15|leukopenia_19|(_30|p_31|reticulocytes_70 (r_amod) anemia_43\NN\14189204|in_213|,_104|administration_88|)_33|partially_31|p_86|,_102|increased_104|._169 (l_conj) leukopenia_45\NN\14189204|induced_19|and_4|(_11|p_12|reticulocytes_51
C034753_D000740 NONE benzylacyclouridine_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|the_12|effect_32 (r_prep) ability_12\NN\4723816|because_83|,_6|,_46|in_48|,_55|anemia_69|was_91|._103 (r_nsubjpass) assessed_31\VBN\670261|NONE_0 (l_nsubjpass) anemia_27\NN\14189204|because_152|,_75|ability_69|,_23|in_21|,_14|was_22|._34
C034753_D000740 NONE bau_16\NNP\0|(_1|)_3 (r_appos) benzylacyclouridine_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|the_12|effect_32 (r_prep) ability_12\NN\4723816|because_83|,_6|,_46|in_48|,_55|anemia_69|was_91|._103 (r_nsubjpass) assessed_31\VBN\670261|NONE_0 (l_nsubjpass) anemia_27\NN\14189204|because_152|,_75|ability_69|,_23|in_21|,_14|was_22|._34
C034753_D000740 NONE bau_31\NNP\0|plus_11|(_4|mg/kg_9|,_14 (r_conj) azt_28\NNP\3834836|NONE_0 (r_pobj) of_27\IN\0|the_29|continued_25|orally_34 (r_prep) administration_26\NN\1133281|in_125|,_16|)_55|partially_57|anemia_88|p_174|,_190|increased_192|._257 (r_nsubj) reversed_39\VBD\109660|NONE_0 (l_prep) in_0\IN\13603305|,_109|administration_125|)_180|partially_182|anemia_213|p_299|,_315|increased_317|._382 (l_pobj) mice_1\NNS\2329401|NONE_0 (l_acl) rendered_2\VBD\120316|NONE_0 (l_oprd) anemic_3\JJ\0|and_7|leukopenic_11
C034753_D000740 NONE bau_31\NNP\0|plus_11|(_4|mg/kg_9|,_14 (r_conj) azt_28\NNP\3834836|NONE_0 (r_pobj) of_27\IN\0|the_29|continued_25|orally_34 (r_prep) administration_26\NN\1133281|in_125|,_16|)_55|partially_57|anemia_88|p_174|,_190|increased_192|._257 (r_nsubj) reversed_39\VBD\109660|NONE_0 (l_dobj) anemia_43\NN\14189204|in_213|,_104|administration_88|)_33|partially_31|p_86|,_102|increased_104|._169
C034753_D007153 NONE benzylacyclouridine_0\NN\0|suppression_59|without_71|._135 (r_nsubj) reverses_1\VBZ\13854649|NONE_0 (l_prep) without_7\IN\0|benzylacyclouridine_71|suppression_12|._64 (l_pobj) impairment_8\NN\7296428|NONE_0 (l_prep) of_9\IN\0|NONE_0 (l_pobj) activity_15\NN\30358|NONE_0 (l_compound) virus_14\NN\9312843|human_23 (l_compound) immunodeficiency_13\NN\13973990|NONE_0
D015215_D000740 CID azt_24\NNP\3834836|-_3 (r_npadvmod) induced_26\VBN\1627355|and_15|leukopenia_19 (r_amod) anemia_27\NN\14189204|because_152|,_75|ability_69|,_23|in_21|,_14|was_22|._34
D015215_D000740 CID azt_10\NNP\3834836|NONE_0 (r_pobj) of_9\IN\0|the_19 (r_prep) administration_8\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|for_29|(_59|ml_67|)_69 (r_prep) leukopenic_5\JJ\0|anemic_11|and_4 (r_conj) rendered_2\VBD\120316|NONE_0 (l_oprd) anemic_3\JJ\0|and_7|leukopenic_11
D015215_D000740 CID azt_10\NNP\3834836|NONE_0 (r_pobj) of_9\IN\0|the_19 (r_prep) administration_8\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|for_29|(_59|ml_67|)_69 (r_prep) leukopenic_5\JJ\0|anemic_11|and_4 (r_conj) rendered_2\VBD\120316|NONE_0 (r_acl) mice_1\NNS\2329401|NONE_0 (r_pobj) in_0\IN\13603305|,_109|administration_125|)_180|partially_182|anemia_213|p_299|,_315|increased_317|._382 (r_prep) reversed_39\VBD\109660|NONE_0 (l_dobj) anemia_43\NN\14189204|in_213|,_104|administration_88|)_33|partially_31|p_86|,_102|increased_104|._169
D015215_D000740 CID azt_28\NNP\3834836|NONE_0 (r_pobj) of_27\IN\0|the_29|continued_25|orally_34 (r_prep) administration_26\NN\1133281|in_125|,_16|)_55|partially_57|anemia_88|p_174|,_190|increased_192|._257 (r_nsubj) reversed_39\VBD\109660|NONE_0 (l_prep) in_0\IN\13603305|,_109|administration_125|)_180|partially_182|anemia_213|p_299|,_315|increased_317|._382 (l_pobj) mice_1\NNS\2329401|NONE_0 (l_acl) rendered_2\VBD\120316|NONE_0 (l_oprd) anemic_3\JJ\0|and_7|leukopenic_11
D015215_D000740 CID azt_28\NNP\3834836|NONE_0 (r_pobj) of_27\IN\0|the_29|continued_25|orally_34 (r_prep) administration_26\NN\1133281|in_125|,_16|)_55|partially_57|anemia_88|p_174|,_190|increased_192|._257 (r_nsubj) reversed_39\VBD\109660|NONE_0 (l_dobj) anemia_43\NN\14189204|in_213|,_104|administration_88|)_33|partially_31|p_86|,_102|increased_104|._169
D015215_D000740 CID azt_40\NNP\3834836|-_3 (r_npadvmod) induced_42\VBN\1627355|and_15|leukopenia_19|(_30|p_31|reticulocytes_70 (r_amod) anemia_43\NN\14189204|in_213|,_104|administration_88|)_33|partially_31|p_86|,_102|increased_104|._169 (r_dobj) reversed_39\VBD\109660|NONE_0 (l_prep) in_0\IN\13603305|,_109|administration_125|)_180|partially_182|anemia_213|p_299|,_315|increased_317|._382 (l_pobj) mice_1\NNS\2329401|NONE_0 (l_acl) rendered_2\VBD\120316|NONE_0 (l_oprd) anemic_3\JJ\0|and_7|leukopenic_11
D015215_D000740 CID azt_40\NNP\3834836|-_3 (r_npadvmod) induced_42\VBN\1627355|and_15|leukopenia_19|(_30|p_31|reticulocytes_70 (r_amod) anemia_43\NN\14189204|in_213|,_104|administration_88|)_33|partially_31|p_86|,_102|increased_104|._169
C034753_D007970 NONE benzylacyclouridine_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|the_12|effect_32 (r_prep) ability_12\NN\4723816|because_83|,_6|,_46|in_48|,_55|anemia_69|was_91|._103 (r_nsubjpass) assessed_31\VBN\670261|NONE_0 (l_nsubjpass) anemia_27\NN\14189204|because_152|,_75|ability_69|,_23|in_21|,_14|was_22|._34 (l_conj) leukopenia_29\NN\14189204|induced_19|and_4
C034753_D007970 NONE bau_16\NNP\0|(_1|)_3 (r_appos) benzylacyclouridine_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|the_12|effect_32 (r_prep) ability_12\NN\4723816|because_83|,_6|,_46|in_48|,_55|anemia_69|was_91|._103 (r_nsubjpass) assessed_31\VBN\670261|NONE_0 (l_nsubjpass) anemia_27\NN\14189204|because_152|,_75|ability_69|,_23|in_21|,_14|was_22|._34 (l_conj) leukopenia_29\NN\14189204|induced_19|and_4
C034753_D007970 NONE bau_31\NNP\0|plus_11|(_4|mg/kg_9|,_14 (r_conj) azt_28\NNP\3834836|NONE_0 (r_pobj) of_27\IN\0|the_29|continued_25|orally_34 (r_prep) administration_26\NN\1133281|in_125|,_16|)_55|partially_57|anemia_88|p_174|,_190|increased_192|._257 (r_nsubj) reversed_39\VBD\109660|NONE_0 (l_prep) in_0\IN\13603305|,_109|administration_125|)_180|partially_182|anemia_213|p_299|,_315|increased_317|._382 (l_pobj) mice_1\NNS\2329401|NONE_0 (l_acl) rendered_2\VBD\120316|NONE_0 (l_conj) leukopenic_5\JJ\0|anemic_11|and_4
C034753_D007970 NONE bau_31\NNP\0|plus_11|(_4|mg/kg_9|,_14 (r_conj) azt_28\NNP\3834836|NONE_0 (r_pobj) of_27\IN\0|the_29|continued_25|orally_34 (r_prep) administration_26\NN\1133281|in_125|,_16|)_55|partially_57|anemia_88|p_174|,_190|increased_192|._257 (r_nsubj) reversed_39\VBD\109660|NONE_0 (l_dobj) anemia_43\NN\14189204|in_213|,_104|administration_88|)_33|partially_31|p_86|,_102|increased_104|._169 (l_conj) leukopenia_45\NN\14189204|induced_19|and_4|(_11|p_12|reticulocytes_51
D015215_-1 NONE azt_10\NNP\3834836|NONE_0 (r_pobj) of_9\IN\0|the_19 (r_prep) administration_8\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|for_29|(_59|ml_67|)_69 (r_prep) leukopenic_5\JJ\0|anemic_11|and_4 (r_conj) rendered_2\VBD\120316|NONE_0 (r_acl) mice_1\NNS\2329401|NONE_0 (r_pobj) in_0\IN\13603305|,_109|administration_125|)_180|partially_182|anemia_213|p_299|,_315|increased_317|._382 (r_prep) reversed_39\VBD\109660|NONE_0 (l_conj) increased_67\VBN\169651|in_317|,_208|administration_192|)_137|partially_135|anemia_104|p_18|,_2|._65 (l_conj) improved_74\VBN\126264|cellularity_31|in_19|,_6|and_4 (l_dobj) megaloblastosis_75\NN\0|NONE_0
D015215_-1 NONE azt_28\NNP\3834836|NONE_0 (r_pobj) of_27\IN\0|the_29|continued_25|orally_34 (r_prep) administration_26\NN\1133281|in_125|,_16|)_55|partially_57|anemia_88|p_174|,_190|increased_192|._257 (r_nsubj) reversed_39\VBD\109660|NONE_0 (l_conj) increased_67\VBN\169651|in_317|,_208|administration_192|)_137|partially_135|anemia_104|p_18|,_2|._65 (l_conj) improved_74\VBN\126264|cellularity_31|in_19|,_6|and_4 (l_dobj) megaloblastosis_75\NN\0|NONE_0
D015215_-1 NONE azt_40\NNP\3834836|-_3 (r_npadvmod) induced_42\VBN\1627355|and_15|leukopenia_19|(_30|p_31|reticulocytes_70 (r_amod) anemia_43\NN\14189204|in_213|,_104|administration_88|)_33|partially_31|p_86|,_102|increased_104|._169 (r_dobj) reversed_39\VBD\109660|NONE_0 (l_conj) increased_67\VBN\169651|in_317|,_208|administration_192|)_137|partially_135|anemia_104|p_18|,_2|._65 (l_conj) improved_74\VBN\126264|cellularity_31|in_19|,_6|and_4 (l_dobj) megaloblastosis_75\NN\0|NONE_0
D015215_D007153 NONE azidothymidine_2\RB\0|-_14 (r_advmod) induced_4\VBN\1627355|marrow_8 (r_amod) suppression_6\NN\13489037|benzylacyclouridine_59|without_12|._76 (r_dobj) reverses_1\VBZ\13854649|NONE_0 (l_prep) without_7\IN\0|benzylacyclouridine_71|suppression_12|._64 (l_pobj) impairment_8\NN\7296428|NONE_0 (l_prep) of_9\IN\0|NONE_0 (l_pobj) activity_15\NN\30358|NONE_0 (l_compound) virus_14\NN\9312843|human_23 (l_compound) immunodeficiency_13\NN\13973990|NONE_0
D015215_D007153 NONE azidothymidine_17\NN\0|,_2 (r_advmod) vitro_15\FW\0|NONE_0 (r_amod) in_14\IN\13603305|to_11|,_2|inhibition_39 (r_prep) reduce_12\VB\441445|concentrations_54|have_22|been_17|._180 (l_dobj) inhibition_20\NN\1068773|to_50|,_41|in_39 (l_prep) without_28\IN\0|(_74|azt)-induced_73|of_49 (l_pobj) impairment_29\NN\7296428|NONE_0 (l_prep) of_30\IN\0|NONE_0 (l_pobj) virus_34\NN\9312843|NONE_0 (l_compound) immunodeficiency_33\NN\13973990|its_14|antihuman_10|activity_29
D015215_D007153 NONE azt)-induced_19\JJ\0|(_1|of_24|without_73 (r_compound) inhibition_20\NN\1068773|to_50|,_41|in_39 (l_prep) without_28\IN\0|(_74|azt)-induced_73|of_49 (l_pobj) impairment_29\NN\7296428|NONE_0 (l_prep) of_30\IN\0|NONE_0 (l_pobj) virus_34\NN\9312843|NONE_0 (l_compound) immunodeficiency_33\NN\13973990|its_14|antihuman_10|activity_29
20103708
D010100_D003928 NONE oxygen_20\NN\14622893|reactive_9|(_15|ros_16|)_19 (r_compound) species_21\NNS\7992450|NONE_0 (r_pobj) of_18\IN\0|the_15 (r_prep) production_17\NN\30358|NONE_0 (r_pobj) by_15\IN\0|which_21|is_15 (r_agent) accompanied_14\VBN\0|the_44|major_40|of_27|,_11 (r_relcl) causes_7\NNS\7323922|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) one_3\CD\13741022|nephropathy_15|._113 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) nephropathy_1\NN\14573196|one_15|._128
D013311_D058186 NONE streptozotocin_13\RB\0|-_14 (r_npadvmod) induced_15\VBN\1627355|renal_8 (r_amod) damage_17\NN\7296428|NONE_0
D010100_D051437 NONE oxygen_20\NN\14622893|reactive_9|(_15|ros_16|)_19 (r_compound) species_21\NNS\7992450|NONE_0 (r_pobj) of_18\IN\0|the_15 (r_prep) production_17\NN\30358|NONE_0 (r_pobj) by_15\IN\0|which_21|is_15 (r_agent) accompanied_14\VBN\0|the_44|major_40|of_27|,_11 (r_relcl) causes_7\NNS\7323922|NONE_0 (l_prep) of_8\IN\0|the_17|major_13|,_16|accompanied_27 (l_pobj) failure_10\NN\66216|NONE_0
D013311_D003928 CID streptozotocin_6\JJ\0|-_14 (r_npadvmod) induced_8\VBN\1627355|diabetic_8 (r_amod) nephropathy_10\NN\14573196|NONE_0
D013311_D003928 CID streptozotocin_22\RB\0|-_14 (r_npadvmod) induced_24\VBN\1627355|:_157|explore_152|,_19|a_17|nephropathy_17|in_35|._88 (r_amod) model_27\NN\5888929|NONE_0 (l_ccomp) explore_2\VBP\789138|:_5|,_133|a_135|induced_152|nephropathy_169|in_187|._240 (l_dobj) role_5\NN\719494|we_26 (l_prep) against_8\IN\0|the_28|protective_24|of_8 (l_pobj) nephropathy_10\NN\14573196|NONE_0
D013311_D003928 CID streptozotocin_22\RB\0|-_14 (r_npadvmod) induced_24\VBN\1627355|:_157|explore_152|,_19|a_17|nephropathy_17|in_35|._88 (r_amod) model_27\NN\5888929|NONE_0 (l_ccomp) explore_2\VBP\789138|:_5|,_133|a_135|induced_152|nephropathy_169|in_187|._240 (l_dobj) role_5\NN\719494|we_26 (l_prep) against_8\IN\0|the_28|protective_24|of_8 (l_pobj) nephropathy_10\NN\14573196|NONE_0 (l_acl) using_11\VBG\418025|diabetic_21 (l_prep) from_16\IN\0|tissues_8 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_compound) nephropathy_18\NN\14573196|diabetic_9
D013311_D003928 CID streptozotocin_22\RB\0|-_14 (r_npadvmod) induced_24\VBN\1627355|:_157|explore_152|,_19|a_17|nephropathy_17|in_35|._88 (r_amod) model_27\NN\5888929|NONE_0 (l_compound) nephropathy_26\NN\14573196|:_174|explore_169|,_36|a_34|induced_17|in_18|._71
18997632
D002110_D018879 CID caffeine_1\NN\14712692|is_9|commonly_12|improve_29|and_83|tolerated_105|._184 (r_nsubjpass) used_4\VBN\0|NONE_0 (l_conj) tolerated_18\VBN\802318|caffeine_105|is_96|commonly_93|improve_76|and_22|._79 (l_prep) from_20\IN\0|is_34|generally_31|well_21|aside_6 (l_pobj) reports_22\NNS\6470073|NONE_0 (l_prep) of_23\IN\0|occasional_19 (l_pobj) ectopy_27\NN\0|NONE_0
D002110_D006331 NONE caffeine_25\NN\14712692|NONE_0 (r_compound) administration_26\NN\1133281|NONE_0 (r_pobj) after_24\IN\0|who_77|bigeminy_53 (r_prep) developed_14\VBD\1753788|cardiac_34|or_18|arrhythmia_15 (r_relcl) disease_10\NN\14061805|NONE_0
D002110_D012640 CID caffeine_1\NN\14712692|is_9|commonly_12|improve_29|and_83|tolerated_105|._184 (r_nsubjpass) used_4\VBN\0|NONE_0 (l_xcomp) improve_6\VB\126264|caffeine_29|is_20|commonly_17|and_54|tolerated_76|._155 (l_dobj) duration_8\NN\15113229|to_19 (l_compound) seizure_7\NN\14081375|and_17|quality_21|in_29
D002110_D017180 CID caffeine_7\NN\14712692|NONE_0 (r_compound) pretreatment_8\NN\0|NONE_0 (r_pobj) to_6\IN\0|NONE_0 (r_prep) related_5\VBN\628491|ventricular_24 (r_acl) tachycardia_4\NN\14110674|NONE_0
D002110_D017180 CID caffeine_25\NN\14712692|NONE_0 (r_compound) administration_26\NN\1133281|NONE_0 (r_pobj) after_24\IN\0|who_77|bigeminy_53 (r_prep) developed_14\VBD\1753788|cardiac_34|or_18|arrhythmia_15 (l_dobj) bigeminy_16\JJ\0|who_24|after_53 (l_conj) runs_20\NNS\186634|sustained_31|and_12 (l_prep) of_21\IN\0|2_13|brief_11 (l_pobj) tachycardia_23\NN\14110674|NONE_0
D002110_D001145 NONE caffeine_25\NN\14712692|NONE_0 (r_compound) administration_26\NN\1133281|NONE_0 (r_pobj) after_24\IN\0|who_77|bigeminy_53 (r_prep) developed_14\VBD\1753788|cardiac_34|or_18|arrhythmia_15 (r_relcl) disease_10\NN\14061805|NONE_0 (l_conj) arrhythmia_12\NN\14103288|cardiac_19|or_3|developed_15
D002110_D001145 NONE caffeine_2\NN\14712692|although_21|is_9|generally_12|well_22 (r_nsubjpass) tolerated_6\VBN\802318|,_9|clinician_15|should_25|aware_35|._111 (r_advcl) be_11\VB\14625458|NONE_0 (l_acomp) aware_12\JJ\0|tolerated_35|,_26|clinician_20|should_10|._76 (l_prep) of_13\IN\0|NONE_0 (l_pobj) potential_15\NN\14481929|NONE_0 (l_prep) for_16\IN\0|the_14 (l_pobj) arrhythmias_21\NNS\14103288|NONE_0
14633084
D015080_D006470 NONE mesna_4\NN\0|NONE_0 (r_pobj) with_3\IN\0|of_17|for_11|._72 (r_prep) use_0\NN\407535|NONE_0 (l_prep) for_5\IN\0|of_28|with_11|._61 (l_pobj) prevention_7\NN\1073995|NONE_0 (l_prep) of_8\IN\0|the_15 (l_pobj) cystitis_13\NN\14566129|NONE_0
D015080_D006470 NONE mesna_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) combination_13\NN\7951464|NONE_0 (r_pobj) in_12\IN\13603305|the_25|of_17|for_26 (r_prep) use_9\NN\407535|in_49|,_22|we_20|._83 (l_prep) for_16\IN\0|the_51|of_43|in_26 (l_pobj) prevention_18\NN\1073995|NONE_0 (l_prep) of_19\IN\0|the_15 (l_pobj) hc_23\NN\0|NONE_0
D015080_D006470 NONE mesna_4\NN\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) combination_2\NN\7951464|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) dexamethasone_0\NN\2721538|efficient_44|._80 (r_nsubj) was_5\VBD\0|NONE_0 (l_acomp) efficient_6\JJ\0|dexamethasone_44|._36 (l_prep) in_7\IN\13603305|NONE_0 (l_pcomp) blocking_8\VBG\562280|NONE_0 (l_dobj) hc_12\NN\0|NONE_0
D015080_D006470 NONE mesna_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|last_15|two_10|with_9 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) of_4\IN\0|the_16 (r_prep) replacement_3\NN\196485|however_13|,_6|did_96|not_100|hc_112|._114 (r_nsubj) prevent_22\VB\0|NONE_0 (l_dobj) hc_23\NN\0|however_125|,_118|replacement_112|did_16|not_12|._2
D015080_D006470 NONE mesna_16\JJ\0|the_4|with_12 (r_amod) doses_17\NNS\3740161|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) all_13\DT\0|or_3 (r_conj) saline_11\NN\14849367|NONE_0 (r_pobj) with_10\IN\0|last_24|two_19|of_9 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) of_4\IN\0|the_16 (r_prep) replacement_3\NN\196485|however_13|,_6|did_96|not_100|hc_112|._114 (r_nsubj) prevent_22\VB\0|NONE_0 (l_dobj) hc_23\NN\0|however_125|,_118|replacement_112|did_16|not_12|._2
D015080_D003556 NONE mesna_4\NN\0|NONE_0 (r_pobj) with_3\IN\0|of_17|for_11|._72 (r_prep) use_0\NN\407535|NONE_0 (l_prep) for_5\IN\0|of_28|with_11|._61 (l_pobj) prevention_7\NN\1073995|NONE_0 (l_prep) of_8\IN\0|the_15 (l_pobj) cystitis_13\NN\14566129|NONE_0
D015080_D003556 NONE mesna_15\NN\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) combination_13\NN\7951464|NONE_0 (r_pobj) in_12\IN\13603305|the_25|of_17|for_26 (r_prep) use_9\NN\407535|in_49|,_22|we_20|._83 (l_prep) for_16\IN\0|the_51|of_43|in_26 (l_pobj) prevention_18\NN\1073995|NONE_0 (l_prep) of_19\IN\0|the_15 (l_pobj) hc_23\NN\0|NONE_0
D015080_D003556 NONE mesna_4\NN\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) combination_2\NN\7951464|NONE_0 (r_pobj) in_1\IN\13603305|NONE_0 (r_prep) dexamethasone_0\NN\2721538|efficient_44|._80 (r_nsubj) was_5\VBD\0|NONE_0 (l_acomp) efficient_6\JJ\0|dexamethasone_44|._36 (l_prep) in_7\IN\13603305|NONE_0 (l_pcomp) blocking_8\VBG\562280|NONE_0 (l_dobj) hc_12\NN\0|NONE_0
D015080_D003556 NONE mesna_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|last_15|two_10|with_9 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) of_4\IN\0|the_16 (r_prep) replacement_3\NN\196485|however_13|,_6|did_96|not_100|hc_112|._114 (r_nsubj) prevent_22\VB\0|NONE_0 (l_dobj) hc_23\NN\0|however_125|,_118|replacement_112|did_16|not_12|._2
D015080_D003556 NONE mesna_16\JJ\0|the_4|with_12 (r_amod) doses_17\NNS\3740161|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) all_13\DT\0|or_3 (r_conj) saline_11\NN\14849367|NONE_0 (r_pobj) with_10\IN\0|last_24|two_19|of_9 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) of_4\IN\0|the_16 (r_prep) replacement_3\NN\196485|however_13|,_6|did_96|not_100|hc_112|._114 (r_nsubj) prevent_22\VB\0|NONE_0 (l_dobj) hc_23\NN\0|however_125|,_118|replacement_112|did_16|not_12|._2
D007069_D003556 CID ifosfamide_9\RB\0|-_10 (r_advmod) induced_11\VBN\1627355|hemorrhagic_8 (r_amod) cystitis_13\NN\14566129|NONE_0
D007069_D003556 CID ifosfamide_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|a_39|limiting_37|side_28|-_24|of_16 (r_prep) effect_12\NN\34213|aim_50|._44 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) aim_0\VB\5980875|effect_50|._94 (l_appos) cystitis_3\NN\14566129|:_14
D007069_D003556 CID ifosfamide_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|a_39|limiting_37|side_28|-_24|of_16 (r_prep) effect_12\NN\34213|aim_50|._44 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) aim_0\VB\5980875|effect_50|._94 (l_appos) cystitis_3\NN\14566129|:_14 (l_appos) hc_5\NNP\0|hemorrhagic_22|(_1|)_2
D007069_D003556 CID ifs_18\NNP\0|(_1|)_3 (r_appos) ifosfamide_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|a_39|limiting_37|side_28|-_24|of_16 (r_prep) effect_12\NN\34213|aim_50|._44 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) aim_0\VB\5980875|effect_50|._94 (l_appos) cystitis_3\NN\14566129|:_14
D007069_D003556 CID ifs_18\NNP\0|(_1|)_3 (r_appos) ifosfamide_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|a_39|limiting_37|side_28|-_24|of_16 (r_prep) effect_12\NN\34213|aim_50|._44 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) aim_0\VB\5980875|effect_50|._94 (l_appos) cystitis_3\NN\14566129|:_14 (l_appos) hc_5\NNP\0|hemorrhagic_22|(_1|)_2
D007069_D003556 CID ifs_20\NNP\0|-_3 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) hc_23\NN\0|NONE_0
D007069_D003556 CID ifs_9\NNP\0|-_3 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) hc_12\NN\0|NONE_0
D007069_D006470 CID ifosfamide_9\RB\0|-_10 (r_advmod) induced_11\VBN\1627355|hemorrhagic_8 (r_amod) cystitis_13\NN\14566129|NONE_0
D007069_D006470 CID ifosfamide_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|a_39|limiting_37|side_28|-_24|of_16 (r_prep) effect_12\NN\34213|aim_50|._44 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) aim_0\VB\5980875|effect_50|._94 (l_appos) cystitis_3\NN\14566129|:_14
D007069_D006470 CID ifosfamide_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|a_39|limiting_37|side_28|-_24|of_16 (r_prep) effect_12\NN\34213|aim_50|._44 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) aim_0\VB\5980875|effect_50|._94 (l_appos) cystitis_3\NN\14566129|:_14 (l_appos) hc_5\NNP\0|hemorrhagic_22|(_1|)_2
D007069_D006470 CID ifs_18\NNP\0|(_1|)_3 (r_appos) ifosfamide_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|a_39|limiting_37|side_28|-_24|of_16 (r_prep) effect_12\NN\34213|aim_50|._44 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) aim_0\VB\5980875|effect_50|._94 (l_appos) cystitis_3\NN\14566129|:_14
D007069_D006470 CID ifs_18\NNP\0|(_1|)_3 (r_appos) ifosfamide_16\NN\0|NONE_0 (r_pobj) with_15\IN\0|a_39|limiting_37|side_28|-_24|of_16 (r_prep) effect_12\NN\34213|aim_50|._44 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) aim_0\VB\5980875|effect_50|._94 (l_appos) cystitis_3\NN\14566129|:_14 (l_appos) hc_5\NNP\0|hemorrhagic_22|(_1|)_2
D007069_D006470 CID ifs_20\NNP\0|-_3 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) hc_23\NN\0|NONE_0
D007069_D006470 CID ifs_9\NNP\0|-_3 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) hc_12\NN\0|NONE_0
D003907_D006470 NONE dexamethasone_2\NN\2721538|NONE_0 (r_pobj) of_1\IN\0|with_17|for_28|._89 (r_prep) use_0\NN\407535|NONE_0 (l_prep) for_5\IN\0|of_28|with_11|._61 (l_pobj) prevention_7\NN\1073995|NONE_0 (l_prep) of_8\IN\0|the_15 (l_pobj) cystitis_13\NN\14566129|NONE_0
D003907_D006470 NONE dexamethasone_11\NN\2721538|NONE_0 (r_pobj) of_10\IN\0|the_8|in_17|for_43 (r_prep) use_9\NN\407535|in_49|,_22|we_20|._83 (l_prep) for_16\IN\0|the_51|of_43|in_26 (l_pobj) prevention_18\NN\1073995|NONE_0 (l_prep) of_19\IN\0|the_15 (l_pobj) hc_23\NN\0|NONE_0
D003907_D006470 NONE dexamethasone_0\NN\2721538|efficient_44|._80 (r_nsubj) was_5\VBD\0|NONE_0 (l_acomp) efficient_6\JJ\0|dexamethasone_44|._36 (l_prep) in_7\IN\13603305|NONE_0 (l_pcomp) blocking_8\VBG\562280|NONE_0 (l_dobj) hc_12\NN\0|NONE_0
D003907_D006470 NONE dexamethasone_19\NN\2721538|NONE_0 (r_pobj) with_18\IN\0|the_16|mesna_12 (r_prep) doses_17\NNS\3740161|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) all_13\DT\0|or_3 (r_conj) saline_11\NN\14849367|NONE_0 (r_pobj) with_10\IN\0|last_24|two_19|of_9 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) of_4\IN\0|the_16 (r_prep) replacement_3\NN\196485|however_13|,_6|did_96|not_100|hc_112|._114 (r_nsubj) prevent_22\VB\0|NONE_0 (l_dobj) hc_23\NN\0|however_125|,_118|replacement_112|did_16|not_12|._2
D003907_D003556 NONE dexamethasone_2\NN\2721538|NONE_0 (r_pobj) of_1\IN\0|with_17|for_28|._89 (r_prep) use_0\NN\407535|NONE_0 (l_prep) for_5\IN\0|of_28|with_11|._61 (l_pobj) prevention_7\NN\1073995|NONE_0 (l_prep) of_8\IN\0|the_15 (l_pobj) cystitis_13\NN\14566129|NONE_0
D003907_D003556 NONE dexamethasone_11\NN\2721538|NONE_0 (r_pobj) of_10\IN\0|the_8|in_17|for_43 (r_prep) use_9\NN\407535|in_49|,_22|we_20|._83 (l_prep) for_16\IN\0|the_51|of_43|in_26 (l_pobj) prevention_18\NN\1073995|NONE_0 (l_prep) of_19\IN\0|the_15 (l_pobj) hc_23\NN\0|NONE_0
D003907_D003556 NONE dexamethasone_0\NN\2721538|efficient_44|._80 (r_nsubj) was_5\VBD\0|NONE_0 (l_acomp) efficient_6\JJ\0|dexamethasone_44|._36 (l_prep) in_7\IN\13603305|NONE_0 (l_pcomp) blocking_8\VBG\562280|NONE_0 (l_dobj) hc_12\NN\0|NONE_0
D003907_D003556 NONE dexamethasone_19\NN\2721538|NONE_0 (r_pobj) with_18\IN\0|the_16|mesna_12 (r_prep) doses_17\NNS\3740161|NONE_0 (r_pobj) of_14\IN\0|NONE_0 (r_prep) all_13\DT\0|or_3 (r_conj) saline_11\NN\14849367|NONE_0 (r_pobj) with_10\IN\0|last_24|two_19|of_9 (r_prep) doses_7\NNS\3740161|NONE_0 (r_pobj) of_4\IN\0|the_16 (r_prep) replacement_3\NN\196485|however_13|,_6|did_96|not_100|hc_112|._114 (r_nsubj) prevent_22\VB\0|NONE_0 (l_dobj) hc_23\NN\0|however_125|,_118|replacement_112|did_16|not_12|._2
19274460
D003907_D009101 NONE dexamethasone_14\NN\2721538|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) combination_10\NN\7951464|NONE_0 (r_pobj) in_9\IN\13603305|dose_49|for_33|for_45 (r_prep) definition_5\NN\6738281|xi_15|:_7|._153 (l_prep) for_15\IN\0|dose_94|for_78|in_45 (l_pobj) induction_17\NN\7450842|NONE_0 (l_prep) in_18\IN\13603305|remission_20 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) myeloma_23\NN\14239425|NONE_0
D003907_D009101 NONE dexamethasone_17\NN\2721538|and_4 (r_conj) bortezomib_15\NNS\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) combination_13\NN\7951464|NONE_0 (r_pobj) in_12\IN\13603305|to_53|dose_25|as_49 (r_prep) evaluate_6\VB\670261|trial_23|was_17|._218 (l_prep) as_18\IN\14622893|to_102|dose_74|in_49 (l_pobj) treatment_20\NN\654885|NONE_0 (l_prep) before_21\IN\0|induction_20 (l_pobj) transplantation_24\NN\671351|NONE_0 (l_prep) for_25\IN\0|cell_21 (l_pobj) patients_27\NNS\9898892|NONE_0 (l_prep) with_28\IN\0|younger_17 (l_pobj) myeloma_32\NN\14239425|NONE_0
D003907_D009101 NONE dexamethasone_17\NN\2721538|and_4 (r_conj) bortezomib_15\NNS\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) combination_13\NN\7951464|NONE_0 (r_pobj) in_12\IN\13603305|to_53|dose_25|as_49 (r_prep) evaluate_6\VB\670261|trial_23|was_17|._218 (l_prep) as_18\IN\14622893|to_102|dose_74|in_49 (l_pobj) treatment_20\NN\654885|NONE_0 (l_prep) before_21\IN\0|induction_20 (l_pobj) transplantation_24\NN\671351|NONE_0 (l_prep) for_25\IN\0|cell_21 (l_pobj) patients_27\NNS\9898892|NONE_0 (l_prep) with_28\IN\0|younger_17 (l_pobj) myeloma_32\NN\14239425|NONE_0 (l_appos) mm_34\NNP\13649268|diagnosed_28|multiple_18
D003907_D009101 NONE dexamethasone_16\NN\2721538|that_72|bortezomib_67|treatment_40 (r_nsubj) is_17\VBZ\0|results_102|._108 (l_attr) treatment_21\NN\654885|that_112|bortezomib_107|dexamethasone_40 (l_prep) for_22\IN\0|an_33|effective_30|induction_20|warrants_42 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_prep) with_24\IN\0|NONE_0 (l_pobj) mm_27\NNP\13649268|NONE_0
C400082_D009101 NONE bortezomib_12\NNS\0|/_10 (r_amod) dexamethasone_14\NN\2721538|NONE_0 (r_pobj) with_11\IN\0|NONE_0 (r_prep) combination_10\NN\7951464|NONE_0 (r_pobj) in_9\IN\13603305|dose_49|for_33|for_45 (r_prep) definition_5\NN\6738281|xi_15|:_7|._153 (l_prep) for_15\IN\0|dose_94|for_78|in_45 (l_pobj) induction_17\NN\7450842|NONE_0 (l_prep) in_18\IN\13603305|remission_20 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) myeloma_23\NN\14239425|NONE_0
C400082_D009101 NONE bortezomib_15\NNS\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) combination_13\NN\7951464|NONE_0 (r_pobj) in_12\IN\13603305|to_53|dose_25|as_49 (r_prep) evaluate_6\VB\670261|trial_23|was_17|._218 (l_prep) as_18\IN\14622893|to_102|dose_74|in_49 (l_pobj) treatment_20\NN\654885|NONE_0 (l_prep) before_21\IN\0|induction_20 (l_pobj) transplantation_24\NN\671351|NONE_0 (l_prep) for_25\IN\0|cell_21 (l_pobj) patients_27\NNS\9898892|NONE_0 (l_prep) with_28\IN\0|younger_17 (l_pobj) myeloma_32\NN\14239425|NONE_0
C400082_D009101 NONE bortezomib_15\NNS\0|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) combination_13\NN\7951464|NONE_0 (r_pobj) in_12\IN\13603305|to_53|dose_25|as_49 (r_prep) evaluate_6\VB\670261|trial_23|was_17|._218 (l_prep) as_18\IN\14622893|to_102|dose_74|in_49 (l_pobj) treatment_20\NN\654885|NONE_0 (l_prep) before_21\IN\0|induction_20 (l_pobj) transplantation_24\NN\671351|NONE_0 (l_prep) for_25\IN\0|cell_21 (l_pobj) patients_27\NNS\9898892|NONE_0 (l_prep) with_28\IN\0|younger_17 (l_pobj) myeloma_32\NN\14239425|NONE_0 (l_appos) mm_34\NNP\13649268|diagnosed_28|multiple_18
C400082_D009101 NONE bortezomib_4\NNS\0|that_5|dexamethasone_67|treatment_107 (r_nsubj) is_17\VBZ\0|results_102|._108 (l_attr) treatment_21\NN\654885|that_112|bortezomib_107|dexamethasone_40 (l_prep) for_22\IN\0|an_33|effective_30|induction_20|warrants_42 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_prep) with_24\IN\0|NONE_0 (l_pobj) mm_27\NNP\13649268|NONE_0
D003520_D009101 NONE cyclophosphamide_8\NN\0|NONE_0 (r_pobj) for_6\IN\0|dose_16|in_33|for_78 (r_prep) definition_5\NN\6738281|xi_15|:_7|._153 (l_prep) for_15\IN\0|dose_94|for_78|in_45 (l_pobj) induction_17\NN\7450842|NONE_0 (l_prep) in_18\IN\13603305|remission_20 (l_pobj) patients_19\NNS\9898892|NONE_0 (l_prep) with_20\IN\0|NONE_0 (l_pobj) myeloma_23\NN\14239425|NONE_0
D003520_D009101 NONE cyclophosphamide_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|the_21|recommended_17 (r_prep) dose_9\NN\3740161|to_28|in_25|as_74 (r_dobj) evaluate_6\VB\670261|trial_23|was_17|._218 (l_prep) as_18\IN\14622893|to_102|dose_74|in_49 (l_pobj) treatment_20\NN\654885|NONE_0 (l_prep) before_21\IN\0|induction_20 (l_pobj) transplantation_24\NN\671351|NONE_0 (l_prep) for_25\IN\0|cell_21 (l_pobj) patients_27\NNS\9898892|NONE_0 (l_prep) with_28\IN\0|younger_17 (l_pobj) myeloma_32\NN\14239425|NONE_0
D003520_D009101 NONE cyclophosphamide_11\NN\0|NONE_0 (r_pobj) of_10\IN\0|the_21|recommended_17 (r_prep) dose_9\NN\3740161|to_28|in_25|as_74 (r_dobj) evaluate_6\VB\670261|trial_23|was_17|._218 (l_prep) as_18\IN\14622893|to_102|dose_74|in_49 (l_pobj) treatment_20\NN\654885|NONE_0 (l_prep) before_21\IN\0|induction_20 (l_pobj) transplantation_24\NN\671351|NONE_0 (l_prep) for_25\IN\0|cell_21 (l_pobj) patients_27\NNS\9898892|NONE_0 (l_prep) with_28\IN\0|younger_17 (l_pobj) myeloma_32\NN\14239425|NONE_0 (l_appos) mm_34\NNP\13649268|diagnosed_28|multiple_18
D003520_D009101 NONE cyclophosphamide_8\NN\0|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) combination_6\NN\7951464|NONE_0 (r_pobj) in_5\IN\13603305|at_37|and_52 (r_prep) bortezomib_4\NNS\0|that_5|dexamethasone_67|treatment_107 (r_nsubj) is_17\VBZ\0|results_102|._108 (l_attr) treatment_21\NN\654885|that_112|bortezomib_107|dexamethasone_40 (l_prep) for_22\IN\0|an_33|effective_30|induction_20|warrants_42 (l_pobj) patients_23\NNS\9898892|NONE_0 (l_prep) with_24\IN\0|NONE_0 (l_pobj) mm_27\NNP\13649268|NONE_0
6769133
D004317_D006333 CID adriamycin_13\NNS\0|an_22|average_19|cumulative_11|m2_24|below_33|considered_44 (r_compound) dose_14\NN\3740161|NONE_0 (r_pobj) at_9\IN\14622893|8_55|failure_8|._119 (r_prep) developed_5\VBD\1753788|NONE_0 (l_dobj) failure_8\NN\66216|8_47|at_8|._127
D018943_D009202 NONE anthracycline_10\NN\0|-_13 (r_amod) induced_12\VBN\1627355|human_20 (r_amod) cardiomyopathy_13\NN\14103288|NONE_0
D004317_D066126 NONE adriamycin_6\NNS\0|NONE_0 (r_pobj) of_5\IN\0|possible_30|leukemogenic_21|in_14 (r_prep) effects_4\NNS\13245626|and_26|._42 (r_conj) cardiotoxic_0\NNP\0|NONE_0
D018943_D001768 NONE anthracycline_10\NN\0|-_13 (r_amod) induced_12\VBN\1627355|human_20 (r_amod) cardiomyopathy_13\NN\14103288|NONE_0 (r_pobj) in_8\IN\13603305|NONE_0 (r_prep) found_7\VBN\13279262|NONE_0 (r_acl) those_6\DT\0|histologically_49|,_35|lesions_18|._57 (r_dobj) resembled_5\VBD\2657219|NONE_0 (l_nsubj) lesions_4\NNS\14204950|histologically_31|,_17|those_18|._75
D004317_D015470 CID adriamycin_16\NNS\0|NONE_0 (r_pobj) of_15\IN\0|324_10|mg_6|/_4 (r_prep) m2_14\CD\13357178|NONE_0 (r_dobj) receiving_10\VBG\2210855|NONE_0 (r_pcomp) after_9\IN\0|1_58|leukemia_9 (r_prep) developed_5\VBD\1753788|;_77|monkey_88|alive_98|after_123|._150 (l_dobj) leukemia_8\NN\14239918|1_49|after_9
D004317_D007938 NONE adriamycin_4\NN\0|that_5|cardiotoxin_28|than_51|,_62|and_64|be_86 (r_nsubj) is_5\VBZ\0|results_32|._129 (l_conj) be_20\VB\14625458|that_91|adriamycin_86|cardiotoxin_58|than_35|,_24|and_22 (l_nsubj) leukemia_18\NN\14239918|that_5|may_9|consequence_18
3762968
D013835_D014899 NONE pyrophosphate_42\NN\15010703|NONE_0 (r_pobj) for_40\IN\0|[_9|high_8|]_32 (r_prep) km_39\NNP\13649268|transketolase_32 (r_appos) abnormality_36\NN\14034177|if_39|patient_31|also_23|,_54|reported_70 (r_dobj) had_34\VBD\0|to_34 (r_ccomp) delineate_29\VB\2137132|NONE_0 (r_acl) order_27\NN\7168131|NONE_0 (r_pobj) in_26\IN\13603305|we_164|enzyme_132|from_109|,_2|._184 (r_prep) studied_1\VBD\0|NONE_0 (l_prep) from_10\IN\0|we_55|enzyme_23|,_107|in_109|._293 (l_pobj) fibroblasts_11\NNS\5447757|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) patient_15\NN\9898892|NONE_0 (l_relcl) developed_17\VBD\1753788|a_23|diabetic_21 (l_dobj) encephalopathy_20\NN\14084880|who_25|treated_20
D013835_D014899 NONE tpp_44\NNP\0|thiamine_24|(_1|)_3 (r_appos) pyrophosphate_42\NN\15010703|NONE_0 (r_pobj) for_40\IN\0|[_9|high_8|]_32 (r_prep) km_39\NNP\13649268|transketolase_32 (r_appos) abnormality_36\NN\14034177|if_39|patient_31|also_23|,_54|reported_70 (r_dobj) had_34\VBD\0|to_34 (r_ccomp) delineate_29\VB\2137132|NONE_0 (r_acl) order_27\NN\7168131|NONE_0 (r_pobj) in_26\IN\13603305|we_164|enzyme_132|from_109|,_2|._184 (r_prep) studied_1\VBD\0|NONE_0 (l_prep) from_10\IN\0|we_55|enzyme_23|,_107|in_109|._293 (l_pobj) fibroblasts_11\NNS\5447757|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) patient_15\NN\9898892|NONE_0 (l_relcl) developed_17\VBD\1753788|a_23|diabetic_21 (l_dobj) encephalopathy_20\NN\14084880|who_25|treated_20
D013835_D014899 NONE tpp_30\NNP\0|NONE_0 (r_pobj) for_29\IN\0|its_7 (r_prep) km_28\NNP\13649268|NONE_0 (r_pobj) by_26\IN\0|as_14 (r_agent) determined_25\VBN\0|that_141|patient_116|transketolase_17 (r_advcl) had_21\VBD\0|we_120|._58 (l_nsubj) patient_7\NN\9898892|that_25|transketolase_99|determined_116 (l_prep) with_14\IN\0|the_61|mentioned_51|and_33|one_29 (l_pobj) history_16\NN\15120823|NONE_0 (l_prep) of_17\IN\0|no_11 (l_pobj) encephalopathy_20\NN\14084880|NONE_0
D014042_D020915 NONE tolazamide_24\NN\4353189|NONE_0 (r_pobj) with_23\IN\0|when_13 (r_prep) treated_22\VBN\2376958|who_45|encephalopathy_20 (r_advcl) developed_17\VBD\1753788|a_23|diabetic_21 (r_relcl) patient_15\NN\9898892|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) fibroblasts_11\NNS\5447757|NONE_0 (r_pobj) from_10\IN\0|we_55|enzyme_23|,_107|in_109|._293 (r_prep) studied_1\VBD\0|NONE_0 (l_prep) in_26\IN\13603305|we_164|enzyme_132|from_109|,_2|._184 (l_pobj) order_27\NN\7168131|NONE_0 (l_acl) delineate_29\VB\2137132|NONE_0 (l_ccomp) had_34\VBD\0|to_34 (l_advcl) reported_50\VBN\831651|if_109|patient_101|also_93|abnormality_70|,_16 (l_prep) in_51\IN\13603305|as_23|previously_20 (l_pobj) syndrome_56\NN\5870365|NONE_0
D014042_D020915 NONE tolazamide_15\NN\4353189|-_10 (r_npadvmod) induced_17\VBN\1627355|wernicke_8|from_34 (r_amod) encephalopathy_20\NN\14084880|NONE_0 (r_pobj) with_14\IN\0|the_12 (r_prep) patient_13\NN\9898892|postalcoholic_50|korsakoff_27|and_8 (r_conj) syndrome_10\NN\5870365|NONE_0
D013831_D014899 NONE thiamine_3\NN\15090742|-_8 (r_npadvmod) dependent_5\JJ\9627906|a_11|,_16|transketolase_18|,_31 (r_amod) enzyme_6\NN\14723628|we_32|from_23|,_130|in_132|._316 (r_dobj) studied_1\VBD\0|NONE_0 (l_prep) from_10\IN\0|we_55|enzyme_23|,_107|in_109|._293 (l_pobj) fibroblasts_11\NNS\5447757|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) patient_15\NN\9898892|NONE_0 (l_relcl) developed_17\VBD\1753788|a_23|diabetic_21 (l_dobj) encephalopathy_20\NN\14084880|who_25|treated_20
D013835_D003920 NONE pyrophosphate_42\NN\15010703|NONE_0 (r_pobj) for_40\IN\0|[_9|high_8|]_32 (r_prep) km_39\NNP\13649268|transketolase_32 (r_appos) abnormality_36\NN\14034177|if_39|patient_31|also_23|,_54|reported_70 (r_dobj) had_34\VBD\0|to_34 (r_ccomp) delineate_29\VB\2137132|NONE_0 (r_acl) order_27\NN\7168131|NONE_0 (r_pobj) in_26\IN\13603305|we_164|enzyme_132|from_109|,_2|._184 (r_prep) studied_1\VBD\0|NONE_0 (l_prep) from_10\IN\0|we_55|enzyme_23|,_107|in_109|._293 (l_pobj) fibroblasts_11\NNS\5447757|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) patient_15\NN\9898892|NONE_0 (l_amod) diabetic_14\JJ\10595647|a_2|developed_21
D013835_D003920 NONE tpp_44\NNP\0|thiamine_24|(_1|)_3 (r_appos) pyrophosphate_42\NN\15010703|NONE_0 (r_pobj) for_40\IN\0|[_9|high_8|]_32 (r_prep) km_39\NNP\13649268|transketolase_32 (r_appos) abnormality_36\NN\14034177|if_39|patient_31|also_23|,_54|reported_70 (r_dobj) had_34\VBD\0|to_34 (r_ccomp) delineate_29\VB\2137132|NONE_0 (r_acl) order_27\NN\7168131|NONE_0 (r_pobj) in_26\IN\13603305|we_164|enzyme_132|from_109|,_2|._184 (r_prep) studied_1\VBD\0|NONE_0 (l_prep) from_10\IN\0|we_55|enzyme_23|,_107|in_109|._293 (l_pobj) fibroblasts_11\NNS\5447757|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) patient_15\NN\9898892|NONE_0 (l_amod) diabetic_14\JJ\10595647|a_2|developed_21
D013835_D003920 NONE tpp_30\NNP\0|NONE_0 (r_pobj) for_29\IN\0|its_7 (r_prep) km_28\NNP\13649268|NONE_0 (r_pobj) by_26\IN\0|as_14 (r_agent) determined_25\VBN\0|that_141|patient_116|transketolase_17 (r_advcl) had_21\VBD\0|we_120|._58 (l_nsubj) patient_7\NN\9898892|that_25|transketolase_99|determined_116 (l_conj) one_9\CD\13741022|the_32|mentioned_22|and_4|with_29 (l_prep) of_10\IN\0|NONE_0 (l_pobj) kindreds_13\NNS\7950920|NONE_0 (l_amod) diabetic_12\JJ\10595647|the_4
D013831_D020915 NONE thiamine_3\NN\15090742|-_8 (r_npadvmod) dependent_5\JJ\9627906|a_11|,_16|transketolase_18|,_31 (r_amod) enzyme_6\NN\14723628|we_32|from_23|,_130|in_132|._316 (r_dobj) studied_1\VBD\0|NONE_0 (l_prep) in_26\IN\13603305|we_164|enzyme_132|from_109|,_2|._184 (l_pobj) order_27\NN\7168131|NONE_0 (l_acl) delineate_29\VB\2137132|NONE_0 (l_ccomp) had_34\VBD\0|to_34 (l_advcl) reported_50\VBN\831651|if_109|patient_101|also_93|abnormality_70|,_16 (l_prep) in_51\IN\13603305|as_23|previously_20 (l_pobj) syndrome_56\NN\5870365|NONE_0
D013835_D020915 NONE pyrophosphate_42\NN\15010703|NONE_0 (r_pobj) for_40\IN\0|[_9|high_8|]_32 (r_prep) km_39\NNP\13649268|transketolase_32 (r_appos) abnormality_36\NN\14034177|if_39|patient_31|also_23|,_54|reported_70 (r_dobj) had_34\VBD\0|to_34 (l_advcl) reported_50\VBN\831651|if_109|patient_101|also_93|abnormality_70|,_16 (l_prep) in_51\IN\13603305|as_23|previously_20 (l_pobj) syndrome_56\NN\5870365|NONE_0
D013835_D020915 NONE tpp_44\NNP\0|thiamine_24|(_1|)_3 (r_appos) pyrophosphate_42\NN\15010703|NONE_0 (r_pobj) for_40\IN\0|[_9|high_8|]_32 (r_prep) km_39\NNP\13649268|transketolase_32 (r_appos) abnormality_36\NN\14034177|if_39|patient_31|also_23|,_54|reported_70 (r_dobj) had_34\VBD\0|to_34 (l_advcl) reported_50\VBN\831651|if_109|patient_101|also_93|abnormality_70|,_16 (l_prep) in_51\IN\13603305|as_23|previously_20 (l_pobj) syndrome_56\NN\5870365|NONE_0
D014042_D014899 CID tolazamide_3\NN\4353189|-_10 (r_npadvmod) induced_5\VBN\1627355|wernicke_8 (r_amod) encephalopathy_8\NN\14084880|NONE_0
D014042_D014899 CID tolazamide_24\NN\4353189|NONE_0 (r_pobj) with_23\IN\0|when_13 (r_prep) treated_22\VBN\2376958|who_45|encephalopathy_20 (r_advcl) developed_17\VBD\1753788|a_23|diabetic_21 (l_dobj) encephalopathy_20\NN\14084880|who_25|treated_20
D014042_D014899 CID tolazamide_15\NN\4353189|-_10 (r_npadvmod) induced_17\VBN\1627355|wernicke_8|from_34 (r_amod) encephalopathy_20\NN\14084880|NONE_0
D014042_D003920 NONE tolazamide_24\NN\4353189|NONE_0 (r_pobj) with_23\IN\0|when_13 (r_prep) treated_22\VBN\2376958|who_45|encephalopathy_20 (r_advcl) developed_17\VBD\1753788|a_23|diabetic_21 (r_relcl) patient_15\NN\9898892|NONE_0 (l_amod) diabetic_14\JJ\10595647|a_2|developed_21
D013831_D003920 NONE thiamine_3\NN\15090742|-_8 (r_npadvmod) dependent_5\JJ\9627906|a_11|,_16|transketolase_18|,_31 (r_amod) enzyme_6\NN\14723628|we_32|from_23|,_130|in_132|._316 (r_dobj) studied_1\VBD\0|NONE_0 (l_prep) from_10\IN\0|we_55|enzyme_23|,_107|in_109|._293 (l_pobj) fibroblasts_11\NNS\5447757|NONE_0 (l_prep) of_12\IN\0|NONE_0 (l_pobj) patient_15\NN\9898892|NONE_0 (l_amod) diabetic_14\JJ\10595647|a_2|developed_21
3732088
D000584_D003324 NONE amiloride_30\NN\0|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) of_21\IN\0|8_8 (r_prep) weeks_20\NNS\15113229|NONE_0 (r_pobj) after_18\IN\0|disease_8|)_74 (r_prep) known_14\VBN\0|thus_103|,_99|excitability_75|was_62|in_49|and_4|and_106|period_120|._196 (l_dobj) disease_17\NN\14061805|after_8|)_82
D011188_D001145 NONE potassium_2\NN\14625458|,_2|in_26|._58 (l_conj) arrhythmias_4\NNS\14103288|and_4
D011188_D001145 NONE potassium_9\NN\14625458|NONE_0 (r_pobj) in_7\IN\13603305|modest_15 (r_prep) changes_6\NNS\7283608|that_12|can_28|tendency_42 (r_nsubj) alter_11\VB\0|it_65|has_62|been_58|._46 (l_dobj) tendency_13\NN\6193203|that_54|changes_42|can_14 (l_prep) towards_14\IN\0|the_13 (l_pobj) arrhythmias_16\NNS\14103288|NONE_0
D002752_D006973 NONE chlorthalidone_43\NN\3214670|NONE_0 (r_pobj) on_36\IN\0|a_17|similar_15|in_48 (r_prep) period_35\NN\13575869|thus_223|,_219|excitability_195|was_182|in_169|and_124|known_120|and_14|._76 (r_conj) measured_6\VBN\697589|NONE_0 (l_prep) in_7\IN\13603305|thus_54|,_50|excitability_26|was_13|and_45|known_49|and_155|period_169|._245 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) hypertension_12\NN\14057371|NONE_0
D011188_D003324 NONE potassium_25\NN\14625458|-_9 (r_npadvmod) conserving_27\VBG\2681795|NONE_0 (r_amod) diuretic_28\JJ\3247620|a_23|(_9 (r_amod) amiloride_30\NN\0|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) of_21\IN\0|8_8 (r_prep) weeks_20\NNS\15113229|NONE_0 (r_pobj) after_18\IN\0|disease_8|)_74 (r_prep) known_14\VBN\0|thus_103|,_99|excitability_75|was_62|in_49|and_4|and_106|period_120|._196 (l_dobj) disease_17\NN\14061805|after_8|)_82
D011188_D003324 NONE potassium_38\NN\14625458|-_9 (r_npadvmod) losing_40\VBG\0|a_12|diuretic_7|(_16|)_31 (r_amod) chlorthalidone_43\NN\3214670|NONE_0 (r_pobj) on_36\IN\0|a_17|similar_15|in_48 (r_prep) period_35\NN\13575869|thus_223|,_219|excitability_195|was_182|in_169|and_124|known_120|and_14|._76 (r_conj) measured_6\VBN\697589|NONE_0 (l_conj) known_14\VBN\0|thus_103|,_99|excitability_75|was_62|in_49|and_4|and_106|period_120|._196 (l_dobj) disease_17\NN\14061805|after_8|)_82
D002752_D018879 CID chlorthalidone_6\NN\3214670|the_4 (r_compound) phase_7\NN\15113229|compared_52|,_21|was_6|with_21|period_243|,_249|and_251|increased_255|._329 (r_nsubjpass) associated_9\VBN\628491|NONE_0 (l_prep) with_10\IN\0|compared_73|,_42|phase_21|was_15|period_222|,_228|and_230|increased_234|._308 (l_pobj) frequency_13\NN\15286249|NONE_0 (l_prep) of_14\IN\0|an_23|increased_20|and_57|grading_75 (l_pobj) beats_17\NNS\8289449|NONE_0
D011188_D003327 NONE potassium_2\NN\14625458|,_2|in_26|._58 (r_conj) diuretics_0\NNS\3247620|NONE_0 (l_prep) in_5\IN\13603305|,_28|potassium_26|._32 (l_pobj) disease_8\NN\14061805|NONE_0
D000584_D006973 NONE amiloride_30\NN\0|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) of_21\IN\0|8_8 (r_prep) weeks_20\NNS\15113229|NONE_0 (r_pobj) after_18\IN\0|disease_8|)_74 (r_prep) known_14\VBN\0|thus_103|,_99|excitability_75|was_62|in_49|and_4|and_106|period_120|._196 (r_conj) measured_6\VBN\697589|NONE_0 (l_prep) in_7\IN\13603305|thus_54|,_50|excitability_26|was_13|and_45|known_49|and_155|period_169|._245 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) hypertension_12\NN\14057371|NONE_0
D011188_D006973 NONE potassium_2\NN\14625458|,_2|in_26|._58 (r_conj) diuretics_0\NNS\3247620|NONE_0 (l_prep) in_5\IN\13603305|,_28|potassium_26|._32 (l_pobj) disease_8\NN\14061805|NONE_0 (l_amod) hypertensive_6\JJ\10405694|coronary_13
D011188_D006973 NONE potassium_25\NN\14625458|-_9 (r_npadvmod) conserving_27\VBG\2681795|NONE_0 (r_amod) diuretic_28\JJ\3247620|a_23|(_9 (r_amod) amiloride_30\NN\0|NONE_0 (r_pobj) with_23\IN\0|NONE_0 (r_prep) treatment_22\NN\654885|NONE_0 (r_pobj) of_21\IN\0|8_8 (r_prep) weeks_20\NNS\15113229|NONE_0 (r_pobj) after_18\IN\0|disease_8|)_74 (r_prep) known_14\VBN\0|thus_103|,_99|excitability_75|was_62|in_49|and_4|and_106|period_120|._196 (r_conj) measured_6\VBN\697589|NONE_0 (l_prep) in_7\IN\13603305|thus_54|,_50|excitability_26|was_13|and_45|known_49|and_155|period_169|._245 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) hypertension_12\NN\14057371|NONE_0
D011188_D006973 NONE potassium_38\NN\14625458|-_9 (r_npadvmod) losing_40\VBG\0|a_12|diuretic_7|(_16|)_31 (r_amod) chlorthalidone_43\NN\3214670|NONE_0 (r_pobj) on_36\IN\0|a_17|similar_15|in_48 (r_prep) period_35\NN\13575869|thus_223|,_219|excitability_195|was_182|in_169|and_124|known_120|and_14|._76 (r_conj) measured_6\VBN\697589|NONE_0 (l_prep) in_7\IN\13603305|thus_54|,_50|excitability_26|was_13|and_45|known_49|and_155|period_169|._245 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) hypertension_12\NN\14057371|NONE_0
D002752_D003324 NONE chlorthalidone_43\NN\3214670|NONE_0 (r_pobj) on_36\IN\0|a_17|similar_15|in_48 (r_prep) period_35\NN\13575869|thus_223|,_219|excitability_195|was_182|in_169|and_124|known_120|and_14|._76 (r_conj) measured_6\VBN\697589|NONE_0 (l_conj) known_14\VBN\0|thus_103|,_99|excitability_75|was_62|in_49|and_4|and_106|period_120|._196 (l_dobj) disease_17\NN\14061805|after_8|)_82
D000584_D018879 NONE amiloride_2\NN\0|NONE_0 (r_compound) treatment_3\NN\654885|NONE_0 (r_pobj) to_1\IN\0|NONE_0 (r_prep) compared_0\VBN\644583|,_31|phase_52|was_58|with_73|period_295|,_301|and_303|increased_307|._381 (r_prep) associated_9\VBN\628491|NONE_0 (l_prep) with_10\IN\0|compared_73|,_42|phase_21|was_15|period_222|,_228|and_230|increased_234|._308 (l_pobj) frequency_13\NN\15286249|NONE_0 (l_prep) of_14\IN\0|an_23|increased_20|and_57|grading_75 (l_pobj) beats_17\NNS\8289449|NONE_0
D011188_D017202 NONE potassium_6\NN\14625458|-_9 (r_npadvmod) losing_8\VBG\0|diuretic_7 (r_amod) therapy_10\NN\657604|because_34|can_8|excitability_43 (r_nsubj) increase_12\VB\13576355|that_51|,_84|minor_91|in_103 (l_dobj) excitability_15\NN\5653575|because_77|therapy_43|can_35 (l_prep) in_16\IN\13603305|myocardial_35|electrical_24 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) disease_21\NN\14061805|NONE_0
D011188_D017202 NONE potassium_28\NN\14625458|plasma_7 (r_compound) concentrations_29\NNS\4916342|NONE_0 (r_pobj) in_26\IN\13603305|that_154|increase_103|,_19|minor_12 (r_prep) falls_25\VBZ\11692265|results_165|avoided_59|._83 (l_advcl) increase_12\VB\13576355|that_51|,_84|minor_91|in_103 (l_dobj) excitability_15\NN\5653575|because_77|therapy_43|can_35 (l_prep) in_16\IN\13603305|myocardial_35|electrical_24 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) disease_21\NN\14061805|NONE_0
3137399
D016685_D066126 NONE c._12\NNP\0|NONE_0 (r_pobj) by_10\IN\0|NONE_0 (r_agent) induced_9\VBN\1627355|a_61|prospective_59|on_41 (r_acl) study_2\NN\635850|NONE_0 (l_prep) on_3\IN\0|a_20|prospective_18|induced_41 (l_pobj) dependency_6\NN\24720|NONE_0 (l_prep) of_7\IN\0|the_20|dose_16 (l_pobj) cardiotoxicity_8\NN\0|NONE_0
D016685_D066126 NONE c_3\NNP\13714184|since_21|has_8|been_12|be_30|,_44|combined_62|._106 (r_nsubjpass) suggested_9\VBN\1010118|NONE_0 (l_xcomp) be_11\VB\14625458|since_51|c_30|has_22|been_18|,_14|combined_32|._76 (l_acomp) cardiotoxic_12\JJ\0|to_6
D016685_D066126 NONE mmc_5\NN\0|mitomycin_13 (r_appos) c_3\NNP\13714184|since_21|has_8|been_12|be_30|,_44|combined_62|._106 (r_nsubjpass) suggested_9\VBN\1010118|NONE_0 (l_xcomp) be_11\VB\14625458|since_51|c_30|has_22|been_18|,_14|combined_32|._76 (l_acomp) cardiotoxic_12\JJ\0|to_6
D016685_D066126 NONE mmc_16\NN\0|-_3 (r_npadvmod) related_18\VBN\628491|NONE_0 (r_amod) cardiotoxicity_19\NN\0|that_17|dependent_23|,_32|occurring_34|,_90|in_99
D016685_D006333 CID mmc_11\NNP\0|NONE_0 (r_pobj) after_7\IN\0|one_46|failure_8|._51 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) failure_6\NN\66216|one_38|after_8|._59
D004317_D006333 CID doxorubicin_17\NN\2716866|30_34|mg_31|m-2_28|and_20 (r_conj) mmc_11\NNP\0|NONE_0 (r_pobj) after_7\IN\0|one_46|failure_8|._51 (r_prep) developed_4\VBD\1753788|NONE_0 (l_dobj) failure_6\NN\66216|one_38|after_8|._59
D004317_D066126 NONE doxorubicin_21\NN\2716866|NONE_0 (r_dobj) following_20\VBG\8180190|NONE_0 (r_pcomp) given_19\VBN\5892096|especially_33|when_22|with_8|or_3 (r_conj) combined_16\VBN\2630189|since_83|c_62|has_54|been_50|be_32|,_18|._44 (r_advcl) suggested_9\VBN\1010118|NONE_0 (l_xcomp) be_11\VB\14625458|since_51|c_30|has_22|been_18|,_14|combined_32|._76 (l_acomp) cardiotoxic_12\JJ\0|to_6
D004317_D066126 NONE doxorubicin_47\NN\2716866|NONE_0 (r_pobj) with_46\IN\0|also_44|(_39|previously_38|)_10 (r_prep) treated_45\VBN\2376958|NONE_0 (r_acl) patients_38\NNS\9898892|mainly_10 (r_pobj) in_37\IN\13603305|that_116|cardiotoxicity_99|dependent_76|,_67|occurring_65|,_9 (r_prep) is_20\VBZ\0|based_113|,_45|we_43|._156 (l_nsubj) cardiotoxicity_19\NN\0|that_17|dependent_23|,_32|occurring_34|,_90|in_99
761833
D000641_D003128 NONE ammonia_2\NN\14940386|in_13 (r_compound) coma_3\NN\5678932|NONE_0
D000641_D003128 NONE ammonia_0\NN\14940386|NONE_0 (r_compound) coma_1\NN\5678932|was_5|in_18|._98
D000641_D003128 NONE ammonia_18\NN\14940386|the_4 (r_compound) coma_19\NN\5678932|did_28|not_24|nor_5|affect_9
D000641_D003128 NONE ammonia_26\NN\14940386|the_20|blood_16 (r_compound) concentrations_27\NNS\4916342|NONE_0 (r_dobj) affect_21\VB\26192|did_37|not_33|coma_9|nor_4 (r_conj) prevent_16\VB\0|infusion_87|raise_52|._78 (l_dobj) coma_19\NN\5678932|did_28|not_24|nor_5|affect_9
D000641_D003128 NONE ammonia_14\NN\14940386|NONE_0 (r_pobj) on_10\IN\0|l_7|-_6|and_27|coma_43 (r_prep) dopa_9\NN\14601829|NONE_0 (l_conj) coma_18\NN\5678932|l_50|-_49|on_43|and_16
D000641_D003128 NONE ammonia_17\NN\14940386|the_4 (r_compound) coma_18\NN\5678932|l_50|-_49|on_43|and_16
D000641_D003128 NONE ammonia_8\NN\14940386|NONE_0 (r_pobj) in_4\IN\13603305|the_14|and_27|prevention_35 (r_prep) reduction_3\NN\351485|thus_10|,_6|,_84|can_86|be_90|for_103|by_107|._192 (l_conj) prevention_11\NN\1073995|the_49|in_35|and_8 (l_prep) of_12\IN\0|the_15|after_16 (l_pobj) coma_14\NN\5678932|NONE_0
D000641_D003128 NONE ammonia_13\NN\14940386|NONE_0 (r_compound) coma_14\NN\5678932|NONE_0
D064751_D003128 NONE salt_19\NN\14818238|the_13 (r_compound) injection_20\NN\320852|minutes_33 (r_pobj) before_16\IN\0|coma_80|was_75|with_61|._34 (r_prep) prevented_3\VBN\0|NONE_0 (l_nsubjpass) coma_1\NN\5678932|was_5|with_19|before_80|._114
D007980_D001927 NONE dopa_18\NNP\14601829|NONE_0 (r_dobj) receiving_15\VBG\2210855|some_30|encephalopathic_25 (r_acl) patients_14\NNS\9898892|NONE_0 (l_amod) encephalopathic_13\JJ\0|some_5|receiving_25
D000643_D003128 CID nh4cl_17\NN\0|NONE_0 (r_pobj) of_14\IN\0|an_28 (r_prep) intraperitonealinjection_13\NN\0|NONE_0 (r_pobj) of_11\IN\0|15_11 (r_prep) minutes_10\NNS\6502378|NONE_0 (r_pobj) within_6\IN\0|NONE_0 (r_prep) rats_5\NNS\2329401|NONE_0 (r_pobj) in_4\IN\13603305|coma_18|was_13|._80 (r_prep) produced_3\VBN\1617192|NONE_0 (l_nsubjpass) coma_1\NN\5678932|was_5|in_18|._98
D007980_D003128 NONE dopa_9\NNP\14601829|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_prep) rats_5\NNS\2329401|NONE_0 (r_pobj) in_4\IN\13603305|ammonia_13 (r_prep) coma_3\NN\5678932|NONE_0
D007980_D003128 NONE dopa_9\NN\14601829|NONE_0 (r_pobj) with_4\IN\0|coma_19|was_14|before_61|._95 (r_prep) prevented_3\VBN\0|NONE_0 (l_nsubjpass) coma_1\NN\5678932|was_5|with_19|before_80|._114
D007980_D003128 NONE dopa_9\NN\14601829|NONE_0 (l_conj) coma_18\NN\5678932|l_50|-_49|on_43|and_16
D007980_D003128 NONE dopa_18\NNP\14601829|NONE_0 (r_pobj) after_15\IN\0|the_31|of_16 (r_prep) prevention_11\NN\1073995|the_49|in_35|and_8 (l_prep) of_12\IN\0|the_15|after_16 (l_pobj) coma_14\NN\5678932|NONE_0
D004298_D003128 NONE dopamine_3\NN\14807737|NONE_0 (r_pobj) of_2\IN\0|intraventricular_26 (r_prep) infusion_1\NN\14589223|raise_35|prevent_87|._165 (r_nsubj) sufficient_4\JJ\0|NONE_0 (l_conj) prevent_16\VB\0|infusion_87|raise_52|._78 (l_dobj) coma_19\NN\5678932|did_28|not_24|nor_5|affect_9
D004298_D003128 NONE dopamine_9\NN\14807737|to_19|to_9 (r_dobj) raise_6\VB\5108947|infusion_35|prevent_52|._130 (r_xcomp) sufficient_4\JJ\0|NONE_0 (l_conj) prevent_16\VB\0|infusion_87|raise_52|._78 (l_dobj) coma_19\NN\5678932|did_28|not_24|nor_5|affect_9
D004298_D003128 NONE dopamine_29\NN\14807737|NONE_0 (r_pobj) of_28\IN\0|the_22|peripheral_18|on_12 (r_prep) effect_27\NN\34213|NONE_0 (r_pobj) by_24\IN\0|thus_117|,_113|reduction_107|,_23|can_21|be_17|for_4|._85 (r_agent) accounted_22\VBN\2604760|NONE_0 (l_nsubjpass) reduction_3\NN\351485|thus_10|,_6|,_84|can_86|be_90|for_103|by_107|._192 (l_conj) prevention_11\NN\1073995|the_49|in_35|and_8 (l_prep) of_12\IN\0|the_15|after_16 (l_pobj) coma_14\NN\5678932|NONE_0
8278214
D009020_D006930 CID morphine_11\NN\2707683|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) treated_7\VBN\2376958|terminal_25|cancer_16 (r_acl) patients_6\NNS\9898892|NONE_0 (r_pobj) in_3\IN\13603305|NONE_0 (r_prep) myoclonus_2\NN\14360459|and_4|._82 (r_conj) hyperalgesia_0\NNP\0|NONE_0
D009020_D006930 CID morphine_16\NN\2707683|NONE_0 (r_pobj) of_14\IN\0|high_11 (r_prep) doses_13\NNS\3740161|NONE_0 (r_pobj) with_11\IN\0|patients_55|developed_40|._62 (r_prep) treated_10\VBN\2376958|NONE_0 (l_advcl) developed_17\VBN\1753788|patients_95|with_40|._22 (l_dobj) hyperalgesia_18\NN\0|NONE_0
D009020_D006930 CID morphine_16\NN\2707683|NONE_0 (r_pobj) of_15\IN\0|high_11 (r_prep) doses_14\NNS\3740161|hyperalgesia_32|/_20|and_9 (r_conj) myoclonus_11\NN\14360459|NONE_0 (l_nmod) hyperalgesia_9\NN\0|/_12|and_23|doses_32
D009020_D006930 CID morphine_27\NN\2707683|that_5|,_28|role_48|for_53 (r_nsubj) plays_33\VBZ\7007684|are_101|,_88|support_73|._60 (r_ccomp) indicates_25\VBZ\952524|NONE_0 (l_advcl) are_17\VBP\13600404|,_13|support_28|plays_101|._161 (l_nsubj) descriptions_4\NNS\6722453|although_27|available_95 (l_prep) of_5\IN\0|few_26|clinical_22 (l_pobj) relationship_7\NN\31921|NONE_0 (l_prep) between_8\IN\0|the_17 (l_pobj) myoclonus_11\NN\14360459|NONE_0 (l_nmod) hyperalgesia_9\NN\0|/_12|and_23|doses_32
D009020_D009369 NONE morphine_11\NN\2707683|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) treated_7\VBN\2376958|terminal_25|cancer_16 (r_acl) patients_6\NNS\9898892|NONE_0 (l_compound) cancer_5\NN\14239425|terminal_9|treated_16
D009020_D009369 NONE morphine_16\NN\2707683|NONE_0 (r_pobj) of_14\IN\0|high_11 (r_prep) doses_13\NNS\3740161|NONE_0 (r_pobj) with_11\IN\0|patients_55|developed_40|._62 (r_prep) treated_10\VBN\2376958|NONE_0 (l_nsubj) patients_2\NNS\9898892|with_55|developed_95|._117 (l_compound) cancer_1\NN\14239425|eight_6|in_16
D009020_D009207 CID morphine_11\NN\2707683|NONE_0 (r_pobj) with_8\IN\0|NONE_0 (r_prep) treated_7\VBN\2376958|terminal_25|cancer_16 (r_acl) patients_6\NNS\9898892|NONE_0 (r_pobj) in_3\IN\13603305|NONE_0 (r_prep) myoclonus_2\NN\14360459|and_4|._82
D009020_D009207 CID morphine_16\NN\2707683|NONE_0 (r_pobj) of_15\IN\0|high_11 (r_prep) doses_14\NNS\3740161|hyperalgesia_32|/_20|and_9 (r_conj) myoclonus_11\NN\14360459|NONE_0
D009020_D009207 CID morphine_27\NN\2707683|that_5|,_28|role_48|for_53 (r_nsubj) plays_33\VBZ\7007684|are_101|,_88|support_73|._60 (r_ccomp) indicates_25\VBZ\952524|NONE_0 (l_advcl) are_17\VBP\13600404|,_13|support_28|plays_101|._161 (l_nsubj) descriptions_4\NNS\6722453|although_27|available_95 (l_prep) of_5\IN\0|few_26|clinical_22 (l_pobj) relationship_7\NN\31921|NONE_0 (l_prep) between_8\IN\0|the_17 (l_pobj) myoclonus_11\NN\14360459|NONE_0
10728962
D014667_D006333 NONE vasopressin_0\NN\5407119|NONE_0 (l_prep) in_1\IN\13603305|._73 (l_pobj) treatment_3\NN\654885|NONE_0 (l_prep) of_4\IN\0|the_14 (l_pobj) hypotension_8\NN\14057371|NONE_0 (l_prep) in_9\IN\13603305|induced_20 (l_pobj) failure_12\NN\66216|NONE_0
D014667_D006333 NONE vasopressin_16\NN\5407119|NONE_0 (r_pobj) of_15\IN\0|low_10 (r_prep) doses_14\NNS\3740161|in_98|pressure_36|without_45|._97 (r_nsubj) restored_17\VBD\1631072|NONE_0 (l_prep) in_0\IN\13603305|doses_98|pressure_134|without_143|._195 (l_pobj) patients_1\NNS\9898892|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) failure_5\NN\66216|NONE_0
D020105_D006333 NONE milrinone_5\NN\0|-_9 (r_npadvmod) induced_7\VBN\1627355|in_20 (r_amod) hypotension_8\NN\14057371|NONE_0 (l_prep) in_9\IN\13603305|induced_20 (l_pobj) failure_12\NN\66216|NONE_0
D020105_D006333 NONE milrinone_7\NN\0|such_8 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) treatment_10\NN\654885|NONE_0 (l_prep) of_11\IN\0|the_14 (l_pobj) failure_14\NN\66216|NONE_0
D020105_D006333 NONE milrinone_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treatment_9\NN\654885|NONE_0 (r_pobj) after_8\IN\0|NONE_0 (r_prep) hypotension_7\NN\14057371|NONE_0 (r_pobj) with_6\IN\0|decompensated_28|heart_14 (r_prep) failure_5\NN\66216|NONE_0
D020105_D006333 NONE milrinone_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|the_21|inotropic_17 (r_prep) effect_24\NN\34213|NONE_0 (r_dobj) inhibiting_21\VBG\2510337|NONE_0 (r_pcomp) without_20\IN\0|in_143|doses_45|pressure_9|._52 (r_prep) restored_17\VBD\1631072|NONE_0 (l_prep) in_0\IN\13603305|doses_98|pressure_134|without_143|._195 (l_pobj) patients_1\NNS\9898892|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) failure_5\NN\66216|NONE_0
D020105_D007022 CID milrinone_5\NN\0|-_9 (r_npadvmod) induced_7\VBN\1627355|in_20 (r_amod) hypotension_8\NN\14057371|NONE_0
D020105_D007022 CID milrinone_7\NN\0|such_8 (r_pobj) as_6\IN\14622893|phosphodiesterase_34 (r_prep) inhibitors_4\NNS\20090|NONE_0 (r_pobj) of_2\IN\0|the_8 (r_prep) use_1\NN\407535|is_95|frequently_98|cause_133|._167 (r_nsubjpass) restricted_17\VBN\235368|NONE_0 (l_advcl) cause_20\VBP\7323922|use_133|is_38|frequently_35|._34 (l_dobj) vasodilation_21\NN\365995|because_19|they_11 (l_conj) hypotension_23\NN\14057371|and_4
D020105_D007022 CID milrinone_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|NONE_0 (r_prep) treatment_9\NN\654885|NONE_0 (r_pobj) after_8\IN\0|NONE_0 (r_prep) hypotension_7\NN\14057371|NONE_0
D020105_D007022 CID milrinone_26\NN\0|NONE_0 (r_pobj) of_25\IN\0|the_21|inotropic_17 (r_prep) effect_24\NN\34213|NONE_0 (r_dobj) inhibiting_21\VBG\2510337|NONE_0 (r_pcomp) without_20\IN\0|in_143|doses_45|pressure_9|._52 (r_prep) restored_17\VBD\1631072|NONE_0 (l_prep) in_0\IN\13603305|doses_98|pressure_134|without_143|._195 (l_pobj) patients_1\NNS\9898892|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) failure_5\NN\66216|NONE_0 (l_prep) with_6\IN\0|decompensated_28|heart_14 (l_pobj) hypotension_7\NN\14057371|NONE_0
D014667_D007022 CID vasopressin_0\NN\5407119|NONE_0 (l_prep) in_1\IN\13603305|._73 (l_pobj) treatment_3\NN\654885|NONE_0 (l_prep) of_4\IN\0|the_14 (l_pobj) hypotension_8\NN\14057371|NONE_0
D014667_D007022 CID vasopressin_16\NN\5407119|NONE_0 (r_pobj) of_15\IN\0|low_10 (r_prep) doses_14\NNS\3740161|in_98|pressure_36|without_45|._97 (r_nsubj) restored_17\VBD\1631072|NONE_0 (l_prep) in_0\IN\13603305|doses_98|pressure_134|without_143|._195 (l_pobj) patients_1\NNS\9898892|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) failure_5\NN\66216|NONE_0 (l_prep) with_6\IN\0|decompensated_28|heart_14 (l_pobj) hypotension_7\NN\14057371|NONE_0
343678
D006514_D006509 NONE antigen_43\NN\20090|(_8|hbsag)-positive_9 (r_nmod) donors_46\NNS\9608709|NONE_0 (r_pobj) to_39\IN\0|stick_15 (r_prep) exposure_38\NN\5042871|NONE_0 (r_pobj) after_34\IN\0|hepatitis_10 (r_prep) preventing_30\VBG\0|NONE_0 (r_pcomp) in_29\IN\13603305|their_26|relative_20 (r_prep) efficacies_28\NNS\5199286|to_25 (r_dobj) assess_25\VB\5220461|globulin_101|were_53|in_39|._146 (r_advcl) examined_15\VBN\0|NONE_0 (l_nsubjpass) globulin_3\NN\14736972|were_48|in_62|assess_101|._247 (l_compound) b_1\NN\1355326|immune_2|hbig_19|and_25|globulin_42
D006514_D006509 NONE antigen_43\NN\20090|(_8|hbsag)-positive_9 (r_nmod) donors_46\NNS\9608709|NONE_0 (r_pobj) to_39\IN\0|stick_15 (r_prep) exposure_38\NN\5042871|NONE_0 (r_pobj) after_34\IN\0|hepatitis_10 (r_prep) preventing_30\VBG\0|NONE_0 (l_dobj) hepatitis_33\NN\14127211|after_10
D006514_D006509 NONE hbsag)-positive_45\JJ\0|antigen_9|(_1 (r_compound) donors_46\NNS\9608709|NONE_0 (r_pobj) to_39\IN\0|stick_15 (r_prep) exposure_38\NN\5042871|NONE_0 (r_pobj) after_34\IN\0|hepatitis_10 (r_prep) preventing_30\VBG\0|NONE_0 (r_pcomp) in_29\IN\13603305|their_26|relative_20 (r_prep) efficacies_28\NNS\5199286|to_25 (r_dobj) assess_25\VB\5220461|globulin_101|were_53|in_39|._146 (r_advcl) examined_15\VBN\0|NONE_0 (l_nsubjpass) globulin_3\NN\14736972|were_48|in_62|assess_101|._247 (l_compound) b_1\NN\1355326|immune_2|hbig_19|and_25|globulin_42
D006514_D006509 NONE hbsag)-positive_45\JJ\0|antigen_9|(_1 (r_compound) donors_46\NNS\9608709|NONE_0 (r_pobj) to_39\IN\0|stick_15 (r_prep) exposure_38\NN\5042871|NONE_0 (r_pobj) after_34\IN\0|hepatitis_10 (r_prep) preventing_30\VBG\0|NONE_0 (l_dobj) hepatitis_33\NN\14127211|after_10
430165
D010672_D064420 NONE diphenylhydantoin_7\JJ\3550533|NONE_0 (r_compound) toxicity_8\NN\13576101|NONE_0
D010672_D064420 NONE dph_13\NNP\6702458|NONE_0 (r_compound) toxicity_14\NN\13576101|to_16|as_9
D010672_D002526 CID diphenylhydantoin_6\NN\3550533|(_18|dph_19|)_22 (r_nmod) overdose_10\NN\84738|NONE_0 (r_pobj) of_5\IN\0|the_24|common_20|side_13 (r_prep) effects_4\NNS\13245626|NONE_0 (r_pobj) among_0\IN\0|,_65|signs_112|those_122|._153 (r_prep) are_18\VBP\13600404|NONE_0 (l_nsubj) those_19\DT\0|among_122|,_57|signs_10|._31 (l_prep) of_20\IN\0|NONE_0 (l_pobj) dysfunction_22\NN\14204950|NONE_0
D010672_D002526 CID dph_8\NNP\6702458|diphenylhydantoin_19|(_1|)_3 (r_nmod) overdose_10\NN\84738|NONE_0 (r_pobj) of_5\IN\0|the_24|common_20|side_13 (r_prep) effects_4\NNS\13245626|NONE_0 (r_pobj) among_0\IN\0|,_65|signs_112|those_122|._153 (r_prep) are_18\VBP\13600404|NONE_0 (l_nsubj) those_19\DT\0|among_122|,_57|signs_10|._31 (l_prep) of_20\IN\0|NONE_0 (l_pobj) dysfunction_22\NN\14204950|NONE_0
D010672_D062787 CID diphenylhydantoin_6\NN\3550533|(_18|dph_19|)_22 (r_nmod) overdose_10\NN\84738|NONE_0
D010672_D062787 CID dph_8\NNP\6702458|diphenylhydantoin_19|(_1|)_3 (r_nmod) overdose_10\NN\84738|NONE_0
D010672_D062787 CID dph_10\NNP\6702458|NONE_0 (r_compound) overdose_11\NN\84738|to_7
D010672_D010291 CID diphenylhydantoin_7\JJ\3550533|NONE_0 (r_compound) toxicity_8\NN\13576101|NONE_0 (r_pobj) of_6\IN\0|a_21|rare_19 (r_prep) manifestation_5\NN\7321772|transient_30|:_9|._43 (r_appos) hemiparesis_1\NN\0|NONE_0
D010672_D010291 CID dph_10\NNP\6702458|NONE_0 (r_compound) overdose_11\NN\84738|to_7 (r_pobj) due_8\IN\5174653|who_37|hemiparesis_12 (r_prep) suffered_5\VBD\2110220|patients_27|are_18|._52 (l_dobj) hemiparesis_7\NN\0|who_25|due_12
D010672_D001927 NONE dph_13\NNP\6702458|NONE_0 (r_compound) toxicity_14\NN\13576101|to_16|as_9 (r_dobj) manifest_12\VB\6479665|NONE_0 (r_xcomp) liable_10\JJ\0|that_44|patients_39 (r_acomp) are_9\VBP\13600404|it_54|is_51|._63 (l_nsubj) patients_4\NNS\9898892|that_5|liable_39 (l_prep) with_5\IN\0|NONE_0 (l_pobj) damage_8\NN\7296428|NONE_0
1628552
D002738_D006327 NONE chloroquine_0\NNP\2721948|block_35|:_55 (r_nsubj) related_1\VBD\628491|case_45|._56 (l_dobj) block_4\NN\21939|chloroquine_35|:_20
D002738_D006327 NONE chloroquine_5\NN\2721948|NONE_0 (r_amod) retinopathy_6\NN\14252864|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) features_3\NNS\5849040|assessment_20 (r_dobj) revealed_2\VBD\2137132|,_44|assessment_54|features_74|._165 (r_ccomp) revealed_10\VBD\2137132|NONE_0 (l_dobj) features_11\NNS\5849040|revealed_74|,_30|assessment_20|._91 (l_conj) block_19\NN\21939|of_38|and_21
D002738_D006327 NONE chloroquine_15\NN\2721948|NONE_0 (r_amod) discontinuation_16\NN\209943|NONE_0 (r_dobj) following_14\VBG\8180190|failure_31|spontaneously_14|._37 (r_prep) resolved_12\VBD\352826|block_63|was_57|by_45|and_22 (r_conj) treated_4\VBN\2376958|NONE_0 (l_nsubjpass) block_2\NN\21939|was_6|by_18|and_41|resolved_63
D002738_D015354 NONE chloroquine_9\NN\2721948|regular_8 (r_amod) ingestion_10\NN\13440063|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) history_6\NN\15120823|NONE_0 (r_pobj) with_5\IN\0|a_28|27-year_26|old_18|african_14 (r_prep) woman_4\NN\9605289|with_62|._175 (r_nsubj) presented_11\VBN\2137132|NONE_0 (l_prep) with_12\IN\0|woman_62|._113 (l_pobj) deterioration_14\NN\14560612|NONE_0 (l_prep) of_15\IN\0|progressive_26|,_9|fatiguability_16 (l_pobj) vision_16\NN\5767733|NONE_0
D002738_D013575 CID chloroquine_9\NN\2721948|regular_8 (r_amod) ingestion_10\NN\13440063|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) history_6\NN\15120823|NONE_0 (r_pobj) with_5\IN\0|a_28|27-year_26|old_18|african_14 (r_prep) woman_4\NN\9605289|with_62|._175 (r_nsubj) presented_11\VBN\2137132|NONE_0 (l_prep) with_12\IN\0|woman_62|._113 (l_pobj) deterioration_14\NN\14560612|NONE_0 (l_conj) fatiguability_19\NN\0|progressive_42|of_16|,_7 (l_conj) dyspnoea_21\NN\14299637|easy_20|,_2 (l_conj) dizziness_23\NN\14299637|,_2 (l_acl) progressing_24\VBG\252019|NONE_0 (l_prep) to_25\IN\0|NONE_0 (l_pobj) attacks_27\NNS\955060|NONE_0
D002738_D004417 CID chloroquine_9\NN\2721948|regular_8 (r_amod) ingestion_10\NN\13440063|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) history_6\NN\15120823|NONE_0 (r_pobj) with_5\IN\0|a_28|27-year_26|old_18|african_14 (r_prep) woman_4\NN\9605289|with_62|._175 (r_nsubj) presented_11\VBN\2137132|NONE_0 (l_prep) with_12\IN\0|woman_62|._113 (l_pobj) deterioration_14\NN\14560612|NONE_0 (l_conj) fatiguability_19\NN\0|progressive_42|of_16|,_7 (l_conj) dyspnoea_21\NN\14299637|easy_20|,_2
D002738_D004244 CID chloroquine_9\NN\2721948|regular_8 (r_amod) ingestion_10\NN\13440063|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) history_6\NN\15120823|NONE_0 (r_pobj) with_5\IN\0|a_28|27-year_26|old_18|african_14 (r_prep) woman_4\NN\9605289|with_62|._175 (r_nsubj) presented_11\VBN\2137132|NONE_0 (l_prep) with_12\IN\0|woman_62|._113 (l_pobj) deterioration_14\NN\14560612|NONE_0 (l_conj) fatiguability_19\NN\0|progressive_42|of_16|,_7 (l_conj) dyspnoea_21\NN\14299637|easy_20|,_2 (l_conj) dizziness_23\NN\14299637|,_2
D002738_D005221 CID chloroquine_9\NN\2721948|regular_8 (r_amod) ingestion_10\NN\13440063|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) history_6\NN\15120823|NONE_0 (r_pobj) with_5\IN\0|a_28|27-year_26|old_18|african_14 (r_prep) woman_4\NN\9605289|with_62|._175 (r_nsubj) presented_11\VBN\2137132|NONE_0 (l_prep) with_12\IN\0|woman_62|._113 (l_pobj) deterioration_14\NN\14560612|NONE_0 (l_conj) fatiguability_19\NN\0|progressive_42|of_16|,_7
D002738_D001766 CID chloroquine_0\NNP\2721948|block_35|:_55 (r_nsubj) related_1\VBD\628491|case_45|._56 (l_dobj) block_4\NN\21939|chloroquine_35|:_20 (l_prep) with_5\IN\0|complete_21|heart_12 (l_pobj) blindness_6\NN\14552802|NONE_0
D002738_D006333 CID chloroquine_5\NN\2721948|NONE_0 (r_amod) retinopathy_6\NN\14252864|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) features_3\NNS\5849040|assessment_20 (r_dobj) revealed_2\VBD\2137132|,_44|assessment_54|features_74|._165 (r_ccomp) revealed_10\VBD\2137132|NONE_0 (l_dobj) features_11\NNS\5849040|revealed_74|,_30|assessment_20|._91 (l_prep) of_12\IN\0|and_17|block_38 (l_pobj) failure_14\NN\66216|NONE_0
D002738_D006333 CID chloroquine_15\NN\2721948|NONE_0 (r_amod) discontinuation_16\NN\209943|NONE_0 (r_dobj) following_14\VBG\8180190|failure_31|spontaneously_14|._37 (r_prep) resolved_12\VBD\352826|block_63|was_57|by_45|and_22 (l_nsubj) failure_11\NN\66216|spontaneously_17|following_31|._68
D002738_D002037 CID chloroquine_5\NN\2721948|NONE_0 (r_amod) retinopathy_6\NN\14252864|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) features_3\NNS\5849040|assessment_20 (r_dobj) revealed_2\VBD\2137132|,_44|assessment_54|features_74|._165 (r_ccomp) revealed_10\VBD\2137132|NONE_0 (l_dobj) features_11\NNS\5849040|revealed_74|,_30|assessment_20|._91 (l_conj) block_19\NN\21939|of_38|and_21 (l_prep) with_20\IN\0|a_23|complete_21|heart_12 (l_pobj) pattern_25\NN\5726345|NONE_0 (l_compound) block_24\NN\21939|right_20|bundle_14
D002738_D012164 CID chloroquine_5\NN\2721948|NONE_0 (r_amod) retinopathy_6\NN\14252864|NONE_0
1445986
D015313_D000743 CID cefotetan_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|immune_8|hemolytic_15|._31 (r_amod) anemia_5\NN\14189204|NONE_0
D010406_D000743 NONE penicillins_17\NNS\2716866|NONE_0 (r_dobj) receiving_16\VBG\2210855|NONE_0 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) in_14\IN\13603305|anemia_71|has_29|been_25|primarily_10|._69 (r_prep) described_12\VBN\1001294|NONE_0 (l_nsubjpass) anemia_2\NN\14189204|has_42|been_46|primarily_61|in_71|._140
D002511_D000743 NONE cephalosporins_22\NNS\2716866|and_21 (r_conj) penicillins_17\NNS\2716866|NONE_0 (r_dobj) receiving_16\VBG\2210855|NONE_0 (r_acl) patients_15\NNS\9898892|NONE_0 (r_pobj) in_14\IN\13603305|anemia_71|has_29|been_25|primarily_10|._69 (r_prep) described_12\VBN\1001294|NONE_0 (l_nsubjpass) anemia_2\NN\14189204|has_42|been_46|primarily_61|in_71|._140
D015313_D000740 NONE cefotetan_10\NN\0|while_28 (r_dobj) receiving_8\VBG\2210855|who_27|anemia_13 (r_advcl) developed_5\VBD\1753788|a_14 (l_dobj) anemia_6\NN\14189204|who_14|receiving_13
20042557
D015742_D011183 CID propofol_4\NN\0|light_6 (r_amod) sedation_5\NN\14034177|NONE_0 (r_pobj) of_2\IN\0|the_8 (r_prep) use_1\NN\407535|prevalence_45|._116 (r_nsubj) decreased_6\VBD\169651|NONE_0 (l_dobj) prevalence_8\NN\4764412|use_45|._71 (l_prep) of_9\IN\0|the_15|by_26|compared_33 (l_pobj) delirium_11\NN\14391660|NONE_0
D015742_D003704 NONE propofol_39\NN\0|NONE_0 (r_amod) sedation_40\NN\14034177|NONE_0 (r_pobj) with_38\IN\0|spinal_18 (r_prep) anesthesia_37\NN\14034177|NONE_0 (r_pobj) under_35\IN\0|fracture_16 (r_prep) repair_34\NN\248977|who_27 (r_dobj) underwent_31\VBD\109660|preoperative_45|or_23|dementia_13 (r_relcl) delirium_26\NN\14391660|NONE_0 (l_conj) dementia_29\NN\14395018|preoperative_32|or_10|underwent_13
D015742_D006620 NONE propofol_39\NN\0|NONE_0 (r_amod) sedation_40\NN\14034177|NONE_0 (r_pobj) with_38\IN\0|spinal_18 (r_prep) anesthesia_37\NN\14034177|NONE_0 (r_pobj) under_35\IN\0|fracture_16 (r_prep) repair_34\NN\248977|who_27 (l_compound) fracture_33\NN\14285662|under_16
D015742_D003693 CID propofol_39\NN\0|NONE_0 (r_amod) sedation_40\NN\14034177|NONE_0 (r_pobj) with_38\IN\0|spinal_18 (r_prep) anesthesia_37\NN\14034177|NONE_0 (r_pobj) under_35\IN\0|fracture_16 (r_prep) repair_34\NN\248977|who_27 (r_dobj) underwent_31\VBD\109660|preoperative_45|or_23|dementia_13 (r_relcl) delirium_26\NN\14391660|NONE_0
D015742_D003693 CID propofol_4\NN\0|light_6 (r_amod) sedation_5\NN\14034177|NONE_0 (r_pobj) of_2\IN\0|the_8 (r_prep) use_1\NN\407535|prevalence_45|._116 (r_nsubj) decreased_6\VBD\169651|NONE_0 (l_dobj) prevalence_8\NN\4764412|use_45|._71 (l_prep) of_9\IN\0|the_15|by_26|compared_33 (l_pobj) delirium_11\NN\14391660|NONE_0
10840460
D009020_D001523 NONE morphine_0\NNP\2707683|dependently_14|disorders_52|._61 (r_nsubj) reversed_4\VBD\109660|NONE_0 (l_dobj) disorders_7\NNS\14034177|morphine_52|dependently_38|._9
D009020_D004487 NONE morphine_6\NN\2707683|NONE_0 (r_pobj) of_5\IN\0|,_11|modifications_26 (r_prep) administration_4\NN\1133281|NONE_0 (l_appos) modifications_9\NNS\191142|of_26|,_15 (l_prep) as_16\IN\14622893|histological_53|of_26|,_7 (l_pobj) edema_21\NN\14315192|such_35
D003520_D059265 NONE cyclophosphamide_0\NNP\0|-_16 (r_npadvmod) induced_2\VBN\1627355|in_17|:_48|approach_61|._101 (r_amod) cystitis_3\NN\14566129|NONE_0 (l_appos) approach_12\NN\940842|induced_61|in_44|:_13|._40 (l_prep) to_13\IN\0|behavioral_20 (l_pobj) model_16\NN\5888929|NONE_0 (l_prep) of_17\IN\0|a_12|new_10 (l_pobj) pain_19\NN\14299637|NONE_0
D003520_D059265 NONE cp_10\NNP\0|-_2 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) cystitis_13\NN\14566129|NONE_0 (r_pobj) of_9\IN\0|this_24|experimental_19 (r_prep) model_8\NN\5888929|that_23|may_29|model_66|,_101|allowing_103 (r_nsubj) be_15\VB\14625458|overall_88|,_81|results_73|._175 (l_attr) model_20\NN\5888929|that_89|model_66|may_37|,_35|allowing_37 (l_prep) of_21\IN\0|an_36|interesting_33|new_21|behavioral_17 (l_pobj) pain_24\NN\14299637|NONE_0
D003520_D010146 CID cp_10\NNP\0|-_2 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) cystitis_13\NN\14566129|NONE_0 (r_pobj) of_9\IN\0|this_24|experimental_19 (r_prep) model_8\NN\5888929|that_23|may_29|model_66|,_101|allowing_103 (r_nsubj) be_15\VB\14625458|overall_88|,_81|results_73|._175 (l_advcl) allowing_26\VBG\0|that_126|model_103|may_74|model_37|,_2 (l_dobj) understanding_29\NN\5804793|NONE_0 (l_prep) of_30\IN\0|a_23|better_21|and_27|approach_57 (l_pobj) syndromes_33\NNS\5870365|NONE_0
D000171_D003556 NONE acrolein_22\NN\14584765|NONE_0 (r_pobj) through_17\IN\0|to_45|effects_28 (r_prep) produce_10\VB\7555863|NONE_0 (r_xcomp) known_8\VBN\0|an_21|antitumoral_18 (r_acl) agent_7\NN\7347|cp_20|,_17|,_99 (r_appos) cyclophosphamide_0\NNP\0|was_139|induce_151|._166 (r_nsubjpass) used_25\VBN\0|NONE_0 (l_xcomp) induce_27\VB\1627355|cyclophosphamide_151|was_12|._15 (l_dobj) cystitis_28\NN\14566129|to_10
D003520_D003556 CID cyclophosphamide_0\NNP\0|-_16 (r_npadvmod) induced_2\VBN\1627355|in_17|:_48|approach_61|._101 (r_amod) cystitis_3\NN\14566129|NONE_0
D003520_D003556 CID cyclophosphamide_0\NNP\0|was_139|induce_151|._166 (r_nsubjpass) used_25\VBN\0|NONE_0 (l_xcomp) induce_27\VB\1627355|cyclophosphamide_151|was_12|._15 (l_dobj) cystitis_28\NN\14566129|to_10
D003520_D003556 CID cp_2\NNP\0|,_3|agent_20|,_119 (r_appos) cyclophosphamide_0\NNP\0|was_139|induce_151|._166 (r_nsubjpass) used_25\VBN\0|NONE_0 (l_xcomp) induce_27\VB\1627355|cyclophosphamide_151|was_12|._15 (l_dobj) cystitis_28\NN\14566129|to_10
D003520_D003556 CID cp_10\NNP\0|-_2 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) cystitis_13\NN\14566129|NONE_0
11860278
D004298_D004827 NONE dopamine_0\NNP\14807737|,_56|role_72|in_77|._142 (r_nsubj) plays_12\VBZ\7007684|NONE_0 (l_prep) in_16\IN\13603305|dopamine_77|,_21|role_5|._65 (l_pobj) control_18\NN\5190804|NONE_0 (l_prep) of_19\IN\0|the_12 (l_pobj) seizures_21\NNS\14081375|NONE_0
D004298_D004827 NONE da_2\NNP\10484858|,_3|through_5 (r_appos) dopamine_0\NNP\14807737|,_56|role_72|in_77|._142 (r_nsubj) plays_12\VBZ\7007684|NONE_0 (l_prep) in_16\IN\13603305|dopamine_77|,_21|role_5|._65 (l_pobj) control_18\NN\5190804|NONE_0 (l_prep) of_19\IN\0|the_12 (l_pobj) seizures_21\NNS\14081375|NONE_0
D004298_D004827 NONE da_11\NNP\10484858|NONE_0 (r_compound) receptors_12\NNS\5225602|NONE_0 (r_pobj) of_10\IN\0|the_9|in_16 (r_prep) role_9\NN\719494|NONE_0 (l_prep) in_13\IN\13603305|the_25|of_16 (l_pobj) occurrence_15\NN\29378|NONE_0 (l_prep) of_16\IN\0|the_15 (l_pobj) death_22\NN\7296428|NONE_0 (l_amod) induced_19\VBN\1627355|neuronal_8|cell_17 (l_npadvmod) epilepsy_17\NN\14085708|-_8
D000109_D012640 NONE acetylcholine_16\NN\14807558|both_19|and_4 (r_conj) glutamate_14\NN\15010703|NONE_0 (r_pobj) by_12\IN\0|NONE_0 (r_agent) induced_11\VBN\1627355|NONE_0 (r_acl) seizures_10\NNS\14081375|NONE_0
D010862_D020258 NONE pilocarpine_18\NN\14712692|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|d2r_13|-/-_9 (r_acl) mice_12\NNS\2329401|NONE_0 (r_pobj) in_9\IN\13603305|and_18|neurotoxicity_14 (r_prep) seizures_6\NNS\14081375|NONE_0 (l_conj) neurotoxicity_8\NN\0|and_4|in_14
D010862_D012640 CID pilocarpine_18\NN\14712692|NONE_0 (r_pobj) with_14\IN\0|NONE_0 (r_prep) treated_13\VBN\2376958|d2r_13|-/-_9 (r_acl) mice_12\NNS\2329401|NONE_0 (r_pobj) in_9\IN\13603305|and_18|neurotoxicity_14 (r_prep) seizures_6\NNS\14081375|NONE_0
D010862_D012640 CID pilocarpine_2\NN\14712692|-_11 (r_npadvmod) induced_4\VBN\1627355|NONE_0 (r_amod) seizures_5\NNS\14081375|however_29|,_22|in_16|._101
D018698_D012640 NONE glutamate_14\NN\15010703|NONE_0 (r_pobj) by_12\IN\0|NONE_0 (r_agent) induced_11\VBN\1627355|NONE_0 (r_acl) seizures_10\NNS\14081375|NONE_0
D007608_D012640 CID ka_23\NNP\0|NONE_0 (r_pobj) to_22\IN\0|NONE_0 (r_prep) comparison_21\NN\635850|NONE_0 (r_pobj) in_20\IN\13603305|a_63|widespread_56|neuronal_45|in_30 (r_prep) death_12\NN\7296428|NONE_0 (r_pobj) in_7\IN\13603305|however_45|,_38|seizures_16|._85 (r_prep) result_6\VBP\34213|NONE_0 (l_nsubj) seizures_5\NNS\14081375|however_29|,_22|in_16|._101
2819587
11302406
D015725_D017180 NONE fluconazole_4\NN\0|when_5|was_12 (r_nsubjpass) discontinued_6\VBN\0|tdp_34 (r_advcl) resolved_2\VBD\352826|;_42|however_44|,_51|patient_57|have_78|and_118|tachycardia_147|until_166|:_212 (r_ccomp) continued_12\VBD\2367363|NONE_0 (l_conj) tachycardia_21\NN\14110674|resolved_147|;_105|however_103|,_96|patient_90|have_69|and_29|until_19|:_65
D015725_D017180 NONE fluconazole_4\NN\0|when_5|was_12 (r_nsubjpass) discontinued_6\VBN\0|tdp_34 (r_advcl) resolved_2\VBD\352826|;_42|however_44|,_51|patient_57|have_78|and_118|tachycardia_147|until_166|:_212 (r_ccomp) continued_12\VBD\2367363|NONE_0 (l_conj) tachycardia_21\NN\14110674|resolved_147|;_105|however_103|,_96|patient_90|have_69|and_29|until_19|:_65 (l_appos) nsvt_23\NNP\0|nonsustained_38|ventricular_25|(_1|)_4
D015725_D017180 NONE fluconazole_22\NN\0|followed_86|strongly_18|as_12|._27 (r_dobj) suggests_21\VBZ\1010118|NONE_0 (l_csubj) followed_9\VBN\1835496|strongly_68|fluconazole_86|as_98|._113 (l_nsubj) disappearance_2\NN\42757|by_70|stopped_121 (l_prep) of_3\IN\0|the_27|complete_23|and_8|contractions_34 (l_pobj) nsvt_4\NNP\0|NONE_0
D011188_D003866 NONE potassium_10\NN\14625458|rectifier_10 (r_compound) currents_11\NNS\11449002|rapidly_47 (r_dobj) activating_7\VBG\407535|NONE_0 (r_pcomp) of_5\IN\0|NONE_0 (r_prep) depression_4\NN\14373582|mechanism_13|._69
D015725_D016171 CID fluconazole_0\NNP\0|-_11 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) torsade_3\NN\0|de_8|._18 (r_nmod) pointes_5\FW\831651|NONE_0
D015725_D016171 CID fluconazole_5\NN\0|-_11 (r_advmod) associated_7\VBN\628491|torsade_11|de_19|(_30|tdp_31|)_34 (r_amod) pointes_10\FW\831651|NONE_0
D015725_D016171 CID fluconazole_5\NN\0|-_11 (r_advmod) associated_7\VBN\628491|torsade_11|de_19|(_30|tdp_31|)_34 (r_amod) pointes_10\FW\831651|NONE_0 (l_appos) tdp_12\NNP\0|associated_31|torsade_20|de_12|(_1|)_3
D015725_D016171 CID fluconazole_5\NN\0|-_11 (r_advmod) associated_7\VBN\628491|torsade_11|de_19|(_30|tdp_31|)_34 (r_amod) pointes_10\FW\831651|NONE_0 (r_pobj) of_4\IN\0|a_7 (r_prep) case_3\NN\7283608|to_13|and_56|discuss_60|._101 (r_dobj) present_1\VB\28270|NONE_0 (l_conj) discuss_15\VB\7466557|to_73|case_60|and_4|._41 (l_dobj) role_18\NN\719494|NONE_0 (l_prep) in_19\IN\13603305|fluconazole_19 (l_pcomp) causing_20\VBG\30358|NONE_0 (l_dobj) tdp_21\NNP\0|NONE_0
D015725_D016171 CID fluconazole_16\NN\0|in_19 (r_poss) role_18\NN\719494|NONE_0 (r_dobj) discuss_15\VB\7466557|to_73|case_60|and_4|._41 (r_conj) present_1\VB\28270|NONE_0 (l_dobj) case_3\NN\7283608|to_13|and_56|discuss_60|._101 (l_prep) of_4\IN\0|a_7 (l_pobj) pointes_10\FW\831651|NONE_0
D015725_D016171 CID fluconazole_16\NN\0|in_19 (r_poss) role_18\NN\719494|NONE_0 (r_dobj) discuss_15\VB\7466557|to_73|case_60|and_4|._41 (r_conj) present_1\VB\28270|NONE_0 (l_dobj) case_3\NN\7283608|to_13|and_56|discuss_60|._101 (l_prep) of_4\IN\0|a_7 (l_pobj) pointes_10\FW\831651|NONE_0 (l_appos) tdp_12\NNP\0|associated_31|torsade_20|de_12|(_1|)_3
D015725_D016171 CID fluconazole_16\NN\0|in_19 (r_poss) role_18\NN\719494|NONE_0 (l_prep) in_19\IN\13603305|fluconazole_19 (l_pcomp) causing_20\VBG\30358|NONE_0 (l_dobj) tdp_21\NNP\0|NONE_0
D015725_D016171 CID fluconazole_21\NN\0|NONE_0 (r_dobj) commencing_19\VBG\0|days_11 (r_pcomp) after_18\IN\0|woman_87|isolated_59 (r_prep) glabrata_8\NNS\0|NONE_0 (l_xcomp) isolated_9\VBN\2512305|woman_28|after_59 (l_prep) from_10\IN\0|NONE_0 (l_pobj) abscess_13\NN\14299637|NONE_0 (l_acl) developed_14\VBD\1753788|a_20|presacral_18 (l_dobj) tdp_15\NNP\0|NONE_0
D015725_D016171 CID fluconazole_33\NN\0|NONE_0 (r_pobj) of_32\IN\0|the_15 (r_prep) initiation_31\NN\7450842|NONE_0 (r_pobj) between_29\IN\0|a_23|temporal_21 (r_prep) association_28\NN\8008335|there_21 (r_attr) was_25\VBD\0|no_144|other_141|risk_135|for_122|,_115|including_113 (r_relcl) factors_6\NNS\7326557|patient_26|._202 (l_prep) for_7\IN\0|no_22|other_19|risk_13|,_7|including_9|was_122 (l_pobj) tdp_8\NNP\0|NONE_0
D015725_D016171 CID fluconazole_33\NN\0|NONE_0 (l_conj) tdp_35\NNP\0|and_4
D015725_D016171 CID fluconazole_4\NN\0|when_5|was_12 (r_nsubjpass) discontinued_6\VBN\0|tdp_34 (r_advcl) resolved_2\VBD\352826|;_42|however_44|,_51|patient_57|have_78|and_118|tachycardia_147|until_166|:_212 (l_nsubj) tdp_1\NNP\0|discontinued_34
D015725_D016171 CID fluconazole_14\NN\0|NONE_0 (r_pobj) of_13\IN\0|the_8|and_15|development_23 (r_prep) use_12\NN\407535|NONE_0 (l_conj) development_17\NN\248977|the_31|of_23|and_8 (l_prep) of_18\IN\0|the_16 (l_pobj) tdp_19\NNP\0|NONE_0
D015725_D016171 CID fluconazole_5\NN\0|,_11 (r_ccomp) aware_3\JJ\0|clinicians_21|should_10|at_29|,_41|cause_47|._100 (r_acomp) be_2\VB\14625458|NONE_0 (l_conj) cause_13\VB\7323922|clinicians_68|should_57|aware_47|at_18|,_6|._53 (l_advcl) leading_20\VBG\4339291|may_43|prolongation_33|,_2 (l_prep) to_21\IN\0|NONE_0 (l_pobj) tdp_22\NNP\0|NONE_0
D015725_D009202 NONE fluconazole_33\NN\0|NONE_0 (r_pobj) of_32\IN\0|the_15 (r_prep) initiation_31\NN\7450842|NONE_0 (r_pobj) between_29\IN\0|a_23|temporal_21 (r_prep) association_28\NN\8008335|there_21 (r_attr) was_25\VBD\0|no_144|other_141|risk_135|for_122|,_115|including_113 (r_relcl) factors_6\NNS\7326557|patient_26|._202 (l_prep) including_10\VBG\0|no_31|other_28|risk_22|for_9|,_2|was_113 (l_pobj) disease_13\NN\14061805|NONE_0 (l_amod) cardiomyopathy_15\NN\14103288|coronary_25|artery_16|,_2
D015725_D006333 NONE fluconazole_33\NN\0|NONE_0 (r_pobj) of_32\IN\0|the_15 (r_prep) initiation_31\NN\7450842|NONE_0 (r_pobj) between_29\IN\0|a_23|temporal_21 (r_prep) association_28\NN\8008335|there_21 (r_attr) was_25\VBD\0|no_144|other_141|risk_135|for_122|,_115|including_113 (r_relcl) factors_6\NNS\7326557|patient_26|._202 (l_prep) including_10\VBG\0|no_31|other_28|risk_22|for_9|,_2|was_113 (l_pobj) disease_13\NN\14061805|NONE_0 (l_amod) cardiomyopathy_15\NN\14103288|coronary_25|artery_16|,_2 (l_conj) failure_19\NN\66216|,_19
D015725_D008133 NONE fluconazole_5\NN\0|,_11 (r_ccomp) aware_3\JJ\0|clinicians_21|should_10|at_29|,_41|cause_47|._100 (r_acomp) be_2\VB\14625458|NONE_0 (l_conj) cause_13\VB\7323922|clinicians_68|should_57|aware_47|at_18|,_6|._53 (l_dobj) prolongation_14\NN\1017987|may_10|,_31|leading_33 (l_prep) of_15\IN\0|NONE_0 (l_pobj) interval_18\NN\33615|NONE_0
D015725_D003324 NONE fluconazole_33\NN\0|NONE_0 (r_pobj) of_32\IN\0|the_15 (r_prep) initiation_31\NN\7450842|NONE_0 (r_pobj) between_29\IN\0|a_23|temporal_21 (r_prep) association_28\NN\8008335|there_21 (r_attr) was_25\VBD\0|no_144|other_141|risk_135|for_122|,_115|including_113 (r_relcl) factors_6\NNS\7326557|patient_26|._202 (l_prep) including_10\VBG\0|no_31|other_28|risk_22|for_9|,_2|was_113 (l_pobj) disease_13\NN\14061805|NONE_0
D015725_D018879 NONE fluconazole_4\NN\0|when_5|was_12 (r_nsubjpass) discontinued_6\VBN\0|tdp_34 (r_advcl) resolved_2\VBD\352826|;_42|however_44|,_51|patient_57|have_78|and_118|tachycardia_147|until_166|:_212 (r_ccomp) continued_12\VBD\2367363|NONE_0 (l_xcomp) have_14\VB\7846|resolved_78|;_36|however_34|,_27|patient_21|and_40|tachycardia_69|until_88|:_134 (l_dobj) contractions_17\NNS\358931|to_30
D015725_D018879 NONE fluconazole_22\NN\0|followed_86|strongly_18|as_12|._27 (r_dobj) suggests_21\VBZ\1010118|NONE_0 (l_csubj) followed_9\VBN\1835496|strongly_68|fluconazole_86|as_98|._113 (l_nsubj) disappearance_2\NN\42757|by_70|stopped_121 (l_conj) contractions_8\NNS\358931|the_61|complete_57|of_34|and_26
D015725_D001145 NONE fluconazole_7\NN\0|when_5|is_12|in_28 (r_nsubjpass) administered_9\VBN\2436349|monitoring_49|may_38|be_34|._68 (l_prep) in_10\IN\13603305|when_33|fluconazole_28|is_16 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_relcl) are_13\VBP\13600404|NONE_0 (l_prep) at_14\IN\14622893|who_8 (l_pobj) risk_15\NN\14541044|NONE_0 (l_prep) for_16\IN\0|NONE_0 (l_pobj) arrhythmias_18\NNS\14103288|NONE_0
11271907
D003520_D009205 CID cyclophosphamide_5\NN\0|NONE_0 (r_compound) therapy_6\NN\657604|NONE_0 (r_pobj) to_4\IN\0|haemorrhagic_35|myocarditis_22 (r_prep) secondary_3\JJ\8426461|._37 (l_amod) myocarditis_2\NN\14338942|haemorrhagic_13|to_22
D003520_D009205 CID cyclophosphamide_9\NN\0|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) of_8\IN\0|a_34|rare_32 (r_prep) complication_7\NN\1073995|myocarditis_36|._40 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) myocarditis_1\NN\14338942|complication_36|._76
D003520_D006470 CID cyclophosphamide_5\NN\0|NONE_0 (r_compound) therapy_6\NN\657604|NONE_0 (r_pobj) to_4\IN\0|haemorrhagic_35|myocarditis_22 (r_prep) secondary_3\JJ\8426461|._37 (l_amod) myocarditis_2\NN\14338942|haemorrhagic_13|to_22
D003520_D006470 CID cyclophosphamide_9\NN\0|NONE_0 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) of_8\IN\0|a_34|rare_32 (r_prep) complication_7\NN\1073995|myocarditis_36|._40 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) myocarditis_1\NN\14338942|complication_36|._76
20304337
D003042_-1 NONE cocaine_8\NN\3492717|NONE_0 (r_pobj) to_7\IN\0|dysgenesis_43|prenatally_19|._10 (r_prep) exposed_6\VBN\2110927|NONE_0 (l_nsubj) dysgenesis_1\NN\14045507|prenatally_24|to_43|._53
1255900
D006493_D013924 NONE heparin_8\JJ\2718259|NONE_0 (r_compound) therapy_9\NN\657604|NONE_0 (r_pobj) of_7\IN\0|the_15|for_19 (r_prep) initiation_6\NN\7450842|NONE_0 (l_prep) for_10\IN\0|the_34|of_19 (l_pobj) thrombophlebitis_13\NN\14352890|NONE_0
18405372
D012460_D001168 NONE sulfasalazine_3\NN\0|NONE_0 (l_prep) in_4\IN\13603305|NONE_0 (l_pobj) arthritis_6\NN\14171682|NONE_0
D012460_D056486 CID sulfasalazine_3\NN\0|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|:_55 (r_acl) hepatotoxicity_0\NN\0|NONE_0
D012460_D056486 CID sulfasalazine_7\NN\0|NONE_0 (r_pobj) on_6\IN\0|who_23|hepatotoxicity_15|and_17|met_21 (r_prep) had_4\VBD\0|'_7|,_6|,_73 (l_dobj) hepatotoxicity_5\NN\0|who_8|on_15|and_32|met_36
D012460_D056486 CID sulfasalazine_6\NN\0|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) hepatotoxicity_4\NN\0|NONE_0
D012460_D056486 CID sulfasalazine_7\NN\0|NONE_0 (r_pobj) with_6\IN\0|serious_23 (r_prep) hepatotoxicity_5\NN\0|NONE_0
D012460_D056486 CID sulfasalazine_4\NN\0|NONE_0 (r_pobj) with_3\IN\0|NONE_0 (r_prep) associated_2\VBN\628491|serious_23 (r_acl) hepatotoxicity_1\NN\0|be_56|is_150|._173
7565311
D016190_D018233 NONE carboplatin_15\NN\0|NONE_0 (r_pobj) with_11\IN\0|who_16|was_12|for_27 (r_prep) treated_10\VBN\2376958|a_30|4_28|old_17 (l_prep) for_16\IN\0|who_43|was_39|with_27 (l_pobj) rhabdomyosarcoma_20\NN\14246359|NONE_0
D016190_D058186 CID carboplatin_6\NN\0|high_10|dose_5 (r_compound) chemotherapy_7\NN\661091|NONE_0 (r_pobj) in_3\IN\13603305|acute_20|renal_14|._37 (r_prep) failure_2\NN\66216|NONE_0
D016190_D058186 CID carboplatin_0\NNP\0|has_12|been_16|cause_33|._108 (r_nsubjpass) reported_3\VBN\831651|NONE_0 (l_xcomp) cause_5\VB\7323922|carboplatin_33|has_21|been_17|._75 (l_dobj) failure_8\NN\66216|to_21|administered_13
6695415
D010665_D002543 CID phenylpropanolamine_4\NN\2682038|NONE_0 (r_pobj) with_3\IN\0|in_25 (r_prep) associated_2\VBN\628491|cerebral_20|._64 (r_acl) hemorrhage_1\NN\14285662|NONE_0
D010665_D002543 CID ppa_4\NNP\0|/_3 (r_nmod) caffeine_6\NN\14712692|that_9|can_9|to_18|administered_81 (r_nsubj) lead_8\VB\5155821|results_38|._115 (l_prep) to_9\IN\0|that_27|caffeine_18|can_9|administered_63 (l_pobj) hemorrhage_11\NN\14285662|NONE_0
D002110_D006973 CID caffeine_7\NN\14712692|if_7|can_9|to_18|in_28 (r_nsubj) lead_9\VB\5155821|to_33 (l_prep) in_12\IN\13603305|if_35|caffeine_28|can_19|to_10 (l_pobj) rats_16\NNS\2329401|NONE_0 (l_amod) normotensive_13\NN\0|NONE_0 (l_conj) hypertensive_15\JJ\10405694|and/or_7
D002110_D006973 CID caffeine_4\NN\14712692|a_13|single_11|(_24|dose_30|)_34 (r_compound) administration_5\NN\1133281|to_32|._103 (r_nsubj) lead_10\NN\5155821|NONE_0 (l_prep) to_11\IN\0|administration_32|._71 (l_pobj) hypertension_13\NN\14057371|NONE_0
D002110_D006973 CID caffeine_4\NN\14712692|a_13|single_11|(_24|dose_30|)_34 (r_compound) administration_5\NN\1133281|to_32|._103 (r_nsubj) lead_10\NN\5155821|NONE_0 (l_prep) to_11\IN\0|administration_32|._71 (l_pobj) hypertension_13\NN\14057371|NONE_0 (l_prep) in_14\IN\13603305|acute_19 (l_pobj) animals_20\NNS\4475|NONE_0 (l_amod) normotensive_17\NN\0|both_9|the_4 (l_conj) hypertensive_19\JJ\10405694|and_4
D002110_D006973 CID caffeine_6\NN\14712692|that_9|can_9|to_18|administered_81 (r_nsubj) lead_8\VB\5155821|results_38|._115 (l_prep) to_9\IN\0|that_27|caffeine_18|can_9|administered_63 (l_pobj) hemorrhage_11\NN\14285662|NONE_0 (l_prep) in_12\IN\13603305|cerebral_20 (l_pobj) animals_15\NNS\4475|NONE_0 (l_amod) hypertensive_14\JJ\10405694|NONE_0
D002110_D002543 CID caffeine_8\NN\14712692|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) combination_6\NN\7951464|NONE_0 (r_pobj) in_5\IN\13603305|with_25 (r_prep) associated_2\VBN\628491|cerebral_20|._64 (r_acl) hemorrhage_1\NN\14285662|NONE_0
D002110_D002543 CID caffeine_6\NN\14712692|that_9|can_9|to_18|administered_81 (r_nsubj) lead_8\VB\5155821|results_38|._115 (l_prep) to_9\IN\0|that_27|caffeine_18|can_9|administered_63 (l_pobj) hemorrhage_11\NN\14285662|NONE_0
D010665_D006973 CID ppa_5\NNP\0|/_3 (r_nmod) caffeine_7\NN\14712692|if_7|can_9|to_18|in_28 (r_nsubj) lead_9\VB\5155821|to_33 (l_prep) in_12\IN\13603305|if_35|caffeine_28|can_19|to_10 (l_pobj) rats_16\NNS\2329401|NONE_0 (l_amod) normotensive_13\NN\0|NONE_0 (l_conj) hypertensive_15\JJ\10405694|and/or_7
D010665_D006973 CID ppa_2\NNP\0|/_3 (r_nmod) caffeine_4\NN\14712692|a_13|single_11|(_24|dose_30|)_34 (r_compound) administration_5\NN\1133281|to_32|._103 (r_nsubj) lead_10\NN\5155821|NONE_0 (l_prep) to_11\IN\0|administration_32|._71 (l_pobj) hypertension_13\NN\14057371|NONE_0
D010665_D006973 CID ppa_2\NNP\0|/_3 (r_nmod) caffeine_4\NN\14712692|a_13|single_11|(_24|dose_30|)_34 (r_compound) administration_5\NN\1133281|to_32|._103 (r_nsubj) lead_10\NN\5155821|NONE_0 (l_prep) to_11\IN\0|administration_32|._71 (l_pobj) hypertension_13\NN\14057371|NONE_0 (l_prep) in_14\IN\13603305|acute_19 (l_pobj) animals_20\NNS\4475|NONE_0 (l_amod) normotensive_17\NN\0|both_9|the_4 (l_conj) hypertensive_19\JJ\10405694|and_4
D010665_D006973 CID ppa_4\NNP\0|/_3 (r_nmod) caffeine_6\NN\14712692|that_9|can_9|to_18|administered_81 (r_nsubj) lead_8\VB\5155821|results_38|._115 (l_prep) to_9\IN\0|that_27|caffeine_18|can_9|administered_63 (l_pobj) hemorrhage_11\NN\14285662|NONE_0 (l_prep) in_12\IN\13603305|cerebral_20 (l_pobj) animals_15\NNS\4475|NONE_0 (l_amod) hypertensive_14\JJ\10405694|NONE_0
D002110_D020521 NONE caffeine_7\NN\14712692|if_7|can_9|to_18|in_28 (r_nsubj) lead_9\VB\5155821|to_33 (l_prep) to_10\IN\0|if_25|caffeine_18|can_9|in_10 (l_pobj) stroke_11\NN\556313|NONE_0
D010665_D020521 CID phenylpropanolamine_0\NNP\2682038|drug_31|._103 (r_nsubj) is_4\VBZ\0|NONE_0 (l_attr) drug_6\NN\14778436|phenylpropanolamine_31|._72 (l_relcl) associated_10\VBN\628491|a_21 (l_prep) with_11\IN\0|that_25|has_20|been_16 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_prep) including_15\VBG\0|serious_21|side_13 (l_pobj) stroke_16\NN\556313|NONE_0
D010665_D020521 CID ppa_2\NNP\0|(_1|)_3 (r_appos) phenylpropanolamine_0\NNP\2682038|drug_31|._103 (r_nsubj) is_4\VBZ\0|NONE_0 (l_attr) drug_6\NN\14778436|phenylpropanolamine_31|._72 (l_relcl) associated_10\VBN\628491|a_21 (l_prep) with_11\IN\0|that_25|has_20|been_16 (l_pobj) effects_14\NNS\13245626|NONE_0 (l_prep) including_15\VBG\0|serious_21|side_13 (l_pobj) stroke_16\NN\556313|NONE_0
D010665_D020521 CID ppa_5\NNP\0|/_3 (r_nmod) caffeine_7\NN\14712692|if_7|can_9|to_18|in_28 (r_nsubj) lead_9\VB\5155821|to_33 (l_prep) to_10\IN\0|if_25|caffeine_18|can_9|in_10 (l_pobj) stroke_11\NN\556313|NONE_0
7596955
D000242_D001791 NONE camp_19\NNS\3763727|NONE_0 (r_pobj) of_17\IN\0|NONE_0 (r_prep) determination_16\NN\43195|ex_33|platelet_25|and_4 (r_conj) aggregation_14\NN\31264|NONE_0
C045645_D005483 CID clz_25\NNP\0|NONE_0 (r_pobj) of_24\IN\0|NONE_0 (r_prep) ingestion_23\NN\13440063|especially_17 (r_pobj) after_22\IN\0|flush_43|in_19|,_13 (r_prep) accompanying_11\VBG\0|a_17|short_15 (l_dobj) flush_13\NN\15113229|in_24|,_30|after_43
C045645_D006261 CID clz_25\NNP\0|NONE_0 (r_pobj) of_24\IN\0|NONE_0 (r_prep) ingestion_23\NN\13440063|especially_17 (r_pobj) after_22\IN\0|flush_43|in_19|,_13 (r_prep) accompanying_11\VBG\0|a_17|short_15 (r_acl) duration_10\NN\15113229|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) headache_6\NN\5829480|subjects_21|._114
C045645_D009325 CID clz_25\NNP\0|NONE_0 (r_pobj) of_24\IN\0|NONE_0 (r_prep) ingestion_23\NN\13440063|especially_17 (r_pobj) after_22\IN\0|flush_43|in_19|,_13 (r_prep) accompanying_11\VBG\0|a_17|short_15 (l_dobj) flush_13\NN\15113229|in_24|,_30|after_43 (l_prep) in_14\IN\13603305|facial_13 (l_pobj) one_15\CD\13741022|NONE_0 (l_conj) nausea_17\NN\14299637|and_4
20510337
C024989_D058186 NONE q10_5\NNP\0|NONE_0 (r_pobj) of_3\IN\0|the_28|nephroprotective_24 (r_prep) effect_2\NN\34213|was_23|in_40|induced_72|._129 (r_nsubjpass) investigated_7\VBN\644583|NONE_0 (l_prep) in_8\IN\13603305|effect_40|was_17|induced_32|._89 (l_pobj) mice_9\NNS\2329401|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) injury_13\NN\14052046|NONE_0
D002945_D009369 NONE cisplatin_55\JJ\0|NONE_0 (r_amod) administration_56\NN\1133281|NONE_0 (r_pobj) from_54\IN\0|NONE_0 (r_prep) resulted_53\VBD\2633881|reductions_53 (r_advcl) attenuated_42\VBD\224901|elevations_92|,_6|and_4 (r_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) tumor_28\NN\14234074|necrosis_6|alpha_22
D002945_D007674 NONE cisplatin_5\NN\0|acute_6|in_25 (r_amod) nephrotoxicity_6\NN\0|treatment_38|._22
D002945_D007674 NONE cisplatin_8\NN\0|NONE_0 (r_pobj) by_7\IN\0|NONE_0 (r_agent) mediated_6\VBN\761713|histopathological_38|renal_20|tissue_14 (r_acl) damage_5\NN\7296428|also_37|,_33|was_29|by_45|._70
D002945_D007674 NONE cisplatin_15\NN\0|acute_6|encountered_34 (r_amod) nephrotoxicity_16\NN\0|NONE_0
C024989_D009336 NONE q10_1\NNP\0|significantly_4|deficits_30|(_77|level_98|)_137|,_138|suppressed_140|,_169|decreased_171|._383 (r_nsubj) compensated_3\VBD\2673134|NONE_0 (l_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) necrosis_29\NN\11444117|tumor_6|alpha_16
D005978_D009369 NONE glutathione_12\NN\0|reduced_8|and_18|activity_43 (r_compound) level_13\NN\4916342|q10_98|significantly_94|deficits_68|(_21|)_39|,_40|suppressed_42|,_71|decreased_73|._285 (r_dobj) compensated_3\VBD\2673134|NONE_0 (l_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) tumor_28\NN\14234074|necrosis_6|alpha_22
D013481_D009336 NONE superoxide_15\NN\14971519|dismutase_11 (r_amod) activity_17\NN\30358|reduced_51|glutathione_43|and_25 (r_conj) level_13\NN\4916342|q10_98|significantly_94|deficits_68|(_21|)_39|,_40|suppressed_42|,_71|decreased_73|._285 (r_dobj) compensated_3\VBD\2673134|NONE_0 (l_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) necrosis_29\NN\11444117|tumor_6|alpha_16
D012643_D009336 NONE selenium_46\NN\14724645|in_23 (r_nmod) ions_49\NNS\9386422|NONE_0 (r_pobj) of_45\IN\0|the_15 (r_prep) reductions_44\NNS\351485|resulted_53 (r_dobj) attenuated_42\VBD\224901|elevations_92|,_6|and_4 (r_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) necrosis_29\NN\11444117|tumor_6|alpha_16
D010984_D009369 NONE platinum_37\NN\14627081|NONE_0 (r_compound) ion_38\NN\9386422|NONE_0 (r_compound) concentration_39\NN\4916342|nitric_30|and_17 (r_conj) oxide_35\NN\14818238|-_15|,_9 (r_conj) alpha_32\NN\6828818|tumor_22|necrosis_16 (r_appos) factor_30\NN\7326557|NONE_0 (l_compound) tumor_28\NN\14234074|necrosis_6|alpha_22
C024989_D009369 NONE q10_1\NNP\0|significantly_4|deficits_30|(_77|level_98|)_137|,_138|suppressed_140|,_169|decreased_171|._383 (r_nsubj) compensated_3\VBD\2673134|NONE_0 (l_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) tumor_28\NN\14234074|necrosis_6|alpha_22
D010984_D009336 NONE platinum_37\NN\14627081|NONE_0 (r_compound) ion_38\NN\9386422|NONE_0 (r_compound) concentration_39\NN\4916342|nitric_30|and_17 (r_conj) oxide_35\NN\14818238|-_15|,_9 (r_conj) alpha_32\NN\6828818|tumor_22|necrosis_16 (r_appos) factor_30\NN\7326557|NONE_0 (l_compound) necrosis_29\NN\11444117|tumor_6|alpha_16
C024989_D007674 NONE q10_1\NNP\0|coenzyme_9 (r_compound) treatment_2\NN\654885|nephrotoxicity_38|._60 (r_nsubj) ameliorates_3\VBZ\126264|NONE_0 (l_dobj) nephrotoxicity_6\NN\0|treatment_38|._22
C024989_D007674 NONE q10_13\NNP\0|coenzyme_9 (r_compound) treatment_14\NN\654885|NONE_0 (r_pobj) by_11\IN\0|also_82|,_78|damage_45|was_16|._25 (r_agent) ameliorated_10\VBN\126264|NONE_0 (l_nsubjpass) damage_5\NN\7296428|also_37|,_33|was_29|by_45|._70
C024989_D007674 NONE q10_5\NNP\0|that_14|option_39 (r_nsubj) represents_6\VBZ\2664769|it_35|was_32|._133 (l_dobj) option_10\NN\6480506|that_53|q10_39 (l_acl) protect_12\VB\1127795|a_34|potential_32|therapeutic_22 (l_prep) against_13\IN\0|to_11 (l_pobj) nephrotoxicity_16\NN\0|NONE_0
D009569_D009336 NONE oxide_35\NN\14818238|-_15|,_9 (r_conj) alpha_32\NN\6828818|tumor_22|necrosis_16 (r_appos) factor_30\NN\7326557|NONE_0 (l_compound) necrosis_29\NN\11444117|tumor_6|alpha_16
D015032_D009369 NONE zinc_48\NN\14625458|and_4 (r_conj) selenium_46\NN\14724645|in_23 (r_nmod) ions_49\NNS\9386422|NONE_0 (r_pobj) of_45\IN\0|the_15 (r_prep) reductions_44\NNS\351485|resulted_53 (r_dobj) attenuated_42\VBD\224901|elevations_92|,_6|and_4 (r_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) tumor_28\NN\14234074|necrosis_6|alpha_22
D005978_D009336 NONE glutathione_12\NN\0|reduced_8|and_18|activity_43 (r_compound) level_13\NN\4916342|q10_98|significantly_94|deficits_68|(_21|)_39|,_40|suppressed_42|,_71|decreased_73|._285 (r_dobj) compensated_3\VBD\2673134|NONE_0 (l_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) necrosis_29\NN\11444117|tumor_6|alpha_16
D013481_D009369 NONE superoxide_15\NN\14971519|dismutase_11 (r_amod) activity_17\NN\30358|reduced_51|glutathione_43|and_25 (r_conj) level_13\NN\4916342|q10_98|significantly_94|deficits_68|(_21|)_39|,_40|suppressed_42|,_71|decreased_73|._285 (r_dobj) compensated_3\VBD\2673134|NONE_0 (l_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) tumor_28\NN\14234074|necrosis_6|alpha_22
D015032_D009336 NONE zinc_48\NN\14625458|and_4 (r_conj) selenium_46\NN\14724645|in_23 (r_nmod) ions_49\NNS\9386422|NONE_0 (r_pobj) of_45\IN\0|the_15 (r_prep) reductions_44\NNS\351485|resulted_53 (r_dobj) attenuated_42\VBD\224901|elevations_92|,_6|and_4 (r_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) necrosis_29\NN\11444117|tumor_6|alpha_16
D002945_D058186 CID cisplatin_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|a_24|single_22|i.p._15|(_13|mg/kg_16|)_21 (r_prep) injection_19\NN\320852|NONE_0 (r_pobj) by_15\IN\0|NONE_0 (r_agent) induced_14\VBN\1627355|effect_72|was_49|in_32|._57 (r_advcl) investigated_7\VBN\644583|NONE_0 (l_prep) in_8\IN\13603305|effect_40|was_17|induced_32|._89 (l_pobj) mice_9\NNS\2329401|NONE_0 (l_prep) with_10\IN\0|NONE_0 (l_pobj) injury_13\NN\14052046|NONE_0
D012643_D009369 NONE selenium_46\NN\14724645|in_23 (r_nmod) ions_49\NNS\9386422|NONE_0 (r_pobj) of_45\IN\0|the_15 (r_prep) reductions_44\NNS\351485|resulted_53 (r_dobj) attenuated_42\VBD\224901|elevations_92|,_6|and_4 (r_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) tumor_28\NN\14234074|necrosis_6|alpha_22
D002945_D009336 NONE cisplatin_55\JJ\0|NONE_0 (r_amod) administration_56\NN\1133281|NONE_0 (r_pobj) from_54\IN\0|NONE_0 (r_prep) resulted_53\VBD\2633881|reductions_53 (r_advcl) attenuated_42\VBD\224901|elevations_92|,_6|and_4 (r_conj) decreased_24\VBD\169651|q10_171|significantly_167|deficits_141|(_94|level_73|)_34|,_33|suppressed_31|,_2|._212 (l_dobj) elevations_26\NNS\7445480|,_86|and_88|attenuated_92 (l_prep) of_27\IN\0|the_15 (l_pobj) factor_30\NN\7326557|NONE_0 (l_compound) necrosis_29\NN\11444117|tumor_6|alpha_16
D009569_D009369 NONE oxide_35\NN\14818238|-_15|,_9 (r_conj) alpha_32\NN\6828818|tumor_22|necrosis_16 (r_appos) factor_30\NN\7326557|NONE_0 (l_compound) tumor_28\NN\14234074|necrosis_6|alpha_22
17511042
C417083_D063726 CID alpha-2b_16\NN\0|NONE_0 (r_pobj) during_13\IN\0|delusional_56|in_33 (r_prep) parasitosis_6\NN\0|NONE_0
C417083_D063726 CID alpha-2b_17\CD\0|we_113|woman_88|._29 (r_prep) present_1\VBP\28270|NONE_0 (l_dobj) woman_6\NN\9605289|we_25|alpha-2b_88|._117 (l_relcl) developed_8\VBD\1753788|a_24|old_14 (l_dobj) parasitosis_11\NN\0|who_27
D012254_D019698 NONE ribavirin_18\JJ\2725367|NONE_0 (r_compound) treatment_19\NN\654885|pegylated_44|interferon_34|and_14 (r_conj) alpha-2b_16\NN\0|NONE_0 (r_pobj) during_13\IN\0|delusional_56|in_33 (r_prep) parasitosis_6\NN\0|NONE_0 (l_prep) in_7\IN\13603305|delusional_23|during_33 (l_pobj) patient_12\NN\9898892|NONE_0 (l_compound) c_11\NN\13714184|a_20|chronic_18
D012254_D019698 NONE ribavirin_10\RB\2725367|and_4 (r_conj) interferon_8\NN\2725367|NONE_0 (r_pobj) with_7\IN\0|chronic_29|c_11 (r_prep) patients_6\NNS\9898892|NONE_0 (l_compound) c_5\NNP\13714184|chronic_18|with_11
D012254_D063726 CID ribavirin_18\JJ\2725367|NONE_0 (r_compound) treatment_19\NN\654885|pegylated_44|interferon_34|and_14 (r_conj) alpha-2b_16\NN\0|NONE_0 (r_pobj) during_13\IN\0|delusional_56|in_33 (r_prep) parasitosis_6\NN\0|NONE_0
D012254_D063726 CID ribavirin_20\RB\2725367|and_4 (r_conj) weekly_18\RB\6593803|NONE_0 (r_amod) alpha-2b_17\CD\0|we_113|woman_88|._29 (r_prep) present_1\VBP\28270|NONE_0 (l_dobj) woman_6\NN\9605289|we_25|alpha-2b_88|._117 (l_relcl) developed_8\VBD\1753788|a_24|old_14 (l_dobj) parasitosis_11\NN\0|who_27
C417083_D019698 NONE alpha-2b_16\NN\0|NONE_0 (r_pobj) during_13\IN\0|delusional_56|in_33 (r_prep) parasitosis_6\NN\0|NONE_0 (l_prep) in_7\IN\13603305|delusional_23|during_33 (l_pobj) patient_12\NN\9898892|NONE_0 (l_compound) c_11\NN\13714184|a_20|chronic_18
1928887
D009270_D062787 NONE naloxone_0\NN\3808977|of_18|due_33|._58 (r_compound) reversal_1\NN\199130|NONE_0 (l_prep) due_4\IN\5174653|naloxone_33|of_15|._25 (l_pobj) overdose_7\NN\84738|to_13
D009270_D062787 NONE naloxone_22\NN\3808977|NONE_0 (r_pobj) of_21\IN\0|the_19 (r_prep) administration_20\NN\1133281|NONE_0 (r_pobj) with_18\IN\0|,_25|that_23|promptly_9 (r_prep) resolved_16\VBD\352826|we_94|case_82|,_41|manifested_39|._53 (r_ccomp) report_1\VBP\6470073|NONE_0 (l_dobj) case_3\NN\7283608|we_12|,_41|manifested_43|resolved_82|._135 (l_prep) of_4\IN\0|a_7 (l_pobj) overdose_8\NN\84738|NONE_0
D002216_D062787 NONE captopril_6\NN\2673637|NONE_0 (r_compound) overdose_7\NN\84738|to_13
D002216_D062787 NONE captopril_7\NN\2673637|an_15|intentional_12 (r_compound) overdose_8\NN\84738|NONE_0
D002216_D007022 NONE captopril_6\NN\2673637|NONE_0 (r_compound) overdose_7\NN\84738|to_13 (r_pobj) due_4\IN\5174653|naloxone_33|of_15|._25 (r_prep) reversal_1\NN\199130|NONE_0 (l_prep) of_2\IN\0|naloxone_18|due_15|._40 (l_pobj) hypotension_3\NN\14057371|NONE_0
D002216_D007022 NONE captopril_15\NN\2673637|NONE_0 (r_pobj) of_14\IN\0|the_24|hypotensive_20 (r_prep) actions_13\NNS\30358|NONE_0 (l_amod) hypotensive_12\JJ\10405694|the_4|of_20
D002216_D007022 NONE captopril_7\NN\2673637|an_15|intentional_12 (r_compound) overdose_8\NN\84738|NONE_0 (r_pobj) of_4\IN\0|a_7 (r_prep) case_3\NN\7283608|we_12|,_41|manifested_43|resolved_82|._135 (r_dobj) report_1\VBP\6470073|NONE_0 (l_advcl) manifested_10\VBN\1015244|we_55|case_43|,_2|resolved_39|._92 (l_agent) by_11\IN\0|NONE_0 (l_pobj) hypotension_13\NN\14057371|NONE_0
D002216_D007022 NONE captopril_11\NN\2673637|-_9 (r_npadvmod) induced_13\VBN\1627355|treated_20 (r_amod) hypotension_14\NN\14057371|NONE_0
D002216_D007022 NONE captopril_15\NN\2673637|NONE_0 (r_pobj) from_14\IN\0|NONE_0 (r_prep) resulting_13\VBG\2633881|NONE_0 (r_acl) hypotension_12\NN\14057371|NONE_0
D009270_D007022 NONE naloxone_0\NN\3808977|of_18|due_33|._58 (r_compound) reversal_1\NN\199130|NONE_0 (l_prep) of_2\IN\0|naloxone_18|due_15|._40 (l_pobj) hypotension_3\NN\14057371|NONE_0
D009270_D007022 NONE naloxone_3\NN\3808977|the_22|opioid_18 (r_appos) antagonist_2\NN\7846|has_20|been_24|block_38|._91 (r_nsubjpass) shown_6\VBN\2137132|NONE_0 (l_xcomp) block_8\VB\21939|antagonist_38|has_18|been_14|._53 (l_conj) reverse_10\VB\13854649|to_12|or_3 (l_dobj) actions_13\NNS\30358|NONE_0 (l_amod) hypotensive_12\JJ\10405694|the_4|of_20
D009270_D007022 NONE naloxone_22\NN\3808977|NONE_0 (r_pobj) of_21\IN\0|the_19 (r_prep) administration_20\NN\1133281|NONE_0 (r_pobj) with_18\IN\0|,_25|that_23|promptly_9 (r_prep) resolved_16\VBD\352826|we_94|case_82|,_41|manifested_39|._53 (r_ccomp) report_1\VBP\6470073|NONE_0 (l_advcl) manifested_10\VBN\1015244|we_55|case_43|,_2|resolved_39|._92 (l_agent) by_11\IN\0|NONE_0 (l_pobj) hypotension_13\NN\14057371|NONE_0
D009270_D007022 NONE naloxone_17\NN\3808977|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) treated_15\VBN\2376958|induced_20 (r_acl) hypotension_14\NN\14057371|NONE_0
D009270_D007022 NONE naloxone_7\NN\3808977|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) reversal_10\NN\199130|NONE_0 (l_prep) of_11\IN\0|the_13 (l_pobj) hypotension_12\NN\14057371|NONE_0
10354657
D008094_D007037 CID lithium_22\NN\14625458|NONE_0 (r_compound) therapy_23\NN\657604|NONE_0 (r_pobj) of_21\IN\0|NONE_0 (r_prep) onset_20\NN\7325190|years_12 (r_pobj) after_19\IN\0|patients_118|had_51|onset_35|)_30|compared_32|(_80|after_91|)_121|._122 (r_prep) accelerated_12\VBN\226566|NONE_0 (l_dobj) onset_13\NN\7325190|patients_83|had_16|after_35|)_65|compared_67|(_115|after_126|)_156|._157 (l_prep) of_14\IN\0|(_18 (l_pobj) hypothyroidism_15\NN\14059928|NONE_0
D008094_D007037 CID lithium_38\NN\14625458|NONE_0 (r_compound) therapy_39\NN\657604|NONE_0 (r_pobj) of_37\IN\0|NONE_0 (r_prep) onset_36\NN\7325190|years_12 (r_pobj) after_35\IN\0|patients_209|had_142|onset_126|after_91|)_61|compared_59|(_11|)_30|._31 (r_prep) accelerated_12\VBN\226566|NONE_0 (l_dobj) onset_13\NN\7325190|patients_83|had_16|after_35|)_65|compared_67|(_115|after_126|)_156|._157 (l_prep) of_14\IN\0|(_18 (l_pobj) hypothyroidism_15\NN\14059928|NONE_0
D008094_D007037 CID lithium_12\NN\14625458|NONE_0 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) during_11\IN\0|a_51|risk_49|for_37 (r_prep) factor_6\NN\7326557|illness_18|._66 (l_prep) for_7\IN\0|a_14|risk_12|during_37 (l_pobj) hypothyroidism_8\NN\14059928|NONE_0
D008094_D006934 NONE lithium_12\NN\14625458|NONE_0 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) during_11\IN\0|a_51|risk_49|for_37 (r_prep) factor_6\NN\7326557|illness_18|._66 (l_prep) for_7\IN\0|a_14|risk_12|during_37 (l_pobj) hypothyroidism_8\NN\14059928|NONE_0 (l_conj) hypercalcemia_10\NN\14299637|and_4
D008094_D013959 NONE lithium_9\NN\14625458|,_15|age_17 (r_compound) therapy_10\NN\657604|NONE_0 (r_pobj) of_8\IN\0|the_13 (r_prep) duration_7\NN\15113229|NONE_0 (r_pobj) to_5\IN\0|NONE_0 (r_prep) respect_4\NN\5817845|NONE_0 (r_pobj) with_3\IN\0|these_21|were_15|had_106|._155 (r_prep) evaluated_2\VBN\670261|NONE_0 (l_parataxis) had_25\VBD\0|these_127|were_121|with_106|._49 (l_dobj) relative_30\NN\7846|(_47|whether_46|or_38|not_35|patient_27|)_29 (l_prep) with_31\IN\0|a_24|degree_16 (l_pobj) disease_33\NN\14061805|NONE_0
D008094_D013959 NONE lithium_22\NN\14625458|NONE_0 (r_compound) therapy_23\NN\657604|NONE_0 (r_pobj) of_21\IN\0|NONE_0 (r_prep) onset_20\NN\7325190|years_12 (r_pobj) after_19\IN\0|patients_118|had_51|onset_35|)_30|compared_32|(_80|after_91|)_121|._122 (r_prep) accelerated_12\VBN\226566|NONE_0 (l_nsubj) patients_1\NNS\9898892|had_67|onset_83|after_118|)_148|compared_150|(_198|after_209|)_239|._240 (l_acl) having_2\VBG\0|all_13 (l_dobj) relatives_6\NNS\7846|NONE_0 (l_acl) affected_7\VBN\126264|degree_17 (l_agent) by_8\IN\0|NONE_0 (l_pobj) illness_10\NN\14052046|NONE_0
D008094_D013959 NONE lithium_38\NN\14625458|NONE_0 (r_compound) therapy_39\NN\657604|NONE_0 (r_pobj) of_37\IN\0|NONE_0 (r_prep) onset_36\NN\7325190|years_12 (r_pobj) after_35\IN\0|patients_209|had_142|onset_126|after_91|)_61|compared_59|(_11|)_30|._31 (r_prep) accelerated_12\VBN\226566|NONE_0 (l_nsubj) patients_1\NNS\9898892|had_67|onset_83|after_118|)_148|compared_150|(_198|after_209|)_239|._240 (l_acl) having_2\VBG\0|all_13 (l_dobj) relatives_6\NNS\7846|NONE_0 (l_acl) affected_7\VBN\126264|degree_17 (l_agent) by_8\IN\0|NONE_0 (l_pobj) illness_10\NN\14052046|NONE_0
D008094_D013959 NONE lithium_12\NN\14625458|NONE_0 (r_compound) therapy_13\NN\657604|NONE_0 (r_pobj) during_11\IN\0|a_51|risk_49|for_37 (r_prep) factor_6\NN\7326557|illness_18|._66 (r_attr) is_3\VBZ\0|NONE_0 (l_nsubj) illness_2\NN\14052046|factor_18|._84
D008094_D001714 NONE lithium_16\NN\14625458|maintenance_8|ranging_28 (r_compound) therapy_18\NN\657604|disorder_39 (r_dobj) receiving_15\VBG\2210855|NONE_0 (l_nsubj) disorder_14\NN\14034177|therapy_39
18086064
D020927_D009203 NONE dexmedetomidine_0\NNP\0|was_16|with_31 (r_nsubjpass) associated_2\VBN\628491|;_57|cause_63|(_79|ci_93|infarction_139|%_162|,_176 (r_ccomp) mortality_14\NN\5054863|NONE_0 (l_appos) infarction_35\NN\14204950|associated_139|;_82|cause_76|(_60|ci_46|%_23|,_37
1899352
D015080_D006417 NONE mesna_22\NNP\0|to_6 (r_dobj) adding_21\VBG\156601|monitoring_43|essential_11|,_2|._66 (r_advcl) is_18\VBZ\0|frequency_107|not_61|precise_57|,_50|and_48 (r_conj) are_6\VBP\13600404|NONE_0 (l_nsubj) frequency_1\NN\15286249|not_46|precise_50|,_57|and_59|is_107 (l_conj) predictability_3\NN\4753455|the_18|and_4 (l_prep) of_4\IN\0|NONE_0 (l_pobj) hematuria_5\NN\14299637|NONE_0
D015080_D006417 NONE mesna_22\NNP\0|to_6 (r_dobj) adding_21\VBG\156601|monitoring_43|essential_11|,_2|._66 (l_prep) to_23\IN\0|mesna_6 (l_pobj) infusate_25\NN\0|NONE_0 (l_prep) in_26\IN\13603305|the_13 (l_pobj) patients_27\NNS\9898892|NONE_0 (l_prep) with_28\IN\0|NONE_0 (l_pobj) hematuria_30\NN\14299637|NONE_0
16725121
D003891_D012640 NONE desipramine_12\NN\4482543|NONE_0 (r_pobj) of_11\IN\0|chronic_23 (r_prep) administration_10\NN\1133281|NONE_0 (r_pobj) by_8\IN\0|linking_41 (r_agent) induced_7\VBN\1627355|down_55|-_51|of_39|._196 (l_xcomp) linking_13\VBG\628491|by_41 (l_prep) to_14\IN\0|NONE_0 (l_pobj) alteration_16\NN\7283608|NONE_0 (l_prep) of_17\IN\0|the_15|and_56|counteraction_64 (l_pobj) sensitivity_18\NN\5651971|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) convulsions_25\NNS\14081375|NONE_0
D003891_D012640 NONE desipramine_3\NN\4482543|NONE_0 (r_pobj) of_2\IN\0|daily_21 (r_prep) administration_1\NN\1133281|incidence_44|and_101|decreased_105|._150 (r_nsubj) increased_4\VBD\169651|NONE_0 (l_dobj) incidence_6\NN\13821570|administration_44|and_57|decreased_61|._106 (l_prep) of_7\IN\0|the_14 (l_pobj) appearance_8\NN\4723816|NONE_0 (l_prep) of_9\IN\0|NONE_0 (l_pobj) convulsions_13\NNS\14081375|NONE_0
D003891_D012640 NONE desipramine_3\NN\4482543|NONE_0 (r_pobj) of_2\IN\0|daily_21 (r_prep) administration_1\NN\1133281|incidence_44|and_101|decreased_105|._150 (r_nsubj) increased_4\VBD\169651|NONE_0 (l_conj) decreased_15\VBD\169651|administration_105|incidence_61|and_4|._45 (l_dobj) that_16\DT\0|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) convulsions_21\NNS\14081375|NONE_0
D003891_D012640 NONE desipramine_6\NN\4482543|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) lidocaine_4\NN\3681148|NONE_0 (r_pobj) of_3\IN\0|co_18|-_16 (r_prep) administration_2\NN\1133281|changes_58|._163 (r_nsubj) reversed_7\VBD\109660|NONE_0 (l_dobj) changes_9\NNS\7283608|administration_58|._105 (l_prep) of_10\IN\0|the_12|induced_48 (l_pobj) activity_12\NN\30358|NONE_0 (l_amod) convulsive_11\JJ\0|of_20
D003891_D012640 NONE desipramine_22\NN\4482543|NONE_0 (r_pobj) of_21\IN\0|repeated_24 (r_prep) administration_20\NN\1133281|NONE_0 (r_pobj) by_18\IN\0|NONE_0 (r_agent) induced_17\VBN\1627355|the_60|of_48 (r_acl) changes_9\NNS\7283608|administration_58|._105 (l_prep) of_10\IN\0|the_12|induced_48 (l_pobj) activity_12\NN\30358|NONE_0 (l_amod) convulsive_11\JJ\0|of_20
D003891_D012640 NONE desipramine_15\NN\4482543|NONE_0 (r_pobj) of_14\IN\0|chronic_23 (r_prep) administration_13\NN\1133281|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|down_35|-_31|of_19 (r_acl) regulation_6\NN\6652242|that_10|may_79|relevant_86 (r_nsubj) be_17\VB\14625458|results_109|._73 (l_acomp) relevant_18\JJ\0|that_96|regulation_86|may_7 (l_prep) to_19\IN\0|NONE_0 (l_pobj) sensitization_23\NN\14531772|NONE_0 (l_prep) of_24\IN\0|induced_22 (l_pobj) convulsions_26\NNS\14081375|NONE_0
D003891_D012640 NONE desipramine_20\NN\4482543|-_11 (r_advmod) induced_22\VBN\1627355|of_22 (r_amod) sensitization_23\NN\14531772|NONE_0 (l_prep) of_24\IN\0|induced_22 (l_pobj) convulsions_26\NNS\14081375|NONE_0
D003891_D012640 NONE desipramine_0\NN\4482543|-_11 (r_nsubj) induced_2\VBN\1627355|of_22 (r_amod) sensitization_3\NN\14531772|may_36|mechanism_47|._129 (l_prep) of_4\IN\0|induced_22 (l_pobj) seizures_6\NNS\14081375|NONE_0
D009638_D012640 NONE norepinephrine_4\NN\14807929|transporter_15 (r_amod) function_6\NN\13783581|NONE_0 (r_pobj) of_3\IN\0|down_16|-_12|induced_39|._235 (r_prep) regulation_2\NN\6652242|NONE_0 (l_acl) induced_7\VBN\1627355|down_55|-_51|of_39|._196 (l_xcomp) linking_13\VBG\628491|by_41 (l_prep) to_14\IN\0|NONE_0 (l_pobj) alteration_16\NN\7283608|NONE_0 (l_prep) of_17\IN\0|the_15|and_56|counteraction_64 (l_pobj) sensitivity_18\NN\5651971|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) convulsions_25\NNS\14081375|NONE_0
D009638_D012640 NONE norepinephrine_2\NN\14807929|net_28|)_31 (r_compound) transporter_3\NN\4490091|by_27 (r_nmod) function_7\NN\13783581|NONE_0 (l_prep) by_8\IN\0|transporter_27 (l_pobj) inhibition_10\NN\1068773|NONE_0 (l_prep) in_13\IN\13603305|chronic_26|of_7 (l_pobj) relation_14\NN\2137|NONE_0 (l_prep) to_15\IN\0|NONE_0 (l_pobj) sensitization_16\NN\14531772|NONE_0 (l_prep) to_17\IN\0|NONE_0 (l_pobj) seizures_18\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_21\NN\3492717|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induce_19\VB\1627355|NONE_0 (r_acl) seizures_18\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_18\NN\3492717|-_7 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_amod) convulsions_21\NNS\14081375|NONE_0 (r_pobj) of_17\IN\0|NONE_0 (r_prep) that_16\DT\0|NONE_0 (r_dobj) decreased_15\VBD\169651|administration_105|incidence_61|and_4|._45 (r_conj) increased_4\VBD\169651|NONE_0 (l_dobj) incidence_6\NN\13821570|administration_44|and_57|decreased_61|._106 (l_prep) of_7\IN\0|the_14 (l_pobj) appearance_8\NN\4723816|NONE_0 (l_prep) of_9\IN\0|NONE_0 (l_pobj) convulsions_13\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_18\NN\3492717|-_7 (r_npadvmod) induced_20\VBN\1627355|NONE_0 (r_amod) convulsions_21\NNS\14081375|NONE_0
D003042_D012640 CID cocaine_16\NN\3492717|and_4 (r_conj) lidocaine_14\NN\3681148|NONE_0 (r_pobj) of_13\IN\0|convulsive_20 (r_prep) activity_12\NN\30358|NONE_0 (l_amod) convulsive_11\JJ\0|of_20
D003042_D012640 CID cocaine_19\NN\3492717|NONE_0 (r_pobj) of_18\IN\0|repeated_24 (r_prep) administration_17\NN\1133281|NONE_0 (r_pobj) from_15\IN\0|NONE_0 (r_prep) resulting_14\VBG\2633881|NONE_0 (r_acl) kindling_13\VBG\15101361|NONE_0 (r_pobj) from_12\IN\0|NONE_0 (r_prep) distinct_11\JJ\0|a_12 (r_amod) mechanism_10\NN\13446390|sensitization_47|may_11|._82 (r_dobj) have_8\VB\7846|NONE_0 (l_nsubj) sensitization_3\NN\14531772|may_36|mechanism_47|._129 (l_prep) of_4\IN\0|induced_22 (l_pobj) seizures_6\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine_10\NN\3681148|-_9 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) convulsions_13\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine_10\NN\3681148|-_9 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) convulsions_13\NNS\14081375|NONE_0 (r_pobj) of_9\IN\0|NONE_0 (r_prep) appearance_8\NN\4723816|NONE_0 (r_pobj) of_7\IN\0|the_14 (r_prep) incidence_6\NN\13821570|administration_44|and_57|decreased_61|._106 (r_dobj) increased_4\VBD\169651|NONE_0 (l_conj) decreased_15\VBD\169651|administration_105|incidence_61|and_4|._45 (l_dobj) that_16\DT\0|NONE_0 (l_prep) of_17\IN\0|NONE_0 (l_pobj) convulsions_21\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine_4\NN\3681148|NONE_0 (r_pobj) of_3\IN\0|co_18|-_16 (r_prep) administration_2\NN\1133281|changes_58|._163 (r_nsubj) reversed_7\VBD\109660|NONE_0 (l_dobj) changes_9\NNS\7283608|administration_58|._105 (l_prep) of_10\IN\0|the_12|induced_48 (l_pobj) activity_12\NN\30358|NONE_0 (l_amod) convulsive_11\JJ\0|of_20
D008012_D012640 CID lidocaine_14\NN\3681148|NONE_0 (r_pobj) of_13\IN\0|convulsive_20 (r_prep) activity_12\NN\30358|NONE_0 (l_amod) convulsive_11\JJ\0|of_20
D008012_D012640 CID lidocaine_25\NN\3681148|NONE_0 (r_compound) convulsions_26\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine_5\NN\3681148|NONE_0 (r_compound) seizures_6\NNS\14081375|NONE_0
2917114
D004491_D001919 CID edrophonium_17\NN\0|NONE_0 (r_pobj) before_15\IN\0|1_6 (r_prep) min_14\NN\15154774|,_10|,_26|was_28 (r_dobj) given_12\VBN\5892096|of_83|micrograms_63|._102 (l_conj) was_19\VBD\0|,_38|min_28|,_2 (l_acomp) sufficient_20\JJ\0|NONE_0 (l_xcomp) minimize_22\VB\441445|NONE_0 (l_dobj) bradycardias_28\NNS\14110674|to_39
D004491_D001919 CID edrophonium_25\NN\0|-_11 (r_npadvmod) induced_27\VBN\1627355|early_19|,_14 (r_amod) bradycardias_28\NNS\14110674|to_39
D006024_D001919 NONE glycopyrronium_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|micrograms_20|given_83|._185 (r_prep) use_0\NN\407535|NONE_0 (l_acl) given_12\VBN\5892096|of_83|micrograms_63|._102 (l_conj) was_19\VBD\0|,_38|min_28|,_2 (l_acomp) sufficient_20\JJ\0|NONE_0 (l_xcomp) minimize_22\VB\441445|NONE_0 (l_dobj) bradycardias_28\NNS\14110674|to_39
19139001
D013467_D034381 CID sulindac_14\NN\3828465|the_14|dfmo_10|experienced_19 (r_compound) group_15\NN\2137|NONE_0 (l_relcl) experienced_17\VBD\2108377|the_33|dfmo_29|sulindac_19 (l_dobj) loss_21\NN\13252973|who_47|compared_5
D013467_D015179 NONE sulindac_15\NN\3828465|and_4 (l_prep) for_16\IN\0|NONE_0 (l_pobj) prevention_17\NN\1073995|NONE_0 (l_prep) of_18\IN\0|NONE_0 (l_pobj) adenomas_21\NNS\14236226|NONE_0
D000518_D015179 NONE difluoromethylornithine_13\NN\0|NONE_0 (l_conj) sulindac_15\NN\3828465|and_4 (l_prep) for_16\IN\0|NONE_0 (l_pobj) prevention_17\NN\1073995|NONE_0 (l_prep) of_18\IN\0|NONE_0 (l_pobj) adenomas_21\NNS\14236226|NONE_0
D000518_D064420 NONE dfmo_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) treatment_8\NN\654885|NONE_0 (r_pobj) of_7\IN\0|a_17|known_15|,_22 (r_prep) toxicity_6\NN\13576101|loss_16|developed_67|._120
D000518_D034381 NONE dfmo_10\NN\0|NONE_0 (r_pobj) with_9\IN\0|NONE_0 (r_prep) treatment_8\NN\654885|NONE_0 (r_pobj) of_7\IN\0|a_17|known_15|,_22 (r_prep) toxicity_6\NN\13576101|loss_16|developed_67|._120 (r_attr) is_3\VBZ\0|NONE_0 (l_nsubj) loss_2\NN\13252973|toxicity_16|developed_83|._136
D000518_D034381 NONE dfmo_12\NN\0|the_4|sulindac_10|experienced_29 (r_nmod) group_15\NN\2137|NONE_0 (l_relcl) experienced_17\VBD\2108377|the_33|dfmo_29|sulindac_19 (l_dobj) loss_21\NN\13252973|who_47|compared_5
D013467_D018256 NONE sulindac_22\NN\3828465|(_12|dfmo_11|)_7|plus_5 (r_conj) difluoromethylornithine_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|36_10 (r_prep) months_15\NNS\15113229|NONE_0 (r_pobj) for_13\IN\0|NONE_0 (r_prep) treatment_12\NN\654885|NONE_0 (r_pobj) after_11\IN\0|adenomatous_19 (r_prep) polyps_10\NNS\14234074|NONE_0
D000518_D018256 NONE difluoromethylornithine_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|36_10 (r_prep) months_15\NNS\15113229|NONE_0 (r_pobj) for_13\IN\0|NONE_0 (r_prep) treatment_12\NN\654885|NONE_0 (r_pobj) after_11\IN\0|adenomatous_19 (r_prep) polyps_10\NNS\14234074|NONE_0
D000518_D018256 NONE dfmo_19\NN\0|(_1|)_4|plus_6|sulindac_11 (r_appos) difluoromethylornithine_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|36_10 (r_prep) months_15\NNS\15113229|NONE_0 (r_pobj) for_13\IN\0|NONE_0 (r_prep) treatment_12\NN\654885|NONE_0 (r_pobj) after_11\IN\0|adenomatous_19 (r_prep) polyps_10\NNS\14234074|NONE_0
14745746
8854309
D003042_D010259 CID cocaine_9\NN\3492717|-_7 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) paranoia_12\NN\14398067|NONE_0
D003042_D010259 CID cocaine_0\NN\3492717|-_7 (r_npadvmod) induced_2\VBN\1627355|(_17|cip_18|)_21 (r_amod) paranoia_3\NN\14398067|model_49|._131
D003042_D010259 CID cocaine_0\NN\3492717|-_7 (r_npadvmod) induced_2\VBN\1627355|(_17|cip_18|)_21 (r_amod) paranoia_3\NN\14398067|model_49|._131 (l_appos) cip_5\NNP\0|induced_18|(_1|)_3
D003042_D010259 CID cocaine_0\NN\3492717|-_7 (r_npadvmod) induced_2\VBN\1627355|(_17|cip_18|)_21 (r_amod) paranoia_3\NN\14398067|model_49|._131 (r_nsubj) remains_7\VBZ\2684|NONE_0 (l_attr) model_13\NN\5888929|paranoia_49|._82 (l_prep) of_14\IN\0|an_32|important_29|induced_14 (l_pobj) paranoia_16\NN\14398067|NONE_0
D016578_D010259 NONE cocaine_14\NN\3492717|crack_6|endorsing_16 (r_compound) abusers_15\NNS\9633969|NONE_0 (l_acl) endorsing_16\VBG\806502|crack_22|cocaine_16 (l_prep) past_17\IN\28270|from_18 (l_pobj) cip_18\NNP\0|NONE_0
D016578_D010259 NONE cocaine_14\NN\3492717|crack_6|endorsing_16 (r_compound) abusers_15\NNS\9633969|NONE_0 (l_acl) endorsing_16\VBG\806502|crack_22|cocaine_16 (l_prep) from_24\IN\0|past_18 (l_pobj) group_26\NN\2137|NONE_0 (l_relcl) denied_31\VBD\823436|another_35|of_21 (l_prep) past_32\IN\28270|who_11 (l_pobj) cip_33\NNP\0|NONE_0
D016578_D010259 NONE crack_28\NN\9379111|NONE_0 (r_compound) addicts_29\NNS\10059582|NONE_0 (r_pobj) of_27\IN\0|another_14|denied_21 (r_prep) group_26\NN\2137|NONE_0 (r_pobj) from_24\IN\0|past_18 (r_prep) endorsing_16\VBG\806502|crack_22|cocaine_16 (l_prep) past_17\IN\28270|from_18 (l_pobj) cip_18\NNP\0|NONE_0
D016578_D010259 NONE crack_28\NN\9379111|NONE_0 (r_compound) addicts_29\NNS\10059582|NONE_0 (r_pobj) of_27\IN\0|another_14|denied_21 (r_prep) group_26\NN\2137|NONE_0 (l_relcl) denied_31\VBD\823436|another_35|of_21 (l_prep) past_32\IN\28270|who_11 (l_pobj) cip_33\NNP\0|NONE_0
D016578_D011681 NONE cocaine_14\NN\3492717|crack_6|endorsing_16 (r_compound) abusers_15\NNS\9633969|NONE_0 (r_pobj) of_11\IN\0|a_8 (r_prep) group_10\NN\2137|to_31|significantly_28 (r_dobj) distinguish_8\VB\618878|NONE_0 (r_xcomp) able_5\JJ\0|measures_39|._169 (r_acomp) were_4\VBD\0|NONE_0 (l_nsubj) measures_0\NNS\168237|able_39|._208 (l_prep) of_1\IN\0|NONE_0 (l_pobj) oscillation_3\NN\13518963|NONE_0
D016578_D011681 NONE crack_28\NN\9379111|NONE_0 (r_compound) addicts_29\NNS\10059582|NONE_0 (r_pobj) of_27\IN\0|another_14|denied_21 (r_prep) group_26\NN\2137|NONE_0 (r_pobj) from_24\IN\0|past_18 (r_prep) endorsing_16\VBG\806502|crack_22|cocaine_16 (r_acl) abusers_15\NNS\9633969|NONE_0 (r_pobj) of_11\IN\0|a_8 (r_prep) group_10\NN\2137|to_31|significantly_28 (r_dobj) distinguish_8\VB\618878|NONE_0 (r_xcomp) able_5\JJ\0|measures_39|._169 (r_acomp) were_4\VBD\0|NONE_0 (l_nsubj) measures_0\NNS\168237|able_39|._208 (l_prep) of_1\IN\0|NONE_0 (l_pobj) oscillation_3\NN\13518963|NONE_0
D003042_D011681 CID cocaine_9\NN\3492717|-_7 (r_npadvmod) induced_11\VBN\1627355|NONE_0 (r_amod) paranoia_12\NN\14398067|NONE_0 (r_pobj) of_8\IN\0|a_9 (r_prep) marker_7\NN\21939|NONE_0 (r_pobj) as_5\IN\14622893|a_35|of_25|._39 (r_prep) measure_1\NN\168237|NONE_0 (l_prep) of_2\IN\0|a_10|as_25|._64 (l_pobj) oscillation_4\NN\13518963|NONE_0
9321531
D007980_D004409 CID levodopa_11\RB\14604959|-_8 (r_npadvmod) induced_13\VBN\1627355|and_20|disability_35 (r_amod) dyskinesias_14\NNS\14084880|in_86|,_53|pallidotomy_51|significantly_39|._37
D007980_D010300 NONE levodopa_11\RB\14604959|-_8 (r_npadvmod) induced_13\VBN\1627355|and_20|disability_35 (r_amod) dyskinesias_14\NNS\14084880|in_86|,_53|pallidotomy_51|significantly_39|._37 (r_dobj) reduces_10\VBZ\441445|NONE_0 (l_prep) in_0\IN\13603305|,_33|pallidotomy_35|significantly_47|dyskinesias_86|._123 (l_pobj) disease_6\NN\14061805|NONE_0
8617710
D020280_D003072 NONE sertraline_4\NN\4169152|NONE_0 (r_pobj) of_3\IN\0|on_14 (r_prep) effect_2\NN\34213|NONE_0 (l_prep) on_5\IN\0|of_14 (l_pobj) sensitization_9\NN\14531772|NONE_0 (l_prep) of_10\IN\0|based_20 (l_pobj) impairment_12\NN\7296428|NONE_0
D020280_D003072 NONE sertraline_14\NN\4169152|concomitant_12 (r_compound) administration_15\NN\1133281|NONE_0 (r_pobj) by_12\IN\0|that_22|was_17|not_13 (r_agent) worsened_11\VBN\146138|a_53|clear_51|of_37 (r_relcl) profile_4\NN\6999802|haloperidol_29|._94 (l_prep) of_5\IN\0|a_16|clear_14|worsened_37 (l_pobj) impairment_7\NN\7296428|NONE_0
D006220_D003072 CID haloperidol_14\NN\3713736|NONE_0 (r_pobj) with_13\IN\0|cognitive_21 (r_prep) impairment_12\NN\7296428|NONE_0
D006220_D003072 CID haloperidol_13\NN\3713736|NONE_0 (r_pobj) of_12\IN\0|NONE_0 (r_prep) administration_11\NN\1133281|hours_12 (r_pobj) after_10\IN\0|impairment_59|was_26|on_36|but_45|was_49|._86 (r_prep) observed_5\VBN\2163746|NONE_0 (l_nsubjpass) impairment_0\NN\7296428|was_33|after_59|on_95|but_104|was_108|._145 (l_prep) of_1\IN\0|NONE_0 (l_pobj) function_3\NN\13783581|NONE_0
D006220_D003072 CID haloperidol_0\NNP\3713736|profile_29|._123 (r_nsubj) produced_1\VBD\1617192|NONE_0 (l_dobj) profile_4\NN\6999802|haloperidol_29|._94 (l_prep) of_5\IN\0|a_16|clear_14|worsened_37 (l_pobj) impairment_7\NN\7296428|NONE_0
384871
D004977_D064420 NONE ethambutol_8\NN\0|to_3 (r_pobj) due_6\IN\5174653|the_36|of_24 (r_amod) hazards_1\NNS\14541044|are_50|._59 (l_prep) of_2\IN\0|the_12|due_24 (l_pobj) toxicity_5\NN\13576101|NONE_0
D004977_D009901 CID ethambutol_6\NN\0|NONE_0 (r_nmod) treatment_9\NN\654885|to_37 (r_pobj) due_3\IN\5174653|optic_17|._50 (r_prep) neuropathy_2\NN\14204950|NONE_0
D007538_D009901 CID isoniazid_8\NN\2716205|combined_24|and_4 (r_conj) ethambutol_6\NN\0|NONE_0 (r_nmod) treatment_9\NN\654885|to_37 (r_pobj) due_3\IN\5174653|optic_17|._50 (r_prep) neuropathy_2\NN\14204950|NONE_0
16629641
C026956_D000743 NONE viramidine_0\NNP\0|potential_60 (r_nsubj) has_10\VBZ\13888491|NONE_0 (l_dobj) potential_12\NN\14481929|viramidine_60 (l_acl) maintain_14\VB\0|the_17 (l_advcl) decreasing_21\VBG\169651|to_54|efficacy_28 (l_dobj) risk_23\NN\14541044|while_21 (l_prep) of_24\IN\0|the_9 (l_pobj) anemia_26\NN\14189204|NONE_0
D012254_D007674 NONE ribavirin_8\RB\2725367|-_9 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) hemolysis_11\NN\13509528|NONE_0 (r_pobj) of_7\IN\0|a_9 (r_prep) result_6\NN\34213|mainly_12 (r_pobj) as_4\IN\14622893|concentrations_31|,_42|and_44|be_64 (r_prep) decrease_2\VBP\7296428|NONE_0 (l_conj) be_17\VB\14625458|concentrations_95|as_64|,_22|and_20 (l_conj) comorbid_29\VBN\0|anemia_84|can_77|problematic_70|in_58|._42 (l_dobj) disorders_33\NNS\14034177|those_48|have_38
D007372_D006526 NONE interferon_12\NN\2725367|NONE_0 (r_pobj) with_10\IN\0|combination_20 (r_prep) therapy_9\NN\657604|treatment_43|._47 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) treatment_3\NN\654885|therapy_43|._90 (l_prep) for_4\IN\0|the_27|current_23|best_15 (l_pobj) infection_6\NN\14052046|NONE_0
D012254_D002318 NONE ribavirin_8\RB\2725367|-_9 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) hemolysis_11\NN\13509528|NONE_0 (r_pobj) of_7\IN\0|a_9 (r_prep) result_6\NN\34213|mainly_12 (r_pobj) as_4\IN\14622893|concentrations_31|,_42|and_44|be_64 (r_prep) decrease_2\VBP\7296428|NONE_0 (l_conj) be_17\VB\14625458|concentrations_95|as_64|,_22|and_20 (l_conj) comorbid_29\VBN\0|anemia_84|can_77|problematic_70|in_58|._42 (l_dobj) disorders_33\NNS\14034177|those_48|have_38
D012254_D000740 NONE ribavirin_8\RB\2725367|-_9 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) hemolysis_11\NN\13509528|NONE_0 (r_pobj) of_7\IN\0|a_9 (r_prep) result_6\NN\34213|mainly_12 (r_pobj) as_4\IN\14622893|concentrations_31|,_42|and_44|be_64 (r_prep) decrease_2\VBP\7296428|NONE_0 (l_conj) be_17\VB\14625458|concentrations_95|as_64|,_22|and_20 (l_nsubj) anemia_15\NN\14189204|can_7|problematic_14|in_26|comorbid_84|._126
D012254_D000740 NONE ribavirin_1\RB\2725367|-_9 (r_npadvmod) associated_3\VBN\628491|NONE_0 (r_amod) anemia_4\NN\14189204|although_30|can_7|be_11|by_23
D012254_D000740 NONE ribavirin_8\RB\2725367|-_9 (r_npadvmod) associated_10\VBN\628491|NONE_0 (r_amod) anemia_11\NN\14189204|to_31
D012254_D019698 NONE ribavirin_8\NN\2725367|NONE_0 (r_pobj) of_7\IN\0|a_26|targeting_18 (r_prep) prodrug_6\NN\0|,_20|,_20 (r_appos) viramidine_0\NNP\0|potential_60 (r_nsubj) has_10\VBZ\13888491|NONE_0 (l_dobj) potential_12\NN\14481929|viramidine_60 (l_acl) maintain_14\VB\0|the_17 (l_advcl) decreasing_21\VBG\169651|to_54|efficacy_28 (l_dobj) risk_23\NN\14541044|while_21 (l_prep) of_24\IN\0|the_9 (l_pobj) anemia_26\NN\14189204|NONE_0 (l_prep) in_27\IN\13603305|hemolytic_17 (l_pobj) patients_28\NNS\9898892|NONE_0 (l_prep) with_29\IN\0|NONE_0 (l_pobj) c._32\NNP\0|NONE_0
D012254_D019698 NONE ribavirin_19\RB\2725367|NONE_0 (r_pobj) of_18\IN\0|the_23|virologic_19 (r_prep) efficacy_17\NN\5199286|to_26|decreasing_28 (r_dobj) maintain_14\VB\0|the_17 (l_advcl) decreasing_21\VBG\169651|to_54|efficacy_28 (l_dobj) risk_23\NN\14541044|while_21 (l_prep) of_24\IN\0|the_9 (l_pobj) anemia_26\NN\14189204|NONE_0 (l_prep) in_27\IN\13603305|hemolytic_17 (l_pobj) patients_28\NNS\9898892|NONE_0 (l_prep) with_29\IN\0|NONE_0 (l_pobj) c._32\NNP\0|NONE_0
D012254_D006461 NONE ribavirin_8\RB\2725367|-_9 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) hemolysis_11\NN\13509528|NONE_0
D012254_D000743 CID ribavirin_8\NN\2725367|NONE_0 (r_pobj) of_7\IN\0|a_26|targeting_18 (r_prep) prodrug_6\NN\0|,_20|,_20 (r_appos) viramidine_0\NNP\0|potential_60 (r_nsubj) has_10\VBZ\13888491|NONE_0 (l_dobj) potential_12\NN\14481929|viramidine_60 (l_acl) maintain_14\VB\0|the_17 (l_advcl) decreasing_21\VBG\169651|to_54|efficacy_28 (l_dobj) risk_23\NN\14541044|while_21 (l_prep) of_24\IN\0|the_9 (l_pobj) anemia_26\NN\14189204|NONE_0
D012254_D000743 CID ribavirin_19\RB\2725367|NONE_0 (r_pobj) of_18\IN\0|the_23|virologic_19 (r_prep) efficacy_17\NN\5199286|to_26|decreasing_28 (r_dobj) maintain_14\VB\0|the_17 (l_advcl) decreasing_21\VBG\169651|to_54|efficacy_28 (l_dobj) risk_23\NN\14541044|while_21 (l_prep) of_24\IN\0|the_9 (l_pobj) anemia_26\NN\14189204|NONE_0
D012254_D006526 NONE ribavirin_14\NN\2725367|pegylated_25|and_4 (r_conj) interferon_12\NN\2725367|NONE_0 (r_pobj) with_10\IN\0|combination_20 (r_prep) therapy_9\NN\657604|treatment_43|._47 (r_attr) is_7\VBZ\0|NONE_0 (l_nsubj) treatment_3\NN\654885|therapy_43|._90 (l_prep) for_4\IN\0|the_27|current_23|best_15 (l_pobj) infection_6\NN\14052046|NONE_0
D012254_D006526 NONE ribavirin_8\RB\2725367|-_9 (r_npadvmod) induced_10\VBN\1627355|NONE_0 (r_amod) hemolysis_11\NN\13509528|NONE_0 (r_pobj) of_7\IN\0|a_9 (r_prep) result_6\NN\34213|mainly_12 (r_pobj) as_4\IN\14622893|concentrations_31|,_42|and_44|be_64 (r_prep) decrease_2\VBP\7296428|NONE_0 (l_conj) be_17\VB\14625458|concentrations_95|as_64|,_22|and_20 (l_prep) in_19\IN\13603305|anemia_26|can_19|problematic_12|comorbid_58|._100 (l_pobj) patients_20\NNS\9898892|NONE_0 (l_prep) with_21\IN\0|NONE_0 (l_pobj) infection_23\NN\14052046|NONE_0
C026956_D019698 NONE viramidine_0\NNP\0|potential_60 (r_nsubj) has_10\VBZ\13888491|NONE_0 (l_dobj) potential_12\NN\14481929|viramidine_60 (l_acl) maintain_14\VB\0|the_17 (l_advcl) decreasing_21\VBG\169651|to_54|efficacy_28 (l_dobj) risk_23\NN\14541044|while_21 (l_prep) of_24\IN\0|the_9 (l_pobj) anemia_26\NN\14189204|NONE_0 (l_prep) in_27\IN\13603305|hemolytic_17 (l_pobj) patients_28\NNS\9898892|NONE_0 (l_prep) with_29\IN\0|NONE_0 (l_pobj) c._32\NNP\0|NONE_0
16132524
D017239_D001929 CID paclitaxel_9\NN\0|six_45|and_11|suffered_15|._131 (r_dobj) received_4\VBD\2210855|NONE_0 (l_conj) suffered_11\VBD\2110220|six_60|paclitaxel_15|and_4|._116 (l_prep) from_12\IN\0|,_35|received_66 (l_prep) to_14\TO\0|moderate_9 (l_pobj) edema_17\NN\14315192|NONE_0
D017239_D001929 CID paclitaxel_30\NN\0|NONE_0 (r_pobj) of_27\IN\0|only_13|a_8 (r_prep) total_26\NN\3553|while_45|patients_25 (r_dobj) received_23\VBD\2210855|from_66|,_31 (r_advcl) suffered_11\VBD\2110220|six_60|paclitaxel_15|and_4|._116 (l_prep) from_12\IN\0|,_35|received_66 (l_prep) to_14\TO\0|moderate_9 (l_pobj) edema_17\NN\14315192|NONE_0
D017239_D005909 NONE paclitaxel_3\NN\0|/_10 (r_nmod) carboplatin_5\VB\0|liquid_12|crystalline_19|cubic_31|)_43|for_45 (r_amod) phases_9\NNS\15113229|intracavitary_76|(_49|._59 (l_prep) for_11\IN\0|carboplatin_45|liquid_33|crystalline_26|cubic_14|)_2 (l_pobj) glioblastoma_13\NN\14236743|NONE_0
D017239_D005909 NONE paclitaxel_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|a_37|surgical_35|intracavitary_26 (r_prep) application_19\NN\947128|NONE_0 (r_pobj) of_15\IN\0|term_13|and_54|encapsulated_70 (r_prep) effects_14\NNS\13245626|,_17|and_15 (r_conj) safety_8\NN\13920835|the_17|,_2 (r_conj) feasibility_6\NN\5152150|for_40|,_6|are_162|in_175|._191 (r_nsubjpass) examined_31\VBN\0|NONE_0 (l_prep) for_0\IN\0|,_34|feasibility_40|are_202|in_215|._231 (l_pobj) recurrences_3\NNS\7342049|NONE_0 (l_compound) glioblastoma_2\NN\14236743|human_6
D017239_D005909 NONE paclitaxel_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|an_29|intracavitary_26 (r_prep) application_20\NN\947128|and_26|phases_48 (r_dobj) received_17\VBD\2210855|and_4 (r_conj) underwent_12\VBN\109660|a_26|glioblastoma_24 (r_acl) multiforme_11\NN\0|NONE_0 (l_compound) glioblastoma_10\NN\14236743|a_2|underwent_24
D016190_D005909 NONE carboplatin_5\VB\0|liquid_12|crystalline_19|cubic_31|)_43|for_45 (r_amod) phases_9\NNS\15113229|intracavitary_76|(_49|._59 (l_prep) for_11\IN\0|carboplatin_45|liquid_33|crystalline_26|cubic_14|)_2 (l_pobj) glioblastoma_13\NN\14236743|NONE_0
D016190_D005909 NONE carboplatin_23\NN\0|by_25 (r_advmod) encapsulated_24\VBN\1587062|term_83|of_70|and_16 (r_conj) effects_14\NNS\13245626|,_17|and_15 (r_conj) safety_8\NN\13920835|the_17|,_2 (r_conj) feasibility_6\NN\5152150|for_40|,_6|are_162|in_175|._191 (r_nsubjpass) examined_31\VBN\0|NONE_0 (l_prep) for_0\IN\0|,_34|feasibility_40|are_202|in_215|._231 (l_pobj) recurrences_3\NNS\7342049|NONE_0 (l_compound) glioblastoma_2\NN\14236743|human_6
D016190_D005909 NONE carboplatin_24\VB\0|cubic_12|in_25 (r_amod) phases_26\NNS\15113229|application_48|and_22 (r_conj) received_17\VBD\2210855|and_4 (r_conj) underwent_12\VBN\109660|a_26|glioblastoma_24 (r_acl) multiforme_11\NN\0|NONE_0 (l_compound) glioblastoma_10\NN\14236743|a_2|underwent_24
8841157
D000804_D006973 NONE ii_5\CD\13741022|a_18|angiotensin_12|for_14 (r_compound) antagonist_6\NN\7846|,_23|:_54|study_70|._121 (l_prep) for_7\IN\0|a_32|angiotensin_26|ii_14 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) of_10\IN\0|the_14 (l_pobj) hypertension_12\NN\14057371|NONE_0
C081489_D006973 NONE valsartan_0\NNP\2712393|NONE_0 (l_appos) antagonist_6\NN\7846|,_23|:_54|study_70|._121 (l_prep) for_7\IN\0|a_32|angiotensin_26|ii_14 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) of_10\IN\0|the_14 (l_pobj) hypertension_12\NN\14057371|NONE_0
C081489_D006973 NONE valsartan_27\NN\2712393|to_17 (r_dobj) receive_24\VB\2210855|outpatients_115|were_68|randomly_63|in_44|._55 (r_advcl) allocated_14\VBN\2228698|NONE_0 (l_nsubjpass) outpatients_6\NNS\10405694|were_47|randomly_52|in_71|receive_115|._170 (l_prep) with_7\IN\0|hundred_38|eight_24|adult_18 (l_pobj) hypertension_11\NN\14057371|NONE_0
C081489_D006973 NONE valsartan_4\NN\2712393|that_5|effective_25 (r_nsubj) is_5\VBZ\0|data_25|._88 (l_acomp) effective_9\JJ\0|that_30|valsartan_25 (l_prep) as_10\IN\14622893|least_19|as_13 (l_pobj) amlodipine_11\NN\0|NONE_0 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|the_14 (l_pobj) hypertension_19\NN\14057371|NONE_0
D017311_D004487 CID amlodipine_13\NN\0|the_4 (r_compound) group_14\NN\2137|NONE_0 (r_pobj) in_11\IN\13603305|incidence_62|higher_7|,_23|at_38|%_95|._184 (r_prep) was_8\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|higher_55|in_62|,_85|at_100|%_157|._246 (l_prep) of_2\IN\0|the_14 (l_pobj) edema_7\NN\14315192|NONE_0
D017311_D004487 CID amlodipine_38\NN\0|NONE_0 (r_pobj) for_35\IN\0|3.6_5|;_19|%_22|;_58|%_64|)_86 (r_prep) %_34\NN\0|incidence_157|higher_102|in_95|,_72|at_57|._89 (r_npadvmod) was_8\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|higher_55|in_62|,_85|at_100|%_157|._246 (l_prep) of_2\IN\0|the_14 (l_pobj) edema_7\NN\14315192|NONE_0
D017311_D004487 CID amlodipine_47\NN\0|0_27|for_24|plus_10 (r_conj) %_41\NN\0|3.6_27|for_22|;_3|;_36|%_42|)_64 (r_conj) %_34\NN\0|incidence_157|higher_102|in_95|,_72|at_57|._89 (r_npadvmod) was_8\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|higher_55|in_62|,_85|at_100|%_157|._246 (l_prep) of_2\IN\0|the_14 (l_pobj) edema_7\NN\14315192|NONE_0
D017311_D004487 CID amlodipine_54\NN\0|NONE_0 (r_pobj) for_51\IN\0|14.3_6 (r_prep) %_50\NN\0|3.6_69|for_64|;_45|%_42|;_6|)_22 (r_appos) %_34\NN\0|incidence_157|higher_102|in_95|,_72|at_57|._89 (r_npadvmod) was_8\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|higher_55|in_62|,_85|at_100|%_157|._246 (l_prep) of_2\IN\0|the_14 (l_pobj) edema_7\NN\14315192|NONE_0
D017311_D006973 NONE amlodipine_23\NN\0|NONE_0 (r_pobj) against_22\IN\0|NONE_0 (r_prep) safety_21\NN\13920835|the_17|and_4 (r_conj) efficacy_19\NN\5199286|NONE_0 (r_pobj) of_17\IN\0|a_20|comparative_18 (r_prep) study_16\NN\635850|,_93|antagonist_70|:_16|._51 (r_appos) valsartan_0\NNP\2712393|NONE_0 (l_appos) antagonist_6\NN\7846|,_23|:_54|study_70|._121 (l_prep) for_7\IN\0|a_32|angiotensin_26|ii_14 (l_pobj) treatment_9\NN\654885|NONE_0 (l_prep) of_10\IN\0|the_14 (l_pobj) hypertension_12\NN\14057371|NONE_0
D017311_D006973 NONE amlodipine_31\NN\0|80_24|mg_21|or_8 (r_conj) valsartan_27\NN\2712393|to_17 (r_dobj) receive_24\VB\2210855|outpatients_115|were_68|randomly_63|in_44|._55 (r_advcl) allocated_14\VBN\2228698|NONE_0 (l_nsubjpass) outpatients_6\NNS\10405694|were_47|randomly_52|in_71|receive_115|._170 (l_prep) with_7\IN\0|hundred_38|eight_24|adult_18 (l_pobj) hypertension_11\NN\14057371|NONE_0
D017311_D006973 NONE amlodipine_11\NN\0|NONE_0 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|the_14 (l_pobj) hypertension_19\NN\14057371|NONE_0
C081489_D004487 CID valsartan_31\NN\2712393|NONE_0 (r_pobj) for_28\IN\0|2.4_5 (r_prep) %_27\NN\0|a_28|of_21|(_4|;_21 (r_appos) dose_19\NN\3740161|particularly_18 (r_pobj) at_17\IN\14622893|incidence_100|higher_45|in_38|,_15|%_57|._146 (r_prep) was_8\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|higher_55|in_62|,_85|at_100|%_157|._246 (l_prep) of_2\IN\0|the_14 (l_pobj) edema_7\NN\14315192|NONE_0
C081489_D004487 CID valsartan_43\NN\2712393|NONE_0 (r_pobj) for_42\IN\0|0_3|plus_14|amlodipine_24 (r_prep) %_41\NN\0|3.6_27|for_22|;_3|;_36|%_42|)_64 (r_conj) %_34\NN\0|incidence_157|higher_102|in_95|,_72|at_57|._89 (r_npadvmod) was_8\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|higher_55|in_62|,_85|at_100|%_157|._246 (l_prep) of_2\IN\0|the_14 (l_pobj) edema_7\NN\14315192|NONE_0
12180796
D009569_D001167 NONE oxide_21\NN\14818238|nitric_7|(_15|inos_16|)_20|,_21|factor_47 (r_compound) synthase_22\NN\0|NONE_0 (r_pobj) of_19\IN\0|inducible_15 (r_prep) type_18\NN\5839024|NONE_0 (r_pobj) of_16\IN\0|NONE_0 (r_prep) expressions_15\NNS\4679549|NONE_0 (r_pobj) for_14\IN\0|,_37|was_35|immunohistochemically_22|._146 (r_prep) examined_12\VBN\0|arteritis_76|in_58|,_35|fenoldopam_33 (r_conj) induced_1\VBN\1627355|NONE_0 (l_nsubj) arteritis_0\NNP\14336539|in_18|,_41|fenoldopam_43|examined_76
D018818_D001167 CID fenoldopam_12\NN\0|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_prep) rats_10\NNS\2329401|NONE_0 (r_pobj) in_9\IN\13603305|beta1_39|,_38|vasodilators_40|._52 (r_prep) induced_8\VBN\1627355|NONE_0 (l_nsubj) beta1_0\NNP\0|in_39|,_77|vasodilators_79|._91 (l_prep) in_6\IN\13603305|(_12|beta1_7|)_2 (l_pobj) arteritis_7\NN\14336539|NONE_0
D018818_D001167 CID fenoldopam_7\NN\0|arteritis_43|in_25|,_2|examined_33 (r_npadvmod) induced_1\VBN\1627355|NONE_0 (l_nsubj) arteritis_0\NNP\14336539|in_18|,_41|fenoldopam_43|examined_76
D013806_D001167 CID theophylline_14\NN\2905612|and_4 (r_conj) fenoldopam_12\NN\0|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_prep) rats_10\NNS\2329401|NONE_0 (r_pobj) in_9\IN\13603305|beta1_39|,_38|vasodilators_40|._52 (r_prep) induced_8\VBN\1627355|NONE_0 (l_nsubj) beta1_0\NNP\0|in_39|,_77|vasodilators_79|._91 (l_prep) in_6\IN\13603305|(_12|beta1_7|)_2 (l_pobj) arteritis_7\NN\14336539|NONE_0
D013806_D001167 CID theophylline_9\NN\2905612|and_4 (r_conj) fenoldopam_7\NN\0|arteritis_43|in_25|,_2|examined_33 (r_npadvmod) induced_1\VBN\1627355|NONE_0 (l_nsubj) arteritis_0\NNP\14336539|in_18|,_41|fenoldopam_43|examined_76
D013806_D009369 NONE theophylline_9\NN\2905612|and_4 (r_conj) fenoldopam_7\NN\0|arteritis_43|in_25|,_2|examined_33 (r_npadvmod) induced_1\VBN\1627355|NONE_0 (l_conj) examined_12\VBN\0|arteritis_76|in_58|,_35|fenoldopam_33 (l_prep) for_14\IN\0|,_37|was_35|immunohistochemically_22|._146 (l_pobj) expressions_15\NNS\4679549|NONE_0 (l_prep) of_16\IN\0|NONE_0 (l_pobj) type_18\NN\5839024|NONE_0 (l_prep) of_19\IN\0|inducible_15 (l_pobj) synthase_22\NN\0|NONE_0 (l_appos) factor_30\NN\7326557|nitric_54|oxide_47|(_32|inos_31|)_27|,_26 (l_conj) beta1_39\NNP\0|basic_62|growth_45|(_31|bfgf_30|)_26|and_24 (l_compound) factor_37\NN\7326557|(_13|beta1_18|)_23 (l_compound) tumor_35\NN\14234074|growth_6|-_19
D018818_D009369 NONE fenoldopam_7\NN\0|arteritis_43|in_25|,_2|examined_33 (r_npadvmod) induced_1\VBN\1627355|NONE_0 (l_conj) examined_12\VBN\0|arteritis_76|in_58|,_35|fenoldopam_33 (l_prep) for_14\IN\0|,_37|was_35|immunohistochemically_22|._146 (l_pobj) expressions_15\NNS\4679549|NONE_0 (l_prep) of_16\IN\0|NONE_0 (l_pobj) type_18\NN\5839024|NONE_0 (l_prep) of_19\IN\0|inducible_15 (l_pobj) synthase_22\NN\0|NONE_0 (l_appos) factor_30\NN\7326557|nitric_54|oxide_47|(_32|inos_31|)_27|,_26 (l_conj) beta1_39\NNP\0|basic_62|growth_45|(_31|bfgf_30|)_26|and_24 (l_compound) factor_37\NN\7326557|(_13|beta1_18|)_23 (l_compound) tumor_35\NN\14234074|growth_6|-_19
D009569_D009369 NONE oxide_7\NN\14818238|NONE_0 (l_appos) factor_15\NN\7326557|nitric_45|(_32|inos_31|)_27|,_26 (l_conj) growth_21\NN\13526110|basic_48|growth_31|(_17|bfgf_16|)_12|and_10 (l_compound) tumor_20\NN\14234074|NONE_0
D009569_D009369 NONE oxide_21\NN\14818238|nitric_7|(_15|inos_16|)_20|,_21|factor_47 (r_compound) synthase_22\NN\0|NONE_0 (l_appos) factor_30\NN\7326557|nitric_54|oxide_47|(_32|inos_31|)_27|,_26 (l_conj) beta1_39\NNP\0|basic_62|growth_45|(_31|bfgf_30|)_26|and_24 (l_compound) factor_37\NN\7326557|(_13|beta1_18|)_23 (l_compound) tumor_35\NN\14234074|growth_6|-_19
9431903
D005996_D046628 NONE trinitrate_3\NN\0|NONE_0 (l_prep) on_4\IN\0|glyceryl_20 (l_pobj) sphincter_6\NN\5289297|NONE_0 (l_prep) of_7\IN\0|the_14 (l_pobj) spasm_9\NN\14299637|NONE_0
D005996_D046628 NONE trinitrate_9\NN\0|NONE_0 (l_prep) on_10\IN\0|glyceryl_20 (l_pobj) sphincter_17\NN\5289297|NONE_0 (l_prep) of_18\IN\0|the_43|induced_18 (l_pobj) spasm_20\NN\14299637|NONE_0
D005996_D046628 NONE trinitrate_9\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) effect_6\NN\34213|objective_29|:_20|in_18|was_90|in_104|with_128|._161 (r_nsubjpass) evaluated_22\VBN\670261|NONE_0 (l_prep) with_27\IN\0|objective_157|:_148|in_146|effect_128|was_38|in_24|._33 (l_pobj) sphincter_28\NN\5289297|NONE_0 (l_prep) of_29\IN\0|NONE_0 (l_pobj) dyskinesia_31\NN\14084880|NONE_0
D005996_D046628 NONE trinitrate_11\NN\0|NONE_0 (l_prep) on_12\IN\0|glyceryl_20 (l_pobj) sphincter_17\NN\5289297|NONE_0 (l_prep) of_18\IN\0|the_31|induced_18 (l_pobj) spasm_20\NN\14299637|NONE_0
D005996_D046628 NONE trinitrate_2\NN\0|since_15|able_14 (r_nsubj) is_3\VBZ\0|,_55|it_57|might_60|of_69|in_82|._130 (r_advcl) be_16\VB\14625458|NONE_0 (l_prep) in_19\IN\13603305|is_82|,_27|it_25|might_22|of_13|._48 (l_pobj) treatment_21\NN\654885|NONE_0 (l_prep) of_22\IN\0|the_14 (l_pobj) sphincter_23\NN\5289297|NONE_0 (l_prep) of_24\IN\0|NONE_0 (l_pobj) dyskinesia_26\NN\14084880|NONE_0
D009388_D013035 CID prostigmine_12\JJ\0|-_11 (r_compound) morphine_14\NN\2707683|NONE_0 (r_compound) administration_15\NN\1133281|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) evoked_10\VBN\1617192|oddi_11 (r_acl) spasm_9\NN\14299637|NONE_0
D009388_D013035 CID prostigmine_12\JJ\0|-_11 (r_compound) morphine_14\NN\2707683|-_8 (r_npadvmod) induced_16\VBN\1627355|the_25|of_18 (r_amod) sphincter_17\NN\5289297|NONE_0 (l_prep) of_18\IN\0|the_43|induced_18 (l_pobj) spasm_20\NN\14299637|NONE_0
D009388_D013035 CID prostigmine_7\JJ\0|-_11 (r_compound) morphine_9\NN\2707683|prostigmine_32 (r_compound) administration_10\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|spasm_18|was_12|and_110|visualized_114|._167 (r_agent) induced_5\VBN\1627355|NONE_0 (l_nsubjpass) spasm_3\NN\14299637|was_6|by_18|and_128|visualized_132|._185
D009388_D013035 CID prostigmine_14\NN\0|morphine_32 (r_parataxis) administration_10\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|spasm_18|was_12|and_110|visualized_114|._167 (r_agent) induced_5\VBN\1627355|NONE_0 (l_nsubjpass) spasm_3\NN\14299637|was_6|by_18|and_128|visualized_132|._185
D009388_D013035 CID prostigmine_1\JJ\0|-_11 (r_compound) morphine_3\NN\2707683|NONE_0 (r_compound) provocation_4\NN\1221611|:_23|increases_31|5.05_115|)_138|and_140|+/-_177|indicating_401|._466 (r_nsubj) caused_5\VBD\1617192|NONE_0 (l_advcl) indicating_97\VBG\952524|:_424|provocation_401|increases_370|5.05_286|)_263|and_261|+/-_224|._65 (l_dobj) spasm_100\NN\14299637|NONE_0
D009388_D046628 CID prostigmine_12\JJ\0|-_11 (r_compound) morphine_14\NN\2707683|NONE_0 (r_compound) administration_15\NN\1133281|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) evoked_10\VBN\1617192|oddi_11 (r_acl) spasm_9\NN\14299637|NONE_0
D009388_D046628 CID prostigmine_12\JJ\0|-_11 (r_compound) morphine_14\NN\2707683|-_8 (r_npadvmod) induced_16\VBN\1627355|the_25|of_18 (r_amod) sphincter_17\NN\5289297|NONE_0 (l_prep) of_18\IN\0|the_43|induced_18 (l_pobj) spasm_20\NN\14299637|NONE_0
D009388_D046628 CID prostigmine_12\JJ\0|-_11 (r_compound) morphine_14\NN\2707683|-_8 (r_npadvmod) induced_16\VBN\1627355|the_25|of_18 (r_amod) sphincter_17\NN\5289297|NONE_0 (r_pobj) on_10\IN\0|glyceryl_20 (r_prep) trinitrate_9\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) effect_6\NN\34213|objective_29|:_20|in_18|was_90|in_104|with_128|._161 (r_nsubjpass) evaluated_22\VBN\670261|NONE_0 (l_prep) with_27\IN\0|objective_157|:_148|in_146|effect_128|was_38|in_24|._33 (l_pobj) sphincter_28\NN\5289297|NONE_0 (l_prep) of_29\IN\0|NONE_0 (l_pobj) dyskinesia_31\NN\14084880|NONE_0
D009388_D046628 CID prostigmine_7\JJ\0|-_11 (r_compound) morphine_9\NN\2707683|prostigmine_32 (r_compound) administration_10\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|spasm_18|was_12|and_110|visualized_114|._167 (r_agent) induced_5\VBN\1627355|NONE_0 (l_nsubjpass) spasm_3\NN\14299637|was_6|by_18|and_128|visualized_132|._185
D009388_D046628 CID prostigmine_14\NN\0|morphine_32 (r_parataxis) administration_10\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|spasm_18|was_12|and_110|visualized_114|._167 (r_agent) induced_5\VBN\1627355|NONE_0 (l_nsubjpass) spasm_3\NN\14299637|was_6|by_18|and_128|visualized_132|._185
D009020_D013035 CID morphine_14\NN\2707683|NONE_0 (r_compound) administration_15\NN\1133281|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) evoked_10\VBN\1617192|oddi_11 (r_acl) spasm_9\NN\14299637|NONE_0
D009020_D013035 CID morphine_14\NN\2707683|-_8 (r_npadvmod) induced_16\VBN\1627355|the_25|of_18 (r_amod) sphincter_17\NN\5289297|NONE_0 (l_prep) of_18\IN\0|the_43|induced_18 (l_pobj) spasm_20\NN\14299637|NONE_0
D009020_D013035 CID morphine_9\NN\2707683|prostigmine_32 (r_compound) administration_10\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|spasm_18|was_12|and_110|visualized_114|._167 (r_agent) induced_5\VBN\1627355|NONE_0 (l_nsubjpass) spasm_3\NN\14299637|was_6|by_18|and_128|visualized_132|._185
D009020_D013035 CID morphine_19\NN\2707683|(_46|mg_41|intramuscularly_26|and_10|subcutaneously_9|)_23 (r_conj) prostigmine_14\NN\0|morphine_32 (r_parataxis) administration_10\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|spasm_18|was_12|and_110|visualized_114|._167 (r_agent) induced_5\VBN\1627355|NONE_0 (l_nsubjpass) spasm_3\NN\14299637|was_6|by_18|and_128|visualized_132|._185
D009020_D013035 CID morphine_3\NN\2707683|NONE_0 (r_compound) provocation_4\NN\1221611|:_23|increases_31|5.05_115|)_138|and_140|+/-_177|indicating_401|._466 (r_nsubj) caused_5\VBD\1617192|NONE_0 (l_advcl) indicating_97\VBG\952524|:_424|provocation_401|increases_370|5.05_286|)_263|and_261|+/-_224|._65 (l_dobj) spasm_100\NN\14299637|NONE_0
D009020_D013035 CID morphine_14\NN\2707683|-_8 (r_npadvmod) induced_16\VBN\1627355|the_13|of_18 (r_amod) sphincter_17\NN\5289297|NONE_0 (l_prep) of_18\IN\0|the_31|induced_18 (l_pobj) spasm_20\NN\14299637|NONE_0
D005996_D013035 NONE trinitrate_3\NN\0|NONE_0 (l_prep) on_4\IN\0|glyceryl_20 (l_pobj) sphincter_6\NN\5289297|NONE_0 (l_prep) of_7\IN\0|the_14 (l_pobj) spasm_9\NN\14299637|NONE_0
D005996_D013035 NONE trinitrate_9\NN\0|NONE_0 (l_prep) on_10\IN\0|glyceryl_20 (l_pobj) sphincter_17\NN\5289297|NONE_0 (l_prep) of_18\IN\0|the_43|induced_18 (l_pobj) spasm_20\NN\14299637|NONE_0
D005996_D013035 NONE trinitrate_11\NN\0|NONE_0 (l_prep) on_12\IN\0|glyceryl_20 (l_pobj) sphincter_17\NN\5289297|NONE_0 (l_prep) of_18\IN\0|the_31|induced_18 (l_pobj) spasm_20\NN\14299637|NONE_0
D009020_D046628 CID morphine_14\NN\2707683|NONE_0 (r_compound) administration_15\NN\1133281|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_agent) evoked_10\VBN\1617192|oddi_11 (r_acl) spasm_9\NN\14299637|NONE_0
D009020_D046628 CID morphine_14\NN\2707683|-_8 (r_npadvmod) induced_16\VBN\1627355|the_25|of_18 (r_amod) sphincter_17\NN\5289297|NONE_0 (l_prep) of_18\IN\0|the_43|induced_18 (l_pobj) spasm_20\NN\14299637|NONE_0
D009020_D046628 CID morphine_14\NN\2707683|-_8 (r_npadvmod) induced_16\VBN\1627355|the_25|of_18 (r_amod) sphincter_17\NN\5289297|NONE_0 (r_pobj) on_10\IN\0|glyceryl_20 (r_prep) trinitrate_9\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_11 (r_prep) effect_6\NN\34213|objective_29|:_20|in_18|was_90|in_104|with_128|._161 (r_nsubjpass) evaluated_22\VBN\670261|NONE_0 (l_prep) with_27\IN\0|objective_157|:_148|in_146|effect_128|was_38|in_24|._33 (l_pobj) sphincter_28\NN\5289297|NONE_0 (l_prep) of_29\IN\0|NONE_0 (l_pobj) dyskinesia_31\NN\14084880|NONE_0
D009020_D046628 CID morphine_9\NN\2707683|prostigmine_32 (r_compound) administration_10\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|spasm_18|was_12|and_110|visualized_114|._167 (r_agent) induced_5\VBN\1627355|NONE_0 (l_nsubjpass) spasm_3\NN\14299637|was_6|by_18|and_128|visualized_132|._185
D009020_D046628 CID morphine_19\NN\2707683|(_46|mg_41|intramuscularly_26|and_10|subcutaneously_9|)_23 (r_conj) prostigmine_14\NN\0|morphine_32 (r_parataxis) administration_10\NN\1133281|NONE_0 (r_pobj) by_6\IN\0|spasm_18|was_12|and_110|visualized_114|._167 (r_agent) induced_5\VBN\1627355|NONE_0 (l_nsubjpass) spasm_3\NN\14299637|was_6|by_18|and_128|visualized_132|._185
D009020_D046628 CID morphine_14\NN\2707683|-_8 (r_npadvmod) induced_16\VBN\1627355|the_13|of_18 (r_amod) sphincter_17\NN\5289297|NONE_0 (l_prep) of_18\IN\0|the_31|induced_18 (l_pobj) spasm_20\NN\14299637|NONE_0
D009020_D046628 CID morphine_12\NN\2707683|NONE_0 (r_pobj) of_11\IN\0|even_24|the_19|drastic_15 (r_prep) effect_10\NN\34213|to_29 (r_dobj) overcome_6\VB\0|NONE_0 (r_xcomp) able_4\JJ\0|since_29|trinitrate_14 (r_acomp) is_3\VBZ\0|,_55|it_57|might_60|of_69|in_82|._130 (r_advcl) be_16\VB\14625458|NONE_0 (l_prep) in_19\IN\13603305|is_82|,_27|it_25|might_22|of_13|._48 (l_pobj) treatment_21\NN\654885|NONE_0 (l_prep) of_22\IN\0|the_14 (l_pobj) sphincter_23\NN\5289297|NONE_0 (l_prep) of_24\IN\0|NONE_0 (l_pobj) dyskinesia_26\NN\14084880|NONE_0
3015327
D007538_D009422 CID isoniazid_6\NN\2716205|in_21 (r_compound) neuropathy_7\NN\14204950|NONE_0
D007538_D009422 CID isoniazid_8\NN\2716205|NONE_0 (r_pobj) of_7\IN\0|a_14|single_12|in_13 (r_prep) dose_6\NN\3740161|NONE_0 (r_pobj) by_3\IN\0|NONE_0 (r_agent) caused_2\VBN\1617192|the_15 (r_acl) neuropathy_1\NN\14204950|was_56|with_68|._112
9201797
D002354_D002375 NONE hydrochloride_5\NN\14817592|NONE_0 (r_pobj) of_3\IN\0|the_23|attenuating_19|on_60|._100 (r_prep) effect_2\NN\34213|NONE_0 (l_prep) on_13\IN\0|the_83|attenuating_79|of_60|._40 (l_pobj) catalepsy_17\NN\14023236|NONE_0
D002354_D002375 NONE carteolol_5\NN\0|NONE_0 (r_pobj) of_4\IN\0|the_12|,_12|antagonist_34 (r_prep) effects_3\NNS\13245626|therefore_15|,_6|were_95|behaviorally_100|and_121|compared_125|._207 (l_appos) antagonist_11\NN\7846|the_46|of_34|,_22 (l_prep) on_13\IN\0|a_32|adrenoceptor_25|,_2 (l_pobj) catalepsy_17\NN\14023236|NONE_0
D002354_D002375 NONE carteolol_0\NNP\0|NONE_0 (l_conj) propranolol_5\NN\0|,_13|as_3|._70 (l_conj) inhibited_9\VBD\2510337|and_15|biperiden_11|,_2 (l_dobj) catalepsy_14\NN\14023236|NONE_0
D002354_D002375 NONE carteolol_5\NN\0|that_5|catalepsy_39|via_49|and_97|expected_104 (r_nsubj) improves_6\VBZ\126264|results_40|strongly_32|._274 (l_dobj) catalepsy_10\NN\14023236|that_44|carteolol_39|via_10|and_58|expected_65
D006220_D002375 CID haloperidol_14\NN\3713736|-_11 (r_npadvmod) induced_16\VBN\1627355|in_18 (r_amod) catalepsy_17\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_11\NN\3713736|-_11 (r_npadvmod) induced_13\VBN\1627355|the_16 (r_amod) catalepsy_14\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_7\NN\3713736|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) catalepsy_10\NN\14023236|that_44|carteolol_39|via_10|and_58|expected_65
D004298_D017109 NONE dopamine_40\NN\14807737|NONE_0 (r_nmod) receptor_41\NN\5225602|its_26|postsynaptic_22|antagonistic_9 (r_nmod) activity_43\NN\30358|NONE_0 (r_pobj) to_37\IN\0|NONE_0 (r_pcomp) due_36\IN\5174653|effects_8 (r_prep) attenuating_30\VBG\224901|NONE_0 (r_pcomp) without_29\IN\0|the_27|of_13 (r_prep) treatment_26\NN\654885|NONE_0 (l_prep) of_27\IN\0|the_14|without_13 (l_pobj) akathisia_28\NN\0|NONE_0
D002354_D009069 NONE carteolol_0\NNP\0|did_10|not_14|signs_78|._130 (r_nsubj) evoke_3\VB\1617192|NONE_0 (l_dobj) signs_10\NNS\6643763|carteolol_78|did_68|not_64|._52 (l_prep) as_12\IN\14622893|postsynaptic_65|dopamine_52|stimulating_34|behavioral_22 (l_pobj) stereotypy_13\NN\0|such_8 (l_conj) hyperlocomotion_15\NN\0|and_4|in_16
D004298_D009069 NONE dopamine_5\NN\14807737|postsynaptic_13|stimulating_18|behavioral_30|as_52 (r_nmod) signs_10\NNS\6643763|carteolol_78|did_68|not_64|._52 (l_prep) as_12\IN\14622893|postsynaptic_65|dopamine_52|stimulating_34|behavioral_22 (l_pobj) stereotypy_13\NN\0|such_8 (l_conj) hyperlocomotion_15\NN\0|and_4|in_16
D004298_D002375 NONE dopamine_40\NN\14807737|NONE_0 (r_nmod) receptor_41\NN\5225602|its_26|postsynaptic_22|antagonistic_9 (r_nmod) activity_43\NN\30358|NONE_0 (r_pobj) to_37\IN\0|NONE_0 (r_pcomp) due_36\IN\5174653|effects_8 (r_prep) attenuating_30\VBG\224901|NONE_0 (r_pcomp) without_29\IN\0|the_27|of_13 (r_prep) treatment_26\NN\654885|NONE_0 (r_pobj) in_24\IN\13603305|NONE_0 (r_prep) effective_23\JJ\0|to_6 (r_acomp) be_22\VB\14625458|is_15 (r_xcomp) expected_20\VBN\670261|that_109|carteolol_104|catalepsy_65|via_55|and_7 (r_conj) improves_6\VBZ\126264|results_40|strongly_32|._274 (l_dobj) catalepsy_10\NN\14023236|that_44|carteolol_39|via_10|and_58|expected_65
D006220_D017109 NONE haloperidol_7\NN\3713736|-_11 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (r_amod) catalepsy_10\NN\14023236|that_44|carteolol_39|via_10|and_58|expected_65 (r_dobj) improves_6\VBZ\126264|results_40|strongly_32|._274 (l_conj) expected_20\VBN\670261|that_109|carteolol_104|catalepsy_65|via_55|and_7 (l_xcomp) be_22\VB\14625458|is_15 (l_acomp) effective_23\JJ\0|to_6 (l_prep) in_24\IN\13603305|NONE_0 (l_pobj) treatment_26\NN\654885|NONE_0 (l_prep) of_27\IN\0|the_14|without_13 (l_pobj) akathisia_28\NN\0|NONE_0
D001712_D002375 NONE biperiden_30\VBN\0|and_4 (r_conj) propranolol_28\NN\0|NONE_0 (r_pobj) of_27\IN\0|,_28|antagonist_52 (r_prep) those_26\DT\0|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) compared_24\VBN\644583|therefore_140|,_131|effects_125|were_30|behaviorally_25|and_4|._82 (r_conj) studied_22\VBN\0|NONE_0 (l_nsubjpass) effects_3\NNS\13245626|therefore_15|,_6|were_95|behaviorally_100|and_121|compared_125|._207 (l_appos) antagonist_11\NN\7846|the_46|of_34|,_22 (l_prep) on_13\IN\0|a_32|adrenoceptor_25|,_2 (l_pobj) catalepsy_17\NN\14023236|NONE_0
D001712_D002375 NONE biperiden_7\RB\0|and_4|,_9|inhibited_11 (r_conj) propranolol_5\NN\0|,_13|as_3|._70 (l_conj) inhibited_9\VBD\2510337|and_15|biperiden_11|,_2 (l_dobj) catalepsy_14\NN\14023236|NONE_0
D011433_D002375 NONE propranolol_28\NN\0|NONE_0 (r_pobj) of_27\IN\0|,_28|antagonist_52 (r_prep) those_26\DT\0|NONE_0 (r_pobj) with_25\IN\0|NONE_0 (r_prep) compared_24\VBN\644583|therefore_140|,_131|effects_125|were_30|behaviorally_25|and_4|._82 (r_conj) studied_22\VBN\0|NONE_0 (l_nsubjpass) effects_3\NNS\13245626|therefore_15|,_6|were_95|behaviorally_100|and_121|compared_125|._207 (l_appos) antagonist_11\NN\7846|the_46|of_34|,_22 (l_prep) on_13\IN\0|a_32|adrenoceptor_25|,_2 (l_pobj) catalepsy_17\NN\14023236|NONE_0
D011433_D002375 NONE propranolol_5\NN\0|,_13|as_3|._70 (l_conj) inhibited_9\VBD\2510337|and_15|biperiden_11|,_2 (l_dobj) catalepsy_14\NN\14023236|NONE_0
D002354_D017109 NONE carteolol_5\NN\0|that_5|catalepsy_39|via_49|and_97|expected_104 (r_nsubj) improves_6\VBZ\126264|results_40|strongly_32|._274 (l_conj) expected_20\VBN\670261|that_109|carteolol_104|catalepsy_65|via_55|and_7 (l_xcomp) be_22\VB\14625458|is_15 (l_acomp) effective_23\JJ\0|to_6 (l_prep) in_24\IN\13603305|NONE_0 (l_pobj) treatment_26\NN\654885|NONE_0 (l_prep) of_27\IN\0|the_14|without_13 (l_pobj) akathisia_28\NN\0|NONE_0
15042318
D004317_D009136 NONE doxorubicin_34\NN\2716866|-_11 (r_npadvmod) based_36\VBN\0|NONE_0 (r_amod) chemotherapy_37\NN\661091|NONE_0 (r_pobj) of_33\IN\0|one_10 (r_prep) cycle_32\NN\15269513|in_40 (r_pobj) following_30\VBG\8180190|sudden_27|atrial_20 (r_prep) fibrillation_29\NN\14361664|the_68|common_59|of_47|,_20|and_18 (r_conj) form_20\NN\6286395|diffuse_72|lymphoma_49|,_18 (l_prep) of_21\IN\0|the_21|common_12|,_27|and_29|fibrillation_47 (l_pobj) dystrophy_24\NN\14151139|NONE_0
D004317_C535648 NONE doxorubicin_34\NN\2716866|-_11 (r_npadvmod) based_36\VBN\0|NONE_0 (r_amod) chemotherapy_37\NN\661091|NONE_0 (r_pobj) of_33\IN\0|one_10 (r_prep) cycle_32\NN\15269513|in_40 (r_pobj) following_30\VBG\8180190|sudden_27|atrial_20 (r_prep) fibrillation_29\NN\14361664|the_68|common_59|of_47|,_20|and_18 (r_conj) form_20\NN\6286395|diffuse_72|lymphoma_49|,_18 (r_appos) dystrophy_15\NN\14151139|NONE_0 (l_nmod) lymphoma_12\NN\14239918|diffuse_23|,_31|form_49
D004317_D009223 NONE doxorubicin_34\NN\2716866|-_11 (r_npadvmod) based_36\VBN\0|NONE_0 (r_amod) chemotherapy_37\NN\661091|NONE_0 (r_pobj) of_33\IN\0|one_10 (r_prep) cycle_32\NN\15269513|in_40 (r_pobj) following_30\VBG\8180190|sudden_27|atrial_20 (r_prep) fibrillation_29\NN\14361664|the_68|common_59|of_47|,_20|and_18 (r_conj) form_20\NN\6286395|diffuse_72|lymphoma_49|,_18 (r_appos) dystrophy_15\NN\14151139|NONE_0
D004317_D001281 CID doxorubicin_34\NN\2716866|-_11 (r_npadvmod) based_36\VBN\0|NONE_0 (r_amod) chemotherapy_37\NN\661091|NONE_0 (r_pobj) of_33\IN\0|one_10 (r_prep) cycle_32\NN\15269513|in_40 (r_pobj) following_30\VBG\8180190|sudden_27|atrial_20 (r_prep) fibrillation_29\NN\14361664|the_68|common_59|of_47|,_20|and_18
8492347
D011188_D013746 NONE potassium_23\NN\14625458|alone_38 (r_nmod) supplementation_26\NN\5108947|NONE_0 (r_pobj) by_22\IN\0|which_26|can_20|not_17|be_13 (r_agent) corrected_21\VBN\138508|cause_105|,_84|hypomagnesemia_75|is_60|with_46|._62 (r_ccomp) associated_11\VBN\628491|NONE_0 (l_prep) with_12\IN\0|cause_59|,_38|hypomagnesemia_29|is_14|corrected_46|._108 (l_pobj) spasms_14\NNS\14299637|NONE_0 (l_conj) tetany_16\NN\14304060|muscle_18|and_4
D008274_D013746 NONE magnesium_10\NN\14625458|NONE_0 (r_compound) supplementation_11\NN\5108947|NONE_0 (r_pobj) of_9\IN\0|NONE_0 (r_prep) importance_8\NN\5138488|and_52|rhabdomyolysis_48|due_33|--_2|._39 (r_appos) tetany_0\NNP\14304060|NONE_0
D011188_D007008 NONE potassium_23\NN\14625458|alone_38 (r_nmod) supplementation_26\NN\5108947|NONE_0 (r_pobj) by_22\IN\0|which_26|can_20|not_17|be_13 (r_agent) corrected_21\VBN\138508|cause_105|,_84|hypomagnesemia_75|is_60|with_46|._62 (r_ccomp) associated_11\VBN\628491|NONE_0 (l_advcl) cause_4\VB\7323922|,_21|hypomagnesemia_30|is_45|with_59|corrected_105|._167 (l_nsubj) hypokalemia_2\NN\14299637|while_13|may_12|weakness_29
D002118_C537153 NONE calcium_25\NN\14625458|and_4 (r_conj) potassium_23\NN\14625458|alone_38 (r_nmod) supplementation_26\NN\5108947|NONE_0 (r_pobj) by_22\IN\0|which_26|can_20|not_17|be_13 (r_agent) corrected_21\VBN\138508|cause_105|,_84|hypomagnesemia_75|is_60|with_46|._62 (r_ccomp) associated_11\VBN\628491|NONE_0 (l_nsubjpass) hypomagnesemia_9\NN\0|cause_30|,_9|is_15|with_29|corrected_75|._137
D008274_D007008 NONE magnesium_27\NN\14625458|NONE_0 (r_compound) depletion_28\NN\351638|NONE_0 (r_pobj) of_26\IN\0|the_12 (r_prep) effects_25\NNS\13245626|were_31|not_36|in_46|._63 (r_nsubjpass) noted_31\VBN\1009240|in_91|was_66|(_53|8)_52|,_50|but_48 (r_conj) observed_19\VBN\2163746|hypokalemia_86|has_74|been_70|in_56|(_39|3_38|)_35|and_33 (r_conj) reported_4\VBN\831651|NONE_0 (l_nsubjpass) hypokalemia_1\NN\14299637|has_12|been_16|in_30|(_47|3_48|)_51|and_53|observed_86
D008274_D006996 NONE magnesium_27\NN\14625458|NONE_0 (r_compound) depletion_28\NN\351638|NONE_0 (r_pobj) of_26\IN\0|the_12 (r_prep) effects_25\NNS\13245626|were_31|not_36|in_46|._63 (r_nsubjpass) noted_31\VBN\1009240|in_91|was_66|(_53|8)_52|,_50|but_48 (r_conj) observed_19\VBN\2163746|hypokalemia_86|has_74|been_70|in_56|(_39|3_38|)_35|and_33 (l_prep) in_14\IN\13603305|was_25|(_38|8)_39|,_41|but_43|noted_91 (l_pobj) hypocalcemia_17\NN\14299637|NONE_0
D011188_C537153 NONE potassium_23\NN\14625458|alone_38 (r_nmod) supplementation_26\NN\5108947|NONE_0 (r_pobj) by_22\IN\0|which_26|can_20|not_17|be_13 (r_agent) corrected_21\VBN\138508|cause_105|,_84|hypomagnesemia_75|is_60|with_46|._62 (r_ccomp) associated_11\VBN\628491|NONE_0 (l_nsubjpass) hypomagnesemia_9\NN\0|cause_30|,_9|is_15|with_29|corrected_75|._137
D011188_D018908 NONE potassium_23\NN\14625458|alone_38 (r_nmod) supplementation_26\NN\5108947|NONE_0 (r_pobj) by_22\IN\0|which_26|can_20|not_17|be_13 (r_agent) corrected_21\VBN\138508|cause_105|,_84|hypomagnesemia_75|is_60|with_46|._62 (r_ccomp) associated_11\VBN\628491|NONE_0 (l_advcl) cause_4\VB\7323922|,_21|hypomagnesemia_30|is_45|with_59|corrected_105|._167 (l_dobj) weakness_6\NN\14462666|while_42|hypokalemia_29|may_17
D002118_D013746 NONE calcium_25\NN\14625458|and_4 (r_conj) potassium_23\NN\14625458|alone_38 (r_nmod) supplementation_26\NN\5108947|NONE_0 (r_pobj) by_22\IN\0|which_26|can_20|not_17|be_13 (r_agent) corrected_21\VBN\138508|cause_105|,_84|hypomagnesemia_75|is_60|with_46|._62 (r_ccomp) associated_11\VBN\628491|NONE_0 (l_prep) with_12\IN\0|cause_59|,_38|hypomagnesemia_29|is_14|corrected_46|._108 (l_pobj) spasms_14\NNS\14299637|NONE_0 (l_conj) tetany_16\NN\14304060|muscle_18|and_4
D005665_D012206 CID furosemide_6\NN\3214670|to_17 (r_pobj) due_3\JJ\5174653|and_19|rhabdomyolysis_15|--_31|importance_33|._72 (r_prep) tetany_0\NNP\14304060|NONE_0 (l_conj) rhabdomyolysis_2\NN\0|and_4|due_15|--_46|importance_48|._87
D005665_D013746 CID furosemide_6\NN\3214670|to_17 (r_pobj) due_3\JJ\5174653|and_19|rhabdomyolysis_15|--_31|importance_33|._72 (r_prep) tetany_0\NNP\14304060|NONE_0
D008274_D012206 NONE magnesium_10\NN\14625458|NONE_0 (r_compound) supplementation_11\NN\5108947|NONE_0 (r_pobj) of_9\IN\0|NONE_0 (r_prep) importance_8\NN\5138488|and_52|rhabdomyolysis_48|due_33|--_2|._39 (r_appos) tetany_0\NNP\14304060|NONE_0 (l_conj) rhabdomyolysis_2\NN\0|and_4|due_15|--_46|importance_48|._87
D002118_D007008 NONE calcium_25\NN\14625458|and_4 (r_conj) potassium_23\NN\14625458|alone_38 (r_nmod) supplementation_26\NN\5108947|NONE_0 (r_pobj) by_22\IN\0|which_26|can_20|not_17|be_13 (r_agent) corrected_21\VBN\138508|cause_105|,_84|hypomagnesemia_75|is_60|with_46|._62 (r_ccomp) associated_11\VBN\628491|NONE_0 (l_advcl) cause_4\VB\7323922|,_21|hypomagnesemia_30|is_45|with_59|corrected_105|._167 (l_nsubj) hypokalemia_2\NN\14299637|while_13|may_12|weakness_29
D002118_D013035 NONE calcium_25\NN\14625458|and_4 (r_conj) potassium_23\NN\14625458|alone_38 (r_nmod) supplementation_26\NN\5108947|NONE_0 (r_pobj) by_22\IN\0|which_26|can_20|not_17|be_13 (r_agent) corrected_21\VBN\138508|cause_105|,_84|hypomagnesemia_75|is_60|with_46|._62 (r_ccomp) associated_11\VBN\628491|NONE_0 (l_prep) with_12\IN\0|cause_59|,_38|hypomagnesemia_29|is_14|corrected_46|._108 (l_pobj) spasms_14\NNS\14299637|NONE_0
D002118_D018908 NONE calcium_25\NN\14625458|and_4 (r_conj) potassium_23\NN\14625458|alone_38 (r_nmod) supplementation_26\NN\5108947|NONE_0 (r_pobj) by_22\IN\0|which_26|can_20|not_17|be_13 (r_agent) corrected_21\VBN\138508|cause_105|,_84|hypomagnesemia_75|is_60|with_46|._62 (r_ccomp) associated_11\VBN\628491|NONE_0 (l_advcl) cause_4\VB\7323922|,_21|hypomagnesemia_30|is_45|with_59|corrected_105|._167 (l_dobj) weakness_6\NN\14462666|while_42|hypokalemia_29|may_17
D011188_D013035 NONE potassium_23\NN\14625458|alone_38 (r_nmod) supplementation_26\NN\5108947|NONE_0 (r_pobj) by_22\IN\0|which_26|can_20|not_17|be_13 (r_agent) corrected_21\VBN\138508|cause_105|,_84|hypomagnesemia_75|is_60|with_46|._62 (r_ccomp) associated_11\VBN\628491|NONE_0 (l_prep) with_12\IN\0|cause_59|,_38|hypomagnesemia_29|is_14|corrected_46|._108 (l_pobj) spasms_14\NNS\14299637|NONE_0
10414674
D000082_D001791 NONE acetaminophen_9\NN\2707683|the_4 (r_compound) group_10\NN\2137|NONE_0 (r_pobj) in_7\IN\13603305|in_52|,_41|aggregation_22|on_27|compared_61|._130 (r_prep) increased_6\VBD\169651|NONE_0 (l_nsubj) aggregation_5\NN\31264|in_30|,_19|in_22|on_49|compared_83|._152
D000082_D001791 NONE acetaminophen_9\NN\2707683|the_4 (r_compound) group_10\NN\2137|NONE_0 (r_pobj) in_7\IN\13603305|in_52|,_41|aggregation_22|on_27|compared_61|._130 (r_prep) increased_6\VBD\169651|NONE_0 (l_advcl) compared_17\VBN\644583|in_113|,_102|aggregation_83|in_61|on_34|._69 (l_prep) with_18\IN\0|as_12 (l_pobj) results_23\NNS\34213|NONE_0 (l_compound) aggregation_22\NN\31264|the_26|(_20|p_21|)_28
D000082_D013345 NONE acetaminophen_35\RB\2707683|a_14|weak_12|,_2|,_13 (r_advmod) nsaid_33\NNP\2721538|(_36|ketoprofen_35|,_19|n_17|9_13|)_12|or_10|g_24|,_25|times_33 (r_conj) group_24\NN\2137|to_68|ketoprofen_50|times_24|starting_98 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (r_xcomp) randomized_9\VBN\278117|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|(_49|)_53|were_55|receive_74|._295 (l_prep) with_1\IN\0|NONE_0 (l_pobj) hemorrhage_4\NN\14285662|NONE_0
D000082_D013345 NONE acetaminophen_35\RB\2707683|a_14|weak_12|,_2|,_13 (r_advmod) nsaid_33\NNP\2721538|(_36|ketoprofen_35|,_19|n_17|9_13|)_12|or_10|g_24|,_25|times_33 (r_conj) group_24\NN\2137|to_68|ketoprofen_50|times_24|starting_98 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (r_xcomp) randomized_9\VBN\278117|NONE_0 (l_punct) (_5\-LRB-\0|patients_49|)_4|were_6|receive_25|._246 (l_preconj) sah_6\NNP\0|NONE_0
D000082_D013345 NONE acetaminophen_35\RB\2707683|a_14|weak_12|,_2|,_13 (r_advmod) nsaid_33\NNP\2721538|(_36|ketoprofen_35|,_19|n_17|9_13|)_12|or_10|g_24|,_25|times_33 (r_conj) group_24\NN\2137|to_68|ketoprofen_50|times_24|starting_98 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (l_parataxis) starting_52\VBG\457382|to_166|ketoprofen_148|times_122|group_98 (l_prep) after_54\IN\0|(_50|group_35|immediately_12 (l_pobj) diagnosis_56\NN\152018|NONE_0 (l_prep) of_57\IN\0|the_14 (l_pobj) sah_59\NNP\0|NONE_0
D000082_D013345 NONE acetaminophen_45\NN\2707683|,_19|n_21|9_25 (r_compound) group_46\NN\2137|(_15|immediately_23|after_35 (r_nsubj) starting_52\VBG\457382|to_166|ketoprofen_148|times_122|group_98 (r_parataxis) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (r_xcomp) randomized_9\VBN\278117|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|(_49|)_53|were_55|receive_74|._295 (l_prep) with_1\IN\0|NONE_0 (l_pobj) hemorrhage_4\NN\14285662|NONE_0
D000082_D013345 NONE acetaminophen_45\NN\2707683|,_19|n_21|9_25 (r_compound) group_46\NN\2137|(_15|immediately_23|after_35 (r_nsubj) starting_52\VBG\457382|to_166|ketoprofen_148|times_122|group_98 (r_parataxis) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (r_xcomp) randomized_9\VBN\278117|NONE_0 (l_punct) (_5\-LRB-\0|patients_49|)_4|were_6|receive_25|._246 (l_preconj) sah_6\NNP\0|NONE_0
D000082_D013345 NONE acetaminophen_45\NN\2707683|,_19|n_21|9_25 (r_compound) group_46\NN\2137|(_15|immediately_23|after_35 (r_nsubj) starting_52\VBG\457382|to_166|ketoprofen_148|times_122|group_98 (l_prep) after_54\IN\0|(_50|group_35|immediately_12 (l_pobj) diagnosis_56\NN\152018|NONE_0 (l_prep) of_57\IN\0|the_14 (l_pobj) sah_59\NNP\0|NONE_0
D000082_D013345 NONE acetaminophen_3\RB\2707683|but_8 (l_dobj) function_6\NN\13783581|not_36|._29 (l_prep) in_7\IN\13603305|impaired_27|platelet_18 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) sah_10\NNP\0|NONE_0
D007660_D006470 NONE ketoprofen_1\NN\3828465|if_3|is_11|before_19|on_34 (r_nsubjpass) used_3\VBN\0|,_48|it_50|may_53|factor_81|._102 (r_advcl) pose_13\VB\4787763|NONE_0 (l_dobj) factor_17\NN\7326557|used_81|,_33|it_31|may_28|._21 (l_prep) for_18\IN\0|an_26|additional_23|risk_12 (l_pobj) hemorrhage_19\NN\14285662|NONE_0
D007660_D001791 CID ketoprofen_14\NN\3828465|NONE_0 (r_pobj) of_13\IN\0|NONE_0 (r_prep) administration_12\NN\1133281|NONE_0 (r_pobj) after_11\IN\0|NONE_0 (r_prep) decreased_10\VBD\169651|aggregation_57|by_37|._44 (r_conj) induced_3\VBN\1627355|NONE_0 (l_nsubj) aggregation_2\NN\31264|by_20|decreased_57|._101
D007660_D013345 NONE ketoprofen_13\JJ\3828465|to_18|times_26|group_50|starting_148 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (r_xcomp) randomized_9\VBN\278117|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|(_49|)_53|were_55|receive_74|._295 (l_prep) with_1\IN\0|NONE_0 (l_pobj) hemorrhage_4\NN\14285662|NONE_0
D007660_D013345 NONE ketoprofen_13\JJ\3828465|to_18|times_26|group_50|starting_148 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (r_xcomp) randomized_9\VBN\278117|NONE_0 (l_punct) (_5\-LRB-\0|patients_49|)_4|were_6|receive_25|._246 (l_preconj) sah_6\NNP\0|NONE_0
D007660_D013345 NONE ketoprofen_13\JJ\3828465|to_18|times_26|group_50|starting_148 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (l_parataxis) starting_52\VBG\457382|to_166|ketoprofen_148|times_122|group_98 (l_prep) after_54\IN\0|(_50|group_35|immediately_12 (l_pobj) diagnosis_56\NN\152018|NONE_0 (l_prep) of_57\IN\0|the_14 (l_pobj) sah_59\NNP\0|NONE_0
D007660_D013345 NONE ketoprofen_23\JJ\3828465|(_1|,_16|n_18|9_22|)_23|or_25|nsaid_35|g_59|,_60|times_68 (r_compound) group_24\NN\2137|to_68|ketoprofen_50|times_24|starting_98 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (r_xcomp) randomized_9\VBN\278117|NONE_0 (l_nsubjpass) patients_0\NNS\9898892|(_49|)_53|were_55|receive_74|._295 (l_prep) with_1\IN\0|NONE_0 (l_pobj) hemorrhage_4\NN\14285662|NONE_0
D007660_D013345 NONE ketoprofen_23\JJ\3828465|(_1|,_16|n_18|9_22|)_23|or_25|nsaid_35|g_59|,_60|times_68 (r_compound) group_24\NN\2137|to_68|ketoprofen_50|times_24|starting_98 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (r_xcomp) randomized_9\VBN\278117|NONE_0 (l_punct) (_5\-LRB-\0|patients_49|)_4|were_6|receive_25|._246 (l_preconj) sah_6\NNP\0|NONE_0
D007660_D013345 NONE ketoprofen_23\JJ\3828465|(_1|,_16|n_18|9_22|)_23|or_25|nsaid_35|g_59|,_60|times_68 (r_compound) group_24\NN\2137|to_68|ketoprofen_50|times_24|starting_98 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (l_parataxis) starting_52\VBG\457382|to_166|ketoprofen_148|times_122|group_98 (l_prep) after_54\IN\0|(_50|group_35|immediately_12 (l_pobj) diagnosis_56\NN\152018|NONE_0 (l_prep) of_57\IN\0|the_14 (l_pobj) sah_59\NNP\0|NONE_0
D007660_D013345 NONE ketoprofen_0\NNP\3828465|NONE_0 (l_conj) acetaminophen_3\RB\2707683|but_8 (l_dobj) function_6\NN\13783581|not_36|._29 (l_prep) in_7\IN\13603305|impaired_27|platelet_18 (l_pobj) patients_8\NNS\9898892|NONE_0 (l_prep) with_9\IN\0|NONE_0 (l_pobj) sah_10\NNP\0|NONE_0
D007660_D017542 NONE ketoprofen_13\JJ\3828465|to_18|times_26|group_50|starting_148 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (l_parataxis) starting_52\VBG\457382|to_166|ketoprofen_148|times_122|group_98 (l_prep) after_54\IN\0|(_50|group_35|immediately_12 (l_pobj) diagnosis_56\NN\152018|NONE_0 (l_prep) of_57\IN\0|the_14 (l_pobj) sah_59\NNP\0|NONE_0 (l_amod) aneurysmal_58\JJ\0|NONE_0
D007660_D017542 NONE ketoprofen_23\JJ\3828465|(_1|,_16|n_18|9_22|)_23|or_25|nsaid_35|g_59|,_60|times_68 (r_compound) group_24\NN\2137|to_68|ketoprofen_50|times_24|starting_98 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (l_parataxis) starting_52\VBG\457382|to_166|ketoprofen_148|times_122|group_98 (l_prep) after_54\IN\0|(_50|group_35|immediately_12 (l_pobj) diagnosis_56\NN\152018|NONE_0 (l_prep) of_57\IN\0|the_14 (l_pobj) sah_59\NNP\0|NONE_0 (l_amod) aneurysmal_58\JJ\0|NONE_0
D000082_D017542 NONE acetaminophen_35\RB\2707683|a_14|weak_12|,_2|,_13 (r_advmod) nsaid_33\NNP\2721538|(_36|ketoprofen_35|,_19|n_17|9_13|)_12|or_10|g_24|,_25|times_33 (r_conj) group_24\NN\2137|to_68|ketoprofen_50|times_24|starting_98 (r_dobj) receive_11\VB\2210855|patients_74|(_25|)_21|were_19|._221 (l_parataxis) starting_52\VBG\457382|to_166|ketoprofen_148|times_122|group_98 (l_prep) after_54\IN\0|(_50|group_35|immediately_12 (l_pobj) diagnosis_56\NN\152018|NONE_0 (l_prep) of_57\IN\0|the_14 (l_pobj) sah_59\NNP\0|NONE_0 (l_amod) aneurysmal_58\JJ\0|NONE_0
D000082_D017542 NONE acetaminophen_45\NN\2707683|,_19|n_21|9_25 (r_compound) group_46\NN\2137|(_15|immediately_23|after_35 (r_nsubj) starting_52\VBG\457382|to_166|ketoprofen_148|times_122|group_98 (l_prep) after_54\IN\0|(_50|group_35|immediately_12 (l_pobj) diagnosis_56\NN\152018|NONE_0 (l_prep) of_57\IN\0|the_14 (l_pobj) sah_59\NNP\0|NONE_0 (l_amod) aneurysmal_58\JJ\0|NONE_0
D007660_D006406 CID ketoprofen_4\JJ\3828465|the_4 (r_compound) group_5\NN\2137|NONE_0 (r_pobj) in_2\IN\13603305|one_12 (r_prep) patient_1\NN\9898892|hematoma_71|._79 (r_nsubj) developed_6\VBD\1753788|NONE_0 (l_dobj) hematoma_10\NN\14317720|patient_71|._8
D000244_D001791 NONE diphosphate_9\NN\0|NONE_0 (r_pobj) of_7\IN\0|6_9 (r_prep) microm_6\NNS\0|NONE_0 (r_pobj) by_4\IN\0|aggregation_20|decreased_37|._81 (r_prep) induced_3\VBN\1627355|NONE_0 (l_nsubj) aggregation_2\NN\31264|by_20|decreased_57|._101
D007660_D002532 NONE ketoprofen_1\NN\3828465|if_3|is_11|before_19|on_34 (r_nsubjpass) used_3\VBN\0|,_48|it_50|may_53|factor_81|._102 (l_prep) on_6\IN\0|if_37|ketoprofen_34|is_23|before_15 (l_pobj) aneurysms_9\NNS\14057371|NONE_0
8643966
D017239_D001943 NONE paclitaxel_0\NNP\0|has_64|activity_108|._184 (r_nsubj) demonstrated_15\VBN\2137132|NONE_0 (l_dobj) activity_18\NN\30358|paclitaxel_108|has_44|._76 (l_prep) against_19\IN\0|significant_36|antineoplastic_24 (l_pobj) types_22\NNS\5839024|NONE_0 (l_appos) carcinoma_28\NN\14239918|different_50|tumor_40|,_29
D017239_D001943 NONE taxol_2\NNP\0|company_28 (r_appos) paclitaxel_0\NNP\0|has_64|activity_108|._184 (r_nsubj) demonstrated_15\VBN\2137132|NONE_0 (l_dobj) activity_18\NN\30358|paclitaxel_108|has_44|._76 (l_prep) against_19\IN\0|significant_36|antineoplastic_24 (l_pobj) types_22\NNS\5839024|NONE_0 (l_appos) carcinoma_28\NN\14239918|different_50|tumor_40|,_29
D017239_D010051 NONE paclitaxel_0\NNP\0|has_64|activity_108|._184 (r_nsubj) demonstrated_15\VBN\2137132|NONE_0 (l_dobj) activity_18\NN\30358|paclitaxel_108|has_44|._76 (l_prep) against_19\IN\0|significant_36|antineoplastic_24 (l_pobj) types_22\NNS\5839024|NONE_0 (l_appos) carcinoma_28\NN\14239918|different_50|tumor_40|,_29
D017239_D010051 NONE taxol_2\NNP\0|company_28 (r_appos) paclitaxel_0\NNP\0|has_64|activity_108|._184 (r_nsubj) demonstrated_15\VBN\2137132|NONE_0 (l_dobj) activity_18\NN\30358|paclitaxel_108|has_44|._76 (l_prep) against_19\IN\0|significant_36|antineoplastic_24 (l_pobj) types_22\NNS\5839024|NONE_0 (l_appos) carcinoma_28\NN\14239918|different_50|tumor_40|,_29
D017239_D064420 NONE paclitaxel_9\NN\0|a_9|3-hour_7|in_20 (r_compound) infusion_10\NN\14589223|NONE_0 (r_pobj) of_6\IN\0|the_26|and_13|toxicity_9 (r_prep) efficacy_3\NN\5199286|we_20|._124 (l_conj) toxicity_5\NN\13576101|the_17|and_4|of_9
D017239_D064420 NONE paclitaxel_0\NNP\0|thus_14|agent_36|,_68|with_70|._225 (r_nsubj) is_1\VBZ\0|NONE_0 (l_prep) with_12\IN\0|paclitaxel_70|thus_56|agent_34|,_2|._155 (l_pobj) infusion_15\NN\14589223|NONE_0 (l_acl) proving_16\VBG\2604760|a_18|3-hour_16 (l_oprd) effective_18\JJ\0|NONE_0 (l_prep) to_19\IN\0|comparably_21 (l_pobj) infusion_22\NN\14589223|NONE_0 (l_conj) superior_24\JJ\9623038|a_23|24-hour_21|and_4 (l_prep) in_25\IN\13603305|NONE_0 (l_pobj) terms_26\NNS\13945919|NONE_0 (l_prep) of_27\IN\0|NONE_0 (l_pobj) incidence_29\NN\13821570|NONE_0 (l_prep) of_30\IN\0|the_14 (l_pobj) toxicity_34\NN\13576101|NONE_0
D017239_D002289 NONE paclitaxel_11\NN\0|NONE_0 (r_pobj) with_10\IN\0|advanced_47|inoperable_38|small_23|lung_12 (r_prep) cancer_9\NN\14239425|NONE_0
D017239_D002289 NONE paclitaxel_6\NN\0|24-hour_8|in_21 (r_compound) infusions_7\NNS\14589223|NONE_0 (l_prep) in_8\IN\13603305|24-hour_29|paclitaxel_21 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|naive_15 (l_pobj) iiib_15\NNS\0|NONE_0 (l_conj) cancer_23\NN\14239425|stage_37|or_26
D017239_D002289 NONE paclitaxel_6\NN\0|24-hour_8|in_21 (r_compound) infusions_7\NNS\14589223|NONE_0 (l_prep) in_8\IN\13603305|24-hour_29|paclitaxel_21 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|naive_15 (l_pobj) iiib_15\NNS\0|NONE_0 (l_conj) cancer_23\NN\14239425|stage_37|or_26 (l_appos) nsclc_25\NNP\0|iv_31|small_24|lung_13|(_1|)_5
D017239_D002289 NONE paclitaxel_9\NN\0|a_9|3-hour_7|in_20 (r_compound) infusion_10\NN\14589223|NONE_0 (l_prep) in_11\IN\13603305|a_29|3-hour_27|paclitaxel_20 (l_pobj) trial_15\NN\786195|NONE_0 (l_prep) in_16\IN\13603305|phase_15|ii_9 (l_pobj) patients_17\NNS\9898892|NONE_0 (l_prep) with_18\IN\0|NONE_0 (l_pobj) iiib_21\NNS\0|NONE_0 (l_conj) nsclc_24\NNP\0|stage_17|or_6
D017239_D002289 NONE paclitaxel_5\NN\0|NONE_0 (r_pobj) with_4\IN\0|ii_11|combined_16 (r_prep) studies_3\NNS\635850|further_17 (l_acl) combined_6\VBN\2630189|ii_27|with_16 (l_prep) with_7\IN\0|NONE_0 (l_pobj) drugs_9\NNS\14778436|NONE_0 (l_amod) active_10\JJ\14779550|other_12 (l_prep) against_11\IN\0|NONE_0 (l_pobj) nsclc_12\NNP\0|NONE_0
D017239_D002289 NONE paclitaxel_21\NN\0|with_11 (r_dobj) comparing_20\VBG\635850|iii_12 (r_acl) studies_19\NNS\635850|remain_56 (r_dobj) phase_17\NN\15113229|phase_99|are_19|,_6|and_4|._88 (r_conj) indicated_14\VBN\952524|NONE_0 (l_nsubjpass) phase_1\NN\15113229|are_80|,_93|and_95|phase_99|._187 (l_dobj) studies_3\NNS\635850|further_17 (l_acl) combined_6\VBN\2630189|ii_27|with_16 (l_prep) with_7\IN\0|NONE_0 (l_pobj) drugs_9\NNS\14778436|NONE_0 (l_amod) active_10\JJ\14779550|other_12 (l_prep) against_11\IN\0|NONE_0 (l_pobj) nsclc_12\NNP\0|NONE_0
D017239_D009369 NONE paclitaxel_0\NNP\0|has_64|activity_108|._184 (r_nsubj) demonstrated_15\VBN\2137132|NONE_0 (l_dobj) activity_18\NN\30358|paclitaxel_108|has_44|._76 (l_prep) against_19\IN\0|significant_36|antineoplastic_24 (l_pobj) types_22\NNS\5839024|NONE_0 (l_compound) tumor_21\NN\14234074|different_10|,_11|carcinoma_40
D017239_D009369 NONE taxol_2\NNP\0|company_28 (r_appos) paclitaxel_0\NNP\0|has_64|activity_108|._184 (r_nsubj) demonstrated_15\VBN\2137132|NONE_0 (l_dobj) activity_18\NN\30358|paclitaxel_108|has_44|._76 (l_prep) against_19\IN\0|significant_36|antineoplastic_24 (l_pobj) types_22\NNS\5839024|NONE_0 (l_compound) tumor_21\NN\14234074|different_10|,_11|carcinoma_40
9041081
D013256_D009798 NONE steroid_13\NN\14727670|-_7 (r_npadvmod) induced_15\VBN\1627355|elevated_8|intraocular_17|(_38|iop_39 (r_amod) pressure_18\NN\11419404|during_86|,_66|patients_62|._74
D013256_D009798 NONE steroid_2\NN\14727670|-_7 (r_npadvmod) induced_4\VBN\1627355|iop_8 (r_amod) rise_6\NN\7324673|did_5|not_9|cause_21|._48
D000305_D009798 CID corticosteroid_25\NN\14745635|NONE_0 (r_compound) therapy_26\NN\657604|after_21|was_8 (r_nsubjpass) discontinued_28\VBN\0|that_47 (r_advcl) resolved_23\VBD\352826|)_7 (r_relcl) iop_20\NNP\11495041|induced_39|elevated_31|intraocular_22|(_1 (r_appos) pressure_18\NN\11419404|during_86|,_66|patients_62|._74
16710500
D004977_D014376 NONE ethambutol_2\NNP\0|introduction_14|:_2|is_11|in_19|,_95|and_97|associated_108|._145 (r_nsubjpass) used_4\VBN\0|NONE_0 (l_prep) in_5\IN\13603305|introduction_33|:_21|ethambutol_19|is_8|,_76|and_78|associated_89|._126 (l_pobj) treatment_7\NN\654885|NONE_0 (l_prep) of_8\IN\0|the_14|,_15|is_23 (l_pobj) tuberculosis_9\NN\14127211|NONE_0
D004977_D009901 CID ethambutol_0\NN\0|-_10 (r_npadvmod) associated_2\VBN\628491|optic_11|._27 (r_amod) neuropathy_4\NN\14204950|NONE_0
D004977_D009901 CID ethambutol_3\NN\0|-_10 (r_npadvmod) associated_5\VBN\628491|optic_17 (r_amod) neuropathy_8\NNS\14204950|NONE_0
D004977_D014786 CID ethambutol_2\NNP\0|introduction_14|:_2|is_11|in_19|,_95|and_97|associated_108|._145 (r_nsubjpass) used_4\VBN\0|NONE_0 (l_conj) associated_22\VBN\628491|introduction_122|:_110|ethambutol_108|is_97|in_89|,_13|and_11|._37 (l_prep) with_23\IN\0|can_18|be_14 (l_pobj) loss_26\NN\13252973|NONE_0
D004977_D014786 CID ethambutol_0\NNP\0|NONE_0 (r_compound) usage_1\NN\407535|is_6|with_20|and_47|avoided_61|._139 (r_nsubjpass) associated_3\VBN\628491|NONE_0 (l_prep) with_4\IN\0|usage_20|is_14|and_27|avoided_41|._119 (l_pobj) loss_7\NN\13252973|NONE_0
12093990
C059262_D009503 CID cidofovir_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|in_13 (r_prep) use_0\NN\407535|was_28|with_43|._89 (r_nsubjpass) associated_7\VBN\628491|NONE_0 (l_prep) with_8\IN\0|use_43|was_15|._46 (l_pobj) failure_11\NN\66216|NONE_0 (l_conj) neutropenia_13\NN\14196405|progressive_30|renal_18|and_4
D012254_D000257 NONE ribavirin_1\JJ\2725367|intravenous_12|for_20|in_50|._79 (r_compound) treatment_2\NN\654885|NONE_0 (l_prep) for_3\IN\0|intravenous_32|ribavirin_20|in_30|._59 (l_pobj) disease_6\NN\14061805|NONE_0
D012254_D000257 NONE ribavirin_7\NN\2725367|intravenous_12 (r_compound) therapy_8\NN\657604|NONE_0 (r_pobj) with_5\IN\0|our_15|for_35|in_65 (r_prep) experience_4\NN\5984287|:_16|we_14|and_118|review_122|._143 (l_prep) for_9\IN\0|our_50|with_35|in_30 (l_pobj) disease_12\NN\14061805|NONE_0
D012254_D000257 NONE ribavirin_12\RB\2725367|NONE_0 (r_pobj) with_10\IN\0|for_27 (r_prep) treated_9\VBN\2376958|5_11 (l_prep) for_13\IN\0|with_27 (l_pobj) disease_17\NN\14061805|NONE_0
D012254_D000257 NONE ribavirin_2\NN\2725367|although_21|not_14|effective_18 (r_nsubj) was_3\VBD\0|,_101|therapy_103|unlikely_114|begun_143|._184 (l_acomp) effective_5\JJ\0|although_39|ribavirin_18|not_4 (l_prep) for_6\IN\0|NONE_0 (l_pobj) children_8\NNS\9622049|NONE_0 (l_prep) with_9\IN\0|all_13 (l_pobj) disease_12\NN\14061805|NONE_0
D012254_D000257 NONE ribavirin_11\RB\2725367|NONE_0 (r_pobj) with_9\IN\0|children_48|recovered_27|._36 (r_prep) treated_8\VBN\2376958|NONE_0 (l_nsubj) children_3\NNS\9622049|with_48|recovered_75|._84 (l_prep) with_4\IN\0|5_11 (l_pobj) disease_7\NN\14061805|NONE_0
D012254_D000257 NONE ribavirin_33\NN\2725367|such_20 (r_pobj) as_31\IN\14622893|useful_39|adenoviral_27|,_7|,_24 (r_prep) therapies_28\NNS\657604|NONE_0 (r_pobj) of_22\IN\0|a_36|large_34|,_29|multicenter_27|clinical_15 (r_prep) trial_21\NN\786195|especially_51|,_32 (r_conj) children_14\NNS\9622049|certain_26|,_13 (r_appos) hosts_11\NNS\9605289|NONE_0 (r_pobj) in_9\IN\13603305|of_22 (r_prep) prevalence_5\NN\4764412|the_31|and_15|increasing_11 (l_prep) of_6\IN\0|in_22 (l_pobj) disease_8\NN\14061805|NONE_0
C059262_D000257 NONE cidofovir_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_8|in_13 (r_prep) use_1\NN\407535|has_48|been_52|by_65 (l_prep) in_4\IN\13603305|the_21|of_13 (l_pobj) infection_7\NN\14052046|NONE_0
D012254_D000740 NONE ribavirin_7\RB\2725367|NONE_0 (r_pobj) of_5\IN\0|the_31|common_22|adverse_15 (r_prep) effect_4\NN\34213|anemia_51|._57 (r_nsubj) is_8\VBZ\0|NONE_0 (l_attr) anemia_11\NN\14189204|effect_51|._6
D012254_D006482 NONE ribavirin_0\NNP\2725367|is_10|in_22|,_96|and_98|treat_143|is_184|._255 (r_nsubjpass) licensed_2\VBN\803325|NONE_0 (l_conj) is_27\VBZ\0|ribavirin_184|is_174|in_162|,_88|and_86|treat_41|._71 (l_attr) treatment_29\NN\654885|NONE_0 (l_prep) for_32\IN\0|the_24|of_10 (l_pobj) infection_33\NN\14052046|NONE_0 (l_prep) with_34\IN\0|NONE_0 (l_pobj) viruses_37\NNS\9312843|NONE_0
D012254_D006482 NONE ribavirin_26\RB\2725367|in_65|to_34 (r_dobj) treat_22\VB\7570720|ribavirin_143|is_133|in_121|,_47|and_45|is_41|._112 (r_conj) licensed_2\VBN\803325|NONE_0 (l_conj) is_27\VBZ\0|ribavirin_184|is_174|in_162|,_88|and_86|treat_41|._71 (l_attr) treatment_29\NN\654885|NONE_0 (l_prep) for_32\IN\0|the_24|of_10 (l_pobj) infection_33\NN\14052046|NONE_0 (l_prep) with_34\IN\0|NONE_0 (l_pobj) viruses_37\NNS\9312843|NONE_0
D012254_D007239 NONE ribavirin_2\NN\2725367|although_21|not_14|effective_18 (r_nsubj) was_3\VBD\0|,_101|therapy_103|unlikely_114|begun_143|._184 (r_advcl) is_22\VBZ\0|NONE_0 (l_advcl) begun_29\VBN\0|was_143|,_42|therapy_40|unlikely_29|._41 (l_prep) in_31\IN\13603305|if_14 (l_pobj) course_33\NN\883297|late_12 (l_prep) of_34\IN\0|the_11 (l_pobj) infection_36\NN\14052046|NONE_0
C059262_D058186 CID cidofovir_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|in_13 (r_prep) use_0\NN\407535|was_28|with_43|._89 (r_nsubjpass) associated_7\VBN\628491|NONE_0 (l_prep) with_8\IN\0|use_43|was_15|._46 (l_pobj) failure_11\NN\66216|NONE_0
D012254_D006526 NONE ribavirin_0\NNP\2725367|is_10|in_22|,_96|and_98|treat_143|is_184|._255 (r_nsubjpass) licensed_2\VBN\803325|NONE_0 (l_conj) treat_22\VB\7570720|ribavirin_143|is_133|in_121|,_47|and_45|is_41|._112 (l_dobj) ribavirin_26\RB\2725367|in_65|to_34 (l_compound) intravenous_25\NNP\0|NONE_0 (l_compound) c._24\NNP\0|hepatitis_10
D012254_D006526 NONE ribavirin_26\RB\2725367|in_65|to_34 (l_compound) intravenous_25\NNP\0|NONE_0 (l_compound) c._24\NNP\0|hepatitis_10
D012254_D018357 NONE ribavirin_0\NNP\2725367|is_10|in_22|,_96|and_98|treat_143|is_184|._255 (r_nsubjpass) licensed_2\VBN\803325|NONE_0 (l_prep) in_3\IN\13603305|ribavirin_22|is_12|,_74|and_76|treat_121|is_162|._233 (l_pobj) form_5\NN\6286395|NONE_0 (l_prep) for_6\IN\0|aerosol_13 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) infection_13\NN\14052046|NONE_0
D012254_D018357 NONE ribavirin_26\RB\2725367|in_65|to_34 (r_dobj) treat_22\VB\7570720|ribavirin_143|is_133|in_121|,_47|and_45|is_41|._112 (r_conj) licensed_2\VBN\803325|NONE_0 (l_prep) in_3\IN\13603305|ribavirin_22|is_12|,_74|and_76|treat_121|is_162|._233 (l_pobj) form_5\NN\6286395|NONE_0 (l_prep) for_6\IN\0|aerosol_13 (l_pobj) treatment_8\NN\654885|NONE_0 (l_prep) of_9\IN\0|the_14 (l_pobj) infection_13\NN\14052046|NONE_0
C059262_D007674 NONE cidofovir_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_8|in_13 (r_prep) use_1\NN\407535|has_48|been_52|by_65 (r_nsubjpass) limited_10\VBN\4019101|,_26|significant_37|nephrotoxicity_61|._75 (r_ccomp) is_20\VBZ\0|NONE_0 (l_attr) nephrotoxicity_21\NN\0|limited_61|,_35|significant_24|._14
17049862
D010672_D001919 CID phenytoin_1\JJ\3550533|NONE_0 (r_compound) administration_2\NN\1133281|NONE_0 (r_pobj) following_0\VBG\8180190|,_34|patient_40|bradycardia_71|,_82|refractory_84|._121 (r_prep) developed_6\VBD\1753788|NONE_0 (l_dobj) bradycardia_9\NN\14110674|following_71|,_37|patient_31|,_11|refractory_13|._50
D001285_D001919 NONE atropine_13\NN\14712692|NONE_0 (r_pobj) to_12\IN\0|NONE_0 (r_prep) refractory_11\JJ\3673767|following_84|,_50|patient_44|bradycardia_13|,_2|._37 (r_advcl) developed_6\VBD\1753788|NONE_0 (l_dobj) bradycardia_9\NN\14110674|following_71|,_37|patient_31|,_11|refractory_13|._50
D010672_D012640 NONE phenytoin_1\NN\3550533|was_10|during_27|._87 (r_nsubjpass) administered_3\VBN\2436349|NONE_0 (l_prep) during_4\IN\0|phenytoin_27|was_17|._60 (l_pobj) part_7\NN\31921|NONE_0 (l_prep) of_8\IN\0|the_15|later_11 (l_pobj) surgery_10\NN\6045562|NONE_0 (l_prep) for_11\IN\0|the_12 (l_pobj) prophylaxis_13\NN\1077350|NONE_0 (l_compound) seizure_12\NN\14081375|NONE_0
D004837_D001919 NONE adrenaline_15\NN\14807929|and_4 (r_conj) atropine_13\NN\14712692|NONE_0 (r_pobj) to_12\IN\0|NONE_0 (r_prep) refractory_11\JJ\3673767|following_84|,_50|patient_44|bradycardia_13|,_2|._37 (r_advcl) developed_6\VBD\1753788|NONE_0 (l_dobj) bradycardia_9\NN\14110674|following_71|,_37|patient_31|,_11|refractory_13|._50
D010672_D007035 NONE phenytoin_1\JJ\3550533|NONE_0 (r_compound) administration_2\NN\1133281|safe_15|?_42 (r_nsubj) is_0\VBZ\0|NONE_0 (l_acomp) safe_3\JJ\4340750|administration_15|?_27 (l_prep) in_4\IN\13603305|NONE_0 (l_pobj) child_7\NN\9622049|NONE_0 (l_amod) hypothermic_6\JJ\0|a_2
D010672_D007035 NONE phenytoin_5\NN\3550533|NONE_0 (l_conj) hypothermia_7\NN\14034177|and_4
D010672_D007035 NONE phenytoin_2\NN\3550533|NONE_0 (r_pobj) of_1\IN\0|in_13 (r_prep) administration_0\NN\1133281|may_59|to_68|._107 (l_prep) in_3\IN\13603305|of_13 (l_pobj) presence_5\NN\13954253|NONE_0 (l_prep) of_6\IN\0|the_13 (l_pobj) hypothermia_7\NN\14034177|NONE_0
11063349
D016572_D064420 NONE cyclosporine_16\NN\0|NONE_0 (l_appos) csa_18\NNP\0|NONE_0 (l_conj) toxicity_25\NN\13576101|(_26|)_22|or_20
D016572_D064420 NONE csa_18\NNP\0|NONE_0 (l_conj) toxicity_25\NN\13576101|(_26|)_22|or_20
D016572_D064420 NONE csa_6\NNP\0|indications_36|._186 (l_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (l_conj) toxicity_18\NN\13576101|acute_17|or_7|3_10|,_12|dysmorphism_28
D016572_D064420 NONE csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (l_conj) toxicity_18\NN\13576101|acute_17|or_7|3_10|,_12|dysmorphism_28
D003404_D007674 NONE creatinine_17\NN\0|NONE_0 (r_pobj) in_15\IN\13603305|a_23|significant_21|233+/-34_21|to_30|at_66 (r_prep) decrease_14\NN\7296428|:_88|in_86|there_24|]_86|._87 (r_attr) was_11\VBD\0|NONE_0 (l_prep) in_1\IN\13603305|:_2|there_62|decrease_86|]_172|._173 (l_pobj) patients_4\NNS\9898892|NONE_0 (l_acl) switched_5\VBD\138508|the_16|12_12 (l_prep) because_6\IN\0|NONE_0 (l_pobj) nephrotoxicity_9\NN\0|of_11
D016572_D056486 NONE csa_6\NNP\0|indications_36|._186 (l_conj) hepatotoxicity_43\NN\0|chronic_175|or_163|nephrotoxicity_156|in_22|,_6|and_4
D016572_D056486 NONE csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (r_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (r_conj) csa_6\NNP\0|indications_36|._186 (l_conj) hepatotoxicity_43\NN\0|chronic_175|or_163|nephrotoxicity_156|in_22|,_6|and_4
D020123_D011014 NONE rapa_0\NNP\0|was_5|in_22|,_38|because_40|ptld_69|._112 (r_nsubjpass) discontinued_2\VBN\0|NONE_0 (l_prep) because_7\IN\0|rapa_40|was_35|in_18|,_2|ptld_29|._72 (l_pobj) pneumonia_9\NN\14145095|of_3
D016559_-1 NONE tac_8\NNP\0|12_20|,_23|csa_31|,_85|disorder_122 (r_compound) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (l_conj) dysmorphism_25\NN\0|acute_45|or_35|toxicity_28|3_18|,_16
D016559_-1 NONE tac_17\NNP\0|NONE_0 (r_compound) toxicity_18\NN\13576101|acute_17|or_7|3_10|,_12|dysmorphism_28 (r_conj) csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (l_conj) dysmorphism_25\NN\0|acute_45|or_35|toxicity_28|3_18|,_16
D016572_D007674 CID csa_6\NNP\0|indications_36|._186 (l_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156
D016572_D007674 CID csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (r_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156
D016572_D008232 NONE csa_6\NNP\0|indications_36|._186 (l_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) disorder_32\NN\14034177|tac_122|12_102|,_99|csa_91|,_37
D016572_D008232 NONE csa_6\NNP\0|indications_36|._186 (l_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) disorder_32\NN\14034177|tac_122|12_102|,_99|csa_91|,_37 (l_appos) ptld_34\NN\0|posttransplant_45|lymphoproliferative_30|(_1|)_4
D016572_D008232 NONE csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (r_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) disorder_32\NN\14034177|tac_122|12_102|,_99|csa_91|,_37
D016572_D008232 NONE csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (r_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) disorder_32\NN\14034177|tac_122|12_102|,_99|csa_91|,_37 (l_appos) ptld_34\NN\0|posttransplant_45|lymphoproliferative_30|(_1|)_4
D020123_D013281 NONE rapa_0\NNP\0|was_5|in_22|,_38|because_40|ptld_69|._112 (r_nsubjpass) discontinued_2\VBN\0|NONE_0 (l_appos) ptld_13\NN\0|rapa_69|was_64|in_47|,_31|because_29|._43 (l_conj) ulcers_20\NNS\14211294|,_32|in_25|,_19|and_17
D016572_-1 NONE csa_6\NNP\0|indications_36|._186 (l_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (l_conj) dysmorphism_25\NN\0|acute_45|or_35|toxicity_28|3_18|,_16
D016572_-1 NONE csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (l_conj) dysmorphism_25\NN\0|acute_45|or_35|toxicity_28|3_18|,_16
D016559_D007674 CID tac_8\NNP\0|12_20|,_23|csa_31|,_85|disorder_122 (r_compound) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156
D016559_D007674 CID tac_17\NNP\0|NONE_0 (r_compound) toxicity_18\NN\13576101|acute_17|or_7|3_10|,_12|dysmorphism_28 (r_conj) csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (r_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156
D016559_D008232 NONE tac_8\NNP\0|12_20|,_23|csa_31|,_85|disorder_122 (r_compound) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) disorder_32\NN\14034177|tac_122|12_102|,_99|csa_91|,_37
D016559_D008232 NONE tac_8\NNP\0|12_20|,_23|csa_31|,_85|disorder_122 (r_compound) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) disorder_32\NN\14034177|tac_122|12_102|,_99|csa_91|,_37 (l_appos) ptld_34\NN\0|posttransplant_45|lymphoproliferative_30|(_1|)_4
D016559_D008232 NONE tac_17\NNP\0|NONE_0 (r_compound) toxicity_18\NN\13576101|acute_17|or_7|3_10|,_12|dysmorphism_28 (r_conj) csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (r_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) disorder_32\NN\14034177|tac_122|12_102|,_99|csa_91|,_37
D016559_D008232 NONE tac_17\NNP\0|NONE_0 (r_compound) toxicity_18\NN\13576101|acute_17|or_7|3_10|,_12|dysmorphism_28 (r_conj) csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (r_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) disorder_32\NN\14034177|tac_122|12_102|,_99|csa_91|,_37 (l_appos) ptld_34\NN\0|posttransplant_45|lymphoproliferative_30|(_1|)_4
D020123_D008232 NONE rapa_0\NNP\0|was_5|in_22|,_38|because_40|ptld_69|._112 (r_nsubjpass) discontinued_2\VBN\0|NONE_0 (l_appos) ptld_13\NN\0|rapa_69|was_64|in_47|,_31|because_29|._43
D020123_D011020 NONE rapa_6\NNP\0|drug_5 (r_compound) levels_8\NNS\4916342|NONE_0 (r_pobj) to_5\IN\0|when_25|patients_9 (r_prep) converting_3\VBG\126264|however_14|,_7|should_40|be_47|avoid_63|over_69 (r_csubjpass) monitored_11\VBN\2169352|prophylaxis_100|should_112|be_119|._127 (r_advcl) given_27\VBN\5892096|NONE_0 (l_nsubjpass) prophylaxis_24\NN\1077350|monitored_100|should_12|be_19|._27 (l_compound) pneumonia_23\NN\14145095|NONE_0
D020123_D064420 NONE rapa_11\NNP\0|in_16 (r_compound) conversion_12\NN\7359599|NONE_0 (l_prep) in_13\IN\13603305|rapa_16 (l_pobj) patients_14\NNS\9898892|NONE_0 (l_acl) undergoing_15\VBG\109660|NONE_0 (l_dobj) cyclosporine_16\NN\0|NONE_0 (l_appos) csa_18\NNP\0|NONE_0 (l_conj) toxicity_25\NN\13576101|(_26|)_22|or_20
D016559_D064420 NONE tacrolimus_21\NN\0|(_11|tac_12|)_15 (r_nmod) toxicity_25\NN\13576101|(_26|)_22|or_20
D016559_D064420 NONE tac_23\NN\0|tacrolimus_12|(_1|)_3 (r_nmod) toxicity_25\NN\13576101|(_26|)_22|or_20
D016559_D064420 NONE tac_8\NNP\0|12_20|,_23|csa_31|,_85|disorder_122 (r_compound) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (l_conj) csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (l_conj) toxicity_18\NN\13576101|acute_17|or_7|3_10|,_12|dysmorphism_28
D016559_D064420 NONE tac_17\NNP\0|NONE_0 (r_compound) toxicity_18\NN\13576101|acute_17|or_7|3_10|,_12|dysmorphism_28
D016559_D056486 NONE tac_8\NNP\0|12_20|,_23|csa_31|,_85|disorder_122 (r_compound) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (r_conj) csa_6\NNP\0|indications_36|._186 (l_conj) hepatotoxicity_43\NN\0|chronic_175|or_163|nephrotoxicity_156|in_22|,_6|and_4
D016559_D056486 NONE tac_17\NNP\0|NONE_0 (r_compound) toxicity_18\NN\13576101|acute_17|or_7|3_10|,_12|dysmorphism_28 (r_conj) csa_15\NNP\0|tac_31|12_11|,_8|,_54|disorder_91 (r_conj) nephrotoxicity_9\NN\0|chronic_19|or_7|in_134|,_150|and_152|hepatotoxicity_156 (r_conj) csa_6\NNP\0|indications_36|._186 (l_conj) hepatotoxicity_43\NN\0|chronic_175|or_163|nephrotoxicity_156|in_22|,_6|and_4
11900788
D018738_D002375 NONE hexamethonium_10\NN\0|,_6|and_4 (r_conj) mecamylamine_7\NN\0|,_2 (r_conj) naloxone_5\NN\3808977|intraperitoneal_44|of_13|,_2|catalepsy_58|._118 (r_appos) administration_1\NN\1133281|NONE_0 (l_appos) catalepsy_14\NN\14023236|intraperitoneal_102|of_71|,_60|naloxone_58|._60
D018738_D002375 NONE hexamethonium_5\NN\0|,_2 (r_conj) atropine_3\NN\14712692|NONE_0 (r_pobj) of_2\IN\0|intracerebroventricular_34 (r_prep) injection_1\NN\320852|also_51|catalepsy_66|._109 (r_nsubj) decreased_10\VBD\169651|NONE_0 (l_dobj) catalepsy_11\NN\14023236|injection_66|also_15|._43
D001285_D002375 NONE atropine_3\NN\14712692|NONE_0 (r_pobj) of_2\IN\0|intraperitoneal_31|,_11|naloxone_13|catalepsy_71|._131 (r_prep) administration_1\NN\1133281|NONE_0 (l_appos) catalepsy_14\NN\14023236|intraperitoneal_102|of_71|,_60|naloxone_58|._60
D001285_D002375 NONE atropine_3\NN\14712692|NONE_0 (r_pobj) of_2\IN\0|intracerebroventricular_34 (r_prep) injection_1\NN\320852|also_51|catalepsy_66|._109 (r_nsubj) decreased_10\VBD\169651|NONE_0 (l_dobj) catalepsy_11\NN\14023236|injection_66|also_15|._43
D008464_D002375 NONE mecamylamine_7\NN\0|,_2 (r_conj) naloxone_5\NN\3808977|intraperitoneal_44|of_13|,_2|catalepsy_58|._118 (r_appos) administration_1\NN\1133281|NONE_0 (l_appos) catalepsy_14\NN\14023236|intraperitoneal_102|of_71|,_60|naloxone_58|._60
D009538_D002375 CID nicotine_0\NN\14712692|of_22|in_52|._59 (r_compound) potentiation_1\NN\13564910|NONE_0 (l_prep) of_2\IN\0|nicotine_22|in_30|._37 (l_pobj) catalepsy_6\NN\14023236|NONE_0
D009538_D002375 CID nicotine_7\NN\14712692|NONE_0 (r_pobj) of_6\IN\0|on_12|induced_25 (r_prep) effects_5\NNS\13245626|in_22|,_2|have_61|been_66|._83 (l_prep) on_8\IN\0|of_12|induced_13 (l_pobj) catalepsy_9\NN\14023236|NONE_0
D009538_D002375 CID nicotine_3\NN\14712692|but_8 (r_conj) morphine_0\NNP\2707683|catalepsy_51|._60 (r_nsubj) induced_4\VBD\1627355|NONE_0 (l_dobj) catalepsy_9\NN\14023236|morphine_51|._9
D009538_D002375 CID nicotine_22\NN\14712692|NONE_0 (r_pobj) with_21\IN\0|a_26|of_12 (r_prep) combination_18\NN\7951464|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|reduced_18 (r_acl) catalepsy_14\NN\14023236|intraperitoneal_102|of_71|,_60|naloxone_58|._60
D009538_D002375 CID nicotine_16\NN\14712692|plus_5 (r_conj) morphine_14\NN\2707683|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) induced_12\VBN\1627355|NONE_0 (r_acl) catalepsy_11\NN\14023236|injection_66|also_15|._43
D009538_D002375 CID nicotine_22\NN\14712692|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) induced_20\VBN\1627355|the_29|of_12 (r_acl) potentiation_17\NN\13564910|may_45|also_49|be_54|through_66 (r_nsubjpass) mediated_26\VBN\761713|that_142|catalepsy_128|can_118|be_114|by_102|,_67|and_65 (r_conj) elicited_8\VBN\1617192|it_48|was_45|._159 (l_nsubjpass) catalepsy_5\NN\14023236|that_14|can_10|be_14|by_26|,_61|and_63|mediated_128
D009020_D002375 CID morphine_3\NN\2707683|-_8 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) catalepsy_6\NN\14023236|NONE_0
D009020_D002375 CID morphine_12\NN\2707683|NONE_0 (r_pobj) by_11\IN\0|in_12 (r_agent) induced_10\VBN\1627355|of_25|on_13 (r_acl) effects_5\NNS\13245626|in_22|,_2|have_61|been_66|._83 (l_prep) on_8\IN\0|of_12|induced_13 (l_pobj) catalepsy_9\NN\14023236|NONE_0
D009020_D002375 CID morphine_0\NNP\2707683|catalepsy_51|._60 (r_nsubj) induced_4\VBD\1627355|NONE_0 (l_dobj) catalepsy_9\NN\14023236|morphine_51|._9
D009020_D002375 CID morphine_20\NN\2707683|NONE_0 (r_pobj) of_19\IN\0|a_14|with_12 (r_prep) combination_18\NN\7951464|NONE_0 (r_pobj) by_16\IN\0|NONE_0 (r_agent) induced_15\VBN\1627355|reduced_18 (r_acl) catalepsy_14\NN\14023236|intraperitoneal_102|of_71|,_60|naloxone_58|._60
D009020_D002375 CID morphine_14\NN\2707683|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) induced_12\VBN\1627355|NONE_0 (r_acl) catalepsy_11\NN\14023236|injection_66|also_15|._43
D009020_D002375 CID morphine_4\NN\2707683|NONE_0 (r_compound) catalepsy_5\NN\14023236|that_14|can_10|be_14|by_26|,_61|and_63|mediated_128
D009020_D002375 CID morphine_19\NN\2707683|NONE_0 (r_pobj) of_18\IN\0|the_17|induced_12 (r_prep) potentiation_17\NN\13564910|may_45|also_49|be_54|through_66 (r_nsubjpass) mediated_26\VBN\761713|that_142|catalepsy_128|can_118|be_114|by_102|,_67|and_65 (r_conj) elicited_8\VBN\1617192|it_48|was_45|._159 (l_nsubjpass) catalepsy_5\NN\14023236|that_14|can_10|be_14|by_26|,_61|and_63|mediated_128
D009270_D002375 NONE naloxone_5\NN\3808977|intraperitoneal_44|of_13|,_2|catalepsy_58|._118 (r_appos) administration_1\NN\1133281|NONE_0 (l_appos) catalepsy_14\NN\14023236|intraperitoneal_102|of_71|,_60|naloxone_58|._60
D009270_D002375 NONE naloxone_8\NN\3808977|,_6|and_4 (r_conj) hexamethonium_5\NN\0|,_2 (r_conj) atropine_3\NN\14712692|NONE_0 (r_pobj) of_2\IN\0|intracerebroventricular_34 (r_prep) injection_1\NN\320852|also_51|catalepsy_66|._109 (r_nsubj) decreased_10\VBD\169651|NONE_0 (l_dobj) catalepsy_11\NN\14023236|injection_66|also_15|._43
11583940
C063008_D007674 NONE mofetil_7\NNS\0|agents_22|,_33|have_35|._57 (r_dobj) mycophenolate_6\VB\0|NONE_0 (l_dep) have_14\VBP\7846|agents_57|mofetil_35|,_2|._22 (l_dobj) nephrotoxicity_16\NN\0|NONE_0
D020123_D007674 NONE sirolimus_9\NN\0|and_4|rapamycin_11 (r_conj) mofetil_7\NNS\0|agents_22|,_33|have_35|._57 (r_dobj) mycophenolate_6\VB\0|NONE_0 (l_dep) have_14\VBP\7846|agents_57|mofetil_35|,_2|._22 (l_dobj) nephrotoxicity_16\NN\0|NONE_0
D020123_D007674 NONE rapamycin_11\NNS\0|and_15|sirolimus_11 (r_appos) mofetil_7\NNS\0|agents_22|,_33|have_35|._57 (r_dobj) mycophenolate_6\VB\0|NONE_0 (l_dep) have_14\VBP\7846|agents_57|mofetil_35|,_2|._22 (l_dobj) nephrotoxicity_16\NN\0|NONE_0
1700207
D006221_D001145 NONE halothane_17\NN\3570838|-_9 (r_npadvmod) anesthetized_19\VBN\84738|NONE_0 (r_amod) dogs_20\NNS\2083346|NONE_0 (r_pobj) in_16\IN\13603305|adrenaline_20 (r_prep) infusion_15\NN\14589223|NONE_0 (r_pobj) by_13\IN\0|arrhythmia_68|was_12|._53 (r_agent) induced_12\VBN\1627355|NONE_0 (l_nsubjpass) arrhythmia_1\NN\14103288|was_56|by_68|._121
D012964_D001145 NONE na_7\NNP\14625458|channel_3 (r_compound) blockers_9\NNS\10101634|NONE_0 (r_pobj) by_6\IN\0|which_20|is_14 (r_agent) suppressed_5\VBN\2510337|digitalis_31|,_11|,_33 (r_relcl) arrhythmia_1\NN\14103288|was_56|by_68|._158
D010042_D001145 CID ouabain_21\NN\0|NONE_0 (r_pobj) of_20\IN\0|(_17|i.v._16|)_12|in_11 (r_prep) injection_19\NN\320852|intermittent_32 (r_appos) intravenous_15\JJ\0|NONE_0 (r_pobj) by_13\IN\0|arrhythmia_68|was_12|._90 (r_agent) induced_12\VBN\1627355|NONE_0 (l_nsubjpass) arrhythmia_1\NN\14103288|was_56|by_68|._158
C032151_D001145 NONE cibenzoline_6\NN\0|NONE_0 (l_prep) on_7\IN\0|NONE_0 (l_pobj) arrhythmias_10\NNS\14103288|NONE_0
C032151_D001145 NONE -cibenzoline_6\:\0|(_3|+_2 (r_conj) of_2\IN\0|antiarrhythmic_23|and_19|examined_44 (r_prep) effects_1\NNS\13245626|NONE_0 (l_conj) examined_11\VBN\0|antiarrhythmic_67|of_44|and_25 (l_advcl) using_12\VBG\418025|(_30|-)-cibenzoline_29|were_14|._46 (l_dobj) models_17\NNS\5888929|NONE_0 (l_compound) arrhythmia_16\NN\14103288|two_23|canine_19
C032151_D001145 NONE -)-cibenzoline_9\:\0|(_1|were_15|using_29|._75 (r_nsubjpass) examined_11\VBN\0|antiarrhythmic_67|of_44|and_25 (l_advcl) using_12\VBG\418025|(_30|-)-cibenzoline_29|were_14|._46 (l_dobj) models_17\NNS\5888929|NONE_0 (l_compound) arrhythmia_16\NN\14103288|two_23|canine_19
C032151_D001145 NONE -cibenzoline_8\,\0|)_1 (r_punct) suppressed_9\VBN\2510337|i.v._21|digitalis-_11|,_56|respectively_58|._70 (r_amod) arrhythmias_15\NNS\14103288|NONE_0
C032151_D001145 NONE -cibenzoline_9\:\0|arrhythmias_51 (r_punct) for_10\IN\0|the_63|minimum_59|effective_51|plasma_41|of_19 (l_pobj) arrhythmias_16\NNS\14103288|-cibenzoline_51
C032151_D001145 NONE -)-cibenzoline_9\NNP\0|(_1|arrhythmia_48|,_58 (r_nsubj) suppressed_10\VBD\2510337|NONE_0 (l_dobj) arrhythmia_15\NN\14103288|(_49|-)-cibenzoline_48|,_10
C032151_D001145 NONE -)-cibenzoline_9\NNP\0|(_1|arrhythmia_48|,_58 (r_nsubj) suppressed_10\VBD\2510337|NONE_0 (r_pcomp) of_7\IN\0|NONE_0 (r_prep) i.v._6\NN\0|a_24|lower_22|of_11 (r_appos) dose_2\NN\3740161|whereas_85|mg/kg_95|was_106|suppress_120|._159 (r_nsubjpass) needed_22\VBN\0|NONE_0 (l_advcl) suppress_24\VB\2510337|dose_120|whereas_35|mg/kg_25|was_14|._39 (l_dobj) arrhythmias_28\NNS\14103288|to_31
C032151_D001145 NONE -)-cibenzoline_7\:\0|the_48|minimum_44|effective_36|plasma_26|of_4 (l_prep) for_8\IN\0|(_16 (l_pobj) arrhythmia_14\NN\14103288|NONE_0
D004837_D001145 CID adrenaline_14\NN\14807929|in_20 (r_amod) infusion_15\NN\14589223|NONE_0 (r_pobj) by_13\IN\0|arrhythmia_68|was_12|._53 (r_agent) induced_12\VBN\1627355|NONE_0 (l_nsubjpass) arrhythmia_1\NN\14103288|was_56|by_68|._121
D004837_D001145 CID adrenaline_12\NN\14807929|-_10 (r_npadvmod) induced_14\VBN\1627355|and_15 (r_conj) digitalis-_10\NN\0|i.v._32|suppressed_11|,_45|respectively_47|._59 (r_amod) arrhythmias_15\NNS\14103288|NONE_0
D004837_D001145 CID adrenaline_13\NN\14807929|-_10 (r_npadvmod) induced_15\VBN\1627355|and_15 (r_conj) digitalis-_11\NN\0|NONE_0 (r_amod) arrhythmias_16\NNS\14103288|-cibenzoline_51
D004837_D001145 CID adrenaline_25\NN\14807929|-_10 (r_npadvmod) induced_27\VBN\1627355|NONE_0 (r_amod) arrhythmias_28\NNS\14103288|to_31 (r_dobj) suppress_24\VB\2510337|dose_120|whereas_35|mg/kg_25|was_14|._39 (r_advcl) needed_22\VBN\0|NONE_0 (l_nsubjpass) dose_2\NN\3740161|whereas_85|mg/kg_95|was_106|suppress_120|._159 (l_appos) i.v._6\NN\0|a_24|lower_22|of_11 (l_prep) of_7\IN\0|NONE_0 (l_pcomp) suppressed_10\VBD\2510337|NONE_0 (l_dobj) arrhythmia_15\NN\14103288|(_49|-)-cibenzoline_48|,_10
D004837_D001145 CID adrenaline_25\NN\14807929|-_10 (r_npadvmod) induced_27\VBN\1627355|NONE_0 (r_amod) arrhythmias_28\NNS\14103288|to_31
D004837_D001145 CID adrenaline_11\NN\14807929|-_10 (r_npadvmod) induced_13\VBN\1627355|and_15 (r_conj) digitalis-_9\NN\0|NONE_0 (r_amod) arrhythmia_14\NN\14103288|NONE_0
D010424_D001145 NONE pentobarbital_23\NN\2792049|-_13 (r_npadvmod) anesthetized_25\VBN\84738|NONE_0 (r_amod) dogs_26\NNS\2083346|NONE_0 (r_pobj) in_22\IN\13603305|(_28|i.v._27|)_23|of_11 (r_prep) injection_19\NN\320852|intermittent_32 (r_appos) intravenous_15\JJ\0|NONE_0 (r_pobj) by_13\IN\0|arrhythmia_68|was_12|._90 (r_agent) induced_12\VBN\1627355|NONE_0 (l_nsubjpass) arrhythmia_1\NN\14103288|was_56|by_68|._158
D002118_D001145 NONE ca_7\NNP\14625458|NONE_0 (r_aux) channel_8\NN\6251781|NONE_0 (r_compound) blockers_9\NNS\10101634|NONE_0 (r_pobj) by_6\IN\0|which_20|is_14 (r_agent) suppressed_5\VBN\2510337|adrenaline_32|,_11|,_33 (r_relcl) arrhythmia_1\NN\14103288|was_56|by_68|._121
D004070_D001145 NONE digitalis_0\NNP\15059939|,_20|suppressed_31|,_64 (r_compound) arrhythmia_1\NN\14103288|was_56|by_68|._158
D004070_D001145 NONE digitalis-_10\NN\0|i.v._32|suppressed_11|,_45|respectively_47|._59 (r_amod) arrhythmias_15\NNS\14103288|NONE_0
D004070_D001145 NONE digitalis-_11\NN\0|NONE_0 (r_amod) arrhythmias_16\NNS\14103288|-cibenzoline_51
D004070_D001145 NONE digitalis_12\NN\15059939|-_9 (r_npadvmod) induced_14\VBN\1627355|the_14 (r_amod) arrhythmia_15\NN\14103288|(_49|-)-cibenzoline_48|,_10
D004070_D001145 NONE digitalis_12\NN\15059939|-_9 (r_npadvmod) induced_14\VBN\1627355|the_14 (r_amod) arrhythmia_15\NN\14103288|(_49|-)-cibenzoline_48|,_10 (r_dobj) suppressed_10\VBD\2510337|NONE_0 (r_pcomp) of_7\IN\0|NONE_0 (r_prep) i.v._6\NN\0|a_24|lower_22|of_11 (r_appos) dose_2\NN\3740161|whereas_85|mg/kg_95|was_106|suppress_120|._159 (r_nsubjpass) needed_22\VBN\0|NONE_0 (l_advcl) suppress_24\VB\2510337|dose_120|whereas_35|mg/kg_25|was_14|._39 (l_dobj) arrhythmias_28\NNS\14103288|to_31
D004070_D001145 NONE digitalis-_9\NN\0|NONE_0 (r_amod) arrhythmia_14\NN\14103288|NONE_0
6118280
D002998_D009207 NONE clonazepam_4\NN\0|of_24|,_2|was_27|be_40|._127 (r_nsubjpass) found_12\VBN\13279262|NONE_0 (l_xcomp) be_14\VB\14625458|of_64|,_42|clonazepam_40|was_13|._87 (l_prep) in_27\IN\13603305|to_59|potent_35|mg/kg_7 (l_pcomp) blocking_28\VBG\562280|NONE_0 (l_dobj) jerks_31\NNS\10322238|NONE_0
D009118_D009207 CID muscimol_7\NNS\0|drugs_42|-_8|jerks_27|in_33|._52 (r_npadvmod) induced_9\VBN\1627355|NONE_0 (l_dobj) jerks_11\NNS\10322238|drugs_69|muscimol_27|-_19|in_6|._25
D009118_D009207 CID muscimol_5\NNS\0|in_20|,_2|jerks_28|._33 (r_nsubj) produced_6\VBD\1617192|NONE_0 (l_dobj) jerks_8\NNS\10322238|in_48|,_30|muscimol_28|._5
D009118_D009207 CID muscimol_22\NN\0|-_8 (r_npadvmod) induced_24\VBN\1627355|the_13 (r_amod) myoclonus_25\NN\14360459|clinical_41|,_23 (r_appos) myoclonus_19\NN\14360459|NONE_0
D009118_D009207 CID muscimol_22\NN\0|-_8 (r_npadvmod) induced_24\VBN\1627355|the_13 (r_amod) myoclonus_25\NN\14360459|clinical_41|,_23
D001418_D009207 NONE baclofen_5\JJ\0|NONE_0 (r_compound) block_6\NN\21939|and_13 (r_conj) benzodiazepines_3\NNS\3771443|serotonergic_20|,_2 (r_conj) drugs_1\NNS\14778436|muscimol_42|-_50|jerks_69|in_75|._94 (r_nsubj) induced_9\VBN\1627355|NONE_0 (l_dobj) jerks_11\NNS\10322238|drugs_69|muscimol_27|-_19|in_6|._25
D001418_D009207 NONE -)-baclofen_11\:\0|management_19 (r_punct) in_12\IN\13603305|the_46|possible_42|of_27 (l_pobj) management_14\NN\1123598|-)-baclofen_19 (l_prep) of_15\IN\0|the_15 (l_pobj) myoclonus_17\NN\14360459|NONE_0
D003975_D009207 NONE diazepam_20\NN\2830852|NONE_0 (r_pobj) than_19\IN\0|fold_17|more_12 (r_prep) potent_18\JJ\0|to_24|mg/kg_28|in_35 (r_acomp) be_14\VB\14625458|of_64|,_42|clonazepam_40|was_13|._87 (l_prep) in_27\IN\13603305|to_59|potent_35|mg/kg_7 (l_pcomp) blocking_28\VBG\562280|NONE_0 (l_dobj) jerks_31\NNS\10322238|NONE_0
D001569_D009207 NONE benzodiazepines_3\NNS\3771443|serotonergic_20|,_2 (r_conj) drugs_1\NNS\14778436|muscimol_42|-_50|jerks_69|in_75|._94 (r_nsubj) induced_9\VBN\1627355|NONE_0 (l_dobj) jerks_11\NNS\10322238|drugs_69|muscimol_27|-_19|in_6|._25
D001569_D009207 NONE benzodiazepines_2\NNS\3771443|NONE_0 (r_pobj) of_0\IN\0|,_22|clonazepam_24|was_51|be_64|._151 (r_prep) found_12\VBN\13279262|NONE_0 (l_xcomp) be_14\VB\14625458|of_64|,_42|clonazepam_40|was_13|._87 (l_prep) in_27\IN\13603305|to_59|potent_35|mg/kg_7 (l_pcomp) blocking_28\VBG\562280|NONE_0 (l_dobj) jerks_31\NNS\10322238|NONE_0
D001569_D009207 NONE benzodiazepines_7\NNS\3771443|and_8 (r_conj) 5-htp_4\NN\0|that_5|have_30|been_35|be_49 (r_nsubjpass) found_10\VBN\13279262|the_54 (l_xcomp) be_12\VB\14625458|that_54|5-htp_49|have_19|been_14 (l_acomp) beneficial_13\JJ\0|to_6 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) management_16\NN\1123598|NONE_0 (l_prep) of_17\IN\0|the_15 (l_pobj) myoclonus_19\NN\14360459|NONE_0
D001569_D009207 NONE benzodiazepines_7\NNS\3771443|and_8 (r_conj) 5-htp_4\NN\0|that_5|have_30|been_35|be_49 (r_nsubjpass) found_10\VBN\13279262|the_54 (l_xcomp) be_12\VB\14625458|that_54|5-htp_49|have_19|been_14 (l_acomp) beneficial_13\JJ\0|to_6 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) management_16\NN\1123598|NONE_0 (l_prep) of_17\IN\0|the_15 (l_pobj) myoclonus_19\NN\14360459|NONE_0 (l_appos) myoclonus_25\NN\14360459|clinical_41|,_23
D006916_D009207 NONE 5-htp_4\NN\0|that_5|have_30|been_35|be_49 (r_nsubjpass) found_10\VBN\13279262|the_54 (l_xcomp) be_12\VB\14625458|that_54|5-htp_49|have_19|been_14 (l_acomp) beneficial_13\JJ\0|to_6 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) management_16\NN\1123598|NONE_0 (l_prep) of_17\IN\0|the_15 (l_pobj) myoclonus_19\NN\14360459|NONE_0
D006916_D009207 NONE 5-htp_4\NN\0|that_5|have_30|been_35|be_49 (r_nsubjpass) found_10\VBN\13279262|the_54 (l_xcomp) be_12\VB\14625458|that_54|5-htp_49|have_19|been_14 (l_acomp) beneficial_13\JJ\0|to_6 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) management_16\NN\1123598|NONE_0 (l_prep) of_17\IN\0|the_15 (l_pobj) myoclonus_19\NN\14360459|NONE_0 (l_appos) myoclonus_25\NN\14360459|clinical_41|,_23
C014896_D009207 NONE mk-212_8\NNP\0|NONE_0 (r_punct) and_9\CC\0|(_4 (r_punct) -)-baclofen_11\:\0|management_19 (r_punct) in_12\IN\13603305|the_46|possible_42|of_27 (l_pobj) management_14\NN\1123598|-)-baclofen_19 (l_prep) of_15\IN\0|the_15 (l_pobj) myoclonus_17\NN\14360459|NONE_0
20552622
D000420_D013617 CID salbutamol_7\NN\0|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) triggered_5\VBN\1641914|induced_31|atrial_23|report_30 (r_acl) tachyarrhythmia_4\NN\0|NONE_0
D000420_D013617 CID salbutamol_0\NNP\0|is_11|here_24|as_29|._59 (r_nsubjpass) presented_2\VBN\2137132|NONE_0 (l_prep) as_4\IN\14622893|salbutamol_29|is_18|here_5|._30 (l_pobj) trigger_7\NN\3659292|NONE_0 (l_prep) for_8\IN\0|a_19|possible_17 (l_pobj) siat_9\NNP\0|NONE_0
D001262_D013610 NONE atenolol_51\NN\2832168|such_8 (r_pobj) as_50\IN\14622893|a_20|beta_18|-_14 (r_prep) blocker_48\NN\10101634|that_12|may_63|it_75 (r_nsubj) relieve_60\VB\205885|while_100|and_83 (r_conj) swallowing_42\VBG\1156834|that_143|agonist_131|may_77|trigger_66 (r_advcl) be_31\VB\14625458|to_79 (l_nsubj) agonist_21\NN\0|that_12|may_54|trigger_65|swallowing_131 (l_acl) known_25\VBN\0|a_32|beta_30|-_26|like_17 (l_xcomp) induce_27\VB\1627355|(_10|)_18 (l_dobj) tachycardia_28\NN\14110674|to_10
D001262_D001145 NONE atenolol_6\NN\2832168|NONE_0 (r_pobj) with_5\IN\0|arrhythmia_34|after_14|,_13|but_15|recurred_19|._40 (r_prep) resolved_2\VBD\352826|NONE_0 (l_nsubj) arrhythmia_1\NN\14103288|after_20|with_34|,_47|but_49|recurred_53|._74
D001262_D001145 NONE atenolol_13\NN\2832168|NONE_0 (r_pobj) with_11\IN\0|a_7 (r_prep) week_10\NN\15113229|NONE_0 (r_pobj) after_8\IN\0|after_37|,_30|arrhythmia_36|._58 (r_prep) disappeared_17\VBD\0|NONE_0 (l_nsubj) arrhythmia_16\NN\14103288|after_73|after_36|,_6|._22
D000420_D013610 NONE salbutamol_23\NN\0|NONE_0 (r_pobj) like_22\IN\5839024|a_15|beta_13|-_9|known_17 (r_prep) agonist_21\NN\0|that_12|may_54|trigger_65|swallowing_131 (l_acl) known_25\VBN\0|a_32|beta_30|-_26|like_17 (l_xcomp) induce_27\VB\1627355|(_10|)_18 (l_dobj) tachycardia_28\NN\14110674|to_10
11282081
D002698_D001281 NONE chloralose_21\NN\0|anesthetized_11 (r_amod) dogs_23\NNS\2083346|NONE_0 (r_pobj) to_18\IN\0|evaluate_104|,_28|we_26|verapamil_10|._40 (r_prep) administered_16\VBD\2436349|NONE_0 (l_advcl) evaluate_1\VB\670261|,_76|we_78|verapamil_94|to_104|._144 (l_dobj) mechanisms_4\NNS\13446390|to_26 (l_prep) of_5\IN\0|the_25|potential_21 (l_pobj) promotion_7\NN\6598915|NONE_0 (l_compound) af_6\NNP\0|by_13
D004110_D001281 NONE diltiazem_0\NNP\2938514|did_10|not_14|erp_25|,_60|but_62|produced_66|._140 (r_nsubj) affect_3\VB\26192|NONE_0 (l_dobj) erp_4\NNP\0|diltiazem_25|did_15|not_11|,_35|but_37|produced_41|._115 (l_conj) length_8\NN\5093581|,_11 (l_compound) af_6\NNP\0|cycle_3|or_16|duration_22
D004110_D001281 NONE diltiazem_0\NNP\2938514|did_10|not_14|erp_25|,_60|but_62|produced_66|._140 (r_nsubj) affect_3\VB\26192|NONE_0 (l_dobj) erp_4\NNP\0|diltiazem_25|did_15|not_11|,_35|but_37|produced_41|._115 (l_conj) length_8\NN\5093581|,_11 (l_conj) duration_11\NN\15113229|af_22|cycle_19|or_6 (l_compound) af_10\NNP\0|NONE_0
D004110_D001281 NONE diltiazem_23\NN\2938514|NONE_0 (r_pobj) by_22\IN\0|not_11 (r_agent) shared_21\VBN\2660631|an_53|dependent_43|and_8 (r_conj) effect_13\NN\34213|verapamil_79|af_60|in_57|by_42|,_5|._69 (r_dobj) promotes_1\VBZ\2556126|NONE_0 (l_dobj) af_2\NNP\0|verapamil_19|in_3|by_18|,_55|effect_60|._129
D009020_D001281 NONE morphine_19\NN\2707683|-_8 (r_npadvmod) chloralose_21\NN\0|anesthetized_11 (r_amod) dogs_23\NNS\2083346|NONE_0 (r_pobj) to_18\IN\0|evaluate_104|,_28|we_26|verapamil_10|._40 (r_prep) administered_16\VBD\2436349|NONE_0 (l_advcl) evaluate_1\VB\670261|,_76|we_78|verapamil_94|to_104|._144 (l_dobj) mechanisms_4\NNS\13446390|to_26 (l_prep) of_5\IN\0|the_25|potential_21 (l_pobj) promotion_7\NN\6598915|NONE_0 (l_compound) af_6\NNP\0|by_13
D002118_D013617 NONE ca(2_23\NNP\0|NONE_0 (r_dobj) decreases_19\VBZ\7296428|tachycardia_103|occurrence_59|and_4 (r_conj) promotes_7\VBZ\2556126|:_40|._103 (l_nsubj) tachycardia_3\NN\14110674|occurrence_44|and_99|decreases_103
D002118_D001281 NONE ca(2_23\NNP\0|NONE_0 (r_dobj) decreases_19\VBZ\7296428|tachycardia_103|occurrence_59|and_4 (r_conj) promotes_7\VBZ\2556126|:_40|._103 (l_dobj) occurrence_9\NN\29378|tachycardia_44|and_55|decreases_59 (l_prep) of_12\IN\0|the_31|and_16|maintenance_12 (l_pobj) fibrillation_14\NN\14361664|NONE_0
D002118_D001281 NONE ca(2_23\NNP\0|NONE_0 (r_dobj) decreases_19\VBZ\7296428|tachycardia_103|occurrence_59|and_4 (r_conj) promotes_7\VBZ\2556126|:_40|._103 (l_dobj) occurrence_9\NN\29378|tachycardia_44|and_55|decreases_59 (l_prep) of_12\IN\0|the_31|and_16|maintenance_12 (l_pobj) fibrillation_14\NN\14361664|NONE_0 (l_appos) af_16\NNP\0|atrial_21|(_1|)_2
D002118_D001281 NONE ca(2_11\NN\0|)_4 (r_nmod) channel_13\NN\6251781|acute_19|type_11 (r_compound) blockade_14\NN\952963|that_32|can_9|af_21|,_23|consistent_25 (r_nsubj) promote_16\VB\2556126|a_67|clinical_65 (l_dobj) af_17\NNP\0|that_53|blockade_21|can_12|,_2|consistent_4
D002118_D001281 NONE ca(2_11\NN\0|)_4 (r_nmod) channel_13\NN\6251781|acute_19|type_11 (r_compound) blockade_14\NN\952963|that_32|can_9|af_21|,_23|consistent_25 (r_nsubj) promote_16\VB\2556126|a_67|clinical_65 (l_advcl) consistent_19\JJ\0|that_57|blockade_25|can_16|af_4|,_2 (l_prep) with_20\IN\0|NONE_0 (l_pobj) effect_24\NN\34213|NONE_0 (l_compound) af_22\NNP\0|an_3|promoting_3|of_20
D002118_D001281 NONE ca(2_26\NNP\0|channel_7 (r_nmod) inhibition_30\NN\1068773|NONE_0 (r_pobj) of_25\IN\0|an_23|af_20|promoting_17 (r_prep) effect_24\NN\34213|NONE_0 (r_pobj) with_20\IN\0|NONE_0 (r_prep) consistent_19\JJ\0|that_57|blockade_25|can_16|af_4|,_2 (r_advcl) promote_16\VB\2556126|a_67|clinical_65 (l_dobj) af_17\NNP\0|that_53|blockade_21|can_12|,_2|consistent_4
D002118_D001281 NONE ca(2_26\NNP\0|channel_7 (r_nmod) inhibition_30\NN\1068773|NONE_0 (r_pobj) of_25\IN\0|an_23|af_20|promoting_17 (r_prep) effect_24\NN\34213|NONE_0 (l_compound) af_22\NNP\0|an_3|promoting_3|of_20
D002118_D001281 NONE ca(2_9\NNP\0|channel_7 (r_nmod) blockers_13\NNS\10101634|NONE_0 (r_pobj) by_8\IN\0|af_13 (r_prep) promotion_7\NN\6598915|NONE_0 (l_compound) af_6\NNP\0|by_13
D014700_D001281 CID verapamil_2\NN\2938514|NONE_0 (r_pobj) of_1\IN\0|on_13|and_36|determinants_65|._85 (r_prep) effects_0\NNS\13245626|NONE_0 (l_prep) on_3\IN\0|of_13|and_23|determinants_52|._72 (l_pobj) fibrillation_5\NN\14361664|NONE_0
D014700_D001281 CID verapamil_17\NN\2938514|evaluate_94|,_18|we_16|to_10|._50 (r_dobj) administered_16\VBD\2436349|NONE_0 (l_advcl) evaluate_1\VB\670261|,_76|we_78|verapamil_94|to_104|._144 (l_dobj) mechanisms_4\NNS\13446390|to_26 (l_prep) of_5\IN\0|the_25|potential_21 (l_pobj) promotion_7\NN\6598915|NONE_0 (l_compound) af_6\NNP\0|by_13
D014700_D001281 CID verapamil_1\NNP\2938514|:_2|promotion_20|in_30|,_41|increasing_43 (r_nsubj) caused_2\VBD\1617192|NONE_0 (l_dobj) promotion_4\NN\6598915|:_22|verapamil_20|in_10|,_21|increasing_23 (l_compound) af_3\NNP\0|NONE_0
D014700_D001281 CID verapamil_1\NNP\2938514|:_2|promotion_20|in_30|,_41|increasing_43 (r_nsubj) caused_2\VBD\1617192|NONE_0 (l_advcl) increasing_9\VBG\169651|:_45|verapamil_43|promotion_23|in_13|,_2 (l_dobj) duration_11\NN\15113229|NONE_0 (l_prep) of_12\IN\0|mean_14|induced_6 (l_pobj) af_13\NNP\0|NONE_0
D014700_D001281 CID verapamil_4\NN\2938514|in_22|,_2|mean_20|period_46|from_59|,_122|decreased_124|,_184|accelerated_202|._299 (r_nsubj) shortened_5\VBN\429060|NONE_0 (l_conj) accelerated_43\VBN\226566|in_224|,_204|verapamil_202|mean_182|period_156|from_143|,_80|decreased_78|,_18|._97 (l_conj) decreased_47\VBD\169651|heterogeneously_50|conduction_15|and_4 (l_dobj) length_50\NN\5093581|to_21 (l_prep) of_51\IN\0|the_17|cycle_13 (l_pobj) 94+/-4_54\CD\0|NONE_0 (l_nmod) af_52\NNP\0|(_3
D014700_D001281 CID verapamil_22\NNP\2938514|(_10 (r_nmod) n=5_24\NNS\0|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) caused_20\VBN\1617192|NONE_0 (r_acl) that_19\DT\0|NONE_0 (r_pobj) to_18\IN\0|NONE_0 (r_prep) similar_17\JJ\0|conduction_24 (r_amod) acceleration_16\NN\7296428|)_53 (r_dobj) produced_14\VBD\1617192|diltiazem_66|did_56|not_52|erp_41|,_6|but_4|._74 (r_conj) affect_3\VB\26192|NONE_0 (l_dobj) erp_4\NNP\0|diltiazem_25|did_15|not_11|,_35|but_37|produced_41|._115 (l_conj) length_8\NN\5093581|,_11 (l_compound) af_6\NNP\0|cycle_3|or_16|duration_22
D014700_D001281 CID verapamil_22\NNP\2938514|(_10 (r_nmod) n=5_24\NNS\0|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) caused_20\VBN\1617192|NONE_0 (r_acl) that_19\DT\0|NONE_0 (r_pobj) to_18\IN\0|NONE_0 (r_prep) similar_17\JJ\0|conduction_24 (r_amod) acceleration_16\NN\7296428|)_53 (r_dobj) produced_14\VBD\1617192|diltiazem_66|did_56|not_52|erp_41|,_6|but_4|._74 (r_conj) affect_3\VB\26192|NONE_0 (l_dobj) erp_4\NNP\0|diltiazem_25|did_15|not_11|,_35|but_37|produced_41|._115 (l_conj) length_8\NN\5093581|,_11 (l_conj) duration_11\NN\15113229|af_22|cycle_19|or_6 (l_compound) af_10\NNP\0|NONE_0
D014700_D001281 CID verapamil_7\NN\2938514|in_39|,_2|promote_20|refractoriness_70|._84 (r_nsubj) failed_8\VBD\0|NONE_0 (l_xcomp) promote_10\VB\2556126|in_59|,_22|verapamil_20|refractoriness_50|._64 (l_dobj) af_11\NNP\0|to_11|and_3|increased_7
D014700_D001281 CID verapamil_4\NN\2938514|that_5|af_19|by_22 (r_nsubj) promoted_5\VBD\2556126|mapping_33|._121 (l_dobj) af_6\NNP\0|that_24|verapamil_19|by_3
D014700_D001281 CID verapamil_0\NNP\2938514|af_19|in_22|by_37|,_74|effect_79|._148 (r_nsubj) promotes_1\VBZ\2556126|NONE_0 (l_dobj) af_2\NNP\0|verapamil_19|in_3|by_18|,_55|effect_60|._129
7650771
D004456_D064420 NONE iodide_8\NN\14904359|echothiophate_14|eye_7 (r_compound) drops_10\VBZ\13899200|NONE_0 (r_pobj) of_6\IN\0|ocular_20 (r_prep) instillation_5\NN\320852|NONE_0 (r_pobj) from_3\IN\0|NONE_0 (r_prep) resulting_2\VBG\2633881|cholinergic_21|._68 (r_acl) toxicity_1\NN\13576101|NONE_0
D004456_D018908 CID iodide_12\NN\14904359|echothiophate_14|ophthalmic_7 (r_nmod) drops_14\NNS\13899200|NONE_0 (r_pobj) of_10\IN\0|the_8 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) from_7\IN\0|a_30|severe_28|cholinergic_21 (r_prep) syndrome_6\NN\5870365|patient_39|,_62|presented_64|._162 (r_dobj) developed_2\VBD\1753788|NONE_0 (l_conj) presented_16\VBN\2137132|patient_103|syndrome_64|,_2|._98 (l_prep) with_17\IN\0|and_30|given_48 (l_pobj) weakness_20\NN\14462666|NONE_0
D004456_D009157 NONE iodide_12\NN\14904359|echothiophate_14|ophthalmic_7 (r_nmod) drops_14\NNS\13899200|NONE_0 (r_pobj) of_10\IN\0|the_8 (r_prep) use_9\NN\407535|NONE_0 (r_pobj) from_7\IN\0|a_30|severe_28|cholinergic_21 (r_prep) syndrome_6\NN\5870365|patient_39|,_62|presented_64|._162 (r_dobj) developed_2\VBD\1753788|NONE_0 (l_conj) presented_16\VBN\2137132|patient_103|syndrome_64|,_2|._98 (l_conj) given_24\VBN\5892096|with_48|and_18 (l_dobj) diagnosis_26\NN\152018|was_24|initially_20 (l_prep) of_27\IN\0|the_14 (l_pobj) gravis_29\NN\0|NONE_0
19893084
D005839_D058186 CID gentamicin_12\NN\2716866|NONE_0 (r_pcomp) by_11\IN\0|NONE_0 (r_agent) induced_10\VBN\1627355|acute_20|renal_14 (r_acl) failure_9\NN\66216|NONE_0
7066357
D011692_D009404 CID aminonucleoside_18\RB\0|plasma_120|in_24|by_13|._15 (r_advmod) induced_12\VBN\1627355|NONE_0 (l_nsubj) plasma_0\NN\5398023|in_96|by_107|aminonucleoside_120|._135 (l_prep) during_6\IN\0|and_36|lipids_24 (l_pobj) development_8\NN\248977|NONE_0 (l_prep) of_9\IN\0|the_16 (l_pobj) syndrome_11\NN\5870365|NONE_0
D011692_D009404 CID aminonucleoside_19\NN\0|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|the_67|of_51 (r_acl) alterations_8\NNS\7283608|whether_12|due_105|,_137|or_139|,_141|to_161 (l_prep) of_9\IN\0|the_16|induced_51 (l_pobj) lipoproteins_11\NNS\14731135|NONE_0 (l_acl) found_12\VBN\13279262|plasma_20 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) syndrome_15\NN\5870365|NONE_0
D011692_D009404 CID aminonucleoside_19\NN\0|NONE_0 (r_pobj) by_17\IN\0|NONE_0 (r_agent) induced_16\VBN\1627355|the_67|of_51 (r_acl) alterations_8\NNS\7283608|whether_12|due_105|,_137|or_139|,_141|to_161 (r_nsubj) were_20\VBD\0|to_125 (l_acomp) due_21\JJ\5174653|whether_117|alterations_105|,_32|or_34|,_36|to_56 (l_prep) to_22\IN\0|NONE_0 (l_pobj) syndrome_24\NN\5870365|NONE_0
D011692_D009404 CID aminonucleoside_37\NN\0|NONE_0 (r_pobj) to_35\IN\0|whether_173|alterations_161|due_56|,_24|or_22|,_20 (r_prep) were_20\VBD\0|to_125 (l_nsubj) alterations_8\NNS\7283608|whether_12|due_105|,_137|or_139|,_141|to_161 (l_prep) of_9\IN\0|the_16|induced_51 (l_pobj) lipoproteins_11\NNS\14731135|NONE_0 (l_acl) found_12\VBN\13279262|plasma_20 (l_prep) in_13\IN\13603305|NONE_0 (l_pobj) syndrome_15\NN\5870365|NONE_0
D011692_D009404 CID aminonucleoside_37\NN\0|NONE_0 (r_pobj) to_35\IN\0|whether_173|alterations_161|due_56|,_24|or_22|,_20 (r_prep) were_20\VBD\0|to_125 (l_acomp) due_21\JJ\5174653|whether_117|alterations_105|,_32|or_34|,_36|to_56 (l_prep) to_22\IN\0|NONE_0 (l_pobj) syndrome_24\NN\5870365|NONE_0
D011692_D009404 CID aminonucleoside_21\NN\0|purpose_134|investigate_98|._90 (l_conj) development_32\NN\248977|mg/kg_37|and_19 (l_prep) of_33\IN\0|the_27|subsequent_23 (l_pobj) syndrome_35\NN\5870365|NONE_0
D005227_D009404 NONE acids_10\NNS\14818238|NONE_0 (r_pobj) of_8\IN\0|the_17|plasma_13 (r_prep) level_7\NN\4916342|in_34|remained_112|._129 (r_nsubj) decreased_15\VBD\169651|NONE_0 (l_prep) in_0\IN\13603305|level_34|remained_146|._163 (l_pobj) stage_4\NN\15113229|NONE_0 (l_amod) nephrotic_3\JJ\0|NONE_0
D002788_D009404 NONE esters_22\NNS\14727670|while_40|that_34|constant_24 (r_nsubj) remained_25\VBD\2604760|in_146|level_112|._17 (r_advcl) decreased_15\VBD\169651|NONE_0 (l_prep) in_0\IN\13603305|level_34|remained_146|._163 (l_pobj) stage_4\NN\15113229|NONE_0 (l_amod) nephrotic_3\JJ\0|NONE_0
D014280_D009404 NONE triacylglycerol_12\NN\0|fatty_13|,_2 (r_conj) acids_10\NNS\14818238|NONE_0 (r_pobj) of_8\IN\0|the_17|plasma_13 (r_prep) level_7\NN\4916342|in_34|remained_112|._129 (r_nsubj) decreased_15\VBD\169651|NONE_0 (l_prep) in_0\IN\13603305|level_34|remained_146|._163 (l_pobj) stage_4\NN\15113229|NONE_0 (l_amod) nephrotic_3\JJ\0|NONE_0
3962737
D000638_D056486 CID amiodarone_2\NN\2715941|NONE_0 (r_pobj) of_1\IN\0|._13 (r_prep) hepatotoxicity_0\NN\0|NONE_0
D000638_D056486 CID amiodarone_7\NN\2715941|NONE_0 (r_compound) treatment_8\NN\654885|a_55|with_45|due_18 (r_appos) patient_1\NN\9898892|is_63|below_76|and_82|given_134 (l_prep) with_2\IN\0|a_10|due_27|treatment_45 (l_pobj) hepatitis_4\NN\14127211|NONE_0
D000638_D056486 CID amiodarone_7\NN\2715941|NONE_0 (r_compound) treatment_8\NN\654885|a_55|with_45|due_18 (r_appos) patient_1\NN\9898892|is_63|below_76|and_82|given_134 (r_nsubjpass) presented_10\VBN\2137132|NONE_0 (l_conj) given_21\VBN\5892096|patient_134|is_71|below_58|and_52 (l_nsubjpass) review_14\NN\5733583|is_43|._51 (l_prep) of_15\IN\0|a_9 (l_pobj) hepatotoxicity_17\NN\0|NONE_0
D000638_D056486 CID amiodarone_19\NN\2715941|NONE_0 (r_pobj) of_18\IN\0|the_19 (r_prep) hepatotoxicity_17\NN\0|NONE_0 (r_pobj) of_15\IN\0|a_9 (r_prep) review_14\NN\5733583|is_43|._51 (r_nsubjpass) given_21\VBN\5892096|patient_134|is_71|below_58|and_52 (r_conj) presented_10\VBN\2137132|NONE_0 (l_nsubjpass) patient_1\NN\9898892|is_63|below_76|and_82|given_134 (l_prep) with_2\IN\0|a_10|due_27|treatment_45 (l_pobj) hepatitis_4\NN\14127211|NONE_0
D000638_D056486 CID amiodarone_19\NN\2715941|NONE_0 (r_pobj) of_18\IN\0|the_19 (r_prep) hepatotoxicity_17\NN\0|NONE_0
D000638_D056486 CID amiodarone_12\NN\2715941|,_20|including_22|,_41 (r_compound) treatment_13\NN\654885|NONE_0 (r_pobj) to_11\IN\0|alterations_46 (r_pcomp) due_10\IN\5174653|that_45|evidence_34|of_18 (r_prep) exists_6\VBZ\0|it_36|is_33|._180 (l_prep) of_7\IN\0|that_27|evidence_16|due_18 (l_pobj) injury_9\NN\14052046|NONE_0
D000638_D056486 CID amiodarone_12\NN\2715941|,_20|including_22|,_41 (r_compound) treatment_13\NN\654885|NONE_0 (r_pobj) to_11\IN\0|alterations_46 (r_pcomp) due_10\IN\5174653|that_45|evidence_34|of_18 (l_pobj) alterations_18\NNS\7283608|to_46 (l_acl) resembling_19\VBG\2657219|NONE_0 (l_dobj) hepatitis_21\NN\14127211|NONE_0 (l_appos) cirrhosis_27\NN\14116321|alcoholic_60|,_41 (l_nmod) hepatitis_24\NN\14127211|cholestatic_12|of_37
D000638_D013610 NONE amiodarone_0\NNP\2715941|has_11|effective_27|in_37|._101 (r_nsubj) proved_2\VBN\2604760|NONE_0 (l_prep) in_5\IN\13603305|amiodarone_37|has_26|effective_10|._64 (l_pobj) treatment_7\NN\654885|NONE_0 (l_prep) of_8\IN\0|the_14 (l_pobj) tachyarrhythmias_12\NNS\0|NONE_0
D000638_D006519 NONE amiodarone_12\NN\2715941|,_20|including_22|,_41 (r_compound) treatment_13\NN\654885|NONE_0 (r_pobj) to_11\IN\0|alterations_46 (r_pcomp) due_10\IN\5174653|that_45|evidence_34|of_18 (l_pobj) alterations_18\NNS\7283608|to_46 (l_acl) resembling_19\VBG\2657219|NONE_0 (l_dobj) hepatitis_21\NN\14127211|NONE_0
D000638_D008103 CID amiodarone_12\NN\2715941|,_20|including_22|,_41 (r_compound) treatment_13\NN\654885|NONE_0 (r_pobj) to_11\IN\0|alterations_46 (r_pcomp) due_10\IN\5174653|that_45|evidence_34|of_18 (l_pobj) alterations_18\NNS\7283608|to_46 (l_acl) resembling_19\VBG\2657219|NONE_0 (l_dobj) hepatitis_21\NN\14127211|NONE_0 (l_appos) cirrhosis_27\NN\14116321|alcoholic_60|,_41 (l_prep) of_28\IN\0|cholestatic_49|hepatitis_37 (l_pobj) liver_30\NN\5298729|NONE_0
D000638_D002779 CID amiodarone_7\NN\2715941|NONE_0 (r_compound) treatment_8\NN\654885|a_55|with_45|due_18 (r_appos) patient_1\NN\9898892|is_63|below_76|and_82|given_134 (l_prep) with_2\IN\0|a_10|due_27|treatment_45 (l_pobj) hepatitis_4\NN\14127211|NONE_0
D000638_D002779 CID amiodarone_19\NN\2715941|NONE_0 (r_pobj) of_18\IN\0|the_19 (r_prep) hepatotoxicity_17\NN\0|NONE_0 (r_pobj) of_15\IN\0|a_9 (r_prep) review_14\NN\5733583|is_43|._51 (r_nsubjpass) given_21\VBN\5892096|patient_134|is_71|below_58|and_52 (r_conj) presented_10\VBN\2137132|NONE_0 (l_nsubjpass) patient_1\NN\9898892|is_63|below_76|and_82|given_134 (l_prep) with_2\IN\0|a_10|due_27|treatment_45 (l_pobj) hepatitis_4\NN\14127211|NONE_0
D000638_D002779 CID amiodarone_12\NN\2715941|,_20|including_22|,_41 (r_compound) treatment_13\NN\654885|NONE_0 (r_pobj) to_11\IN\0|alterations_46 (r_pcomp) due_10\IN\5174653|that_45|evidence_34|of_18 (l_pobj) alterations_18\NNS\7283608|to_46 (l_acl) resembling_19\VBG\2657219|NONE_0 (l_dobj) hepatitis_21\NN\14127211|NONE_0 (l_appos) cirrhosis_27\NN\14116321|alcoholic_60|,_41 (l_nmod) hepatitis_24\NN\14127211|cholestatic_12|of_37
D000638_D005234 CID amiodarone_12\NN\2715941|,_20|including_22|,_41 (r_compound) treatment_13\NN\654885|NONE_0 (l_prep) including_15\VBG\0|amiodarone_22|,_2|,_19 (l_pobj) steatosis_16\NN\0|NONE_0
15096016
D007980_D018476 NONE levodopa_20\RB\14604959|-_8 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) dyskinesias_23\NNS\14084880|NONE_0 (r_dobj) improving_19\VBG\126264|NONE_0 (r_pcomp) in_18\IN\13603305|to_6 (r_prep) be_17\VB\14625458|improves_85|;_33|however_31|,_24|strength_18|._44 (r_xcomp) seems_15\VBZ\2604760|NONE_0 (l_ccomp) improves_2\VBZ\126264|;_52|however_54|,_61|strength_67|be_85|._129 (l_dobj) bradykinesia_3\JJ\0|stimulation_21|to_26
D007980_D009127 NONE levodopa_20\RB\14604959|-_8 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) dyskinesias_23\NNS\14084880|NONE_0 (r_dobj) improving_19\VBG\126264|NONE_0 (r_pcomp) in_18\IN\13603305|to_6 (r_prep) be_17\VB\14625458|improves_85|;_33|however_31|,_24|strength_18|._44 (r_xcomp) seems_15\VBZ\2604760|NONE_0 (l_ccomp) improves_2\VBZ\126264|;_52|however_54|,_61|strength_67|be_85|._129 (l_dobj) bradykinesia_3\JJ\0|stimulation_21|to_26 (l_conj) rigidity_5\NN\5023233|and_4
D007980_D004409 CID levodopa_20\RB\14604959|-_8 (r_npadvmod) induced_22\VBN\1627355|NONE_0 (r_amod) dyskinesias_23\NNS\14084880|NONE_0
8586822
D017673_D006973 CID chloride_31\NN\14818238|dietary_15 (r_compound) supplementation_32\NN\5108947|NONE_0 (r_pobj) of_28\IN\0|the_24|hypertensive_20 (r_prep) effect_27\NN\34213|NONE_0 (r_pobj) to_24\IN\0|test_150|,_57|system_31|importantly_12|._69 (r_prep) contributes_22\VBZ\126264|NONE_0 (l_advcl) test_1\VB\5798043|,_93|system_119|importantly_138|to_150|._219 (l_dobj) hypothesis_3\NN\7162194|to_12 (l_relcl) treated_10\VBN\2376958|the_43 (l_dobj) rats_13\NNS\2329401|that_63|,_59|in_57|captopril_45|-_36|spontaneously_27 (l_amod) hypertensive_12\JJ\10405694|(_18|shr_19|)_22
D017673_D006973 CID chloride_31\NN\14818238|dietary_15 (r_compound) supplementation_32\NN\5108947|NONE_0 (r_pobj) of_28\IN\0|the_24|hypertensive_20 (r_prep) effect_27\NN\34213|NONE_0 (l_amod) hypertensive_26\JJ\10405694|the_4|of_20
D017673_D006973 CID chloride_19\NN\14818238|-_8 (r_npadvmod) induced_21\VBN\1627355|the_28|sodium_16|in_17|in_24 (r_amod) increase_22\NN\13576355|that_52 (l_prep) in_23\IN\13603305|the_45|sodium_33|induced_17|in_7 (l_pobj) map_24\NNP\4076846|NONE_0
D002216_D006973 NONE captopril_12\FW\2673637|contribution_79|-_9|rats_45|._49 (r_npadvmod) treated_14\VBN\2376958|NONE_0 (l_dobj) rats_17\NNS\2329401|contribution_124|captopril_45|-_36|._4 (l_amod) hypertensive_16\JJ\10405694|NONE_0
D002216_D006973 NONE captopril_8\FW\2673637|that_18|,_14|in_12|-_9|spontaneously_18|rats_45 (r_npadvmod) treated_10\VBN\2376958|the_43 (l_dobj) rats_13\NNS\2329401|that_63|,_59|in_57|captopril_45|-_36|spontaneously_27 (l_amod) hypertensive_12\JJ\10405694|(_18|shr_19|)_22
D002216_D006973 NONE captopril_8\FW\2673637|that_18|,_14|in_12|-_9|spontaneously_18|rats_45 (r_npadvmod) treated_10\VBN\2376958|the_43 (r_relcl) hypothesis_3\NN\7162194|to_12 (r_dobj) test_1\VB\5798043|,_93|system_119|importantly_138|to_150|._219 (r_advcl) contributes_22\VBZ\126264|NONE_0 (l_prep) to_24\IN\0|test_150|,_57|system_31|importantly_12|._69 (l_pobj) effect_27\NN\34213|NONE_0 (l_amod) hypertensive_26\JJ\10405694|the_4|of_20
D018738_D006973 NONE hexamethonium_6\NN\0|NONE_0 (r_pobj) of_2\IN\0|intravenous_21 (r_prep) infusion_1\NN\14589223|in_58|._166 (r_nsubj) resulted_7\VBD\2633881|NONE_0 (l_prep) in_8\IN\13603305|infusion_58|._108 (l_pobj) decline_11\NN\13458571|NONE_0 (l_relcl) eliminated_15\VBD\1619929|a_28|rapid_26|in_12 (l_dobj) increase_22\NN\13576355|that_52 (l_prep) in_23\IN\13603305|the_45|sodium_33|induced_17|in_7 (l_pobj) map_24\NNP\4076846|NONE_0
7651879
D001569_D012131 NONE benzodiazepine_3\JJ\3771443|a_2|receptor_15|used_35 (r_amod) antagonist_5\NN\7846|flumazenil_40|._89 (l_acl) used_6\VBD\0|a_37|benzodiazepine_35|receptor_20 (l_xcomp) reverse_8\VB\13854649|NONE_0 (l_dobj) sedation_9\NN\14034177|to_11 (l_conj) depression_12\NN\14373582|and_16|induced_11
D001569_D012131 NONE benzodiazepines_15\NNS\3771443|NONE_0 (r_pobj) by_14\IN\0|NONE_0 (r_agent) induced_13\VBN\1627355|and_27|depression_11 (r_acl) sedation_9\NN\14034177|to_11 (l_conj) depression_12\NN\14373582|and_16|induced_11
D005442_D012131 NONE flumazenil_0\NNP\0|antagonist_40|._129 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) antagonist_5\NN\7846|flumazenil_40|._89 (l_acl) used_6\VBD\0|a_37|benzodiazepine_35|receptor_20 (l_xcomp) reverse_8\VB\13854649|NONE_0 (l_dobj) sedation_9\NN\14034177|to_11 (l_conj) depression_12\NN\14373582|and_16|induced_11
D005442_D012640 CID flumazenil_2\JJ\0|in_26 (r_compound) administration_3\NN\1133281|NONE_0 (r_pobj) after_1\IN\0|._54 (r_prep) seizure_0\NN\14081375|NONE_0
D005442_D012640 CID flumazenil_19\JJ\0|NONE_0 (r_pobj) of_18\IN\0|the_19 (r_prep) administration_17\NN\1133281|NONE_0 (r_pobj) following_15\VBG\8180190|a_20|pediatric_18 (r_acl) patient_14\NN\9898892|NONE_0 (r_pobj) in_11\IN\13603305|a_35|generalized_33|clonic_15 (r_prep) seizure_10\NN\14081375|NONE_0
6402369
D015080_D064420 NONE mesna_7\NNP\0|the_4|and_13|series_46 (r_compound) series_8\NN\8456993|NONE_0 (l_conj) series_13\NN\8456993|the_50|mesna_46|and_33 (l_prep) with_14\IN\0|the_36|conventional_32|prophylaxis_19 (l_pobj) respect_15\NN\5817845|NONE_0 (l_prep) to_16\IN\0|NONE_0 (l_pobj) toxicity_21\NN\13576101|NONE_0
D015080_D008175 NONE sulphonate_13\JJ\0|NONE_0 (r_pobj) of_10\IN\0|oral_20 (r_prep) administration_9\NN\1133281|NONE_0 (r_pobj) by_7\IN\0|induced_28|urothelial_20 (r_prep) toxicity_6\NN\13576101|NONE_0 (r_pobj) of_1\IN\0|to_111|._150 (r_prep) treatment_0\NN\654885|NONE_0 (l_prep) to_17\IN\0|of_111|._39 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) cancer_22\NN\14239425|NONE_0
D015080_D008175 NONE mesna_15\NNP\0|sodium_36|2-mercaptoethane_29 (r_appos) sulphonate_13\JJ\0|NONE_0 (r_pobj) of_10\IN\0|oral_20 (r_prep) administration_9\NN\1133281|NONE_0 (r_pobj) by_7\IN\0|induced_28|urothelial_20 (r_prep) toxicity_6\NN\13576101|NONE_0 (r_pobj) of_1\IN\0|to_111|._150 (r_prep) treatment_0\NN\654885|NONE_0 (l_prep) to_17\IN\0|of_111|._39 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) cancer_22\NN\14239425|NONE_0
D015080_D008175 NONE sulphonate_12\JJ\0|NONE_0 (r_pobj) of_6\IN\0|oral_20 (r_prep) administration_5\NN\1133281|NONE_0 (r_pobj) of_3\IN\0|the_22|protective_18|against_88 (r_prep) effect_2\NN\34213|(_145|if_146|)_148|was_150|in_161|as_264|._328 (r_nsubjpass) tested_26\VBN\670261|NONE_0 (l_prep) in_27\IN\13603305|effect_161|(_16|if_15|)_13|was_11|as_103|._167 (l_pobj) group_29\NN\2137|NONE_0 (l_prep) of_30\IN\0|a_8 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) with_33\IN\0|45_12 (l_pobj) cancer_36\NN\14239425|NONE_0
D015080_D008175 NONE mesna_14\NNP\0|the_55|thiol_51|compound_45|sodium_36|2-mercaptoethane_29 (r_appos) sulphonate_12\JJ\0|NONE_0 (r_pobj) of_6\IN\0|oral_20 (r_prep) administration_5\NN\1133281|NONE_0 (r_pobj) of_3\IN\0|the_22|protective_18|against_88 (r_prep) effect_2\NN\34213|(_145|if_146|)_148|was_150|in_161|as_264|._328 (r_nsubjpass) tested_26\VBN\670261|NONE_0 (l_prep) in_27\IN\13603305|effect_161|(_16|if_15|)_13|was_11|as_103|._167 (l_pobj) group_29\NN\2137|NONE_0 (l_prep) of_30\IN\0|a_8 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) with_33\IN\0|45_12 (l_pobj) cancer_36\NN\14239425|NONE_0
D013438_D001745 NONE thiol_8\JJ\0|the_4|compound_6|sodium_15|2-mercaptoethane_22|mesna_51 (r_compound) sulphonate_12\JJ\0|NONE_0 (r_pobj) of_6\IN\0|oral_20 (r_prep) administration_5\NN\1133281|NONE_0 (r_pobj) of_3\IN\0|the_22|protective_18|against_88 (r_prep) effect_2\NN\34213|(_145|if_146|)_148|was_150|in_161|as_264|._328 (l_prep) against_16\IN\0|the_110|protective_106|of_88 (l_pobj) toxicity_18\NN\13576101|NONE_0
D013438_D008175 NONE thiol_8\JJ\0|the_4|compound_6|sodium_15|2-mercaptoethane_22|mesna_51 (r_compound) sulphonate_12\JJ\0|NONE_0 (r_pobj) of_6\IN\0|oral_20 (r_prep) administration_5\NN\1133281|NONE_0 (r_pobj) of_3\IN\0|the_22|protective_18|against_88 (r_prep) effect_2\NN\34213|(_145|if_146|)_148|was_150|in_161|as_264|._328 (r_nsubjpass) tested_26\VBN\670261|NONE_0 (l_prep) in_27\IN\13603305|effect_161|(_16|if_15|)_13|was_11|as_103|._167 (l_pobj) group_29\NN\2137|NONE_0 (l_prep) of_30\IN\0|a_8 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) with_33\IN\0|45_12 (l_pobj) cancer_36\NN\14239425|NONE_0
D015080_D001745 NONE sulphonate_13\JJ\0|NONE_0 (r_pobj) of_10\IN\0|oral_20 (r_prep) administration_9\NN\1133281|NONE_0 (r_pobj) by_7\IN\0|induced_28|urothelial_20 (r_prep) toxicity_6\NN\13576101|NONE_0
D015080_D001745 NONE mesna_15\NNP\0|sodium_36|2-mercaptoethane_29 (r_appos) sulphonate_13\JJ\0|NONE_0 (r_pobj) of_10\IN\0|oral_20 (r_prep) administration_9\NN\1133281|NONE_0 (r_pobj) by_7\IN\0|induced_28|urothelial_20 (r_prep) toxicity_6\NN\13576101|NONE_0
D015080_D001745 NONE sulphonate_12\JJ\0|NONE_0 (r_pobj) of_6\IN\0|oral_20 (r_prep) administration_5\NN\1133281|NONE_0 (r_pobj) of_3\IN\0|the_22|protective_18|against_88 (r_prep) effect_2\NN\34213|(_145|if_146|)_148|was_150|in_161|as_264|._328 (l_prep) against_16\IN\0|the_110|protective_106|of_88 (l_pobj) toxicity_18\NN\13576101|NONE_0
D015080_D001745 NONE mesna_14\NNP\0|the_55|thiol_51|compound_45|sodium_36|2-mercaptoethane_29 (r_appos) sulphonate_12\JJ\0|NONE_0 (r_pobj) of_6\IN\0|oral_20 (r_prep) administration_5\NN\1133281|NONE_0 (r_pobj) of_3\IN\0|the_22|protective_18|against_88 (r_prep) effect_2\NN\34213|(_145|if_146|)_148|was_150|in_161|as_264|._328 (l_prep) against_16\IN\0|the_110|protective_106|of_88 (l_pobj) toxicity_18\NN\13576101|NONE_0
D007069_D001745 CID ifosfamide_2\RB\0|-_10 (r_advmod) induced_4\VBN\1627355|urothelial_8|by_28 (r_amod) toxicity_6\NN\13576101|NONE_0
D007069_D001745 CID ifosfamide_21\NN\0|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|urothelial_20 (r_acl) toxicity_18\NN\13576101|NONE_0
D007069_D001745 CID if_23\IN\0|effect_146|(_1|)_2|was_4|in_15|as_118|._182 (r_mark) tested_26\VBN\670261|NONE_0 (l_nsubjpass) effect_2\NN\34213|(_145|if_146|)_148|was_150|in_161|as_264|._328 (l_prep) against_16\IN\0|the_110|protective_106|of_88 (l_pobj) toxicity_18\NN\13576101|NONE_0
D007069_D001745 CID if_40\IN\0|(_3|2250_4|mg_9|/_11|on_15|)_26 (r_mark) m2_45\NN\13357178|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) treatment_38\NN\654885|NONE_0 (r_pobj) under_37\IN\0|inoperable_23|lung_12 (r_prep) cancer_36\NN\14239425|NONE_0 (r_pobj) with_33\IN\0|45_12 (r_prep) patients_32\NNS\9898892|NONE_0 (r_pobj) of_30\IN\0|a_8 (r_prep) group_29\NN\2137|NONE_0 (r_pobj) in_27\IN\13603305|effect_161|(_16|if_15|)_13|was_11|as_103|._167 (r_prep) tested_26\VBN\670261|NONE_0 (l_nsubjpass) effect_2\NN\34213|(_145|if_146|)_148|was_150|in_161|as_264|._328 (l_prep) against_16\IN\0|the_110|protective_106|of_88 (l_pobj) toxicity_18\NN\13576101|NONE_0
D007069_D008175 NONE ifosfamide_2\RB\0|-_10 (r_advmod) induced_4\VBN\1627355|urothelial_8|by_28 (r_amod) toxicity_6\NN\13576101|NONE_0 (r_pobj) of_1\IN\0|to_111|._150 (r_prep) treatment_0\NN\654885|NONE_0 (l_prep) to_17\IN\0|of_111|._39 (l_pobj) patients_18\NNS\9898892|NONE_0 (l_prep) with_19\IN\0|NONE_0 (l_pobj) cancer_22\NN\14239425|NONE_0
D007069_D008175 NONE ifosfamide_21\NN\0|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|urothelial_20 (r_acl) toxicity_18\NN\13576101|NONE_0 (r_pobj) against_16\IN\0|the_110|protective_106|of_88 (r_prep) effect_2\NN\34213|(_145|if_146|)_148|was_150|in_161|as_264|._328 (r_nsubjpass) tested_26\VBN\670261|NONE_0 (l_prep) in_27\IN\13603305|effect_161|(_16|if_15|)_13|was_11|as_103|._167 (l_pobj) group_29\NN\2137|NONE_0 (l_prep) of_30\IN\0|a_8 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) with_33\IN\0|45_12 (l_pobj) cancer_36\NN\14239425|NONE_0
D007069_D008175 NONE if_23\IN\0|effect_146|(_1|)_2|was_4|in_15|as_118|._182 (r_mark) tested_26\VBN\670261|NONE_0 (l_prep) in_27\IN\13603305|effect_161|(_16|if_15|)_13|was_11|as_103|._167 (l_pobj) group_29\NN\2137|NONE_0 (l_prep) of_30\IN\0|a_8 (l_pobj) patients_32\NNS\9898892|NONE_0 (l_prep) with_33\IN\0|45_12 (l_pobj) cancer_36\NN\14239425|NONE_0
D007069_D008175 NONE if_40\IN\0|(_3|2250_4|mg_9|/_11|on_15|)_26 (r_mark) m2_45\NN\13357178|NONE_0 (r_pobj) with_39\IN\0|NONE_0 (r_prep) treatment_38\NN\654885|NONE_0 (r_pobj) under_37\IN\0|inoperable_23|lung_12 (r_prep) cancer_36\NN\14239425|NONE_0
8958188
C045894_D009369 NONE lometrexol_9\NN\0|that_5|activity_15 (r_nsubj) has_10\VBZ\13888491|data_32|have_27|._86 (l_dobj) activity_11\NN\30358|that_20|lometrexol_15 (l_prep) against_12\IN\0|NONE_0 (l_pobj) tumours_13\NNS\14234074|NONE_0
D005492_D064420 NONE acid_16\NN\14818238|low_15|dose_11|folic_6|,_19 (r_compound) administration_17\NN\1133281|NONE_0 (r_pobj) by_12\IN\0|that_49|toxicity_40|can_17|be_13|for_44|following_75 (r_agent) prevented_11\VBN\0|studies_60|._114 (l_nsubjpass) toxicity_6\NN\13576101|that_9|can_23|be_27|by_40|for_84|following_115
D005492_D064420 NONE acid_13\NN\14818238|folic_6|confirmed_31 (r_compound) supplementation_14\NN\5108947|NONE_0 (l_relcl) confirmed_17\VBN\0|folic_37|acid_31 (l_ccomp) reduced_26\VBN\441445|which_68|has_62 (l_nsubjpass) toxicity_20\NN\13576101|that_9|can_23|be_27|markedly_30|by_47
D005492_D064420 NONE acid_29\NN\14818238|folic_6 (r_compound) supplementation_30\NN\5108947|NONE_0 (r_pobj) by_27\IN\0|that_56|toxicity_47|can_24|be_20|markedly_17 (r_agent) reduced_26\VBN\441445|which_68|has_62 (l_nsubjpass) toxicity_20\NN\13576101|that_9|can_23|be_27|markedly_30|by_47
D005492_D064420 NONE folate_13\JJ\15090742|plasma_7 (r_compound) elevation_14\NN\7445480|NONE_0 (r_pobj) of_11\IN\0|the_11 (r_prep) extent_10\NN\13939892|clinical_26|and_8 (r_conj) toxicity_7\NN\13576101|NONE_0
D005492_D064420 NONE acid_12\NN\14818238|folic_6 (r_compound) administration_13\NN\1133281|NONE_0 (r_pobj) by_10\IN\0|that_57|pharmacokinetics_34|were_17|not_12|indicating_29 (r_agent) altered_9\VBN\0|studies_70|._140 (l_advcl) indicating_14\VBG\952524|that_86|pharmacokinetics_63|were_46|not_41|by_29 (l_ccomp) is_17\VBZ\0|NONE_0 (l_acomp) unlikely_18\JJ\0|that_24|supplementation_19 (l_xcomp) reduce_20\VB\441445|NONE_0 (l_dobj) toxicity_21\NN\13576101|to_10|by_9
D008727_D009369 NONE methotrexate_22\NNP\2722166|other_21|,_10 (r_appos) drugs_19\NNS\14778436|NONE_0 (r_pobj) to_17\IN\0|NONE_0 (r_prep) refractory_16\JJ\3673767|which_10 (r_acomp) are_15\VBP\13600404|NONE_0 (r_relcl) tumours_13\NNS\14234074|NONE_0
C045894_D064420 NONE lometrexol_7\NN\0|NONE_0 (r_pobj) of_6\IN\0|the_33|initial_29|clinical_21 (r_prep) development_5\NN\248977|however_30|,_23|was_26|because_40|._101 (r_nsubjpass) curtailed_9\VBN\235368|NONE_0 (l_prep) because_10\IN\0|however_70|,_63|development_40|was_14|._61 (l_pobj) toxicities_16\NNS\13576101|of_43
C045894_D064420 NONE lometrexol_8\NN\0|NONE_0 (r_pobj) of_7\IN\0|the_13 (r_prep) toxicity_6\NN\13576101|that_9|can_23|be_27|by_40|for_84|following_115
C045894_D064420 NONE lometrexol_9\NN\0|NONE_0 (r_pobj) of_8\IN\0|i_17|clinical_15|given_14 (r_prep) study_7\NN\635850|observation_40|phase_17|._163 (l_acl) given_10\VBN\5892096|i_31|clinical_29|of_14 (l_prep) with_11\IN\0|NONE_0 (l_pobj) supplementation_14\NN\5108947|NONE_0 (l_relcl) confirmed_17\VBN\0|folic_37|acid_31 (l_ccomp) reduced_26\VBN\441445|which_68|has_62 (l_nsubjpass) toxicity_20\NN\13576101|that_9|can_23|be_27|markedly_30|by_47
C045894_D064420 NONE lometrexol_22\NN\0|NONE_0 (r_pobj) of_21\IN\0|the_13 (r_prep) toxicity_20\NN\13576101|that_9|can_23|be_27|markedly_30|by_47
C045894_D064420 NONE lometrexol_4\NN\0|NONE_0 (r_compound) plasma_5\NN\5398023|NONE_0 (r_compound) pharmacokinetics_6\NNS\6054892|that_23|were_17|not_22|by_34|indicating_63 (r_nsubjpass) altered_9\VBN\0|studies_70|._140 (l_advcl) indicating_14\VBG\952524|that_86|pharmacokinetics_63|were_46|not_41|by_29 (l_ccomp) is_17\VBZ\0|NONE_0 (l_acomp) unlikely_18\JJ\0|that_24|supplementation_19 (l_xcomp) reduce_20\VB\441445|NONE_0 (l_dobj) toxicity_21\NN\13576101|to_10|by_9
C045894_D064420 NONE lometrexol_24\NN\0|NONE_0 (r_compound) plasma_25\NN\5398023|NONE_0 (r_compound) clearance_26\NN\5089947|NONE_0 (r_dobj) enhancing_23\VBG\227165|NONE_0 (r_pcomp) by_22\IN\0|to_19|toxicity_9 (r_prep) reduce_20\VB\441445|NONE_0 (l_dobj) toxicity_21\NN\13576101|to_10|by_9
10743694
1535072
D012701_D001008 NONE serotonin_23\NN\14807737|reuptake_10 (r_compound) blockers_25\NNS\10101634|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) after_20\IN\0|who_33|effects_8 (r_prep) suffered_16\VBD\2110220|affective_24 (r_relcl) disorders_14\NNS\14034177|,_15|or_13 (r_conj) anxiety_10\NN\14373582|,_2
D015016_D020018 NONE yohimbine_0\NNP\0|of_20|induced_43|._81 (r_compound) treatment_1\NN\654885|NONE_0 (l_prep) of_2\IN\0|yohimbine_20|induced_23|._61 (l_pobj) effects_5\NNS\13245626|NONE_0
D015016_D020018 NONE yohimbine_6\NN\0|that_5|may_10|be_14|treat_25 (r_nsubjpass) used_9\VBN\0|report_38|._53 (l_xcomp) treat_11\VB\7570720|that_30|yohimbine_25|may_15|be_11 (l_dobj) effects_15\NNS\13245626|to_25
D015016_D020018 NONE yohimbine_3\NN\0|study_16|as_10|._90 (r_dobj) evaluated_2\VBD\670261|NONE_0 (l_prep) as_4\IN\14622893|study_26|yohimbine_10|._80 (l_pobj) treatment_6\NN\654885|NONE_0 (l_prep) for_7\IN\0|a_12 (l_pobj) effects_11\NNS\13245626|NONE_0
D015016_D020018 NONE yohimbine_28\NN\0|patients_195|were_11|on_10|basis_22|._53 (r_dobj) given_27\VBN\5892096|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_184|yohimbine_195|on_205|basis_217|._248 (l_prep) with_2\IN\0|six_13 (l_pobj) disorder_6\NN\14034177|NONE_0 (l_conj) trichotillomania_8\NN\9181557|either_38|obsessive_31|compulsive_21|,_2 (l_conj) anxiety_10\NN\14373582|,_2 (l_conj) disorders_14\NNS\14034177|,_15|or_13 (l_relcl) suffered_16\VBD\2110220|affective_24 (l_dobj) effects_19\NNS\13245626|who_25|after_8
D015016_D020018 NONE yohimbine_7\NN\0|that_5|may_10|treatment_30 (r_nsubj) be_9\VB\14625458|results_50|._91 (l_attr) treatment_12\NN\654885|that_35|yohimbine_30|may_20 (l_prep) for_13\IN\0|an_23|effective_20 (l_pobj) effects_17\NNS\13245626|NONE_0
D012701_D020018 NONE serotonin_8\NN\14807737|reuptake_10 (r_compound) blockers_10\NNS\10101634|NONE_0 (r_pobj) by_7\IN\0|NONE_0 (r_agent) induced_6\VBN\1627355|yohimbine_43|of_23|._38 (r_acl) treatment_1\NN\654885|NONE_0 (l_prep) of_2\IN\0|yohimbine_20|induced_23|._61 (l_pobj) effects_5\NNS\13245626|NONE_0
D012701_D020018 NONE serotonin_14\NN\14807737|reuptake_10 (r_compound) blockers_16\NNS\10101634|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) caused_12\VBN\1617192|the_24|sexual_20|side_13 (r_acl) effects_11\NNS\13245626|NONE_0
D012701_D020018 NONE serotonin_23\NN\14807737|reuptake_10 (r_compound) blockers_25\NNS\10101634|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) after_20\IN\0|who_33|effects_8 (r_prep) suffered_16\VBD\2110220|affective_24 (l_dobj) effects_19\NNS\13245626|who_25|after_8
D012701_D020018 NONE serotonin_20\NN\14807737|reuptake_10 (r_compound) blockers_22\NNS\10101634|NONE_0 (r_pobj) by_19\IN\0|NONE_0 (r_agent) caused_18\VBN\1617192|the_24|sexual_20|side_13 (r_acl) effects_17\NNS\13245626|NONE_0
D015016_D009771 NONE yohimbine_28\NN\0|patients_195|were_11|on_10|basis_22|._53 (r_dobj) given_27\VBN\5892096|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_184|yohimbine_195|on_205|basis_217|._248 (l_prep) with_2\IN\0|six_13 (l_pobj) disorder_6\NN\14034177|NONE_0
D012701_D019964 NONE serotonin_23\NN\14807737|reuptake_10 (r_compound) blockers_25\NNS\10101634|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) after_20\IN\0|who_33|effects_8 (r_prep) suffered_16\VBD\2110220|affective_24 (r_relcl) disorders_14\NNS\14034177|,_15|or_13
D015016_D014256 NONE yohimbine_28\NN\0|patients_195|were_11|on_10|basis_22|._53 (r_dobj) given_27\VBN\5892096|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_184|yohimbine_195|on_205|basis_217|._248 (l_prep) with_2\IN\0|six_13 (l_pobj) disorder_6\NN\14034177|NONE_0 (l_conj) trichotillomania_8\NN\9181557|either_38|obsessive_31|compulsive_21|,_2
D015016_D007172 NONE yohimbine_6\NN\0|that_5|behavior_29|and_38|be_46 (r_nsubj) facilitates_7\VBZ\2547586|studies_31|._81 (l_conj) be_12\VB\14625458|that_51|yohimbine_46|behavior_17|and_8 (l_acomp) helpful_13\JJ\0|may_7 (l_prep) in_14\IN\13603305|NONE_0 (l_pobj) treatment_16\NN\654885|NONE_0 (l_prep) of_17\IN\0|the_14 (l_pobj) impotence_19\NN\4723816|NONE_0
D012701_D009771 NONE serotonin_23\NN\14807737|reuptake_10 (r_compound) blockers_25\NNS\10101634|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) after_20\IN\0|who_33|effects_8 (r_prep) suffered_16\VBD\2110220|affective_24 (r_relcl) disorders_14\NNS\14034177|,_15|or_13 (r_conj) anxiety_10\NN\14373582|,_2 (r_conj) trichotillomania_8\NN\9181557|either_38|obsessive_31|compulsive_21|,_2 (r_conj) disorder_6\NN\14034177|NONE_0
D002997_D020018 CID clomipramine_17\NN\4482543|NONE_0 (r_pobj) of_16\IN\0|the_24|side_13 (r_prep) effects_15\NNS\13245626|to_25
D015016_D019964 NONE yohimbine_28\NN\0|patients_195|were_11|on_10|basis_22|._53 (r_dobj) given_27\VBN\5892096|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_184|yohimbine_195|on_205|basis_217|._248 (l_prep) with_2\IN\0|six_13 (l_pobj) disorder_6\NN\14034177|NONE_0 (l_conj) trichotillomania_8\NN\9181557|either_38|obsessive_31|compulsive_21|,_2 (l_conj) anxiety_10\NN\14373582|,_2 (l_conj) disorders_14\NNS\14034177|,_15|or_13
D012701_D014256 NONE serotonin_23\NN\14807737|reuptake_10 (r_compound) blockers_25\NNS\10101634|NONE_0 (r_pobj) with_22\IN\0|NONE_0 (r_prep) treatment_21\NN\654885|NONE_0 (r_pobj) after_20\IN\0|who_33|effects_8 (r_prep) suffered_16\VBD\2110220|affective_24 (r_relcl) disorders_14\NNS\14034177|,_15|or_13 (r_conj) anxiety_10\NN\14373582|,_2 (r_conj) trichotillomania_8\NN\9181557|either_38|obsessive_31|compulsive_21|,_2
D015016_D001008 NONE yohimbine_28\NN\0|patients_195|were_11|on_10|basis_22|._53 (r_dobj) given_27\VBN\5892096|NONE_0 (l_nsubjpass) patients_1\NNS\9898892|were_184|yohimbine_195|on_205|basis_217|._248 (l_prep) with_2\IN\0|six_13 (l_pobj) disorder_6\NN\14034177|NONE_0 (l_conj) trichotillomania_8\NN\9181557|either_38|obsessive_31|compulsive_21|,_2 (l_conj) anxiety_10\NN\14373582|,_2
D015016_D001008 NONE yohimbine_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|side_13 (r_prep) effects_1\NNS\13245626|sweating_40|._108 (r_nsubj) included_4\VBD\0|NONE_0 (l_dobj) sweating_6\NN\13440063|effects_40|._68 (l_conj) anxiety_9\NN\14373582|excessive_30|,_12
7880714
7053705
D013866_D006504 CID 6-thioguanine_7\CD\0|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) caused_5\VBN\1617192|hepatic_31|occlusive_18|._23 (r_acl) disease_4\NN\14061805|NONE_0
D013866_D006504 CID 6-thioguanine_27\CD\0|NONE_0 (r_punct) ._28\.\0|reversible_167|occlusive_151|of_133 (r_punct) disease_5\NN\14061805|NONE_0 (l_prep) of_6\IN\0|reversible_34|occlusive_18|._133 (l_pobj) liver_8\NN\5298729|NONE_0
D013866_D006504 CID 6-thioguanine_35\CD\0|solely_10 (r_pobj) to_34\IN\0|occlusive_25 (r_prep) related_32\VBN\628491|NONE_0 (r_pobj) of_28\IN\0|the_15|first_11 (r_prep) case_27\NN\7283608|may_17 (r_attr) be_24\VB\14625458|case_146|opportunity_122|,_10|and_8|._67 (r_conj) presented_2\VBD\2137132|NONE_0 (l_dobj) opportunity_5\NN\14481929|case_24|,_112|and_114|be_122|._189 (l_acl) observe_7\VB\2163746|a_24|unique_22 (l_dobj) features_10\NNS\5849040|to_26|over_65 (l_prep) of_11\IN\0|the_24|histologic_20 (l_pobj) disease_18\NN\14061805|NONE_0
D013866_D054198 NONE 6-thioguanine_27\CD\0|NONE_0 (r_punct) ._28\.\0|reversible_167|occlusive_151|of_133 (r_punct) disease_5\NN\14061805|NONE_0 (l_prep) of_6\IN\0|reversible_34|occlusive_18|._133 (l_pobj) liver_8\NN\5298729|NONE_0 (l_acl) developed_9\VBN\1753788|the_10 (l_prep) in_10\IN\13603305|after_53|with_92 (l_pobj) man_15\NN\9605289|NONE_0 (l_prep) with_16\IN\0|a_18|old_8 (l_pobj) leukemia_19\NN\14239918|NONE_0
8384253
D014750_D008228 NONE vincristine_10\NN\3917455|NONE_0 (r_pobj) with_9\IN\0|patients_45|between_17|investigated_83|._186 (r_prep) treated_8\VBN\2376958|NONE_0 (l_nsubj) patients_1\NNS\9898892|with_45|between_62|investigated_128|._231 (l_prep) with_2\IN\0|forty_15 (l_pobj) lymphoma_7\NNP\14239918|NONE_0
D014750_D008228 NONE vincristine_37\NN\3917455|NONE_0 (r_pobj) of_36\IN\0|the_22|term_13|on_15 (r_prep) effects_35\NNS\13245626|to_26 (r_dobj) evaluate_31\VB\670261|NONE_0 (r_acl) order_29\NN\7168131|NONE_0 (r_pobj) in_28\IN\13603305|(_57|dose_45|were_18 (r_prep) investigated_27\VBN\644583|patients_128|with_83|between_66|._103 (r_parataxis) treated_8\VBN\2376958|NONE_0 (l_nsubj) patients_1\NNS\9898892|with_45|between_62|investigated_128|._231 (l_prep) with_2\IN\0|forty_15 (l_pobj) lymphoma_7\NNP\14239918|NONE_0
D014750_D009422 NONE vincristine_8\NN\3917455|NONE_0 (r_pobj) with_4\IN\0|that_5|signs_51|reversible_100 (r_prep) are_17\VBP\13600404|good_56 (l_nsubj) signs_11\NNS\6643763|that_56|with_51|reversible_49 (l_conj) symptoms_13\NNS\5823932|dose_24|schedule_19|and_4 (l_prep) of_14\IN\0|NONE_0 (l_pobj) neuropathy_16\NN\14204950|NONE_0
D014750_D009422 NONE vincristine_15\NN\3917455|NONE_0 (r_compound) neuropathy_16\NN\14204950|NONE_0
8111719
D007069_D006212 CID ifosfamide_2\RB\0|-_10 (r_advmod) induced_4\VBN\1627355|NONE_0 (r_amod) neurotoxicity_5\NN\0|and_23|._13 (r_conj) hallucinations_0\NNS\14376855|NONE_0
D007069_D006212 CID ifosfamide_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|a_41|known_39|side_12 (r_prep) effect_14\NN\34213|hallucinations_91|._20 (r_attr) are_7\VBP\13600404|NONE_0 (l_nsubj) hallucinations_0\NNS\14376855|effect_91|._111
D007069_D006212 CID ifosfamide_3\RB\0|-_10 (r_npadvmod) induced_5\VBN\1627355|NONE_0 (r_amod) hallucinations_6\NNS\14376855|NONE_0
D007069_D006212 CID ifosfamide_6\RB\0|-_10 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) hallucinations_9\NNS\14376855|NONE_0
D007069_D006212 CID ifosfamide_7\RB\0|-_10 (r_npadvmod) induced_9\VBN\1627355|possible_20|,_22|occur_34 (r_amod) hallucinations_10\NNS\14376855|NONE_0
D007069_D020258 NONE ifosfamide_2\RB\0|-_10 (r_advmod) induced_4\VBN\1627355|NONE_0 (r_amod) neurotoxicity_5\NN\0|and_23|._13
D007069_D020258 NONE ifosfamide_16\NN\0|NONE_0 (r_pobj) of_15\IN\0|a_41|known_39|side_12 (r_prep) effect_14\NN\34213|hallucinations_91|._20 (r_attr) are_7\VBP\13600404|NONE_0 (l_nsubj) hallucinations_0\NNS\14376855|effect_91|._111 (l_prep) as_1\IN\14622893|NONE_0 (l_pobj) symptom_3\NN\5823932|NONE_0 (l_prep) of_4\IN\0|a_10 (l_pobj) neurotoxicity_6\NN\0|NONE_0
D007069_D020258 NONE ifosfamide_7\RB\0|-_10 (r_npadvmod) induced_9\VBN\1627355|possible_20|,_22|occur_34 (r_amod) hallucinations_10\NNS\14376855|NONE_0 (l_relcl) occur_14\VB\0|possible_54|induced_34|,_12 (l_prep) without_15\IN\0|which_16|may_10 (l_pobj) signs_17\NNS\6643763|NONE_0 (l_prep) of_18\IN\0|other_12 (l_pobj) neurotoxicity_19\NN\0|NONE_0
D006220_D011595 NONE haloperidol_12\NN\3713736|marked_41|,_35|potency_28|(_7|)_11 (r_appos) neuroleptics_8\NNS\4470232|may_33|effective_40|._49 (l_amod) marked_3\JJ\1296462|,_6|potency_13|(_34|haloperidol_41|)_52 (l_auxpass) becomes_2\VBZ\146138|NONE_0 (l_nsubj) agitation_1\NN\14373582|if_3
9579567
D013629_D016889 CID tamoxifen_9\NN\2714883|or_14|treatments_23 (r_compound) use_10\NN\407535|endometrial_33|and_14 (r_conj) cancer_7\NN\14239425|NONE_0
D013629_D016889 CID tamoxifen_4\NN\2714883|who_17|had_13 (r_dobj) received_3\VBN\2210855|NONE_0 (r_relcl) women_0\NNS\9605289|likely_57|._163 (r_nsubj) were_5\VBD\0|NONE_0 (l_acomp) likely_8\JJ\0|women_57|._106 (l_xcomp) have_10\VB\7846|more_15 (l_dobj) cancer_12\NN\14239425|to_20
D013629_D016889 CID tamoxifen_8\NN\2714883|had_13 (r_advmod) received_7\VBN\2210855|who_35|cancer_15|and_8 (r_conj) had_2\VBD\0|NONE_0 (l_dobj) cancer_4\NN\14239425|who_20|and_7|received_15
D013629_D016889 CID tamoxifen_8\NN\2714883|had_13 (r_advmod) received_7\VBN\2210855|who_35|cancer_15|and_8 (r_conj) had_2\VBD\0|NONE_0 (r_relcl) women_0\NNS\9605289|disease_78|._177 (r_nsubj) had_9\VBD\0|NONE_0 (l_dobj) disease_12\NN\14061805|women_78|._99 (l_conj) prognosis_15\NN\6748969|advanced_28|and_11 (l_prep) than_16\IN\0|poorer_17 (l_pobj) those_17\DT\0|NONE_0 (l_prep) with_18\IN\0|received_36 (l_pobj) cancer_20\NN\14239425|NONE_0
D013629_D016889 CID tamoxifen_7\NN\2714883|NONE_0 (r_pobj) of_6\IN\0|a_14|causal_12|in_13 (r_prep) role_5\NN\719494|results_25|,_39|used_59|._114 (l_prep) in_8\IN\13603305|a_27|causal_25|of_13 (l_pobj) cancer_10\NN\14239425|NONE_0
D013629_D016889 CID tamoxifen_7\NN\2714883|NONE_0 (r_pobj) with_6\IN\0|NONE_0 (r_prep) treated_5\VBN\2376958|NONE_0 (r_acl) women_4\NNS\9605289|NONE_0 (r_pobj) in_3\IN\13603305|NONE_0 (r_prep) diagnosed_2\VBD\644583|endometrial_20 (r_acl) cancers_1\NNS\14239425|prognosis_62|._71
D013629_D001943 NONE tamoxifen_1\NN\2714883|since_6|is_10|widely_13|in_25|and_52|proposed_65 (r_nsubjpass) used_4\VBN\0|,_89|effects_118|must_126|be_131|carefully_134|._152 (l_prep) in_5\IN\13603305|since_31|tamoxifen_25|is_15|widely_12|and_27|proposed_40 (l_pobj) treatment_8\NN\654885|NONE_0 (l_compound) cancer_7\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_1\NN\2714883|since_6|is_10|widely_13|in_25|and_52|proposed_65 (r_nsubjpass) used_4\VBN\0|,_89|effects_118|must_126|be_131|carefully_134|._152 (l_conj) proposed_12\VBN\1010118|since_71|tamoxifen_65|is_55|widely_52|in_40|and_13 (l_prep) for_13\IN\0|has_18|been_14 (l_pobj) prevention_15\NN\1073995|NONE_0 (l_prep) of_16\IN\0|the_15 (l_pobj) cancer_18\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_9\NN\2714883|or_14|treatments_23 (r_compound) use_10\NN\407535|endometrial_33|and_14 (r_conj) cancer_7\NN\14239425|NONE_0 (r_pobj) between_5\IN\0|the_16|treated_74 (r_prep) association_4\NN\8008335|we_25|have_22|._135 (l_acl) treated_16\VBN\2376958|the_90|between_74 (l_prep) for_17\IN\0|in_18 (l_pobj) cancer_19\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_7\NN\2714883|NONE_0 (r_pobj) of_6\IN\0|a_14|causal_12|in_13 (r_prep) role_5\NN\719494|results_25|,_39|used_59|._114 (r_dobj) suggest_2\VBP\1010118|NONE_0 (l_advcl) used_14\VBN\0|results_84|role_59|,_20|._55 (l_xcomp) proposed_17\VBN\1010118|particularly_36|when_23 (l_prep) for_18\IN\0|as_22|currently_19 (l_pobj) prevention_21\NN\1073995|NONE_0 (l_compound) cancer_20\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_3\NN\2714883|who_12|for_10 (r_dobj) receive_2\VBP\2210855|NONE_0 (l_prep) for_4\IN\0|who_22|tamoxifen_10 (l_pobj) cancer_6\NN\14239425|NONE_0
D013629_D001943 NONE tamoxifen_12\NN\2714883|NONE_0 (r_pobj) of_11\IN\0|the_23|benefit_14 (r_prep) ratio_10\NN\13815152|NONE_0 (r_pobj) of_5\IN\0|a_23|term_16|as_39 (r_prep) evaluation_4\NN\874067|is_94|clearly_97|._114 (l_prep) as_13\IN\14622893|a_62|term_55|of_39 (l_pobj) treatment_16\NN\654885|NONE_0 (l_prep) for_17\IN\0|a_23|preventive_21 (l_pobj) cancer_19\NN\14239425|NONE_0
D013629_D020178 NONE tamoxifen_8\NN\2714883|had_13 (r_advmod) received_7\VBN\2210855|who_35|cancer_15|and_8 (r_conj) had_2\VBD\0|NONE_0 (r_relcl) women_0\NNS\9605289|disease_78|._177 (r_nsubj) had_9\VBD\0|NONE_0 (l_dobj) disease_12\NN\14061805|women_78|._99
9669632
D020117_D010146 NONE cisapride_11\NN\0|NONE_0 (r_compound) therapy_12\NN\657604|after_16|[_8|,_14|+/-_19|,_45|cisapride_47|(_72|p_73|)_81 (r_nmod) score_14\NN\5736149|patients_58|score_31|;_73|pretreatment_75|._102 (r_advcl) had_5\VBD\0|NONE_0 (l_dobj) score_9\NN\5736149|patients_27|score_31|;_104|pretreatment_106|._133 (l_compound) pain_8\NN\14299637|a_9|higher_7
D020117_D010146 NONE cisapride_25\NN\0|after_63|therapy_47|[_39|,_33|+/-_28|,_2|(_25|p_26|)_34 (r_conj) score_14\NN\5736149|patients_58|score_31|;_73|pretreatment_75|._102 (r_advcl) had_5\VBD\0|NONE_0 (l_dobj) score_9\NN\5736149|patients_27|score_31|;_104|pretreatment_106|._133 (l_compound) pain_8\NN\14299637|a_9|higher_7
D020117_D003248 NONE cisapride_36\NN\0|and_31 (r_conj) before_28\IN\0|patients_128|;_77|,_54|)_46|manometry_10|,_47|daily_66|._101 (r_advmod) underwent_23\VBD\109660|NONE_0 (l_nsubj) patients_3\NNS\9898892|;_51|,_74|)_82|manometry_118|before_128|,_175|daily_194|._229 (l_prep) with_4\IN\0|eight_15 (l_pobj) ibs_5\NNP\0|NONE_0 (l_appos) predominant_9\JJ\0|(_14 (l_compound) constipation_7\NN\14299637|-_12|,_24
D020117_D003248 NONE cisapride_11\NN\0|-_9 (r_npadvmod) treated_13\VBN\2376958|predominant_21|ibs_33|score_47 (r_amod) patients_18\NNS\9898892|NONE_0 (r_pobj) in_10\IN\13603305|scores_59|lower_6 (r_prep) were_8\VBD\0|NONE_0 (l_nsubj) scores_1\NNS\13757724|lower_53|in_59 (l_acl) relating_2\VBG\628491|symptom_15 (l_prep) to_3\IN\0|NONE_0 (l_pobj) severity_5\NN\5036394|NONE_0 (l_prep) of_6\IN\0|the_13 (l_pobj) constipation_7\NN\14299637|NONE_0
D020117_D003248 NONE cisapride_11\NN\0|-_9 (r_npadvmod) treated_13\VBN\2376958|predominant_21|ibs_33|score_47 (r_amod) patients_18\NNS\9898892|NONE_0 (l_amod) predominant_16\JJ\0|treated_21|ibs_12|score_26 (l_compound) constipation_14\NN\14299637|-_12
D020117_D003967 NONE cisapride_36\NN\0|and_31 (r_conj) before_28\IN\0|patients_128|;_77|,_54|)_46|manometry_10|,_47|daily_66|._101 (r_advmod) underwent_23\VBD\109660|NONE_0 (l_punct) ;_14\:\0|patients_51|,_23|)_31|manometry_67|before_77|,_124|daily_143|._178 (l_preconj) predominant_17\JJ\0|NONE_0 (l_compound) diarrhoea_15\NN\14299637|-_9
D020117_D003967 NONE cisapride_14\NN\0|the_4 (r_nmod) groups_17\NNS\2137|NONE_0 (r_pobj) between_12\IN\0|in_103|differences_57|were_14|._40 (r_prep) observed_11\VBN\2163746|NONE_0 (l_prep) in_0\IN\13603305|differences_46|were_89|between_103|._143 (l_pobj) patients_4\NNS\9898892|NONE_0 (l_amod) predominant_3\JJ\0|NONE_0 (l_npadvmod) diarrhoea_1\NN\14299637|-_9
D020117_D003967 NONE cisapride_1\NN\0|-_9 (r_npadvmod) treated_3\VBN\2376958|predominant_18 (r_amod) patients_7\NNS\9898892|NONE_0 (l_amod) predominant_6\JJ\0|treated_18 (l_npadvmod) diarrhoea_4\NN\14299637|-_9
D020117_D003967 NONE cisapride_11\NN\0|NONE_0 (r_compound) therapy_12\NN\657604|after_16|[_8|,_14|+/-_19|,_45|cisapride_47|(_72|p_73|)_81 (r_nmod) score_14\NN\5736149|patients_58|score_31|;_73|pretreatment_75|._102 (r_advcl) had_5\VBD\0|NONE_0 (l_nsubj) patients_4\NNS\9898892|score_27|score_58|;_131|pretreatment_133|._160 (l_amod) predominant_2\JJ\0|ibs_12 (l_npadvmod) diarrhoea_0\NN\14299637|-_9
D020117_D003967 NONE cisapride_25\NN\0|after_63|therapy_47|[_39|,_33|+/-_28|,_2|(_25|p_26|)_34 (r_conj) score_14\NN\5736149|patients_58|score_31|;_73|pretreatment_75|._102 (r_advcl) had_5\VBD\0|NONE_0 (l_nsubj) patients_4\NNS\9898892|score_27|score_58|;_131|pretreatment_133|._160 (l_amod) predominant_2\JJ\0|ibs_12 (l_npadvmod) diarrhoea_0\NN\14299637|-_9
D020117_D043183 NONE cisapride_2\NN\0|NONE_0 (r_pobj) of_1\IN\0|on_13|and_25|function_57|._107 (r_prep) effects_0\NNS\13245626|NONE_0 (l_conj) function_11\NN\13783581|of_57|on_44|and_32|._50 (l_prep) in_12\IN\13603305|postcibal_37|bowel_21|motor_15 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) syndrome_17\NN\5870365|NONE_0
D020117_D043183 NONE cisapride_17\NN\0|to_70|effects_56 (l_prep) on_19\IN\0|,_2 (l_pobj) motility_22\NN\4773351|NONE_0 (l_prep) in_25\IN\13603305|postprandial_43|jejunal_30|and_13|symptoms_9 (l_pobj) syndrome_29\NN\5870365|NONE_0
D020117_D043183 NONE cisapride_17\NN\0|to_70|effects_56 (l_prep) on_19\IN\0|,_2 (l_pobj) motility_22\NN\4773351|NONE_0 (l_prep) in_25\IN\13603305|postprandial_43|jejunal_30|and_13|symptoms_9 (l_pobj) syndrome_29\NN\5870365|NONE_0 (l_appos) ibs_31\NNP\0|the_30|irritable_26|bowel_16|(_1|)_3
D020117_D043183 NONE cisapride_36\NN\0|and_31 (r_conj) before_28\IN\0|patients_128|;_77|,_54|)_46|manometry_10|,_47|daily_66|._101 (r_advmod) underwent_23\VBD\109660|NONE_0 (l_nsubj) patients_3\NNS\9898892|;_51|,_74|)_82|manometry_118|before_128|,_175|daily_194|._229 (l_prep) with_4\IN\0|eight_15 (l_pobj) ibs_5\NNP\0|NONE_0
D020117_D043183 NONE cisapride_11\NN\0|-_9 (r_npadvmod) treated_13\VBN\2376958|predominant_21|ibs_33|score_47 (r_amod) patients_18\NNS\9898892|NONE_0 (l_compound) ibs_17\NNP\0|treated_33|predominant_12|score_14
D020117_D043183 NONE cisapride_11\NN\0|NONE_0 (r_compound) therapy_12\NN\657604|after_16|[_8|,_14|+/-_19|,_45|cisapride_47|(_72|p_73|)_81 (r_nmod) score_14\NN\5736149|patients_58|score_31|;_73|pretreatment_75|._102 (r_advcl) had_5\VBD\0|NONE_0 (l_nsubj) patients_4\NNS\9898892|score_27|score_58|;_131|pretreatment_133|._160 (l_compound) ibs_3\NNP\0|predominant_12
D020117_D043183 NONE cisapride_25\NN\0|after_63|therapy_47|[_39|,_33|+/-_28|,_2|(_25|p_26|)_34 (r_conj) score_14\NN\5736149|patients_58|score_31|;_73|pretreatment_75|._102 (r_advcl) had_5\VBD\0|NONE_0 (l_nsubj) patients_4\NNS\9898892|score_27|score_58|;_131|pretreatment_133|._160 (l_compound) ibs_3\NNP\0|predominant_12
D020117_D043183 NONE cisapride_0\NNP\0|characteristics_38|._78 (r_nsubj) affects_1\VBZ\26192|NONE_0 (l_dobj) characteristics_4\NNS\5849040|cisapride_38|._40 (l_conj) symptoms_7\NNS\5823932|jejunal_45|contraction_37|and_9 (l_prep) in_8\IN\13603305|some_14 (l_pobj) ibs_9\NNP\0|NONE_0
873132
D004997_D002779 CID estradiol_12\NN\14749794|-_9 (r_npadvmod) induced_14\VBN\1627355|in_20 (r_amod) cholestasis_15\NN\14052403|sulfation_94|hydroxylation_63|._19
D003840_D002779 NONE acid_9\NN\14818238|NONE_0 (r_pobj) of_7\IN\0|7alpha_21|-_15|in_20 (r_prep) hydroxylation_6\NN\0|sulfation_31|cholestasis_63|._82 (r_dobj) decreased_3\VBD\169651|NONE_0 (l_dobj) cholestasis_15\NN\14052403|sulfation_94|hydroxylation_63|._19
20973483
D006220_D002375 CID haloperidol_53\NN\3713736|-_11 (r_npadvmod) induced_55\VBN\1627355|,_17|model_25|,_60|model_100 (r_amod) catalepsy_56\NN\14023236|NONE_0
D015632_D002375 NONE mptp_80\NNP\0|-_4 (r_npadvmod) treated_82\VBN\2376958|human_12|primate_18 (r_amod) model_87\NN\5888929|number_260|and_35 (r_conj) across_37\IN\0|compound_162|antagonist_119|,_29|after_27|,_2|._274 (l_pobj) number_39\NN\5107765|and_225|model_260 (l_prep) of_40\IN\0|a_9 (l_pobj) models_42\NNS\5888929|NONE_0 (l_prep) of_43\IN\0|animal_14 (l_pobj) disease_46\NN\14061805|NONE_0 (l_prep) including_47\VBG\0|parkinson_20 (l_pobj) models_51\NNS\5888929|NONE_0 (l_prep) of_52\IN\0|mouse_21 (l_pobj) catalepsy_56\NN\14023236|NONE_0
D006220_D004409 NONE haloperidol_53\NN\3713736|-_11 (r_npadvmod) induced_55\VBN\1627355|,_17|model_25|,_60|model_100 (r_amod) catalepsy_56\NN\14023236|NONE_0 (l_appos) model_59\NN\5888929|induced_25|,_8|,_35|model_75 (l_prep) of_60\IN\0|mouse_12 (l_pobj) akinesia_64\NN\14558226|NONE_0
D058915_D010300 NONE antagonist_11\NN\7846|NONE_0 (l_prep) in_12\IN\13603305|a_44|adenosine_37|a2a_27|a1_23|receptor_20 (l_pobj) models_14\NNS\5888929|NONE_0 (l_prep) of_15\IN\0|animal_14 (l_pobj) disease_18\NN\14061805|NONE_0
D058915_D010300 NONE antagonist_11\NN\7846|NONE_0 (l_prep) in_12\IN\13603305|a_48|adenosine_41|a(2a)/a(1_31|)_22|receptor_20 (l_pobj) models_15\NNS\5888929|NONE_0 (l_prep) of_16\IN\0|several_22|animal_14 (l_pobj) disease_19\NN\14061805|NONE_0
D015632_D004409 NONE mptp_80\NNP\0|-_4 (r_npadvmod) treated_82\VBN\2376958|human_12|primate_18 (r_amod) model_87\NN\5888929|number_260|and_35 (r_conj) across_37\IN\0|compound_162|antagonist_119|,_29|after_27|,_2|._274 (l_pobj) number_39\NN\5107765|and_225|model_260 (l_prep) of_40\IN\0|a_9 (l_pobj) models_42\NNS\5888929|NONE_0 (l_prep) of_43\IN\0|animal_14 (l_pobj) disease_46\NN\14061805|NONE_0 (l_prep) including_47\VBG\0|parkinson_20 (l_pobj) models_51\NNS\5888929|NONE_0 (l_prep) of_52\IN\0|mouse_21 (l_pobj) catalepsy_56\NN\14023236|NONE_0 (l_appos) model_59\NN\5888929|induced_25|,_8|,_35|model_75 (l_prep) of_60\IN\0|mouse_12 (l_pobj) akinesia_64\NN\14558226|NONE_0
D016627_D002375 NONE 6-hydroxydopamine_67\NN\0|(_18|)_25 (r_nmod) 6-ohda_69\CD\0|rat_23|lesion_8|of_21|,_45 (r_nummod) model_72\NN\5888929|induced_100|,_83|model_75|,_40 (r_appos) catalepsy_56\NN\14023236|NONE_0
D016627_D002375 NONE 6-ohda_69\CD\0|rat_23|lesion_8|of_21|,_45 (r_nummod) model_72\NN\5888929|induced_100|,_83|model_75|,_40 (r_appos) catalepsy_56\NN\14023236|NONE_0
D012110_D004409 CID reserpine_61\NN\2721160|-_9 (r_npadvmod) induced_63\VBN\1627355|NONE_0 (r_compound) akinesia_64\NN\14558226|NONE_0
D016627_D010300 NONE 6-hydroxydopamine_67\NN\0|(_18|)_25 (r_nmod) 6-ohda_69\CD\0|rat_23|lesion_8|of_21|,_45 (r_nummod) model_72\NN\5888929|induced_100|,_83|model_75|,_40 (r_appos) catalepsy_56\NN\14023236|NONE_0 (r_pobj) of_52\IN\0|mouse_21 (r_prep) models_51\NNS\5888929|NONE_0 (r_pobj) including_47\VBG\0|parkinson_20 (r_prep) disease_46\NN\14061805|NONE_0
D016627_D010300 NONE 6-ohda_69\CD\0|rat_23|lesion_8|of_21|,_45 (r_nummod) model_72\NN\5888929|induced_100|,_83|model_75|,_40 (r_appos) catalepsy_56\NN\14023236|NONE_0 (r_pobj) of_52\IN\0|mouse_21 (r_prep) models_51\NNS\5888929|NONE_0 (r_pobj) including_47\VBG\0|parkinson_20 (r_prep) disease_46\NN\14061805|NONE_0
D012110_D010300 NONE reserpine_61\NN\2721160|-_9 (r_npadvmod) induced_63\VBN\1627355|NONE_0 (r_compound) akinesia_64\NN\14558226|NONE_0 (r_pobj) of_60\IN\0|mouse_12 (r_prep) model_59\NN\5888929|induced_25|,_8|,_35|model_75 (r_appos) catalepsy_56\NN\14023236|NONE_0 (r_pobj) of_52\IN\0|mouse_21 (r_prep) models_51\NNS\5888929|NONE_0 (r_pobj) including_47\VBG\0|parkinson_20 (r_prep) disease_46\NN\14061805|NONE_0
D012110_D002375 NONE reserpine_61\NN\2721160|-_9 (r_npadvmod) induced_63\VBN\1627355|NONE_0 (r_compound) akinesia_64\NN\14558226|NONE_0 (r_pobj) of_60\IN\0|mouse_12 (r_prep) model_59\NN\5888929|induced_25|,_8|,_35|model_75 (r_appos) catalepsy_56\NN\14023236|NONE_0
D006220_D010300 NONE haloperidol_53\NN\3713736|-_11 (r_npadvmod) induced_55\VBN\1627355|,_17|model_25|,_60|model_100 (r_amod) catalepsy_56\NN\14023236|NONE_0 (r_pobj) of_52\IN\0|mouse_21 (r_prep) models_51\NNS\5888929|NONE_0 (r_pobj) including_47\VBG\0|parkinson_20 (r_prep) disease_46\NN\14061805|NONE_0
D016627_D004409 NONE 6-hydroxydopamine_67\NN\0|(_18|)_25 (r_nmod) 6-ohda_69\CD\0|rat_23|lesion_8|of_21|,_45 (r_nummod) model_72\NN\5888929|induced_100|,_83|model_75|,_40 (r_appos) catalepsy_56\NN\14023236|NONE_0 (l_appos) model_59\NN\5888929|induced_25|,_8|,_35|model_75 (l_prep) of_60\IN\0|mouse_12 (l_pobj) akinesia_64\NN\14558226|NONE_0
D016627_D004409 NONE 6-ohda_69\CD\0|rat_23|lesion_8|of_21|,_45 (r_nummod) model_72\NN\5888929|induced_100|,_83|model_75|,_40 (r_appos) catalepsy_56\NN\14023236|NONE_0 (l_appos) model_59\NN\5888929|induced_25|,_8|,_35|model_75 (l_prep) of_60\IN\0|mouse_12 (l_pobj) akinesia_64\NN\14558226|NONE_0
D015632_D010300 NONE mptp_80\NNP\0|-_4 (r_npadvmod) treated_82\VBN\2376958|human_12|primate_18 (r_amod) model_87\NN\5888929|number_260|and_35 (r_conj) across_37\IN\0|compound_162|antagonist_119|,_29|after_27|,_2|._274 (l_pobj) number_39\NN\5107765|and_225|model_260 (l_prep) of_40\IN\0|a_9 (l_pobj) models_42\NNS\5888929|NONE_0 (l_prep) of_43\IN\0|animal_14 (l_pobj) disease_46\NN\14061805|NONE_0
3183120
C033706_D001927 CID tiazofurin_5\NN\0|NONE_0 (r_compound) usage_6\NN\407535|NONE_0 (r_pobj) with_4\IN\0|NONE_0 (r_prep) associated_3\VBN\628491|reversible_28|cerebral_17|:_32|demonstration_37|._50 (r_acl) lesions_2\NNS\14204950|NONE_0
9549528
D007980_D020734 NONE dopa_9\NN\14601829|-_4 (r_npadvmod) induced_11\VBN\1627355|dose_13 (r_amod) dyskinesia_15\NN\14084880|NONE_0 (r_pobj) with_6\IN\0|parkinsonian_22 (r_prep) patients_5\NNS\9898892|NONE_0 (l_amod) parkinsonian_4\JJ\0|with_22
D007980_D020734 NONE dopa_42\NN\14601829|,_15 (r_compound) medication_43\NN\3247620|NONE_0 (r_pobj) on_39\IN\0|parkinsonian_22 (r_prep) patients_38\NNS\9898892|NONE_0 (l_amod) parkinsonian_37\JJ\0|on_22
D007980_D020734 NONE dopa_51\NN\14601829|NONE_0 (r_pobj) without_48\IN\0|the_14|first_10 (r_prep) one_47\NN\13741022|dyskinesia_27|,_104|and_106|of_110 (r_nsubj) induced_52\VBD\1627355|we_268|have_265|flow_224|._123 (r_conj) studied_2\VBN\0|NONE_0 (l_dobj) flow_7\NN\7311115|we_44|have_41|induced_224|._347 (l_conj) changes_11\NNS\7283608|the_40|regional_36|cerebral_27|blood_18|(_7|rcbf_6 (l_acl) induced_12\VBN\1627355|)_10 (l_agent) by_13\IN\0|NONE_0 (l_pobj) execution_15\NN\1161161|NONE_0 (l_prep) in_26\IN\13603305|the_57|of_43 (l_pobj) cortex_32\NN\5462674|NONE_0 (l_prep) of_33\IN\0|the_43|supplementary_39|motor_13 (l_pobj) groups_35\NNS\2137|NONE_0 (l_prep) of_36\IN\0|two_11 (l_pobj) patients_38\NNS\9898892|NONE_0 (l_amod) parkinsonian_37\JJ\0|on_22
D007980_D004409 CID dopa_9\NN\14601829|-_4 (r_npadvmod) induced_11\VBN\1627355|dose_13 (r_amod) dyskinesia_15\NN\14084880|NONE_0
D007980_D004409 CID dopa_42\NN\14601829|,_15 (r_compound) medication_43\NN\3247620|NONE_0 (r_pobj) on_39\IN\0|parkinsonian_22 (r_prep) patients_38\NNS\9898892|NONE_0 (r_pobj) of_36\IN\0|two_11 (r_prep) groups_35\NNS\2137|NONE_0 (r_pobj) of_33\IN\0|the_43|supplementary_39|motor_13 (r_prep) cortex_32\NN\5462674|NONE_0 (r_pobj) in_26\IN\13603305|the_57|of_43 (r_prep) execution_15\NN\1161161|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) induced_12\VBN\1627355|)_10 (r_acl) changes_11\NNS\7283608|the_40|regional_36|cerebral_27|blood_18|(_7|rcbf_6 (r_conj) flow_7\NN\7311115|we_44|have_41|induced_224|._347 (r_dobj) studied_2\VBN\0|NONE_0 (l_conj) induced_52\VBD\1627355|we_268|have_265|flow_224|._123 (l_dobj) dyskinesia_53\NN\14084880|one_27|,_77|and_79|of_83
D007980_D004409 CID dopa_42\NN\14601829|,_15 (r_compound) medication_43\NN\3247620|NONE_0 (r_pobj) on_39\IN\0|parkinsonian_22 (r_prep) patients_38\NNS\9898892|NONE_0 (r_pobj) of_36\IN\0|two_11 (r_prep) groups_35\NNS\2137|NONE_0 (r_pobj) of_33\IN\0|the_43|supplementary_39|motor_13 (r_prep) cortex_32\NN\5462674|NONE_0 (r_pobj) in_26\IN\13603305|the_57|of_43 (r_prep) execution_15\NN\1161161|NONE_0 (r_pobj) by_13\IN\0|NONE_0 (r_agent) induced_12\VBN\1627355|)_10 (r_acl) changes_11\NNS\7283608|the_40|regional_36|cerebral_27|blood_18|(_7|rcbf_6 (r_conj) flow_7\NN\7311115|we_44|have_41|induced_224|._347 (r_dobj) studied_2\VBN\0|NONE_0 (l_conj) induced_52\VBD\1627355|we_268|have_265|flow_224|._123 (l_dobj) dyskinesia_53\NN\14084880|one_27|,_77|and_79|of_83 (l_conj) other_61\JJ\0|(_17|n_16|23_12|)_10|and_8 (l_prep) with_62\IN\0|the_10 (l_pobj) dyskinesia_67\NN\14084880|NONE_0
D007980_D004409 CID dopa_51\NN\14601829|NONE_0 (r_pobj) without_48\IN\0|the_14|first_10 (r_prep) one_47\NN\13741022|dyskinesia_27|,_104|and_106|of_110 (r_nsubj) induced_52\VBD\1627355|we_268|have_265|flow_224|._123 (l_dobj) dyskinesia_53\NN\14084880|one_27|,_77|and_79|of_83
D007980_D004409 CID dopa_51\NN\14601829|NONE_0 (r_pobj) without_48\IN\0|the_14|first_10 (r_prep) one_47\NN\13741022|dyskinesia_27|,_104|and_106|of_110 (r_nsubj) induced_52\VBD\1627355|we_268|have_265|flow_224|._123 (l_dobj) dyskinesia_53\NN\14084880|one_27|,_77|and_79|of_83 (l_conj) other_61\JJ\0|(_17|n_16|23_12|)_10|and_8 (l_prep) with_62\IN\0|the_10 (l_pobj) dyskinesia_67\NN\14084880|NONE_0
D007980_D004409 CID dopa_17\NN\14601829|-_4 (r_npadvmod) induced_19\VBN\1627355|dose_13 (r_amod) dyskinesia_22\NN\14084880|NONE_0 (r_pobj) like_14\IN\5839024|an_47|hyperkinetic_44|abnormal_31|involuntary_22|,_2 (r_prep) movement_12\NN\191142|that_42|,_50|due_55
D007980_D004409 CID dopa_17\NN\14601829|-_4 (r_npadvmod) induced_19\VBN\1627355|dose_13 (r_amod) dyskinesia_22\NN\14084880|NONE_0
D007980_D006948 NONE dopa_17\NN\14601829|-_4 (r_npadvmod) induced_19\VBN\1627355|dose_13 (r_amod) dyskinesia_22\NN\14084880|NONE_0 (r_pobj) like_14\IN\5839024|an_47|hyperkinetic_44|abnormal_31|involuntary_22|,_2 (r_prep) movement_12\NN\191142|that_42|,_50|due_55 (l_amod) hyperkinetic_9\JJ\0|an_3|abnormal_13|involuntary_22|,_42|like_44
18239197
D014282_D003072 CID trihexyphenidyl_10\JJ\0|NONE_0 (r_pcomp) after_9\IN\0|with_30 (r_prep) associated_3\VBN\628491|increased_25|mental_15|._112 (r_acl) slowing_2\NN\7296428|NONE_0
D014282_D003072 CID trihexyphenidyl_5\JJ\0|NONE_0 (r_pobj) of_4\IN\0|a_19|2.0-mg_17|oral_10 (r_prep) dose_3\NN\3740161|in_33|._128 (r_nsubj) resulted_6\VBD\2633881|NONE_0 (l_prep) in_7\IN\13603305|dose_33|._95 (l_pobj) ratings_10\NNS\5733583|NONE_0 (l_prep) of_11\IN\0|increased_29|subjective_19 (l_pobj) slowness_13\NN\5648247|NONE_0
D014282_D003072 CID trihexyphenidyl_10\JJ\0|NONE_0 (r_pobj) between_7\IN\0|difference_18|on_43 (r_prep) scores_6\NNS\13757724|NONE_0 (l_prep) on_13\IN\0|difference_61|between_43 (l_pobj) ratings_14\NNS\5733583|NONE_0 (l_prep) of_15\IN\0|NONE_0 (l_pobj) slowness_17\NN\5648247|NONE_0
D014282_D003072 CID trihexyphenidyl_14\JJ\0|anticholinergic_16 (r_amod) challenge_16\NN\13927383|NONE_0 (r_pobj) after_13\IN\0|increased_36|subjective_26|mental_15 (r_prep) slowing_12\NN\7296428|NONE_0
D014282_D003221 NONE trihexyphenidyl_19\NN\0|NONE_0 (l_prep) on_20\IN\0|NONE_0 (l_pobj) measures_21\NNS\168237|NONE_0 (l_acl) reflecting_22\VBG\923793|NONE_0 (l_dobj) sedation_23\NN\14034177|NONE_0 (l_conj) confusion_25\NN\13972797|and_4
D014282_D003221 NONE trihexyphenidyl_32\NN\0|-_15 (r_npadvmod) induced_34\VBN\1627355|subjective_8|and_27|performance_48 (r_amod) effects_36\NNS\13245626|NONE_0 (r_pobj) between_31\IN\0|the_17 (r_prep) relationship_30\NN\31921|to_19 (r_dobj) investigate_28\VB\644583|to_145|relationship_130|and_7 (r_conj) examine_9\VB\0|objectives_33|._254 (l_dobj) relationship_11\NN\31921|to_15|and_123|investigate_130 (l_conj) effects_17\NNS\13245626|the_54|between_37 (l_prep) of_18\IN\0|subjective_19 (l_pobj) trihexyphenidyl_19\NN\0|NONE_0 (l_prep) on_20\IN\0|NONE_0 (l_pobj) measures_21\NNS\168237|NONE_0 (l_acl) reflecting_22\VBG\923793|NONE_0 (l_dobj) sedation_23\NN\14034177|NONE_0 (l_conj) confusion_25\NN\13972797|and_4
17241657
C107044_D012640 NONE 21_15\CD\13745420|NONE_0 (r_nummod) /-)-sm_14\SYM\0|or_5|(_2|+_1 (r_conj) umb24_10\NNP\0|NONE_0 (r_pobj) with_9\IN\0|of_22 (r_prep) pretreatment_4\NN\0|in_23|,_2|significantly_61|convulsions_102|,_136|but_138|lethality_146|._155 (r_nsubj) attenuated_17\VBN\224901|NONE_0 (l_dobj) convulsions_21\NNS\14081375|in_125|,_104|pretreatment_102|significantly_41|,_34|but_36|lethality_44|._53
C519696_D012640 NONE umb24_10\NNP\0|NONE_0 (r_pobj) with_9\IN\0|of_22 (r_prep) pretreatment_4\NN\0|in_23|,_2|significantly_61|convulsions_102|,_136|but_138|lethality_146|._155 (r_nsubj) attenuated_17\VBN\224901|NONE_0 (l_dobj) convulsions_21\NNS\14081375|in_125|,_104|pretreatment_102|significantly_41|,_34|but_36|lethality_44|._53
D003042_D012640 CID cocaine_21\NN\3492717|NONE_0 (r_pobj) of_20\IN\0|the_68|convulsive_64|,_54|lethal_52|,_46|locomotor_44|stimulatory_34 (r_prep) actions_19\NNS\30358|that_107|antagonism_102 (l_amod) convulsive_11\JJ\0|the_4|,_10|lethal_12|,_18|locomotor_20|stimulatory_30|of_64
D003042_D012640 CID cocaine_18\NN\3492717|-_7 (r_npadvmod) induced_20\VBN\1627355|and_20|activity_34 (r_amod) convulsions_21\NNS\14081375|in_125|,_104|pretreatment_102|significantly_41|,_34|but_36|lethality_44|._53
20558148
D006220_D002375 CID haloperidol_12\NN\3713736|-_11 (r_npadvmod) induced_14\VBN\1627355|NONE_0 (r_amod) catalepsy_15\NN\14023236|neurotransmission_105|can_33|._9
D006220_D002375 CID haloperidol_25\NN\3713736|the_30|receptor_17 (r_appos) blocker_24\NN\10101634|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|the_14 (r_acl) catalepsy_18\NN\14023236|NONE_0
D006220_D002375 CID haloperidol_0\NN\3713736|-_11 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) catalepsy_3\NN\14023236|was_10|with_25|microl_134|microl_256|)_262|._263
D006220_D002375 CID haloperidol_15\NN\3713736|NONE_0 (r_pobj) of_14\IN\0|systemic_20 (r_prep) injections_13\NNS\320852|NONE_0 (r_pobj) to_11\IN\0|NONE_0 (r_prep) previous_10\JJ\0|NONE_0 (r_amod) ap7_9\RB\0|that_50|intracollicular_45|of_14|and_4 (r_conj) microinjection_5\NN\0|results_36|attenuated_94|._188 (r_dobj) showed_2\VBD\2137132|NONE_0 (l_ccomp) attenuated_17\VBD\224901|results_130|microinjection_94|._94 (l_dobj) catalepsy_19\NN\14023236|significantly_29|,_9|indicated_14
D006220_D002375 CID haloperidol_17\NN\3713736|-_11 (r_npadvmod) induced_19\VBN\1627355|influence_22 (r_amod) catalepsy_20\NN\14023236|NONE_0
D018698_D002375 NONE glutamate_11\NN\15010703|receptor_15|,_35 (r_compound) antagonists_14\NNS\7846|NONE_0 (r_pobj) of_10\IN\0|prior_38|intracollicular_32 (r_prep) microinjections_9\NNS\0|NONE_0 (r_pobj) with_6\IN\0|catalepsy_25|was_15|microl_109|microl_231|)_237|._238 (r_prep) challenged_5\VBN\869596|NONE_0 (l_nsubjpass) catalepsy_3\NN\14023236|was_10|with_25|microl_134|microl_256|)_262|._263
D018698_D002375 NONE glutamate_4\NN\15010703|-_9 (r_npadvmod) mediated_6\VBN\761713|that_15|in_20|and_99|participate_103 (r_amod) mechanisms_7\NNS\13446390|findings_41|._141 (l_prep) in_8\IN\13603305|that_35|mediated_20|and_79|participate_83 (l_pobj) circuits_11\NNS\3269401|NONE_0 (l_prep) at_12\IN\14622893|the_20|neural_16 (l_pobj) catalepsy_20\NN\14023236|NONE_0
D016291_D002375 NONE mk-801_16\NNP\0|(_7|15_8|mmol/0.5_17|)_32|and_34|ap7_38|or_70|of_73 (r_punct) microl_22\NN\0|catalepsy_134|was_124|with_109|microl_122|)_128|._129 (r_dobj) challenged_5\VBN\869596|NONE_0 (l_nsubjpass) catalepsy_3\NN\14023236|was_10|with_25|microl_134|microl_256|)_262|._263
D016291_D002375 NONE mk-801_7\NNP\0|NONE_0 (r_punct) and_8\CC\0|that_46|intracollicular_41|of_10|ap7_4 (r_cc) microinjection_5\NN\0|results_36|attenuated_94|._188 (r_dobj) showed_2\VBD\2137132|NONE_0 (l_ccomp) attenuated_17\VBD\224901|results_130|microinjection_94|._94 (l_dobj) catalepsy_19\NN\14023236|significantly_29|,_9|indicated_14
C031231_D002375 NONE ap7_25\RB\0|mk-801_38|(_31|15_30|mmol/0.5_21|)_6|and_4|or_32|of_35 (r_conj) microl_22\NN\0|catalepsy_134|was_124|with_109|microl_122|)_128|._129 (r_dobj) challenged_5\VBN\869596|NONE_0 (l_nsubjpass) catalepsy_3\NN\14023236|was_10|with_25|microl_134|microl_256|)_262|._263
C031231_D002375 NONE ap7_9\RB\0|that_50|intracollicular_45|of_14|and_4 (r_conj) microinjection_5\NN\0|results_36|attenuated_94|._188 (r_dobj) showed_2\VBD\2137132|NONE_0 (l_ccomp) attenuated_17\VBD\224901|results_130|microinjection_94|._94 (l_dobj) catalepsy_19\NN\14023236|significantly_29|,_9|indicated_14
D004298_D002375 NONE dopamine_22\NN\14807737|NONE_0 (r_compound) receptor_23\NN\5225602|the_13|haloperidol_17 (r_compound) blocker_24\NN\10101634|NONE_0 (r_pobj) by_20\IN\0|NONE_0 (r_agent) induced_19\VBN\1627355|the_14 (r_acl) catalepsy_18\NN\14023236|NONE_0
D016202_D002375 NONE nmda_4\NNP\0|NONE_0 (r_compound) receptors_5\NNS\5225602|NONE_0 (r_pobj) by_3\IN\0|in_18 (r_agent) mediated_2\VBN\761713|glutamatergic_32 (r_acl) neurotransmission_1\NN\0|can_72|catalepsy_105|._114 (r_nsubj) modulate_11\VB\1724459|NONE_0 (l_dobj) catalepsy_15\NN\14023236|neurotransmission_105|can_33|._9
D016202_D002375 NONE nmda_12\NNP\0|NONE_0 (r_compound) receptor_13\NN\5225602|glutamate_15|,_20 (r_compound) antagonists_14\NNS\7846|NONE_0 (r_pobj) of_10\IN\0|prior_38|intracollicular_32 (r_prep) microinjections_9\NNS\0|NONE_0 (r_pobj) with_6\IN\0|catalepsy_25|was_15|microl_109|microl_231|)_237|._238 (r_prep) challenged_5\VBN\869596|NONE_0 (l_nsubjpass) catalepsy_3\NN\14023236|was_10|with_25|microl_134|microl_256|)_262|._263
D016202_D002375 NONE nmda_37\NNP\0|the_4|nmda_44 (r_compound) receptor_38\NN\5225602|NONE_0 (r_pobj) of_35\IN\0|mk-801_73|(_66|15_65|mmol/0.5_56|)_41|and_39|ap7_35|or_3 (r_prep) microl_22\NN\0|catalepsy_134|was_124|with_109|microl_122|)_128|._129 (r_dobj) challenged_5\VBN\869596|NONE_0 (l_nsubjpass) catalepsy_3\NN\14023236|was_10|with_25|microl_134|microl_256|)_262|._263
D016202_D002375 NONE aspartate_46\NNP\0|agonist_19|(_10|,_15 (r_nmod) nmda_48\NNP\0|the_48|nmda_44 (r_appos) receptor_38\NN\5225602|NONE_0 (r_pobj) of_35\IN\0|mk-801_73|(_66|15_65|mmol/0.5_56|)_41|and_39|ap7_35|or_3 (r_prep) microl_22\NN\0|catalepsy_134|was_124|with_109|microl_122|)_128|._129 (r_dobj) challenged_5\VBN\869596|NONE_0 (l_nsubjpass) catalepsy_3\NN\14023236|was_10|with_25|microl_134|microl_256|)_262|._263
D016202_D002375 NONE nmda_48\NNP\0|the_48|nmda_44 (r_appos) receptor_38\NN\5225602|NONE_0 (r_pobj) of_35\IN\0|mk-801_73|(_66|15_65|mmol/0.5_56|)_41|and_39|ap7_35|or_3 (r_prep) microl_22\NN\0|catalepsy_134|was_124|with_109|microl_122|)_128|._129 (r_dobj) challenged_5\VBN\869596|NONE_0 (l_nsubjpass) catalepsy_3\NN\14023236|was_10|with_25|microl_134|microl_256|)_262|._263
D000596_D002375 NONE acid_9\NN\14818238|-_4 (r_npadvmod) mediated_11\VBN\761713|excitatory_22|amino_11 (r_amod) mechanisms_12\NNS\13446390|NONE_0 (r_pobj) of_6\IN\0|the_14|in_45|on_55 (r_prep) influence_5\NN\5190804|study_19 (l_prep) on_16\IN\0|the_69|of_55|in_10 (l_pobj) catalepsy_18\NN\14023236|NONE_0
10027919
D002117_D001851 CID calcitriol_0\NNP\0|NONE_0 (r_compound) therapy_1\NN\657604|levels_25|in_61|but_92|has_96|._226 (r_nsubj) suppresses_2\VBZ\2510337|NONE_0 (l_conj) has_17\VBZ\13888491|therapy_96|levels_71|in_35|but_4|._130 (l_dobj) drawbacks_19\NNS\5161614|NONE_0 (l_prep) including_21\VBG\0|several_19|,_2 (l_pobj) hypercalcemia_22\NN\14299637|NONE_0 (l_conj) suppression_25\NN\13489037|and/or_14 (l_prep) of_26\IN\0|marked_19 (l_pobj) turnover_28\NN\13819207|NONE_0
D002117_D001851 CID calcitriol_0\NNP\0|NONE_0 (r_compound) therapy_1\NN\657604|levels_25|in_61|but_92|has_96|._226 (r_nsubj) suppresses_2\VBZ\2510337|NONE_0 (l_conj) has_17\VBZ\13888491|therapy_96|levels_71|in_35|but_4|._130 (l_dobj) drawbacks_19\NNS\5161614|NONE_0 (l_prep) including_21\VBG\0|several_19|,_2 (l_pobj) hypercalcemia_22\NN\14299637|NONE_0 (l_conj) suppression_25\NN\13489037|and/or_14 (l_prep) of_26\IN\0|marked_19 (l_pobj) turnover_28\NN\13819207|NONE_0 (l_relcl) lead_32\VB\5155821|bone_25|,_12 (l_prep) to_33\IN\0|which_15|may_9 (l_pobj) disease_36\NN\14061805|NONE_0
D002117_D006934 CID calcitriol_0\NNP\0|NONE_0 (r_compound) therapy_1\NN\657604|levels_25|in_61|but_92|has_96|._226 (r_nsubj) suppresses_2\VBZ\2510337|NONE_0 (l_conj) has_17\VBZ\13888491|therapy_96|levels_71|in_35|but_4|._130 (l_dobj) drawbacks_19\NNS\5161614|NONE_0 (l_prep) including_21\VBG\0|several_19|,_2 (l_pobj) hypercalcemia_22\NN\14299637|NONE_0
C051883_D001851 NONE 22-oxacalcitriol_0\JJ\0|hyperparathyroidism_38|without_58|._119 (r_nsubj) suppresses_1\VBZ\2510337|NONE_0 (l_prep) without_4\IN\0|22-oxacalcitriol_58|hyperparathyroidism_20|._61 (l_pcomp) inducing_5\VBG\42311|NONE_0 (l_dobj) turnover_8\NN\13819207|NONE_0
C051883_D001851 NONE oct_6\NNP\15209706|even_12|though_7|does_4|not_9|completely_13|occurrence_36 (r_nsubj) prevent_10\VB\0|that_41|,_85|it_87|may_90|of_97|in_104|induce_175 (r_advcl) be_24\VB\14625458|results_152|._173 (l_advcl) induce_37\VB\1627355|that_216|prevent_175|,_90|it_88|may_85|of_78|in_71 (l_dobj) turnover_40\NN\13819207|because_36|it_28|does_25|not_20|and_9|,_12|increase_34
C051883_D001851 NONE oct_6\NNP\15209706|even_12|though_7|does_4|not_9|completely_13|occurrence_36 (r_nsubj) prevent_10\VB\0|that_41|,_85|it_87|may_90|of_97|in_104|induce_175 (r_advcl) be_24\VB\14625458|results_152|._173 (l_advcl) induce_37\VB\1627355|that_216|prevent_175|,_90|it_88|may_85|of_78|in_71 (l_conj) increase_47\VB\13576355|because_70|it_62|does_59|not_54|turnover_34|and_25|,_22 (l_dobj) risk_49\NN\14541044|therefore_33|,_24|does_22|not_17 (l_prep) of_50\IN\0|the_9 (l_pobj) disease_53\NN\14061805|NONE_0
C051883_-1 NONE oct_4\NNP\15209706|in_12|,_2|formation_27|,_72|but_74|alter_100|._132 (r_nsubj) reversed_5\VBD\109660|NONE_0 (l_dobj) formation_8\NN\7938773|in_39|,_29|oct_27|,_45|but_47|alter_73|._105 (l_prep) as_11\IN\14622893|abnormal_30|bone_21|,_7 (l_pobj) osteoid_13\NN\0|such_14
C051883_D006934 CID oct_6\NNP\15209706|even_12|though_7|does_4|not_9|completely_13|occurrence_36 (r_nsubj) prevent_10\VB\0|that_41|,_85|it_87|may_90|of_97|in_104|induce_175 (l_dobj) occurrence_12\NN\29378|even_48|though_43|oct_36|does_32|not_27|completely_23 (l_prep) of_13\IN\0|the_15|in_17 (l_pobj) hypercalcemia_14\NN\14299637|NONE_0
C051883_D005355 NONE oct_4\NNP\15209706|in_12|,_2|formation_27|,_72|but_74|alter_100|._132 (r_nsubj) reversed_5\VBD\109660|NONE_0 (l_dobj) formation_8\NN\7938773|in_39|,_29|oct_27|,_45|but_47|alter_73|._105 (l_prep) as_11\IN\14622893|abnormal_30|bone_21|,_7 (l_pobj) osteoid_13\NN\0|such_14 (l_conj) fibrosis_15\NN\14204950|woven_18|and_4
C051883_D006962 NONE 22-oxacalcitriol_0\JJ\0|hyperparathyroidism_38|without_58|._119 (r_nsubj) suppresses_1\VBZ\2510337|NONE_0 (l_dobj) hyperparathyroidism_3\NN\14059928|22-oxacalcitriol_38|without_20|._81
C051883_D006962 NONE oct_7\NNP\15209706|in_48|,_2|levels_42|during_49|._72 (r_nsubj) stabilized_14\VBD\126264|NONE_0 (l_prep) in_0\IN\13603305|,_46|oct_48|levels_90|during_97|._120 (l_pobj) hyperparathyroidism_5\NN\14059928|NONE_0
C051883_D006962 NONE oct_6\NNP\15209706|even_12|though_7|does_4|not_9|completely_13|occurrence_36 (r_nsubj) prevent_10\VB\0|that_41|,_85|it_87|may_90|of_97|in_104|induce_175 (r_advcl) be_24\VB\14625458|results_152|._173 (l_prep) in_27\IN\13603305|that_145|prevent_104|,_19|it_17|may_14|of_7|induce_71 (l_pobj) management_29\NN\1123598|NONE_0 (l_prep) of_30\IN\0|the_15 (l_pobj) hyperparathyroidism_32\NN\14059928|NONE_0
D002117_D051437 NONE calcitriol_0\NNP\0|NONE_0 (r_compound) therapy_1\NN\657604|levels_25|in_61|but_92|has_96|._226 (r_nsubj) suppresses_2\VBZ\2510337|NONE_0 (l_prep) in_11\IN\13603305|therapy_61|levels_36|but_31|has_35|._165 (l_pobj) patients_12\NNS\9898892|NONE_0 (l_prep) with_13\IN\0|NONE_0 (l_pobj) failure_15\NN\66216|NONE_0
C051883_D051437 NONE 22-oxacalcitriol_0\JJ\0|hyperparathyroidism_38|without_58|._119 (r_nsubj) suppresses_1\VBZ\2510337|NONE_0 (l_prep) without_4\IN\0|22-oxacalcitriol_58|hyperparathyroidism_20|._61 (l_pcomp) inducing_5\VBG\42311|NONE_0 (l_dobj) turnover_8\NN\13819207|NONE_0 (l_prep) in_9\IN\13603305|low_18|bone_14 (l_pobj) dogs_10\NNS\2083346|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) failure_13\NN\66216|NONE_0
C051883_D051437 NONE oct_4\NNP\15209706|in_12|,_2|significantly_4|levels_38|after_50|._92 (r_nsubj) decreased_6\VBD\169651|NONE_0 (l_prep) after_11\IN\0|in_62|,_52|oct_50|significantly_46|levels_12|._42 (l_pobj) induction_13\NN\7450842|soon_15 (l_prep) of_14\IN\0|the_14 (l_pobj) insufficiency_16\NN\14462946|NONE_0
C051883_D051437 NONE oct_6\NNP\15209706|even_12|though_7|does_4|not_9|completely_13|occurrence_36 (r_nsubj) prevent_10\VB\0|that_41|,_85|it_87|may_90|of_97|in_104|induce_175 (l_dobj) occurrence_12\NN\29378|even_48|though_43|oct_36|does_32|not_27|completely_23 (l_prep) in_15\IN\13603305|the_32|of_17 (l_pobj) dogs_17\NNS\2083346|NONE_0 (l_prep) with_18\IN\0|experimental_18 (l_pobj) insufficiency_20\NN\14462946|NONE_0
C051883_D007674 NONE oct_9\NNP\15209706|NONE_0 (r_pobj) of_8\IN\0|the_12|on_7 (r_prep) effects_7\NNS\13245626|to_17 (l_prep) on_10\IN\0|the_19|of_7 (l_pobj) levels_13\NNS\4916342|NONE_0 (l_conj) turnover_16\NN\13819207|serum_26|pth_20|and_9 (l_prep) in_17\IN\13603305|bone_14 (l_pobj) states_18\NNS\8491826|NONE_0 (l_prep) of_19\IN\0|NONE_0 (l_pobj) function_24\NN\13783581|NONE_0
7189975
C004616_D012640 CID chloroprocaine_31\NN\0|the_4 (r_compound) group_32\NN\2137|NONE_0 (r_pobj) of_29\IN\0|57_4 (r_prep) %_28\NN\0|,_29|and_31|in_35 (r_pobj) in_26\IN\13603305|dose_112|fatal_46|in_40|,_2|._68 (r_prep) was_15\VBD\0|NONE_0 (l_nsubj) dose_2\NN\3740161|fatal_66|in_72|,_110|in_112|._180 (l_appos) convulsions_8\NNS\14081375|a_41|cd50_39|of_29|)_26
C004616_D012640 CID chloroprocaine_31\NN\0|the_4 (r_compound) group_32\NN\2137|NONE_0 (r_pobj) of_29\IN\0|57_4 (r_prep) %_28\NN\0|,_29|and_31|in_35 (r_pobj) in_26\IN\13603305|dose_112|fatal_46|in_40|,_2|._68 (r_prep) was_15\VBD\0|NONE_0 (l_prep) in_17\IN\13603305|dose_72|fatal_6|,_38|in_40|._108 (l_pobj) %_19\NN\0|NONE_0 (l_prep) of_20\IN\0|90_4 (l_pobj) seizures_24\NNS\14081375|NONE_0
D002045_D012640 CID bupivacaine_21\NN\0|-_11 (r_npadvmod) induced_23\VBN\1627355|NONE_0 (r_amod) seizures_24\NNS\14081375|NONE_0 (r_pobj) of_20\IN\0|90_4 (r_prep) %_19\NN\0|NONE_0 (r_pobj) in_17\IN\13603305|dose_72|fatal_6|,_38|in_40|._108 (r_prep) was_15\VBD\0|NONE_0 (l_nsubj) dose_2\NN\3740161|fatal_66|in_72|,_110|in_112|._180 (l_appos) convulsions_8\NNS\14081375|a_41|cd50_39|of_29|)_26
D002045_D012640 CID bupivacaine_21\NN\0|-_11 (r_npadvmod) induced_23\VBN\1627355|NONE_0 (r_amod) seizures_24\NNS\14081375|NONE_0
D008012_D012640 CID lidocaine_40\NN\3681148|the_4 (r_compound) group_41\NN\2137|NONE_0 (r_pobj) of_38\IN\0|6_3 (r_prep) %_37\NN\0|NONE_0 (r_pobj) in_35\IN\13603305|%_35|,_6|and_4 (r_conj) in_26\IN\13603305|dose_112|fatal_46|in_40|,_2|._68 (r_prep) was_15\VBD\0|NONE_0 (l_nsubj) dose_2\NN\3740161|fatal_66|in_72|,_110|in_112|._180 (l_appos) convulsions_8\NNS\14081375|a_41|cd50_39|of_29|)_26
D008012_D012640 CID lidocaine_40\NN\3681148|the_4 (r_compound) group_41\NN\2137|NONE_0 (r_pobj) of_38\IN\0|6_3 (r_prep) %_37\NN\0|NONE_0 (r_pobj) in_35\IN\13603305|%_35|,_6|and_4 (r_conj) in_26\IN\13603305|dose_112|fatal_46|in_40|,_2|._68 (r_prep) was_15\VBD\0|NONE_0 (l_prep) in_17\IN\13603305|dose_72|fatal_6|,_38|in_40|._108 (l_pobj) %_19\NN\0|NONE_0 (l_prep) of_20\IN\0|90_4 (l_pobj) seizures_24\NNS\14081375|NONE_0
7724492
D003487_D007674 NONE cyanoacrylate_7\JJ\0|doxorubicin_32|(_20|adriamycin)-loaded_19 (r_compound) nanoparticles_8\NNS\0|NONE_0 (r_pobj) of_3\IN\0|acute_21|renal_15|._62 (r_prep) toxicity_2\NN\13576101|NONE_0
D004317_D005921 NONE doxorubicin_1\NN\2716866|-_11 (r_npadvmod) loaded_3\VBN\452512|NONE_0 (r_amod) nanoparticle_4\NN\0|acute_25|dxnp_14|renal_20 (r_nmod) toxicity_9\NN\13576101|was_9|in_22|._87 (r_nsubjpass) explored_11\VBN\789138|NONE_0 (l_prep) in_12\IN\13603305|toxicity_22|was_13|._65 (l_pobj) rats_15\NNS\2329401|NONE_0 (l_conj) rats_17\NNS\2329401|both_21|normal_16|and_4 (l_prep) with_18\IN\0|NONE_0 (l_pobj) glomerulonephritis_20\NN\14113798|NONE_0
D004317_D005921 NONE dx_10\NNP\0|NONE_0 (r_pobj) given_9\VBN\5892096|5/6_9 (r_prep) rats_8\NNS\2329401|in_57|,_6|within_19|,_32|in_34|._110 (r_nsubj) died_11\VBD\146138|NONE_0 (l_prep) in_0\IN\13603305|,_51|rats_57|within_76|,_89|in_91|._167 (l_pobj) rats_1\NNS\2329401|NONE_0 (l_prep) with_2\IN\0|NONE_0 (l_pobj) glomerulonephritis_5\NN\14113798|NONE_0
D004317_D011507 CID dx_16\NNP\0|NONE_0 (r_pobj) with_15\IN\0|NONE_0 (r_prep) treated_14\VBN\2376958|NONE_0 (r_acl) those_13\DT\0|NONE_0 (r_pobj) in_12\IN\13603305|NONE_0 (r_prep) than_11\IN\0|with_10 (r_prep) treated_8\VBN\2376958|NONE_0 (r_acl) animals_7\NNS\4475|NONE_0 (r_pobj) in_6\IN\13603305|proteinuria_21|._58 (r_prep) appeared_5\VBD\2604760|NONE_0 (l_nsubj) proteinuria_4\NN\14299637|in_21|._79
D004317_D011507 CID doxorubicin_22\NN\2716866|day_34 (r_compound) treatment_23\NN\654885|NONE_0 (r_pobj) after_21\IN\0|NONE_0 (r_prep) prolonged_20\VBN\317700|2_39|more_29|0.001_11|and_4 (r_conj) intense_13\JJ\0|,_78|without_80 (r_acomp) was_7\VBD\0|proteinuria_40|in_19|,_6|but_4|._149 (r_conj) appeared_1\VBD\2604760|NONE_0 (l_nsubj) proteinuria_0\NNP\14299637|in_21|,_34|but_36|was_40|._189
D004317_D011507 CID dx_39\NNP\0|and_4 (r_conj) dxnp_37\NNP\0|NONE_0 (r_pobj) between_36\IN\0|significant_23 (r_prep) difference_35\NN\4723816|NONE_0 (r_pobj) without_33\IN\0|intense_80|,_2 (r_prep) was_7\VBD\0|proteinuria_40|in_19|,_6|but_4|._149 (r_conj) appeared_1\VBD\2604760|NONE_0 (l_nsubj) proteinuria_0\NNP\14299637|in_21|,_34|but_36|was_40|._189
D004317_D007674 NONE doxorubicin_4\NN\2716866|(_12|adriamycin)-loaded_13|cyanoacrylate_32 (r_nmod) nanoparticles_8\NNS\0|NONE_0 (r_pobj) of_3\IN\0|acute_21|renal_15|._62 (r_prep) toxicity_2\NN\13576101|NONE_0
D004317_D007674 NONE adriamycin)-loaded_6\VBN\0|doxorubicin_13|(_1|cyanoacrylate_19 (r_amod) nanoparticles_8\NNS\0|NONE_0 (r_pobj) of_3\IN\0|acute_21|renal_15|._62 (r_prep) toxicity_2\NN\13576101|NONE_0
D004317_D007674 NONE doxorubicin_1\NN\2716866|-_11 (r_npadvmod) loaded_3\VBN\452512|NONE_0 (r_amod) nanoparticle_4\NN\0|acute_25|dxnp_14|renal_20 (r_nmod) toxicity_9\NN\13576101|was_9|in_22|._87
D004317_D007674 NONE dx_16\NNP\0|NONE_0 (r_pobj) than_14\IN\0|less_13 (r_prep) animals_13\NNS\4475|that_57|,_53|in_51|,_19|dxnp_17|,_20|despite_22 (r_dobj) killed_11\VBD\0|results_65|._85 (l_prep) despite_18\IN\7501545|that_79|,_75|in_73|,_41|dxnp_39|animals_22|,_2 (l_prep) of_19\IN\0|NONE_0 (l_pobj) toxicity_23\NN\13576101|NONE_0
15565293
D004977_D051437 NONE emb_7\NNP\0|-_3 (r_npadvmod) induced_9\VBN\1627355|optic_8 (r_amod) neuropathy_11\NN\14204950|NONE_0 (r_pobj) of_6\IN\0|NONE_0 (r_prep) management_5\NN\1123598|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) terms_3\NNS\13945919|NONE_0 (r_pobj) in_2\IN\13603305|additionally_14|,_2|,_54|it_56|important_62|reached_240|._247 (r_prep) is_14\VBZ\0|NONE_0 (l_acomp) important_15\JJ\0|additionally_76|,_64|in_62|,_8|it_6|reached_178|._185 (l_xcomp) manage_18\VB\2524171|NONE_0 (l_dobj) dosing_20\VBG\515154|to_30|properly_27|and_41|achieve_48 (l_prep) in_21\IN\13603305|ethambutol_18 (l_pobj) patients_22\NNS\9898892|NONE_0 (l_prep) with_23\IN\0|NONE_0 (l_pobj) impairment_25\NN\7296428|NONE_0
D004977_D051437 NONE ethambutol_19\NN\0|in_18 (r_amod) dosing_20\VBG\515154|to_30|properly_27|and_41|achieve_48 (l_prep) in_21\IN\13603305|ethambutol_18 (l_pobj) patients_22\NNS\9898892|NONE_0 (l_prep) with_23\IN\0|NONE_0 (l_pobj) impairment_25\NN\7296428|NONE_0
D004977_D014376 NONE ethambutol_0\NNP\0|agent_35|._73 (r_nsubj) is_1\VBZ\0|NONE_0 (l_attr) agent_4\NN\7347|ethambutol_35|._38 (l_acl) used_6\VBD\0|an_33|antimycobacterial_30 (l_xcomp) treat_8\VB\7570720|often_14 (l_dobj) tuberculosis_9\NN\14127211|to_9
D004977_D009901 CID ethambutol_10\NN\0|-_10 (r_advmod) induced_12\VBN\1627355|optic_8 (r_amod) neuropathy_14\NN\14204950|NONE_0
D004977_D009901 CID ethambutol_14\NN\0|-_10 (r_advmod) induced_16\VBN\1627355|optic_8 (r_amod) neuropathy_18\NN\14204950|NONE_0
D004977_D009901 CID ethambutol_4\NN\0|NONE_0 (r_pobj) of_3\IN\0|a_23|serious_21 (r_prep) complication_2\NN\1073995|neuropathy_39|._116 (r_nsubj) is_5\VBZ\0|NONE_0 (l_attr) neuropathy_8\NN\14204950|complication_39|._77
D004977_D009901 CID ethambutol_6\NN\0|(_11|optic_25|of_42|,_66|and_68 (r_amod) neuropathy_10\NN\14204950|NONE_0
D004977_D009901 CID emb)-induced_8\VBN\0|NONE_0 (r_amod) optic_9\JJ\5299178|ethambutol_25|(_14|of_17|,_41|and_43 (r_compound) neuropathy_10\NN\14204950|NONE_0
D004977_D009901 CID emb_6\NNP\0|-_3 (r_npadvmod) induced_8\VBN\1627355|optic_8 (r_amod) neuropathy_10\NN\14204950|NONE_0
D004977_D009901 CID emb_7\NNP\0|-_3 (r_npadvmod) induced_9\VBN\1627355|optic_8 (r_amod) neuropathy_11\NN\14204950|NONE_0
D004977_D009901 CID emb_7\NNP\0|-_3 (r_npadvmod) induced_9\VBN\1627355|optic_8 (r_amod) neuropathy_11\NN\14204950|NONE_0
D004977_D009901 CID ethambutol_19\NN\0|in_18 (r_amod) dosing_20\VBG\515154|to_30|properly_27|and_41|achieve_48 (r_dobj) manage_18\VB\2524171|NONE_0 (r_xcomp) important_15\JJ\0|additionally_76|,_64|in_62|,_8|it_6|reached_178|._185 (r_acomp) is_14\VBZ\0|NONE_0 (l_prep) in_2\IN\13603305|additionally_14|,_2|,_54|it_56|important_62|reached_240|._247 (l_pobj) terms_3\NNS\13945919|NONE_0 (l_prep) of_4\IN\0|NONE_0 (l_pobj) management_5\NN\1123598|NONE_0 (l_prep) of_6\IN\0|NONE_0 (l_pobj) neuropathy_11\NN\14204950|NONE_0
D004977_D009410 NONE ethambutol_14\NN\0|-_10 (r_advmod) induced_16\VBN\1627355|optic_8 (r_amod) neuropathy_18\NN\14204950|NONE_0 (r_pobj) in_13\IN\13603305|axonal_20|using_39 (r_prep) degeneration_12\NN\29677|NONE_0
D004977_D014786 CID ethambutol_6\NN\0|(_11|optic_25|of_42|,_66|and_68 (r_amod) neuropathy_10\NN\14204950|NONE_0 (r_pobj) of_5\IN\0|a_10 (r_prep) history_4\NN\15120823|NONE_0 (r_pobj) with_2\IN\0|three_15 (r_prep) subjects_1\NNS\6598915|deficits_116|were_125|examination_171|._266 (r_nsubjpass) administered_23\VBN\2436349|NONE_0 (l_nsubjpass) deficits_21\NNS\5113133|subjects_116|were_9|examination_55|._150
D004977_D014786 CID emb)-induced_8\VBN\0|NONE_0 (r_amod) optic_9\JJ\5299178|ethambutol_25|(_14|of_17|,_41|and_43 (r_compound) neuropathy_10\NN\14204950|NONE_0 (r_pobj) of_5\IN\0|a_10 (r_prep) history_4\NN\15120823|NONE_0 (r_pobj) with_2\IN\0|three_15 (r_prep) subjects_1\NNS\6598915|deficits_116|were_125|examination_171|._266 (r_nsubjpass) administered_23\VBN\2436349|NONE_0 (l_nsubjpass) deficits_21\NNS\5113133|subjects_116|were_9|examination_55|._150
D004977_D014786 CID emb_6\NNP\0|-_3 (r_npadvmod) induced_8\VBN\1627355|optic_8 (r_amod) neuropathy_10\NN\14204950|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) history_4\NN\15120823|NONE_0 (r_pobj) with_3\IN\0|all_13 (r_prep) subjects_2\NNS\6598915|NONE_0 (r_pobj) in_0\IN\13603305|,_60|there_62|loss_79|,_324|with_326|._386 (r_prep) was_13\VBD\0|NONE_0 (l_attr) loss_16\NN\13252973|in_79|,_19|there_17|,_245|with_247|._307 (l_prep) with_32\IN\0|a_84|mean_82|of_72|in_37|,_106|loss_112|)_167 (l_pobj) recovery_34\NN\7357388|NONE_0 (l_prep) with_48\IN\0|eventual_68|of_50 (l_pobj) deficits_51\NNS\5113133|NONE_0
D004977_D014786 CID emb_6\NNP\0|-_3 (r_npadvmod) induced_8\VBN\1627355|optic_8 (r_amod) neuropathy_10\NN\14204950|NONE_0 (r_pobj) of_5\IN\0|NONE_0 (r_prep) history_4\NN\15120823|NONE_0 (r_pobj) with_3\IN\0|all_13 (r_prep) subjects_2\NNS\6598915|NONE_0 (r_pobj) in_0\IN\13603305|,_60|there_62|loss_79|,_324|with_326|._386 (r_prep) was_13\VBD\0|NONE_0 (l_attr) loss_16\NN\13252973|in_79|,_19|there_17|,_245|with_247|._307 (l_conj) loss_55\NN\13252973|a_196|mean_194|of_184|in_149|with_112|,_6|)_55 (l_conj) c_58\NN\13714184|%_16|;_10 (l_prep) with_60\IN\0|patient_11|,_2|,_28|loss_34 (l_pobj) deficits_63\NNS\5113133|NONE_0
17074608
D014635_D002819 CID valproate_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|and_15|encephalopathy_19|._72 (r_amod) chorea_3\NN\14253124|NONE_0
D014635_D002819 CID valproate_32\NN\0|NONE_0 (r_amod) therapy_33\NN\657604|NONE_0 (r_pobj) of_31\IN\0|NONE_0 (r_prep) initiation_30\NN\7450842|shortly_14 (r_pobj) after_29\IN\0|her_62|with_45 (r_prep) presentation_22\NN\1027379|NONE_0 (l_prep) with_23\IN\0|her_17|after_45 (l_pobj) encephalopathy_25\NN\14084880|NONE_0 (l_conj) chorea_27\NN\14253124|acute_25|and_4
D005998_D000592 NONE glycine_15\NN\14601829|the_4|cleavage_8 (r_compound) system_17\NN\3575240|NONE_0 (r_pobj) in_13\IN\13603305|a_9 (r_prep) defect_12\NN\14462666|in_11|to_44 (r_nsubj) leads_18\VBZ\5155821|acid_65 (r_relcl) metabolism_8\NN\13526110|NONE_0
D005998_D000592 NONE glycine_23\NN\14601829|NONE_0 (r_pobj) of_22\IN\0|an_16|in_11 (r_prep) accumulation_21\NN\13497135|NONE_0 (r_pobj) to_19\IN\0|in_55|defect_44 (r_prep) leads_18\VBZ\5155821|acid_65 (r_relcl) metabolism_8\NN\13526110|NONE_0
D005998_D020158 NONE glycine_15\NN\14601829|the_4|cleavage_8 (r_compound) system_17\NN\3575240|NONE_0 (r_pobj) in_13\IN\13603305|a_9 (r_prep) defect_12\NN\14462666|in_11|to_44 (r_nsubj) leads_18\VBZ\5155821|acid_65 (r_relcl) metabolism_8\NN\13526110|NONE_0 (r_pobj) of_5\IN\0|a_11 (r_prep) disorder_4\NN\14034177|hyperglycinemia_21|._159 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) hyperglycinemia_1\NN\0|disorder_21|._180
D005998_D020158 NONE glycine_23\NN\14601829|NONE_0 (r_pobj) of_22\IN\0|an_16|in_11 (r_prep) accumulation_21\NN\13497135|NONE_0 (r_pobj) to_19\IN\0|in_55|defect_44 (r_prep) leads_18\VBZ\5155821|acid_65 (r_relcl) metabolism_8\NN\13526110|NONE_0 (r_pobj) of_5\IN\0|a_11 (r_prep) disorder_4\NN\14034177|hyperglycinemia_21|._159 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) hyperglycinemia_1\NN\0|disorder_21|._180
D014635_D020158 NONE valproate_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|and_15|encephalopathy_19|._72 (r_amod) chorea_3\NN\14253124|NONE_0 (l_conj) encephalopathy_5\JJ\14084880|induced_19|and_4|._53 (l_prep) in_6\IN\13603305|NONE_0 (l_pobj) hyperglycinemia_9\NN\0|NONE_0
D014635_D020158 NONE valproate_32\NN\0|NONE_0 (r_amod) therapy_33\NN\657604|NONE_0 (r_pobj) of_31\IN\0|NONE_0 (r_prep) initiation_30\NN\7450842|shortly_14 (r_pobj) after_29\IN\0|her_62|with_45 (r_prep) presentation_22\NN\1027379|NONE_0 (r_pobj) following_20\VBG\8180190|who_49|was_45|have_32 (r_prep) found_15\VBN\13279262|mild_52|language_47|and_32|retardation_21|,_10 (l_xcomp) have_17\VB\7846|who_17|was_13|following_32 (l_dobj) hyperglycinemia_19\NN\0|to_19
D014635_D001927 CID valproate_0\NNP\0|-_9 (r_npadvmod) induced_2\VBN\1627355|and_15|encephalopathy_19|._72 (r_amod) chorea_3\NN\14253124|NONE_0 (l_conj) encephalopathy_5\JJ\14084880|induced_19|and_4|._53
D014635_D001927 CID valproate_32\NN\0|NONE_0 (r_amod) therapy_33\NN\657604|NONE_0 (r_pobj) of_31\IN\0|NONE_0 (r_prep) initiation_30\NN\7450842|shortly_14 (r_pobj) after_29\IN\0|her_62|with_45 (r_prep) presentation_22\NN\1027379|NONE_0 (l_prep) with_23\IN\0|her_17|after_45 (l_pobj) encephalopathy_25\NN\14084880|NONE_0
D014635_D008607 NONE valproate_32\NN\0|NONE_0 (r_amod) therapy_33\NN\657604|NONE_0 (r_pobj) of_31\IN\0|NONE_0 (r_prep) initiation_30\NN\7450842|shortly_14 (r_pobj) after_29\IN\0|her_62|with_45 (r_prep) presentation_22\NN\1027379|NONE_0 (r_pobj) following_20\VBG\8180190|who_49|was_45|have_32 (r_prep) found_15\VBN\13279262|mild_52|language_47|and_32|retardation_21|,_10 (r_relcl) delay_8\NN\15271008|NONE_0 (l_conj) retardation_11\NN\7296428|mild_31|language_26|and_11|,_11|found_21
D014635_D007805 NONE valproate_32\NN\0|NONE_0 (r_amod) therapy_33\NN\657604|NONE_0 (r_pobj) of_31\IN\0|NONE_0 (r_prep) initiation_30\NN\7450842|shortly_14 (r_pobj) after_29\IN\0|her_62|with_45 (r_prep) presentation_22\NN\1027379|NONE_0 (r_pobj) following_20\VBG\8180190|who_49|was_45|have_32 (r_prep) found_15\VBN\13279262|mild_52|language_47|and_32|retardation_21|,_10 (r_relcl) delay_8\NN\15271008|NONE_0
15580403
D012254_D019698 NONE ribavirin_3\JJ\2725367|in_20 (r_compound) reduction_4\NN\351485|NONE_0 (l_prep) in_5\IN\13603305|ribavirin_20 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|NONE_0 (l_pobj) hemolysis_8\NN\13509528|NONE_0 (l_prep) during_9\IN\0|NONE_0 (l_pobj) therapy_11\NN\657604|NONE_0 (l_prep) for_16\IN\0|combination_48|of_28 (l_pobj) c._19\NNP\0|NONE_0
D012254_D019698 NONE ribavirin_15\RB\2725367|and_4 (r_conj) interferon_13\NN\2725367|NONE_0 (r_pobj) of_12\IN\0|combination_20|for_28 (r_prep) therapy_11\NN\657604|NONE_0 (l_prep) for_16\IN\0|combination_48|of_28 (l_pobj) c._19\NNP\0|NONE_0
D007372_D000743 CID interferon_14\NN\2725367|NONE_0 (r_pobj) of_13\IN\0|the_24|combination_20 (r_prep) therapy_12\NN\657604|NONE_0 (r_pobj) of_9\IN\0|the_25|major_21|adverse_15 (r_prep) events_8\NNS\23100|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) one_3\CD\13741022|anemia_10|._86 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) anemia_1\NN\14189204|one_10|._96
D012254_D000740 NONE ribavirin_9\NN\2725367|NONE_0 (r_pobj) of_8\IN\0|NONE_0 (r_prep) reduction_7\NN\351485|NONE_0 (r_pobj) with_6\IN\0|37_12 (r_prep) patients_5\NNS\9898892|however_18|,_11|could_37|not_43|therapy_68|decreased_118|._187 (r_nsubj) continue_12\VB\2367363|NONE_0 (l_advcl) decreased_24\VBD\169651|however_136|,_129|patients_118|could_81|not_75|therapy_50|._69 (l_conj) occurred_33\VBD\0|because_93|values_58|to_41|or_38 (l_nsubj) effects_32\NNS\13245626|b_24|)_25 (l_amod) related_29\VBN\628491|severe_8|side_15 (l_npadvmod) anemia_27\NN\14189204|-_6
D007372_D019698 NONE interferon_13\NN\2725367|NONE_0 (r_pobj) of_12\IN\0|combination_20|for_28 (r_prep) therapy_11\NN\657604|NONE_0 (l_prep) for_16\IN\0|combination_48|of_28 (l_pobj) c._19\NNP\0|NONE_0
D007372_D006461 NONE interferon_13\NN\2725367|NONE_0 (r_pobj) of_12\IN\0|combination_20|for_28 (r_prep) therapy_11\NN\657604|NONE_0 (r_pobj) during_9\IN\0|NONE_0 (r_prep) hemolysis_8\NN\13509528|NONE_0
D012254_D006461 NONE ribavirin_3\JJ\2725367|in_20 (r_compound) reduction_4\NN\351485|NONE_0 (l_prep) in_5\IN\13603305|ribavirin_20 (l_pobj) patients_6\NNS\9898892|NONE_0 (l_prep) with_7\IN\0|NONE_0 (l_pobj) hemolysis_8\NN\13509528|NONE_0
D012254_D006461 NONE ribavirin_15\RB\2725367|and_4 (r_conj) interferon_13\NN\2725367|NONE_0 (r_pobj) of_12\IN\0|combination_20|for_28 (r_prep) therapy_11\NN\657604|NONE_0 (r_pobj) during_9\IN\0|NONE_0 (r_prep) hemolysis_8\NN\13509528|NONE_0
D012254_D006461 NONE ribavirin_13\JJ\2725367|in_20 (r_compound) reduction_14\NN\351485|NONE_0 (l_prep) in_15\IN\13603305|ribavirin_20 (l_pobj) patients_16\NNS\9898892|NONE_0 (l_prep) with_17\IN\0|NONE_0 (l_pobj) hemolysis_18\NN\13509528|NONE_0
D012254_D000743 CID ribavirin_16\NN\2725367|and_4 (r_conj) interferon_14\NN\2725367|NONE_0 (r_pobj) of_13\IN\0|the_24|combination_20 (r_prep) therapy_12\NN\657604|NONE_0 (r_pobj) of_9\IN\0|the_25|major_21|adverse_15 (r_prep) events_8\NNS\23100|NONE_0 (r_pobj) of_4\IN\0|NONE_0 (r_prep) one_3\CD\13741022|anemia_10|._86 (r_attr) is_2\VBZ\0|NONE_0 (l_nsubj) anemia_1\NN\14189204|one_10|._96
D012254_D000743 CID ribavirin_2\RB\2725367|-_9 (r_npadvmod) related_4\VBN\628491|hemolytic_8 (r_amod) anemia_6\NN\14189204|of_31
12600698
D013307_D015837 CID streptomycin_5\NN\2716866|-_12 (r_npadvmod) induced_7\VBN\1627355|in_26 (r_amod) vestibulotoxicity_8\NN\0|NONE_0
D013307_D015837 CID streptomycin_5\NNS\2716866|-_12 (r_npadvmod) induced_7\VBN\1627355|NONE_0 (r_amod) vestibulotoxicity_8\NN\0|NONE_0
D013307_D015837 CID streptomycin_6\NN\2716866|-_12 (r_npadvmod) induced_8\VBN\1627355|NONE_0 (r_amod) vestibulotoxicity_9\NN\0|that_47|edaravone_42
C005435_D015837 NONE edaravone_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|protective_18|against_13|._77 (r_prep) effect_1\NN\34213|NONE_0 (l_prep) against_4\IN\0|protective_31|of_13|._64 (l_pobj) vestibulotoxicity_8\NN\0|NONE_0
C005435_D015837 NONE edaravone_10\NN\0|NONE_0 (r_pobj) by_9\IN\0|of_42|in_13 (r_prep) alleviation_3\NN\7492516|study_19|._81 (l_prep) of_4\IN\0|by_42|in_55 (l_pobj) vestibulotoxicity_8\NN\0|NONE_0
C005435_D015837 NONE edaravone_4\NN\0|that_5|vestibulotoxicity_42 (r_nsubj) suppresses_5\VBZ\2510337|results_31|._49 (l_dobj) vestibulotoxicity_9\NN\0|that_47|edaravone_42
C005435_D002544 NONE edaravone_0\NNP\0|action_71|and_78|used_85|._139 (r_nsubj) has_7\VBZ\13888491|NONE_0 (l_conj) used_15\VBN\0|edaravone_85|action_14|and_7|._54 (l_xcomp) treat_20\VB\7570720|is_32|in_24 (l_dobj) infarction_22\NN\14204950|to_18
18541230
D011692_D006402 NONE aminonucleoside_6\NN\0|-_15 (r_advmod) induced_8\VBN\1627355|hematological_8 (r_amod) abnormalities_10\NNS\14034177|treatment_91|puromycin_48|._13
D011692_D009404 NONE aminonucleoside_18\RB\0|-_15 (r_advmod) induced_20\VBN\1627355|puromycin_26|,_17|is_25 (r_amod) nephrosis_21\NN\14304060|NONE_0 (l_relcl) is_24\VBZ\0|puromycin_51|induced_25|,_8 (l_attr) model_27\NN\5888929|which_25 (l_prep) of_28\IN\0|an_22|experimental_19 (l_pobj) syndrome_31\NN\5870365|NONE_0
D011692_D009404 NONE aminonucleoside_14\RB\0|-_15 (r_advmod) induced_16\VBN\1627355|puromycin_26|nephrotic_8 (r_amod) syndrome_18\NN\5870365|NONE_0
D011692_D009401 CID aminonucleoside_6\JJ\0|in_26 (r_amod) nephrosis_7\NN\14304060|puromycin_26
D011692_D009401 CID aminonucleoside_18\RB\0|-_15 (r_advmod) induced_20\VBN\1627355|puromycin_26|,_17|is_25 (r_amod) nephrosis_21\NN\14304060|NONE_0
D011692_D006949 NONE aminonucleoside_1\RB\0|-_15 (r_advmod) induced_3\VBN\1627355|puromycin_26|renal_8|and_26|hyperlipidemia_30 (r_amod) dysfunction_5\NN\14204950|were_31|also_36|._51 (l_conj) hyperlipidemia_7\NN\14299637|puromycin_56|induced_30|renal_22|and_4
D011692_D007674 NONE aminonucleoside_1\RB\0|-_15 (r_advmod) induced_3\VBN\1627355|puromycin_26|renal_8|and_26|hyperlipidemia_30 (r_amod) dysfunction_5\NN\14204950|were_31|also_36|._51
48362
D011802_D056486 CID quinidine_0\NN\2715941|._19 (r_compound) hepatitis_1\NN\14127211|NONE_0
D011802_D056486 CID quinidine_6\VBN\2715941|NONE_0 (r_poss) hepatotoxicity_7\NN\0|that_32|patient_22|and_15|believe_19
17263743
D003000_D001008 NONE clonidine_16\NN\2721160|NONE_0 (r_pobj) of_15\IN\0|three_12 (r_prep) doses_14\NNS\3740161|without_88|,_42|mother_26|during_19|before_38|reduce_71|._85 (r_dobj) administered_12\VBD\2436349|NONE_0 (l_advcl) reduce_26\VB\441445|without_159|,_113|mother_97|doses_71|during_52|before_33|._14 (l_dobj) anxiety_27\NN\14373582|to_10
D003000_D004827 NONE clonidine_18\NN\2721160|for_10 (r_dobj) receiving_17\VBG\2210855|we_82|case_69|,_2|._84 (r_advcl) present_1\VBP\28270|NONE_0 (l_dobj) case_3\NN\7283608|we_13|,_67|receiving_69|._153 (l_prep) of_4\IN\0|a_7 (l_pobj) child_9\NN\9622049|NONE_0 (l_prep) with_10\IN\0|a_19|old_10 (l_pobj) disorder_15\NN\14034177|NONE_0
D001418_D002547 NONE baclofen_28\JJ\0|a_2 (r_compound) pump_29\NN\3736970|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) placement_25\NN\5074774|NONE_0 (r_pobj) for_24\IN\0|who_14 (r_prep) presented_23\VBD\2137132|,_6 (r_relcl) restlessness_20\NN\4773351|NONE_0 (r_pobj) for_19\IN\0|clonidine_10 (r_prep) receiving_17\VBG\2210855|we_82|case_69|,_2|._84 (r_advcl) present_1\VBP\28270|NONE_0 (l_dobj) case_3\NN\7283608|we_13|,_67|receiving_69|._153 (l_prep) of_4\IN\0|a_7 (l_pobj) child_9\NN\9622049|NONE_0 (l_prep) with_10\IN\0|a_19|old_10 (l_pobj) disorder_15\NN\14034177|NONE_0 (l_nmod) palsy_12\JJ\14557898|seizure_10
C009250_D006323 NONE sevoflurane_9\NN\0|of_22 (r_amod) induction_10\NN\7450842|NONE_0 (r_dobj) undergoing_8\VBG\109660|cardiac_46|in_31|._75 (r_acl) arrest_1\NN\88481|NONE_0
D003000_D011595 NONE clonidine_18\NN\2721160|for_10 (r_dobj) receiving_17\VBG\2210855|we_82|case_69|,_2|._84 (l_prep) for_19\IN\0|clonidine_10 (l_pobj) restlessness_20\NN\4773351|NONE_0
D003000_D006323 CID clonidine_15\NN\2721160|NONE_0 (r_pobj) after_13\IN\0|NONE_0 (r_prep) anesthesia_12\NN\14034177|NONE_0 (r_pobj) of_11\IN\0|sevoflurane_22 (r_prep) induction_10\NN\7450842|NONE_0 (r_dobj) undergoing_8\VBG\109660|cardiac_46|in_31|._75 (r_acl) arrest_1\NN\88481|NONE_0
D003000_D006323 CID clonidine_6\NN\2721160|-_9 (r_npadvmod) associated_8\VBN\628491|cardiac_11|in_26 (r_amod) arrest_10\NN\88481|NONE_0
C009250_D002547 NONE sevoflurane_9\NN\0|of_22 (r_amod) induction_10\NN\7450842|NONE_0 (r_dobj) undergoing_8\VBG\109660|cardiac_46|in_31|._75 (r_acl) arrest_1\NN\88481|NONE_0 (l_prep) in_2\IN\13603305|cardiac_15|undergoing_31|._106 (l_pobj) child_4\NN\9622049|NONE_0 (l_prep) with_5\IN\0|a_8 (l_pobj) palsy_7\JJ\14557898|NONE_0
D003000_D002547 NONE clonidine_15\NN\2721160|NONE_0 (r_pobj) after_13\IN\0|NONE_0 (r_prep) anesthesia_12\NN\14034177|NONE_0 (r_pobj) of_11\IN\0|sevoflurane_22 (r_prep) induction_10\NN\7450842|NONE_0 (r_dobj) undergoing_8\VBG\109660|cardiac_46|in_31|._75 (r_acl) arrest_1\NN\88481|NONE_0 (l_prep) in_2\IN\13603305|cardiac_15|undergoing_31|._106 (l_pobj) child_4\NN\9622049|NONE_0 (l_prep) with_5\IN\0|a_8 (l_pobj) palsy_7\JJ\14557898|NONE_0
D003000_D002547 NONE clonidine_18\NN\2721160|for_10 (r_dobj) receiving_17\VBG\2210855|we_82|case_69|,_2|._84 (r_advcl) present_1\VBP\28270|NONE_0 (l_dobj) case_3\NN\7283608|we_13|,_67|receiving_69|._153 (l_prep) of_4\IN\0|a_7 (l_pobj) child_9\NN\9622049|NONE_0 (l_prep) with_10\IN\0|a_19|old_10 (l_pobj) disorder_15\NN\14034177|NONE_0 (l_nmod) palsy_12\JJ\14557898|seizure_10
D001418_D011595 NONE baclofen_28\JJ\0|a_2 (r_compound) pump_29\NN\3736970|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) placement_25\NN\5074774|NONE_0 (r_pobj) for_24\IN\0|who_14 (r_prep) presented_23\VBD\2137132|,_6 (r_relcl) restlessness_20\NN\4773351|NONE_0
D001418_D004827 NONE baclofen_28\JJ\0|a_2 (r_compound) pump_29\NN\3736970|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) placement_25\NN\5074774|NONE_0 (r_pobj) for_24\IN\0|who_14 (r_prep) presented_23\VBD\2137132|,_6 (r_relcl) restlessness_20\NN\4773351|NONE_0 (r_pobj) for_19\IN\0|clonidine_10 (r_prep) receiving_17\VBG\2210855|we_82|case_69|,_2|._84 (r_advcl) present_1\VBP\28270|NONE_0 (l_dobj) case_3\NN\7283608|we_13|,_67|receiving_69|._153 (l_prep) of_4\IN\0|a_7 (l_pobj) child_9\NN\9622049|NONE_0 (l_prep) with_10\IN\0|a_19|old_10 (l_pobj) disorder_15\NN\14034177|NONE_0
10910842
D011239_D009468 NONE prednisolone_8\NN\2721538|NONE_0 (r_pobj) after_7\IN\0|the_30|neuromuscular_26 (r_prep) dysfunction_6\NN\14204950|that_23|dependent_39|,_48|and_50|derives_54
D000109_D009133 NONE acetylcholine_22\NN\14807558|receptor_14 (r_compound) expression_24\NN\4679549|NONE_0 (r_pobj) in_21\IN\13603305|NONE_0 (r_prep) changes_20\NNS\7283608|NONE_0 (r_pobj) from_19\IN\0|NONE_0 (r_prep) less_18\JJR\14187378|NONE_0 (r_advmod) derive_17\VB\634472|primarily_34|from_24|and_4 (r_conj) derive_11\VBP\634472|that_49|effects_31|dependent_14|and_4 (l_prep) from_13\IN\0|primarily_10|and_20|derive_24 (l_pobj) atrophy_15\NN\14299637|NONE_0
D011239_D009133 CID prednisolone_8\NN\2721538|NONE_0 (r_pobj) after_7\IN\0|the_30|neuromuscular_26 (r_prep) dysfunction_6\NN\14204950|that_23|dependent_39|,_48|and_50|derives_54 (r_nsubj) is_9\VBZ\0|results_70|._112 (l_conj) derives_15\VBZ\634472|that_77|dysfunction_54|dependent_15|,_6|and_4 (l_prep) from_17\IN\0|primarily_10|and_20|derives_24 (l_pobj) atrophy_19\NN\14299637|NONE_0
D000109_D001284 NONE acetylcholine_13\NN\14807558|altered_8|receptor_14 (r_compound) expression_15\NN\4679549|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_prep) than_10\IN\0|NONE_0 (r_prep) atrophy_9\NN\14299637|NONE_0
D014403_D013746 NONE tubocurarine_27\NN\14712692|NONE_0 (r_pobj) of_24\IN\0|the_25|response_16|in_18 (r_prep) curves_23\NNS\13863771|,_24|and_22 (r_conj) fatigability_16\NN\5040275|tetanic_22|,_6|and_4 (r_conj) tensions_13\NNS\14375890|the_47|evoked_37|peak_30|twitch_25|,_10 (l_compound) tetanic_12\JJ\0|,_16|and_18|fatigability_22
D011239_D018908 CID prednisolone_0\NNP\2721538|-_12 (r_npadvmod) induced_2\VBN\1627355|muscle_8 (r_amod) dysfunction_4\NN\14204950|is_12|more_22|by_27|._87
D000109_D018908 NONE acetylcholine_13\NN\14807558|altered_8|receptor_14 (r_compound) expression_15\NN\4679549|NONE_0 (r_pobj) by_11\IN\0|NONE_0 (r_prep) than_10\IN\0|NONE_0 (r_prep) atrophy_9\NN\14299637|NONE_0 (r_pobj) by_8\IN\0|dysfunction_27|is_15|more_5|._60 (r_agent) caused_6\VBN\1617192|NONE_0 (l_nsubjpass) dysfunction_4\NN\14204950|is_12|more_22|by_27|._87
D011239_D001284 NONE prednisolone_0\NNP\2721538|-_12 (r_npadvmod) induced_2\VBN\1627355|muscle_8 (r_amod) dysfunction_4\NN\14204950|is_12|more_22|by_27|._87 (r_nsubjpass) caused_6\VBN\1617192|NONE_0 (l_agent) by_8\IN\0|dysfunction_27|is_15|more_5|._60 (l_pobj) atrophy_9\NN\14299637|NONE_0
2750819
D008278_D020879 CID sulfate_4\NN\15010703|NONE_0 (r_pobj) with_2\IN\0|neuromuscular_23|._37 (r_prep) blockade_1\NN\952963|NONE_0
D008278_D020879 CID sulfate_15\NN\15010703|NONE_0 (r_pobj) of_13\IN\0|500_7 (r_prep) mg_12\NN\13717155|patient_90|after_10|was_24|._40 (r_nsubjpass) administered_17\VBN\2436349|NONE_0 (l_nsubjpass) patient_1\NN\9898892|after_80|mg_90|was_114|._130 (l_relcl) received_3\VBD\2210855|a_14 (l_dobj) tocolysis_4\NN\0|who_13 (l_prep) with_5\IN\0|NONE_0 (l_pobj) blockade_9\NN\952963|NONE_0
D008274_D064420 NONE magnesium_11\NN\14625458|NONE_0 (r_pobj) of_10\IN\0|the_13 (r_prep) toxicity_9\NN\13576101|that_45|nifedipine_40|can_29|seriously_25
D009543_D064420 NONE nifedipine_4\NN\2938514|that_5|can_11|seriously_15|toxicity_40 (r_nsubj) potentiate_7\VB\229605|reaction_52|._36 (l_dobj) toxicity_9\NN\13576101|that_45|nifedipine_40|can_29|seriously_25
D009543_D020879 CID nifedipine_6\NN\2938514|magnesium_22|and_4 (r_conj) sulfate_4\NN\15010703|NONE_0 (r_pobj) with_2\IN\0|neuromuscular_23|._37 (r_prep) blockade_1\NN\952963|NONE_0
D009543_D020879 CID nifedipine_6\NN\2938514|developed_11|neuromuscular_21 (r_nmod) blockade_9\NN\952963|NONE_0
8494478
D002939_D007674 NONE ciprofloxacin_0\NNP\2716866|-_13|nephrotoxicity_22|._60 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) nephrotoxicity_3\NN\0|ciprofloxacin_22|-_9|._38
D002939_D007674 NONE ciprofloxacin_3\NNS\2716866|NONE_0 (r_pobj) with_2\IN\0|NONE_0 (r_prep) associated_1\VBN\628491|NONE_0 (r_acl) nephrotoxicity_0\NN\0|uncommon_48|._56
D002939_D058186 CID ciprofloxacin_13\NNS\2716866|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treatment_11\NN\654885|that_14 (r_dobj) followed_10\VBD\1835496|acute_25|renal_19 (r_relcl) failure_8\NN\66216|who_26
D002939_D058186 CID ciprofloxacin_18\NNS\2716866|-_13 (r_npadvmod) induced_20\VBN\1627355|acute_8|renal_14 (r_amod) failure_23\NN\66216|NONE_0
D002939_D009369 NONE ciprofloxacin_0\NNP\2716866|-_13|nephrotoxicity_22|._60 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) nephrotoxicity_3\NN\0|ciprofloxacin_22|-_9|._38 (l_prep) in_4\IN\13603305|NONE_0 (l_pobj) patients_5\NNS\9898892|NONE_0 (l_prep) with_6\IN\0|NONE_0 (l_pobj) cancer_7\NN\14239425|NONE_0
D002939_D009369 NONE ciprofloxacin_13\NNS\2716866|NONE_0 (r_pobj) with_12\IN\0|NONE_0 (r_prep) treatment_11\NN\654885|that_14 (r_dobj) followed_10\VBD\1835496|acute_25|renal_19 (r_relcl) failure_8\NN\66216|who_26 (r_dobj) developed_5\VBD\1753788|five_30|with_16 (r_relcl) patients_1\NNS\9898892|are_98|and_112|reviewed_170 (l_prep) with_2\IN\0|five_14|developed_16 (l_pobj) cancer_3\NN\14239425|NONE_0
10524660
D005996_D008881 NONE gtn_14\NNP\0|after_6|p=0.037_14|as_31|during_34 (r_compound) infusion_15\NN\14589223|headache_94|severe_76|._67 (r_advcl) was_1\VBD\0|NONE_0 (l_acomp) severe_3\JJ\0|headache_18|infusion_76|._143 (l_prep) in_4\IN\13603305|more_12|than_15 (l_pobj) migraineurs_5\NNS\0|NONE_0
D005996_D008881 NONE gtn_5\NNP\0|-_3 (r_npadvmod) induced_7\VBN\1627355|the_8 (r_amod) headache_8\NN\5829480|in_33|,_18|gradually_9|,_30|peak_55|._127 (r_nsubj) disappeared_10\VBD\0|NONE_0 (l_advcl) peak_15\JJ\13758296|in_88|,_73|headache_55|gradually_46|,_25|._72 (l_prep) in_13\IN\13603305|whereas_8|occurred_39 (l_pobj) migraineurs_14\NNS\0|NONE_0
D009569_D020325 NONE no_5\DT\7204911|that_5|is_3|in_15 (r_nsubjpass) involved_7\VBN\2676054|results_37|therefore_29|._53 (l_prep) in_8\IN\13603305|that_20|no_15|is_12 (l_pobj) mechanisms_11\NNS\13446390|NONE_0 (l_prep) with_14\IN\0|the_32|pain_28|of_12 (l_pobj) aura_15\NN\14299637|NONE_0
D009569_D020325 NONE no_9\DT\7204911|to_12|in_3 (r_intj) liberate_8\VB\146138|since_54|depression_29|has_18|been_14 (r_xcomp) shown_6\VBN\2137132|,_31|finding_38|may_46|understanding_59|._161 (r_advcl) help_16\VB\407535|NONE_0 (l_dobj) understanding_18\NN\5804793|shown_59|,_28|finding_21|may_13|._102 (l_prep) of_19\IN\0|our_18 (l_pobj) coupling_21\NN\3091374|NONE_0 (l_prep) between_22\IN\0|the_13 (l_pobj) depression_25\NN\14373582|NONE_0 (l_conj) headache_27\NN\5829480|cortical_34|spreading_25|and_4 (l_prep) with_30\IN\0|in_12 (l_pobj) aura_31\NN\14299637|NONE_0
D009569_D010146 NONE oxide_13\NN\14818238|that_35|is_11|in_23 (r_nsubjpass) involved_18\VBN\2676054|in_100|,_85|evidence_72|has_63|._52 (l_prep) in_19\IN\13603305|that_58|oxide_23|is_12 (l_pobj) mechanisms_21\NNS\13446390|NONE_0 (l_compound) pain_20\NN\14299637|of_16|without_28
D009569_D010146 NONE no_15\NNP\7204911|the_37|molecule_23|nitric_14|(_1|)_2 (r_appos) oxide_13\NN\14818238|that_35|is_11|in_23 (r_nsubjpass) involved_18\VBN\2676054|in_100|,_85|evidence_72|has_63|._52 (l_prep) in_19\IN\13603305|that_58|oxide_23|is_12 (l_pobj) mechanisms_21\NNS\13446390|NONE_0 (l_compound) pain_20\NN\14299637|of_16|without_28
D009569_D010146 NONE no_5\DT\7204911|that_5|is_3|in_15 (r_nsubjpass) involved_7\VBN\2676054|results_37|therefore_29|._53 (l_prep) in_8\IN\13603305|that_20|no_15|is_12 (l_pobj) mechanisms_11\NNS\13446390|NONE_0 (l_compound) pain_10\NN\14299637|the_4|of_16|with_28
D005996_D020326 CID trinitrate_1\NN\0|attacks_19|._86 (r_nsubj) induces_2\VBZ\1627355|NONE_0 (l_dobj) attacks_3\NNS\955060|trinitrate_19|._67 (l_prep) without_6\IN\0|of_12 (l_pobj) aura_7\NN\14299637|NONE_0
D005996_D020325 NONE trinitrate_1\NN\0|attacks_19|._86 (r_nsubj) induces_2\VBZ\1627355|NONE_0 (l_dobj) attacks_3\NNS\955060|trinitrate_19|._67 (l_prep) without_6\IN\0|of_12 (l_pobj) aura_7\NN\14299637|NONE_0 (l_prep) in_8\IN\13603305|NONE_0 (l_pobj) sufferers_9\NNS\9630641|NONE_0 (l_prep) with_12\IN\0|of_12 (l_pobj) aura_13\NN\14299637|NONE_0
D005996_D020325 NONE trinitrate_28\NN\0|NONE_0 (r_pobj) of_26\IN\0|intravenous_21 (r_prep) infusion_25\NN\14589223|NONE_0 (r_pobj) to_23\IN\0|the_22|headache_18 (r_prep) response_22\NN\11410625|in_115|,_48|in_46|we_25|min_77|._130 (r_dobj) examined_19\VBD\0|NONE_0 (l_prep) in_0\IN\13603305|,_67|in_69|we_90|response_115|min_192|._245 (l_pobj) order_1\NN\7168131|NONE_0 (l_acl) clarify_3\VB\939277|NONE_0 (l_ccomp) is_7\VBZ\0|to_28 (l_acomp) true_8\JJ\5077146|whether_20|same_8 (l_prep) for_9\IN\0|NONE_0 (l_pobj) migraine_10\NN\14326607|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) aura_12\NN\14299637|NONE_0
D005996_D020325 NONE trinitrate_28\NN\0|NONE_0 (r_pobj) of_26\IN\0|intravenous_21 (r_prep) infusion_25\NN\14589223|NONE_0 (r_pobj) to_23\IN\0|the_22|headache_18 (r_prep) response_22\NN\11410625|in_115|,_48|in_46|we_25|min_77|._130 (r_dobj) examined_19\VBD\0|NONE_0 (l_parataxis) min_38\NN\15154774|in_192|,_125|in_123|we_102|response_77|._53 (l_prep) in_43\IN\13603305|(_31|0.5_30|microg_26|/_17|for_12|)_2 (l_pobj) sufferers_45\NNS\9630641|NONE_0 (l_prep) with_48\IN\0|12_25|of_12 (l_pobj) aura_49\NN\14299637|NONE_0
D005996_D020325 NONE gtn_30\NNP\0|glyceryl_21|(_1|)_3 (r_appos) trinitrate_28\NN\0|NONE_0 (r_pobj) of_26\IN\0|intravenous_21 (r_prep) infusion_25\NN\14589223|NONE_0 (r_pobj) to_23\IN\0|the_22|headache_18 (r_prep) response_22\NN\11410625|in_115|,_48|in_46|we_25|min_77|._130 (r_dobj) examined_19\VBD\0|NONE_0 (l_prep) in_0\IN\13603305|,_67|in_69|we_90|response_115|min_192|._245 (l_pobj) order_1\NN\7168131|NONE_0 (l_acl) clarify_3\VB\939277|NONE_0 (l_ccomp) is_7\VBZ\0|to_28 (l_acomp) true_8\JJ\5077146|whether_20|same_8 (l_prep) for_9\IN\0|NONE_0 (l_pobj) migraine_10\NN\14326607|NONE_0 (l_prep) with_11\IN\0|NONE_0 (l_pobj) aura_12\NN\14299637|NONE_0
D005996_D020325 NONE gtn_30\NNP\0|glyceryl_21|(_1|)_3 (r_appos) trinitrate_28\NN\0|NONE_0 (r_pobj) of_26\IN\0|intravenous_21 (r_prep) infusion_25\NN\14589223|NONE_0 (r_pobj) to_23\IN\0|the_22|headache_18 (r_prep) response_22\NN\11410625|in_115|,_48|in_46|we_25|min_77|._130 (r_dobj) examined_19\VBD\0|NONE_0 (l_parataxis) min_38\NN\15154774|in_192|,_125|in_123|we_102|response_77|._53 (l_prep) in_43\IN\13603305|(_31|0.5_30|microg_26|/_17|for_12|)_2 (l_pobj) sufferers_45\NNS\9630641|NONE_0 (l_prep) with_48\IN\0|12_25|of_12 (l_pobj) aura_49\NN\14299637|NONE_0
D009569_D003866 NONE no_9\DT\7204911|to_12|in_3 (r_intj) liberate_8\VB\146138|since_54|depression_29|has_18|been_14 (r_xcomp) shown_6\VBN\2137132|,_31|finding_38|may_46|understanding_59|._161 (l_nsubjpass) depression_3\NN\14373582|since_25|has_11|been_15|liberate_29
D009569_D003866 NONE no_9\DT\7204911|to_12|in_3 (r_intj) liberate_8\VB\146138|since_54|depression_29|has_18|been_14 (r_xcomp) shown_6\VBN\2137132|,_31|finding_38|may_46|understanding_59|._161 (r_advcl) help_16\VB\407535|NONE_0 (l_dobj) understanding_18\NN\5804793|shown_59|,_28|finding_21|may_13|._102 (l_prep) of_19\IN\0|our_18 (l_pobj) coupling_21\NN\3091374|NONE_0 (l_prep) between_22\IN\0|the_13 (l_pobj) depression_25\NN\14373582|NONE_0
D009569_D020326 CID oxide_13\NN\14818238|that_35|is_11|in_23 (r_nsubjpass) involved_18\VBN\2676054|in_100|,_85|evidence_72|has_63|._52 (l_prep) in_19\IN\13603305|that_58|oxide_23|is_12 (l_pobj) mechanisms_21\NNS\13446390|NONE_0 (l_prep) without_24\IN\0|pain_28|of_12 (l_pobj) aura_25\NN\14299637|NONE_0
D009569_D020326 CID no_15\NNP\7204911|the_37|molecule_23|nitric_14|(_1|)_2 (r_appos) oxide_13\NN\14818238|that_35|is_11|in_23 (r_nsubjpass) involved_18\VBN\2676054|in_100|,_85|evidence_72|has_63|._52 (l_prep) in_19\IN\13603305|that_58|oxide_23|is_12 (l_pobj) mechanisms_21\NNS\13446390|NONE_0 (l_prep) without_24\IN\0|pain_28|of_12 (l_pobj) aura_25\NN\14299637|NONE_0
D009569_D006261 NONE no_9\DT\7204911|to_12|in_3 (r_intj) liberate_8\VB\146138|since_54|depression_29|has_18|been_14 (r_xcomp) shown_6\VBN\2137132|,_31|finding_38|may_46|understanding_59|._161 (r_advcl) help_16\VB\407535|NONE_0 (l_dobj) understanding_18\NN\5804793|shown_59|,_28|finding_21|may_13|._102 (l_prep) of_19\IN\0|our_18 (l_pobj) coupling_21\NN\3091374|NONE_0 (l_prep) between_22\IN\0|the_13 (l_pobj) depression_25\NN\14373582|NONE_0 (l_conj) headache_27\NN\5829480|cortical_34|spreading_25|and_4
D005996_D006261 NONE trinitrate_28\NN\0|NONE_0 (r_pobj) of_26\IN\0|intravenous_21 (r_prep) infusion_25\NN\14589223|NONE_0 (r_pobj) to_23\IN\0|the_22|headache_18 (r_prep) response_22\NN\11410625|in_115|,_48|in_46|we_25|min_77|._130 (l_compound) headache_21\NN\5829480|the_4|to_18
D005996_D006261 NONE gtn_30\NNP\0|glyceryl_21|(_1|)_3 (r_appos) trinitrate_28\NN\0|NONE_0 (r_pobj) of_26\IN\0|intravenous_21 (r_prep) infusion_25\NN\14589223|NONE_0 (r_pobj) to_23\IN\0|the_22|headache_18 (r_prep) response_22\NN\11410625|in_115|,_48|in_46|we_25|min_77|._130 (l_compound) headache_21\NN\5829480|the_4|to_18
D005996_D006261 NONE gtn_14\NNP\0|after_6|p=0.037_14|as_31|during_34 (r_compound) infusion_15\NN\14589223|headache_94|severe_76|._67 (r_advcl) was_1\VBD\0|NONE_0 (l_nsubj) headache_0\NNP\5829480|severe_18|infusion_94|._161
D005996_D006261 NONE gtn_5\NNP\0|-_3 (r_npadvmod) induced_7\VBN\1627355|the_8 (r_amod) headache_8\NN\5829480|in_33|,_18|gradually_9|,_30|peak_55|._127
D005996_D006261 NONE gtn_5\NNP\0|-_3 (r_npadvmod) induced_7\VBN\1627355|the_8 (r_amod) headache_8\NN\5829480|in_33|,_18|gradually_9|,_30|peak_55|._127 (r_nsubj) disappeared_10\VBD\0|NONE_0 (l_advcl) peak_15\JJ\13758296|in_88|,_73|headache_55|gradually_46|,_25|._72 (l_ccomp) occurred_18\VBD\0|whereas_47|in_39 (l_nsubj) intensity_17\NN\5090441|at_19 (l_compound) headache_16\NN\5829480|NONE_0
9154656
D000809_D009404 NONE angiotensin_9\NN\4522421|the_10|system_12 (r_compound) proteins_11\NNS\14944888|NONE_0 (r_pobj) of_5\IN\0|plasma_41|and_20|excretion_10 (r_prep) concentration_1\NN\4916342|are_75|in_87|._123 (r_nsubjpass) altered_13\VBN\0|NONE_0 (l_prep) in_14\IN\13603305|concentration_87|are_12|._36 (l_pobj) rats_15\NNS\2329401|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) syndrome_18\NN\5870365|NONE_0
D000809_D009404 NONE angiotensin_9\NN\4522421|the_10|system_12 (r_compound) proteins_11\NNS\14944888|NONE_0 (r_pobj) of_5\IN\0|plasma_41|and_20|excretion_10 (r_prep) concentration_1\NN\4916342|are_75|in_87|._123 (r_nsubjpass) altered_13\VBN\0|NONE_0 (l_prep) in_14\IN\13603305|concentration_87|are_12|._36 (l_pobj) rats_15\NNS\2329401|NONE_0 (l_prep) with_16\IN\0|NONE_0 (l_pobj) syndrome_18\NN\5870365|NONE_0 (l_appos) ns_20\NNP\14622893|nephrotic_20
D011692_D009404 CID nucleoside_11\NN\14887305|puromycin_16|(_11 (r_nmod) pan_13\NNP\3101986|NONE_0 (r_pobj) of_7\IN\0|a_19|single_17 (r_prep) injection_6\NN\320852|NONE_0 (r_pobj) by_3\IN\0|ns_15|was_12|)_56|._57 (r_agent) induced_2\VBN\1627355|NONE_0 (l_nsubjpass) ns_0\NNP\14622893|was_3|by_15|)_71|._72
D011692_D009404 CID pan_13\NNP\3101986|NONE_0 (r_pobj) of_7\IN\0|a_19|single_17 (r_prep) injection_6\NN\320852|NONE_0 (r_pobj) by_3\IN\0|ns_15|was_12|)_56|._57 (r_agent) induced_2\VBN\1627355|NONE_0 (l_nsubjpass) ns_0\NNP\14622893|was_3|by_15|)_71|._72
D011692_D009404 CID pan_19\NNP\3101986|NONE_0 (r_compound) injection_20\NN\320852|NONE_0 (r_pobj) after_18\IN\0|although_94|excretion_69|were_23|on_9 (r_prep) observed_14\VBN\2163746|,_37|established_59|,_70|levels_88|did_95|not_99|._109 (r_advcl) change_34\VB\7283608|NONE_0 (l_advcl) established_26\VBN\2426171|observed_59|,_22|,_11|levels_29|did_36|not_40|._50 (l_nsubjpass) ns_23\NNP\14622893|when_5|was_3|clearly_7
D011692_D009404 CID pan_22\NNP\3101986|NONE_0 (r_pobj) by_21\IN\0|NONE_0 (r_agent) induced_20\VBN\1627355|the_32|of_16 (r_acl) development_15\NN\248977|NONE_0 (l_prep) of_16\IN\0|the_16|induced_16 (l_pobj) ns_19\NNP\14622893|NONE_0
7619765
D005047_D009203 CID etoposide_0\RB\0|-_9 (r_npadvmod) related_2\VBN\628491|myocardial_8|._29 (r_amod) infarction_4\NN\14204950|NONE_0
D005047_D009203 CID etoposide_11\RB\0|NONE_0 (r_dobj) containing_10\VBG\2632940|NONE_0 (r_acl) chemotherapy_9\NN\661091|NONE_0 (r_pobj) after_8\IN\0|occurrence_50|is_12|,_39|in_41|._97 (r_prep) reported_7\VBN\831651|NONE_0 (l_nsubjpass) occurrence_1\NN\29378|is_38|after_50|,_89|in_91|._147 (l_prep) of_2\IN\0|the_15 (l_pobj) infarction_5\NN\14204950|NONE_0
D005047_D003327 NONE etoposide_11\RB\0|NONE_0 (r_dobj) containing_10\VBG\2632940|NONE_0 (r_acl) chemotherapy_9\NN\661091|NONE_0 (r_pobj) after_8\IN\0|occurrence_50|is_12|,_39|in_41|._97 (r_prep) reported_7\VBN\831651|NONE_0 (l_prep) in_13\IN\13603305|occurrence_91|is_53|after_41|,_2|._56 (l_pobj) man_15\NN\9605289|NONE_0 (l_prep) with_16\IN\0|a_6 (l_pobj) factors_19\NNS\7326557|NONE_0 (l_prep) for_20\IN\0|no_16|risk_13 (l_pobj) disease_23\NN\14061805|NONE_0
12571256
D007472_D007674 CID iohexol_45\NN\0|nonionic_37 (r_pobj) of_33\IN\0|NONE_0 (r_prep) those_32\DT\0|NONE_0 (r_pobj) with_31\IN\0|the_89|nephrotoxic_85|of_65 (r_prep) effects_16\NNS\13245626|NONE_0 (l_amod) nephrotoxic_15\JJ\0|the_4|of_20|with_85
C044834_D007674 NONE iodixanol_29\NN\0|an_51|osmolar_44|,_37|dimeric_35|,_28|nonionic_26|contrast_17|,_2|,_9 (r_appos) medium_27\NN\3575240|NONE_0 (r_pobj) of_17\IN\0|the_24|nephrotoxic_20|with_65 (r_prep) effects_16\NNS\13245626|NONE_0 (l_amod) nephrotoxic_15\JJ\0|the_4|of_20|with_85
C044834_D007674 NONE iodixanol_17\NN\0|when_5|is_10|than_25 (r_nsubjpass) used_19\VBN\0|to_51|in_40 (r_advcl) develop_10\VB\1753788|less_15 (r_xcomp) likely_8\JJ\0|induced_39|may_12|._114 (r_acomp) be_6\VB\14625458|NONE_0 (l_csubj) induced_1\VBN\1627355|may_27|likely_39|._153 (l_nsubj) nephropathy_0\NNP\14573196|by_20
D003404_D003920 NONE creatinine_9\JJ\0|serum_6|of_26|underwent_61 (r_compound) concentrations_10\NNS\4916342|NONE_0 (r_pobj) with_7\IN\0|NONE_0 (r_prep) diabetes_6\NNS\14075199|NONE_0
1848636
D008790_D007008 NONE metoprolol_8\NN\2832168|NONE_0 (l_prep) of_9\IN\0|NONE_0 (l_pobj) hypokalemia_13\NN\14299637|NONE_0
D013726_D007008 CID terbutaline_10\NN\0|-_11 (r_npadvmod) induced_12\VBN\1627355|NONE_0 (r_amod) hypokalemia_13\NN\14299637|NONE_0
10225068
D008012_D011128 CID lignocaine_10\NN\0|NONE_0 (r_pobj) with_6\IN\0|spinal_19 (r_prep) anaesthesia_5\NN\14034177|NONE_0 (r_pobj) after_3\IN\0|equina_16|:_54|review_58|._161 (r_prep) syndrome_2\NN\5870365|NONE_0
D008012_D011128 CID lignocaine_10\NN\0|NONE_0 (r_pobj) with_6\IN\0|spinal_19 (r_prep) anaesthesia_5\NN\14034177|NONE_0 (r_pobj) after_3\IN\0|equina_16|:_54|review_58|._161 (r_prep) syndrome_2\NN\5870365|NONE_0 (l_appos) review_13\NN\5733583|equina_74|after_58|:_4|._103 (l_prep) of_14\IN\0|a_9|reported_38 (l_pobj) cases_16\NNS\7283608|NONE_0 (l_prep) of_17\IN\0|six_10 (l_pobj) syndrome_20\NN\5870365|NONE_0
D008012_D020258 NONE lignocaine_6\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_9 (r_prep) dose_1\NN\3740161|from_53 (r_nsubj) ranged_8\VBD\2604760|were_45|likely_55|by_69|._120 (r_ccomp) caused_21\VBN\1617192|NONE_0 (l_agent) by_22\IN\0|ranged_69|were_24|likely_14|._51 (l_pobj) neurotoxicity_24\NN\0|NONE_0
D008012_D020258 NONE lignocaine_29\NN\0|NONE_0 (r_pobj) of_25\IN\0|direct_21 (r_prep) neurotoxicity_24\NN\0|NONE_0
11284996
D005996_D018781 NONE trinitrate_20\NN\0|NONE_0 (r_pobj) by_15\IN\0|in_42 (r_agent) induced_14\VBN\1627355|NONE_0 (l_prep) in_24\IN\13603305|by_42 (l_pobj) patients_26\NNS\9898892|NONE_0 (l_prep) with_27\IN\0|16_12 (l_pobj) headache_32\NN\5829480|NONE_0
D005996_D018781 NONE gtn_22\NNP\0|the_34|no_30|glyceryl_21|(_1|)_3 (r_appos) trinitrate_20\NN\0|NONE_0 (r_pobj) by_15\IN\0|in_42 (r_agent) induced_14\VBN\1627355|NONE_0 (l_prep) in_24\IN\13603305|by_42 (l_pobj) patients_26\NNS\9898892|NONE_0 (l_prep) with_27\IN\0|16_12 (l_pobj) headache_32\NN\5829480|NONE_0
D009569_D006261 CID oxide_8\NN\14818238|-_5 (r_npadvmod) induced_10\VBN\1627355|nitric_13|in_17 (r_amod) headache_11\NN\5829480|NONE_0
D009569_D006261 CID oxide_6\NN\14818238|that_12|associated_56 (r_nsubj) induced_10\VBN\1627355|it_44|has_41|been_37|._110 (l_ccomp) associated_17\VBN\628491|that_68|oxide_56 (l_nsubjpass) headache_11\NN\5829480|may_30|be_34|with_48
D009569_D006261 CID no_8\NNP\7204911|nitric_14|(_1|)_2 (r_intj) oxide_6\NN\14818238|that_12|associated_56 (r_nsubj) induced_10\VBN\1627355|it_44|has_41|been_37|._110 (l_ccomp) associated_17\VBN\628491|that_68|oxide_56 (l_nsubjpass) headache_11\NN\5829480|may_30|be_34|with_48
D009569_D006261 CID no_17\JJ\7204911|the_4|glyceryl_9|(_29|gtn_30|)_33 (r_det) trinitrate_20\NN\0|NONE_0 (r_pobj) by_15\IN\0|in_42 (r_agent) induced_14\VBN\1627355|NONE_0 (r_acl) headache_13\NN\5829480|NONE_0
D009569_D006261 CID no_5\RB\7204911|-_2 (r_intj) induced_7\VBN\1627355|immediate_8 (r_amod) headache_9\NN\5829480|that_26|is_9|not_12|with_27
D009569_D051270 NONE oxide_6\NN\14818238|that_12|associated_56 (r_nsubj) induced_10\VBN\1627355|it_44|has_41|been_37|._110 (l_ccomp) associated_17\VBN\628491|that_68|oxide_56 (l_nsubjpass) headache_11\NN\5829480|may_30|be_34|with_48 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) headaches_14\NNS\5829480|NONE_0
D009569_D051270 NONE no_8\NNP\7204911|nitric_14|(_1|)_2 (r_intj) oxide_6\NN\14818238|that_12|associated_56 (r_nsubj) induced_10\VBN\1627355|it_44|has_41|been_37|._110 (l_ccomp) associated_17\VBN\628491|that_68|oxide_56 (l_nsubjpass) headache_11\NN\5829480|may_30|be_34|with_48 (l_prep) in_12\IN\13603305|NONE_0 (l_pobj) headaches_14\NNS\5829480|NONE_0
D009569_D018781 NONE oxide_8\NN\14818238|-_5 (r_npadvmod) induced_10\VBN\1627355|nitric_13|in_17 (r_amod) headache_11\NN\5829480|NONE_0 (l_prep) in_12\IN\13603305|nitric_30|induced_17 (l_pobj) patients_13\NNS\9898892|NONE_0 (l_prep) with_14\IN\0|NONE_0 (l_pobj) headache_19\NN\5829480|NONE_0
D009569_D018781 NONE no_17\JJ\7204911|the_4|glyceryl_9|(_29|gtn_30|)_33 (r_det) trinitrate_20\NN\0|NONE_0 (r_pobj) by_15\IN\0|in_42 (r_agent) induced_14\VBN\1627355|NONE_0 (l_prep) in_24\IN\13603305|by_42 (l_pobj) patients_26\NNS\9898892|NONE_0 (l_prep) with_27\IN\0|16_12 (l_pobj) headache_32\NN\5829480|NONE_0
D005996_D006261 CID trinitrate_20\NN\0|NONE_0 (r_pobj) by_15\IN\0|in_42 (r_agent) induced_14\VBN\1627355|NONE_0 (r_acl) headache_13\NN\5829480|NONE_0
D005996_D006261 CID gtn_22\NNP\0|the_34|no_30|glyceryl_21|(_1|)_3 (r_appos) trinitrate_20\NN\0|NONE_0 (r_pobj) by_15\IN\0|in_42 (r_agent) induced_14\VBN\1627355|NONE_0 (r_acl) headache_13\NN\5829480|NONE_0
D005996_D006261 CID gtn_13\NNP\0|to_29 (l_conj) placebo_15\NN\3740161|min_11|or_3 (l_prep) over_16\IN\5867413|NONE_0 (l_pobj) min_18\NN\15154774|NONE_0 (l_prep) on_19\IN\0|20_7 (l_pobj) days_24\NNS\15140892|NONE_0 (l_amod) free_23\JJ\7942152|two_13 (l_npadvmod) headache_21\NN\5829480|-_8
D005996_D006261 CID gtn_11\NNP\0|the_4 (r_compound) day_12\NN\15154774|NONE_0 (r_pobj) on_9\IN\0|stronger_28|immediate_19|than_15 (r_prep) headache_8\NN\5829480|patients_65|and_48|was_65
D005996_D006261 CID gtn_11\NNP\0|the_4 (r_compound) day_12\NN\15154774|NONE_0 (r_pobj) on_9\IN\0|stronger_28|immediate_19|than_15 (r_prep) headache_8\NN\5829480|patients_65|and_48|was_65 (r_dobj) developed_4\VBD\1753788|NONE_0 (l_conj) was_21\VBD\0|patients_130|headache_65|and_17 (l_nsubj) headache_20\NN\5829480|pronounced_32|._71
921394
D007649_D013610 CID ketamine_18\NN\3054098|-_8 (r_npadvmod) induced_20\VBN\1627355|the_13 (r_amod) tachycardia_21\NN\14110674|NONE_0
D007649_D003866 NONE ketamine_2\NN\3054098|NONE_0 (r_pobj) of_1\IN\0|in_12|mg_45|._129 (r_prep) injections_0\NNS\320852|NONE_0 (l_dep) mg_10\NN\13717155|of_45|in_33|._84 (l_prep) into_11\IN\0|NONE_0 (l_pobj) artery_13\NN\5417975|NONE_0 (l_acl) produced_14\VBD\1617192|the_11 (l_dobj) depression_16\NN\14373582|by_36
6817363
C036466_D007859 NONE aniracetam_5\RB\0|NONE_0 (l_appos) ro_7\NNP\6894544|the_31|novel_27|compound_21|(_1 (l_prep) upon_12\IN\0|13_9|)_2 (l_pobj) learning_14\NN\5701944|NONE_0 (l_conj) memory_16\NN\5926676|impaired_22|and_4|in_7
C036466_D007859 NONE 5057_10\CD\0|NONE_0 (r_prep) 13_8\CD\13745420|)_7|upon_9 (r_nummod) ro_7\NNP\6894544|the_31|novel_27|compound_21|(_1 (l_prep) upon_12\IN\0|13_9|)_2 (l_pobj) learning_14\NN\5701944|NONE_0 (l_conj) memory_16\NN\5926676|impaired_22|and_4|in_7
C036466_D008569 NONE aniracetam_5\RB\0|NONE_0 (l_appos) ro_7\NNP\6894544|the_31|novel_27|compound_21|(_1 (l_prep) upon_12\IN\0|13_9|)_2 (l_pobj) learning_14\NN\5701944|NONE_0 (l_conj) memory_16\NN\5926676|impaired_22|and_4|in_7
C036466_D008569 NONE 5057_10\CD\0|NONE_0 (r_prep) 13_8\CD\13745420|)_7|upon_9 (r_nummod) ro_7\NNP\6894544|the_31|novel_27|compound_21|(_1 (l_prep) upon_12\IN\0|13_9|)_2 (l_pobj) learning_14\NN\5701944|NONE_0 (l_conj) memory_16\NN\5926676|impaired_22|and_4|in_7
D003513_D000647 NONE cycloheximide_140\NN\0|or_3 (r_conj) chloramphenicol_138\NN\2716866|NONE_0 (r_pobj) by_137\IN\0|in_17 (r_agent) induced_132\VBN\1627355|a_25|passive_23|avoidance_15|administered_61 (r_acl) task_131\NN\575741|NONE_0 (r_pobj) for_127\IN\0|(_64|4_63|)_62|of_49|;_132|reversal_138 (r_prep) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (r_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_prep) of_75\IN\0|complete_27|(_18|mice_17|)_13|for_46|;_74|protection_89 (l_pobj) amnesia_83\NN\5669934|NONE_0
D003513_D000647 NONE cycloheximide_140\NN\0|or_3 (r_conj) chloramphenicol_138\NN\2716866|NONE_0 (r_pobj) by_137\IN\0|in_17 (r_agent) induced_132\VBN\1627355|a_25|passive_23|avoidance_15|administered_61 (r_acl) task_131\NN\575741|NONE_0 (r_pobj) for_127\IN\0|(_64|4_63|)_62|of_49|;_132|reversal_138 (r_prep) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (l_prep) against_95\IN\0|3_23|complete_20|for_16|;_129|prevention_135 (l_pobj) amnesia_96\NN\5669934|NONE_0
D003513_D000647 NONE cycloheximide_177\NN\0|NONE_0 (r_pobj) by_176\IN\0|NONE_0 (r_agent) induced_175\VBN\1627355|a_25|passive_23|avoidance_15 (r_acl) task_174\NN\575741|NONE_0 (r_pobj) of_170\IN\0|or_13|retrieval_10 (r_prep) retention_167\NN\809465|NONE_0 (r_pobj) in_166\IN\13603305|the_12 (r_prep) deficit_165\NN\5113133|NONE_0 (r_pobj) of_163\IN\0|(_74|5_73|)_72|,_62|administered_55|h_29|,_2|injected_94|;_120|prevention_126 (r_prep) reversal_149\NN\199130|(_202|4_201|)_200|of_187|for_138|;_6 (r_conj) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (r_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_prep) of_75\IN\0|complete_27|(_18|mice_17|)_13|for_46|;_74|protection_89 (l_pobj) amnesia_83\NN\5669934|NONE_0
D003513_D000647 NONE cycloheximide_177\NN\0|NONE_0 (r_pobj) by_176\IN\0|NONE_0 (r_agent) induced_175\VBN\1627355|a_25|passive_23|avoidance_15 (r_acl) task_174\NN\575741|NONE_0 (r_pobj) of_170\IN\0|or_13|retrieval_10 (r_prep) retention_167\NN\809465|NONE_0 (r_pobj) in_166\IN\13603305|the_12 (r_prep) deficit_165\NN\5113133|NONE_0 (r_pobj) of_163\IN\0|(_74|5_73|)_72|,_62|administered_55|h_29|,_2|injected_94|;_120|prevention_126 (r_prep) reversal_149\NN\199130|(_202|4_201|)_200|of_187|for_138|;_6 (r_conj) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (l_prep) against_95\IN\0|3_23|complete_20|for_16|;_129|prevention_135 (l_pobj) amnesia_96\NN\5669934|NONE_0
D003513_D006935 NONE cycloheximide_140\NN\0|or_3 (r_conj) chloramphenicol_138\NN\2716866|NONE_0 (r_pobj) by_137\IN\0|in_17 (r_agent) induced_132\VBN\1627355|a_25|passive_23|avoidance_15|administered_61 (r_acl) task_131\NN\575741|NONE_0 (r_pobj) for_127\IN\0|(_64|4_63|)_62|of_49|;_132|reversal_138 (r_prep) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (r_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (r_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (r_conj) prevention_40\NN\1073995|the_43|following_39|:_22 (l_prep) of_41\IN\0|1_30|complete_20|;_137|rats_152 (l_pobj) incapacity_43\NN\5644922|NONE_0 (l_acl) learn_45\VB\0|the_18 (l_dobj) response_49\NN\11410625|to_27 (l_prep) in_50\IN\13603305|a_27|discrete_25|escape_16 (l_pobj) rats_51\NNS\2329401|NONE_0 (l_acl) exposed_52\VBN\2110927|NONE_0 (l_prep) to_53\IN\0|before_37 (l_pobj) hypercapnia_55\NN\14034177|NONE_0
D003513_D006935 NONE cycloheximide_140\NN\0|or_3 (r_conj) chloramphenicol_138\NN\2716866|NONE_0 (r_pobj) by_137\IN\0|in_17 (r_agent) induced_132\VBN\1627355|a_25|passive_23|avoidance_15|administered_61 (r_acl) task_131\NN\575741|NONE_0 (r_pobj) for_127\IN\0|(_64|4_63|)_62|of_49|;_132|reversal_138 (r_prep) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (l_conj) reversal_149\NN\199130|(_202|4_201|)_200|of_187|for_138|;_6 (l_conj) prevention_186\NN\1073995|(_200|5_199|)_198|,_188|administered_181|h_155|,_128|of_126|injected_32|;_6 (l_prep) in_190\IN\13603305|(_30|6_29|)_28|of_15 (l_pobj) retrieval_192\NN\13450862|NONE_0 (l_prep) of_193\IN\0|the_14 (l_pobj) task_197\NN\575741|NONE_0 (l_acl) induced_198\VBN\1627355|an_25|active_22|avoidance_15|applied_61 (l_agent) by_201\IN\0|in_8 (l_pobj) electroshock_203\NN\662681|NONE_0 (l_conj) hypercapnia_205\NN\14034177|subconvulsant_30|or_3
D003513_D006935 NONE cycloheximide_177\NN\0|NONE_0 (r_pobj) by_176\IN\0|NONE_0 (r_agent) induced_175\VBN\1627355|a_25|passive_23|avoidance_15 (r_acl) task_174\NN\575741|NONE_0 (r_pobj) of_170\IN\0|or_13|retrieval_10 (r_prep) retention_167\NN\809465|NONE_0 (r_pobj) in_166\IN\13603305|the_12 (r_prep) deficit_165\NN\5113133|NONE_0 (r_pobj) of_163\IN\0|(_74|5_73|)_72|,_62|administered_55|h_29|,_2|injected_94|;_120|prevention_126 (r_prep) reversal_149\NN\199130|(_202|4_201|)_200|of_187|for_138|;_6 (r_conj) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (r_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (r_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (r_conj) prevention_40\NN\1073995|the_43|following_39|:_22 (l_prep) of_41\IN\0|1_30|complete_20|;_137|rats_152 (l_pobj) incapacity_43\NN\5644922|NONE_0 (l_acl) learn_45\VB\0|the_18 (l_dobj) response_49\NN\11410625|to_27 (l_prep) in_50\IN\13603305|a_27|discrete_25|escape_16 (l_pobj) rats_51\NNS\2329401|NONE_0 (l_acl) exposed_52\VBN\2110927|NONE_0 (l_prep) to_53\IN\0|before_37 (l_pobj) hypercapnia_55\NN\14034177|NONE_0
D003513_D006935 NONE cycloheximide_177\NN\0|NONE_0 (r_pobj) by_176\IN\0|NONE_0 (r_agent) induced_175\VBN\1627355|a_25|passive_23|avoidance_15 (r_acl) task_174\NN\575741|NONE_0 (r_pobj) of_170\IN\0|or_13|retrieval_10 (r_prep) retention_167\NN\809465|NONE_0 (r_pobj) in_166\IN\13603305|the_12 (r_prep) deficit_165\NN\5113133|NONE_0 (r_pobj) of_163\IN\0|(_74|5_73|)_72|,_62|administered_55|h_29|,_2|injected_94|;_120|prevention_126 (r_prep) reversal_149\NN\199130|(_202|4_201|)_200|of_187|for_138|;_6 (l_conj) prevention_186\NN\1073995|(_200|5_199|)_198|,_188|administered_181|h_155|,_128|of_126|injected_32|;_6 (l_prep) in_190\IN\13603305|(_30|6_29|)_28|of_15 (l_pobj) retrieval_192\NN\13450862|NONE_0 (l_prep) of_193\IN\0|the_14 (l_pobj) task_197\NN\575741|NONE_0 (l_acl) induced_198\VBN\1627355|an_25|active_22|avoidance_15|applied_61 (l_agent) by_201\IN\0|in_8 (l_pobj) electroshock_203\NN\662681|NONE_0 (l_conj) hypercapnia_205\NN\14034177|subconvulsant_30|or_3
C036466_D006935 NONE aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_prep) of_41\IN\0|1_30|complete_20|;_137|rats_152 (l_pobj) incapacity_43\NN\5644922|NONE_0 (l_acl) learn_45\VB\0|the_18 (l_dobj) response_49\NN\11410625|to_27 (l_prep) in_50\IN\13603305|a_27|discrete_25|escape_16 (l_pobj) rats_51\NNS\2329401|NONE_0 (l_acl) exposed_52\VBN\2110927|NONE_0 (l_prep) to_53\IN\0|before_37 (l_pobj) hypercapnia_55\NN\14034177|NONE_0
C036466_D006935 NONE aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (l_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (l_conj) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (l_conj) reversal_149\NN\199130|(_202|4_201|)_200|of_187|for_138|;_6 (l_conj) prevention_186\NN\1073995|(_200|5_199|)_198|,_188|administered_181|h_155|,_128|of_126|injected_32|;_6 (l_prep) in_190\IN\13603305|(_30|6_29|)_28|of_15 (l_pobj) retrieval_192\NN\13450862|NONE_0 (l_prep) of_193\IN\0|the_14 (l_pobj) task_197\NN\575741|NONE_0 (l_acl) induced_198\VBN\1627355|an_25|active_22|avoidance_15|applied_61 (l_agent) by_201\IN\0|in_8 (l_pobj) electroshock_203\NN\662681|NONE_0 (l_conj) hypercapnia_205\NN\14034177|subconvulsant_30|or_3
C036466_D006935 NONE 5057_8\CD\0|NONE_0 (r_prep) 13_6\CD\13745420|,_7|1-anisoyl-2-pyrrolidinone_9 (r_nummod) ro_5\NNP\6894544|(_1|)_37 (r_appos) aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_prep) of_41\IN\0|1_30|complete_20|;_137|rats_152 (l_pobj) incapacity_43\NN\5644922|NONE_0 (l_acl) learn_45\VB\0|the_18 (l_dobj) response_49\NN\11410625|to_27 (l_prep) in_50\IN\13603305|a_27|discrete_25|escape_16 (l_pobj) rats_51\NNS\2329401|NONE_0 (l_acl) exposed_52\VBN\2110927|NONE_0 (l_prep) to_53\IN\0|before_37 (l_pobj) hypercapnia_55\NN\14034177|NONE_0
C036466_D006935 NONE 5057_8\CD\0|NONE_0 (r_prep) 13_6\CD\13745420|,_7|1-anisoyl-2-pyrrolidinone_9 (r_nummod) ro_5\NNP\6894544|(_1|)_37 (r_appos) aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (l_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (l_conj) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (l_conj) reversal_149\NN\199130|(_202|4_201|)_200|of_187|for_138|;_6 (l_conj) prevention_186\NN\1073995|(_200|5_199|)_198|,_188|administered_181|h_155|,_128|of_126|injected_32|;_6 (l_prep) in_190\IN\13603305|(_30|6_29|)_28|of_15 (l_pobj) retrieval_192\NN\13450862|NONE_0 (l_prep) of_193\IN\0|the_14 (l_pobj) task_197\NN\575741|NONE_0 (l_acl) induced_198\VBN\1627355|an_25|active_22|avoidance_15|applied_61 (l_agent) by_201\IN\0|in_8 (l_pobj) electroshock_203\NN\662681|NONE_0 (l_conj) hypercapnia_205\NN\14034177|subconvulsant_30|or_3
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\CD\0|13_9|,_2 (r_appos) ro_5\NNP\6894544|(_1|)_37 (r_appos) aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_prep) of_41\IN\0|1_30|complete_20|;_137|rats_152 (l_pobj) incapacity_43\NN\5644922|NONE_0 (l_acl) learn_45\VB\0|the_18 (l_dobj) response_49\NN\11410625|to_27 (l_prep) in_50\IN\13603305|a_27|discrete_25|escape_16 (l_pobj) rats_51\NNS\2329401|NONE_0 (l_acl) exposed_52\VBN\2110927|NONE_0 (l_prep) to_53\IN\0|before_37 (l_pobj) hypercapnia_55\NN\14034177|NONE_0
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\CD\0|13_9|,_2 (r_appos) ro_5\NNP\6894544|(_1|)_37 (r_appos) aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (l_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (l_conj) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (l_conj) reversal_149\NN\199130|(_202|4_201|)_200|of_187|for_138|;_6 (l_conj) prevention_186\NN\1073995|(_200|5_199|)_198|,_188|administered_181|h_155|,_128|of_126|injected_32|;_6 (l_prep) in_190\IN\13603305|(_30|6_29|)_28|of_15 (l_pobj) retrieval_192\NN\13450862|NONE_0 (l_prep) of_193\IN\0|the_14 (l_pobj) task_197\NN\575741|NONE_0 (l_acl) induced_198\VBN\1627355|an_25|active_22|avoidance_15|applied_61 (l_agent) by_201\IN\0|in_8 (l_pobj) electroshock_203\NN\662681|NONE_0 (l_conj) hypercapnia_205\NN\14034177|subconvulsant_30|or_3
D002701_D000647 NONE chloramphenicol_138\NN\2716866|NONE_0 (r_pobj) by_137\IN\0|in_17 (r_agent) induced_132\VBN\1627355|a_25|passive_23|avoidance_15|administered_61 (r_acl) task_131\NN\575741|NONE_0 (r_pobj) for_127\IN\0|(_64|4_63|)_62|of_49|;_132|reversal_138 (r_prep) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (r_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_prep) of_75\IN\0|complete_27|(_18|mice_17|)_13|for_46|;_74|protection_89 (l_pobj) amnesia_83\NN\5669934|NONE_0
D002701_D000647 NONE chloramphenicol_138\NN\2716866|NONE_0 (r_pobj) by_137\IN\0|in_17 (r_agent) induced_132\VBN\1627355|a_25|passive_23|avoidance_15|administered_61 (r_acl) task_131\NN\575741|NONE_0 (r_pobj) for_127\IN\0|(_64|4_63|)_62|of_49|;_132|reversal_138 (r_prep) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (l_prep) against_95\IN\0|3_23|complete_20|for_16|;_129|prevention_135 (l_pobj) amnesia_96\NN\5669934|NONE_0
D012601_D003072 NONE scopolamine_77\NN\14712692|-_11 (r_npadvmod) induced_79\VBN\1627355|the_16|term_14 (r_amod) amnesia_83\NN\5669934|NONE_0 (r_pobj) of_75\IN\0|complete_27|(_18|mice_17|)_13|for_46|;_74|protection_89 (r_prep) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (r_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (r_conj) prevention_40\NN\1073995|the_43|following_39|:_22 (r_appos) effects_33\NNS\13245626|NONE_0 (r_dobj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (r_conj) studied_13\VBN\0|NONE_0 (l_prep) on_14\IN\0|effect_73|was_12|and_97|produced_101|._1182 (l_pobj) forms_16\NNS\6286395|NONE_0 (l_prep) of_17\IN\0|various_14|in_69 (l_pobj) functions_21\NNS\13783581|NONE_0
C036466_D000647 NONE aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (l_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_prep) of_75\IN\0|complete_27|(_18|mice_17|)_13|for_46|;_74|protection_89 (l_pobj) amnesia_83\NN\5669934|NONE_0
C036466_D000647 NONE aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (l_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (l_prep) against_95\IN\0|3_23|complete_20|for_16|;_129|prevention_135 (l_pobj) amnesia_96\NN\5669934|NONE_0
C036466_D000647 NONE 5057_8\CD\0|NONE_0 (r_prep) 13_6\CD\13745420|,_7|1-anisoyl-2-pyrrolidinone_9 (r_nummod) ro_5\NNP\6894544|(_1|)_37 (r_appos) aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (l_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_prep) of_75\IN\0|complete_27|(_18|mice_17|)_13|for_46|;_74|protection_89 (l_pobj) amnesia_83\NN\5669934|NONE_0
C036466_D000647 NONE 5057_8\CD\0|NONE_0 (r_prep) 13_6\CD\13745420|,_7|1-anisoyl-2-pyrrolidinone_9 (r_nummod) ro_5\NNP\6894544|(_1|)_37 (r_appos) aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (l_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (l_prep) against_95\IN\0|3_23|complete_20|for_16|;_129|prevention_135 (l_pobj) amnesia_96\NN\5669934|NONE_0
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\CD\0|13_9|,_2 (r_appos) ro_5\NNP\6894544|(_1|)_37 (r_appos) aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (l_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_prep) of_75\IN\0|complete_27|(_18|mice_17|)_13|for_46|;_74|protection_89 (l_pobj) amnesia_83\NN\5669934|NONE_0
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\CD\0|13_9|,_2 (r_appos) ro_5\NNP\6894544|(_1|)_37 (r_appos) aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_conj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (l_dobj) effects_33\NNS\13245626|NONE_0 (l_appos) prevention_40\NN\1073995|the_43|following_39|:_22 (l_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (l_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (l_prep) against_95\IN\0|3_23|complete_20|for_16|;_129|prevention_135 (l_pobj) amnesia_96\NN\5669934|NONE_0
D012601_D006935 NONE scopolamine_77\NN\14712692|-_11 (r_npadvmod) induced_79\VBN\1627355|the_16|term_14 (r_amod) amnesia_83\NN\5669934|NONE_0 (r_pobj) of_75\IN\0|complete_27|(_18|mice_17|)_13|for_46|;_74|protection_89 (r_prep) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (r_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (r_conj) prevention_40\NN\1073995|the_43|following_39|:_22 (l_prep) of_41\IN\0|1_30|complete_20|;_137|rats_152 (l_pobj) incapacity_43\NN\5644922|NONE_0 (l_acl) learn_45\VB\0|the_18 (l_dobj) response_49\NN\11410625|to_27 (l_prep) in_50\IN\13603305|a_27|discrete_25|escape_16 (l_pobj) rats_51\NNS\2329401|NONE_0 (l_acl) exposed_52\VBN\2110927|NONE_0 (l_prep) to_53\IN\0|before_37 (l_pobj) hypercapnia_55\NN\14034177|NONE_0
D012601_D006935 NONE scopolamine_77\NN\14712692|-_11 (r_npadvmod) induced_79\VBN\1627355|the_16|term_14 (r_amod) amnesia_83\NN\5669934|NONE_0 (r_pobj) of_75\IN\0|complete_27|(_18|mice_17|)_13|for_46|;_74|protection_89 (r_prep) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (l_conj) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (l_conj) reversal_149\NN\199130|(_202|4_201|)_200|of_187|for_138|;_6 (l_conj) prevention_186\NN\1073995|(_200|5_199|)_198|,_188|administered_181|h_155|,_128|of_126|injected_32|;_6 (l_prep) in_190\IN\13603305|(_30|6_29|)_28|of_15 (l_pobj) retrieval_192\NN\13450862|NONE_0 (l_prep) of_193\IN\0|the_14 (l_pobj) task_197\NN\575741|NONE_0 (l_acl) induced_198\VBN\1627355|an_25|active_22|avoidance_15|applied_61 (l_agent) by_201\IN\0|in_8 (l_pobj) electroshock_203\NN\662681|NONE_0 (l_conj) hypercapnia_205\NN\14034177|subconvulsant_30|or_3
D012601_D000647 CID scopolamine_77\NN\14712692|-_11 (r_npadvmod) induced_79\VBN\1627355|the_16|term_14 (r_amod) amnesia_83\NN\5669934|NONE_0
D012601_D000647 CID scopolamine_77\NN\14712692|-_11 (r_npadvmod) induced_79\VBN\1627355|the_16|term_14 (r_amod) amnesia_83\NN\5669934|NONE_0 (r_pobj) of_75\IN\0|complete_27|(_18|mice_17|)_13|for_46|;_74|protection_89 (r_prep) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (l_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (l_prep) against_95\IN\0|3_23|complete_20|for_16|;_129|prevention_135 (l_pobj) amnesia_96\NN\5669934|NONE_0
D002701_D003072 NONE chloramphenicol_138\NN\2716866|NONE_0 (r_pobj) by_137\IN\0|in_17 (r_agent) induced_132\VBN\1627355|a_25|passive_23|avoidance_15|administered_61 (r_acl) task_131\NN\575741|NONE_0 (r_pobj) for_127\IN\0|(_64|4_63|)_62|of_49|;_132|reversal_138 (r_prep) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (r_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (r_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (r_conj) prevention_40\NN\1073995|the_43|following_39|:_22 (r_appos) effects_33\NNS\13245626|NONE_0 (r_dobj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (r_conj) studied_13\VBN\0|NONE_0 (l_prep) on_14\IN\0|effect_73|was_12|and_97|produced_101|._1182 (l_pobj) forms_16\NNS\6286395|NONE_0 (l_prep) of_17\IN\0|various_14|in_69 (l_pobj) functions_21\NNS\13783581|NONE_0
C036466_D003072 NONE aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_prep) on_14\IN\0|effect_73|was_12|and_97|produced_101|._1182 (l_pobj) forms_16\NNS\6286395|NONE_0 (l_prep) of_17\IN\0|various_14|in_69 (l_pobj) functions_21\NNS\13783581|NONE_0
C036466_D003072 NONE 5057_8\CD\0|NONE_0 (r_prep) 13_6\CD\13745420|,_7|1-anisoyl-2-pyrrolidinone_9 (r_nummod) ro_5\NNP\6894544|(_1|)_37 (r_appos) aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_prep) on_14\IN\0|effect_73|was_12|and_97|produced_101|._1182 (l_pobj) forms_16\NNS\6286395|NONE_0 (l_prep) of_17\IN\0|various_14|in_69 (l_pobj) functions_21\NNS\13783581|NONE_0
C036466_D003072 NONE 1-anisoyl-2-pyrrolidinone_10\CD\0|13_9|,_2 (r_appos) ro_5\NNP\6894544|(_1|)_37 (r_appos) aniracetam_3\NN\0|NONE_0 (r_pobj) of_2\IN\0|the_11 (r_prep) effect_1\NN\34213|was_61|on_73|and_170|produced_174|._1255 (r_nsubjpass) studied_13\VBN\0|NONE_0 (l_prep) on_14\IN\0|effect_73|was_12|and_97|produced_101|._1182 (l_pobj) forms_16\NNS\6286395|NONE_0 (l_prep) of_17\IN\0|various_14|in_69 (l_pobj) functions_21\NNS\13783581|NONE_0
C036466_D003072 NONE aniracetam_12\JJ\0|oral_5|of_17 (r_amod) doses_13\NNS\3740161|NONE_0 (r_pobj) at_10\IN\14622893|improvements_73|were_10|._40 (r_prep) seen_9\VBN\2106506|NONE_0 (l_nsubjpass) improvements_1\NNS\7359599|were_63|at_73|._113 (l_conj) normalizations_3\NNS\1123598|these_22|or_3 (l_prep) of_4\IN\0|NONE_0 (l_pobj) functions_7\NNS\13783581|NONE_0
D003513_D003072 NONE cycloheximide_140\NN\0|or_3 (r_conj) chloramphenicol_138\NN\2716866|NONE_0 (r_pobj) by_137\IN\0|in_17 (r_agent) induced_132\VBN\1627355|a_25|passive_23|avoidance_15|administered_61 (r_acl) task_131\NN\575741|NONE_0 (r_pobj) for_127\IN\0|(_64|4_63|)_62|of_49|;_132|reversal_138 (r_prep) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (r_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (r_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (r_conj) prevention_40\NN\1073995|the_43|following_39|:_22 (r_appos) effects_33\NNS\13245626|NONE_0 (r_dobj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (r_conj) studied_13\VBN\0|NONE_0 (l_prep) on_14\IN\0|effect_73|was_12|and_97|produced_101|._1182 (l_pobj) forms_16\NNS\6286395|NONE_0 (l_prep) of_17\IN\0|various_14|in_69 (l_pobj) functions_21\NNS\13783581|NONE_0
D003513_D003072 NONE cycloheximide_177\NN\0|NONE_0 (r_pobj) by_176\IN\0|NONE_0 (r_agent) induced_175\VBN\1627355|a_25|passive_23|avoidance_15 (r_acl) task_174\NN\575741|NONE_0 (r_pobj) of_170\IN\0|or_13|retrieval_10 (r_prep) retention_167\NN\809465|NONE_0 (r_pobj) in_166\IN\13603305|the_12 (r_prep) deficit_165\NN\5113133|NONE_0 (r_pobj) of_163\IN\0|(_74|5_73|)_72|,_62|administered_55|h_29|,_2|injected_94|;_120|prevention_126 (r_prep) reversal_149\NN\199130|(_202|4_201|)_200|of_187|for_138|;_6 (r_conj) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (r_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (r_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (r_conj) prevention_40\NN\1073995|the_43|following_39|:_22 (r_appos) effects_33\NNS\13245626|NONE_0 (r_dobj) produced_30\VBD\1617192|effect_174|was_113|on_101|and_4|._1081 (r_conj) studied_13\VBN\0|NONE_0 (l_prep) on_14\IN\0|effect_73|was_12|and_97|produced_101|._1182 (l_pobj) forms_16\NNS\6286395|NONE_0 (l_prep) of_17\IN\0|various_14|in_69 (l_pobj) functions_21\NNS\13783581|NONE_0
D002701_D006935 NONE chloramphenicol_138\NN\2716866|NONE_0 (r_pobj) by_137\IN\0|in_17 (r_agent) induced_132\VBN\1627355|a_25|passive_23|avoidance_15|administered_61 (r_acl) task_131\NN\575741|NONE_0 (r_pobj) for_127\IN\0|(_64|4_63|)_62|of_49|;_132|reversal_138 (r_prep) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (r_conj) protection_94\NN\407535|complete_116|(_107|mice_106|)_102|of_89|for_43|;_15 (r_conj) prevention_74\NN\1073995|(_38|2_37|(_26|)_21|or_19 (r_conj) rats_67\NNS\2329401|1_182|complete_172|of_152|;_15 (r_conj) prevention_40\NN\1073995|the_43|following_39|:_22 (l_prep) of_41\IN\0|1_30|complete_20|;_137|rats_152 (l_pobj) incapacity_43\NN\5644922|NONE_0 (l_acl) learn_45\VB\0|the_18 (l_dobj) response_49\NN\11410625|to_27 (l_prep) in_50\IN\13603305|a_27|discrete_25|escape_16 (l_pobj) rats_51\NNS\2329401|NONE_0 (l_acl) exposed_52\VBN\2110927|NONE_0 (l_prep) to_53\IN\0|before_37 (l_pobj) hypercapnia_55\NN\14034177|NONE_0
D002701_D006935 NONE chloramphenicol_138\NN\2716866|NONE_0 (r_pobj) by_137\IN\0|in_17 (r_agent) induced_132\VBN\1627355|a_25|passive_23|avoidance_15|administered_61 (r_acl) task_131\NN\575741|NONE_0 (r_pobj) for_127\IN\0|(_64|4_63|)_62|of_49|;_132|reversal_138 (r_prep) prevention_116\NN\1073995|3_158|complete_155|against_135|for_119|;_6 (l_conj) reversal_149\NN\199130|(_202|4_201|)_200|of_187|for_138|;_6 (l_conj) prevention_186\NN\1073995|(_200|5_199|)_198|,_188|administered_181|h_155|,_128|of_126|injected_32|;_6 (l_prep) in_190\IN\13603305|(_30|6_29|)_28|of_15 (l_pobj) retrieval_192\NN\13450862|NONE_0 (l_prep) of_193\IN\0|the_14 (l_pobj) task_197\NN\575741|NONE_0 (l_acl) induced_198\VBN\1627355|an_25|active_22|avoidance_15|applied_61 (l_agent) by_201\IN\0|in_8 (l_pobj) electroshock_203\NN\662681|NONE_0 (l_conj) hypercapnia_205\NN\14034177|subconvulsant_30|or_3
8742498
D000431_D056486 CID ethanol_35\NN\14708720|simultaneous_13|in_20 (r_compound) consumption_36\NN\13440063|NONE_0 (r_pobj) of_33\IN\0|the_14 (r_prep) influence_32\NN\5190804|NONE_0 (r_dobj) evaluates_30\VBZ\670261|on_63|parp_54|,_45|in_43|and_4 (r_conj) acts_20\VBZ\0|the_28 (l_prep) in_22\IN\13603305|on_20|parp_11|,_2|and_39|evaluates_43 (l_pobj) mice_25\NNS\2329401|NONE_0 (l_prep) with_26\IN\0|female_17|nmri_10 (l_pobj) hepatitis_28\NN\14127211|NONE_0
D000431_D056486 CID ethanol_25\NN\14708720|NONE_0 (r_pobj) by_24\IN\0|in_11|on_19 (r_agent) caused_23\VBN\1617192|the_17 (r_acl) exacerbation_22\NN\374224|NONE_0 (r_pobj) unlike_20\IN\0|,_68|damage_80|was_87|by_101|._118 (r_prep) inhibited_37\VBN\2510337|in_205|,_189|increases_176|were_133|in_119|,_97|and_95 (l_nsubjpass) damage_35\NN\7296428|unlike_80|,_12|was_7|by_21|._38
D000431_D056486 CID ethanol_42\NN\14708720|NONE_0 (r_pobj) by_41\IN\0|50_4 (r_prep) %_40\NN\0|NONE_0 (r_pobj) by_38\IN\0|unlike_101|,_33|damage_21|was_14|._17 (r_agent) inhibited_37\VBN\2510337|in_205|,_189|increases_176|were_133|in_119|,_97|and_95 (l_nsubjpass) damage_35\NN\7296428|unlike_80|,_12|was_7|by_21|._38
D000431_D056486 CID ethanol_15\NN\14708720|/_7|aap_8|-_11 (r_nmod) mice_19\NNS\2329401|NONE_0 (r_pobj) to_14\IN\0|when_19|naa_14|was_10 (r_dative) given_13\VBN\5892096|reduction_50|was_27|,_15|._25 (r_advcl) observed_8\VBN\2163746|NONE_0 (l_nsubjpass) reduction_4\NN\351485|was_23|,_35|given_50|._75 (l_prep) of_5\IN\0|a_24|further_22|%_12 (l_pobj) hepatitis_6\NN\14127211|NONE_0
D000431_D056486 CID ethanol_14\NN\14708720|NONE_0 (r_pobj) by_13\IN\0|its_17 (r_prep) exacerbation_12\NN\374224|the_34|induced_26|and_8 (r_conj) hepatitis_9\NN\14127211|that_21|can_42|either_46|be_53|by_64
D019289_D056486 NONE pyruvate_18\NN\0|(_22|gpt_23|)_26 (r_compound) transaminase_19\NN\15077571|oxaloacetate_55|(_29|got_28|)_25|and_23 (r_conj) transaminase_11\NN\15077571|NONE_0 (r_pobj) of_7\IN\0|serum_17 (r_prep) activities_6\NNS\30358|NONE_0 (r_pobj) as_4\IN\14622893|injuries_25|were_16|._106 (r_prep) quantified_3\VBN\947077|NONE_0 (l_nsubjpass) injuries_1\NNS\14052046|were_9|as_25|._131
D018698_D056486 NONE glutamate_8\NN\15010703|-_9 (r_compound) oxaloacetate_10\NN\15010703|(_26|got_27|)_30|and_32|transaminase_55 (r_compound) transaminase_11\NN\15077571|NONE_0 (r_pobj) of_7\IN\0|serum_17 (r_prep) activities_6\NNS\30358|NONE_0 (r_pobj) as_4\IN\14622893|injuries_25|were_16|._106 (r_prep) quantified_3\VBN\947077|NONE_0 (l_nsubjpass) injuries_1\NNS\14052046|were_9|as_25|._131
D018698_D056486 NONE glutamate_16\NN\15010703|-_9 (r_npadvmod) pyruvate_18\NN\0|(_22|gpt_23|)_26 (r_compound) transaminase_19\NN\15077571|oxaloacetate_55|(_29|got_28|)_25|and_23 (r_conj) transaminase_11\NN\15077571|NONE_0 (r_pobj) of_7\IN\0|serum_17 (r_prep) activities_6\NNS\30358|NONE_0 (r_pobj) as_4\IN\14622893|injuries_25|were_16|._106 (r_prep) quantified_3\VBN\947077|NONE_0 (l_nsubjpass) injuries_1\NNS\14052046|were_9|as_25|._131
D009536_D056486 NONE amide_10\NN\14727670|NONE_0 (r_pobj) of_7\IN\0|the_29|hepatoprotective_25 (r_prep) effects_6\NNS\13245626|recently_47|,_39|we_37|aap)-hepatitis_144|,_158|suggesting_160|._255 (r_dobj) demonstrated_3\VBD\2137132|NONE_0 (l_npadvmod) aap)-hepatitis_33\NNP\0|recently_191|,_183|we_181|effects_144|,_14|suggesting_16|._111
D009536_D056486 NONE amide_10\NN\14727670|NONE_0 (r_pobj) of_7\IN\0|the_29|hepatoprotective_25 (r_prep) effects_6\NNS\13245626|recently_47|,_39|we_37|aap)-hepatitis_144|,_158|suggesting_160|._255 (r_dobj) demonstrated_3\VBD\2137132|NONE_0 (l_advcl) suggesting_35\VBG\1010118|recently_207|,_199|we_197|effects_160|aap)-hepatitis_16|,_2|._95 (l_ccomp) involves_43\VBZ\2676054|NONE_0 (l_nsubj) injury_42\NN\14052046|that_27|step_18
D009536_D056486 NONE naa_11\NNP\0|when_5|was_4|to_14 (r_nsubjpass) given_13\VBN\5892096|reduction_50|was_27|,_15|._25 (r_advcl) observed_8\VBN\2163746|NONE_0 (l_nsubjpass) reduction_4\NN\351485|was_23|,_35|given_50|._75 (l_prep) of_5\IN\0|a_24|further_22|%_12 (l_pobj) hepatitis_6\NN\14127211|NONE_0
D009536_D056486 NONE naa_27\NNP\0|or_4|by_7 (r_pobj) by_26\IN\0|product_27|of_8 (r_prep) inhibition_23\NN\1068773|NONE_0 (r_pobj) by_19\IN\0|that_85|hepatitis_64|can_22|either_18|be_11 (r_agent) reduced_18\VBN\441445|NONE_0 (l_nsubjpass) hepatitis_9\NN\14127211|that_21|can_42|either_46|be_53|by_64
D009536_D056486 NONE naa_6\NNP\0|NONE_0 (r_pobj) of_5\IN\0|the_21|main_17 (r_prep) application_4\NN\947128|we_16|as_19|in_96|._180 (r_dobj) see_1\VBP\8647945|NONE_0 (l_prep) in_17\IN\13603305|we_112|application_96|as_77|._84 (l_pobj) order_18\NN\7168131|NONE_0 (l_acl) avoid_20\VB\0|NONE_0 (l_dobj) damage_22\NN\7296428|to_17
D011064_D056486 NONE )_19\-RRB-\0|ribose_6|(_13|parp_14|;_18|ec_20|)_31 (r_punct) polymerase_20\NN\14732946|NONE_0 (r_pobj) of_15\IN\0|a_22|selective_20|on_51 (r_prep) inhibitor_14\NN\20090|nicotinic_34|acid_24|,_14 (r_appos) amide_10\NN\14727670|NONE_0 (r_pobj) of_7\IN\0|the_29|hepatoprotective_25 (r_prep) effects_6\NNS\13245626|recently_47|,_39|we_37|aap)-hepatitis_144|,_158|suggesting_160|._255 (r_dobj) demonstrated_3\VBD\2137132|NONE_0 (l_npadvmod) aap)-hepatitis_33\NNP\0|recently_191|,_183|we_181|effects_144|,_14|suggesting_16|._111
D011064_D056486 NONE )_19\-RRB-\0|ribose_6|(_13|parp_14|;_18|ec_20|)_31 (r_punct) polymerase_20\NN\14732946|NONE_0 (r_pobj) of_15\IN\0|a_22|selective_20|on_51 (r_prep) inhibitor_14\NN\20090|nicotinic_34|acid_24|,_14 (r_appos) amide_10\NN\14727670|NONE_0 (r_pobj) of_7\IN\0|the_29|hepatoprotective_25 (r_prep) effects_6\NNS\13245626|recently_47|,_39|we_37|aap)-hepatitis_144|,_158|suggesting_160|._255 (r_dobj) demonstrated_3\VBD\2137132|NONE_0 (l_advcl) suggesting_35\VBG\1010118|recently_207|,_199|we_197|effects_160|aap)-hepatitis_16|,_2|._95 (l_ccomp) involves_43\VBZ\2676054|NONE_0 (l_nsubj) injury_42\NN\14052046|that_27|step_18
D000082_D056486 CID acetaminophen_9\NN\2707683|hepatotoxicity_14 (r_pobj) on_8\IN\0|of_18 (l_pobj) hepatotoxicity_10\NN\0|acetaminophen_14
D000082_D056486 CID acetaminophen_31\NN\2707683|NONE_0 (r_pobj) from_30\IN\0|mice_15 (r_prep) suffering_29\VBG\14322699|NONE_0 (r_pcomp) on_27\IN\0|a_73|selective_71|of_51 (r_prep) inhibitor_14\NN\20090|nicotinic_34|acid_24|,_14 (r_appos) amide_10\NN\14727670|NONE_0 (r_pobj) of_7\IN\0|the_29|hepatoprotective_25 (r_prep) effects_6\NNS\13245626|recently_47|,_39|we_37|aap)-hepatitis_144|,_158|suggesting_160|._255 (r_dobj) demonstrated_3\VBD\2137132|NONE_0 (l_npadvmod) aap)-hepatitis_33\NNP\0|recently_191|,_183|we_181|effects_144|,_14|suggesting_16|._111
D000082_D056486 CID acetaminophen_31\NN\2707683|NONE_0 (r_pobj) from_30\IN\0|mice_15 (r_prep) suffering_29\VBG\14322699|NONE_0 (r_pcomp) on_27\IN\0|a_73|selective_71|of_51 (r_prep) inhibitor_14\NN\20090|nicotinic_34|acid_24|,_14 (r_appos) amide_10\NN\14727670|NONE_0 (r_pobj) of_7\IN\0|the_29|hepatoprotective_25 (r_prep) effects_6\NNS\13245626|recently_47|,_39|we_37|aap)-hepatitis_144|,_158|suggesting_160|._255 (r_dobj) demonstrated_3\VBD\2137132|NONE_0 (l_advcl) suggesting_35\VBG\1010118|recently_207|,_199|we_197|effects_160|aap)-hepatitis_16|,_2|._95 (l_ccomp) involves_43\VBZ\2676054|NONE_0 (l_nsubj) injury_42\NN\14052046|that_27|step_18
D000082_D056486 CID aap)-hepatitis_33\NNP\0|recently_191|,_183|we_181|effects_144|,_14|suggesting_16|._111
D000082_D056486 CID aap)-hepatitis_33\NNP\0|recently_191|,_183|we_181|effects_144|,_14|suggesting_16|._111 (r_npadvmod) demonstrated_3\VBD\2137132|NONE_0 (l_advcl) suggesting_35\VBG\1010118|recently_207|,_199|we_197|effects_160|aap)-hepatitis_16|,_2|._95 (l_ccomp) involves_43\VBZ\2676054|NONE_0 (l_nsubj) injury_42\NN\14052046|that_27|step_18
D000082_D056486 CID aap_38\NNP\0|-_3 (r_npadvmod) induced_40\VBN\1627355|the_8|liver_8 (r_amod) injury_42\NN\14052046|that_27|step_18 (r_nsubj) involves_43\VBZ\2676054|NONE_0 (r_ccomp) suggesting_35\VBG\1010118|recently_207|,_199|we_197|effects_160|aap)-hepatitis_16|,_2|._95 (r_advcl) demonstrated_3\VBD\2137132|NONE_0 (l_npadvmod) aap)-hepatitis_33\NNP\0|recently_191|,_183|we_181|effects_144|,_14|suggesting_16|._111
D000082_D056486 CID aap_38\NNP\0|-_3 (r_npadvmod) induced_40\VBN\1627355|the_8|liver_8 (r_amod) injury_42\NN\14052046|that_27|step_18
D000082_D056486 CID aap_27\NNP\0|NONE_0 (r_compound) hepatitis_28\NN\14127211|NONE_0
D000082_D056486 CID aap_17\NNP\0|NONE_0 (r_pobj) of_16\IN\0|the_13 (r_prep) presence_15\NN\13954253|NONE_0 (r_pobj) in_13\IN\13603305|in_86|,_70|increases_57|were_14|,_22|and_24|inhibited_119 (r_prep) measured_12\VBN\697589|NONE_0 (l_conj) inhibited_37\VBN\2510337|in_205|,_189|increases_176|were_133|in_119|,_97|and_95 (l_nsubjpass) damage_35\NN\7296428|unlike_80|,_12|was_7|by_21|._38
D000082_D056486 CID aap_17\NNP\0|ethanol_8|/_1|-_3 (r_compound) mice_19\NNS\2329401|NONE_0 (r_pobj) to_14\IN\0|when_19|naa_14|was_10 (r_dative) given_13\VBN\5892096|reduction_50|was_27|,_15|._25 (r_advcl) observed_8\VBN\2163746|NONE_0 (l_nsubjpass) reduction_4\NN\351485|was_23|,_35|given_50|._75 (l_prep) of_5\IN\0|a_24|further_22|%_12 (l_pobj) hepatitis_6\NN\14127211|NONE_0
D000082_D056486 CID aap_6\NNP\0|-_3 (r_npadvmod) induced_8\VBN\1627355|the_8|and_18|exacerbation_26 (r_amod) hepatitis_9\NN\14127211|that_21|can_42|either_46|be_53|by_64
D000082_D056486 CID acetaminophen_16\NN\2707683|NONE_0 (r_pobj) of_15\IN\0|pharmaceutical_28 (r_prep) preparations_14\NNS\407535|NONE_0 (r_pobj) in_12\IN\13603305|the_22|combinational_18 (r_prep) use_11\NN\407535|NONE_0 (r_pobj) for_8\IN\0|NONE_0 (r_prep) as_7\IN\14622893|we_35|application_19|in_77|._161 (r_prep) see_1\VBP\8647945|NONE_0 (l_prep) in_17\IN\13603305|we_112|application_96|as_77|._84 (l_pobj) order_18\NN\7168131|NONE_0 (l_acl) avoid_20\VB\0|NONE_0 (l_dobj) damage_22\NN\7296428|to_17
D062907_D056486 NONE oxaloacetate_10\NN\15010703|(_26|got_27|)_30|and_32|transaminase_55 (r_compound) transaminase_11\NN\15077571|NONE_0 (r_pobj) of_7\IN\0|serum_17 (r_prep) activities_6\NNS\30358|NONE_0 (r_pobj) as_4\IN\14622893|injuries_25|were_16|._106 (r_prep) quantified_3\VBN\947077|NONE_0 (l_nsubjpass) injuries_1\NNS\14052046|were_9|as_25|._131
D009243_D056486 NONE nad_5\NNP\14800277|-_3 (r_compound) precursors_7\NNS\14580897|NONE_0 (r_pobj) of_4\IN\0|on_18 (r_prep) free_3\JJ\7942152|of_8|._62 (l_prep) on_8\IN\0|of_18 (l_pobj) hepatotoxicity_10\NN\0|acetaminophen_14
D009243_D056486 NONE nad_13\NNP\14800277|NONE_0 (l_appos) substrate_16\NN\19613|,_6 (l_relcl) acts_20\VBZ\0|the_28 (l_prep) in_22\IN\13603305|on_20|parp_11|,_2|and_39|evaluates_43 (l_pobj) mice_25\NNS\2329401|NONE_0 (l_prep) with_26\IN\0|female_17|nmri_10 (l_pobj) hepatitis_28\NN\14127211|NONE_0
D009243_D056486 NONE nad_37\NNP\14800277|enzyme_19 (r_appos) substrate_36\NN\19613|NONE_0 (r_pobj) of_32\IN\0|dietary_18 (r_prep) depletion_31\NN\351638|NONE_0 (r_pobj) by_29\IN\0|naa_7|or_3 (r_conj) by_26\IN\0|product_27|of_8 (r_prep) inhibition_23\NN\1068773|NONE_0 (r_pobj) by_19\IN\0|that_85|hepatitis_64|can_22|either_18|be_11 (r_agent) reduced_18\VBN\441445|NONE_0 (l_nsubjpass) hepatitis_9\NN\14127211|that_21|can_42|either_46|be_53|by_64
1415380
D011803_D006463 CID quinine_8\NN\2721948|NONE_0 (r_pobj) of_7\IN\0|NONE_0 (r_prep) ingestion_6\NN\13440063|NONE_0 (r_pobj) with_5\IN\0|NONE_0 (r_prep) associated_4\VBN\628491|uremic_16|._36 (r_acl) syndrome_3\NN\5870365|NONE_0
D011803_D006463 CID quinine_5\NN\2721948|NONE_0 (r_compound) ingestion_6\NN\13440063|NONE_0 (r_pobj) following_4\VBG\8180190|uremic_16 (r_prep) syndrome_3\NN\5870365|phenomenon_58|,_68|with_70|._134
D011803_D006463 CID quinine_0\NN\2721948|-_7 (r_npadvmod) associated_2\VBN\628491|uremic_21 (r_amod) syndrome_6\NN\5870365|probably_9|often_30|._54
8480959
D003401_D009135 NONE creatine_7\NN\14601829|NONE_0 (r_compound) kinase_8\NN\14732946|greater_18 (r_compound) elevations_9\NNS\7445480|NONE_0 (r_pobj) with_6\IN\0|muscle_16 (r_prep) symptoms_5\NNS\5823932|NONE_0 (r_pobj) as_3\IN\14622893|,_10 (r_prep) defined_2\VBN\2604760|NONE_0 (r_acl) myopathy_0\NNP\14204950|,_116|rare_122|and_127|associated_131|._203
D008148_D006937 NONE lovastatin_4\NN\3676175|NONE_0 (r_pobj) of_3\IN\0|and_17|tolerability_13|in_14|._62 (r_prep) efficacy_0\NN\5199286|NONE_0 (l_prep) in_5\IN\13603305|and_31|tolerability_27|of_14|._48 (l_pobj) women_7\NNS\9605289|NONE_0 (l_prep) with_8\IN\0|3390_11 (l_pobj) hypercholesterolemia_10\NN\14299637|NONE_0
D008148_D006937 NONE lovastatin_7\NN\3676175|NONE_0 (r_pobj) of_6\IN\0|the_24|and_11|safety_7|in_14 (r_prep) efficacy_3\NN\5199286|to_16|with_43|._77 (r_dobj) evaluate_1\VB\670261|NONE_0 (l_prep) with_10\IN\0|to_59|efficacy_43|._34 (l_pobj) hypercholesterolemia_12\NN\14299637|NONE_0
D008148_D006937 NONE lovastatin_0\NNP\3676175|effective_21|and_31|tolerated_50|._112 (r_nsubj) is_1\VBZ\0|NONE_0 (l_conj) tolerated_7\VBN\802318|lovastatin_50|effective_29|and_19|._62 (l_prep) as_8\IN\14622893|generally_25|well_15 (l_pobj) therapy_9\NN\657604|NONE_0 (l_prep) for_10\IN\0|NONE_0 (l_pobj) hypercholesterolemia_12\NN\14299637|NONE_0
D008148_D009135 CID lovastatin_31\NN\3676175|NONE_0 (r_pobj) of_30\IN\0|the_35|recommended_23|daily_11|mg_18 (r_prep) dose_29\NN\3740161|NONE_0 (r_pobj) with_24\IN\0|NONE_0 (r_prep) associated_23\VBN\628491|myopathy_131|,_15|rare_9|and_4|._72 (r_conj) was_20\VBD\0|NONE_0 (l_nsubj) myopathy_0\NNP\14204950|,_116|rare_122|and_127|associated_131|._203
17965424
D004008_D005767 CID diclofenac_14\NNP\0|NONE_0 (r_pobj) than_13\IN\0|NONE_0 (r_prep) etoricoxib_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|significantly_20 (r_prep) lower_10\JJR\2831724|rate_37|;_92|ratio_101|._145 (r_acomp) was_8\VBD\0|NONE_0 (l_nsubj) rate_3\NN\13815152|lower_37|;_129|ratio_138|._182 (l_amod) due_4\IN\5174653|the_36|cumulative_32|discontinuation_21 (l_pcomp) to_5\IN\0|NONE_0 (l_pobj) aes_7\NNS\0|NONE_0
D004008_D005767 CID diclofenac_17\NNP\0|150_11|mg._15|from_36 (r_nmod) discontinuations_20\NNS\209943|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) compared_15\VBN\644583|treatment_24|due_14 (r_prep) discontinuing_9\VBG\0|NONE_0 (l_prep) due_11\IN\5174653|treatment_10|compared_14 (l_pcomp) to_12\IN\0|NONE_0 (l_pobj) aes_14\NNS\0|NONE_0
D004008_D005767 CID diclofenac_17\NNP\0|150_11|mg._15|from_36 (r_nmod) discontinuations_20\NNS\209943|NONE_0 (r_pobj) with_16\IN\0|NONE_0 (r_prep) compared_15\VBN\644583|treatment_24|due_14 (r_prep) discontinuing_9\VBG\0|NONE_0 (r_pcomp) for_8\IN\0|a_27|lower_11 (r_prep) risk_7\NN\14541044|etoricoxib_52|mg_38|,_118|common_134 (r_dobj) demonstrated_3\VBD\2137132|,_209|higher_230|._252 (l_advcl) common_27\JJ\8673395|etoricoxib_186|mg_172|risk_134|,_16 (l_prep) than_28\IN\0|although_21|less_12 (l_pobj) discontinuations_29\NNS\209943|NONE_0 (l_prep) from_30\IN\0|NONE_0 (l_pobj) aes_32\NNS\0|NONE_0
C422649_D004487 CID etoricoxib_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|significantly_21 (r_prep) higher_15\JJR\0|incidence_97|compared_52|;_104|p<0.001_106|._153 (r_acomp) were_13\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|higher_97|compared_149|;_201|p<0.001_203|._250 (l_prep) of_2\IN\0|the_14 (l_pobj) discontinuations_3\NNS\209943|NONE_0 (l_prep) for_4\IN\0|NONE_0 (l_pobj) aes_12\NNS\0|NONE_0 (l_amod) related_7\VBN\628491|NONE_0 (l_conj) related_11\VBN\628491|hypertension_32|-_20|and_11 (l_npadvmod) oedema_9\NN\14315192|-_6
C422649_D004487 CID etoricoxib_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|significantly_21 (r_prep) higher_15\JJR\0|incidence_97|compared_52|;_104|p<0.001_106|._153 (r_acomp) were_13\VBD\0|NONE_0 (l_dep) p<0.001_37\VB\0|incidence_203|higher_106|compared_54|;_2|._47 (l_prep) for_38\IN\0|)_38 (l_pobj) hypertension_39\NN\14057371|NONE_0 (l_conj) p<0.01_41\NN\0|and_4 (l_prep) for_42\IN\0|NONE_0 (l_pobj) oedema_43\NN\14315192|NONE_0
D004008_D001172 NONE sodium_15\NN\14625458|diclofenac_11|gastrointestinal_7|and_37|trial_55|ii_67 (r_compound) tolerability_17\NN\0|NONE_0 (r_pobj) vs_13\IN\13634784|the_15 (r_prep) etoricoxib_12\NN\0|NONE_0 (r_pobj) of_10\IN\0|)_101 (r_prep) results_9\NNS\34213|gastrointestinal_78|of_48|:_2|._110 (r_appos) tolerability_1\NN\0|NONE_0 (l_prep) of_2\IN\0|gastrointestinal_30|:_46|results_48|._158 (l_pobj) etoricoxib_3\NN\0|NONE_0 (l_prep) in_4\IN\13603305|NONE_0 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_compound) arthritis_6\NN\14171682|rheumatoid_11
D004008_D001172 NONE diclofenac_22\NN\0|and_4 (r_conj) etoricoxib_20\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_60|gastrointestinal_56|(_39|gi_38|)_36|,_22|safety_20 (r_prep) tolerability_14\NN\0|to_37|in_63 (r_dobj) compare_8\VB\4744814|a_36|randomised_34|,_24|blind_15|._139 (l_prep) in_23\IN\13603305|to_100|tolerability_63 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) arthritis_27\NN\14171682|NONE_0
D004008_D001172 NONE diclofenac_22\NN\0|and_4 (r_conj) etoricoxib_20\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_60|gastrointestinal_56|(_39|gi_38|)_36|,_22|safety_20 (r_prep) tolerability_14\NN\0|to_37|in_63 (r_dobj) compare_8\VB\4744814|a_36|randomised_34|,_24|blind_15|._139 (l_prep) in_23\IN\13603305|to_100|tolerability_63 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) arthritis_27\NN\14171682|NONE_0 (l_appos) ra_29\NNP\14625458|rheumatoid_22|(_1|)_2
D004008_D001172 NONE diclofenac_28\NN\0|75_11 (r_nmod) mg_30\NN\13717155|daily_9|2054_20|)_24 (r_compound) twice_31\RB\0|years_106|were_81|and_67|received_63|or_20|._22 (r_conj) enrolled_15\VBN\2471690|NONE_0 (l_nsubjpass) years_9\NNS\15144371|were_25|and_39|received_43|or_86|twice_106|._128 (l_acl) diagnosed_11\VBD\644583|a_47|age_16|60.8_12|)_2 (l_prep) with_12\IN\0|NONE_0 (l_pobj) ra_13\NNP\14625458|NONE_0
C422649_D006973 CID etoricoxib_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|significantly_21 (r_prep) higher_15\JJR\0|incidence_97|compared_52|;_104|p<0.001_106|._153 (r_acomp) were_13\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|higher_97|compared_149|;_201|p<0.001_203|._250 (l_prep) of_2\IN\0|the_14 (l_pobj) discontinuations_3\NNS\209943|NONE_0 (l_prep) for_4\IN\0|NONE_0 (l_pobj) aes_12\NNS\0|NONE_0 (l_amod) related_7\VBN\628491|NONE_0 (l_npadvmod) hypertension_5\NN\14057371|-_12|and_21|related_32
C422649_D006973 CID etoricoxib_17\NN\0|NONE_0 (r_pobj) with_16\IN\0|significantly_21 (r_prep) higher_15\JJR\0|incidence_97|compared_52|;_104|p<0.001_106|._153 (r_acomp) were_13\VBD\0|NONE_0 (l_dep) p<0.001_37\VB\0|incidence_203|higher_106|compared_54|;_2|._47 (l_prep) for_38\IN\0|)_38 (l_pobj) hypertension_39\NN\14057371|NONE_0
C422649_D001172 NONE etoricoxib_3\NN\0|NONE_0 (l_prep) in_4\IN\13603305|NONE_0 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_compound) arthritis_6\NN\14171682|rheumatoid_11
C422649_D001172 NONE etoricoxib_12\NN\0|NONE_0 (r_pobj) of_10\IN\0|)_101 (r_prep) results_9\NNS\34213|gastrointestinal_78|of_48|:_2|._110 (r_appos) tolerability_1\NN\0|NONE_0 (l_prep) of_2\IN\0|gastrointestinal_30|:_46|results_48|._158 (l_pobj) etoricoxib_3\NN\0|NONE_0 (l_prep) in_4\IN\13603305|NONE_0 (l_pobj) patients_7\NNS\9898892|NONE_0 (l_compound) arthritis_6\NN\14171682|rheumatoid_11
C422649_D001172 NONE etoricoxib_20\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_60|gastrointestinal_56|(_39|gi_38|)_36|,_22|safety_20 (r_prep) tolerability_14\NN\0|to_37|in_63 (r_dobj) compare_8\VB\4744814|a_36|randomised_34|,_24|blind_15|._139 (l_prep) in_23\IN\13603305|to_100|tolerability_63 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) arthritis_27\NN\14171682|NONE_0
C422649_D001172 NONE etoricoxib_20\NN\0|NONE_0 (r_pobj) of_19\IN\0|the_60|gastrointestinal_56|(_39|gi_38|)_36|,_22|safety_20 (r_prep) tolerability_14\NN\0|to_37|in_63 (r_dobj) compare_8\VB\4744814|a_36|randomised_34|,_24|blind_15|._139 (l_prep) in_23\IN\13603305|to_100|tolerability_63 (l_pobj) patients_24\NNS\9898892|NONE_0 (l_prep) with_25\IN\0|NONE_0 (l_pobj) arthritis_27\NN\14171682|NONE_0 (l_appos) ra_29\NNP\14625458|rheumatoid_22|(_1|)_2
C422649_D001172 NONE etoricoxib_18\RB\0|daily_17 (r_dobj) received_17\VBN\2210855|years_43|were_18|and_4|or_43|twice_63|._85 (r_conj) enrolled_15\VBN\2471690|NONE_0 (l_nsubjpass) years_9\NNS\15144371|were_25|and_39|received_43|or_86|twice_106|._128 (l_acl) diagnosed_11\VBD\644583|a_47|age_16|60.8_12|)_2 (l_prep) with_12\IN\0|NONE_0 (l_pobj) ra_13\NNP\14625458|NONE_0
C422649_D005767 NONE etoricoxib_12\NN\0|NONE_0 (r_pobj) with_11\IN\0|significantly_20 (r_prep) lower_10\JJR\2831724|rate_37|;_92|ratio_101|._145 (r_acomp) was_8\VBD\0|NONE_0 (l_nsubj) rate_3\NN\13815152|lower_37|;_129|ratio_138|._182 (l_amod) due_4\IN\5174653|the_36|cumulative_32|discontinuation_21 (l_pcomp) to_5\IN\0|NONE_0 (l_pobj) aes_7\NNS\0|NONE_0
C422649_D005767 NONE etoricoxib_0\NNP\0|mg_14|risk_52|,_170|common_186 (r_nsubj) demonstrated_3\VBD\2137132|,_209|higher_230|._252 (l_dobj) risk_7\NN\14541044|etoricoxib_52|mg_38|,_118|common_134 (l_prep) for_8\IN\0|a_27|lower_11 (l_pcomp) discontinuing_9\VBG\0|NONE_0 (l_prep) due_11\IN\5174653|treatment_10|compared_14 (l_pcomp) to_12\IN\0|NONE_0 (l_pobj) aes_14\NNS\0|NONE_0
C422649_D005767 NONE etoricoxib_0\NNP\0|mg_14|risk_52|,_170|common_186 (r_nsubj) demonstrated_3\VBD\2137132|,_209|higher_230|._252 (l_advcl) common_27\JJ\8673395|etoricoxib_186|mg_172|risk_134|,_16 (l_prep) than_28\IN\0|although_21|less_12 (l_pobj) discontinuations_29\NNS\209943|NONE_0 (l_prep) from_30\IN\0|NONE_0 (l_pobj) aes_32\NNS\0|NONE_0
C422649_D005767 NONE etoricoxib_38\NN\0|NONE_0 (r_pobj) with_37\IN\0|significantly_21 (r_prep) higher_36\JJR\0|demonstrated_230|,_21|._22 (r_acomp) were_34\VBD\0|NONE_0 (l_ccomp) demonstrated_3\VBD\2137132|,_209|higher_230|._252 (l_dobj) risk_7\NN\14541044|etoricoxib_52|mg_38|,_118|common_134 (l_prep) for_8\IN\0|a_27|lower_11 (l_pcomp) discontinuing_9\VBG\0|NONE_0 (l_prep) due_11\IN\5174653|treatment_10|compared_14 (l_pcomp) to_12\IN\0|NONE_0 (l_pobj) aes_14\NNS\0|NONE_0
C422649_D005767 NONE etoricoxib_38\NN\0|NONE_0 (r_pobj) with_37\IN\0|significantly_21 (r_prep) higher_36\JJR\0|demonstrated_230|,_21|._22 (r_acomp) were_34\VBD\0|NONE_0 (l_ccomp) demonstrated_3\VBD\2137132|,_209|higher_230|._252 (l_advcl) common_27\JJ\8673395|etoricoxib_186|mg_172|risk_134|,_16 (l_prep) than_28\IN\0|although_21|less_12 (l_pobj) discontinuations_29\NNS\209943|NONE_0 (l_prep) from_30\IN\0|NONE_0 (l_pobj) aes_32\NNS\0|NONE_0
D004008_D006973 NONE diclofenac_28\NNP\0|NONE_0 (r_pobj) with_27\IN\0|respectively_31 (r_prep) compared_26\VBN\644583|incidence_149|higher_52|;_52|p<0.001_54|._101 (r_prep) were_13\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|higher_97|compared_149|;_201|p<0.001_203|._250 (l_prep) of_2\IN\0|the_14 (l_pobj) discontinuations_3\NNS\209943|NONE_0 (l_prep) for_4\IN\0|NONE_0 (l_pobj) aes_12\NNS\0|NONE_0 (l_amod) related_7\VBN\628491|NONE_0 (l_npadvmod) hypertension_5\NN\14057371|-_12|and_21|related_32
D004008_D006973 NONE diclofenac_28\NNP\0|NONE_0 (r_pobj) with_27\IN\0|respectively_31 (r_prep) compared_26\VBN\644583|incidence_149|higher_52|;_52|p<0.001_54|._101 (r_prep) were_13\VBD\0|NONE_0 (l_dep) p<0.001_37\VB\0|incidence_203|higher_106|compared_54|;_2|._47 (l_prep) for_38\IN\0|)_38 (l_pobj) hypertension_39\NN\14057371|NONE_0
D004008_D004487 NONE diclofenac_28\NNP\0|NONE_0 (r_pobj) with_27\IN\0|respectively_31 (r_prep) compared_26\VBN\644583|incidence_149|higher_52|;_52|p<0.001_54|._101 (r_prep) were_13\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|higher_97|compared_149|;_201|p<0.001_203|._250 (l_prep) of_2\IN\0|the_14 (l_pobj) discontinuations_3\NNS\209943|NONE_0 (l_prep) for_4\IN\0|NONE_0 (l_pobj) aes_12\NNS\0|NONE_0 (l_amod) related_7\VBN\628491|NONE_0 (l_conj) related_11\VBN\628491|hypertension_32|-_20|and_11 (l_npadvmod) oedema_9\NN\14315192|-_6
D004008_D004487 NONE diclofenac_28\NNP\0|NONE_0 (r_pobj) with_27\IN\0|respectively_31 (r_prep) compared_26\VBN\644583|incidence_149|higher_52|;_52|p<0.001_54|._101 (r_prep) were_13\VBD\0|NONE_0 (l_dep) p<0.001_37\VB\0|incidence_203|higher_106|compared_54|;_2|._47 (l_prep) for_38\IN\0|)_38 (l_pobj) hypertension_39\NN\14057371|NONE_0 (l_conj) p<0.01_41\NN\0|and_4 (l_prep) for_42\IN\0|NONE_0 (l_pobj) oedema_43\NN\14315192|NONE_0
6381653
D007980_D004409 CID levodopa_0\NNP\14604959|-_8 (r_npadvmod) induced_2\VBN\1627355|and_19|thalamotomy_23|._34 (r_amod) dyskinesia_3\JJ\14084880|NONE_0
D007980_D004409 CID levodopa_0\NNP\14604959|-_8|dyskinesia_17|alleviated_130|._337 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) dyskinesia_3\NN\14084880|levodopa_17|-_9|alleviated_113|._320
D007980_D004409 CID levodopa_2\NN\14604959|-_8 (r_npadvmod) induced_4\VBN\1627355|by_20 (r_amod) dyskinesias_5\NNS\14084880|NONE_0
D007980_D020821 NONE levodopa_0\NNP\14604959|-_8|dyskinesia_17|alleviated_130|._337 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) dyskinesia_3\NN\14084880|levodopa_17|-_9|alleviated_113|._320 (l_prep) in_7\IN\13603305|of_13 (l_pobj) cases_9\NNS\7283608|NONE_0 (l_prep) of_10\IN\0|thirteen_15 (l_pobj) parkinsonism_11\NNP\14085708|NONE_0 (l_relcl) was_14\VBD\0|,_8|,_42 (l_attr) choreic_15\JJ\0|which_10 (l_conj) ballistic_17\JJ\0|,_2|in_22 (l_conj) dystonic_19\JJ\0|or_3
D007980_D013786 NONE levodopa_2\NN\14604959|-_8 (r_npadvmod) induced_4\VBN\1627355|by_20 (r_amod) dyskinesias_5\NNS\14084880|NONE_0 (l_prep) by_6\IN\0|induced_20 (l_pobj) lesions_8\NNS\14204950|NONE_0
D007980_D010302 NONE levodopa_0\NNP\14604959|-_8|dyskinesia_17|alleviated_130|._337 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) dyskinesia_3\NN\14084880|levodopa_17|-_9|alleviated_113|._320 (l_prep) in_7\IN\13603305|of_13 (l_pobj) cases_9\NNS\7283608|NONE_0 (l_prep) of_10\IN\0|thirteen_15 (l_pobj) parkinsonism_11\NNP\14085708|NONE_0
D007980_D010302 NONE levodopa_2\NN\14604959|-_8 (r_npadvmod) induced_4\VBN\1627355|by_20 (r_amod) dyskinesias_5\NNS\14084880|NONE_0 (r_pobj) of_1\IN\0|in_52 (r_prep) control_0\NN\5190804|is_111|._123 (l_prep) in_9\IN\13603305|of_52 (l_pobj) course_11\NN\883297|NONE_0 (l_prep) of_12\IN\0|the_11 (l_pobj) treatment_14\NN\654885|NONE_0 (l_prep) of_15\IN\0|routine_18 (l_pobj) parkinsonism_16\NNP\14085708|NONE_0
12691807
D007980_D008538 NONE levodopa_10\NN\14604959|-_8 (r_npadvmod) induced_12\VBN\1627355|reversible_20|oromandibular_8|(_31|omd_32|)_35 (r_amod) dystonia_14\NN\0|NONE_0
D007980_D008538 NONE levodopa_10\NN\14604959|-_8 (r_npadvmod) induced_12\VBN\1627355|reversible_20|oromandibular_8|(_31|omd_32|)_35 (r_amod) dystonia_14\NN\0|NONE_0 (l_appos) omd_16\NNP\0|reversible_52|induced_32|oromandibular_24|(_1|)_3
D007980_D004421 CID levodopa_0\NNP\14604959|-_8|dystonia_31|._73 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) dystonia_4\NN\0|levodopa_31|-_23|._42
D007980_D004409 NONE levodopa_0\NNP\14604959|-_8 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) dyskinesias_3\NNS\14084880|have_12|been_17|in_31|._81
D007980_D019578 NONE levodopa_0\NNP\14604959|-_8 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) dyskinesias_3\NNS\14084880|have_12|been_17|in_31|._81 (r_nsubjpass) reported_6\VBN\831651|NONE_0 (l_prep) in_7\IN\13603305|dyskinesias_31|have_19|been_14|._50 (l_pobj) disease_10\NN\14061805|NONE_0 (l_conj) atrophy_14\NN\14299637|parkinson_40|and_20
D007980_D013494 NONE levodopa_0\NNP\14604959|-_8|dystonia_31|._73 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (l_dobj) dystonia_4\NN\0|levodopa_31|-_23|._42 (l_prep) in_5\IN\13603305|oromandibular_23 (l_pobj) palsy_8\JJ\14557898|NONE_0
D007980_D013494 NONE levodopa_10\NN\14604959|-_8 (r_npadvmod) induced_12\VBN\1627355|reversible_20|oromandibular_8|(_31|omd_32|)_35 (r_amod) dystonia_14\NN\0|NONE_0 (r_pobj) of_8\IN\0|an_16|unusual_13|in_60 (r_prep) case_7\NN\7283608|in_38|we_23|highlight_85|._233 (l_prep) in_18\IN\13603305|an_76|unusual_73|of_60 (l_pobj) patient_21\NN\9898892|NONE_0 (l_compound) psp_20\NNP\0|a_2
D007980_D013494 NONE levodopa_10\NN\14604959|-_8 (r_npadvmod) induced_12\VBN\1627355|reversible_20|oromandibular_8|(_31|omd_32|)_35 (r_amod) dystonia_14\NN\0|NONE_0 (r_pobj) of_8\IN\0|an_16|unusual_13|in_60 (r_prep) case_7\NN\7283608|in_38|we_23|highlight_85|._233 (r_dobj) describe_4\VBP\1001294|NONE_0 (l_advcl) highlight_23\VB\13809920|in_123|we_108|case_85|._148 (l_dobj) importance_25\NN\5138488|to_17 (l_prep) of_26\IN\0|the_15 (l_pcomp) recognizing_27\VBG\686447|NONE_0 (l_dobj) complication_31\NN\1073995|,_37|and_39|discuss_43 (l_prep) in_32\IN\13603305|this_31|related_21 (l_pobj) management_34\NN\1123598|NONE_0 (l_prep) of_35\IN\0|the_15 (l_pobj) psp_36\NNP\0|NONE_0
D007980_D010300 NONE levodopa_0\NNP\14604959|-_8 (r_npadvmod) induced_2\VBN\1627355|NONE_0 (r_amod) dyskinesias_3\NNS\14084880|have_12|been_17|in_31|._81 (r_nsubjpass) reported_6\VBN\831651|NONE_0 (l_prep) in_7\IN\13603305|dyskinesias_31|have_19|been_14|._50 (l_pobj) disease_10\NN\14061805|NONE_0
2055425
D018723_D003920 NONE bethanechol_23\NN\0|,_6|and_4 (r_conj) atp_20\NNP\14964590|nerve_19|,_2 (r_conj) stimulation_18\NN\242808|NONE_0 (r_pobj) to_16\TO\0|contractile_64|of_42|from_19 (r_prep) responses_8\NNS\11410625|NONE_0 (l_prep) from_13\IN\0|contractile_45|of_23|to_19 (l_pobj) rats_15\NNS\2329401|NONE_0 (l_amod) diabetic_14\JJ\10595647|NONE_0
D018723_D003920 NONE bethanechol_22\NN\0|,_6|and_4 (r_conj) atp_19\NNP\14964590|nerve_19|,_2 (r_conj) stimulation_17\NN\242808|NONE_0 (r_pobj) to_15\TO\0|contractile_64|of_42|from_19 (r_prep) responses_7\NNS\11410625|NONE_0 (l_prep) from_12\IN\0|contractile_45|of_23|to_19 (l_pobj) rats_14\NNS\2329401|NONE_0 (l_amod) diabetic_13\JJ\10595647|NONE_0
D013311_D003920 CID streptozotocin_17\NNS\0|-_14 (r_npadvmod) induced_19\VBN\1627355|NONE_0 (r_amod) diabetes_20\NN\14075199|NONE_0 (r_compound) mellitus_21\NN\0|NONE_0
D013311_D003920 CID streptozotocin_15\JJ\0|-_14 (r_npadvmod) diabetic_17\JJ\10595647|NONE_0
D013311_D003920 CID streptozotocin_7\NNS\0|-_14 (r_npadvmod) induced_9\VBN\1627355|on_17 (r_amod) diabetes_10\NNS\14075199|NONE_0
D000255_D003920 NONE atp_20\NNP\14964590|nerve_19|,_2 (r_conj) stimulation_18\NN\242808|NONE_0 (r_pobj) to_16\TO\0|contractile_64|of_42|from_19 (r_prep) responses_8\NNS\11410625|NONE_0 (l_prep) from_13\IN\0|contractile_45|of_23|to_19 (l_pobj) rats_15\NNS\2329401|NONE_0 (l_amod) diabetic_14\JJ\10595647|NONE_0
D000255_D003920 NONE atp_19\NNP\14964590|nerve_19|,_2 (r_conj) stimulation_17\NN\242808|NONE_0 (r_pobj) to_15\TO\0|contractile_64|of_42|from_19 (r_prep) responses_7\NNS\11410625|NONE_0 (l_prep) from_12\IN\0|contractile_45|of_23|to_19 (l_pobj) rats_14\NNS\2329401|NONE_0 (l_amod) diabetic_13\JJ\10595647|NONE_0
3769769
D014282_D012559 NONE hydrochloride_12\NN\14817592|NONE_0 (r_dobj) trihexyphenidyl_11\JJ\0|patient_50|was_42|with_30|._29 (r_conj) treated_5\VBN\2376958|NONE_0 (l_nsubjpass) patient_3\NN\9898892|was_8|with_20|trihexyphenidyl_50|._79 (l_amod) schizophrenic_2\JJ\10490141|a_10|chronic_8
D014282_D001919 CID hydrochloride_4\NN\14817592|to_19 (r_pobj) due_1\JJ\5174653|._36 (r_amod) bradycardia_0\NNS\14110674|NONE_0
6674249
D015119_D013345 NONE acid_12\NN\14818238|(_5|)_10 (r_nmod) eaca_14\NNP\0|a_35|short_33|aminocaproic_19|in_16 (r_nmod) treatment_16\NN\654885|to_44 (l_prep) in_17\IN\13603305|a_51|short_49|aminocaproic_35|eaca_16 (l_pobj) patient_23\NN\9898892|NONE_0 (l_prep) with_24\IN\0|a_22|old_12 (l_pobj) haemorrhage_26\NN\14285662|NONE_0
D015119_D013345 NONE acid_12\NN\14818238|(_5|)_10 (r_nmod) eaca_14\NNP\0|a_35|short_33|aminocaproic_19|in_16 (r_nmod) treatment_16\NN\654885|to_44 (r_pobj) due_5\IN\5174653|myopathy_9 (r_prep) necrotizing_3\VBG\0|NONE_0 (r_pcomp) of_2\IN\0|a_7 (r_prep) case_1\NN\7283608|(_142|)_146|is_148|._160 (r_nsubjpass) described_31\VBN\1001294|NONE_0 (l_punct) (_27\-LRB-\0|case_142|)_4|is_6|._18 (l_preconj) sah_28\NNP\0|NONE_0
D015119_D013345 NONE eaca_14\NNP\0|a_35|short_33|aminocaproic_19|in_16 (r_nmod) treatment_16\NN\654885|to_44 (l_prep) in_17\IN\13603305|a_51|short_49|aminocaproic_35|eaca_16 (l_pobj) patient_23\NN\9898892|NONE_0 (l_prep) with_24\IN\0|a_22|old_12 (l_pobj) haemorrhage_26\NN\14285662|NONE_0
D015119_D013345 NONE eaca_14\NNP\0|a_35|short_33|aminocaproic_19|in_16 (r_nmod) treatment_16\NN\654885|to_44 (r_pobj) due_5\IN\5174653|myopathy_9 (r_prep) necrotizing_3\VBG\0|NONE_0 (r_pcomp) of_2\IN\0|a_7 (r_prep) case_1\NN\7283608|(_142|)_146|is_148|._160 (r_nsubjpass) described_31\VBN\1001294|NONE_0 (l_punct) (_27\-LRB-\0|case_142|)_4|is_6|._18 (l_preconj) sah_28\NNP\0|NONE_0
D015119_D009336 CID acid_12\NN\14818238|(_5|)_10 (r_nmod) eaca_14\NNP\0|a_35|short_33|aminocaproic_19|in_16 (r_nmod) treatment_16\NN\654885|to_44 (r_pobj) due_5\IN\5174653|myopathy_9 (r_prep) necrotizing_3\VBG\0|NONE_0 (l_advmod) myopathy_4\NNS\14204950|due_9
D015119_D009336 CID eaca_14\NNP\0|a_35|short_33|aminocaproic_19|in_16 (r_nmod) treatment_16\NN\654885|to_44 (r_pobj) due_5\IN\5174653|myopathy_9 (r_prep) necrotizing_3\VBG\0|NONE_0 (l_advmod) myopathy_4\NNS\14204950|due_9
D015119_D009135 CID acid_5\NN\14818238|why_29|may_25|myopathy_19|in_28|?_34 (r_nsubj) induce_9\VBP\1627355|NONE_0 (l_dobj) myopathy_10\NNS\14204950|why_48|may_44|acid_19|in_9|?_15
D015119_D009135 CID eaca_7\NNP\0|aminocaproic_19 (r_appos) acid_5\NN\14818238|why_29|may_25|myopathy_19|in_28|?_34 (r_nsubj) induce_9\VBP\1627355|NONE_0 (l_dobj) myopathy_10\NNS\14204950|why_48|may_44|acid_19|in_9|?_15
D015119_D009135 CID acid_12\NN\14818238|(_5|)_10 (r_nmod) eaca_14\NNP\0|a_35|short_33|aminocaproic_19|in_16 (r_nmod) treatment_16\NN\654885|to_44 (r_pobj) due_5\IN\5174653|myopathy_9 (r_prep) necrotizing_3\VBG\0|NONE_0 (l_advmod) myopathy_4\NNS\14204950|due_9
D015119_D009135 CID eaca_14\NNP\0|a_35|short_33|aminocaproic_19|in_16 (r_nmod) treatment_16\NN\654885|to_44 (r_pobj) due_5\IN\5174653|myopathy_9 (r_prep) necrotizing_3\VBG\0|NONE_0 (l_advmod) myopathy_4\NNS\14204950|due_9
15686794
D000638_D001281 NONE amiodarone_0\NNP\2715941|drug_50|._145 (r_nsubj) represents_1\VBZ\2664769|NONE_0 (l_dobj) drug_5\NN\14778436|amiodarone_50|._95 (l_prep) for_6\IN\0|an_33|effective_30|antiarrhythmic_20 (l_pobj) cardioversion_7\NN\0|NONE_0 (l_prep) of_8\IN\0|NONE_0 (l_pobj) fibrillation_13\NN\14361664|NONE_0
D000638_D001281 NONE amiodarone_0\NNP\2715941|drug_50|._145 (r_nsubj) represents_1\VBZ\2664769|NONE_0 (l_dobj) drug_5\NN\14778436|amiodarone_50|._95 (l_prep) for_6\IN\0|an_33|effective_30|antiarrhythmic_20 (l_pobj) cardioversion_7\NN\0|NONE_0 (l_prep) of_8\IN\0|NONE_0 (l_pobj) fibrillation_13\NN\14361664|NONE_0 (l_appos) af_15\NNP\0|onset_27|atrial_21|(_1
D000638_D001281 NONE amiodarone_28\NN\2715941|intravenous_12 (r_compound) loading_29\NN\4571088|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) initiation_25\NN\7450842|minutes_14 (r_pobj) after_24\IN\0|who_65|pain_19 (r_prep) experienced_14\VBD\2108377|onset_31|atrial_25|,_6 (r_relcl) fibrillation_11\NN\14361664|NONE_0
D000638_D017116 CID amiodarone_8\NN\2715941|NONE_0 (r_pobj) of_7\IN\0|intravenous_27 (r_prep) administration_6\NN\1133281|NONE_0 (r_pobj) during_4\IN\0|acute_20|back_10|:_47|report_51|._70 (r_prep) pain_3\NN\14299637|NONE_0
D000638_D017116 CID amiodarone_28\NN\2715941|intravenous_12 (r_compound) loading_29\NN\4571088|NONE_0 (r_pobj) of_26\IN\0|NONE_0 (r_prep) initiation_25\NN\7450842|minutes_14 (r_pobj) after_24\IN\0|who_65|pain_19 (r_prep) experienced_14\VBD\2108377|onset_31|atrial_25|,_6 (l_dobj) pain_20\NN\14299637|who_46|after_19
3413271
D004837_D003866 NONE epinephrine_1\NN\14807929|ischemia_45|evidenced_57|._102 (r_nsubj) produced_4\VBD\1617192|NONE_0 (l_advcl) evidenced_8\VBN\1015244|epinephrine_57|ischemia_12|._45 (l_agent) by_9\IN\0|as_13 (l_pobj) depression_12\NN\14373582|NONE_0
D010100_D007511 NONE oxygen_8\NN\14622893|increasing_22|myocardial_11 (r_compound) consumption_9\NN\13440063|signs_59|were_12|during_26|._81 (r_nsubjpass) compared_11\VBN\644583|NONE_0 (l_nsubjpass) signs_1\NNS\6643763|consumption_59|were_71|during_85|._140 (l_prep) of_2\IN\0|objective_16 (l_pobj) ischemia_3\NN\14195315|NONE_0
D004837_D000787 NONE epinephrine_1\NN\14807929|ischemia_45|evidenced_57|._102 (r_nsubj) produced_4\VBD\1617192|NONE_0 (l_advcl) evidenced_8\VBN\1015244|epinephrine_57|ischemia_12|._45 (l_agent) by_9\IN\0|as_13 (l_pobj) depression_12\NN\14373582|NONE_0 (l_conj) angina_14\NN\14171682|st_26|segment_23|and_4
D004837_D003324 NONE epinephrine_3\NN\14807929|NONE_0 (r_pobj) of_2\IN\0|the_9|in_15 (r_prep) role_1\NN\719494|was_53|in_66|._106 (r_nsubjpass) examined_9\VBN\0|NONE_0 (l_prep) in_10\IN\13603305|role_66|was_13|._40 (l_pobj) patients_11\NNS\9898892|NONE_0 (l_prep) with_12\IN\0|NONE_0 (l_pobj) disease_15\NN\14061805|NONE_0
D004837_D017202 CID epinephrine_6\NN\14807929|NONE_0 (r_pobj) by_5\IN\0|mechanisms_42|._57 (r_prep) induced_4\VBN\1627355|NONE_0 (l_nsubj) mechanisms_0\NNS\13446390|by_42|._99 (l_prep) of_1\IN\0|NONE_0 (l_pobj) ischemia_3\NN\14195315|NONE_0
D004837_D017202 CID epinephrine_3\NN\14807929|NONE_0 (r_pobj) of_2\IN\0|the_9|in_15 (r_prep) role_1\NN\719494|was_53|in_66|._106 (l_prep) in_4\IN\13603305|the_24|of_15 (l_pcomp) eliciting_5\VBG\1617192|NONE_0 (l_dobj) ischemia_7\NN\14195315|NONE_0
D004837_D017202 CID epinephrine_1\NN\14807929|ischemia_45|evidenced_57|._102 (r_nsubj) produced_4\VBD\1617192|NONE_0 (l_dobj) ischemia_6\NN\14195315|epinephrine_45|evidenced_12|._57
D004837_D017202 CID epinephrine_9\NN\14807929|NONE_0 (r_pobj) by_8\IN\0|NONE_0 (r_agent) induced_7\VBN\1627355|the_38|of_23 (r_acl) mechanisms_3\NNS\13446390|however_13|,_6|different_76|._108 (l_prep) of_4\IN\0|the_15|induced_23 (l_pobj) ischemia_6\NN\14195315|NONE_0
D004837_D017202 CID epinephrine_28\NN\14807929|-_11 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) ischemia_31\NN\14195315|while_26|was_9|by_27 (r_nsubjpass) characterized_33\VBN\609683|ischemia_174|was_165|predominantly_154|by_140|with_90|,_41|._122 (r_advcl) marked_6\VBN\1296462|NONE_0 (l_nsubjpass) ischemia_4\NN\14195315|was_9|predominantly_20|by_34|with_84|,_133|characterized_174|._296
D004837_D007511 NONE epinephrine_6\NN\14807929|NONE_0 (l_appos) comparison_8\NN\635850|:_2 (l_prep) with_9\IN\0|NONE_0 (l_pobj) ischemia_13\NN\14195315|NONE_0
D004837_D007511 NONE epinephrine_13\NN\14807929|and_21|exercise_40 (r_amod) infusion_14\NN\14589223|NONE_0 (r_pobj) during_12\IN\0|signs_85|consumption_26|were_14|._55 (r_prep) compared_11\VBN\644583|NONE_0 (l_nsubjpass) signs_1\NNS\6643763|consumption_59|were_71|during_85|._140 (l_prep) of_2\IN\0|objective_16 (l_pobj) ischemia_3\NN\14195315|NONE_0
D004837_D007511 NONE epinephrine_28\NN\14807929|-_11 (r_npadvmod) induced_30\VBN\1627355|NONE_0 (r_amod) ischemia_31\NN\14195315|while_26|was_9|by_27
D004837_D007511 NONE epinephrine_7\NN\14807929|NONE_0 (r_pobj) by_6\IN\0|NONE_0 (r_agent) produced_5\VBN\1617192|that_14|,_23 (r_acl) ischemia_4\NN\14195315|as_34|may_37|during_47
7161250
D006220_D010302 CID haloperidol_10\NN\3713736|NONE_0 (r_pobj) of_9\IN\0|higher_13 (r_prep) doses_8\NNS\3740161|and_21|in_25 (r_pobj) at_6\IN\14622893|incidence_37|higher_7|._54 (r_prep) was_4\VBD\0|NONE_0 (l_nsubj) incidence_1\NN\13821570|higher_30|at_37|._91 (l_prep) of_2\IN\0|the_14 (l_pobj) parkinsonism_3\NN\14085708|NONE_0
D008140_D017109 NONE lorazepam_6\NN\2830852|NONE_0 (r_pobj) by_3\IN\0|akathisia_25|was_15|,_56|were_95|._111 (r_agent) controlled_2\VBN\0|NONE_0 (l_nsubjpass) akathisia_0\NNP\0|was_10|by_25|,_81|were_120|._136
D001569_D017109 NONE benzodiazepine_5\JJ\3771443|the_4|in_25|out_31 (r_amod) lorazepam_6\NN\2830852|NONE_0 (r_pobj) by_3\IN\0|akathisia_25|was_15|,_56|were_95|._111 (r_agent) controlled_2\VBN\0|NONE_0 (l_nsubjpass) akathisia_0\NNP\0|was_10|by_25|,_81|were_120|._136
19996135
D014148_D012640 CID acid_4\NNP\14818238|is_5|with_19|._82 (r_nsubjpass) associated_6\VBN\628491|NONE_0 (l_prep) with_7\IN\0|acid_19|is_14|._63 (l_pobj) seizures_10\NNS\14081375|NONE_0
D014148_D012640 CID txa_19\NNP\0|and_10|seizures_14 (r_compound) usage_20\NN\407535|NONE_0 (l_conj) seizures_22\NNS\14081375|txa_14|and_4
D014148_D012640 CID txa_9\NNP\0|NONE_0 (r_compound) intraoperatively_10\NN\0|NONE_0 (r_pobj) of_8\IN\0|high_11|ranging_24 (r_prep) doses_7\NNS\3740161|patients_37|,_58|had_60|._168 (r_dobj) received_5\VBD\2210855|NONE_0 (l_nsubj) patients_2\NNS\9898892|doses_37|,_95|had_97|._205 (l_prep) with_3\IN\0|all_16|24_12 (l_pobj) seizures_4\NNS\14081375|NONE_0
D014148_D012640 CID txa_9\NN\0|NONE_0 (r_pobj) of_5\IN\0|in_17|in_35 (r_prep) use_4\NN\407535|that_5|is_115|with_129 (r_nsubjpass) associated_25\VBN\628491|results_139|._57 (l_prep) with_26\IN\0|that_134|use_129|is_14 (l_pobj) seizures_28\NNS\14081375|NONE_0
